<SEC-DOCUMENT>0001628908-22-000141.txt : 20221103
<SEC-HEADER>0001628908-22-000141.hdr.sgml : 20221103
<ACCEPTANCE-DATETIME>20221103162836
ACCESSION NUMBER:		0001628908-22-000141
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		119
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221103
DATE AS OF CHANGE:		20221103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolent Health, Inc.
		CENTRAL INDEX KEY:			0001628908
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT SERVICES [8741]
		IRS NUMBER:				320454912
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37415
		FILM NUMBER:		221358478

	BUSINESS ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
		BUSINESS PHONE:		571-389-6000

	MAIL ADDRESS:	
		STREET 1:		800 NORTH GLEBE RD, SUITE 500
		CITY:			ARLINGTON
		STATE:			VA
		ZIP:			22203
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>evh-20220930.htm
<DESCRIPTION>Q3 2022 10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:b69e33fa-4fec-4147-99e6-af63e8e14083,g:752cd8d8-fa1c-4165-8528-47511781866b,d:4a25f060abc946f28c4a0095422c2513--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:evh="http://www.evolenthealth.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>evh-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180L2ZyYWc6MzlkYWEwOWVjZjU3NDQ0ZWI2OWI5NWU0OGE5ZDgwMmEvdGFibGU6NGU5M2U0MWIwY2RlNDJlZDkwNmQ5ZTZiNGMzNDYzMjkvdGFibGVyYW5nZTo0ZTkzZTQxYjBjZGU0MmVkOTA2ZDllNmI0YzM0NjMyOV8xLTEtMS0xLTY2OTEw_6d371aad-169a-439b-94f8-7bdfb250d232">0001628908</ix:nonNumeric><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180L2ZyYWc6MzlkYWEwOWVjZjU3NDQ0ZWI2OWI5NWU0OGE5ZDgwMmEvdGFibGU6NGU5M2U0MWIwY2RlNDJlZDkwNmQ5ZTZiNGMzNDYzMjkvdGFibGVyYW5nZTo0ZTkzZTQxYjBjZGU0MmVkOTA2ZDllNmI0YzM0NjMyOV8yLTEtMS0xLTY2OTEw_02ca41c5-8dde-4fc6-b4b6-ee0e5d38ea37">false</ix:nonNumeric><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180L2ZyYWc6MzlkYWEwOWVjZjU3NDQ0ZWI2OWI5NWU0OGE5ZDgwMmEvdGFibGU6NGU5M2U0MWIwY2RlNDJlZDkwNmQ5ZTZiNGMzNDYzMjkvdGFibGVyYW5nZTo0ZTkzZTQxYjBjZGU0MmVkOTA2ZDllNmI0YzM0NjMyOV8zLTEtMS0xLTY2OTEw_36276d4b-9de8-4a10-a510-f757925a4b66">2022</ix:nonNumeric><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180L2ZyYWc6MzlkYWEwOWVjZjU3NDQ0ZWI2OWI5NWU0OGE5ZDgwMmEvdGFibGU6NGU5M2U0MWIwY2RlNDJlZDkwNmQ5ZTZiNGMzNDYzMjkvdGFibGVyYW5nZTo0ZTkzZTQxYjBjZGU0MmVkOTA2ZDllNmI0YzM0NjMyOV80LTEtMS0xLTY2OTEw_d069254b-ab8f-4d37-80e8-ab49e1ba2903">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180L2ZyYWc6MzlkYWEwOWVjZjU3NDQ0ZWI2OWI5NWU0OGE5ZDgwMmEvdGFibGU6NGU5M2U0MWIwY2RlNDJlZDkwNmQ5ZTZiNGMzNDYzMjkvdGFibGVyYW5nZTo0ZTkzZTQxYjBjZGU0MmVkOTA2ZDllNmI0YzM0NjMyOV81LTEtMS0xLTY2OTEw_f17ad16f-9769-402d-8688-a68226895afe">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ia396cf00f66343f282dc8aa9862707b9_D20210101-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNS0wLTEtMS02NjkxMA_408fa599-0cbb-46b4-89df-85994f18cc54">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="iba9bddef4c7947819c9a666d386809f7_I20220930" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181OC9mcmFnOjVmY2U5YjA3YTNhZDRmMDBhNzcxYzhmZjE5MzAyMjg2L3RhYmxlOjJhOGMzYzM5ZmJmZTQwNzY4MGUxMmY1NzQ4ZjRkZTU2L3RhYmxlcmFuZ2U6MmE4YzNjMzlmYmZlNDA3NjgwZTEyZjU3NDhmNGRlNTZfMi0xLTEtMS02NjkxMA_a3452b3f-a39d-4993-8e10-eefa876e5921">3</ix:nonNumeric><ix:nonNumeric contextRef="i7717c83097bb48c298d7cd0c08b877cc_I20220930" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181OC9mcmFnOjVmY2U5YjA3YTNhZDRmMDBhNzcxYzhmZjE5MzAyMjg2L3RhYmxlOjJhOGMzYzM5ZmJmZTQwNzY4MGUxMmY1NzQ4ZjRkZTU2L3RhYmxlcmFuZ2U6MmE4YzNjMzlmYmZlNDA3NjgwZTEyZjU3NDhmNGRlNTZfMy0xLTEtMS02NjkxMA_5ca169fc-1959-4b91-a821-57b538ce8124">15</ix:nonNumeric><ix:nonNumeric contextRef="i622d6d21df814836a91bfc0e4f88e5e0_I20220930" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181OC9mcmFnOjVmY2U5YjA3YTNhZDRmMDBhNzcxYzhmZjE5MzAyMjg2L3RhYmxlOjJhOGMzYzM5ZmJmZTQwNzY4MGUxMmY1NzQ4ZjRkZTU2L3RhYmxlcmFuZ2U6MmE4YzNjMzlmYmZlNDA3NjgwZTEyZjU3NDhmNGRlNTZfNC0xLTEtMS02NjkxMA_404cff94-93ca-4826-9fd7-6b1237a96e9c">27</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i0effece2bf1a40ffaf0063bf427e9d14_D20200801-20200831" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183My9mcmFnOjU0N2I3NzVmODhjNzQ5ZTk4MWVmNGQ3OWQzZTlmYmQ4L3RleHRyZWdpb246NTQ3Yjc3NWY4OGM3NDllOTgxZWY0ZDc5ZDNlOWZiZDhfNQ_f52872cc-8f72-4c10-aa6f-f0fd17005b3e">.0548667</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i13ee5de32afb476bb8a168331d1b1c9c_D20181001-20181031" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183My9mcmFnOjU0N2I3NzVmODhjNzQ5ZTk4MWVmNGQ3OWQzZTlmYmQ4L3RleHRyZWdpb246NTQ3Yjc3NWY4OGM3NDllOTgxZWY0ZDc5ZDNlOWZiZDhfMjE1_ca0941d5-7679-4927-b76d-e24f0fe9048e">.0299135</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="evh-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if244d443b7414b5a802b83cdda1133e3_I20221028"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i4e7829cceaeb4c139799230c0383d092_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ic1c85bf2a0144950a682573f957154ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17e8b3c5da9a4abf8639a0d3c5015910_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb83f20a7c61479b93a83e23998b1c89_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfb31ce6eb9e4668992f11294921cfad_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc0ca7083bdc4ebe842729dbd273685c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1dd537792b6e421ba9639adbfe4474c4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a15fb8f7fe94bf88c8a8a9847578001_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9f34759559a4dfd86efcb145ce3357e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34fded2f74a147099334cfa413800c2c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2946b2f4742c436b9ec38ed088adddf3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i774f0c895b93475580cf9bffc1f4d401_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d92a7bff72d4283b5a2abc070339ddf_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic61eea28d6e24e17b1c838a89e833091_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0deb2b8e664f400a93e847d75c9f7461_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f7fbb4a3598436a82370c985cafd671_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7743c9436eda44b9a29866c882a8d051_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf7540828b6542ccbb0c439bd8d9be10_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47799e4f502f42c98c9d834440ff6d03_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3859fe1f193413e80c660d7cd13bb43_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2153e00392cb428692eb552f22b89475_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie13e8e5c1c8f442db97081f5b187e36a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22d0f81c708f4d62b2c2ba75e4549659_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08eed5034fa6469aa0775ddf5e8edf38_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89f4cf78a38147c4a67ccbc5f1b70b5e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if579391e2dd946e28f4975df65264f3e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i434deea731b3493cafdecab4e0f513df_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic863a6e2b5314131a58086e3e72c0388_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1d69eae660647b891b8545b7593243a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie40e239beadc4317b3c499f7eea02fb6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f69dcb0c02046a8b06f845c2daa4737_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i179c3fe310ef4e61a6d5a2f2721eedc5_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63b3ddd7486946c2a0a8151832317d14_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2bb3fdaea8f41d1a5b926350a34b34f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f6814f5fa1246a687d35a28833137b0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f73e9dc3b2a45679bdcc5b130649934_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04896f930bff47dda34bb3798c357daf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb4cc675813847809003fabf765db881_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia396cf00f66343f282dc8aa9862707b9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7382beeecb6460d9d7d2b36a822b970_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i749e0b18e9154afab9acf4c974f1cf8b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2ed53ed57f5412e8fa51e1b7648fde0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44adf89b2b3d45209e9135d9c2231fda_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1ad6cf9dd3347cb949a440b44766e97_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc261b79d9f841ad8560ed98593f9621_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if90b80996d524ed6b89fbfebe2cedda5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i694c8eca95b44aa281ff19a36e240b13_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5b6a0decc62412fb5b58744bd94543b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57e089b648ff473aba749cdaa85824a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93b026baeacf472babb208203c15aa89_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcb7e5d5de6d4fb9bd1b47d49e170108_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eb7badc179d4dd4b0b439120c44e492_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38d9971f78fb49c3a0ecdff39b8115f9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd86661e66444c48b5ef3429b01488ee_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa111bc1b6fc47e39a435526dc19640d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibee79f04f3964be9b790dfd8e4d6f320_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2301f18558fd44eda53696a9fcbd9108_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia95931a1eeb74ea2a219a48e6a5e3328_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2575f96f53440259166edbd4dbce19b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fd66acfff6549699d6732faf4b2192f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id22c0c0a7d0e4c22bc5e825bcd93a594_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83916efaa57f426f9c3bed9248c24cd6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbbe90d495a24914843d600386432165_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="reporting_unit"><xbrli:measure>evh:reporting_unit</xbrli:measure></xbrli:unit><xbrli:context id="ie70e3951b11d47189d49176b477c53cb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4553368113754e9985da5aee1e1e2e13_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9941ebd90552418b96575575d27a7ebe_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30eb020f19524dfb97afd3fef2c5b9ea_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia71efd024b264a23aa0d21ad75741277_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i495e837d54f24a0d9dc7d49185d44a77_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10d8689dfe304f3bb138eb921170cc2a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="option_to_renew_lease"><xbrli:measure>evh:option_to_renew_lease</xbrli:measure></xbrli:unit><xbrli:unit id="source"><xbrli:measure>evh:source</xbrli:measure></xbrli:unit><xbrli:context id="i102291920e804daab7d25e75918ff73b_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e521093d1374140ac95361a6c2a311e_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i970cc1ff98954def888f92d6e27ed9e0_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6b921fd4b544f439a08e3802c74b054_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae24c6c30eb94d5c82ae99d747a61a52_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0aac7a30651e4f168f37aa5b96ca404e_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47850eb51205454eb531a4e4a24c6b67_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81468ffa8e794bc0b59baa9867b5834c_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2def591b7f54106a7fa0735840fe2d2_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76392d607ac741ffa9749e4c5191c116_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib13556ea35bd419f840924ad34329091_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8980c17573b14788b07301046fa212f8_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i873c819d3f8246cda155f0714de1ce57_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i011e460895d3476ea9ce07169b756846_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdafd4f64587494f9814a1d89347c981_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief648c5f4b1449d2be6c08727632b653_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63c007d9f492486b853449a269099b25_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie493e2b859384dbab23b7cc294e31dbe_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i522030bffa474e539994d8f7437146bb_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib15c968ec28447719bfe672cf73f9c1f_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9acb52a4a7c949db9847508394a446ad_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i644999860f68467f8589953496d35dcd_D20211001-20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47a4ccf5040a4a66b194e116ca3958b2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d45489205434204959192b27c4c154c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8eeb2030bc104024b411081939f02ec5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a06e059e5d544dfae30aab44f20002e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i084df9c8155a461a930377e4e05f1fda_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0eabf8957ae644bea9de5ff585037c2e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0f69a9ba3a84c17bce7dd867c4d59f5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i275229cc10b9470089d55c668922f2bd_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i367c749bbd734fe5936e4963fe777810_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94fd241bcaa64da1931a65e62a56ec7c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cdccd94a8564ff29b795220b3f3ab9b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ee4e484cf964a788bb699155c8d3460_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i942d2a04b516474fad491df3467fe4a1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae1fd07e7a684627bcc4060576e5441e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fa189959b70490991b00541c0e766b4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7cb9ce8372844c4a246769d6a86d26f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20e72ff3374e40b7b9ef61f986ed1c3f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic60baf9264bb4217b1b8574383a06caf_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8ff5e19f6d8424a8f324dfbee51fafc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f643fc0caed4180a8f4262624ceb1d5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d938e0b3b4949498896da9cf968d0e2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f0e4a5e2538465489ed74ed4df71f17_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c0881f057a14f60b11d5202ba4254d6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia663b5d5862c44d3bb9df7816b437214_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2145c8132b345cdbc155aef50b5b24d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5ecc514fd2f4b63b7f68dd819b7abdd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cf09e09764f4e7ba983e1073e89d28e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d1acdaafc0b49afb61eac49debda354_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21f251cda7464cffa6ec9eebf7e8f211_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibde168bb02b0431892729b1d49c5bbbd_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b5c3ea113b04213b765d3be37ec88ce_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ab4a9b7f10b466b8aed9afde209544a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5053a77df20d49178d0acdd07e80fb9f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieef521b6cb2644d59433c4a98ac67edb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4dfdc7272dc4a849a6c7e48dfcc4f74_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5af61dbd97844f2cb160b48a3a35d4e8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e55c1b3affc496aa10cbd0b6538c957_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba9bddef4c7947819c9a666d386809f7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="evh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis">evh:December312022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7717c83097bb48c298d7cd0c08b877cc_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="evh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis">evh:December312023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i622d6d21df814836a91bfc0e4f88e5e0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="evh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis">evh:December312024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8df943109acf43b1beae85454cf38885_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9767cf7dd34a49aca4c626b25a0137e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1edb69a16cb6459691cb056b595c5885_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id614a39adbe643b4aa5b5af050be49fd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i632714a677b64a15983dae3dbbde9997_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7383d04203184df1accf6ee901f03030_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id740d1bbcfed47e0aaa7894c6b8e4f13_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60bde46c214b463b872f8fed94fe0fd3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8d6b3d636ef48789c73c450718514b3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if801b9c8aab245d5b731f391ad5348b2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21ab12969f634adfa6cdd08a0aaf4fad_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5994da9b8f9641029f5d64b5faece604_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibff905a18b1f40209cb5ca0efef086b5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5637ed5c72c44080978d3cd0ea34cfda_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04596f10134947b6acb9bac1698947da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i124df651628843dabf0bf39cef2a4f10_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5730da3ff5444c0fbe524c644c202af4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3e288bad13b4a5e8fbf6a82c2389ad6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5c4d433d31d4a2a84d11ae0257cc18f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ebfbd6230a54574b1ed03cade006714_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabc0377cf6c84950aafa636df7d7c185_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id32484f46aaa490dafecdb5a20db36fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i311d2b7cdbe24f8ebdf190a94aa1332f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49599e7727614d2697e205fcf5b794f4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i216238f5c4204e818ee9557f67bc5b08_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idadb3eda60994bfc9bf46cb46e81e8b4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ab5726f3d7c43e9b4c48c383620aa05_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i597e5acb0181498a985baa0c47467de9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic75e54e0b5564ba5bdf3845c85ae6efa_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2b23b62d2314ba29f31148feecadf97_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c9b3945ac9741d4843b49c10f8dcd40_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffa15ee70390496c89f205bdc8f3731b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i358169d308bf4641ad0dca36755b47d1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0291d88c45549ebb15674a1bf82c1a2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b7c2c9eb4d24e95a2fb3597a736a55d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1859c2ae121649f09ad595e92fb8e96c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44a8b1c85fc24294af85eb3f3327612d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaa4680cab4245c48c966ba93e130b60_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84135b0576f249ae8003b7e81a024ba5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic68a9db5aae1478fadff12a779202797_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if41217b3022a48ed94e3723c3e0071e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6843d02651b4eb19d0b68edf6087afd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25182b4f6fce43fda0e5ebbe2cc7f240_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59ff2088dd3d487c93a983e025043b03_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0792eb2a4584a8b95e0d513e6752d62_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2ec2a15830e4d0e87fe2230ea0e7474_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cdb2defd328413a8f5c7e2f8ae2c1f0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58352bc33d9d47e7b266d367548f4196_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bd97829624644b3a76e8a12f04957c7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34a0859bcb414bc7b9fafe316f673bca_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0f42e14adcf450990dc48ddf76f1496_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0fd0d41813c458fa01a9b4a323d16c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1df90080b3ad4844b8125e0a4c7547e9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c22c7e8a0aa46c294ef5bcb1985120c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie029cabfd7164a66bdeb9807be351813_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f3b6e992ace40abb1f986f35d3efc3c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23031c0b6b3349ac87a0dd3718ded62f_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if02e0ede9ff94b57bd4e150fe4f1c424_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib85258a5944847a799568304dbd3b847_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i397f99c968184e23a3239fd5df224e34_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>evh:day</xbrli:measure></xbrli:unit><xbrli:context id="ia09ce527d9154016aed6990fcdea728d_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i023a2e0781824e51aac26656357a04e5_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3728ee01b28446c5b8e4e913f63db0c1_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia11fc3353efe46e19266ef78af24da63_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f90d550a67b49a1b9b6999f0941d947_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89cb6508f7a645e3b79e3ad7df4206de_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia44b9d3c20ff4e6cb60de6ff8ecd5783_D20220801-20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if44e132eb50c4b2b961cecf1fb497c82_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e534dd28b704e32ae748c0e79ebc74b_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i971d328b42fe456798f158d581d7e9f1_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6070c04ec514eb1b72630be44af9d9d_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b673721ad2140dc92b0e7de4a1c58b1_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i173d3fd170d1453abafbccbcc3311581_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:NewNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i247174c3d444488082c85f25293301f0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i703a0ee08afb4b42a1e3c2eed2680471_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9412f1389708421ebab698307b0652e5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54f3f1eeedc94eaf8493438a2310988b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf3800946de143f0bb536bae6a5686d3_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e4ac76e97a341ee8fbcc6dfa4aba611_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i281bd5c057904435bc8629de116dd37a_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:EquityComponentOfLongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1cdd64507cd4f068665c06a3f09861d_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:DeferredFinancingFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a248420ba824c9d8f7efebff5855664_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0780a0fee7594b46b08c694f8172b826_D20220811-20220811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-11</xbrli:startDate><xbrli:endDate>2022-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d823b0fe92347a08c084c665a3f3d9b_D20220817-20220818"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-17</xbrli:startDate><xbrli:endDate>2022-08-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic25d64a2c23948ee96a46fb336fc19be_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if893b79edc40422a846ee7d717983c69_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:InitialTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic570e916fb874a79be763e4769336d66_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:DelayedDrawTermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if526c9a8decf4411aa6798f771fb8f2e_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if34c7918f26d4075a90353ac93a20071_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i237f03b5f1ae46209253a55eef0acbd7_I20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i346643136a3d4c2ca53d05972479a685_D20191230-20191230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2019-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1b9711d99314be699395b69414db087_D20210108-20210108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-08</xbrli:startDate><xbrli:endDate>2021-01-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaadf8da35c2642b1baae4f9f8ec5b1ec_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83e14bd5c2bc4351a905d0c781f6f2e1_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83a29e272d0e42f1a62606a14f9bcb44_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i943bcfabb119462c92e5b274885f9058_I20181022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6a0939c098e417591c54c728c4656b1_I20181024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73b993a88b6d4a83ba73f75a35a0dd70_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82c2c5f321e645a3b56a3aecae93056e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id732329530cf43d0808c84c8df54ccc4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26243e36f2374ba5a987cdb451132b3d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9de8dee931674cb18c65e45a7b1e4f2c_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ac8f2155d3b40999c6630d7228cc990_I20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ad79143dac24d9fb4e767f03a9199d5_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:EquityComponentOfLongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f199ebd90ef433e8b368de1394c5180_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:DeferredFinancingFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fb3858a372e487fb6337c1636d1f938_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a62eaff28ea42a28e86090e3e7b8dd7_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e5305e5d35d418385b8e523b11422f4_D20161201-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-12-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e0b4bf0b8594fd0baf9242862d641ec_D20211201-20211201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iada79ebd92cc43c4a68b4aa5846a5940_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2ba2e5b9e234d4fb2a1474c09951db0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5270f847008248a6bad1874588389f6f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bce8ea980fc40fe86deba0a1244f385_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i624e27774ed54173a7c197935a253285_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if03270431ded404994880052552c5e20_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21df7ec9dc5145d0bad6dac81a893732_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d09652a0b6b48dbbae7e55d51a86ced_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0effece2bf1a40ffaf0063bf427e9d14_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13ee5de32afb476bb8a168331d1b1c9c_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d2101c3205e40fbb7350d3a97444a2b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bc1e4679a644ab9ac8f129c984adf2c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e2f3f30574a46129384a30992e3c3f9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56823a0a37a14bc28d21c2c9d3140588_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fefdbdcfbff4feb9724eb08693b3aae_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">evh:UPMCResellerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="customer"><xbrli:measure>evh:customer</xbrli:measure></xbrli:unit><xbrli:context id="i8a7f1b54fe7b435899399c232e3c82eb_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">evh:UPMCResellerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia13de1649ce14d5ba2486e13d566c4de_D20220802-20220802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">evh:ShareholderClassActionComplaintMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-02</xbrli:startDate><xbrli:endDate>2022-08-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i812113f21d0f4ddab105da97d5259847_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebb100753030431db53c2c0fcb076812_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a78877350444f218b04a44d9a5a67f2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9063068a17484ebd913c39f47d497ab4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:BrightHealthManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d9342a7219542d0b80d6351bbbf951e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id66d64f0da484276ac264af8e9113d8b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if15154cdcab04d8c8d65acb536587c6c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5853227e398a4d7793e949610404e4cb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65657a6b51904fa0b718ad005efbdff6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8be069ea831c4019bdd30e5903c02c34_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb0f8ea17a2a4c8084b696133732c541_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia751c62398344050a4fa0f25431a1c20_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5109fae1e1f447d9ba05497deddbfdc1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8a8fe953a844510b46e6007aa3d8a39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c22768950824185b381d31f0d376c88_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:VA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b26e20c9d404df3839bead28654fb46_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia01578a302554a74b33916abc13ae563_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i911c93fdeef8463595874d62c2e77c23_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:GA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib15e0e31d88444c0b1538bbb061a978e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i159210da82754513ad12fdb0f55d6185_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8493de5c288b4d2a960001285f09a7d5_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13c42161e64b48038d3f19a5af627a85_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae5571384d234210beca38a208484402_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i698aa6c02364400ebedf039f90402307_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fd339cb95b94daea292e551ad2fe6f3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bcd97c207a54e5ab3166f83c04c3bb0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31ffa1624215451292f3bc38304028d0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22491be6a23246d796d54f3c45790776_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bef61a150eb4c7a881bdf01c6a5f488_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9dbe0e582d74777ae8810f8d192e1d8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22bf8d1d47ce4219b999f81df2fed5e7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd9f231f9ee2464db9a170de0151bca4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb50d04ea7474a3ca01d54e55b1a55f6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i325a5d1124ab41b9a84347a873d3e51b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea400d223b0743bdad51be17ed4b50ee_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2a7bc06fc954c4b817161cd6406f509_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i582d7dedfcac46f99a84eb6ef808e641_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aa29b39545e4c3ba7d7690b3e215975_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b17f35850394b8dba4f2022f71b47ca_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a875e7e581644ddb5ae0ea1dd6d828d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80cf2c1a304b4b419a652fc1e0cb1937_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c541a9c8aa847a880c6ab10e684b4c9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cc6de998c6c41a2918343e7a2029cbe_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44b9048d914e4b6fbb6f301354a4b9b0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i647fb470e87444d6a627e33d5d70965b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide5f51cc3ef84de6a0fd4b47abd3c1e8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcffb900db284c32b9e3d8cb934a505f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee1649a9b5bf47f7917cfe5843b5b4a8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i725c229475cf49689226a91cc11b751c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2612dbadf05a4362aad60d096eb1a7e4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iada2bf5d0400417ba62e194126135b75_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6f6b8c71225423c8a5684cc55be31ce_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i631da77b97724fd1b7043025f1733fe1_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1a0e6a4f8b84f88b30c7341d4f1c393_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd568013557c46eb981fa85a87040eba_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e14d567f9f24b93870cd21943387f1c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i595e611ec9ae489dbce4f7eda441f246_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eda68985c9842cdaf3b26312b15d4c2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if02fc4db2c9b4fa8b2f8b4664e01eea1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i277f0bf297354d94af61e257c3ec7ff7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebd3f639166d44039bd8edc98238a383_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4b322c66f3e45b08685a4ae028887d8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i396bb0edd68c430189127d5633e8e1a4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2240a4a6255943e4bf456dfd07e73621_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1d99a70db5f43208858b7f0f954c2d1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e61be204d694c09879235c63a790f71_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bc89218c26643328b21b1506819b3a0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88c58b8bf6804181b9ae7aa0ce6fa7e0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i328717c857f2404dba9ba20b9433ea18_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id142ae030d514564a81b2bb1eadfeaba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i867837f495ba4b65886161a03a0def38_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c1e69c3b48346c3b0514ad1ccceb5f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5a543708cce4e1587fc2f618e7c92b7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28495d82fa994f08b28b8dfc1e3a47e6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd65a2db6ad04df8b047a7d81b2023ee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30e706fd844d4e009a8b34652d74f93b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb038b091b7344c29e48adca13ed03ae_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6387c494ab8746e7b6c8beed248da58e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie08f13f16382418ea5ec290830f60d8c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12e6f929d457432287e5c6cd1f183f5f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5df79eb68c444ab9cb77a56bf677989_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cace99351664c7ca949a3e0200ac20d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60fada84ac4946cb9b4e805a57e3cf0b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9bdab906b4a4d49a48fe38f018eb8bc_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a5ea59bbc694c93968f7c1ff417d386_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d139443bb3e4ce086f6d2c6a7b557b2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73540c5f613d403b832d91b574a59f07_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice64acee7f3f46179553cd75809b106f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic86b2c3d20a443a49da566ae4eaf14cd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia91f376f9d6846eb84ca11a8a358cf74_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6e2ba14bf4d472691df13b609cc514b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie38f3231de914c44a9c3146fc55eb3b8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3044ccef126a4375824fc8fc3a6c3ce3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91cfb2c56b99413c9fb95814cfb285f4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3adb4e55cc4e45a7911caff2dbcc7a00_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ed21b2abe494c07b71ec32367fb20d9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>evh:segment</xbrli:measure></xbrli:unit><xbrli:context id="i806263fe61f14f33b5cdbd7eee333ff7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacbe24e15241450eb5814aef67850f85_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7b76ebaaef241a09456df69e9f56730_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id47a9c894a7d46569bed9ed6ad4e9987_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie593e243a4f94ded8dcc0cbd2124556d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e9c2f26074c434280c915a00ab6b2fe_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26289f6ee3444cf484ed38a01409bbfe_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i338af69a6f0948e5a6b88db8f9f14704_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbee25bccde9417b9684147c13bfd340_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f35093a1db04660afd25caee273d0f0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd61671a0d0442d5ad34be35130c449e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1cf7a17cbbf4a65b3324ddb3a731532_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0870ad9619a8495f9f783b300266e2bf_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia108ecb595104f0e8ed9def9f229176e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59101f8a3ac14ae493956a62379f494f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceebbb78aaf945b48c2e1e0c956749dd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3311fd1bb12e4f44944b34e49f4f81c7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71b35f78e61e4fd6a8f76ed882b8104b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14e6f529e4db48d8894cb30eac5feba5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8abf6d4aad764b85af854f18bc243f26_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001628908</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjUtMy0xLTEtNjY5MTA_e4abb8b3-aa8f-4832-83bc-f87e164b3de8 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjAtMS0xLTEtNjY5MTA_48d0844c-9fb0-4d5c-b7d4-6304a399f74d id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNS0zLTEtMS02NjkxMA_6db68019-f8ed-4595-afcd-b595ba408e42 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjAtMy0xLTEtNjY5MTA_c65b73ea-18ea-457b-b53e-8321cc519932 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNi0zLTEtMS02NjkxMA_3fbe5349-c50f-488a-926f-cebbbb5e3145 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTItMS0xLTEtNjY5MTA_34f9420f-1f29-4dd2-a3b4-4616ca572376 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjEtMS0xLTEtNjY5MTA_503f1e92-bc1a-4c1c-88de-3f62af41dfea id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNS0xLTEtMS02NjkxMA_f64a8628-8343-4da0-954d-ffe1f203e1f5 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjEtMy0xLTEtNjY5MTA_f0410fb4-f54a-4562-8220-80148a84a87a id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjUtMS0xLTEtNjY5MTA_48ec7316-cea1-4cf6-8f66-13d156e589bd id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNi0xLTEtMS02NjkxMA_d3e0c599-491f-46df-a5b8-1ef55dddf91e id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTItMy0xLTEtNjY5MTA_e780754b-becf-412a-9a90-ad6423472439" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RleHRyZWdpb246Y2NiZWRlZjE1MGEzNDA0Y2E0MWUyMzkzN2Y0YjU0YWVfMTkw_99d40318-14a9-4059-9180-0d35bf3232a0" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy0xLTEtMS02NjkxMA_0f209cfa-8504-4ac9-b758-ac2a0a61b1b2 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtMy0xLTEtNjY5MTA_43c76fef-6b2e-4467-b3ef-343e76af8f09 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy03LTEtMS02NjkxMA_d20e63e0-6ca3-40ec-8951-ef7d1c289504 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtMS0xLTEtNjY5MTA_0f209cfa-8504-4ac9-b758-ac2a0a61b1b2 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy0zLTEtMS02NjkxMA_43c76fef-6b2e-4467-b3ef-343e76af8f09 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtNy0xLTEtNjY5MTA_d20e63e0-6ca3-40ec-8951-ef7d1c289504 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtNS0xLTEtNjY5MTA_00f03ad2-b82d-44e7-b7c4-221872011c79 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy01LTEtMS02NjkxMA_00f03ad2-b82d-44e7-b7c4-221872011c79" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDA5_2476b5e9-95ac-459d-a77e-7144819457ee" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi03LTEtMS02NjkxMA_34edd863-f4e2-4813-bb92-2662eebf4a0a id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi01LTEtMS02NjkxMA_5f2e275b-70f9-47fe-8b15-566555a7bfb6 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS0xLTEtMS02NjkxMA_c1e43070-1906-4b95-918c-de3e2d6ad751 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi0xLTEtMS02NjkxMA_28d6ffce-89e9-459b-a59c-bdfa2cfd0ac0 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS03LTEtMS02NjkxMA_a4472a6b-b093-4b73-b6c8-ee80bcaf0c75 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi03LTEtMS02NjkxMA_1ca38dea-5804-491f-b6f7-af17f48eb3ee id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi0zLTEtMS02NjkxMA_11533d2f-70b8-49ef-8326-e453614be690 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi0xLTEtMS02NjkxMA_db29f41c-bce7-4327-9bf4-be3e93d52a0f id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS0zLTEtMS02NjkxMA_edb76492-aae3-4861-9dce-2a945e70053d id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS01LTEtMS02NjkxMA_b18d0ce1-acbd-45aa-9cdc-ac7e018922e2 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi0zLTEtMS02NjkxMA_a61cab80-88da-43a6-aa65-391f42890dab id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi01LTEtMS02NjkxMA_526c1f97-4796-4d78-a5f7-ea1044f251d4" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDE0_fb645b76-e589-4eda-a1e7-a776efc5d3ae" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDctMS0xLTEtNjY5MTA_503dff85-023e-41ac-9baf-a5d4bdb07ad4 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDgtMS0xLTEtNjY5MTA_b751326e-4f93-4c44-a804-68bbee4f159f id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDctMy0xLTEtNjY5MTA_f538f3d6-8112-40a3-81e2-b534540a0098 id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDgtMy0xLTEtNjY5MTA_922cadfc-cfbc-4114-8f67-576e593a58f6" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RleHRyZWdpb246YTVkOWE1YzhmNDI0NGI1OTljNmI2ZjhkMTgwNGUxNmZfNTY3_7b3fb7d1-25f9-4617-9e42-722c10fba725" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i4a25f060abc946f28c4a0095422c2513_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">UNITED STATES</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">WASHINGTON, D.C. 20549</span></div></td></tr></table></div><div style="padding-left:38.25pt;padding-right:38.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8yMzEw_6a9e881f-d43a-409e-8d4f-9fee8c5328e8">10-Q</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-right:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8yMzEx_64814b67-e062-4cc9-8308-656c22c27ff2">S</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8yMDc_a4fdf488-89b4-4fbd-8af4-bded1990434d">September&#160;30, 2022</ix:nonNumeric></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:19.12pt;padding-right:19.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">OR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:19.12pt;padding-right:19.12pt;text-align:center"><span><br/></span></div><div style="padding-left:18pt;padding-right:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8yMTY_137c4c8f-5f9c-4d48-a31c-6a15505f73a2">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">For the transition period from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#160;</span></div><div style="padding-left:38.25pt;padding-right:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Commission File Number:&#160;&#160;<ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8zOTg_b7934118-ab08-46f6-a12f-9720e23b7de0">001-37415</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV80Mjg_cee9713a-b8a3-492f-ad03-1b62e648a7fd">Evolent Health, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:479.25pt"><tr><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:102.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:7.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:34.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:75.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:49.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGFibGU6MmJjYTkwNDYyZjBkNGIwZjhiMzM2NjNkZWM4MWE4NWUvdGFibGVyYW5nZToyYmNhOTA0NjJmMGQ0YjBmOGIzMzY2M2RlYzgxYTg1ZV8wLTEtMS0xLTY2OTEw_27383283-fc7f-4139-9058-1e46c4eabe0f">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGFibGU6MmJjYTkwNDYyZjBkNGIwZjhiMzM2NjNkZWM4MWE4NWUvdGFibGVyYW5nZToyYmNhOTA0NjJmMGQ0YjBmOGIzMzY2M2RlYzgxYTg1ZV8wLTktMS0xLTY2OTEw_396bedc1-33c5-443f-a02f-6e22a7f431cf">32-0454912</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGFibGU6MmJjYTkwNDYyZjBkNGIwZjhiMzM2NjNkZWM4MWE4NWUvdGFibGVyYW5nZToyYmNhOTA0NjJmMGQ0YjBmOGIzMzY2M2RlYzgxYTg1ZV8zLTEtMS0xLTY2OTEw_75bd89c6-555e-4b68-a1af-8925481755ce">800 N. Glebe Road</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGFibGU6MmJjYTkwNDYyZjBkNGIwZjhiMzM2NjNkZWM4MWE4NWUvdGFibGVyYW5nZToyYmNhOTA0NjJmMGQ0YjBmOGIzMzY2M2RlYzgxYTg1ZV8zLTMtMS0xLTY2OTEw_fb1be725-6bca-430e-bd7c-82c168344f87">Suite 500</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGFibGU6MmJjYTkwNDYyZjBkNGIwZjhiMzM2NjNkZWM4MWE4NWUvdGFibGVyYW5nZToyYmNhOTA0NjJmMGQ0YjBmOGIzMzY2M2RlYzgxYTg1ZV8zLTUtMS0xLTY2OTEw_8418d2f2-da7a-4921-b3c6-d19620e1cd4f">Arlington</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGFibGU6MmJjYTkwNDYyZjBkNGIwZjhiMzM2NjNkZWM4MWE4NWUvdGFibGVyYW5nZToyYmNhOTA0NjJmMGQ0YjBmOGIzMzY2M2RlYzgxYTg1ZV8zLTctMS0xLTY2OTEw_f7691103-1d2c-4e1d-99f4-8a3ad5cc6e08">Virginia</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGFibGU6MmJjYTkwNDYyZjBkNGIwZjhiMzM2NjNkZWM4MWE4NWUvdGFibGVyYW5nZToyYmNhOTA0NjJmMGQ0YjBmOGIzMzY2M2RlYzgxYTg1ZV8zLTktMS0xLTY2OTEw_d50e8fa1-f716-4fa7-8cd7-64f9086c63a2">22203</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">(Zip Code)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;           </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV81MzY_da560835-7329-4441-8592-726dab6907e2">571</ix:nonNumeric>) <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV81NDA_63fb70f2-dd8f-48c1-9154-b26a353025ba">389-6000</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">_________________________</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:256.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:190.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:24pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGFibGU6ZDhkNmU3ZWQzZDU3NDk5ZGIwYTAzZGM5ZjMzNDUyZDcvdGFibGVyYW5nZTpkOGQ2ZTdlZDNkNTc0OTlkYjBhMDNkYzlmMzM0NTJkN18xLTAtMS0xLTY2OTEw_0c9c6c68-029f-4884-9b46-32702218d2ad">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGFibGU6ZDhkNmU3ZWQzZDU3NDk5ZGIwYTAzZGM5ZjMzNDUyZDcvdGFibGVyYW5nZTpkOGQ2ZTdlZDNkNTc0OTlkYjBhMDNkYzlmMzM0NTJkN18xLTEtMS0xLTY2OTEw_0c5672b6-82cc-406b-884a-7171e7e5b074">EVH</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGFibGU6ZDhkNmU3ZWQzZDU3NDk5ZGIwYTAzZGM5ZjMzNDUyZDcvdGFibGVyYW5nZTpkOGQ2ZTdlZDNkNTc0OTlkYjBhMDNkYzlmMzM0NTJkN18xLTItMS0xLTY2OTEw_2b29fd34-b70e-4a98-8aa1-96391c540d8c">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8xMDQx_74883968-e846-4a4a-888a-be2cd809d28e">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  No &#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8xMzYz_c6078621-bf12-425d-9c2a-ff69f4112cc2">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  No  &#9744;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;  &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8xNzMw_6a0faa6c-7043-4fc6-82fb-57f3b80209fe">Large accelerated filer</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">  Accelerated filer  &#9744;  Non-accelerated filer &#9744;  Smaller reporting company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8xODEx_b20c7469-f673-492a-a301-78e2b2d11208">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8yMzEy_abe9356c-1423-4024-8d40-5ab9aa443db1">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 (a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;Yes </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No&#160; </span><span style="color:#000000;font-family:'Wingdings 2',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8zMjk4NTM0ODg1NjQz_507c83c6-073e-44e7-909d-94eeb8d22ed1">S</ix:nonNumeric></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">As of October&#160;28, 2022, there were <ix:nonFraction unitRef="shares" contextRef="if244d443b7414b5a802b83cdda1133e3_I20221028" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8yMjQ3_5a02aead-f43d-42e7-af19-de42fb496202">101,190,965</ix:nonFraction> shares of the registrant&#8217;s Class A common stock outstanding.</span></div><div><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i4a25f060abc946f28c4a0095422c2513_10"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.318%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_19">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_22">1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_22">Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_22">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_115">2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_115">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_115">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_139">3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_139">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_139">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_142">4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_142">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_142">54</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_145">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_148">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_148">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_148">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_211">1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_211">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_151">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_154">2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_154">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_154">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_157">3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_157">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_157">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_160">4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_160">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_160">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_163">5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_163">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_163">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_166">6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_166">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_166">57</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_172">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4a25f060abc946f28c4a0095422c2513_172">58</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i4a25f060abc946f28c4a0095422c2513_13"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Explanatory Note</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Quarterly Report on Form 10-Q, unless the context otherwise requires, &#8220;Evolent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer to Evolent Health, Inc. and its consolidated subsidiaries. Evolent Health LLC, a subsidiary of Evolent Health, Inc. through which we conduct our operations, has owned all of our operating assets and substantially all of our business since inception. Evolent Health, Inc. is a holding company and its principal asset is all of the Class A common units of Evolent Health LLC.</span></div><div><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_16"></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS - CAUTIONARY LANGUAGE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements made in this report and in other written or oral statements made by us or on our behalf are &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 (&#8220;PSLRA&#8221;). A forward-looking statement is a statement that is not a historical fact and, without limitation, includes any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like: &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;aim,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;shall,&#8221; &#8220;may,&#8221; &#8220;might&#8221; and other words or phrases with similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to our ability to grow our impact significantly throughout this year and beyond, future actions, trends in our businesses, prospective services, new partner additions/expansions, our guidance and business outlook and future performance or financial results, and the closing of pending transactions and the outcome of contingencies, such as legal proceedings. We claim the protection afforded by the safe harbor for forward-looking statements provided by the PSLRA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements are only predictions based on our current expectations and projections about future events. Forward-looking statements involve risks and uncertainties that may cause actual results, level of activity, performance or achievements to differ materially from the results contained in the forward-looking statements.&#160;Risks and uncertainties that may cause actual results to vary materially, some of which are described within the forward-looking statements, include, among others:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the significant portion of revenue we derive from our largest partners, and the potential loss, non-renewal, termination or renegotiation of our relationship or contract with any significant partner, or multiple partners in the aggregate;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">evolution in the market for value-based care;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">uncertainty in the health care regulatory framework, including the potential impact of policy changes;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to offer new and innovative products and services;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to completed and future acquisitions, investments, alliances and joint ventures, including our acquisitions of Vital Decisions and the Implantable Provider Group, Inc., which could divert management resources, result in unanticipated costs or dilute our stockholders;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the financial benefits we expect to receive as a result of the sale of certain assets of Passport may not be realized;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the growth and success of our partners, which is difficult to predict and is subject to factors outside of our control, including governmental funding reductions and other policy changes, enrollment numbers for our partners&#8217; plans, premium pricing reductions, selection bias in at-risk membership and the ability to control and, if necessary, reduce health care costs;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks relating to our ability to maintain profitability for our total cost of care and New Century Health&#8217;s performance-based contracts and products, including capitation and risk-bearing contracts;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to effectively manage our growth and maintain an efficient cost structure, and to successfully implement cost cutting measures;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">changes in general economic conditions nationally and regionally in our markets, including inflation and economic and business conditions and the impact thereof on the economy resulting from the COVID-19 pandemic and other public health emergencies;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to recover the significant upfront costs in our partner relationships;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to attract new partners and successfully capture new growth opportunities;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the increasing number of risk-sharing arrangements we enter into with our partners;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to estimate the size of our target markets;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to maintain and enhance our reputation and brand recognition;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">consolidation in the health care industry;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">competition which could limit our ability to maintain or expand market share within our industry;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to governmental payer audits and actions, including whistleblower claims;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to partner with providers due to exclusivity provisions in our contracts;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">risks related to our offshore operations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to contain health care costs, implement increases in premium rates on a timely basis, maintain adequate reserves for policy benefits or maintain cost effective provider agreements;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our dependency on our key personnel, and our ability to attract, hire, integrate and retain key personnel;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of additional goodwill and intangible asset impairments on our results of operations;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our indebtedness, our ability to service our indebtedness, and our ability to obtain additional financing;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to achieve profitability in the future;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of litigation, including the ongoing class action lawsuit;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">material weaknesses in the future may impact our ability to conclude that our internal control over financial reporting is not effective and we may be unable to produce timely and accurate financial statements;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions and penalties as a result of privacy and data protection laws;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">data loss or corruption due to failures or errors in our systems and service disruptions at our data centers;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">restrictions and penalties as a result of privacy and data protection laws;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">adequate protection of our intellectual property, including trademarks;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any alleged infringement, misappropriation or violation of third-party proprietary rights;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our use of &#8220;open source&#8221; software;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to protect the confidentiality of our trade secrets, know-how and other proprietary information;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on third parties and licensed technologies;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to use, disclose, de-identify or license data and to integrate third-party technologies;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on Internet infrastructure, bandwidth providers, data center providers, other third parties and our own systems for providing services to our partners;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our reliance on third-party vendors to host and maintain our technology platform;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our obligations to make payments to certain of our pre-IPO investors for certain tax benefits we may claim in the future;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to utilize benefits under the tax receivables agreement described herein;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our obligations to make payments under the tax receivables agreement that may be accelerated or may exceed the tax benefits we realize;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the terms of agreements between us and certain of our pre-IPO investors;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the conditional conversion features of the 2024 and 2025 convertible notes, which, if triggered, could require us to settle the 2024 or 2025 convertible notes in cash;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential volatility of our Class A common stock price;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the potential decline of our Class A common stock price if a substantial number of shares are sold or become available for sale;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions in our second amended and restated certificate of incorporation and third amended and restated by-laws and provisions of Delaware law that discourage or prevent strategic transactions, including a takeover of us;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability of certain of our investors to compete with us without restrictions;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">provisions in our second amended and restated certificate of incorporation which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our intention not to pay cash dividends on our Class A common stock.</span></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The risks included here are not exhaustive. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements.  Our Annual Report on Form 10-K for the year ended December 31, 2021 (the "2021 Form 10-K") and other documents filed with the SEC include additional factors that could affect our businesses and financial performance. Moreover, we operate in a rapidly changing and competitive environment.  New risk factors emerge from time to time, and it is not possible for management to predict all such risk factors.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, it is not possible to assess the effect of all risk factors on our businesses or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results. In addition, we disclaim any obligation to update any forward-looking statements to reflect events or circumstances that occur after the date of this report.</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii</span></div></div></div><div id="i4a25f060abc946f28c4a0095422c2513_19"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div style="text-align:center"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  Financial Statements</span></div><div><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_25"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in thousands, except share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:521.25pt"><tr><td style="width:1.0pt"></td><td style="width:325.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:93.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:93.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMy0xLTEtMS02NjkxMA_4adfd785-0067-43b4-8b3f-7f733aa313f9">156,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMy0zLTEtMS02NjkxMA_10feef25-ed4e-4e73-ac78-859bb8e9ed56">266,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNC0xLTEtMS02NjkxMA_91f8298f-7423-4369-9cdf-9245fd3a7b3a">25,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNC0zLTEtMS02NjkxMA_ddf47620-1f0e-4c3a-b99b-0657990da4d4">75,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNS0xLTEtMS02NjkxMA_f64a8628-8343-4da0-954d-ffe1f203e1f5">187,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNS0zLTEtMS02NjkxMA_6db68019-f8ed-4595-afcd-b595ba408e42">130,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNi0xLTEtMS02NjkxMA_d3e0c599-491f-46df-a5b8-1ef55dddf91e">24,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNi0zLTEtMS02NjkxMA_3fbe5349-c50f-488a-926f-cebbbb5e3145">51,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNy0xLTEtMS02NjkxMA_bbfedc42-271b-48ec-83b3-88dbfd6e1cfd">393,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNy0zLTEtMS02NjkxMA_5809fd6a-aa3c-44b2-b176-a6bf491aeffa">523,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfOC0xLTEtMS02NjkxMA_7c9340cb-1c01-49f5-8e41-7cf9f8f84437">13,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfOC0zLTEtMS02NjkxMA_ace7db65-a5ad-4488-94ef-6b3f08425d70">12,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfOS0xLTEtMS02NjkxMA_5b1b24d3-3d00-4f4f-b03a-0e84cb51ecb4">5,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfOS0zLTEtMS02NjkxMA_e3dcdbfd-e50d-43eb-949e-356b1e41e7f4">5,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTAtMS0xLTEtNjY5MTA_afd7dd72-13e1-4019-8f2b-eecdd8dc03ad">94,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTAtMy0xLTEtNjY5MTA_10f88e74-65af-4b0e-ba13-ea8fd7267221">81,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets - operating</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTEtMS0xLTEtNjY5MTA_aa891742-4094-4888-8ae4-85e864e0f131">50,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTEtMy0xLTEtNjY5MTA_4f16e435-bcd1-4cee-8b62-65cac9dcb2ae">50,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTItMS0xLTEtNjY5MTA_34f9420f-1f29-4dd2-a3b4-4616ca572376">3,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTItMy0xLTEtNjY5MTA_e780754b-becf-412a-9a90-ad6423472439">6,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:CapitalizedContractCostNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTMtMS0xLTEtNjY5MTA_03df4466-d0fc-4feb-9cf7-513baacda088">24,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:CapitalizedContractCostNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTMtMy0xLTEtNjY5MTA_2ef3278d-14d5-443b-acb1-ce6d55f69fad">32,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTQtMS0xLTEtNjY5MTA_e39dbb61-b4fc-4cb4-a7d9-946c1955edb1">451,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTQtMy0xLTEtNjY5MTA_b24711c5-29f6-4f33-9f01-e9ce3d3fe8fe">279,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTUtMS0xLTEtNjY5MTA_65819eec-0816-4a9c-8506-a0082b6b7b1d">722,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTUtMy0xLTEtNjY5MTA_cb55692b-0968-444a-a243-a4d27f84daeb">426,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTYtMS0xLTEtNjY5MTA_d7087929-e588-4ca2-bb48-02bd86ed9f5c">1,759,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTYtMy0xLTEtNjY5MTA_49bb6714-bf55-4ddf-9d19-0c81beb10450">1,419,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjAtMS0xLTEtNjY5MTA_48d0844c-9fb0-4d5c-b7d4-6304a399f74d">61,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjAtMy0xLTEtNjY5MTA_c65b73ea-18ea-457b-b53e-8321cc519932">96,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjEtMS0xLTEtNjY5MTA_503f1e92-bc1a-4c1c-88de-3f62af41dfea">132,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjEtMy0xLTEtNjY5MTA_f0410fb4-f54a-4562-8220-80148a84a87a">107,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability - current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjItMS0xLTEtNjY5MTA_04bd69df-f408-4689-8a25-0109a3dd5a7f">7,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjItMy0xLTEtNjY5MTA_81ea11e8-3476-42d3-8240-0d0374899629">7,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjMtMS0xLTEtNjY5MTA_32bce8b5-71d3-4131-8757-918414ba8082">37,646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjMtMy0xLTEtNjY5MTA_39020dbe-d7bb-4cd2-a69c-05da8dfd8506">51,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjQtMS0xLTEtNjY5MTA_577ab0ee-3da1-4651-863a-0c108f9e8742">7,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjQtMy0xLTEtNjY5MTA_9966f0b3-8f73-4028-96a9-4af3eed4f33b">11,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance - based arrangements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjUtMS0xLTEtNjY5MTA_48ec7316-cea1-4cf6-8f66-13d156e589bd">135,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjUtMy0xLTEtNjY5MTA_e4abb8b3-aa8f-4832-83bc-f87e164b3de8">171,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjYtMS0xLTEtNjY5MTA_1f23f22f-de10-4269-80de-8b0c4780db86">382,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjYtMy0xLTEtNjY5MTA_b076bd94-8e42-4154-b8a7-6eb3fd077bb5">445,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjctMS0xLTEtNjY5MTA_07633416-b668-474d-a51f-e076f902ddfc">412,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjctMy0xLTEtNjY5MTA_e6794af0-5740-4652-b74d-c5577529d558">215,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjgtMS0xLTEtNjY5MTA_6bcf8df3-1f3e-4110-8fbe-403dcf4265d6">4,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjgtMy0xLTEtNjY5MTA_1cc51f0e-522f-43b1-9a37-b00971772025">5,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax receivable agreement liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="evh:TaxReceivableAgreementLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjktMS0xLTEtODA2Njg_9a496223-f052-45ce-935c-30ad89ccc804">42,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="evh:TaxReceivableAgreementLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjktMy0xLTEtODA2Njg_3af20049-5783-4027-a3cd-840d9e5ccf75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - noncurrent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjktMS0xLTEtNjY5MTA_99b85750-cdfb-4bd0-8efe-20fd4bd40323">57,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjktMy0xLTEtNjY5MTA_d673bef3-2fc4-42a1-b84d-e280e7c881ff">57,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzAtMS0xLTEtNjY5MTA_6e5826cc-b3e1-42cb-ab83-bd95c48808df">3,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzAtMy0xLTEtNjY5MTA_9693fc96-e549-4337-b656-e96f0527ecb3">1,403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzEtMS0xLTEtNjY5MTA_47154242-d084-4ecf-a000-d5c6e891903b">903,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzEtMy0xLTEtNjY5MTA_8af1a695-4490-4992-b64d-fc670dbfdcc2">725,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and Contingencies (See Note 11)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzItMS0xLTEtNjY5MTA_a3907a8a-681e-4466-a3ea-5c096b1e7038"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzItMy0xLTEtNjY5MTA_fb0f0850-e771-4b3a-9d24-baa3570a403c"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock - $<ix:nonFraction unitRef="usdPerShare" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzQtMC0xLTEtNjY5MTAvdGV4dHJlZ2lvbjpjY2MxZTA0MTBmNGE0YTU2YWMzMGQ5ZGE2Yzc1MWVmZl8yNw_89e56627-9dff-4f3a-9d1c-145ef23da800"><ix:nonFraction unitRef="usdPerShare" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzQtMC0xLTEtNjY5MTAvdGV4dHJlZ2lvbjpjY2MxZTA0MTBmNGE0YTU2YWMzMGQ5ZGE2Yzc1MWVmZl8yNw_d6bda1de-12ac-4feb-bba6-9f12835a8748">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzQtMC0xLTEtNjY5MTAvdGV4dHJlZ2lvbjpjY2MxZTA0MTBmNGE0YTU2YWMzMGQ5ZGE2Yzc1MWVmZl80MQ_bacb8716-28de-42d2-bdfc-96e83b094286"><ix:nonFraction unitRef="shares" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzQtMC0xLTEtNjY5MTAvdGV4dHJlZ2lvbjpjY2MxZTA0MTBmNGE0YTU2YWMzMGQ5ZGE2Yzc1MWVmZl80MQ_e9268d07-25bc-4e71-917d-10e91701bd67">750,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzQtMC0xLTEtNjY5MTAvdGV4dHJlZ2lvbjpjY2MxZTA0MTBmNGE0YTU2YWMzMGQ5ZGE2Yzc1MWVmZl82Mw_d8bf4457-41ef-4170-b6ed-6c10468f215e">101,159,072</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzQtMC0xLTEtNjY5MTAvdGV4dHJlZ2lvbjpjY2MxZTA0MTBmNGE0YTU2YWMzMGQ5ZGE2Yzc1MWVmZl83MA_e17f93a7-f0a2-481d-8b2a-0fe7900b2c68">90,758,318</ix:nonFraction> shares issued, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzQtMS0xLTEtNjY5MTA_8c14fd40-e9e9-40d3-9277-dd38fada9422">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzQtMy0xLTEtNjY5MTA_3914b511-5143-430e-aca7-8f3a2be387a9">908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in-capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzUtMS0xLTEtNjY5MTA_86e95e50-fb8f-437d-adb0-64ce9abe4c4a">1,472,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzUtMy0xLTEtNjY5MTA_bed9321f-f495-4306-ba88-1c3a06a356ea">1,340,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzYtMS0xLTEtNjY5MTA_29bd24d4-2038-4c5d-9146-a11e9b144621">1,044</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzYtMy0xLTEtNjY5MTA_38adf771-f3e9-41e0-a762-4430b7f614e9">362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings (accumulated deficit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzctMS0xLTEtNjY5MTA_7be390ca-e381-4216-8870-d8c2ff949cf6">594,805</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzctMy0xLTEtNjY5MTA_d98e4361-c5f9-450a-b1e9-db0f3c342ebf">626,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost; <ix:nonFraction unitRef="shares" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzgtMC0xLTEtNjY5MTAvdGV4dHJlZ2lvbjpjZDRkOTE0NWY2YjE0NDgzYjdlZTI4ZGQwNzdkOTVjYV8yOQ_7940e372-b959-4569-8642-c17453427740"><ix:nonFraction unitRef="shares" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzgtMC0xLTEtNjY5MTAvdGV4dHJlZ2lvbjpjZDRkOTE0NWY2YjE0NDgzYjdlZTI4ZGQwNzdkOTVjYV8yOQ_eb0d6f78-7309-48b6-a45f-59899b6d93b9">1,537,582</ix:nonFraction></ix:nonFraction> shares issued, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzgtMS0xLTEtNjY5MTA_d165f017-1aea-400c-a845-dec2600a1fe1">21,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzgtMy0xLTEtNjY5MTA_63609d96-b151-4c0b-8923-5f09e6b8c420">21,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzktMS0xLTEtNjY5MTA_f1bd6b3d-c4f8-4882-a901-68dc59456666">856,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzktMy0xLTEtNjY5MTA_21641b07-f2b3-421a-9e2c-c2d877b1cb87">693,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and shareholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNDAtMS0xLTEtNjY5MTA_08962c34-3324-42a2-a9b1-8bf22cbe3f80">1,759,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNDAtMy0xLTEtNjY5MTA_d50e60ec-4d1e-498e-9f2f-fe4101bd5341">1,419,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RleHRyZWdpb246Y2NiZWRlZjE1MGEzNDA0Y2E0MWUyMzkzN2Y0YjU0YWVfMTkw_99d40318-14a9-4059-9180-0d35bf3232a0" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Note 18 for amounts attributable to related parties included in these line items.</ix:footnote></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i4a25f060abc946f28c4a0095422c2513_28"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br/>(unaudited, in thousands, except per share data)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:543.00pt"><tr><td style="width:1.0pt"></td><td style="width:271.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi0xLTEtMS02NjkxMA_28d6ffce-89e9-459b-a59c-bdfa2cfd0ac0">352,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi0zLTEtMS02NjkxMA_a61cab80-88da-43a6-aa65-391f42890dab">222,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi01LTEtMS02NjkxMA_5f2e275b-70f9-47fe-8b15-566555a7bfb6">969,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi03LTEtMS02NjkxMA_1ca38dea-5804-491f-b6f7-af17f48eb3ee">659,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS0xLTEtMS02NjkxMA_c1e43070-1906-4b95-918c-de3e2d6ad751">266,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS0zLTEtMS02NjkxMA_edb76492-aae3-4861-9dce-2a945e70053d">163,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS01LTEtMS02NjkxMA_b18d0ce1-acbd-45aa-9cdc-ac7e018922e2">736,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS03LTEtMS02NjkxMA_a4472a6b-b093-4b73-b6c8-ee80bcaf0c75">493,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi0xLTEtMS02NjkxMA_db29f41c-bce7-4327-9bf4-be3e93d52a0f">68,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi0zLTEtMS02NjkxMA_11533d2f-70b8-49ef-8326-e453614be690">51,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi01LTEtMS02NjkxMA_526c1f97-4796-4d78-a5f7-ea1044f251d4">186,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi03LTEtMS02NjkxMA_34edd863-f4e2-4813-bb92-2662eebf4a0a">152,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNy0xLTEtMS02NjkxMA_8cf27764-39ba-43f9-a774-acdaffc6eec4">17,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNy0zLTEtMS02NjkxMA_c994bc94-f58b-4e09-b211-f2ad27149c61">14,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNy01LTEtMS02NjkxMA_a16c83d4-4057-438b-8635-020c271210de">47,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNy03LTEtMS02NjkxMA_1f9a20af-f6db-43f0-94da-97b51e885fc5">44,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfOC0xLTEtMS02NjkxMA_ce1251f6-9f9e-43fc-bb5d-00975c50a02e">12,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfOC0zLTEtMS02NjkxMA_d35a970b-472e-45d2-9394-6354fff787ac">225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfOC01LTEtMS02NjkxMA_cc39e450-2fec-4dac-9c5f-625c9729584d">5,822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfOC03LTEtMS02NjkxMA_ff4c8aff-f4ef-48ed-aa69-ec78ffccaf2b">819</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfOS0xLTEtMS02NjkxMA_df740d3d-b758-415f-9fce-43790a591e34">339,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfOS0zLTEtMS02NjkxMA_788123dc-e3e5-499b-8c3b-46151962c333">229,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfOS01LTEtMS02NjkxMA_2c4d0b9d-5892-40c6-9725-5f5343d0ae48">964,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfOS03LTEtMS02NjkxMA_cac853f7-c4e1-45e5-9b99-85be0d714298">689,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTAtMS0xLTEtNjY5MTA_4cefd6fc-bcfa-4c2e-a4a8-1e4c697204a0">12,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTAtMy0xLTEtNjY5MTA_52de9c7b-1d7f-43cc-9884-018d9db34861">6,581</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTAtNS0xLTEtNjY5MTA_917cee60-3db9-4ef2-afb5-0d1acf755f83">5,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTAtNy0xLTEtNjY5MTA_f54ffe7a-4434-48f7-8a84-a27e4b8bbce6">30,197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTEtMS0xLTEtNjY5MTA_85192df2-d85c-4f99-8f26-9626ed56fe53">425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTEtMy0xLTEtNjY5MTA_ace17bc9-5e30-4b68-8e5e-0a96691a1f67">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTEtNS0xLTEtNjY5MTA_a5cf1b7e-ae1f-4538-9aba-233f19a72974">765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTEtNy0xLTEtNjY5MTA_9ecbcb71-682f-4063-968b-6ff5cf81c8b7">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTItMS0xLTEtNjY5MTA_47b0e39d-ee84-420a-b763-82e814acb7c5">4,754</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTItMy0xLTEtNjY5MTA_90682a5a-c38f-4944-858e-d6eb2b7beb74">6,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTItNS0xLTEtNjY5MTA_904a8787-e2ee-4f22-a129-a4fc1568c6e1">9,143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTItNy0xLTEtNjY5MTA_845803bd-53d6-48c4-971f-7bc75d32752a">18,978</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTMtMS0xLTEtNjY5MTA_be789f20-1dac-4bdb-9cd6-a0bab8ffa879">1,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTMtMy0xLTEtNjY5MTA_4e2953e3-7c26-447a-9170-e7d8df3759aa">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTMtNS0xLTEtNjY5MTA_12a64fcc-617a-460d-a25a-25f1254e3cd8">3,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTMtNy0xLTEtNjY5MTA_7da8184d-dc94-4aa8-b552-2d9b9cea41d2">12,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTQtMS0xLTEtNjY5MTA_dd009c38-9f13-486a-8906-b86db72ae488">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTQtMy0xLTEtNjY5MTA_c254f828-f544-415e-bb39-cd9480c82cf1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTQtNS0xLTEtNjY5MTA_e43a9971-a203-42c1-aae7-af910959b912">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTQtNy0xLTEtNjY5MTA_f8eaf329-d45e-430c-8c44-b53825eda753">22,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment/repayment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTUtMS0xLTEtNjY5MTA_30662400-ab2b-45da-aa42-5052d1522eef">10,192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTUtMy0xLTEtNjY5MTA_1418a7af-3ac3-41d6-affb-116a9832c16f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTUtNS0xLTEtNjY5MTA_fc7355c4-8b0e-4186-b51a-c10578aa6e54">10,192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTUtNy0xLTEtNjY5MTA_0d0c5c35-6e8c-4caa-8b8e-f196b5f3e571">19,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivable agreement liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="evh:ChangesInTaxReceivablesAgreementLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTctMS0xLTEtNzY5NTc_6844db84-1c59-43e7-abee-eb35b5597679">42,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="evh:ChangesInTaxReceivablesAgreementLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTctMy0xLTEtNzY5NTc_baac1a98-c0f1-4e9e-a05c-b742bad4a5ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:ChangesInTaxReceivablesAgreementLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTctNS0xLTEtNzY5NTc_4037720a-0584-41f6-8dbe-5d796b69e39a">42,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:ChangesInTaxReceivablesAgreementLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTctNy0xLTEtNzY5NTc_8a30c784-ee64-43a2-8de5-fa1603112c72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTYtMS0xLTEtNjY5MTA_0102d585-287d-45d5-9cd1-010b0ae47c35">345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTYtMy0xLTEtNjY5MTA_c8ae7ebd-4b5d-42bf-a41d-88eaca0689f4">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTYtNS0xLTEtNjY5MTA_9ff522d7-d156-46e2-bcff-c423a4ffdb42">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTYtNy0xLTEtNjY5MTA_28358777-4249-4e26-b31c-92eb1f1ff38f">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTctMS0xLTEtNjY5MTA_ee96c530-b53d-4103-be3f-f3b607529c48">43,393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTctMy0xLTEtNjY5MTA_7f61cc81-24c2-4080-be6f-de32fb665c70">12,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTctNS0xLTEtNjY5MTA_cfe93f6e-f0ed-44eb-83d4-64354b27e8a7">51,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTctNy0xLTEtNjY5MTA_a5f680ae-5526-4aea-9f54-9b7864e39929">32,401</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for (benefit from) income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTgtMS0xLTEtNjY5MTA_4e279b5d-c2e2-4ec4-acc4-f1e51cb41a17">45,516</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTgtMy0xLTEtNjY5MTA_bd1f43ed-086f-4b62-970c-4c156caed6b4">234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTgtNS0xLTEtNjY5MTA_6461e9ad-ce80-4045-97f3-2868333b6e54">44,498</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTgtNy0xLTEtNjY5MTA_fb90a166-5486-4401-b195-5e493574c446">936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTktMS0xLTEtNjY5MTA_e6d82b3d-96a8-469c-9b36-a0745946c155">2,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTktMy0xLTEtNjY5MTA_52b4c26f-4fd8-4024-acd6-e8cd828ae0d1">13,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTktNS0xLTEtNjY5MTA_814325c3-c4f8-43f1-9549-889093d349d2">7,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTktNy0xLTEtNjY5MTA_748f7b05-deb5-4d61-92cf-0fd288b80628">33,337</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtMS0xLTEtNjY5MTA_0f209cfa-8504-4ac9-b758-ac2a0a61b1b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtMy0xLTEtNjY5MTA_43c76fef-6b2e-4467-b3ef-343e76af8f09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtNS0xLTEtNjY5MTA_00f03ad2-b82d-44e7-b7c4-221872011c79">463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtNy0xLTEtNjY5MTA_d20e63e0-6ca3-40ec-8951-ef7d1c289504">1,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjEtMS0xLTEtNjY5MTA_2b938c91-768d-4a4f-8358-38803e7bee1a"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjEtMS0xLTEtNjY5MTA_8a5e256b-80e4-42cf-af24-64cd9b4784bb">2,123</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjEtMy0xLTEtNjY5MTA_397a327f-e62b-4749-b951-90aced6dbbc5"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjEtMy0xLTEtNjY5MTA_a78aadeb-78c2-4ac2-9c9d-3eccc69aefe1">13,040</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjEtNS0xLTEtNjY5MTA_24b21c64-6c5a-4a02-97de-8f53c437bf87"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjEtNS0xLTEtNjY5MTA_d788c378-db82-467c-8e05-8cfe8f97a8bc">7,815</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjEtNy0xLTEtNjY5MTA_429a395c-c7d4-453c-8ccb-d8c9dcda3225"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjEtNy0xLTEtNjY5MTA_54c48a0b-87c4-4c6d-afdd-8e3229629feb">31,954</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjUtMS0xLTEtNjY5MTA_5d78348a-1ede-42f3-9c66-3e19d04d192b">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjUtMy0xLTEtNjY5MTA_94406da4-bba3-4f7b-9a48-470977dba9ed">0.15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjUtNS0xLTEtNjY5MTA_04698b35-8bc1-4fd1-b051-1674a602e6ca">0.08</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjUtNy0xLTEtNjY5MTA_594c02a6-9adc-4b51-8a3b-49e7df85a3ba">0.39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjYtMS0xLTEtNjY5MTA_b04bb2aa-e06c-4725-a979-417393867246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjYtMy0xLTEtNjY5MTA_51f2919e-d948-43e1-b8fe-353c355f98aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjYtNS0xLTEtNjY5MTA_b02eb601-91c3-4df9-824f-4b86bfd50033">0.01</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjYtNy0xLTEtNjY5MTA_92a71a9f-9843-4f08-bcfa-9a531cf1884c">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic income (loss) per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjctMS0xLTEtNjY5MTA_3532a326-e3a6-4a72-bf8a-62b392719771">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjctMy0xLTEtNjY5MTA_6531b55f-f41b-4ab9-ba40-c11e9a2c2159">0.15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjctNS0xLTEtNjY5MTA_dc29ff25-a8f0-4a3c-a9ac-cc086468d8e9">0.09</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjctNy0xLTEtNjY5MTA_ee2b491b-a03c-4b79-b603-6b46c67d2ad3">0.37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzEtMS0xLTEtNzcwMTU_c0bc64f5-cd2d-48be-8ace-aa6e4d481486">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzEtMy0xLTEtNzcwMTU_2ebf6c1c-71c6-4384-8606-b4152dbb6d7d">0.15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzEtNS0xLTEtNzcwMTU_b559917c-1929-4bc9-bf4d-69a8feff1d5d">0.08</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzEtNy0xLTEtNzcwMTU_01899fe7-98ba-4bca-a762-25a2204f5eb5">0.39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzItMS0xLTEtNzcwMTU_df0eb775-ca69-403d-b4d5-5d2a0bbb0973">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzItMy0xLTEtNzcwMTU_13066bf6-b1e7-43da-9b52-2cc3045e00a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzItNS0xLTEtNzcwMTU_ddf5b5b3-765f-4c63-a2d4-44bb2fbb4d0b">0.01</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzItNy0xLTEtNzcwMTU_4f04f922-c15e-48e6-b6d7-1344cd429489">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzMtMS0xLTEtNzcwMjk_1cc75002-3e6b-4439-886b-d35b708cfd77">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzMtMy0xLTEtNzcwMjk_180fac62-bd77-4452-89a2-404577c7ea37">0.15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzMtNS0xLTEtNzcwMjk_6642db39-b9b4-4146-856f-f11cc4bccf6d">0.09</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzMtNy0xLTEtNzcwMjk_dfa295c9-4f3f-4d71-8344-393a4f8a3c2f">0.37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzAtMS0xLTEtNjY5MTA_c9125b58-b588-457a-a723-f2fd3650c980">95,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzAtMy0xLTEtNjY5MTA_ce167901-b270-400d-bedc-5241c8a1b3bb">85,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzAtNS0xLTEtNjY5MTA_f9c66f3f-75a5-4c1d-9db9-f53c0be43420">91,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzAtNy0xLTEtNjY5MTA_60086fc8-e0b2-4a6a-94cc-387bd5265ddc">85,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzItMS0xLTEtNzY3NDY_2341bad9-a548-48e7-9ae5-631e4a6a4c60">99,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzItMy0xLTEtNzY3NDY_48dcf8ec-89b1-44ba-8bb9-2bcdb2fa21e7">85,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzItNS0xLTEtNzY3NDY_2f7662e5-8c53-4a1b-854c-c2af04a62059">91,643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzItNy0xLTEtNzY3NDY_c728ec08-cae6-40f3-877d-ae2ae8416dec">85,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive income (loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzMtMS0xLTEtNjY5MTA_db47e02e-7f1a-4e61-b286-4de56945e7e6">2,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzMtMy0xLTEtNjY5MTA_64aec95c-81a6-44c0-a970-9e909a3957c6">13,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzMtNS0xLTEtNjY5MTA_3e88cc78-18a0-4adc-b8d6-a701c458dbb0">7,815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzMtNy0xLTEtNjY5MTA_acbd1652-d79b-4d22-948a-3fda768396e0">31,954</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes, related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzUtMS0xLTEtNjY5MTA_4eae2c3e-c6aa-453c-bb6e-cb34ad35f488">262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzUtMy0xLTEtNjY5MTA_c35d7758-f955-4f9d-b0b0-456a4439a547">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzUtNS0xLTEtNjY5MTA_e300779e-1394-4a3e-87ea-c494325e1d82">682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzUtNy0xLTEtNjY5MTA_64f2ab62-14a2-4db0-9354-ad14d788ce39">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive income (loss) attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzYtMS0xLTEtNjY5MTA_c27d981f-7481-40b8-8bb4-c699be76a053">1,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzYtMy0xLTEtNjY5MTA_4799c6d3-59a7-4164-847e-74d7db487516">13,036</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzYtNS0xLTEtNjY5MTA_93998ada-86a1-48a5-ac8e-12eaed3cc39b">8,497</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzYtNy0xLTEtNjY5MTA_04ffe756-b1a5-4c14-bf50-8a61d64aebf8">32,039</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDE0_fb645b76-e589-4eda-a1e7-a776efc5d3ae" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</ix:footnote></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDA5_2476b5e9-95ac-459d-a77e-7144819457ee" footnoteRole="http://www.xbrl.org/2003/role/footnote">Includes $(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfMjY5_cd162837-63ed-45d0-8343-6d6ea621bb0f">0.5</ix:nonFraction>)&#160;million loss on disposal of discontinued operations for the nine months ended September 30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-5" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfMzQy_d4a7dbf8-c781-4433-9ce3-297fee23c41b">1.9</ix:nonFraction>&#160;million gain on disposal of discontinued operations for the nine months ended September 30, 2021, respectively</ix:footnote>.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i4a25f060abc946f28c4a0095422c2513_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in thousands)</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.230%"><tr><td style="width:1.0%"></td><td style="width:34.467%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.848%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.315%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.570%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2022</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17e8b3c5da9a4abf8639a0d3c5015910_I20220630" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMy0xLTEtMS02NjkxMA_39e26d99-02ba-4da4-9eaf-9802e09b396f">91,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e8b3c5da9a4abf8639a0d3c5015910_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMy0zLTEtMS02NjkxMA_9ead2206-283d-4fb8-8ea5-2a3ca123ef8d">916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb83f20a7c61479b93a83e23998b1c89_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMy01LTEtMS02NjkxMA_1d3f820a-4052-4b92-a156-6a5226ed0c6d">1,231,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idfb31ce6eb9e4668992f11294921cfad_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMy03LTEtMS02NjkxMA_3a3cc4a9-3790-4f8e-b01d-01317616d9c6">782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc0ca7083bdc4ebe842729dbd273685c_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMy05LTEtMS02NjkxMA_46a812a1-e91e-4754-8af7-d06bd023dbe4">596,928</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1dd537792b6e421ba9639adbfe4474c4_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMy0xMS0xLTEtNjY5MTA_c1f6b2fd-5f5d-4e67-9bfe-8fd143718d59">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a15fb8f7fe94bf88c8a8a9847578001_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMy0xMy0xLTEtNjY5MTA_4751d7bc-bcab-480a-90e5-dcdcfcd40a0d">613,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f34759559a4dfd86efcb145ce3357e_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNS01LTEtMS02NjkxMA_3f21cb08-4283-48b0-80b4-15a70869d0a7">6,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNS0xMy0xLTEtNjY5MTA_6ecf5a8f-612c-41f4-84e9-e22352c1c537">6,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34fded2f74a147099334cfa413800c2c_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNi0xLTEtMS03Mzc2Ng_f7829d29-0114-46c1-b983-a7c335ff922f">317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34fded2f74a147099334cfa413800c2c_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNi0zLTEtMS03Mzc2Ng_2dad9e36-9c71-4a57-a655-fe2535d05ff6">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f34759559a4dfd86efcb145ce3357e_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNi01LTEtMS03Mzc2Ng_aeb77b99-a0e9-45e3-8bc2-8cad6cbb88d9">2,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNi0xMy0xLTEtNzM3NDk_2a1913b2-4e0d-4161-89c4-157ddaac0ad4">2,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34fded2f74a147099334cfa413800c2c_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNi0xLTEtMS02NjkxMA_1e1fb9ad-ceaf-4a62-b720-4bf0e94494a6">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34fded2f74a147099334cfa413800c2c_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNi0zLTEtMS02NjkxMA_5c86ac7d-5a51-4a44-8db1-fba33de28096">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9f34759559a4dfd86efcb145ce3357e_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNi01LTEtMS02NjkxMA_a04a0b0b-cf2d-47ee-9a2f-0b586d8befa9">949</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNi0xMy0xLTEtNjY5MTA_83b1d0ce-15bd-46ea-9949-034a62ca90bf">948</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exchange of 2024 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34fded2f74a147099334cfa413800c2c_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfOC0xLTEtMS03NDczNA_8bd3d415-e87f-44d2-83eb-4d83fc28b928">5,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34fded2f74a147099334cfa413800c2c_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfOC0zLTEtMS03NDczNA_6a20ec9a-f365-438f-9d95-0955412d9f5d">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f34759559a4dfd86efcb145ce3357e_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfOC01LTEtMS03NDc0Nw_a113a05b-2b32-436d-9e7d-07eb1be47956">101,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfOC0xMy0xLTEtNzM3NTQ_31f73cae-fc5e-4984-bffb-414199aeb113">101,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued for acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34fded2f74a147099334cfa413800c2c_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfOS0xLTEtMS03NDczNA_8390c0ee-b44e-4002-b0d1-b1a698f462a9">3,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34fded2f74a147099334cfa413800c2c_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfOS0zLTEtMS03NDczNA_5cc3da95-5d44-4a3c-b6da-b23c0c1c507e">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9f34759559a4dfd86efcb145ce3357e_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfOS01LTEtMS03NDc0Nw_623bfdff-f3c2-48ee-bd95-545e15016b48">130,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfOS0xMy0xLTEtNzM5NDI_ce07d0fa-fa32-4464-b0ed-2dfe501df581">130,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2946b2f4742c436b9ec38ed088adddf3_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNy03LTEtMS02NjkxMA_0f15e2d8-d0ee-4f63-a5aa-b02f2b2e8e5d">262</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNy0xMy0xLTEtNjY5MTA_bc4a1f4b-c077-46c9-b3b2-0be2571ee56d">262</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i774f0c895b93475580cf9bffc1f4d401_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfOC05LTEtMS02NjkxMA_b567e840-f996-4731-a6f4-80ce5a799a19">2,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfOC0xMy0xLTEtNjY5MTA_bf53d59d-9b51-4eb2-b142-97e7fc61004f">2,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d92a7bff72d4283b5a2abc070339ddf_I20220930" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTAtMS0xLTEtNjY5MTA_c86d81b0-995d-4d8d-9d10-4d9c77bd2e3d">101,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d92a7bff72d4283b5a2abc070339ddf_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTAtMy0xLTEtNjY5MTA_dac48440-c315-4072-82d4-4dad8b48f650">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic61eea28d6e24e17b1c838a89e833091_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTAtNS0xLTEtNjY5MTA_39f27395-1c69-4e18-a052-72d1d91ffbe1">1,472,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0deb2b8e664f400a93e847d75c9f7461_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTAtNy0xLTEtNjY5MTA_480f1b86-9fc4-4a5f-b25d-9f36f68da627">1,044</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f7fbb4a3598436a82370c985cafd671_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTAtOS0xLTEtNjY5MTA_8da86ca4-cd37-4d18-8f7f-2f43158769c4">594,805</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7743c9436eda44b9a29866c882a8d051_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTAtMTEtMS0xLTY2OTEw_9228f31c-11b8-4083-9022-0133a878a3e0">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTAtMTMtMS0xLTY2OTEw_33ed2410-042f-49f9-96b0-7b385d5d2cf8">856,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf7540828b6542ccbb0c439bd8d9be10_I20210630" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTYtMS0xLTEtNjY5MTA_1617f15b-f9bc-4c7a-8793-69cc63b95a62">87,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf7540828b6542ccbb0c439bd8d9be10_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTYtMy0xLTEtNjY5MTA_bec9dbda-9537-479f-a419-2e533736a447">872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47799e4f502f42c98c9d834440ff6d03_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTYtNS0xLTEtNjY5MTA_ac78ce41-386b-421a-99ee-5626ddff759b">1,242,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3859fe1f193413e80c660d7cd13bb43_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTYtNy0xLTEtNjY5MTA_5108ffe1-06fb-4b69-a7b1-9c727b43b3da">367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2153e00392cb428692eb552f22b89475_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTYtOS0xLTEtNjY5MTA_3e363657-36dd-40f6-9839-32102cc59472">608,092</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie13e8e5c1c8f442db97081f5b187e36a_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTYtMTEtMS0xLTY2OTEw_61e0a7b6-b487-4f4d-b896-5850504256c1">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22d0f81c708f4d62b2c2ba75e4549659_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTYtMTMtMS0xLTY2OTEw_62964db2-8d93-41ad-883e-d377f1e2089c">614,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08eed5034fa6469aa0775ddf5e8edf38_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTgtNS0xLTEtNjY5MTA_21d45f1d-3ae3-492f-8786-9b0c662fd141">4,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTgtMTMtMS0xLTY2OTEw_1dbe0eb4-920b-4bc6-a7af-1577d6650d56">4,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89f4cf78a38147c4a67ccbc5f1b70b5e_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTktMS0xLTEtNjY5MTA_2efe3cde-62ba-469d-837d-4199d2bba21f">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f4cf78a38147c4a67ccbc5f1b70b5e_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTktMy0xLTEtNjY5MTA_8bc5de01-fad5-4b05-aded-9b5b56135bbc">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08eed5034fa6469aa0775ddf5e8edf38_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTktNS0xLTEtNjY5MTA_6a8e0cb9-5514-4af0-b58c-eccc51a2c794">2,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTktMTMtMS0xLTY2OTEw_f12d1071-7fb2-4078-b464-9ab9b492c9e1">2,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89f4cf78a38147c4a67ccbc5f1b70b5e_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjAtMS0xLTEtNjY5MTA_36f16806-dfae-4e32-89ff-b456ae55b6dd">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89f4cf78a38147c4a67ccbc5f1b70b5e_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjAtMy0xLTEtNjY5MTA_61faa8b3-9615-44d0-80ab-a95222920457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08eed5034fa6469aa0775ddf5e8edf38_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjAtNS0xLTEtNjY5MTA_23c1d218-3106-42d6-b92d-2b4e6371798f">255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjAtMTMtMS0xLTY2OTEw_c5dabb05-8f8c-4ec0-baa0-9d71c652f3b6">255</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if579391e2dd946e28f4975df65264f3e_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjEtNy0xLTEtNjY5MTA_b43cc33d-487e-42cd-a266-c7933a8c0284">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjEtMTMtMS0xLTY2OTEw_6f166f4e-769c-49c5-babb-21a6a46fb440">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i434deea731b3493cafdecab4e0f513df_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjItOS0xLTEtNjY5MTA_9b8ac5fa-f639-48cf-8d47-90dcf2df818b">13,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjItMTMtMS0xLTY2OTEw_d646aedb-d737-469b-b8bd-ce6ef7c8602b">13,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic863a6e2b5314131a58086e3e72c0388_I20210930" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjQtMS0xLTEtNjY5MTA_cabf45c8-83c7-4785-a7a6-8f2dc133c18b">87,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic863a6e2b5314131a58086e3e72c0388_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjQtMy0xLTEtNjY5MTA_4b589964-d80b-4d03-a958-df616c238f30">874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d69eae660647b891b8545b7593243a_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjQtNS0xLTEtNjY5MTA_403e0953-790a-4aa8-a7c4-c45941f98896">1,249,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie40e239beadc4317b3c499f7eea02fb6_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjQtNy0xLTEtNjY5MTA_9ec3fb31-4bae-4039-ab22-0009df35a026">363</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f69dcb0c02046a8b06f845c2daa4737_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjQtOS0xLTEtNjY5MTA_22a31e7b-4f10-4b28-82d7-1951be8ae313">621,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i179c3fe310ef4e61a6d5a2f2721eedc5_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjQtMTEtMS0xLTY2OTEw_789c5b3b-8194-4827-b5a9-517f0346fa44">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63b3ddd7486946c2a0a8151832317d14_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjQtMTMtMS0xLTY2OTEw_0e77e516-2947-40f2-b923-43cda8af0502">607,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:727.50pt"><tr><td style="width:1.0pt"></td><td style="width:256.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:41.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:34.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:41.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:108.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:82.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:39.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:79.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2022</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2bb3fdaea8f41d1a5b926350a34b34f_I20211231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMy0xLTEtMS02NjkxMA_0bf767b4-ee8a-41bc-a930-39c244542b6b">90,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2bb3fdaea8f41d1a5b926350a34b34f_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMy0zLTEtMS02NjkxMA_e3370fe5-f3ee-4ada-bdb9-29b607e75487">908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f6814f5fa1246a687d35a28833137b0_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMy01LTEtMS02NjkxMA_f0b43f31-912a-4657-9264-568dded85ec6">1,340,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f73e9dc3b2a45679bdcc5b130649934_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMy03LTEtMS02NjkxMA_b9311462-512c-489b-9a04-a9c2e1ba52c1">362</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04896f930bff47dda34bb3798c357daf_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMy05LTEtMS02NjkxMA_dee04778-ba85-4744-ac67-133374ec1839">626,779</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb4cc675813847809003fabf765db881_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMy0xMS0xLTEtNjY5MTA_61cf36be-bc70-439f-9baa-55277bcfa992">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMy0xMy0xLTEtNjY5MTA_e091bff5-6551-4b65-b6f2-9327a9ed7b51">693,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNS0wLTEtMS02NjkxMA_408fa599-0cbb-46b4-89df-85994f18cc54">Cumulative-effect adjustment from adoption of ASC 2020-06</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic7382beeecb6460d9d7d2b36a822b970_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNS01LTEtMS02NjkxMA_bef13197-b762-496d-a06f-3cf08e21cdd7">106,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i749e0b18e9154afab9acf4c974f1cf8b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNS05LTEtMS02NjkxMA_b79c8ceb-9c09-4bc4-8e7c-fbd0e935c954">39,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2ed53ed57f5412e8fa51e1b7648fde0_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNS0xMy0xLTEtNjY5MTA_b8b39b49-1708-4760-9414-8ac23d50a9a6">66,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44adf89b2b3d45209e9135d9c2231fda_D20220101-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNi01LTEtMS02NjkxMA_847b1431-6b8a-4df7-8b37-ad6b6138fcb1">19,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNi0xMy0xLTEtNjY5MTA_d0c5d108-2191-46ee-aef5-eec98688c543">19,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNy0xLTEtMS02NjkxMA_c96eea06-87db-4c77-904f-70afcd9f4cf8">354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNy0zLTEtMS02NjkxMA_898504c3-8dde-4282-b0c1-be7908856900">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44adf89b2b3d45209e9135d9c2231fda_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNy01LTEtMS02NjkxMA_8ef9cda3-df79-410e-bd5c-b43c464f0d78">3,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNy0xMy0xLTEtNjY5MTA_4d950940-c7c2-4781-9b64-1bf79d117562">3,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfOC0xLTEtMS02NjkxMA_4e0f47a4-526e-4f21-ba51-0555741af4c7">452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfOC0zLTEtMS02NjkxMA_1c9890aa-d2f5-4e1e-8156-550e91e0926f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44adf89b2b3d45209e9135d9c2231fda_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfOC01LTEtMS02NjkxMA_f27c1a2f-4a49-46e4-bc8c-a494d92ef546">6,192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfOC0xMy0xLTEtNjY5MTA_51bf60ac-dc3e-42ca-8fef-7d4d57fa7e78">6,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leveraged stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfOS0xLTEtMS02NjkxMA_7e0caa00-3dcd-42d1-89f0-599917334d92">459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfOS0zLTEtMS02NjkxMA_9c7749b9-bf4b-4ffe-8b68-794c952092dc">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44adf89b2b3d45209e9135d9c2231fda_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfOS01LTEtMS02NjkxMA_fb26f1a1-426e-4275-9d93-49adb55a6d15">11,237</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfOS0xMy0xLTEtNjY5MTA_337b298b-3e68-4859-a5b6-5c842dd59bc0">11,232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exchange of 2024 Notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTAtMS0xLTEtNzM5MDQ_18de8dc2-d707-4699-86c1-f50dc96bafe0">5,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTAtMy0xLTEtNzM5MDQ_d0348ab4-5ea3-409e-888f-a63919e65c1e">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44adf89b2b3d45209e9135d9c2231fda_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTAtNS0xLTEtNzM5MTI_cd054396-e463-4abd-adac-29190bcec057">101,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTAtMTMtMS0xLTczNzU3_bab27c5b-c181-46f5-a3f7-4eff11a9e330">101,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares issued for acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTEtMS0xLTEtNzM5MDQ_736c8676-b3c8-40f5-8a2c-fb521a4fb4f4">3,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTEtMy0xLTEtNzM5MDQ_35144496-5748-4225-ae6d-7fefe1e49935">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44adf89b2b3d45209e9135d9c2231fda_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTEtNS0xLTEtNzM5MTI_a3b234c2-5093-4b17-a2ad-2e6e755467d9">130,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTEtMTMtMS0xLTczOTEy_8a056915-e831-4918-97a0-0c9a94f86c46">130,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1ad6cf9dd3347cb949a440b44766e97_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTAtNy0xLTEtNjY5MTA_607ef50f-a8cf-4299-9ef6-fb4377a55437">682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTAtMTMtMS0xLTY2OTEw_0c143692-86df-4fad-857f-cb571a6722f0">682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc261b79d9f841ad8560ed98593f9621_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTEtOS0xLTEtNjY5MTA_7ac6edfa-6534-4f05-aed6-41563cff77da">7,815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTEtMTMtMS0xLTY2OTEw_b257de4b-898c-4bed-bc13-1bacc2c10046">7,815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3d92a7bff72d4283b5a2abc070339ddf_I20220930" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTMtMS0xLTEtNjY5MTA_d6206b06-5614-4ea8-9391-364f20ca13fc">101,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d92a7bff72d4283b5a2abc070339ddf_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTMtMy0xLTEtNjY5MTA_73144995-6e37-4233-9f56-a741c7d09b47">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic61eea28d6e24e17b1c838a89e833091_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTMtNS0xLTEtNjY5MTA_f295a54d-bd33-420f-aedb-3cd50a96dca3">1,472,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0deb2b8e664f400a93e847d75c9f7461_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTMtNy0xLTEtNjY5MTA_c369e976-105d-42af-a9b2-aaad5dfc1f45">1,044</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f7fbb4a3598436a82370c985cafd671_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTMtOS0xLTEtNjY5MTA_f853f9e5-0804-460d-8983-85f6fe0be1cd">594,805</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7743c9436eda44b9a29866c882a8d051_I20220930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTMtMTEtMS0xLTY2OTEw_aeeda320-8f00-4165-a206-6d476d481c66">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTMtMTMtMS0xLTY2OTEw_2256e004-9ea4-4a8c-b371-c98339bba103">856,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class A Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Shareholders&#8217; Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if90b80996d524ed6b89fbfebe2cedda5_I20201231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTktMS0xLTEtNjY5MTA_ce71d873-298c-4368-84fe-640111cfbfb7">85,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if90b80996d524ed6b89fbfebe2cedda5_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTktMy0xLTEtNjY5MTA_00d1c866-8d7d-46ee-b42d-5a6327afa624">859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i694c8eca95b44aa281ff19a36e240b13_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTktNS0xLTEtNjY5MTA_08b52ba6-0668-4f92-aa3a-c9393a8ea7dc">1,229,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5b6a0decc62412fb5b58744bd94543b_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTktNy0xLTEtNjY5MTA_a56fd276-fa12-45ae-b9a5-ef6389534dd8">278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57e089b648ff473aba749cdaa85824a5_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTktOS0xLTEtNjY5MTA_4a7f654b-ff26-4abf-97cb-a2ee7a3800be">589,178</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i93b026baeacf472babb208203c15aa89_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTktMTEtMS0xLTY2OTEw_f84c2edc-7bc0-454b-8c70-6a580b6e85e5">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcb7e5d5de6d4fb9bd1b47d49e170108_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTktMTMtMS0xLTY2OTEw_caf4a4db-ad7f-44d0-adf6-b0af8c156917">619,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eb7badc179d4dd4b0b439120c44e492_D20210101-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjEtNS0xLTEtNjY5MTA_e4f2bf72-dcbb-4b4b-b814-9e86ad5f38a5">11,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjEtMTMtMS0xLTY2OTEw_ac72c109-8065-404c-b763-433374663e35">11,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38d9971f78fb49c3a0ecdff39b8115f9_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjItMS0xLTEtNjY5MTA_2d203560-10bd-4e94-8dd0-48fbf77a5421">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d9971f78fb49c3a0ecdff39b8115f9_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjItMy0xLTEtNjY5MTA_dc050d6c-fa99-43a5-8ef3-62d21dbd15a9">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eb7badc179d4dd4b0b439120c44e492_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjItNS0xLTEtNjY5MTA_6c350b0d-077b-4f7a-ab5d-4c96f202b969">11,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjItMTMtMS0xLTY2OTEw_39f7f084-da74-442b-836b-5e8ca8de5f0d">11,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units vested, net of shares withheld for taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38d9971f78fb49c3a0ecdff39b8115f9_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjMtMS0xLTEtNjY5MTA_cd59a74d-b6be-4df4-a75e-dfd07c42d122">419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38d9971f78fb49c3a0ecdff39b8115f9_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjMtMy0xLTEtNjY5MTA_66304911-ae0b-48d6-999f-3dd287acad35">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7eb7badc179d4dd4b0b439120c44e492_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjMtNS0xLTEtNjY5MTA_2988f04d-f3b8-41e4-a088-28d15b5325f6">3,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjMtMTMtMS0xLTY2OTEw_4f667ce4-e772-4948-b26a-cae479ca8cc6">3,397</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifd86661e66444c48b5ef3429b01488ee_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjQtNy0xLTEtNjY5MTA_8d7b88f7-e528-4304-839d-467361fdbccd">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjQtMTMtMS0xLTY2OTEw_6a245b19-7975-47f7-9104-0e581538d542">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa111bc1b6fc47e39a435526dc19640d_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjUtOS0xLTEtNjY5MTA_09bede0f-a35a-41fa-b3ca-63d5380bd03a">31,954</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjUtMTMtMS0xLTY2OTEw_aa25776d-cb9d-41e9-8166-5e35841adc9c">31,954</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance as of September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic863a6e2b5314131a58086e3e72c0388_I20210930" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjctMS0xLTEtNjY5MTA_fc05456f-98d7-485c-acb4-c1e8f7cf8094">87,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic863a6e2b5314131a58086e3e72c0388_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjctMy0xLTEtNjY5MTA_78f196a8-22eb-4281-a340-5d2fcd101f0b">874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d69eae660647b891b8545b7593243a_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjctNS0xLTEtNjY5MTA_55fffb17-450d-4f3b-82f8-5cef428a3e97">1,249,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie40e239beadc4317b3c499f7eea02fb6_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjctNy0xLTEtNjY5MTA_cffe47a7-32cd-4eac-ae53-3e8e8cd56b61">363</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f69dcb0c02046a8b06f845c2daa4737_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjctOS0xLTEtNjY5MTA_909bd3eb-0ef2-45f5-b3b8-36c2de88a4a8">621,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i179c3fe310ef4e61a6d5a2f2721eedc5_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjctMTEtMS0xLTY2OTEw_2929f1c6-5fa3-4820-94c8-44d71b02ab68">21,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63b3ddd7486946c2a0a8151832317d14_I20210930" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjctMTMtMS0xLTY2OTEw_622fca40-e571-422e-9e83-6d6550a6af24">607,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i4a25f060abc946f28c4a0095422c2513_34"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.75pt"><tr><td style="width:1.0pt"></td><td style="width:326.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Used In Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMy0xLTEtMS02NjkxMA_e873b4e1-dc10-41a1-82c5-76afe4338f8a">7,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMy0zLTEtMS02NjkxMA_68da5375-ea96-41fa-bae1-cb96d4bc8f12">31,954</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNS0xLTEtMS02NjkxMA_cd5ea9b0-b7bc-4de5-9fb9-24deba3ec14f">5,822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNS0zLTEtMS02NjkxMA_0949f868-71b1-43d3-a6c8-8164a5c830ea">819</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (gain) on discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="evh:GainLossOnDispositionOfAssetsOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNi0xLTEtMS02NjkxMA_cf92af18-7633-408c-8c6d-2422ed22a452">463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:GainLossOnDispositionOfAssetsOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNi0zLTEtMS02NjkxMA_0ee84394-1291-4483-a036-00d281db5d25">1,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNy0xLTEtMS02NjkxMA_dd2ffd14-a0a3-4d8b-a439-b55efbf2322d">3,940</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNy0zLTEtMS02NjkxMA_5a8d492d-41c9-4e26-85e6-7c29af52dbb9">12,725</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfOC0xLTEtMS02NjkxMA_e6871801-8b23-46e1-825c-35446641906c">47,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfOC0zLTEtMS02NjkxMA_b8e65f39-64ec-48fb-a304-6879dbb89764">45,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfOS0xLTEtMS02NjkxMA_70757c0d-6b5b-489c-b292-c1c40d6abc32">19,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfOS0zLTEtMS02NjkxMA_c858871a-3fd6-4389-ac22-23a597fe152d">11,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTAtMS0xLTEtNjY5MTA_0a12d864-9432-40aa-b050-60ba81a2872e">46,385</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTAtMy0xLTEtNjY5MTA_af006232-bb42-4c19-b5da-2010fd660399">288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTEtMS0xLTEtNjY5MTA_f279e84b-f9fd-4579-a7d6-9c959ef624bf">14,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTEtMy0xLTEtNjY5MTA_c6560d9f-8530-4f19-96ac-2e70439ae2d3">9,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTItMS0xLTEtNjY5MTA_946b06dd-5a63-4788-be67-1f7d51455aa1">1,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTItMy0xLTEtNjY5MTA_47f1b3b9-cc7b-49b6-b2ec-471da60a5bb8">13,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTMtMS0xLTEtNjY5MTA_c2bd18cc-bb92-4cf1-8175-5fa555c03a30">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTMtMy0xLTEtNjY5MTA_ced8dcd4-5ad4-481b-b0ef-0d428cc99216">22,969</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment/repayment of debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTQtMS0xLTEtNjY5MTA_82c1c7f1-81f8-43f1-b92c-6d39f16d5366">10,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTQtMy0xLTEtNjY5MTA_2d5a299c-972a-4f44-9e20-a53196bb9ab6">19,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivable agreement liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:IncreaseDecreaseInTaxReceivableAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTYtMS0xLTEtODI0Mjk_cbd9c093-7ba7-4457-a61d-89f3b8245b60">42,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:IncreaseDecreaseInTaxReceivableAgreement" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTYtMy0xLTEtODI0Mjk_22a2d863-c626-43a6-8589-27f970a40b02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current operating cash inflows (outflows), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTUtMS0xLTEtNjY5MTA_f19b780d-ded3-47af-9ac2-31d152834306">2,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTUtMy0xLTEtNjY5MTA_ec8efb31-c10e-45f8-8c6f-dab69c18d67d">472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of acquisitions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net and contract assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTctMS0xLTEtNjY5MTA_346ed3d9-f515-4d6c-835e-f966d865c428">34,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTctMy0xLTEtNjY5MTA_4722bb63-4f5a-497a-a0ae-f7623be3e314">52,878</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current and non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTgtMS0xLTEtNjY5MTA_0c650ec6-6cec-4730-99a7-299a1ca1cd16">2,409</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTgtMy0xLTEtNjY5MTA_bf0b7347-0eef-4baf-a960-1a55e040f513">140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract cost assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:IncreaseDecreaseInCapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTktMS0xLTEtNjY5MTA_c1d62c9b-5d8a-4e00-8835-101df96e3a5a">6,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:IncreaseDecreaseInCapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTktMy0xLTEtNjY5MTA_5d64e769-7122-486b-9208-277b6a41f7dd">8,439</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjAtMS0xLTEtNjY5MTA_34fc9ecc-19ae-4669-a80c-29ad81fc7e20">5,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjAtMy0xLTEtNjY5MTA_1a095815-755b-430a-a157-5c7969ad689e">8,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjEtMS0xLTEtNjY5MTA_c8ae6885-35e1-4601-97ca-11a0a35b2020">27,903</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjEtMy0xLTEtNjY5MTA_2015ef77-e189-4e5d-a7ed-3036556b8586">13,893</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjItMS0xLTEtNjY5MTA_20ff68c8-897f-4c93-9115-c23fe7003985">14,451</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjItMy0xLTEtNjY5MTA_085a238a-acac-47bf-840f-a84eb0c64368">12,811</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjMtMS0xLTEtNjY5MTA_71737941-a975-49ea-b551-2156e386e25e">4,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjMtMy0xLTEtNjY5MTA_b1dd39a5-aa45-46be-b0b8-7cc7373e72c2">3,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjQtMS0xLTEtNjY5MTA_374fe97c-27ee-4b44-8610-d7135d8efec5">35,596</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjQtMy0xLTEtNjY5MTA_1cdc273c-6788-436a-8ce6-38933c9ddbb7">16,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use operating assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjUtMS0xLTEtNjY5MTA_bb6855be-b587-4532-ace6-6fb564eba406">831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjUtMy0xLTEtNjY5MTA_8b9f9121-2b56-4362-ac98-61863ee0590a">6,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjYtMS0xLTEtNjY5MTA_c912519b-aa68-4191-a448-0b473d6a3375">1,223</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjYtMy0xLTEtNjY5MTA_8f75fe9e-3f94-44e7-b3dc-1d72a1daacf5">4,589</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjctMS0xLTEtNjY5MTA_636ac5ac-c613-4c01-8727-565f57b86c51">1,184</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjctMy0xLTEtNjY5MTA_85af2b81-ef56-4ecd-8f79-bd179f23b174">1,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjgtMS0xLTEtNjY5MTA_d3d4e1a6-f234-4fc7-8fba-71e80f67f366">47,248</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjgtMy0xLTEtNjY5MTA_1c3b6552-19fb-47ae-94b9-91aa76434542">27,909</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Provided by (Used In) Investing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for asset acquisitions and business combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzAtMS0xLTEtNjY5MTA_8225014a-5090-4ad3-8aac-4fa98f13a583">245,021</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzAtMy0xLTEtNjY5MTA_dcdb9759-184b-4fc6-b3fc-73715ae12ac5">1,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from transfer of membership and release of Passport escrow</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzEtMS0xLTEtNjY5MTA_40019bc0-802a-4f30-8582-ced62940fc7e">22,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzEtMy0xLTEtNjY5MTA_d9e5a00a-ff22-49a4-8a3b-097b47648f81">42,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disposal of non-strategic assets and divestiture of discontinued operations, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzItMS0xLTEtNjY5MTA_0b7a5ea8-072a-4104-a9af-ab339a28b1f0">9,164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzItMy0xLTEtNjY5MTA_d49cb400-e8c0-4280-9a1e-41a53ea4d276">3,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return of equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzMtMS0xLTEtNjY5MTA_a4f05a3d-3fa9-44c4-afe6-2a4efc973f62">4,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzMtMy0xLTEtNjY5MTA_525521ef-08f4-44a6-be77-81ff1dd328d1">14,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzQtMS0xLTEtNjY5MTA_feced0ce-c5d9-4f58-890a-20ff82e941ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireHeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzQtMy0xLTEtNjY5MTA_f8c5e768-2c21-4dac-9005-d2274e7e1ff0">2,994</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities and sales of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:ProceedsFromMaturityOfInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzUtMS0xLTEtNjY5MTA_d723bd14-d027-4019-99ee-80f514d2e355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:ProceedsFromMaturityOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzUtMy0xLTEtNjY5MTA_38c51cf7-48c1-4bd3-b7d9-d1a1a85a05e6">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in internal-use software and purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzYtMS0xLTEtNjY5MTA_f71975f9-5950-478a-b3e3-05b9a64904b3">27,618</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquireOtherProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzYtMy0xLTEtNjY5MTA_59160ee5-2108-4298-b277-fc010dd3bd8b">17,739</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzctMS0xLTEtNjY5MTA_70f74ce9-b6de-4c29-b27b-b5b5ac8e42fd">254,659</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzctMy0xLTEtNjY5MTA_860c3791-df15-4868-83e2-21b1211d770b">38,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows Provided by (Used In) Financing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in working capital balances related to claims processing on behalf of partners</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzktMS0xLTEtNjY5MTA_fabcc330-3292-4939-91f2-f5de49edf3a7">48,322</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzktMy0xLTEtNjY5MTA_b46d6bf0-5c01-466d-beef-76139eb49e90">1,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of Credit Agreement including settlement of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDAtMS0xLTEtNjY5MTA_8518db18-19a7-43be-b063-c35081dbf20a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDAtMy0xLTEtNjY5MTA_5186fde9-e180-4e3e-bd85-77df948b9242">98,420</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDEtMS0xLTEtNjY5MTA_9ab9943f-da7d-48ae-9726-1847cab38362">3,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDEtMy0xLTEtNjY5MTA_6900504d-6f2d-4d58-ac21-ab0d89581c60">11,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of long term debt, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDMtMS0xLTEtNzc1Mjk_a25950f7-48a4-46d0-9d07-0ab318829570">219,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDMtMy0xLTEtNzc1Mjk_e5b88252-3834-43f9-b87c-a9461910f60e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Distributions to Sponsors</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDItMS0xLTEtNjY5MTA_b125e3df-411a-42d7-8bcd-28caf973ba88">14,884</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDItMy0xLTEtNjY5MTA_eb2d0d54-17cf-4cee-9a81-f923a037c836">1,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:468.75pt"><tr><td style="width:1.0pt"></td><td style="width:326.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:66.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes withheld and paid for vesting of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDMtMS0xLTEtNjY5MTA_346908e5-002e-465b-b662-c1f67c80c980">17,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDMtMy0xLTEtNjY5MTA_dd673fd7-a2c0-4ff7-a6c3-4801f3179487">3,397</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDQtMS0xLTEtNjY5MTA_9482cfb7-1948-4e69-8834-8feeb4e314ed">142,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDQtMy0xLTEtNjY5MTA_28ee3810-8b39-40cd-b376-20f773479af2">90,446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate on cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDUtMS0xLTEtNjY5MTA_e75b1a9e-3baf-49b0-b003-c4e9ec1fb08f">612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDUtMy0xLTEtNjY5MTA_70a3862f-2fb4-41e4-895d-cadb51d7d7ce">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDYtMS0xLTEtNjY5MTA_f6e473b2-6106-4f54-a64a-d118e178d303">160,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDYtMy0xLTEtNjY5MTA_ece28c07-70dc-4837-8fa3-3d8c40168144">79,826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of beginning-of-period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDctMS0xLTEtNjY5MTA_503dff85-023e-41ac-9baf-a5d4bdb07ad4">354,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcb7e5d5de6d4fb9bd1b47d49e170108_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDctMy0xLTEtNjY5MTA_f538f3d6-8112-40a3-81e2-b534540a0098">361,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents and restricted cash as of end-of-period </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDgtMS0xLTEtNjY5MTA_b751326e-4f93-4c44-a804-68bbee4f159f">194,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63b3ddd7486946c2a0a8151832317d14_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDgtMy0xLTEtNjY5MTA_922cadfc-cfbc-4114-8f67-576e593a58f6">281,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RleHRyZWdpb246YTVkOWE1YzhmNDI0NGI1OTljNmI2ZjhkMTgwNGUxNmZfNTY3_7b3fb7d1-25f9-4617-9e42-722c10fba725" footnoteRole="http://www.xbrl.org/2003/role/footnote">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the nine months ended September 30, 2021. See Note 5.</ix:footnote></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i4a25f060abc946f28c4a0095422c2513_37"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i4a25f060abc946f28c4a0095422c2513_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1.  <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180MC9mcmFnOmIzNmQ3YmVhMTlkNjQ3MzJhOTE0MmZhMGJjMjc4ZDI2L3RleHRyZWdpb246YjM2ZDdiZWExOWQ2NDczMmE5MTQyZmEwYmMyNzhkMjZfMTA3Ng_a405cecf-33e7-4b04-ad14-0fa129b48ab7" continuedAt="ide00d3e9fc2d445a9505e92140a90e74" escape="true">Organization </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ide00d3e9fc2d445a9505e92140a90e74" continuedAt="i1ebe0ca1d0d345289608ddea70342c9f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations to move their business models from traditional fee for service reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company had unrestricted cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180MC9mcmFnOmIzNmQ3YmVhMTlkNjQ3MzJhOTE0MmZhMGJjMjc4ZDI2L3RleHRyZWdpb246YjM2ZDdiZWExOWQ2NDczMmE5MTQyZmEwYmMyNzhkMjZfNTMw_b645a4c1-ff9c-457d-99ab-0d0a6667626c">156.8</ix:nonFraction> million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s headquarters is located in Arlington, Virginia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evolent Health LLC Governance</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1ebe0ca1d0d345289608ddea70342c9f">Our operations are conducted through Evolent Health LLC. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#8217;s business and affairs and is responsible for the management of its business.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_43"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2.  <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1NjI_407ace48-b3c6-4bec-8310-3d9c98b64a9a" continuedAt="i51df12af914b4f3581e6cd5797bff202" escape="true">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i51df12af914b4f3581e6cd5797bff202" continuedAt="icd4502182b454e288e2cddddf1862d7d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1NDY_7fa9cdcd-d92c-471d-b858-be16a0f4ceba" continuedAt="i91f018ecafe04fe3998036f3df4bee21" escape="true">Basis of Presentation</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i91f018ecafe04fe3998036f3df4bee21">In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#8220;GAAP&#8221;) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2021 Form 10-K.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 2&#8221; in our 2021 Form 10-K for a complete summary of our significant accounting policies.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTY0OTI2NzQ1Nzk1MA_4cf16aab-c9b1-41e8-8671-47060bfea313" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassification</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current period presentation specifically as it relates to the reclassification of assets, liabilities, operating results and cash flows.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1OTA_9ba9b2f7-2e56-4cf1-8d6a-54015c7ae31b" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icd4502182b454e288e2cddddf1862d7d" continuedAt="ie880a5f033a146d282168245b299728a"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1Mjg_a605dda8-5a58-42cd-87e8-2f255f7c44bf" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1Mjk_937ee52d-52ef-40c0-bb0c-3acd8c7522af" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1ODA_95ac106a-e804-41a4-b209-cd43160bc622" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibee79f04f3964be9b790dfd8e4d6f320_I20220930" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfMS0xLTEtMS02NjkxMA_bc2fe1e4-a011-421a-85e4-ca6431917e58">2,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2301f18558fd44eda53696a9fcbd9108_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfMS0zLTEtMS02NjkxMA_97bb17f4-bd1c-433a-8a92-2a03f78dcc1c">3,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95931a1eeb74ea2a219a48e6a5e3328_I20220930" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfMi0xLTEtMS02NjkxMA_3f11d6c8-1df6-4f3c-8059-3e0e23cfaa18">10,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2575f96f53440259166edbd4dbce19b_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfMi0zLTEtMS02NjkxMA_87419269-d9f7-41b2-810a-84df9bc1e81a">11,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fd66acfff6549699d6732faf4b2192f_I20220930" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfMy0xLTEtMS02NjkxMA_61052676-b224-4d4d-9aaa-57df620f1e0a">24,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22c0c0a7d0e4c22bc5e825bcd93a594_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfMy0zLTEtMS02NjkxMA_6b01fa22-dac0-477d-9e88-5a48eddfc737">73,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83916efaa57f426f9c3bed9248c24cd6_I20220930" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfNC0xLTEtMS02NjkxMA_089da846-c4af-4bc2-a90d-5b22ede8ad43">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbbe90d495a24914843d600386432165_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfNC0zLTEtMS02NjkxMA_d81e4ed1-478f-44a1-84f6-08c6b7f0c350">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfNS0xLTEtMS02NjkxMA_1798bffc-f23a-4d68-ac68-270dcbd0ac96">38,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfNS0zLTEtMS02NjkxMA_0f341ad0-f39d-4146-960d-c438e200f8a1">88,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfNy0xLTEtMS02NjkxMA_1b9c2c61-2b46-4599-ab02-31d7e8e6549f">25,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfNy0zLTEtMS02NjkxMA_e1baf76b-c2b8-42da-b3af-ad1768092684">75,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfOC0xLTEtMS02NjkxMA_95163017-d824-4572-9fba-14af76044333">25,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfOC0zLTEtMS02NjkxMA_88130127-6b6b-4918-9a69-743fc379a33d">75,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfMTAtMS0xLTEtNjY5MTA_efa64363-cfb5-4315-a9e8-e68140897e0b">13,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfMTAtMy0xLTEtNjY5MTA_686c1417-bc0b-4071-ac63-9c2f69d56229">12,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfMTEtMS0xLTEtNjY5MTA_b591a5a6-8da9-4052-8b70-90695bce3419">13,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndInvestmentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfMTEtMy0xLTEtNjY5MTA_e288ec88-47e4-4884-a812-639bc9af78ec">12,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1Mzc_14ba165f-6d06-4eb4-ad55-cec88c9c9013" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOjBiMzBmZTg1MGE0NTQzN2RhZWYxYzNiMWM5NzgyYTYxL3RhYmxlcmFuZ2U6MGIzMGZlODUwYTQ1NDM3ZGFlZjFjM2IxYzk3ODJhNjFfMi0xLTEtMS02NjkxMA_34fb1274-220f-4ec9-9c8e-84a7f98af9a7">156,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63b3ddd7486946c2a0a8151832317d14_I20210930" decimals="-3" name="evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOjBiMzBmZTg1MGE0NTQzN2RhZWYxYzNiMWM5NzgyYTYxL3RhYmxlcmFuZ2U6MGIzMGZlODUwYTQ1NDM3ZGFlZjFjM2IxYzk3ODJhNjFfMi0zLTEtMS02NjkxMA_f86e3cc7-81ea-4059-a2fc-707ded796c67">252,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOjBiMzBmZTg1MGE0NTQzN2RhZWYxYzNiMWM5NzgyYTYxL3RhYmxlcmFuZ2U6MGIzMGZlODUwYTQ1NDM3ZGFlZjFjM2IxYzk3ODJhNjFfMy0xLTEtMS02NjkxMA_98132348-3030-442e-b9d2-1d73e15079e6">38,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63b3ddd7486946c2a0a8151832317d14_I20210930" decimals="-3" name="us-gaap:RestrictedCashAndInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOjBiMzBmZTg1MGE0NTQzN2RhZWYxYzNiMWM5NzgyYTYxL3RhYmxlcmFuZ2U6MGIzMGZlODUwYTQ1NDM3ZGFlZjFjM2IxYzk3ODJhNjFfMy0zLTEtMS02NjkxMA_7860cd96-e3e4-48f0-b4d9-219a20654206">29,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOjBiMzBmZTg1MGE0NTQzN2RhZWYxYzNiMWM5NzgyYTYxL3RhYmxlcmFuZ2U6MGIzMGZlODUwYTQ1NDM3ZGFlZjFjM2IxYzk3ODJhNjFfNC0xLTEtMS02NjkxMA_9a2d0dac-46dd-4725-b9fb-d738c7e63b9f">194,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63b3ddd7486946c2a0a8151832317d14_I20210930" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOjBiMzBmZTg1MGE0NTQzN2RhZWYxYzNiMWM5NzgyYTYxL3RhYmxlcmFuZ2U6MGIzMGZlODUwYTQ1NDM3ZGFlZjFjM2IxYzk3ODJhNjFfNC0zLTEtMS02NjkxMA_b194b343-9996-4a67-a145-ae9f467687f0">281,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the nine months ended September 30, 2021. See Note 5.</span></div></ix:nonNumeric></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1NjA_3963482e-a1dd-4802-b985-f80ed1cc08aa" continuedAt="ia841c8097e944c5a8cdaf0a5712e0777" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. </span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie880a5f033a146d282168245b299728a" continuedAt="i703a39004a404012b941ddf3d27ce0e3"><ix:continuation id="ia841c8097e944c5a8cdaf0a5712e0777"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1MzM_a6b8d11c-7e8a-4c23-982e-655e12b76619" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has <ix:nonFraction unitRef="reporting_unit" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfNzU0MQ_bcede2eb-d3a6-4fa1-8dc8-e5be4d66e5a3">three</ix:nonFraction> reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1Nzc_424d11a9-f211-4ac0-b0d6-32464934d62e" continuedAt="id8444fd8a229483295a37a47047b5f1e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1ODc_7f203da8-e4cf-4561-abef-8aa17902f5b7" continuedAt="i1e0cbae1eefd4e7390eb22bfa164a4b8" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:438.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie70e3951b11d47189d49176b477c53cb_D20220101-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmQ1NThkMDNiYWU2MzRhMmRiZDA1NDFmNWY3ZmFmMzg0L3RhYmxlcmFuZ2U6ZDU1OGQwM2JhZTYzNGEyZGJkMDU0MWY1ZjdmYWYzODRfMC0xLTEtMS02NjkxMC90ZXh0cmVnaW9uOjVkOWUzNGY5OGYzZDQ0MTVhNDlhNTE1NGU2ZTU5ZTBkXzQ_28794a19-ba99-4c18-96b2-6bdaf6c404e1">10</ix:nonNumeric> - <ix:nonNumeric contextRef="i4553368113754e9985da5aee1e1e2e13_D20220101-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmQ1NThkMDNiYWU2MzRhMmRiZDA1NDFmNWY3ZmFmMzg0L3RhYmxlcmFuZ2U6ZDU1OGQwM2JhZTYzNGEyZGJkMDU0MWY1ZjdmYWYzODRfMC0xLTEtMS02NjkxMC90ZXh0cmVnaW9uOjVkOWUzNGY5OGYzZDQ0MTVhNDlhNTE1NGU2ZTU5ZTBkXzk_1e590f07-5e67-4b6e-86ae-30388c250d16">20</ix:nonNumeric> years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9941ebd90552418b96575575d27a7ebe_D20220101-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmQ1NThkMDNiYWU2MzRhMmRiZDA1NDFmNWY3ZmFmMzg0L3RhYmxlcmFuZ2U6ZDU1OGQwM2JhZTYzNGEyZGJkMDU0MWY1ZjdmYWYzODRfMS0xLTEtMS02NjkxMC90ZXh0cmVnaW9uOjE5NGVkYTcyZDNmZjQ0MjNhOTBmMWRlMDM5OGQ2MGY2XzQ_43323b38-f3eb-4194-8c9c-cc0766405766">10</ix:nonNumeric> - <ix:nonNumeric contextRef="i30eb020f19524dfb97afd3fef2c5b9ea_D20220101-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmQ1NThkMDNiYWU2MzRhMmRiZDA1NDFmNWY3ZmFmMzg0L3RhYmxlcmFuZ2U6ZDU1OGQwM2JhZTYzNGEyZGJkMDU0MWY1ZjdmYWYzODRfMS0xLTEtMS02NjkxMC90ZXh0cmVnaW9uOjE5NGVkYTcyZDNmZjQ0MjNhOTBmMWRlMDM5OGQ2MGY2Xzk_ad592482-72c1-486a-95d5-b0d570c55450">25</ix:nonNumeric> years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia71efd024b264a23aa0d21ad75741277_D20220101-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmQ1NThkMDNiYWU2MzRhMmRiZDA1NDFmNWY3ZmFmMzg0L3RhYmxlcmFuZ2U6ZDU1OGQwM2JhZTYzNGEyZGJkMDU0MWY1ZjdmYWYzODRfMi0xLTEtMS02NjkxMA_95e81e27-ff29-426c-893f-239da3c2aeb0">5</ix:nonNumeric> years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i495e837d54f24a0d9dc7d49185d44a77_D20220101-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmQ1NThkMDNiYWU2MzRhMmRiZDA1NDFmNWY3ZmFmMzg0L3RhYmxlcmFuZ2U6ZDU1OGQwM2JhZTYzNGEyZGJkMDU0MWY1ZjdmYWYzODRfMy0xLTEtMS02NjkxMC90ZXh0cmVnaW9uOmU1OTYxM2RlODg4ODRhMWE4MmRmNTBjZjQ2MDU0YjYwXzQ_7bba5db2-ec87-4689-9e88-078bad88804d">3</ix:nonNumeric> - <ix:nonNumeric contextRef="i10d8689dfe304f3bb138eb921170cc2a_D20220101-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmQ1NThkMDNiYWU2MzRhMmRiZDA1NDFmNWY3ZmFmMzg0L3RhYmxlcmFuZ2U6ZDU1OGQwM2JhZTYzNGEyZGJkMDU0MWY1ZjdmYWYzODRfMy0xLTEtMS02NjkxMC90ZXh0cmVnaW9uOmU1OTYxM2RlODg4ODRhMWE4MmRmNTBjZjQ2MDU0YjYwXzk_99f3a309-1b66-4549-816f-1d455b512226">5</ix:nonNumeric> years</span></div></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id8444fd8a229483295a37a47047b5f1e">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value.</ix:continuation> See Note 9 for additional discussion regarding our intangible assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1NTk_66881a08-9670-4c9b-b09e-263dda847f48" continuedAt="i52475c7ce9fb4dbe9cfc28ac9f1d8637" escape="true">Research and Development Costs</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i52475c7ce9fb4dbe9cfc28ac9f1d8637">Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss).</ix:continuation> Total research and development costs for the three and nine months ended September 30, 2022, was $<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTA1Nzg_16c16dd8-fc83-46ec-8563-b666ff03bf87">3.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTA1ODU_95990dfd-780b-4129-89d7-375d25694963">11.7</ix:nonFraction>&#160;million, respectively, and, $<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTA5OTUxMTY0NDEzNA_c67453c0-95c4-4b34-990d-380f46d8d515">4.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTA5OTUxMTY0NDE0OQ_2472f029-cd22-4394-8d5e-d474f9bce578">11.1</ix:nonFraction>&#160;million for the three and nine months ended September 30, 2021, respectively.  </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i703a39004a404012b941ddf3d27ce0e3" continuedAt="i18d7da15bdc549b0ae59f3f1c74bed2a"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:LiabilityReserveEstimatePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1MzA_fd98227c-cfd3-459b-af04-b3ea3b14dbfe" continuedAt="i66b597bf8f514e309d6ac4a671d8bdf2" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i66b597bf8f514e309d6ac4a671d8bdf2">The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known.</ix:continuation> See Note 21 for additional discussion regarding our reserves for claims and performance-based arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="evh:RightOfOffsetPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1NTE_f716d33e-4d36-4b49-9cf2-c476452577ea" continuedAt="i0fc911626901401db47742881d55025a" escape="true">Right of Offset</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0fc911626901401db47742881d55025a">Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable.</ix:continuation> As of September&#160;30, 2022, and December&#160;31, 2021, approximately <ix:nonFraction unitRef="number" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="2" name="evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTIyMzE_a4acdd27-f8b5-4ab3-8dd1-ec87065fa9f4">47</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="2" name="evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTIyMzg_e91309e8-c0b4-416b-bbfa-df65961de01f">42</ix:nonFraction>%, respectively, of gross accounts receivable was netted against claims payable in lieu of cash receipt. Furthermore, as of September&#160;30, 2022, approximately <ix:nonFraction unitRef="number" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="2" name="evh:RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTIzNjY_80541f21-fb6a-4079-ab38-555444ea1496">11</ix:nonFraction>% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1NzE_ea900311-91f7-4129-94b4-9a71d4ec01af" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include <ix:nonFraction unitRef="option_to_renew_lease" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="INF" name="evh:NumberOfOptionsToRenewLeases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfNDk0NzgwMjM0MDgyOQ_75d88115-4bea-40de-8d71-0d256ba42d5c">one</ix:nonFraction> or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 12 for additional lease disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1NDQ_0d9fae46-d8b7-4a2b-965c-d7c0ec9a97dd" continuedAt="i549049e7ad44481f875dd638c562490e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from <ix:nonFraction unitRef="source" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="INF" name="evh:NumberOfSourcesOfRevenue" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTQwNjI_39fe363c-e511-42e6-9f82-5d6d9b1bb202">two</ix:nonFraction> sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i18d7da15bdc549b0ae59f3f1c74bed2a">See Note 6 for further discussion of our policies related to revenue recognition.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3.  <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180Ni9mcmFnOjNjN2U2YmYyNmI5ODRjMjNhOWYxNWM2Mzk1ZWEzZTAxL3RleHRyZWdpb246M2M3ZTZiZjI2Yjk4NGMyM2E5ZjE1YzYzOTVlYTNlMDFfMzE3OA_a4532529-610d-41a4-b585-d3b94a384fd7" continuedAt="i19aaf2a6e82f40cd90685856aa986fd4" escape="true">Recently Issued Accounting Standards</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i19aaf2a6e82f40cd90685856aa986fd4"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180Ni9mcmFnOjNjN2U2YmYyNmI5ODRjMjNhOWYxNWM2Mzk1ZWEzZTAxL3RleHRyZWdpb246M2M3ZTZiZjI2Yjk4NGMyM2E5ZjE1YzYzOTVlYTNlMDFfMzE4MQ_95d4ff0b-6af4-4c9b-b1f5-9fd79e517522" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $<ix:nonFraction unitRef="usd" contextRef="i102291920e804daab7d25e75918ff73b_I20220101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180Ni9mcmFnOjNjN2U2YmYyNmI5ODRjMjNhOWYxNWM2Mzk1ZWEzZTAxL3RleHRyZWdpb246M2M3ZTZiZjI2Yjk4NGMyM2E5ZjE1YzYzOTVlYTNlMDFfMjIxMQ_91785114-3287-4a48-8e23-99d67f29a438">39.8</ix:nonFraction>&#160;million, reduced additional paid-in capital by $<ix:nonFraction unitRef="usd" contextRef="i2e521093d1374140ac95361a6c2a311e_I20220101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180Ni9mcmFnOjNjN2U2YmYyNmI5ODRjMjNhOWYxNWM2Mzk1ZWEzZTAxL3RleHRyZWdpb246M2M3ZTZiZjI2Yjk4NGMyM2E5ZjE1YzYzOTVlYTNlMDFfMjI1Mw_a680eea7-15a4-453c-a9a9-2d3642e21022">106.2</ix:nonFraction>&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $<ix:nonFraction unitRef="usd" contextRef="i970cc1ff98954def888f92d6e27ed9e0_I20220101" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180Ni9mcmFnOjNjN2U2YmYyNmI5ODRjMjNhOWYxNWM2Mzk1ZWEzZTAxL3RleHRyZWdpb246M2M3ZTZiZjI2Yjk4NGMyM2E5ZjE1YzYzOTVlYTNlMDFfMjMyNA_bd22018a-724a-44d0-8359-26c7c9113a03">25.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if6b921fd4b544f439a08e3802c74b054_I20220101" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180Ni9mcmFnOjNjN2U2YmYyNmI5ODRjMjNhOWYxNWM2Mzk1ZWEzZTAxL3RleHRyZWdpb246M2M3ZTZiZjI2Yjk4NGMyM2E5ZjE1YzYzOTVlYTNlMDFfMjMzMQ_23fbdf86-ab7d-44ea-8876-5e3ccefa0bfa">41.3</ix:nonFraction>&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Effective</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. This new standard is effective for our interim and annual periods beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the adoption impacts on our consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_49"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4.  <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMzI5ODUzNDg5MTMzOQ_5a8ad1af-119d-4d28-98d4-0a1d882b2e92" continuedAt="i69410f7c8081416aa839fcbdae246637" escape="true">Transactions</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i69410f7c8081416aa839fcbdae246637" continuedAt="i9459e9393b094e5fa9f45b931783f8f6"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implantable Provider Group</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022, the Company completed its acquisition of Implantable Provider Group, Inc. (&#8220;IPG&#8221;), including <ix:nonFraction unitRef="number" contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfNTQ5NzU1ODE3NzI3_e1843a42-2e87-420a-a659-3af4cbcb1da4">100</ix:nonFraction>% of the voting equity interests. IPG is a leader in providing surgical management solutions for musculoskeletal conditions. The transaction is expected to accelerate our strategy to become a leading provider of value-based specialty care solutions as well as diversify our revenue streams with a larger customer portfolio. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total merger consideration, net of cash on hand and certain closing adjustments, was $<ix:nonFraction unitRef="usd" contextRef="i0aac7a30651e4f168f37aa5b96ca404e_D20220801-20220801" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTY0OTI2NzQ1NTE2Mg_9ab3bf2a-bfef-4ddf-af96-41d6d8ea59e2">461.7</ix:nonFraction>&#160;million, based on the closing price of the Company&#8217;s Class A common stock on the NYSE on August 1, 2022. The merger consideration consisted of $<ix:nonFraction unitRef="usd" contextRef="i0aac7a30651e4f168f37aa5b96ca404e_D20220801-20220801" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTY0OTI2NzQ1NTE5Mw_48ace1e9-585e-4cbf-94ef-b549b753f368">256.5</ix:nonFraction>&#160;million of cash consideration, <ix:nonFraction unitRef="shares" contextRef="i0aac7a30651e4f168f37aa5b96ca404e_D20220801-20220801" decimals="-5" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfNTQ5NzU1ODIxNjQ2_cb628c7f-b65c-4867-861e-fd03dac4c9a2">3.7</ix:nonFraction>&#160;million shares of Class A common stock, fair valued at $<ix:nonFraction unitRef="usd" contextRef="i0aac7a30651e4f168f37aa5b96ca404e_D20220801-20220801" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTY0OTI2NzQ1NTIyNA_2b2ca61c-cb35-4f83-af5c-72f8b1ea8dc7">130.2</ix:nonFraction>&#160;million as of August 1, 2022, and an earn-out of up to $<ix:nonFraction unitRef="usd" contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMzI5ODUzNDg5MTM0MQ_9f4e11ee-642f-4ea5-b2c2-1022cd06718c">87.0</ix:nonFraction>&#160;million, fair valued at $<ix:nonFraction unitRef="usd" contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTY0OTI2NzQ1NTI1NA_08b0d0ad-53b2-4b02-a4c4-782344305747">75.0</ix:nonFraction>&#160;million as of August 1, 2022 is payable in cash and/or shares of the Company&#8217;s Class A Common Stock, at the Company&#8217;s option. See Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 for additional information regarding the fair value determination of the earn-out consideration.</span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMzI5ODUzNDg5MTM1NQ_6aff2c5c-6113-4c0b-99a6-b6c03a0de059" continuedAt="i89921e322da8459abdc643a72d336213" escape="true"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMzI5ODUzNDg5MTM1NQ_9dd8cab4-21a8-482d-97a4-b832eb916c7c" continuedAt="i697ba544ba42491a82c50a64781c6ff9" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aac7a30651e4f168f37aa5b96ca404e_D20220801-20220801" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMS0xLTEtMS03MDk0Mw_7ed07a22-8f7e-4a77-b7d3-85bd1c5d189a">256,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9459e9393b094e5fa9f45b931783f8f6" continuedAt="ia58a5ac6be5a4f59a690666db10d637c"><div><ix:continuation id="i89921e322da8459abdc643a72d336213" continuedAt="i46d4f14fac1345658204e2601abf23bd"><ix:continuation id="i697ba544ba42491a82c50a64781c6ff9" continuedAt="ic685ede516e447e28ce99c19c2346f9a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aac7a30651e4f168f37aa5b96ca404e_D20220801-20220801" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMi0xLTEtMS03MDk0Mw_5a580672-756b-4bb9-aab5-1fff747ad337">130,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aac7a30651e4f168f37aa5b96ca404e_D20220801-20220801" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMy0xLTEtMS03MDk0Mw_6615ca5a-7e01-47c9-bc25-5ca4c4797466">75,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aac7a30651e4f168f37aa5b96ca404e_D20220801-20220801" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfNC0xLTEtMS03MDk0Mw_06437636-b35b-4682-93c2-e24b3587cd95">461,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfOC0xLTEtMS03MDk0NQ_7cc1a360-375b-4b6f-9be7-2b0faeecb791">34,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfOS0xLTEtMS03MDk0NQ_f73b0187-c34a-4eb8-a655-39f50283978b">636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMTAtMS0xLTEtNzA5NDU_2a881e55-6ca8-4fa1-83b7-4b975d49f1f3">1,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMTEtMS0xLTEtNzA5NDU_676cccc1-4c34-403b-a869-2af37dbf9cc4">36,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47850eb51205454eb531a4e4a24c6b67_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMTQtMS0xLTEtNzA5NDc_37508e68-de66-4e07-a86c-3835bd9dac24">154,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81468ffa8e794bc0b59baa9867b5834c_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMTUtMS0xLTEtNzA5NDc_4efe1544-1e10-453f-aeb5-df96e8e2799f">23,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2def591b7f54106a7fa0735840fe2d2_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMTYtMS0xLTEtNzA5NDc_92be7502-22d5-439a-9ac7-527d4e28cd21">17,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMTctMS0xLTEtNzA5NDc_56bd4a9d-2633-4b6e-989f-4dc6ec504ab6">195,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMjAtMS0xLTEtNzA5NDk_2ff0d706-6711-472f-81db-293a1de81cd2">7,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMjEtMS0xLTEtNzA5NDk_aa080676-fe1b-4153-b0b0-c0be2875fcfa">8,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMjItMS0xLTEtNzA5NDk_561bed46-b490-4dd3-a24f-072fbbcba318">423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMjMtMS0xLTEtNzA5NDk_dea6e7b5-7ed3-4cb6-97da-68966d03eb08">48,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMjQtMS0xLTEtNzA5NDk_5a5cbdb2-0ac7-4ea3-8c60-81ae086a59f1">321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMjUtMS0xLTEtNzA5NDk_39c679cf-2949-4969-9065-97085eab3f80">1,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMjYtMS0xLTEtNzA5NDk_f515a826-3737-4a75-82de-68333ffb6de2">66,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMjgtMS0xLTEtNzA5NTE_e5828527-46c8-481d-bec7-b645912a21c7">296,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMjktMS0xLTEtNzA5NTE_f87a8763-917a-41d1-bf55-65c889d3f1af">461,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and the corporate trade name will be amortized on a straight-line basis over their preliminary estimated useful lives of <ix:nonNumeric contextRef="i76392d607ac741ffa9749e4c5191c116_D20220801-20220801" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfNTQ5NzU1ODIwMDMz_cd5951b2-67cd-4819-9556-9500b0e5622b">20</ix:nonNumeric> years, <ix:nonNumeric contextRef="ib13556ea35bd419f840924ad34329091_D20220801-20220801" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfNTQ5NzU1ODIwMDM2_976d5626-23c1-4cc5-b44e-866e86c18c71">5</ix:nonNumeric> years, and <ix:nonNumeric contextRef="i8980c17573b14788b07301046fa212f8_D20220801-20220801" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfNTQ5NzU1ODIwMDM3_961f5431-371f-4b47-b7bf-a9650c5069b9">15</ix:nonNumeric> years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary customer relationship management and analytics platform that supports reporting to payors with respect to medical device pricing and associated analytics. The corporate trade name reflects the value that we believe the IPG brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. The Company received carryover tax basis in the assets and liabilities acquired; accordingly, the Company recognized net deferred tax liabilities associated with the difference between the book basis and the tax basis for the assets and liabilities acquired. The goodwill is <ix:nonFraction unitRef="usd" contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801" decimals="-5" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTY0OTI2NzQ1NjU3MQ_24d7de49-cd53-4568-a7c9-a977ec7b5610">no</ix:nonFraction>t deductible for tax purposes. Additionally, a discrete tax benefit of $<ix:nonFraction unitRef="usd" contextRef="i873c819d3f8246cda155f0714de1ce57_D20220101-20220930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTA5OTUxMTYyOTI2NTA_05d2ac44-56b7-489c-b5fc-c9f4e6817da2"><ix:nonFraction unitRef="usd" contextRef="i011e460895d3476ea9ce07169b756846_D20220701-20220930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTA5OTUxMTYyOTI2NTA_0c34e346-9254-46a0-9ab1-fed07d6b9ec8">46.8</ix:nonFraction></ix:nonFraction>&#160;million was recorded in the consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2022, to account for the valuation allowance release primarily related to the acquired intangible assets, which resulted in a deferred tax liability that provided a source of income supporting realization of other deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts above reflect management&#8217;s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. Any necessary adjustments are expected to be finalized by the end of the third quarter of 2023.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><ix:continuation id="ia58a5ac6be5a4f59a690666db10d637c" continuedAt="i4c245f75a51d44cc8342fbdd1c1db239"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vital Decisions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, the Company completed its acquisition of Vital Decisions, including <ix:nonFraction unitRef="number" contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTU2_eb0e64c0-cb74-4ba6-b085-d8de3ba76487">100</ix:nonFraction>% of the voting equity interests. Vital Decisions is a leading provider of technology-enabled advance care planning services, ensuring that the care of individuals with serious illness aligns with their values and changing preferences throughout their health journey and, in particular, as they approach end-of-life decisions. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total merger consideration, net of cash on hand and certain closing adjustments, was $<ix:nonFraction unitRef="usd" contextRef="ief648c5f4b1449d2be6c08727632b653_D20211001-20211001" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfNzE2_03db4d6e-4d7a-47c1-9a3d-6e0ab1c1fd93">117.7</ix:nonFraction> million, based on the closing price of the Company&#8217;s Class A common stock on the NYSE on October 1, 2021. The merger consideration consisted of $<ix:nonFraction unitRef="usd" contextRef="ief648c5f4b1449d2be6c08727632b653_D20211001-20211001" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfODU1_cf6d7012-f8ad-43d2-9758-8606e5112c51">46.5</ix:nonFraction> million of cash consideration, <ix:nonFraction unitRef="shares" contextRef="ief648c5f4b1449d2be6c08727632b653_D20211001-20211001" decimals="-5" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfODgx_24511eee-a45a-42e4-842b-6ba99ac17c0a">1.8</ix:nonFraction>&#160;million shares of Class A common stock, fair valued at $<ix:nonFraction unitRef="usd" contextRef="ief648c5f4b1449d2be6c08727632b653_D20211001-20211001" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfOTMx_0b88134e-8bd0-4dad-8c9c-d9dbe2c3fec2">56.6</ix:nonFraction> million as of October 1, 2021, and an earn-out of up to $<ix:nonFraction unitRef="usd" contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfOTgy_204dd09a-0c10-4f23-86be-0544978b2d69">45.0</ix:nonFraction>&#160;million, fair valued at $<ix:nonFraction unitRef="usd" contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTAwMQ_616051d9-6331-4a2a-a62f-f7f43e074889">14.6</ix:nonFraction> million as of October 1, 2021 is payable in cash and/or shares of the Company&#8217;s Class A Common Stock, at the Company&#8217;s option. See Note 17 for additional information regarding the fair value determination of the earn-out consideration.</span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i46d4f14fac1345658204e2601abf23bd"><ix:continuation id="ic685ede516e447e28ce99c19c2346f9a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief648c5f4b1449d2be6c08727632b653_D20211001-20211001" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMS0xLTEtMS02NjkxMA_78c1693c-3e0d-43f6-ae03-eb3d6476a171">46,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief648c5f4b1449d2be6c08727632b653_D20211001-20211001" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMi0xLTEtMS02NjkxMA_0994733e-6d17-414e-b0a0-3d72ff21ae49">56,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief648c5f4b1449d2be6c08727632b653_D20211001-20211001" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMy0xLTEtMS02NjkxMA_d7ce9d59-9df0-4927-a64a-d0b60d3315db">14,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief648c5f4b1449d2be6c08727632b653_D20211001-20211001" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfNC0xLTEtMS02NjkxMA_a7cf7dcd-75cc-4bd4-91c7-1f85ced5af49">117,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfNy0xLTEtMS02NjkxMA_b8328458-4c74-4dc1-9d79-ae55a1646873">1,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfOC0xLTEtMS02NjkxMA_c898fe06-0b92-46b4-bf36-517cba2d5c6c">3,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfOS0xLTEtMS02NjkxMA_b8677de2-c448-41a3-9ef2-2371bd85db2d">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMTAtMS0xLTEtNjY5MTA_6593d958-9a0d-40e5-8ec5-fe47a49b6eaa">2,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMTEtMS0xLTEtNjY5MTA_8eaa07d8-03a5-410f-93a4-1719cc141f2e">7,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63c007d9f492486b853449a269099b25_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMTQtMS0xLTEtNjY5MTA_c0fc205c-de5c-4aaf-8ff9-c8eb7ade0c6d">32,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie493e2b859384dbab23b7cc294e31dbe_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMTUtMS0xLTEtNjY5MTA_d96c3194-f93f-41f5-ace6-fe4626074715">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i522030bffa474e539994d8f7437146bb_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMTYtMS0xLTEtNjY5MTA_d39d4ff3-cdcb-48e2-a8f5-d1f80f4ed317">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMTctMS0xLTEtNjY5MTA_8c3b5d51-7b78-4c68-b2b8-c776ed9df51f">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMjAtMS0xLTEtNjY5MTA_c8e48c78-4894-41c6-9440-3048ddb9089c">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMjEtMS0xLTEtNjY5MTA_a4c5876a-a27e-4c89-8551-c0b7f84cf066">661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001" decimals="-3" name="evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMjItMS0xLTEtNjY5MTA_e2a7527c-c8a9-4488-8ad8-1da473c7392d">970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMjMtMS0xLTEtNjY5MTA_cd6a8036-799d-4e92-bb20-84305d445bcd">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMjQtMS0xLTEtNjY5MTA_657627ab-c5a2-4baf-8376-502abb1f7136">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMjUtMS0xLTEtNjY5MTA_c0bb51dd-90bd-4f10-a01f-579c67ff00d3">2,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMjYtMS0xLTEtNjY5MTA_14471d5c-1c2a-49fd-8ab0-6f3c980fd243">6,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMjgtMS0xLTEtNjY5MTA_6e3255b3-b78d-4b48-93ba-139847b97c72">77,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMjktMS0xLTEtNjY5MTA_845c5c43-7363-4316-811a-37835ead3b44">117,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i4c245f75a51d44cc8342fbdd1c1db239">The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and corporate trade names will be amortized on a straight-line basis over their preliminary estimated useful lives of <ix:nonNumeric contextRef="ib15c968ec28447719bfe672cf73f9c1f_D20211001-20211001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTY2Nw_7ea253ce-73c6-4b1b-82db-1ab802bf8f64">13</ix:nonNumeric> years, <ix:nonNumeric contextRef="i9acb52a4a7c949db9847508394a446ad_D20211001-20211001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTY3MQ_dccd83ec-2ae1-4c09-acba-c1c6b4744904">5</ix:nonNumeric> years, and <ix:nonNumeric contextRef="i644999860f68467f8589953496d35dcd_D20211001-20211001" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTY3OQ_8dc165c8-75e2-46f8-ada2-3e6aeb99bcbc">15</ix:nonNumeric> years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary advance care planning documentation portal where patients can input information, and doctor/patient conversations are populated for later reference. The corporate trade name reflects the value that we believe the Vital Decisions brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. Goodwill is considered to be an indefinite lived asset. $<ix:nonFraction unitRef="usd" contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001" decimals="-5" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMzE0NQ_cedb4ab8-9ea1-4d4d-b2d2-3c0bbb1b92b7">69.6</ix:nonFraction>&#160;million of the goodwill recorded on the transaction is deductible for tax purposes.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5.  <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RleHRyZWdpb246MGQ3MjhiYjYzZWI4NDYyNzg2YWE5NWM1MDE0YTFkNzFfMjI3Nw_1bf85e92-f976-4ae4-8048-a6a64865fb60" continuedAt="iebc6304c479049fda39be8a2cafeaf0f" escape="true">Discontinued Operations</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="iebc6304c479049fda39be8a2cafeaf0f" continuedAt="i15b3b0c5134148669a1d84c4c3388f3a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the &#8220;True Health SPA&#8221;) with Bright Health Management, Inc. (&#8220;Bright HealthCare&#8221;), pursuant to which EH Holdings agreed to sell all of its equity interests in True Health to Bright HealthCare. Closing of the transactions contemplated by the True Health SPA occurred on March 31, 2021 (the &#8220;True Health Closing&#8221;) and the Company has had no continuing involvement with True Health subsequent to the closing except a pre-existing services agreement for claims processing and other health plan administrative functions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 205, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RleHRyZWdpb246MGQ3MjhiYjYzZWI4NDYyNzg2YWE5NWM1MDE0YTFkNzFfMjI3OA_86a7bbe6-7833-4ac2-9705-62dae1e0d3ad" continuedAt="i54f47807cf894900b0cb3725d7829fe1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.291%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine <br/>Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47a4ccf5040a4a66b194e116ca3958b2_D20210701-20210930" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMi0xLTEtMS02NjkxMA_f375ded6-1674-493b-a30e-06d0fe73a516">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d45489205434204959192b27c4c154c_D20210101-20210930" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMi0zLTEtMS02NjkxMA_d0d37891-4568-4af6-a94c-a639cb0dce3a">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eeb2030bc104024b411081939f02ec5_D20210701-20210930" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMy0xLTEtMS02NjkxMA_62b2ba33-fbf7-4c70-8985-1a157f134145">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a06e059e5d544dfae30aab44f20002e_D20210101-20210930" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMy0zLTEtMS02NjkxMA_69234b36-410b-44b9-9162-e74dc0412f40">44,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfNC0xLTEtMS02NjkxMA_966d2a48-8912-43a0-8970-e02d16c13d34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfNC0zLTEtMS02NjkxMA_e067b113-3934-4820-934f-a992d0cd2b7e">44,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfNy0xLTEtMS02NjkxMA_b86d92c5-671e-406b-a715-4bf357e17ea7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfNy0zLTEtMS02NjkxMA_d712ae54-e231-42fb-8344-9605e4e9bb10">5,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930" decimals="-3" name="evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfOC0xLTEtMS02NjkxMA_caa44b40-4a68-45da-922c-897ca7bf890c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930" decimals="-3" name="evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfOC0zLTEtMS02NjkxMA_f1ec7f47-e5ee-4dcf-baf1-f1a39e7f8d66">33,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfOS0xLTEtMS02NjkxMA_f64dc046-5310-4240-b527-a8fee9d1f1b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfOS0zLTEtMS02NjkxMA_37985853-f2ed-453e-ac0d-8860c0994686">5,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930" decimals="-3" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTAtMS0xLTEtNjY5MTA_606a499b-68ad-4ddc-90b1-29725f6806fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTAtMy0xLTEtNjY5MTA_bf9e02af-332c-41db-8264-a313a1ada123">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTEtMS0xLTEtNjY5MTA_82486c70-aaac-4b85-8bb4-fa18b758c293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTEtMy0xLTEtNjY5MTA_e14fdeec-c5f9-438b-b96b-1e126e7988a2">45,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTItMS0xLTEtNjY5MTA_9166ab02-b5af-4413-ad82-f54a0ac10ed4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTItMy0xLTEtNjY5MTA_5b1e980c-c1df-4ae6-ba66-697af34a4107">930</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTMtMS0xLTEtNjY5MTA_edcfa9e3-4000-489a-85d8-382471b5e9a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTMtMy0xLTEtNjY5MTA_1befb93d-1aa7-4c00-be0f-6abe86f118dc">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTQtMS0xLTEtNjY5MTA_464ff927-4984-49c6-bb2d-0efa5bd485fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTQtMy0xLTEtNjY5MTA_6f8c226a-8100-4be7-81d6-06d584f310ee">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTUtMS0xLTEtNjY5MTA_cbfe76d9-b7db-442c-86a5-148ac5bc49bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTUtMy0xLTEtNjY5MTA_b424e1bb-54e5-4afb-93db-22fee388437a">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930" decimals="-3" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTYtMS0xLTEtNjY5MTA_a0f7eeee-7588-4609-bbde-11a45d3b5093">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTYtMy0xLTEtNjY5MTA_005baebf-431f-497f-9a0a-13dde90d27f4">847</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i15b3b0c5134148669a1d84c4c3388f3a"><ix:continuation id="i54f47807cf894900b0cb3725d7829fe1" continuedAt="ic4e757dadd6f49e68289954679e8de2a"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.427%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.288%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.291%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930" decimals="-3" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTctMS0xLTEtNjY5MTA_7fe478cc-bdc5-4cf0-88d8-01eca2229323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTctMy0xLTEtNjY5MTA_11f078a1-4781-4d0e-a41e-dea5be4756c3">326</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTgtMS0xLTEtNjY5MTA_d0d49db4-af68-4d94-bb0c-7f13540d5863">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTgtMy0xLTEtNjY5MTA_05476485-20f7-428a-ab7e-2d1573826cd2">521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $<ix:nonFraction unitRef="usd" contextRef="i084df9c8155a461a930377e4e05f1fda_D20210101-20210930" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RleHRyZWdpb246MGQ3MjhiYjYzZWI4NDYyNzg2YWE5NWM1MDE0YTFkNzFfMTY4NQ_891cd1e8-4faf-4ca8-bddd-6634b395c5a8">2.8</ix:nonFraction>&#160;million for the nine months ended September 30, 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses include intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $<ix:nonFraction unitRef="usd" contextRef="i084df9c8155a461a930377e4e05f1fda_D20210101-20210930" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RleHRyZWdpb246MGQ3MjhiYjYzZWI4NDYyNzg2YWE5NWM1MDE0YTFkNzFfMjA1NA_bc39560f-2417-49e3-b62e-4be540185477">1.1</ix:nonFraction> million for the nine months ended September 30, 2021.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. <ix:continuation id="ic4e757dadd6f49e68289954679e8de2a" continuedAt="i4c59c742414a43b28b1a034bc240bbb9">Cash flows related to the True Health business during the nine months ended September 30, 2021:</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="i4c59c742414a43b28b1a034bc240bbb9"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"></td><td style="width:89.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930" decimals="-3" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmQ2NDFhOTk3NzUwNDQ2MGVhMjg0MjE2OWU5Y2VkOTJmL3RhYmxlcmFuZ2U6ZDY0MWE5OTc3NTA0NDYwZWEyODQyMTY5ZTljZWQ5MmZfMC0xLTEtMS02NjkxMA_4734c035-3e7b-4fed-95ef-a79b9cecd30a">5,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmQ2NDFhOTk3NzUwNDQ2MGVhMjg0MjE2OWU5Y2VkOTJmL3RhYmxlcmFuZ2U6ZDY0MWE5OTc3NTA0NDYwZWEyODQyMTY5ZTljZWQ5MmZfMS0xLTEtMS02NjkxMA_75a859d0-4e8f-4557-8595-c8899f04935d">2,494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6.  <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfOTQ5MA_167a9738-ba1a-430f-bbcd-a07a46d38c1e" continuedAt="i45970a55890d422cb94e02911658f0f9" escape="true">Revenue Recognition</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i549049e7ad44481f875dd638c562490e"><ix:continuation id="i45970a55890d422cb94e02911658f0f9" continuedAt="ieabab3feddc24772a9a88f571f36c407"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily third-party administration (&#8220;TPA&#8221;) services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into performance-based arrangements that may include capitation and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal vs. Agent</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the goods and services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer thereby recognizing revenue on a net basis.</span></div></ix:continuation></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ieabab3feddc24772a9a88f571f36c407" continuedAt="if5f203a46c5d4c20bcdf86d377672791"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfOTQ5Mg_5ec092db-aa98-4dcb-b2f1-40e7d262c9ca" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:114.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eabf8957ae644bea9de5ff585037c2e_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfMy0xLTEtMS02NjkxMA_bc5f89c2-4a20-435d-a31d-e6cd41113bac">60,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f69a9ba3a84c17bce7dd867c4d59f5_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfMy0zLTEtMS02NjkxMA_2ac0a0b1-6447-49e4-ba4e-776ddaa878a6">41,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i275229cc10b9470089d55c668922f2bd_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfMy01LTEtMS02NjkxMA_63b1e65e-3b08-43ad-82b3-bde4ecfc0d6e">79,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i367c749bbd734fe5936e4963fe777810_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfMy03LTEtMS02NjkxMA_ecd81185-7f30-4883-b06c-c0eabf346b54">51,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94fd241bcaa64da1931a65e62a56ec7c_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfMy05LTEtMS02NjkxMA_a29c9c52-4e62-4950-b6b8-e268ad908332">183,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cdccd94a8564ff29b795220b3f3ab9b_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfMy0xMS0xLTEtNjY5MTA_02fefc65-94b0-47f7-b573-becf022ca28d">154,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ee4e484cf964a788bb699155c8d3460_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfMy0xMy0xLTEtNjY5MTA_b78e4dc9-28f7-437f-b052-2970f7938d02">226,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i942d2a04b516474fad491df3467fe4a1_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfMy0xNS0xLTEtNjY5MTA_29350379-d18e-4432-bb9a-145b51a4ca70">148,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae1fd07e7a684627bcc4060576e5441e_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNC0xLTEtMS02NjkxMA_050c0bfa-a877-42de-8e93-939bd54623a2">6,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa189959b70490991b00541c0e766b4_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNC0zLTEtMS02NjkxMA_a71964b2-998a-432b-8575-930d69f9b56f">4,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7cb9ce8372844c4a246769d6a86d26f_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNC01LTEtMS02NjkxMA_78952fd9-b67d-4e9a-bb04-dc388f380057">111,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e72ff3374e40b7b9ef61f986ed1c3f_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNC03LTEtMS02NjkxMA_6b79ff1d-9059-4be7-bd9c-df37adb2139a">105,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic60baf9264bb4217b1b8574383a06caf_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNC05LTEtMS02NjkxMA_50573f30-467a-4fcf-91e8-af08a1860e08">21,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ff5e19f6d8424a8f324dfbee51fafc_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNC0xMS0xLTEtNjY5MTA_04cb8c9f-9785-47c8-b539-25cf94d2a67f">19,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f643fc0caed4180a8f4262624ceb1d5_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNC0xMy0xLTEtNjY5MTA_5b983d81-98e9-4aa7-93f9-b0ed0f7f1228">315,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d938e0b3b4949498896da9cf968d0e2_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNC0xNS0xLTEtNjY5MTA_ed4f461f-b8de-4385-a2aa-256be70c653c">281,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f0e4a5e2538465489ed74ed4df71f17_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNS0xLTEtMS02NjkxMA_f8fbc7bc-d8b1-4158-a439-33a1925301ea">40,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c0881f057a14f60b11d5202ba4254d6_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNS0zLTEtMS02NjkxMA_3a1126c4-ff11-4317-8e93-9a90d1fa8d21">16,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia663b5d5862c44d3bb9df7816b437214_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNS01LTEtMS02NjkxMA_94718ac4-bea1-47b2-9e9d-b05499152db5">53,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2145c8132b345cdbc155aef50b5b24d_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNS03LTEtMS02NjkxMA_7c614cc4-e1f6-4dc6-8982-38f3aefb4b0a">2,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5ecc514fd2f4b63b7f68dd819b7abdd_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNS05LTEtMS02NjkxMA_99104fed-5a62-48ec-9181-51d2c949d3d4">101,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cf09e09764f4e7ba983e1073e89d28e_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNS0xMS0xLTEtNjY5MTA_2115bc0a-7131-47f4-a5a9-999b8eef6e63">48,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d1acdaafc0b49afb61eac49debda354_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNS0xMy0xLTEtNjY5MTA_42cae10b-ea09-44e1-91bd-90f93e9743b2">121,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21f251cda7464cffa6ec9eebf7e8f211_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNS0xNS0xLTEtNjY5MTA_1d32d5a2-9eee-40d8-a7cd-3631547b7a4d">6,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibde168bb02b0431892729b1d49c5bbbd_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNi0xLTEtMS02NjkxMA_126399ec-d566-4a54-9777-9cd159fb1e7a">107,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b5c3ea113b04213b765d3be37ec88ce_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNi0zLTEtMS02NjkxMA_f8d16b12-dce5-4166-83ee-47a9469aac2b">62,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ab4a9b7f10b466b8aed9afde209544a_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNi01LTEtMS02NjkxMA_35e2dc2e-8e37-467d-8b69-83c8b491d8ad">245,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5053a77df20d49178d0acdd07e80fb9f_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNi03LTEtMS02NjkxMA_e1b51453-9884-42ad-be42-4dd5149a2772">159,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieef521b6cb2644d59433c4a98ac67edb_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNi05LTEtMS02NjkxMA_d94c034b-d28c-47ef-8050-ef2e4819c423">306,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4dfdc7272dc4a849a6c7e48dfcc4f74_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNi0xMS0xLTEtNjY5MTA_6a709b2e-d39a-4b4f-969d-79c1c52d07d3">222,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5af61dbd97844f2cb160b48a3a35d4e8_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNi0xMy0xLTEtNjY5MTA_efa86eca-b6b2-4096-804f-de9a16ebf36c">663,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e55c1b3affc496aa10cbd0b6538c957_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNi0xNS0xLTEtNjY5MTA_bd4df381-bcd4-46f3-9655-a7b81099d1ff">437,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to the Remaining Performance Obligations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with a term greater than one year, we have allocated approximately $<ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfNDM0OQ_74e51dde-b54b-497a-8f49-a19a6e418689">69.1</ix:nonFraction> million of transaction price to performance obligations that are unsatisfied as of September&#160;30, 2022. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately <ix:nonFraction unitRef="number" contextRef="iba9bddef4c7947819c9a666d386809f7_I20220930" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfNDk2OA_50c8d199-683a-442d-b37f-767a7aa67961">37</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i7717c83097bb48c298d7cd0c08b877cc_I20220930" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfNDk3Mg_e2785dac-258d-4411-b4ac-67f876b6874d">85</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i622d6d21df814836a91bfc0e4f88e5e0_I20220930" decimals="2" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfNDk3OQ_5908af02-d128-4165-b396-fe869796bf91">98</ix:nonFraction>% of these remaining performance obligations by December 31, 2022, 2023 and 2024, respectively, with the remaining balance to be recognized thereafter. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be less or greater than this estimate and the timing of recognition may not be as expected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfOTQ4OA_c16267b8-c205-48ea-8650-dd645528132c" continuedAt="id536db6d793f402a91b42c7d96421592" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of September&#160;30, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOmUyYjk0N2M4NGQ5YzQxMGViMDhlMjBkZDgzNjAxNThmL3RhYmxlcmFuZ2U6ZTJiOTQ3Yzg0ZDljNDEwZWIwOGUyMGRkODM2MDE1OGZfMS0xLTEtMS02NjkxMA_ef5ebf8a-c322-4d9e-95c4-5fd82235a5f8">185,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:AccountsNotesAndLoansReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOmUyYjk0N2M4NGQ5YzQxMGViMDhlMjBkZDgzNjAxNThmL3RhYmxlcmFuZ2U6ZTJiOTQ3Yzg0ZDljNDEwZWIwOGUyMGRkODM2MDE1OGZfMS0zLTEtMS02NjkxMA_2a7ca601-19eb-43b7-b9b5-4a944ab8f906">129,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOmUyYjk0N2M4NGQ5YzQxMGViMDhlMjBkZDgzNjAxNThmL3RhYmxlcmFuZ2U6ZTJiOTQ3Yzg0ZDljNDEwZWIwOGUyMGRkODM2MDE1OGZfMi0xLTEtMS02NjkxMA_b59bb1d3-da8c-42c1-ae0f-0bfd42004aab">884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOmUyYjk0N2M4NGQ5YzQxMGViMDhlMjBkZDgzNjAxNThmL3RhYmxlcmFuZ2U6ZTJiOTQ3Yzg0ZDljNDEwZWIwOGUyMGRkODM2MDE1OGZfMi0zLTEtMS02NjkxMA_5ff71e38-ce98-431d-951c-3ed932f1dda1">4,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOmUyYjk0N2M4NGQ5YzQxMGViMDhlMjBkZDgzNjAxNThmL3RhYmxlcmFuZ2U6ZTJiOTQ3Yzg0ZDljNDEwZWIwOGUyMGRkODM2MDE1OGZfMy0xLTEtMS02NjkxMA_a11c78f3-2e50-41a4-8cf0-32f119d8f7a7">7,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOmUyYjk0N2M4NGQ5YzQxMGViMDhlMjBkZDgzNjAxNThmL3RhYmxlcmFuZ2U6ZTJiOTQ3Yzg0ZDljNDEwZWIwOGUyMGRkODM2MDE1OGZfMy0zLTEtMS02NjkxMA_d575817f-094a-4f3e-8a8e-e5dea6c97e79">11,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOmUyYjk0N2M4NGQ5YzQxMGViMDhlMjBkZDgzNjAxNThmL3RhYmxlcmFuZ2U6ZTJiOTQ3Yzg0ZDljNDEwZWIwOGUyMGRkODM2MDE1OGZfNC0xLTEtMS02NjkxMA_53eb670d-b796-41c8-9d05-56bdf7ef4edc">3,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOmUyYjk0N2M4NGQ5YzQxMGViMDhlMjBkZDgzNjAxNThmL3RhYmxlcmFuZ2U6ZTJiOTQ3Yzg0ZDljNDEwZWIwOGUyMGRkODM2MDE1OGZfNC0zLTEtMS02NjkxMA_5d6cf9c0-50f1-4dcd-9a90-422ed1f7208b">4,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if5f203a46c5d4c20bcdf86d377672791"><ix:continuation id="id536db6d793f402a91b42c7d96421592"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the nine months ended September 30, 2022 are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:102.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjMyODZiZDRlODBiMDQyYmRhNDFkYzhjN2RlMDc4NGI3L3RhYmxlcmFuZ2U6MzI4NmJkNGU4MGIwNDJiZGE0MWRjOGM3ZGUwNzg0YjdfMS0xLTEtMS02NjkxMA_5a7384d4-6d74-48b9-986e-069db310fd72">16,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjMyODZiZDRlODBiMDQyYmRhNDFkYzhjN2RlMDc4NGI3L3RhYmxlcmFuZ2U6MzI4NmJkNGU4MGIwNDJiZGE0MWRjOGM3ZGUwNzg0YjdfMi0xLTEtMS02NjkxMA_6b4d5052-d75c-40eb-a773-3a41a4ae2352">11,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjMyODZiZDRlODBiMDQyYmRhNDFkYzhjN2RlMDc4NGI3L3RhYmxlcmFuZ2U6MzI4NmJkNGU4MGIwNDJiZGE0MWRjOGM3ZGUwNzg0YjdfMy0xLTEtMS02NjkxMA_a04d5e42-c5b6-42cd-9980-77ec6ebc5a27">5,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjMyODZiZDRlODBiMDQyYmRhNDFkYzhjN2RlMDc4NGI3L3RhYmxlcmFuZ2U6MzI4NmJkNGU4MGIwNDJiZGE0MWRjOGM3ZGUwNzg0YjdfNC0xLTEtMS02NjkxMA_74af4943-914b-4111-b0bb-0c14d0300846">10,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in a previous period was $<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfNzE3Nw_8c9cfa59-a3b9-4a7d-b55a-aed7044ed6f3">10.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfNzE4NA_7d47d725-6b33-4788-b56d-5a551da3351c">56.4</ix:nonFraction>&#160;million for the three and nine months ended September 30, 2022, due primarily to net gain share as well as changes in other estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Cost Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of September&#160;30, 2022 and December 31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i8df943109acf43b1beae85454cf38885_I20220930" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfNzgzNA_51f5a9b1-7cb5-463d-a93a-d77f27e734ac">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9767cf7dd34a49aca4c626b25a0137e8_I20211231" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfNzg0MQ_a39453b0-4ef5-4388-a277-0ff4f2016d84">5.2</ix:nonFraction> million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortiza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tion expense of $<ix:nonFraction unitRef="usd" contextRef="i1edb69a16cb6459691cb056b595c5885_D20220701-20220930" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfODA1NQ_ed06f713-0e00-4cbf-b0d0-8a55cd4f3a25">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id614a39adbe643b4aa5b5af050be49fd_D20220101-20220930" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfODA2Mg_784fbb55-3003-4fb9-8c30-7c2ef3eb3fbc">2.0</ix:nonFraction> million for the three and nine months ended September 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i632714a677b64a15983dae3dbbde9997_D20210701-20210930" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfODA5MQ_6adb04ae-9211-4314-b33f-8b9702edd811">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7383d04203184df1accf6ee901f03030_D20210101-20210930" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfODA5OA_5d682521-9582-4ace-9d87-49e5dd1d934c">1.3</ix:nonFraction> million for the three and nine months ended September 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our platform and operations arrangements, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of September&#160;30, 2022 and December 31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="id740d1bbcfed47e0aaa7894c6b8e4f13_I20220930" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfODg0MQ_4c493ec9-77ce-4db1-9011-0c6f36374980">21.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i60bde46c214b463b872f8fed94fe0fd3_I20211231" decimals="-5" name="us-gaap:CapitalizedContractCostNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfODg0OA_498eacdd-9f6f-4abe-b05f-3250937cda56">27.4</ix:nonFraction> million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense including the acceleration of amortization of contract costs for certain customers of $<ix:nonFraction unitRef="usd" contextRef="id8d6b3d636ef48789c73c450718514b3_D20220701-20220930" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfOTE0NQ_717d2f1e-1b48-43e2-aad5-20cd1eb78d27">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if801b9c8aab245d5b731f391ad5348b2_D20220101-20220930" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfOTE1Mg_c99740f5-3c6d-44d9-bbe9-5be7eea7244c">12.8</ix:nonFraction> million for the three and nine months ended September 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i21ab12969f634adfa6cdd08a0aaf4fad_D20210701-20210930" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfOTE4MQ_f3649059-4c40-4e28-845e-bbdb10096a8e">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5994da9b8f9641029f5d64b5faece604_D20210101-20210930" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfOTE4OA_f7fc2dad-6b3a-45d8-ba3a-4802afb4e23e">8.6</ix:nonFraction> million for the three and nine months ended September 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be the shorter of the contract term or <ix:nonNumeric contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" name="us-gaap:CapitalizedContractCostAmortizationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfOTM3NA_d13fc8cc-f84c-47a7-995b-dcdae8bbaeb0">five years</ix:nonNumeric>. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7. <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:CreditLossFinancialInstrumentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMzAwMg_d80a9861-9c7c-433d-b06c-ad494013daae" continuedAt="ifa979643fb874ffbafa9d26657482cb1" escape="true">Credit Losses </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ifa979643fb874ffbafa9d26657482cb1" continuedAt="ia46ce1f6892d44bb8cf9a744ea6c8e9a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic and current inflationary pressures on our customers&#8217; and other third parties&#8217; ability to pay. We did not observe notable increases in delinquencies during the three and nine months ended September 30, 2022. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the three and nine months ended September 30, 2022.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable from Revenue Transactions</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#8217;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#8217;s consolidated balance sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia46ce1f6892d44bb8cf9a744ea6c8e9a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets as of&#160;September&#160;30, 2022,&#160;<ix:nonFraction unitRef="number" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="2" name="evh:FinancingReceivablePercentNotPastDue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMjM2OQ_86601d28-5948-46af-9234-946b14fbac31">83</ix:nonFraction>% were current, <ix:nonFraction unitRef="number" contextRef="ibff905a18b1f40209cb5ca0efef086b5_I20220930" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMjM4Ng_b671c353-e398-470f-a455-886e6dae63ec">9</ix:nonFraction>%&#160;were past due less than 60 days, with <ix:nonFraction unitRef="number" contextRef="i5637ed5c72c44080978d3cd0ea34cfda_I20220930" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMjQyNw_d301c781-025b-469d-93c2-f15da2c37439">11</ix:nonFraction>% past due less than 120 days and at December 31, 2021, <ix:nonFraction unitRef="number" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="2" name="evh:FinancingReceivablePercentNotPastDue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMjQ4NA_c1b80880-9346-4242-8ec4-88713b2eccf8">90</ix:nonFraction>% was current, <ix:nonFraction unitRef="number" contextRef="i04596f10134947b6acb9bac1698947da_I20211231" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMjUwMA_455279ca-961a-4b27-944f-1539f84419b0">2</ix:nonFraction>% was past due less than 60 days, with <ix:nonFraction unitRef="number" contextRef="i124df651628843dabf0bf39cef2a4f10_I20211231" decimals="2" name="us-gaap:FinancingReceivablePercentPastDue1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMjU0MA_3b4d54a3-0cdc-4c8b-8b51-e3f1985d4dc4">3</ix:nonFraction>% past due less than 120 days. As of&#160;September&#160;30, 2022 and December 31, 2021, in total we reported on the consolidated balance sheet&#160;$<ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMjY1OQ_a2a0a9b3-d92c-447f-baf8-0c8fb5560b08">201.5</ix:nonFraction> million&#160;and $<ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMjY2Ng_03272d06-fe1d-43c3-833c-4d1a5fc563f6">171.5</ix:nonFraction>&#160;million of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other assets, net of allowances of&#160;$<ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMjc5OQ_1eaf78bd-38a5-4bed-a83b-af42a00a2682">9.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMjgwNg_88d90117-a0bc-420a-a966-a798007f4a7f">3.4</ix:nonFraction> million, respectively. <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMzAwMw_915d36ac-f5e8-4950-9811-8ad89de740c9" continuedAt="iee304fd3086b442085b39a32dcafc975" escape="true">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):</ix:nonNumeric></span></div><ix:continuation id="iee304fd3086b442085b39a32dcafc975"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RhYmxlOjc0NTQxOTQyZjY3MTRlYTQ5ZjIzNGNhZWNlMjJmYzdhL3RhYmxlcmFuZ2U6NzQ1NDE5NDJmNjcxNGVhNDlmMjM0Y2FlY2UyMmZjN2FfMi0xLTEtMS02NjkxMA_e874da1a-f6a2-4043-93f7-22357d9364c8">3,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcb7e5d5de6d4fb9bd1b47d49e170108_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RhYmxlOjc0NTQxOTQyZjY3MTRlYTQ5ZjIzNGNhZWNlMjJmYzdhL3RhYmxlcmFuZ2U6NzQ1NDE5NDJmNjcxNGVhNDlmMjM0Y2FlY2UyMmZjN2FfMi0zLTEtMS02NjkxMA_85e0cc7c-b175-44a9-bde0-2e29037e2377">7,056</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPG acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RhYmxlOjc0NTQxOTQyZjY3MTRlYTQ5ZjIzNGNhZWNlMjJmYzdhL3RhYmxlcmFuZ2U6NzQ1NDE5NDJmNjcxNGVhNDlmMjM0Y2FlY2UyMmZjN2FfMy0xLTEtMS03NTg3OA_a5ba634d-e12b-4f83-abbb-fea9415849a5">5,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RhYmxlOjc0NTQxOTQyZjY3MTRlYTQ5ZjIzNGNhZWNlMjJmYzdhL3RhYmxlcmFuZ2U6NzQ1NDE5NDJmNjcxNGVhNDlmMjM0Y2FlY2UyMmZjN2FfMy0zLTEtMS03NTg3OA_1090cb9f-6917-4506-8546-320eb76b995a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RhYmxlOjc0NTQxOTQyZjY3MTRlYTQ5ZjIzNGNhZWNlMjJmYzdhL3RhYmxlcmFuZ2U6NzQ1NDE5NDJmNjcxNGVhNDlmMjM0Y2FlY2UyMmZjN2FfMy0xLTEtMS02NjkxMA_f5cb19de-5c96-4d5b-a014-f098dc7ea631">1,134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RhYmxlOjc0NTQxOTQyZjY3MTRlYTQ5ZjIzNGNhZWNlMjJmYzdhL3RhYmxlcmFuZ2U6NzQ1NDE5NDJmNjcxNGVhNDlmMjM0Y2FlY2UyMmZjN2FfMy0zLTEtMS02NjkxMA_469ce924-f75c-40de-8c6b-3000753f3942">1,949</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge-offs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RhYmxlOjc0NTQxOTQyZjY3MTRlYTQ5ZjIzNGNhZWNlMjJmYzdhL3RhYmxlcmFuZ2U6NzQ1NDE5NDJmNjcxNGVhNDlmMjM0Y2FlY2UyMmZjN2FfNC0xLTEtMS02NzgzNA_59c12260-245a-41c5-bdd1-2a957851b4d5">422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RhYmxlOjc0NTQxOTQyZjY3MTRlYTQ5ZjIzNGNhZWNlMjJmYzdhL3RhYmxlcmFuZ2U6NzQ1NDE5NDJmNjcxNGVhNDlmMjM0Y2FlY2UyMmZjN2FfNC0zLTEtMS02NzgzNA_0ac7a671-7690-4cb6-8d29-9c10560d44c1">5,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RhYmxlOjc0NTQxOTQyZjY3MTRlYTQ5ZjIzNGNhZWNlMjJmYzdhL3RhYmxlcmFuZ2U6NzQ1NDE5NDJmNjcxNGVhNDlmMjM0Y2FlY2UyMmZjN2FfNC0xLTEtMS02NjkxMA_c8abfc32-1a2d-4988-a25f-42f550889c75">9,355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63b3ddd7486946c2a0a8151832317d14_I20210930" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RhYmxlOjc0NTQxOTQyZjY3MTRlYTQ5ZjIzNGNhZWNlMjJmYzdhL3RhYmxlcmFuZ2U6NzQ1NDE5NDJmNjcxNGVhNDlmMjM0Y2FlY2UyMmZjN2FfNC0zLTEtMS02NjkxMA_cc953e08-7cc1-43ce-be3b-81b2905a0cce">3,929</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Charge offs for the nine months ended September 30, 2021, are due to balances written-off that were previously fully reserved as part of the Passport transaction.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8.  <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfNjg1_64cd2db3-bbdf-4cee-9e2a-f1d0c02b8d18" continuedAt="i4d16291c9f0e4488918c4a7e83716e71" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i4d16291c9f0e4488918c4a7e83716e71"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfNjg3_b2f984d1-76ef-48b3-b05f-95cb149f8bd2" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5730da3ff5444c0fbe524c644c202af4_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfMS0xLTEtMS02NjkxMA_09a56522-0e72-41eb-9876-b2dd49f89694">27,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3e288bad13b4a5e8fbf6a82c2389ad6_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfMS0zLTEtMS02NjkxMA_c1fedc26-11b4-4ec7-95fc-99e63950a4bb">21,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5c4d433d31d4a2a84d11ae0257cc18f_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfMi0xLTEtMS02NjkxMA_239b6f93-6433-4ff6-94b2-b6c07246b7fb">4,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ebfbd6230a54574b1ed03cade006714_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfMi0zLTEtMS02NjkxMA_a84a635c-7e70-4eb8-bed5-755933361cad">3,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabc0377cf6c84950aafa636df7d7c185_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfMy0xLTEtMS02NjkxMA_69c11a69-6214-4788-9a2a-c61286376313">181,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id32484f46aaa490dafecdb5a20db36fc_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfMy0zLTEtMS02NjkxMA_32e322a7-d696-48e0-914b-87ab9eb7c578">159,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i311d2b7cdbe24f8ebdf190a94aa1332f_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfNC0xLTEtMS02NjkxMA_e69aa5de-23e4-49a4-a1eb-2a91d6ee26a8">23,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49599e7727614d2697e205fcf5b794f4_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfNC0zLTEtMS02NjkxMA_5ab0d0cf-67ad-452f-886d-41d1244984a6">15,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfNS0xLTEtMS02NjkxMA_67907508-7e30-4e3c-801e-8a54c8bd3abd">236,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfNS0zLTEtMS02NjkxMA_4c5500c4-66b0-4602-8a8c-8afefd5d6756">200,463</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfNi0xLTEtMS02NjkxMA_ff37573d-4502-4b3d-bc61-057e80b7847f">141,707</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfNi0zLTEtMS02NjkxMA_91e1df6a-1cc1-4f8b-a626-c5a1018631d0">119,098</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfNy0xLTEtMS02NjkxMA_053cc2c0-5938-4fa1-ae9f-a6cb95aaf2f5">94,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfNy0zLTEtMS02NjkxMA_052dd2c3-8725-44c2-9f4f-d2bbdb8b6c72">81,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalized $<ix:nonFraction unitRef="usd" contextRef="i216238f5c4204e818ee9557f67bc5b08_D20220701-20220930" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfMTM5_9ada03ba-008b-4700-8c54-75d57412d79e">8.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idadb3eda60994bfc9bf46cb46e81e8b4_D20220101-20220930" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfMTQ2_cc0b5eee-16ff-4b3f-acec-592366dd370e">21.5</ix:nonFraction> million for the three and nine months ended September 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i4ab5726f3d7c43e9b4c48c383620aa05_D20210701-20210930" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfMTc1_7bad5e54-70d7-490c-8903-1cb1c671170e">5.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i597e5acb0181498a985baa0c47467de9_D20210101-20210930" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfMTgy_9695ee68-a96d-4793-b6fe-a90b42455538">16.5</ix:nonFraction> million for the three and nine months ended September 30, 2021, respectively, of internal-use software development costs. The net book value of capitalized internal-use software development costs was $<ix:nonFraction unitRef="usd" contextRef="iabc0377cf6c84950aafa636df7d7c185_I20220930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfMzI5_23ab527d-40a7-4221-b66d-a6d25934088f">73.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id32484f46aaa490dafecdb5a20db36fc_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfMzM2_55b6620c-fc3f-410e-8979-1929c1532491">71.2</ix:nonFraction> million as of September&#160;30, 2022 and December 31, 2021, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfNDQ2_6b185cc9-b9b1-4581-8815-b6d6012e69c2">7.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfNDUz_d228e24c-eeaf-4909-a409-3a04231c1244">23.1</ix:nonFraction> million for the three and nine months ended September 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfNDgy_52bc6a15-5c3e-49f9-97d6-56562f6517f8">7.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfNDg5_734e4c9b-44c3-4c7d-831d-2a907f044c79">22.8</ix:nonFraction> million for the three and nine months ended September 30, 2021, respectively, of which amortization expense related to capitalized internal-use software development costs was $<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfNjEx_5be75d1b-56e3-418e-8d8d-da39d90da9ab">6.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfNjE4_5b1c2f75-2440-4291-80a4-dbd851e8fe56">19.6</ix:nonFraction> million for the three and nine months ended September 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfNjQ3_90684fb6-4379-48d4-b34a-21fa582d2819">6.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-5" name="us-gaap:CapitalizedComputerSoftwareAmortization1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfNjU0_f832d1af-c80b-415d-bb32-f0d1c0a72cf1">20.0</ix:nonFraction> million for the three and nine months ended September 30, 2021, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_67"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9.  <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMjkyOA_6f5ab9e4-5128-42b5-ba89-39ae72358dd1" continuedAt="i306209c83789493dbcebb27eaf79907b" escape="true">Goodwill and Intangible Assets, Net</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i306209c83789493dbcebb27eaf79907b" continuedAt="i9d0449344ba047e584dbb117ebea7f74"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="reporting_unit" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMzE3_a24f4fa5-771f-4062-9496-e22a16a37dad">three</ix:nonFraction> reporting units, each with </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9d0449344ba047e584dbb117ebea7f74" continuedAt="i5ba9a7748f6a4841ad857f28c82442cc"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual goodwill impairment review occurs on October 31 of each fiscal </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the three and nine months ended September 30, 2022</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We will perform our annual impairment test on October 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Goodwill Impairment Test</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest the fair value of any of our <ix:nonFraction unitRef="reporting_unit" contextRef="ic75e54e0b5564ba5bdf3845c85ae6efa_D20211001-20211031" decimals="INF" name="us-gaap:NumberOfReportingUnits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMTg4NA_fb82980a-8f04-4f7a-96d5-09064a651de8">three</ix:nonFraction> reporting units was below their respective carrying values. As a result, a quantitative goodwill impairment analysis was not required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMjkzMQ_5c075a6a-d6c4-496b-86e2-69da7cb5da1f" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b23b62d2314ba29f31148feecadf97_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMS0xLTEtMS02NjkxMA_80cefe02-a148-4915-9a30-25a188aadb8d">214,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9b3945ac9741d4843b49c10f8dcd40_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMS0zLTEtMS02NjkxMA_74b50f94-3011-486b-9c6c-337a88353d5b">211,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMS01LTEtMS02NjkxMA_fb048d8f-fa3f-4bfb-98b4-6fad24811ea1">426,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4dfdc7272dc4a849a6c7e48dfcc4f74_D20210101-20210930" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMi0xLTEtMS03NTA3MQ_ab5c9fd8-2a7e-4ca4-b529-810d9700b87d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e55c1b3affc496aa10cbd0b6538c957_D20210101-20210930" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMi0zLTEtMS03NTA2Mw_59661b2a-8074-414a-a180-2d96afaf2049">296,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMi01LTEtMS03NTA3OQ_b69a95c3-aae7-459a-931b-8e7b8b8f1aaf">296,597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieef521b6cb2644d59433c4a98ac67edb_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMi0xLTEtMS02NjkxMA_5a0fdce0-32d0-4299-a527-ecca6a8eaafd">104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5af61dbd97844f2cb160b48a3a35d4e8_D20220101-20220930" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMi0zLTEtMS02NjkxMA_600a1c42-5388-40c9-bfbd-946453f28335">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMi01LTEtMS02NjkxMA_025bd8f3-6cf0-4453-9cd7-83d6d4ee924c">104</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffa15ee70390496c89f205bdc8f3731b_I20220930" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMy0xLTEtMS02NjkxMA_386b3d97-6683-40c3-a066-a07ea1fc04b0">214,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i358169d308bf4641ad0dca36755b47d1_I20220930" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMy0zLTEtMS02NjkxMA_e04793f4-6834-47c6-a8cc-bfca04bb9f62">508,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMy01LTEtMS02NjkxMA_b61b59dd-508c-4a56-ba2d-e76d23a2aa18">722,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0291d88c45549ebb15674a1bf82c1a2_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfNS0xLTEtMS02NjkxMA_dbe3665b-45fa-4d81-a63b-07d70092f8b2">214,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b7c2c9eb4d24e95a2fb3597a736a55d_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfNS0zLTEtMS02NjkxMA_6308fab7-e31b-4338-9d9a-257ca29a5c2f">134,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcb7e5d5de6d4fb9bd1b47d49e170108_I20201231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfNS01LTEtMS02NjkxMA_82f61258-1587-4730-a777-0fa090afdb78">349,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4dfdc7272dc4a849a6c7e48dfcc4f74_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfNi0xLTEtMS02NjkxMA_1d3f8bdb-a111-4985-b63a-78336bb0b9b7">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e55c1b3affc496aa10cbd0b6538c957_D20210101-20210930" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfNi0zLTEtMS02NjkxMA_76078246-11c5-4cfe-b059-65187bfa8851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfNi01LTEtMS02NjkxMA_04708167-b821-42b6-9632-334631447ec7">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1859c2ae121649f09ad595e92fb8e96c_I20210930" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfNy0xLTEtMS02NjkxMA_fd253cf7-5cab-4878-8bdc-41d761189f02">214,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44a8b1c85fc24294af85eb3f3327612d_I20210930" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfNy0zLTEtMS02NjkxMA_d4d92524-0a9a-4ec6-928b-c71d6bc68aef">134,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63b3ddd7486946c2a0a8151832317d14_I20210930" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfNy01LTEtMS02NjkxMA_58f59b7f-d22f-4044-8ef2-bef8e2971de9">349,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $<ix:nonFraction unitRef="usd" contextRef="idcb7e5d5de6d4fb9bd1b47d49e170108_I20201231" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMjI0OQ_23658686-52b6-45ac-8d68-3386d01d8373"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMjI0OQ_315f8c02-6299-40e1-95a0-7c6b2b058ed6">575.5</ix:nonFraction></ix:nonFraction> million as of both December 31, 2021 and 2020.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Goodwill acquired from the addition of IPG in the third quarter of 2022.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i5ba9a7748f6a4841ad857f28c82442cc"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net</span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i1e0cbae1eefd4e7390eb22bfa164a4b8"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) as of September&#160;30, 2022 and December&#160;31, 2021 are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:72.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:46.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:45.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ifaa4680cab4245c48c966ba93e130b60_D20220101-20220930" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMi0xLTEtMS02NjkxMA_463b69c2-c129-46c9-ab11-e35ff460bba9">13.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84135b0576f249ae8003b7e81a024ba5_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMi0zLTEtMS02NjkxMA_28ce3999-2c0a-46aa-8505-dce608f5b703">43,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84135b0576f249ae8003b7e81a024ba5_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMi01LTEtMS02NjkxMA_3dee55d8-215f-4a22-8c47-c39030223a3b">9,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84135b0576f249ae8003b7e81a024ba5_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMi03LTEtMS02NjkxMA_0806a3ed-8203-419c-ae5d-375775717dfd">33,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic68a9db5aae1478fadff12a779202797_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMi05LTEtMS02NjkxMA_cc564afc-e40e-4759-99c7-b294eb4be2d7">12.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if41217b3022a48ed94e3723c3e0071e5_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMi0xMS0xLTEtNjY5MTA_9c82ed26-f05a-44c1-b77c-bd2f4bb6244e">25,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if41217b3022a48ed94e3723c3e0071e5_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMi0xMy0xLTEtNjY5MTA_2455fde7-31f3-4d1c-a9b7-5c8c15f367f9">7,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if41217b3022a48ed94e3723c3e0071e5_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMi0xNS0xLTEtNjY5MTA_529a7903-e556-469b-a024-adf3b24415a8">18,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie6843d02651b4eb19d0b68edf6087afd_D20220101-20220930" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMy0xLTEtMS02NjkxMA_beba97bb-8f44-445f-95bf-c6dd4b2e124e">16.0</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25182b4f6fce43fda0e5ebbe2cc7f240_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMy0zLTEtMS02NjkxMA_98105468-ec9c-4168-bf01-998620151f8e">465,019</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25182b4f6fce43fda0e5ebbe2cc7f240_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMy01LTEtMS02NjkxMA_611011b0-ce91-4055-8853-19e6c5a56745">86,623</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25182b4f6fce43fda0e5ebbe2cc7f240_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMy03LTEtMS02NjkxMA_95187c19-45ec-4f7f-9ed1-7cd55b3c4c04">378,396</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i59ff2088dd3d487c93a983e025043b03_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMy05LTEtMS02NjkxMA_eafc9251-0566-42ce-b1c8-4633d4f3899a">14.9</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0792eb2a4584a8b95e0d513e6752d62_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMy0xMS0xLTEtNjY5MTA_d079c6ab-6abc-4f2d-b84e-2822be3038e0">311,019</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0792eb2a4584a8b95e0d513e6752d62_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMy0xMy0xLTEtNjY5MTA_07c88f58-9d80-4209-abd3-16c7441e0a41">72,697</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0792eb2a4584a8b95e0d513e6752d62_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMy0xNS0xLTEtNjY5MTA_8e1e585a-ff64-4d34-918c-c3cb52862251">238,322</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia71efd024b264a23aa0d21ad75741277_D20220101-20220930" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNC0xLTEtMS02NjkxMA_863cb776-822f-43da-9fe0-f72fc421401d">2.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ec2a15830e4d0e87fe2230ea0e7474_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNC0zLTEtMS02NjkxMA_58ee607e-306c-467d-a828-a9648e992d8d">111,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ec2a15830e4d0e87fe2230ea0e7474_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNC01LTEtMS02NjkxMA_e2483fc1-7dfd-4adb-ad1a-8e31761a8245">78,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ec2a15830e4d0e87fe2230ea0e7474_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNC03LTEtMS02NjkxMA_1dcf7d51-5e7f-420d-bf34-b41cda145f3d">33,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6cdb2defd328413a8f5c7e2f8ae2c1f0_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNC05LTEtMS02NjkxMA_cb306163-730b-4f8c-bd6f-350b27bc5293">2.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58352bc33d9d47e7b266d367548f4196_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNC0xMS0xLTEtNjY5MTA_cb1a4028-235a-4b7a-9fde-95ac1badc82e">87,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58352bc33d9d47e7b266d367548f4196_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNC0xMy0xLTEtNjY5MTA_cdb7e4b3-5deb-4e05-90a3-bbe68cfc232e">73,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58352bc33d9d47e7b266d367548f4196_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNC0xNS0xLTEtNjY5MTA_18b42cec-9a01-41a5-93d5-1901730f717a">14,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7bd97829624644b3a76e8a12f04957c7_D20220101-20220930" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNS0xLTEtMS02NjkxMA_f84f8d08-4919-4dfa-9bde-7c767c5be3a0">0.6</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a0859bcb414bc7b9fafe316f673bca_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNS0zLTEtMS02NjkxMA_a1f6f567-1bc7-47b1-bc08-b931f30c8964">1,218</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a0859bcb414bc7b9fafe316f673bca_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNS01LTEtMS02NjkxMA_c4229759-595f-4ed9-a0cf-38c4f0c48279">1,100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a0859bcb414bc7b9fafe316f673bca_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNS03LTEtMS02NjkxMA_55e88f9e-5f9c-47b2-b518-bbc3c718e885">118</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic0f42e14adcf450990dc48ddf76f1496_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNS05LTEtMS02NjkxMA_b01e3ffb-4c87-4623-afa4-b58bc45156cb">1.3</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0fd0d41813c458fa01a9b4a323d16c6_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNS0xMS0xLTEtNjY5MTA_1a7cc326-1ee8-4a57-9757-c6086ae61b2d">1,218</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0fd0d41813c458fa01a9b4a323d16c6_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNS0xMy0xLTEtNjY5MTA_6daf6af7-7b07-41a7-a0a6-f977cbf8ee4e">950</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0fd0d41813c458fa01a9b4a323d16c6_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNS0xNS0xLTEtNjY5MTA_4841d1b7-5e40-4f7c-b9b7-9869b00ab819">268</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1df90080b3ad4844b8125e0a4c7547e9_D20220101-20220930" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNi0xLTEtMS02NjkxMA_f1c467ae-bb8a-4893-bc78-79e7c09f3db6">1.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c22c7e8a0aa46c294ef5bcb1985120c_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNi0zLTEtMS02NjkxMA_d1ef59b2-1291-4676-9b21-5daaa0aa0857">16,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c22c7e8a0aa46c294ef5bcb1985120c_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNi01LTEtMS02NjkxMA_aa243966-c4e6-4dad-8c5c-beee383553de">10,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c22c7e8a0aa46c294ef5bcb1985120c_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNi03LTEtMS02NjkxMA_3108f620-ee4f-4349-85b7-b1e71a64ffaf">5,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie029cabfd7164a66bdeb9807be351813_D20210101-20211231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNi05LTEtMS02NjkxMA_ad024bca-5829-490b-95eb-d80348d4a1b0">2.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f3b6e992ace40abb1f986f35d3efc3c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNi0xMS0xLTEtNjY5MTA_ccd452c8-b6fb-410f-b1ea-6e141ed3bb5d">16,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f3b6e992ace40abb1f986f35d3efc3c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNi0xMy0xLTEtNjY5MTA_172685b9-5d5e-46e2-a268-8c5c2e9f6879">7,874</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f3b6e992ace40abb1f986f35d3efc3c_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNi0xNS0xLTEtNjY5MTA_9c1fc180-c572-4774-806f-fdc13f97c8b5">8,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNy0zLTEtMS02NjkxMA_ff4b57b3-e764-48a9-b29c-98a2c5e4d0a3">638,212</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNy01LTEtMS02NjkxMA_ea08ed5d-3052-4e5e-a29c-9c201860fc3f">186,814</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNy03LTEtMS02NjkxMA_148de35c-51d6-4b31-910b-bb61feb88897">451,398</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNy0xMS0xLTEtNjY5MTA_9f7243b7-f87b-4724-9b90-2a9b6d8dfb0b">442,376</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNy0xMy0xLTEtNjY5MTA_848880cb-5a5a-4498-bee5-c442735a6937">162,592</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNy0xNS0xLTEtNjY5MTA_96132551-e09f-4bd2-8515-a659fa0bab39">279,784</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMjQ5OA_47fdc3d7-654b-4405-8899-3ae25f2f4eff">9.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMjUwNQ_8dbb8e33-4400-43b4-bdad-b3b673dfd071">24.3</ix:nonFraction> million for the three and nine months ended September 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMjUzNA_4cfa7b3d-43a2-4115-b76b-6c19f365fd8d">7.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMjU0MQ_393a05b4-cc6b-419f-8a09-191070f802dc">22.1</ix:nonFraction> million for the three and nine months ended September 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMjkyMQ_551b8a75-4657-42d4-8847-e1b2c2d72884" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of September&#160;30, 2022, is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:478.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjk3Yjk0ZjI2ZTI0MjQxNDNhNTQxYjI0MDU3Y2EzNDBhL3RhYmxlcmFuZ2U6OTdiOTRmMjZlMjQyNDE0M2E1NDFiMjQwNTdjYTM0MGFfMC0xLTEtMS02NjkxMA_07a4f6b3-7c3a-4b2b-a05d-94355868cc2f">10,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjk3Yjk0ZjI2ZTI0MjQxNDNhNTQxYjI0MDU3Y2EzNDBhL3RhYmxlcmFuZ2U6OTdiOTRmMjZlMjQyNDE0M2E1NDFiMjQwNTdjYTM0MGFfMS0xLTEtMS02NjkxMA_ad4b946e-7774-49d1-986c-d8c6e9e3f0ca">40,487</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjk3Yjk0ZjI2ZTI0MjQxNDNhNTQxYjI0MDU3Y2EzNDBhL3RhYmxlcmFuZ2U6OTdiOTRmMjZlMjQyNDE0M2E1NDFiMjQwNTdjYTM0MGFfMi0xLTEtMS02NjkxMA_e498ee66-46fa-43bd-acac-6b55605ccc41">34,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjk3Yjk0ZjI2ZTI0MjQxNDNhNTQxYjI0MDU3Y2EzNDBhL3RhYmxlcmFuZ2U6OTdiOTRmMjZlMjQyNDE0M2E1NDFiMjQwNTdjYTM0MGFfMy0xLTEtMS02NjkxMA_2929b9e2-c6af-4f6d-a1b1-f14e5d70f214">33,057</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjk3Yjk0ZjI2ZTI0MjQxNDNhNTQxYjI0MDU3Y2EzNDBhL3RhYmxlcmFuZ2U6OTdiOTRmMjZlMjQyNDE0M2E1NDFiMjQwNTdjYTM0MGFfNC0xLTEtMS02NjkxMA_0e73cdc6-0413-4e7f-b0f3-af53c5f7fe95">32,880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="evh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjk3Yjk0ZjI2ZTI0MjQxNDNhNTQxYjI0MDU3Y2EzNDBhL3RhYmxlcmFuZ2U6OTdiOTRmMjZlMjQyNDE0M2E1NDFiMjQwNTdjYTM0MGFfNS0xLTEtMS02NjkxMA_ea86a4be-27e4-4ccb-9f7e-debe70cd0ebb">299,751</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjk3Yjk0ZjI2ZTI0MjQxNDNhNTQxYjI0MDU3Y2EzNDBhL3RhYmxlcmFuZ2U6OTdiOTRmMjZlMjQyNDE0M2E1NDFiMjQwNTdjYTM0MGFfNi0xLTEtMS02NjkxMA_854e0cd5-9451-4bc1-b917-2e261738e3e8">451,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#8217; carrying value. We did not identify any circumstances during&#160;the three and nine months ended September 30, 2022, that would require an impairment test for our intangible assets.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="i4a25f060abc946f28c4a0095422c2513_70"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10.  <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTc3MTE_3f122f8b-5b15-4c66-ba09-c234cda7c3bf" continuedAt="ia61c475fda8c4fdfb8672cf2295930ea" escape="true">Long-term Debt</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ia61c475fda8c4fdfb8672cf2295930ea" continuedAt="i53ce15ca6f7144f29583843e8931ca02"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022 (&#8220;IPG Closing Date&#8221;), the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent and revolver agent, together with the Company (the &#8220;2022 Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial term loan in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="i23031c0b6b3349ac87a0dd3718ded62f_I20220801" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM1ODMy_3f32bbdd-5b2c-404a-ade9-58fa288fbb6e">175.0</ix:nonFraction>&#160;million (the &#8220;Initial Term Loan Facility&#8221;) and (ii) a revolving credit facility in the aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="if02e0ede9ff94b57bd4e150fe4f1c424_I20220801" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM1ODQ4_ecd17bb4-181a-48d7-89a1-02e58f249292">50.0</ix:nonFraction>&#160;million, to be determined by reference to the lesser of $<ix:nonFraction unitRef="usd" contextRef="if02e0ede9ff94b57bd4e150fe4f1c424_I20220801" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM2NDcw_962aaab0-c0bd-4342-a4a1-082540cdd01f">50.0</ix:nonFraction>&#160;million and a borrowing base (the &#8220;Revolving Facility&#8221; and, together with the Initial Term Loan Facility, the &#8220;Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrowers borrowed the loan under the Initial Term Loan Facility on August 1, 2022 (the &#8220;Initial Term Loan&#8221;), and also borrowed $<ix:nonFraction unitRef="usd" contextRef="ib85258a5944847a799568304dbd3b847_D20220801-20220801" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM2NDU1_9c949999-92a7-4853-9ebe-75368f8d3af1">50.0</ix:nonFraction>&#160;million under the Revolving Facility on the IPG Closing Date. The Credit Facilities are guaranteed by the Company and the Company&#8217;s domestic subsidiaries, subject to certain exceptions. The Credit Facilities are secured by a first priority security interest in all of the capital stock of each borrower and guarantor (other than the Company) and substantially all of the assets of each borrower and guarantor, subject to certain exceptions. The Initial Term Loan and loans under the Revolving Facility will mature on the date that is the earliest of (a) August 1, 2027, (b) the date on which all amounts outstanding under the 2022 Credit Agreement have been declared or have automatically become due and payable under the terms of the Credit Agreement and (c) the date that is ninety-one (<ix:nonFraction unitRef="day" contextRef="i397f99c968184e23a3239fd5df224e34_D20220801-20220801" decimals="INF" name="evh:DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNDk0NzgwMjM1MjAwMA_8a9c65b4-ca63-4f54-90c4-576c7b6e4e76">91</ix:nonFraction>) days prior to the maturity date of any Junior Debt (as defined in the 2022 Credit Agreement) unless certain liquidity conditions are satisfied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds of the Initial Term Loan and Revolving Facility were used to finance the IPG transaction and fund fees and expenses incurred in connection therewith and thereafter may be used to fund acquisitions, ongoing working capital needs and other growth capital investments and to pay fees and expenses in connection therewith. The interest rate for each loan under the Credit Facilities is calculated, at the option of the Borrowers, (a) in the case of a Term Loan, at either the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus <ix:nonFraction unitRef="number" contextRef="ia09ce527d9154016aed6990fcdea728d_D20220801-20220801" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM3NzM2_7c11899b-de79-4158-b667-dbfbd0b114f7">5.50</ix:nonFraction>%, or the base rate plus <ix:nonFraction unitRef="number" contextRef="i023a2e0781824e51aac26656357a04e5_D20220801-20220801" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM3NzQz_ca1a5f7b-0618-4c07-ae5a-66658fbf821a">4.50</ix:nonFraction>% and (b) in the case of a Revolving Loan, at either the Adjusted Term SOFR Rate plus <ix:nonFraction unitRef="number" contextRef="i3728ee01b28446c5b8e4e913f63db0c1_D20220801-20220801" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM3NzY0_1cf74287-7e6b-49f5-856b-fd1ecfa5d328">3.50</ix:nonFraction>%, or the base rate plus <ix:nonFraction unitRef="number" contextRef="ia11fc3353efe46e19266ef78af24da63_D20220801-20220801" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM3Nzc3_fa867048-ef0c-4efa-9b6f-feed6c41aa5a">2.50</ix:nonFraction>%. A commitment fee of (a) <ix:nonFraction unitRef="number" contextRef="i397f99c968184e23a3239fd5df224e34_D20220801-20220801" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM3NzUw_42a2d3c7-36c4-4dc2-bfef-254c290f1b66">2.00</ix:nonFraction>% of the aggregate amount of the commitments in respect of the Term Loan Facility as of the closing and (b) <ix:nonFraction unitRef="number" contextRef="ib85258a5944847a799568304dbd3b847_D20220801-20220801" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM3NzU3_3835d48d-dda5-4aaf-9932-adddcdc891a2">2.00</ix:nonFraction>% of the aggregate amount of the commitments in respect of the Revolving Facility was paid as of the closing. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="i8f90d550a67b49a1b9b6999f0941d947_D20220701-20220930" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM3NzMw_66445607-7ecf-4ad0-92be-8ae09092acd8"><ix:nonFraction unitRef="usd" contextRef="i89cb6508f7a645e3b79e3ad7df4206de_D20220101-20220930" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM3NzMw_f00e4ead-5d45-4a86-9181-defc3d1cc54b">2.9</ix:nonFraction></ix:nonFraction>&#160;million in interest expense related to our 2022 Credit Agreement for the three and nine months ended September 30, 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts outstanding under the Credit Facility may be prepaid at the option of the Company subject to applicable premiums and a call protection premium payable on the amount prepaid in certain instances as follows: (1) <ix:nonFraction unitRef="number" contextRef="ia44b9d3c20ff4e6cb60de6ff8ecd5783_D20220801-20220801" decimals="INF" name="evh:DebtInstrumentPrepaymentPenaltyPeriodOnePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM2NDQw_db6bd4b2-49a6-431a-ab65-bbdfd2662e7c">3.00</ix:nonFraction>% of the principal amount so prepaid after the closing but prior to the first anniversary of the IPG Closing Date; (2) <ix:nonFraction unitRef="number" contextRef="ia44b9d3c20ff4e6cb60de6ff8ecd5783_D20220801-20220801" decimals="INF" name="evh:DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM2NDQ3_b59d54d2-4c3c-4559-8840-d8f68fb50728">2.00</ix:nonFraction>% of the principal amount so prepaid after the first anniversary of the closing but prior to the second anniversary of the IPG Closing Date; (3) <ix:nonFraction unitRef="number" contextRef="ia44b9d3c20ff4e6cb60de6ff8ecd5783_D20220801-20220801" decimals="INF" name="evh:DebtInstrumentPrepaymentPenaltyPeriodThreePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM2NDI2_e950375f-bde5-4fcf-bf52-352686183011">1.00</ix:nonFraction>% of the principal amount so prepaid after the second anniversary of the closing but prior to the third anniversary of the IPG Closing Date; and (4) <ix:nonFraction unitRef="number" contextRef="ia44b9d3c20ff4e6cb60de6ff8ecd5783_D20220801-20220801" decimals="INF" name="evh:DebtInstrumentPrepaymentPenaltyPeriodFourPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM2NDMz_613ad07b-c007-4d77-a42f-40f213caa34e">0.00</ix:nonFraction>% of the principal amount so prepaid on or after the third anniversary of the IPG Closing Date. Amounts outstanding under the Credit Facility are subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facilities contain customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company is required to comply at certain times with certain financial covenants comprised of a minimum liquidity test commencing upon closing of the Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending September 30, 2022. If an event of default occurs, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Credit Facilities. We incurred $<ix:nonFraction unitRef="usd" contextRef="if44e132eb50c4b2b961cecf1fb497c82_I20220801" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM2MzIz_419780e6-42b2-4e19-bfac-94739669fe1e">5.3</ix:nonFraction>&#160;million of debt issuance costs in connection with this Credit Agreement, which was included in long-term debt, net of discount on our consolidated balance sheets and amortized into interest expense over the life of the agreement. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="i8f90d550a67b49a1b9b6999f0941d947_D20220701-20220930" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM2NDIw_1a33688a-df47-4f27-ab60-802dcf65e414"><ix:nonFraction unitRef="usd" contextRef="i89cb6508f7a645e3b79e3ad7df4206de_D20220101-20220930" decimals="-5" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM2NDIw_3fdc9130-5855-4927-9e18-45d79fb50d09">0.2</ix:nonFraction></ix:nonFraction>&#160;million in interest expense related to the amortization of the debt discount and the issuance costs for the three and nine months ended September 30, 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i0e534dd28b704e32ae748c0e79ebc74b_I20200831" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNzg_b2250822-d64b-4af5-95af-e8dc4c836da3">117.1</ix:nonFraction>&#160;million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i0e534dd28b704e32ae748c0e79ebc74b_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTE1_1b14e0e4-3216-4d12-aaa6-42c850c9d277">3.50</ix:nonFraction>% Convertible Senior Notes due 2024 (the &#8220;2024 Notes&#8221;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $<ix:nonFraction unitRef="usd" contextRef="i971d328b42fe456798f158d581d7e9f1_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMzMz_1e0ecd06-bdb4-4409-b52d-4441fcef9932">84.2</ix:nonFraction> million aggregate principal amount of 2024 Notes in exchange for $<ix:nonFraction unitRef="usd" contextRef="ib6070c04ec514eb1b72630be44af9d9d_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNDAx_71aad370-5ab5-47a2-bdd2-338ed77db3ef">84.2</ix:nonFraction> million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $<ix:nonFraction unitRef="usd" contextRef="i0b673721ad2140dc92b0e7de4a1c58b1_D20200801-20200831" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNDkw_fcd624bc-8326-4db4-ae9c-48a47b62fbef">2.5</ix:nonFraction>&#160;million, and issued $<ix:nonFraction unitRef="usd" contextRef="i173d3fd170d1453abafbccbcc3311581_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTA1_b1c9c2f5-6f47-4386-9799-15057e18be55">32.8</ix:nonFraction> million aggregate principal amount of New Notes for cash at par. We incurred $<ix:nonFraction unitRef="usd" contextRef="i0e534dd28b704e32ae748c0e79ebc74b_I20200831" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTg1_d830bb43-f5f3-4f5a-9297-b487db53edcc">3.0</ix:nonFraction>&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes,  since this method was not materially different from the effective interest method. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i53ce15ca6f7144f29583843e8931ca02" continuedAt="i7232e8817b564458961b48a465e6249e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to <ix:nonFraction unitRef="number" contextRef="i0e534dd28b704e32ae748c0e79ebc74b_I20200831" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTA1Nw_a3ff8c3b-e432-4846-8448-0030be13d75d">3.50</ix:nonFraction>% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#8217;s Class A common stock. We recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="i247174c3d444488082c85f25293301f0_D20220701-20220930" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODQwMTUz_266f88de-de79-467c-9a38-3201f4a74f0c">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i703a0ee08afb4b42a1e3c2eed2680471_D20220101-20220930" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTM2NQ_b6df7e23-3737-4296-8934-23366a1cf411">2.5</ix:nonFraction> million for the three and nine months ended September 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i9412f1389708421ebab698307b0652e5_D20210701-20210930" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODQwMTU5_15b5592c-0a29-4094-abdb-7fe4bbc33266">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i54f3f1eeedc94eaf8493438a2310988b_D20210101-20210930" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODQwMTY3_2513281d-e372-4ef3-9c7f-bad96646498a">3.0</ix:nonFraction> million for the three and nine months ended September 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i0e534dd28b704e32ae748c0e79ebc74b_I20200831" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTc5NQ_26fc7eed-a82a-4436-a435-4179fbeb3c08">18.23</ix:nonFraction> per share of the Company&#8217;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into <ix:nonFraction unitRef="shares" contextRef="i971d328b42fe456798f158d581d7e9f1_D20200801-20200831" decimals="-5" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTkxMQ_3f360ed6-689d-4b7c-906f-c9b38f5d93f2">6.4</ix:nonFraction>&#160;million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2024 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $<ix:nonFraction unitRef="usd" contextRef="i0e534dd28b704e32ae748c0e79ebc74b_I20200831" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMjgyNg_199f831f-ab84-42e7-98c2-96c9cf74ba07">78.9</ix:nonFraction>&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $<ix:nonFraction unitRef="usd" contextRef="ibf3800946de143f0bb536bae6a5686d3_D20200801-20200831" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMjk3NQ_1f020dc2-b0e7-487d-9d2f-01c10d864be9">38.1</ix:nonFraction>&#160;million before issuance costs and was recorded within additional paid-in capital. Issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i0e534dd28b704e32ae748c0e79ebc74b_I20200831" decimals="-5" name="evh:DebtIssuanceCostsNetDebtComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMzA3MA_fc890f63-0dba-4d24-9514-b78ee2b67037">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8e4ac76e97a341ee8fbcc6dfa4aba611_I20200831" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMzA3Nw_1b8dde56-7af9-4d17-a42e-fde6372b38cb">1.3</ix:nonFraction>&#160;million were allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $<ix:nonFraction unitRef="usd" contextRef="ibf3800946de143f0bb536bae6a5686d3_D20200801-20200831" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMzIwOQ_5c040089-ebfc-4201-be4e-c4c224012e8f">38.1</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i0e534dd28b704e32ae748c0e79ebc74b_I20200831" decimals="-5" name="evh:DebtIssuanceCostsNetDebtComponent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMzIxMw_d5ce3b6f-d8aa-4509-aaca-f66c0d143c9f">1.7</ix:nonFraction>&#160;million of issuance costs was amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $<ix:nonFraction unitRef="usd" contextRef="i281bd5c057904435bc8629de116dd37a_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMzg5Mg_f0bf83fc-e973-458f-b0c6-caa34f9af066">38.1</ix:nonFraction>&#160;million decrease in additional paid-in capital and a $<ix:nonFraction unitRef="usd" contextRef="ia1cdd64507cd4f068665c06a3f09861d_I20220101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMzk0MA_b7320d94-61d2-474b-9b15-d7c40ff49d9a">1.3</ix:nonFraction>&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and an $<ix:nonFraction unitRef="usd" contextRef="i5a248420ba824c9d8f7efebff5855664_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNDA4MQ_1e8aec21-8bef-48cd-846c-0249a9c1698c">11.7</ix:nonFraction>&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2024 Notes. These adjustments resulted in an increase of $<ix:nonFraction unitRef="usd" contextRef="i970cc1ff98954def888f92d6e27ed9e0_I20220101" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNDM2Mw_bd22018a-724a-44d0-8359-26c7c9113a03">25.1</ix:nonFraction>&#160;million to the debt component of the 2024 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2024 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2024 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i247174c3d444488082c85f25293301f0_D20220701-20220930" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNDgzNg_6ec1442a-6be9-4525-9fdc-885ec680a78f">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i703a0ee08afb4b42a1e3c2eed2680471_D20220101-20220930" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNDg0Mw_85ac9ed6-5f58-4a72-b8d8-bc99dcfcf079">0.5</ix:nonFraction> million for the three and nine months ended September 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i9412f1389708421ebab698307b0652e5_D20210701-20210930" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNDg3Mg_2c6b61a8-f49b-436c-be21-5f37083af623">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i54f3f1eeedc94eaf8493438a2310988b_D20210101-20210930" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNDg3OQ_9b60ed56-d4db-48c3-bdb6-867812f58a0d">5.9</ix:nonFraction> million for the three and nine months ended September 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to <ix:nonFraction unitRef="number" contextRef="i971d328b42fe456798f158d581d7e9f1_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTA2MA_fc7cfea9-91b5-4894-a845-95c3035f7db4">100.0</ix:nonFraction>% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#8217;s Class A common stock has been at least <ix:nonFraction unitRef="number" contextRef="i971d328b42fe456798f158d581d7e9f1_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ4MQ_53ac4485-c2bf-459f-82c4-9b767411ca1f">130.0</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="i971d328b42fe456798f158d581d7e9f1_D20200801-20200831" name="evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTUzNg_bac6f0f8-f2e0-498c-9bcb-fc5e02b41614">20</ix:nonNumeric> trading days (whether or not consecutive) during any <ix:nonNumeric contextRef="i971d328b42fe456798f158d581d7e9f1_D20200801-20200831" name="evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTU5Mg_772caf3b-be85-45f9-955a-9cc7ef4cda1f">30</ix:nonNumeric> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="i971d328b42fe456798f158d581d7e9f1_D20200801-20200831" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTgzMA_5b770848-d82e-42ff-ac8b-8c21c0b77f5a">100.0</ix:nonFraction>% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 11, 2022, the Company entered into exchange agreements with certain holders of the 2024 Notes. Pursuant to the agreements, these holders exchanged $<ix:nonFraction unitRef="usd" contextRef="i0780a0fee7594b46b08c694f8172b826_D20220811-20220811" decimals="-5" name="us-gaap:DebtConversionOriginalDebtAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMzI5ODUzNDkwODkxMQ_15a293f0-287b-454c-b734-25554ec55a07">92.8</ix:nonFraction>&#160;million in aggregate principal amount of such notes for shares of the Company&#8217;s Class A common stock. On August 17 and 18, 2022, the Company consummated the exchanges and issued an aggregate of <ix:nonFraction unitRef="shares" contextRef="i2d823b0fe92347a08c084c665a3f3d9b_D20220817-20220818" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMzI5ODUzNDkwODkyNg_68bd29a4-c1a8-4a80-b697-dc299de2321e">5,394,165</ix:nonFraction> shares of Class A common stock to the holders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2022 exchanges of the 2024 Notes for Class A common stock resulted in a $<ix:nonFraction unitRef="usd" contextRef="ic25d64a2c23948ee96a46fb336fc19be_D20220801-20220831" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMzI5ODUzNDkwODkzNg_88cb7da1-c282-49e5-a87d-472c16601f36">10.2</ix:nonFraction>&#160;million loss on extinguishment/repayment of debt, net, on the consolidated statements of operations and comprehensive income (loss).</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7232e8817b564458961b48a465e6249e" continuedAt="i1feeb8be3e404e7391a42cd7ec4d7bc8"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the &#8220;2019 Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial secured term loan in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="if893b79edc40422a846ee7d717983c69_I20191230" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNjUxMA_4b9ca727-894a-4fbb-a8ae-dce3abcc3fd6">75.0</ix:nonFraction> million (the &#8220;Initial Term Loan Facility&#8221;) and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $<ix:nonFraction unitRef="usd" contextRef="ic570e916fb874a79be763e4769336d66_I20191230" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNjY0Mg_2136c47a-f3fc-4231-a5f5-ac1cfe825c5e">50.0</ix:nonFraction> million (the &#8220;DDTL Facility&#8221; and, together with the Initial Term Loan Facility, the &#8220;Senior Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the Initial Term Loan Facility on December 30, 2019. The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport Asset Purchase Agreement and pay fees and expenses incurred in connection therewith. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2020, an amendment to the Company's 2019 Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company repaid all outstanding amounts owed under and terminated the 2019 Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the 2019 Credit Agreement in connection with the prepayment was $<ix:nonFraction unitRef="usd" contextRef="if526c9a8decf4411aa6798f771fb8f2e_D20210108-20210108" decimals="-5" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNzc0MA_ade22167-9ae3-4f23-a7e3-b7d5d483d8b5">98.6</ix:nonFraction>&#160;million, which included $<ix:nonFraction unitRef="usd" contextRef="if526c9a8decf4411aa6798f771fb8f2e_D20210108-20210108" decimals="-5" name="evh:PaymentsOfMakeWholePremium" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNzc1OQ_6d7ee723-0ada-48cb-bdc3-e01cfb70d13f">9.7</ix:nonFraction>&#160;million for the make-whole premium as well as $<ix:nonFraction unitRef="usd" contextRef="if526c9a8decf4411aa6798f771fb8f2e_D20210108-20210108" decimals="-5" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNzgwMA_97777e92-b583-4bc6-a914-33157bb162ee">0.2</ix:nonFraction>&#160;million in accrued interest. As a result of this transaction, the Company recorded a loss on the repayment of debt of $<ix:nonFraction unitRef="usd" contextRef="if34c7918f26d4075a90353ac93a20071_D20210108-20210108" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNzkxMw_c31661dd-0931-4e41-893f-5db840fd5c7c">19.2</ix:nonFraction>&#160;million, representing the remaining unamortized debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="if34c7918f26d4075a90353ac93a20071_D20210108-20210108" decimals="-5" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNzk3OQ_510ebfd9-8fab-4cbc-b701-4e3f07e9b538">9.5</ix:nonFraction>&#160;million, the make-whole premium and $<ix:nonFraction unitRef="usd" contextRef="if34c7918f26d4075a90353ac93a20071_D20210108-20210108" decimals="-3" name="us-gaap:LegalFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfODAxMA_d659ae8e-ab5a-4db5-88b0-86187c0c8ef1">35</ix:nonFraction>&#160;thousand of legal expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Company&#8217;s entry into the 2019 Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of <ix:nonFraction unitRef="shares" contextRef="i237f03b5f1ae46209253a55eef0acbd7_I20191230" decimals="INF" name="us-gaap:ClassOfWarrantOrRightUnissued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfODI0MQ_90ca7643-0c31-473e-969a-bc4a188fc70e">1,513,786</ix:nonFraction> shares of Class A common stock at a per share purchase price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="i237f03b5f1ae46209253a55eef0acbd7_I20191230" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfODMxNA_e57e3d1c-0801-4541-876c-020021fed935">8.05</ix:nonFraction>. The holders could exercise the warrants at any time until <ix:nonNumeric contextRef="i346643136a3d4c2ca53d05972479a685_D20191230-20191230" name="evh:ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfODM3Ng_74e506a8-c2fb-4afc-9399-d7162c1d4c32">thirty days</ix:nonNumeric> after the maturity of the 2019 Credit Agreement.  The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company settled the outstanding warrants associated with the 2019 Credit Agreement for $<ix:nonFraction unitRef="usd" contextRef="id1b9711d99314be699395b69414db087_D20210108-20210108" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfWarrants" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfODgxMg_41d723a3-5975-43bc-b658-51e756791943">13.7</ix:nonFraction>&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company issued $<ix:nonFraction unitRef="usd" contextRef="iaadf8da35c2642b1baae4f9f8ec5b1ec_I20181031" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfODg2NQ_ffd7523b-1298-4753-b50c-c99571c6ef3a">172.5</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="iaadf8da35c2642b1baae4f9f8ec5b1ec_I20181031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfODkwMg_fcbc34de-64bd-4d6e-8bd0-0a88f929c35d">1.50</ix:nonFraction>% Convertible Senior Notes due 2025 (the &#8220;2025 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The 2025 Notes were issued at par for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i83e14bd5c2bc4351a905d0c781f6f2e1_D20181001-20181031" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfOTE3MA_c0c935c8-98c4-4017-bb6d-62a70446741d">166.6</ix:nonFraction> million. We incurred $<ix:nonFraction unitRef="usd" contextRef="i83a29e272d0e42f1a62606a14f9bcb44_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfOTE4Ng_90a9c369-0448-4c5b-b8dc-0f6d34333058">5.9</ix:nonFraction> million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $<ix:nonFraction unitRef="usd" contextRef="i943bcfabb119462c92e5b274885f9058_I20181022" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfOTI4Nw_f9586bb9-0f47-483f-8288-50e0754ac851">150.0</ix:nonFraction> million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018 and the Company completed the offering and sale of an additional $<ix:nonFraction unitRef="usd" contextRef="ib6a0939c098e417591c54c728c4656b1_I20181024" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfOTQxNQ_6cc22883-f382-4cbd-adbb-ead87ff212c9">22.5</ix:nonFraction> million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#8217; exercise in full of their option to purchase additional notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;<ix:nonFraction unitRef="number" contextRef="iaadf8da35c2642b1baae4f9f8ec5b1ec_I20181031" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfOTc1NQ_fcbc34de-64bd-4d6e-8bd0-0a88f929c35d">1.50</ix:nonFraction>%&#160;per annum. The Company recorded interest expense of $<ix:nonFraction unitRef="usd" contextRef="i73b993a88b6d4a83ba73f75a35a0dd70_D20220701-20220930" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfOTgxMA_34037426-bacd-4194-82c2-80b87caf869b"><ix:nonFraction unitRef="usd" contextRef="i82c2c5f321e645a3b56a3aecae93056e_D20220101-20220930" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfOTgxMA_cf91793f-f9d7-4ac5-91e9-a38584ce066c">0.6</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id732329530cf43d0808c84c8df54ccc4_D20210101-20210930" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfOTgxNw_5f02a564-df74-4608-b916-473a63b501a7"><ix:nonFraction unitRef="usd" contextRef="i26243e36f2374ba5a987cdb451132b3d_D20210701-20210930" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfOTgxNw_92824a03-d90c-4fcf-bab0-4f78c766ffa4">1.9</ix:nonFraction></ix:nonFraction> million for both the three and nine months ended September 30, 2022 and 2021, respectively. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="iaadf8da35c2642b1baae4f9f8ec5b1ec_I20181031" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTA3MTU_1174e24a-9829-46b5-85d3-f97d57fcb340">33.43</ix:nonFraction> per share of the Company&#8217;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into <ix:nonFraction unitRef="shares" contextRef="i83e14bd5c2bc4351a905d0c781f6f2e1_D20181001-20181031" decimals="-5" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTA4MzE_e0a45810-02cd-4c47-9633-e76f2980b326">5.2</ix:nonFraction> million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1feeb8be3e404e7391a42cd7ec4d7bc8" continuedAt="ie42113c9d2e44d8582ff2a8c32f8c918"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2025 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $<ix:nonFraction unitRef="usd" contextRef="iaadf8da35c2642b1baae4f9f8ec5b1ec_I20181031" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTE3Mzk_00bea8f4-dbb7-4276-82ab-2648f8a416fe">100.7</ix:nonFraction> million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $<ix:nonFraction unitRef="usd" contextRef="i9de8dee931674cb18c65e45a7b1e4f2c_D20181001-20181031" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTE4ODg_2db2666b-8811-4569-bb32-045fa44e2470">71.8</ix:nonFraction> million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $<ix:nonFraction unitRef="usd" contextRef="iaadf8da35c2642b1baae4f9f8ec5b1ec_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTIwOTk_e58c4bf3-3409-42a3-b35d-a53cdbcf2120">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3ac8f2155d3b40999c6630d7228cc990_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTIxMDY_0af1a8c4-d825-4a64-b92e-88c28357e497">2.5</ix:nonFraction> million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $<ix:nonFraction unitRef="usd" contextRef="i9de8dee931674cb18c65e45a7b1e4f2c_D20181001-20181031" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTIyMzc_2db2666b-8811-4569-bb32-045fa44e2470">71.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="iaadf8da35c2642b1baae4f9f8ec5b1ec_I20181031" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTIyNDE_e58c4bf3-3409-42a3-b35d-a53cdbcf2120">3.4</ix:nonFraction> million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $<ix:nonFraction unitRef="usd" contextRef="i1ad79143dac24d9fb4e767f03a9199d5_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTI5Njc_2a1b401e-aa3c-4549-979a-a18f3c14022e">71.8</ix:nonFraction>&#160;million decrease in additional paid-in capital and a $<ix:nonFraction unitRef="usd" contextRef="i7f199ebd90ef433e8b368de1394c5180_I20220101" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTMwMTU_8edcaede-1e73-47d3-931f-622646a6d2a9">2.5</ix:nonFraction>&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and a $<ix:nonFraction unitRef="usd" contextRef="i9fb3858a372e487fb6337c1636d1f938_I20220101" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTMxNTU_9496a2dd-984c-4494-9573-fd7c2118c10b">28.1</ix:nonFraction>&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2025 Notes. These adjustments resulted in an increase of $<ix:nonFraction unitRef="usd" contextRef="if6b921fd4b544f439a08e3802c74b054_I20220101" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTM0Mzc_23fbdf86-ab7d-44ea-8876-5e3ccefa0bfa">41.3</ix:nonFraction>&#160;million to the debt component of the 2025 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2025 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2025 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i73b993a88b6d4a83ba73f75a35a0dd70_D20220701-20220930" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTM5MTA_8e1cdb22-d668-4fd1-b9a7-597f16fe3e11">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i82c2c5f321e645a3b56a3aecae93056e_D20220101-20220930" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTM5MTc_7697f343-5f21-48d2-9857-fcbdfc90313e">1.0</ix:nonFraction> million for the three and nine months ended September 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i26243e36f2374ba5a987cdb451132b3d_D20210701-20210930" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTM5NDY_cb7ca025-6bc6-46e4-bcdb-aae1b76d1013">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id732329530cf43d0808c84c8df54ccc4_D20210101-20210930" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTM5NTM_b98cb1db-f0ca-48e0-ad6d-6752ec0bee4f">7.4</ix:nonFraction> million for the three and nine months ended September 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to <ix:nonFraction unitRef="number" contextRef="i83e14bd5c2bc4351a905d0c781f6f2e1_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTQxMzQ_288e32a5-27c0-41ab-bebb-169b9cb3b8e9">100.0</ix:nonFraction>% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale price of the Company&#8217;s Class A common stock has been at least <ix:nonFraction unitRef="number" contextRef="i83e14bd5c2bc4351a905d0c781f6f2e1_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTQ1MzM_e30adaac-b7b5-4308-8d5a-a31a39a95c3d">130.0</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonNumeric contextRef="i83e14bd5c2bc4351a905d0c781f6f2e1_D20181001-20181031" name="evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTQ1ODg_93596d4a-0cba-4346-84a8-1bc500af29fc">20</ix:nonNumeric> trading days (whether or not consecutive) during any <ix:nonNumeric contextRef="i83e14bd5c2bc4351a905d0c781f6f2e1_D20181001-20181031" name="evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTQ2NDQ_a00fa5ae-6756-4d25-bce1-087005af5f6c">30</ix:nonNumeric> consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="i83e14bd5c2bc4351a905d0c781f6f2e1_D20181001-20181031" decimals="INF" name="evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTQ4ODI_d5e75c47-854c-4114-95c0-e4d2100b2155">100.0</ix:nonFraction>% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i7a62eaff28ea42a28e86090e3e7b8dd7_I20161231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTUwNTA_2107fc3c-0a08-4ead-bb85-3b9c88844ddd">125.0</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i7a62eaff28ea42a28e86090e3e7b8dd7_I20161231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTUwODc_45a36d4f-7038-483a-97de-063603e509a0">2.00</ix:nonFraction>% Convertible Senior Notes due 2021 (the &#8220;2021 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i5e5305e5d35d418385b8e523b11422f4_D20161201-20161231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTUzMTA_ab4b46ec-976c-4256-9e93-a2bc5ac45225">120.4</ix:nonFraction> million. We incurred $<ix:nonFraction unitRef="usd" contextRef="i7a62eaff28ea42a28e86090e3e7b8dd7_I20161231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTUzMjY_30d36488-2d49-4f5e-889f-470018636761">4.6</ix:nonFraction> million of debt issuance costs in connection with the 2021 Notes, which we amortized to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December&#160;5, 2016.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, as part of the issuance of the 2024 Notes, the Company issued $<ix:nonFraction unitRef="usd" contextRef="i971d328b42fe456798f158d581d7e9f1_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTU3NDQ_3b3a0a67-9fa2-47a0-b58a-aa8b56f18170">84.2</ix:nonFraction>&#160;million aggregate principal amount of the 2024 Notes in exchange for $<ix:nonFraction unitRef="usd" contextRef="ib6070c04ec514eb1b72630be44af9d9d_D20200801-20200831" decimals="-5" name="us-gaap:DebtConversionOriginalDebtAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTU4MDg_91400fe7-9607-46f7-b494-c695497e28ca">84.2</ix:nonFraction>&#160;million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of $<ix:nonFraction unitRef="usd" contextRef="i0b673721ad2140dc92b0e7de4a1c58b1_D20200801-20200831" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTU5NDE_57da2af0-fed6-48ef-922d-7480c4fc0b48">2.5</ix:nonFraction>&#160;million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $<ix:nonFraction unitRef="usd" contextRef="i0b673721ad2140dc92b0e7de4a1c58b1_D20200801-20200831" decimals="-5" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTYwODU_6b416b40-e704-453c-9e22-956c93fd6b10">4.8</ix:nonFraction>&#160;million, including an aggregate cash payment of $<ix:nonFraction unitRef="usd" contextRef="i0b673721ad2140dc92b0e7de4a1c58b1_D20200801-20200831" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTYxMjg_ab1d89f8-8d21-402c-9560-296636ce3327">2.5</ix:nonFraction>&#160;million paid to exchanging noteholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we also repurchased $<ix:nonFraction unitRef="usd" contextRef="ib6070c04ec514eb1b72630be44af9d9d_D20200801-20200831" decimals="-5" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTYyMDE_92df11eb-4a1a-4545-b32b-8a716c9854ca">14.0</ix:nonFraction>&#160;million of the 2021 Notes with $<ix:nonFraction unitRef="usd" contextRef="ib6070c04ec514eb1b72630be44af9d9d_D20200801-20200831" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTYyMjc_35ccda57-2eb0-4ff5-8a08-c619a1305bd8">13.9</ix:nonFraction>&#160;million of cash and recorded an immaterial gain on extinguishment of debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon maturity of the 2021 Notes on December 1, 2021, outstanding 2021 Notes with a principal amount of $<ix:nonFraction unitRef="usd" contextRef="i3e0b4bf0b8594fd0baf9242862d641ec_D20211201-20211201" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTY0MDE_a26afe22-43b1-4d75-b60b-568cca712921">26.7</ix:nonFraction>&#160;million were settled, at the option of the holders, by converting $<ix:nonFraction unitRef="usd" contextRef="i3e0b4bf0b8594fd0baf9242862d641ec_D20211201-20211201" decimals="-5" name="us-gaap:DebtConversionOriginalDebtAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTY0NjI_12741b7d-4801-4bca-986d-7c34fb7e9401">26.3</ix:nonFraction>&#160;million aggregate principal amount of 2021 Notes to common shares and cash repayment of $<ix:nonFraction unitRef="usd" contextRef="i3e0b4bf0b8594fd0baf9242862d641ec_D20211201-20211201" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTY1NDU_8a799a36-9353-4d90-be9c-b809ee8e6b43">0.4</ix:nonFraction>&#160;million aggregate principal amount of 2021 Notes. </span></div></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie42113c9d2e44d8582ff2a8c32f8c918"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Convertible Senior Notes Carrying Value</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes and 2025 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of September&#160;30, 2022. However, the 2024 Notes and 2025 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2024 Notes and 2025 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTc3MTQ_ef985399-5c00-489e-839c-8977f20602aa" continuedAt="i7c74763152234737b79a037e3e2bff51" escape="true">The following table summarizes the carrying value of the long-term convertible debt as of September&#160;30, 2022 and December 31, 2021 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i7c74763152234737b79a037e3e2bff51"><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iada79ebd92cc43c4a68b4aa5846a5940_I20220930" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMi0xLTEtMS02NjkxMA_c1c89bcc-4765-46b2-9120-e988b132f8a8">23,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ba2e5b9e234d4fb2a1474c09951db0_I20211231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMi0zLTEtMS02NjkxMA_b9934545-7a21-499b-b2f8-217881589beb">89,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iada79ebd92cc43c4a68b4aa5846a5940_I20220930" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMy0xLTEtMS02NjkxMA_c2c1524d-5c5c-4dfe-a0b4-6ea7b1b0dc3f">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ba2e5b9e234d4fb2a1474c09951db0_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMy0zLTEtMS02NjkxMA_4c823b1d-fb4f-4f21-8382-d3fc48f3b2bc">27,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iada79ebd92cc43c4a68b4aa5846a5940_I20220930" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfNC0xLTEtMS02NjkxMA_15a92b0c-ce01-4a3f-aa3a-d2214f497263">24,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2ba2e5b9e234d4fb2a1474c09951db0_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfNC0zLTEtMS02NjkxMA_a0da10ea-0477-4dab-90ba-1a032930a664">117,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i703a0ee08afb4b42a1e3c2eed2680471_D20220101-20220930" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfNS0xLTEtMS02NjkxMA_134fad69-5815-4713-b7dd-7ddc2f8ac39c">2.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i54f3f1eeedc94eaf8493438a2310988b_D20210101-20210930" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfNS0zLTEtMS02NjkxMA_075a2492-8bd1-4aed-a39b-324ff02f5f2b">2.9</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5270f847008248a6bad1874588389f6f_I20220930" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfNi0xLTEtMS02NjkxMA_699c2c38-ce06-4f51-b6ff-6f744f276f15">49,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bce8ea980fc40fe86deba0a1244f385_I20211231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfNi0zLTEtMS02NjkxMA_fc47b596-9768-4f3d-895f-907c65f88997">195,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i624e27774ed54173a7c197935a253285_I20220930" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfOS0xLTEtMS02NjkxMA_214a8859-6eca-4d39-baf1-6de838240dad">168,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03270431ded404994880052552c5e20_I20211231" decimals="-3" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfOS0zLTEtMS02NjkxMA_9515ec76-4d15-4873-b652-cff38557a29a">126,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i624e27774ed54173a7c197935a253285_I20220930" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMTAtMS0xLTEtNjY5MTA_2f36e7af-196b-4806-9d83-12d70302b84d">3,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03270431ded404994880052552c5e20_I20211231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMTAtMy0xLTEtNjY5MTA_b57a7f58-18e5-4400-b3c1-d07a8a31b017">46,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i624e27774ed54173a7c197935a253285_I20220930" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMTEtMS0xLTEtNjY5MTA_719173e5-5263-4990-a0c5-c8458b7a101d">172,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03270431ded404994880052552c5e20_I20211231" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMTEtMy0xLTEtNjY5MTA_fda624de-8e5c-47b4-bfcb-4fc8c41f9fb3">172,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i82c2c5f321e645a3b56a3aecae93056e_D20220101-20220930" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMTItMS0xLTEtNjY5MTA_fc94665d-3915-4ea2-a296-bf058c6366a6">3.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id732329530cf43d0808c84c8df54ccc4_D20210101-20210930" name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMTItMy0xLTEtNjY5MTA_9c5b8a0a-9634-4f53-a934-65d4a23c4184">3.8</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21df7ec9dc5145d0bad6dac81a893732_I20220930" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMTMtMS0xLTEtNjY5MTA_af7a8a82-0d19-4b0a-b651-a9415493fc47">215,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d09652a0b6b48dbbae7e55d51a86ced_I20211231" decimals="-3" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMTMtMy0xLTEtNjY5MTA_fc835432-a851-4a9d-a2af-d344a8336f2c">177,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Fair values for notes are derived from available trading prices closest to the respective balance sheet date.</span></div></ix:continuation></ix:continuation><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 11.  <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMTIzNTA_0a16aeef-3c35-49db-a75f-52ce161589fa" continuedAt="i9ce6aa73a3e444cbb8f817b8a58b7caa" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i9ce6aa73a3e444cbb8f817b8a58b7caa" continuedAt="i1b46326ffdc44e928f5caeac69ecc04d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letters of Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021, the Company was party to irrevocable standby letters of credit&#160;with a bank for $<ix:nonFraction unitRef="usd" contextRef="i9d2101c3205e40fbb7350d3a97444a2b_I20220930" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMTc1_dce5dbf1-7bd3-41bc-b6dd-fd4f93315258">13.1</ix:nonFraction>&#160;million and&#160;$<ix:nonFraction unitRef="usd" contextRef="i5bc1e4679a644ab9ac8f129c984adf2c_I20211231" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMTgy_a3c59891-62c3-471d-b391-7df725899cca">15.4</ix:nonFraction> million, respectively, for the benefit of regulatory authorities, real estate and risk-sharing agreements. As such, we held $<ix:nonFraction unitRef="usd" contextRef="i7e2f3f30574a46129384a30992e3c3f9_I20220930" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMzAx_1405b632-2a72-4e28-b10f-5fec6e9c8e2e">13.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i56823a0a37a14bc28d21c2c9d3140588_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMzA4_13f6d4ad-08ae-4109-bd1f-2f9d207cdaf7">15.4</ix:nonFraction> million, respectively, in restricted cash and restricted investments as collateral as of September&#160;30, 2022 and December&#160;31, 2021. The letters of credit have current expiration dates between December 2022 and March 2032 and will automatically extend without amendment for an additional <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="evh:LineOfCreditFacilityAutomaticExtensionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMzI5ODUzNDg5NTczNQ_a49b5667-b6dc-48d8-922d-12772ecfa335">one-year</ix:nonNumeric> period and will continue to automatically extend after each <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="evh:LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMzI5ODUzNDg5NTc1Mg_bdf3188c-399b-4962-9001-5fe9c3c42304">one-year</ix:nonNumeric> term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-IPO Investor Registration Rights Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i1b46326ffdc44e928f5caeac69ecc04d" continuedAt="ia828f753fd9f48ecab4e5effe3d9bbd6"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the three and nine months ended September 30, 2022, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#8220;Molina&#8221;) entered into an Asset Purchase Agreement (the &#8220;Molina APA&#8221;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#8217;s rights under the Passport Medicaid Contract. On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#8220;Molina Closing&#8221;) and the Passport Medicaid Contract was novated to Molina. In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#8220;KY DOI&#8221;) regarding the wind down of its operations throughout 2021 and 2022. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of September&#160;30, 2022, no amounts have been funded under this guarantee.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reinsurance Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the &#8220;Passport Closing&#8221;). As part of the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport. On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#8217;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business was officially transferred to Molina effective September 1, 2021. As of September&#160;30, 2022, there are no material outstanding amounts under this reinsurance agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UPMC Reseller Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#8220;UPMC Reseller Agreement&#8221;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#8217;s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of <ix:nonFraction unitRef="customer" contextRef="i1fefdbdcfbff4feb9724eb08693b3aae_D20220101-20220930" decimals="INF" name="evh:NumberOfCustomers" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMzI5ODUzNDg5NTczNw_64117647-004c-4e43-961f-52bad7ed5e02">20</ix:nonFraction> of the Company&#8217;s customers. Revenue associated with the UPMC Reseller Agreement in the three and nine months ending September 30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i8a7f1b54fe7b435899399c232e3c82eb_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMjE5OTAyMzI4MTM2MA_48a16293-7082-4ad6-8941-0de4e3649d7d">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1fefdbdcfbff4feb9724eb08693b3aae_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMjE5OTAyMzI4MTM0NQ_cafcf00d-e008-4583-a7a7-7c35acc90eab">1.2</ix:nonFraction>&#160;million, respectively, and is in wind-down. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#8220;TRA&#8221;) with certain of its investors, which provides for the payment by the Company to these investors of <ix:nonFraction unitRef="number" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="INF" name="evh:TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfNjY3Ng_3f679ec3-ec6d-428e-a2c6-99841d9f9eab">85</ix:nonFraction>% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the reduction in the Company&#8217;s valuation allowance primarily resulting from deferred tax liabilities established as part of the IPG acquisition, the Company has recorded a partial TRA liability of $<ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-5" name="evh:TaxReceivableAgreementLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMTY0OTI2NzQ1NzMxMA_32e1965f-c2c8-4b16-9498-6ee5303c3715">42.9</ix:nonFraction>&#160;million as of September 30, 2022, which represents <ix:nonFraction unitRef="number" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="INF" name="evh:TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMzI5ODUzNDg5NzAxNw_accd48f0-96f3-47a0-ab19-3c1ddb9de70b">85</ix:nonFraction>% </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia828f753fd9f48ecab4e5effe3d9bbd6" continuedAt="ic6aacbfcb6cf4ef19e4b930492c76d0e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the deferred tax assets related to the Company&#8217;s unrealized tax benefits on historical pre-IPO losses and tax basis increases from exchanges, offset with the related valuation allowance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will assess the realizability of the deferred tax assets at each reporting period, and a change in our estimate of our liability associated with the tax receivable agreement may result as additional information becomes available, including results of operations in future periods. The realizability of the deferred tax assets is evaluated based on all positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division. An amended complaint was filed on January 10, 2020, a second amended complaint was filed on June 8, 2020, and a third amended complaint, now titled Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley, was filed on December 2, 2021. On July 13, 2022, the parties to the class action executed a term sheet for settlement of the litigation, subject to documentation of the settlement and approval of the court after notice to class members. On August 2, 2022, the lead plaintiff in the case filed an unopposed motion seeking preliminary approval of the settlement and related exhibits, including draft notice to class members and a proposed final order. The settlement stipulation is subject to preliminary and final approval by the court. The Final Settlement Hearing is scheduled for November 18, 2022. If the settlement is approved, we expect that the agreed-upon settlement payment of $<ix:nonFraction unitRef="usd" contextRef="ia13de1649ce14d5ba2486e13d566c4de_D20220802-20220802" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfOTE0NQ_c8f47e07-e00a-458a-8f15-460707b132e2">23.5</ix:nonFraction>&#160;million will be funded entirely by applicable directors&#8217; and officers&#8217; liability insurance. As such, we do not expect to incur a significant net loss or cash outflow as a result of the settlement of this matter.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#8217;s Board was negligent in its oversight of the Company&#8217;s relationship with Passport Health Plan. The case is Lincolnshire Police Pension Fund, derivatively on behalf of Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#8217;Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc. (&#8220;Derivative Action&#8221;). The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021. Plaintiffs have not yet responded to the motion to dismiss and there is not currently a briefing schedule on file with the Delaware Chancery Court. Based on the Company&#8217;s investigation, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit and Concentration Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of September&#160;30, 2022, approximately <ix:nonFraction unitRef="number" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="3" name="evh:CashFDICInsuredAmountPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMTA2NDc_fb77f755-f128-4102-b276-dc8f8ef46f60">98.2</ix:nonFraction>% of our $<ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMTA2NTc_8b8065b7-7021-4f8a-aca7-3b6dcfe05689">194.8</ix:nonFraction> million of cash and cash equivalents, restricted cash and restricted investments were held in bank deposits with FDIC participating banks and approximately <ix:nonFraction unitRef="number" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="3" name="evh:CashHeldInInternationalBanksPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMTA4MDg_b56b1aa9-0632-4bab-aba9-44c450089091">1.0</ix:nonFraction>% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic6aacbfcb6cf4ef19e4b930492c76d0e" continuedAt="idbe2992f28524cd6bf4444a8405da1ee"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMTIzNTk_940012d8-86fa-4634-9f05-db74b3d85a5e" continuedAt="i91df0734323148cb9ef3bd03fe464d8e" escape="true">The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable, as of September&#160;30, 2022 and December&#160;31, 2021:</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i91df0734323148cb9ef3bd03fe464d8e" continuedAt="i4db79ada28f04facb4d5863e6184d24d"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:354.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i812113f21d0f4ddab105da97d5259847_D20220101-20220930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjNjZmUwYTgyODI3MjQ5MWQ4YWE5ZjUyMjkxNDgwNTkzL3RhYmxlcmFuZ2U6M2NmZTBhODI4MjcyNDkxZDhhYTlmNTIyOTE0ODA1OTNfMS0xLTEtMS02NjkxMA_9f43ed97-49a8-4125-978e-72a6f0b9bff5">30.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebb100753030431db53c2c0fcb076812_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjNjZmUwYTgyODI3MjQ5MWQ4YWE5ZjUyMjkxNDgwNTkzL3RhYmxlcmFuZ2U6M2NmZTBhODI4MjcyNDkxZDhhYTlmNTIyOTE0ODA1OTNfMi0zLTEtMS02NjkxMA_d51345da-f09a-4e5f-97d4-694f37a82555">46.4</ix:nonFraction>%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9a78877350444f218b04a44d9a5a67f2_D20210101-20211231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjNjZmUwYTgyODI3MjQ5MWQ4YWE5ZjUyMjkxNDgwNTkzL3RhYmxlcmFuZ2U6M2NmZTBhODI4MjcyNDkxZDhhYTlmNTIyOTE0ODA1OTNfMy0zLTEtMS02NjkxMA_a6ccc832-9790-4fb2-96f7-07aa0c27f3e5">10.4</ix:nonFraction>%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bright Health Management, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9063068a17484ebd913c39f47d497ab4_D20220101-20220930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjNjZmUwYTgyODI3MjQ5MWQ4YWE5ZjUyMjkxNDgwNTkzL3RhYmxlcmFuZ2U6M2NmZTBhODI4MjcyNDkxZDhhYTlmNTIyOTE0ODA1OTNfNS0xLTEtMS02NjkxMA_72ac79ca-7e0a-4ef3-938b-7ea6347c6d50">12.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.</span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i4db79ada28f04facb4d5863e6184d24d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three and nine months ended September 30, 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6d9342a7219542d0b80d6351bbbf951e_D20220701-20220930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjMxMzkxMjI4NTQ0NzQwYTk4Nzk1MGE4MDU2ZjQ2ODkwL3RhYmxlcmFuZ2U6MzEzOTEyMjg1NDQ3NDBhOTg3OTUwYTgwNTZmNDY4OTBfMi0xLTEtMS02NjkxMA_1b86b76d-b9e0-4025-a498-880c43f0f961">21.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id66d64f0da484276ac264af8e9113d8b_D20210701-20210930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjMxMzkxMjI4NTQ0NzQwYTk4Nzk1MGE4MDU2ZjQ2ODkwL3RhYmxlcmFuZ2U6MzEzOTEyMjg1NDQ3NDBhOTg3OTUwYTgwNTZmNDY4OTBfMi0zLTEtMS02NjkxMA_e51365b2-a22e-4453-8101-eb627e64c6b5">29.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if15154cdcab04d8c8d65acb536587c6c_D20220101-20220930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjMxMzkxMjI4NTQ0NzQwYTk4Nzk1MGE4MDU2ZjQ2ODkwL3RhYmxlcmFuZ2U6MzEzOTEyMjg1NDQ3NDBhOTg3OTUwYTgwNTZmNDY4OTBfMi01LTEtMS02NjkxMA_74d52a8c-c26d-4cdc-a512-57e7459c2e2d">23.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5853227e398a4d7793e949610404e4cb_D20210101-20210930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjMxMzkxMjI4NTQ0NzQwYTk4Nzk1MGE4MDU2ZjQ2ODkwL3RhYmxlcmFuZ2U6MzEzOTEyMjg1NDQ3NDBhOTg3OTUwYTgwNTZmNDY4OTBfMi03LTEtMS02NjkxMA_85626ae8-5b95-45b9-b331-add38650217d">29.0</ix:nonFraction>%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i65657a6b51904fa0b718ad005efbdff6_D20220701-20220930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjMxMzkxMjI4NTQ0NzQwYTk4Nzk1MGE4MDU2ZjQ2ODkwL3RhYmxlcmFuZ2U6MzEzOTEyMjg1NDQ3NDBhOTg3OTUwYTgwNTZmNDY4OTBfMy0xLTEtMS02NjkxMA_b17f3314-3df6-4878-af66-b93cb017dc5d">13.7</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8be069ea831c4019bdd30e5903c02c34_D20210701-20210930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjMxMzkxMjI4NTQ0NzQwYTk4Nzk1MGE4MDU2ZjQ2ODkwL3RhYmxlcmFuZ2U6MzEzOTEyMjg1NDQ3NDBhOTg3OTUwYTgwNTZmNDY4OTBfMy0zLTEtMS02NjkxMA_e38a8f5a-2da5-4a51-be0a-8af530b3100c">13.8</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb0f8ea17a2a4c8084b696133732c541_D20220101-20220930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjMxMzkxMjI4NTQ0NzQwYTk4Nzk1MGE4MDU2ZjQ2ODkwL3RhYmxlcmFuZ2U6MzEzOTEyMjg1NDQ3NDBhOTg3OTUwYTgwNTZmNDY4OTBfMy01LTEtMS02NjkxMA_9fad2ff1-5f3c-4147-9239-bdfbe313b2e8">12.5</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia751c62398344050a4fa0f25431a1c20_D20210101-20210930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjMxMzkxMjI4NTQ0NzQwYTk4Nzk1MGE4MDU2ZjQ2ODkwL3RhYmxlcmFuZ2U6MzEzOTEyMjg1NDQ3NDBhOTg3OTUwYTgwNTZmNDY4OTBfMy03LTEtMS02NjkxMA_24c2048a-5e32-468b-afcc-cf10780a3fad">14.2</ix:nonFraction>%</span></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idbe2992f28524cd6bf4444a8405da1ee">We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.</ix:continuation>&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_79"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 12. <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RleHRyZWdpb246YjI2OTBkMTE4NDk4NGQxNDk0Zjc4YTBjNzdiNGY5MDZfMzI1Ng_6eb64f0c-63dd-4649-9caa-38ace5e5c6b3" continuedAt="i2500479e660f4ea384bb39745ebd30c7" escape="true">Leases</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i2500479e660f4ea384bb39745ebd30c7" continuedAt="i3b252b6d2a3349c1a42f7ee2ba3f2299"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include <ix:nonFraction unitRef="option_to_renew_lease" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="INF" name="evh:NumberOfOptionsToRenewLeases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RleHRyZWdpb246YjI2OTBkMTE4NDk4NGQxNDk0Zjc4YTBjNzdiNGY5MDZfNDk0NzgwMjMyODI1NA_e3bae14c-0ba8-4de4-8e97-56bab14e8b3a">one</ix:nonFraction> or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses.  The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2032. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#8217;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with various lease agreements, the Company is required to maintain $<ix:nonFraction unitRef="usd" contextRef="i5109fae1e1f447d9ba05497deddbfdc1_I20220930" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RleHRyZWdpb246YjI2OTBkMTE4NDk4NGQxNDk0Zjc4YTBjNzdiNGY5MDZfMjY2Mw_4e7f7733-d7cd-475e-b945-40e20014b4c6">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib8a8fe953a844510b46e6007aa3d8a39_I20211231" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RleHRyZWdpb246YjI2OTBkMTE4NDk4NGQxNDk0Zjc4YTBjNzdiNGY5MDZfMjY3MA_aa53630d-0ba0-4d59-86d8-462db1bb67b3">3.8</ix:nonFraction> million in letters of credit as of September&#160;30, 2022 and December&#160;31, 2021. As of September&#160;30, 2022 and December&#160;31, 2021, the Company held $<ix:nonFraction unitRef="usd" contextRef="i5109fae1e1f447d9ba05497deddbfdc1_I20220930" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RleHRyZWdpb246YjI2OTBkMTE4NDk4NGQxNDk0Zjc4YTBjNzdiNGY5MDZfMjc0NQ_a520a399-d923-4b38-913c-a895ba211a7c">2.3</ix:nonFraction> million </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3b252b6d2a3349c1a42f7ee2ba3f2299"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="ib8a8fe953a844510b46e6007aa3d8a39_I20211231" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RleHRyZWdpb246YjI2OTBkMTE4NDk4NGQxNDk0Zjc4YTBjNzdiNGY5MDZfMjc1Mg_f9863d21-2ef1-4d00-b72a-27d47e145d39">3.8</ix:nonFraction> million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RleHRyZWdpb246YjI2OTBkMTE4NDk4NGQxNDk0Zjc4YTBjNzdiNGY5MDZfMzI1Nw_e73ef9d3-a136-4f7a-b701-1b6a46814327" continuedAt="i3004c5158b9a410891fd4dc5618e3b0d" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of September&#160;30, 2022 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:237.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:94.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1c22768950824185b381d31f0d376c88_I20220930" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfMS0yLTEtMS02NjkxMA_b2e04241-822c-4e67-9b0e-cb87862d6bd0">9.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c22768950824185b381d31f0d376c88_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfMS00LTEtMS02NjkxMA_be3152f8-7d13-4439-984c-08e3eb4f7649">33,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c22768950824185b381d31f0d376c88_I20220930" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfMS02LTEtMS02NjkxMA_f2b6b422-c29c-4e7d-a53a-e06643bb55fe">1,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6b26e20c9d404df3839bead28654fb46_I20220930" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfMi0yLTEtMS02NjkxMA_d051dfe5-b730-4fc3-b0e2-65803d7c6fde">8.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b26e20c9d404df3839bead28654fb46_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfMi00LTEtMS02NjkxMA_a5effcd7-e048-4afd-8fda-a867e1145274">38,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b26e20c9d404df3839bead28654fb46_I20220930" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfMi02LTEtMS02NjkxMA_a5e56b6b-9091-4bb8-8e5e-fecfd4520e01">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edison, NJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia01578a302554a74b33916abc13ae563_I20220930" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfMy0yLTEtMS02NjkxMA_09ada3e6-b2be-4cf9-8323-a99573fdb8f4">3.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia01578a302554a74b33916abc13ae563_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfMy00LTEtMS02NjkxMA_6f8f04a3-ae73-4946-9709-07c727bf991c">1,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia01578a302554a74b33916abc13ae563_I20220930" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfMy02LTEtMS02NjkxMA_086e37cd-402b-444d-be98-55982e922eb7">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpharetta, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i911c93fdeef8463595874d62c2e77c23_I20220930" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfNC0yLTEtMS03NjUyMA_5a78ddbd-738c-4b12-8632-8dad69fa6d5c">3.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911c93fdeef8463595874d62c2e77c23_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfNC00LTEtMS03NjUxMg_a3786327-000a-4e64-a300-0ab4526427b0">1,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i911c93fdeef8463595874d62c2e77c23_I20220930" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfNC02LTEtMS03NjUxMg_dc28a832-c8de-4be9-b452-371e66a77cdd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib15e0e31d88444c0b1538bbb061a978e_I20220930" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfNC0yLTEtMS02NjkxMA_4f50814f-467b-4f97-8689-21c849c42f2f">1.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib15e0e31d88444c0b1538bbb061a978e_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfNC00LTEtMS02NjkxMA_07680628-fb0c-4d62-9aa9-caff296810a1">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib15e0e31d88444c0b1538bbb061a978e_I20220930" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfNC02LTEtMS02NjkxMA_f4bdac00-4e3e-44b8-af89-84c39191fb34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i159210da82754513ad12fdb0f55d6185_I20220930" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfNS0yLTEtMS02NjkxMA_fbf72c2a-cdb2-43d0-ab6d-a3091f715251">4.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i159210da82754513ad12fdb0f55d6185_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfNS00LTEtMS02NjkxMA_2857c4af-4a48-46e2-8978-9034709338bf">4,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i159210da82754513ad12fdb0f55d6185_I20220930" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfNS02LTEtMS02NjkxMA_4f9c25ba-fd8a-436b-a716-e1f31a58c44c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RleHRyZWdpb246YjI2OTBkMTE4NDk4NGQxNDk0Zjc4YTBjNzdiNGY5MDZfMzI1OA_6b27d369-b9e0-4e5e-94cc-b56e5d9fc382" continuedAt="i81f6fb120da349aaa208c927f20532e3" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfMi0xLTEtMS02NjkxMA_8c3a304a-4327-4df0-bd80-2f5d56e6d6b6">2,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfMi0zLTEtMS02NjkxMA_7a73f198-b1d9-415c-838f-34c8abe54188">2,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfMi01LTEtMS02NjkxMA_3688d43c-320d-4d86-aa2b-4edd7c798735">6,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfMi03LTEtMS02NjkxMA_07961bb2-6978-48b3-9333-09b4438241ba">9,672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfMy0xLTEtMS02NjkxMA_960d09ff-88ff-4d50-80a1-0d32ab77de28">1,599</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfMy0zLTEtMS02NjkxMA_70385cb1-a279-4d4b-940b-3ad0d3a32910">1,183</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfMy01LTEtMS02NjkxMA_473d05d9-a850-427b-a282-31c56b398fd7">4,096</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfMy03LTEtMS02NjkxMA_0734defa-bd85-4a4b-a138-ad30db7f4ba6">3,696</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfNC0xLTEtMS02NjkxMA_d8750a3e-16b8-4fd6-8f32-a3d8c5426b7f">3,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfNC0zLTEtMS02NjkxMA_bdf0dce7-9586-4536-9f4d-b3178be1beb5">3,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfNC01LTEtMS02NjkxMA_44681fe4-f064-42c1-a35e-75274e49cf9f">10,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfNC03LTEtMS02NjkxMA_d3941d0f-827d-42c4-9142-ec21baff26bd">13,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i3004c5158b9a410891fd4dc5618e3b0d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of September&#160;30, 2022, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjBlODdlODdmZjhkYTQyYzhiMzFmMTg0OWI2MjdjMDE1L3RhYmxlcmFuZ2U6MGU4N2U4N2ZmOGRhNDJjOGIzMWYxODQ5YjYyN2MwMTVfMS0xLTEtMS02NjkxMA_660d39c5-2a8a-446b-b2f1-4bd680e0ea5f">2,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjBlODdlODdmZjhkYTQyYzhiMzFmMTg0OWI2MjdjMDE1L3RhYmxlcmFuZ2U6MGU4N2U4N2ZmOGRhNDJjOGIzMWYxODQ5YjYyN2MwMTVfMi0xLTEtMS02NjkxMA_a950231f-d276-4651-af84-83dedc49704e">10,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjBlODdlODdmZjhkYTQyYzhiMzFmMTg0OWI2MjdjMDE1L3RhYmxlcmFuZ2U6MGU4N2U4N2ZmOGRhNDJjOGIzMWYxODQ5YjYyN2MwMTVfMy0xLTEtMS02NjkxMA_70903f2e-dca5-4ef8-99e0-27c2f7722967">10,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjBlODdlODdmZjhkYTQyYzhiMzFmMTg0OWI2MjdjMDE1L3RhYmxlcmFuZ2U6MGU4N2U4N2ZmOGRhNDJjOGIzMWYxODQ5YjYyN2MwMTVfNC0xLTEtMS02NjkxMA_1d689e64-bfcd-42f3-b950-d6a7a90ae818">10,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjBlODdlODdmZjhkYTQyYzhiMzFmMTg0OWI2MjdjMDE1L3RhYmxlcmFuZ2U6MGU4N2U4N2ZmOGRhNDJjOGIzMWYxODQ5YjYyN2MwMTVfNS0xLTEtMS02NjkxMA_b4ad7628-ab99-49cf-9a61-8c686dd18bc0">8,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="evh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjBlODdlODdmZjhkYTQyYzhiMzFmMTg0OWI2MjdjMDE1L3RhYmxlcmFuZ2U6MGU4N2U4N2ZmOGRhNDJjOGIzMWYxODQ5YjYyN2MwMTVfNi0xLTEtMS02NjkxMA_eff69bc0-83d7-420c-8312-855a3cecc02c">40,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjBlODdlODdmZjhkYTQyYzhiMzFmMTg0OWI2MjdjMDE1L3RhYmxlcmFuZ2U6MGU4N2U4N2ZmOGRhNDJjOGIzMWYxODQ5YjYyN2MwMTVfNy0xLTEtMS02NjkxMA_f7b32fe7-b7a8-4db2-aca3-8d1354ade619">83,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjBlODdlODdmZjhkYTQyYzhiMzFmMTg0OWI2MjdjMDE1L3RhYmxlcmFuZ2U6MGU4N2U4N2ZmOGRhNDJjOGIzMWYxODQ5YjYyN2MwMTVfOS0xLTEtMS02NjkxMA_7109ed96-3b3e-4c2a-b014-d704095f3d8b">18,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjBlODdlODdmZjhkYTQyYzhiMzFmMTg0OWI2MjdjMDE1L3RhYmxlcmFuZ2U6MGU4N2U4N2ZmOGRhNDJjOGIzMWYxODQ5YjYyN2MwMTVfMTAtMS0xLTEtNjY5MTA_39efe2a1-646e-444b-9009-0b0b79affbb6">64,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i81f6fb120da349aaa208c927f20532e3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjlmYmY3NTEyMGMwYjQ3ZjY5ZTg0ZTNiOGU2M2RiZTYxL3RhYmxlcmFuZ2U6OWZiZjc1MTIwYzBiNDdmNjllODRlM2I4ZTYzZGJlNjFfMS0xLTEtMS02NjkxMA_bfaf5dbf-737c-4380-b5d8-82e1c9960041">6.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjlmYmY3NTEyMGMwYjQ3ZjY5ZTg0ZTNiOGU2M2RiZTYxL3RhYmxlcmFuZ2U6OWZiZjc1MTIwYzBiNDdmNjllODRlM2I4ZTYzZGJlNjFfMi0xLTEtMS02NjkxMA_1900dcdc-272a-47a6-a56f-faab76f5b7c5">8.0</ix:nonNumeric></span></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i4a25f060abc946f28c4a0095422c2513_82"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 13.  <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RleHRyZWdpb246MDE4NzgwODhmZDkxNGIwMDk1YzExYjY1MzkxNDgzMjlfMzQ2_9f3e0d28-bd7a-4d5f-a9d8-ab697a70bf58" continuedAt="i30d41b3d587443c18aeae3173082e043" escape="true">Income (Loss) Per Common Share</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i30d41b3d587443c18aeae3173082e043"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RleHRyZWdpb246MDE4NzgwODhmZDkxNGIwMDk1YzExYjY1MzkxNDgzMjlfMzQ4_49ac7917-18d4-4a52-8f83-290a74a35fe8" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:288.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMi0xLTEtMS02NjkxMA_e6d82b3d-96a8-469c-9b36-a0745946c155">2,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMi0zLTEtMS02NjkxMA_52b4c26f-4fd8-4024-acd6-e8cd828ae0d1">13,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMi01LTEtMS02NjkxMA_814325c3-c4f8-43f1-9549-889093d349d2">7,352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMi03LTEtMS02NjkxMA_748f7b05-deb5-4d61-92cf-0fd288b80628">33,337</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy0xLTEtMS02NjkxMA_0f209cfa-8504-4ac9-b758-ac2a0a61b1b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy0zLTEtMS02NjkxMA_43c76fef-6b2e-4467-b3ef-343e76af8f09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy01LTEtMS02NjkxMA_00f03ad2-b82d-44e7-b7c4-221872011c79">463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy03LTEtMS02NjkxMA_d20e63e0-6ca3-40ec-8951-ef7d1c289504">1,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNC0xLTEtMS02NjkxMA_1c62408f-d7c4-4bf3-9201-aa2f5ad07bff"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNC0xLTEtMS02NjkxMA_418e1725-6f05-4986-9c4a-b48ab9c60da6">2,123</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNC0zLTEtMS02NjkxMA_3bf755bd-69e0-4e5d-8db0-7be22ff376fc"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNC0zLTEtMS02NjkxMA_6d8f73ae-488a-4e7c-9c41-0a500eacbb30">13,040</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNC01LTEtMS02NjkxMA_73a898f4-adfb-4ae1-a5b1-997c8d436a45"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNC01LTEtMS02NjkxMA_817b6502-2ab5-48ff-bb32-0a656ebaf587">7,815</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNC03LTEtMS02NjkxMA_374bb7fe-b864-4da2-80a1-d5a2e7df2874"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNC03LTEtMS02NjkxMA_d88ca28a-da35-453e-a5b9-58cb61aa0014">31,954</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNi0xLTEtMS02NjkxMA_fa3febef-4e8c-48f9-b9c0-b0b1c2b8e6d0">95,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNi0zLTEtMS02NjkxMA_8196ecfc-cd41-4565-8cc6-e3c48f677fa0">85,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNi01LTEtMS02NjkxMA_16f5ddf6-4ec8-448a-b76d-5f5c2a3b2f18">91,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNi03LTEtMS02NjkxMA_60086fc8-e0b2-4a6a-94cc-387bd5265ddc">85,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental diluted shares from stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="evh:IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNy0xLTEtMS03Njg3MQ_88dc22c6-bd00-43a8-9b26-c16ad9084659">1,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="evh:IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNy0zLTEtMS03Njg3MQ_40475a77-835e-4253-9b3a-c4bfb8333747">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNy01LTEtMS03Njg3MQ_34d5faf8-0d86-4e04-abad-ee870e368f40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNy03LTEtMS03Njg3MQ_dd749c70-c610-4809-9f4b-a899120bf135">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental diluted shares from Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfOC0xLTEtMS03Njg3MQ_95202291-db92-424f-bbee-43648a311ab3">2,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfOC0zLTEtMS03Njg3MQ_d2ec16d5-b61e-41af-8d80-13cb97a1502d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfOC01LTEtMS03Njg3MQ_cb281853-d3eb-48d6-a740-9f6b2be4d5b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfOC03LTEtMS03Njg3MQ_5edd8829-0e3b-4f1b-97f3-0f717a8be55b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfOS0xLTEtMS03Njg3MQ_a51971cc-ad60-42ed-9222-875192e7941c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfOS0zLTEtMS03Njg3MQ_8fb72867-5bfb-49b1-9911-3de1ae33b146">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfOS01LTEtMS03Njg3MQ_635c65e1-130e-4fec-96b2-5f63b51c55bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfOS03LTEtMS03Njg3MQ_1e4cd097-c301-4d53-9481-8ca3260ea8a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNy0xLTEtMS03Njc2MA_b0d31914-371d-462f-84e7-2bd333824083">99,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNy0zLTEtMS03Njc2MA_cc7c99d8-3fb3-4661-87b0-934f99532027">85,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNy01LTEtMS03Njc2MA_435dc0d5-1b7d-4db0-b15d-0dc3636c2b52">91,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNy03LTEtMS03Njc2MA_7f8bc27a-b11a-4130-9e66-f9d46247fb96">85,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTAtMS0xLTEtNjY5MTA_5d78348a-1ede-42f3-9c66-3e19d04d192b">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTAtMy0xLTEtNjY5MTA_94406da4-bba3-4f7b-9a48-470977dba9ed">0.15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTAtNS0xLTEtNjY5MTA_04698b35-8bc1-4fd1-b051-1674a602e6ca">0.08</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTAtNy0xLTEtNjY5MTA_594c02a6-9adc-4b51-8a3b-49e7df85a3ba">0.39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTEtMS0xLTEtNjY5MTA_b04bb2aa-e06c-4725-a979-417393867246">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTEtMy0xLTEtNjY5MTA_51f2919e-d948-43e1-b8fe-353c355f98aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTEtNS0xLTEtNjY5MTA_b02eb601-91c3-4df9-824f-4b86bfd50033">0.01</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTEtNy0xLTEtNjY5MTA_92a71a9f-9843-4f08-bcfa-9a531cf1884c">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic income (loss) per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTItMS0xLTEtNjY5MTA_3532a326-e3a6-4a72-bf8a-62b392719771">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTItMy0xLTEtNjY5MTA_6531b55f-f41b-4ab9-ba40-c11e9a2c2159">0.15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTItNS0xLTEtNjY5MTA_dc29ff25-a8f0-4a3c-a9ac-cc086468d8e9">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTItNy0xLTEtNjY5MTA_ee2b491b-a03c-4b79-b603-6b46c67d2ad3">0.37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTgtMS0xLTEtNzcxMDE_c0bc64f5-cd2d-48be-8ace-aa6e4d481486">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTgtMy0xLTEtNzcxMDE_2ebf6c1c-71c6-4384-8606-b4152dbb6d7d">0.15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTgtNS0xLTEtNzcxMDE_b559917c-1929-4bc9-bf4d-69a8feff1d5d">0.08</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTgtNy0xLTEtNzcxMDE_01899fe7-98ba-4bca-a762-25a2204f5eb5">0.39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTktMS0xLTEtNzcxMDE_df0eb775-ca69-403d-b4d5-5d2a0bbb0973">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTktMy0xLTEtNzcxMDE_13066bf6-b1e7-43da-9b52-2cc3045e00a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTktNS0xLTEtNzcxMDE_ddf5b5b3-765f-4c63-a2d4-44bb2fbb4d0b">0.01</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTktNy0xLTEtNzcxMDE_4f04f922-c15e-48e6-b6d7-1344cd429489">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMjAtMS0xLTEtNzcxMDE_1cc75002-3e6b-4439-886b-d35b708cfd77">0.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMjAtMy0xLTEtNzcxMDE_180fac62-bd77-4452-89a2-404577c7ea37">0.15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMjAtNS0xLTEtNzcxMDE_6642db39-b9b4-4146-856f-f11cc4bccf6d">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMjAtNy0xLTEtNzcxMDE_dfa295c9-4f3f-4d71-8344-393a4f8a3c2f">0.37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted net earnings per common share, if any, gives effect to diluted stock options (calculated based on the treasury stock method), shares issuable upon debt conversion (calculated using an as-if converted method).</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RleHRyZWdpb246MDE4NzgwODhmZDkxNGIwMDk1YzExYjY1MzkxNDgzMjlfMzQy_b7c4b515-6536-4c8e-a5d3-2b3da5fa33a8" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:288.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8493de5c288b4d2a960001285f09a7d5_D20220701-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfMi0xLTEtMS02NjkxMA_32e8124b-7b42-4605-b0cd-cda29f3653e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i13c42161e64b48038d3f19a5af627a85_D20210701-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfMi0zLTEtMS02NjkxMA_482cacb5-4f92-4089-a04f-eb0046675d5c">2,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iae5571384d234210beca38a208484402_D20220101-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfMi01LTEtMS02NjkxMA_2006ad33-b340-4641-8ac2-3fa7b7a1b8aa">1,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i698aa6c02364400ebedf039f90402307_D20210101-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfMi03LTEtMS02NjkxMA_3b9bf999-c7b8-40a4-ab06-79bca6657176">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3fd339cb95b94daea292e551ad2fe6f3_D20220701-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfMy0xLTEtMS02NjkxMA_ccd4f28e-e0b8-4778-b180-a4fa6d7ddb88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3bcd97c207a54e5ab3166f83c04c3bb0_D20210701-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfMy0zLTEtMS02NjkxMA_5bacad76-3719-4406-bb32-638a7458e70a">2,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31ffa1624215451292f3bc38304028d0_D20220101-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfMy01LTEtMS02NjkxMA_5bfb02c2-b365-4764-b47e-4c27dce28738">1,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22491be6a23246d796d54f3c45790776_D20210101-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfMy03LTEtMS02NjkxMA_9386354a-6f62-42fa-9c03-83e77c2c8ac4">2,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5bef61a150eb4c7a881bdf01c6a5f488_D20220701-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfNC0xLTEtMS02NjkxMA_a4ecb97d-5c66-4ebc-ae94-83312b223b91">9,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if9dbe0e582d74777ae8810f8d192e1d8_D20210701-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfNC0zLTEtMS02NjkxMA_9d74756a-87c7-4faf-bea4-53236be98f44">12,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i22bf8d1d47ce4219b999f81df2fed5e7_D20220101-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfNC01LTEtMS02NjkxMA_9ce00062-bc43-45f6-a09f-c48c198d0e13">10,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifd9f231f9ee2464db9a170de0151bca4_D20210101-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfNC03LTEtMS02NjkxMA_51394b76-9bf3-48be-b242-e67e175e6a22">12,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfNS0xLTEtMS02NjkxMA_7e271efd-9778-46ac-9cd2-20199dd5a1a4">9,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfNS0zLTEtMS02NjkxMA_6d1e3d2a-88dc-478a-866b-4eae7999c9f6">16,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfNS01LTEtMS02NjkxMA_283e6942-27f6-4752-8a83-f2a92e611b2f">14,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfNS03LTEtMS02NjkxMA_db67400a-419b-4ab6-af7a-604bb788b36d">16,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_85"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 14.  <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RleHRyZWdpb246MjNiNDZhY2JmOWVmNDJkYWJkMGQ1NzA3MDBiOGZiODlfMzI1_741d07cb-4129-4a2e-9554-bd0f2f5e9005" continuedAt="i8358650fd91340c3a48361843d749177" escape="true">Stock-based Compensation</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i8358650fd91340c3a48361843d749177" continuedAt="idb0d25a6208d4578bc94bc2b7c235ff6"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RleHRyZWdpb246MjNiNDZhY2JmOWVmNDJkYWJkMGQ1NzA3MDBiOGZiODlfMzIz_85e20798-8647-4357-a7eb-d11506c5828f" continuedAt="iedad3fb7ac994fae80b1103a052b99d0" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:288.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idb0d25a6208d4578bc94bc2b7c235ff6"><div style="margin-top:5pt;text-align:justify"><ix:continuation id="iedad3fb7ac994fae80b1103a052b99d0"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:288.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:58.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb50d04ea7474a3ca01d54e55b1a55f6_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMy0xLTEtMS02NjkxMA_35038b35-3fa5-417d-b435-800c2b2f39a5">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i325a5d1124ab41b9a84347a873d3e51b_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMy0zLTEtMS02NjkxMA_33129632-a0c2-434b-bba7-b517171544ca">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea400d223b0743bdad51be17ed4b50ee_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMy01LTEtMS02NjkxMA_fecd3647-7947-496d-9dd4-af7a3a621ed2">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2a7bc06fc954c4b817161cd6406f509_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMy03LTEtMS02NjkxMA_b394d885-3f59-4b3e-8401-4b480865c6d1">945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i582d7dedfcac46f99a84eb6ef808e641_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNC0xLTEtMS02NjkxMA_958f02e8-96fc-47f1-bb95-579c988f71a9">4,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aa29b39545e4c3ba7d7690b3e215975_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNC0zLTEtMS02NjkxMA_c0ce85f1-66b9-4b8b-b229-24ceedf07e6b">2,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b17f35850394b8dba4f2022f71b47ca_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNC01LTEtMS02NjkxMA_d854e0ca-5c41-43d2-adce-85ef1c952280">12,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a875e7e581644ddb5ae0ea1dd6d828d_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNC03LTEtMS02NjkxMA_a9efa066-8a28-4c1f-b7b8-67b8c3adde4e">6,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80cf2c1a304b4b419a652fc1e0cb1937_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNS0xLTEtMS02NjkxMA_a7b7fe5e-4377-4a7f-88b9-74c6e828aa7b">387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c541a9c8aa847a880c6ab10e684b4c9_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNS0zLTEtMS02NjkxMA_55eb214d-131f-4062-91fd-cb1338ea4120">995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cc6de998c6c41a2918343e7a2029cbe_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNS01LTEtMS02NjkxMA_314b3dc6-3223-4655-b49c-7804ad5b4ef9">1,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b9048d914e4b6fbb6f301354a4b9b0_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNS03LTEtMS02NjkxMA_c4b2bf8a-cca2-42da-a07d-189117fc044b">2,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i647fb470e87444d6a627e33d5d70965b_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNi0xLTEtMS02NjkxMA_eb78fff3-c5cf-468a-bfa4-4146bb9efad9">1,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide5f51cc3ef84de6a0fd4b47abd3c1e8_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNi0zLTEtMS02NjkxMA_01e26313-efb8-4156-ac35-d8612ab45835">745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcffb900db284c32b9e3d8cb934a505f_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNi01LTEtMS02NjkxMA_46725409-9210-42d1-8f55-03893e116cfe">4,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1649a9b5bf47f7917cfe5843b5b4a8_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNi03LTEtMS02NjkxMA_73759c57-4a63-4a20-ad2c-3b9efe29cf3a">1,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNy0xLTEtMS02NjkxMA_b9e514bf-8be2-4b93-8a33-047c09e3f24d">6,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNy0zLTEtMS02NjkxMA_497ed6dc-5fec-44b0-abe8-c58f4235ca79">4,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNy01LTEtMS02NjkxMA_734923d9-5776-4971-86de-6a93d1a5771e">19,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNy03LTEtMS02NjkxMA_cda4ae22-f7ad-4022-abc6-a0eff3a9f5c0">11,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i725c229475cf49689226a91cc11b751c_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTAtMS0xLTEtNjY5MTA_db16ac50-1b27-47c2-b3ba-fd66e1840168">1,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2612dbadf05a4362aad60d096eb1a7e4_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTAtMy0xLTEtNjY5MTA_0e559c3b-4654-4f60-a5e6-1f90db982b0e">131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iada2bf5d0400417ba62e194126135b75_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTAtNS0xLTEtNjY5MTA_9a5d91c3-1b44-4900-a174-63c3908cd090">2,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6f6b8c71225423c8a5684cc55be31ce_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTAtNy0xLTEtNjY5MTA_6ad7fe09-2e3e-4363-9259-927e33ac662a">1,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i631da77b97724fd1b7043025f1733fe1_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTEtMS0xLTEtNjY5MTA_ba613533-5a47-4c6b-a665-844c5c520987">5,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a0e6a4f8b84f88b30c7341d4f1c393_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTEtMy0xLTEtNjY5MTA_0b19a74c-578b-4f05-b5b8-8924e5b12208">4,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd568013557c46eb981fa85a87040eba_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTEtNS0xLTEtNjY5MTA_cce601f9-56c8-4248-a4f0-eceb5d0fa21a">16,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e14d567f9f24b93870cd21943387f1c_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTEtNy0xLTEtNjY5MTA_4bc03b8a-3c94-48b3-af3e-be994b8aa203">10,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTItMS0xLTEtNjY5MTA_0bd756fe-2943-4396-8d0f-033cb54c7234">6,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTItMy0xLTEtNjY5MTA_307c6c29-0861-4c6f-9744-9771d65bad52">4,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTItNS0xLTEtNjY5MTA_be1bc892-0de8-47a6-a62e-0a7773fb8451">19,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTItNy0xLTEtNjY5MTA_cda4ae22-f7ad-4022-abc6-a0eff3a9f5c0">11,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RleHRyZWdpb246MjNiNDZhY2JmOWVmNDJkYWJkMGQ1NzA3MDBiOGZiODlfMTcx_046eefaa-53ce-4b80-a817-19a264f26177"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RleHRyZWdpb246MjNiNDZhY2JmOWVmNDJkYWJkMGQ1NzA3MDBiOGZiODlfMTcx_a1db02d9-5a0e-4541-ba11-93ed1fd4dd86"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RleHRyZWdpb246MjNiNDZhY2JmOWVmNDJkYWJkMGQ1NzA3MDBiOGZiODlfMTcx_ce5c0492-d41b-4f41-b076-f336b2e623e0"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="INF" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RleHRyZWdpb246MjNiNDZhY2JmOWVmNDJkYWJkMGQ1NzA3MDBiOGZiODlfMTcx_e6d840af-19eb-48fd-b7a9-325a8c4bb3ca">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> stock-based compensation was capitalized as software development costs for the three and nine months ended September 30, 2022 and 2021.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RleHRyZWdpb246MjNiNDZhY2JmOWVmNDJkYWJkMGQ1NzA3MDBiOGZiODlfMzI0_eec913d6-4e33-4073-b8e4-cdfdd071c906" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards were granted as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i582d7dedfcac46f99a84eb6ef808e641_D20220701-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOjg1YThiMWU5YmQ4YTQ4ODY5YTJmOGQwMDQ1NmEyYzMwL3RhYmxlcmFuZ2U6ODVhOGIxZTliZDhhNDg4NjlhMmY4ZDAwNDU2YTJjMzBfMi0xLTEtMS02NjkxMA_bef6fd9e-3401-403e-a097-4ff1d0b7dc16">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8aa29b39545e4c3ba7d7690b3e215975_D20210701-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOjg1YThiMWU5YmQ4YTQ4ODY5YTJmOGQwMDQ1NmEyYzMwL3RhYmxlcmFuZ2U6ODVhOGIxZTliZDhhNDg4NjlhMmY4ZDAwNDU2YTJjMzBfMi0zLTEtMS02NjkxMA_71b52c7b-7ba2-4e24-b654-081e7d16634b">134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b17f35850394b8dba4f2022f71b47ca_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOjg1YThiMWU5YmQ4YTQ4ODY5YTJmOGQwMDQ1NmEyYzMwL3RhYmxlcmFuZ2U6ODVhOGIxZTliZDhhNDg4NjlhMmY4ZDAwNDU2YTJjMzBfMi01LTEtMS02NjkxMA_44705ffd-0365-4f1e-b999-9ce989905cf2">1,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a875e7e581644ddb5ae0ea1dd6d828d_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOjg1YThiMWU5YmQ4YTQ4ODY5YTJmOGQwMDQ1NmEyYzMwL3RhYmxlcmFuZ2U6ODVhOGIxZTliZDhhNDg4NjlhMmY4ZDAwNDU2YTJjMzBfMi03LTEtMS02NjkxMA_b8dfef62-caab-4861-a274-91cea36b158d">1,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i647fb470e87444d6a627e33d5d70965b_D20220701-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOjg1YThiMWU5YmQ4YTQ4ODY5YTJmOGQwMDQ1NmEyYzMwL3RhYmxlcmFuZ2U6ODVhOGIxZTliZDhhNDg4NjlhMmY4ZDAwNDU2YTJjMzBfMy0xLTEtMS02NjkxMA_3f9a05d0-9f5c-4c76-8e28-c3b647dceb07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ide5f51cc3ef84de6a0fd4b47abd3c1e8_D20210701-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOjg1YThiMWU5YmQ4YTQ4ODY5YTJmOGQwMDQ1NmEyYzMwL3RhYmxlcmFuZ2U6ODVhOGIxZTliZDhhNDg4NjlhMmY4ZDAwNDU2YTJjMzBfMy0zLTEtMS02NjkxMA_2642b91a-7bcf-4db8-89a0-7fffcb5d7c52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcffb900db284c32b9e3d8cb934a505f_D20220101-20220930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOjg1YThiMWU5YmQ4YTQ4ODY5YTJmOGQwMDQ1NmEyYzMwL3RhYmxlcmFuZ2U6ODVhOGIxZTliZDhhNDg4NjlhMmY4ZDAwNDU2YTJjMzBfMy01LTEtMS02NjkxMA_09e68e83-00fc-4bf8-bf29-3d80923b2a97">479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee1649a9b5bf47f7917cfe5843b5b4a8_D20210101-20210930" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOjg1YThiMWU5YmQ4YTQ4ODY5YTJmOGQwMDQ1NmEyYzMwL3RhYmxlcmFuZ2U6ODVhOGIxZTliZDhhNDg4NjlhMmY4ZDAwNDU2YTJjMzBfMy03LTEtMS02NjkxMA_3761510b-618b-43c8-a5e5-f1cab7ce049c">319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_88"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 15.  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMTYwNw_1c6c2b1f-6eb0-45b9-8a77-3012020f95ce" continuedAt="i7ff79b6081904556b49a649dd551654e" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i7ff79b6081904556b49a649dd551654e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For interim periods, we recognize an income tax provision (benefit) based on our estimated annual effective tax rate expected for the full year, adjusted for discrete items recognized during the interim period. Discrete items (e.g., significant or unusual items) are separately recognized in the quarter during which they occur and can cause the effective tax rate to vary from quarter to quarter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An income tax benefit of $(<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMjEw_009f1efe-7f5e-44be-8f6f-504af2ec0e7c">45.5</ix:nonFraction>)&#160;million and $(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMjE3_7faa7a94-2c89-4075-a3c5-9cf3b9f90f16">44.5</ix:nonFraction>)&#160;million and was recognized for the three and nine months ended September 30, 2022, respectively, which resulted in effective tax rates of <ix:nonFraction unitRef="number" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMzI5ODUzNDg4NzY5Nw_f34a02cf-cc8c-43da-94e3-da280e3c3bc7">104.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMzI5ODUzNDg4NzcwNQ_49b0951f-0fa8-4056-b072-f4ee41f5b388">85.8</ix:nonFraction>%, respectively. An income tax expense of $<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMzYy_f471ec16-d05a-48b8-9b85-23e04a1dd377">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMzY5_408c62fb-5c9b-449c-9cdb-a9024f793d07">0.9</ix:nonFraction>&#160;million was recognized for the three and nine months ended September 30, 2021, respectively, which resulted in effective tax rates of (<ix:nonFraction unitRef="number" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMzI5ODUzNDg4NzcxMg_c01e5088-a393-4618-b9cb-2dfbb5e274f8">1.8</ix:nonFraction>)% and (<ix:nonFraction unitRef="number" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMzI5ODUzNDg4NzcyMA_ca0393a0-02f7-45ba-9c59-df17981ade67">2.9</ix:nonFraction>)%, respectively. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components. The income tax benefit recorded during the three and nine months ended September 30, 2022 primarily relates to the $<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMTA5OTUxMTYyODIxNzQ_32380c11-d002-4281-814b-322d5fc877cf"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMTA5OTUxMTYyODIxNzQ_d4b90e54-3119-48f0-bc72-24a23d029f60">46.8</ix:nonFraction></ix:nonFraction>&#160;million reduction in the valuation allowance resulting from deferred tax liabilities established as part of the IPG acquisition accounting, partially offset by state and foreign taxes. The income tax expense recorded during the three and nine months ended September 30, 2021, primarily relates to foreign taxes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2021, the Company had unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfNzg1_aa6ca4b9-227a-45b7-9b94-9d427c92ecc8">0.6</ix:nonFraction> million that, if recognized, would not affect the effective tax rate due to the valuation allowance against its net deferred tax asset. As of September 30, 2022, the Company has additional unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfNTQ5NzU1ODE4MDgw_ded24e86-ecda-45eb-9597-5ded0cff82ad">0.4</ix:nonFraction>&#160;million that, if recognized, would affect the effective tax rate. The Company is not currently subject to income tax audits in any U.S., state, or foreign jurisdictions for any tax year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the TRA with certain of its investors, which provides for the payment by the Company to these investors of <ix:nonFraction unitRef="number" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="INF" name="evh:TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMTMxMA_ede6fcdb-0a5e-4c92-a71c-e9b2f55069b1">85</ix:nonFraction>% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. See Note 11 above for discussion of our TRA.</span></div></ix:continuation><div><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_91"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 16.  <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMjE5MQ_75b51e12-c739-4c64-a797-f685aba0b047" continuedAt="id9691a9ec71b4ac9b88a996462cf4c70" escape="true">Investments in Equity Method Investees</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id9691a9ec71b4ac9b88a996462cf4c70" continuedAt="icc7f154e0cf440e6a6f38df6b0f1a0b3">The Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable </ix:continuation></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="icc7f154e0cf440e6a6f38df6b0f1a0b3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;September&#160;30, 2022 and December&#160;31, 2021, the Company&#8217;s economic interests in its equity method investments ranged between <ix:nonFraction unitRef="number" contextRef="i595e611ec9ae489dbce4f7eda441f246_I20220930" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTI0NA_87ea46dd-d3cf-463c-be0d-1af733b12e29">4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i7eda68985c9842cdaf3b26312b15d4c2_I20220930" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTI1MQ_aa1e05ec-e3d3-4962-a2eb-ca7b3d1050b5">38</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if02fc4db2c9b4fa8b2f8b4664e01eea1_I20211231" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTI1OA_405ae3cb-b6a1-45cc-866e-eb2e9c4a1226">4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i277f0bf297354d94af61e257c3ec7ff7_I20211231" decimals="2" name="evh:EquityMethodInvestmentEconomicInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTI2NQ_b7afa911-bcef-4c0a-b8cb-fb24cc1a8a96">39</ix:nonFraction>%, respectively, and voting interests in its equity method investments ranged between <ix:nonFraction unitRef="number" contextRef="i595e611ec9ae489dbce4f7eda441f246_I20220930" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTM1Mg_0405e20a-4b2b-40de-afb5-c6d4d4a263ed"><ix:nonFraction unitRef="number" contextRef="if02fc4db2c9b4fa8b2f8b4664e01eea1_I20211231" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTM1Mg_90264cca-f456-43e0-a02a-29114e8946e3">25</ix:nonFraction></ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i7eda68985c9842cdaf3b26312b15d4c2_I20220930" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTM1OQ_5177940d-6e0c-4107-8b09-719c4f633380"><ix:nonFraction unitRef="number" contextRef="i277f0bf297354d94af61e257c3ec7ff7_I20211231" decimals="2" name="evh:EquityMethodInvestmentVotingInterestPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTM1OQ_f0ef8058-59e9-455b-be19-7397e846ee51">40</ix:nonFraction></ix:nonFraction>%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#8217; earnings and losses for each reporting period. The Company&#8217;s proportional share of the gain from these investments was approximately $<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTgwMQ_7739a3c9-8e47-4f50-9bbe-9f121eedd433">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTgwOA_52219cca-dc2f-4445-8e6a-43a5ce1d28be">3.9</ix:nonFraction> million for the three and nine months ended September 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTgzNw_83ca4237-efb5-4a36-8a62-5a8d69572c9b">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTg0NA_b134175f-9d25-4610-b656-8331030b48c7">12.7</ix:nonFraction> million for the three and nine months ended September 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $<ix:nonFraction unitRef="usd" contextRef="iebd3f639166d44039bd8edc98238a383_D20220701-20220930" decimals="-5" name="evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMjExOQ_229f8612-011f-4076-a082-c97fdea5e527">5.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id4b322c66f3e45b08685a4ae028887d8_D20220101-20220930" decimals="-5" name="evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMjEyNg_3bf8388d-f44f-4fae-87b9-a4f2275d181f">12.5</ix:nonFraction> million for the three and nine months ended September 30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i396bb0edd68c430189127d5633e8e1a4_D20210701-20210930" decimals="-5" name="evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMjE1NQ_d10688e3-7a9e-4d0a-96a5-8704a53a7e20">4.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2240a4a6255943e4bf456dfd07e73621_D20210101-20210930" decimals="-5" name="evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMjE2Mg_15d42def-7043-4500-af45-74f6417d5499">12.6</ix:nonFraction> million for the three and nine months ended September 30, 2021, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_2316"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 17. <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGV4dHJlZ2lvbjphNWY5MTFjNThlOGI0OTU5YjUwN2JkOGY3Mzc2NTc2MF8zMjk4NTM0ODg5MDUy_94fa398f-ad3b-47ac-a3e1-8a69c8fb125d" continuedAt="ia45070d5c6704b4b9417ac0a79f8b766" escape="true"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGV4dHJlZ2lvbjphNWY5MTFjNThlOGI0OTU5YjUwN2JkOGY3Mzc2NTc2MF8zMjk4NTM0ODg5MDUz_3aff9ff4-824e-48b2-850f-dc2ed5a02d4a" continuedAt="i93ef9f52aad54905a0888caf6a3ff2d6" escape="true">Fair Value Measurement</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i93ef9f52aad54905a0888caf6a3ff2d6" continuedAt="i1a84af2c475c4fbaa949fad04c4d9808"><ix:continuation id="ia45070d5c6704b4b9417ac0a79f8b766" continuedAt="ie509a30ec74b42a79206b48ddcea2a16"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGV4dHJlZ2lvbjphNWY5MTFjNThlOGI0OTU5YjUwN2JkOGY3Mzc2NTc2MF8zMjk4NTM0ODg5MDU0_fe61535c-5d86-4c25-9aa9-77a8095141da" continuedAt="id3a67b841a854a9bb532a636df134435" escape="true">The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis (in thousands):</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:continuation id="id3a67b841a854a9bb532a636df134435" continuedAt="id2f1959bbcf8492c91d687452594a5f3"> </ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="id2f1959bbcf8492c91d687452594a5f3"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1d99a70db5f43208858b7f0f954c2d1_I20220930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTBlZGY2MWM1NTVkNGY1YWFlZDM2YjA5ZjJlYmNlMDkvdGFibGVyYW5nZTo1MGVkZjYxYzU1NWQ0ZjVhYWVkMzZiMDlmMmViY2UwOV8zLTEtMS0xLTc0ODAy_d377e277-b26e-4457-8539-6c3561f50d19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e61be204d694c09879235c63a790f71_I20220930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTBlZGY2MWM1NTVkNGY1YWFlZDM2YjA5ZjJlYmNlMDkvdGFibGVyYW5nZTo1MGVkZjYxYzU1NWQ0ZjVhYWVkMzZiMDlmMmViY2UwOV8zLTMtMS0xLTc0ODAy_c5ba6073-8b72-4ea2-a693-24790a87779f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bc89218c26643328b21b1506819b3a0_I20220930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTBlZGY2MWM1NTVkNGY1YWFlZDM2YjA5ZjJlYmNlMDkvdGFibGVyYW5nZTo1MGVkZjYxYzU1NWQ0ZjVhYWVkMzZiMDlmMmViY2UwOV8zLTUtMS0xLTc0ODAy_3745a046-d2f3-4a3e-9039-a67008754088">95,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c58b8bf6804181b9ae7aa0ce6fa7e0_I20220930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTBlZGY2MWM1NTVkNGY1YWFlZDM2YjA5ZjJlYmNlMDkvdGFibGVyYW5nZTo1MGVkZjYxYzU1NWQ0ZjVhYWVkMzZiMDlmMmViY2UwOV8zLTctMS0xLTc0ODAy_8b38c9e4-3aad-4d99-95a6-f651c7bc0253">95,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1d99a70db5f43208858b7f0f954c2d1_I20220930" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTBlZGY2MWM1NTVkNGY1YWFlZDM2YjA5ZjJlYmNlMDkvdGFibGVyYW5nZTo1MGVkZjYxYzU1NWQ0ZjVhYWVkMzZiMDlmMmViY2UwOV80LTEtMS0xLTc0ODAy_bbe7d6b5-c5bc-4a61-9f72-87643dfff1db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e61be204d694c09879235c63a790f71_I20220930" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTBlZGY2MWM1NTVkNGY1YWFlZDM2YjA5ZjJlYmNlMDkvdGFibGVyYW5nZTo1MGVkZjYxYzU1NWQ0ZjVhYWVkMzZiMDlmMmViY2UwOV80LTMtMS0xLTc0ODAy_030a37ad-7128-4de0-a451-f185d26766df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bc89218c26643328b21b1506819b3a0_I20220930" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTBlZGY2MWM1NTVkNGY1YWFlZDM2YjA5ZjJlYmNlMDkvdGFibGVyYW5nZTo1MGVkZjYxYzU1NWQ0ZjVhYWVkMzZiMDlmMmViY2UwOV80LTUtMS0xLTc0ODAy_d9ffefb3-9a1f-4cf5-b46d-88d98a72b9ff">95,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88c58b8bf6804181b9ae7aa0ce6fa7e0_I20220930" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTBlZGY2MWM1NTVkNGY1YWFlZDM2YjA5ZjJlYmNlMDkvdGFibGVyYW5nZTo1MGVkZjYxYzU1NWQ0ZjVhYWVkMzZiMDlmMmViY2UwOV80LTctMS0xLTc0ODAy_2864e523-3353-4e7c-9e4a-7a15d4b40c7f">95,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:325.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i328717c857f2404dba9ba20b9433ea18_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTNjYjczNGQ4ODg3NGI1N2ExMGEyYjBkYzhlMjMxOGEvdGFibGVyYW5nZTo1M2NiNzM0ZDg4ODc0YjU3YTEwYTJiMGRjOGUyMzE4YV8zLTEtMS0xLTc0ODAy_fafd1b2c-03dd-472f-99b0-810c83f9aa36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id142ae030d514564a81b2bb1eadfeaba_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTNjYjczNGQ4ODg3NGI1N2ExMGEyYjBkYzhlMjMxOGEvdGFibGVyYW5nZTo1M2NiNzM0ZDg4ODc0YjU3YTEwYTJiMGRjOGUyMzE4YV8zLTMtMS0xLTc0ODAy_fea7124a-d38f-486a-aa83-86da7c30dcfe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867837f495ba4b65886161a03a0def38_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTNjYjczNGQ4ODg3NGI1N2ExMGEyYjBkYzhlMjMxOGEvdGFibGVyYW5nZTo1M2NiNzM0ZDg4ODc0YjU3YTEwYTJiMGRjOGUyMzE4YV8zLTUtMS0xLTc0ODAy_a4da73cc-0cad-4c7f-bcbb-065b2ea0cd97">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1e69c3b48346c3b0514ad1ccceb5f8_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTNjYjczNGQ4ODg3NGI1N2ExMGEyYjBkYzhlMjMxOGEvdGFibGVyYW5nZTo1M2NiNzM0ZDg4ODc0YjU3YTEwYTJiMGRjOGUyMzE4YV8zLTctMS0xLTc0OTQ0_b1f05b1f-0139-4ec2-817e-ec3126c83f1a">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i328717c857f2404dba9ba20b9433ea18_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTNjYjczNGQ4ODg3NGI1N2ExMGEyYjBkYzhlMjMxOGEvdGFibGVyYW5nZTo1M2NiNzM0ZDg4ODc0YjU3YTEwYTJiMGRjOGUyMzE4YV80LTEtMS0xLTc0ODAy_bce6f1c0-94cc-444a-9417-739837374228">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id142ae030d514564a81b2bb1eadfeaba_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTNjYjczNGQ4ODg3NGI1N2ExMGEyYjBkYzhlMjMxOGEvdGFibGVyYW5nZTo1M2NiNzM0ZDg4ODc0YjU3YTEwYTJiMGRjOGUyMzE4YV80LTMtMS0xLTc0ODAy_f137315c-4bf3-46cf-bd09-a2ebbf606f31">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867837f495ba4b65886161a03a0def38_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTNjYjczNGQ4ODg3NGI1N2ExMGEyYjBkYzhlMjMxOGEvdGFibGVyYW5nZTo1M2NiNzM0ZDg4ODc0YjU3YTEwYTJiMGRjOGUyMzE4YV80LTUtMS0xLTc0ODAy_37a1b184-3d35-4751-8044-68350081d0b7">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1e69c3b48346c3b0514ad1ccceb5f8_I20211231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTNjYjczNGQ4ODg3NGI1N2ExMGEyYjBkYzhlMjMxOGEvdGFibGVyYW5nZTo1M2NiNzM0ZDg4ODc0YjU3YTEwYTJiMGRjOGUyMzE4YV80LTctMS0xLTc0ODAy_fec6a459-ea31-4853-b8ae-f4fc77cbc76a">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of earn-out consideration related to the IPG and Vital transactions as described in Note 4.</span></div></ix:continuation><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the three and nine months ended September 30, 2022 and 2021, respectively.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i1a84af2c475c4fbaa949fad04c4d9808"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the acquisitions of IPG and Vital Decisions include a provision for additional equity consideration, at the Company&#8217;s option, contingent upon the Company obtaining certain performance metrics. The earnout period for the Vital Decisions contingent considering is the three months ending December 31, 2022, and the earnout periods for IPG are the four months ended December 31, 2022 and the nine months ended September 30, 2023. The fair value of the contingent equity considerations was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurements of the IPG and Vital Decisions contingent considerations are the risk-neutral (probability weighted) earnout consideration and the applicable discount rate. A significant increase in the risk-neutral (probability weighted) earnout consideration or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGV4dHJlZ2lvbjphNWY5MTFjNThlOGI0OTU5YjUwN2JkOGY3Mzc2NTc2MF8zMjk4NTM0ODg5MDU1_80d3283d-ed4b-47ce-8bf3-8e554e77209c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OGQ4OGVkZGM1OGY1NDE5MTgxZWI3Mjc2NmZhNmE3NWUvdGFibGVyYW5nZTo4ZDg4ZWRkYzU4ZjU0MTkxODFlYjcyNzY2ZmE2YTc1ZV8yLTEtMS0xLTc0ODAy_9ed744fa-615b-4d43-9af4-058fadc3ee13">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcb7e5d5de6d4fb9bd1b47d49e170108_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OGQ4OGVkZGM1OGY1NDE5MTgxZWI3Mjc2NmZhNmE3NWUvdGFibGVyYW5nZTo4ZDg4ZWRkYzU4ZjU0MTkxODFlYjcyNzY2ZmE2YTc1ZV8yLTMtMS0xLTc0ODAy_f1595d0a-531d-4900-862f-f5be05c16eb8">13,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OGQ4OGVkZGM1OGY1NDE5MTgxZWI3Mjc2NmZhNmE3NWUvdGFibGVyYW5nZTo4ZDg4ZWRkYzU4ZjU0MTkxODFlYjcyNzY2ZmE2YTc1ZV8zLTEtMS0xLTc0ODAy_d2bf8946-c43e-4fa5-b9dc-da526a19a17b">75,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OGQ4OGVkZGM1OGY1NDE5MTgxZWI3Mjc2NmZhNmE3NWUvdGFibGVyYW5nZTo4ZDg4ZWRkYzU4ZjU0MTkxODFlYjcyNzY2ZmE2YTc1ZV8zLTMtMS0xLTc0ODAy_f654655b-62f3-4bc2-a55d-45e63e3972be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OGQ4OGVkZGM1OGY1NDE5MTgxZWI3Mjc2NmZhNmE3NWUvdGFibGVyYW5nZTo4ZDg4ZWRkYzU4ZjU0MTkxODFlYjcyNzY2ZmE2YTc1ZV80LTEtMS0xLTc0ODAy_e3b35051-459e-49e0-a6f9-ec853b127a8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OGQ4OGVkZGM1OGY1NDE5MTgxZWI3Mjc2NmZhNmE3NWUvdGFibGVyYW5nZTo4ZDg4ZWRkYzU4ZjU0MTkxODFlYjcyNzY2ZmE2YTc1ZV80LTMtMS0xLTc0ODAy_9a847713-0bee-4d34-a74e-f30edbfd2821">13,730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OGQ4OGVkZGM1OGY1NDE5MTgxZWI3Mjc2NmZhNmE3NWUvdGFibGVyYW5nZTo4ZDg4ZWRkYzU4ZjU0MTkxODFlYjcyNzY2ZmE2YTc1ZV81LTEtMS0xLTc0ODAy_0c81ca24-0f6f-4d36-a5f0-0544bd5d320c">8,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OGQ4OGVkZGM1OGY1NDE5MTgxZWI3Mjc2NmZhNmE3NWUvdGFibGVyYW5nZTo4ZDg4ZWRkYzU4ZjU0MTkxODFlYjcyNzY2ZmE2YTc1ZV81LTMtMS0xLTc0ODAy_1224de57-a6d1-4025-ba75-44ffe6b98844">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OGQ4OGVkZGM1OGY1NDE5MTgxZWI3Mjc2NmZhNmE3NWUvdGFibGVyYW5nZTo4ZDg4ZWRkYzU4ZjU0MTkxODFlYjcyNzY2ZmE2YTc1ZV82LTEtMS0xLTc0ODAy_b459ea44-5750-404e-a1c4-bec045a9d8b5">95,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63b3ddd7486946c2a0a8151832317d14_I20210930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OGQ4OGVkZGM1OGY1NDE5MTgxZWI3Mjc2NmZhNmE3NWUvdGFibGVyYW5nZTo4ZDg4ZWRkYzU4ZjU0MTkxODFlYjcyNzY2ZmE2YTc1ZV82LTMtMS0xLTc0ODAy_4ec9b714-30da-4fbd-9ed9-9a05914b110e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGV4dHJlZ2lvbjphNWY5MTFjNThlOGI0OTU5YjUwN2JkOGY3Mzc2NTc2MF8zMjk4NTM0ODg5MDU2_dabb7fb3-3640-48c4-b027-3a4434b55d49" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bc89218c26643328b21b1506819b3a0_I20220930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6Zjg4N2FiOTNhOWNlNDU5ZTkwNDc4NjUzMTZhN2U3MzMvdGFibGVyYW5nZTpmODg3YWI5M2E5Y2U0NTllOTA0Nzg2NTMxNmE3ZTczM18zLTEtMS0xLTc0OTUw_26c631ad-df5f-4194-884f-4c685d878031">95,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5a543708cce4e1587fc2f618e7c92b7_I20220930" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6Zjg4N2FiOTNhOWNlNDU5ZTkwNDc4NjUzMTZhN2U3MzMvdGFibGVyYW5nZTpmODg3YWI5M2E5Y2U0NTllOTA0Nzg2NTMxNmE3ZTczM18zLTctMS0xLTc0OTUw_47b3e0f9-a6e2-4b4b-971e-2437d21e6be6">95,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i28495d82fa994f08b28b8dfc1e3a47e6_I20220930" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6Zjg4N2FiOTNhOWNlNDU5ZTkwNDc4NjUzMTZhN2U3MzMvdGFibGVyYW5nZTpmODg3YWI5M2E5Y2U0NTllOTA0Nzg2NTMxNmE3ZTczM180LTctMS0xLTc0OTUw_61fc7008-a03e-42a4-9266-37907f64f279">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.821%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i867837f495ba4b65886161a03a0def38_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OTZjNWQ5MDQ3M2ZmNDYxNGFmNmI1MzUxYTUyODJiN2MvdGFibGVyYW5nZTo5NmM1ZDkwNDczZmY0NjE0YWY2YjUzNTFhNTI4MmI3Y18zLTEtMS0xLTc0OTUy_86624291-67e1-453b-b42b-70b17caeb462">28,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd65a2db6ad04df8b047a7d81b2023ee_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OTZjNWQ5MDQ3M2ZmNDYxNGFmNmI1MzUxYTUyODJiN2MvdGFibGVyYW5nZTo5NmM1ZDkwNDczZmY0NjE0YWY2YjUzNTFhNTI4MmI3Y18zLTctMS0xLTc0OTUy_86e5b232-8ae3-4129-bf14-d746683381b9">30,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i30e706fd844d4e009a8b34652d74f93b_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OTZjNWQ5MDQ3M2ZmNDYxNGFmNmI1MzUxYTUyODJiN2MvdGFibGVyYW5nZTo5NmM1ZDkwNDczZmY0NjE0YWY2YjUzNTFhNTI4MmI3Y180LTctMS0xLTc0OTUy_591d95e8-9590-4d14-9bd6-7a4d5f1a3507">6.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ie509a30ec74b42a79206b48ddcea2a16"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10 for information regarding the fair value of the 2024 Notes and 2025 Notes.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i4a25f060abc946f28c4a0095422c2513_97"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 18. <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RleHRyZWdpb246OTkyNjg0NjEzNWViNDc1YTg3NGU4Mjc2ZjNhZmFjZDZfMTE3NA_399b75a6-feec-41d0-b8f8-eedd5dcbd6ef" continuedAt="ideab9e1d88fd48ed8161510ed8c55b12" escape="true">Related Parties </ix:nonNumeric><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ideab9e1d88fd48ed8161510ed8c55b12" continuedAt="i26a70fe2762a4c8ab990edc971f1f937"> </ix:continuation></span></div><ix:continuation id="i26a70fe2762a4c8ab990edc971f1f937"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in Note&#160;16, the Company had economic interests in several entities that are accounted for under the equity method of accounting. The Company has allocated its proportional share of the investees&#8217; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also works with UPMC, one of its founding investors. The Company&#8217;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. This relationship is currently in wind-down.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RleHRyZWdpb246OTkyNjg0NjEzNWViNDc1YTg3NGU4Mjc2ZjNhZmFjZDZfMTE3Ng_0ee7ea29-f009-4a81-9916-f7ce3c150392" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.494%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb038b091b7344c29e48adca13ed03ae_I20220930" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfMi0xLTEtMS02NjkxMA_08c2e60b-8c3f-4bbe-83fc-d7b0063d6c9e">10,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6387c494ab8746e7b6c8beed248da58e_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfMi0zLTEtMS02NjkxMA_3ad3eb98-b45d-4bdc-9a10-34e272eb84a4">2,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb038b091b7344c29e48adca13ed03ae_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfMy0xLTEtMS02NjkxMA_53021713-5b6c-420a-8f2b-fa58b48827a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6387c494ab8746e7b6c8beed248da58e_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfMy0zLTEtMS02NjkxMA_20ae3468-8d5b-497e-9441-1eb6ecd0cc7e">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb038b091b7344c29e48adca13ed03ae_I20220930" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfNC0xLTEtMS02NjkxMA_f5b51c4c-8b66-4ab2-84c2-06bd51b7b4ed">884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6387c494ab8746e7b6c8beed248da58e_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfNC0zLTEtMS02NjkxMA_4a44b13e-c071-4da4-9389-5b90ecdaa76d">4,877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb038b091b7344c29e48adca13ed03ae_I20220930" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfNy0xLTEtMS02NjkxMA_719eb63f-2c06-4b85-9f9b-9c97f2c77275">432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6387c494ab8746e7b6c8beed248da58e_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfNy0zLTEtMS02NjkxMA_e5912507-033d-431a-a07f-dc3cb2111d3f">1,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb038b091b7344c29e48adca13ed03ae_I20220930" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfOC0xLTEtMS02NjkxMA_58aa18ad-5924-4515-8d90-9c7e08e8273a">954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6387c494ab8746e7b6c8beed248da58e_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfOC0zLTEtMS02NjkxMA_9630fc12-6e22-44ce-9fcf-375789b2fa19">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb038b091b7344c29e48adca13ed03ae_I20220930" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfOS0xLTEtMS02NjkxMA_bb03de77-0d99-44c9-aa71-910233c62bc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6387c494ab8746e7b6c8beed248da58e_I20211231" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfOS0zLTEtMS02NjkxMA_a8f6f7bc-6aed-4d95-a397-0149e3fd01e0">734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:319.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:49.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:49.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:49.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:54.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie08f13f16382418ea5ec290830f60d8c_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfMi0xLTEtMS02NjkxMA_40a91c7a-2d48-4648-91d7-a77f52089951">36,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12e6f929d457432287e5c6cd1f183f5f_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfMi0zLTEtMS02NjkxMA_ba1caec4-c74b-4c28-914d-0231c4e517e3">9,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5df79eb68c444ab9cb77a56bf677989_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfMi01LTEtMS02NjkxMA_785724da-d4b5-4061-829b-c077b45495cd">111,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cace99351664c7ca949a3e0200ac20d_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfMi03LTEtMS02NjkxMA_a5ccae19-0bf6-4f44-9fef-95b3a2afd86e">35,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60fada84ac4946cb9b4e805a57e3cf0b_D20220701-20220930" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfNS0xLTEtMS02NjkxMA_ece5d465-47cf-4023-8b0f-811ebb17d0a9">30,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9bdab906b4a4d49a48fe38f018eb8bc_D20210701-20210930" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfNS0zLTEtMS02NjkxMA_d30a06cc-e429-43c3-991c-a7bf0ae839e1">751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a5ea59bbc694c93968f7c1ff417d386_D20220101-20220930" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfNS01LTEtMS02NjkxMA_303bd1be-6789-4028-b699-fc29b0bbb4a2">93,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d139443bb3e4ce086f6d2c6a7b557b2_D20210101-20210930" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfNS03LTEtMS02NjkxMA_b9a2b6e7-11e5-470d-9d72-be63cd68383c">1,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73540c5f613d403b832d91b574a59f07_D20220701-20220930" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfNi0xLTEtMS02NjkxMA_17bd9dd7-ef18-4ed1-a59e-9a119fab9ac0">443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice64acee7f3f46179553cd75809b106f_D20210701-20210930" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfNi0zLTEtMS02NjkxMA_efde17ff-233b-4599-8988-a97190913a90">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic86b2c3d20a443a49da566ae4eaf14cd_D20220101-20220930" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfNi01LTEtMS02NjkxMA_8c0741b9-80ac-4c71-a78f-5f11493ec7ae">745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia91f376f9d6846eb84ca11a8a358cf74_D20210101-20210930" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfNi03LTEtMS02NjkxMA_6a86a354-bc84-4a1e-9949-41055ad9d7ee">186</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 19. <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDAvZnJhZzplMTQ2MjMwNThlYjQ0NjgyYmVjZDZiNTk5YTI4ZTc0Mi90ZXh0cmVnaW9uOmUxNDYyMzA1OGViNDQ2ODJiZWNkNmI1OTlhMjhlNzQyXzE0NjU_4e1a0319-b391-4cf0-b445-e8978241fd41" continuedAt="iad4497411f094be6b5eb24ef234e1912" escape="true">Repositioning and Other Changes</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="iad4497411f094be6b5eb24ef234e1912" continuedAt="ib02e88176e2e4d0ba0b1d0449de7bd19"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#8220;Repositioning Plan&#8221;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives that will provide future benefit to the Company. The Repositioning Plan concluded in the fourth quarter of 2021.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib02e88176e2e4d0ba0b1d0449de7bd19"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDAvZnJhZzplMTQ2MjMwNThlYjQ0NjgyYmVjZDZiNTk5YTI4ZTc0Mi90ZXh0cmVnaW9uOmUxNDYyMzA1OGViNDQ2ODJiZWNkNmI1OTlhMjhlNzQyXzE0NjQ_a06ce549-1ccc-4eb7-9fb3-1c3e20504ccc" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total costs associated with the Repositioning Plan by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.094%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Costs Incurred through December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred For the Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6e2ba14bf4d472691df13b609cc514b_I20211231" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDAvZnJhZzplMTQ2MjMwNThlYjQ0NjgyYmVjZDZiNTk5YTI4ZTc0Mi90YWJsZTplODc5OWM0ZjdkYjk0NDM4OWJhNGFjMWVjM2IxYjkyZC90YWJsZXJhbmdlOmU4Nzk5YzRmN2RiOTQ0Mzg5YmE0YWMxZWMzYjFiOTJkXzEtMS0xLTEtNjY5MTA_386c6142-a1e0-405e-abfa-574a6d45312a">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38f3231de914c44a9c3146fc55eb3b8_D20210101-20210930" decimals="-3" name="us-gaap:RestructuringCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDAvZnJhZzplMTQ2MjMwNThlYjQ0NjgyYmVjZDZiNTk5YTI4ZTc0Mi90YWJsZTplODc5OWM0ZjdkYjk0NDM4OWJhNGFjMWVjM2IxYjkyZC90YWJsZXJhbmdlOmU4Nzk5YzRmN2RiOTQ0Mzg5YmE0YWMxZWMzYjFiOTJkXzEtNS0xLTEtNjY5MTA_4d863d38-a8e7-4161-8be0-6167e806aa4d">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3044ccef126a4375824fc8fc3a6c3ce3_I20211231" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDAvZnJhZzplMTQ2MjMwNThlYjQ0NjgyYmVjZDZiNTk5YTI4ZTc0Mi90YWJsZTplODc5OWM0ZjdkYjk0NDM4OWJhNGFjMWVjM2IxYjkyZC90YWJsZXJhbmdlOmU4Nzk5YzRmN2RiOTQ0Mzg5YmE0YWMxZWMzYjFiOTJkXzItMS0xLTEtNjY5MTA_2ed49512-7f68-4775-9c1c-ebc9dd443ede">2,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91cfb2c56b99413c9fb95814cfb285f4_D20210101-20210930" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDAvZnJhZzplMTQ2MjMwNThlYjQ0NjgyYmVjZDZiNTk5YTI4ZTc0Mi90YWJsZTplODc5OWM0ZjdkYjk0NDM4OWJhNGFjMWVjM2IxYjkyZC90YWJsZXJhbmdlOmU4Nzk5YzRmN2RiOTQ0Mzg5YmE0YWMxZWMzYjFiOTJkXzItNS0xLTEtNjY5MTA_d9144da4-82a9-4650-8823-84f83aa964b9">2,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3adb4e55cc4e45a7911caff2dbcc7a00_I20211231" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDAvZnJhZzplMTQ2MjMwNThlYjQ0NjgyYmVjZDZiNTk5YTI4ZTc0Mi90YWJsZTplODc5OWM0ZjdkYjk0NDM4OWJhNGFjMWVjM2IxYjkyZC90YWJsZXJhbmdlOmU4Nzk5YzRmN2RiOTQ0Mzg5YmE0YWMxZWMzYjFiOTJkXzMtMS0xLTEtNjY5MTA_76e5f86e-8022-43de-ae78-12201478b8b4">5,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ed21b2abe494c07b71ec32367fb20d9_D20210101-20210930" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDAvZnJhZzplMTQ2MjMwNThlYjQ0NjgyYmVjZDZiNTk5YTI4ZTc0Mi90YWJsZTplODc5OWM0ZjdkYjk0NDM4OWJhNGFjMWVjM2IxYjkyZC90YWJsZXJhbmdlOmU4Nzk5YzRmN2RiOTQ0Mzg5YmE0YWMxZWMzYjFiOTJkXzMtNS0xLTEtNjY5MTA_32a72054-8445-48ec-8626-7ca4d5cfe846">3,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDAvZnJhZzplMTQ2MjMwNThlYjQ0NjgyYmVjZDZiNTk5YTI4ZTc0Mi90YWJsZTplODc5OWM0ZjdkYjk0NDM4OWJhNGFjMWVjM2IxYjkyZC90YWJsZXJhbmdlOmU4Nzk5YzRmN2RiOTQ0Mzg5YmE0YWMxZWMzYjFiOTJkXzQtMS0xLTEtNjY5MTA_e603de34-02bd-4aa7-a225-0315f93d15cb">8,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDAvZnJhZzplMTQ2MjMwNThlYjQ0NjgyYmVjZDZiNTk5YTI4ZTc0Mi90YWJsZTplODc5OWM0ZjdkYjk0NDM4OWJhNGFjMWVjM2IxYjkyZC90YWJsZXJhbmdlOmU4Nzk5YzRmN2RiOTQ0Mzg5YmE0YWMxZWMzYjFiOTJkXzQtNS0xLTEtNjY5MTA_d356d476-612a-4947-9578-f492b87372c9">6,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_103"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 20. <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90ZXh0cmVnaW9uOmUzNTdjZjJjZWI1MDQ4MmFiNzMwNGMyZmNjZTBhNjA2XzMwODA_997d0a2c-b98e-4d32-bb96-68b03d041824" continuedAt="i516d2238c64d4d95946ec029044ffa45" escape="true">Segment Reporting</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i516d2238c64d4d95946ec029044ffa45" continuedAt="ib2057f5b7cbd494d8d93fa69ce53aa0f"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define our reportable segments based on the way the CODM, the chief executive officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into <ix:nonFraction unitRef="segment" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90ZXh0cmVnaW9uOmUzNTdjZjJjZWI1MDQ4MmFiNzMwNGMyZmNjZTBhNjA2XzI0Mg_c6763688-a6b8-4053-967d-fc2ce601b195">two</ix:nonFraction> reportable segments as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Clinical Solutions, which includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is defined as net income (loss) attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, provision (benefit) for income taxes, depreciation and amortization expenses, adjusted to exclude gain on transfer of membership, loss on extinguishment/repayment of debt, net, gain from equity method investees, changes in fair value of contingent consideration, change in the tax receivable agreement liability, other income (expense), net, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, strategy and shareholder advisory services, acquisition-related costs and gain (loss) from discontinued operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90ZXh0cmVnaW9uOmUzNTdjZjJjZWI1MDQ4MmFiNzMwNGMyZmNjZTBhNjA2XzMwNzY_b72625e2-b0f0-4a0a-840d-0cae57bfd597" continuedAt="ia3535994d6cc4e2fb0ebd81ccf2e47c9" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:145.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i806263fe61f14f33b5cdbd7eee333ff7_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzMtMS0xLTEtNjY5MTA_a15f5ed7-343f-47f1-b95f-4c60cbc4faa5">107,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacbe24e15241450eb5814aef67850f85_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzMtMy0xLTEtNjY5MTA_8e00e519-d988-4a53-bd8f-191e40be7a6e">245,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7b76ebaaef241a09456df69e9f56730_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzMtNS0xLTEtNjY5MTA_337d4b5c-6f56-4d5f-975b-3bf1bc0588fb">295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47a9c894a7d46569bed9ed6ad4e9987_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzMtNy0xLTEtNjY5MTA_3385a705-8762-4553-9668-6a220cf79811">352,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie593e243a4f94ded8dcc0cbd2124556d_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzMtOS0xLTEtNjY5MTA_b00c13c9-cdbc-4e87-9aec-f5356f81dfbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzMtMTEtMS0xLTY2OTEw_6d0969e3-fe5f-4519-97b5-870a4d492108">352,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e9c2f26074c434280c915a00ab6b2fe_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzYtMS0xLTEtNjY5MTA_ff74aeb7-8c94-4c0c-b880-bddcbb6f50e1">63,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26289f6ee3444cf484ed38a01409bbfe_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzYtMy0xLTEtNjY5MTA_5faf0c04-bde5-427d-a7b2-8b4477f306bd">159,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i338af69a6f0948e5a6b88db8f9f14704_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzYtNS0xLTEtNjY5MTA_0950d7b5-17cf-4668-8bc3-a5a42ad8de6d">458</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbee25bccde9417b9684147c13bfd340_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzYtNy0xLTEtNjY5MTA_9cee1b69-97e1-4500-b798-751529ee6204">222,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f35093a1db04660afd25caee273d0f0_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzYtOS0xLTEtNjY5MTA_255c6a2e-5408-489b-9f10-99085f0be9ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzYtMTEtMS0xLTY2OTEw_db0c11c7-13e1-4415-92b0-98f4b4285a3b">222,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib2057f5b7cbd494d8d93fa69ce53aa0f" continuedAt="if27c5dfc9a0e4da090bc974c9fb5be86"><ix:continuation id="ia3535994d6cc4e2fb0ebd81ccf2e47c9"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:145.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i806263fe61f14f33b5cdbd7eee333ff7_D20220701-20220930" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzEwLTEtMS0xLTY2OTEw_03c4026c-1dc9-4748-9207-1b5f19a3ed76">18,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacbe24e15241450eb5814aef67850f85_D20220701-20220930" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzEwLTMtMS0xLTY2OTEw_35863bf5-e760-4853-8165-f6146ade2289">16,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id47a9c894a7d46569bed9ed6ad4e9987_D20220701-20220930" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzEwLTUtMS0xLTY2OTEw_aa15c947-f579-4c38-adf7-01955663fe0c">34,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie593e243a4f94ded8dcc0cbd2124556d_D20220701-20220930" decimals="-3" sign="-" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzEwLTctMS0xLTY2OTEw_d55edef2-1989-4268-ac7c-f207637df64d">6,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzEwLTktMS0xLTY2OTEw_6fa21dda-6025-4e38-a3fa-5dc728efece9">28,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e9c2f26074c434280c915a00ab6b2fe_D20210701-20210930" decimals="-3" sign="-" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzEzLTEtMS0xLTY2OTEw_c64d1736-5193-4c39-9b48-68692fffa270">3,353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26289f6ee3444cf484ed38a01409bbfe_D20210701-20210930" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzEzLTMtMS0xLTY2OTEw_47e01476-eb7a-4652-a815-9964b1280a90">23,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbee25bccde9417b9684147c13bfd340_D20210701-20210930" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzEzLTUtMS0xLTY2OTEw_7d9fd000-d297-43b4-93bc-2b9118818b1a">20,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f35093a1db04660afd25caee273d0f0_D20210701-20210930" decimals="-3" sign="-" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzEzLTctMS0xLTY2OTEw_a954d418-5b37-4fb4-86e9-19c4da48ea7c">6,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzEzLTktMS0xLTY2OTEw_3ce847db-4f92-48ce-878c-698454a89632">13,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:145.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:52.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:60.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:61.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:67.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd61671a0d0442d5ad34be35130c449e_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzMtMS0xLTEtNjY5MTA_8ef5dc9a-dd98-4307-b064-11b9a03d0ec7">307,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cf7a17cbbf4a65b3324ddb3a731532_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzMtMy0xLTEtNjY5MTA_1a2ae0d3-a95d-46da-bb4e-7d5b417b297a">663,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0870ad9619a8495f9f783b300266e2bf_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzMtNS0xLTEtNjY5MTA_77cd9b9e-fc2b-4204-9201-6ac32a0ec954">626</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia108ecb595104f0e8ed9def9f229176e_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzMtNy0xLTEtNjY5MTA_9938df44-921d-4d34-92c7-083b90c334b4">969,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59101f8a3ac14ae493956a62379f494f_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzMtOS0xLTEtNjY5MTA_6e565580-3c97-41d7-a8be-f07b73837585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzMtMTEtMS0xLTY2OTEw_7867b864-e80b-47b2-9f69-5245df5b0d8f">969,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceebbb78aaf945b48c2e1e0c956749dd_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzYtMS0xLTEtNjY5MTA_1d03f357-49cf-44d6-ab6b-360478925df0">223,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3311fd1bb12e4f44944b34e49f4f81c7_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzYtMy0xLTEtNjY5MTA_2e312c49-5836-4143-b229-c4b1d59a6cfd">437,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71b35f78e61e4fd6a8f76ed882b8104b_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzYtNS0xLTEtNjY5MTA_10b5d017-f23a-41d1-b6aa-c985815e3850">1,356</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e6f529e4db48d8894cb30eac5feba5_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzYtNy0xLTEtNjY5MTA_68a8a27a-e173-4b42-9c8f-333a6be1937f">659,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8abf6d4aad764b85af854f18bc243f26_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzYtOS0xLTEtNjY5MTA_1feb478a-1bb8-4be9-9aeb-4ed8bd6395c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzYtMTEtMS0xLTY2OTEw_39565f45-90a0-4579-8f1c-6235a33574b7">659,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd61671a0d0442d5ad34be35130c449e_D20220101-20220930" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzEwLTEtMS0xLTY2OTEw_2a37ae34-ed92-4f80-aadc-1b5725b4a5a1">41,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1cf7a17cbbf4a65b3324ddb3a731532_D20220101-20220930" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzEwLTMtMS0xLTY2OTEw_487a488e-276a-4b00-a84c-3400f3be313b">51,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia108ecb595104f0e8ed9def9f229176e_D20220101-20220930" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzEwLTUtMS0xLTY2OTEw_a77b860f-c811-4720-99dc-bc97cdb95b43">93,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59101f8a3ac14ae493956a62379f494f_D20220101-20220930" decimals="-3" sign="-" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzEwLTctMS0xLTY2OTEw_e3a2ec66-79d7-4ea8-85d1-b5a980337789">19,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzEwLTktMS0xLTY2OTEw_a7242b0d-9928-4820-9f99-53a89b62b7b9">74,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceebbb78aaf945b48c2e1e0c956749dd_D20210101-20210930" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzEzLTEtMS0xLTY2OTEw_e3a95099-9d53-4ae2-8cd5-9511f5cb7a1a">9,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3311fd1bb12e4f44944b34e49f4f81c7_D20210101-20210930" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzEzLTMtMS0xLTY2OTEw_c86ca6fe-e904-4194-bf37-8cc1c850bdd6">53,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14e6f529e4db48d8894cb30eac5feba5_D20210101-20210930" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzEzLTUtMS0xLTY2OTEw_a89314c2-d62e-4f16-96e5-bc7985bda355">62,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8abf6d4aad764b85af854f18bc243f26_D20210101-20210930" decimals="-3" sign="-" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzEzLTctMS0xLTY2OTEw_ef619b6b-e8b5-4785-821f-28ff882d1bf2">20,558</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzEzLTktMS0xLTY2OTEw_9fe03c72-ba45-4ec5-831d-7915019b0be5">42,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.</span></div></ix:continuation><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90ZXh0cmVnaW9uOmUzNTdjZjJjZWI1MDQ4MmFiNzMwNGMyZmNjZTBhNjA2XzMwNzg_02e4741c-c4e8-47d6-ba63-e9d2b11c56dd" continuedAt="i65a99d90517f4db6af019b2e9251fb52" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzItMS0xLTEtNjY5MTA_caa7cda7-3cac-4e59-aa54-07d756a654f7">2,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzItMy0xLTEtNjY5MTA_38f004e3-9cff-402f-b687-f3fa9b29250d">13,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzItNS0xLTEtNjY5MTA_10955c01-f722-43fd-ab8b-1a080d194611">7,815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzItNy0xLTEtNjY5MTA_f88f8deb-4af6-48ef-afde-6988130f9d21">31,954</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzQtMS0xLTEtNjY5MTA_85192df2-d85c-4f99-8f26-9626ed56fe53">425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzQtMy0xLTEtNjY5MTA_d3a6469d-2976-4321-b114-52347be18f37">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzQtNS0xLTEtNjY5MTA_a5cf1b7e-ae1f-4538-9aba-233f19a72974">765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzQtNy0xLTEtNjY5MTA_a3c095e4-b462-4cf0-8dda-3d2a3585447c">311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzUtMS0xLTEtNjY5MTA_47b0e39d-ee84-420a-b763-82e814acb7c5">4,754</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzUtMy0xLTEtNjY5MTA_d3df82f7-ab86-4f9a-9d31-e5e9827ea22b">6,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzUtNS0xLTEtNjY5MTA_904a8787-e2ee-4f22-a129-a4fc1568c6e1">9,143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzUtNy0xLTEtNjY5MTA_84c06e08-85bf-4961-bb4a-c677f5b7c40f">18,978</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from (provision for) income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzYtMS0xLTEtNjY5MTA_0d0eb2b0-09bd-4929-95c2-e2db4e43818a">45,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzYtMy0xLTEtNjY5MTA_8a7ced05-4c23-44cb-bfe6-ec9cec66afbb">234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzYtNS0xLTEtNjY5MTA_9ba73afe-5a22-4111-87af-1f9cecc83f45">44,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzYtNy0xLTEtNjY5MTA_ba3be594-48bd-4d02-8913-b66c15944a7e">936</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivable agreement liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="evh:ChangesInTaxReceivablesAgreementLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzctMS0xLTEtODAzMzU_3f8af3fc-8665-444d-acec-66fad7476471">42,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="evh:ChangesInTaxReceivablesAgreementLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzctMy0xLTEtODAzMzU_c7c9b365-9d3d-4a1c-bc00-baf77ceb7c63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:ChangesInTaxReceivablesAgreementLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzctNS0xLTEtODAzMzU_82aba65e-e4ac-4e1b-a3f3-22efe04b6584">42,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:ChangesInTaxReceivablesAgreementLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzctNy0xLTEtODAzMzU_55efbc15-6c58-4fac-be01-55975e485349">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzctMS0xLTEtNjY5MTA_4febb18e-b545-4f0d-9fb2-c6bc46ca5366">17,196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzctMy0xLTEtNjY5MTA_1476fd83-0915-4ded-b18a-df8dd6f0f132">14,859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzctNS0xLTEtNjY5MTA_8761ca06-f9fc-49a4-8f5c-53bcfd8327d4">47,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzctNy0xLTEtNjY5MTA_242f8be7-626d-4cda-b56c-b6593c8ac4d0">44,962</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzgtMS0xLTEtNjY5MTA_cb85489c-6f0d-49da-9781-cebf5611f7dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzgtMy0xLTEtNjY5MTA_6ff20a6f-1155-4b91-b891-d80b33f4d04a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzgtNS0xLTEtNjY5MTA_8c59907f-44c0-4708-b2f0-27872999609c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:GainOnTransferOfMembership" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzgtNy0xLTEtNjY5MTA_f864d378-5bd6-4a0a-ba81-f68b0fadd65a">22,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment/repayment of debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzktMS0xLTEtNjY5MTA_5e42a7a1-1921-47c5-bcd8-94879ff1d171">10,192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzktMy0xLTEtNjY5MTA_575262f0-8248-445e-a8a0-b7bac172a647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzktNS0xLTEtNjY5MTA_9021fc7a-982c-4354-94d6-a2011268533f">10,192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzktNy0xLTEtNjY5MTA_5c929f9c-5f52-4d44-a06b-2b9566e0fc10">19,158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEwLTEtMS0xLTY2OTEw_f3ec9730-cc89-488e-9c61-8b649698cbf4">1,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEwLTMtMS0xLTY2OTEw_e1da764b-f4aa-48f6-9e5d-9eea0eedd3c8">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEwLTUtMS0xLTY2OTEw_ea7ccc5a-04f0-4e07-9f71-2e99afde943c">3,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEwLTctMS0xLTY2OTEw_a46f6a32-85a9-4816-8f16-40dd58605ac5">12,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzExLTEtMS0xLTY2OTEw_adbd047c-e7da-4373-b479-58b1873cb565">12,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzExLTMtMS0xLTY2OTEw_509f2e88-be39-462b-9227-89d15fd7a22f">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzExLTUtMS0xLTY2OTEw_e66ce63e-fe3a-4ba3-80bf-a7ba65daec17">5,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzExLTctMS0xLTY2OTEw_45d8a5e9-0164-423d-9417-ce25e9e49b12">819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEyLTEtMS0xLTY2OTEw_7f5633e1-1711-4576-a418-8865837b0e32">345</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEyLTMtMS0xLTY2OTEw_73c811b8-be36-4604-8eb9-e8becfe561f4">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEyLTUtMS0xLTY2OTEw_760a8ab0-a887-4d27-8474-2173b047d978">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEyLTctMS0xLTY2OTEw_eac41071-1f1b-4e33-bd0c-77f335aba105">73</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEzLTEtMS0xLTY2OTEw_28aad537-dc42-4c8d-83b9-d7fd2ad48c09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEzLTMtMS0xLTY2OTEw_fbdf844f-b64e-4faf-852b-75426727a381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEzLTUtMS0xLTY2OTEw_255e3eea-85ef-4a39-a6bb-bf3ad28edd2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEzLTctMS0xLTY2OTEw_6b8e5f6d-2af4-45bc-9cd7-9e84aa1821ee">6,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="evh:SharebasedCompensationIncludingOnetimeAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE0LTEtMS0xLTY2OTEw_a99e27d7-e518-4299-a6ac-8b4b7a6a31db">6,992</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="evh:SharebasedCompensationIncludingOnetimeAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE0LTMtMS0xLTY2OTEw_69118ed2-4cc2-43a8-8acb-51a02bc8d020">4,395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:SharebasedCompensationIncludingOnetimeAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE0LTUtMS0xLTY2OTEw_406dfd05-d5af-4101-91b1-af488f44da60">19,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:SharebasedCompensationIncludingOnetimeAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE0LTctMS0xLTY2OTEw_68a7e5bd-697d-41a1-b345-31ae216f2f21">11,754</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:SeveranceCosts1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE1LTEtMS0xLTY2OTEw_f09b6676-6589-48b5-978d-f21500d2dc45">996</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE1LTMtMS0xLTY2OTEw_1319bf77-2aad-45f0-961f-c5eec3231e07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE1LTUtMS0xLTY2OTEw_b71c39ec-7310-4204-b25f-5d78685a50b4">1,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:SeveranceCosts1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE1LTctMS0xLTY2OTEw_0faca54b-6b19-44c4-9a9c-3ba9fb3d6d0a">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE2LTEtMS0xLTY2OTEw_1115ab41-1cca-4ddd-85af-c5b42e0b8f48">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE2LTMtMS0xLTY2OTEw_fb62645e-455b-4b95-a080-a5f9ea7da022">110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE2LTUtMS0xLTY2OTEw_2cb3798b-8820-4531-8c5e-0f57de9bf97a">79</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE2LTctMS0xLTY2OTEw_6ab5bd06-6ef4-4c8d-9b09-2e88c398b69e">433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="evh:ShareholderAdvisoryServices" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE3LTEtMS0xLTY2OTEw_1620a4b6-431c-42f1-9613-0c7e4f59b2e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="evh:ShareholderAdvisoryServices" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE3LTMtMS0xLTY2OTEw_6a8021a3-6611-40e9-be44-ccaadb936782">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:ShareholderAdvisoryServices" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE3LTUtMS0xLTY2OTEw_f041a61e-168a-42b1-9aaf-7441781a238b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:ShareholderAdvisoryServices" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE3LTctMS0xLTY2OTEw_b2f7619c-fc92-4385-8e82-dca3680f53d2">6,513</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="evh:TransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE4LTEtMS0xLTY2OTEw_98a403af-7fe2-4efb-b46c-8327f2391968">2,595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="evh:TransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE4LTMtMS0xLTY2OTEw_d2201ef6-7750-4e68-85af-554453bb6ada">1,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:TransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE4LTUtMS0xLTY2OTEw_c290cdc0-d358-4451-a536-2666a3293798">6,473</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:TransactionCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE4LTctMS0xLTY2OTEw_b6f7146d-9f55-4253-bd57-b0f59c4fc619">3,277</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE5LTEtMS0xLTY2OTEw_0f3f1e42-b028-4ad8-82ff-e31136f81e66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE5LTMtMS0xLTY2OTEw_bce5d4fe-a79d-4aff-b23e-1041b79bc187">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE5LTUtMS0xLTY2OTEw_03bea6d6-9beb-486b-9e8c-a0700c93a8d0">463</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE5LTctMS0xLTY2OTEw_c89021c2-f5a6-40c5-b06d-40e177f9e480">1,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzIwLTEtMS0xLTY2OTEw_8d530af7-7e0e-4df7-9c1e-e539d2fe3c17">28,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzIwLTMtMS0xLTY2OTEw_a880952c-1c60-4738-897a-57c22aa45857">13,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzIwLTUtMS0xLTY2OTEw_2d07f6df-f264-481d-be6b-5b1c59bccb06">74,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzIwLTctMS0xLTY2OTEw_f65c497a-27c7-405f-a949-3b8aa06dfecb">42,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if27c5dfc9a0e4da090bc974c9fb5be86"><ix:continuation id="i65a99d90517f4db6af019b2e9251fb52"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes $(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90ZXh0cmVnaW9uOmUzNTdjZjJjZWI1MDQ4MmFiNzMwNGMyZmNjZTBhNjA2XzI3NTg_cd162837-63ed-45d0-8343-6d6ea621bb0f">0.5</ix:nonFraction>)&#160;million loss on disposal of discontinued operations for the nine months ended September 30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-5" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90ZXh0cmVnaW9uOmUzNTdjZjJjZWI1MDQ4MmFiNzMwNGMyZmNjZTBhNjA2XzI4NTg_d4a7dbf8-c781-4433-9ce3-297fee23c41b">1.9</ix:nonFraction>&#160;million gain on disposal of discontinued operations for the nine months ended September 30, 2021, respectively.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_106"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 21. <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:InsuranceDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90ZXh0cmVnaW9uOjA4NDJkMTViYzY3MTRmZjRhMDYxZGEyMGI5NTcxODYxXzQ2MjU_5c6289f4-f417-42e5-8d97-2762a16df38b" continuedAt="i1fd3c8ffb0634a5f9b17c10031cde2cc" escape="true">Reserve for Claims and Performance-Based Arrangements</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i1fd3c8ffb0634a5f9b17c10031cde2cc" continuedAt="i716f885f2f6e470b837ffa9291d3d391"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements for our EHS and Clinical Solutions segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 11.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs based on authorizations per thousand members basis and assigning an average cost per authorization. This is also adjusted for the impact of copays, deductibles, unit cost and historic discontinuation rates for treatment are considered. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i716f885f2f6e470b837ffa9291d3d391"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90ZXh0cmVnaW9uOjA4NDJkMTViYzY3MTRmZjRhMDYxZGEyMGI5NTcxODYxXzQ2Mjc_98cb659b-5248-4569-9b31-0cc85208e245" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"></td><td style="width:226.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:41.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:57.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:3.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b23b62d2314ba29f31148feecadf97_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzMtMS0xLTEtNjY5MTA_a2bb0832-c1e5-4487-90ca-b7228592557a">25,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c9b3945ac9741d4843b49c10f8dcd40_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzMtMy0xLTEtNjY5MTA_99b1ab20-603e-4fdd-b7de-85c581dd415f">145,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzMtNS0xLTEtNjY5MTA_a5cf5cab-27b6-4e81-901d-d3917a6e5189">171,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0291d88c45549ebb15674a1bf82c1a2_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzMtNy0xLTEtNjY5MTA_deca7ced-7a41-4dc0-b45f-61a90088fb72">56,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b7c2c9eb4d24e95a2fb3597a736a55d_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzMtOS0xLTEtNjY5MTA_9095b140-dc99-4021-aa51-ca5366dfb120">122,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcb7e5d5de6d4fb9bd1b47d49e170108_I20201231" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzMtMTEtMS0xLTY2OTEw_189a138f-2a0c-4982-a6b2-77ac0c701ccc">178,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred health care costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year to date period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieef521b6cb2644d59433c4a98ac67edb_D20220101-20220930" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzUtMS0xLTEtNjY5MTA_9c290c1b-8797-48a0-9fc5-a839e3511834">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5af61dbd97844f2cb160b48a3a35d4e8_D20220101-20220930" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzUtMy0xLTEtNjY5MTA_a2c3381c-2df4-40fc-a4c4-a8ab9932a72f">471,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzUtNS0xLTEtNjY5MTA_6120cecc-aec0-4a0d-b710-5dc2c54ac91c">471,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4dfdc7272dc4a849a6c7e48dfcc4f74_D20210101-20210930" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzUtNy0xLTEtNjY5MTA_fb0786c5-5d7a-42ea-ac33-005f281b09b7">6,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e55c1b3affc496aa10cbd0b6538c957_D20210101-20210930" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzUtOS0xLTEtNjY5MTA_14164e0c-9df8-4852-99c7-013a477d0ed0">376,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzUtMTEtMS0xLTY2OTEw_b91097b6-989f-45c3-87b6-2f9839b5cb4d">383,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year to date period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieef521b6cb2644d59433c4a98ac67edb_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzYtMS0xLTEtNjY5MTA_d7d56845-9de8-48c7-a5bb-d00eb87a7686">5,714</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5af61dbd97844f2cb160b48a3a35d4e8_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzYtMy0xLTEtNjY5MTA_138cf0ac-c3e7-4941-89ee-5bd9cf8f200e">2,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzYtNS0xLTEtNjY5MTA_4a37ec0e-8ab1-4350-88b0-4d4707572b46">8,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4dfdc7272dc4a849a6c7e48dfcc4f74_D20210101-20210930" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzYtNy0xLTEtNjY5MTA_d1505e3e-9c79-421e-bf5a-2376c9eab1e2">527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e55c1b3affc496aa10cbd0b6538c957_D20210101-20210930" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzYtOS0xLTEtNjY5MTA_915e800c-8c79-44d4-9bf3-50df9fe8f839">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzYtMTEtMS0xLTY2OTEw_107d1c77-b4ae-411e-a429-1fb4e7850014">619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims incurred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieef521b6cb2644d59433c4a98ac67edb_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzctMS0xLTEtNzQxMzc_c92f354b-2ddc-4b84-a4ef-d26f80127d65">5,714</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5af61dbd97844f2cb160b48a3a35d4e8_D20220101-20220930" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzctMy0xLTEtNzQxNTM_102b24ae-b258-4aaa-9ec2-9df34a599a2e">469,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzctNS0xLTEtNzQxNjE_5453da15-a740-46b7-b9f8-6363086228f9">463,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4dfdc7272dc4a849a6c7e48dfcc4f74_D20210101-20210930" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzctNy0xLTEtNzQxNDU_7e0c9cd3-680a-4e55-b019-e331e1247cc7">7,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e55c1b3affc496aa10cbd0b6538c957_D20210101-20210930" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzctOS0xLTEtNzQxNzI_b3a60fc4-0f5a-4662-8486-723408f624d9">376,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzctMTEtMS0xLTc0MTgw_3bf6f6b7-db84-4769-9abb-8843d24b7827">383,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year to date period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieef521b6cb2644d59433c4a98ac67edb_D20220101-20220930" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzgtMS0xLTEtNjY5MTA_f101d90e-fae5-40fe-a90b-2345da2ebf4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5af61dbd97844f2cb160b48a3a35d4e8_D20220101-20220930" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzgtMy0xLTEtNjY5MTA_7b9bd2c0-a6fa-40c4-b995-144ac03d568f">369,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzgtNS0xLTEtNjY5MTA_7c173228-98d4-4a63-88b7-e4647b899c30">369,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4dfdc7272dc4a849a6c7e48dfcc4f74_D20210101-20210930" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzgtNy0xLTEtNjY5MTA_e9dacc34-3685-4488-a120-d31ecda9c7eb">20,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e55c1b3affc496aa10cbd0b6538c957_D20210101-20210930" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzgtOS0xLTEtNjY5MTA_85f4a15c-dd0a-4747-aba4-6c3c2c250dfb">229,315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzgtMTEtMS0xLTY2OTEw_cd38edf3-ae5b-4074-b79c-4de8d7c17d3b">250,116</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year to date period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieef521b6cb2644d59433c4a98ac67edb_D20220101-20220930" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzktMS0xLTEtNjY5MTA_889d654e-a376-4b6a-b394-da803907dd28">10,846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5af61dbd97844f2cb160b48a3a35d4e8_D20220101-20220930" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzktMy0xLTEtNjY5MTA_f9952286-7522-425b-8eac-d4519b7738ee">118,390</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzktNS0xLTEtNjY5MTA_9a8230d3-8926-4b14-b630-57b0682c6277">129,236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4dfdc7272dc4a849a6c7e48dfcc4f74_D20210101-20210930" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzktNy0xLTEtNjY5MTA_3fb62c79-087c-4006-89c4-6cf670eec545">19,174</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e55c1b3affc496aa10cbd0b6538c957_D20210101-20210930" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzktOS0xLTEtNjY5MTA_577d6e3e-5c43-4efe-9851-d4e59877c315">101,406</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzktMTEtMS0xLTY2OTEw_30d9b28b-5a60-4e4e-b40e-be6f78ccf384">120,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieef521b6cb2644d59433c4a98ac67edb_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzEwLTEtMS0xLTY2OTEw_8307450a-3526-40ae-8f7b-1c21af8158d3">10,846</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5af61dbd97844f2cb160b48a3a35d4e8_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzEwLTMtMS0xLTY2OTEw_a36811d5-32b7-4b07-9485-25ad9c85f3f0">488,098</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzEwLTUtMS0xLTY2OTEw_63359b7b-8d3f-4fef-b50b-65835b364e93">498,944</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4dfdc7272dc4a849a6c7e48dfcc4f74_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzEwLTctMS0xLTY2OTEw_a8304b60-a59f-4447-bb29-6d066dc819a5">39,975</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e55c1b3affc496aa10cbd0b6538c957_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzEwLTktMS0xLTY2OTEw_ca330808-11b5-4a7d-834f-d582aff72780">330,721</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzEwLTExLTEtMS02NjkxMA_1cc163f8-932f-423f-920c-51bed8fa7477">370,696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffa15ee70390496c89f205bdc8f3731b_I20220930" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzE0LTEtMS0xLTY2OTEw_8f9e1686-6527-40cc-b27a-679097ef020d">9,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i358169d308bf4641ad0dca36755b47d1_I20220930" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzE0LTMtMS0xLTY2OTEw_15a63003-872b-4def-9d39-500e4a5d1606">126,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzE0LTUtMS0xLTY2OTEw_87e79cf9-be69-4af0-829d-46f9be427175">135,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1859c2ae121649f09ad595e92fb8e96c_I20210930" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzE0LTctMS0xLTY2OTEw_19f40a39-c658-4051-bdee-4f053eac0b52">23,469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44a8b1c85fc24294af85eb3f3327612d_I20210930" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzE0LTktMS0xLTY2OTEw_640c37d6-f5d2-4b9f-9fed-9cc09804d925">168,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63b3ddd7486946c2a0a8151832317d14_I20210930" decimals="-3" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzE0LTExLTEtMS02NjkxMA_b1b756fa-4d60-4c32-873e-8bbddedc7025">191,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_109"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 22.  <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90ZXh0cmVnaW9uOjliZWQ0NmQ1ZTQ0NjRjMDRiN2Q4ODJiYWEyZGY1MTI2XzEzNA_a69f0bd2-ed07-4498-bb64-c90e97ec0a31" continuedAt="ic00cf3ead71040729379dd5c867a4ae1" escape="true">Supplemental Cash Flow Information </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ic00cf3ead71040729379dd5c867a4ae1"><ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90ZXh0cmVnaW9uOjliZWQ0NmQ1ZTQ0NjRjMDRiN2Q4ODJiYWEyZGY1MTI2XzEyOQ_bc6f1c32-4bd9-426f-ba64-0363b71a6d77" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzMtMS0xLTEtNjY5MTA_12275fac-bf2c-4bfd-b77d-6a945b3bc2da">1,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzMtMy0xLTEtNjY5MTA_cf50f527-e2d9-417e-b20a-282b91d6e747">497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued in connection with business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:StockIssued1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzQtMS0xLTEtNzczNzg_5d243207-4b88-4716-99b6-08987dbccfa7">130,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:StockIssued1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzQtMy0xLTEtNzczNzg_158221ce-d5ab-4bbb-bbd0-e6d6cebf0f7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued in connection with debt repayment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="evh:StockIssuedInConnectionWithDebtRepayment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzUtMS0xLTEtNzczOTQ_8aad34d7-6d02-447c-bc78-74f9c5863389">101,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:StockIssuedInConnectionWithDebtRepayment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzUtMy0xLTEtNzczOTQ_1227e65c-575b-43b8-8692-8d7010a83b39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued net working capital adjustment with business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzYtMS0xLTEtNzc1MDA_af9d0769-4ada-48e8-bc64-ab5ea307294a">791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzYtMy0xLTEtNzc1MDA_fac1588c-cbac-4682-867b-22dd3317d1c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzUtMS0xLTEtNjY5MTA_391f5772-09b4-4315-8759-fd8833eb7ce5">14,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzUtMy0xLTEtNjY5MTA_1f0cca75-a6fc-42e4-997d-f3ac5fddc940">9,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets disposed of (obtained in) exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzYtMS0xLTEtNjY5MTA_a6a947f9-d452-4c38-b339-9bd5e9a4dfed">4,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="evh:RightOfUseAssetAcquiredAndDisposedOf" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzYtMy0xLTEtNjY5MTA_034a62ab-cbd6-4297-ac4e-4fb880d25ac7">2,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzExLTEtMS0xLTc5MTgz_afabf729-6f08-4428-b0ec-ba118bfe0b30">6,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzExLTMtMS0xLTc5MTgz_2844da75-90cf-4b3b-a343-52190b52d643">3,771</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" decimals="-3" sign="-" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzEyLTEtMS0xLTc5MTgz_8324e217-4ddc-4ad2-aa7f-180f7f111cfd">955</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzEyLTMtMS0xLTc5MTgz_51d8fab1-f144-473d-9125-48936bbbbfa9">734</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_112"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 23.  <ix:nonNumeric contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMTIvZnJhZzoxYzY4MmVjNzQxMWM0ZWM4YWJmNjdkMDA0ZjFmN2MyNS90ZXh0cmVnaW9uOjFjNjgyZWM3NDExYzRlYzhhYmY2N2QwMDRmMWY3YzI1XzY4MDc_c0994c6f-5fe6-4a88-8bb1-a80d944a7031" continuedAt="i7527ecc26d4b4c28aa7efbfb3dbc29e9" escape="true">Subsequent Events</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i7527ecc26d4b4c28aa7efbfb3dbc29e9" continuedAt="ifecd38aca02d4bf3b7d401b4022f6c24">Goodwill Impairment</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifecd38aca02d4bf3b7d401b4022f6c24">On October 11, 2022, our Evolent Health Services segment was notified by Bright Health Group that it intended to exit its Individual and Family lines of business. Due to an expected decrease in projected future cash flows which could impact our estimated fair value, our existing goodwill in the EHS segment may require an adjustment. Such adjustment could be material. As of the date of this filing, the Company has not yet completed the analysis due to the complexities and time involved in determining the implied fair value of the goodwill. The analysis will be completed in the fourth quarter of 2022. As of September 30, 2022, goodwill in our EHS segment is $<ix:nonFraction unitRef="usd" contextRef="iffa15ee70390496c89f205bdc8f3731b_I20220930" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMTIvZnJhZzoxYzY4MmVjNzQxMWM0ZWM4YWJmNjdkMDA0ZjFmN2MyNS90ZXh0cmVnaW9uOjFjNjgyZWM3NDExYzRlYzhhYmY2N2QwMDRmMWY3YzI1XzE2NDkyNjc0NjMzMDk_0c5f6c12-52a3-48fe-b791-caca5b212296">214.2</ix:nonFraction>&#160;million. If the fair value of the EHS segment is determined to be less than the carrying value, an adjustment to goodwill will be required, and such amount could be material.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_115"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&amp;A&#8221;) is intended to help the reader understand the Company&#8217;s financial condition and results of operations. The MD&amp;A is provided as a supplement to, and should be read in conjunction with our consolidated financial statements and the accompanying notes to consolidated financial statements presented in &#8220;Part I &#8211; Item 1. Financial Statements&#8221; of this Form 10-Q; our 2021 Form 10-K, including the sections entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;; and our current reports on Form 8-K filed in 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_118"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i4a25f060abc946f28c4a0095422c2513_121"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Background</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. is a holding company whose principal asset is all of the Class A common units it holds in Evolent Health LLC, and its only business is to act as sole managing member of Evolent Health LLC. Substantially all of our operations are conducted through Evolent Health LLC and its consolidated subsidiaries. The financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a market leader in the new era of value-based care, in which the delivery of health care is increasingly funded by at-risk payment models.  We provide integrated solutions to both health care providers, including independent physicians and health systems, as well as payers, including health plans and other risk-bearing organizations, with a common end: to improve health care quality and outcomes while reducing cost. We consider value-based care to be the necessary convergence of health care payment and delivery. We believe the pace of this convergence is accelerating, driven by price pressure in traditional FFS health care, a market environment that is incentivizing value-based care models, growth in consumer-focused insurance programs, such as Medicare Advantage and managed Medicaid, and innovation in data and technology. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were an early innovator in value-based care, founded in 2011 by members of our management team, UPMC, an integrated delivery system based in Pittsburgh, Pennsylvania, and The Advisory Board Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our operations and allocate resources across two reportable segments: Evolent Health Services and Clinical Solutions. The Company&#8217;s EHS segment provides an integrated administrative and clinical platform for health plan administration and population health management. Our Clinical Solutions segment addresses a broad spectrum of clinical needs, with tailored solutions for Specialty Care Management in Oncology and Cardiology and holistic Total Cost of Care improvement. Our economic opportunity in the Clinical Solutions segment, which we believe to be significant, is largely based on (a) the total amount of medical expenses under management, and (b) the amount of savings we are able to generate relative to a benchmark or target. These partnerships, which we refer to as performance-based arrangements, include both capitation and shared savings arrangements. We also generate Clinical Solutions revenue by providing our technology and services platform on a fee basis. We go to market for our Specialty Care Management under the brand name New Century Health, and for our Total Cost of Care solution under the brand name Evolent Care Partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our revenue is recognized in the United States and substantially all of our long-lived assets are located in the United States.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred operating losses since our inception, in part because we have invested heavily in resources to support our growth. We intend to invest aggressively in the success of our partners, expand our geographic footprint and further develop our capabilities. </span></div><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_124"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Events</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health&#8217;s Response to COVID-19</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the services we provide and market dynamics in our end markets and with our significant customers, to date the COVID-19 pandemic has not materially impacted our financial condition, the results of operations, or our outlook. As of September&#160;30, 2022, we had cash and cash equivalents of $156.8 million and as of the date the financial statements were available to be issued, we believe our current cash balance is sufficient to meet our liquidity needs for the next twelve months. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has also affected global access to capital and caused significant volatility in financial markets. In addition, we have and are experiencing varying levels of inflation resulting in part from higher labor costs. Significant deterioration of the U.S. and global economies or rapid increases in inflation could have an adverse impact on our future liquidity needs. Although the impact </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the COVID-19 pandemic on our business has not been severe to date, the long-term impact of the pandemic on medical costs (including in oncology and cardiology), our partners and the global economy is uncertain and will depend on various factors, including the scope, severity and duration of the pandemic, including resurgence of COVID-19 cases due to more contagious variants such as Omicron and the effectiveness of vaccines. A prolonged economic downturn or recession resulting from the pandemic or more broadly, including from macroeconomic conditions could adversely affect many of our partners which could, in turn, adversely impact our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent&#8217;s focus throughout this pandemic has been the health and safety of its employees and their families, as well as ensuring that we continue to furnish uninterrupted high-quality service to our partners. Evolent has deployed a multi-faceted response to COVID-19, overseen by its Emergency Preparedness Team, led by the General Counsel, Chief Compliance Officer and Chief People and Brand Officer, that focuses on maintaining its workforce in a manner that does not disrupt service delivery or operations. Evolent is closely monitoring and overseeing any issues of noncompliance or deficiencies with client operational service level agreements and continuing to review contractual business requirements in light of state and federal mandates, emergency laws and orders, and available financial support opportunities.  Evolent is also mindful of the impact COVID-19 has on its vendors and subcontractors and we will continue to work with them regarding our collective obligations to Evolent&#8217;s customers. We require a COVID-19 Business Continuity Attestation from subcontractors and vendors, confirming that operational and financial obligations will be met and aiming to ensure that privacy and security risks or incidents can be mitigated and disclosed in a timely manner. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent has instituted a voluntary return to the office. Fully vaccinated employees and those who have provided an approved religious or medical exemption are permitted to return to the Company&#8217;s offices in-person.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Impact of COVID-19</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In evaluating the impact of COVID-19 on our business, we considered, among other factors, the nature of the services we provide, end market trends and outlook and customer-specific trends. In addition, we focused on possible changes in membership and medical utilization trends. Based on our analysis, we do not believe that our overall membership has been significantly impacted by the pandemic to date.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">With regards to medical utilization trends, in particular in our two largest specialties oncology and cardiology, while forecasting future impact is challenging, our analysis suggests that utilization during the nine months ended September 30, 2022 (as measured by authorizations per thousand members) is similar to what it was before the pandemic.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our two most significant service offerings in terms of revenue are specialty care management and administrative simplification services.&#160;Because both of these services offerings provide critical services to our clients and their members and have relatively long lead times to implement such services, we currently do not anticipate any material near-term disruption to the relevant contracts as a result of the pandemic. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of Inflation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We experience pricing pressures in the form of competitive prices in addition to rising costs for certain inflation-sensitive operating expenses such as labor, employee benefits and facility leases. We do not believe these impacts were material to our revenues or net income during the nine months ended September 30, 2022. However, significant sustained inflation driven by the macroeconomic environment or other factors could negatively impact our margins, profitability and results of operations in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customers</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has undertaken several transactions, some of which may impact year-to-year comparisons. The following is a discussion of certain of those transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of IPG</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022, the Company completed its acquisition of IPG, including 100% of the voting equity interests. IPG is a leader in providing surgical management solutions for musculoskeletal conditions. The transaction is expected to accelerate our strategy to become a leading provider of value-based specialty care solutions as well as diversify our revenue streams with a larger customer portfolio. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total merger consideration, net of cash on hand and certain closing adjustments, was $461.7&#160;million, based on the closing price of the Company&#8217;s Class A common stock on the NYSE on August 1, 2022. The merger consideration consisted of $256.5&#160;million of cash consideration, 3.7&#160;million shares of Class A common stock, fair valued at $130.2&#160;million as of August 1, 2022, and an earn-out of up to $87.0&#160;million, fair valued at $75.0&#160;million as of August 1, 2022 is payable in cash and/or shares of the Company&#8217;s Class A Common Stock, at the Company&#8217;s option. IPG will report into Evolent&#8217;s specialty care management offering, New Century Health, and will be consolidated into the Company&#8217;s Clinical Solutions segment. Refer to &#8220;Part I - Item 1. Financial Statements - Note 4&#8221; for additional discussion regarding the IPG transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ares Secured Credit Facilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022 (the &#8220;Closing Date&#8221;), the Company entered into a Credit Agreement, by and among the Company, Evolent Health LLC (&#8220;Evolent&#8221;), Endzone Merger Sub, Inc. (&#8220;Endzone&#8221; or &#8220;Initial Borrower&#8221;), which upon consummation of the transactions contemplated by the Merger Agreement was merged with and into TPG Growth Iceman Parent, Inc., Implantable Provider Group, Inc. (&#8220;Implantable&#8221;, collectively with Evolent, Endzone and TPG Growth Iceman Parent, the &#8220;Borrowers&#8221; and each a &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, Ares Capital Corporation, as administrative agent, and ACF Finco I LP, as collateral agent and as revolver agent (the &#8220;2022 Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrowers in the form of (i) an initial term loan in the aggregate principal amount of $175.0&#160;million (the &#8220;Initial Term Loan Facility&#8221;) and (ii) a revolving credit facility in the aggregate principal amount of up to $50.0&#160;million, to be determined by reference to the lesser of $50.0&#160;million and a borrowing base (the &#8220;Revolving Facility&#8221; and, together with the Initial Term Loan Facility, the &#8220;2022 Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrowers borrowed the loan under the Initial Term Loan Facility on August 1, 2022 (the &#8220;Initial Term Loan&#8221;), and also borrowed $50.0 million under the Revolving Facility on the Closing Date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The interest rate for each loan under the 2022 Credit Facilities is calculated, at the option of the Borrowers, (a) in the case of the Term Loan, at either the Adjusted Term SOFR Rate (as defined in the 2022 Credit Agreement) plus 5.50%, or the base rate plus 4.50% and (b) in the case of a Revolving Loan, at either the Adjusted Term SOFR Rate plus 3.50%, or the base rate plus 2.50%. A commitment fee of (a) 2.00% of the aggregate amount of the commitments in respect of the Term Loan Facility as of the Closing Date and (b) 2.00% of the aggregate amount of the commitments in respect of the Revolving Facility was paid as of the Closing Date. Refer to &#8220;Part I - Item 1. Financial Statements - Note 10&#8221; for additional discussion regarding the 2022 Credit Facilities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">2024 Notes Conversion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 11, 2022, the Company entered into exchange agreements with certain holders of the 2024 Notes. Pursuant to the agreements, these holders exchanged $92.8&#160;million in aggregate principal amount of such notes for shares of the Company&#8217;s Class A common stock. On August 17 and 18, 2022, the Company consummated the exchanges and issued an aggregate of 5,394,165 shares of Class A common stock to the holders. The August 2022 exchanges of the 2024 Notes resulted in a $10.2&#160;million loss on extinguishment/repayment of debt, net, on the consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Subsequent Events</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 11, 2022, our Evolent Health Services segment was notified by Bright Health Group that it intended to exit its Individual and Family lines of business. Due to an expected decrease in projected future cash flows which could impact our estimated fair value, our existing goodwill in the EHS segment may require an adjustment. Such adjustment could be material. As of the date of this filing, the Company has not yet completed the analysis due to the complexities and time involved in determining the implied fair value of the goodwill. The analysis will be completed in the fourth quarter of 2022. As of September 30, 2022, goodwill in our EHS segment is $214.2&#160;million. If the fair value of the EHS segment is determined to be less than the carrying value, an adjustment to goodwill will be required, and such amount could be material. </span></div><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_127"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MD&amp;A included in our 2021 Form 10-K contains a detailed discussion of our critical accounting policies and estimates. There have been no material changes to our critical accounting policies and estimates since our 2021 Form 10-K. See &#8220;Item 1. Financial </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statements - Note 2&#8221; in this Form 10-Q for a summary of our significant accounting policies and see &#8220;Item 1. Financial Statements - Note 3&#8221; in this Form 10-Q for information regarding the Company&#8217;s adoption of new accounting standards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 2&#8221; in our 2021 Form 10-K for a complete summary of our significant accounting policies.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price plus the fair value of any non-controlling interests in the acquiree over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. The Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. Qualitative factors include macroeconomic, industry and market considerations, overall financial performance, industry, legal and other relevant events and factors affecting the reporting unit. Additionally, as part of this assessment, we may perform a quantitative analysis to support the qualitative factors above by applying sensitivities to assumptions and inputs used in measuring a reporting unit&#8217;s fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss). We use discounted cash flow analyses and market multiple analyses in order to estimate reporting unit fair values. Discounted cash flow analyses rely on significant judgement and assumptions about expected future cash flows, weighted-average cost of capital, discount rates, expected long-term growth rates and operating margins. These assumptions are based on estimates of future revenue and earnings after considering such factors as general economic and market conditions which drive key assumptions of revenue growth rates, operating margins, capital expenditures and working capital requirements. The weighted average cost of capital is based on market-based factors/inputs but also considers the specific risk characteristics of the reporting unit&#8217;s cash flow forecast. A significant change to these estimates and assumptions could cause the estimated fair values of our reporting units and intangible assets to decline and increase the risk of an impairment charge to earnings. Intangible assets with finite lives are assessed for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest fair value of our single reporting unit was below the carrying value. As a result, a quantitative goodwill impairment analysis was not required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the nine months ended September 30, 2022</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We will perform our annual impairment test on October 31, 2022, including assessing the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">qualitative and quantitative indicators from the shutdown of Bright Health Group&#8217;s Individual and Family Plans line of business</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard on January 1, 2022 however, it did not have a material impact on our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we will not separately present in equity an embedded conversion feature of such debt. Instead, we will account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The Company adopted the standard using a modified retrospective method as of January 1, 2022, with adjustments which reduced additional paid-in capital by $106.2&#160;million and increased retained earnings by $39.8&#160;million and increased the net carrying amount of the 2024 Notes and 2025 Notes by $25.1&#160;million and $41.3&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_130"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. is a holding company and its principal asset is all of the Class&#160;A common units in Evolent Health LLC, which has owned all of our operating assets and substantially all of our business since inception. The financial results of Evolent Health LLC are consolidated in the financial statements of Evolent Health, Inc.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Components of our Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and Operations Services Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily TPA services.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into capitation arrangements that may include performance-based arrangements and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue (exclusive of depreciation and amortization)</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our cost of revenue includes direct expenses and shared resources that perform services in direct support of clients. Costs consist primarily of employee-related expenses (including compensation, benefits and stock-based compensation), expenses for TPA support and other services, as well as other professional fees. In certain cases, our cost of revenue also includes claims and capitation payments to providers and payments for pharmaceutical treatments and other health care expenditures through performance-based arrangements.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our selling, general and administrative expenses consist of employee-related expenses (including compensation, benefits and stock-based compensation) for selling and marketing, corporate development, finance, legal, human resources, corporate information technology, professional fees and other corporate expenses associated with these functional areas. Selling, general and administrative expenses also include costs associated with our centralized infrastructure and research and development activities to support our network development capabilities, claims processing services, including PBM administration, technology infrastructure, clinical program development and data analytics.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses consist of the amortization of intangible assets associated with the step up in fair value of Evolent Health LLC&#8217;s assets and liabilities for the Offering Reorganization, amortization of intangible assets recorded as part of our various business combinations and asset acquisitions and depreciation of property and equipment, including the amortization of capitalized software.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lives on Platform and PMPM Fees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Lives on Platform are calculated by summing our Evolent Health Services Lives on Platform and our Clinical Solutions Lives on Platform. Evolent Health Services Lives on Platform are calculated by summing members on our value-based care and comprehensive health plan administrative platform. Clinical Solutions Lives on Platform are calculated by summing the Clinical Solutions Lives on Platform in our Performance suite and New Century Health Technology and Services suite Lives on Platform. Clinical Solutions Lives on Platform in our Performance suite are calculated by summing members covered for oncology specialty care services and members covered for cardiology specialty care services for contracts not under ASO arrangements. New Century Health Technology and Services suite Lives on Platform are calculated by summing members covered for oncology specialty care services, members covered for cardiology specialty care services and members covered for advance care planning services for contracts under ASO arrangements. Members covered for more than one category are counted in each category. Clinical Solutions Cases are calculated by summing the number of individuals receiving services through our IPG and Vital Decisions programs in a given period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health Services average per member per month (&#8220;PMPM&#8221;) fee is defined as platform and operations revenue pertaining to the Evolent Health Services segment during the period reported divided by the average of the beginning and ending Evolent Health Services segment membership during the period reported divided by the number of months in the period. Clinical Solutions Performance suite Average PMPM fee is defined as platform and operations services revenue pertaining to our Clinical Solutions Performance suite during the period reported divided by the average of the beginning and ending Clinical Solutions Performance suite membership during the period reported divided by the number of months in the period. New Century Health Technology and Services suite Average PMPM fee is defined as platform and operations revenue pertaining to the New Century Health Technology and Services suite during the period reported divided by the average of the beginning and ending New Century Health Technology and Services suite membership during the period reported divided by the number of months in the period. Clinical Solutions Revenue per Case is calculated by the revenue pertaining to IPG and Vital divided by the number of cases for a given period.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management uses lives on platform, PMPM fees, cases and revenue per case because we believe that they provide insight into the unit economics of our services. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance. We believe that these measures are also useful to investors because they allow further insight into the period over period operational performance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evolent Health, Inc. Consolidated Results</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:114.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:43.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(in thousands, except percentages)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change Over Prior Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change Over Prior Period</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">352,585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">969,581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">659,599&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47.0%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:39pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.4%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">736,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">493,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.3%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,826&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.2%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5%</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,700)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,475)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,544.4)%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,822)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(819)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,003)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(610.9)%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339,634&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">229,052&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,582&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">964,061&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">689,796&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274,265&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39.8%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,581)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30,197)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,717&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118.3%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of revenue as a % of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses as a % of revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Results for the Three Months Ended September&#160;30, 2022 to 2021 </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue increased by $130.1 million, or 58.5%, to $352.6 million for the three months ended September 30, 2022, as compared to 2021. This increase is primarily due to the addition of new partners and expansion with existing partners. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,054&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,328&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,857&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,257&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,614&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from our Evolent Health Services segment increased by $44.5&#160;million for the three months ended September 30, 2022, as compared to 2021 due to the addition of new partners. Revenue from our Clinical Solutions segment increased by $85.6&#160;million for three months ended September 30, 2022 as compared to 2021 due to new partner additions as well as expansion into new markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company&#8217;s lives on platform as of September&#160;30, 2022 and 2021 and PMPM fees for the three months ended September 30, 2022 and 2021 (Lives on Platform in thousands):</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lives on Platform/ Cases during Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average PMPM Fees / Revenue per Case </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evolent Health Services</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance suite</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Century Health Technology and Services suite</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,201.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> We had 52 and 41 operating partners as of September&#160;30, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Cost of Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total cost of revenue by segment (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.361%"><tr><td style="width:1.0%"></td><td style="width:25.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,651&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,377&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,894&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,617&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,126&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue increased by $103.5 million, or 63.4%, to $266.6 million for the three months ended September 30, 2022, as compared to 2021, principally as a result of the growth in our revenue. By key line items, the increase was driven by approximately $68.6 million due to higher claims activity in our Clinical Solutions and Evolent Health Services segments, $11.7 million due to higher personnel costs due to increased headcount and benefits to employees, $15.1 million of surgical management device costs at IPG and $5.4 million in higher professional fees primarily due to costs incurred for contracts that went live during the quarter and third-party service fees for existing customers. Approximately $1.0 million and $0.1 million of total personnel costs was attributable to stock-based compensation expense for the three months ended September 30, 2022 and 2021, respectively. Cost of revenue represented 75.6% and 73.3% of total revenue for the three months ended September 30, 2022 and 2021, respectively. Our cost of revenue increased as a percentage of our total revenue due to a change in the mix of our service offerings towards higher gross margin services with divestiture of our health plans combined with our Repositioning Plan. We expect our cost of revenue to decrease as a percentage of total revenue over the longer-term subject to the composition of our growth.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total selling, general and administrative by segment (amounts in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:29.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,867&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,826&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,314&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,242&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,152&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,292&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses increased by $17.2 million, or 33.6%, to $68.5 million for the three months ended September 30, 2022, as compared to 2021. The increase is driven primarily by the acquisitions of Vital Decisions and IPG. By key line items, the increase was driven by higher personnel fees due to increased headcount and expected benefits accruals to employees of $8.1 million, higher stock compensation of $1.7 million, higher insurance costs of $0.5 million and technology services due to higher headcount of $2.6 million. Approximately $6.0 million and $4.3 million of total personnel costs were attributable to stock-based compensation expense for the three months ended September 30, 2022 and 2021, respectively. Acquisition and severance costs accounted for approximately $3.6 million and $1.2 million of total selling, general and administrative expenses for the three months ended September 30, 2022 and 2021, respectively. Selling, general and administrative expenses represented 19.4% and 23.1% of total revenue for the three months ended September 30, 2022, as compared to 2021, respectively. While our selling, general and administrative expenses are expected to grow as our business grows, we expect them to decrease as a percentage of our total revenue over the long term due to cost saving initiatives completed in the fourth quarter of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses increased $2.3 million, or 15.7%, to $17.2 million for the three months ended September 30, 2022, as compared to 2021 due primarily to amortization of intangible assets acquired through our asset acquisitions and business combinations. We expect depreciation and amortization expenses to increase in future periods as we continue to capitalize internal-use software and amortize intangible assets resulting from asset acquisitions and business combinations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recorded a (gain) loss on change in fair value of contingent consideration of&#160;$(12.7) million&#160;and $(0.2) million for the three months ended September 30, 2022 as compared to 2021. The change in fair value of contingent consideration for the three months ended September 30, 2022 is due to changes in the fair values of contingent liabilities incurred as a result of the acquisition of Vital Decisions in October 2021 and IPG in August 2022. The change in fair value of contingent consideration for the three months ended September 30, 2021 is due to liabilities incurred from entering into the warrant agreements as part of the 2019 Credit Agreement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Results for the Nine Months Ended September&#160;30, 2022 to 2021 </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue increased by $310.0 million, or 47.0%, to $969.6 million for the nine months ended September 30, 2022, as compared to 2021. This increase is primarily due to the addition of new partners and expansion with existing partners. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:327.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,521&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,557&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,060&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,042&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Revenue from our Evolent Health Services segment increased by $84.0 million for the nine months ended September 30, 2022, as compared to 2021 due to expansion of services with existing customers. Revenue from our Clinical Solutions segment increased by $226.0 million for the nine months ended September 30, 2022 as compared to 2021 due to new partner additions as well as expansion into new markets within current New Century Health Technology and Services Suite partners. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table represents the Company&#8217;s lives on platform as of September&#160;30, 2022 and 2021 and PMPM fees for the nine months ended September 30, 2022 and 2021 (Lives on Platform in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lives on Platform/ Cases during Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average PMPM Fees / Revenue per Case </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance suite</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,498</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Century Health Technology and Services suite</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,853</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Revenue</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total cost of revenue by segment for the nine months ended September 30, 2022, as compared to 2021 (amounts in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.361%"><tr><td style="width:1.0%"></td><td style="width:25.290%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.743%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.370%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,354&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,628&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345,874&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,821&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,843&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736,061&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493,071&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue increased by $243.0 million, or 49.3%, to $736.1 million for the nine months ended September 30, 2022, as compared to 2021, principally as a result of the growth in our revenue. By key line items, the increase was driven by approximately $164.7 million due to higher claims activity in our Clinical Solutions and Evolent Health Services segments, $32.9 million of higher personnel costs due to increased headcount, employee benefits and expected bonus accruals to employees, $22.6 million in higher professional fees primarily due to costs incurred for contracts that went live during the quarter and third-party service fees for existing customers and $15.1 million of surgical management device costs at IPG. Approximately $3.0 million and $1.6 million of total personnel costs was attributable to stock-based compensation expense for the nine months ended September 30, 2022 and 2021, respectively. Cost of revenue represented 75.9% and 74.8% of total revenue for the nine months ended September 30, 2022 and 2021, respectively. Our cost of revenue increased as a percentage of our total revenue due to a change in the mix of our service offerings towards higher gross margin services with divestiture of our health plans combined with our Repositioning Plan. We expect our cost of revenue to decrease as a percentage of total revenue over the longer-term subject to the composition of our growth.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total selling, general and administrative by segment for the nine months ended September 30, 2022, as compared to 2021 (amounts in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"></td><td style="width:29.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.115%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,264&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,555&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,086&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,746&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,941&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,408&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,582&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative expenses increased by $33.8 million, or 22.2%, to $186.4 million for the nine months ended September 30, 2022, as compared to 2021, principally as a result of acquisitions. By key line items, the increase was driven by higher personnel fees due to increased headcount and expected benefits accruals to employees of $26.1 million, higher stock compensation of $6.3 million, technology services due to higher headcount of $6.8 million and higher insurance costs of $1.0 million offset, in part by lower professional fees from the Repositioning Plan and shareholder advisory services of $9.2 million and the termination of certain leases of $2.6 million. Approximately $16.4 million and $10.1 million of total personnel costs were attributable to stock-based compensation expense for the nine months ended September 30, 2022 and 2021, respectively. Acquisition and severance costs accounted for approximately $7.5&#160;million and $3.3&#160;million of total selling, general and administrative expenses for the nine months ended September 30, 2022 and 2021, respectively. Selling, general and administrative expenses represented 19.2% and 23.1% of total revenue for the nine months ended September 30, 2022, as compared to 2021, respectively. While our selling, general and administrative expenses are expected to grow as our business grows, we expect them to decrease as a percentage of our total revenue over the long term due to cost saving initiatives completed in the fourth quarter of 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Depreciation and Amortization Expenses</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses increased $2.5 million, or 5.5%, to $47.4 million for the nine months ended September 30, 2022, as compared to 2021 due primarily to amortization of intangible assets acquired through our asset acquisitions and business combinations. We expect depreciation and amortization expenses to increase in future periods as we continue to capitalize internal-use software and amortize intangible assets resulting from asset acquisitions and business combinations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We recorded a gain on change in fair value of contingent consideration of&#160;$(5.8) million&#160;for the nine months ended September 30, 2022, related to the liabilities acquired as a result of the acquisitions of Vital Decisions in October 2021 and IPG in August 2022 and&#160;$(0.8) million for the nine months ended September 30, 2021, related to liabilities incurred from entering into our warrant agreements as part of the 2019 Credit Agreement that were settled in January 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discussion of Non-Operating Results</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our interest expense is primarily attributable to our 2021, 2024 and 2025 Notes as well as our 2022 and 2019 Credit Agreements with Ares Capital Corporation. We recorded interest expense (including amortization of deferred financing costs) of approximately $4.8 million and $9.1 million for the three and nine months ended September 30, 2022, respectively, and $6.4 million and $19.0 million for the three and nine months ended September 30, 2021, respectively. The decrease in interest expense during the three and nine months ended September 30, 2022 compared to 2021 is driven primarily by the adoption of ASU 2020-06 and conversion of the 2024 Notes offset, in part by interest expense incurred on our 2022 Credit Agreement See &#8220;Part I - Item 1.  Financial Statements - Note 10&#8221; in this Form 10-Q for the information related to interest expense.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain from Equity Method Investees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated its proportional share of the investees&#8217; earnings and losses each reporting period. The Company&#8217;s proportional share of the gain from these investments was approximately $1.4 million and $3.9 million for the three and nine months ended September 30, 2022, respectively, and $0.1 million and $12.7 million for the three and nine months ended September 30, 2021, respectively. The change in gain from equity method investees for the three and nine months ended September 30, 2022 compared to 2021 is driven primarily by the sale of our Florida equity investee&#8217;s membership during the three months ended March 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain from Transfer of Membership</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March 31, 2021, EVH Passport received a cash payment from Molina in the amount of $23.0 million based on the number of enrollees above a certain threshold in the D-SNP Business and Molina's Medicaid plan following the open enrollment period for plan year 2021. The foregoing amount represents 50% of the payment that EVH Passport is eligible to receive based on the number of such enrollees. The remaining 50% was received in the first quarter of 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Extinguishment/Repayment of Debt</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 11, 2022, the Company entered into exchange agreements with certain holders of  the 2024 Notes. Pursuant to the agreements, these holders exchanged $92.8&#160;million in aggregate principal amount of such notes for shares of the Company&#8217;s Class A common stock. On August 17 and 18, 2022, the Company consummated the exchanges and issued an aggregate of 5,394,165 shares of Class A common stock to the holders. The August 2022 exchanges of the 2024 Notes resulted in a $10.2&#160;million loss on extinguishment/repayment of debt, net, on the consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company repaid all outstanding amounts owed under, and terminated, the 2019 Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the 2019 Credit Agreement in connection with the prepayment was $98.6&#160;million, which included $9.7&#160;million for the make-whole premium as well as $0.2&#160;million in accrued interest. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this transaction, the Company recorded loss on the repayment of debt of $19.2&#160;million, representing the remaining unamortized debt issuance costs of $9.5&#160;million, the make-whole premium and legal expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Tax Receivable Agreement Liability</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the reduction in the valuation allowance resulting from deferred tax liabilities established as part of the IPG acquisition, the Company has recorded a partial TRA liability of $42.9 million as of September 30, 2022, which represents 85% of the deferred tax assets related to the Company&#8217;s unrealized tax benefits on historical pre-IPO losses and tax basis increases from exchanges, offset with the related valuation allowance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for (Benefit from) Income Taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An income benefit of $(45.5) million and $(44.5) million and was recognized for the three and nine months ended September 30, 2022, respectively, which resulted in effective tax rates of 104.9% and 85.8%, respectively. An income tax expense of $0.2 million and $0.9 million for the three and nine months ended September 30, 2021, respectively, which resulted in effective tax rates of (1.8)% and (2.9)%, respectively. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_133"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REVIEW OF CONSOLIDATED FINANCIAL CONDITION</span></div><div style="text-align:center"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_136"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception, the Company has incurred operating losses and net cash outflows from operations. The Company incurred operating losses of $5.5 million and $30.2 million for the nine months ended September 30, 2022 and 2021, respectively. Net cash and restricted cash used in operating activities was $47.2 million and $27.9 million for the nine months ended September 30, 2022 and 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company had $156.8 million of cash and cash equivalents and $38.1 million in restricted cash and restricted investments. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our current cash and cash equivalents will be sufficient to meet our working capital and capital expenditure requirements for the next twelve months. Our future capital requirements will depend on many factors, including our rate of revenue growth, the expansion of our sales and marketing activities and the timing and extent of our spending to support our investment efforts and expansion into other markets. We may also seek to invest in, or acquire complementary businesses, applications or technologies, which may require us o seek sources of financing.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flows</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary of cash flows</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands) has been derived from our financial statements included in &#8220;Part I - Item 1.  Financial Statements - Consolidated Statements of Cash Flows:&#8221;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:433.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,248)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,909)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254,659)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash and restricted cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in operating activities of $47.2 million for the nine months ended September 30, 2022 were primarily due to our net loss of $7.8 million, non-cash items including depreciation and amortization expenses of $47.4 million, stock-based compensation expense of $19.4 million, deferred tax benefit of $(46.4) million, amortization of contract cost assets of $14.8 million, loss on extinguishment of debt of $10.2 million, change in fair value of contingent consideration of $(5.8) million and change in our tax receivable liability of $42.9 million. Our operating cash outflows were affected by the timing of our customer and vendor payments driven by increases in accounts receivables and reductions in reserves for claims and performance-based arrangements, accrued compensation and employee benefits and accrued liabilities contributed approximately $112.7 million to our cash outflows. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in operating activities of $27.9 million for the nine months ended September 30, 2021 were primarily due to our net loss of $32.0 million, a loss on the repayment and termination of our Credit Agreement of $19.2 million, a gain on the disposal of assets of $1.9 million, gain on the transfer of memberships of $23.0 million and non cash items including depreciation and amortization expenses of $45.1 million and stock-based compensation expense of $11.8 million. Our operating cash inflows were affected by the timing of our customer and vendor payments. In addition to these non-cash items, increases in accounts receivables and contract cost assets and reductions in accrued liabilities and accrued compensation and employee benefits contributed approximately $88.0 million to our cash outflows. Those cash outflows were offset, in part by increased reserves for claims and performance-based arrangements of approximately $16.8 million.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in investing activities of $254.7 million in the nine months ended September 30, 2022 were primarily attributable to $245.0 million paid for the acquisition of IPG, $9.2 million paid for a purchase price adjustment related to our disposal of True Health New Mexico and $27.6 million of investments in internal-use software and purchases of property and equipment offset, in part by $23.0 million from the transfer of membership and release of Passport escrow and $4.2 million from returns from our equity method investments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows provided by investing activities of $38.6 million in the nine months ended September 30, 2021 were primarily attributable to cash flows of $43.0 million from the transfer of membership and release of Passport escrow and returns of investment on equity method investments of $14.2 million offset, in part by $17.7 million from investments in internal-use software and purchases of property and equipment and $3.0 million of purchases of investments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing Activities </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in financing activities of $142.4 million in the nine months ended September 30, 2022 were primarily related to $219.7 million received from our 2022 Credit Agreement offset in part by $48.3 million of cash outflows related to claims processing services on behalf of partners and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$17.4 million from taxes withheld for restricted stock unit vesting. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows used in financing activities of $90.4 million in the nine months ended September 30, 2021 were primarily related to the repayment and termination of our Credit Agreement and settlement of our outstanding warrant agreements with Ares Capital Corporation of $98.4 million, offset, in part by a $1.1 million decrease in net working capital balances held on behalf of our partners for claims processing services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash flows from Discontinued Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business during the nine months ended September 30, 2021 were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:89.594%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Obligations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the amount of cash and cash equivalents on hand and cash flows from operations will be adequate for us to execute our business strategy and meet anticipated requirements for lease obligations, capital expenditures working capital and debt service for 2022. Our estimated contractual obligations (in thousands) as of September&#160;30, 2022, were as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:268.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:51.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:48.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023-2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025-2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2027+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases for facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,519&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase obligations related to vendor contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt interest and termination payments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt principal repayment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual obligations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,856&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234,359&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,377&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">641,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Operating leases for facilities includes $77.1 million and $40.3 million of leases not yet commenced for the 2023-2024 and 2025-2026 time periods, respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Debt interest and termination payments does not include potential interest payments on our floating rate 2022 Credit Facilities. The interest rate for each loan under the 2022 Credit Facilities is calculated, at the option of the Borrowers, (a) in the case of a Term Loan, at either the Adjusted Term SOFR Rate (as defined in the 2022 Credit Agreement) plus 5.50%, or the base rate plus 4.50% and (b) in the case of a Revolving Loan, at either the Adjusted Term SOFR Rate plus 3.50%, or the base rate plus 2.50%. Refer to &#8220;Part I - Item 1. Financial Statements - Note 10&#8221; for additional discussion regarding the 2022 Credit Facilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Accounts Receivable, net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded and carried at the original invoiced amount less an allowance for any potential uncollectible amounts. During the nine months ended September 30, 2022, accounts receivable, net, increased due primarily to the timing of cash receipts from existing customers combined with $34.2 million of receivables acquired as part of the IPG acquisition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments of $38.1 million is carried at cost and includes cash held on behalf of other entities for pharmacy and claims management services of $24.9 million, collateral for letters of credit required as security deposits for facility leases of $2.3 million, amounts held with financial institutions for risk-sharing arrangements of $10.9 million as of September&#160;30, 2022. See &#8220;Part I - Item 1. Financial Statements - Note 2&#8221; for further details of the Company&#8217;s restricted cash balances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Intangible Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Uses of Capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal uses of cash are in the operation and expansion of our business. The Company does not anticipate paying a cash dividend on our Class A common stock in the foreseeable future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i4a25f060abc946f28c4a0095422c2513_139"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.  Quantitative and Qualitative Disclosures About Market Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company had cash and cash equivalents and restricted cash and restricted investments of $194.8 million, which consisted of bank deposits with FDIC participating banks of $191.3 million, bank deposits in international banks of $2.0 million and investments in money market funds of $1.5 million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in interest rates affect the interest earned on our cash and cash equivalents (including restricted cash). Our investments (including restricted investments) are classified as held-to-maturity and therefore are not subject to interest rate risk. We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate risk exposure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, we had $196.8 million of aggregate principal amount of convertible notes outstanding, which are fixed rate instruments and not subject to fluctuations in interest rates. In addition, as of September 30, 2022, we had $175.0 million of aggregate principal amount in a secured term loan and $50.0 million of aggregate principal amount in a secured revolving credit facility, both of which are floating rate instruments based on the Secured Overnight Funding Rate (&#8220;SOFR&#8221;) and subject to fluctuations in interest rates. For every 1% increase in SOFR, Company would record additional interest expense of $2.3 million per annum.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the discussion in &#8220;Part I - Item 1.  Financial Statements - Note 10&#8221; for additional information on our long-term debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2018, we have foreign currency risks related to our revenue and operating expenses denominated in currencies other than the U.S. dollar, primarily the Indian Rupee. In general, we are a net payor of currencies other than the U.S. dollar. Accordingly, changes in exchange rates, and in particular a strengthening of the U.S. dollar, may, in the future, negatively affect our operating results as expressed in U.S. dollars. At this time, we have not entered into, but in the future, we may enter into, derivatives or other financial instruments in an attempt to hedge our foreign currency exchange risk. It is difficult to predict the effect hedging activities would have on our results of operations. We recognized a foreign currency translation losses of $0.3 million and $0.7 million for the three and nine months ended September 30, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_142"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.  Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, as of the end of the period covered by this Quarterly Report on Form 10-Q. The Chief Executive Officer (&#8220;CEO&#8221;) and the Chief Financial Officer (&#8220;CFO&#8221;), with assistance from other members of management, have reviewed the effectiveness of our disclosure controls and procedures as of September&#160;30, 2022, based on their evaluation, have concluded that the disclosure controls and procedures were effective as of such date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended September&#160;30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not experienced any material impact to our internal controls over financial reporting despite most of our employees working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inherent Limitations of Internal Controls</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="i4a25f060abc946f28c4a0095422c2513_145"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_148"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion of legal proceedings included within &#8220;Part I &#8211; Item 1. Financial Statements and Supplementary Data - Note 11 - Commitments and Contingencies - Litigation Matters&#8221; is incorporated by reference into this Item 1.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_151"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant business risks are described in Item 1A to our Annual Report on Form 10-K for the year ended December 31, 2021 (the &#8220;2021 Form 10-K&#8221;). These risk factors are supplemented for the item described below. The risks and uncertainties we describe are not the only ones facing us. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business or operations. Any adverse effect on our business, financial condition or operating results could result in a decline in the value of our securities and the loss of all or part of your investment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Increasing inflationary pressures and consumer costs may have a negative effect on our margins, profitability and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The broader U.S. economy has experienced higher than expected inflationary pressures during the first nine months of 2022 related to continued supply chain disruptions, labor shortages and geopolitical instability. Increasing inflationary pressures may have a negative effect on our profit margins and earnings due to associated costs increases. Additionally, we face an increasingly competitive labor market due to sustained labor shortages in part from the COVID-19 pandemic and are subject to inflationary pressures on employee wages and salaries which may increase labor costs. Failure to retain highly skilled employees due to wage inflation could have a material adverse impact on our business, results of operations or financial condition. See the risk factor captioned &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we lose key members of our management team or employees or are unable to attract and retain the employees we need, our compensation costs will increase and our business and operating results will be adversely affected</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; in our 2021 Form 10-K. While we are unable to predict the direction of the economy or if inflation will increase or revert to normal levels, if the current inflationary trends continue for a sustained period of time, our margins, profitability and results of operations could be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are exposed to interest rate risk under the 2022 Credit Agreement, which could cause the Company&#8217;s debt service obligations to increase significantly.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk from changes in interest rates. Both the Initial Term Loan Facility and Revolving Facility that comprise the Credit Facilities is based on the SOFR, a floating rate, subject to a minimum rate set in the Credit Agreement. The Federal Reserve has raised, and may in the future further raise, interest rates to combat the effects of recent high inflation. Any further increase in the SOFR will increase the Company&#8217;s debt service obligations, which could have a negative impact on the Company&#8217;s cash flow, financial position or operating results, including cash available for servicing the Company&#8217;s indebtedness, or result in increased borrowing costs in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Servicing our debt requires a significant amount of cash, and we may not have sufficient cash flow from our business to pay our debt</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%">.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our indebtedness depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may not generate cash flow from operations in the future sufficient to service our debt and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Restrictive covenants in our 2022 Credit Agreement may interfere with our ability to access the revolving credit facility under the 2022 Credit Agreement, or to obtain new financing or to engage in other business activities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2022 Credit Agreement imposes significant operating and financial restrictions on us. These restrictions limit our ability and/or the ability of certain of our subsidiaries to, among other things:</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">incur or guarantee additional debt;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">incur certain liens;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">merge or consolidate;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">transfer or sell assets;</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">make certain investments;</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">pay dividends and make other distributions on, or redeem or repurchase, capital stock; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">enter into transactions with affiliates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are required to comply with certain financial covenants consisting of a minimum liquidity test, and, commencing on the last day of the fiscal quarter ending September 30, 2022, a total secured leverage test. As a result of these restrictions, we will be limited as to how we conduct our business and we may be unable to raise additional debt or equity financing to compete effectively or to take advantage of new business opportunities. The terms of any future indebtedness we may incur could include more restrictive covenants. We cannot assure you that the Company will be able to maintain compliance with these covenants in the future and, if it fails to do so, that it will be able to obtain waivers from the lenders and/or amend the covenants. The Company&#8217;s failure to comply with the restrictive covenants described above as well as the terms of any future indebtedness could result in an event of default, which, if not cured or waived, could result in it being required to repay these borrowings before their due date and the lenders would be entitled to foreclose on collateral. If the Company is forced to refinance these borrowings on less favorable terms or cannot refinance these borrowings, our results of operations and financial condition could be adversely affected.  In addition, we may be unable to access future borrowings under our revolving facility if we are unable to satisfy the applicable conditions precedent.  </span></div><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_154"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_157"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_160"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.  Mine Safety Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_163"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.  Other Information</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i4a25f060abc946f28c4a0095422c2513_166"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.  Exhibits</span></div><div style="text-align:justify"><span><br/></span></div><div id="i4a25f060abc946f28c4a0095422c2513_169"></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EVOLENT HEALTH, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"></td><td style="width:42.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:490.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000059/a063019exhibit24.htm">2.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000059/a063019exhibit24.htm">Asset Purchase Agreement, dated May 28, 2019, by and among University Health Care, Inc., d/b/a Passport Health Plan, Passport Health Solutions, LLC, Evolent Health, Inc. and Justify Holdings, Inc., filed as Exhibit 2.4 to the Company&#8217;s Report on Form 10-Q filed with the SEC on August 9, 2019, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000084/exhibit21passportfirst.htm">2.2*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890819000084/exhibit21passportfirst.htm">First Amendment to Asset Purchase Agreement, dated as of December 30, 2019, by and among University Health Care, Inc., d/b/a Passport Health Plan, Passport Health Solutions, LLC, Justify Holdings, Inc., and Evolent Health, Inc., filed as Exhibit 2.1 to the Company&#8217;s Report on Form 8-K with the SEC on December 31, 2019, and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:47pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000109/a202108048-kexhibit21.htm">2.3*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000109/a202108048-kexhibit21.htm">Purchase Agreement and Plan of Merger, dated August 2, 2021, by and among Evolent Health, Inc., Evolent Health LLC, EV Thunder Merger Sub, LLC, WindRose Health Investors III, L.P., Vital Decisions Acquisition, LLC and WindRose Health Investors, LLC, as the representative,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1628908/000162890821000109/a202108048-kexhibit21.htm"> filed as Exhibit 2.1 to the Company&#8217;s report on Form 8-K filed with the SEC on August 4, 2021 and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex24.htm">2.4*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex24.htm">Agreement and Plan of Merger, dated August 1, 2022, by and among Evolent Health, Inc., Evolent Health LLC, Endzone Merger Sub, Inc, TPG Growth Iceman Parent, Inc. and the Sellers&#8217; Representative</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex24.htm">, filed as Exhibit 2.4 t</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex24.htm">o the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex24.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex24.htm">s Form 10-Q with the SEC on August 3, 2022 and incorporated herein by reference</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex24.htm">.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex41.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex41.htm">Registration Rights Agreement, dated August 1, 2022, by and between Evolent Health, Inc., TPG Growth V Iceman, L.P.,  and the individuals in Schedule I of the agreemen</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex41.htm">t</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex41.htm">, filed as Exhibit 4.1 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex41.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex41.htm">s Form </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex41.htm">10-Q with the SEC on</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex41.htm"> August 3, 2022 and incorporated herein by reference</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex101.htm">10.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex101.htm">Credit Agreement, by and among Evolent Health, Inc., Evolent Health LLC, certain subsidiaries of Evolent Health, Inc, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent, and ACF Finco I LP, as revolving agent and collateral agent, dated as of August 1, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex101.htm">, filed as </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex101.htm">E</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex101.htm">xhibit 10.1 to the C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex101.htm">ompany</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex101.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex101.htm">s Form 10-Q with the SEC on August 3, 2022 and incorporated herein by reference</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex101.htm">.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex102.htm">10.2*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex102.htm">Security Agreement, by and among Evolent Health, Inc., Evolent Health LLC, the other guarantors and ACF Finco I LP, as collateral agent for the benefit of the secured parties, dated as of August 1, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex102.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex102.htm">, filed as E</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex102.htm">xhibit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex102.htm"> 10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex102.htm">2 to the C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex102.htm">ompany</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex102.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex102.htm">s Form 10-Q with the SEC on August 3, 2022 and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex102.htm">incorporated herein by reference</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex102.htm">.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:33pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex103.htm">10.3*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex103.htm">Guarantee Agreement, by Evolent Health, Inc. and each of the other guarantors in favor of Ares Capital Corporation, as administrative agent for the lenders, and ACF Finco I LP, as collateral agent for the lenders, dated as of August 1, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex103.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex103.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex103.htm"> filed as Exhibit 10.3 to the Company</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex103.htm">&#8217;</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex103.htm">s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex103.htm">Form 10-Q with the SEC on A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex103.htm">ugust 3, 2022 and incorporated herein by referenc</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1628908/000162890822000098/a2022q2form10qex103.htm">e</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a93022exhibit311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a93022exhibit311.htm">Certification of the Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a93022exhibit312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a93022exhibit312.htm">Certification of the Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a93022exhibit321.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a93022exhibit321.htm">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a93022exhibit322.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a93022exhibit322.htm">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Quarterly Report on Form 10-Q, formatted as Inline XBRL</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">* The Company agrees to furnish supplementally to the SEC a copy of any omitted schedule or exhibit upon the request of the SEC in accordance with Item 601(b)(2) of Regulation S-K. </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><div id="i4a25f060abc946f28c4a0095422c2513_172"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><span><br/></span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:249.00pt"><tr><td style="width:1.0pt"></td><td style="width:43.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:100.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:100.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EVOLENT HEALTH, INC.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Registrant</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ John Johnson</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">John Johnson</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Aammaad Shams</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aammaad Shams</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Accounting Officer and Controller</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated:  November&#160;3, 2022 </span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a93022exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4822c9c9307c4867a4e15b0ba9adea45_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to Section 302 of the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Seth Blackley, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Evolent Health, Inc.&#59;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.944%"><tr><td style="width:1.0%"></td><td style="width:5.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a93022exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i36f999b107e3425390f8ef3cf53be50a_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to Section 302 of the</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Johnson, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Evolent Health, Inc.&#59;</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.944%"><tr><td style="width:1.0%"></td><td style="width:5.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a93022exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i82cecc7757434b07b48d7ead4cb88f61_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="padding-left:24.75pt;text-align:right;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to 18 U.S.C. Section 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to Section 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Seth Blackley, Chief Executive Officer of Evolent Health, Inc. (the &#8220;Company&#8221;), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Quarterly Report on Form 10-Q of the Company for the quarter ended September&#160;30, 2022 (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:33.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:133.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:234.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  Seth Blackley</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a93022exhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia7ac0c17360a4a01b3f54c9338a1d0a1_1"></div><div style="min-height:18pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to 18 U.S.C. Section 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to Section 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Of the Sarbanes-Oxley Act of 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John Johnson, Chief Financial Officer of Evolent Health, Inc. (the &#8220;Company&#8221;), certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that&#58;</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Quarterly Report on Form 10-Q of the Company for the quarter ended September&#160;30, 2022 (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m)&#59; and</font></div><div style="padding-left:18pt"><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:496.50pt"><tr><td style="width:1.0pt"></td><td style="width:33.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:133.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:234.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 3, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;  John Johnson</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;  Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>evh-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b69e33fa-4fec-4147-99e6-af63e8e14083,g:752cd8d8-fa1c-4165-8528-47511781866b-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:evh="http://www.evolenthealth.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.evolenthealth.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="evh-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.evolenthealth.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS">
        <link:definition>0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.evolenthealth.com/role/Organization">
        <link:definition>0000008 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples">
        <link:definition>0000009 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentlyIssuedAccountingStandards" roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards">
        <link:definition>0000010 - Disclosure - Recently Issued Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Transactions" roleURI="http://www.evolenthealth.com/role/Transactions">
        <link:definition>0000011 - Disclosure - Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperations" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperations">
        <link:definition>0000012 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.evolenthealth.com/role/RevenueRecognition">
        <link:definition>0000013 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLosses" roleURI="http://www.evolenthealth.com/role/CreditLosses">
        <link:definition>0000014 - Disclosure - Credit Losses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNet">
        <link:definition>0000015 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNet" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet">
        <link:definition>0000016 - Disclosure - Goodwill and Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt" roleURI="http://www.evolenthealth.com/role/LongtermDebt">
        <link:definition>0000017 - Disclosure - Long-term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingencies">
        <link:definition>0000018 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.evolenthealth.com/role/Leases">
        <link:definition>0000019 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerCommonShare" roleURI="http://www.evolenthealth.com/role/IncomeLossPerCommonShare">
        <link:definition>0000020 - Disclosure - Income (Loss) Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensation" roleURI="http://www.evolenthealth.com/role/StockbasedCompensation">
        <link:definition>0000021 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.evolenthealth.com/role/IncomeTaxes">
        <link:definition>0000022 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinEquityMethodInvestees" roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees">
        <link:definition>0000023 - Disclosure - Investments in Equity Method Investees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.evolenthealth.com/role/FairValueMeasurement">
        <link:definition>0000024 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedParties" roleURI="http://www.evolenthealth.com/role/RelatedParties">
        <link:definition>0000025 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RepositioningandOtherChanges" roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChanges">
        <link:definition>0000026 - Disclosure - Repositioning and Other Changes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReporting" roleURI="http://www.evolenthealth.com/role/SegmentReporting">
        <link:definition>0000027 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangements" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements">
        <link:definition>0000028 - Disclosure - Reserves for Claims and Performance-Based Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformation" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformation">
        <link:definition>0000029 - Disclosure - Supplemental Cash Flow Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.evolenthealth.com/role/SubsequentEvents">
        <link:definition>0000030 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies">
        <link:definition>0000031 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables">
        <link:definition>0000032 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransactionsTables" roleURI="http://www.evolenthealth.com/role/TransactionsTables">
        <link:definition>0000033 - Disclosure - Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsTables" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsTables">
        <link:definition>0000034 - Disclosure - Discontinued Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTables">
        <link:definition>0000035 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesTables" roleURI="http://www.evolenthealth.com/role/CreditLossesTables">
        <link:definition>0000036 - Disclosure - Credit Losses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables">
        <link:definition>0000037 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetTables" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables">
        <link:definition>0000038 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtTables" roleURI="http://www.evolenthealth.com/role/LongtermDebtTables">
        <link:definition>0000039 - Disclosure - Long-term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000040 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.evolenthealth.com/role/LeasesTables">
        <link:definition>0000041 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerCommonShareTables" roleURI="http://www.evolenthealth.com/role/IncomeLossPerCommonShareTables">
        <link:definition>0000042 - Disclosure - Income (Loss) Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationTables" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationTables">
        <link:definition>0000043 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementTables">
        <link:definition>0000044 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesTables" roleURI="http://www.evolenthealth.com/role/RelatedPartiesTables">
        <link:definition>0000045 - Disclosure - Related Parties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RepositioningandOtherChangesTables" roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesTables">
        <link:definition>0000046 - Disclosure - Repositioning and Other Changes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingTables" roleURI="http://www.evolenthealth.com/role/SegmentReportingTables">
        <link:definition>0000047 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangementsTables" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables">
        <link:definition>0000048 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationTables" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables">
        <link:definition>0000049 - Disclosure - Supplemental Cash Flow Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.evolenthealth.com/role/OrganizationDetails">
        <link:definition>0000050 - Disclosure - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails">
        <link:definition>0000051 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails">
        <link:definition>0000052 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails">
        <link:definition>0000053 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentlyIssuedAccountingStandardsDetails" roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails">
        <link:definition>0000054 - Disclosure - Recently Issued Accounting Standards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransactionsNarrativeDetails" roleURI="http://www.evolenthealth.com/role/TransactionsNarrativeDetails">
        <link:definition>0000055 - Disclosure - Transactions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TransactionsAllocationofAcquisitionCostDetails" roleURI="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails">
        <link:definition>0000056 - Disclosure - Transactions - Allocation of Acquisition Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsSummaryofResultsofOperationsDetails" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails">
        <link:definition>0000057 - Disclosure - Discontinued Operations - Summary of Results of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsSummaryofCashFlowsDetails" roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails">
        <link:definition>0000058 - Disclosure - Discontinued Operations - Summary of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionDisaggregationofRevenueDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails">
        <link:definition>0000059 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails">
        <link:definition>0000060 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1">
        <link:definition>0000060 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractBalancesDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails">
        <link:definition>0000061 - Disclosure - Revenue Recognition - Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionContractCostsDetails" roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails">
        <link:definition>0000062 - Disclosure - Revenue Recognition - Contract Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesAccountsReceivableNarrativeDetails" roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails">
        <link:definition>0000063 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" roleURI="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails">
        <link:definition>0000064 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDetails" roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails">
        <link:definition>0000065 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetImpairmentTestingDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails">
        <link:definition>0000066 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails">
        <link:definition>0000067 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails">
        <link:definition>0000068 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails">
        <link:definition>0000069 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2022CreditAgreementDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails">
        <link:definition>0000070 - Disclosure - Long-term Debt - 2022 Credit Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2024NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails">
        <link:definition>0000071 - Disclosure - Long-term Debt - 2024 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2019CreditAgreementDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails">
        <link:definition>0000072 - Disclosure - Long-term Debt - 2019 Credit Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtWarrantAgreementDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails">
        <link:definition>0000073 - Disclosure - Long-term Debt - Warrant Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2025NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails">
        <link:definition>0000074 - Disclosure - Long-term Debt - 2025 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebt2021NotesDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails">
        <link:definition>0000075 - Disclosure - Long-term Debt - 2021 Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongtermDebtConvertibleSeniorNotesCarryingValueDetails" roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails">
        <link:definition>0000076 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>0000077 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesConcentrationRiskDetails" roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails">
        <link:definition>0000078 - Disclosure - Commitments and Contingencies - Concentration Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails">
        <link:definition>0000079 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesPrimaryOfficeLeasesDetails" roleURI="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails">
        <link:definition>0000080 - Disclosure - Leases - Primary Office Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>0000081 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofLeaseLiabilitiesDetails" roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails">
        <link:definition>0000082 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityofLeaseLiabilitiesDetails_1" roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1">
        <link:definition>0000082 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" roleURI="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails">
        <link:definition>0000083 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerCommonShareComputationofEarningsperShareDetails" roleURI="http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails">
        <link:definition>0000084 - Disclosure - Income (Loss) Per Common Share - Computation of Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeLossPerCommonShareAntidilutiveSecuritiesDetails" roleURI="http://www.evolenthealth.com/role/IncomeLossPerCommonShareAntidilutiveSecuritiesDetails">
        <link:definition>0000085 - Disclosure - Income (Loss) Per Common Share - Antidilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationStockbasedCompensationExpenseDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails">
        <link:definition>0000086 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails">
        <link:definition>0000087 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails" roleURI="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails">
        <link:definition>0000088 - Disclosure - Stock-based Compensation - Schedule of Share-based Awards Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000089 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinEquityMethodInvesteesDetails" roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails">
        <link:definition>0000090 - Disclosure - Investments in Equity Method Investees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails">
        <link:definition>0000091 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementChangesinContingentConsiderationandOtherDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails">
        <link:definition>0000092 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails">
        <link:definition>0000093 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesAssetsandLiabilitiesDetails" roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails">
        <link:definition>0000094 - Disclosure - Related Parties - Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesRevenuesandExpensesDetails" roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails">
        <link:definition>0000095 - Disclosure - Related Parties - Revenues and Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RepositioningandOtherChangesDetails" roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails">
        <link:definition>0000096 - Disclosure - Repositioning and Other Changes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingAdditionalInformationDetails" roleURI="http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails">
        <link:definition>0000097 - Disclosure - Segment Reporting - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingRevenuefromSegmentstoConsolidatedDetails" roleURI="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails">
        <link:definition>0000098 - Disclosure - Segment Reporting - Revenue from Segments to Consolidated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentReportingReconciliationofAdjustedEBITDADetails" roleURI="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails">
        <link:definition>0000099 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReservesforClaimsandPerformanceBasedArrangementsDetails" roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails">
        <link:definition>0000100 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalCashFlowInformationDetails" roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails">
        <link:definition>0000101 - Disclosure - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.evolenthealth.com/role/SubsequentEventsDetails">
        <link:definition>0000102 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" abstract="false" name="DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_EquityMethodInvestmentVotingInterestPercentage" abstract="false" name="EquityMethodInvestmentVotingInterestPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_December312024Member" abstract="true" name="December312024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ConvertibleSeniorNotesdue2021Member" abstract="true" name="ConvertibleSeniorNotesdue2021Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" abstract="false" name="DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="evh_ImplantableProviderGroupIMPMember" abstract="true" name="ImplantableProviderGroupIMPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_VitalDecisionsMember" abstract="true" name="VitalDecisionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" abstract="false" name="RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_ProfessionalServicesRestructuringMember" abstract="true" name="ProfessionalServicesRestructuringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" abstract="false" name="RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_LineOfCreditFacilityAutomaticExtensionPeriod" abstract="false" name="LineOfCreditFacilityAutomaticExtensionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationClaimsExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_CashFlowLesseeAbstract" abstract="true" name="CashFlowLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_SecuredOvernightFinancingRateSOFRMember" abstract="true" name="SecuredOvernightFinancingRateSOFRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PremiumsRevenueMember" abstract="true" name="PremiumsRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ChangeInContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DebtIssuanceCostsNetDebtComponent" abstract="false" name="DebtIssuanceCostsNetDebtComponent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_RightOfUseAssetAcquiredAndDisposedOf" abstract="false" name="RightOfUseAssetAcquiredAndDisposedOf" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_InitialTermLoanFacilityMember" abstract="true" name="InitialTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" abstract="false" name="CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_MedicareCustomersMember" abstract="true" name="MedicareCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_BonusesAndCommissionsMember" abstract="true" name="BonusesAndCommissionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" abstract="false" name="PaymentsForProceedsFromClaimsProcessingFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_UPMCResellerAgreementMember" abstract="true" name="UPMCResellerAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_RightOfOffsetPolicyPolicyTextBlock" abstract="false" name="RightOfOffsetPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="evh_CashHeldInInternationalBanksPercentage" abstract="false" name="CashHeldInInternationalBanksPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_RestrictedCashforOtherContractualCommitmentsMember" abstract="true" name="RestrictedCashforOtherContractualCommitmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CashFDICInsuredAmountPercentage" abstract="false" name="CashFDICInsuredAmountPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" abstract="false" name="DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_EvolentHealthServicesSegmentMember" abstract="true" name="EvolentHealthServicesSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_MedicaidCustomersMember" abstract="true" name="MedicaidCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" abstract="false" name="LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_EmployeeSeveranceAndTerminationBenefitsMember" abstract="true" name="EmployeeSeveranceAndTerminationBenefitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" abstract="false" name="ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DelayedDrawTermLoanFacilityMember" abstract="true" name="DelayedDrawTermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_GainOnTransferOfMembership" abstract="false" name="GainOnTransferOfMembership" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ServicesAgreementsMember" abstract="true" name="ServicesAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_RestrictedCashforBenefitManagementServicesMember" abstract="true" name="RestrictedCashforBenefitManagementServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ContractFulfillmentCostsMember" abstract="true" name="ContractFulfillmentCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" abstract="false" name="IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" abstract="false" name="AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards" abstract="false" name="IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="evh_LeveragedStockUnitsLSUsMember" abstract="true" name="LeveragedStockUnitsLSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_FloridaBlueMedicareIncMember" abstract="true" name="FloridaBlueMedicareIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CommercialAndOtherCustomersMember" abstract="true" name="CommercialAndOtherCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_December312022Member" abstract="true" name="December312022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SeniorConvertibleNotesDue2025Member" abstract="true" name="SeniorConvertibleNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_FInancialAssetLessThan120DaysPastDueMember" abstract="true" name="FInancialAssetLessThan120DaysPastDueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SeniorCreditFacilitiesMember" abstract="true" name="SeniorCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_BasicAndDilutedEarningsPerShareAbstract" abstract="true" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_EquityMethodInvestmentEconomicInterestPercentage" abstract="false" name="EquityMethodInvestmentEconomicInterestPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_DeferredFinancingFeesMember" abstract="true" name="DeferredFinancingFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_BelowMarketLeasesMember" abstract="true" name="BelowMarketLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_TaxReceivableAgreementLiability" abstract="false" name="TaxReceivableAgreementLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ProceedsFromMaturityOfInvestments" abstract="false" name="ProceedsFromMaturityOfInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ShareholderAdvisoryServices" abstract="false" name="ShareholderAdvisoryServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_A2022CreditFacilitiesMember" abstract="true" name="A2022CreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_TransactionCosts" abstract="false" name="TransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" abstract="false" name="DebtInstrumentRepurchaseCovenantTradingDaysMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_EquityComponentOfLongTermDebtMember" abstract="true" name="EquityComponentOfLongTermDebtMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_PerformanceBasedRestrictedStockUnitsPSUsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsPSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SeniorConvertibleNotesDue2024Member" abstract="true" name="SeniorConvertibleNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" abstract="false" name="CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" abstract="false" name="TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_FInancialAssetLessThan60DaysMember" abstract="true" name="FInancialAssetLessThan60DaysMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_NumberOfCustomers" abstract="false" name="NumberOfCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="evh_CookCountyHealthAndHospitalsSystemMember" abstract="true" name="CookCountyHealthAndHospitalsSystemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_ChangesInTaxReceivablesAgreementLiability" abstract="false" name="ChangesInTaxReceivablesAgreementLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" abstract="false" name="ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_IncreaseDecreaseInCapitalizedContractCostNet" abstract="false" name="IncreaseDecreaseInCapitalizedContractCostNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_NumberOfOptionsToRenewLeases" abstract="false" name="NumberOfOptionsToRenewLeases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="evh_PlatformsAndOperationsServicesMember" abstract="true" name="PlatformsAndOperationsServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" abstract="false" name="IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" abstract="true" name="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="evh_WeightedAverageCommonSharesOutstandingAbstract" abstract="true" name="WeightedAverageCommonSharesOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" abstract="false" name="DebtInstrumentPrepaymentPenaltyPeriodThreePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_IncreaseDecreaseInTaxReceivableAgreement" abstract="false" name="IncreaseDecreaseInTaxReceivableAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_December312023Member" abstract="true" name="December312023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_NumberOfSourcesOfRevenue" abstract="false" name="NumberOfSourcesOfRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" abstract="false" name="TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" abstract="true" name="RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" abstract="false" name="DebtInstrumentPrepaymentPenaltyPeriodFourPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_FinancingReceivablePercentNotPastDue" abstract="false" name="FinancingReceivablePercentNotPastDue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" abstract="false" name="DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_ClinicalSolutionsSegmentMember" abstract="true" name="ClinicalSolutionsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" abstract="true" name="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" abstract="true" name="MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_TrueHealthMember" abstract="true" name="TrueHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" abstract="false" name="DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_CollateralwithFinancialInstitutionsMember" abstract="true" name="CollateralwithFinancialInstitutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_GainLossOnDispositionOfAssetsOperatingActivities" abstract="false" name="GainLossOnDispositionOfAssetsOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" abstract="false" name="PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_MolinaHealthcareMember" abstract="true" name="MolinaHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_SharebasedCompensationIncludingOnetimeAdjustment" abstract="false" name="SharebasedCompensationIncludingOnetimeAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" abstract="false" name="DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" abstract="false" name="DebtInstrumentPrepaymentPenaltyPeriodOnePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="evh_BrightHealthManagementIncMember" abstract="true" name="BrightHealthManagementIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" abstract="false" name="AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_NewNotesMember" abstract="true" name="NewNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" abstract="false" name="LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" abstract="false" name="IncomeLossFromEquityMethodInvestmentsServicesAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_StockIssuedInConnectionWithDebtRepayment" abstract="false" name="StockIssuedInConnectionWithDebtRepayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_PaymentsOfMakeWholePremium" abstract="false" name="PaymentsOfMakeWholePremium" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="evh_ShareholderClassActionComplaintMember" abstract="true" name="ShareholderClassActionComplaintMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" abstract="true" name="RestrictedCashforLettersofCreditforFacilityLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>evh-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b69e33fa-4fec-4147-99e6-af63e8e14083,g:752cd8d8-fa1c-4165-8528-47511781866b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="evh-20220930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_794889dc-fbfe-4b8d-823f-987bd0f7401d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1fea8572-87cc-4184-9ce8-745b06b5f35e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_794889dc-fbfe-4b8d-823f-987bd0f7401d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1fea8572-87cc-4184-9ce8-745b06b5f35e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a49d5ff3-ebab-4d70-81ae-ec81feea788b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_794889dc-fbfe-4b8d-823f-987bd0f7401d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a49d5ff3-ebab-4d70-81ae-ec81feea788b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7abfaec0-2e4a-4c5d-9128-5be1fbac55ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_794889dc-fbfe-4b8d-823f-987bd0f7401d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7abfaec0-2e4a-4c5d-9128-5be1fbac55ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f7ccdfae-3230-4fe2-be88-056675fc013a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_794889dc-fbfe-4b8d-823f-987bd0f7401d" xlink:to="loc_us-gaap_CommonStockValue_f7ccdfae-3230-4fe2-be88-056675fc013a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_7c72a0e1-b862-481d-89ef-2fccefa2d04b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_794889dc-fbfe-4b8d-823f-987bd0f7401d" xlink:to="loc_us-gaap_TreasuryStockCommonValue_7c72a0e1-b862-481d-89ef-2fccefa2d04b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2d3fc3d0-4c56-4390-b4d3-c0d1b4796fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f9d149ea-e914-42bc-a359-18f0ebf25e12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2d3fc3d0-4c56-4390-b4d3-c0d1b4796fff" xlink:to="loc_us-gaap_AccountsPayableCurrent_f9d149ea-e914-42bc-a359-18f0ebf25e12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_43d3d91c-9fac-48e9-9580-e3b935e11b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2d3fc3d0-4c56-4390-b4d3-c0d1b4796fff" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_43d3d91c-9fac-48e9-9580-e3b935e11b3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_11776669-31b5-4e95-852e-d49068393f6c" xlink:href="evh-20220930.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2d3fc3d0-4c56-4390-b4d3-c0d1b4796fff" xlink:to="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_11776669-31b5-4e95-852e-d49068393f6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_159c3c9b-c168-4066-a14d-ae3a3ea9eedb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2d3fc3d0-4c56-4390-b4d3-c0d1b4796fff" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_159c3c9b-c168-4066-a14d-ae3a3ea9eedb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_78870958-4b0c-409f-90b9-23d0b922ca9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2d3fc3d0-4c56-4390-b4d3-c0d1b4796fff" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_78870958-4b0c-409f-90b9-23d0b922ca9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_54f801b0-10fe-4dfc-823e-838e39830fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2d3fc3d0-4c56-4390-b4d3-c0d1b4796fff" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_54f801b0-10fe-4dfc-823e-838e39830fc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9ef4cfb7-e0e2-425b-b8df-07476fbe6aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9bb395fe-8d66-44ed-891a-024b69782916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9ef4cfb7-e0e2-425b-b8df-07476fbe6aa6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9bb395fe-8d66-44ed-891a-024b69782916" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_f993f76b-b22c-4fa5-a690-ad7e5be9523e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9ef4cfb7-e0e2-425b-b8df-07476fbe6aa6" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_f993f76b-b22c-4fa5-a690-ad7e5be9523e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_68e8a5b2-3ac1-4b05-81d0-7c12a978b2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9ef4cfb7-e0e2-425b-b8df-07476fbe6aa6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_68e8a5b2-3ac1-4b05-81d0-7c12a978b2c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ca3e8600-9e65-4b6a-b60b-71048b2fd475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9ef4cfb7-e0e2-425b-b8df-07476fbe6aa6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ca3e8600-9e65-4b6a-b60b-71048b2fd475" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f33ee2cb-f089-4932-92cb-fa02883d3897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_22f83e9d-879a-48f1-b042-3dc28190b6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f33ee2cb-f089-4932-92cb-fa02883d3897" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_22f83e9d-879a-48f1-b042-3dc28190b6cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a5e4d226-4bb6-4abf-aa63-61377fb79b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f33ee2cb-f089-4932-92cb-fa02883d3897" xlink:to="loc_us-gaap_AssetsCurrent_a5e4d226-4bb6-4abf-aa63-61377fb79b4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8ede7f54-ac44-40ed-be82-3b42658339ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f33ee2cb-f089-4932-92cb-fa02883d3897" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8ede7f54-ac44-40ed-be82-3b42658339ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a5a44a31-8a23-4c0a-81f9-fa4cf76c96f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f33ee2cb-f089-4932-92cb-fa02883d3897" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a5a44a31-8a23-4c0a-81f9-fa4cf76c96f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_b46bac91-1b22-4512-839d-b53fdef60aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f33ee2cb-f089-4932-92cb-fa02883d3897" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_b46bac91-1b22-4512-839d-b53fdef60aad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_69e0b91a-ffe7-452c-ab51-707d6569b342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f33ee2cb-f089-4932-92cb-fa02883d3897" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_69e0b91a-ffe7-452c-ab51-707d6569b342" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_a093b3d9-06b2-48b8-947f-0631ff1f85d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f33ee2cb-f089-4932-92cb-fa02883d3897" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_a093b3d9-06b2-48b8-947f-0631ff1f85d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fbe0d0b7-c229-4253-a9bb-b2eb0253e8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f33ee2cb-f089-4932-92cb-fa02883d3897" xlink:to="loc_us-gaap_Goodwill_fbe0d0b7-c229-4253-a9bb-b2eb0253e8ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_f1ed8f8c-de3e-4a02-a5cd-dbf5b00c1926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f33ee2cb-f089-4932-92cb-fa02883d3897" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_f1ed8f8c-de3e-4a02-a5cd-dbf5b00c1926" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c59bde14-5e32-4a8d-ba43-af5fdb68f5dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_636b0aa5-38f0-41a2-bb10-89daa166c857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c59bde14-5e32-4a8d-ba43-af5fdb68f5dc" xlink:to="loc_us-gaap_LiabilitiesCurrent_636b0aa5-38f0-41a2-bb10-89daa166c857" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_bf8222ca-da69-4150-abab-013746489c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c59bde14-5e32-4a8d-ba43-af5fdb68f5dc" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_bf8222ca-da69-4150-abab-013746489c46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e3dcdbd5-9016-4be9-95ff-1219b216c9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c59bde14-5e32-4a8d-ba43-af5fdb68f5dc" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e3dcdbd5-9016-4be9-95ff-1219b216c9dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8281f3b1-e66c-436a-8100-fa2058258d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c59bde14-5e32-4a8d-ba43-af5fdb68f5dc" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8281f3b1-e66c-436a-8100-fa2058258d6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementLiability_4dc9e13e-f6d4-4478-804a-095505c89dcc" xlink:href="evh-20220930.xsd#evh_TaxReceivableAgreementLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c59bde14-5e32-4a8d-ba43-af5fdb68f5dc" xlink:to="loc_evh_TaxReceivableAgreementLiability_4dc9e13e-f6d4-4478-804a-095505c89dcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e8659a53-6cef-43e6-b849-8bc0b6a4f01a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c59bde14-5e32-4a8d-ba43-af5fdb68f5dc" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e8659a53-6cef-43e6-b849-8bc0b6a4f01a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5bc10d12-775b-49d3-b9e6-df39fe0ccc35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c54fbb9a-715a-4b15-94c7-00da3adb16b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5bc10d12-775b-49d3-b9e6-df39fe0ccc35" xlink:to="loc_us-gaap_Liabilities_c54fbb9a-715a-4b15-94c7-00da3adb16b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a890bdb0-1a0c-408b-89a9-091fd73e5671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5bc10d12-775b-49d3-b9e6-df39fe0ccc35" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a890bdb0-1a0c-408b-89a9-091fd73e5671" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1796e399-2721-405e-a0bc-a487258177e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_5bc10d12-775b-49d3-b9e6-df39fe0ccc35" xlink:to="loc_us-gaap_StockholdersEquity_1796e399-2721-405e-a0bc-a487258177e1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="evh-20220930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a6f40d2d-38c3-4831-8d8b-8908a3849f81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_f27d6a36-f187-478b-b1ee-e71114703926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_a6f40d2d-38c3-4831-8d8b-8908a3849f81" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_f27d6a36-f187-478b-b1ee-e71114703926" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_74b214d0-3e4f-4c49-b9d5-2efe14c45112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_a6f40d2d-38c3-4831-8d8b-8908a3849f81" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_74b214d0-3e4f-4c49-b9d5-2efe14c45112" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_896301a2-d9dc-4912-86d4-86dd039fefcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_e1285eab-fab3-4c55-9f1f-fbb52a2e3bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_896301a2-d9dc-4912-86d4-86dd039fefcc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_e1285eab-fab3-4c55-9f1f-fbb52a2e3bec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_c7fc281f-cf92-41e1-9e11-caa9d0813a86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_896301a2-d9dc-4912-86d4-86dd039fefcc" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_c7fc281f-cf92-41e1-9e11-caa9d0813a86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4180383b-3dc0-4d60-b7e5-9012171b029a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_832bdef9-6620-4e36-8a11-5a5fe9dd4c13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4180383b-3dc0-4d60-b7e5-9012171b029a" xlink:to="loc_us-gaap_NetIncomeLoss_832bdef9-6620-4e36-8a11-5a5fe9dd4c13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_fd1e1685-d67c-44ba-8a17-ad200c9bb994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_4180383b-3dc0-4d60-b7e5-9012171b029a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_fd1e1685-d67c-44ba-8a17-ad200c9bb994" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15a645f7-63a5-421e-abe7-0c21c4a5f8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6c450efe-76c0-4250-bab5-0113a1073890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15a645f7-63a5-421e-abe7-0c21c4a5f8a0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6c450efe-76c0-4250-bab5-0113a1073890" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_fd3b0829-922a-40f5-995d-dc3af2ad7101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15a645f7-63a5-421e-abe7-0c21c4a5f8a0" xlink:to="loc_us-gaap_InvestmentIncomeInterest_fd3b0829-922a-40f5-995d-dc3af2ad7101" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d005995a-1986-42f4-a197-3c32cc1f417f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15a645f7-63a5-421e-abe7-0c21c4a5f8a0" xlink:to="loc_us-gaap_OperatingIncomeLoss_d005995a-1986-42f4-a197-3c32cc1f417f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e0772abe-314f-40cf-a79a-7a39171df9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15a645f7-63a5-421e-abe7-0c21c4a5f8a0" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e0772abe-314f-40cf-a79a-7a39171df9fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8755e7c9-530e-412f-a1ce-74d39067b784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15a645f7-63a5-421e-abe7-0c21c4a5f8a0" xlink:to="loc_us-gaap_InterestExpense_8755e7c9-530e-412f-a1ce-74d39067b784" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_dcde8d61-4119-44e8-b8b3-c9943bd67caf" xlink:href="evh-20220930.xsd#evh_GainOnTransferOfMembership"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15a645f7-63a5-421e-abe7-0c21c4a5f8a0" xlink:to="loc_evh_GainOnTransferOfMembership_dcde8d61-4119-44e8-b8b3-c9943bd67caf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b52d219c-7e69-4531-9e76-6f5cfc16e8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15a645f7-63a5-421e-abe7-0c21c4a5f8a0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b52d219c-7e69-4531-9e76-6f5cfc16e8ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangesInTaxReceivablesAgreementLiability_8f653093-789e-4a9a-9928-a481a752f3fa" xlink:href="evh-20220930.xsd#evh_ChangesInTaxReceivablesAgreementLiability"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15a645f7-63a5-421e-abe7-0c21c4a5f8a0" xlink:to="loc_evh_ChangesInTaxReceivablesAgreementLiability_8f653093-789e-4a9a-9928-a481a752f3fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b07fd4c7-bb15-4ce6-b4c9-837e6a651dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_99bf0af3-eb2a-4822-91ff-a47850c8b799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b07fd4c7-bb15-4ce6-b4c9-837e6a651dfc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_99bf0af3-eb2a-4822-91ff-a47850c8b799" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_ed89eb78-035f-4df1-a700-4bcd8e3d5a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b07fd4c7-bb15-4ce6-b4c9-837e6a651dfc" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_ed89eb78-035f-4df1-a700-4bcd8e3d5a3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_55bb28d3-cf1b-4831-ba62-db644127a446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_43f30528-cdf1-4eb9-8bbd-37e0bdec944b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_55bb28d3-cf1b-4831-ba62-db644127a446" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_43f30528-cdf1-4eb9-8bbd-37e0bdec944b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_06f27bab-aff9-4773-9e48-78eddd9ae239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_55bb28d3-cf1b-4831-ba62-db644127a446" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_06f27bab-aff9-4773-9e48-78eddd9ae239" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_d5bd434c-77ab-4e3a-8727-98968f6bf1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_55bb28d3-cf1b-4831-ba62-db644127a446" xlink:to="loc_us-gaap_DepreciationAndAmortization_d5bd434c-77ab-4e3a-8727-98968f6bf1fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4c3d6710-bf3f-4c36-a44a-e5f64eaa5808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_55bb28d3-cf1b-4831-ba62-db644127a446" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_4c3d6710-bf3f-4c36-a44a-e5f64eaa5808" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_261275f5-b23a-433e-b33e-bf37c5c0f0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5c8527f4-e046-4dd0-aab5-36d7389ef342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_261275f5-b23a-433e-b33e-bf37c5c0f0fe" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5c8527f4-e046-4dd0-aab5-36d7389ef342" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f3806036-5778-4ebd-acb6-56dff0131ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_261275f5-b23a-433e-b33e-bf37c5c0f0fe" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f3806036-5778-4ebd-acb6-56dff0131ffa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_655954b3-287c-4d78-ae74-b55ee00e63fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e59fcae7-a5c1-4192-9359-26dab2f9378c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_655954b3-287c-4d78-ae74-b55ee00e63fe" xlink:to="loc_us-gaap_CostsAndExpenses_e59fcae7-a5c1-4192-9359-26dab2f9378c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8b25a0ae-fd15-46c7-8a94-f605206c05ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_655954b3-287c-4d78-ae74-b55ee00e63fe" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8b25a0ae-fd15-46c7-8a94-f605206c05ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_f1fb89f5-e3c4-4b4f-877b-fb57790de66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_728f196b-058d-4037-b47f-069740698654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_f1fb89f5-e3c4-4b4f-877b-fb57790de66d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_728f196b-058d-4037-b47f-069740698654" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_4e4a2d7e-819b-4c92-a035-849518c4245b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_f1fb89f5-e3c4-4b4f-877b-fb57790de66d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_4e4a2d7e-819b-4c92-a035-849518c4245b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="evh-20220930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2b2b3df3-b663-435d-98ec-f0d0c7e908e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_af31f9c0-e262-4fb5-bdfb-3a0d9e7146dc" xlink:href="evh-20220930.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2b2b3df3-b663-435d-98ec-f0d0c7e908e2" xlink:to="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_af31f9c0-e262-4fb5-bdfb-3a0d9e7146dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_6789a72c-cfd8-45a5-a810-b715fb3ea603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2b2b3df3-b663-435d-98ec-f0d0c7e908e2" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_6789a72c-cfd8-45a5-a810-b715fb3ea603" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_b44fbcec-494c-46b5-ba82-d0b8dae38818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2b2b3df3-b663-435d-98ec-f0d0c7e908e2" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_b44fbcec-494c-46b5-ba82-d0b8dae38818" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_425fb03e-a520-48b2-a010-6975593879d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2b2b3df3-b663-435d-98ec-f0d0c7e908e2" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_425fb03e-a520-48b2-a010-6975593879d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d77a47fa-d80d-4f1c-8766-980e7d73e0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2b2b3df3-b663-435d-98ec-f0d0c7e908e2" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d77a47fa-d80d-4f1c-8766-980e7d73e0ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_4c421185-691e-4421-89fb-6a20dbf3101f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2b2b3df3-b663-435d-98ec-f0d0c7e908e2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_4c421185-691e-4421-89fb-6a20dbf3101f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_b38236dc-38ee-416b-9df4-f9cb9dd4d9c7" xlink:href="evh-20220930.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_b38236dc-38ee-416b-9df4-f9cb9dd4d9c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2c0d4a4c-d68c-43ba-97cc-79ff3f150af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2c0d4a4c-d68c-43ba-97cc-79ff3f150af2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_5925386f-561f-4a96-b835-49847d1e2721" xlink:href="evh-20220930.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_5925386f-561f-4a96-b835-49847d1e2721" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_8d12f012-af2d-46f9-9735-0f732d516733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_8d12f012-af2d-46f9-9735-0f732d516733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_01620282-1a1b-4272-9169-da018618cc91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_us-gaap_NetIncomeLoss_01620282-1a1b-4272-9169-da018618cc91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_0e7b3af8-cfb1-4e8d-bd26-53bcfb247a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_0e7b3af8-cfb1-4e8d-bd26-53bcfb247a13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_d29182e3-7178-4ec2-8a2c-72fda06eb1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_d29182e3-7178-4ec2-8a2c-72fda06eb1b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e10fcf02-e8dd-4835-a03e-8102fde703b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e10fcf02-e8dd-4835-a03e-8102fde703b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_d39b168e-4e1f-4b84-9540-83a21fa21f8a" xlink:href="evh-20220930.xsd#evh_GainLossOnDispositionOfAssetsOperatingActivities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_d39b168e-4e1f-4b84-9540-83a21fa21f8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_61377d93-f518-425c-989c-5093fefc83b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_61377d93-f518-425c-989c-5093fefc83b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_08a9b621-12d9-4e7f-ad92-2dd2523f6e77" xlink:href="evh-20220930.xsd#evh_GainOnTransferOfMembership"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_evh_GainOnTransferOfMembership_08a9b621-12d9-4e7f-ad92-2dd2523f6e77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b51709c4-1fc8-4613-b4e8-53ef29866f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_us-gaap_ShareBasedCompensation_b51709c4-1fc8-4613-b4e8-53ef29866f3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInTaxReceivableAgreement_62207e48-cbc8-41c8-a6a0-84504fdc2787" xlink:href="evh-20220930.xsd#evh_IncreaseDecreaseInTaxReceivableAgreement"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_evh_IncreaseDecreaseInTaxReceivableAgreement_62207e48-cbc8-41c8-a6a0-84504fdc2787" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_4d13946c-9f12-48fc-9865-4c5b61d8adf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_4d13946c-9f12-48fc-9865-4c5b61d8adf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_9b1d80ed-5193-4ad1-bee2-6d2335d8f3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_9b1d80ed-5193-4ad1-bee2-6d2335d8f3f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_887226ad-0a34-4085-aabe-c347645e6cde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_887226ad-0a34-4085-aabe-c347645e6cde" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_336d773b-d6c0-42ed-b6d7-471359a545eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_336d773b-d6c0-42ed-b6d7-471359a545eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_2b7f2dc8-37d7-47ee-8a5a-865dc83e3e27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_2b7f2dc8-37d7-47ee-8a5a-865dc83e3e27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4ec587b6-e234-444d-97f6-9a40b770e271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4ec587b6-e234-444d-97f6-9a40b770e271" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_547388a6-c2e3-4418-b570-f17e52b9711c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_547388a6-c2e3-4418-b570-f17e52b9711c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4e667fe5-b36f-442e-8715-7217fd5b93a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4e667fe5-b36f-442e-8715-7217fd5b93a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_700902fe-a94b-4b9c-a873-2ceb86ce8c94" xlink:href="evh-20220930.xsd#evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="22" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_700902fe-a94b-4b9c-a873-2ceb86ce8c94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_e3249eaa-0547-4305-a569-21ca64b6db9a" xlink:href="evh-20220930.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:calculationArc order="23" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_e3249eaa-0547-4305-a569-21ca64b6db9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f2095917-d42b-4747-baa6-6c3f44081e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="24" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f14b329a-9a7c-47db-8762-c02ad8e69f7a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f2095917-d42b-4747-baa6-6c3f44081e76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97251d36-511a-4be1-be49-cc35ef397bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_2a984478-698b-4709-a137-f23a6d31722b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97251d36-511a-4be1-be49-cc35ef397bae" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_2a984478-698b-4709-a137-f23a6d31722b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_24b1357d-24ac-4ad8-b585-b4d3130535b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97251d36-511a-4be1-be49-cc35ef397bae" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_24b1357d-24ac-4ad8-b585-b4d3130535b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_39550adf-5a49-446f-a361-7b494444c6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97251d36-511a-4be1-be49-cc35ef397bae" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_39550adf-5a49-446f-a361-7b494444c6f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_1a7dd1f6-b058-4df5-afa8-3ea8e0559cdd" xlink:href="evh-20220930.xsd#evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97251d36-511a-4be1-be49-cc35ef397bae" xlink:to="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_1a7dd1f6-b058-4df5-afa8-3ea8e0559cdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_9373e34f-8ce1-41d8-a203-b59a805e4aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97251d36-511a-4be1-be49-cc35ef397bae" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_9373e34f-8ce1-41d8-a203-b59a805e4aa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromMaturityOfInvestments_525641c4-2b99-422d-a5e8-0b9f7c31bfdf" xlink:href="evh-20220930.xsd#evh_ProceedsFromMaturityOfInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97251d36-511a-4be1-be49-cc35ef397bae" xlink:to="loc_evh_ProceedsFromMaturityOfInvestments_525641c4-2b99-422d-a5e8-0b9f7c31bfdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_7ddead9e-11e7-4650-ab3e-5a21189ff86d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_97251d36-511a-4be1-be49-cc35ef397bae" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_7ddead9e-11e7-4650-ab3e-5a21189ff86d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_548c7e8a-7bde-491e-8739-683176ed888c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_197b81d9-0531-416a-9957-47738d2c4905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_548c7e8a-7bde-491e-8739-683176ed888c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_197b81d9-0531-416a-9957-47738d2c4905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bff09e0c-6fdd-431d-8cd9-b565e824b5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_548c7e8a-7bde-491e-8739-683176ed888c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bff09e0c-6fdd-431d-8cd9-b565e824b5ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d4667818-2633-4ee7-8dcc-611c480e92c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_548c7e8a-7bde-491e-8739-683176ed888c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d4667818-2633-4ee7-8dcc-611c480e92c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_07d27840-e0cd-431a-9482-3d6265923059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_548c7e8a-7bde-491e-8739-683176ed888c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_07d27840-e0cd-431a-9482-3d6265923059" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_0d5cfb45-a46f-40bb-bed3-a69ef856a9e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_246ae507-30d2-4fb1-88d4-c4fc4cd2ac7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_0d5cfb45-a46f-40bb-bed3-a69ef856a9e9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_246ae507-30d2-4fb1-88d4-c4fc4cd2ac7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16a58e57-b4dc-4e5f-848c-61e5c533488a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments_4a1fbdf7-1c2e-4bef-96ee-8de3be0014b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16a58e57-b4dc-4e5f-848c-61e5c533488a" xlink:to="loc_us-gaap_RestrictedCashAndInvestments_4a1fbdf7-1c2e-4bef-96ee-8de3be0014b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_fd25bf71-4a9b-46c2-b4ab-1291435a0298" xlink:href="evh-20220930.xsd#evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_16a58e57-b4dc-4e5f-848c-61e5c533488a" xlink:to="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_fd25bf71-4a9b-46c2-b4ab-1291435a0298" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_53c570a0-29d4-4c6b-be16-11927d747053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_823e92f5-d739-4a85-ae51-10199652c121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_53c570a0-29d4-4c6b-be16-11927d747053" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_823e92f5-d739-4a85-ae51-10199652c121" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#TransactionsAllocationofAcquisitionCostDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fc4c1611-f0a3-4adb-b565-cecc90704f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_299320a1-cad3-43d1-8aa8-4c1dfc484922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fc4c1611-f0a3-4adb-b565-cecc90704f4b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_299320a1-cad3-43d1-8aa8-4c1dfc484922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_49d7a611-9f6a-4d72-a5ae-91a4894ba18d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fc4c1611-f0a3-4adb-b565-cecc90704f4b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_49d7a611-9f6a-4d72-a5ae-91a4894ba18d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_bf544b43-19ed-4954-a960-6f9c04675c81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_fc4c1611-f0a3-4adb-b565-cecc90704f4b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_bf544b43-19ed-4954-a960-6f9c04675c81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b0a07b87-1132-4177-9a64-d7c7c44fad32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_3e6e0e45-c305-41c3-9cce-ad90382c5c59" xlink:href="evh-20220930.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b0a07b87-1132-4177-9a64-d7c7c44fad32" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_3e6e0e45-c305-41c3-9cce-ad90382c5c59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_ad6dfaf6-968f-454e-825b-cadf94dbfdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b0a07b87-1132-4177-9a64-d7c7c44fad32" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_ad6dfaf6-968f-454e-825b-cadf94dbfdf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_e8df5dbe-04b2-48c8-a26e-4683c2ebd79b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b0a07b87-1132-4177-9a64-d7c7c44fad32" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_e8df5dbe-04b2-48c8-a26e-4683c2ebd79b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_62256cb2-2981-4cf5-b64b-b83e5acd311c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b0a07b87-1132-4177-9a64-d7c7c44fad32" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_62256cb2-2981-4cf5-b64b-b83e5acd311c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_02b0cd6a-6089-4cd8-90f1-654f7b2ca165" xlink:href="evh-20220930.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b0a07b87-1132-4177-9a64-d7c7c44fad32" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_02b0cd6a-6089-4cd8-90f1-654f7b2ca165" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1e935215-557d-469f-99fa-f13a4bb43809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b0a07b87-1132-4177-9a64-d7c7c44fad32" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_1e935215-557d-469f-99fa-f13a4bb43809" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3e40888a-b268-491a-add3-a88284139ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2544b0ec-d01d-4c20-a2e2-9ad5d579e2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3e40888a-b268-491a-add3-a88284139ca6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_2544b0ec-d01d-4c20-a2e2-9ad5d579e2d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_d7f54679-7073-46ae-81aa-427580a5310a" xlink:href="evh-20220930.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3e40888a-b268-491a-add3-a88284139ca6" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_d7f54679-7073-46ae-81aa-427580a5310a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_0774c265-621a-4152-8068-5101f2f8feb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3e40888a-b268-491a-add3-a88284139ca6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_0774c265-621a-4152-8068-5101f2f8feb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f998a6b3-db0f-4334-9b3e-110663de045f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_3e40888a-b268-491a-add3-a88284139ca6" xlink:to="loc_us-gaap_Goodwill_f998a6b3-db0f-4334-9b3e-110663de045f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_f1939524-4b99-42f4-8df0-9a4f1dcc3b2a" xlink:href="evh-20220930.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_27974cbf-faaa-440d-96b5-8ef1f386faa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_f1939524-4b99-42f4-8df0-9a4f1dcc3b2a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_27974cbf-faaa-440d-96b5-8ef1f386faa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_e3d174da-2922-4aef-a3dd-207d0a74b644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_f1939524-4b99-42f4-8df0-9a4f1dcc3b2a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_e3d174da-2922-4aef-a3dd-207d0a74b644" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_9f75954f-3a94-459b-8804-15772d15f93c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_f1939524-4b99-42f4-8df0-9a4f1dcc3b2a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_9f75954f-3a94-459b-8804-15772d15f93c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_571d4a80-ad3d-4d0d-b7b9-bfb65d2588cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_f1939524-4b99-42f4-8df0-9a4f1dcc3b2a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_571d4a80-ad3d-4d0d-b7b9-bfb65d2588cb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#DiscontinuedOperationsSummaryofResultsofOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_3a6ad781-4dae-40b2-8ea2-a00bd9175e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8ed9076a-6ed9-4823-ab58-dad54a7c915c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_3a6ad781-4dae-40b2-8ea2-a00bd9175e8f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_8ed9076a-6ed9-4823-ab58-dad54a7c915c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_187125c2-88b3-410a-9e70-f6f76816fb93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_3a6ad781-4dae-40b2-8ea2-a00bd9175e8f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_187125c2-88b3-410a-9e70-f6f76816fb93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_472c335c-29dd-4c67-9e5e-90c8556a4b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_598c8093-f52c-413f-a7c0-68a66ade26fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_472c335c-29dd-4c67-9e5e-90c8556a4b97" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_598c8093-f52c-413f-a7c0-68a66ade26fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_768550b4-b2e5-4016-a33b-6c22b176057f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_472c335c-29dd-4c67-9e5e-90c8556a4b97" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_768550b4-b2e5-4016-a33b-6c22b176057f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_e9195131-ce05-4071-932f-ed873130d99e" xlink:href="evh-20220930.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_472c335c-29dd-4c67-9e5e-90c8556a4b97" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_e9195131-ce05-4071-932f-ed873130d99e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_5c6ce01e-10b1-4a23-9164-97906ff64567" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_472c335c-29dd-4c67-9e5e-90c8556a4b97" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_5c6ce01e-10b1-4a23-9164-97906ff64567" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_8900e27d-a8ad-4b8f-9301-7932f09cde8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6dd83968-61df-48ac-b690-6821345967b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_8900e27d-a8ad-4b8f-9301-7932f09cde8a" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6dd83968-61df-48ac-b690-6821345967b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_72a65f28-e347-40e3-b1a1-7b970c9351b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_8900e27d-a8ad-4b8f-9301-7932f09cde8a" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_72a65f28-e347-40e3-b1a1-7b970c9351b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_d6b791f7-5a70-42aa-bc3c-e0a5bf9ac0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_4e447dc8-27c5-4913-80dc-d08e4a0e85ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_d6b791f7-5a70-42aa-bc3c-e0a5bf9ac0c3" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_4e447dc8-27c5-4913-80dc-d08e4a0e85ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_d3199feb-487a-44c9-b64b-127ff50dafce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_d6b791f7-5a70-42aa-bc3c-e0a5bf9ac0c3" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_d3199feb-487a-44c9-b64b-127ff50dafce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_f4766db4-a778-49a9-8b7c-0d63b248fd61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_d6b791f7-5a70-42aa-bc3c-e0a5bf9ac0c3" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_f4766db4-a778-49a9-8b7c-0d63b248fd61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_13c04e35-d60a-4a13-9443-fa9cde5c176c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_d6b791f7-5a70-42aa-bc3c-e0a5bf9ac0c3" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_13c04e35-d60a-4a13-9443-fa9cde5c176c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#PropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_de220367-cc15-4b0c-b3fa-88c29e99e11e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4b6b8cb4-7306-4b8a-a291-3e29cb173167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_de220367-cc15-4b0c-b3fa-88c29e99e11e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4b6b8cb4-7306-4b8a-a291-3e29cb173167" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a032e14-7a76-4acb-b835-7e4a64f76e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_de220367-cc15-4b0c-b3fa-88c29e99e11e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0a032e14-7a76-4acb-b835-7e4a64f76e2b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b2c3d7d1-9c4e-47f4-af47-e4fd35a0e3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_14405fa9-eae0-42c6-b1fa-7e799679b229" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b2c3d7d1-9c4e-47f4-af47-e4fd35a0e3b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_14405fa9-eae0-42c6-b1fa-7e799679b229" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ccb9a506-b02a-40f7-b3d4-19d68be14cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b2c3d7d1-9c4e-47f4-af47-e4fd35a0e3b9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ccb9a506-b02a-40f7-b3d4-19d68be14cf1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cb59735a-f520-4745-84c6-9982c737ae47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6fa1b402-a4cb-4e88-91dc-b9bd0909af85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cb59735a-f520-4745-84c6-9982c737ae47" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_6fa1b402-a4cb-4e88-91dc-b9bd0909af85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_1c35a1e0-8c84-4d64-b2c8-2454b5e08adc" xlink:href="evh-20220930.xsd#evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cb59735a-f520-4745-84c6-9982c737ae47" xlink:to="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_1c35a1e0-8c84-4d64-b2c8-2454b5e08adc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_885a73c3-bb4c-4691-807b-7ab007505c80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cb59735a-f520-4745-84c6-9982c737ae47" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_885a73c3-bb4c-4691-807b-7ab007505c80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_cfc1bb06-cecf-438a-874d-378f286b37e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cb59735a-f520-4745-84c6-9982c737ae47" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_cfc1bb06-cecf-438a-874d-378f286b37e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6061f0d4-338f-4475-944e-7c644ef909f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cb59735a-f520-4745-84c6-9982c737ae47" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6061f0d4-338f-4475-944e-7c644ef909f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9401a54b-0750-4895-96f5-e462e860f4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_cb59735a-f520-4745-84c6-9982c737ae47" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9401a54b-0750-4895-96f5-e462e860f4b4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_76c02429-7270-4883-b912-925bf4d78d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f9d511e0-3a75-4234-94f9-407844c425f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebt_76c02429-7270-4883-b912-925bf4d78d03" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_f9d511e0-3a75-4234-94f9-407844c425f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_8bb4c72b-bdaf-4210-a3b5-625e3fc066cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ConvertibleDebt_76c02429-7270-4883-b912-925bf4d78d03" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_8bb4c72b-bdaf-4210-a3b5-625e3fc066cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_91df6dba-129f-401c-aa38-1b4ca7dfeb55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_4bfa150e-77ea-4c5c-99bc-46883a0229f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_91df6dba-129f-401c-aa38-1b4ca7dfeb55" xlink:to="loc_us-gaap_OperatingLeaseCost_4bfa150e-77ea-4c5c-99bc-46883a0229f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_d0dc6128-597f-4916-80f2-d69883357842" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_91df6dba-129f-401c-aa38-1b4ca7dfeb55" xlink:to="loc_us-gaap_VariableLeaseCost_d0dc6128-597f-4916-80f2-d69883357842" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LeasesMaturityofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_868c8152-b7f0-467b-9739-d91eb9bc8a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9118af01-95e6-42f6-b492-40a85849a3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_868c8152-b7f0-467b-9739-d91eb9bc8a3f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9118af01-95e6-42f6-b492-40a85849a3c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d776a904-4962-44fb-8ef9-b5cb77665511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_868c8152-b7f0-467b-9739-d91eb9bc8a3f" xlink:to="loc_us-gaap_OperatingLeaseLiability_d776a904-4962-44fb-8ef9-b5cb77665511" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="evh-20220930.xsd#LeasesMaturityofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_afbd2f48-a84d-4d9d-ae1a-bf79e5f0d764" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_294ecb7c-81fe-492a-86ce-506718a5cc62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_afbd2f48-a84d-4d9d-ae1a-bf79e5f0d764" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_294ecb7c-81fe-492a-86ce-506718a5cc62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a2f1ecc3-da93-4f90-b398-ca92c167baac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_afbd2f48-a84d-4d9d-ae1a-bf79e5f0d764" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a2f1ecc3-da93-4f90-b398-ca92c167baac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_135ceed3-940a-4c08-9e91-77c9b6cfcbdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_afbd2f48-a84d-4d9d-ae1a-bf79e5f0d764" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_135ceed3-940a-4c08-9e91-77c9b6cfcbdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f4aeb14c-bb1e-4406-b403-dbbc8ceee526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_afbd2f48-a84d-4d9d-ae1a-bf79e5f0d764" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_f4aeb14c-bb1e-4406-b403-dbbc8ceee526" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_e5914b61-d6ea-44c7-9f61-f7a3525502f9" xlink:href="evh-20220930.xsd#evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_afbd2f48-a84d-4d9d-ae1a-bf79e5f0d764" xlink:to="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_e5914b61-d6ea-44c7-9f61-f7a3525502f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_15967f4e-707c-41a9-b5f2-911a72763f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_afbd2f48-a84d-4d9d-ae1a-bf79e5f0d764" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_15967f4e-707c-41a9-b5f2-911a72763f5a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_58af5ceb-0df1-402d-9b75-ad98f4a4cb83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_cf09bfec-b445-4df4-8c76-ff250dee2d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_58af5ceb-0df1-402d-9b75-ad98f4a4cb83" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_cf09bfec-b445-4df4-8c76-ff250dee2d39" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="simple" xlink:href="evh-20220930.xsd#SegmentReportingReconciliationofAdjustedEBITDADetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_97886c2d-3e0b-4d73-b324-f07e4daab534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_a69e8e97-8a02-4f66-a58c-ebef327bd7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_97886c2d-3e0b-4d73-b324-f07e4daab534" xlink:to="loc_us-gaap_InvestmentIncomeInterest_a69e8e97-8a02-4f66-a58c-ebef327bd7dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_70662a88-388b-45e6-81ad-d13aed67d838" xlink:href="evh-20220930.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_97886c2d-3e0b-4d73-b324-f07e4daab534" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_70662a88-388b-45e6-81ad-d13aed67d838" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_f81bccad-b528-4783-a7f9-959a38b9ca17" xlink:href="evh-20220930.xsd#evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_97886c2d-3e0b-4d73-b324-f07e4daab534" xlink:to="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_f81bccad-b528-4783-a7f9-959a38b9ca17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderAdvisoryServices_82e876ad-1aff-42eb-9bb6-2f3a97f1dfd0" xlink:href="evh-20220930.xsd#evh_ShareholderAdvisoryServices"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_97886c2d-3e0b-4d73-b324-f07e4daab534" xlink:to="loc_evh_ShareholderAdvisoryServices_82e876ad-1aff-42eb-9bb6-2f3a97f1dfd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransactionCosts_b6cbfb3e-66e0-4e45-8c8c-06e90c976dc7" xlink:href="evh-20220930.xsd#evh_TransactionCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_97886c2d-3e0b-4d73-b324-f07e4daab534" xlink:to="loc_evh_TransactionCosts_b6cbfb3e-66e0-4e45-8c8c-06e90c976dc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4f07754b-e217-4cc1-9c9f-f3b1edf66253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_97886c2d-3e0b-4d73-b324-f07e4daab534" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_4f07754b-e217-4cc1-9c9f-f3b1edf66253" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4a3637c6-fdfb-4b66-9a58-dc826832f15d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_97886c2d-3e0b-4d73-b324-f07e4daab534" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4a3637c6-fdfb-4b66-9a58-dc826832f15d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f5979e93-3f07-48ee-ad7d-2011ac450896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_97886c2d-3e0b-4d73-b324-f07e4daab534" xlink:to="loc_us-gaap_RestructuringCharges_f5979e93-3f07-48ee-ad7d-2011ac450896" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_74e31c4b-8b00-423f-9765-06085f24eb12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_97886c2d-3e0b-4d73-b324-f07e4daab534" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_74e31c4b-8b00-423f-9765-06085f24eb12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_4ff2e887-37df-4434-816d-4ca05e67f0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_97886c2d-3e0b-4d73-b324-f07e4daab534" xlink:to="loc_us-gaap_DepreciationAndAmortization_4ff2e887-37df-4434-816d-4ca05e67f0c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fc11b2d6-1e76-474f-a407-abe23ccdb98f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_97886c2d-3e0b-4d73-b324-f07e4daab534" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_fc11b2d6-1e76-474f-a407-abe23ccdb98f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a8cefadd-d94c-4923-bf3c-bb95a721dda6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_97886c2d-3e0b-4d73-b324-f07e4daab534" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a8cefadd-d94c-4923-bf3c-bb95a721dda6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_fd978860-e2dd-42c8-8ac7-ec878f117f93" xlink:href="evh-20220930.xsd#evh_GainOnTransferOfMembership"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_97886c2d-3e0b-4d73-b324-f07e4daab534" xlink:to="loc_evh_GainOnTransferOfMembership_fd978860-e2dd-42c8-8ac7-ec878f117f93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0a9c33ab-c861-4117-bbc7-e599004697f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_97886c2d-3e0b-4d73-b324-f07e4daab534" xlink:to="loc_us-gaap_InterestExpense_0a9c33ab-c861-4117-bbc7-e599004697f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_cb927a37-b8a5-4e55-bfd5-34ebee8f327a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_97886c2d-3e0b-4d73-b324-f07e4daab534" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_cb927a37-b8a5-4e55-bfd5-34ebee8f327a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment_e5e4f909-2343-4ceb-a54b-306a361b00e1" xlink:href="evh-20220930.xsd#evh_SharebasedCompensationIncludingOnetimeAdjustment"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_97886c2d-3e0b-4d73-b324-f07e4daab534" xlink:to="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment_e5e4f909-2343-4ceb-a54b-306a361b00e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_3fec45ee-33b5-44c7-9221-77acf23946d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_97886c2d-3e0b-4d73-b324-f07e4daab534" xlink:to="loc_us-gaap_SeveranceCosts1_3fec45ee-33b5-44c7-9221-77acf23946d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangesInTaxReceivablesAgreementLiability_21ca16fa-7852-4c06-a9b6-332c4b53da64" xlink:href="evh-20220930.xsd#evh_ChangesInTaxReceivablesAgreementLiability"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_97886c2d-3e0b-4d73-b324-f07e4daab534" xlink:to="loc_evh_ChangesInTaxReceivablesAgreementLiability_21ca16fa-7852-4c06-a9b6-332c4b53da64" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#ReservesforClaimsandPerformanceBasedArrangementsDetails"/>
  <link:calculationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_0aee1832-7893-444e-8511-607265b59ade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_56ec9751-7f32-4348-aca7-fc69e7ca68ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_0aee1832-7893-444e-8511-607265b59ade" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_56ec9751-7f32-4348-aca7-fc69e7ca68ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_2ddde449-98d5-4c82-b93b-6c568e1575da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_0aee1832-7893-444e-8511-607265b59ade" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_2ddde449-98d5-4c82-b93b-6c568e1575da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_6d70f4d1-a187-4822-9cbc-9123dfc8bb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_30559dee-10dc-4f5a-9f8d-c06963e9917a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_6d70f4d1-a187-4822-9cbc-9123dfc8bb7e" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_30559dee-10dc-4f5a-9f8d-c06963e9917a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_149be2d3-4eb4-4e7e-8cc2-8bbadfd4bc23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_6d70f4d1-a187-4822-9cbc-9123dfc8bb7e" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_149be2d3-4eb4-4e7e-8cc2-8bbadfd4bc23" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>evh-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b69e33fa-4fec-4147-99e6-af63e8e14083,g:752cd8d8-fa1c-4165-8528-47511781866b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="evh-20220930.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended" id="ic0a17422a53748708b9ab26b01cbf459_CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4ee60496-8bab-4712-a63e-84347b4b8ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4ee60496-8bab-4712-a63e-84347b4b8ca4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_fca65126-21be-44fe-817d-541103c97e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_SharesIssued_fca65126-21be-44fe-817d-541103c97e4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8937e2c1-8df9-4795-aaf9-e741ea051f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockholdersEquity_8937e2c1-8df9-4795-aaf9-e741ea051f45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b91190e2-907d-4850-86f9-407ad4fe80bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b91190e2-907d-4850-86f9-407ad4fe80bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0943d828-1132-473d-ab47-dd50b0f638e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0943d828-1132-473d-ab47-dd50b0f638e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b1c63d35-e3f8-4bcd-89bd-f9af0b0dd056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b1c63d35-e3f8-4bcd-89bd-f9af0b0dd056" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_770a07e3-b016-48ab-a26f-5e3a3b15edab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_770a07e3-b016-48ab-a26f-5e3a3b15edab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_98556079-2e17-473d-bbcf-2493281cd0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_98556079-2e17-473d-bbcf-2493281cd0ef" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_20f78268-a897-43d1-b397-9646e68a1828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_20f78268-a897-43d1-b397-9646e68a1828" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_34b4af19-86cc-4bea-af63-1057899b5769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_34b4af19-86cc-4bea-af63-1057899b5769" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_b4a12672-48ea-483d-8f8b-8b24d83acd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_b4a12672-48ea-483d-8f8b-8b24d83acd0e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_ddf76fea-97b0-4eb2-b99a-61a48e53f887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_ddf76fea-97b0-4eb2-b99a-61a48e53f887" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1f725034-01fb-4d69-bb9c-0de272c6be4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1f725034-01fb-4d69-bb9c-0de272c6be4b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8681c1b0-467b-44b6-8039-825d58e33d12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8681c1b0-467b-44b6-8039-825d58e33d12" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a25e93da-d3c0-483c-8e2f-c47ac61999f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a25e93da-d3c0-483c-8e2f-c47ac61999f5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5d732319-68d1-4b20-9937-38e6770f08b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_NetIncomeLoss_5d732319-68d1-4b20-9937-38e6770f08b5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_3b408008-9150-4954-9307-17e3ea596ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ac0cb410-afd0-4480-8e15-33044d964423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_72987cd8-5ef5-4b3a-8e9a-f3f0a33886cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4ee60496-8bab-4712-a63e-84347b4b8ca4" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_72987cd8-5ef5-4b3a-8e9a-f3f0a33886cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6aafa344-beb6-424d-be7d-3d87428ad149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4ee60496-8bab-4712-a63e-84347b4b8ca4" xlink:to="loc_us-gaap_StatementTable_6aafa344-beb6-424d-be7d-3d87428ad149" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b17bfbad-c859-4b97-a53f-849134b6a5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6aafa344-beb6-424d-be7d-3d87428ad149" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b17bfbad-c859-4b97-a53f-849134b6a5c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b17bfbad-c859-4b97-a53f-849134b6a5c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b17bfbad-c859-4b97-a53f-849134b6a5c5" xlink:to="loc_us-gaap_EquityComponentDomain_b17bfbad-c859-4b97-a53f-849134b6a5c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_944a9b06-e315-491f-aed6-7404e49f620a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b17bfbad-c859-4b97-a53f-849134b6a5c5" xlink:to="loc_us-gaap_EquityComponentDomain_944a9b06-e315-491f-aed6-7404e49f620a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_344e439c-cb69-4c89-bdb9-61a13cfa61f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_944a9b06-e315-491f-aed6-7404e49f620a" xlink:to="loc_us-gaap_CommonStockMember_344e439c-cb69-4c89-bdb9-61a13cfa61f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6aff8ce2-c543-4b35-b972-00faaba02e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_944a9b06-e315-491f-aed6-7404e49f620a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6aff8ce2-c543-4b35-b972-00faaba02e0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_0ed0f90f-90bf-4c0f-88d6-5d448455ef36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_944a9b06-e315-491f-aed6-7404e49f620a" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_0ed0f90f-90bf-4c0f-88d6-5d448455ef36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4e743422-7927-4f52-9382-cdc836269675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_944a9b06-e315-491f-aed6-7404e49f620a" xlink:to="loc_us-gaap_RetainedEarningsMember_4e743422-7927-4f52-9382-cdc836269675" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_e7ecc11e-531e-448e-a17c-a3971fe06a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_944a9b06-e315-491f-aed6-7404e49f620a" xlink:to="loc_us-gaap_TreasuryStockMember_e7ecc11e-531e-448e-a17c-a3971fe06a0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_06691936-6af6-47cb-bf0d-eedc484ddb08" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6aafa344-beb6-424d-be7d-3d87428ad149" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_06691936-6af6-47cb-bf0d-eedc484ddb08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_06691936-6af6-47cb-bf0d-eedc484ddb08_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_06691936-6af6-47cb-bf0d-eedc484ddb08" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_06691936-6af6-47cb-bf0d-eedc484ddb08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ed52851d-9e26-4d29-b418-4e07c986c8bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_06691936-6af6-47cb-bf0d-eedc484ddb08" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ed52851d-9e26-4d29-b418-4e07c986c8bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5c31b53e-c048-4c9c-8f7a-5faa2343c50c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ed52851d-9e26-4d29-b418-4e07c986c8bf" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5c31b53e-c048-4c9c-8f7a-5faa2343c50c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended" id="i97c89b4af4a1466783503c9d2b43c2a9_BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_96b43915-162a-4910-9eea-7764d01517cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_60d90f54-c74d-4b51-8043-5dc9f18e6587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_96b43915-162a-4910-9eea-7764d01517cf" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_60d90f54-c74d-4b51-8043-5dc9f18e6587" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_608dfda0-6c36-4f48-a2e6-2ce064804c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_96b43915-162a-4910-9eea-7764d01517cf" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_608dfda0-6c36-4f48-a2e6-2ce064804c9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_aaffde95-1652-4bc1-8383-6ee10e2b6356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_96b43915-162a-4910-9eea-7764d01517cf" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_aaffde95-1652-4bc1-8383-6ee10e2b6356" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_50e77b1d-3a50-46d7-be67-8a84ec4d5a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_96b43915-162a-4910-9eea-7764d01517cf" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_50e77b1d-3a50-46d7-be67-8a84ec4d5a8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_f09293b9-8423-4346-994b-42ca665d1925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_96b43915-162a-4910-9eea-7764d01517cf" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_f09293b9-8423-4346-994b-42ca665d1925" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_e60062ca-b1ed-436a-8d40-a87dd7a132f1" xlink:href="evh-20220930.xsd#evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_96b43915-162a-4910-9eea-7764d01517cf" xlink:to="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_e60062ca-b1ed-436a-8d40-a87dd7a132f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments_5aae6e3f-27f7-42ef-a79a-6b519c0f6ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_96b43915-162a-4910-9eea-7764d01517cf" xlink:to="loc_us-gaap_RestrictedCashAndInvestments_5aae6e3f-27f7-42ef-a79a-6b519c0f6ad6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_022874b8-75b2-4fc6-8eca-cfe89cf5b6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_96b43915-162a-4910-9eea-7764d01517cf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_022874b8-75b2-4fc6-8eca-cfe89cf5b6f0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_5b31ee35-3499-4225-b559-9f48932335b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_96b43915-162a-4910-9eea-7764d01517cf" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_5b31ee35-3499-4225-b559-9f48932335b7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_35dd26f1-ead6-4ef0-8aaa-1be60c57d569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_5b31ee35-3499-4225-b559-9f48932335b7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_35dd26f1-ead6-4ef0-8aaa-1be60c57d569" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35dd26f1-ead6-4ef0-8aaa-1be60c57d569_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_35dd26f1-ead6-4ef0-8aaa-1be60c57d569" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_35dd26f1-ead6-4ef0-8aaa-1be60c57d569_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10a0352c-6cef-46a3-95cf-f43d3436914d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_35dd26f1-ead6-4ef0-8aaa-1be60c57d569" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10a0352c-6cef-46a3-95cf-f43d3436914d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_4a8eca5f-4bac-4f44-bfeb-9b224b84d994" xlink:href="evh-20220930.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10a0352c-6cef-46a3-95cf-f43d3436914d" xlink:to="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_4a8eca5f-4bac-4f44-bfeb-9b224b84d994" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_5e7a9174-1c15-4e49-b311-b6fb04d716b7" xlink:href="evh-20220930.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10a0352c-6cef-46a3-95cf-f43d3436914d" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_5e7a9174-1c15-4e49-b311-b6fb04d716b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember_a9918dc5-c6bf-49e8-a089-c051a7b12976" xlink:href="evh-20220930.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10a0352c-6cef-46a3-95cf-f43d3436914d" xlink:to="loc_evh_RestrictedCashforBenefitManagementServicesMember_a9918dc5-c6bf-49e8-a089-c051a7b12976" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_5d406bd0-874b-4af0-8421-d876f40274a0" xlink:href="evh-20220930.xsd#evh_RestrictedCashforOtherContractualCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10a0352c-6cef-46a3-95cf-f43d3436914d" xlink:to="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_5d406bd0-874b-4af0-8421-d876f40274a0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="extended" id="i4af1c85b9b2e458f96bd90ced555f15e_BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_74e37dd1-ec92-411b-9982-8720c66c1710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1ddbe76d-c929-432a-b66b-7fbf9ce1c8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_74e37dd1-ec92-411b-9982-8720c66c1710" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1ddbe76d-c929-432a-b66b-7fbf9ce1c8e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bfdb65d1-f8ea-4994-ae47-f9b61ea6df6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_74e37dd1-ec92-411b-9982-8720c66c1710" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bfdb65d1-f8ea-4994-ae47-f9b61ea6df6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_de0c45cd-4a25-4b87-bad7-eb8be931abd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bfdb65d1-f8ea-4994-ae47-f9b61ea6df6b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_de0c45cd-4a25-4b87-bad7-eb8be931abd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_de0c45cd-4a25-4b87-bad7-eb8be931abd8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_de0c45cd-4a25-4b87-bad7-eb8be931abd8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_de0c45cd-4a25-4b87-bad7-eb8be931abd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76e30753-3370-49f9-826a-bfd790ddaec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_de0c45cd-4a25-4b87-bad7-eb8be931abd8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76e30753-3370-49f9-826a-bfd790ddaec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_7e977781-408c-4323-9726-3b68f4ceac5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76e30753-3370-49f9-826a-bfd790ddaec8" xlink:to="loc_us-gaap_TradeNamesMember_7e977781-408c-4323-9726-3b68f4ceac5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_6cbfae1b-04fd-4b1f-a649-06bee8675333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76e30753-3370-49f9-826a-bfd790ddaec8" xlink:to="loc_us-gaap_CustomerRelationshipsMember_6cbfae1b-04fd-4b1f-a649-06bee8675333" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_6aea277c-3071-4601-8673-00ea9846d395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76e30753-3370-49f9-826a-bfd790ddaec8" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_6aea277c-3071-4601-8673-00ea9846d395" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_ce62e719-04bf-4382-8cb7-0a0de0aefba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76e30753-3370-49f9-826a-bfd790ddaec8" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_ce62e719-04bf-4382-8cb7-0a0de0aefba4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7654f9fb-4974-4ce9-8f67-4517555acecd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bfdb65d1-f8ea-4994-ae47-f9b61ea6df6b" xlink:to="loc_srt_RangeAxis_7654f9fb-4974-4ce9-8f67-4517555acecd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7654f9fb-4974-4ce9-8f67-4517555acecd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7654f9fb-4974-4ce9-8f67-4517555acecd" xlink:to="loc_srt_RangeMember_7654f9fb-4974-4ce9-8f67-4517555acecd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7521fee0-7cbb-4138-a699-07ba57e2d6ff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7654f9fb-4974-4ce9-8f67-4517555acecd" xlink:to="loc_srt_RangeMember_7521fee0-7cbb-4138-a699-07ba57e2d6ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_69b7d9f9-1845-4d91-976b-7eba8e17f522" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7521fee0-7cbb-4138-a699-07ba57e2d6ff" xlink:to="loc_srt_MinimumMember_69b7d9f9-1845-4d91-976b-7eba8e17f522" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6da1c9d4-42d6-42bd-a2f5-ab79b784b3e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7521fee0-7cbb-4138-a699-07ba57e2d6ff" xlink:to="loc_srt_MaximumMember_6da1c9d4-42d6-42bd-a2f5-ab79b784b3e4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#RecentlyIssuedAccountingStandardsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="extended" id="iaa5bc368ce934359bd3355e035e4e63f_RecentlyIssuedAccountingStandardsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bbd1ba57-be9e-4137-b9c9-2ee31cee8f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7c96d61e-9aa6-4350-bf21-385c3c649254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bbd1ba57-be9e-4137-b9c9-2ee31cee8f8c" xlink:to="loc_us-gaap_StockholdersEquity_7c96d61e-9aa6-4350-bf21-385c3c649254" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f833cb5e-3eb6-4b96-adfc-a86212f530bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bbd1ba57-be9e-4137-b9c9-2ee31cee8f8c" xlink:to="loc_us-gaap_LongTermDebt_f833cb5e-3eb6-4b96-adfc-a86212f530bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8d46ea15-3a50-4c82-816e-8efe70eaad64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bbd1ba57-be9e-4137-b9c9-2ee31cee8f8c" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8d46ea15-3a50-4c82-816e-8efe70eaad64" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23bbf722-11ab-40e2-a5c8-7cd29f5e1cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8d46ea15-3a50-4c82-816e-8efe70eaad64" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23bbf722-11ab-40e2-a5c8-7cd29f5e1cc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_23bbf722-11ab-40e2-a5c8-7cd29f5e1cc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23bbf722-11ab-40e2-a5c8-7cd29f5e1cc3" xlink:to="loc_us-gaap_TypeOfAdoptionMember_23bbf722-11ab-40e2-a5c8-7cd29f5e1cc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_36ea34d2-2fff-4fcb-ad2e-c954e09960a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23bbf722-11ab-40e2-a5c8-7cd29f5e1cc3" xlink:to="loc_us-gaap_TypeOfAdoptionMember_36ea34d2-2fff-4fcb-ad2e-c954e09960a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_daf66dc1-91ae-47a4-8996-f3b7ad6cb195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_36ea34d2-2fff-4fcb-ad2e-c954e09960a6" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_daf66dc1-91ae-47a4-8996-f3b7ad6cb195" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_90c01d58-5308-4771-970d-eb5fb889047c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8d46ea15-3a50-4c82-816e-8efe70eaad64" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_90c01d58-5308-4771-970d-eb5fb889047c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_90c01d58-5308-4771-970d-eb5fb889047c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_90c01d58-5308-4771-970d-eb5fb889047c" xlink:to="loc_us-gaap_EquityComponentDomain_90c01d58-5308-4771-970d-eb5fb889047c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_84860e81-af37-4577-90a0-640bcb76505d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_90c01d58-5308-4771-970d-eb5fb889047c" xlink:to="loc_us-gaap_EquityComponentDomain_84860e81-af37-4577-90a0-640bcb76505d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_28f4fbb1-b02a-4c19-9be2-a2803208b919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_84860e81-af37-4577-90a0-640bcb76505d" xlink:to="loc_us-gaap_RetainedEarningsMember_28f4fbb1-b02a-4c19-9be2-a2803208b919" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_04243da0-0b17-4082-981f-5a346b780f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_84860e81-af37-4577-90a0-640bcb76505d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_04243da0-0b17-4082-981f-5a346b780f05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_99efe91a-f596-4471-949a-ba3ede1cc401" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8d46ea15-3a50-4c82-816e-8efe70eaad64" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_99efe91a-f596-4471-949a-ba3ede1cc401" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_99efe91a-f596-4471-949a-ba3ede1cc401_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_99efe91a-f596-4471-949a-ba3ede1cc401" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_99efe91a-f596-4471-949a-ba3ede1cc401_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f1c2ed2d-eee6-4327-989a-ac0da70f707b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_99efe91a-f596-4471-949a-ba3ede1cc401" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f1c2ed2d-eee6-4327-989a-ac0da70f707b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1e87a654-e720-4b02-896c-d527704ea64a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f1c2ed2d-eee6-4327-989a-ac0da70f707b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1e87a654-e720-4b02-896c-d527704ea64a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_368ce47d-0d41-4cf4-b687-37c0d898ff3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8d46ea15-3a50-4c82-816e-8efe70eaad64" xlink:to="loc_us-gaap_DebtInstrumentAxis_368ce47d-0d41-4cf4-b687-37c0d898ff3f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_368ce47d-0d41-4cf4-b687-37c0d898ff3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_368ce47d-0d41-4cf4-b687-37c0d898ff3f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_368ce47d-0d41-4cf4-b687-37c0d898ff3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2342e73f-e64a-4c61-9404-3a4bc0e3fbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_368ce47d-0d41-4cf4-b687-37c0d898ff3f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2342e73f-e64a-4c61-9404-3a4bc0e3fbe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_9b89dbe9-ce1c-40ec-84e5-23cd492f8464" xlink:href="evh-20220930.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2342e73f-e64a-4c61-9404-3a4bc0e3fbe2" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_9b89dbe9-ce1c-40ec-84e5-23cd492f8464" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_073de9be-218d-4d17-990c-3bc6c216dbf9" xlink:href="evh-20220930.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2342e73f-e64a-4c61-9404-3a4bc0e3fbe2" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_073de9be-218d-4d17-990c-3bc6c216dbf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_274ad714-06b9-4d33-811d-edd6fe1b6703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8d46ea15-3a50-4c82-816e-8efe70eaad64" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_274ad714-06b9-4d33-811d-edd6fe1b6703" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_274ad714-06b9-4d33-811d-edd6fe1b6703_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_274ad714-06b9-4d33-811d-edd6fe1b6703" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_274ad714-06b9-4d33-811d-edd6fe1b6703_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_20cb83f6-2aed-4834-8045-19e92bc35044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_274ad714-06b9-4d33-811d-edd6fe1b6703" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_20cb83f6-2aed-4834-8045-19e92bc35044" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_760e8cb2-3ed5-49be-8648-6017bea7f6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_20cb83f6-2aed-4834-8045-19e92bc35044" xlink:to="loc_us-gaap_SeniorNotesMember_760e8cb2-3ed5-49be-8648-6017bea7f6fb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsNarrativeDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#TransactionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/TransactionsNarrativeDetails" xlink:type="extended" id="ic7747bb5c2a0403d962d7e170d7e789f_TransactionsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8752118a-2499-4018-b216-a6b7c1c59f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8752118a-2499-4018-b216-a6b7c1c59f3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_78491677-b6cb-4bc0-8c5d-550e7de47f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_78491677-b6cb-4bc0-8c5d-550e7de47f6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_06ea5f0f-f045-4b7e-ae8c-c3b432d30a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_06ea5f0f-f045-4b7e-ae8c-c3b432d30a98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_ebb00e33-39b7-4e90-9d41-dd394fa3866a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_ebb00e33-39b7-4e90-9d41-dd394fa3866a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_9f28f360-0eac-40b3-bc02-d67cb0c0e4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_9f28f360-0eac-40b3-bc02-d67cb0c0e4b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_7680f699-efb7-4aeb-922d-1eadf9f794b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_7680f699-efb7-4aeb-922d-1eadf9f794b6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_223bec4f-28a3-4d8d-8815-fc8fb46a0b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_223bec4f-28a3-4d8d-8815-fc8fb46a0b36" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_942091c3-53db-4804-9992-75cd73041489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_942091c3-53db-4804-9992-75cd73041489" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_5faddeae-292c-4e00-bb12-f860f003dd80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_5faddeae-292c-4e00-bb12-f860f003dd80" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_88469865-7e5a-419d-b929-2bf4b0ad5b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_88469865-7e5a-419d-b929-2bf4b0ad5b7f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5c4fb414-4a04-4edc-a85b-577d7bc2735d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5c4fb414-4a04-4edc-a85b-577d7bc2735d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_79a58779-b1f7-4e05-ab1b-16bd5a3f7c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5c4fb414-4a04-4edc-a85b-577d7bc2735d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_79a58779-b1f7-4e05-ab1b-16bd5a3f7c14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_79a58779-b1f7-4e05-ab1b-16bd5a3f7c14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_79a58779-b1f7-4e05-ab1b-16bd5a3f7c14" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_79a58779-b1f7-4e05-ab1b-16bd5a3f7c14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6daa5087-313e-4b0b-af89-b460c37b0859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_79a58779-b1f7-4e05-ab1b-16bd5a3f7c14" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6daa5087-313e-4b0b-af89-b460c37b0859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ImplantableProviderGroupIMPMember_390329e9-6b9f-40cf-9b57-857b2925d89a" xlink:href="evh-20220930.xsd#evh_ImplantableProviderGroupIMPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6daa5087-313e-4b0b-af89-b460c37b0859" xlink:to="loc_evh_ImplantableProviderGroupIMPMember_390329e9-6b9f-40cf-9b57-857b2925d89a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VitalDecisionsMember_7efc1e9d-2fbb-497a-a001-8b3594ee8ba5" xlink:href="evh-20220930.xsd#evh_VitalDecisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6daa5087-313e-4b0b-af89-b460c37b0859" xlink:to="loc_evh_VitalDecisionsMember_7efc1e9d-2fbb-497a-a001-8b3594ee8ba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0197b3b1-e97a-4d40-a48a-1504210920b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5c4fb414-4a04-4edc-a85b-577d7bc2735d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0197b3b1-e97a-4d40-a48a-1504210920b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0197b3b1-e97a-4d40-a48a-1504210920b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0197b3b1-e97a-4d40-a48a-1504210920b7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0197b3b1-e97a-4d40-a48a-1504210920b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5cc5cdf-cb57-4647-b67c-c45ae10d9e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0197b3b1-e97a-4d40-a48a-1504210920b7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5cc5cdf-cb57-4647-b67c-c45ae10d9e1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_9701a162-f284-4bd3-81ba-f1025262aad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5cc5cdf-cb57-4647-b67c-c45ae10d9e1f" xlink:to="loc_us-gaap_CustomerRelationshipsMember_9701a162-f284-4bd3-81ba-f1025262aad6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_b68d678c-5eb8-4003-b2ae-29f549f0ac03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5cc5cdf-cb57-4647-b67c-c45ae10d9e1f" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_b68d678c-5eb8-4003-b2ae-29f549f0ac03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_7aaa7e97-7045-4de5-917e-9527e5f13ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5cc5cdf-cb57-4647-b67c-c45ae10d9e1f" xlink:to="loc_us-gaap_TradeNamesMember_7aaa7e97-7045-4de5-917e-9527e5f13ad3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#TransactionsAllocationofAcquisitionCostDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails" xlink:type="extended" id="idbb88787741642aca689c0d8d437b357_TransactionsAllocationofAcquisitionCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_31208220-b72f-44b1-9e20-3cc91a464001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d7419f9d-a6b7-4453-a00b-759ab6e79c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31208220-b72f-44b1-9e20-3cc91a464001" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d7419f9d-a6b7-4453-a00b-759ab6e79c70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_f2de3f1c-a77c-4d83-92a6-f8f59f1b1729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d7419f9d-a6b7-4453-a00b-759ab6e79c70" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_f2de3f1c-a77c-4d83-92a6-f8f59f1b1729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_5999d777-6ade-433c-8d7b-e7a2d6365d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d7419f9d-a6b7-4453-a00b-759ab6e79c70" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_5999d777-6ade-433c-8d7b-e7a2d6365d53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_772bbed0-8c79-429a-b35c-00201c02ce7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d7419f9d-a6b7-4453-a00b-759ab6e79c70" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_772bbed0-8c79-429a-b35c-00201c02ce7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ee34e147-a8e0-4d07-a719-7bd9732afbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d7419f9d-a6b7-4453-a00b-759ab6e79c70" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ee34e147-a8e0-4d07-a719-7bd9732afbc8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7f6b661d-ac66-40f6-a966-aa1455568df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31208220-b72f-44b1-9e20-3cc91a464001" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7f6b661d-ac66-40f6-a966-aa1455568df8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b2ca63a4-d223-4b3b-a3f9-a9863135655f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7f6b661d-ac66-40f6-a966-aa1455568df8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b2ca63a4-d223-4b3b-a3f9-a9863135655f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_25b8b2be-259a-43b6-8a9a-a4c6135b83ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7f6b661d-ac66-40f6-a966-aa1455568df8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_25b8b2be-259a-43b6-8a9a-a4c6135b83ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_c9f45dd5-4c6c-4591-9225-3544dac7b9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7f6b661d-ac66-40f6-a966-aa1455568df8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_c9f45dd5-4c6c-4591-9225-3544dac7b9ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_279df401-b5d7-4cc4-bc22-e65153d83ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7f6b661d-ac66-40f6-a966-aa1455568df8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_279df401-b5d7-4cc4-bc22-e65153d83ab4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_6dfe9334-14e9-45bf-895d-5d79590e6844" xlink:href="evh-20220930.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7f6b661d-ac66-40f6-a966-aa1455568df8" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_6dfe9334-14e9-45bf-895d-5d79590e6844" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_19131fe9-f8a5-4cb3-b20b-0409a6eac4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31208220-b72f-44b1-9e20-3cc91a464001" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_19131fe9-f8a5-4cb3-b20b-0409a6eac4e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_fb599a2d-3c5d-4ecd-9aa7-1bb7c5258bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_19131fe9-f8a5-4cb3-b20b-0409a6eac4e2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_fb599a2d-3c5d-4ecd-9aa7-1bb7c5258bda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_29c120c0-3115-4770-b720-0a09ab3b9bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31208220-b72f-44b1-9e20-3cc91a464001" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_29c120c0-3115-4770-b720-0a09ab3b9bf0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9bfe102c-070c-4004-a9de-552a9ddf5bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_29c120c0-3115-4770-b720-0a09ab3b9bf0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9bfe102c-070c-4004-a9de-552a9ddf5bde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_d0eb8cb6-d5f9-450a-aca2-759540b96737" xlink:href="evh-20220930.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_29c120c0-3115-4770-b720-0a09ab3b9bf0" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_d0eb8cb6-d5f9-450a-aca2-759540b96737" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_7b1e7b47-aef2-4014-9be0-3f376bb0710f" xlink:href="evh-20220930.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_29c120c0-3115-4770-b720-0a09ab3b9bf0" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_7b1e7b47-aef2-4014-9be0-3f376bb0710f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_218402f7-70f1-42bc-9ee0-a50b5840c352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_29c120c0-3115-4770-b720-0a09ab3b9bf0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_218402f7-70f1-42bc-9ee0-a50b5840c352" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_a61da8a9-892c-460d-a2d1-f41e3011dabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_29c120c0-3115-4770-b720-0a09ab3b9bf0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_a61da8a9-892c-460d-a2d1-f41e3011dabf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_68cd5dd8-c298-4277-8764-e2774da85cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_29c120c0-3115-4770-b720-0a09ab3b9bf0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_68cd5dd8-c298-4277-8764-e2774da85cfd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_67e1a470-3f22-43de-84bc-7854736f1fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_29c120c0-3115-4770-b720-0a09ab3b9bf0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_67e1a470-3f22-43de-84bc-7854736f1fca" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_00d5f84d-9759-43a6-aac0-87cdcbe86b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31208220-b72f-44b1-9e20-3cc91a464001" xlink:to="loc_us-gaap_Goodwill_00d5f84d-9759-43a6-aac0-87cdcbe86b60" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0058d2ac-fd99-4cec-8931-9703ed327d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31208220-b72f-44b1-9e20-3cc91a464001" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0058d2ac-fd99-4cec-8931-9703ed327d8f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fad07cb-f023-4f78-b1d3-cd93bf237b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31208220-b72f-44b1-9e20-3cc91a464001" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fad07cb-f023-4f78-b1d3-cd93bf237b1f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d06ef4b5-1bac-4d26-8301-059c0f738aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fad07cb-f023-4f78-b1d3-cd93bf237b1f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d06ef4b5-1bac-4d26-8301-059c0f738aa9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d06ef4b5-1bac-4d26-8301-059c0f738aa9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d06ef4b5-1bac-4d26-8301-059c0f738aa9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d06ef4b5-1bac-4d26-8301-059c0f738aa9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57cf6d63-de78-4076-b294-da504a277ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d06ef4b5-1bac-4d26-8301-059c0f738aa9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57cf6d63-de78-4076-b294-da504a277ada" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ImplantableProviderGroupIMPMember_d93635c4-9442-4b77-8ac4-972d7000e376" xlink:href="evh-20220930.xsd#evh_ImplantableProviderGroupIMPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57cf6d63-de78-4076-b294-da504a277ada" xlink:to="loc_evh_ImplantableProviderGroupIMPMember_d93635c4-9442-4b77-8ac4-972d7000e376" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VitalDecisionsMember_ed39aee3-0bfe-4038-9587-da4408aa2a8a" xlink:href="evh-20220930.xsd#evh_VitalDecisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57cf6d63-de78-4076-b294-da504a277ada" xlink:to="loc_evh_VitalDecisionsMember_ed39aee3-0bfe-4038-9587-da4408aa2a8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e0c6491-2522-4e23-8e19-a959fffc3978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fad07cb-f023-4f78-b1d3-cd93bf237b1f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e0c6491-2522-4e23-8e19-a959fffc3978" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e0c6491-2522-4e23-8e19-a959fffc3978_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e0c6491-2522-4e23-8e19-a959fffc3978" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7e0c6491-2522-4e23-8e19-a959fffc3978_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84f59308-f41b-490f-ba82-62586a5c0b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e0c6491-2522-4e23-8e19-a959fffc3978" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84f59308-f41b-490f-ba82-62586a5c0b00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_34151501-90ff-45f9-90ea-dfd5a0b11cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84f59308-f41b-490f-ba82-62586a5c0b00" xlink:to="loc_us-gaap_CustomerRelationshipsMember_34151501-90ff-45f9-90ea-dfd5a0b11cc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_a8253c72-1b69-4e75-9086-bd94fa7333da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84f59308-f41b-490f-ba82-62586a5c0b00" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_a8253c72-1b69-4e75-9086-bd94fa7333da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_cb206610-0c1a-484d-8cc5-54c61c381d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84f59308-f41b-490f-ba82-62586a5c0b00" xlink:to="loc_us-gaap_TradeNamesMember_cb206610-0c1a-484d-8cc5-54c61c381d1d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#DiscontinuedOperationsSummaryofResultsofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="extended" id="i0bd59e3e2558495b94a2267cf4146738_DiscontinuedOperationsSummaryofResultsofOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_7bd98f34-bbff-4a37-ab2a-a96a40485071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:to="loc_us-gaap_RevenuesAbstract_7bd98f34-bbff-4a37-ab2a-a96a40485071" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_d6b57b27-c5dd-40df-9515-401092d1d64e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_7bd98f34-bbff-4a37-ab2a-a96a40485071" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_d6b57b27-c5dd-40df-9515-401092d1d64e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d9f85055-7cb4-4a03-b1c5-79bd21dcbd25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d9f85055-7cb4-4a03-b1c5-79bd21dcbd25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_759559e2-8a0c-4ee0-bef6-b1d56c4ae7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9f85055-7cb4-4a03-b1c5-79bd21dcbd25" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_759559e2-8a0c-4ee0-bef6-b1d56c4ae7c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_98322cb0-dd85-4e72-9b33-c5fcd18139bc" xlink:href="evh-20220930.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9f85055-7cb4-4a03-b1c5-79bd21dcbd25" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_98322cb0-dd85-4e72-9b33-c5fcd18139bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_90651c75-4e51-47c1-9b31-8df7842f7ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9f85055-7cb4-4a03-b1c5-79bd21dcbd25" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_90651c75-4e51-47c1-9b31-8df7842f7ee0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_2938eb60-122c-4218-9baa-eaff8b55ca7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9f85055-7cb4-4a03-b1c5-79bd21dcbd25" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_2938eb60-122c-4218-9baa-eaff8b55ca7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_829a128b-919f-4b09-a0ae-36adb9aa8382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9f85055-7cb4-4a03-b1c5-79bd21dcbd25" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_829a128b-919f-4b09-a0ae-36adb9aa8382" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_a66fef05-4349-443e-aed4-47361bccd165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_a66fef05-4349-443e-aed4-47361bccd165" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_f2f15f99-2cee-4e16-8e83-527b5531c578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_f2f15f99-2cee-4e16-8e83-527b5531c578" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_e3bec0db-b809-4b22-98b1-42f8ea60141c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_e3bec0db-b809-4b22-98b1-42f8ea60141c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_372505e6-c310-4bc7-99b2-3827a1379d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_372505e6-c310-4bc7-99b2-3827a1379d54" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_23c93b67-dc83-4572-8091-ba72d3e7660b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_23c93b67-dc83-4572-8091-ba72d3e7660b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6fd76237-443d-4c14-adb0-2623c542a7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6fd76237-443d-4c14-adb0-2623c542a7a8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_aaf3048c-6081-4782-a3fd-fe816a7ccb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_aaf3048c-6081-4782-a3fd-fe816a7ccb1b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e02a116a-bb4a-4ef1-9622-2c0ee9720568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e02a116a-bb4a-4ef1-9622-2c0ee9720568" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_003f2fd7-6e2a-4829-8a23-ae480eb97af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e02a116a-bb4a-4ef1-9622-2c0ee9720568" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_003f2fd7-6e2a-4829-8a23-ae480eb97af6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_003f2fd7-6e2a-4829-8a23-ae480eb97af6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_003f2fd7-6e2a-4829-8a23-ae480eb97af6" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_003f2fd7-6e2a-4829-8a23-ae480eb97af6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_debd755b-75cc-46a4-a45f-aad93e28a45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_003f2fd7-6e2a-4829-8a23-ae480eb97af6" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_debd755b-75cc-46a4-a45f-aad93e28a45b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_51a39b0d-406a-4d1c-9939-a84c64f23a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_debd755b-75cc-46a4-a45f-aad93e28a45b" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_51a39b0d-406a-4d1c-9939-a84c64f23a98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_72c3d61b-d81b-452a-a04d-84fb0f76f96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e02a116a-bb4a-4ef1-9622-2c0ee9720568" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_72c3d61b-d81b-452a-a04d-84fb0f76f96a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_72c3d61b-d81b-452a-a04d-84fb0f76f96a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_72c3d61b-d81b-452a-a04d-84fb0f76f96a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_72c3d61b-d81b-452a-a04d-84fb0f76f96a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_299265db-1aa3-4ba3-91d5-a874714bf167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_72c3d61b-d81b-452a-a04d-84fb0f76f96a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_299265db-1aa3-4ba3-91d5-a874714bf167" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_e95bc699-0a7f-40d8-af99-1e7715b9cd86" xlink:href="evh-20220930.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_299265db-1aa3-4ba3-91d5-a874714bf167" xlink:to="loc_evh_TrueHealthMember_e95bc699-0a7f-40d8-af99-1e7715b9cd86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bfe54656-4d3a-4afa-8369-a96c42dca55f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e02a116a-bb4a-4ef1-9622-2c0ee9720568" xlink:to="loc_srt_ProductOrServiceAxis_bfe54656-4d3a-4afa-8369-a96c42dca55f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bfe54656-4d3a-4afa-8369-a96c42dca55f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_bfe54656-4d3a-4afa-8369-a96c42dca55f" xlink:to="loc_srt_ProductsAndServicesDomain_bfe54656-4d3a-4afa-8369-a96c42dca55f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2a201c26-5008-4c7f-85b5-cbc55ee886c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_bfe54656-4d3a-4afa-8369-a96c42dca55f" xlink:to="loc_srt_ProductsAndServicesDomain_2a201c26-5008-4c7f-85b5-cbc55ee886c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_e335c870-e770-409f-a6bf-a799894eeae3" xlink:href="evh-20220930.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2a201c26-5008-4c7f-85b5-cbc55ee886c4" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_e335c870-e770-409f-a6bf-a799894eeae3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember_08402c9e-e3e7-4854-beee-05c9dccc61a7" xlink:href="evh-20220930.xsd#evh_PremiumsRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2a201c26-5008-4c7f-85b5-cbc55ee886c4" xlink:to="loc_evh_PremiumsRevenueMember_08402c9e-e3e7-4854-beee-05c9dccc61a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_fefc395c-94f4-49d5-aed6-d493b8b59621" xlink:href="evh-20220930.xsd#evh_ServicesAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2a201c26-5008-4c7f-85b5-cbc55ee886c4" xlink:to="loc_evh_ServicesAgreementsMember_fefc395c-94f4-49d5-aed6-d493b8b59621" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#DiscontinuedOperationsSummaryofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="extended" id="i8b98a61e1505493191b89d23c77c0f16_DiscontinuedOperationsSummaryofCashFlowsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fa0dad8-d67d-4e0d-9831-65533bc8d340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_1309a320-6b49-47a8-aee1-f60d58b0bc62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fa0dad8-d67d-4e0d-9831-65533bc8d340" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_1309a320-6b49-47a8-aee1-f60d58b0bc62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_932cea2c-a6b6-4eca-917a-8f73b50c80dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fa0dad8-d67d-4e0d-9831-65533bc8d340" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_932cea2c-a6b6-4eca-917a-8f73b50c80dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ed3ecf35-8768-4d0c-a412-9f78883885b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fa0dad8-d67d-4e0d-9831-65533bc8d340" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ed3ecf35-8768-4d0c-a412-9f78883885b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d62455ba-64f4-4ab3-bcaa-4c5229da1b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ed3ecf35-8768-4d0c-a412-9f78883885b3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d62455ba-64f4-4ab3-bcaa-4c5229da1b15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d62455ba-64f4-4ab3-bcaa-4c5229da1b15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d62455ba-64f4-4ab3-bcaa-4c5229da1b15" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d62455ba-64f4-4ab3-bcaa-4c5229da1b15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3cdcfea5-48ac-4a12-a7df-02182df951f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d62455ba-64f4-4ab3-bcaa-4c5229da1b15" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3cdcfea5-48ac-4a12-a7df-02182df951f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_9c8b8f2d-b622-42f0-b692-cbb26a8675b1" xlink:href="evh-20220930.xsd#evh_TrueHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3cdcfea5-48ac-4a12-a7df-02182df951f1" xlink:to="loc_evh_TrueHealthMember_9c8b8f2d-b622-42f0-b692-cbb26a8675b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6f474724-f7a8-4801-a984-002b239cb7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ed3ecf35-8768-4d0c-a412-9f78883885b3" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6f474724-f7a8-4801-a984-002b239cb7e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_6f474724-f7a8-4801-a984-002b239cb7e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6f474724-f7a8-4801-a984-002b239cb7e1" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_6f474724-f7a8-4801-a984-002b239cb7e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ba611084-6e03-4fe9-b56c-c12c85cc0f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6f474724-f7a8-4801-a984-002b239cb7e1" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ba611084-6e03-4fe9-b56c-c12c85cc0f0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_b153f766-b46c-4e24-a7c3-85a4050cadac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ba611084-6e03-4fe9-b56c-c12c85cc0f0d" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_b153f766-b46c-4e24-a7c3-85a4050cadac" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended" id="i9dd6341937e44a139b08c61cb94d4cf4_RevenueRecognitionDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_78051e39-75c8-4889-be73-ab18569c943f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b24ee28a-ee84-4b72-a3a6-2c7095207b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_78051e39-75c8-4889-be73-ab18569c943f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b24ee28a-ee84-4b72-a3a6-2c7095207b7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a54052ca-d2a0-408b-99bf-227c53e29e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_78051e39-75c8-4889-be73-ab18569c943f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a54052ca-d2a0-408b-99bf-227c53e29e9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8b6d0bf4-0c1a-4d36-90ec-576c07c7f4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a54052ca-d2a0-408b-99bf-227c53e29e9e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8b6d0bf4-0c1a-4d36-90ec-576c07c7f4ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8b6d0bf4-0c1a-4d36-90ec-576c07c7f4ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8b6d0bf4-0c1a-4d36-90ec-576c07c7f4ab" xlink:to="loc_us-gaap_SegmentDomain_8b6d0bf4-0c1a-4d36-90ec-576c07c7f4ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1a9d817d-befa-44b0-96db-7de30a8509f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8b6d0bf4-0c1a-4d36-90ec-576c07c7f4ab" xlink:to="loc_us-gaap_SegmentDomain_1a9d817d-befa-44b0-96db-7de30a8509f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_8f175882-f1ac-4412-ab92-96b5c43919d9" xlink:href="evh-20220930.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1a9d817d-befa-44b0-96db-7de30a8509f6" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_8f175882-f1ac-4412-ab92-96b5c43919d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_ec56c86f-0ed4-4eba-bfa7-ce1540bee04d" xlink:href="evh-20220930.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1a9d817d-befa-44b0-96db-7de30a8509f6" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_ec56c86f-0ed4-4eba-bfa7-ce1540bee04d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f8a26586-fc0c-45d9-a839-bf1905a35088" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a54052ca-d2a0-408b-99bf-227c53e29e9e" xlink:to="loc_srt_MajorCustomersAxis_f8a26586-fc0c-45d9-a839-bf1905a35088" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f8a26586-fc0c-45d9-a839-bf1905a35088_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_f8a26586-fc0c-45d9-a839-bf1905a35088" xlink:to="loc_srt_NameOfMajorCustomerDomain_f8a26586-fc0c-45d9-a839-bf1905a35088_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_18404063-e618-460a-9c52-05a9cd38dc8c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_f8a26586-fc0c-45d9-a839-bf1905a35088" xlink:to="loc_srt_NameOfMajorCustomerDomain_18404063-e618-460a-9c52-05a9cd38dc8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember_e390432e-eabf-48b6-a1ca-e47af15dfbd1" xlink:href="evh-20220930.xsd#evh_MedicaidCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_18404063-e618-460a-9c52-05a9cd38dc8c" xlink:to="loc_evh_MedicaidCustomersMember_e390432e-eabf-48b6-a1ca-e47af15dfbd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember_b16673e1-ae64-4188-9fd5-adab4a27692b" xlink:href="evh-20220930.xsd#evh_MedicareCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_18404063-e618-460a-9c52-05a9cd38dc8c" xlink:to="loc_evh_MedicareCustomersMember_b16673e1-ae64-4188-9fd5-adab4a27692b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember_1f5924b0-dc9a-4edc-a126-f9b160246b1a" xlink:href="evh-20220930.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_18404063-e618-460a-9c52-05a9cd38dc8c" xlink:to="loc_evh_CommercialAndOtherCustomersMember_1f5924b0-dc9a-4edc-a126-f9b160246b1a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="extended" id="i0c1a62bcb9ac4021a7941da01b08c401_RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4b1bc363-fd06-4ce3-986c-01e7965eafe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_0c0295ef-50ad-4b77-b1f4-4e2b00d53dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4b1bc363-fd06-4ce3-986c-01e7965eafe8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_0c0295ef-50ad-4b77-b1f4-4e2b00d53dbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_54404180-9fb1-45eb-b7f1-a95b5f958a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4b1bc363-fd06-4ce3-986c-01e7965eafe8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_54404180-9fb1-45eb-b7f1-a95b5f958a3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e59eaef9-a566-4446-8bdf-7c504bcd22e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4b1bc363-fd06-4ce3-986c-01e7965eafe8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e59eaef9-a566-4446-8bdf-7c504bcd22e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_43bebdfb-7b4c-4ce3-8a5d-6967bc12230a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e59eaef9-a566-4446-8bdf-7c504bcd22e7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_43bebdfb-7b4c-4ce3-8a5d-6967bc12230a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_5959e369-0d1d-4af8-b328-4e1c91544955" xlink:href="evh-20220930.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e59eaef9-a566-4446-8bdf-7c504bcd22e7" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_5959e369-0d1d-4af8-b328-4e1c91544955" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_5959e369-0d1d-4af8-b328-4e1c91544955_default" xlink:href="evh-20220930.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_5959e369-0d1d-4af8-b328-4e1c91544955" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_5959e369-0d1d-4af8-b328-4e1c91544955_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_12db1fd3-af7b-4e0b-912b-10ccc35ac1b4" xlink:href="evh-20220930.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_5959e369-0d1d-4af8-b328-4e1c91544955" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_12db1fd3-af7b-4e0b-912b-10ccc35ac1b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312022Member_13f9bb12-b1e5-4c22-a9d0-ad0a6443479b" xlink:href="evh-20220930.xsd#evh_December312022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_12db1fd3-af7b-4e0b-912b-10ccc35ac1b4" xlink:to="loc_evh_December312022Member_13f9bb12-b1e5-4c22-a9d0-ad0a6443479b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312023Member_67351821-bfb3-49bc-b04a-09e94a96a5d8" xlink:href="evh-20220930.xsd#evh_December312023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_12db1fd3-af7b-4e0b-912b-10ccc35ac1b4" xlink:to="loc_evh_December312023Member_67351821-bfb3-49bc-b04a-09e94a96a5d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312024Member_e4e6167e-f1d7-4a48-a125-bcdfdef5a16d" xlink:href="evh-20220930.xsd#evh_December312024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_12db1fd3-af7b-4e0b-912b-10ccc35ac1b4" xlink:to="loc_evh_December312024Member_e4e6167e-f1d7-4a48-a125-bcdfdef5a16d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="evh-20220930.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="extended" id="i5f8404375b534657bb8dae32f1d98949_RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4b1bc363-fd06-4ce3-986c-01e7965eafe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_0c0295ef-50ad-4b77-b1f4-4e2b00d53dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4b1bc363-fd06-4ce3-986c-01e7965eafe8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_0c0295ef-50ad-4b77-b1f4-4e2b00d53dbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_54404180-9fb1-45eb-b7f1-a95b5f958a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4b1bc363-fd06-4ce3-986c-01e7965eafe8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_54404180-9fb1-45eb-b7f1-a95b5f958a3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e59eaef9-a566-4446-8bdf-7c504bcd22e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4b1bc363-fd06-4ce3-986c-01e7965eafe8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e59eaef9-a566-4446-8bdf-7c504bcd22e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_5959e369-0d1d-4af8-b328-4e1c91544955" xlink:href="evh-20220930.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e59eaef9-a566-4446-8bdf-7c504bcd22e7" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_5959e369-0d1d-4af8-b328-4e1c91544955" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_5959e369-0d1d-4af8-b328-4e1c91544955_default" xlink:href="evh-20220930.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_5959e369-0d1d-4af8-b328-4e1c91544955" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_5959e369-0d1d-4af8-b328-4e1c91544955_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_12db1fd3-af7b-4e0b-912b-10ccc35ac1b4" xlink:href="evh-20220930.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_5959e369-0d1d-4af8-b328-4e1c91544955" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_12db1fd3-af7b-4e0b-912b-10ccc35ac1b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312022Member_13f9bb12-b1e5-4c22-a9d0-ad0a6443479b" xlink:href="evh-20220930.xsd#evh_December312022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_12db1fd3-af7b-4e0b-912b-10ccc35ac1b4" xlink:to="loc_evh_December312022Member_13f9bb12-b1e5-4c22-a9d0-ad0a6443479b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312023Member_67351821-bfb3-49bc-b04a-09e94a96a5d8" xlink:href="evh-20220930.xsd#evh_December312023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_12db1fd3-af7b-4e0b-912b-10ccc35ac1b4" xlink:to="loc_evh_December312023Member_67351821-bfb3-49bc-b04a-09e94a96a5d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312024Member_e4e6167e-f1d7-4a48-a125-bcdfdef5a16d" xlink:href="evh-20220930.xsd#evh_December312024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_12db1fd3-af7b-4e0b-912b-10ccc35ac1b4" xlink:to="loc_evh_December312024Member_e4e6167e-f1d7-4a48-a125-bcdfdef5a16d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#RevenueRecognitionContractCostsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="extended" id="i9f48e223356548ee9a554975a4b59072_RevenueRecognitionContractCostsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems_bc15608e-4b7f-4a1b-80ed-cf1aa64e45a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_cc9a53b8-352c-460c-8466-758feb842dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_bc15608e-4b7f-4a1b-80ed-cf1aa64e45a2" xlink:to="loc_us-gaap_CapitalizedContractCostNet_cc9a53b8-352c-460c-8466-758feb842dc4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_280f01d1-5b6f-4375-b96b-bf2817274fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_bc15608e-4b7f-4a1b-80ed-cf1aa64e45a2" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_280f01d1-5b6f-4375-b96b-bf2817274fa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_0e2b6cf9-4e13-426c-b5c9-84da41e49fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_bc15608e-4b7f-4a1b-80ed-cf1aa64e45a2" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_0e2b6cf9-4e13-426c-b5c9-84da41e49fec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable_d4ce1827-78b6-4e68-af7e-5d9282f072cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_bc15608e-4b7f-4a1b-80ed-cf1aa64e45a2" xlink:to="loc_us-gaap_CapitalizedContractCostTable_d4ce1827-78b6-4e68-af7e-5d9282f072cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis_00c08964-d3cf-41c1-8d8d-cfc186fb75e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_CapitalizedContractCostTable_d4ce1827-78b6-4e68-af7e-5d9282f072cc" xlink:to="loc_us-gaap_CapitalizedContractCostAxis_00c08964-d3cf-41c1-8d8d-cfc186fb75e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_00c08964-d3cf-41c1-8d8d-cfc186fb75e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_00c08964-d3cf-41c1-8d8d-cfc186fb75e8" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_00c08964-d3cf-41c1-8d8d-cfc186fb75e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_7905172d-71b9-4b31-8a61-f0e09093474f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_00c08964-d3cf-41c1-8d8d-cfc186fb75e8" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_7905172d-71b9-4b31-8a61-f0e09093474f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember_c1966abe-4f77-41dc-9949-1fcd4dada6a2" xlink:href="evh-20220930.xsd#evh_BonusesAndCommissionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_7905172d-71b9-4b31-8a61-f0e09093474f" xlink:to="loc_evh_BonusesAndCommissionsMember_c1966abe-4f77-41dc-9949-1fcd4dada6a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember_10b290f8-ed97-41be-a0b3-fc79dd9401b4" xlink:href="evh-20220930.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_7905172d-71b9-4b31-8a61-f0e09093474f" xlink:to="loc_evh_ContractFulfillmentCostsMember_10b290f8-ed97-41be-a0b3-fc79dd9401b4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#CreditLossesAccountsReceivableNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="extended" id="ibec6fe5c15884728bd53c77566b8e06c_CreditLossesAccountsReceivableNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_4227bc99-83f1-48b1-992a-c5e13d0e7893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue_ae253011-847d-4797-8840-35a924ecbd17" xlink:href="evh-20220930.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_4227bc99-83f1-48b1-992a-c5e13d0e7893" xlink:to="loc_evh_FinancingReceivablePercentNotPastDue_ae253011-847d-4797-8840-35a924ecbd17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1_b8fe0005-5dfc-48d5-a4b3-4aafde89fdd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_4227bc99-83f1-48b1-992a-c5e13d0e7893" xlink:to="loc_us-gaap_FinancingReceivablePercentPastDue1_b8fe0005-5dfc-48d5-a4b3-4aafde89fdd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_2d1f1ad3-0b84-424b-9561-44bd9ecf3ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_4227bc99-83f1-48b1-992a-c5e13d0e7893" xlink:to="loc_us-gaap_AccountsReceivableNet_2d1f1ad3-0b84-424b-9561-44bd9ecf3ed3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4e402aca-42f5-47a4-a37c-f8784dc09700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_4227bc99-83f1-48b1-992a-c5e13d0e7893" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4e402aca-42f5-47a4-a37c-f8784dc09700" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_9630d66f-afea-4317-8651-bb854214020f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_4227bc99-83f1-48b1-992a-c5e13d0e7893" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_9630d66f-afea-4317-8651-bb854214020f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_0e097f58-f656-48c9-971b-53696d66e51c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_9630d66f-afea-4317-8651-bb854214020f" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_0e097f58-f656-48c9-971b-53696d66e51c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_0e097f58-f656-48c9-971b-53696d66e51c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_0e097f58-f656-48c9-971b-53696d66e51c" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_0e097f58-f656-48c9-971b-53696d66e51c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_94b83323-3b86-4714-b736-1681c9f389ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_0e097f58-f656-48c9-971b-53696d66e51c" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_94b83323-3b86-4714-b736-1681c9f389ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember_32279fc1-f088-410b-b3d2-0788e714a242" xlink:href="evh-20220930.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_94b83323-3b86-4714-b736-1681c9f389ab" xlink:to="loc_evh_FInancialAssetLessThan60DaysMember_32279fc1-f088-410b-b3d2-0788e714a242" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember_74e39fb4-522e-4d28-a269-e85585b6bed6" xlink:href="evh-20220930.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_94b83323-3b86-4714-b736-1681c9f389ab" xlink:to="loc_evh_FInancialAssetLessThan120DaysPastDueMember_74e39fb4-522e-4d28-a269-e85585b6bed6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#PropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended" id="i37299aa9a16b48939f49a06c7a9ad6ec_PropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b5d80dc5-3213-4ff2-afe7-a178e29c2a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c719a2c5-6e0e-4bbf-888e-a8e9cb332c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b5d80dc5-3213-4ff2-afe7-a178e29c2a40" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c719a2c5-6e0e-4bbf-888e-a8e9cb332c38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_432e75d9-51cc-4571-81a5-bda9beb5f2df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b5d80dc5-3213-4ff2-afe7-a178e29c2a40" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_432e75d9-51cc-4571-81a5-bda9beb5f2df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ac5fb188-0c89-472c-b7ae-3f164cc1c1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b5d80dc5-3213-4ff2-afe7-a178e29c2a40" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ac5fb188-0c89-472c-b7ae-3f164cc1c1ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_c75e897b-7a5e-4ca5-aacc-2c675889d4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b5d80dc5-3213-4ff2-afe7-a178e29c2a40" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_c75e897b-7a5e-4ca5-aacc-2c675889d4fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_1a01b381-bbd2-4fe5-a373-fd83a8272632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b5d80dc5-3213-4ff2-afe7-a178e29c2a40" xlink:to="loc_us-gaap_Depreciation_1a01b381-bbd2-4fe5-a373-fd83a8272632" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_2d61d4c6-7350-4370-83cc-7f9d59acc4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b5d80dc5-3213-4ff2-afe7-a178e29c2a40" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_2d61d4c6-7350-4370-83cc-7f9d59acc4f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5e80cbd6-b145-44af-9304-28406e4f3457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b5d80dc5-3213-4ff2-afe7-a178e29c2a40" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5e80cbd6-b145-44af-9304-28406e4f3457" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1e13941-2cfb-42f8-bd38-1b9286f085de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5e80cbd6-b145-44af-9304-28406e4f3457" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1e13941-2cfb-42f8-bd38-1b9286f085de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1e13941-2cfb-42f8-bd38-1b9286f085de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1e13941-2cfb-42f8-bd38-1b9286f085de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1e13941-2cfb-42f8-bd38-1b9286f085de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb3fdbcd-7612-4c35-9b84-a6d850abbb70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1e13941-2cfb-42f8-bd38-1b9286f085de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb3fdbcd-7612-4c35-9b84-a6d850abbb70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_a25024c1-3750-4c8f-ab95-3529cca3cf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb3fdbcd-7612-4c35-9b84-a6d850abbb70" xlink:to="loc_us-gaap_ComputerEquipmentMember_a25024c1-3750-4c8f-ab95-3529cca3cf9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d8fb94c2-e67a-43b1-b937-022008f60f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb3fdbcd-7612-4c35-9b84-a6d850abbb70" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d8fb94c2-e67a-43b1-b937-022008f60f05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_88dbde92-637e-47b2-a9fa-1da7c8ed586e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb3fdbcd-7612-4c35-9b84-a6d850abbb70" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_88dbde92-637e-47b2-a9fa-1da7c8ed586e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_90ffecc3-b1c1-4149-9278-dc44c9d50a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb3fdbcd-7612-4c35-9b84-a6d850abbb70" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_90ffecc3-b1c1-4149-9278-dc44c9d50a24" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="extended" id="i22a6f0b92ad54450aa8b40a389f58421_GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_dec25bd2-f5a7-4e1f-8cb5-e6be4c636ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_fac87225-d9bc-46ae-a87a-d7fa79f5e85b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_dec25bd2-f5a7-4e1f-8cb5-e6be4c636ef7" xlink:to="loc_us-gaap_GoodwillRollForward_fac87225-d9bc-46ae-a87a-d7fa79f5e85b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7b8027c4-683c-4c2e-a254-ce1b2b810a44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_fac87225-d9bc-46ae-a87a-d7fa79f5e85b" xlink:to="loc_us-gaap_Goodwill_7b8027c4-683c-4c2e-a254-ce1b2b810a44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_b2db6fdb-091f-4787-bd26-978dc8d7e026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_fac87225-d9bc-46ae-a87a-d7fa79f5e85b" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_b2db6fdb-091f-4787-bd26-978dc8d7e026" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_49af9d55-8bb1-4bc3-99dc-969ff33e82d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_fac87225-d9bc-46ae-a87a-d7fa79f5e85b" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_49af9d55-8bb1-4bc3-99dc-969ff33e82d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c9edc625-da3f-4013-acd7-581e4cb9d72c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1a612008-a8c0-43bd-8074-5f6c1f5f3b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_dec25bd2-f5a7-4e1f-8cb5-e6be4c636ef7" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1a612008-a8c0-43bd-8074-5f6c1f5f3b7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_a232aeb2-81d6-47c6-a249-8b288a76d65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_dec25bd2-f5a7-4e1f-8cb5-e6be4c636ef7" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_a232aeb2-81d6-47c6-a249-8b288a76d65c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_69e4567e-9a98-4c11-b42d-c51d3d4d84e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a232aeb2-81d6-47c6-a249-8b288a76d65c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_69e4567e-9a98-4c11-b42d-c51d3d4d84e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_69e4567e-9a98-4c11-b42d-c51d3d4d84e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_69e4567e-9a98-4c11-b42d-c51d3d4d84e8" xlink:to="loc_us-gaap_SegmentDomain_69e4567e-9a98-4c11-b42d-c51d3d4d84e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_41c2c5da-511a-4c88-9735-51d136013119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_69e4567e-9a98-4c11-b42d-c51d3d4d84e8" xlink:to="loc_us-gaap_SegmentDomain_41c2c5da-511a-4c88-9735-51d136013119" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_95f5002f-da82-4220-8ff0-f2eca45fd7a8" xlink:href="evh-20220930.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_41c2c5da-511a-4c88-9735-51d136013119" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_95f5002f-da82-4220-8ff0-f2eca45fd7a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_bf386986-0fee-4897-885e-1dca6b57a735" xlink:href="evh-20220930.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_41c2c5da-511a-4c88-9735-51d136013119" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_bf386986-0fee-4897-885e-1dca6b57a735" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended" id="icfc3a164461442eebf7d5fd5dc444af0_GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fc899321-6b23-47f5-bff6-7d52d9e520e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_9303b3e2-dc84-4f33-bf87-fcb0ca3ee66e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fc899321-6b23-47f5-bff6-7d52d9e520e3" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_9303b3e2-dc84-4f33-bf87-fcb0ca3ee66e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9efd0f00-48ec-40ec-ac22-e7fc6f37fbf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fc899321-6b23-47f5-bff6-7d52d9e520e3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9efd0f00-48ec-40ec-ac22-e7fc6f37fbf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_add3ef35-69a5-436e-adf7-df4da00cda34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fc899321-6b23-47f5-bff6-7d52d9e520e3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_add3ef35-69a5-436e-adf7-df4da00cda34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_97ae50d1-b4eb-45f1-bdef-536298a5ab3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fc899321-6b23-47f5-bff6-7d52d9e520e3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_97ae50d1-b4eb-45f1-bdef-536298a5ab3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5a45f755-0b56-41f8-be27-e02523fccc50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fc899321-6b23-47f5-bff6-7d52d9e520e3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5a45f755-0b56-41f8-be27-e02523fccc50" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e99272a4-59e9-4b25-b83d-26a8665dd73d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fc899321-6b23-47f5-bff6-7d52d9e520e3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e99272a4-59e9-4b25-b83d-26a8665dd73d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ccd00419-36c4-4d1d-9adc-fbe6bf0d2a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e99272a4-59e9-4b25-b83d-26a8665dd73d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ccd00419-36c4-4d1d-9adc-fbe6bf0d2a56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ccd00419-36c4-4d1d-9adc-fbe6bf0d2a56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ccd00419-36c4-4d1d-9adc-fbe6bf0d2a56" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ccd00419-36c4-4d1d-9adc-fbe6bf0d2a56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2cc9d194-96f9-4124-85d3-6ecbbf24a608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ccd00419-36c4-4d1d-9adc-fbe6bf0d2a56" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2cc9d194-96f9-4124-85d3-6ecbbf24a608" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_a8b6e1b5-848b-402d-9d75-665147487b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2cc9d194-96f9-4124-85d3-6ecbbf24a608" xlink:to="loc_us-gaap_TradeNamesMember_a8b6e1b5-848b-402d-9d75-665147487b68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_4f7a3468-a64b-4312-8227-a50f9a37a312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2cc9d194-96f9-4124-85d3-6ecbbf24a608" xlink:to="loc_us-gaap_CustomerRelationshipsMember_4f7a3468-a64b-4312-8227-a50f9a37a312" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_297c1283-b7ea-478f-9554-a0833fdd3914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2cc9d194-96f9-4124-85d3-6ecbbf24a608" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_297c1283-b7ea-478f-9554-a0833fdd3914" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember_2fb2033a-9e17-49d7-8c7a-e092a210b780" xlink:href="evh-20220930.xsd#evh_BelowMarketLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2cc9d194-96f9-4124-85d3-6ecbbf24a608" xlink:to="loc_evh_BelowMarketLeasesMember_2fb2033a-9e17-49d7-8c7a-e092a210b780" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_250a1b61-b50a-4baf-b06c-5cc8a76e1c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2cc9d194-96f9-4124-85d3-6ecbbf24a608" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_250a1b61-b50a-4baf-b06c-5cc8a76e1c71" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LongtermDebt2022CreditAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails" xlink:type="extended" id="ia1df0ef926d14a119b7860b562827aac_LongtermDebt2022CreditAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_533b720f-205c-4e23-8b63-1d5f610c288d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_533b720f-205c-4e23-8b63-1d5f610c288d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_959cd85b-3a09-4ac1-bba0-95ffc52964de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_959cd85b-3a09-4ac1-bba0-95ffc52964de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_7614312c-7451-41a9-b726-98881cf65873" xlink:href="evh-20220930.xsd#evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_7614312c-7451-41a9-b726-98881cf65873" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f404ae74-b766-424b-8f7e-cb5bd38af448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f404ae74-b766-424b-8f7e-cb5bd38af448" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_3dcfb196-11bd-4a28-8708-ce03eec16a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_3dcfb196-11bd-4a28-8708-ce03eec16a5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_7aebc211-ecc4-4fef-80a2-50a3b90a9ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_us-gaap_InterestExpenseDebt_7aebc211-ecc4-4fef-80a2-50a3b90a9ea0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_e40b8fd7-2bd6-4f4a-b8b4-149d65e2195e" xlink:href="evh-20220930.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_e40b8fd7-2bd6-4f4a-b8b4-149d65e2195e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_67708fb3-92b7-48dd-92e8-cf228a72365c" xlink:href="evh-20220930.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_67708fb3-92b7-48dd-92e8-cf228a72365c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_c0c22a5d-6b11-408d-b2f6-57f49cae83a5" xlink:href="evh-20220930.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_c0c22a5d-6b11-408d-b2f6-57f49cae83a5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_7cd94439-9d89-4b80-8096-9ce60f26c553" xlink:href="evh-20220930.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_7cd94439-9d89-4b80-8096-9ce60f26c553" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1eafa51b-490a-4119-a4e1-2b7b12d7aa94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1eafa51b-490a-4119-a4e1-2b7b12d7aa94" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_15cb3e7f-6381-4642-92e6-94c6319dfe7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_15cb3e7f-6381-4642-92e6-94c6319dfe7a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e615de63-ed7d-41cd-a98e-b9c88da3e4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e615de63-ed7d-41cd-a98e-b9c88da3e4dd" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_02774dc9-f067-45f9-ac6a-d03f2c1f97d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_us-gaap_DebtInstrumentTable_02774dc9-f067-45f9-ac6a-d03f2c1f97d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_36d27e3e-0475-4d48-99bc-c02a54e76ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_02774dc9-f067-45f9-ac6a-d03f2c1f97d1" xlink:to="loc_us-gaap_CreditFacilityAxis_36d27e3e-0475-4d48-99bc-c02a54e76ae4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_36d27e3e-0475-4d48-99bc-c02a54e76ae4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_36d27e3e-0475-4d48-99bc-c02a54e76ae4" xlink:to="loc_us-gaap_CreditFacilityDomain_36d27e3e-0475-4d48-99bc-c02a54e76ae4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2862e8ee-5746-4ab4-b7b6-329a26a01df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_36d27e3e-0475-4d48-99bc-c02a54e76ae4" xlink:to="loc_us-gaap_CreditFacilityDomain_2862e8ee-5746-4ab4-b7b6-329a26a01df7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_b75bc939-9823-4f4a-b3b8-392a7511690c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2862e8ee-5746-4ab4-b7b6-329a26a01df7" xlink:to="loc_us-gaap_SecuredDebtMember_b75bc939-9823-4f4a-b3b8-392a7511690c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_df99d684-a577-4a44-ba56-4d729d069f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2862e8ee-5746-4ab4-b7b6-329a26a01df7" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_df99d684-a577-4a44-ba56-4d729d069f85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_A2022CreditFacilitiesMember_6d591c0f-86e5-40a0-9960-b533fc57bd73" xlink:href="evh-20220930.xsd#evh_A2022CreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2862e8ee-5746-4ab4-b7b6-329a26a01df7" xlink:to="loc_evh_A2022CreditFacilitiesMember_6d591c0f-86e5-40a0-9960-b533fc57bd73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_eea0eb7b-280c-4ae8-afdf-1f49ee8845b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_02774dc9-f067-45f9-ac6a-d03f2c1f97d1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_eea0eb7b-280c-4ae8-afdf-1f49ee8845b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_eea0eb7b-280c-4ae8-afdf-1f49ee8845b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_eea0eb7b-280c-4ae8-afdf-1f49ee8845b4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_eea0eb7b-280c-4ae8-afdf-1f49ee8845b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1a7f8e11-40cb-4c03-a7d3-1a360da99e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_eea0eb7b-280c-4ae8-afdf-1f49ee8845b4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1a7f8e11-40cb-4c03-a7d3-1a360da99e5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_27e15a93-1f0b-43fa-9769-bb3fea8cf260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1a7f8e11-40cb-4c03-a7d3-1a360da99e5e" xlink:to="loc_us-gaap_LineOfCreditMember_27e15a93-1f0b-43fa-9769-bb3fea8cf260" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_188e9c26-4da1-48d0-92ed-27b6315f1942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1a7f8e11-40cb-4c03-a7d3-1a360da99e5e" xlink:to="loc_us-gaap_SecuredDebtMember_188e9c26-4da1-48d0-92ed-27b6315f1942" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_2e46654f-2d5a-4ac4-b3e3-f9fa68559fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_02774dc9-f067-45f9-ac6a-d03f2c1f97d1" xlink:to="loc_us-gaap_VariableRateAxis_2e46654f-2d5a-4ac4-b3e3-f9fa68559fc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_2e46654f-2d5a-4ac4-b3e3-f9fa68559fc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_2e46654f-2d5a-4ac4-b3e3-f9fa68559fc5" xlink:to="loc_us-gaap_VariableRateDomain_2e46654f-2d5a-4ac4-b3e3-f9fa68559fc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b11ebeb4-d032-400e-8abc-f9e6e423381c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_2e46654f-2d5a-4ac4-b3e3-f9fa68559fc5" xlink:to="loc_us-gaap_VariableRateDomain_b11ebeb4-d032-400e-8abc-f9e6e423381c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SecuredOvernightFinancingRateSOFRMember_1138d5ae-4422-45cd-98cb-f47930497af1" xlink:href="evh-20220930.xsd#evh_SecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_b11ebeb4-d032-400e-8abc-f9e6e423381c" xlink:to="loc_evh_SecuredOvernightFinancingRateSOFRMember_1138d5ae-4422-45cd-98cb-f47930497af1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_c8cc0b7b-eaea-4640-9684-d10b18ef0791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_b11ebeb4-d032-400e-8abc-f9e6e423381c" xlink:to="loc_us-gaap_BaseRateMember_c8cc0b7b-eaea-4640-9684-d10b18ef0791" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b1b53126-00b1-46d7-b0df-846cb16a2391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_02774dc9-f067-45f9-ac6a-d03f2c1f97d1" xlink:to="loc_us-gaap_DebtInstrumentAxis_b1b53126-00b1-46d7-b0df-846cb16a2391" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b1b53126-00b1-46d7-b0df-846cb16a2391_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1b53126-00b1-46d7-b0df-846cb16a2391" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b1b53126-00b1-46d7-b0df-846cb16a2391_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d5fe71ba-f231-4a17-a454-903630dc07ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1b53126-00b1-46d7-b0df-846cb16a2391" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d5fe71ba-f231-4a17-a454-903630dc07ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_A2022CreditFacilitiesMember_84bd9d1a-37a4-4d26-b4d2-27051eccd181" xlink:href="evh-20220930.xsd#evh_A2022CreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d5fe71ba-f231-4a17-a454-903630dc07ed" xlink:to="loc_evh_A2022CreditFacilitiesMember_84bd9d1a-37a4-4d26-b4d2-27051eccd181" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LongtermDebt2024NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="extended" id="i3a13a21774ea4411b1d0c82ee8b04a03_LongtermDebt2024NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_712675f0-4aa3-4749-8430-8e05c7e91394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_712675f0-4aa3-4749-8430-8e05c7e91394" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_58fad1fd-4924-497b-9019-92b8f4a4ebd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_58fad1fd-4924-497b-9019-92b8f4a4ebd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0aab7c34-b6b8-4dd4-ba30-6a48864107fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0aab7c34-b6b8-4dd4-ba30-6a48864107fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_cdeaf5e7-62c7-4273-babb-6d7f3d75b350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_cdeaf5e7-62c7-4273-babb-6d7f3d75b350" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_c6be8e8f-6396-4eea-b0c6-fbb1a0805a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_c6be8e8f-6396-4eea-b0c6-fbb1a0805a29" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_64f94fc6-2128-4ef0-8e2b-64b8fb8457f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_64f94fc6-2128-4ef0-8e2b-64b8fb8457f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_676b0863-39f7-4927-b812-513db14f4409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_InterestExpenseDebt_676b0863-39f7-4927-b812-513db14f4409" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_30126255-8fb4-4c11-91a3-8bcfeeb07dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_30126255-8fb4-4c11-91a3-8bcfeeb07dcc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_5821aced-7f37-45cb-a698-89bc8bc6d5be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_5821aced-7f37-45cb-a698-89bc8bc6d5be" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_a37b5d1f-2ec7-4aab-bcdf-aff49a5ffe51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_a37b5d1f-2ec7-4aab-bcdf-aff49a5ffe51" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4d86ae05-2f59-42cc-9787-2cf9ce51606c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_LongTermDebt_4d86ae05-2f59-42cc-9787-2cf9ce51606c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_01d66fc7-7741-4886-89d7-82e71a1390db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_01d66fc7-7741-4886-89d7-82e71a1390db" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent_c117332e-f8e8-4bf3-8710-7a3ed63a38a7" xlink:href="evh-20220930.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_evh_DebtIssuanceCostsNetDebtComponent_c117332e-f8e8-4bf3-8710-7a3ed63a38a7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e47748c5-3bd0-49c6-bc87-3cb300ff4e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_StockholdersEquity_e47748c5-3bd0-49c6-bc87-3cb300ff4e4e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_1e1e8b77-0620-4921-91bb-d1ed1d39dd01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_1e1e8b77-0620-4921-91bb-d1ed1d39dd01" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_42bc1e84-6fdf-433f-83cc-f790e2fbc7ca" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_42bc1e84-6fdf-433f-83cc-f790e2fbc7ca" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_03cdb4da-a57f-45ec-8bc5-ac247068e409" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_03cdb4da-a57f-45ec-8bc5-ac247068e409" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_7801dca5-fdff-4ae7-81f7-3d2a739f4457" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_7801dca5-fdff-4ae7-81f7-3d2a739f4457" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_497c6dd0-c953-4c6c-966d-a9830ef75e37" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_497c6dd0-c953-4c6c-966d-a9830ef75e37" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_29f84357-ef1a-47d9-8763-a850a0836357" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_29f84357-ef1a-47d9-8763-a850a0836357" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_cb44f7d8-44b5-4a0d-b8cf-634f3bc602f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_cb44f7d8-44b5-4a0d-b8cf-634f3bc602f1" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_897f95fa-9c20-477c-82f4-d4ac64200049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_897f95fa-9c20-477c-82f4-d4ac64200049" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b68a44a6-d3dd-4282-8cb7-641e720ec58e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_DebtInstrumentTable_b68a44a6-d3dd-4282-8cb7-641e720ec58e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5ed18103-5f97-41e3-b4db-6423201811c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b68a44a6-d3dd-4282-8cb7-641e720ec58e" xlink:to="loc_us-gaap_DebtInstrumentAxis_5ed18103-5f97-41e3-b4db-6423201811c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5ed18103-5f97-41e3-b4db-6423201811c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_5ed18103-5f97-41e3-b4db-6423201811c8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5ed18103-5f97-41e3-b4db-6423201811c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7af1e6c0-b7f8-40e3-8b20-472e59f42deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_5ed18103-5f97-41e3-b4db-6423201811c8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7af1e6c0-b7f8-40e3-8b20-472e59f42deb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_d6d420ea-3b95-4b01-a4dc-de99685d7a43" xlink:href="evh-20220930.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7af1e6c0-b7f8-40e3-8b20-472e59f42deb" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_d6d420ea-3b95-4b01-a4dc-de99685d7a43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_d4a17733-8aa1-470d-bc7a-8a67512205b0" xlink:href="evh-20220930.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7af1e6c0-b7f8-40e3-8b20-472e59f42deb" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_d4a17733-8aa1-470d-bc7a-8a67512205b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember_51409912-1cac-4a5a-809c-928ff6616750" xlink:href="evh-20220930.xsd#evh_NewNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7af1e6c0-b7f8-40e3-8b20-472e59f42deb" xlink:to="loc_evh_NewNotesMember_51409912-1cac-4a5a-809c-928ff6616750" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1a5d1691-fb9d-4306-b0fd-279c179e84fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b68a44a6-d3dd-4282-8cb7-641e720ec58e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1a5d1691-fb9d-4306-b0fd-279c179e84fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1a5d1691-fb9d-4306-b0fd-279c179e84fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1a5d1691-fb9d-4306-b0fd-279c179e84fd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1a5d1691-fb9d-4306-b0fd-279c179e84fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dc233183-9084-41f5-8421-fdd723f32840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1a5d1691-fb9d-4306-b0fd-279c179e84fd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dc233183-9084-41f5-8421-fdd723f32840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_b1aa83a1-af5f-4fce-ae39-60c28d851b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dc233183-9084-41f5-8421-fdd723f32840" xlink:to="loc_us-gaap_SeniorNotesMember_b1aa83a1-af5f-4fce-ae39-60c28d851b9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3937aa78-88a3-499c-b84c-6a6e3d12bbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b68a44a6-d3dd-4282-8cb7-641e720ec58e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3937aa78-88a3-499c-b84c-6a6e3d12bbe0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3937aa78-88a3-499c-b84c-6a6e3d12bbe0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3937aa78-88a3-499c-b84c-6a6e3d12bbe0" xlink:to="loc_us-gaap_EquityComponentDomain_3937aa78-88a3-499c-b84c-6a6e3d12bbe0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b3b7a4b2-20c7-4666-b060-2e2bc4a4b7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3937aa78-88a3-499c-b84c-6a6e3d12bbe0" xlink:to="loc_us-gaap_EquityComponentDomain_b3b7a4b2-20c7-4666-b060-2e2bc4a4b7a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d7d32eaf-b573-427e-b051-20e90736b24d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b3b7a4b2-20c7-4666-b060-2e2bc4a4b7a3" xlink:to="loc_us-gaap_CommonStockMember_d7d32eaf-b573-427e-b051-20e90736b24d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_15a7d02e-f62a-4643-8c01-8c097fc2b93b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b3b7a4b2-20c7-4666-b060-2e2bc4a4b7a3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_15a7d02e-f62a-4643-8c01-8c097fc2b93b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8b17e698-824c-4434-9097-d1b12ad28cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b3b7a4b2-20c7-4666-b060-2e2bc4a4b7a3" xlink:to="loc_us-gaap_RetainedEarningsMember_8b17e698-824c-4434-9097-d1b12ad28cbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_0a317e63-e13d-441d-8e14-8215647aff1c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b68a44a6-d3dd-4282-8cb7-641e720ec58e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_0a317e63-e13d-441d-8e14-8215647aff1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_0a317e63-e13d-441d-8e14-8215647aff1c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_0a317e63-e13d-441d-8e14-8215647aff1c" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_0a317e63-e13d-441d-8e14-8215647aff1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a3243861-1cf2-49bc-9afa-8501cf2d6df9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_0a317e63-e13d-441d-8e14-8215647aff1c" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a3243861-1cf2-49bc-9afa-8501cf2d6df9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7f601f92-1c32-48fb-aab3-86cf8e1c9353" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a3243861-1cf2-49bc-9afa-8501cf2d6df9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7f601f92-1c32-48fb-aab3-86cf8e1c9353" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b7229b23-9f31-467e-af30-e18fca138c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b68a44a6-d3dd-4282-8cb7-641e720ec58e" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b7229b23-9f31-467e-af30-e18fca138c52" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_b7229b23-9f31-467e-af30-e18fca138c52_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b7229b23-9f31-467e-af30-e18fca138c52" xlink:to="loc_us-gaap_TypeOfAdoptionMember_b7229b23-9f31-467e-af30-e18fca138c52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_db8f48e8-a560-4090-9e33-797f9b072fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b7229b23-9f31-467e-af30-e18fca138c52" xlink:to="loc_us-gaap_TypeOfAdoptionMember_db8f48e8-a560-4090-9e33-797f9b072fb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_a7bee64c-0a88-4e4d-8cc0-f5ee763b8c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_db8f48e8-a560-4090-9e33-797f9b072fb7" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_a7bee64c-0a88-4e4d-8cc0-f5ee763b8c41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6c34e177-7a0a-416f-b613-ce09090ff660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b68a44a6-d3dd-4282-8cb7-641e720ec58e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6c34e177-7a0a-416f-b613-ce09090ff660" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6c34e177-7a0a-416f-b613-ce09090ff660_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6c34e177-7a0a-416f-b613-ce09090ff660" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6c34e177-7a0a-416f-b613-ce09090ff660_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_284eae7d-ed04-4d3a-9f8b-4363cdc36cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6c34e177-7a0a-416f-b613-ce09090ff660" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_284eae7d-ed04-4d3a-9f8b-4363cdc36cb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember_4f22f5d6-fff6-4655-9b8a-d49e7fae43b4" xlink:href="evh-20220930.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_284eae7d-ed04-4d3a-9f8b-4363cdc36cb8" xlink:to="loc_evh_EquityComponentOfLongTermDebtMember_4f22f5d6-fff6-4655-9b8a-d49e7fae43b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember_6857595e-a216-403c-a2a1-2f700b1e0613" xlink:href="evh-20220930.xsd#evh_DeferredFinancingFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_284eae7d-ed04-4d3a-9f8b-4363cdc36cb8" xlink:to="loc_evh_DeferredFinancingFeesMember_6857595e-a216-403c-a2a1-2f700b1e0613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7ff0dfc6-20db-4897-b98b-b0ff32d0f568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b68a44a6-d3dd-4282-8cb7-641e720ec58e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7ff0dfc6-20db-4897-b98b-b0ff32d0f568" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7ff0dfc6-20db-4897-b98b-b0ff32d0f568_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7ff0dfc6-20db-4897-b98b-b0ff32d0f568" xlink:to="loc_us-gaap_ClassOfStockDomain_7ff0dfc6-20db-4897-b98b-b0ff32d0f568_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_46fc003f-d86e-4a35-9432-33ccb4c75447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7ff0dfc6-20db-4897-b98b-b0ff32d0f568" xlink:to="loc_us-gaap_ClassOfStockDomain_46fc003f-d86e-4a35-9432-33ccb4c75447" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_99d86826-d51a-4b45-bf16-bb55cb9768c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_46fc003f-d86e-4a35-9432-33ccb4c75447" xlink:to="loc_us-gaap_CommonClassAMember_99d86826-d51a-4b45-bf16-bb55cb9768c9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LongtermDebt2019CreditAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails" xlink:type="extended" id="i7fa0f7ecf6194a4cba29104fd0c14303_LongtermDebt2019CreditAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b786f3a6-2ad9-42d8-8d18-94a43b42bb28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a34fc4ff-f42f-47d3-9413-ec54243c0531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b786f3a6-2ad9-42d8-8d18-94a43b42bb28" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a34fc4ff-f42f-47d3-9413-ec54243c0531" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f4f441dd-fe03-48a7-bb06-e24fed2de462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b786f3a6-2ad9-42d8-8d18-94a43b42bb28" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f4f441dd-fe03-48a7-bb06-e24fed2de462" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_20a7253e-1f55-4fa5-bcf2-3770fc8c417f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b786f3a6-2ad9-42d8-8d18-94a43b42bb28" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_20a7253e-1f55-4fa5-bcf2-3770fc8c417f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsOfMakeWholePremium_a5539c3f-4029-47e7-948a-3d3de41e1b6a" xlink:href="evh-20220930.xsd#evh_PaymentsOfMakeWholePremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b786f3a6-2ad9-42d8-8d18-94a43b42bb28" xlink:to="loc_evh_PaymentsOfMakeWholePremium_a5539c3f-4029-47e7-948a-3d3de41e1b6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_eeb05d73-f862-4805-a156-edd24259a84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b786f3a6-2ad9-42d8-8d18-94a43b42bb28" xlink:to="loc_us-gaap_InterestPaidNet_eeb05d73-f862-4805-a156-edd24259a84c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_52b69fdf-21d3-4f8e-ab1f-ad55d5b5852b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b786f3a6-2ad9-42d8-8d18-94a43b42bb28" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_52b69fdf-21d3-4f8e-ab1f-ad55d5b5852b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_4b278519-cd3f-4378-b928-fb80ecb57d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b786f3a6-2ad9-42d8-8d18-94a43b42bb28" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_4b278519-cd3f-4378-b928-fb80ecb57d1d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_7fcd7f9c-15c7-44d4-8295-b59da9d2247c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b786f3a6-2ad9-42d8-8d18-94a43b42bb28" xlink:to="loc_us-gaap_LegalFees_7fcd7f9c-15c7-44d4-8295-b59da9d2247c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_78300e80-2f07-4ce6-ad91-ba8f2e4e4e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b786f3a6-2ad9-42d8-8d18-94a43b42bb28" xlink:to="loc_us-gaap_DebtInstrumentTable_78300e80-2f07-4ce6-ad91-ba8f2e4e4e6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_02ae2de7-d4c2-4af2-bb57-7d6aaa3419bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_78300e80-2f07-4ce6-ad91-ba8f2e4e4e6f" xlink:to="loc_us-gaap_DebtInstrumentAxis_02ae2de7-d4c2-4af2-bb57-7d6aaa3419bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_02ae2de7-d4c2-4af2-bb57-7d6aaa3419bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_02ae2de7-d4c2-4af2-bb57-7d6aaa3419bd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_02ae2de7-d4c2-4af2-bb57-7d6aaa3419bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_129392ab-5f0d-4b3a-9a96-bd35233c5b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_02ae2de7-d4c2-4af2-bb57-7d6aaa3419bd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_129392ab-5f0d-4b3a-9a96-bd35233c5b79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_InitialTermLoanFacilityMember_6d4d0d74-6ec2-4b4e-a4b8-5375074e7eb6" xlink:href="evh-20220930.xsd#evh_InitialTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_129392ab-5f0d-4b3a-9a96-bd35233c5b79" xlink:to="loc_evh_InitialTermLoanFacilityMember_6d4d0d74-6ec2-4b4e-a4b8-5375074e7eb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CreditAgreementMember_6a8c58bc-1761-4585-b640-5a7021bd8704" xlink:href="evh-20220930.xsd#evh_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_129392ab-5f0d-4b3a-9a96-bd35233c5b79" xlink:to="loc_evh_CreditAgreementMember_6a8c58bc-1761-4585-b640-5a7021bd8704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorCreditFacilitiesMember_2f6a0d8e-a9d6-41e8-b6f0-192b146ec210" xlink:href="evh-20220930.xsd#evh_SeniorCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_129392ab-5f0d-4b3a-9a96-bd35233c5b79" xlink:to="loc_evh_SeniorCreditFacilitiesMember_2f6a0d8e-a9d6-41e8-b6f0-192b146ec210" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a090a1bf-7175-446f-be98-edc2187a0b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_78300e80-2f07-4ce6-ad91-ba8f2e4e4e6f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a090a1bf-7175-446f-be98-edc2187a0b7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a090a1bf-7175-446f-be98-edc2187a0b7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a090a1bf-7175-446f-be98-edc2187a0b7a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a090a1bf-7175-446f-be98-edc2187a0b7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7b347e2a-99ac-4368-bffd-54d773306b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a090a1bf-7175-446f-be98-edc2187a0b7a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7b347e2a-99ac-4368-bffd-54d773306b08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_50f37a64-4d66-4736-8065-77c3859be0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7b347e2a-99ac-4368-bffd-54d773306b08" xlink:to="loc_us-gaap_SecuredDebtMember_50f37a64-4d66-4736-8065-77c3859be0a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_f9800776-496c-40b2-9549-4e91b0130a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7b347e2a-99ac-4368-bffd-54d773306b08" xlink:to="loc_us-gaap_LineOfCreditMember_f9800776-496c-40b2-9549-4e91b0130a0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_821a2d59-5fee-4408-b32b-8e9329646a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_78300e80-2f07-4ce6-ad91-ba8f2e4e4e6f" xlink:to="loc_us-gaap_CreditFacilityAxis_821a2d59-5fee-4408-b32b-8e9329646a19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_821a2d59-5fee-4408-b32b-8e9329646a19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_821a2d59-5fee-4408-b32b-8e9329646a19" xlink:to="loc_us-gaap_CreditFacilityDomain_821a2d59-5fee-4408-b32b-8e9329646a19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d9f8f1cd-ee5c-4a6f-9cee-7fc5d62cab38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_821a2d59-5fee-4408-b32b-8e9329646a19" xlink:to="loc_us-gaap_CreditFacilityDomain_d9f8f1cd-ee5c-4a6f-9cee-7fc5d62cab38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DelayedDrawTermLoanFacilityMember_ab060fe6-a419-4b03-9e7c-58f154b5299a" xlink:href="evh-20220930.xsd#evh_DelayedDrawTermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d9f8f1cd-ee5c-4a6f-9cee-7fc5d62cab38" xlink:to="loc_evh_DelayedDrawTermLoanFacilityMember_ab060fe6-a419-4b03-9e7c-58f154b5299a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LongtermDebtWarrantAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="extended" id="iaee3bcac85bb46d0a8d8485ab665ea80_LongtermDebtWarrantAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_6d3ce71b-eb33-409f-97a9-1a1032b7d826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued_c9e3ccad-6a99-45c8-a56e-c326a6509158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6d3ce71b-eb33-409f-97a9-1a1032b7d826" xlink:to="loc_us-gaap_ClassOfWarrantOrRightUnissued_c9e3ccad-6a99-45c8-a56e-c326a6509158" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_13acba97-7da4-49d3-981a-d26c5b8c7125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6d3ce71b-eb33-409f-97a9-1a1032b7d826" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_13acba97-7da4-49d3-981a-d26c5b8c7125" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_a6bc123c-d30d-4d05-a8f5-d32b33f2d3d3" xlink:href="evh-20220930.xsd#evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6d3ce71b-eb33-409f-97a9-1a1032b7d826" xlink:to="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_a6bc123c-d30d-4d05-a8f5-d32b33f2d3d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_35c960ce-3dd8-4ecd-a88a-3a264bf1b877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6d3ce71b-eb33-409f-97a9-1a1032b7d826" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_35c960ce-3dd8-4ecd-a88a-3a264bf1b877" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_4fbbb47a-77ed-441b-9680-a4ed0c53e909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6d3ce71b-eb33-409f-97a9-1a1032b7d826" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_4fbbb47a-77ed-441b-9680-a4ed0c53e909" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_895041db-3ce6-4fec-82eb-74f0972cee56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4fbbb47a-77ed-441b-9680-a4ed0c53e909" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_895041db-3ce6-4fec-82eb-74f0972cee56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_895041db-3ce6-4fec-82eb-74f0972cee56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_895041db-3ce6-4fec-82eb-74f0972cee56" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_895041db-3ce6-4fec-82eb-74f0972cee56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5b09ce37-f1f1-4516-b184-38db6864178c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_895041db-3ce6-4fec-82eb-74f0972cee56" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5b09ce37-f1f1-4516-b184-38db6864178c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_8aef5aeb-d9a3-4c29-aa83-7f7fa69c204f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5b09ce37-f1f1-4516-b184-38db6864178c" xlink:to="loc_us-gaap_CommonClassAMember_8aef5aeb-d9a3-4c29-aa83-7f7fa69c204f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LongtermDebt2025NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="extended" id="i125c572f88f34b5fb3f401b467678579_LongtermDebt2025NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ebc7ec74-4e84-49bf-b0f2-23ec314570dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ebc7ec74-4e84-49bf-b0f2-23ec314570dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5cdd06aa-d3d0-491d-8d0c-ea1b17fba177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5cdd06aa-d3d0-491d-8d0c-ea1b17fba177" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_146d6b41-ede5-4de2-8360-81d0d6f0df2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_InterestExpenseDebt_146d6b41-ede5-4de2-8360-81d0d6f0df2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_75e4379c-3445-472c-9181-fb32028c0c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_75e4379c-3445-472c-9181-fb32028c0c9f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_47cc550a-cbce-4ae1-b63b-7f6895ab0ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_47cc550a-cbce-4ae1-b63b-7f6895ab0ae9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_fb520899-606e-422e-ad57-1936717d2943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_fb520899-606e-422e-ad57-1936717d2943" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3da52b75-63a7-4ea1-8ddc-3ee551319117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_LongTermDebt_3da52b75-63a7-4ea1-8ddc-3ee551319117" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_106b1e8f-caf3-4232-ab1b-919d8132f4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_106b1e8f-caf3-4232-ab1b-919d8132f4f5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_82793b95-8fd7-4604-a469-0debeb8c06bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_82793b95-8fd7-4604-a469-0debeb8c06bc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5e0c1a83-3125-4b8c-8f92-a63aec4ffc39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_StockholdersEquity_5e0c1a83-3125-4b8c-8f92-a63aec4ffc39" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_7a9e3509-479d-4c7d-ab15-4c3afa5a637b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_7a9e3509-479d-4c7d-ab15-4c3afa5a637b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_a3b8d8ec-cbe5-44cb-aae7-487c26640ec1" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_a3b8d8ec-cbe5-44cb-aae7-487c26640ec1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_3047a9b4-9bb1-4dbf-aa54-4288559d663c" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_3047a9b4-9bb1-4dbf-aa54-4288559d663c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_3b7b8506-f65d-461f-89e3-ae85fbbbdaba" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_3b7b8506-f65d-461f-89e3-ae85fbbbdaba" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_8305a732-faff-4d2c-8ebc-461c8ac57c7b" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_8305a732-faff-4d2c-8ebc-461c8ac57c7b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_4ebe083a-d1d4-48dd-a0c4-0a981378eb66" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_4ebe083a-d1d4-48dd-a0c4-0a981378eb66" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e27002f1-20c2-4b71-a7f4-293650d079af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_DebtInstrumentTable_e27002f1-20c2-4b71-a7f4-293650d079af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_94ef2ab8-a134-4da2-8f47-62644bf053bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e27002f1-20c2-4b71-a7f4-293650d079af" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_94ef2ab8-a134-4da2-8f47-62644bf053bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_94ef2ab8-a134-4da2-8f47-62644bf053bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_94ef2ab8-a134-4da2-8f47-62644bf053bd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_94ef2ab8-a134-4da2-8f47-62644bf053bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4b75317c-e30a-4d75-bad8-63c58bfd8290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_94ef2ab8-a134-4da2-8f47-62644bf053bd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4b75317c-e30a-4d75-bad8-63c58bfd8290" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_297244f9-0081-4b50-b7dd-343c3e22294c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4b75317c-e30a-4d75-bad8-63c58bfd8290" xlink:to="loc_us-gaap_SeniorNotesMember_297244f9-0081-4b50-b7dd-343c3e22294c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a58584fa-c005-4e65-a8e6-8907e7f5deb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e27002f1-20c2-4b71-a7f4-293650d079af" xlink:to="loc_us-gaap_DebtInstrumentAxis_a58584fa-c005-4e65-a8e6-8907e7f5deb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a58584fa-c005-4e65-a8e6-8907e7f5deb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a58584fa-c005-4e65-a8e6-8907e7f5deb4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a58584fa-c005-4e65-a8e6-8907e7f5deb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bd7766fa-5067-4846-9e53-fe028d7cec6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a58584fa-c005-4e65-a8e6-8907e7f5deb4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bd7766fa-5067-4846-9e53-fe028d7cec6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_6ba20290-88cc-44e9-9d86-894b53505942" xlink:href="evh-20220930.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd7766fa-5067-4846-9e53-fe028d7cec6a" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_6ba20290-88cc-44e9-9d86-894b53505942" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_65e5d171-578b-4c35-9625-ffe072f45628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e27002f1-20c2-4b71-a7f4-293650d079af" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_65e5d171-578b-4c35-9625-ffe072f45628" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_65e5d171-578b-4c35-9625-ffe072f45628_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_65e5d171-578b-4c35-9625-ffe072f45628" xlink:to="loc_us-gaap_EquityComponentDomain_65e5d171-578b-4c35-9625-ffe072f45628_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_13657f1b-9590-4501-a58b-74fde6fb4386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_65e5d171-578b-4c35-9625-ffe072f45628" xlink:to="loc_us-gaap_EquityComponentDomain_13657f1b-9590-4501-a58b-74fde6fb4386" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_491b9782-6121-4e10-967b-131d3d504677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_13657f1b-9590-4501-a58b-74fde6fb4386" xlink:to="loc_us-gaap_CommonStockMember_491b9782-6121-4e10-967b-131d3d504677" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c79f5c19-7326-4f34-a73f-40b1434113f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_13657f1b-9590-4501-a58b-74fde6fb4386" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c79f5c19-7326-4f34-a73f-40b1434113f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1657a4fc-6ee4-4927-9870-e8ad089c47ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_13657f1b-9590-4501-a58b-74fde6fb4386" xlink:to="loc_us-gaap_RetainedEarningsMember_1657a4fc-6ee4-4927-9870-e8ad089c47ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c65853ac-33bf-44b0-bb06-7bc256b963e9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e27002f1-20c2-4b71-a7f4-293650d079af" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c65853ac-33bf-44b0-bb06-7bc256b963e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c65853ac-33bf-44b0-bb06-7bc256b963e9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c65853ac-33bf-44b0-bb06-7bc256b963e9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c65853ac-33bf-44b0-bb06-7bc256b963e9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7d20b6de-95ff-4e1c-bf21-cc2198994e58" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c65853ac-33bf-44b0-bb06-7bc256b963e9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7d20b6de-95ff-4e1c-bf21-cc2198994e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_16702748-eb7e-4bbb-b4ad-5439be4257b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7d20b6de-95ff-4e1c-bf21-cc2198994e58" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_16702748-eb7e-4bbb-b4ad-5439be4257b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_56143251-bd86-427d-928f-5bbdb3833f17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e27002f1-20c2-4b71-a7f4-293650d079af" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_56143251-bd86-427d-928f-5bbdb3833f17" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_56143251-bd86-427d-928f-5bbdb3833f17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_56143251-bd86-427d-928f-5bbdb3833f17" xlink:to="loc_us-gaap_TypeOfAdoptionMember_56143251-bd86-427d-928f-5bbdb3833f17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1325dfba-953a-41e7-b722-7036fa27668e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_56143251-bd86-427d-928f-5bbdb3833f17" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1325dfba-953a-41e7-b722-7036fa27668e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_bddc9c5c-6c79-4f48-90cb-88bfca4f3d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1325dfba-953a-41e7-b722-7036fa27668e" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_bddc9c5c-6c79-4f48-90cb-88bfca4f3d3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f3ee8ee5-2bfe-4df7-aae4-e88bb84461e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e27002f1-20c2-4b71-a7f4-293650d079af" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f3ee8ee5-2bfe-4df7-aae4-e88bb84461e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f3ee8ee5-2bfe-4df7-aae4-e88bb84461e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f3ee8ee5-2bfe-4df7-aae4-e88bb84461e7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f3ee8ee5-2bfe-4df7-aae4-e88bb84461e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b532deed-708f-4393-86ee-509f28fdc7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f3ee8ee5-2bfe-4df7-aae4-e88bb84461e7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b532deed-708f-4393-86ee-509f28fdc7dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember_e126e53a-d282-4e39-9312-a3384acaed47" xlink:href="evh-20220930.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b532deed-708f-4393-86ee-509f28fdc7dd" xlink:to="loc_evh_EquityComponentOfLongTermDebtMember_e126e53a-d282-4e39-9312-a3384acaed47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember_96b3846f-c570-4ce3-8f7c-e1155976785d" xlink:href="evh-20220930.xsd#evh_DeferredFinancingFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b532deed-708f-4393-86ee-509f28fdc7dd" xlink:to="loc_evh_DeferredFinancingFeesMember_96b3846f-c570-4ce3-8f7c-e1155976785d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_63dc355e-d8dd-4dff-b942-6e1049f51eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e27002f1-20c2-4b71-a7f4-293650d079af" xlink:to="loc_us-gaap_StatementClassOfStockAxis_63dc355e-d8dd-4dff-b942-6e1049f51eb5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_63dc355e-d8dd-4dff-b942-6e1049f51eb5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_63dc355e-d8dd-4dff-b942-6e1049f51eb5" xlink:to="loc_us-gaap_ClassOfStockDomain_63dc355e-d8dd-4dff-b942-6e1049f51eb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4c3db930-b8ea-4bd0-b24d-b08436f52c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_63dc355e-d8dd-4dff-b942-6e1049f51eb5" xlink:to="loc_us-gaap_ClassOfStockDomain_4c3db930-b8ea-4bd0-b24d-b08436f52c40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_9c3ff36a-9c79-4b1d-a6cf-683d213e358d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4c3db930-b8ea-4bd0-b24d-b08436f52c40" xlink:to="loc_us-gaap_CommonClassAMember_9c3ff36a-9c79-4b1d-a6cf-683d213e358d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LongtermDebt2021NotesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="extended" id="i8b8f8e417d044b5fba039d21d628eb59_LongtermDebt2021NotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b0fc146e-bf49-48a5-9528-fad8ebc0e265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b0fc146e-bf49-48a5-9528-fad8ebc0e265" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e2d1c590-4e77-4805-bd8d-602c373aaa51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e2d1c590-4e77-4805-bd8d-602c373aaa51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_cea6f702-490f-453a-a158-191f5dea3713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_cea6f702-490f-453a-a158-191f5dea3713" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_aececcf4-a68d-4438-9ab1-2fed5c271f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_aececcf4-a68d-4438-9ab1-2fed5c271f54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_c585359d-d634-4adf-9636-06bc1e5bc3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_c585359d-d634-4adf-9636-06bc1e5bc3a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_9c0d7eb0-1c5f-429d-b1dc-dc8dab2b917a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_9c0d7eb0-1c5f-429d-b1dc-dc8dab2b917a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_63e930d3-4d70-40d5-83a7-332889400c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_63e930d3-4d70-40d5-83a7-332889400c9d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_d8117551-c3f8-4f26-9660-a36c237a8873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_d8117551-c3f8-4f26-9660-a36c237a8873" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_b973473c-2713-4fc6-aa7b-d7e6b36882ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_b973473c-2713-4fc6-aa7b-d7e6b36882ba" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_ead32858-31ca-491e-8cf2-2c03e786b99c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_ead32858-31ca-491e-8cf2-2c03e786b99c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_622d9caf-3b94-4274-847a-57fc1836c2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_DebtInstrumentTable_622d9caf-3b94-4274-847a-57fc1836c2b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7b0dca93-2b66-4254-94f2-8b6c8e7624ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_622d9caf-3b94-4274-847a-57fc1836c2b6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7b0dca93-2b66-4254-94f2-8b6c8e7624ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7b0dca93-2b66-4254-94f2-8b6c8e7624ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7b0dca93-2b66-4254-94f2-8b6c8e7624ef" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7b0dca93-2b66-4254-94f2-8b6c8e7624ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b85da9dd-770b-4103-ba74-af0a12ebec2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7b0dca93-2b66-4254-94f2-8b6c8e7624ef" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b85da9dd-770b-4103-ba74-af0a12ebec2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_7f02cefc-f289-4ff9-890e-1efeda23b1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b85da9dd-770b-4103-ba74-af0a12ebec2d" xlink:to="loc_us-gaap_SeniorNotesMember_7f02cefc-f289-4ff9-890e-1efeda23b1b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_031d7afd-c1b5-47a2-a203-df611be54763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_622d9caf-3b94-4274-847a-57fc1836c2b6" xlink:to="loc_us-gaap_DebtInstrumentAxis_031d7afd-c1b5-47a2-a203-df611be54763" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_031d7afd-c1b5-47a2-a203-df611be54763_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_031d7afd-c1b5-47a2-a203-df611be54763" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_031d7afd-c1b5-47a2-a203-df611be54763_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7e57db68-0c87-4e0f-98a0-2856c9bc4443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_031d7afd-c1b5-47a2-a203-df611be54763" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7e57db68-0c87-4e0f-98a0-2856c9bc4443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_5d29d159-6033-478c-85ec-b3fa74b36a35" xlink:href="evh-20220930.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e57db68-0c87-4e0f-98a0-2856c9bc4443" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_5d29d159-6033-478c-85ec-b3fa74b36a35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_b37731c1-01cd-40e2-b0fc-e4222a48999d" xlink:href="evh-20220930.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e57db68-0c87-4e0f-98a0-2856c9bc4443" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_b37731c1-01cd-40e2-b0fc-e4222a48999d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended" id="i70de7c177db7414ea79e2e94aba74b07_LongtermDebtConvertibleSeniorNotesCarryingValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a2fd676f-959a-496b-abc8-1f849648f352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_f87fcef9-110f-44aa-a0b0-358ac1112813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a2fd676f-959a-496b-abc8-1f849648f352" xlink:to="loc_us-gaap_ConvertibleDebt_f87fcef9-110f-44aa-a0b0-358ac1112813" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_922945db-7893-42d9-8962-83fe73c82d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a2fd676f-959a-496b-abc8-1f849648f352" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_922945db-7893-42d9-8962-83fe73c82d13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1ada9308-24ad-44f6-ae15-b9ed5531e1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a2fd676f-959a-496b-abc8-1f849648f352" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1ada9308-24ad-44f6-ae15-b9ed5531e1fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_5b368f05-1b69-46f2-953b-47dab12c0a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a2fd676f-959a-496b-abc8-1f849648f352" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_5b368f05-1b69-46f2-953b-47dab12c0a7d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_bd97589c-8eaa-451e-87ef-5a4335fc2f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a2fd676f-959a-496b-abc8-1f849648f352" xlink:to="loc_us-gaap_LongTermDebtFairValue_bd97589c-8eaa-451e-87ef-5a4335fc2f00" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_013f3708-b4b2-4811-ba10-2d82929f45e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a2fd676f-959a-496b-abc8-1f849648f352" xlink:to="loc_us-gaap_DebtInstrumentTable_013f3708-b4b2-4811-ba10-2d82929f45e7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c7fdb032-4014-4682-a3fb-8b15a384f4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_013f3708-b4b2-4811-ba10-2d82929f45e7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c7fdb032-4014-4682-a3fb-8b15a384f4b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c7fdb032-4014-4682-a3fb-8b15a384f4b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c7fdb032-4014-4682-a3fb-8b15a384f4b5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c7fdb032-4014-4682-a3fb-8b15a384f4b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_33c8349a-a602-4d0f-b706-be82d62f8414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c7fdb032-4014-4682-a3fb-8b15a384f4b5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_33c8349a-a602-4d0f-b706-be82d62f8414" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_22a1808c-2a3f-428a-a5f1-079da2714234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_33c8349a-a602-4d0f-b706-be82d62f8414" xlink:to="loc_us-gaap_SeniorNotesMember_22a1808c-2a3f-428a-a5f1-079da2714234" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6032d1f1-277e-43e6-9f14-ef6463824126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_013f3708-b4b2-4811-ba10-2d82929f45e7" xlink:to="loc_us-gaap_DebtInstrumentAxis_6032d1f1-277e-43e6-9f14-ef6463824126" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6032d1f1-277e-43e6-9f14-ef6463824126_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_6032d1f1-277e-43e6-9f14-ef6463824126" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6032d1f1-277e-43e6-9f14-ef6463824126_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_44312f10-86da-49bf-bc89-f3ffdce6b27b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_6032d1f1-277e-43e6-9f14-ef6463824126" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_44312f10-86da-49bf-bc89-f3ffdce6b27b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_0e582b93-8405-4b4b-8e62-5141e489b3d9" xlink:href="evh-20220930.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44312f10-86da-49bf-bc89-f3ffdce6b27b" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_0e582b93-8405-4b4b-8e62-5141e489b3d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_6f53bb5e-9a72-439c-bcc7-3f542c01d44e" xlink:href="evh-20220930.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44312f10-86da-49bf-bc89-f3ffdce6b27b" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_6f53bb5e-9a72-439c-bcc7-3f542c01d44e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_59c0c1e0-31ee-496a-873e-4e7bc240875e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_013f3708-b4b2-4811-ba10-2d82929f45e7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_59c0c1e0-31ee-496a-873e-4e7bc240875e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_59c0c1e0-31ee-496a-873e-4e7bc240875e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_59c0c1e0-31ee-496a-873e-4e7bc240875e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_59c0c1e0-31ee-496a-873e-4e7bc240875e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_21377317-a53d-4671-811d-e9abf1e7bcce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_59c0c1e0-31ee-496a-873e-4e7bc240875e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_21377317-a53d-4671-811d-e9abf1e7bcce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2412fd02-4993-4c31-a582-d966ee909275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_21377317-a53d-4671-811d-e9abf1e7bcce" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2412fd02-4993-4c31-a582-d966ee909275" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i5d46acc9d10a4061b32303919f9dbec5_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c4da226c-95f5-4e08-bd84-8e5815faba0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c4da226c-95f5-4e08-bd84-8e5815faba0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_938392b6-229b-45c8-b3ea-0eb9fc2627b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_938392b6-229b-45c8-b3ea-0eb9fc2627b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LineOfCreditFacilityAutomaticExtensionPeriod_91ad95f6-89c6-4bee-b6a2-643c732d9e8c" xlink:href="evh-20220930.xsd#evh_LineOfCreditFacilityAutomaticExtensionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:to="loc_evh_LineOfCreditFacilityAutomaticExtensionPeriod_91ad95f6-89c6-4bee-b6a2-643c732d9e8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_d09c8188-b740-49f1-8c3b-56cb6018b1f0" xlink:href="evh-20220930.xsd#evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:to="loc_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_d09c8188-b740-49f1-8c3b-56cb6018b1f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfCustomers_9fbc8573-827f-40a7-afef-aa62ea7830c2" xlink:href="evh-20220930.xsd#evh_NumberOfCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:to="loc_evh_NumberOfCustomers_9fbc8573-827f-40a7-afef-aa62ea7830c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9bc2fb7b-a1cd-43c2-8064-18246910c072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:to="loc_us-gaap_Revenues_9bc2fb7b-a1cd-43c2-8064-18246910c072" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_0efbf644-9ea3-4780-8ee4-d1f1b6761bda" xlink:href="evh-20220930.xsd#evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:to="loc_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_0efbf644-9ea3-4780-8ee4-d1f1b6761bda" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementLiability_4d172f2f-2eb4-4265-9375-1dd619afe5dd" xlink:href="evh-20220930.xsd#evh_TaxReceivableAgreementLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:to="loc_evh_TaxReceivableAgreementLiability_4d172f2f-2eb4-4265-9375-1dd619afe5dd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_d26a4369-aaf8-4363-a299-9e720b603d76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_d26a4369-aaf8-4363-a299-9e720b603d76" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_c4d1448c-3d62-4ef4-b10c-c256c8dddc72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_c4d1448c-3d62-4ef4-b10c-c256c8dddc72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_4b4bb4a7-3c5e-436e-9081-4cb4c14cad7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_c4d1448c-3d62-4ef4-b10c-c256c8dddc72" xlink:to="loc_us-gaap_CreditFacilityAxis_4b4bb4a7-3c5e-436e-9081-4cb4c14cad7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_4b4bb4a7-3c5e-436e-9081-4cb4c14cad7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_4b4bb4a7-3c5e-436e-9081-4cb4c14cad7e" xlink:to="loc_us-gaap_CreditFacilityDomain_4b4bb4a7-3c5e-436e-9081-4cb4c14cad7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_962bc5a5-5858-4341-94e3-7e776b9caf13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_4b4bb4a7-3c5e-436e-9081-4cb4c14cad7e" xlink:to="loc_us-gaap_CreditFacilityDomain_962bc5a5-5858-4341-94e3-7e776b9caf13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_a0c4408f-2866-4ece-8ba3-04dd75cf3d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_962bc5a5-5858-4341-94e3-7e776b9caf13" xlink:to="loc_us-gaap_LetterOfCreditMember_a0c4408f-2866-4ece-8ba3-04dd75cf3d8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6483492b-a165-44fa-97a1-47ff50786f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_c4d1448c-3d62-4ef4-b10c-c256c8dddc72" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6483492b-a165-44fa-97a1-47ff50786f1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6483492b-a165-44fa-97a1-47ff50786f1c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6483492b-a165-44fa-97a1-47ff50786f1c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6483492b-a165-44fa-97a1-47ff50786f1c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1f39506e-0ed1-494f-a1be-9765db9acb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6483492b-a165-44fa-97a1-47ff50786f1c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1f39506e-0ed1-494f-a1be-9765db9acb3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_ec086d52-3d07-4dc4-b707-0de11c367822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1f39506e-0ed1-494f-a1be-9765db9acb3b" xlink:to="loc_us-gaap_LineOfCreditMember_ec086d52-3d07-4dc4-b707-0de11c367822" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_dcab2687-5219-4fb9-acdf-8a340e2e7dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_c4d1448c-3d62-4ef4-b10c-c256c8dddc72" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_dcab2687-5219-4fb9-acdf-8a340e2e7dc4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dcab2687-5219-4fb9-acdf-8a340e2e7dc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_dcab2687-5219-4fb9-acdf-8a340e2e7dc4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_dcab2687-5219-4fb9-acdf-8a340e2e7dc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0bf3fae5-6ee2-45d2-b196-3a0affb15ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_dcab2687-5219-4fb9-acdf-8a340e2e7dc4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0bf3fae5-6ee2-45d2-b196-3a0affb15ed9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_2ad66637-3c24-4b6b-905d-9cc10bd58011" xlink:href="evh-20220930.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0bf3fae5-6ee2-45d2-b196-3a0affb15ed9" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_2ad66637-3c24-4b6b-905d-9cc10bd58011" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_83651d31-ca2c-499a-8045-f7ba71a029fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_c4d1448c-3d62-4ef4-b10c-c256c8dddc72" xlink:to="loc_srt_LitigationCaseAxis_83651d31-ca2c-499a-8045-f7ba71a029fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_83651d31-ca2c-499a-8045-f7ba71a029fd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_83651d31-ca2c-499a-8045-f7ba71a029fd" xlink:to="loc_srt_LitigationCaseTypeDomain_83651d31-ca2c-499a-8045-f7ba71a029fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0fd85ff4-9f69-49a4-ad2c-1e40fdf5b590" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_83651d31-ca2c-499a-8045-f7ba71a029fd" xlink:to="loc_srt_LitigationCaseTypeDomain_0fd85ff4-9f69-49a4-ad2c-1e40fdf5b590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderClassActionComplaintMember_762c37c9-a3f1-454e-8a86-bc4e6ebbab32" xlink:href="evh-20220930.xsd#evh_ShareholderClassActionComplaintMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0fd85ff4-9f69-49a4-ad2c-1e40fdf5b590" xlink:to="loc_evh_ShareholderClassActionComplaintMember_762c37c9-a3f1-454e-8a86-bc4e6ebbab32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_1b74b0ff-0b05-4fc4-8bf6-1a74da9887d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_c4d1448c-3d62-4ef4-b10c-c256c8dddc72" xlink:to="loc_us-gaap_OtherCommitmentsAxis_1b74b0ff-0b05-4fc4-8bf6-1a74da9887d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_1b74b0ff-0b05-4fc4-8bf6-1a74da9887d0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_1b74b0ff-0b05-4fc4-8bf6-1a74da9887d0" xlink:to="loc_us-gaap_OtherCommitmentsDomain_1b74b0ff-0b05-4fc4-8bf6-1a74da9887d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_82a77f99-0148-446c-8d33-3ded45d027d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_1b74b0ff-0b05-4fc4-8bf6-1a74da9887d0" xlink:to="loc_us-gaap_OtherCommitmentsDomain_82a77f99-0148-446c-8d33-3ded45d027d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UPMCResellerAgreementMember_7b4e9207-c05d-44fa-8808-58747bbcc003" xlink:href="evh-20220930.xsd#evh_UPMCResellerAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_82a77f99-0148-446c-8d33-3ded45d027d6" xlink:to="loc_evh_UPMCResellerAgreementMember_7b4e9207-c05d-44fa-8808-58747bbcc003" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#CommitmentsandContingenciesConcentrationRiskDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="extended" id="ic056888d1261467694ca61ba1f11124a_CommitmentsandContingenciesConcentrationRiskDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_f7988614-7114-426d-bc4a-0fbedf3fc50d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage_5894899f-0b47-412e-8a29-cf451f2f5fcb" xlink:href="evh-20220930.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f7988614-7114-426d-bc4a-0fbedf3fc50d" xlink:to="loc_evh_CashFDICInsuredAmountPercentage_5894899f-0b47-412e-8a29-cf451f2f5fcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18f02771-702a-4367-9d40-415039019500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f7988614-7114-426d-bc4a-0fbedf3fc50d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18f02771-702a-4367-9d40-415039019500" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage_978d7586-df0d-453f-9319-a65424344de3" xlink:href="evh-20220930.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f7988614-7114-426d-bc4a-0fbedf3fc50d" xlink:to="loc_evh_CashHeldInInternationalBanksPercentage_978d7586-df0d-453f-9319-a65424344de3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_534e25e6-5cd8-4000-87d2-710838282e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f7988614-7114-426d-bc4a-0fbedf3fc50d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_534e25e6-5cd8-4000-87d2-710838282e66" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_dcadb080-cf15-4ec0-9700-1bd5e7539173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f7988614-7114-426d-bc4a-0fbedf3fc50d" xlink:to="loc_us-gaap_ConcentrationRiskTable_dcadb080-cf15-4ec0-9700-1bd5e7539173" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0ff5594b-f9eb-40a2-9370-a162d0f9c35c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_dcadb080-cf15-4ec0-9700-1bd5e7539173" xlink:to="loc_srt_MajorCustomersAxis_0ff5594b-f9eb-40a2-9370-a162d0f9c35c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_0ff5594b-f9eb-40a2-9370-a162d0f9c35c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_0ff5594b-f9eb-40a2-9370-a162d0f9c35c" xlink:to="loc_srt_NameOfMajorCustomerDomain_0ff5594b-f9eb-40a2-9370-a162d0f9c35c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f3bed6cb-6b0b-496c-b7a3-494be8587439" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_0ff5594b-f9eb-40a2-9370-a162d0f9c35c" xlink:to="loc_srt_NameOfMajorCustomerDomain_f3bed6cb-6b0b-496c-b7a3-494be8587439" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember_c5e61d96-863b-4e11-b67f-44ef1ad30c7d" xlink:href="evh-20220930.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f3bed6cb-6b0b-496c-b7a3-494be8587439" xlink:to="loc_evh_CookCountyHealthAndHospitalsSystemMember_c5e61d96-863b-4e11-b67f-44ef1ad30c7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember_d77e746a-0104-489e-ab04-b541301020b0" xlink:href="evh-20220930.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f3bed6cb-6b0b-496c-b7a3-494be8587439" xlink:to="loc_evh_FloridaBlueMedicareIncMember_d77e746a-0104-489e-ab04-b541301020b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareMember_f28f492e-00dd-488e-81c7-ae586d73cdb8" xlink:href="evh-20220930.xsd#evh_MolinaHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f3bed6cb-6b0b-496c-b7a3-494be8587439" xlink:to="loc_evh_MolinaHealthcareMember_f28f492e-00dd-488e-81c7-ae586d73cdb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BrightHealthManagementIncMember_40e06600-a735-4099-8999-439cee39f52e" xlink:href="evh-20220930.xsd#evh_BrightHealthManagementIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f3bed6cb-6b0b-496c-b7a3-494be8587439" xlink:to="loc_evh_BrightHealthManagementIncMember_40e06600-a735-4099-8999-439cee39f52e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_cdd8365e-dc50-47b6-bbad-784296b631d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_dcadb080-cf15-4ec0-9700-1bd5e7539173" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_cdd8365e-dc50-47b6-bbad-784296b631d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_cdd8365e-dc50-47b6-bbad-784296b631d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_cdd8365e-dc50-47b6-bbad-784296b631d1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_cdd8365e-dc50-47b6-bbad-784296b631d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_26d2da70-93ba-4ae6-8906-4659d0307f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_cdd8365e-dc50-47b6-bbad-784296b631d1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_26d2da70-93ba-4ae6-8906-4659d0307f46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_94970573-7ba5-4082-bbc2-5c8c52e49a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_26d2da70-93ba-4ae6-8906-4659d0307f46" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_94970573-7ba5-4082-bbc2-5c8c52e49a14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_03006185-bdd8-4afc-8c95-b2106379af00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_dcadb080-cf15-4ec0-9700-1bd5e7539173" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_03006185-bdd8-4afc-8c95-b2106379af00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_03006185-bdd8-4afc-8c95-b2106379af00_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_03006185-bdd8-4afc-8c95-b2106379af00" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_03006185-bdd8-4afc-8c95-b2106379af00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_489bb3da-4347-4afb-a910-5f5a8c5a2099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_03006185-bdd8-4afc-8c95-b2106379af00" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_489bb3da-4347-4afb-a910-5f5a8c5a2099" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_59a456e2-e76c-41e1-8adf-5fd9bf3a4777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_489bb3da-4347-4afb-a910-5f5a8c5a2099" xlink:to="loc_us-gaap_AccountsReceivableMember_59a456e2-e76c-41e1-8adf-5fd9bf3a4777" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_8b402575-6327-4bec-87fd-38289c94fee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_489bb3da-4347-4afb-a910-5f5a8c5a2099" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_8b402575-6327-4bec-87fd-38289c94fee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1f26c57f-47db-4bdd-9488-37d3261fa98c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_dcadb080-cf15-4ec0-9700-1bd5e7539173" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1f26c57f-47db-4bdd-9488-37d3261fa98c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_1f26c57f-47db-4bdd-9488-37d3261fa98c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1f26c57f-47db-4bdd-9488-37d3261fa98c" xlink:to="loc_us-gaap_ReceivableTypeDomain_1f26c57f-47db-4bdd-9488-37d3261fa98c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_3081b8a6-c298-48d0-80c7-d2ce347ffa52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1f26c57f-47db-4bdd-9488-37d3261fa98c" xlink:to="loc_us-gaap_ReceivableTypeDomain_3081b8a6-c298-48d0-80c7-d2ce347ffa52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_1a685d72-435e-41ad-8a03-4c169192c2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_3081b8a6-c298-48d0-80c7-d2ce347ffa52" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_1a685d72-435e-41ad-8a03-4c169192c2e2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i8fdb4b0075474f7596d1d006d9070274_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_c919acad-175c-4dc8-892b-46adb98b605c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfOptionsToRenewLeases_b88dd9e9-5aee-40fb-b59d-efee5b87d628" xlink:href="evh-20220930.xsd#evh_NumberOfOptionsToRenewLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c919acad-175c-4dc8-892b-46adb98b605c" xlink:to="loc_evh_NumberOfOptionsToRenewLeases_b88dd9e9-5aee-40fb-b59d-efee5b87d628" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_d1688f4d-e1b3-4a8a-84f3-c752bbde7b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c919acad-175c-4dc8-892b-46adb98b605c" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_d1688f4d-e1b3-4a8a-84f3-c752bbde7b2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_9b2ceb41-8055-4d0c-aca1-246e1e2fe33b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c919acad-175c-4dc8-892b-46adb98b605c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_9b2ceb41-8055-4d0c-aca1-246e1e2fe33b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_d0e918c3-85d2-4388-aef4-f3053a8c2b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c919acad-175c-4dc8-892b-46adb98b605c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_d0e918c3-85d2-4388-aef4-f3053a8c2b17" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_254a99e7-ae01-47b4-a1d0-18c0f136ff0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d0e918c3-85d2-4388-aef4-f3053a8c2b17" xlink:to="loc_us-gaap_OtherCommitmentsAxis_254a99e7-ae01-47b4-a1d0-18c0f136ff0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_254a99e7-ae01-47b4-a1d0-18c0f136ff0c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_254a99e7-ae01-47b4-a1d0-18c0f136ff0c" xlink:to="loc_us-gaap_OtherCommitmentsDomain_254a99e7-ae01-47b4-a1d0-18c0f136ff0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_b65ad3cd-201d-4924-ac41-17bfe3ee48a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_254a99e7-ae01-47b4-a1d0-18c0f136ff0c" xlink:to="loc_us-gaap_OtherCommitmentsDomain_b65ad3cd-201d-4924-ac41-17bfe3ee48a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember_9938c2a8-22b2-400f-b046-ef9549ee511e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_b65ad3cd-201d-4924-ac41-17bfe3ee48a6" xlink:to="loc_us-gaap_LeaseAgreementsMember_9938c2a8-22b2-400f-b046-ef9549ee511e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LeasesPrimaryOfficeLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="extended" id="ibba44e741b934a4cbabf03ff994e233c_LeasesPrimaryOfficeLeasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f65f0c88-a5ca-4616-95c4-a2c0b55fe232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e5aab555-3068-4db4-8e57-f1476fd30c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f65f0c88-a5ca-4616-95c4-a2c0b55fe232" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e5aab555-3068-4db4-8e57-f1476fd30c7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84080514-0c7b-4dc4-adba-f4ab50255788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f65f0c88-a5ca-4616-95c4-a2c0b55fe232" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84080514-0c7b-4dc4-adba-f4ab50255788" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_2c44890b-8c59-4600-a523-45d7fdd25e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f65f0c88-a5ca-4616-95c4-a2c0b55fe232" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_2c44890b-8c59-4600-a523-45d7fdd25e9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_59cea058-85eb-4e58-b486-36bc1fb015fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f65f0c88-a5ca-4616-95c4-a2c0b55fe232" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_59cea058-85eb-4e58-b486-36bc1fb015fc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7244693a-9fef-4690-a1af-d996acc148bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_59cea058-85eb-4e58-b486-36bc1fb015fc" xlink:to="loc_srt_StatementGeographicalAxis_7244693a-9fef-4690-a1af-d996acc148bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_7244693a-9fef-4690-a1af-d996acc148bd_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_7244693a-9fef-4690-a1af-d996acc148bd" xlink:to="loc_srt_SegmentGeographicalDomain_7244693a-9fef-4690-a1af-d996acc148bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5e6598a7-1a6e-43dd-9516-02cfa8fdf9a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_7244693a-9fef-4690-a1af-d996acc148bd" xlink:to="loc_srt_SegmentGeographicalDomain_5e6598a7-1a6e-43dd-9516-02cfa8fdf9a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA_aecaa782-91ef-421a-8b99-ce5ebb557576" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_VA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5e6598a7-1a6e-43dd-9516-02cfa8fdf9a5" xlink:to="loc_stpr_VA_aecaa782-91ef-421a-8b99-ce5ebb557576" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_24538499-6753-4e1e-831e-02fd6470fad4" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5e6598a7-1a6e-43dd-9516-02cfa8fdf9a5" xlink:to="loc_stpr_IL_24538499-6753-4e1e-831e-02fd6470fad4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_d6177752-3a86-471c-ac75-464f0c1bbf43" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5e6598a7-1a6e-43dd-9516-02cfa8fdf9a5" xlink:to="loc_stpr_NJ_d6177752-3a86-471c-ac75-464f0c1bbf43" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_765a5d36-0a42-494f-933c-cd3c904a74e7" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5e6598a7-1a6e-43dd-9516-02cfa8fdf9a5" xlink:to="loc_country_IN_765a5d36-0a42-494f-933c-cd3c904a74e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_4e0208d8-a0a0-45aa-820d-5a525071c71e" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5e6598a7-1a6e-43dd-9516-02cfa8fdf9a5" xlink:to="loc_stpr_CA_4e0208d8-a0a0-45aa-820d-5a525071c71e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA_51755c1c-f7c4-40b1-90be-610ee2c94b2c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_GA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_5e6598a7-1a6e-43dd-9516-02cfa8fdf9a5" xlink:to="loc_stpr_GA_51755c1c-f7c4-40b1-90be-610ee2c94b2c" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#IncomeLossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/IncomeLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended" id="i2029ee2d55bf4038ad601842ebbd410c_IncomeLossPerCommonShareAntidilutiveSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_47523696-2214-41b6-9e1f-072ddc7eafe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8746d252-768f-4103-9e04-e0220be78b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_47523696-2214-41b6-9e1f-072ddc7eafe8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8746d252-768f-4103-9e04-e0220be78b32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c0496625-a88f-44e9-a419-1dd5d30ea489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_47523696-2214-41b6-9e1f-072ddc7eafe8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c0496625-a88f-44e9-a419-1dd5d30ea489" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a6853564-e30b-437d-bc17-30027d6dcbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c0496625-a88f-44e9-a419-1dd5d30ea489" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a6853564-e30b-437d-bc17-30027d6dcbd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a6853564-e30b-437d-bc17-30027d6dcbd0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a6853564-e30b-437d-bc17-30027d6dcbd0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_a6853564-e30b-437d-bc17-30027d6dcbd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3938948b-4613-4205-91ef-004c5b4927ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a6853564-e30b-437d-bc17-30027d6dcbd0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3938948b-4613-4205-91ef-004c5b4927ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_f3dba875-1bad-4be5-89cb-9803a16f9ecd" xlink:href="evh-20220930.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3938948b-4613-4205-91ef-004c5b4927ff" xlink:to="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_f3dba875-1bad-4be5-89cb-9803a16f9ecd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2d6a80bd-f9bf-4509-9747-4e481ab98846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3938948b-4613-4205-91ef-004c5b4927ff" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2d6a80bd-f9bf-4509-9747-4e481ab98846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_67fe9777-4b96-412e-8f11-37282f45fd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3938948b-4613-4205-91ef-004c5b4927ff" xlink:to="loc_us-gaap_ConvertibleDebtMember_67fe9777-4b96-412e-8f11-37282f45fd1b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended" id="i6e3c64797cff4aa7a954b396bd9bbac3_StockbasedCompensationStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_97dff280-b07e-42f4-8532-6d2921bfec48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_24cad10f-ff8a-4787-ae43-ab6c9834e745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_97dff280-b07e-42f4-8532-6d2921bfec48" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_24cad10f-ff8a-4787-ae43-ab6c9834e745" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d856def4-d3f9-42c5-9552-ad8cde270016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_97dff280-b07e-42f4-8532-6d2921bfec48" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d856def4-d3f9-42c5-9552-ad8cde270016" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b71d7a11-03e7-4f78-a1ae-29c71d1c6e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d856def4-d3f9-42c5-9552-ad8cde270016" xlink:to="loc_us-gaap_AwardTypeAxis_b71d7a11-03e7-4f78-a1ae-29c71d1c6e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b71d7a11-03e7-4f78-a1ae-29c71d1c6e58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b71d7a11-03e7-4f78-a1ae-29c71d1c6e58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b71d7a11-03e7-4f78-a1ae-29c71d1c6e58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3a39572-0207-403d-9739-fadbfd70ab96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b71d7a11-03e7-4f78-a1ae-29c71d1c6e58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3a39572-0207-403d-9739-fadbfd70ab96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1c19dbe4-4e54-4f47-8ede-dae3d2fbc45d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3a39572-0207-403d-9739-fadbfd70ab96" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1c19dbe4-4e54-4f47-8ede-dae3d2fbc45d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3c9aa6e1-61bc-4e6a-832c-250323b49356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3a39572-0207-403d-9739-fadbfd70ab96" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3c9aa6e1-61bc-4e6a-832c-250323b49356" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_a9a62961-4608-4ce1-9e8f-621013ae9333" xlink:href="evh-20220930.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3a39572-0207-403d-9739-fadbfd70ab96" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_a9a62961-4608-4ce1-9e8f-621013ae9333" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_55fe484d-878f-449f-a240-07506faa5df0" xlink:href="evh-20220930.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3a39572-0207-403d-9739-fadbfd70ab96" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_55fe484d-878f-449f-a240-07506faa5df0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f3617c0a-3782-4a71-ab13-0d69b2301580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d856def4-d3f9-42c5-9552-ad8cde270016" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f3617c0a-3782-4a71-ab13-0d69b2301580" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f3617c0a-3782-4a71-ab13-0d69b2301580_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f3617c0a-3782-4a71-ab13-0d69b2301580" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f3617c0a-3782-4a71-ab13-0d69b2301580_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8849bd7a-a98a-45b8-b1f7-991034a4ba76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f3617c0a-3782-4a71-ab13-0d69b2301580" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8849bd7a-a98a-45b8-b1f7-991034a4ba76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_696c4a75-620e-4f18-b25f-c1a6cccb5d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8849bd7a-a98a-45b8-b1f7-991034a4ba76" xlink:to="loc_us-gaap_CostOfSalesMember_696c4a75-620e-4f18-b25f-c1a6cccb5d2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3a70e43b-9888-41ab-8738-bd0ae62d9a51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8849bd7a-a98a-45b8-b1f7-991034a4ba76" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3a70e43b-9888-41ab-8738-bd0ae62d9a51" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails" xlink:type="extended" id="i4caaa43fdc1f4b519998b5d6003bb240_StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77e64c42-026c-41d9-a78a-88e7972b80bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5ba2df01-67a1-47a9-9ad4-f52b5fc37ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77e64c42-026c-41d9-a78a-88e7972b80bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5ba2df01-67a1-47a9-9ad4-f52b5fc37ae2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7eead3d-2aef-4a41-90df-fbb13137f92b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77e64c42-026c-41d9-a78a-88e7972b80bd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7eead3d-2aef-4a41-90df-fbb13137f92b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_81cf4ea3-ed2c-496b-a843-f823293f493a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7eead3d-2aef-4a41-90df-fbb13137f92b" xlink:to="loc_us-gaap_AwardTypeAxis_81cf4ea3-ed2c-496b-a843-f823293f493a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81cf4ea3-ed2c-496b-a843-f823293f493a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_81cf4ea3-ed2c-496b-a843-f823293f493a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_81cf4ea3-ed2c-496b-a843-f823293f493a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9b31278-9abd-4301-9474-88ebc5b542cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_81cf4ea3-ed2c-496b-a843-f823293f493a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9b31278-9abd-4301-9474-88ebc5b542cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_84b694fd-0366-409b-a0f2-fc1e93ec595a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9b31278-9abd-4301-9474-88ebc5b542cd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_84b694fd-0366-409b-a0f2-fc1e93ec595a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_790c047d-e449-44b3-882a-9c1601192c4f" xlink:href="evh-20220930.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9b31278-9abd-4301-9474-88ebc5b542cd" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_790c047d-e449-44b3-882a-9c1601192c4f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#InvestmentsinEquityMethodInvesteesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="extended" id="i6033614b484b43d792841ad38429c817_InvestmentsinEquityMethodInvesteesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9c2343f2-68fe-451a-b3b0-a4df6458c09e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_540184bd-1769-428a-9d61-e51d56b0f0c9" xlink:href="evh-20220930.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9c2343f2-68fe-451a-b3b0-a4df6458c09e" xlink:to="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_540184bd-1769-428a-9d61-e51d56b0f0c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage_5bcbe5b0-1547-4ef1-b8ed-03727f410bcf" xlink:href="evh-20220930.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9c2343f2-68fe-451a-b3b0-a4df6458c09e" xlink:to="loc_evh_EquityMethodInvestmentVotingInterestPercentage_5bcbe5b0-1547-4ef1-b8ed-03727f410bcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3d6e53b8-47b2-4d40-85ce-3b2486be2f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9c2343f2-68fe-451a-b3b0-a4df6458c09e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3d6e53b8-47b2-4d40-85ce-3b2486be2f24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_9e84003f-861e-4420-93f6-9f41da792654" xlink:href="evh-20220930.xsd#evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9c2343f2-68fe-451a-b3b0-a4df6458c09e" xlink:to="loc_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_9e84003f-861e-4420-93f6-9f41da792654" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cc701e8b-8b5c-4a6b-bdd1-0da279e18cce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9c2343f2-68fe-451a-b3b0-a4df6458c09e" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cc701e8b-8b5c-4a6b-bdd1-0da279e18cce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1a5aa8de-83e5-4f6a-b57d-2b676970b3a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cc701e8b-8b5c-4a6b-bdd1-0da279e18cce" xlink:to="loc_srt_RangeAxis_1a5aa8de-83e5-4f6a-b57d-2b676970b3a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1a5aa8de-83e5-4f6a-b57d-2b676970b3a4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1a5aa8de-83e5-4f6a-b57d-2b676970b3a4" xlink:to="loc_srt_RangeMember_1a5aa8de-83e5-4f6a-b57d-2b676970b3a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0df4f2b5-351d-4401-85f8-bae080a4cf27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1a5aa8de-83e5-4f6a-b57d-2b676970b3a4" xlink:to="loc_srt_RangeMember_0df4f2b5-351d-4401-85f8-bae080a4cf27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6e86caf2-e0ff-4b77-8143-8c512e76bdbe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0df4f2b5-351d-4401-85f8-bae080a4cf27" xlink:to="loc_srt_MinimumMember_6e86caf2-e0ff-4b77-8143-8c512e76bdbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3737f99d-0c9a-408c-9b20-58fff1f259fa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0df4f2b5-351d-4401-85f8-bae080a4cf27" xlink:to="loc_srt_MaximumMember_3737f99d-0c9a-408c-9b20-58fff1f259fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_08e00c60-2539-4054-9fb7-1b47b5d51ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cc701e8b-8b5c-4a6b-bdd1-0da279e18cce" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_08e00c60-2539-4054-9fb7-1b47b5d51ca1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_08e00c60-2539-4054-9fb7-1b47b5d51ca1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_08e00c60-2539-4054-9fb7-1b47b5d51ca1" xlink:to="loc_us-gaap_RelatedPartyDomain_08e00c60-2539-4054-9fb7-1b47b5d51ca1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8b4a7a19-a47a-4d93-af94-3bb37df16ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_08e00c60-2539-4054-9fb7-1b47b5d51ca1" xlink:to="loc_us-gaap_RelatedPartyDomain_8b4a7a19-a47a-4d93-af94-3bb37df16ed1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_e8fbd408-9c18-4db4-a025-e0f6ebd6dffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_8b4a7a19-a47a-4d93-af94-3bb37df16ed1" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_e8fbd408-9c18-4db4-a025-e0f6ebd6dffa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1a327b9b-24a4-46f0-b1e0-442ff10b873e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cc701e8b-8b5c-4a6b-bdd1-0da279e18cce" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1a327b9b-24a4-46f0-b1e0-442ff10b873e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1a327b9b-24a4-46f0-b1e0-442ff10b873e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1a327b9b-24a4-46f0-b1e0-442ff10b873e" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1a327b9b-24a4-46f0-b1e0-442ff10b873e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_53773e93-3fc8-43ef-83cf-c4bdf573b845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1a327b9b-24a4-46f0-b1e0-442ff10b873e" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_53773e93-3fc8-43ef-83cf-c4bdf573b845" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_539cbcc1-395d-4e5c-87c6-19b4b911bb3c" xlink:href="evh-20220930.xsd#evh_ServicesAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_53773e93-3fc8-43ef-83cf-c4bdf573b845" xlink:to="loc_evh_ServicesAgreementsMember_539cbcc1-395d-4e5c-87c6-19b4b911bb3c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended" id="ic0f9d606d0f040b9a87737896f3b775b_FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_704c238c-b3b4-4778-ac15-7513251fb098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_f2cdde11-2111-40e6-9099-0ca70bddbc46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_704c238c-b3b4-4778-ac15-7513251fb098" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_f2cdde11-2111-40e6-9099-0ca70bddbc46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ab96df86-b155-462b-931b-052e7ebd0e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_f2cdde11-2111-40e6-9099-0ca70bddbc46" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ab96df86-b155-462b-931b-052e7ebd0e74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_421e54fe-2067-4ea9-b4a2-23c8d8530620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_f2cdde11-2111-40e6-9099-0ca70bddbc46" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_421e54fe-2067-4ea9-b4a2-23c8d8530620" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8354ae40-34c3-43d5-bf0c-98cab44008fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_704c238c-b3b4-4778-ac15-7513251fb098" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8354ae40-34c3-43d5-bf0c-98cab44008fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_177eb947-fc9a-40a6-aadb-ec54b8dda30b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8354ae40-34c3-43d5-bf0c-98cab44008fe" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_177eb947-fc9a-40a6-aadb-ec54b8dda30b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_177eb947-fc9a-40a6-aadb-ec54b8dda30b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_177eb947-fc9a-40a6-aadb-ec54b8dda30b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_177eb947-fc9a-40a6-aadb-ec54b8dda30b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cdaf5e0-d596-49cc-b53e-1db3a09fa510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_177eb947-fc9a-40a6-aadb-ec54b8dda30b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cdaf5e0-d596-49cc-b53e-1db3a09fa510" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f62ec7f8-fc32-43aa-998e-45a7ee3b894e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cdaf5e0-d596-49cc-b53e-1db3a09fa510" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f62ec7f8-fc32-43aa-998e-45a7ee3b894e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6325499a-39b3-4808-be41-f01ba0af0675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cdaf5e0-d596-49cc-b53e-1db3a09fa510" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6325499a-39b3-4808-be41-f01ba0af0675" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_651828ec-05f4-42d8-a7bd-207211631b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cdaf5e0-d596-49cc-b53e-1db3a09fa510" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_651828ec-05f4-42d8-a7bd-207211631b06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0524dff5-ea78-4f48-be1a-54960b609596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8354ae40-34c3-43d5-bf0c-98cab44008fe" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0524dff5-ea78-4f48-be1a-54960b609596" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0524dff5-ea78-4f48-be1a-54960b609596_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0524dff5-ea78-4f48-be1a-54960b609596" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0524dff5-ea78-4f48-be1a-54960b609596_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c44e14df-4d1f-4ff2-bc86-aa39c892c39b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0524dff5-ea78-4f48-be1a-54960b609596" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c44e14df-4d1f-4ff2-bc86-aa39c892c39b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_da5cf220-076c-4cda-8e93-1b332d04478d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c44e14df-4d1f-4ff2-bc86-aa39c892c39b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_da5cf220-076c-4cda-8e93-1b332d04478d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="extended" id="i137ce5af768f472ca5cdd5ca26a7ea13_FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_83299e16-e52d-4dee-a8c8-d887c6a5643d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_110d9500-10ef-4839-93d9-57394a45cbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_83299e16-e52d-4dee-a8c8-d887c6a5643d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_110d9500-10ef-4839-93d9-57394a45cbcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_48b73c04-d218-422a-8a2d-f9eb10319181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_83299e16-e52d-4dee-a8c8-d887c6a5643d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_48b73c04-d218-422a-8a2d-f9eb10319181" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8106d386-7787-4357-8f30-33a6db52ad51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_83299e16-e52d-4dee-a8c8-d887c6a5643d" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8106d386-7787-4357-8f30-33a6db52ad51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_eaa7f8d5-9929-4ac6-b6fa-c901555895dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_83299e16-e52d-4dee-a8c8-d887c6a5643d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_eaa7f8d5-9929-4ac6-b6fa-c901555895dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7edb0d6a-16c2-47c9-a0a5-72326af7c8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_eaa7f8d5-9929-4ac6-b6fa-c901555895dc" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7edb0d6a-16c2-47c9-a0a5-72326af7c8d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7edb0d6a-16c2-47c9-a0a5-72326af7c8d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7edb0d6a-16c2-47c9-a0a5-72326af7c8d3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7edb0d6a-16c2-47c9-a0a5-72326af7c8d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2ccd738d-940e-4d59-8351-09ada246754e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7edb0d6a-16c2-47c9-a0a5-72326af7c8d3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2ccd738d-940e-4d59-8351-09ada246754e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a8892385-03c5-4982-940a-8549cf174968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2ccd738d-940e-4d59-8351-09ada246754e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a8892385-03c5-4982-940a-8549cf174968" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9206e559-56d4-4f7d-9702-25d363a77080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_eaa7f8d5-9929-4ac6-b6fa-c901555895dc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9206e559-56d4-4f7d-9702-25d363a77080" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9206e559-56d4-4f7d-9702-25d363a77080_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9206e559-56d4-4f7d-9702-25d363a77080" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9206e559-56d4-4f7d-9702-25d363a77080_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a16f6d68-2e92-400a-8f99-aa982e952a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9206e559-56d4-4f7d-9702-25d363a77080" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a16f6d68-2e92-400a-8f99-aa982e952a9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_286b8337-9b65-4730-9895-6523627990cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a16f6d68-2e92-400a-8f99-aa982e952a9c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_286b8337-9b65-4730-9895-6523627990cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_d51df59c-9f9f-4bd0-b782-a83cae265ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_eaa7f8d5-9929-4ac6-b6fa-c901555895dc" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_d51df59c-9f9f-4bd0-b782-a83cae265ebe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d51df59c-9f9f-4bd0-b782-a83cae265ebe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d51df59c-9f9f-4bd0-b782-a83cae265ebe" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d51df59c-9f9f-4bd0-b782-a83cae265ebe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6267839a-68fa-4e74-bab3-67a554eaf7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d51df59c-9f9f-4bd0-b782-a83cae265ebe" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6267839a-68fa-4e74-bab3-67a554eaf7b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_8b1d7bfe-2004-4000-b9b0-429b0827aef0" xlink:href="evh-20220930.xsd#evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6267839a-68fa-4e74-bab3-67a554eaf7b4" xlink:to="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_8b1d7bfe-2004-4000-b9b0-429b0827aef0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_2f2697a9-a576-4a40-83f3-62a2fb4bda8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6267839a-68fa-4e74-bab3-67a554eaf7b4" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_2f2697a9-a576-4a40-83f3-62a2fb4bda8d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#RelatedPartiesAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="extended" id="ie5dbbbe57cc0474c9e5350a9a2b1a4e5_RelatedPartiesAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_a9fd31cd-9afb-476e-ae57-ecc412c7944c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7bd5fa85-48dd-45a7-af89-df272b1ec61e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a9fd31cd-9afb-476e-ae57-ecc412c7944c" xlink:to="loc_us-gaap_AssetsAbstract_7bd5fa85-48dd-45a7-af89-df272b1ec61e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_29383b11-a9b8-4215-a242-5136c9720808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_7bd5fa85-48dd-45a7-af89-df272b1ec61e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_29383b11-a9b8-4215-a242-5136c9720808" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_09338c7b-6b35-403a-ae1a-f05e4e21d310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_7bd5fa85-48dd-45a7-af89-df272b1ec61e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_09338c7b-6b35-403a-ae1a-f05e4e21d310" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_0508a50e-23d6-4232-8482-40c4c7beef3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_7bd5fa85-48dd-45a7-af89-df272b1ec61e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_0508a50e-23d6-4232-8482-40c4c7beef3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_2c0859d4-c5cc-4b92-b1ce-91a8a6507424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a9fd31cd-9afb-476e-ae57-ecc412c7944c" xlink:to="loc_us-gaap_LiabilitiesAbstract_2c0859d4-c5cc-4b92-b1ce-91a8a6507424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_04cbed4d-e675-44bf-a4a3-c82cf7452319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_2c0859d4-c5cc-4b92-b1ce-91a8a6507424" xlink:to="loc_us-gaap_AccountsPayableCurrent_04cbed4d-e675-44bf-a4a3-c82cf7452319" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0555ca19-5158-44ec-bbd2-1c492bf84540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_2c0859d4-c5cc-4b92-b1ce-91a8a6507424" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0555ca19-5158-44ec-bbd2-1c492bf84540" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_fe8c4225-ca4a-4aa6-8bcc-49f5fa807802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAbstract_2c0859d4-c5cc-4b92-b1ce-91a8a6507424" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_fe8c4225-ca4a-4aa6-8bcc-49f5fa807802" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bc2e3fe9-8265-4058-9a38-a674c14972da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a9fd31cd-9afb-476e-ae57-ecc412c7944c" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bc2e3fe9-8265-4058-9a38-a674c14972da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_232a64e5-7408-40c1-be9b-3f821cf87d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bc2e3fe9-8265-4058-9a38-a674c14972da" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_232a64e5-7408-40c1-be9b-3f821cf87d8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_232a64e5-7408-40c1-be9b-3f821cf87d8a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_232a64e5-7408-40c1-be9b-3f821cf87d8a" xlink:to="loc_us-gaap_RelatedPartyDomain_232a64e5-7408-40c1-be9b-3f821cf87d8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e2ea0210-a1b2-4ca2-8a58-c3a19a0a45bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_232a64e5-7408-40c1-be9b-3f821cf87d8a" xlink:to="loc_us-gaap_RelatedPartyDomain_e2ea0210-a1b2-4ca2-8a58-c3a19a0a45bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_91949642-1645-429b-a200-2bbd7e82a37d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_e2ea0210-a1b2-4ca2-8a58-c3a19a0a45bc" xlink:to="loc_srt_AffiliatedEntityMember_91949642-1645-429b-a200-2bbd7e82a37d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#RelatedPartiesRevenuesandExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="extended" id="ib4dff68df9924b89baa38cad7ce7a313_RelatedPartiesRevenuesandExpensesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_e65013c1-a4d0-40bd-bde0-a81df65e9e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_a97c9d7b-e504-47cb-a435-d26d6eefe050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e65013c1-a4d0-40bd-bde0-a81df65e9e41" xlink:to="loc_us-gaap_RevenueFromRelatedParties_a97c9d7b-e504-47cb-a435-d26d6eefe050" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_ccb82d6f-8e6a-4518-938b-4059a7d5ca19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e65013c1-a4d0-40bd-bde0-a81df65e9e41" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_ccb82d6f-8e6a-4518-938b-4059a7d5ca19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8a1396a3-022e-46b3-8718-0d8e58311946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e65013c1-a4d0-40bd-bde0-a81df65e9e41" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8a1396a3-022e-46b3-8718-0d8e58311946" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_956b998a-fbe2-4622-80b8-594f48a88ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8a1396a3-022e-46b3-8718-0d8e58311946" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_956b998a-fbe2-4622-80b8-594f48a88ae6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_956b998a-fbe2-4622-80b8-594f48a88ae6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_956b998a-fbe2-4622-80b8-594f48a88ae6" xlink:to="loc_us-gaap_RelatedPartyDomain_956b998a-fbe2-4622-80b8-594f48a88ae6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c487d3bf-f72e-422b-a6d2-a4ed1452a85d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_956b998a-fbe2-4622-80b8-594f48a88ae6" xlink:to="loc_us-gaap_RelatedPartyDomain_c487d3bf-f72e-422b-a6d2-a4ed1452a85d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_4bd1b21a-8c71-489a-8637-22da4e8467f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_c487d3bf-f72e-422b-a6d2-a4ed1452a85d" xlink:to="loc_srt_AffiliatedEntityMember_4bd1b21a-8c71-489a-8637-22da4e8467f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e5753930-d2bf-4ebe-aa61-d1e2b1943090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8a1396a3-022e-46b3-8718-0d8e58311946" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e5753930-d2bf-4ebe-aa61-d1e2b1943090" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e5753930-d2bf-4ebe-aa61-d1e2b1943090_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e5753930-d2bf-4ebe-aa61-d1e2b1943090" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e5753930-d2bf-4ebe-aa61-d1e2b1943090_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_412ed734-db89-462c-a838-3f5068ec854e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e5753930-d2bf-4ebe-aa61-d1e2b1943090" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_412ed734-db89-462c-a838-3f5068ec854e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_6f6bed09-dbcb-4203-b571-bf92114cb025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_412ed734-db89-462c-a838-3f5068ec854e" xlink:to="loc_us-gaap_CostOfSalesMember_6f6bed09-dbcb-4203-b571-bf92114cb025" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0d8f8233-3ee7-4e0c-b8d7-4a9e7f89d503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_412ed734-db89-462c-a838-3f5068ec854e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0d8f8233-3ee7-4e0c-b8d7-4a9e7f89d503" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#RepositioningandOtherChangesDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="extended" id="i8082d6c346b0454e9e1fa292c5e9c7dd_RepositioningandOtherChangesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_b1b80bc9-88fc-445b-ba00-6524e081d533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_61d06352-a494-49b0-878e-f3c1eee93a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b1b80bc9-88fc-445b-ba00-6524e081d533" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_61d06352-a494-49b0-878e-f3c1eee93a56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ba0a1299-4b08-468a-a013-3d54b7e0ae8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b1b80bc9-88fc-445b-ba00-6524e081d533" xlink:to="loc_us-gaap_RestructuringCharges_ba0a1299-4b08-468a-a013-3d54b7e0ae8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d21df77d-9ecd-4464-87de-f8177fe1a1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b1b80bc9-88fc-445b-ba00-6524e081d533" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d21df77d-9ecd-4464-87de-f8177fe1a1f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_251a52bd-012d-473e-8371-adbcdcb42591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d21df77d-9ecd-4464-87de-f8177fe1a1f5" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_251a52bd-012d-473e-8371-adbcdcb42591" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_251a52bd-012d-473e-8371-adbcdcb42591_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_251a52bd-012d-473e-8371-adbcdcb42591" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_251a52bd-012d-473e-8371-adbcdcb42591_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_5655775a-5f50-4644-a8e6-9d4fb5be7b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_251a52bd-012d-473e-8371-adbcdcb42591" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_5655775a-5f50-4644-a8e6-9d4fb5be7b30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_237250d9-d63e-4c22-9591-ffeb1f8c6cc6" xlink:href="evh-20220930.xsd#evh_EmployeeSeveranceAndTerminationBenefitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_5655775a-5f50-4644-a8e6-9d4fb5be7b30" xlink:to="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_237250d9-d63e-4c22-9591-ffeb1f8c6cc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_7020eaf0-0ea2-4afc-805b-cf8d87f8b0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_5655775a-5f50-4644-a8e6-9d4fb5be7b30" xlink:to="loc_us-gaap_FacilityClosingMember_7020eaf0-0ea2-4afc-805b-cf8d87f8b0b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProfessionalServicesRestructuringMember_73db5966-bad6-4a22-b934-3516651c0e7e" xlink:href="evh-20220930.xsd#evh_ProfessionalServicesRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_5655775a-5f50-4644-a8e6-9d4fb5be7b30" xlink:to="loc_evh_ProfessionalServicesRestructuringMember_73db5966-bad6-4a22-b934-3516651c0e7e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#SegmentReportingRevenuefromSegmentstoConsolidatedDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="extended" id="i31174902062c440b931754b26f37858f_SegmentReportingRevenuefromSegmentstoConsolidatedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_45bd3876-9636-4c3c-8542-661ccb097dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f976a10d-2ce8-4d8a-8df3-8c5d85de5a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_45bd3876-9636-4c3c-8542-661ccb097dd7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f976a10d-2ce8-4d8a-8df3-8c5d85de5a24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_3369dfbe-ffdf-440b-a67d-95f7c42a29c6" xlink:href="evh-20220930.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_45bd3876-9636-4c3c-8542-661ccb097dd7" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_3369dfbe-ffdf-440b-a67d-95f7c42a29c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_975a837d-c7a6-4a20-baf8-08cfb199eb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_45bd3876-9636-4c3c-8542-661ccb097dd7" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_975a837d-c7a6-4a20-baf8-08cfb199eb7b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_6590a645-f5a4-460b-9f73-c7c09a3671a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_975a837d-c7a6-4a20-baf8-08cfb199eb7b" xlink:to="loc_srt_ConsolidationItemsAxis_6590a645-f5a4-460b-9f73-c7c09a3671a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_6590a645-f5a4-460b-9f73-c7c09a3671a4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_6590a645-f5a4-460b-9f73-c7c09a3671a4" xlink:to="loc_srt_ConsolidationItemsDomain_6590a645-f5a4-460b-9f73-c7c09a3671a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_95f8ea34-e03e-43b8-9582-6d51b66cebfa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_6590a645-f5a4-460b-9f73-c7c09a3671a4" xlink:to="loc_srt_ConsolidationItemsDomain_95f8ea34-e03e-43b8-9582-6d51b66cebfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_0a6ae18b-0aea-446a-8102-d0b433433914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_95f8ea34-e03e-43b8-9582-6d51b66cebfa" xlink:to="loc_us-gaap_IntersegmentEliminationMember_0a6ae18b-0aea-446a-8102-d0b433433914" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_54c06458-9065-4b8c-8045-71d0af4e2a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_95f8ea34-e03e-43b8-9582-6d51b66cebfa" xlink:to="loc_us-gaap_OperatingSegmentsMember_54c06458-9065-4b8c-8045-71d0af4e2a78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_a9fde9d1-06a6-43b0-af90-22e1cabc2d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_95f8ea34-e03e-43b8-9582-6d51b66cebfa" xlink:to="loc_us-gaap_CorporateNonSegmentMember_a9fde9d1-06a6-43b0-af90-22e1cabc2d35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0f2695db-0025-4abe-9b53-d93b9bb8f441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_975a837d-c7a6-4a20-baf8-08cfb199eb7b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0f2695db-0025-4abe-9b53-d93b9bb8f441" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0f2695db-0025-4abe-9b53-d93b9bb8f441_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0f2695db-0025-4abe-9b53-d93b9bb8f441" xlink:to="loc_us-gaap_SegmentDomain_0f2695db-0025-4abe-9b53-d93b9bb8f441_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d01edc9a-6c20-4cbd-8111-b3f98259069b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0f2695db-0025-4abe-9b53-d93b9bb8f441" xlink:to="loc_us-gaap_SegmentDomain_d01edc9a-6c20-4cbd-8111-b3f98259069b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_0fee3a6e-d761-44fd-8eea-8153ecbf2370" xlink:href="evh-20220930.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d01edc9a-6c20-4cbd-8111-b3f98259069b" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_0fee3a6e-d761-44fd-8eea-8153ecbf2370" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_9bf86e12-0739-49c8-850e-a2a840485901" xlink:href="evh-20220930.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d01edc9a-6c20-4cbd-8111-b3f98259069b" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_9bf86e12-0739-49c8-850e-a2a840485901" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#ReservesforClaimsandPerformanceBasedArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="extended" id="ibdad6d8d398b4080a84077238a175f77_ReservesforClaimsandPerformanceBasedArrangementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_c1bc7d8e-bfb5-45bc-b071-a8568bf44030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_a9fb7e60-0f2e-4498-a03b-d3fc5b620fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_c1bc7d8e-bfb5-45bc-b071-a8568bf44030" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_a9fb7e60-0f2e-4498-a03b-d3fc5b620fec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_edee1b30-d38c-4bf5-82cf-86437e329513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_a9fb7e60-0f2e-4498-a03b-d3fc5b620fec" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_edee1b30-d38c-4bf5-82cf-86437e329513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_45efa560-be37-441c-92cf-105cad22a3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_a9fb7e60-0f2e-4498-a03b-d3fc5b620fec" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_45efa560-be37-441c-92cf-105cad22a3ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_567c328d-f675-498b-873e-661d76fe0a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_45efa560-be37-441c-92cf-105cad22a3ba" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_567c328d-f675-498b-873e-661d76fe0a8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_d1bc8b0f-d256-4787-aec7-de5095911f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_45efa560-be37-441c-92cf-105cad22a3ba" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_d1bc8b0f-d256-4787-aec7-de5095911f98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_c6a6dfa4-eabe-4327-b323-aa6ce1d614be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_45efa560-be37-441c-92cf-105cad22a3ba" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_c6a6dfa4-eabe-4327-b323-aa6ce1d614be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_ff7a3d75-0c3c-4682-ad51-19b84fcaca0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_a9fb7e60-0f2e-4498-a03b-d3fc5b620fec" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_ff7a3d75-0c3c-4682-ad51-19b84fcaca0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_1051fb8a-5ba5-4a3b-9cb5-ccd56d7342b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_ff7a3d75-0c3c-4682-ad51-19b84fcaca0a" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_1051fb8a-5ba5-4a3b-9cb5-ccd56d7342b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_06ff2927-bdaf-42cb-8b57-d4323ce1c55b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_ff7a3d75-0c3c-4682-ad51-19b84fcaca0a" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_06ff2927-bdaf-42cb-8b57-d4323ce1c55b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_dde597f5-c5d3-4889-acf9-7b1ed7dff93e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_ff7a3d75-0c3c-4682-ad51-19b84fcaca0a" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_dde597f5-c5d3-4889-acf9-7b1ed7dff93e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_06c999b1-b535-4fd3-b0b4-6595034e4058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_e254a628-3c49-433b-abf9-e73f5351181e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_c1bc7d8e-bfb5-45bc-b071-a8568bf44030" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_e254a628-3c49-433b-abf9-e73f5351181e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_559e3ab2-30b5-410b-b021-5d6af82df568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_e254a628-3c49-433b-abf9-e73f5351181e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_559e3ab2-30b5-410b-b021-5d6af82df568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_559e3ab2-30b5-410b-b021-5d6af82df568_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_559e3ab2-30b5-410b-b021-5d6af82df568" xlink:to="loc_us-gaap_SegmentDomain_559e3ab2-30b5-410b-b021-5d6af82df568_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f6025c51-ff05-4887-9c8c-282f6103b299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_559e3ab2-30b5-410b-b021-5d6af82df568" xlink:to="loc_us-gaap_SegmentDomain_f6025c51-ff05-4887-9c8c-282f6103b299" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_cfef1cc1-3157-4723-9f74-abf59717f476" xlink:href="evh-20220930.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f6025c51-ff05-4887-9c8c-282f6103b299" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_cfef1cc1-3157-4723-9f74-abf59717f476" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_0a233604-bcef-4118-adc6-48e4f191706a" xlink:href="evh-20220930.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_f6025c51-ff05-4887-9c8c-282f6103b299" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_0a233604-bcef-4118-adc6-48e4f191706a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.evolenthealth.com/role/SubsequentEventsDetails" xlink:type="extended" id="i8c47aae06db448a1b80b27b080414cb4_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_dc3a54f6-0ddd-4ef8-a660-316221dd95b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e11eb963-28d2-4a9d-bcd9-8543905279ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_dc3a54f6-0ddd-4ef8-a660-316221dd95b3" xlink:to="loc_us-gaap_Goodwill_e11eb963-28d2-4a9d-bcd9-8543905279ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_1d0d15fb-db24-4676-8e32-977abe818336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_dc3a54f6-0ddd-4ef8-a660-316221dd95b3" xlink:to="loc_us-gaap_SubsequentEventTable_1d0d15fb-db24-4676-8e32-977abe818336" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_70ba4e4f-b568-4141-a263-84ae97839289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1d0d15fb-db24-4676-8e32-977abe818336" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_70ba4e4f-b568-4141-a263-84ae97839289" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_70ba4e4f-b568-4141-a263-84ae97839289_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_70ba4e4f-b568-4141-a263-84ae97839289" xlink:to="loc_us-gaap_SegmentDomain_70ba4e4f-b568-4141-a263-84ae97839289_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0b985185-3677-41a4-b9d7-9baa19618e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_70ba4e4f-b568-4141-a263-84ae97839289" xlink:to="loc_us-gaap_SegmentDomain_0b985185-3677-41a4-b9d7-9baa19618e33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_c1b827af-6482-44e9-acba-2f2bc11b2641" xlink:href="evh-20220930.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0b985185-3677-41a4-b9d7-9baa19618e33" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_c1b827af-6482-44e9-acba-2f2bc11b2641" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>evh-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b69e33fa-4fec-4147-99e6-af63e8e14083,g:752cd8d8-fa1c-4165-8528-47511781866b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_bcbc9f35-f3be-46ab-87a3-7624c12e23c3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_e6ed1e46-74db-4fd1-ae21-4d366c9262e7_terseLabel_en-US" xlink:label="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Domain]</link:label>
    <link:label id="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_label_en-US" xlink:label="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Domain]</link:label>
    <link:label id="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_documentation_en-US" xlink:label="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" xlink:href="evh-20220930.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" xlink:to="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f0effbfb-4164-4b7d-a55d-7ab78268844d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a35dd5db-232c-4746-a427-d33da4d96de4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Minimum Lease Commitments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0afa2e19-00a5-40b0-bb1e-c001137c99d0_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_942c1b7a-6d82-4eca-b6df-963b1d7efbb8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash And Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_1dc7d055-fb8c-4915-98a6-483e3d5475fb_verboseLabel_en-US" xlink:label="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue related to services agreements</link:label>
    <link:label id="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_label_en-US" xlink:label="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Services Agreement</link:label>
    <link:label id="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_documentation_en-US" xlink:label="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Services Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" xlink:href="evh-20220930.xsd#evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" xlink:to="lab_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_c610d66d-7afa-44c3-9721-30ff0e3f3a30_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for credit losses</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_d75ab6d9-9d18-4f1a-a5f1-390eeb739cd1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_9fcc74fa-8ce2-40a8-a027-d8172c87294d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_04d11dc4-9815-47c1-a024-be5d07ab5fd6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_6845946c-8e9f-44e3-ab40-ca0e9fdd7d88_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:to="lab_us-gaap_AccountsReceivableNoncurrentPastDueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_c462ab99-d695-4660-9579-4bec2ae9dfb7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_ce8d8d15-c0cd-47fd-871e-50bbcdb6bd91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity in Claims Reserves</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_2c4657f8-5117-477f-b611-9db37664914a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_46b21113-22f5-4afc-965f-820eb0ac0a24_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_9870446c-a666-4d0e-9d8f-312e4ee235f6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_6abe2ff3-e50b-4c22-b350-83b5eda73cfc_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_33a652db-4ec5-4c3d-9d63-3edf6d2eaa98_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_187a4f42-9810-4602-9cce-713b2be722e7_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_ee32af4c-09e7-464f-be13-c0fa21b6e8bd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_7dc407fc-5f9a-4610-846d-8b8c41f81826_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_428f15d9-5148-4e22-bc2e-9e59b580b9dc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_476b255f-a7f7-47d3-bc7b-26cb952a1b7b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_71aeb356-4a08-4dad-a127-2f6c3124cedb_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_f68351a3-2fd5-4241-9427-09029061ac8c_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_9819a02f-0800-4e78-95f0-5bf707ae8fa4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from performed obligations</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_230ce3be-1c10-4561-8dd0-9aafc1691d33_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_1ac9e35f-dea8-4022-8d3c-323a5b5d750d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from transfer of membership and release of Passport escrow</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain_751a73db-885c-46d7-964d-2af01864870d_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Period Past Due [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Aging [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:to="lab_us-gaap_FinancingReceivablesPeriodPastDueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_a0066052-e415-4a0c-b242-083e34babe57_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_be04e3a9-71d9-4c10-8c48-79feeb0bf95a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_b9a296b0-1399-4bd1-b0e2-ea6bc7eb57bb_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_73bcbd40-bca4-4e29-8255-20adfeefd2d1_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_c88cd539-5a2a-454e-8dbc-ba63667709a6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1b4db592-b08b-4bd9-8c6d-d8361e8eda1e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_ddbf1fbf-0781-4bda-a852-7679d6f5dfb7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested, net of shares withheld for taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_676cb207-bc6e-4d5d-9c4f-c46a0cd4cdc0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_826889a2-6dfb-4ee5-acd0-f9525f2d093c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d99673d4-7430-4aa4-be98-edfce7dc26ec_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_81c43039-6d31-4242-910f-4b18dab80251_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange/conversion</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_f3640033-3bf5-4aa1-8a71-200ff7626fa0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Purchase Price</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_422b90b7-b06c-407a-b71f-14955e70e6f1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_497147d8-f22e-421d-8c0c-f845ade959c1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current operating cash inflows (outflows), net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6e4fa864-18ec-4fa7-b074-55cc05f95aa8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_ca4fa976-64f6-449b-91a1-d2d26bc5a133_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3cffc04c-2f5a-4d31-beb7-c75e7e18cede_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_6d4398c8-000c-4b46-8d00-0f55ec252bf9_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_7acb663a-f5a7-4953-9eff-37b57b259eda_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_8dfe3e49-a502-4f2f-b719-cb70972ed4e0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets acquired:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c84c5728-8ac6-4b0e-bb1d-f7b88221a500_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f9123075-16bc-4dd3-ba62-0e77f78300da_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of antidilutive securities excluded from the calculation of earning per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_cff2f976-4869-4e41-9852-51a3e4b9ffa2_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect Period Of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_3a967b19-51d6-4214-89f7-0d092a2cf7ab_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows provided by operating activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Operating Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_0b0e6e9d-e92a-4c4c-b8c1-1e6a6698c77a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_ba830734-48a4-4c5e-8d56-9b9aba9d57ac_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_e32f84b7-7a52-4722-9456-30c3f54e9b8b_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_9b728540-f028-4a4c-b9c6-ccf72dbe8a58_terseLabel_en-US" xlink:label="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_label_en-US" xlink:label="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations</link:label>
    <link:label id="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_documentation_en-US" xlink:label="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:href="evh-20220930.xsd#evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:to="lab_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_7f3f2e67-a4b5-4b76-b36b-496dc52bc68d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_34ccc228-9503-4332-b38c-5b835f45aec4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_3be29e87-c6a3-4598-8792-6b61fae2b638_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_34d7db15-6396-40aa-99a3-5f150bc2cb7e_terseLabel_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting interest percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_label_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Voting Interest Percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentVotingInterestPercentage_documentation_en-US" xlink:label="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Voting Interest Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:href="evh-20220930.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:to="lab_evh_EquityMethodInvestmentVotingInterestPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_0120c9e9-3bf9-4c31-b29e-c3dde0755bfe_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive trading days, minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_cfce5cb2-5072-4435-815c-18a8859bca8f_verboseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:to="lab_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_d641e45d-34dd-48c9-b2f0-17dda94e5472_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized computer software, amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAmortization1_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAmortization1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_344be9b1-638c-4fb0-ba2d-e362b5619046_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_87c50365-6fa5-4a59-b268-a23ed4ae6266_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0633324b-6f0f-49a0-86cb-d2f947fcaaf1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_d8aee2bf-3405-40f1-9f49-5bc06ca804e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost; 1,537,582 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_1609a467-1348-47eb-911e-3d9e836678a4_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_35181f1e-7adc-4736-84c1-f6bad6d0f6aa_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosures</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_2f143fb1-e68d-4349-a3c4-c2e92ce59b26_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_d4fc2c15-483a-478e-b1f3-7f95ee02ce2d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_a382f91e-de75-40df-842e-28c684585afa_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_470b6d7b-4a9c-4090-8685-ef89a5c04974_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNet_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNet" xlink:to="lab_us-gaap_CapitalizedContractCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_aba6d600-f955-4e00-8a97-ffae88e5cf4c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_ce53e7b7-12de-4ada-b4be-977cc842b9a1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_9bdfe96e-3472-4084-b89e-8ac20faebe57_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_c35d515d-e06a-4440-bbd0-d6852e772c70_terseLabel_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial and other</link:label>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_label_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Other Customers [Member]</link:label>
    <link:label id="lab_evh_CommercialAndOtherCustomersMember_documentation_en-US" xlink:label="lab_evh_CommercialAndOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial And Other Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember" xlink:href="evh-20220930.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CommercialAndOtherCustomersMember" xlink:to="lab_evh_CommercialAndOtherCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_bdb8c256-4175-4ea1-83be-18d728f64d3c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f0f342f1-ad47-4335-91cc-ad225cfab885_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment_edd846bf-3845-4397-9c11-77103ac44dfd_negatedLabel_en-US" xlink:label="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment_label_en-US" xlink:label="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Including One-time Adjustment</link:label>
    <link:label id="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment_documentation_en-US" xlink:label="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Including One-time Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:href="evh-20220930.xsd#evh_SharebasedCompensationIncludingOnetimeAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:to="lab_evh_SharebasedCompensationIncludingOnetimeAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_1ca17e65-df01-4b97-afec-5dad6c80a3a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_c4c4d7b4-358c-4107-ab96-48fda3390e56_terseLabel_en-US" xlink:label="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="evh-20220930.xsd#evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_26971de6-ccd2-458b-ba3f-ddea3de04193_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of taxes, related to:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PremiumsRevenueMember_5f623555-e1df-4849-a2ca-3c5ecc9909b6_terseLabel_en-US" xlink:label="lab_evh_PremiumsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums</link:label>
    <link:label id="lab_evh_PremiumsRevenueMember_label_en-US" xlink:label="lab_evh_PremiumsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Revenue [Member]</link:label>
    <link:label id="lab_evh_PremiumsRevenueMember_documentation_en-US" xlink:label="lab_evh_PremiumsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember" xlink:href="evh-20220930.xsd#evh_PremiumsRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PremiumsRevenueMember" xlink:to="lab_evh_PremiumsRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_b579c0ac-dfbb-4c1a-a278-9c2605378c91_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NewNotesMember_6ecaf144-6642-4954-aeb3-d4379c26bd9a_terseLabel_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes</link:label>
    <link:label id="lab_evh_NewNotesMember_label_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes [Member]</link:label>
    <link:label id="lab_evh_NewNotesMember_documentation_en-US" xlink:label="lab_evh_NewNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember" xlink:href="evh-20220930.xsd#evh_NewNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NewNotesMember" xlink:to="lab_evh_NewNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_3203e49e-6b75-41f2-b1e1-d809021f1dc9_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_250eecd5-5b44-4e88-8889-0f1b1930805e_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d7dc8402-7063-49c3-92b0-6288ee0131aa_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_5431d510-e0ba-43ac-b2ba-b168fadff787_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability - current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_af801499-e96d-4f2e-ae8c-ccc46e7c69f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_491b6b7d-0ebb-4689-b578-d7d5d52770f3_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_1923b2bf-5603-4bae-b950-f0b3b3f1ed71_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_7a8474d1-662d-4022-aded-db886927d01b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefits and Unpaid Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_f0f233b8-fb7b-49ec-8977-5ec1813fd05c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_e41572bf-8cb7-49c1-9e84-ff7a746c2a9a_terseLabel_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of receivables, current</link:label>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_label_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Not Past Due</link:label>
    <link:label id="lab_evh_FinancingReceivablePercentNotPastDue_documentation_en-US" xlink:label="lab_evh_FinancingReceivablePercentNotPastDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Not Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue" xlink:href="evh-20220930.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FinancingReceivablePercentNotPastDue" xlink:to="lab_evh_FinancingReceivablePercentNotPastDue" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_9afabbe8-56a4-463b-96af-4e8701c171d1_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty after first anniversary of closing date but prior to second anniversary of closing date (in percent)</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_label_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Two, Percent</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_documentation_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Two, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:href="evh-20220930.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:to="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_b5999c45-ea1c-4756-b622-680b01810c3a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Held-to-Maturity Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:to="lab_us-gaap_PaymentsToAcquireHeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_6b7a1647-5236-41a9-99b7-1b812fa2c99a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_982f1499-2685-48d8-8a7b-280b63233ebe_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_52d0b563-f87a-4272-b745-15d28f3630d3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_eb17ec40-4738-46d3-bf71-c2b63a2640a5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashFlowLesseeAbstract_92841b49-381a-4025-9834-6201d32ece1d_terseLabel_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effects of Leases</link:label>
    <link:label id="lab_evh_CashFlowLesseeAbstract_label_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:label id="lab_evh_CashFlowLesseeAbstract_documentation_en-US" xlink:label="lab_evh_CashFlowLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFlowLesseeAbstract" xlink:href="evh-20220930.xsd#evh_CashFlowLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashFlowLesseeAbstract" xlink:to="lab_evh_CashFlowLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfOffsetPolicyPolicyTextBlock_21e07afb-5aa8-48aa-97b6-c572d6e4c95a_terseLabel_en-US" xlink:label="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset</link:label>
    <link:label id="lab_evh_RightOfOffsetPolicyPolicyTextBlock_label_en-US" xlink:label="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Policy [Policy Text Block]</link:label>
    <link:label id="lab_evh_RightOfOffsetPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:href="evh-20220930.xsd#evh_RightOfOffsetPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:to="lab_evh_RightOfOffsetPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_2d20db22-e08b-42fc-bfaa-bb58f1dbeebf_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b1d0ceb4-dc8b-410f-a6ab-3ec2c68462be_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8d32d4f3-9a27-40dc-9daa-e234c967112d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_e13a668e-952f-462c-bd5d-28466cf714b6_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ba0598a9-2ca5-4f09-aea7-82858b2ceae8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Provided by (Used In) Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_5439387f-a633-4e15-9d65-e6bcfa0b7fe5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_65010523-7b16-4d7e-a605-f2d32e286283_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_1e91a245-5742-4d6e-9ea6-3de87574b1b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior year to date period</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ShareholderClassActionComplaintMember_b3065ef5-04e0-4736-8014-ebcc9daa9afd_terseLabel_en-US" xlink:label="lab_evh_ShareholderClassActionComplaintMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Class Action Complaint</link:label>
    <link:label id="lab_evh_ShareholderClassActionComplaintMember_label_en-US" xlink:label="lab_evh_ShareholderClassActionComplaintMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Class Action Complaint [Member]</link:label>
    <link:label id="lab_evh_ShareholderClassActionComplaintMember_documentation_en-US" xlink:label="lab_evh_ShareholderClassActionComplaintMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Class Action Complaint</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderClassActionComplaintMember" xlink:href="evh-20220930.xsd#evh_ShareholderClassActionComplaintMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ShareholderClassActionComplaintMember" xlink:to="lab_evh_ShareholderClassActionComplaintMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_718231ed-f099-4d3b-982b-6e28413d4bcc_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e4a012b8-8912-4f6f-9d90-f8cf20eb74d1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_d8e50446-937d-4712-9d96-84de823ff346_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1552f277-d31d-46ad-bed7-9ec18131aad2_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_91541100-4165-4d1b-a390-253769ed1f2d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_57e1483e-472f-4ef9-a187-f88eb6817390_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_b28c783c-671f-4696-a6fe-50d2cb36510c_terseLabel_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of tax savings to be paid</link:label>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_label_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivables Agreement, Percent of Tax Savings To Be Paid</link:label>
    <link:label id="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_documentation_en-US" xlink:label="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivables Agreement, Percent of Tax Savings To Be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" xlink:href="evh-20220930.xsd#evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" xlink:to="lab_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_5f587bc4-0288-4ca4-8159-dbc90346dbf6_negatedTerseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Capitalized Contract Cost, Net</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Capitalized Contract Cost, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:href="evh-20220930.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:to="lab_evh_IncreaseDecreaseInCapitalizedContractCostNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis_ee43befe-2ee9-4431-b1ac-2484c6d2ba54_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Period Past Due [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Asset, Aging [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:to="lab_us-gaap_FinancingReceivablesPeriodPastDueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_c9d8f968-9bef-438f-ba52-3964aed9d10b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_502e7f87-bf9c-4ec7-ab1f-6c5bfd33c70f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_aacdef06-3c08-4e8c-b6b0-92276837b48e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_6cdf2b86-fd35-417a-975e-6efa7345f9e4_negatedLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_50e1ac9d-e7ab-46f2-9d65-9d859c12c6d3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return of equity method investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_ffc7ef4b-eddb-426c-aa54-58cf757ea4ea_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_5833d516-d3e0-44a1-ab95-04ffa8685732_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_469cab5e-e039-4af6-a5a9-850c89e5aba1_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_7415f9ab-3d57-4f1f-887c-8fe09c9e4dce_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_e6c8d0b7-c3c1-4a90-9103-b58e80078ad2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_8c8a2284-e1eb-46cf-899b-b0fbb96c63c5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in internal-use software and purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Other Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireOtherProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_645e09df-b885-402e-a156-d0d80a79dc8d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a4d21581-814d-42b6-9edf-fa8ef4d026d3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_d64c112a-555a-4421-8363-3721485e42da_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity interest issued or issuable, number of shares (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_91368fe3-b5e4-4b14-80b9-a31227676f5c_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_189f30c6-27cb-47d5-a0a7-bd79cf2cb25b_verboseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_61af3537-355e-4f93-bf13-942705829395_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty prior to first anniversary of closing date (in percent)</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_label_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period One, Percent</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_documentation_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period One, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:href="evh-20220930.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:to="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_29d3bf37-6098-438b-b9ee-f44773681a18_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_88155049-3cde-483e-aa37-51c9b2e3df3d_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_f73a657c-9a96-4587-8629-3d15e93b25cf_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contract with Customer, Asset and Liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_1784025e-3105-41a5-9558-fa127d12d797_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_26b8371a-64d5-42dd-8366-67b647e38cb0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_61178bfb-6a69-451c-8a07-bacf8beb3c96_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_2356e4e8-8c32-40af-ac7f-41b1f039e99f_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total claims paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_f5075af0-8569-4c10-b73d-73fc6f5112b2_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, sale price as a percentage of conversion price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_5919282e-7236-4e94-bf3f-07ef8144a3e3_verboseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, sale price as a percentage of conversion price (at least)</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_5551420e-fb7e-4984-9026-16ab0a892061_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge-offs</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_f4e75e4c-8e48-4612-a801-284aa83de99b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_2160bda4-a8c3-4c7b-a1ed-84b0a2e531aa_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_bc80554e-a11a-4a4d-a325-67930261accb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5be04b01-b532-45a8-bdc3-348753614c84_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_6f47774d-0123-4117-a7ab-9d32291d4fd6_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAccountsReceivableMember" xlink:to="lab_us-gaap_TradeAccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NumberOfSourcesOfRevenue_d946cfb0-e25d-41f5-bc07-44dd1cdb8c19_terseLabel_en-US" xlink:label="lab_evh_NumberOfSourcesOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of sources of revenue</link:label>
    <link:label id="lab_evh_NumberOfSourcesOfRevenue_label_en-US" xlink:label="lab_evh_NumberOfSourcesOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Sources Of Revenue</link:label>
    <link:label id="lab_evh_NumberOfSourcesOfRevenue_documentation_en-US" xlink:label="lab_evh_NumberOfSourcesOfRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Sources Of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfSourcesOfRevenue" xlink:href="evh-20220930.xsd#evh_NumberOfSourcesOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NumberOfSourcesOfRevenue" xlink:to="lab_evh_NumberOfSourcesOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_016421d3-a8f9-47d0-be8d-ea3740d80024_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_451c71a5-adfb-44f7-aff3-3a9da9e20751_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b58ae4da-6514-48c5-9a9f-297b870ce889_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_6455d177-4877-44b0-8cf4-75874e62efa1_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_fc1d456d-6d93-46e3-be46-b817d3669ec0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_717ffd8b-5104-44de-b58b-40c75d6be944_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_ea9dcd18-36c3-4e6f-b530-25cabfed4688_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_538193db-93e8-436b-9369-66de582e2eef_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_9454f545-a89e-40b3-b142-46017f8b47dc_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_3307094c-80a4-4662-a615-3b116bf54379_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_b504b170-82d5-431f-8f1a-cc2b14585b31_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_e1ebb069-b720-41b7-b4bf-97a9e017e60c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_998422c0-4222-40ee-a131-683922ad6e7e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentTextBlock_901e20cd-5275-462f-9d63-7f20e77de730_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss, Financial Instrument [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossFinancialInstrumentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_December312023Member_f6900b94-13db-4a21-a5be-18f794edc1b6_terseLabel_en-US" xlink:label="lab_evh_December312023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2023</link:label>
    <link:label id="lab_evh_December312023Member_label_en-US" xlink:label="lab_evh_December312023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2023 [Member]</link:label>
    <link:label id="lab_evh_December312023Member_documentation_en-US" xlink:label="lab_evh_December312023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312023Member" xlink:href="evh-20220930.xsd#evh_December312023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_December312023Member" xlink:to="lab_evh_December312023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e7fed459-641c-47c7-a136-5ff36bbb82f1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2589d65c-5866-403e-9273-d57630ab583a_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a39bddbb-2152-4def-ae4b-0241db543331_netLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_5cbea3e3-94cc-43c7-a6f1-4e9e0891475b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_34407b5c-76d7-4166-8f5d-f45a842d6330_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_5f89838b-5885-40a6-b6ac-5d9db3bd0027_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect Period Of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_2223e67e-f220-431a-a4e7-5ec7ec2ef141_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_InitialTermLoanFacilityMember_72a87aae-5ca6-497f-8c39-cceb1dd6ee18_terseLabel_en-US" xlink:label="lab_evh_InitialTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term Loan Facility</link:label>
    <link:label id="lab_evh_InitialTermLoanFacilityMember_label_en-US" xlink:label="lab_evh_InitialTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term Loan Facility [Member]</link:label>
    <link:label id="lab_evh_InitialTermLoanFacilityMember_documentation_en-US" xlink:label="lab_evh_InitialTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_InitialTermLoanFacilityMember" xlink:href="evh-20220930.xsd#evh_InitialTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_InitialTermLoanFacilityMember" xlink:to="lab_evh_InitialTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_26c3d976-a9ee-4585-9419-ad172359520e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of the debt discount and the issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_b1842549-f355-45fa-8072-ec5af827b4cb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_679e5096-32f8-49fb-91c6-cdac7daa7c79_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityReserveEstimatePolicy_aa542a0d-d033-4952-895a-7b1473147eb0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for Claims and Performance-based Arrangements</link:label>
    <link:label id="lab_us-gaap_LiabilityReserveEstimatePolicy_label_en-US" xlink:label="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Reserve Estimate, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityReserveEstimatePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityReserveEstimatePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityReserveEstimatePolicy" xlink:to="lab_us-gaap_LiabilityReserveEstimatePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_3c87953b-ec77-45da-b3fc-de675a977155_terseLabel_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, net, debt component</link:label>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_label_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net, Debt Component</link:label>
    <link:label id="lab_evh_DebtIssuanceCostsNetDebtComponent_documentation_en-US" xlink:label="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net, Debt Component</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent" xlink:href="evh-20220930.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtIssuanceCostsNetDebtComponent" xlink:to="lab_evh_DebtIssuanceCostsNetDebtComponent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EquityComponentOfLongTermDebtMember_81050f70-a1b5-4062-80aa-0683efd3f4f8_terseLabel_en-US" xlink:label="lab_evh_EquityComponentOfLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component of Long Term Debt</link:label>
    <link:label id="lab_evh_EquityComponentOfLongTermDebtMember_label_en-US" xlink:label="lab_evh_EquityComponentOfLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component of Long Term Debt [Member]</link:label>
    <link:label id="lab_evh_EquityComponentOfLongTermDebtMember_documentation_en-US" xlink:label="lab_evh_EquityComponentOfLongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component of Long Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember" xlink:href="evh-20220930.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EquityComponentOfLongTermDebtMember" xlink:to="lab_evh_EquityComponentOfLongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_1379e9da-651b-4dfb-b448-d58e9426821e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e44e77e9-4b79-49ee-b028-03990c87c76a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_4d8326d8-0a11-48d9-adc2-431d200114b6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0e98e1e4-3fa9-4d90-b8ba-7dc2da3f4bf8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_559fa51a-5ee6-4869-b1b0-209cfa5e2c2e_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment/repayment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_f5008663-59b8-4c71-90d3-12113b990574_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment/repayment of debt, net</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_143328ac-47e4-43de-a964-b647b350c18c_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment/repayment of debt, net</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_9e88dde4-ab31-4f8f-abe5-699b531360b3_terseLabel_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows used in investing activities</link:label>
    <link:label id="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Provided by (Used in) Investing Activities, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:to="lab_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_7ef61cc3-89eb-45a7-b445-18a5fc3e277a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_22918809-fa66-4704-bfb0-ba65809b4b45_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets Details</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_e8ba32dc-bb5d-4344-a2dc-6208778aca11_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer hardware</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_ba88729f-0850-46a6-8c79-3d5171ecc79f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for asset acquisitions and business combinations</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_efe88c79-140c-4ae5-b002-31345303fb84_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_3c82e4c3-4a6b-42d3-8d2b-d2204800bb37_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss on extinguishment of debt, including fees paid to lenders</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c1ea0346-b32e-4c1f-b284-742c28222812_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_2e1685dd-1c34-451e-89fe-0e9091be06db_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_5eaed554-505b-4af2-852d-ad7d900294db_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestments_26d1993c-faa2-431b-8435-62e085d320f9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestments_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestments" xlink:to="lab_us-gaap_RestrictedCashAndInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4e1a31d3-8fd9-448b-826c-cca6ea16dbf5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_7ebe830f-6404-47ef-9bb8-e92da58184fa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceAbstract_33c3a0b7-5d76-44c2-99f6-2834fafc4f59_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:label id="lab_us-gaap_InsuranceAbstract_label_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceAbstract" xlink:to="lab_us-gaap_InsuranceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_bf66cedc-292d-4c3e-b991-8b59fc38aa59_verboseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal-use software development costs</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_81954013-8bd4-4df5-bb5a-d4a57d828575_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_004715d5-e9c3-4fee-bad4-b060f5650b04_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c004b180-1e70-4f7d-a946-30fba8b99460_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_01147842-2a11-481c-a66d-3599bc21474b_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_d93c5cf9-5ee1-4051-9ae1-fbdf95f1f2d5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_e36cc544-4ba6-465a-90f2-75211641b0e1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units vested, net of shares withheld for taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_a861e3e5-2ce3-4ca3-8cb4-72aec3c6491b_terseLabel_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations</link:label>
    <link:label id="lab_us-gaap_IntersegmentEliminationMember_label_en-US" xlink:label="lab_us-gaap_IntersegmentEliminationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intersegment Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntersegmentEliminationMember" xlink:to="lab_us-gaap_IntersegmentEliminationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_c48833b0-9ad8-4027-b450-959d75775d1d_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_f18d770d-bef5-475f-a800-04c0c49dbb81_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_56e54ff2-c260-4fd8-b026-f1eedaf836c6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion rate per $ 1000 principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInTaxReceivableAgreement_1b5c7937-450f-465c-800a-49c1a27bdc56_terseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInTaxReceivableAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in tax receivable agreement liability</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInTaxReceivableAgreement_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInTaxReceivableAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Tax Receivable Agreement</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInTaxReceivableAgreement_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInTaxReceivableAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Tax Receivable Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInTaxReceivableAgreement" xlink:href="evh-20220930.xsd#evh_IncreaseDecreaseInTaxReceivableAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInTaxReceivableAgreement" xlink:to="lab_evh_IncreaseDecreaseInTaxReceivableAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0e16f639-def1-4d19-81bb-4deb7a675663_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_e6884709-3321-4955-8aa8-a8da696622b2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2e93631e-abd0-47fa-9e20-c5c70e131ea1_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d6267b82-18ea-46b6-9e9b-a99ea71a75d3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_UPMCResellerAgreementMember_cfe7b2a5-e739-4584-8c29-21f336ee65a3_terseLabel_en-US" xlink:label="lab_evh_UPMCResellerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPMC Reseller Agreement</link:label>
    <link:label id="lab_evh_UPMCResellerAgreementMember_label_en-US" xlink:label="lab_evh_UPMCResellerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPMC Reseller Agreement [Member]</link:label>
    <link:label id="lab_evh_UPMCResellerAgreementMember_documentation_en-US" xlink:label="lab_evh_UPMCResellerAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPMC Reseller Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UPMCResellerAgreementMember" xlink:href="evh-20220930.xsd#evh_UPMCResellerAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_UPMCResellerAgreementMember" xlink:to="lab_evh_UPMCResellerAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_f77a64d7-60d3-4236-b760-cd832529fe6c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3adba3dc-b609-435e-aff3-956a23fcf818_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_14df7e7b-47ed-4730-9fd1-adb3c54c3b7c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_7cc2127c-7165-4425-8e62-e9803cf82800_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_406090d6-1e61-4505-8d65-5e1e08219d9d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c4e4fbe5-ea1a-4025-bb6f-fdf679be3cf8_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_44666df9-ef8b-4723-a8f4-4ed1ed5f32fb_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_741990ec-f3b0-4c4f-87d5-c9271a9dbcf8_terseLabel_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_label_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_documentation_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:href="evh-20220930.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:to="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MedicareCustomersMember_62bc2359-3964-4fb5-8757-fa24a87c1a63_terseLabel_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_evh_MedicareCustomersMember_label_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Customers [Member]</link:label>
    <link:label id="lab_evh_MedicareCustomersMember_documentation_en-US" xlink:label="lab_evh_MedicareCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember" xlink:href="evh-20220930.xsd#evh_MedicareCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MedicareCustomersMember" xlink:to="lab_evh_MedicareCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_06af01af-35cd-4215-9b52-94ab7880d1a6_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_e8ef1e57-d551-4bf0-9da0-b336b87b8005_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_8c4c533b-bc2d-4c80-a4b9-d76e8b8cd19b_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_fa33905d-9c76-43e1-baa9-41363ce8c5e7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_87574640-31b9-432c-aac6-bf30b3a8f676_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_ca42cb63-f618-42e6-be26-5ba63fc6cab9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted funds</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_dab8f3de-5060-4db6-884f-66fac6dd3a4a_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3688f6cd-363e-4679-84dd-4f1f6dfc084c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_bb7ab193-8677-4cf2-8e41-77e2f4905dd2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_cd9796d1-17fd-419b-9566-862fb388c0f3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_December312024Member_f9ea8b4e-91ec-4b60-acf3-a8239db403f3_terseLabel_en-US" xlink:label="lab_evh_December312024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2024</link:label>
    <link:label id="lab_evh_December312024Member_label_en-US" xlink:label="lab_evh_December312024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2024 [Member]</link:label>
    <link:label id="lab_evh_December312024Member_documentation_en-US" xlink:label="lab_evh_December312024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312024Member" xlink:href="evh-20220930.xsd#evh_December312024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_December312024Member" xlink:to="lab_evh_December312024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_ffb6a4f0-7f0e-4f14-bb5a-227c0c0f64a7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_d987b6c3-5b34-43b9-89cb-415103a4441d_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Estimates and Assumptions</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_d3ee618f-e5b0-495d-b490-d687bd3e1937_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transactions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_acc44d87-1990-41f6-b130-f807a413f851_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NumberOfCustomers_7d8bfe67-1ee1-4851-b682-181e783b0111_terseLabel_en-US" xlink:label="lab_evh_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of customers</link:label>
    <link:label id="lab_evh_NumberOfCustomers_label_en-US" xlink:label="lab_evh_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Customers</link:label>
    <link:label id="lab_evh_NumberOfCustomers_documentation_en-US" xlink:label="lab_evh_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfCustomers" xlink:href="evh-20220930.xsd#evh_NumberOfCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NumberOfCustomers" xlink:to="lab_evh_NumberOfCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_e89c4a53-69b5-4472-83aa-2ac5ef5231e9_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_17a63d9e-958c-4e31-b0cf-8ca741805a4c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ed274764-e693-42f7-b5a2-b79e806aa7fe_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_ccef5c6f-74bc-437c-b473-1754d31dac48_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_b7d637da-926b-496d-af75-ce2d0da86881_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (in percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_198fc0d5-e15b-4114-924d-de84191afbee_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_3e45140f-e772-4ad8-a4dc-8d205c71492a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortizationPeriod_3c417411-0509-4af5-9773-3e92148893a1_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization period</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortizationPeriod_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:to="lab_us-gaap_CapitalizedContractCostAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_88a336ed-5c81-4ce0-bcec-5d43e264c68a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Costs Incurred through December 31, 2021</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_d494bebf-7e63-4a8d-ad73-a7b919061e64_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_e34c4738-9288-4d69-91e6-d2704bae35d6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_a2375399-c068-4924-8397-13aeeb440ac4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_d9666251-e816-4d90-a3ac-180c28983bbb_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_5b229571-a6e6-4883-a221-b07f2149cd85_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_d63c3dfc-a564-418e-9a56-fd061a5a902c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_ca41455a-1771-4fd0-9e7c-c22f1cde4796_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Credit Agreement including settlement of warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="lab_us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_0bb34b78-d4b0-4698-8cfd-4ac8fec1e519_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_22a4074b-f70f-46be-99b7-45482c9d60be_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_fd87e8ad-9f25-46f2-811a-49c28e20c33a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants or rights (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_b6abc67d-0233-4388-952b-7b0097998c04_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_909fd15f-ae45-4274-ab15-274b72db4477_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_651b861a-e399-4a99-878e-512c3061fd49_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_cd5c1a8a-6e4f-4f56-a80b-0b624632f4e2_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic income (loss) per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_292475dd-98f9-4b3d-9dc6-b240f6c7c2e6_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty on or after third anniversary of closing date (in percent)</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_label_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Four, Percent</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_documentation_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Four, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:href="evh-20220930.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:to="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_3fc7bcfb-6655-484a-b595-96b554859bf2_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty after second anniversary of closing date but prior to third anniversary of closing date (in percent)</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_label_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Three, Percent</link:label>
    <link:label id="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_documentation_en-US" xlink:label="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Penalty, Period Three, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:href="evh-20220930.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:to="lab_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d2c67c46-1496-47ea-9535-875794fe8623_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_f270e16c-df54-4add-8cb5-aa5096a18039_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9e16f375-793e-44bf-af05-c35feca76c0c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_67d33875-2d62-4d53-be57-93e343416b9b_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_bece483b-9046-4a31-8ddf-b8f4406ee359_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceDisclosureTextBlock_f4c4efce-9ab7-4662-943e-2b786a963ba2_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves for Claims and Performance-Based Arrangements</link:label>
    <link:label id="lab_us-gaap_InsuranceDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceDisclosureTextBlock" xlink:to="lab_us-gaap_InsuranceDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_ed0ee8fd-8e96-47f4-be36-6c596a6fcc82_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributions to Sponsors</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_f9bdf760-57c0-4970-9c81-003c11daa633_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Cash And Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_0acf6473-7444-4d78-8a15-944ada3b72c8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_1127f39d-c560-4a21-91e1-d8c295e6e1cb_terseLabel_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_label_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</link:label>
    <link:label id="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_documentation_en-US" xlink:label="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:href="evh-20220930.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:to="lab_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_dfe938f8-bb85-417c-8367-417d93abd1ec_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_1f4c66c8-b43d-4db1-b680-c43412062309_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_df1808c8-32de-4ed6-8322-7a98ed400e86_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e783f004-ee03-4cad-afe1-d585fda1fe1c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d8225481-36f3-47f6-bc0d-08074658bc69_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_287a1df0-a8e1-4694-8376-b0e485d7d58a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_774c3c71-d8a6-455d-8ac7-7cc812e99b91_terseLabel_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with financial institutions</link:label>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_label_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with Financial Institutions [Member]</link:label>
    <link:label id="lab_evh_CollateralwithFinancialInstitutionsMember_documentation_en-US" xlink:label="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral with Financial Institutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember" xlink:href="evh-20220930.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CollateralwithFinancialInstitutionsMember" xlink:to="lab_evh_CollateralwithFinancialInstitutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_WeightedAverageCommonSharesOutstandingAbstract_fae13646-c0d9-4b89-a087-c7488bdd5700_terseLabel_en-US" xlink:label="lab_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding</link:label>
    <link:label id="lab_evh_WeightedAverageCommonSharesOutstandingAbstract_label_en-US" xlink:label="lab_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Common Shares Outstanding [Abstract]</link:label>
    <link:label id="lab_evh_WeightedAverageCommonSharesOutstandingAbstract_documentation_en-US" xlink:label="lab_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Common Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:href="evh-20220930.xsd#evh_WeightedAverageCommonSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:to="lab_evh_WeightedAverageCommonSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_9d781328-4454-4e62-b54d-42e425c988fa_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_866d7f78-1cb6-453d-937a-f25ae45fe4f4_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_70cfd3a8-4158-4335-a4e2-c4918ed231c1_verboseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost amortization</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_9a0a3cd3-4869-465d-b9c9-f52ace21349a_terseLabel_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past due less than 120 days</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_label_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 120 Days Past Due [Member]</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan120DaysPastDueMember_documentation_en-US" xlink:label="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 120 Days Past Due [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:href="evh-20220930.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:to="lab_evh_FInancialAssetLessThan120DaysPastDueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashforOtherContractualCommitmentsMember_98bbef4f-e494-44d8-96c4-e09fb4b4f417_terseLabel_en-US" xlink:label="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_evh_RestrictedCashforOtherContractualCommitmentsMember_label_en-US" xlink:label="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Other Contractual Commitments [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashforOtherContractualCommitmentsMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Other Contractual Commitments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:href="evh-20220930.xsd#evh_RestrictedCashforOtherContractualCommitmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:to="lab_evh_RestrictedCashforOtherContractualCommitmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_a07990c1-3f1d-4756-aa4a-deb8f4c4461d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e3bce638-0385-4a48-a922-807adbfa9afb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_3fa01f14-68b7-49d7-93ca-152113ee9dd4_negatedTerseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use operating assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="evh-20220930.xsd#evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_bae0237b-2974-4477-a4d1-114b6d0740dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7257ad5c-c614-41d8-ac80-0965791a5ec4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IN_011a4f90-120e-4566-a668-154a63ebb9f0_terseLabel_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pune, India</link:label>
    <link:label id="lab_country_IN_label_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INDIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IN" xlink:to="lab_country_IN" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a6462d63-c726-415f-bdd3-ef5e54a07e43_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_7887ecda-5f7e-4b45-970c-ee2fb1e1f7a7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Contingent Consideration Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_VitalDecisionsMember_547afbfb-a61d-43d5-aa67-7def4c4f4070_terseLabel_en-US" xlink:label="lab_evh_VitalDecisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Decisions</link:label>
    <link:label id="lab_evh_VitalDecisionsMember_label_en-US" xlink:label="lab_evh_VitalDecisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Decisions [Member]</link:label>
    <link:label id="lab_evh_VitalDecisionsMember_documentation_en-US" xlink:label="lab_evh_VitalDecisionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vital Decisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VitalDecisionsMember" xlink:href="evh-20220930.xsd#evh_VitalDecisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_VitalDecisionsMember" xlink:to="lab_evh_VitalDecisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_95ac55e8-128f-453c-9350-1d51033a10d6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_GA_bbb45891-c3b6-4912-9069-b68d393b53e8_terseLabel_en-US" xlink:label="lab_stpr_GA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEORGIA</link:label>
    <link:label id="lab_stpr_GA_label_en-US" xlink:label="lab_stpr_GA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEORGIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_GA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_GA" xlink:to="lab_stpr_GA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_077d6161-195b-43e9-9b06-8a2809e3dd4d_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_38036a97-884a-479a-af91-44d8167ffb58_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_311d451b-a1ad-49d9-82ac-a0f042fceca9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_06f3e28a-c064-44d5-bbcd-436c56d74cb0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged stock units vested, net of shares withheld for taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_December312022Member_1d1a713a-d330-4998-80d3-75da5ea63180_terseLabel_en-US" xlink:label="lab_evh_December312022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2022</link:label>
    <link:label id="lab_evh_December312022Member_label_en-US" xlink:label="lab_evh_December312022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2022 [Member]</link:label>
    <link:label id="lab_evh_December312022Member_documentation_en-US" xlink:label="lab_evh_December312022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312022Member" xlink:href="evh-20220930.xsd#evh_December312022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_December312022Member" xlink:to="lab_evh_December312022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_784f20fe-7e3b-414f-b1ed-a329fa35c486_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Lease Expense, Weighted-Average Discount Rate and Weighted-remaining Lease Terms</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_0ab566f8-6c79-4f0f-8635-2103897824a6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_080c9078-8868-45c0-af18-9536bf1c23d9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_505bd741-e31e-4212-9ccb-45b473f05968_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a4851df0-74f0-4018-9fb8-1f625d7ebb4b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_GainOnTransferOfMembership_a8e82210-c89c-4aa5-9feb-e64f12726a96_terseLabel_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on transfer of membership</link:label>
    <link:label id="lab_evh_GainOnTransferOfMembership_c0792759-289d-47b0-8f80-213ab0853794_negatedTerseLabel_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on transfer of membership</link:label>
    <link:label id="lab_evh_GainOnTransferOfMembership_label_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Transfer Of Membership</link:label>
    <link:label id="lab_evh_GainOnTransferOfMembership_documentation_en-US" xlink:label="lab_evh_GainOnTransferOfMembership" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Transfer Of Membership</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership" xlink:href="evh-20220930.xsd#evh_GainOnTransferOfMembership"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_GainOnTransferOfMembership" xlink:to="lab_evh_GainOnTransferOfMembership" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_ac4cd6a9-9769-4660-8c74-fc0744001797_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_13717040-17c4-44b4-a206-9e5e3f8e9a84_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for acquisition</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_378f0b56-fc4e-48dd-b6eb-2b277b880796_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_2bc6ff36-66e4-4363-9f73-cd4f9a049222_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_1f809050-844d-4a21-9b0a-7e39c95938ae_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_ba337282-8f15-473b-a03c-592ca728a1ab_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_14dc11a1-0412-4f03-a977-0bcf18035c67_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - noncurrent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsOfMakeWholePremium_7d99b132-7ae7-4b60-8282-902fdebfa786_terseLabel_en-US" xlink:label="lab_evh_PaymentsOfMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of make-whole premium</link:label>
    <link:label id="lab_evh_PaymentsOfMakeWholePremium_label_en-US" xlink:label="lab_evh_PaymentsOfMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Make-Whole Premium</link:label>
    <link:label id="lab_evh_PaymentsOfMakeWholePremium_documentation_en-US" xlink:label="lab_evh_PaymentsOfMakeWholePremium" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Make-Whole Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsOfMakeWholePremium" xlink:href="evh-20220930.xsd#evh_PaymentsOfMakeWholePremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsOfMakeWholePremium" xlink:to="lab_evh_PaymentsOfMakeWholePremium" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_6c15fe33-5a27-4038-b855-ebf2f3114534_terseLabel_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs</link:label>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_label_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs [Member]</link:label>
    <link:label id="lab_evh_ContractFulfillmentCostsMember_documentation_en-US" xlink:label="lab_evh_ContractFulfillmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Fulfillment Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember" xlink:href="evh-20220930.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ContractFulfillmentCostsMember" xlink:to="lab_evh_ContractFulfillmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_c401e147-6eeb-4262-af15-c20df9856ba5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Techniques and Significant Unobservable Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_e717b87f-467b-485a-86a5-f7d19a32cd44_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_a4d55d1a-47e1-489a-b3d8-986ab9c2aa87_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_30bcd098-ad55-448d-82f2-67d0c4b1c081_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_39060ba4-f824-4c12-83fd-71bedb48675f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b9d5dd53-e26c-4247-83b4-4e154461bf31_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_1cd522e5-bfc5-4db6-af57-096ee28f7185_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_ac6543c9-ef9b-4eb3-a251-de37dab08f67_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_1a93a39a-f3ee-467f-bca7-a6c68857ed56_netLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1f323877-a78e-403c-8a08-da78b50a49da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_155a9722-df2c-4e95-acd6-3552fd5fcc14_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_4281b825-7db3-4917-8f25-681afa02dd7d_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_f9461ced-c9ad-425e-aa4e-c1681c3cc6de_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_436dd462-204b-4da2-a8ba-8395448f7c21_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod_bc822a41-1651-47de-bc4a-3c4faa212e34_terseLabel_en-US" xlink:label="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automatic extension period</link:label>
    <link:label id="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod_label_en-US" xlink:label="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Automatic Extension Period</link:label>
    <link:label id="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod_documentation_en-US" xlink:label="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Automatic Extension Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LineOfCreditFacilityAutomaticExtensionPeriod" xlink:href="evh-20220930.xsd#evh_LineOfCreditFacilityAutomaticExtensionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LineOfCreditFacilityAutomaticExtensionPeriod" xlink:to="lab_evh_LineOfCreditFacilityAutomaticExtensionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_a0b66f4b-d461-484a-9ecb-8acca2d8873d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e2f822bf-727a-40ef-9f4f-c5b83649040f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_dad29359-f45b-46d7-98bc-e05a5e05f6b2_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_c2ffdda2-dd02-4067-aa35-96e148c1c7d4_terseLabel_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received in advance of satisfaction of performance obligations</link:label>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_label_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</link:label>
    <link:label id="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_documentation_en-US" xlink:label="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:href="evh-20220930.xsd#evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:to="lab_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d27c5f36-4eff-4881-a7a7-d86c9eab2f84_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Used In Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_fedef88c-6cb9-4bad-9001-bb82e8ab8b1b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_34d7c4fe-c7f2-49d6-899b-2992756235ed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards_71055c39-c1bf-476a-805b-9d1d9f84cd14_terseLabel_en-US" xlink:label="lab_evh_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental diluted shares from stock options</link:label>
    <link:label id="lab_evh_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards_label_en-US" xlink:label="lab_evh_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect Of Stock Options Awards</link:label>
    <link:label id="lab_evh_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards_documentation_en-US" xlink:label="lab_evh_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect Of Stock Options Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards" xlink:href="evh-20220930.xsd#evh_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards" xlink:to="lab_evh_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_108648d4-48f8-4438-a11d-20e3220abf56_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents Items [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_6de6d6a7-7222-4103-ac15-437c7693b172_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_e754afe1-5244-4aa2-bf43-97c62f9af054_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_c07b9aea-1eab-4935-bded-de99b5eec5b8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_d640420d-ee49-4165-b429-dc3f868c240c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_593e777f-9133-4df0-b5e6-df85f9833497_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_31834672-a5a6-474b-bc65-d28e4afe74fc_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brea, CA</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_b7692299-3acb-47fe-aef3-f7d174e278e3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_85204fa2-37b0-4ff8-a632-604ff078b145_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_cc22cd89-4605-473c-b8f6-7b4c861fea2a_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_edecad0c-bbb0-48d1-83ea-09e6f7846467_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_aeed0b6c-fa67-4264-9382-40c4c5bc7e56_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets - operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_5793467e-b6a6-4908-a182-fdcbd43836f1_terseLabel_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</link:label>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_label_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs), Performance-based Restricted Stock Units (PBRSUs), And Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:label id="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_documentation_en-US" xlink:label="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock and Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:href="evh-20220930.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:to="lab_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_c992a61f-b4e9-4da8-b482-4ba0dab0ae6c_terseLabel_en-US" xlink:label="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Automatic extension after each period</link:label>
    <link:label id="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_label_en-US" xlink:label="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Period Before Each Automatic Extension</link:label>
    <link:label id="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_documentation_en-US" xlink:label="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Period Before Each Automatic Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" xlink:href="evh-20220930.xsd#evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" xlink:to="lab_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAgreementsMember_8ba0201f-c7dc-4b90-9e5b-19a59f1474e4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreements</link:label>
    <link:label id="lab_us-gaap_LeaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAgreementsMember" xlink:to="lab_us-gaap_LeaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_3a969074-02c1-4d6c-8f94-52d33eae5918_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_c971dfd3-daea-451a-b334-e120549b72b6_terseLabel_en-US" xlink:label="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period during which warrants or rights exercisable, after maturity of credit agreement</link:label>
    <link:label id="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_label_en-US" xlink:label="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement</link:label>
    <link:label id="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_documentation_en-US" xlink:label="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:href="evh-20220930.xsd#evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:to="lab_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_86e35b95-2ed5-43d2-9dfa-2048f0080b46_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_cd970f77-befb-4bc6-a0a7-452251be18af_totalLabel_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total tangible assets acquired</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_label_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_documentation_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:href="evh-20220930.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:to="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_57a5b508-72f9-4085-a064-80d18aa400c5_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_b559ec68-e847-4b23-b116-712d692e469f_terseLabel_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_evh_ChangeInContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:href="evh-20220930.xsd#evh_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:to="lab_evh_ChangeInContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_aca1af22-1024-4224-b236-b9ccc1c904b2_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:to="lab_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_1c7050c5-6a47-4850-8e66-202dc90abc03_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument, amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_de5a1cdc-2dbb-4a33-8e42-365d5a9965d2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_37d1e3cc-b8ff-4597-815b-9aa8b5c8104b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Awards Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ProfessionalServicesRestructuringMember_b5e1fd71-9769-48e8-bd84-3c722f160fe7_terseLabel_en-US" xlink:label="lab_evh_ProfessionalServicesRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional services</link:label>
    <link:label id="lab_evh_ProfessionalServicesRestructuringMember_label_en-US" xlink:label="lab_evh_ProfessionalServicesRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Services, Restructuring [Member]</link:label>
    <link:label id="lab_evh_ProfessionalServicesRestructuringMember_documentation_en-US" xlink:label="lab_evh_ProfessionalServicesRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Services, Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProfessionalServicesRestructuringMember" xlink:href="evh-20220930.xsd#evh_ProfessionalServicesRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ProfessionalServicesRestructuringMember" xlink:to="lab_evh_ProfessionalServicesRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d02d1628-2199-47ac-84f1-a570d69e6d80_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of New Accounting Standards and Recent Accounting Pronouncements Not Yet Effective</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_2500c9e2-81c1-46a3-bca8-08338941bcc2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion issued (in share)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_42593f3c-9982-409c-95d7-364e7b0a3027_negatedTerseLabel_en-US" xlink:label="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPG acquisition</link:label>
    <link:label id="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_label_en-US" xlink:label="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Acquired During Period</link:label>
    <link:label id="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_documentation_en-US" xlink:label="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:href="evh-20220930.xsd#evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:to="lab_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_c71a1799-b189-4276-96ef-9eafb6252f1b_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations, Disposed of by Sale [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:to="lab_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a464ed8a-6853-471b-9d43-de61b6b64d8f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_642b0ca0-23a1-4b08-93c9-36227f181054_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity method investees</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_670af81f-129b-49de-89af-fe62de965834_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_7e290501-691f-44dd-b5a3-3b95ce4d9292_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_c6f5f440-d9de-4ab9-89d5-06f62974d9aa_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_58913d26-e6f6-42fb-ba39-163ec5031f60_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_9f439e72-1a8c-4258-b8dd-b90c0418cd1c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total fair value of liabilities measured on a recurring basis</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d863c01a-2640-439e-a39e-304380260ced_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_59b105f7-34dc-41c8-a5fa-47e3ec655786_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvesteeMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvesteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvesteeMember" xlink:to="lab_us-gaap_EquityMethodInvesteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9630bd62-b707-4076-88cd-6a3e834a0381_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_5d9a17cf-2f47-42db-9060-1792a43ce907_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_dcc219bb-f721-43b6-a027-c79d0b9df4b7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for (benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0228a3ce-57a2-4f04-b52a-5faab8f8ac76_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from (provision for) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_fe6e1131-4a1c-452b-8388-ddaf81461ef5_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_d8560331-8eab-42f8-9152-b6d08a879856_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_57646ad3-d9c4-484b-9c39-f635eb52c343_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b6e3d31f-b873-4c27-8463-e2adbf44bd43_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossAbstract_1f063bd8-4769-4e41-be39-aa43fd559aff_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss [Abstract]</link:label>
    <link:label id="lab_us-gaap_CreditLossAbstract_label_en-US" xlink:label="lab_us-gaap_CreditLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossAbstract" xlink:to="lab_us-gaap_CreditLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DeferredFinancingFeesMember_496e6b3b-1111-4408-9b22-2c21f8fdcd07_terseLabel_en-US" xlink:label="lab_evh_DeferredFinancingFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Fees</link:label>
    <link:label id="lab_evh_DeferredFinancingFeesMember_label_en-US" xlink:label="lab_evh_DeferredFinancingFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Fees [Member]</link:label>
    <link:label id="lab_evh_DeferredFinancingFeesMember_documentation_en-US" xlink:label="lab_evh_DeferredFinancingFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Financing Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember" xlink:href="evh-20220930.xsd#evh_DeferredFinancingFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DeferredFinancingFeesMember" xlink:to="lab_evh_DeferredFinancingFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_f9b47a3b-f51e-45ef-b134-56d8a14a25d7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_67b5841d-b8fc-415a-a617-23979ddbd342_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_c0a06df9-e763-441c-bee4-d92081e36245_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_a17a0082-b5c4-4ea7-a927-1c3de745bbb1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_2ef38dc8-e154-4e45-8a6a-9bf4a8bfd23d_terseLabel_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims expenses</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_label_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Claims Expense</link:label>
    <link:label id="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_documentation_en-US" xlink:label="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Claims Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:href="evh-20220930.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:to="lab_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_89358abc-a2c4-45b9-8d9c-a718257586b9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_35d53057-86bc-4ad7-bc6e-ac78189a1303_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5ad89b5a-f164-4ade-a21d-05eff4a21fd9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9fb41de9-b0ee-4736-85e3-2cd735ed5965_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_IL_ac3c8081-1ffb-49e0-91b9-69bf8cd11493_terseLabel_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Riverside, IL</link:label>
    <link:label id="lab_stpr_IL_label_en-US" xlink:label="lab_stpr_IL" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ILLINOIS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_IL" xlink:to="lab_stpr_IL" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancingReceivablePercentPastDue1_631a1310-a358-4214-bf39-fc926f5bfb19_terseLabel_en-US" xlink:label="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of receivables, past due</link:label>
    <link:label id="lab_us-gaap_FinancingReceivablePercentPastDue1_label_en-US" xlink:label="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Percent Past Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancingReceivablePercentPastDue1" xlink:to="lab_us-gaap_FinancingReceivablePercentPastDue1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MolinaHealthcareMember_b3639c18-d4f8-4f04-8905-4d8487f86869_terseLabel_en-US" xlink:label="lab_evh_MolinaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare</link:label>
    <link:label id="lab_evh_MolinaHealthcareMember_label_en-US" xlink:label="lab_evh_MolinaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare [Member]</link:label>
    <link:label id="lab_evh_MolinaHealthcareMember_documentation_en-US" xlink:label="lab_evh_MolinaHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Molina Healthcare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareMember" xlink:href="evh-20220930.xsd#evh_MolinaHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MolinaHealthcareMember" xlink:to="lab_evh_MolinaHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SeniorCreditFacilitiesMember_b7d3ee2e-fff9-41d3-b933-60f7f6afe595_terseLabel_en-US" xlink:label="lab_evh_SeniorCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities</link:label>
    <link:label id="lab_evh_SeniorCreditFacilitiesMember_label_en-US" xlink:label="lab_evh_SeniorCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities [Member]</link:label>
    <link:label id="lab_evh_SeniorCreditFacilitiesMember_documentation_en-US" xlink:label="lab_evh_SeniorCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Credit Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorCreditFacilitiesMember" xlink:href="evh-20220930.xsd#evh_SeniorCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SeniorCreditFacilitiesMember" xlink:to="lab_evh_SeniorCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_0aef677b-c7bc-43eb-a9be-a478a788708e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider network contracts</link:label>
    <link:label id="lab_us-gaap_ContractBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_ContractBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_162024ce-8f44-49dd-990e-5a32c5fe7483_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BelowMarketLeasesMember_1c672e98-e4ee-4197-8481-61e3d8e181bd_terseLabel_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below market lease, net</link:label>
    <link:label id="lab_evh_BelowMarketLeasesMember_label_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below Market Leases [Member]</link:label>
    <link:label id="lab_evh_BelowMarketLeasesMember_documentation_en-US" xlink:label="lab_evh_BelowMarketLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Below Market Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember" xlink:href="evh-20220930.xsd#evh_BelowMarketLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BelowMarketLeasesMember" xlink:to="lab_evh_BelowMarketLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_db875e98-9e81-4c7e-9fea-d3de75f2f42d_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_970c96c5-8783-45bf-9bbb-f7d8d48df328_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_0ef5d58e-35ac-4b6e-b0bf-c6dc93cabb18_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock - $0.01 par value; 750,000,000 shares authorized; 101,159,072 and 90,758,318 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_09147c39-55a3-4997-b5f8-2763f23e9dff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, original debt, amount</link:label>
    <link:label id="lab_us-gaap_DebtConversionOriginalDebtAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="lab_us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_78a7c7e1-6ace-4c55-bdd5-c433c36693c7_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_87627244-7d84-4de1-85d1-ade8f39efac0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_14c194d3-51ea-4a5f-9dad-596d50aff0bc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_6f729774-cb3a-4e70-a7e8-924cff90e6b2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_777d142d-bb06-48b4-92e6-8d144b0aa1a5_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_55a42f0f-9439-4080-bf77-c13fe48b8e0a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a3f47e85-c571-4c99-b78b-af2f4c6d6a12_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_b361a59a-acae-4aa8-a8f7-47e9b326f76e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible assets acquired:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_2a9ef7ec-6347-4464-a64b-d1d22a972e36_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_d48831c0-029b-4eec-a4c6-f5a0f9c66ecf_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_d4372cf8-bffe-42cb-a4a6-af04e8ab1bfb_terseLabel_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash held in international banks (less than)</link:label>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_label_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Held In International Banks, Percentage</link:label>
    <link:label id="lab_evh_CashHeldInInternationalBanksPercentage_documentation_en-US" xlink:label="lab_evh_CashHeldInInternationalBanksPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Held In International Banks, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage" xlink:href="evh-20220930.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashHeldInInternationalBanksPercentage" xlink:to="lab_evh_CashHeldInInternationalBanksPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostDomain_251116ef-59db-4a62-8d5e-2f30732291fd_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Domain]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostDomain_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostDomain" xlink:to="lab_us-gaap_CapitalizedContractCostDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_7718a4cb-f1c5-4dc2-8ae9-9c98e5b14070_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa3061af-82a8-44de-b46d-a6991e04ebfe_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash as of beginning-of-period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0d6f43da-bc4b-4155-9755-7016143ce482_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and restricted cash as of end-of-period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ec3dcc90-d5ef-43a3-be52-5cc0fd483971_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_43909196-6166-40d5-8bd4-42d9ad639f75_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents (including restricted cash)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f3e18522-d607-424f-9abe-05c2aaa76fcb_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_4d75f068-e04d-4204-b785-2bf79967fe69_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative inception to date impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_57d4c46f-26f8-4f4c-9b6d-3fd29a84fae7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_09336382-e688-4463-8dde-3692c820ab08_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e3d24b43-e529-4fd7-8775-c35eb6c1ee13_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of long term debt, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_12132c9c-34a9-48a7-9413-51d3a402c01f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_cf646cda-e6cd-49c2-b519-f747f122b229_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders of Evolent Health, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_073ffd25-f2c3-4f8f-990b-9af4ccea807a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders of Evolent Health, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0e4ccb2f-2469-40a8-867a-8732b9dd5743_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_58888047-cde2-4268-9deb-7ade47b73b56_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_A2022CreditFacilitiesMember_8c386cb9-8f9b-48f8-86db-0acdac062cf7_terseLabel_en-US" xlink:label="lab_evh_A2022CreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Credit Facilities</link:label>
    <link:label id="lab_evh_A2022CreditFacilitiesMember_label_en-US" xlink:label="lab_evh_A2022CreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Credit Facilities [Member]</link:label>
    <link:label id="lab_evh_A2022CreditFacilitiesMember_documentation_en-US" xlink:label="lab_evh_A2022CreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Credit Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_A2022CreditFacilitiesMember" xlink:href="evh-20220930.xsd#evh_A2022CreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_A2022CreditFacilitiesMember" xlink:to="lab_evh_A2022CreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_5403b084-a6b3-44f7-9d39-64ee3f96f9f1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_9aa7ddf5-a7eb-43db-8bf5-fc6cc02dc1ad_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_65e32e57-5506-46d1-b1db-d40435230006_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued property and equipment purchases</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ba3eea96-e062-4f95-aeb9-7636fd66bebf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FacilityClosingMember_a2ec9325-1224-41ed-8fb6-7da6eb2348e6_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space consolidation</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember" xlink:to="lab_us-gaap_FacilityClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_b5ee6ec5-7831-4039-954b-714f48f2f6f9_terseLabel_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc.</link:label>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_label_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc. [Member]</link:label>
    <link:label id="lab_evh_FloridaBlueMedicareIncMember_documentation_en-US" xlink:label="lab_evh_FloridaBlueMedicareIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Florida Blue Medicare, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember" xlink:href="evh-20220930.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FloridaBlueMedicareIncMember" xlink:to="lab_evh_FloridaBlueMedicareIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5a4dff5d-c2b1-463a-a153-20c2bdc0d352_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0a7a1a3b-82de-4c02-ab30-8714adbfb907_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0c234314-53bb-4ce6-b5d1-d4b21f39d012_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash and restricted cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_cfec738c-b66c-4fd5-ac07-2833e9d58498_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_cc013173-1d3c-4a11-a10e-483c517bf768_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on disposal of discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_a95dd857-a829-4ff5-828e-688b35f3a393_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_b7b22434-f266-4b3c-ae7c-977689b6b6c7_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_905b38cf-cf75-424a-bba2-1c4bf0fb7b1d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income (loss) attributable to common shareholders of Evolent Health, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_91375150-239a-46c9-bd66-05408866134c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_02cca4b8-4106-464f-b37a-0248e5f772fc_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_9e9cd427-4442-4ef7-8f84-7d87823444ca_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill acquired</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_ed4403e8-5705-4b4f-8dde-8fbb50207bc2_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_080358dd-c78c-47cf-8a18-0833905d8bcd_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1339dec1-34fa-44f9-b615-471b57212d76_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_c0c0349a-39b8-4bb4-a932-b0b462cd3e84_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_4c3f60b8-44b2-42dd-b19b-9421265900d6_totalLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Total</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_ad5137cc-b0ca-4257-8b63-7683eefddc30_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ImplantableProviderGroupIMPMember_797ff1f2-4cf4-40f4-a804-fbab16fca726_terseLabel_en-US" xlink:label="lab_evh_ImplantableProviderGroupIMPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPG</link:label>
    <link:label id="lab_evh_ImplantableProviderGroupIMPMember_label_en-US" xlink:label="lab_evh_ImplantableProviderGroupIMPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implantable Provider Group ("IMP") [Member]</link:label>
    <link:label id="lab_evh_ImplantableProviderGroupIMPMember_documentation_en-US" xlink:label="lab_evh_ImplantableProviderGroupIMPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Implantable Provider Group ("IMP")</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ImplantableProviderGroupIMPMember" xlink:href="evh-20220930.xsd#evh_ImplantableProviderGroupIMPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ImplantableProviderGroupIMPMember" xlink:to="lab_evh_ImplantableProviderGroupIMPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_104c9fd0-f298-4d95-8be1-1415107891e5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_b4b27da4-ae54-4066-92ac-4a0a092ac626_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_a5ad8dd4-cdee-4f1e-a9f8-14b9d192e6f5_terseLabel_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Notes</link:label>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_label_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes due 2021 [Member]</link:label>
    <link:label id="lab_evh_ConvertibleSeniorNotesdue2021Member_documentation_en-US" xlink:label="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes due 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member" xlink:href="evh-20220930.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ConvertibleSeniorNotesdue2021Member" xlink:to="lab_evh_ConvertibleSeniorNotesdue2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_b30c5132-42d4-4335-a1f1-2e24385e8d35_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims paid related to:</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_3bdb1c8e-b361-4ce4-a085-f47214f938b5_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_6f6fb501-faf6-4096-8420-90fce271a31c_terseLabel_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cash and cash equivalents held with FDIC participating bank</link:label>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_label_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, FDIC Insured Amount, Percentage</link:label>
    <link:label id="lab_evh_CashFDICInsuredAmountPercentage_documentation_en-US" xlink:label="lab_evh_CashFDICInsuredAmountPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, FDIC Insured Amount, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage" xlink:href="evh-20220930.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CashFDICInsuredAmountPercentage" xlink:to="lab_evh_CashFDICInsuredAmountPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TrueHealthMember_2fadd09e-3207-4821-89d2-16f710ff1842_terseLabel_en-US" xlink:label="lab_evh_TrueHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health</link:label>
    <link:label id="lab_evh_TrueHealthMember_label_en-US" xlink:label="lab_evh_TrueHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health [Member]</link:label>
    <link:label id="lab_evh_TrueHealthMember_documentation_en-US" xlink:label="lab_evh_TrueHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">True Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember" xlink:href="evh-20220930.xsd#evh_TrueHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TrueHealthMember" xlink:to="lab_evh_TrueHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_7fe67a53-fa91-43fb-a9e6-5129b48dab30_negatedTerseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net and contract assets</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:href="evh-20220930.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:to="lab_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_9041be7f-cd6a-4b25-a547-883d3bb8d249_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cost assets</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Net, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:to="lab_us-gaap_CapitalizedContractCostNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_c196211e-2718-428c-af2a-6d1ca757a1db_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Termination Term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TransactionCosts_e4a9a5d1-3271-4789-8497-99cd46b18c93_negatedLabel_en-US" xlink:label="lab_evh_TransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition costs</link:label>
    <link:label id="lab_evh_TransactionCosts_label_en-US" xlink:label="lab_evh_TransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs</link:label>
    <link:label id="lab_evh_TransactionCosts_documentation_en-US" xlink:label="lab_evh_TransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransactionCosts" xlink:href="evh-20220930.xsd#evh_TransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TransactionCosts" xlink:to="lab_evh_TransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_31288290-fec5-4fc1-8528-fc253a53d584_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Parties</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_86d6e178-b7d4-44fe-8ca2-b5da71f30bda_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Assets Acquired</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_4a7d273e-6649-4c4d-97c0-9245634db082_negatedTerseLabel_en-US" xlink:label="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal of non-strategic assets and divestiture of discontinued operations, net</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_label_en-US" xlink:label="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_documentation_en-US" xlink:label="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:href="evh-20220930.xsd#evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:to="lab_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_ccd65bd1-f533-4369-ac1c-ce3f449abb16_verboseLabel_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LSUs</link:label>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_label_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:label id="lab_evh_LeveragedStockUnitsLSUsMember_documentation_en-US" xlink:label="lab_evh_LeveragedStockUnitsLSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged Stock Units (LSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember" xlink:href="evh-20220930.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_LeveragedStockUnitsLSUsMember" xlink:to="lab_evh_LeveragedStockUnitsLSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_4203e694-aa49-4d3f-bb54-514e2e768bec_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_513f372c-0d8a-47a5-bcda-9b31d3ac2146_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6fc06c73-042f-49b7-8c7d-c988649ff6c4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_84bd45b7-ad79-4e35-a4b4-b47739bc2505_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f0d147c1-3bf7-4ad9-a451-020fbb529674_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate on cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_dbcca7f0-77db-4229-ba75-95285fdc8aaf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_fbd6f3fa-7ca6-416c-9a3c-8e00235a7029_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_882495e0-7369-43a4-b55f-f75b48fe13be_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_d0efee5a-0aa8-4a7f-9cff-488c4a56b502_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Supplemental Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:to="lab_us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_4b96b265-e7f9-45d1-bd66-09e0a1809d0c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_e3d1c8f8-6ed0-4584-a615-6c8d6da42a3c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Estimated Amortization of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_e05d0e82-9006-4083-803c-335642e6b4bc_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (gains) losses, net</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_2e1b0e9c-0f62-4c55-93b3-fb819f38a23b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4ee39df9-0744-44d5-bdb4-191065e072b5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration arrangements (up to)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CreditAgreementMember_f746494f-2c74-4bd5-af23-d35cc0b86dc1_terseLabel_en-US" xlink:label="lab_evh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_evh_CreditAgreementMember_label_en-US" xlink:label="lab_evh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_evh_CreditAgreementMember_documentation_en-US" xlink:label="lab_evh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CreditAgreementMember" xlink:href="evh-20220930.xsd#evh_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CreditAgreementMember" xlink:to="lab_evh_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_20db4cdd-4d35-44a5-b370-b5c7419f6adf_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_dcb82e19-c3ce-4212-85ba-30f652a16100_terseLabel_en-US" xlink:label="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Axis]</link:label>
    <link:label id="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_label_en-US" xlink:label="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Axis]</link:label>
    <link:label id="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_documentation_en-US" xlink:label="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" xlink:href="evh-20220930.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" xlink:to="lab_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_cb2657c3-dc90-4f13-8ebd-3c708fce35e3_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts, current</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_8e9c2b21-cb1c-4c99-ae5e-8e10042fdd2d_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_abe565a3-52b5-40a4-8c40-6d7569fccd5c_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0b445550-0475-48e8-b77d-988cdd876acf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_62e3c244-9c11-4159-8052-5aae7d6f6715_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_7cc904ea-2ad3-49c8-9fe5-87b15d6b2d7e_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_3d05b707-cba3-4f45-bd8a-21570acb6d9a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_10161600-f075-4f26-904d-d13a23f1366e_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase covenant, trading days, minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_label_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Trading Days, Minimum</link:label>
    <link:label id="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_documentation_en-US" xlink:label="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchase Covenant, Trading Days, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:to="lab_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_ed3467f6-fce3-404b-a4c3-201e6fbc2fa6_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_d1ed19b5-da3f-4231-b400-d5c6fe9b2836_terseLabel_en-US" xlink:label="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of days prior to any junior debt maturity</link:label>
    <link:label id="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_label_en-US" xlink:label="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity</link:label>
    <link:label id="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_documentation_en-US" xlink:label="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:href="evh-20220930.xsd#evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:to="lab_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_bc6a62c6-6c6c-4b3e-946c-4f0a32d06e0c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repositioning and Other Changes</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_6d86aa9c-da08-44b9-9d42-67b5a85cbc30_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_242b2177-be7b-49e1-99b3-01fe5fe105b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_60f8ea97-0a00-4163-a123-7a33faf0fa67_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_9c5bec05-6f71-47ca-9dda-4ec77473539c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d0a0f419-c020-4d65-bc60-295cc9199a58_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_7e18775d-3c2d-4f91-abd1-7b26607e203f_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e200203d-513d-42b5-84c1-67ab29aa8136_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_572739f5-e06a-48a9-aac9-7d2d46bb924b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_88edbfc1-e12e-46fb-83e8-2be732285f95_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_a64da62a-8662-4743-8bcf-34202060e450_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c6600b4e-350a-4b82-9d76-83b8dd09213c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_b677e4a9-85cd-4dbe-beb7-3b16cc40cf90_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f3da6f15-9ac1-4a7a-8fe6-c98339473357_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_54ed9467-1d8f-4a2e-950c-35f284474f55_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_7377a2c9-9722-4429-ba0a-1a0472eede7d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_74e0b9f9-9455-42e7-a1b9-23027d07d8c0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_95a5a634-59e9-47a8-8352-72ae8d05a423_terseLabel_en-US" xlink:label="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-neutral expected earnout consideration</link:label>
    <link:label id="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_label_en-US" xlink:label="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk-neutral Expected Earnout Consideration [Member]</link:label>
    <link:label id="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_documentation_en-US" xlink:label="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk-neutral Expected Earnout Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:href="evh-20220930.xsd#evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:to="lab_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_4a460469-4d3b-46bc-bcb9-0dbd1b8b33d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification to revenue, as a result of performance obligations satisfied</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_f6d3a01d-fd8c-4bf2-90b8-cc3780a0407a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_1b474225-12a8-4a6f-82f7-5518482dd983_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BonusesAndCommissionsMember_ce05e0aa-6244-4a8d-94d6-d86d8ede80bb_terseLabel_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses and Commissions</link:label>
    <link:label id="lab_evh_BonusesAndCommissionsMember_label_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses And Commissions [Member]</link:label>
    <link:label id="lab_evh_BonusesAndCommissionsMember_documentation_en-US" xlink:label="lab_evh_BonusesAndCommissionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bonuses And Commissions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember" xlink:href="evh-20220930.xsd#evh_BonusesAndCommissionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BonusesAndCommissionsMember" xlink:to="lab_evh_BonusesAndCommissionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_ab980362-2b23-433c-b47a-6f2f5ca9997c_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_a1b65e51-7381-4585-b4a9-e98bf366345a_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_5b911746-89eb-47d2-b800-6b0b1ae13669_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_f806e656-c858-45dd-878f-172185bab7e5_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NJ_09dafe0a-be86-40f0-9b4e-a11731a843c5_terseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Edison, NJ</link:label>
    <link:label id="lab_stpr_NJ_label_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW JERSEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NJ" xlink:to="lab_stpr_NJ" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_fe9ddcf4-c242-4bf5-abe1-b35b9b44eff3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_c9cb3519-c817-4990-9d15-ac414b1fe0a8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Gross Difference [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_2d552a11-5a99-49ba-957e-e8bb901de1d6_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_4e01f5ac-c89d-4d41-a977-faad06719161_terseLabel_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_label_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities</link:label>
    <link:label id="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_documentation_en-US" xlink:label="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:href="evh-20220930.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:to="lab_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities_5f2d1358-0800-4ecd-8288-e8f90b16a22f_negatedLabel_en-US" xlink:label="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on discontinued operations</link:label>
    <link:label id="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities_label_en-US" xlink:label="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition Of Assets, Operating Activities</link:label>
    <link:label id="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities_documentation_en-US" xlink:label="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Disposition Of Assets, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:href="evh-20220930.xsd#evh_GainLossOnDispositionOfAssetsOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:to="lab_evh_GainLossOnDispositionOfAssetsOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_4b144c24-1f5a-4ee5-a286-f660e229c590_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ClinicalSolutionsSegmentMember_345f77c3-9d6f-424c-8a18-8d110cb982a3_terseLabel_en-US" xlink:label="lab_evh_ClinicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Solutions</link:label>
    <link:label id="lab_evh_ClinicalSolutionsSegmentMember_label_en-US" xlink:label="lab_evh_ClinicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Solutions Segment [Member]</link:label>
    <link:label id="lab_evh_ClinicalSolutionsSegmentMember_documentation_en-US" xlink:label="lab_evh_ClinicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Solutions Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember" xlink:href="evh-20220930.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ClinicalSolutionsSegmentMember" xlink:to="lab_evh_ClinicalSolutionsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_31b1f78e-731b-493c-9501-18cdebf977c9_terseLabel_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services</link:label>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_label_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services Segment [Member]</link:label>
    <link:label id="lab_evh_EvolentHealthServicesSegmentMember_documentation_en-US" xlink:label="lab_evh_EvolentHealthServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evolent Health Services Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember" xlink:href="evh-20220930.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EvolentHealthServicesSegmentMember" xlink:to="lab_evh_EvolentHealthServicesSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_1d2dfd48-f7c4-45ee-b6f8-4e041b57eab5_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Major Customers</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2e753e50-d334-4756-ba9f-fa08cfaf682d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_c4cc4e4a-d9d3-4258-be38-f2dce476f03c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_7275098e-9997-4d54-9e30-3da6c0314542_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes and non-controlling interests</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0108a269-d8f8-4762-b95f-1c2a4567c2af_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_c5688ae7-90ce-421e-adee-3e9b3e4e98e4_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6cb2b034-5019-479f-8ec9-ef328f24915d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_MedicaidCustomersMember_ebf00e6a-9583-437b-9d79-2bb5c547ce49_terseLabel_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_evh_MedicaidCustomersMember_label_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid Customers [Member]</link:label>
    <link:label id="lab_evh_MedicaidCustomersMember_documentation_en-US" xlink:label="lab_evh_MedicaidCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember" xlink:href="evh-20220930.xsd#evh_MedicaidCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_MedicaidCustomersMember" xlink:to="lab_evh_MedicaidCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_c9341871-7e02-4ab6-9c6f-36357751a5b8_terseLabel_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024 Notes</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_label_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2024 [Member]</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2024Member_documentation_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member" xlink:href="evh-20220930.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SeniorConvertibleNotesDue2024Member" xlink:to="lab_evh_SeniorConvertibleNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_6502e2c8-c6f6-49da-9d56-78d616207cde_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_39a91d43-2868-4a32-9d97-8a4454d766aa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_77654f11-bd4b-43bc-b277-b6e55736016b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_2e376a23-91b6-41fd-a2c8-0b69632aef74_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightUnissued_38f195f3-121d-429d-b3ad-9c1b3f08a945_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightUnissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants agreed to be sold (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightUnissued_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightUnissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Unissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightUnissued" xlink:to="lab_us-gaap_ClassOfWarrantOrRightUnissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_aca9694b-bf3f-4e39-bd45-44edba1a0438_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leveraged stock units vested, net of shares withheld for taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_4cfbd1bc-5921-475b-85ae-b61eb925a27d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_4ea9094a-3ae8-4eb0-b58a-63016923cae8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_8b63f1ff-0933-4cd3-8095-213854fa972b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_842c70ff-b8ea-4631-97fa-7a9eb5ee02ef_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_aa11f36b-c004-49d1-921e-ab495a3c0c6e_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_9de2e198-d30f-41a7-adbc-ed869f3a6296_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to settle outstanding warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SecuredOvernightFinancingRateSOFRMember_b8dc742d-b683-4de8-ad5b-8873d52756d7_terseLabel_en-US" xlink:label="lab_evh_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:label id="lab_evh_SecuredOvernightFinancingRateSOFRMember_label_en-US" xlink:label="lab_evh_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:label id="lab_evh_SecuredOvernightFinancingRateSOFRMember_documentation_en-US" xlink:label="lab_evh_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SecuredOvernightFinancingRateSOFRMember" xlink:href="evh-20220930.xsd#evh_SecuredOvernightFinancingRateSOFRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SecuredOvernightFinancingRateSOFRMember" xlink:to="lab_evh_SecuredOvernightFinancingRateSOFRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ProceedsFromMaturityOfInvestments_3ab58830-268b-44cc-becf-0902a8a4589b_terseLabel_en-US" xlink:label="lab_evh_ProceedsFromMaturityOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities and sales of investments</link:label>
    <link:label id="lab_evh_ProceedsFromMaturityOfInvestments_label_en-US" xlink:label="lab_evh_ProceedsFromMaturityOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Maturity Of Investments</link:label>
    <link:label id="lab_evh_ProceedsFromMaturityOfInvestments_documentation_en-US" xlink:label="lab_evh_ProceedsFromMaturityOfInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Maturity Of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromMaturityOfInvestments" xlink:href="evh-20220930.xsd#evh_ProceedsFromMaturityOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ProceedsFromMaturityOfInvestments" xlink:to="lab_evh_ProceedsFromMaturityOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_7917e104-2b08-4814-87dc-64f37e8ee337_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_30228f6d-4a59-4d70-b640-e0afe3642fd1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5497a880-4a90-41c9-8e54-a2e01f65fec6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember_51bbd0a4-48e0-4abb-a611-847cee471119_terseLabel_en-US" xlink:label="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance and termination benefits</link:label>
    <link:label id="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember_label_en-US" xlink:label="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance And Termination Benefits [Member]</link:label>
    <link:label id="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember_documentation_en-US" xlink:label="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance And Termination Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:href="evh-20220930.xsd#evh_EmployeeSeveranceAndTerminationBenefitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:to="lab_evh_EmployeeSeveranceAndTerminationBenefitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_DelayedDrawTermLoanFacilityMember_732b87b7-99a9-43b1-993e-88830542052b_terseLabel_en-US" xlink:label="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DDTL Facility</link:label>
    <link:label id="lab_evh_DelayedDrawTermLoanFacilityMember_label_en-US" xlink:label="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delayed Draw Term Loan Facility [Member]</link:label>
    <link:label id="lab_evh_DelayedDrawTermLoanFacilityMember_documentation_en-US" xlink:label="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Delayed Draw Term Loan Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DelayedDrawTermLoanFacilityMember" xlink:href="evh-20220930.xsd#evh_DelayedDrawTermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_DelayedDrawTermLoanFacilityMember" xlink:to="lab_evh_DelayedDrawTermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_55ca9b26-3395-45df-a2c0-cd663ca1e9fa_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_0e28dbc1-121c-4e83-8234-1b8387fbc0bf_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement payment</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_b79d47af-fbdc-4c51-bd83-b633950e4b56_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year to date period</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_44fc49d0-da25-4bdc-aa15-83e403f5447a_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_7cde2533-7d1a-41da-916a-6d5848881afe_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_b5b16d98-d259-4d3b-9d32-801610277a57_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred For the Nine Months Ended September 30, 2021</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_29917535-b07d-4d64-a20c-a229dce69222_negatedLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repositioning costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_59c296d7-c026-427a-9ad6-c4ba20a57675_terseLabel_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Notes</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_label_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2025 [Member]</link:label>
    <link:label id="lab_evh_SeniorConvertibleNotesDue2025Member_documentation_en-US" xlink:label="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Convertible Notes Due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member" xlink:href="evh-20220930.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_SeniorConvertibleNotesDue2025Member" xlink:to="lab_evh_SeniorConvertibleNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract_f6b448fd-e885-4657-b57d-e76c5763745d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase consideration:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_26aaed67-a237-4d4c-85bc-17a61746e94c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_af7e5f11-8413-4f13-a30e-65c0ccc93609_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_8da3a564-bf9a-493d-afb6-3adaa2485942_terseLabel_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write off of Deferred Debt Issuance Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_226dacee-97fd-42d2-a7f4-271bc450b225_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_50de6485-1f8c-4c72-94cc-95a1ce513633_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2bc227a7-d236-4a73-9cd3-72884510db8f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_824ddf99-17aa-41f2-a3f1-40513ec351c7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_40cd9779-921f-4ba7-a3ad-32e56b266bf0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PlatformsAndOperationsServicesMember_0be4e381-a6f5-4fda-a985-f5e270aec5c7_verboseLabel_en-US" xlink:label="lab_evh_PlatformsAndOperationsServicesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Platform and operations</link:label>
    <link:label id="lab_evh_PlatformsAndOperationsServicesMember_label_en-US" xlink:label="lab_evh_PlatformsAndOperationsServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Platforms And Operations Services [Member]</link:label>
    <link:label id="lab_evh_PlatformsAndOperationsServicesMember_documentation_en-US" xlink:label="lab_evh_PlatformsAndOperationsServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Platforms And Operations Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember" xlink:href="evh-20220930.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PlatformsAndOperationsServicesMember" xlink:to="lab_evh_PlatformsAndOperationsServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_77a3f591-2af3-49da-82ca-2381b881cacd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_48e49d57-0f14-4896-a129-6dd208080f33_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_2f570487-ce36-4d57-9260-72c139a5ab39_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior year to date period</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_1f7a0f7f-a1bb-446d-8d72-d4cefaaddaf4_verboseLabel_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral for letters of credit for facility leases</link:label>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_label_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Letters of Credit for Facility Leases [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Letters of Credit for Facility Leases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:href="evh-20220930.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:to="lab_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_26798492-fc0d-4ccf-b537-ac2cff3151d9_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_09bb86c2-f8ee-4321-a27d-ab02db5bc54c_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_eef15959-b3b6-44c2-b9a9-03aedea73c20_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (See Note $11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_822be7a9-c7a4-42a8-8838-9699400fbdda_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_ba8a8bcb-3942-4b8b-a321-1066056bdd60_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_098c1044-4ed7-4aee-a29e-728809edcd39_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Useful Life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ShareholderAdvisoryServices_d67f8d33-266c-4468-bfb9-5080411092eb_negatedLabel_en-US" xlink:label="lab_evh_ShareholderAdvisoryServices" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategy and shareholder advisory expenses</link:label>
    <link:label id="lab_evh_ShareholderAdvisoryServices_label_en-US" xlink:label="lab_evh_ShareholderAdvisoryServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Advisory Services</link:label>
    <link:label id="lab_evh_ShareholderAdvisoryServices_documentation_en-US" xlink:label="lab_evh_ShareholderAdvisoryServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder Advisory Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderAdvisoryServices" xlink:href="evh-20220930.xsd#evh_ShareholderAdvisoryServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ShareholderAdvisoryServices" xlink:to="lab_evh_ShareholderAdvisoryServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_276b55b0-b587-4fa8-ae57-0e2ed671d7a7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ChangesInTaxReceivablesAgreementLiability_722b25fe-36eb-4ed1-ac79-f0e29325d170_negatedTerseLabel_en-US" xlink:label="lab_evh_ChangesInTaxReceivablesAgreementLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in tax receivable agreement liability</link:label>
    <link:label id="lab_evh_ChangesInTaxReceivablesAgreementLiability_label_en-US" xlink:label="lab_evh_ChangesInTaxReceivablesAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Tax Receivables Agreement Liability</link:label>
    <link:label id="lab_evh_ChangesInTaxReceivablesAgreementLiability_documentation_en-US" xlink:label="lab_evh_ChangesInTaxReceivablesAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Tax Receivables Agreement Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangesInTaxReceivablesAgreementLiability" xlink:href="evh-20220930.xsd#evh_ChangesInTaxReceivablesAgreementLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ChangesInTaxReceivablesAgreementLiability" xlink:to="lab_evh_ChangesInTaxReceivablesAgreementLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_9ee3e178-feba-4e19-948b-12c52f216ccf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock issued in connection with business combinations</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_8fe86f18-baf0-44ce-849d-1e5d5dfd94a5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_a66bc5d0-7c0f-446e-a790-1ef8931a46cf_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_bf49eacc-cc2c-42d4-a6b8-84c529425d1b_verboseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of credit outstanding, amount</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_8baefdf7-5ee7-4235-a309-837cbab01bac_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit Amount Required</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_16a44270-d446-416d-8e5c-74488358c074_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d74d3b56-c00a-4a3b-b148-97425470cae0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_50194f3c-4952-491f-9f12-88593e008bea_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9d876c29-3c46-4521-85af-ec7178084cde_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9bf3e96c-8d70-4e20-b314-139aa8d4a56d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange/conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_4e6d262f-2451-4c50-8d94-879bd77b704b_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_30812e1b-76d6-4f5a-97a2-a3e60ba81f6e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Class A common stock issued</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_53f49ad2-1481-411f-a0ed-088d5cfa403b_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_6bc11725-9539-4b69-938a-98a8fd9984f9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_bbcdf806-84a4-46a8-b085-74243db7b371_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_c7372b34-4d58-45f4-b10c-a7d09de022d2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_821a7886-41cc-4272-8f0c-fb2322ee7130_terseLabel_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for claims and performance-based arrangements</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_label_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</link:label>
    <link:label id="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_documentation_en-US" xlink:label="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:href="evh-20220930.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:to="lab_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_7d190930-eff9-4dbc-9a82-22cefbc90ea6_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_67854452-e737-487d-8284-0efaba8cbe06_negatedLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2aa0f771-7c50-4369-9fa3-c066c4eb796d_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_92f06398-ef1b-4c66-b635-ad053f9dfd0b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_62a7fb55-bf4b-4ab2-b5d1-b57a8ad6b4ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_720ddbb6-d2ac-4abf-81da-83e2a6c67416_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_4956bd3d-1bfa-43a7-a1d4-65df4db48f47_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_e93b9ab6-8d99-44f1-8730-8881829b3116_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred health care costs:</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_efe80d74-7439-4403-aec2-c659e33011b3_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expenses</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Amortization, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:to="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_661efe62-f5ff-47a6-94bd-ee51e7fa8787_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes withheld and paid for vesting of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_8e1145dd-4990-4efd-a217-a1aa102f5491_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_17612509-ac87-4008-8ec1-e17e92e2fc16_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year to date period</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_bb3c03e5-6a08-495c-8b8b-1a12fb03cb72_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9aa94a2a-e948-4eed-9e71-429949a13e1e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_d9104510-e9e3-450d-bb10-fac4b19a439c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_b43ddc3a-06b3-4c8e-9ba4-1f9c31772337_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_2c1db030-456e-459a-ad23-2891d3936f38_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount of debt repaid</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_c1d7877a-9887-412f-b2e0-7cf7a11f458a_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term lines of credit</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_0ec41556-8fee-492f-80e3-7a4f00ea7470_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental diluted shares from Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_4274257f-3101-4575-a944-0edd3a2310d8_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_ee2ff1c7-3686-442a-b299-2c183d69621c_negatedLabel_en-US" xlink:label="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of contract cost assets</link:label>
    <link:label id="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments</link:label>
    <link:label id="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_documentation_en-US" xlink:label="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:href="evh-20220930.xsd#evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:to="lab_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_92c8b54d-37c9-44bf-ac7a-d275c2632360_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivableAgreementLiability_c7b2ef36-98ef-4030-ba19-eecd926318bc_terseLabel_en-US" xlink:label="lab_evh_TaxReceivableAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax receivable agreement liability</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementLiability_label_en-US" xlink:label="lab_evh_TaxReceivableAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement Liability</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementLiability_documentation_en-US" xlink:label="lab_evh_TaxReceivableAgreementLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementLiability" xlink:href="evh-20220930.xsd#evh_TaxReceivableAgreementLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivableAgreementLiability" xlink:to="lab_evh_TaxReceivableAgreementLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_6dcf617c-cd67-4242-961b-4ee48a6b8238_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_30f8673c-4dd9-48dc-8d29-ad15cbdbd1aa_terseLabel_en-US" xlink:label="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted EBITDA</link:label>
    <link:label id="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_label_en-US" xlink:label="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</link:label>
    <link:label id="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_documentation_en-US" xlink:label="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:href="evh-20220930.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:to="lab_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_f2edb104-9712-49e7-9f6a-9688a3414092_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_85840e4a-cc51-475b-a212-00671ab46042_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_694146d7-272c-4ae6-bdc5-6f4d2483d272_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_75e8d938-1257-4b6d-9694-7e4884f897a7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, expected tax deductible amount</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_394e4c7a-7595-4765-9489-bdd96fb0fb49_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Adjusted EBITDA to Net Loss</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BrightHealthManagementIncMember_5a6f1adc-9aa5-4bc7-b347-8088f052388e_terseLabel_en-US" xlink:label="lab_evh_BrightHealthManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bright Health Management, Inc.</link:label>
    <link:label id="lab_evh_BrightHealthManagementIncMember_label_en-US" xlink:label="lab_evh_BrightHealthManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bright Health Management, Inc [Member]</link:label>
    <link:label id="lab_evh_BrightHealthManagementIncMember_documentation_en-US" xlink:label="lab_evh_BrightHealthManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bright Health Management, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BrightHealthManagementIncMember" xlink:href="evh-20220930.xsd#evh_BrightHealthManagementIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BrightHealthManagementIncMember" xlink:to="lab_evh_BrightHealthManagementIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ce4b4790-7f0d-4cf1-a2c7-3540447d4631_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_53d9b472-c012-4d17-995a-96e6126eea29_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_234ccee6-bb29-4422-be7f-ed7da066eeaa_terseLabel_en-US" xlink:label="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="evh-20220930.xsd#evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_059b6598-7295-4f2d-8490-195149d4551e_terseLabel_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Economic interest percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_label_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Economic Interest Percentage</link:label>
    <link:label id="lab_evh_EquityMethodInvestmentEconomicInterestPercentage_documentation_en-US" xlink:label="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Economic Interest Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:href="evh-20220930.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:to="lab_evh_EquityMethodInvestmentEconomicInterestPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_1c355662-09af-4af3-947c-1ae1c19123d4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_4d814c69-a383-42d0-9d56-4bd13c8fc239_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_ff0ac030-4d9b-4adb-8388-21677c7c3342_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_a4c8284a-599b-4237-a38b-a0d304124ff2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to common shareholders of Evolent Health, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_a1b036d3-16bf-4ca0-a9b8-2cde0a29c2f5_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_5d3f0f2d-849c-44e4-9b86-2d41c2f92a4e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_72f1613f-cc76-4706-9881-5ffc9f235e89_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial conversion amount (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Number of Equity Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b451c52b-38f4-4a41-bfb7-6542742c123b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_71007467-aea7-446b-ae20-4fb938f9f2c0_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_d1f37c47-c86b-40b9-8c31-a9f7b0f1f7f5_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_708b4a2f-d22c-4d1f-bbbd-0f5be6f97e4a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d123c382-7414-4e87-ba17-7ebe64a3896f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable_38ee1515-9376-4acc-abc8-aa944c05ec15_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Table]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Noncurrent, Past Due [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:to="lab_us-gaap_AccountsReceivableNoncurrentPastDueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_94063219-d631-4b38-9972-bb894a6dc3b9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_a5e21c4c-8632-4917-95d4-3918932d0c14_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_a4983c1b-804d-4bee-9320-74e05391f5c5_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current restricted cash and restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndInvestmentsCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Investments, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:to="lab_us-gaap_RestrictedCashAndInvestmentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_BasicAndDilutedEarningsPerShareAbstract_61103b93-76d8-4aba-89bc-ed8081abb151_verboseLabel_en-US" xlink:label="lab_evh_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) per common share</link:label>
    <link:label id="lab_evh_BasicAndDilutedEarningsPerShareAbstract_label_en-US" xlink:label="lab_evh_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_evh_BasicAndDilutedEarningsPerShareAbstract_documentation_en-US" xlink:label="lab_evh_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Earnings Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BasicAndDilutedEarningsPerShareAbstract" xlink:href="evh-20220930.xsd#evh_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_BasicAndDilutedEarningsPerShareAbstract" xlink:to="lab_evh_BasicAndDilutedEarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_6db37f0f-9042-41a4-98fa-6caed6d5223e_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_286d3992-783c-49de-940c-c6ced2c83eeb_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_586a3beb-d0c5-4050-9213-d00e292dc57e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_c317a89e-7fe5-41a5-bbfd-df3f8dc329fd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term receivables</link:label>
    <link:label id="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:to="lab_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_658ccf9f-73fc-4410-a3e9-428a2eb459e4_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized computer software additions</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_63b9e801-c0eb-4945-a522-719569e2b83a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_d20ae15d-35ba-45ba-a49f-59205833d3ae_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_b0e2698a-1838-4f2a-a17d-946d9f44a889_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_021ce6c7-b3c3-4908-beb7-239a2854c21f_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_2255c5ea-badb-433e-8259-52ef5393fdcb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Allowance for Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:to="lab_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_3ac2c316-cfd0-4c42-98bb-b65de1e1b6e6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_d54505c5-3224-4ee8-aff0-57138fa943c7_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_c92300fc-d262-45de-9c30-881b95426390_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_bfd1b38e-670d-413e-bbdd-e2e2a8506d24_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Primary Office Leases and Maturity of Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_975f0d03-7555-402e-a040-446685e0562e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_341f64bd-3a43-4ea2-8871-36ff0f6852c2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_1b67cfee-aed7-4df2-ab7c-8334a899e197_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation capitalized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_5509ffca-7e39-4096-bc34-232b01d7e002_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of beginning-of-period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_fcbf9752-9026-493a-9e07-57fac6f0ba35_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance as of end of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_78ace4af-3dca-4f79-9f4f-46193e44e854_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_b7285bc1-b920-4514-ac7c-5e263e6786d6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_cd86707a-3709-4fd1-b9e9-82126906e303_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_3768e102-c55e-4ac3-8906-bccc570c78e9_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_VA_36651a5d-6cce-4694-b620-1ba407bf38d1_terseLabel_en-US" xlink:label="lab_stpr_VA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arlington, VA</link:label>
    <link:label id="lab_stpr_VA_label_en-US" xlink:label="lab_stpr_VA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VIRGINIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_VA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_VA" xlink:to="lab_stpr_VA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_bbc37d50-3bb4-434a-9bcf-926e71769269_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_6f5bf90a-5e44-4913-a59e-d31224dcfbd9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total claims incurred</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_0464bc78-21f5-4c2f-a45c-ecbdc67d531a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_4eea5b2b-1d8a-453f-a3d8-7f1e7ff771da_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate trade name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfUseAssetAcquiredAndDisposedOf_2c354fd6-1429-498f-b773-8885643d4f07_negatedTerseLabel_en-US" xlink:label="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased assets disposed of (obtained in) exchange for operating lease liabilities</link:label>
    <link:label id="lab_evh_RightOfUseAssetAcquiredAndDisposedOf_label_en-US" xlink:label="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Acquired And Disposed Of</link:label>
    <link:label id="lab_evh_RightOfUseAssetAcquiredAndDisposedOf_documentation_en-US" xlink:label="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Acquired And Disposed Of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:href="evh-20220930.xsd#evh_RightOfUseAssetAcquiredAndDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:to="lab_evh_RightOfUseAssetAcquiredAndDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_bcf6c96a-f87b-4a26-8660-3e5d17dc6633_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_ServicesAgreementsMember_3610ab17-284f-4418-b1e5-5d8f59c7c9e8_terseLabel_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements</link:label>
    <link:label id="lab_evh_ServicesAgreementsMember_label_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements [Member]</link:label>
    <link:label id="lab_evh_ServicesAgreementsMember_documentation_en-US" xlink:label="lab_evh_ServicesAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember" xlink:href="evh-20220930.xsd#evh_ServicesAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_ServicesAgreementsMember" xlink:to="lab_evh_ServicesAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAxis_d85a2915-8cdf-4374-b82f-0b667ccc95c7_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAxis" xlink:to="lab_us-gaap_CapitalizedContractCostAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ef052ee0-8386-41b5-8b5a-c4eb150789aa_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_69014049-63c4-448c-985e-449dfa8f0d01_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_b4472b58-721c-4c17-90b8-97813f5bbf96_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other loss</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6e0d68e4-6176-4c47-899a-d048a38f6735_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostTable_c9b68c83-0728-47d3-8906-a506e144ee8f_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Table]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostTable_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostTable" xlink:to="lab_us-gaap_CapitalizedContractCostTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_2a169968-b734-4e23-974e-1f1fc4673a1a_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_acde5dcd-8a3d-4cde-9a69-553e1944af69_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_ddefefc5-bc4f-4d52-9c50-0cb7748a557d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_dc544fd0-bb08-492e-aa37-0625538d1490_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_ee857998-c1d0-4d45-80e8-25a222c8494c_terseLabel_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_label_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units (PSUs) [Member]</link:label>
    <link:label id="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_documentation_en-US" xlink:label="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units (PSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:href="evh-20220930.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:to="lab_evh_PerformanceBasedRestrictedStockUnitsPSUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_b41f17b0-97e1-4558-96c1-c70218421a89_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6aa10650-c422-4132-acd0-e80dffa7c84a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_6e98be1d-edb6-42c2-9a60-f9c80c2d279d_terseLabel_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims processing services</link:label>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_label_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Benefit Management Services [Member]</link:label>
    <link:label id="lab_evh_RestrictedCashforBenefitManagementServicesMember_documentation_en-US" xlink:label="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash for Benefit Management Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember" xlink:href="evh-20220930.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RestrictedCashforBenefitManagementServicesMember" xlink:to="lab_evh_RestrictedCashforBenefitManagementServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_73d6bf2e-d141-4a13-86c9-ffb899687f05_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Costs Associated with the Repositioning Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_a9609a1d-f7c7-44c7-bc4e-87bcaf24833a_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumption or input ranges</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_1698bdae-b7cf-400d-9cec-45dfd8e29a93_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining amortization period (years)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Remaining Discount Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3d30e641-d148-4888-b5ca-0b030f6f18d0_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a9d93919-eb9e-41e2-8836-81c5feb99d38_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_53acb454-50f4-4455-bc3b-369448f83903_terseLabel_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health and Hospitals System</link:label>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_label_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health And Hospitals System [Member]</link:label>
    <link:label id="lab_evh_CookCountyHealthAndHospitalsSystemMember_documentation_en-US" xlink:label="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cook County Health And Hospitals System [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember" xlink:href="evh-20220930.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_CookCountyHealthAndHospitalsSystemMember" xlink:to="lab_evh_CookCountyHealthAndHospitalsSystemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_c899aa42-f230-445d-86a4-2824cf5ff222_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_d7d28551-8485-4eea-9b6d-4aa78f8cb013_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_60a42d57-da9c-4e69-a989-790862f8087f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7792dd1c-b398-444b-8987-437392869c31_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_58226a67-7667-41e7-a304-ffe7f03bd980_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_20a6d603-9b75-4644-b54d-fbecad733b7d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_825f197b-61b9-4d8a-b23c-afb6c176197d_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_8c8f25ac-0ed6-490c-bbed-9b7901e88687_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_53e07442-dcbd-4e1e-8b18-d8580d7452f3_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_353c6460-3e21-467b-a65c-1b5d5bc72186_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a4dd7bb3-60b0-4b2b-8388-65db57ff0999_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalFees_cfed8eb0-a715-441c-ba14-c57d846beac7_terseLabel_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal expenses</link:label>
    <link:label id="lab_us-gaap_LegalFees_label_en-US" xlink:label="lab_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalFees" xlink:to="lab_us-gaap_LegalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_936bbc70-a4b2-4202-aa88-0c74d70827f7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_69593d21-5685-40f6-ac3b-b33a7d16553c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_e519ba99-70c0-4125-91e9-1fc1fa1b2ae0_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued net working capital adjustment with business combinations</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_ae5dd97f-9a5f-4da1-8599-ef5930e61309_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_NumberOfOptionsToRenewLeases_8a6400c2-2766-4aea-b48c-c22eb35ed56d_terseLabel_en-US" xlink:label="lab_evh_NumberOfOptionsToRenewLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of leases option</link:label>
    <link:label id="lab_evh_NumberOfOptionsToRenewLeases_label_en-US" xlink:label="lab_evh_NumberOfOptionsToRenewLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Renew Leases</link:label>
    <link:label id="lab_evh_NumberOfOptionsToRenewLeases_documentation_en-US" xlink:label="lab_evh_NumberOfOptionsToRenewLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Renew Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfOptionsToRenewLeases" xlink:href="evh-20220930.xsd#evh_NumberOfOptionsToRenewLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_NumberOfOptionsToRenewLeases" xlink:to="lab_evh_NumberOfOptionsToRenewLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_23e8bf49-9bb7-4206-8d3b-4c30986aa108_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, percentage</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fed89089-73e1-41f1-914c-58b86a52ebad_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows Provided by (Used In) Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostLineItems_809dc0a9-4348-4c13-9a30-e0cc7575d4f8_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostLineItems_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Contract Cost [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems" xlink:to="lab_us-gaap_CapitalizedContractCostLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_810524f9-dd95-4d63-b195-a27735f635ae_negatedTerseLabel_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in working capital balances related to claims processing on behalf of partners</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_label_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Claims Processing, Financing Activities</link:label>
    <link:label id="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_documentation_en-US" xlink:label="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For (Proceeds From) Claims Processing, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:href="evh-20220930.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:to="lab_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7cfcba65-4aec-4137-9447-30913b394ee7_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Disclosure of Non-cash Investing and Financing Activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_05e2c025-1aea-442a-964d-728b737d28c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_3abffd5b-096f-4a2c-94b7-7ab5f87aab7e_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of senior debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_c4fc020f-a9a9-4edd-a32b-4888c081c9a6_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_ebcbacd2-f86a-4fa0-bf62-e7d84a9c2372_terseLabel_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Past due less than 60 days</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_label_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 60 Days [Member]</link:label>
    <link:label id="lab_evh_FInancialAssetLessThan60DaysMember_documentation_en-US" xlink:label="lab_evh_FInancialAssetLessThan60DaysMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FInancial Asset, Less Than 60 Days [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember" xlink:href="evh-20220930.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_FInancialAssetLessThan60DaysMember" xlink:to="lab_evh_FInancialAssetLessThan60DaysMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_cf8da565-608e-463b-8d60-f42460ec5ac7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_f2cdad59-ffcc-4021-b8fc-1e61db167c03_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Equity Method Investees</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_cd4f36b3-101d-4448-81ac-27ff6fcd3f62_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from equity method investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_6f954a72-f4ce-4f64-bebb-66c81dfca2f2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from equity method investees</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_2211530e-6741-4ffa-9ba6-c4a85c0eaccd_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_8e9d8cc4-b5c5-4f3d-b1fa-ad277b775787_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term receivables</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_2b92a5ae-7567-4c6d-9c0f-cf6bcb0f1f87_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ca0f0fe6-f3ae-4dc3-8cf2-9a8ec62f4462_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_db75415a-00f1-4015-b70d-cff3a502babe_terseLabel_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable netted against claims payable</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_label_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_documentation_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:href="evh-20220930.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:to="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_024d5387-b0ac-439b-83e0-2674a38883ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_732b6b20-74bb-43c6-9dfa-e6f0e87e6dfc_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased assets disposed of (obtained in) exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_c69b7dbd-9364-4bf4-907d-1cb726d5e65c_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_StockIssuedInConnectionWithDebtRepayment_5eb63ef9-8099-422d-9251-a368b6efdc4b_terseLabel_en-US" xlink:label="lab_evh_StockIssuedInConnectionWithDebtRepayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class A common stock issued in connection with debt repayment</link:label>
    <link:label id="lab_evh_StockIssuedInConnectionWithDebtRepayment_label_en-US" xlink:label="lab_evh_StockIssuedInConnectionWithDebtRepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued in Connection with Debt Repayment</link:label>
    <link:label id="lab_evh_StockIssuedInConnectionWithDebtRepayment_documentation_en-US" xlink:label="lab_evh_StockIssuedInConnectionWithDebtRepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued in Connection with Debt Repayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedInConnectionWithDebtRepayment" xlink:href="evh-20220930.xsd#evh_StockIssuedInConnectionWithDebtRepayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_StockIssuedInConnectionWithDebtRepayment" xlink:to="lab_evh_StockIssuedInConnectionWithDebtRepayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_f5c165c8-571f-47b9-9661-0eb8e9bd99ce_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders_c29c02bc-a657-4584-b096-2d8b1df4f990_terseLabel_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of tax benefit percent</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders_label_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement, Percent Of Cash Savings Paid To Shareholders</link:label>
    <link:label id="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders_documentation_en-US" xlink:label="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Receivable Agreement, Percent Of Cash Savings Paid To Shareholders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" xlink:href="evh-20220930.xsd#evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" xlink:to="lab_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_15f235d4-630e-40a8-82e3-4906c997b349_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_6971af2b-485a-4c08-aa1e-3ebdef79fd09_terseLabel_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net eligible for net basis settlement</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_label_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement</link:label>
    <link:label id="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_documentation_en-US" xlink:label="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:href="evh-20220930.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:to="lab_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_d472132b-b28f-407f-a6f9-58c7575a23c4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>evh-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:b69e33fa-4fec-4147-99e6-af63e8e14083,g:752cd8d8-fa1c-4165-8528-47511781866b-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CoverPage" xlink:type="simple" xlink:href="evh-20220930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_41b9c087-7f50-4bc2-8807-7f0ad52bf381" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_DocumentType_41b9c087-7f50-4bc2-8807-7f0ad52bf381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_8fe66b9a-453b-43a9-a8bb-a5c2afde6ee4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_DocumentQuarterlyReport_8fe66b9a-453b-43a9-a8bb-a5c2afde6ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_84de52f2-fa18-4386-bce2-cd60f84bd238" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_DocumentPeriodEndDate_84de52f2-fa18-4386-bce2-cd60f84bd238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_8c55e84a-87a7-4d4b-99f0-8c563d23db97" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_DocumentTransitionReport_8c55e84a-87a7-4d4b-99f0-8c563d23db97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_408d0a94-ee2a-42f7-8f78-5659c0e80607" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_EntityFileNumber_408d0a94-ee2a-42f7-8f78-5659c0e80607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_05eaa8ac-1d78-48bd-ba1a-5654e41ab9a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_EntityRegistrantName_05eaa8ac-1d78-48bd-ba1a-5654e41ab9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_965eac4d-8e84-4916-ad4a-6060c02a442e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_EntityIncorporationStateCountryCode_965eac4d-8e84-4916-ad4a-6060c02a442e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f13bc0e8-30a9-4ed4-b412-7db772b72316" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_EntityTaxIdentificationNumber_f13bc0e8-30a9-4ed4-b412-7db772b72316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9e58c96d-44d7-4f10-b2f8-c94a9a81acb5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_EntityAddressAddressLine1_9e58c96d-44d7-4f10-b2f8-c94a9a81acb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_76ffea4d-d9e1-4be6-b72b-60522ab664e2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_EntityAddressAddressLine2_76ffea4d-d9e1-4be6-b72b-60522ab664e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f7c49e26-3d65-4f43-8580-bccf11a43e98" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_EntityAddressCityOrTown_f7c49e26-3d65-4f43-8580-bccf11a43e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c205ae85-9881-4032-92d7-e36807904cc9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_EntityAddressStateOrProvince_c205ae85-9881-4032-92d7-e36807904cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ccafd56a-380a-43ce-abc5-a94c81e55b02" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_EntityAddressPostalZipCode_ccafd56a-380a-43ce-abc5-a94c81e55b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c99df9c2-c3d7-4200-8d78-69dbf8167900" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_CityAreaCode_c99df9c2-c3d7-4200-8d78-69dbf8167900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bfda4e37-266a-41fb-aecb-b2cfc963fda0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_LocalPhoneNumber_bfda4e37-266a-41fb-aecb-b2cfc963fda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_778335e6-5f55-412a-a30c-3d5bbffa054a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_Security12bTitle_778335e6-5f55-412a-a30c-3d5bbffa054a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_15317e0e-0cdf-464b-b5c5-25815c035c25" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_TradingSymbol_15317e0e-0cdf-464b-b5c5-25815c035c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_364512f3-8c32-4f4c-b7f6-dffc6085b4df" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_SecurityExchangeName_364512f3-8c32-4f4c-b7f6-dffc6085b4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_01455c50-3463-4a26-8dc3-561ba9b29734" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_EntityCurrentReportingStatus_01455c50-3463-4a26-8dc3-561ba9b29734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_832f0300-00a3-4ed9-bc53-32079501d212" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_EntityInteractiveDataCurrent_832f0300-00a3-4ed9-bc53-32079501d212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_87da820b-a604-4738-b4a8-79b43d880258" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_EntityFilerCategory_87da820b-a604-4738-b4a8-79b43d880258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6520fd60-5e29-49b8-ad7f-75c4727e6978" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_EntitySmallBusiness_6520fd60-5e29-49b8-ad7f-75c4727e6978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_412da5c5-9cb6-468d-945c-bde4e5b49bfb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_EntityEmergingGrowthCompany_412da5c5-9cb6-468d-945c-bde4e5b49bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_ad1f7cb0-c7d7-47f0-a7fc-b735bd41b5c2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_EntityShellCompany_ad1f7cb0-c7d7-47f0-a7fc-b735bd41b5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_534d6ae2-be6c-49cb-b874-0b5ab14c466b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_534d6ae2-be6c-49cb-b874-0b5ab14c466b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f7551257-d243-47be-b1d4-9c5a2e970293" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_EntityCentralIndexKey_f7551257-d243-47be-b1d4-9c5a2e970293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8912ccad-8b68-4c12-9432-c5c80708eda2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_AmendmentFlag_8912ccad-8b68-4c12-9432-c5c80708eda2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f261fae2-ce17-43e0-be0b-253d6249d158" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_DocumentFiscalYearFocus_f261fae2-ce17-43e0-be0b-253d6249d158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_7aa856ec-acfe-4bed-982b-7da63fbfa0b2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_DocumentFiscalPeriodFocus_7aa856ec-acfe-4bed-982b-7da63fbfa0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9f05de82-f2fb-4ec9-8b99-eae3f42320b6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_126de39a-96af-4f59-bfa1-771a3523c769" xlink:to="loc_dei_CurrentFiscalYearEndDate_9f05de82-f2fb-4ec9-8b99-eae3f42320b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="evh-20220930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_80bb4f11-4534-4a81-a3b2-dbe847cdc1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3fa3114b-87f9-4f2e-905e-6175c0033f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_80bb4f11-4534-4a81-a3b2-dbe847cdc1bc" xlink:to="loc_us-gaap_AssetsAbstract_3fa3114b-87f9-4f2e-905e-6175c0033f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_82954ada-e59d-4dba-a9c6-fc806ff258f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa3114b-87f9-4f2e-905e-6175c0033f34" xlink:to="loc_us-gaap_AssetsCurrentAbstract_82954ada-e59d-4dba-a9c6-fc806ff258f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_faf01c45-71fa-4501-bc90-b13d17b5d6af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_82954ada-e59d-4dba-a9c6-fc806ff258f4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_faf01c45-71fa-4501-bc90-b13d17b5d6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_62b4e810-3d1a-453d-8316-5fb40892b618" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_82954ada-e59d-4dba-a9c6-fc806ff258f4" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_62b4e810-3d1a-453d-8316-5fb40892b618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_55c02e55-a175-413e-b71d-e381e79f0fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_82954ada-e59d-4dba-a9c6-fc806ff258f4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_55c02e55-a175-413e-b71d-e381e79f0fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5a3162fb-8748-46f8-9da4-ca6722bf7205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_82954ada-e59d-4dba-a9c6-fc806ff258f4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5a3162fb-8748-46f8-9da4-ca6722bf7205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2c9492cb-b5a7-452c-901c-e809827fd037" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_82954ada-e59d-4dba-a9c6-fc806ff258f4" xlink:to="loc_us-gaap_AssetsCurrent_2c9492cb-b5a7-452c-901c-e809827fd037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_0cd48709-3a42-4f36-9783-65a6818311de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa3114b-87f9-4f2e-905e-6175c0033f34" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_0cd48709-3a42-4f36-9783-65a6818311de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_c32022cb-89f3-448a-b7e9-75e03ad39cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa3114b-87f9-4f2e-905e-6175c0033f34" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_c32022cb-89f3-448a-b7e9-75e03ad39cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5141de74-1aa0-40d5-b851-aefa040d1d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa3114b-87f9-4f2e-905e-6175c0033f34" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5141de74-1aa0-40d5-b851-aefa040d1d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cdf24001-fa36-4cb8-bdbf-7542330eee73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa3114b-87f9-4f2e-905e-6175c0033f34" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cdf24001-fa36-4cb8-bdbf-7542330eee73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_3e91f472-da61-4d68-aa3e-812ffdf4d222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa3114b-87f9-4f2e-905e-6175c0033f34" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_3e91f472-da61-4d68-aa3e-812ffdf4d222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNetNoncurrent_b8de7aae-4676-48ab-86be-f4890385c1ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNetNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa3114b-87f9-4f2e-905e-6175c0033f34" xlink:to="loc_us-gaap_CapitalizedContractCostNetNoncurrent_b8de7aae-4676-48ab-86be-f4890385c1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_97e68e3f-421b-42bb-8fc4-99111c7232fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa3114b-87f9-4f2e-905e-6175c0033f34" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_97e68e3f-421b-42bb-8fc4-99111c7232fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fabc6ab6-4d58-42d4-b1e6-a87b754e3f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa3114b-87f9-4f2e-905e-6175c0033f34" xlink:to="loc_us-gaap_Goodwill_fabc6ab6-4d58-42d4-b1e6-a87b754e3f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_59052d1f-e41b-4365-ac75-0ea00950d10d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3fa3114b-87f9-4f2e-905e-6175c0033f34" xlink:to="loc_us-gaap_Assets_59052d1f-e41b-4365-ac75-0ea00950d10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b9f2df59-9bd2-439a-98bc-bc93a74a8910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_80bb4f11-4534-4a81-a3b2-dbe847cdc1bc" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b9f2df59-9bd2-439a-98bc-bc93a74a8910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_857b7cf7-fdfc-4594-9e4d-78f45881b8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b9f2df59-9bd2-439a-98bc-bc93a74a8910" xlink:to="loc_us-gaap_LiabilitiesAbstract_857b7cf7-fdfc-4594-9e4d-78f45881b8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a5896f60-7945-4bfd-a61a-36e163a498cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_857b7cf7-fdfc-4594-9e4d-78f45881b8d9" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a5896f60-7945-4bfd-a61a-36e163a498cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8974ed3a-90d4-4eb1-aee9-d4e2425628d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5896f60-7945-4bfd-a61a-36e163a498cd" xlink:to="loc_us-gaap_AccountsPayableCurrent_8974ed3a-90d4-4eb1-aee9-d4e2425628d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_660d86f9-c0f5-42b6-9d60-eed2b3e0be3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5896f60-7945-4bfd-a61a-36e163a498cd" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_660d86f9-c0f5-42b6-9d60-eed2b3e0be3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_da6c74ae-0d89-405b-a576-50d5925879ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5896f60-7945-4bfd-a61a-36e163a498cd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_da6c74ae-0d89-405b-a576-50d5925879ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7110f2ce-f219-4428-b7fb-43d95574d0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5896f60-7945-4bfd-a61a-36e163a498cd" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7110f2ce-f219-4428-b7fb-43d95574d0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7b198814-9289-4bfb-806c-f6af5eb1e349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5896f60-7945-4bfd-a61a-36e163a498cd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7b198814-9289-4bfb-806c-f6af5eb1e349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_799ea2ba-4efa-4126-af1a-7539c724b27a" xlink:href="evh-20220930.xsd#evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5896f60-7945-4bfd-a61a-36e163a498cd" xlink:to="loc_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements_799ea2ba-4efa-4126-af1a-7539c724b27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d59bcd2f-353b-4319-a444-ddea5d62f64b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a5896f60-7945-4bfd-a61a-36e163a498cd" xlink:to="loc_us-gaap_LiabilitiesCurrent_d59bcd2f-353b-4319-a444-ddea5d62f64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_0848923c-b44f-43eb-96b2-c60783e6e99d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_857b7cf7-fdfc-4594-9e4d-78f45881b8d9" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_0848923c-b44f-43eb-96b2-c60783e6e99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_67543566-b150-444d-bfe6-8c7825168d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_857b7cf7-fdfc-4594-9e4d-78f45881b8d9" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_67543566-b150-444d-bfe6-8c7825168d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementLiability_ae5537f1-915e-4501-be87-06388f401dc3" xlink:href="evh-20220930.xsd#evh_TaxReceivableAgreementLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_857b7cf7-fdfc-4594-9e4d-78f45881b8d9" xlink:to="loc_evh_TaxReceivableAgreementLiability_ae5537f1-915e-4501-be87-06388f401dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ac546c67-2897-4038-8bd3-cb252d347056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_857b7cf7-fdfc-4594-9e4d-78f45881b8d9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ac546c67-2897-4038-8bd3-cb252d347056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_23cc1985-a78c-4967-9b09-adcd2d04da67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_857b7cf7-fdfc-4594-9e4d-78f45881b8d9" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_23cc1985-a78c-4967-9b09-adcd2d04da67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_014d3374-700b-4b2f-a0bf-a3fb950a3a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_857b7cf7-fdfc-4594-9e4d-78f45881b8d9" xlink:to="loc_us-gaap_Liabilities_014d3374-700b-4b2f-a0bf-a3fb950a3a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_517d0da8-9fc2-407f-b370-c456af739680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b9f2df59-9bd2-439a-98bc-bc93a74a8910" xlink:to="loc_us-gaap_CommitmentsAndContingencies_517d0da8-9fc2-407f-b370-c456af739680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_54c409e5-2c96-4072-a814-be3927bcff4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b9f2df59-9bd2-439a-98bc-bc93a74a8910" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_54c409e5-2c96-4072-a814-be3927bcff4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_8570df79-4b63-409e-a601-82c97e09d3f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_54c409e5-2c96-4072-a814-be3927bcff4f" xlink:to="loc_us-gaap_CommonStockValue_8570df79-4b63-409e-a601-82c97e09d3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_79bfd798-6db4-453e-a45e-3b0802b95a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_54c409e5-2c96-4072-a814-be3927bcff4f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_79bfd798-6db4-453e-a45e-3b0802b95a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8f4e6602-a31f-4aad-89f1-fe53f1798c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_54c409e5-2c96-4072-a814-be3927bcff4f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8f4e6602-a31f-4aad-89f1-fe53f1798c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2328f02e-69d5-490b-b161-ef1df04abfa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_54c409e5-2c96-4072-a814-be3927bcff4f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2328f02e-69d5-490b-b161-ef1df04abfa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_be5522cf-2365-4df7-a020-bb3ac3802354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_54c409e5-2c96-4072-a814-be3927bcff4f" xlink:to="loc_us-gaap_TreasuryStockCommonValue_be5522cf-2365-4df7-a020-bb3ac3802354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b1bcf32e-4aaf-4ae2-b025-64c283f93947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_54c409e5-2c96-4072-a814-be3927bcff4f" xlink:to="loc_us-gaap_StockholdersEquity_b1bcf32e-4aaf-4ae2-b025-64c283f93947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_22550aef-9fed-4f10-b170-924038d96b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b9f2df59-9bd2-439a-98bc-bc93a74a8910" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_22550aef-9fed-4f10-b170-924038d96b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="evh-20220930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_bc9e251d-20e5-4f40-a8e2-37e69eeb3abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e9c3d744-2e95-4ae8-8329-ad2ebe31a384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bc9e251d-20e5-4f40-a8e2-37e69eeb3abf" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e9c3d744-2e95-4ae8-8329-ad2ebe31a384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_463a3554-0445-4a1c-80e4-676079db3a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bc9e251d-20e5-4f40-a8e2-37e69eeb3abf" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_463a3554-0445-4a1c-80e4-676079db3a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_e54446fe-3117-4c91-aa02-ec722ee01517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bc9e251d-20e5-4f40-a8e2-37e69eeb3abf" xlink:to="loc_us-gaap_CommonStockSharesIssued_e54446fe-3117-4c91-aa02-ec722ee01517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_81f1377b-075d-4bc2-aae0-56e1d31900cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bc9e251d-20e5-4f40-a8e2-37e69eeb3abf" xlink:to="loc_us-gaap_TreasuryStockCommonShares_81f1377b-075d-4bc2-aae0-56e1d31900cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="evh-20220930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4e3d20f1-be27-42ae-b80a-7ed45f77f6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cd74ea78-d678-481b-bf68-a10a2f47bbd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e3d20f1-be27-42ae-b80a-7ed45f77f6d1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cd74ea78-d678-481b-bf68-a10a2f47bbd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_786759e3-5688-4df9-a21e-91d800d41ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e3d20f1-be27-42ae-b80a-7ed45f77f6d1" xlink:to="loc_us-gaap_OperatingExpensesAbstract_786759e3-5688-4df9-a21e-91d800d41ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_1a00937d-d8a2-47bf-b834-af11de9e1177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_786759e3-5688-4df9-a21e-91d800d41ff9" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_1a00937d-d8a2-47bf-b834-af11de9e1177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_64cc6d3b-44f4-4db2-a00c-803a3bf7adba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_786759e3-5688-4df9-a21e-91d800d41ff9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_64cc6d3b-44f4-4db2-a00c-803a3bf7adba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_78f016bb-e3a5-466b-b1b0-9ce16c22ec5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_786759e3-5688-4df9-a21e-91d800d41ff9" xlink:to="loc_us-gaap_DepreciationAndAmortization_78f016bb-e3a5-466b-b1b0-9ce16c22ec5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_21a51b93-d284-408e-a1b4-4f07090af66a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_786759e3-5688-4df9-a21e-91d800d41ff9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_21a51b93-d284-408e-a1b4-4f07090af66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6321c1f1-9f25-4fb5-87f1-781024ad5753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_786759e3-5688-4df9-a21e-91d800d41ff9" xlink:to="loc_us-gaap_CostsAndExpenses_6321c1f1-9f25-4fb5-87f1-781024ad5753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fc21f537-7fca-4873-ab9d-11be6c5e85b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e3d20f1-be27-42ae-b80a-7ed45f77f6d1" xlink:to="loc_us-gaap_OperatingIncomeLoss_fc21f537-7fca-4873-ab9d-11be6c5e85b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_c50072e3-bfd6-47c2-bdcc-22403d6421b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e3d20f1-be27-42ae-b80a-7ed45f77f6d1" xlink:to="loc_us-gaap_InvestmentIncomeInterest_c50072e3-bfd6-47c2-bdcc-22403d6421b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_74ecb227-fd79-4571-a4b0-4ecf2666740b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e3d20f1-be27-42ae-b80a-7ed45f77f6d1" xlink:to="loc_us-gaap_InterestExpense_74ecb227-fd79-4571-a4b0-4ecf2666740b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a4f99495-b6da-40b3-b44e-99a6deeab297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e3d20f1-be27-42ae-b80a-7ed45f77f6d1" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a4f99495-b6da-40b3-b44e-99a6deeab297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_6cea9ef3-76a0-42aa-aa53-df5d15f4b844" xlink:href="evh-20220930.xsd#evh_GainOnTransferOfMembership"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e3d20f1-be27-42ae-b80a-7ed45f77f6d1" xlink:to="loc_evh_GainOnTransferOfMembership_6cea9ef3-76a0-42aa-aa53-df5d15f4b844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ed539b39-8d22-4335-862d-d01a73e2c44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e3d20f1-be27-42ae-b80a-7ed45f77f6d1" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ed539b39-8d22-4335-862d-d01a73e2c44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangesInTaxReceivablesAgreementLiability_61f52d97-99fc-45b1-9607-842c336afc6f" xlink:href="evh-20220930.xsd#evh_ChangesInTaxReceivablesAgreementLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e3d20f1-be27-42ae-b80a-7ed45f77f6d1" xlink:to="loc_evh_ChangesInTaxReceivablesAgreementLiability_61f52d97-99fc-45b1-9607-842c336afc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_06ba3d81-6d24-4078-896e-845688e621d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e3d20f1-be27-42ae-b80a-7ed45f77f6d1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_06ba3d81-6d24-4078-896e-845688e621d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_23d87b8d-280a-472c-8125-7b2dae90a42e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e3d20f1-be27-42ae-b80a-7ed45f77f6d1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_23d87b8d-280a-472c-8125-7b2dae90a42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_24ef0821-e686-4722-8378-43976e1680cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e3d20f1-be27-42ae-b80a-7ed45f77f6d1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_24ef0821-e686-4722-8378-43976e1680cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_e63f1d69-6db1-4d17-9def-c6ecb6a949f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e3d20f1-be27-42ae-b80a-7ed45f77f6d1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_e63f1d69-6db1-4d17-9def-c6ecb6a949f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c33a3051-82fa-4fc3-add9-d161450786ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e3d20f1-be27-42ae-b80a-7ed45f77f6d1" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c33a3051-82fa-4fc3-add9-d161450786ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_03aad5fe-fbec-4e60-91d0-ac69288d0d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e3d20f1-be27-42ae-b80a-7ed45f77f6d1" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_03aad5fe-fbec-4e60-91d0-ac69288d0d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_3eb719e5-06c2-400d-a55a-a9bac9675f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e3d20f1-be27-42ae-b80a-7ed45f77f6d1" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_3eb719e5-06c2-400d-a55a-a9bac9675f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f2fa452f-bfcc-47bb-b292-ce1f7a9a7883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e3d20f1-be27-42ae-b80a-7ed45f77f6d1" xlink:to="loc_us-gaap_EarningsPerShareAbstract_f2fa452f-bfcc-47bb-b292-ce1f7a9a7883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_db6219ac-11f4-43c8-b794-c2b7fbd773eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f2fa452f-bfcc-47bb-b292-ce1f7a9a7883" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_db6219ac-11f4-43c8-b794-c2b7fbd773eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_fe631832-f7d5-4376-8b2b-5329ebe0ac27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_db6219ac-11f4-43c8-b794-c2b7fbd773eb" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_fe631832-f7d5-4376-8b2b-5329ebe0ac27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_3d7751bb-32dc-4f3c-b80c-9c4a7018f303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_db6219ac-11f4-43c8-b794-c2b7fbd773eb" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_3d7751bb-32dc-4f3c-b80c-9c4a7018f303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_02f01c78-e0e0-456a-8a13-1723c5e44d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_db6219ac-11f4-43c8-b794-c2b7fbd773eb" xlink:to="loc_us-gaap_EarningsPerShareBasic_02f01c78-e0e0-456a-8a13-1723c5e44d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_123b7487-ede0-4494-bfa7-595b51ca1564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f2fa452f-bfcc-47bb-b292-ce1f7a9a7883" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_123b7487-ede0-4494-bfa7-595b51ca1564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_7e510a4d-073f-4e08-bc6f-6c14c1a7385e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_123b7487-ede0-4494-bfa7-595b51ca1564" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_7e510a4d-073f-4e08-bc6f-6c14c1a7385e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_80fb91b4-20e7-4036-ac54-09cc280f482d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_123b7487-ede0-4494-bfa7-595b51ca1564" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_80fb91b4-20e7-4036-ac54-09cc280f482d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1774db17-6a2a-4dee-b6ed-6243c99c17fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_123b7487-ede0-4494-bfa7-595b51ca1564" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1774db17-6a2a-4dee-b6ed-6243c99c17fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_WeightedAverageCommonSharesOutstandingAbstract_7dc656cf-ca17-4dd5-ae5a-9b0531671735" xlink:href="evh-20220930.xsd#evh_WeightedAverageCommonSharesOutstandingAbstract"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e3d20f1-be27-42ae-b80a-7ed45f77f6d1" xlink:to="loc_evh_WeightedAverageCommonSharesOutstandingAbstract_7dc656cf-ca17-4dd5-ae5a-9b0531671735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e6c0c730-b718-41a0-b6ab-1ee43f3e411c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_WeightedAverageCommonSharesOutstandingAbstract_7dc656cf-ca17-4dd5-ae5a-9b0531671735" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e6c0c730-b718-41a0-b6ab-1ee43f3e411c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_02d0ab1c-a18c-4290-b419-e422fc4cd498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_WeightedAverageCommonSharesOutstandingAbstract_7dc656cf-ca17-4dd5-ae5a-9b0531671735" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_02d0ab1c-a18c-4290-b419-e422fc4cd498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_f49d85df-6391-4421-b4f7-48fc44674a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4e3d20f1-be27-42ae-b80a-7ed45f77f6d1" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_f49d85df-6391-4421-b4f7-48fc44674a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0ef26bd9-e416-4c79-a2ba-0b4b2ae4ee73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_f49d85df-6391-4421-b4f7-48fc44674a9b" xlink:to="loc_us-gaap_NetIncomeLoss_0ef26bd9-e416-4c79-a2ba-0b4b2ae4ee73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_2baab65a-0e41-4016-8454-3fb53c5c4d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_f49d85df-6391-4421-b4f7-48fc44674a9b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_2baab65a-0e41-4016-8454-3fb53c5c4d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ad1a54a0-6227-4fc0-b6c1-9c5f3131293c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_2baab65a-0e41-4016-8454-3fb53c5c4d1b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ad1a54a0-6227-4fc0-b6c1-9c5f3131293c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_1da2853b-eeb2-4805-aeee-327b6553fe3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_f49d85df-6391-4421-b4f7-48fc44674a9b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_1da2853b-eeb2-4805-aeee-327b6553fe3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="simple" xlink:href="evh-20220930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_041145ee-66f8-4b0c-9639-f4727bb94535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_6d7d3e90-db18-449b-8fbf-d89dd4929785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_041145ee-66f8-4b0c-9639-f4727bb94535" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_6d7d3e90-db18-449b-8fbf-d89dd4929785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="evh-20220930.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_8ebfeb56-d60a-4ef4-8240-8b7d29d1fa6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6aafa344-beb6-424d-be7d-3d87428ad149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_8ebfeb56-d60a-4ef4-8240-8b7d29d1fa6d" xlink:to="loc_us-gaap_StatementTable_6aafa344-beb6-424d-be7d-3d87428ad149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b17bfbad-c859-4b97-a53f-849134b6a5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6aafa344-beb6-424d-be7d-3d87428ad149" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b17bfbad-c859-4b97-a53f-849134b6a5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_944a9b06-e315-491f-aed6-7404e49f620a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b17bfbad-c859-4b97-a53f-849134b6a5c5" xlink:to="loc_us-gaap_EquityComponentDomain_944a9b06-e315-491f-aed6-7404e49f620a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_344e439c-cb69-4c89-bdb9-61a13cfa61f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_944a9b06-e315-491f-aed6-7404e49f620a" xlink:to="loc_us-gaap_CommonStockMember_344e439c-cb69-4c89-bdb9-61a13cfa61f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6aff8ce2-c543-4b35-b972-00faaba02e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_944a9b06-e315-491f-aed6-7404e49f620a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6aff8ce2-c543-4b35-b972-00faaba02e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_0ed0f90f-90bf-4c0f-88d6-5d448455ef36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_944a9b06-e315-491f-aed6-7404e49f620a" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_0ed0f90f-90bf-4c0f-88d6-5d448455ef36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4e743422-7927-4f52-9382-cdc836269675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_944a9b06-e315-491f-aed6-7404e49f620a" xlink:to="loc_us-gaap_RetainedEarningsMember_4e743422-7927-4f52-9382-cdc836269675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_e7ecc11e-531e-448e-a17c-a3971fe06a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_944a9b06-e315-491f-aed6-7404e49f620a" xlink:to="loc_us-gaap_TreasuryStockMember_e7ecc11e-531e-448e-a17c-a3971fe06a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_06691936-6af6-47cb-bf0d-eedc484ddb08" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6aafa344-beb6-424d-be7d-3d87428ad149" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_06691936-6af6-47cb-bf0d-eedc484ddb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ed52851d-9e26-4d29-b418-4e07c986c8bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_06691936-6af6-47cb-bf0d-eedc484ddb08" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ed52851d-9e26-4d29-b418-4e07c986c8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5c31b53e-c048-4c9c-8f7a-5faa2343c50c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_ed52851d-9e26-4d29-b418-4e07c986c8bf" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5c31b53e-c048-4c9c-8f7a-5faa2343c50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4ee60496-8bab-4712-a63e-84347b4b8ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6aafa344-beb6-424d-be7d-3d87428ad149" xlink:to="loc_us-gaap_StatementLineItems_4ee60496-8bab-4712-a63e-84347b4b8ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4ee60496-8bab-4712-a63e-84347b4b8ca4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_fca65126-21be-44fe-817d-541103c97e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_SharesIssued_fca65126-21be-44fe-817d-541103c97e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8937e2c1-8df9-4795-aaf9-e741ea051f45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockholdersEquity_8937e2c1-8df9-4795-aaf9-e741ea051f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b91190e2-907d-4850-86f9-407ad4fe80bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b91190e2-907d-4850-86f9-407ad4fe80bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0943d828-1132-473d-ab47-dd50b0f638e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0943d828-1132-473d-ab47-dd50b0f638e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b1c63d35-e3f8-4bcd-89bd-f9af0b0dd056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_b1c63d35-e3f8-4bcd-89bd-f9af0b0dd056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_770a07e3-b016-48ab-a26f-5e3a3b15edab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_770a07e3-b016-48ab-a26f-5e3a3b15edab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_98556079-2e17-473d-bbcf-2493281cd0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_98556079-2e17-473d-bbcf-2493281cd0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_20f78268-a897-43d1-b397-9646e68a1828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_20f78268-a897-43d1-b397-9646e68a1828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_34b4af19-86cc-4bea-af63-1057899b5769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_34b4af19-86cc-4bea-af63-1057899b5769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_b4a12672-48ea-483d-8f8b-8b24d83acd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_b4a12672-48ea-483d-8f8b-8b24d83acd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_ddf76fea-97b0-4eb2-b99a-61a48e53f887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_ddf76fea-97b0-4eb2-b99a-61a48e53f887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1f725034-01fb-4d69-bb9c-0de272c6be4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1f725034-01fb-4d69-bb9c-0de272c6be4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8681c1b0-467b-44b6-8039-825d58e33d12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8681c1b0-467b-44b6-8039-825d58e33d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a25e93da-d3c0-483c-8e2f-c47ac61999f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_a25e93da-d3c0-483c-8e2f-c47ac61999f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5d732319-68d1-4b20-9937-38e6770f08b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_NetIncomeLoss_5d732319-68d1-4b20-9937-38e6770f08b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_3b408008-9150-4954-9307-17e3ea596ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_SharesIssued_3b408008-9150-4954-9307-17e3ea596ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ac0cb410-afd0-4480-8e15-33044d964423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6b120bd5-2c7e-4500-bf49-2ae8e934deec" xlink:to="loc_us-gaap_StockholdersEquity_ac0cb410-afd0-4480-8e15-33044d964423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_72987cd8-5ef5-4b3a-8e9a-f3f0a33886cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4ee60496-8bab-4712-a63e-84347b4b8ca4" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_72987cd8-5ef5-4b3a-8e9a-f3f0a33886cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="evh-20220930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_02b5d09a-e45e-429c-b444-6698dee3a3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1878671c-6d44-477a-ad88-3ae2b3e36fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02b5d09a-e45e-429c-b444-6698dee3a3a6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1878671c-6d44-477a-ad88-3ae2b3e36fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d3ae13c0-f0e3-42a1-b9b3-9229c561f2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1878671c-6d44-477a-ad88-3ae2b3e36fc2" xlink:to="loc_us-gaap_NetIncomeLoss_d3ae13c0-f0e3-42a1-b9b3-9229c561f2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_827940b8-3200-455f-a705-049add7f3db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1878671c-6d44-477a-ad88-3ae2b3e36fc2" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_827940b8-3200-455f-a705-049add7f3db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f4aa4b31-21aa-4900-b735-28bb380137f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_827940b8-3200-455f-a705-049add7f3db6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f4aa4b31-21aa-4900-b735-28bb380137f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_88cbe564-f367-49ed-830d-7c4e4a0198a7" xlink:href="evh-20220930.xsd#evh_GainLossOnDispositionOfAssetsOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_827940b8-3200-455f-a705-049add7f3db6" xlink:to="loc_evh_GainLossOnDispositionOfAssetsOperatingActivities_88cbe564-f367-49ed-830d-7c4e4a0198a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5604b858-b8e2-41a5-9002-cf62ac8d82d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_827940b8-3200-455f-a705-049add7f3db6" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5604b858-b8e2-41a5-9002-cf62ac8d82d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c27ec76e-fea0-4df1-96d1-e5853c9a70e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_827940b8-3200-455f-a705-049add7f3db6" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c27ec76e-fea0-4df1-96d1-e5853c9a70e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8c0f278b-7d35-46dc-8468-19432dac1af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_827940b8-3200-455f-a705-049add7f3db6" xlink:to="loc_us-gaap_ShareBasedCompensation_8c0f278b-7d35-46dc-8468-19432dac1af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_f63914b8-e575-4a1b-bb6b-ab6d58161f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_827940b8-3200-455f-a705-049add7f3db6" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_f63914b8-e575-4a1b-bb6b-ab6d58161f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_604b2528-48da-473b-a647-ec71b87f7910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_827940b8-3200-455f-a705-049add7f3db6" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_604b2528-48da-473b-a647-ec71b87f7910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_c948fc1b-b053-4954-a5e3-de198e6f4bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_827940b8-3200-455f-a705-049add7f3db6" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_c948fc1b-b053-4954-a5e3-de198e6f4bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_2dee0530-9e93-4d55-af09-a37864910b78" xlink:href="evh-20220930.xsd#evh_GainOnTransferOfMembership"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_827940b8-3200-455f-a705-049add7f3db6" xlink:to="loc_evh_GainOnTransferOfMembership_2dee0530-9e93-4d55-af09-a37864910b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d1c3a5ae-5488-451b-ac31-32bfeaca8863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_827940b8-3200-455f-a705-049add7f3db6" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d1c3a5ae-5488-451b-ac31-32bfeaca8863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInTaxReceivableAgreement_613d67c9-a959-4580-8826-27587ffcef49" xlink:href="evh-20220930.xsd#evh_IncreaseDecreaseInTaxReceivableAgreement"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_827940b8-3200-455f-a705-049add7f3db6" xlink:to="loc_evh_IncreaseDecreaseInTaxReceivableAgreement_613d67c9-a959-4580-8826-27587ffcef49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_84d562c2-b39c-4563-8d79-05f10c1a944b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_827940b8-3200-455f-a705-049add7f3db6" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_84d562c2-b39c-4563-8d79-05f10c1a944b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8836591-db27-4f5f-9e06-c2556396a165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_827940b8-3200-455f-a705-049add7f3db6" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8836591-db27-4f5f-9e06-c2556396a165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_e3b06a60-2a3d-4f16-be65-3963c8a430bb" xlink:href="evh-20220930.xsd#evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8836591-db27-4f5f-9e06-c2556396a165" xlink:to="loc_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset_e3b06a60-2a3d-4f16-be65-3963c8a430bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1f9a3253-e101-4e27-8a6e-5e58a0968960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8836591-db27-4f5f-9e06-c2556396a165" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1f9a3253-e101-4e27-8a6e-5e58a0968960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_7dfa3d62-a697-494d-bcec-2bb9bfcd5df3" xlink:href="evh-20220930.xsd#evh_IncreaseDecreaseInCapitalizedContractCostNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8836591-db27-4f5f-9e06-c2556396a165" xlink:to="loc_evh_IncreaseDecreaseInCapitalizedContractCostNet_7dfa3d62-a697-494d-bcec-2bb9bfcd5df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a4907c4c-8bc6-4eb6-8bf6-921f53183a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8836591-db27-4f5f-9e06-c2556396a165" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a4907c4c-8bc6-4eb6-8bf6-921f53183a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e7dc3747-7943-48d2-b3fd-7e14ce6c3fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8836591-db27-4f5f-9e06-c2556396a165" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_e7dc3747-7943-48d2-b3fd-7e14ce6c3fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_58e1e689-1f36-4f67-b34b-197aece5d08f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8836591-db27-4f5f-9e06-c2556396a165" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_58e1e689-1f36-4f67-b34b-197aece5d08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3bfada28-3577-4669-b29a-52c7957ec239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8836591-db27-4f5f-9e06-c2556396a165" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3bfada28-3577-4669-b29a-52c7957ec239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_01a48496-2412-49bf-b660-71019eb43297" xlink:href="evh-20220930.xsd#evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8836591-db27-4f5f-9e06-c2556396a165" xlink:to="loc_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities_01a48496-2412-49bf-b660-71019eb43297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_26d7dbb9-eb55-4650-b8f8-4958ad5e2a11" xlink:href="evh-20220930.xsd#evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8836591-db27-4f5f-9e06-c2556396a165" xlink:to="loc_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_26d7dbb9-eb55-4650-b8f8-4958ad5e2a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ea603cce-1d35-4da6-ad78-a84467f07ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8836591-db27-4f5f-9e06-c2556396a165" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ea603cce-1d35-4da6-ad78-a84467f07ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_eff7d977-4d92-4e30-8b9b-25a78532f055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f8836591-db27-4f5f-9e06-c2556396a165" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_eff7d977-4d92-4e30-8b9b-25a78532f055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_32ca7c35-75b5-4f1e-9a0b-035174182447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_827940b8-3200-455f-a705-049add7f3db6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_32ca7c35-75b5-4f1e-9a0b-035174182447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2dcb5711-5cb2-428b-b431-96f24e9d4474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02b5d09a-e45e-429c-b444-6698dee3a3a6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2dcb5711-5cb2-428b-b431-96f24e9d4474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_7711b977-dbff-4f6e-8f32-ccb9b8714e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2dcb5711-5cb2-428b-b431-96f24e9d4474" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_7711b977-dbff-4f6e-8f32-ccb9b8714e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_e1a88360-a6f6-4ad6-b67a-f75695e96724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2dcb5711-5cb2-428b-b431-96f24e9d4474" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_e1a88360-a6f6-4ad6-b67a-f75695e96724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_1ad1e1b9-bf64-4984-83a6-5eb3c15c0db7" xlink:href="evh-20220930.xsd#evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2dcb5711-5cb2-428b-b431-96f24e9d4474" xlink:to="loc_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet_1ad1e1b9-bf64-4984-83a6-5eb3c15c0db7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_4b258ec3-a76f-4039-bb74-064302363517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2dcb5711-5cb2-428b-b431-96f24e9d4474" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_4b258ec3-a76f-4039-bb74-064302363517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_343ed751-ed84-46c8-a925-7c0b5e765140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireHeldToMaturitySecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2dcb5711-5cb2-428b-b431-96f24e9d4474" xlink:to="loc_us-gaap_PaymentsToAcquireHeldToMaturitySecurities_343ed751-ed84-46c8-a925-7c0b5e765140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProceedsFromMaturityOfInvestments_010901b4-eed0-4ab8-8a64-990d6072fb10" xlink:href="evh-20220930.xsd#evh_ProceedsFromMaturityOfInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2dcb5711-5cb2-428b-b431-96f24e9d4474" xlink:to="loc_evh_ProceedsFromMaturityOfInvestments_010901b4-eed0-4ab8-8a64-990d6072fb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_953d4840-3e3d-4e74-ab8a-0373fbe0e6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireOtherProductiveAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2dcb5711-5cb2-428b-b431-96f24e9d4474" xlink:to="loc_us-gaap_PaymentsToAcquireOtherProductiveAssets_953d4840-3e3d-4e74-ab8a-0373fbe0e6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_00ef649e-d1a9-419f-b900-9d983b4f6218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2dcb5711-5cb2-428b-b431-96f24e9d4474" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_00ef649e-d1a9-419f-b900-9d983b4f6218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1702f2c7-2f0e-47de-bf94-0a65a6523acb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02b5d09a-e45e-429c-b444-6698dee3a3a6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1702f2c7-2f0e-47de-bf94-0a65a6523acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_05685a14-bc4d-4c2d-8e45-541c038675a1" xlink:href="evh-20220930.xsd#evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1702f2c7-2f0e-47de-bf94-0a65a6523acb" xlink:to="loc_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities_05685a14-bc4d-4c2d-8e45-541c038675a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_a8b85cce-b475-492d-9074-1c39816e4298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1702f2c7-2f0e-47de-bf94-0a65a6523acb" xlink:to="loc_us-gaap_PaymentsOfDebtExtinguishmentCosts_a8b85cce-b475-492d-9074-1c39816e4298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_340451d6-5355-4d5c-b574-3f0a5ceafb5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1702f2c7-2f0e-47de-bf94-0a65a6523acb" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_340451d6-5355-4d5c-b574-3f0a5ceafb5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3095475c-9cc5-433d-aefd-1d95054db1c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1702f2c7-2f0e-47de-bf94-0a65a6523acb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3095475c-9cc5-433d-aefd-1d95054db1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_d1af685e-891a-4d2c-a41b-48b03eeee88b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1702f2c7-2f0e-47de-bf94-0a65a6523acb" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_d1af685e-891a-4d2c-a41b-48b03eeee88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_51405517-f0ca-4091-894e-c234ba0fbd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1702f2c7-2f0e-47de-bf94-0a65a6523acb" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_51405517-f0ca-4091-894e-c234ba0fbd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d5e98c7-0eb2-4fd8-85a8-084218bdcbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1702f2c7-2f0e-47de-bf94-0a65a6523acb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d5e98c7-0eb2-4fd8-85a8-084218bdcbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0feb9b7f-5172-474c-b47b-b8054220e68a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02b5d09a-e45e-429c-b444-6698dee3a3a6" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0feb9b7f-5172-474c-b47b-b8054220e68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1b78920d-5011-4d4a-b3a8-2cce680a1d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02b5d09a-e45e-429c-b444-6698dee3a3a6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1b78920d-5011-4d4a-b3a8-2cce680a1d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_514a0ee7-207e-4fa3-9a0d-32d61d82364b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02b5d09a-e45e-429c-b444-6698dee3a3a6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_514a0ee7-207e-4fa3-9a0d-32d61d82364b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2a041fa2-87f4-454c-a699-da9978b12b07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02b5d09a-e45e-429c-b444-6698dee3a3a6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2a041fa2-87f4-454c-a699-da9978b12b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Organization" xlink:type="simple" xlink:href="evh-20220930.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c979ea57-5599-453d-97d4-3c577f658880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_f1a06ff0-e893-4870-ac52-0f9f0ecabb12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c979ea57-5599-453d-97d4-3c577f658880" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_f1a06ff0-e893-4870-ac52-0f9f0ecabb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" xlink:type="simple" xlink:href="evh-20220930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5f4ef100-eed5-460e-80c7-0e5634b81913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_3d1e3ffd-767f-42d4-8f0e-bd265019f9df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f4ef100-eed5-460e-80c7-0e5634b81913" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_3d1e3ffd-767f-42d4-8f0e-bd265019f9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards" xlink:type="simple" xlink:href="evh-20220930.xsd#RecentlyIssuedAccountingStandards"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b6eacea2-92b0-4a85-9e82-b0fa87c99f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_0b25245b-82ce-4147-8677-d5a9c91d27b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6eacea2-92b0-4a85-9e82-b0fa87c99f6a" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_0b25245b-82ce-4147-8677-d5a9c91d27b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Transactions" xlink:type="simple" xlink:href="evh-20220930.xsd#Transactions"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Transactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b88449c1-c44b-4b31-b092-2fb78f89b149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_32da6f3c-a58b-4a22-939f-7b807181e087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b88449c1-c44b-4b31-b092-2fb78f89b149" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_32da6f3c-a58b-4a22-939f-7b807181e087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperations" xlink:type="simple" xlink:href="evh-20220930.xsd#DiscontinuedOperations"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b3971ec9-2af5-4824-b0f8-85265671ddc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_4547bc43-c285-4909-8707-6c8fc9bf957d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_b3971ec9-2af5-4824-b0f8-85265671ddc4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_4547bc43-c285-4909-8707-6c8fc9bf957d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognition" xlink:type="simple" xlink:href="evh-20220930.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0e5bfa23-5feb-4492-b2f8-5ffa45696d19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_8c34920a-06e1-4854-9df4-193c1b5b8a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0e5bfa23-5feb-4492-b2f8-5ffa45696d19" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_8c34920a-06e1-4854-9df4-193c1b5b8a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLosses" xlink:type="simple" xlink:href="evh-20220930.xsd#CreditLosses"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLosses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_d8577566-6c54-4e2b-adc9-e3d8ac1623fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentTextBlock_24b557e7-c6bd-4e33-b085-f2337a72d35a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossFinancialInstrumentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_d8577566-6c54-4e2b-adc9-e3d8ac1623fb" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentTextBlock_24b557e7-c6bd-4e33-b085-f2337a72d35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="evh-20220930.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_86c1ee3b-cee5-412f-90ed-a2bda81e1c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_f9c67b7b-451c-4706-95de-7c7c357dd1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_86c1ee3b-cee5-412f-90ed-a2bda81e1c63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_f9c67b7b-451c-4706-95de-7c7c357dd1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet" xlink:type="simple" xlink:href="evh-20220930.xsd#GoodwillandIntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_57b4c1de-e62d-44e6-8bad-3ae9accb6031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_fd6ba3aa-a972-4621-89ed-61d616d33690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_57b4c1de-e62d-44e6-8bad-3ae9accb6031" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_fd6ba3aa-a972-4621-89ed-61d616d33690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt" xlink:type="simple" xlink:href="evh-20220930.xsd#LongtermDebt"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_15c7924e-229c-40a0-9de0-3abc12b50d57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_f037311f-9932-4386-b8b5-ca50a42a9340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_15c7924e-229c-40a0-9de0-3abc12b50d57" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_f037311f-9932-4386-b8b5-ca50a42a9340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="evh-20220930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_669f4cad-6c84-4819-9c03-b4868e1bbc67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_aabb37cd-2a31-46b0-b322-ff851706b2db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_669f4cad-6c84-4819-9c03-b4868e1bbc67" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_aabb37cd-2a31-46b0-b322-ff851706b2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/Leases" xlink:type="simple" xlink:href="evh-20220930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7d482053-e065-4952-bb8e-f3c5e573fa04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_82509f4e-89e1-4a5d-802c-780c3a6a7512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7d482053-e065-4952-bb8e-f3c5e573fa04" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_82509f4e-89e1-4a5d-802c-780c3a6a7512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeLossPerCommonShare" xlink:type="simple" xlink:href="evh-20220930.xsd#IncomeLossPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeLossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6715ebce-1886-4ae7-b71e-18f83012e53b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_716fdc1b-01ba-418c-b252-690aa85fa57f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6715ebce-1886-4ae7-b71e-18f83012e53b" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_716fdc1b-01ba-418c-b252-690aa85fa57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensation" xlink:type="simple" xlink:href="evh-20220930.xsd#StockbasedCompensation"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ced5d93-67f5-4234-86c7-8b151a5881a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5b6a2912-1293-4895-a1e4-d3d4631708d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ced5d93-67f5-4234-86c7-8b151a5881a1" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_5b6a2912-1293-4895-a1e4-d3d4631708d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxes" xlink:type="simple" xlink:href="evh-20220930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_73d56416-754a-49ad-9713-aafec4873330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_88af8d25-5a08-4879-83f8-b5908a09bb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_73d56416-754a-49ad-9713-aafec4873330" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_88af8d25-5a08-4879-83f8-b5908a09bb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees" xlink:type="simple" xlink:href="evh-20220930.xsd#InvestmentsinEquityMethodInvestees"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_494360b3-e2cb-49fa-9475-e2d7c674afef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_5315652b-0258-497f-be7c-1283a4c7685f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_494360b3-e2cb-49fa-9475-e2d7c674afef" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_5315652b-0258-497f-be7c-1283a4c7685f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="evh-20220930.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4e55a5e2-4ea5-41f1-bc1d-8c47d2084768" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1b2613a2-edbc-4c33-8b47-70259d674e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4e55a5e2-4ea5-41f1-bc1d-8c47d2084768" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1b2613a2-edbc-4c33-8b47-70259d674e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedParties" xlink:type="simple" xlink:href="evh-20220930.xsd#RelatedParties"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_b37bcd24-12bf-48dd-9bf8-1c3628719cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_5d15ea09-a527-4ea5-9753-ed16527be06c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_b37bcd24-12bf-48dd-9bf8-1c3628719cff" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_5d15ea09-a527-4ea5-9753-ed16527be06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChanges" xlink:type="simple" xlink:href="evh-20220930.xsd#RepositioningandOtherChanges"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChanges" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_262d447f-bee4-4df3-a536-e1bb52880def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7776976f-798f-4055-8487-294862fbaf3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_262d447f-bee4-4df3-a536-e1bb52880def" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7776976f-798f-4055-8487-294862fbaf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReporting" xlink:type="simple" xlink:href="evh-20220930.xsd#SegmentReporting"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReporting" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_100c9ab3-5326-4104-a660-2f48427421d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_b1e670a6-493a-44a1-90dc-4494d7e3375e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_100c9ab3-5326-4104-a660-2f48427421d5" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_b1e670a6-493a-44a1-90dc-4494d7e3375e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements" xlink:type="simple" xlink:href="evh-20220930.xsd#ReservesforClaimsandPerformanceBasedArrangements"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_878a100d-8a6f-4ab2-8b0a-cc09ccf97f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceDisclosureTextBlock_8a386eca-d4ac-469f-8362-bf6aeb172bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_878a100d-8a6f-4ab2-8b0a-cc09ccf97f77" xlink:to="loc_us-gaap_InsuranceDisclosureTextBlock_8a386eca-d4ac-469f-8362-bf6aeb172bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformation" xlink:type="simple" xlink:href="evh-20220930.xsd#SupplementalCashFlowInformation"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_64acc909-4522-4a08-9946-9f541a1bfec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_8b3da97c-8fd3-45bb-883b-088e77bbe541" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_64acc909-4522-4a08-9946-9f541a1bfec9" xlink:to="loc_us-gaap_CashFlowSupplementalDisclosuresTextBlock_8b3da97c-8fd3-45bb-883b-088e77bbe541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SubsequentEvents" xlink:type="simple" xlink:href="evh-20220930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_65f48393-8a6b-415c-8b2f-f24a20ccbb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_2a5e1e9d-8cc8-409b-ba18-b0d20206bfee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_65f48393-8a6b-415c-8b2f-f24a20ccbb4e" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_2a5e1e9d-8cc8-409b-ba18-b0d20206bfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" xlink:type="simple" xlink:href="evh-20220930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_425ac207-693d-4928-870e-a84e3dc31851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_17ae88f9-ceb5-456a-8da6-6a6b6027473e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_425ac207-693d-4928-870e-a84e3dc31851" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_17ae88f9-ceb5-456a-8da6-6a6b6027473e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_375b108d-49cb-402c-aaf6-b9f916c0c0b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_425ac207-693d-4928-870e-a84e3dc31851" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_375b108d-49cb-402c-aaf6-b9f916c0c0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_fc43858b-68ee-4830-8688-88df9bf4c5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_425ac207-693d-4928-870e-a84e3dc31851" xlink:to="loc_us-gaap_UseOfEstimates_fc43858b-68ee-4830-8688-88df9bf4c5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_93c1d646-d94f-46f1-88a6-9648082d41bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_425ac207-693d-4928-870e-a84e3dc31851" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_93c1d646-d94f-46f1-88a6-9648082d41bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_d544b730-b365-4e34-a1dd-616ce1d0437d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_425ac207-693d-4928-870e-a84e3dc31851" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_d544b730-b365-4e34-a1dd-616ce1d0437d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_e76ea598-4e96-4250-8638-aba89af79116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_425ac207-693d-4928-870e-a84e3dc31851" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_e76ea598-4e96-4250-8638-aba89af79116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_a1b52cf7-4883-4f4e-a7dd-163f4290140c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_425ac207-693d-4928-870e-a84e3dc31851" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_a1b52cf7-4883-4f4e-a7dd-163f4290140c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_b91bb588-0e72-4702-b794-2dfa54f97dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_425ac207-693d-4928-870e-a84e3dc31851" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_b91bb588-0e72-4702-b794-2dfa54f97dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8554176c-b94e-4cd6-a64e-6879f1ac8ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_425ac207-693d-4928-870e-a84e3dc31851" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8554176c-b94e-4cd6-a64e-6879f1ac8ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityReserveEstimatePolicy_97004b1c-8991-451d-8762-3763cc6be774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityReserveEstimatePolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_425ac207-693d-4928-870e-a84e3dc31851" xlink:to="loc_us-gaap_LiabilityReserveEstimatePolicy_97004b1c-8991-451d-8762-3763cc6be774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPolicyPolicyTextBlock_b25f7c3d-06c0-492e-b09b-156207768f13" xlink:href="evh-20220930.xsd#evh_RightOfOffsetPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_425ac207-693d-4928-870e-a84e3dc31851" xlink:to="loc_evh_RightOfOffsetPolicyPolicyTextBlock_b25f7c3d-06c0-492e-b09b-156207768f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_0b2eaadd-7f58-49a9-ae17-4c83db235811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_425ac207-693d-4928-870e-a84e3dc31851" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_0b2eaadd-7f58-49a9-ae17-4c83db235811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_14558d9a-01a6-4898-851e-dab1e3495289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_425ac207-693d-4928-870e-a84e3dc31851" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_14558d9a-01a6-4898-851e-dab1e3495289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e7428491-4c04-4219-b70c-3cffc2d61646" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_425ac207-693d-4928-870e-a84e3dc31851" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e7428491-4c04-4219-b70c-3cffc2d61646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_52124613-bafa-400c-a86b-86fbf8116ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_425ac207-693d-4928-870e-a84e3dc31851" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_52124613-bafa-400c-a86b-86fbf8116ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" xlink:type="simple" xlink:href="evh-20220930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e8362042-4c5c-4c86-83f7-14a0639bdd76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9d26cf66-f818-472f-8715-5e033e329e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8362042-4c5c-4c86-83f7-14a0639bdd76" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9d26cf66-f818-472f-8715-5e033e329e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_36af395f-17e4-49f4-8e8c-66f674fc6256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8362042-4c5c-4c86-83f7-14a0639bdd76" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_36af395f-17e4-49f4-8e8c-66f674fc6256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_38868dd7-c040-4b38-ab23-b6b1d1a1d6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e8362042-4c5c-4c86-83f7-14a0639bdd76" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_38868dd7-c040-4b38-ab23-b6b1d1a1d6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsTables" xlink:type="simple" xlink:href="evh-20220930.xsd#TransactionsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/TransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_50b5afc1-11d8-4da8-8230-ea17c7ae2b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_ec7bf69e-afe7-4dbd-8954-a190bed35c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_50b5afc1-11d8-4da8-8230-ea17c7ae2b79" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_ec7bf69e-afe7-4dbd-8954-a190bed35c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_8275cdca-151d-42b4-9239-4d4c6050286b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_50b5afc1-11d8-4da8-8230-ea17c7ae2b79" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_8275cdca-151d-42b4-9239-4d4c6050286b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsTables" xlink:type="simple" xlink:href="evh-20220930.xsd#DiscontinuedOperationsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_222cf3a8-84a3-4530-8635-6a0134d870e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_d612f202-85f2-4621-befd-38248a34644d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_222cf3a8-84a3-4530-8635-6a0134d870e6" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_d612f202-85f2-4621-befd-38248a34644d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="evh-20220930.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_93ef0d5f-a110-483e-b42c-fe3644885b56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_9cede8a8-e5c6-4f39-b5ff-d6f1982f3631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_93ef0d5f-a110-483e-b42c-fe3644885b56" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_9cede8a8-e5c6-4f39-b5ff-d6f1982f3631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_557ed4d1-40bd-4cc5-be9c-d6339c656a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_93ef0d5f-a110-483e-b42c-fe3644885b56" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_557ed4d1-40bd-4cc5-be9c-d6339c656a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesTables" xlink:type="simple" xlink:href="evh-20220930.xsd#CreditLossesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_dcdddab2-aa09-4224-a827-e672582a8b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_ce50d972-12df-41e0-bb2d-472fc2f48250" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_dcdddab2-aa09-4224-a827-e672582a8b90" xlink:to="loc_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock_ce50d972-12df-41e0-bb2d-472fc2f48250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="evh-20220930.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_06f2abd0-17f9-422b-9bba-9b9d00d97138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_015db7b3-50f4-4955-8c97-fec4cfbf7dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_06f2abd0-17f9-422b-9bba-9b9d00d97138" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_015db7b3-50f4-4955-8c97-fec4cfbf7dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="simple" xlink:href="evh-20220930.xsd#GoodwillandIntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_18666bb8-fa9b-43eb-a311-3facaaa5de94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_abafa3df-aba3-41a8-859b-a8c82475912f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_18666bb8-fa9b-43eb-a311-3facaaa5de94" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_abafa3df-aba3-41a8-859b-a8c82475912f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a3ced554-2e79-4319-9694-4cd325fddf80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_18666bb8-fa9b-43eb-a311-3facaaa5de94" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a3ced554-2e79-4319-9694-4cd325fddf80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_72406573-d00f-41d4-bac1-ae4f680be376" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_18666bb8-fa9b-43eb-a311-3facaaa5de94" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_72406573-d00f-41d4-bac1-ae4f680be376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtTables" xlink:type="simple" xlink:href="evh-20220930.xsd#LongtermDebtTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6d17e9c5-8fea-4883-a779-740ed474748f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_f80d79a6-0a84-4b93-aa01-1bc8366f2f03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6d17e9c5-8fea-4883-a779-740ed474748f" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_f80d79a6-0a84-4b93-aa01-1bc8366f2f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="evh-20220930.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2443fb18-7cbc-47c5-a691-eeef4d9388b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_0d3c0971-33bf-4b91-902e-22419f9795ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2443fb18-7cbc-47c5-a691-eeef4d9388b1" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_0d3c0971-33bf-4b91-902e-22419f9795ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesTables" xlink:type="simple" xlink:href="evh-20220930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_52952bb5-eb44-4a17-8ded-dfd4fabc5217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4aedddd9-fbb7-4be0-b273-fd3f21f20347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_52952bb5-eb44-4a17-8ded-dfd4fabc5217" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4aedddd9-fbb7-4be0-b273-fd3f21f20347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_7856014f-68a9-4bb3-a370-8f0384e6111b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_52952bb5-eb44-4a17-8ded-dfd4fabc5217" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_7856014f-68a9-4bb3-a370-8f0384e6111b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeLossPerCommonShareTables" xlink:type="simple" xlink:href="evh-20220930.xsd#IncomeLossPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeLossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_754f0e5c-9e5f-4b28-b94b-028b06a49073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_37e24a76-533c-4c96-88d5-4284d671ec72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_754f0e5c-9e5f-4b28-b94b-028b06a49073" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_37e24a76-533c-4c96-88d5-4284d671ec72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_586faa14-d0c8-4580-b7c5-7ca9f15caec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_754f0e5c-9e5f-4b28-b94b-028b06a49073" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_586faa14-d0c8-4580-b7c5-7ca9f15caec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationTables" xlink:type="simple" xlink:href="evh-20220930.xsd#StockbasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fdb2089d-360c-4411-9ba7-c5c3cfdc79ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_bf5f7ad7-6887-4d43-b770-9ab9186b56fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fdb2089d-360c-4411-9ba7-c5c3cfdc79ba" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_bf5f7ad7-6887-4d43-b770-9ab9186b56fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_7fb07d27-8eae-4417-8699-630890782633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_fdb2089d-360c-4411-9ba7-c5c3cfdc79ba" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_7fb07d27-8eae-4417-8699-630890782633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="evh-20220930.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1ded65b0-0edc-4160-9948-4c920560da22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_36772da9-2a22-4f7d-929d-ecc4689a70ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1ded65b0-0edc-4160-9948-4c920560da22" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_36772da9-2a22-4f7d-929d-ecc4689a70ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_efa05829-a09d-4147-811f-2c3a9d4f36ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1ded65b0-0edc-4160-9948-4c920560da22" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_efa05829-a09d-4147-811f-2c3a9d4f36ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_b9dd12e3-d9b8-4a7c-93e6-4cb8626da462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1ded65b0-0edc-4160-9948-4c920560da22" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_b9dd12e3-d9b8-4a7c-93e6-4cb8626da462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesTables" xlink:type="simple" xlink:href="evh-20220930.xsd#RelatedPartiesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_6aa425f5-c67d-4d79-b549-ebc65bdbb591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_c0662ca6-1242-4bc1-98ba-8c270e389817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_6aa425f5-c67d-4d79-b549-ebc65bdbb591" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_c0662ca6-1242-4bc1-98ba-8c270e389817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesTables" xlink:type="simple" xlink:href="evh-20220930.xsd#RepositioningandOtherChangesTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChangesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_f016e966-c3d2-4246-a4ca-023826af65df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_30c67db5-4d65-4e6b-aff0-18e6f9a7b64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_f016e966-c3d2-4246-a4ca-023826af65df" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_30c67db5-4d65-4e6b-aff0-18e6f9a7b64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingTables" xlink:type="simple" xlink:href="evh-20220930.xsd#SegmentReportingTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_07dd54b0-4558-4a7d-b626-4ba72c13a08e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_f7f5f12b-5c59-4c84-9998-140dfab7827c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_07dd54b0-4558-4a7d-b626-4ba72c13a08e" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_f7f5f12b-5c59-4c84-9998-140dfab7827c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_8060825a-b79a-4ed1-9c83-f2a3b14e69f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_07dd54b0-4558-4a7d-b626-4ba72c13a08e" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_8060825a-b79a-4ed1-9c83-f2a3b14e69f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables" xlink:type="simple" xlink:href="evh-20220930.xsd#ReservesforClaimsandPerformanceBasedArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_40828d34-231b-41fa-ad57-652672c9d096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_ae9a953f-b0c7-47ca-94cd-ae1f328b8b27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_40828d34-231b-41fa-ad57-652672c9d096" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_ae9a953f-b0c7-47ca-94cd-ae1f328b8b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables" xlink:type="simple" xlink:href="evh-20220930.xsd#SupplementalCashFlowInformationTables"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_e2ef7269-48fc-4d6d-932a-3d2c54eca952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_c096e1dc-30b5-43af-bdb0-d64003709785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_e2ef7269-48fc-4d6d-932a-3d2c54eca952" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_c096e1dc-30b5-43af-bdb0-d64003709785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/OrganizationDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#OrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_42d89cdf-5ac1-4180-b930-13aa806858d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_46ddf287-3b79-4f42-9cf7-7da26291f787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_42d89cdf-5ac1-4180-b930-13aa806858d0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_46ddf287-3b79-4f42-9cf7-7da26291f787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b2fd72dc-3bd4-49b3-8139-620b9acd2671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_5b31ee35-3499-4225-b559-9f48932335b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b2fd72dc-3bd4-49b3-8139-620b9acd2671" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_5b31ee35-3499-4225-b559-9f48932335b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_35dd26f1-ead6-4ef0-8aaa-1be60c57d569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_5b31ee35-3499-4225-b559-9f48932335b7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_35dd26f1-ead6-4ef0-8aaa-1be60c57d569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10a0352c-6cef-46a3-95cf-f43d3436914d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_35dd26f1-ead6-4ef0-8aaa-1be60c57d569" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10a0352c-6cef-46a3-95cf-f43d3436914d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_4a8eca5f-4bac-4f44-bfeb-9b224b84d994" xlink:href="evh-20220930.xsd#evh_RestrictedCashforLettersofCreditforFacilityLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10a0352c-6cef-46a3-95cf-f43d3436914d" xlink:to="loc_evh_RestrictedCashforLettersofCreditforFacilityLeasesMember_4a8eca5f-4bac-4f44-bfeb-9b224b84d994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_5e7a9174-1c15-4e49-b311-b6fb04d716b7" xlink:href="evh-20220930.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10a0352c-6cef-46a3-95cf-f43d3436914d" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_5e7a9174-1c15-4e49-b311-b6fb04d716b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforBenefitManagementServicesMember_a9918dc5-c6bf-49e8-a089-c051a7b12976" xlink:href="evh-20220930.xsd#evh_RestrictedCashforBenefitManagementServicesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10a0352c-6cef-46a3-95cf-f43d3436914d" xlink:to="loc_evh_RestrictedCashforBenefitManagementServicesMember_a9918dc5-c6bf-49e8-a089-c051a7b12976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_5d406bd0-874b-4af0-8421-d876f40274a0" xlink:href="evh-20220930.xsd#evh_RestrictedCashforOtherContractualCommitmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10a0352c-6cef-46a3-95cf-f43d3436914d" xlink:to="loc_evh_RestrictedCashforOtherContractualCommitmentsMember_5d406bd0-874b-4af0-8421-d876f40274a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_96b43915-162a-4910-9eea-7764d01517cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_5b31ee35-3499-4225-b559-9f48932335b7" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_96b43915-162a-4910-9eea-7764d01517cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_60d90f54-c74d-4b51-8043-5dc9f18e6587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_96b43915-162a-4910-9eea-7764d01517cf" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_60d90f54-c74d-4b51-8043-5dc9f18e6587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_608dfda0-6c36-4f48-a2e6-2ce064804c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_96b43915-162a-4910-9eea-7764d01517cf" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_608dfda0-6c36-4f48-a2e6-2ce064804c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_aaffde95-1652-4bc1-8383-6ee10e2b6356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_96b43915-162a-4910-9eea-7764d01517cf" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsCurrent_aaffde95-1652-4bc1-8383-6ee10e2b6356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_50e77b1d-3a50-46d7-be67-8a84ec4d5a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_96b43915-162a-4910-9eea-7764d01517cf" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_50e77b1d-3a50-46d7-be67-8a84ec4d5a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_f09293b9-8423-4346-994b-42ca665d1925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestmentsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_96b43915-162a-4910-9eea-7764d01517cf" xlink:to="loc_us-gaap_RestrictedCashAndInvestmentsNoncurrent_f09293b9-8423-4346-994b-42ca665d1925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_e60062ca-b1ed-436a-8d40-a87dd7a132f1" xlink:href="evh-20220930.xsd#evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_96b43915-162a-4910-9eea-7764d01517cf" xlink:to="loc_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations_e60062ca-b1ed-436a-8d40-a87dd7a132f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndInvestments_5aae6e3f-27f7-42ef-a79a-6b519c0f6ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_96b43915-162a-4910-9eea-7764d01517cf" xlink:to="loc_us-gaap_RestrictedCashAndInvestments_5aae6e3f-27f7-42ef-a79a-6b519c0f6ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_022874b8-75b2-4fc6-8eca-cfe89cf5b6f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_96b43915-162a-4910-9eea-7764d01517cf" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_022874b8-75b2-4fc6-8eca-cfe89cf5b6f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_204f66af-2eff-4832-9a9a-59d8cc82bdd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_89c1b7dc-86ae-4412-85c1-c7eb9b1088f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_204f66af-2eff-4832-9a9a-59d8cc82bdd7" xlink:to="loc_us-gaap_NumberOfReportingUnits_89c1b7dc-86ae-4412-85c1-c7eb9b1088f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6bf4bda4-0fa4-41ca-aa4f-5583833e3f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_204f66af-2eff-4832-9a9a-59d8cc82bdd7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6bf4bda4-0fa4-41ca-aa4f-5583833e3f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_cc00ab81-ddb2-4f3d-8142-83c0ade3225f" xlink:href="evh-20220930.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_204f66af-2eff-4832-9a9a-59d8cc82bdd7" xlink:to="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable_cc00ab81-ddb2-4f3d-8142-83c0ade3225f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_ca67f2af-a8d7-45fa-89f0-f0e6c08b24d7" xlink:href="evh-20220930.xsd#evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_204f66af-2eff-4832-9a9a-59d8cc82bdd7" xlink:to="loc_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement_ca67f2af-a8d7-45fa-89f0-f0e6c08b24d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfOptionsToRenewLeases_b587e952-ac84-47aa-962d-97fc7004ec8a" xlink:href="evh-20220930.xsd#evh_NumberOfOptionsToRenewLeases"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_204f66af-2eff-4832-9a9a-59d8cc82bdd7" xlink:to="loc_evh_NumberOfOptionsToRenewLeases_b587e952-ac84-47aa-962d-97fc7004ec8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfSourcesOfRevenue_2a4ac958-e1e8-4395-b35e-33816e680ad9" xlink:href="evh-20220930.xsd#evh_NumberOfSourcesOfRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_204f66af-2eff-4832-9a9a-59d8cc82bdd7" xlink:to="loc_evh_NumberOfSourcesOfRevenue_2a4ac958-e1e8-4395-b35e-33816e680ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aa161270-cab7-46b2-bf4b-79c7de1147c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bfdb65d1-f8ea-4994-ae47-f9b61ea6df6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aa161270-cab7-46b2-bf4b-79c7de1147c3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bfdb65d1-f8ea-4994-ae47-f9b61ea6df6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_de0c45cd-4a25-4b87-bad7-eb8be931abd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bfdb65d1-f8ea-4994-ae47-f9b61ea6df6b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_de0c45cd-4a25-4b87-bad7-eb8be931abd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76e30753-3370-49f9-826a-bfd790ddaec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_de0c45cd-4a25-4b87-bad7-eb8be931abd8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76e30753-3370-49f9-826a-bfd790ddaec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_7e977781-408c-4323-9726-3b68f4ceac5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76e30753-3370-49f9-826a-bfd790ddaec8" xlink:to="loc_us-gaap_TradeNamesMember_7e977781-408c-4323-9726-3b68f4ceac5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_6cbfae1b-04fd-4b1f-a649-06bee8675333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76e30753-3370-49f9-826a-bfd790ddaec8" xlink:to="loc_us-gaap_CustomerRelationshipsMember_6cbfae1b-04fd-4b1f-a649-06bee8675333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_6aea277c-3071-4601-8673-00ea9846d395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76e30753-3370-49f9-826a-bfd790ddaec8" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_6aea277c-3071-4601-8673-00ea9846d395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_ce62e719-04bf-4382-8cb7-0a0de0aefba4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76e30753-3370-49f9-826a-bfd790ddaec8" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_ce62e719-04bf-4382-8cb7-0a0de0aefba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7654f9fb-4974-4ce9-8f67-4517555acecd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bfdb65d1-f8ea-4994-ae47-f9b61ea6df6b" xlink:to="loc_srt_RangeAxis_7654f9fb-4974-4ce9-8f67-4517555acecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7521fee0-7cbb-4138-a699-07ba57e2d6ff" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7654f9fb-4974-4ce9-8f67-4517555acecd" xlink:to="loc_srt_RangeMember_7521fee0-7cbb-4138-a699-07ba57e2d6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_69b7d9f9-1845-4d91-976b-7eba8e17f522" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7521fee0-7cbb-4138-a699-07ba57e2d6ff" xlink:to="loc_srt_MinimumMember_69b7d9f9-1845-4d91-976b-7eba8e17f522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6da1c9d4-42d6-42bd-a2f5-ab79b784b3e4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7521fee0-7cbb-4138-a699-07ba57e2d6ff" xlink:to="loc_srt_MaximumMember_6da1c9d4-42d6-42bd-a2f5-ab79b784b3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_74e37dd1-ec92-411b-9982-8720c66c1710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bfdb65d1-f8ea-4994-ae47-f9b61ea6df6b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_74e37dd1-ec92-411b-9982-8720c66c1710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1ddbe76d-c929-432a-b66b-7fbf9ce1c8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_74e37dd1-ec92-411b-9982-8720c66c1710" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1ddbe76d-c929-432a-b66b-7fbf9ce1c8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#RecentlyIssuedAccountingStandardsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fac49906-524d-40e0-bf9a-8be4c5cdc097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8d46ea15-3a50-4c82-816e-8efe70eaad64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fac49906-524d-40e0-bf9a-8be4c5cdc097" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8d46ea15-3a50-4c82-816e-8efe70eaad64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23bbf722-11ab-40e2-a5c8-7cd29f5e1cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8d46ea15-3a50-4c82-816e-8efe70eaad64" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23bbf722-11ab-40e2-a5c8-7cd29f5e1cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_36ea34d2-2fff-4fcb-ad2e-c954e09960a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_23bbf722-11ab-40e2-a5c8-7cd29f5e1cc3" xlink:to="loc_us-gaap_TypeOfAdoptionMember_36ea34d2-2fff-4fcb-ad2e-c954e09960a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_daf66dc1-91ae-47a4-8996-f3b7ad6cb195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_36ea34d2-2fff-4fcb-ad2e-c954e09960a6" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_daf66dc1-91ae-47a4-8996-f3b7ad6cb195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_90c01d58-5308-4771-970d-eb5fb889047c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8d46ea15-3a50-4c82-816e-8efe70eaad64" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_90c01d58-5308-4771-970d-eb5fb889047c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_84860e81-af37-4577-90a0-640bcb76505d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_90c01d58-5308-4771-970d-eb5fb889047c" xlink:to="loc_us-gaap_EquityComponentDomain_84860e81-af37-4577-90a0-640bcb76505d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_28f4fbb1-b02a-4c19-9be2-a2803208b919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_84860e81-af37-4577-90a0-640bcb76505d" xlink:to="loc_us-gaap_RetainedEarningsMember_28f4fbb1-b02a-4c19-9be2-a2803208b919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_04243da0-0b17-4082-981f-5a346b780f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_84860e81-af37-4577-90a0-640bcb76505d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_04243da0-0b17-4082-981f-5a346b780f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_99efe91a-f596-4471-949a-ba3ede1cc401" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8d46ea15-3a50-4c82-816e-8efe70eaad64" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_99efe91a-f596-4471-949a-ba3ede1cc401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f1c2ed2d-eee6-4327-989a-ac0da70f707b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_99efe91a-f596-4471-949a-ba3ede1cc401" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f1c2ed2d-eee6-4327-989a-ac0da70f707b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1e87a654-e720-4b02-896c-d527704ea64a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f1c2ed2d-eee6-4327-989a-ac0da70f707b" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_1e87a654-e720-4b02-896c-d527704ea64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_368ce47d-0d41-4cf4-b687-37c0d898ff3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8d46ea15-3a50-4c82-816e-8efe70eaad64" xlink:to="loc_us-gaap_DebtInstrumentAxis_368ce47d-0d41-4cf4-b687-37c0d898ff3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2342e73f-e64a-4c61-9404-3a4bc0e3fbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_368ce47d-0d41-4cf4-b687-37c0d898ff3f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2342e73f-e64a-4c61-9404-3a4bc0e3fbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_9b89dbe9-ce1c-40ec-84e5-23cd492f8464" xlink:href="evh-20220930.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2342e73f-e64a-4c61-9404-3a4bc0e3fbe2" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_9b89dbe9-ce1c-40ec-84e5-23cd492f8464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_073de9be-218d-4d17-990c-3bc6c216dbf9" xlink:href="evh-20220930.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_2342e73f-e64a-4c61-9404-3a4bc0e3fbe2" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_073de9be-218d-4d17-990c-3bc6c216dbf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_274ad714-06b9-4d33-811d-edd6fe1b6703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8d46ea15-3a50-4c82-816e-8efe70eaad64" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_274ad714-06b9-4d33-811d-edd6fe1b6703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_20cb83f6-2aed-4834-8045-19e92bc35044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_274ad714-06b9-4d33-811d-edd6fe1b6703" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_20cb83f6-2aed-4834-8045-19e92bc35044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_760e8cb2-3ed5-49be-8648-6017bea7f6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_20cb83f6-2aed-4834-8045-19e92bc35044" xlink:to="loc_us-gaap_SeniorNotesMember_760e8cb2-3ed5-49be-8648-6017bea7f6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bbd1ba57-be9e-4137-b9c9-2ee31cee8f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_8d46ea15-3a50-4c82-816e-8efe70eaad64" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bbd1ba57-be9e-4137-b9c9-2ee31cee8f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7c96d61e-9aa6-4350-bf21-385c3c649254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bbd1ba57-be9e-4137-b9c9-2ee31cee8f8c" xlink:to="loc_us-gaap_StockholdersEquity_7c96d61e-9aa6-4350-bf21-385c3c649254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f833cb5e-3eb6-4b96-adfc-a86212f530bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_bbd1ba57-be9e-4137-b9c9-2ee31cee8f8c" xlink:to="loc_us-gaap_LongTermDebt_f833cb5e-3eb6-4b96-adfc-a86212f530bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsNarrativeDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#TransactionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/TransactionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9a569b52-41f8-4f24-8665-4bf9d829b889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5c4fb414-4a04-4edc-a85b-577d7bc2735d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9a569b52-41f8-4f24-8665-4bf9d829b889" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5c4fb414-4a04-4edc-a85b-577d7bc2735d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_79a58779-b1f7-4e05-ab1b-16bd5a3f7c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5c4fb414-4a04-4edc-a85b-577d7bc2735d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_79a58779-b1f7-4e05-ab1b-16bd5a3f7c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6daa5087-313e-4b0b-af89-b460c37b0859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_79a58779-b1f7-4e05-ab1b-16bd5a3f7c14" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6daa5087-313e-4b0b-af89-b460c37b0859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ImplantableProviderGroupIMPMember_390329e9-6b9f-40cf-9b57-857b2925d89a" xlink:href="evh-20220930.xsd#evh_ImplantableProviderGroupIMPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6daa5087-313e-4b0b-af89-b460c37b0859" xlink:to="loc_evh_ImplantableProviderGroupIMPMember_390329e9-6b9f-40cf-9b57-857b2925d89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VitalDecisionsMember_7efc1e9d-2fbb-497a-a001-8b3594ee8ba5" xlink:href="evh-20220930.xsd#evh_VitalDecisionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6daa5087-313e-4b0b-af89-b460c37b0859" xlink:to="loc_evh_VitalDecisionsMember_7efc1e9d-2fbb-497a-a001-8b3594ee8ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0197b3b1-e97a-4d40-a48a-1504210920b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5c4fb414-4a04-4edc-a85b-577d7bc2735d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0197b3b1-e97a-4d40-a48a-1504210920b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5cc5cdf-cb57-4647-b67c-c45ae10d9e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0197b3b1-e97a-4d40-a48a-1504210920b7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5cc5cdf-cb57-4647-b67c-c45ae10d9e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_9701a162-f284-4bd3-81ba-f1025262aad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5cc5cdf-cb57-4647-b67c-c45ae10d9e1f" xlink:to="loc_us-gaap_CustomerRelationshipsMember_9701a162-f284-4bd3-81ba-f1025262aad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_b68d678c-5eb8-4003-b2ae-29f549f0ac03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5cc5cdf-cb57-4647-b67c-c45ae10d9e1f" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_b68d678c-5eb8-4003-b2ae-29f549f0ac03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_7aaa7e97-7045-4de5-917e-9527e5f13ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_b5cc5cdf-cb57-4647-b67c-c45ae10d9e1f" xlink:to="loc_us-gaap_TradeNamesMember_7aaa7e97-7045-4de5-917e-9527e5f13ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_5c4fb414-4a04-4edc-a85b-577d7bc2735d" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8752118a-2499-4018-b216-a6b7c1c59f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8752118a-2499-4018-b216-a6b7c1c59f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_78491677-b6cb-4bc0-8c5d-550e7de47f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_78491677-b6cb-4bc0-8c5d-550e7de47f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_06ea5f0f-f045-4b7e-ae8c-c3b432d30a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_06ea5f0f-f045-4b7e-ae8c-c3b432d30a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_ebb00e33-39b7-4e90-9d41-dd394fa3866a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_ebb00e33-39b7-4e90-9d41-dd394fa3866a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_9f28f360-0eac-40b3-bc02-d67cb0c0e4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_9f28f360-0eac-40b3-bc02-d67cb0c0e4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_7680f699-efb7-4aeb-922d-1eadf9f794b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_7680f699-efb7-4aeb-922d-1eadf9f794b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_223bec4f-28a3-4d8d-8815-fc8fb46a0b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_223bec4f-28a3-4d8d-8815-fc8fb46a0b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_942091c3-53db-4804-9992-75cd73041489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_942091c3-53db-4804-9992-75cd73041489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_5faddeae-292c-4e00-bb12-f860f003dd80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_5faddeae-292c-4e00-bb12-f860f003dd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_88469865-7e5a-419d-b929-2bf4b0ad5b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_d248c21f-cb9a-4557-868a-0b271fa59b36" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_88469865-7e5a-419d-b929-2bf4b0ad5b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#TransactionsAllocationofAcquisitionCostDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_308c2e87-37aa-4f92-aa74-57fb57735a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fad07cb-f023-4f78-b1d3-cd93bf237b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_308c2e87-37aa-4f92-aa74-57fb57735a4f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fad07cb-f023-4f78-b1d3-cd93bf237b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d06ef4b5-1bac-4d26-8301-059c0f738aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fad07cb-f023-4f78-b1d3-cd93bf237b1f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d06ef4b5-1bac-4d26-8301-059c0f738aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57cf6d63-de78-4076-b294-da504a277ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d06ef4b5-1bac-4d26-8301-059c0f738aa9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57cf6d63-de78-4076-b294-da504a277ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ImplantableProviderGroupIMPMember_d93635c4-9442-4b77-8ac4-972d7000e376" xlink:href="evh-20220930.xsd#evh_ImplantableProviderGroupIMPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57cf6d63-de78-4076-b294-da504a277ada" xlink:to="loc_evh_ImplantableProviderGroupIMPMember_d93635c4-9442-4b77-8ac4-972d7000e376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_VitalDecisionsMember_ed39aee3-0bfe-4038-9587-da4408aa2a8a" xlink:href="evh-20220930.xsd#evh_VitalDecisionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_57cf6d63-de78-4076-b294-da504a277ada" xlink:to="loc_evh_VitalDecisionsMember_ed39aee3-0bfe-4038-9587-da4408aa2a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e0c6491-2522-4e23-8e19-a959fffc3978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fad07cb-f023-4f78-b1d3-cd93bf237b1f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e0c6491-2522-4e23-8e19-a959fffc3978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84f59308-f41b-490f-ba82-62586a5c0b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7e0c6491-2522-4e23-8e19-a959fffc3978" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84f59308-f41b-490f-ba82-62586a5c0b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_34151501-90ff-45f9-90ea-dfd5a0b11cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84f59308-f41b-490f-ba82-62586a5c0b00" xlink:to="loc_us-gaap_CustomerRelationshipsMember_34151501-90ff-45f9-90ea-dfd5a0b11cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_a8253c72-1b69-4e75-9086-bd94fa7333da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84f59308-f41b-490f-ba82-62586a5c0b00" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_a8253c72-1b69-4e75-9086-bd94fa7333da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_cb206610-0c1a-484d-8cc5-54c61c381d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84f59308-f41b-490f-ba82-62586a5c0b00" xlink:to="loc_us-gaap_TradeNamesMember_cb206610-0c1a-484d-8cc5-54c61c381d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_31208220-b72f-44b1-9e20-3cc91a464001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_3fad07cb-f023-4f78-b1d3-cd93bf237b1f" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_31208220-b72f-44b1-9e20-3cc91a464001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d7419f9d-a6b7-4453-a00b-759ab6e79c70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31208220-b72f-44b1-9e20-3cc91a464001" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d7419f9d-a6b7-4453-a00b-759ab6e79c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_f2de3f1c-a77c-4d83-92a6-f8f59f1b1729" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d7419f9d-a6b7-4453-a00b-759ab6e79c70" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_f2de3f1c-a77c-4d83-92a6-f8f59f1b1729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_5999d777-6ade-433c-8d7b-e7a2d6365d53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d7419f9d-a6b7-4453-a00b-759ab6e79c70" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_5999d777-6ade-433c-8d7b-e7a2d6365d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_772bbed0-8c79-429a-b35c-00201c02ce7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d7419f9d-a6b7-4453-a00b-759ab6e79c70" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_772bbed0-8c79-429a-b35c-00201c02ce7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ee34e147-a8e0-4d07-a719-7bd9732afbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredAbstract_d7419f9d-a6b7-4453-a00b-759ab6e79c70" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ee34e147-a8e0-4d07-a719-7bd9732afbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7f6b661d-ac66-40f6-a966-aa1455568df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31208220-b72f-44b1-9e20-3cc91a464001" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7f6b661d-ac66-40f6-a966-aa1455568df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b2ca63a4-d223-4b3b-a3f9-a9863135655f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7f6b661d-ac66-40f6-a966-aa1455568df8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b2ca63a4-d223-4b3b-a3f9-a9863135655f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_25b8b2be-259a-43b6-8a9a-a4c6135b83ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7f6b661d-ac66-40f6-a966-aa1455568df8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_25b8b2be-259a-43b6-8a9a-a4c6135b83ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_c9f45dd5-4c6c-4591-9225-3544dac7b9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7f6b661d-ac66-40f6-a966-aa1455568df8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_c9f45dd5-4c6c-4591-9225-3544dac7b9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_279df401-b5d7-4cc4-bc22-e65153d83ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7f6b661d-ac66-40f6-a966-aa1455568df8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_279df401-b5d7-4cc4-bc22-e65153d83ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_6dfe9334-14e9-45bf-895d-5d79590e6844" xlink:href="evh-20220930.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_7f6b661d-ac66-40f6-a966-aa1455568df8" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_6dfe9334-14e9-45bf-895d-5d79590e6844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_19131fe9-f8a5-4cb3-b20b-0409a6eac4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31208220-b72f-44b1-9e20-3cc91a464001" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_19131fe9-f8a5-4cb3-b20b-0409a6eac4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_fb599a2d-3c5d-4ecd-9aa7-1bb7c5258bda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract_19131fe9-f8a5-4cb3-b20b-0409a6eac4e2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_fb599a2d-3c5d-4ecd-9aa7-1bb7c5258bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_29c120c0-3115-4770-b720-0a09ab3b9bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31208220-b72f-44b1-9e20-3cc91a464001" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_29c120c0-3115-4770-b720-0a09ab3b9bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9bfe102c-070c-4004-a9de-552a9ddf5bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_29c120c0-3115-4770-b720-0a09ab3b9bf0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9bfe102c-070c-4004-a9de-552a9ddf5bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_d0eb8cb6-d5f9-450a-aca2-759540b96737" xlink:href="evh-20220930.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_29c120c0-3115-4770-b720-0a09ab3b9bf0" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities_d0eb8cb6-d5f9-450a-aca2-759540b96737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_7b1e7b47-aef2-4014-9be0-3f376bb0710f" xlink:href="evh-20220930.xsd#evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_29c120c0-3115-4770-b720-0a09ab3b9bf0" xlink:to="loc_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits_7b1e7b47-aef2-4014-9be0-3f376bb0710f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_218402f7-70f1-42bc-9ee0-a50b5840c352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_29c120c0-3115-4770-b720-0a09ab3b9bf0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_218402f7-70f1-42bc-9ee0-a50b5840c352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_a61da8a9-892c-460d-a2d1-f41e3011dabf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_29c120c0-3115-4770-b720-0a09ab3b9bf0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_a61da8a9-892c-460d-a2d1-f41e3011dabf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_68cd5dd8-c298-4277-8764-e2774da85cfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_29c120c0-3115-4770-b720-0a09ab3b9bf0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_68cd5dd8-c298-4277-8764-e2774da85cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_67e1a470-3f22-43de-84bc-7854736f1fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_29c120c0-3115-4770-b720-0a09ab3b9bf0" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_67e1a470-3f22-43de-84bc-7854736f1fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_00d5f84d-9759-43a6-aac0-87cdcbe86b60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31208220-b72f-44b1-9e20-3cc91a464001" xlink:to="loc_us-gaap_Goodwill_00d5f84d-9759-43a6-aac0-87cdcbe86b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0058d2ac-fd99-4cec-8931-9703ed327d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_31208220-b72f-44b1-9e20-3cc91a464001" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_0058d2ac-fd99-4cec-8931-9703ed327d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#DiscontinuedOperationsSummaryofResultsofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_cc341c79-6830-43af-9e83-f548886e6578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e02a116a-bb4a-4ef1-9622-2c0ee9720568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_cc341c79-6830-43af-9e83-f548886e6578" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e02a116a-bb4a-4ef1-9622-2c0ee9720568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_003f2fd7-6e2a-4829-8a23-ae480eb97af6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e02a116a-bb4a-4ef1-9622-2c0ee9720568" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_003f2fd7-6e2a-4829-8a23-ae480eb97af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_debd755b-75cc-46a4-a45f-aad93e28a45b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_003f2fd7-6e2a-4829-8a23-ae480eb97af6" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_debd755b-75cc-46a4-a45f-aad93e28a45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_51a39b0d-406a-4d1c-9939-a84c64f23a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_debd755b-75cc-46a4-a45f-aad93e28a45b" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_51a39b0d-406a-4d1c-9939-a84c64f23a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_72c3d61b-d81b-452a-a04d-84fb0f76f96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e02a116a-bb4a-4ef1-9622-2c0ee9720568" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_72c3d61b-d81b-452a-a04d-84fb0f76f96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_299265db-1aa3-4ba3-91d5-a874714bf167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_72c3d61b-d81b-452a-a04d-84fb0f76f96a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_299265db-1aa3-4ba3-91d5-a874714bf167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_e95bc699-0a7f-40d8-af99-1e7715b9cd86" xlink:href="evh-20220930.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_299265db-1aa3-4ba3-91d5-a874714bf167" xlink:to="loc_evh_TrueHealthMember_e95bc699-0a7f-40d8-af99-1e7715b9cd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_bfe54656-4d3a-4afa-8369-a96c42dca55f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e02a116a-bb4a-4ef1-9622-2c0ee9720568" xlink:to="loc_srt_ProductOrServiceAxis_bfe54656-4d3a-4afa-8369-a96c42dca55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2a201c26-5008-4c7f-85b5-cbc55ee886c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_bfe54656-4d3a-4afa-8369-a96c42dca55f" xlink:to="loc_srt_ProductsAndServicesDomain_2a201c26-5008-4c7f-85b5-cbc55ee886c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PlatformsAndOperationsServicesMember_e335c870-e770-409f-a6bf-a799894eeae3" xlink:href="evh-20220930.xsd#evh_PlatformsAndOperationsServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2a201c26-5008-4c7f-85b5-cbc55ee886c4" xlink:to="loc_evh_PlatformsAndOperationsServicesMember_e335c870-e770-409f-a6bf-a799894eeae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PremiumsRevenueMember_08402c9e-e3e7-4854-beee-05c9dccc61a7" xlink:href="evh-20220930.xsd#evh_PremiumsRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2a201c26-5008-4c7f-85b5-cbc55ee886c4" xlink:to="loc_evh_PremiumsRevenueMember_08402c9e-e3e7-4854-beee-05c9dccc61a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_fefc395c-94f4-49d5-aed6-d493b8b59621" xlink:href="evh-20220930.xsd#evh_ServicesAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2a201c26-5008-4c7f-85b5-cbc55ee886c4" xlink:to="loc_evh_ServicesAgreementsMember_fefc395c-94f4-49d5-aed6-d493b8b59621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e02a116a-bb4a-4ef1-9622-2c0ee9720568" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_7bd98f34-bbff-4a37-ab2a-a96a40485071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:to="loc_us-gaap_RevenuesAbstract_7bd98f34-bbff-4a37-ab2a-a96a40485071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_d6b57b27-c5dd-40df-9515-401092d1d64e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_7bd98f34-bbff-4a37-ab2a-a96a40485071" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_d6b57b27-c5dd-40df-9515-401092d1d64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_d9f85055-7cb4-4a03-b1c5-79bd21dcbd25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:to="loc_us-gaap_OperatingExpensesAbstract_d9f85055-7cb4-4a03-b1c5-79bd21dcbd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_759559e2-8a0c-4ee0-bef6-b1d56c4ae7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9f85055-7cb4-4a03-b1c5-79bd21dcbd25" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_759559e2-8a0c-4ee0-bef6-b1d56c4ae7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_98322cb0-dd85-4e72-9b33-c5fcd18139bc" xlink:href="evh-20220930.xsd#evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9f85055-7cb4-4a03-b1c5-79bd21dcbd25" xlink:to="loc_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense_98322cb0-dd85-4e72-9b33-c5fcd18139bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_90651c75-4e51-47c1-9b31-8df7842f7ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9f85055-7cb4-4a03-b1c5-79bd21dcbd25" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_90651c75-4e51-47c1-9b31-8df7842f7ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_2938eb60-122c-4218-9baa-eaff8b55ca7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9f85055-7cb4-4a03-b1c5-79bd21dcbd25" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_2938eb60-122c-4218-9baa-eaff8b55ca7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_829a128b-919f-4b09-a0ae-36adb9aa8382" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_d9f85055-7cb4-4a03-b1c5-79bd21dcbd25" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_829a128b-919f-4b09-a0ae-36adb9aa8382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_a66fef05-4349-443e-aed4-47361bccd165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_a66fef05-4349-443e-aed4-47361bccd165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_f2f15f99-2cee-4e16-8e83-527b5531c578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome_f2f15f99-2cee-4e16-8e83-527b5531c578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_e3bec0db-b809-4b22-98b1-42f8ea60141c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_e3bec0db-b809-4b22-98b1-42f8ea60141c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_372505e6-c310-4bc7-99b2-3827a1379d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_372505e6-c310-4bc7-99b2-3827a1379d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_23c93b67-dc83-4572-8091-ba72d3e7660b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_23c93b67-dc83-4572-8091-ba72d3e7660b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6fd76237-443d-4c14-adb0-2623c542a7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_6fd76237-443d-4c14-adb0-2623c542a7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_aaf3048c-6081-4782-a3fd-fe816a7ccb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_bc99f9a3-f388-4997-b152-77cda3aa799f" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_aaf3048c-6081-4782-a3fd-fe816a7ccb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#DiscontinuedOperationsSummaryofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_8a69eda4-985f-4ff4-b4ab-c07f665cd4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ed3ecf35-8768-4d0c-a412-9f78883885b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_8a69eda4-985f-4ff4-b4ab-c07f665cd4f1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ed3ecf35-8768-4d0c-a412-9f78883885b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d62455ba-64f4-4ab3-bcaa-4c5229da1b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ed3ecf35-8768-4d0c-a412-9f78883885b3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d62455ba-64f4-4ab3-bcaa-4c5229da1b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3cdcfea5-48ac-4a12-a7df-02182df951f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d62455ba-64f4-4ab3-bcaa-4c5229da1b15" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3cdcfea5-48ac-4a12-a7df-02182df951f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TrueHealthMember_9c8b8f2d-b622-42f0-b692-cbb26a8675b1" xlink:href="evh-20220930.xsd#evh_TrueHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3cdcfea5-48ac-4a12-a7df-02182df951f1" xlink:to="loc_evh_TrueHealthMember_9c8b8f2d-b622-42f0-b692-cbb26a8675b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_6f474724-f7a8-4801-a984-002b239cb7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ed3ecf35-8768-4d0c-a412-9f78883885b3" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_6f474724-f7a8-4801-a984-002b239cb7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ba611084-6e03-4fe9-b56c-c12c85cc0f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_6f474724-f7a8-4801-a984-002b239cb7e1" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ba611084-6e03-4fe9-b56c-c12c85cc0f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_b153f766-b46c-4e24-a7c3-85a4050cadac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationsDisposedOfBySaleMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ba611084-6e03-4fe9-b56c-c12c85cc0f0d" xlink:to="loc_us-gaap_DiscontinuedOperationsDisposedOfBySaleMember_b153f766-b46c-4e24-a7c3-85a4050cadac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fa0dad8-d67d-4e0d-9831-65533bc8d340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ed3ecf35-8768-4d0c-a412-9f78883885b3" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fa0dad8-d67d-4e0d-9831-65533bc8d340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_1309a320-6b49-47a8-aee1-f60d58b0bc62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fa0dad8-d67d-4e0d-9831-65533bc8d340" xlink:to="loc_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_1309a320-6b49-47a8-aee1-f60d58b0bc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_932cea2c-a6b6-4eca-917a-8f73b50c80dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8fa0dad8-d67d-4e0d-9831-65533bc8d340" xlink:to="loc_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_932cea2c-a6b6-4eca-917a-8f73b50c80dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#RevenueRecognitionDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_037d2f78-433d-44a6-81d6-5a6d6e6ffb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a54052ca-d2a0-408b-99bf-227c53e29e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_037d2f78-433d-44a6-81d6-5a6d6e6ffb5b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a54052ca-d2a0-408b-99bf-227c53e29e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8b6d0bf4-0c1a-4d36-90ec-576c07c7f4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a54052ca-d2a0-408b-99bf-227c53e29e9e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8b6d0bf4-0c1a-4d36-90ec-576c07c7f4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1a9d817d-befa-44b0-96db-7de30a8509f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8b6d0bf4-0c1a-4d36-90ec-576c07c7f4ab" xlink:to="loc_us-gaap_SegmentDomain_1a9d817d-befa-44b0-96db-7de30a8509f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_8f175882-f1ac-4412-ab92-96b5c43919d9" xlink:href="evh-20220930.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1a9d817d-befa-44b0-96db-7de30a8509f6" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_8f175882-f1ac-4412-ab92-96b5c43919d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_ec56c86f-0ed4-4eba-bfa7-ce1540bee04d" xlink:href="evh-20220930.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1a9d817d-befa-44b0-96db-7de30a8509f6" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_ec56c86f-0ed4-4eba-bfa7-ce1540bee04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f8a26586-fc0c-45d9-a839-bf1905a35088" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a54052ca-d2a0-408b-99bf-227c53e29e9e" xlink:to="loc_srt_MajorCustomersAxis_f8a26586-fc0c-45d9-a839-bf1905a35088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_18404063-e618-460a-9c52-05a9cd38dc8c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_f8a26586-fc0c-45d9-a839-bf1905a35088" xlink:to="loc_srt_NameOfMajorCustomerDomain_18404063-e618-460a-9c52-05a9cd38dc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicaidCustomersMember_e390432e-eabf-48b6-a1ca-e47af15dfbd1" xlink:href="evh-20220930.xsd#evh_MedicaidCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_18404063-e618-460a-9c52-05a9cd38dc8c" xlink:to="loc_evh_MedicaidCustomersMember_e390432e-eabf-48b6-a1ca-e47af15dfbd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MedicareCustomersMember_b16673e1-ae64-4188-9fd5-adab4a27692b" xlink:href="evh-20220930.xsd#evh_MedicareCustomersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_18404063-e618-460a-9c52-05a9cd38dc8c" xlink:to="loc_evh_MedicareCustomersMember_b16673e1-ae64-4188-9fd5-adab4a27692b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CommercialAndOtherCustomersMember_1f5924b0-dc9a-4edc-a126-f9b160246b1a" xlink:href="evh-20220930.xsd#evh_CommercialAndOtherCustomersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_18404063-e618-460a-9c52-05a9cd38dc8c" xlink:to="loc_evh_CommercialAndOtherCustomersMember_1f5924b0-dc9a-4edc-a126-f9b160246b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_78051e39-75c8-4889-be73-ab18569c943f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a54052ca-d2a0-408b-99bf-227c53e29e9e" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_78051e39-75c8-4889-be73-ab18569c943f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b24ee28a-ee84-4b72-a3a6-2c7095207b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_78051e39-75c8-4889-be73-ab18569c943f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b24ee28a-ee84-4b72-a3a6-2c7095207b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8e18b45b-0239-4ca5-b117-35ee27433344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_493aaa19-fe6c-4029-b82f-d48c8f5e94f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8e18b45b-0239-4ca5-b117-35ee27433344" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_493aaa19-fe6c-4029-b82f-d48c8f5e94f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e59eaef9-a566-4446-8bdf-7c504bcd22e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_8e18b45b-0239-4ca5-b117-35ee27433344" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e59eaef9-a566-4446-8bdf-7c504bcd22e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_43bebdfb-7b4c-4ce3-8a5d-6967bc12230a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e59eaef9-a566-4446-8bdf-7c504bcd22e7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_43bebdfb-7b4c-4ce3-8a5d-6967bc12230a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_5959e369-0d1d-4af8-b328-4e1c91544955" xlink:href="evh-20220930.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e59eaef9-a566-4446-8bdf-7c504bcd22e7" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_5959e369-0d1d-4af8-b328-4e1c91544955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_12db1fd3-af7b-4e0b-912b-10ccc35ac1b4" xlink:href="evh-20220930.xsd#evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis_5959e369-0d1d-4af8-b328-4e1c91544955" xlink:to="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_12db1fd3-af7b-4e0b-912b-10ccc35ac1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312022Member_13f9bb12-b1e5-4c22-a9d0-ad0a6443479b" xlink:href="evh-20220930.xsd#evh_December312022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_12db1fd3-af7b-4e0b-912b-10ccc35ac1b4" xlink:to="loc_evh_December312022Member_13f9bb12-b1e5-4c22-a9d0-ad0a6443479b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312023Member_67351821-bfb3-49bc-b04a-09e94a96a5d8" xlink:href="evh-20220930.xsd#evh_December312023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_12db1fd3-af7b-4e0b-912b-10ccc35ac1b4" xlink:to="loc_evh_December312023Member_67351821-bfb3-49bc-b04a-09e94a96a5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_December312024Member_e4e6167e-f1d7-4a48-a125-bcdfdef5a16d" xlink:href="evh-20220930.xsd#evh_December312024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain_12db1fd3-af7b-4e0b-912b-10ccc35ac1b4" xlink:to="loc_evh_December312024Member_e4e6167e-f1d7-4a48-a125-bcdfdef5a16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4b1bc363-fd06-4ce3-986c-01e7965eafe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_e59eaef9-a566-4446-8bdf-7c504bcd22e7" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4b1bc363-fd06-4ce3-986c-01e7965eafe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_0c0295ef-50ad-4b77-b1f4-4e2b00d53dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4b1bc363-fd06-4ce3-986c-01e7965eafe8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationPercentage_0c0295ef-50ad-4b77-b1f4-4e2b00d53dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_54404180-9fb1-45eb-b7f1-a95b5f958a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_4b1bc363-fd06-4ce3-986c-01e7965eafe8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_54404180-9fb1-45eb-b7f1-a95b5f958a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="evh-20220930.xsd#RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#RevenueRecognitionContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5b33a76c-3bf3-44d2-99ac-ffeeee1184c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_87892ebc-c0e6-4bd5-8291-701d93a0818d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5b33a76c-3bf3-44d2-99ac-ffeeee1184c2" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableNetCurrent_87892ebc-c0e6-4bd5-8291-701d93a0818d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_6cc78a88-c5ca-4e3a-a2ea-06d9ddb3bf46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5b33a76c-3bf3-44d2-99ac-ffeeee1184c2" xlink:to="loc_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent_6cc78a88-c5ca-4e3a-a2ea-06d9ddb3bf46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2b44005d-2d65-4950-b080-18a5681f73eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5b33a76c-3bf3-44d2-99ac-ffeeee1184c2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2b44005d-2d65-4950-b080-18a5681f73eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6cbc9248-fef3-4adf-bfa5-2db301246c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5b33a76c-3bf3-44d2-99ac-ffeeee1184c2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6cbc9248-fef3-4adf-bfa5-2db301246c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_51f5a4c3-208d-4ae6-84c9-0485c79551d9" xlink:href="evh-20220930.xsd#evh_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5b33a76c-3bf3-44d2-99ac-ffeeee1184c2" xlink:to="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_51f5a4c3-208d-4ae6-84c9-0485c79551d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_e815428f-49ac-42ba-b3c1-4110d41fe15f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_51f5a4c3-208d-4ae6-84c9-0485c79551d9" xlink:to="loc_us-gaap_ContractWithCustomerLiability_e815428f-49ac-42ba-b3c1-4110d41fe15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_23a6ec7b-e5f9-4ef1-9663-9a5026649fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_51f5a4c3-208d-4ae6-84c9-0485c79551d9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_23a6ec7b-e5f9-4ef1-9663-9a5026649fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_19904b85-6796-49f0-a76b-ad7aba40182e" xlink:href="evh-20220930.xsd#evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_51f5a4c3-208d-4ae6-84c9-0485c79551d9" xlink:to="loc_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations_19904b85-6796-49f0-a76b-ad7aba40182e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_a4f57863-608f-4975-9c88-ca461cce0351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_ChangeInContractWithCustomerLiabilityRollForward_51f5a4c3-208d-4ae6-84c9-0485c79551d9" xlink:to="loc_us-gaap_ContractWithCustomerLiability_a4f57863-608f-4975-9c88-ca461cce0351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_150a89e2-3bda-4e30-99f2-c8e34373c522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5b33a76c-3bf3-44d2-99ac-ffeeee1184c2" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_150a89e2-3bda-4e30-99f2-c8e34373c522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#RevenueRecognitionContractCostsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3b90fdd4-8613-41e7-b732-15736b4f0526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostTable_d4ce1827-78b6-4e68-af7e-5d9282f072cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3b90fdd4-8613-41e7-b732-15736b4f0526" xlink:to="loc_us-gaap_CapitalizedContractCostTable_d4ce1827-78b6-4e68-af7e-5d9282f072cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAxis_00c08964-d3cf-41c1-8d8d-cfc186fb75e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_d4ce1827-78b6-4e68-af7e-5d9282f072cc" xlink:to="loc_us-gaap_CapitalizedContractCostAxis_00c08964-d3cf-41c1-8d8d-cfc186fb75e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostDomain_7905172d-71b9-4b31-8a61-f0e09093474f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostAxis_00c08964-d3cf-41c1-8d8d-cfc186fb75e8" xlink:to="loc_us-gaap_CapitalizedContractCostDomain_7905172d-71b9-4b31-8a61-f0e09093474f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BonusesAndCommissionsMember_c1966abe-4f77-41dc-9949-1fcd4dada6a2" xlink:href="evh-20220930.xsd#evh_BonusesAndCommissionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_7905172d-71b9-4b31-8a61-f0e09093474f" xlink:to="loc_evh_BonusesAndCommissionsMember_c1966abe-4f77-41dc-9949-1fcd4dada6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ContractFulfillmentCostsMember_10b290f8-ed97-41be-a0b3-fc79dd9401b4" xlink:href="evh-20220930.xsd#evh_ContractFulfillmentCostsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostDomain_7905172d-71b9-4b31-8a61-f0e09093474f" xlink:to="loc_evh_ContractFulfillmentCostsMember_10b290f8-ed97-41be-a0b3-fc79dd9401b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostLineItems_bc15608e-4b7f-4a1b-80ed-cf1aa64e45a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostTable_d4ce1827-78b6-4e68-af7e-5d9282f072cc" xlink:to="loc_us-gaap_CapitalizedContractCostLineItems_bc15608e-4b7f-4a1b-80ed-cf1aa64e45a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostNet_cc9a53b8-352c-460c-8466-758feb842dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_bc15608e-4b7f-4a1b-80ed-cf1aa64e45a2" xlink:to="loc_us-gaap_CapitalizedContractCostNet_cc9a53b8-352c-460c-8466-758feb842dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_280f01d1-5b6f-4375-b96b-bf2817274fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_bc15608e-4b7f-4a1b-80ed-cf1aa64e45a2" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_280f01d1-5b6f-4375-b96b-bf2817274fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_0e2b6cf9-4e13-426c-b5c9-84da41e49fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedContractCostAmortizationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedContractCostLineItems_bc15608e-4b7f-4a1b-80ed-cf1aa64e45a2" xlink:to="loc_us-gaap_CapitalizedContractCostAmortizationPeriod_0e2b6cf9-4e13-426c-b5c9-84da41e49fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#CreditLossesAccountsReceivableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_d20196dd-b28a-4aae-aad9-1e580ddd7848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_9630d66f-afea-4317-8651-bb854214020f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentPastDueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_d20196dd-b28a-4aae-aad9-1e580ddd7848" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_9630d66f-afea-4317-8651-bb854214020f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_0e097f58-f656-48c9-971b-53696d66e51c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_9630d66f-afea-4317-8651-bb854214020f" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_0e097f58-f656-48c9-971b-53696d66e51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_94b83323-3b86-4714-b736-1681c9f389ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablesPeriodPastDueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueAxis_0e097f58-f656-48c9-971b-53696d66e51c" xlink:to="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_94b83323-3b86-4714-b736-1681c9f389ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan60DaysMember_32279fc1-f088-410b-b3d2-0788e714a242" xlink:href="evh-20220930.xsd#evh_FInancialAssetLessThan60DaysMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_94b83323-3b86-4714-b736-1681c9f389ab" xlink:to="loc_evh_FInancialAssetLessThan60DaysMember_32279fc1-f088-410b-b3d2-0788e714a242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FInancialAssetLessThan120DaysPastDueMember_74e39fb4-522e-4d28-a269-e85585b6bed6" xlink:href="evh-20220930.xsd#evh_FInancialAssetLessThan120DaysPastDueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancingReceivablesPeriodPastDueDomain_94b83323-3b86-4714-b736-1681c9f389ab" xlink:to="loc_evh_FInancialAssetLessThan120DaysPastDueMember_74e39fb4-522e-4d28-a269-e85585b6bed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_4227bc99-83f1-48b1-992a-c5e13d0e7893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNoncurrentPastDueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueTable_9630d66f-afea-4317-8651-bb854214020f" xlink:to="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_4227bc99-83f1-48b1-992a-c5e13d0e7893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FinancingReceivablePercentNotPastDue_ae253011-847d-4797-8840-35a924ecbd17" xlink:href="evh-20220930.xsd#evh_FinancingReceivablePercentNotPastDue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_4227bc99-83f1-48b1-992a-c5e13d0e7893" xlink:to="loc_evh_FinancingReceivablePercentNotPastDue_ae253011-847d-4797-8840-35a924ecbd17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancingReceivablePercentPastDue1_b8fe0005-5dfc-48d5-a4b3-4aafde89fdd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivablePercentPastDue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_4227bc99-83f1-48b1-992a-c5e13d0e7893" xlink:to="loc_us-gaap_FinancingReceivablePercentPastDue1_b8fe0005-5dfc-48d5-a4b3-4aafde89fdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_2d1f1ad3-0b84-424b-9561-44bd9ecf3ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_4227bc99-83f1-48b1-992a-c5e13d0e7893" xlink:to="loc_us-gaap_AccountsReceivableNet_2d1f1ad3-0b84-424b-9561-44bd9ecf3ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4e402aca-42f5-47a4-a37c-f8784dc09700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsReceivableNoncurrentPastDueLineItems_4227bc99-83f1-48b1-992a-c5e13d0e7893" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_4e402aca-42f5-47a4-a37c-f8784dc09700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossAbstract_4882e6ad-8c10-4e39-a7ba-4a48a0d678f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e77ad8e6-8a46-41ad-b0f7-229b30148687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditLossAbstract_4882e6ad-8c10-4e39-a7ba-4a48a0d678f7" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e77ad8e6-8a46-41ad-b0f7-229b30148687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_47327cf3-0f01-44d2-912d-5729da468d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e77ad8e6-8a46-41ad-b0f7-229b30148687" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_47327cf3-0f01-44d2-912d-5729da468d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_279750a8-887d-4c80-b9f0-5400ffae1ff9" xlink:href="evh-20220930.xsd#evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e77ad8e6-8a46-41ad-b0f7-229b30148687" xlink:to="loc_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod_279750a8-887d-4c80-b9f0-5400ffae1ff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_1c3ab799-c870-4b55-a55e-fc46d8cc299e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e77ad8e6-8a46-41ad-b0f7-229b30148687" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_1c3ab799-c870-4b55-a55e-fc46d8cc299e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_b0391adf-9a1e-4f17-bb4c-3da925c4359b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e77ad8e6-8a46-41ad-b0f7-229b30148687" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs_b0391adf-9a1e-4f17-bb4c-3da925c4359b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_53760d53-ab06-4bc7-bd9e-99e096590780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward_e77ad8e6-8a46-41ad-b0f7-229b30148687" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_53760d53-ab06-4bc7-bd9e-99e096590780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#PropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d05582a6-8dc6-4323-8760-36fec1fbe888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5e80cbd6-b145-44af-9304-28406e4f3457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d05582a6-8dc6-4323-8760-36fec1fbe888" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5e80cbd6-b145-44af-9304-28406e4f3457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1e13941-2cfb-42f8-bd38-1b9286f085de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5e80cbd6-b145-44af-9304-28406e4f3457" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1e13941-2cfb-42f8-bd38-1b9286f085de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb3fdbcd-7612-4c35-9b84-a6d850abbb70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d1e13941-2cfb-42f8-bd38-1b9286f085de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb3fdbcd-7612-4c35-9b84-a6d850abbb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_a25024c1-3750-4c8f-ab95-3529cca3cf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb3fdbcd-7612-4c35-9b84-a6d850abbb70" xlink:to="loc_us-gaap_ComputerEquipmentMember_a25024c1-3750-4c8f-ab95-3529cca3cf9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_d8fb94c2-e67a-43b1-b937-022008f60f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb3fdbcd-7612-4c35-9b84-a6d850abbb70" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_d8fb94c2-e67a-43b1-b937-022008f60f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_88dbde92-637e-47b2-a9fa-1da7c8ed586e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb3fdbcd-7612-4c35-9b84-a6d850abbb70" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_88dbde92-637e-47b2-a9fa-1da7c8ed586e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_90ffecc3-b1c1-4149-9278-dc44c9d50a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_eb3fdbcd-7612-4c35-9b84-a6d850abbb70" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_90ffecc3-b1c1-4149-9278-dc44c9d50a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b5d80dc5-3213-4ff2-afe7-a178e29c2a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5e80cbd6-b145-44af-9304-28406e4f3457" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b5d80dc5-3213-4ff2-afe7-a178e29c2a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c719a2c5-6e0e-4bbf-888e-a8e9cb332c38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b5d80dc5-3213-4ff2-afe7-a178e29c2a40" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c719a2c5-6e0e-4bbf-888e-a8e9cb332c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_432e75d9-51cc-4571-81a5-bda9beb5f2df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b5d80dc5-3213-4ff2-afe7-a178e29c2a40" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_432e75d9-51cc-4571-81a5-bda9beb5f2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ac5fb188-0c89-472c-b7ae-3f164cc1c1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b5d80dc5-3213-4ff2-afe7-a178e29c2a40" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ac5fb188-0c89-472c-b7ae-3f164cc1c1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_c75e897b-7a5e-4ca5-aacc-2c675889d4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAdditions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b5d80dc5-3213-4ff2-afe7-a178e29c2a40" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_c75e897b-7a5e-4ca5-aacc-2c675889d4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_1a01b381-bbd2-4fe5-a373-fd83a8272632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b5d80dc5-3213-4ff2-afe7-a178e29c2a40" xlink:to="loc_us-gaap_Depreciation_1a01b381-bbd2-4fe5-a373-fd83a8272632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_2d61d4c6-7350-4370-83cc-7f9d59acc4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAmortization1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b5d80dc5-3213-4ff2-afe7-a178e29c2a40" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAmortization1_2d61d4c6-7350-4370-83cc-7f9d59acc4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#GoodwillandIntangibleAssetsNetImpairmentTestingDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8179e1fd-b7bb-49ea-893d-571a947334b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_f4237068-c558-4aad-8dae-6b4d7d1828c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8179e1fd-b7bb-49ea-893d-571a947334b0" xlink:to="loc_us-gaap_NumberOfReportingUnits_f4237068-c558-4aad-8dae-6b4d7d1828c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_33e39417-5166-4497-aa65-24a61185fdb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_a8f1fe7e-5206-4062-a4d8-6ae048b0f67b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_33e39417-5166-4497-aa65-24a61185fdb1" xlink:to="loc_us-gaap_NumberOfReportingUnits_a8f1fe7e-5206-4062-a4d8-6ae048b0f67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_a232aeb2-81d6-47c6-a249-8b288a76d65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_33e39417-5166-4497-aa65-24a61185fdb1" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_a232aeb2-81d6-47c6-a249-8b288a76d65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_69e4567e-9a98-4c11-b42d-c51d3d4d84e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a232aeb2-81d6-47c6-a249-8b288a76d65c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_69e4567e-9a98-4c11-b42d-c51d3d4d84e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_41c2c5da-511a-4c88-9735-51d136013119" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_69e4567e-9a98-4c11-b42d-c51d3d4d84e8" xlink:to="loc_us-gaap_SegmentDomain_41c2c5da-511a-4c88-9735-51d136013119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_95f5002f-da82-4220-8ff0-f2eca45fd7a8" xlink:href="evh-20220930.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_41c2c5da-511a-4c88-9735-51d136013119" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_95f5002f-da82-4220-8ff0-f2eca45fd7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_bf386986-0fee-4897-885e-1dca6b57a735" xlink:href="evh-20220930.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_41c2c5da-511a-4c88-9735-51d136013119" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_bf386986-0fee-4897-885e-1dca6b57a735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_dec25bd2-f5a7-4e1f-8cb5-e6be4c636ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_a232aeb2-81d6-47c6-a249-8b288a76d65c" xlink:to="loc_us-gaap_GoodwillLineItems_dec25bd2-f5a7-4e1f-8cb5-e6be4c636ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_fac87225-d9bc-46ae-a87a-d7fa79f5e85b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_dec25bd2-f5a7-4e1f-8cb5-e6be4c636ef7" xlink:to="loc_us-gaap_GoodwillRollForward_fac87225-d9bc-46ae-a87a-d7fa79f5e85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7b8027c4-683c-4c2e-a254-ce1b2b810a44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_fac87225-d9bc-46ae-a87a-d7fa79f5e85b" xlink:to="loc_us-gaap_Goodwill_7b8027c4-683c-4c2e-a254-ce1b2b810a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_b2db6fdb-091f-4787-bd26-978dc8d7e026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_fac87225-d9bc-46ae-a87a-d7fa79f5e85b" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_b2db6fdb-091f-4787-bd26-978dc8d7e026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_49af9d55-8bb1-4bc3-99dc-969ff33e82d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_fac87225-d9bc-46ae-a87a-d7fa79f5e85b" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_49af9d55-8bb1-4bc3-99dc-969ff33e82d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c9edc625-da3f-4013-acd7-581e4cb9d72c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_fac87225-d9bc-46ae-a87a-d7fa79f5e85b" xlink:to="loc_us-gaap_Goodwill_c9edc625-da3f-4013-acd7-581e4cb9d72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1a612008-a8c0-43bd-8074-5f6c1f5f3b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_dec25bd2-f5a7-4e1f-8cb5-e6be4c636ef7" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1a612008-a8c0-43bd-8074-5f6c1f5f3b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9566f309-79f3-4114-a58f-6e9f2b5b15b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e99272a4-59e9-4b25-b83d-26a8665dd73d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9566f309-79f3-4114-a58f-6e9f2b5b15b8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e99272a4-59e9-4b25-b83d-26a8665dd73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ccd00419-36c4-4d1d-9adc-fbe6bf0d2a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e99272a4-59e9-4b25-b83d-26a8665dd73d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ccd00419-36c4-4d1d-9adc-fbe6bf0d2a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2cc9d194-96f9-4124-85d3-6ecbbf24a608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ccd00419-36c4-4d1d-9adc-fbe6bf0d2a56" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2cc9d194-96f9-4124-85d3-6ecbbf24a608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_a8b6e1b5-848b-402d-9d75-665147487b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2cc9d194-96f9-4124-85d3-6ecbbf24a608" xlink:to="loc_us-gaap_TradeNamesMember_a8b6e1b5-848b-402d-9d75-665147487b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_4f7a3468-a64b-4312-8227-a50f9a37a312" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2cc9d194-96f9-4124-85d3-6ecbbf24a608" xlink:to="loc_us-gaap_CustomerRelationshipsMember_4f7a3468-a64b-4312-8227-a50f9a37a312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_297c1283-b7ea-478f-9554-a0833fdd3914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2cc9d194-96f9-4124-85d3-6ecbbf24a608" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_297c1283-b7ea-478f-9554-a0833fdd3914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BelowMarketLeasesMember_2fb2033a-9e17-49d7-8c7a-e092a210b780" xlink:href="evh-20220930.xsd#evh_BelowMarketLeasesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2cc9d194-96f9-4124-85d3-6ecbbf24a608" xlink:to="loc_evh_BelowMarketLeasesMember_2fb2033a-9e17-49d7-8c7a-e092a210b780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractBasedIntangibleAssetsMember_250a1b61-b50a-4baf-b06c-5cc8a76e1c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractBasedIntangibleAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2cc9d194-96f9-4124-85d3-6ecbbf24a608" xlink:to="loc_us-gaap_ContractBasedIntangibleAssetsMember_250a1b61-b50a-4baf-b06c-5cc8a76e1c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fc899321-6b23-47f5-bff6-7d52d9e520e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e99272a4-59e9-4b25-b83d-26a8665dd73d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fc899321-6b23-47f5-bff6-7d52d9e520e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_9303b3e2-dc84-4f33-bf87-fcb0ca3ee66e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fc899321-6b23-47f5-bff6-7d52d9e520e3" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_9303b3e2-dc84-4f33-bf87-fcb0ca3ee66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9efd0f00-48ec-40ec-ac22-e7fc6f37fbf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fc899321-6b23-47f5-bff6-7d52d9e520e3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9efd0f00-48ec-40ec-ac22-e7fc6f37fbf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_add3ef35-69a5-436e-adf7-df4da00cda34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fc899321-6b23-47f5-bff6-7d52d9e520e3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_add3ef35-69a5-436e-adf7-df4da00cda34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_97ae50d1-b4eb-45f1-bdef-536298a5ab3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fc899321-6b23-47f5-bff6-7d52d9e520e3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_97ae50d1-b4eb-45f1-bdef-536298a5ab3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_5a45f755-0b56-41f8-be27-e02523fccc50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_fc899321-6b23-47f5-bff6-7d52d9e520e3" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_5a45f755-0b56-41f8-be27-e02523fccc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b013b0e7-c533-490e-9fb6-bc3c7c47da6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_3210011b-1405-4905-80bb-7bbe28ef0e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b013b0e7-c533-490e-9fb6-bc3c7c47da6e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_3210011b-1405-4905-80bb-7bbe28ef0e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5faf1e5d-d0b2-4f88-96e6-2acfeb62f00c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b013b0e7-c533-490e-9fb6-bc3c7c47da6e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_5faf1e5d-d0b2-4f88-96e6-2acfeb62f00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d3b3074a-b0ca-415a-8dad-21416c210517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b013b0e7-c533-490e-9fb6-bc3c7c47da6e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d3b3074a-b0ca-415a-8dad-21416c210517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5689e5d6-e1a5-4988-96f6-e5aa1cbf15f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b013b0e7-c533-490e-9fb6-bc3c7c47da6e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5689e5d6-e1a5-4988-96f6-e5aa1cbf15f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_9ac9a56b-51b3-4457-86d3-981dd63f733e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b013b0e7-c533-490e-9fb6-bc3c7c47da6e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_9ac9a56b-51b3-4457-86d3-981dd63f733e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_edbd96fa-abec-437e-a278-855e81fb3a16" xlink:href="evh-20220930.xsd#evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b013b0e7-c533-490e-9fb6-bc3c7c47da6e" xlink:to="loc_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_edbd96fa-abec-437e-a278-855e81fb3a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3fd95ff7-a31a-49cb-beb9-0fe601cd4adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b013b0e7-c533-490e-9fb6-bc3c7c47da6e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_3fd95ff7-a31a-49cb-beb9-0fe601cd4adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LongtermDebt2022CreditAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d690f608-c0aa-462f-a414-592f0a7b5b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_02774dc9-f067-45f9-ac6a-d03f2c1f97d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d690f608-c0aa-462f-a414-592f0a7b5b75" xlink:to="loc_us-gaap_DebtInstrumentTable_02774dc9-f067-45f9-ac6a-d03f2c1f97d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_36d27e3e-0475-4d48-99bc-c02a54e76ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_02774dc9-f067-45f9-ac6a-d03f2c1f97d1" xlink:to="loc_us-gaap_CreditFacilityAxis_36d27e3e-0475-4d48-99bc-c02a54e76ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2862e8ee-5746-4ab4-b7b6-329a26a01df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_36d27e3e-0475-4d48-99bc-c02a54e76ae4" xlink:to="loc_us-gaap_CreditFacilityDomain_2862e8ee-5746-4ab4-b7b6-329a26a01df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_b75bc939-9823-4f4a-b3b8-392a7511690c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2862e8ee-5746-4ab4-b7b6-329a26a01df7" xlink:to="loc_us-gaap_SecuredDebtMember_b75bc939-9823-4f4a-b3b8-392a7511690c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_df99d684-a577-4a44-ba56-4d729d069f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2862e8ee-5746-4ab4-b7b6-329a26a01df7" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_df99d684-a577-4a44-ba56-4d729d069f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_A2022CreditFacilitiesMember_6d591c0f-86e5-40a0-9960-b533fc57bd73" xlink:href="evh-20220930.xsd#evh_A2022CreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2862e8ee-5746-4ab4-b7b6-329a26a01df7" xlink:to="loc_evh_A2022CreditFacilitiesMember_6d591c0f-86e5-40a0-9960-b533fc57bd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_eea0eb7b-280c-4ae8-afdf-1f49ee8845b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_02774dc9-f067-45f9-ac6a-d03f2c1f97d1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_eea0eb7b-280c-4ae8-afdf-1f49ee8845b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1a7f8e11-40cb-4c03-a7d3-1a360da99e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_eea0eb7b-280c-4ae8-afdf-1f49ee8845b4" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1a7f8e11-40cb-4c03-a7d3-1a360da99e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_27e15a93-1f0b-43fa-9769-bb3fea8cf260" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1a7f8e11-40cb-4c03-a7d3-1a360da99e5e" xlink:to="loc_us-gaap_LineOfCreditMember_27e15a93-1f0b-43fa-9769-bb3fea8cf260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_188e9c26-4da1-48d0-92ed-27b6315f1942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1a7f8e11-40cb-4c03-a7d3-1a360da99e5e" xlink:to="loc_us-gaap_SecuredDebtMember_188e9c26-4da1-48d0-92ed-27b6315f1942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_2e46654f-2d5a-4ac4-b3e3-f9fa68559fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_02774dc9-f067-45f9-ac6a-d03f2c1f97d1" xlink:to="loc_us-gaap_VariableRateAxis_2e46654f-2d5a-4ac4-b3e3-f9fa68559fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_b11ebeb4-d032-400e-8abc-f9e6e423381c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_2e46654f-2d5a-4ac4-b3e3-f9fa68559fc5" xlink:to="loc_us-gaap_VariableRateDomain_b11ebeb4-d032-400e-8abc-f9e6e423381c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SecuredOvernightFinancingRateSOFRMember_1138d5ae-4422-45cd-98cb-f47930497af1" xlink:href="evh-20220930.xsd#evh_SecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_b11ebeb4-d032-400e-8abc-f9e6e423381c" xlink:to="loc_evh_SecuredOvernightFinancingRateSOFRMember_1138d5ae-4422-45cd-98cb-f47930497af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_c8cc0b7b-eaea-4640-9684-d10b18ef0791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_b11ebeb4-d032-400e-8abc-f9e6e423381c" xlink:to="loc_us-gaap_BaseRateMember_c8cc0b7b-eaea-4640-9684-d10b18ef0791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b1b53126-00b1-46d7-b0df-846cb16a2391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_02774dc9-f067-45f9-ac6a-d03f2c1f97d1" xlink:to="loc_us-gaap_DebtInstrumentAxis_b1b53126-00b1-46d7-b0df-846cb16a2391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d5fe71ba-f231-4a17-a454-903630dc07ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1b53126-00b1-46d7-b0df-846cb16a2391" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d5fe71ba-f231-4a17-a454-903630dc07ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_A2022CreditFacilitiesMember_84bd9d1a-37a4-4d26-b4d2-27051eccd181" xlink:href="evh-20220930.xsd#evh_A2022CreditFacilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d5fe71ba-f231-4a17-a454-903630dc07ed" xlink:to="loc_evh_A2022CreditFacilitiesMember_84bd9d1a-37a4-4d26-b4d2-27051eccd181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_02774dc9-f067-45f9-ac6a-d03f2c1f97d1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_533b720f-205c-4e23-8b63-1d5f610c288d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_533b720f-205c-4e23-8b63-1d5f610c288d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_959cd85b-3a09-4ac1-bba0-95ffc52964de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_959cd85b-3a09-4ac1-bba0-95ffc52964de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_7614312c-7451-41a9-b726-98881cf65873" xlink:href="evh-20220930.xsd#evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity_7614312c-7451-41a9-b726-98881cf65873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f404ae74-b766-424b-8f7e-cb5bd38af448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_f404ae74-b766-424b-8f7e-cb5bd38af448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_3dcfb196-11bd-4a28-8708-ce03eec16a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_3dcfb196-11bd-4a28-8708-ce03eec16a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_7aebc211-ecc4-4fef-80a2-50a3b90a9ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_us-gaap_InterestExpenseDebt_7aebc211-ecc4-4fef-80a2-50a3b90a9ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_e40b8fd7-2bd6-4f4a-b8b4-149d65e2195e" xlink:href="evh-20220930.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent_e40b8fd7-2bd6-4f4a-b8b4-149d65e2195e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_67708fb3-92b7-48dd-92e8-cf228a72365c" xlink:href="evh-20220930.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent_67708fb3-92b7-48dd-92e8-cf228a72365c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_c0c22a5d-6b11-408d-b2f6-57f49cae83a5" xlink:href="evh-20220930.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent_c0c22a5d-6b11-408d-b2f6-57f49cae83a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_7cd94439-9d89-4b80-8096-9ce60f26c553" xlink:href="evh-20220930.xsd#evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent_7cd94439-9d89-4b80-8096-9ce60f26c553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1eafa51b-490a-4119-a4e1-2b7b12d7aa94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1eafa51b-490a-4119-a4e1-2b7b12d7aa94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_15cb3e7f-6381-4642-92e6-94c6319dfe7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_15cb3e7f-6381-4642-92e6-94c6319dfe7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e615de63-ed7d-41cd-a98e-b9c88da3e4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_112a7f9a-04ff-4d6c-b3a1-e731a7a4b60d" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_e615de63-ed7d-41cd-a98e-b9c88da3e4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LongtermDebt2024NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a045b3f5-580f-4a0a-a3c4-dcb67f9bbeb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b68a44a6-d3dd-4282-8cb7-641e720ec58e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a045b3f5-580f-4a0a-a3c4-dcb67f9bbeb7" xlink:to="loc_us-gaap_DebtInstrumentTable_b68a44a6-d3dd-4282-8cb7-641e720ec58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_5ed18103-5f97-41e3-b4db-6423201811c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b68a44a6-d3dd-4282-8cb7-641e720ec58e" xlink:to="loc_us-gaap_DebtInstrumentAxis_5ed18103-5f97-41e3-b4db-6423201811c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7af1e6c0-b7f8-40e3-8b20-472e59f42deb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_5ed18103-5f97-41e3-b4db-6423201811c8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7af1e6c0-b7f8-40e3-8b20-472e59f42deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_d6d420ea-3b95-4b01-a4dc-de99685d7a43" xlink:href="evh-20220930.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7af1e6c0-b7f8-40e3-8b20-472e59f42deb" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_d6d420ea-3b95-4b01-a4dc-de99685d7a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_d4a17733-8aa1-470d-bc7a-8a67512205b0" xlink:href="evh-20220930.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7af1e6c0-b7f8-40e3-8b20-472e59f42deb" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_d4a17733-8aa1-470d-bc7a-8a67512205b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NewNotesMember_51409912-1cac-4a5a-809c-928ff6616750" xlink:href="evh-20220930.xsd#evh_NewNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7af1e6c0-b7f8-40e3-8b20-472e59f42deb" xlink:to="loc_evh_NewNotesMember_51409912-1cac-4a5a-809c-928ff6616750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1a5d1691-fb9d-4306-b0fd-279c179e84fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b68a44a6-d3dd-4282-8cb7-641e720ec58e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1a5d1691-fb9d-4306-b0fd-279c179e84fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_dc233183-9084-41f5-8421-fdd723f32840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1a5d1691-fb9d-4306-b0fd-279c179e84fd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_dc233183-9084-41f5-8421-fdd723f32840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_b1aa83a1-af5f-4fce-ae39-60c28d851b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_dc233183-9084-41f5-8421-fdd723f32840" xlink:to="loc_us-gaap_SeniorNotesMember_b1aa83a1-af5f-4fce-ae39-60c28d851b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3937aa78-88a3-499c-b84c-6a6e3d12bbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b68a44a6-d3dd-4282-8cb7-641e720ec58e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3937aa78-88a3-499c-b84c-6a6e3d12bbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b3b7a4b2-20c7-4666-b060-2e2bc4a4b7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3937aa78-88a3-499c-b84c-6a6e3d12bbe0" xlink:to="loc_us-gaap_EquityComponentDomain_b3b7a4b2-20c7-4666-b060-2e2bc4a4b7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d7d32eaf-b573-427e-b051-20e90736b24d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b3b7a4b2-20c7-4666-b060-2e2bc4a4b7a3" xlink:to="loc_us-gaap_CommonStockMember_d7d32eaf-b573-427e-b051-20e90736b24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_15a7d02e-f62a-4643-8c01-8c097fc2b93b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b3b7a4b2-20c7-4666-b060-2e2bc4a4b7a3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_15a7d02e-f62a-4643-8c01-8c097fc2b93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8b17e698-824c-4434-9097-d1b12ad28cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b3b7a4b2-20c7-4666-b060-2e2bc4a4b7a3" xlink:to="loc_us-gaap_RetainedEarningsMember_8b17e698-824c-4434-9097-d1b12ad28cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_0a317e63-e13d-441d-8e14-8215647aff1c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b68a44a6-d3dd-4282-8cb7-641e720ec58e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_0a317e63-e13d-441d-8e14-8215647aff1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a3243861-1cf2-49bc-9afa-8501cf2d6df9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_0a317e63-e13d-441d-8e14-8215647aff1c" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a3243861-1cf2-49bc-9afa-8501cf2d6df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7f601f92-1c32-48fb-aab3-86cf8e1c9353" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_a3243861-1cf2-49bc-9afa-8501cf2d6df9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_7f601f92-1c32-48fb-aab3-86cf8e1c9353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b7229b23-9f31-467e-af30-e18fca138c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b68a44a6-d3dd-4282-8cb7-641e720ec58e" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b7229b23-9f31-467e-af30-e18fca138c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_db8f48e8-a560-4090-9e33-797f9b072fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b7229b23-9f31-467e-af30-e18fca138c52" xlink:to="loc_us-gaap_TypeOfAdoptionMember_db8f48e8-a560-4090-9e33-797f9b072fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_a7bee64c-0a88-4e4d-8cc0-f5ee763b8c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_db8f48e8-a560-4090-9e33-797f9b072fb7" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_a7bee64c-0a88-4e4d-8cc0-f5ee763b8c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6c34e177-7a0a-416f-b613-ce09090ff660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b68a44a6-d3dd-4282-8cb7-641e720ec58e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6c34e177-7a0a-416f-b613-ce09090ff660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_284eae7d-ed04-4d3a-9f8b-4363cdc36cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6c34e177-7a0a-416f-b613-ce09090ff660" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_284eae7d-ed04-4d3a-9f8b-4363cdc36cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember_4f22f5d6-fff6-4655-9b8a-d49e7fae43b4" xlink:href="evh-20220930.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_284eae7d-ed04-4d3a-9f8b-4363cdc36cb8" xlink:to="loc_evh_EquityComponentOfLongTermDebtMember_4f22f5d6-fff6-4655-9b8a-d49e7fae43b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember_6857595e-a216-403c-a2a1-2f700b1e0613" xlink:href="evh-20220930.xsd#evh_DeferredFinancingFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_284eae7d-ed04-4d3a-9f8b-4363cdc36cb8" xlink:to="loc_evh_DeferredFinancingFeesMember_6857595e-a216-403c-a2a1-2f700b1e0613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7ff0dfc6-20db-4897-b98b-b0ff32d0f568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b68a44a6-d3dd-4282-8cb7-641e720ec58e" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7ff0dfc6-20db-4897-b98b-b0ff32d0f568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_46fc003f-d86e-4a35-9432-33ccb4c75447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7ff0dfc6-20db-4897-b98b-b0ff32d0f568" xlink:to="loc_us-gaap_ClassOfStockDomain_46fc003f-d86e-4a35-9432-33ccb4c75447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_99d86826-d51a-4b45-bf16-bb55cb9768c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_46fc003f-d86e-4a35-9432-33ccb4c75447" xlink:to="loc_us-gaap_CommonClassAMember_99d86826-d51a-4b45-bf16-bb55cb9768c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b68a44a6-d3dd-4282-8cb7-641e720ec58e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_712675f0-4aa3-4749-8430-8e05c7e91394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_712675f0-4aa3-4749-8430-8e05c7e91394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_58fad1fd-4924-497b-9019-92b8f4a4ebd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_58fad1fd-4924-497b-9019-92b8f4a4ebd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0aab7c34-b6b8-4dd4-ba30-6a48864107fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0aab7c34-b6b8-4dd4-ba30-6a48864107fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_cdeaf5e7-62c7-4273-babb-6d7f3d75b350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_cdeaf5e7-62c7-4273-babb-6d7f3d75b350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_c6be8e8f-6396-4eea-b0c6-fbb1a0805a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_c6be8e8f-6396-4eea-b0c6-fbb1a0805a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_64f94fc6-2128-4ef0-8e2b-64b8fb8457f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_64f94fc6-2128-4ef0-8e2b-64b8fb8457f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_676b0863-39f7-4927-b812-513db14f4409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_InterestExpenseDebt_676b0863-39f7-4927-b812-513db14f4409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_30126255-8fb4-4c11-91a3-8bcfeeb07dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_30126255-8fb4-4c11-91a3-8bcfeeb07dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_5821aced-7f37-45cb-a698-89bc8bc6d5be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_5821aced-7f37-45cb-a698-89bc8bc6d5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_a37b5d1f-2ec7-4aab-bcdf-aff49a5ffe51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_a37b5d1f-2ec7-4aab-bcdf-aff49a5ffe51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_4d86ae05-2f59-42cc-9787-2cf9ce51606c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_LongTermDebt_4d86ae05-2f59-42cc-9787-2cf9ce51606c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_01d66fc7-7741-4886-89d7-82e71a1390db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_01d66fc7-7741-4886-89d7-82e71a1390db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtIssuanceCostsNetDebtComponent_c117332e-f8e8-4bf3-8710-7a3ed63a38a7" xlink:href="evh-20220930.xsd#evh_DebtIssuanceCostsNetDebtComponent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_evh_DebtIssuanceCostsNetDebtComponent_c117332e-f8e8-4bf3-8710-7a3ed63a38a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e47748c5-3bd0-49c6-bc87-3cb300ff4e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_StockholdersEquity_e47748c5-3bd0-49c6-bc87-3cb300ff4e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_1e1e8b77-0620-4921-91bb-d1ed1d39dd01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_1e1e8b77-0620-4921-91bb-d1ed1d39dd01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_42bc1e84-6fdf-433f-83cc-f790e2fbc7ca" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_42bc1e84-6fdf-433f-83cc-f790e2fbc7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_03cdb4da-a57f-45ec-8bc5-ac247068e409" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_03cdb4da-a57f-45ec-8bc5-ac247068e409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_7801dca5-fdff-4ae7-81f7-3d2a739f4457" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_7801dca5-fdff-4ae7-81f7-3d2a739f4457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_497c6dd0-c953-4c6c-966d-a9830ef75e37" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_497c6dd0-c953-4c6c-966d-a9830ef75e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_29f84357-ef1a-47d9-8763-a850a0836357" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_29f84357-ef1a-47d9-8763-a850a0836357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_cb44f7d8-44b5-4a0d-b8cf-634f3bc602f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_cb44f7d8-44b5-4a0d-b8cf-634f3bc602f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_897f95fa-9c20-477c-82f4-d4ac64200049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76abbe69-bb3b-41ff-a67c-c9f582659d3b" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_897f95fa-9c20-477c-82f4-d4ac64200049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LongtermDebt2019CreditAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b8884256-c406-445a-a10f-8ad430f5e0f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_78300e80-2f07-4ce6-ad91-ba8f2e4e4e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b8884256-c406-445a-a10f-8ad430f5e0f9" xlink:to="loc_us-gaap_DebtInstrumentTable_78300e80-2f07-4ce6-ad91-ba8f2e4e4e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_02ae2de7-d4c2-4af2-bb57-7d6aaa3419bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_78300e80-2f07-4ce6-ad91-ba8f2e4e4e6f" xlink:to="loc_us-gaap_DebtInstrumentAxis_02ae2de7-d4c2-4af2-bb57-7d6aaa3419bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_129392ab-5f0d-4b3a-9a96-bd35233c5b79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_02ae2de7-d4c2-4af2-bb57-7d6aaa3419bd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_129392ab-5f0d-4b3a-9a96-bd35233c5b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_InitialTermLoanFacilityMember_6d4d0d74-6ec2-4b4e-a4b8-5375074e7eb6" xlink:href="evh-20220930.xsd#evh_InitialTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_129392ab-5f0d-4b3a-9a96-bd35233c5b79" xlink:to="loc_evh_InitialTermLoanFacilityMember_6d4d0d74-6ec2-4b4e-a4b8-5375074e7eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CreditAgreementMember_6a8c58bc-1761-4585-b640-5a7021bd8704" xlink:href="evh-20220930.xsd#evh_CreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_129392ab-5f0d-4b3a-9a96-bd35233c5b79" xlink:to="loc_evh_CreditAgreementMember_6a8c58bc-1761-4585-b640-5a7021bd8704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorCreditFacilitiesMember_2f6a0d8e-a9d6-41e8-b6f0-192b146ec210" xlink:href="evh-20220930.xsd#evh_SeniorCreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_129392ab-5f0d-4b3a-9a96-bd35233c5b79" xlink:to="loc_evh_SeniorCreditFacilitiesMember_2f6a0d8e-a9d6-41e8-b6f0-192b146ec210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a090a1bf-7175-446f-be98-edc2187a0b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_78300e80-2f07-4ce6-ad91-ba8f2e4e4e6f" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a090a1bf-7175-446f-be98-edc2187a0b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7b347e2a-99ac-4368-bffd-54d773306b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a090a1bf-7175-446f-be98-edc2187a0b7a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7b347e2a-99ac-4368-bffd-54d773306b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_50f37a64-4d66-4736-8065-77c3859be0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7b347e2a-99ac-4368-bffd-54d773306b08" xlink:to="loc_us-gaap_SecuredDebtMember_50f37a64-4d66-4736-8065-77c3859be0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_f9800776-496c-40b2-9549-4e91b0130a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_7b347e2a-99ac-4368-bffd-54d773306b08" xlink:to="loc_us-gaap_LineOfCreditMember_f9800776-496c-40b2-9549-4e91b0130a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_821a2d59-5fee-4408-b32b-8e9329646a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_78300e80-2f07-4ce6-ad91-ba8f2e4e4e6f" xlink:to="loc_us-gaap_CreditFacilityAxis_821a2d59-5fee-4408-b32b-8e9329646a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d9f8f1cd-ee5c-4a6f-9cee-7fc5d62cab38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_821a2d59-5fee-4408-b32b-8e9329646a19" xlink:to="loc_us-gaap_CreditFacilityDomain_d9f8f1cd-ee5c-4a6f-9cee-7fc5d62cab38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DelayedDrawTermLoanFacilityMember_ab060fe6-a419-4b03-9e7c-58f154b5299a" xlink:href="evh-20220930.xsd#evh_DelayedDrawTermLoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d9f8f1cd-ee5c-4a6f-9cee-7fc5d62cab38" xlink:to="loc_evh_DelayedDrawTermLoanFacilityMember_ab060fe6-a419-4b03-9e7c-58f154b5299a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b786f3a6-2ad9-42d8-8d18-94a43b42bb28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_78300e80-2f07-4ce6-ad91-ba8f2e4e4e6f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b786f3a6-2ad9-42d8-8d18-94a43b42bb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_a34fc4ff-f42f-47d3-9413-ec54243c0531" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b786f3a6-2ad9-42d8-8d18-94a43b42bb28" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_a34fc4ff-f42f-47d3-9413-ec54243c0531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f4f441dd-fe03-48a7-bb06-e24fed2de462" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b786f3a6-2ad9-42d8-8d18-94a43b42bb28" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f4f441dd-fe03-48a7-bb06-e24fed2de462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_20a7253e-1f55-4fa5-bcf2-3770fc8c417f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b786f3a6-2ad9-42d8-8d18-94a43b42bb28" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_20a7253e-1f55-4fa5-bcf2-3770fc8c417f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PaymentsOfMakeWholePremium_a5539c3f-4029-47e7-948a-3d3de41e1b6a" xlink:href="evh-20220930.xsd#evh_PaymentsOfMakeWholePremium"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b786f3a6-2ad9-42d8-8d18-94a43b42bb28" xlink:to="loc_evh_PaymentsOfMakeWholePremium_a5539c3f-4029-47e7-948a-3d3de41e1b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_eeb05d73-f862-4805-a156-edd24259a84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b786f3a6-2ad9-42d8-8d18-94a43b42bb28" xlink:to="loc_us-gaap_InterestPaidNet_eeb05d73-f862-4805-a156-edd24259a84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_52b69fdf-21d3-4f8e-ab1f-ad55d5b5852b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b786f3a6-2ad9-42d8-8d18-94a43b42bb28" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_52b69fdf-21d3-4f8e-ab1f-ad55d5b5852b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_4b278519-cd3f-4378-b928-fb80ecb57d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b786f3a6-2ad9-42d8-8d18-94a43b42bb28" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_4b278519-cd3f-4378-b928-fb80ecb57d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalFees_7fcd7f9c-15c7-44d4-8295-b59da9d2247c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b786f3a6-2ad9-42d8-8d18-94a43b42bb28" xlink:to="loc_us-gaap_LegalFees_7fcd7f9c-15c7-44d4-8295-b59da9d2247c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LongtermDebtWarrantAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_12de11f9-fbff-488c-b44d-6bb39c688406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_4fbbb47a-77ed-441b-9680-a4ed0c53e909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_12de11f9-fbff-488c-b44d-6bb39c688406" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_4fbbb47a-77ed-441b-9680-a4ed0c53e909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_895041db-3ce6-4fec-82eb-74f0972cee56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4fbbb47a-77ed-441b-9680-a4ed0c53e909" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_895041db-3ce6-4fec-82eb-74f0972cee56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5b09ce37-f1f1-4516-b184-38db6864178c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_895041db-3ce6-4fec-82eb-74f0972cee56" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5b09ce37-f1f1-4516-b184-38db6864178c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_8aef5aeb-d9a3-4c29-aa83-7f7fa69c204f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5b09ce37-f1f1-4516-b184-38db6864178c" xlink:to="loc_us-gaap_CommonClassAMember_8aef5aeb-d9a3-4c29-aa83-7f7fa69c204f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_6d3ce71b-eb33-409f-97a9-1a1032b7d826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4fbbb47a-77ed-441b-9680-a4ed0c53e909" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_6d3ce71b-eb33-409f-97a9-1a1032b7d826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightUnissued_c9e3ccad-6a99-45c8-a56e-c326a6509158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightUnissued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6d3ce71b-eb33-409f-97a9-1a1032b7d826" xlink:to="loc_us-gaap_ClassOfWarrantOrRightUnissued_c9e3ccad-6a99-45c8-a56e-c326a6509158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_13acba97-7da4-49d3-981a-d26c5b8c7125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6d3ce71b-eb33-409f-97a9-1a1032b7d826" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_13acba97-7da4-49d3-981a-d26c5b8c7125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_a6bc123c-d30d-4d05-a8f5-d32b33f2d3d3" xlink:href="evh-20220930.xsd#evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6d3ce71b-eb33-409f-97a9-1a1032b7d826" xlink:to="loc_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement_a6bc123c-d30d-4d05-a8f5-d32b33f2d3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_35c960ce-3dd8-4ecd-a88a-3a264bf1b877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6d3ce71b-eb33-409f-97a9-1a1032b7d826" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_35c960ce-3dd8-4ecd-a88a-3a264bf1b877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LongtermDebt2025NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1782ed52-46be-4388-b7f3-4022c848541c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e27002f1-20c2-4b71-a7f4-293650d079af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1782ed52-46be-4388-b7f3-4022c848541c" xlink:to="loc_us-gaap_DebtInstrumentTable_e27002f1-20c2-4b71-a7f4-293650d079af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_94ef2ab8-a134-4da2-8f47-62644bf053bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e27002f1-20c2-4b71-a7f4-293650d079af" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_94ef2ab8-a134-4da2-8f47-62644bf053bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4b75317c-e30a-4d75-bad8-63c58bfd8290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_94ef2ab8-a134-4da2-8f47-62644bf053bd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4b75317c-e30a-4d75-bad8-63c58bfd8290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_297244f9-0081-4b50-b7dd-343c3e22294c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4b75317c-e30a-4d75-bad8-63c58bfd8290" xlink:to="loc_us-gaap_SeniorNotesMember_297244f9-0081-4b50-b7dd-343c3e22294c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a58584fa-c005-4e65-a8e6-8907e7f5deb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e27002f1-20c2-4b71-a7f4-293650d079af" xlink:to="loc_us-gaap_DebtInstrumentAxis_a58584fa-c005-4e65-a8e6-8907e7f5deb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bd7766fa-5067-4846-9e53-fe028d7cec6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a58584fa-c005-4e65-a8e6-8907e7f5deb4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bd7766fa-5067-4846-9e53-fe028d7cec6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_6ba20290-88cc-44e9-9d86-894b53505942" xlink:href="evh-20220930.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bd7766fa-5067-4846-9e53-fe028d7cec6a" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_6ba20290-88cc-44e9-9d86-894b53505942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_65e5d171-578b-4c35-9625-ffe072f45628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e27002f1-20c2-4b71-a7f4-293650d079af" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_65e5d171-578b-4c35-9625-ffe072f45628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_13657f1b-9590-4501-a58b-74fde6fb4386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_65e5d171-578b-4c35-9625-ffe072f45628" xlink:to="loc_us-gaap_EquityComponentDomain_13657f1b-9590-4501-a58b-74fde6fb4386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_491b9782-6121-4e10-967b-131d3d504677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_13657f1b-9590-4501-a58b-74fde6fb4386" xlink:to="loc_us-gaap_CommonStockMember_491b9782-6121-4e10-967b-131d3d504677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c79f5c19-7326-4f34-a73f-40b1434113f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_13657f1b-9590-4501-a58b-74fde6fb4386" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c79f5c19-7326-4f34-a73f-40b1434113f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1657a4fc-6ee4-4927-9870-e8ad089c47ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_13657f1b-9590-4501-a58b-74fde6fb4386" xlink:to="loc_us-gaap_RetainedEarningsMember_1657a4fc-6ee4-4927-9870-e8ad089c47ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c65853ac-33bf-44b0-bb06-7bc256b963e9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e27002f1-20c2-4b71-a7f4-293650d079af" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c65853ac-33bf-44b0-bb06-7bc256b963e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7d20b6de-95ff-4e1c-bf21-cc2198994e58" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_c65853ac-33bf-44b0-bb06-7bc256b963e9" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7d20b6de-95ff-4e1c-bf21-cc2198994e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_16702748-eb7e-4bbb-b4ad-5439be4257b0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7d20b6de-95ff-4e1c-bf21-cc2198994e58" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_16702748-eb7e-4bbb-b4ad-5439be4257b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_56143251-bd86-427d-928f-5bbdb3833f17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e27002f1-20c2-4b71-a7f4-293650d079af" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_56143251-bd86-427d-928f-5bbdb3833f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1325dfba-953a-41e7-b722-7036fa27668e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_56143251-bd86-427d-928f-5bbdb3833f17" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1325dfba-953a-41e7-b722-7036fa27668e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_bddc9c5c-6c79-4f48-90cb-88bfca4f3d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1325dfba-953a-41e7-b722-7036fa27668e" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_bddc9c5c-6c79-4f48-90cb-88bfca4f3d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_f3ee8ee5-2bfe-4df7-aae4-e88bb84461e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e27002f1-20c2-4b71-a7f4-293650d079af" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_f3ee8ee5-2bfe-4df7-aae4-e88bb84461e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b532deed-708f-4393-86ee-509f28fdc7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_f3ee8ee5-2bfe-4df7-aae4-e88bb84461e7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b532deed-708f-4393-86ee-509f28fdc7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityComponentOfLongTermDebtMember_e126e53a-d282-4e39-9312-a3384acaed47" xlink:href="evh-20220930.xsd#evh_EquityComponentOfLongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b532deed-708f-4393-86ee-509f28fdc7dd" xlink:to="loc_evh_EquityComponentOfLongTermDebtMember_e126e53a-d282-4e39-9312-a3384acaed47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DeferredFinancingFeesMember_96b3846f-c570-4ce3-8f7c-e1155976785d" xlink:href="evh-20220930.xsd#evh_DeferredFinancingFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b532deed-708f-4393-86ee-509f28fdc7dd" xlink:to="loc_evh_DeferredFinancingFeesMember_96b3846f-c570-4ce3-8f7c-e1155976785d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_63dc355e-d8dd-4dff-b942-6e1049f51eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e27002f1-20c2-4b71-a7f4-293650d079af" xlink:to="loc_us-gaap_StatementClassOfStockAxis_63dc355e-d8dd-4dff-b942-6e1049f51eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4c3db930-b8ea-4bd0-b24d-b08436f52c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_63dc355e-d8dd-4dff-b942-6e1049f51eb5" xlink:to="loc_us-gaap_ClassOfStockDomain_4c3db930-b8ea-4bd0-b24d-b08436f52c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_9c3ff36a-9c79-4b1d-a6cf-683d213e358d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4c3db930-b8ea-4bd0-b24d-b08436f52c40" xlink:to="loc_us-gaap_CommonClassAMember_9c3ff36a-9c79-4b1d-a6cf-683d213e358d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e27002f1-20c2-4b71-a7f4-293650d079af" xlink:to="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_ebc7ec74-4e84-49bf-b0f2-23ec314570dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_ebc7ec74-4e84-49bf-b0f2-23ec314570dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5cdd06aa-d3d0-491d-8d0c-ea1b17fba177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5cdd06aa-d3d0-491d-8d0c-ea1b17fba177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_146d6b41-ede5-4de2-8360-81d0d6f0df2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_InterestExpenseDebt_146d6b41-ede5-4de2-8360-81d0d6f0df2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_75e4379c-3445-472c-9181-fb32028c0c9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_75e4379c-3445-472c-9181-fb32028c0c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_47cc550a-cbce-4ae1-b63b-7f6895ab0ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_47cc550a-cbce-4ae1-b63b-7f6895ab0ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_fb520899-606e-422e-ad57-1936717d2943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_fb520899-606e-422e-ad57-1936717d2943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3da52b75-63a7-4ea1-8ddc-3ee551319117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_LongTermDebt_3da52b75-63a7-4ea1-8ddc-3ee551319117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_106b1e8f-caf3-4232-ab1b-919d8132f4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_106b1e8f-caf3-4232-ab1b-919d8132f4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_82793b95-8fd7-4604-a469-0debeb8c06bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_82793b95-8fd7-4604-a469-0debeb8c06bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5e0c1a83-3125-4b8c-8f92-a63aec4ffc39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_StockholdersEquity_5e0c1a83-3125-4b8c-8f92-a63aec4ffc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_7a9e3509-479d-4c7d-ab15-4c3afa5a637b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_7a9e3509-479d-4c7d-ab15-4c3afa5a637b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_a3b8d8ec-cbe5-44cb-aae7-487c26640ec1" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount_a3b8d8ec-cbe5-44cb-aae7-487c26640ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_3047a9b4-9bb1-4dbf-aa54-4288559d663c" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice_3047a9b4-9bb1-4dbf-aa54-4288559d663c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_3b7b8506-f65d-461f-89e3-ae85fbbbdaba" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum_3b7b8506-f65d-461f-89e3-ae85fbbbdaba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_8305a732-faff-4d2c-8ebc-461c8ac57c7b" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum_8305a732-faff-4d2c-8ebc-461c8ac57c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_4ebe083a-d1d4-48dd-a0c4-0a981378eb66" xlink:href="evh-20220930.xsd#evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cf471888-0a7d-4535-a09d-483b9c168485" xlink:to="loc_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice_4ebe083a-d1d4-48dd-a0c4-0a981378eb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LongtermDebt2021NotesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f5a92cdd-f4e0-483a-a803-a66649d3dac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_622d9caf-3b94-4274-847a-57fc1836c2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f5a92cdd-f4e0-483a-a803-a66649d3dac8" xlink:to="loc_us-gaap_DebtInstrumentTable_622d9caf-3b94-4274-847a-57fc1836c2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7b0dca93-2b66-4254-94f2-8b6c8e7624ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_622d9caf-3b94-4274-847a-57fc1836c2b6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7b0dca93-2b66-4254-94f2-8b6c8e7624ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b85da9dd-770b-4103-ba74-af0a12ebec2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7b0dca93-2b66-4254-94f2-8b6c8e7624ef" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b85da9dd-770b-4103-ba74-af0a12ebec2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_7f02cefc-f289-4ff9-890e-1efeda23b1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b85da9dd-770b-4103-ba74-af0a12ebec2d" xlink:to="loc_us-gaap_SeniorNotesMember_7f02cefc-f289-4ff9-890e-1efeda23b1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_031d7afd-c1b5-47a2-a203-df611be54763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_622d9caf-3b94-4274-847a-57fc1836c2b6" xlink:to="loc_us-gaap_DebtInstrumentAxis_031d7afd-c1b5-47a2-a203-df611be54763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7e57db68-0c87-4e0f-98a0-2856c9bc4443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_031d7afd-c1b5-47a2-a203-df611be54763" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7e57db68-0c87-4e0f-98a0-2856c9bc4443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ConvertibleSeniorNotesdue2021Member_5d29d159-6033-478c-85ec-b3fa74b36a35" xlink:href="evh-20220930.xsd#evh_ConvertibleSeniorNotesdue2021Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e57db68-0c87-4e0f-98a0-2856c9bc4443" xlink:to="loc_evh_ConvertibleSeniorNotesdue2021Member_5d29d159-6033-478c-85ec-b3fa74b36a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_b37731c1-01cd-40e2-b0fc-e4222a48999d" xlink:href="evh-20220930.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7e57db68-0c87-4e0f-98a0-2856c9bc4443" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_b37731c1-01cd-40e2-b0fc-e4222a48999d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_622d9caf-3b94-4274-847a-57fc1836c2b6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b0fc146e-bf49-48a5-9528-fad8ebc0e265" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b0fc146e-bf49-48a5-9528-fad8ebc0e265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e2d1c590-4e77-4805-bd8d-602c373aaa51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e2d1c590-4e77-4805-bd8d-602c373aaa51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_cea6f702-490f-453a-a158-191f5dea3713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_cea6f702-490f-453a-a158-191f5dea3713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_aececcf4-a68d-4438-9ab1-2fed5c271f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_aececcf4-a68d-4438-9ab1-2fed5c271f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_c585359d-d634-4adf-9636-06bc1e5bc3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_c585359d-d634-4adf-9636-06bc1e5bc3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionOriginalDebtAmount1_9c0d7eb0-1c5f-429d-b1dc-dc8dab2b917a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionOriginalDebtAmount1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_DebtConversionOriginalDebtAmount1_9c0d7eb0-1c5f-429d-b1dc-dc8dab2b917a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_63e930d3-4d70-40d5-83a7-332889400c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_63e930d3-4d70-40d5-83a7-332889400c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_d8117551-c3f8-4f26-9660-a36c237a8873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost_d8117551-c3f8-4f26-9660-a36c237a8873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_b973473c-2713-4fc6-aa7b-d7e6b36882ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_b973473c-2713-4fc6-aa7b-d7e6b36882ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_ead32858-31ca-491e-8cf2-2c03e786b99c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5e92a5e4-1c6b-43f4-8822-7554e6d6d0a8" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_ead32858-31ca-491e-8cf2-2c03e786b99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LongtermDebtConvertibleSeniorNotesCarryingValueDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cf522f7d-293a-469d-a348-f9972353563c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_013f3708-b4b2-4811-ba10-2d82929f45e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cf522f7d-293a-469d-a348-f9972353563c" xlink:to="loc_us-gaap_DebtInstrumentTable_013f3708-b4b2-4811-ba10-2d82929f45e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c7fdb032-4014-4682-a3fb-8b15a384f4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_013f3708-b4b2-4811-ba10-2d82929f45e7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c7fdb032-4014-4682-a3fb-8b15a384f4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_33c8349a-a602-4d0f-b706-be82d62f8414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c7fdb032-4014-4682-a3fb-8b15a384f4b5" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_33c8349a-a602-4d0f-b706-be82d62f8414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_22a1808c-2a3f-428a-a5f1-079da2714234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_33c8349a-a602-4d0f-b706-be82d62f8414" xlink:to="loc_us-gaap_SeniorNotesMember_22a1808c-2a3f-428a-a5f1-079da2714234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_6032d1f1-277e-43e6-9f14-ef6463824126" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_013f3708-b4b2-4811-ba10-2d82929f45e7" xlink:to="loc_us-gaap_DebtInstrumentAxis_6032d1f1-277e-43e6-9f14-ef6463824126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_44312f10-86da-49bf-bc89-f3ffdce6b27b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_6032d1f1-277e-43e6-9f14-ef6463824126" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_44312f10-86da-49bf-bc89-f3ffdce6b27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2024Member_0e582b93-8405-4b4b-8e62-5141e489b3d9" xlink:href="evh-20220930.xsd#evh_SeniorConvertibleNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44312f10-86da-49bf-bc89-f3ffdce6b27b" xlink:to="loc_evh_SeniorConvertibleNotesDue2024Member_0e582b93-8405-4b4b-8e62-5141e489b3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SeniorConvertibleNotesDue2025Member_6f53bb5e-9a72-439c-bcc7-3f542c01d44e" xlink:href="evh-20220930.xsd#evh_SeniorConvertibleNotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_44312f10-86da-49bf-bc89-f3ffdce6b27b" xlink:to="loc_evh_SeniorConvertibleNotesDue2025Member_6f53bb5e-9a72-439c-bcc7-3f542c01d44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_59c0c1e0-31ee-496a-873e-4e7bc240875e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_013f3708-b4b2-4811-ba10-2d82929f45e7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_59c0c1e0-31ee-496a-873e-4e7bc240875e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_21377317-a53d-4671-811d-e9abf1e7bcce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_59c0c1e0-31ee-496a-873e-4e7bc240875e" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_21377317-a53d-4671-811d-e9abf1e7bcce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2412fd02-4993-4c31-a582-d966ee909275" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_21377317-a53d-4671-811d-e9abf1e7bcce" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2412fd02-4993-4c31-a582-d966ee909275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a2fd676f-959a-496b-abc8-1f849648f352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_013f3708-b4b2-4811-ba10-2d82929f45e7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a2fd676f-959a-496b-abc8-1f849648f352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_f87fcef9-110f-44aa-a0b0-358ac1112813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a2fd676f-959a-496b-abc8-1f849648f352" xlink:to="loc_us-gaap_ConvertibleDebt_f87fcef9-110f-44aa-a0b0-358ac1112813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_922945db-7893-42d9-8962-83fe73c82d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a2fd676f-959a-496b-abc8-1f849648f352" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_922945db-7893-42d9-8962-83fe73c82d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1ada9308-24ad-44f6-ae15-b9ed5531e1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a2fd676f-959a-496b-abc8-1f849648f352" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1ada9308-24ad-44f6-ae15-b9ed5531e1fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_5b368f05-1b69-46f2-953b-47dab12c0a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a2fd676f-959a-496b-abc8-1f849648f352" xlink:to="loc_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_5b368f05-1b69-46f2-953b-47dab12c0a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_bd97589c-8eaa-451e-87ef-5a4335fc2f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a2fd676f-959a-496b-abc8-1f849648f352" xlink:to="loc_us-gaap_LongTermDebtFairValue_bd97589c-8eaa-451e-87ef-5a4335fc2f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_85f932ad-7aab-4d5a-bb28-42edcd60a56a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_c4d1448c-3d62-4ef4-b10c-c256c8dddc72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_85f932ad-7aab-4d5a-bb28-42edcd60a56a" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_c4d1448c-3d62-4ef4-b10c-c256c8dddc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_4b4bb4a7-3c5e-436e-9081-4cb4c14cad7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_c4d1448c-3d62-4ef4-b10c-c256c8dddc72" xlink:to="loc_us-gaap_CreditFacilityAxis_4b4bb4a7-3c5e-436e-9081-4cb4c14cad7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_962bc5a5-5858-4341-94e3-7e776b9caf13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_4b4bb4a7-3c5e-436e-9081-4cb4c14cad7e" xlink:to="loc_us-gaap_CreditFacilityDomain_962bc5a5-5858-4341-94e3-7e776b9caf13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_a0c4408f-2866-4ece-8ba3-04dd75cf3d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_962bc5a5-5858-4341-94e3-7e776b9caf13" xlink:to="loc_us-gaap_LetterOfCreditMember_a0c4408f-2866-4ece-8ba3-04dd75cf3d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6483492b-a165-44fa-97a1-47ff50786f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_c4d1448c-3d62-4ef4-b10c-c256c8dddc72" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6483492b-a165-44fa-97a1-47ff50786f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1f39506e-0ed1-494f-a1be-9765db9acb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6483492b-a165-44fa-97a1-47ff50786f1c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1f39506e-0ed1-494f-a1be-9765db9acb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_ec086d52-3d07-4dc4-b707-0de11c367822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1f39506e-0ed1-494f-a1be-9765db9acb3b" xlink:to="loc_us-gaap_LineOfCreditMember_ec086d52-3d07-4dc4-b707-0de11c367822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_dcab2687-5219-4fb9-acdf-8a340e2e7dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_c4d1448c-3d62-4ef4-b10c-c256c8dddc72" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_dcab2687-5219-4fb9-acdf-8a340e2e7dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0bf3fae5-6ee2-45d2-b196-3a0affb15ed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_dcab2687-5219-4fb9-acdf-8a340e2e7dc4" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0bf3fae5-6ee2-45d2-b196-3a0affb15ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CollateralwithFinancialInstitutionsMember_2ad66637-3c24-4b6b-905d-9cc10bd58011" xlink:href="evh-20220930.xsd#evh_CollateralwithFinancialInstitutionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0bf3fae5-6ee2-45d2-b196-3a0affb15ed9" xlink:to="loc_evh_CollateralwithFinancialInstitutionsMember_2ad66637-3c24-4b6b-905d-9cc10bd58011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_83651d31-ca2c-499a-8045-f7ba71a029fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_c4d1448c-3d62-4ef4-b10c-c256c8dddc72" xlink:to="loc_srt_LitigationCaseAxis_83651d31-ca2c-499a-8045-f7ba71a029fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0fd85ff4-9f69-49a4-ad2c-1e40fdf5b590" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_83651d31-ca2c-499a-8045-f7ba71a029fd" xlink:to="loc_srt_LitigationCaseTypeDomain_0fd85ff4-9f69-49a4-ad2c-1e40fdf5b590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderClassActionComplaintMember_762c37c9-a3f1-454e-8a86-bc4e6ebbab32" xlink:href="evh-20220930.xsd#evh_ShareholderClassActionComplaintMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0fd85ff4-9f69-49a4-ad2c-1e40fdf5b590" xlink:to="loc_evh_ShareholderClassActionComplaintMember_762c37c9-a3f1-454e-8a86-bc4e6ebbab32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_1b74b0ff-0b05-4fc4-8bf6-1a74da9887d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_c4d1448c-3d62-4ef4-b10c-c256c8dddc72" xlink:to="loc_us-gaap_OtherCommitmentsAxis_1b74b0ff-0b05-4fc4-8bf6-1a74da9887d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_82a77f99-0148-446c-8d33-3ded45d027d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_1b74b0ff-0b05-4fc4-8bf6-1a74da9887d0" xlink:to="loc_us-gaap_OtherCommitmentsDomain_82a77f99-0148-446c-8d33-3ded45d027d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_UPMCResellerAgreementMember_7b4e9207-c05d-44fa-8808-58747bbcc003" xlink:href="evh-20220930.xsd#evh_UPMCResellerAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_82a77f99-0148-446c-8d33-3ded45d027d6" xlink:to="loc_evh_UPMCResellerAgreementMember_7b4e9207-c05d-44fa-8808-58747bbcc003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable_c4d1448c-3d62-4ef4-b10c-c256c8dddc72" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c4da226c-95f5-4e08-bd84-8e5815faba0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c4da226c-95f5-4e08-bd84-8e5815faba0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_938392b6-229b-45c8-b3ea-0eb9fc2627b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_938392b6-229b-45c8-b3ea-0eb9fc2627b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LineOfCreditFacilityAutomaticExtensionPeriod_91ad95f6-89c6-4bee-b6a2-643c732d9e8c" xlink:href="evh-20220930.xsd#evh_LineOfCreditFacilityAutomaticExtensionPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:to="loc_evh_LineOfCreditFacilityAutomaticExtensionPeriod_91ad95f6-89c6-4bee-b6a2-643c732d9e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_d09c8188-b740-49f1-8c3b-56cb6018b1f0" xlink:href="evh-20220930.xsd#evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:to="loc_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension_d09c8188-b740-49f1-8c3b-56cb6018b1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfCustomers_9fbc8573-827f-40a7-afef-aa62ea7830c2" xlink:href="evh-20220930.xsd#evh_NumberOfCustomers"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:to="loc_evh_NumberOfCustomers_9fbc8573-827f-40a7-afef-aa62ea7830c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9bc2fb7b-a1cd-43c2-8064-18246910c072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:to="loc_us-gaap_Revenues_9bc2fb7b-a1cd-43c2-8064-18246910c072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_0efbf644-9ea3-4780-8ee4-d1f1b6761bda" xlink:href="evh-20220930.xsd#evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:to="loc_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid_0efbf644-9ea3-4780-8ee4-d1f1b6761bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementLiability_4d172f2f-2eb4-4265-9375-1dd619afe5dd" xlink:href="evh-20220930.xsd#evh_TaxReceivableAgreementLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:to="loc_evh_TaxReceivableAgreementLiability_4d172f2f-2eb4-4265-9375-1dd619afe5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_d26a4369-aaf8-4363-a299-9e720b603d76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems_fd2a67b4-622e-4814-9fcc-d2dfa69fff68" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_d26a4369-aaf8-4363-a299-9e720b603d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#CommitmentsandContingenciesConcentrationRiskDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_055e2647-c761-4cd5-a145-b4a007fc34b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_dcadb080-cf15-4ec0-9700-1bd5e7539173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_055e2647-c761-4cd5-a145-b4a007fc34b3" xlink:to="loc_us-gaap_ConcentrationRiskTable_dcadb080-cf15-4ec0-9700-1bd5e7539173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_0ff5594b-f9eb-40a2-9370-a162d0f9c35c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_dcadb080-cf15-4ec0-9700-1bd5e7539173" xlink:to="loc_srt_MajorCustomersAxis_0ff5594b-f9eb-40a2-9370-a162d0f9c35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f3bed6cb-6b0b-496c-b7a3-494be8587439" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_0ff5594b-f9eb-40a2-9370-a162d0f9c35c" xlink:to="loc_srt_NameOfMajorCustomerDomain_f3bed6cb-6b0b-496c-b7a3-494be8587439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CookCountyHealthAndHospitalsSystemMember_c5e61d96-863b-4e11-b67f-44ef1ad30c7d" xlink:href="evh-20220930.xsd#evh_CookCountyHealthAndHospitalsSystemMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f3bed6cb-6b0b-496c-b7a3-494be8587439" xlink:to="loc_evh_CookCountyHealthAndHospitalsSystemMember_c5e61d96-863b-4e11-b67f-44ef1ad30c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_FloridaBlueMedicareIncMember_d77e746a-0104-489e-ab04-b541301020b0" xlink:href="evh-20220930.xsd#evh_FloridaBlueMedicareIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f3bed6cb-6b0b-496c-b7a3-494be8587439" xlink:to="loc_evh_FloridaBlueMedicareIncMember_d77e746a-0104-489e-ab04-b541301020b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MolinaHealthcareMember_f28f492e-00dd-488e-81c7-ae586d73cdb8" xlink:href="evh-20220930.xsd#evh_MolinaHealthcareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f3bed6cb-6b0b-496c-b7a3-494be8587439" xlink:to="loc_evh_MolinaHealthcareMember_f28f492e-00dd-488e-81c7-ae586d73cdb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BrightHealthManagementIncMember_40e06600-a735-4099-8999-439cee39f52e" xlink:href="evh-20220930.xsd#evh_BrightHealthManagementIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f3bed6cb-6b0b-496c-b7a3-494be8587439" xlink:to="loc_evh_BrightHealthManagementIncMember_40e06600-a735-4099-8999-439cee39f52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_cdd8365e-dc50-47b6-bbad-784296b631d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_dcadb080-cf15-4ec0-9700-1bd5e7539173" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_cdd8365e-dc50-47b6-bbad-784296b631d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_26d2da70-93ba-4ae6-8906-4659d0307f46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_cdd8365e-dc50-47b6-bbad-784296b631d1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_26d2da70-93ba-4ae6-8906-4659d0307f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_94970573-7ba5-4082-bbc2-5c8c52e49a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_26d2da70-93ba-4ae6-8906-4659d0307f46" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_94970573-7ba5-4082-bbc2-5c8c52e49a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_03006185-bdd8-4afc-8c95-b2106379af00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_dcadb080-cf15-4ec0-9700-1bd5e7539173" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_03006185-bdd8-4afc-8c95-b2106379af00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_489bb3da-4347-4afb-a910-5f5a8c5a2099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_03006185-bdd8-4afc-8c95-b2106379af00" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_489bb3da-4347-4afb-a910-5f5a8c5a2099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_59a456e2-e76c-41e1-8adf-5fd9bf3a4777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_489bb3da-4347-4afb-a910-5f5a8c5a2099" xlink:to="loc_us-gaap_AccountsReceivableMember_59a456e2-e76c-41e1-8adf-5fd9bf3a4777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_8b402575-6327-4bec-87fd-38289c94fee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_489bb3da-4347-4afb-a910-5f5a8c5a2099" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_8b402575-6327-4bec-87fd-38289c94fee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1f26c57f-47db-4bdd-9488-37d3261fa98c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_dcadb080-cf15-4ec0-9700-1bd5e7539173" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1f26c57f-47db-4bdd-9488-37d3261fa98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_3081b8a6-c298-48d0-80c7-d2ce347ffa52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1f26c57f-47db-4bdd-9488-37d3261fa98c" xlink:to="loc_us-gaap_ReceivableTypeDomain_3081b8a6-c298-48d0-80c7-d2ce347ffa52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_1a685d72-435e-41ad-8a03-4c169192c2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_3081b8a6-c298-48d0-80c7-d2ce347ffa52" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_1a685d72-435e-41ad-8a03-4c169192c2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_f7988614-7114-426d-bc4a-0fbedf3fc50d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_dcadb080-cf15-4ec0-9700-1bd5e7539173" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_f7988614-7114-426d-bc4a-0fbedf3fc50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFDICInsuredAmountPercentage_5894899f-0b47-412e-8a29-cf451f2f5fcb" xlink:href="evh-20220930.xsd#evh_CashFDICInsuredAmountPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f7988614-7114-426d-bc4a-0fbedf3fc50d" xlink:to="loc_evh_CashFDICInsuredAmountPercentage_5894899f-0b47-412e-8a29-cf451f2f5fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18f02771-702a-4367-9d40-415039019500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f7988614-7114-426d-bc4a-0fbedf3fc50d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_18f02771-702a-4367-9d40-415039019500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashHeldInInternationalBanksPercentage_978d7586-df0d-453f-9319-a65424344de3" xlink:href="evh-20220930.xsd#evh_CashHeldInInternationalBanksPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f7988614-7114-426d-bc4a-0fbedf3fc50d" xlink:to="loc_evh_CashHeldInInternationalBanksPercentage_978d7586-df0d-453f-9319-a65424344de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_534e25e6-5cd8-4000-87d2-710838282e66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_f7988614-7114-426d-bc4a-0fbedf3fc50d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_534e25e6-5cd8-4000-87d2-710838282e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5310bec1-61e1-4a77-8a05-9a2fc097c9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_d0e918c3-85d2-4388-aef4-f3053a8c2b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5310bec1-61e1-4a77-8a05-9a2fc097c9b4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_d0e918c3-85d2-4388-aef4-f3053a8c2b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_254a99e7-ae01-47b4-a1d0-18c0f136ff0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d0e918c3-85d2-4388-aef4-f3053a8c2b17" xlink:to="loc_us-gaap_OtherCommitmentsAxis_254a99e7-ae01-47b4-a1d0-18c0f136ff0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_b65ad3cd-201d-4924-ac41-17bfe3ee48a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_254a99e7-ae01-47b4-a1d0-18c0f136ff0c" xlink:to="loc_us-gaap_OtherCommitmentsDomain_b65ad3cd-201d-4924-ac41-17bfe3ee48a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAgreementsMember_9938c2a8-22b2-400f-b046-ef9549ee511e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_b65ad3cd-201d-4924-ac41-17bfe3ee48a6" xlink:to="loc_us-gaap_LeaseAgreementsMember_9938c2a8-22b2-400f-b046-ef9549ee511e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_c919acad-175c-4dc8-892b-46adb98b605c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_d0e918c3-85d2-4388-aef4-f3053a8c2b17" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_c919acad-175c-4dc8-892b-46adb98b605c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_NumberOfOptionsToRenewLeases_b88dd9e9-5aee-40fb-b59d-efee5b87d628" xlink:href="evh-20220930.xsd#evh_NumberOfOptionsToRenewLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c919acad-175c-4dc8-892b-46adb98b605c" xlink:to="loc_evh_NumberOfOptionsToRenewLeases_b88dd9e9-5aee-40fb-b59d-efee5b87d628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_d1688f4d-e1b3-4a8a-84f3-c752bbde7b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c919acad-175c-4dc8-892b-46adb98b605c" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_d1688f4d-e1b3-4a8a-84f3-c752bbde7b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_9b2ceb41-8055-4d0c-aca1-246e1e2fe33b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c919acad-175c-4dc8-892b-46adb98b605c" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_9b2ceb41-8055-4d0c-aca1-246e1e2fe33b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LeasesPrimaryOfficeLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e84f65cf-867e-4f6f-9a7e-8dca970047c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_59cea058-85eb-4e58-b486-36bc1fb015fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e84f65cf-867e-4f6f-9a7e-8dca970047c8" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_59cea058-85eb-4e58-b486-36bc1fb015fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_7244693a-9fef-4690-a1af-d996acc148bd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_59cea058-85eb-4e58-b486-36bc1fb015fc" xlink:to="loc_srt_StatementGeographicalAxis_7244693a-9fef-4690-a1af-d996acc148bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5e6598a7-1a6e-43dd-9516-02cfa8fdf9a5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_7244693a-9fef-4690-a1af-d996acc148bd" xlink:to="loc_srt_SegmentGeographicalDomain_5e6598a7-1a6e-43dd-9516-02cfa8fdf9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_VA_aecaa782-91ef-421a-8b99-ce5ebb557576" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_VA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5e6598a7-1a6e-43dd-9516-02cfa8fdf9a5" xlink:to="loc_stpr_VA_aecaa782-91ef-421a-8b99-ce5ebb557576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IL_24538499-6753-4e1e-831e-02fd6470fad4" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IL"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5e6598a7-1a6e-43dd-9516-02cfa8fdf9a5" xlink:to="loc_stpr_IL_24538499-6753-4e1e-831e-02fd6470fad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_d6177752-3a86-471c-ac75-464f0c1bbf43" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NJ"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5e6598a7-1a6e-43dd-9516-02cfa8fdf9a5" xlink:to="loc_stpr_NJ_d6177752-3a86-471c-ac75-464f0c1bbf43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_765a5d36-0a42-494f-933c-cd3c904a74e7" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_IN"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5e6598a7-1a6e-43dd-9516-02cfa8fdf9a5" xlink:to="loc_country_IN_765a5d36-0a42-494f-933c-cd3c904a74e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_4e0208d8-a0a0-45aa-820d-5a525071c71e" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_CA"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5e6598a7-1a6e-43dd-9516-02cfa8fdf9a5" xlink:to="loc_stpr_CA_4e0208d8-a0a0-45aa-820d-5a525071c71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_GA_51755c1c-f7c4-40b1-90be-610ee2c94b2c" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_GA"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_5e6598a7-1a6e-43dd-9516-02cfa8fdf9a5" xlink:to="loc_stpr_GA_51755c1c-f7c4-40b1-90be-610ee2c94b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_f65f0c88-a5ca-4616-95c4-a2c0b55fe232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_59cea058-85eb-4e58-b486-36bc1fb015fc" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_f65f0c88-a5ca-4616-95c4-a2c0b55fe232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e5aab555-3068-4db4-8e57-f1476fd30c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f65f0c88-a5ca-4616-95c4-a2c0b55fe232" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_e5aab555-3068-4db4-8e57-f1476fd30c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84080514-0c7b-4dc4-adba-f4ab50255788" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f65f0c88-a5ca-4616-95c4-a2c0b55fe232" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_84080514-0c7b-4dc4-adba-f4ab50255788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_2c44890b-8c59-4600-a523-45d7fdd25e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_f65f0c88-a5ca-4616-95c4-a2c0b55fe232" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_2c44890b-8c59-4600-a523-45d7fdd25e9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d3befa73-2c47-45af-9ea0-24cbe4340061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_9474499d-cad1-4629-b285-f678915f57e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d3befa73-2c47-45af-9ea0-24cbe4340061" xlink:to="loc_us-gaap_OperatingLeaseCost_9474499d-cad1-4629-b285-f678915f57e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_cfd1efa2-6f86-47eb-8434-35219c68283b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d3befa73-2c47-45af-9ea0-24cbe4340061" xlink:to="loc_us-gaap_VariableLeaseCost_cfd1efa2-6f86-47eb-8434-35219c68283b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_447d9775-0bf8-44e4-8fde-53478c73b767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d3befa73-2c47-45af-9ea0-24cbe4340061" xlink:to="loc_us-gaap_LeaseCost_447d9775-0bf8-44e4-8fde-53478c73b767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LeasesMaturityofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2410c28c-fb0f-40ab-9c0c-f4326ff6132a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_da1a77e6-2208-4588-9387-765bc6f70339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2410c28c-fb0f-40ab-9c0c-f4326ff6132a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_da1a77e6-2208-4588-9387-765bc6f70339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d5d092fa-1e2f-4add-b7a5-86d0a0fead10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2410c28c-fb0f-40ab-9c0c-f4326ff6132a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d5d092fa-1e2f-4add-b7a5-86d0a0fead10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3374ec5b-4ae1-4d0e-a6fa-c40b02f4d352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2410c28c-fb0f-40ab-9c0c-f4326ff6132a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3374ec5b-4ae1-4d0e-a6fa-c40b02f4d352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dc632bac-7782-4781-be89-a62c623fb3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2410c28c-fb0f-40ab-9c0c-f4326ff6132a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dc632bac-7782-4781-be89-a62c623fb3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_be1baf6f-daa3-4e99-8b86-32eb8091cf92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2410c28c-fb0f-40ab-9c0c-f4326ff6132a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_be1baf6f-daa3-4e99-8b86-32eb8091cf92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_27f8873e-b354-433f-b9f6-6f39a90d289a" xlink:href="evh-20220930.xsd#evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2410c28c-fb0f-40ab-9c0c-f4326ff6132a" xlink:to="loc_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_27f8873e-b354-433f-b9f6-6f39a90d289a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_de74f1fe-a320-49fa-bb50-17c8eda9bde4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2410c28c-fb0f-40ab-9c0c-f4326ff6132a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_de74f1fe-a320-49fa-bb50-17c8eda9bde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_7e1ea253-87a1-4f95-8ef7-df10b781ef5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2410c28c-fb0f-40ab-9c0c-f4326ff6132a" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_7e1ea253-87a1-4f95-8ef7-df10b781ef5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e1beb3d6-755d-4951-94a0-9a2ec86e59b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract_7e1ea253-87a1-4f95-8ef7-df10b781ef5f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e1beb3d6-755d-4951-94a0-9a2ec86e59b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9cca378c-a07a-427c-aaa3-aec0dddc35a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2410c28c-fb0f-40ab-9c0c-f4326ff6132a" xlink:to="loc_us-gaap_OperatingLeaseLiability_9cca378c-a07a-427c-aaa3-aec0dddc35a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="evh-20220930.xsd#LeasesMaturityofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3b477d95-99ff-44ba-8c74-a07bed844359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a44e5193-3b9c-4d9a-a8b2-5405450a69ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3b477d95-99ff-44ba-8c74-a07bed844359" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a44e5193-3b9c-4d9a-a8b2-5405450a69ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7cc7dae8-69d6-4de4-b8b7-3e9af56bc6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3b477d95-99ff-44ba-8c74-a07bed844359" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_7cc7dae8-69d6-4de4-b8b7-3e9af56bc6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#IncomeLossPerCommonShareComputationofEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fc202103-6cfc-48ae-b101-8963d81e983b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_d2310122-0e3c-42b9-a140-8e6e32a5dc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc202103-6cfc-48ae-b101-8963d81e983b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_d2310122-0e3c-42b9-a140-8e6e32a5dc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5c724b81-9d40-4da5-9597-c8299fe629d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc202103-6cfc-48ae-b101-8963d81e983b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5c724b81-9d40-4da5-9597-c8299fe629d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1a6ff93e-9e81-494c-8bf3-ec5d0d13223d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc202103-6cfc-48ae-b101-8963d81e983b" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_1a6ff93e-9e81-494c-8bf3-ec5d0d13223d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_b74b5858-2651-435b-a104-4ab669795369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc202103-6cfc-48ae-b101-8963d81e983b" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_b74b5858-2651-435b-a104-4ab669795369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_12b6367d-eeec-4d3c-8344-29bc9c08fbc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc202103-6cfc-48ae-b101-8963d81e983b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_12b6367d-eeec-4d3c-8344-29bc9c08fbc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards_5ffbc145-61bc-4a47-814e-855e87db7442" xlink:href="evh-20220930.xsd#evh_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc202103-6cfc-48ae-b101-8963d81e983b" xlink:to="loc_evh_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards_5ffbc145-61bc-4a47-814e-855e87db7442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ee3baf41-e8d6-4d8c-aa17-ddc9ee4499e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc202103-6cfc-48ae-b101-8963d81e983b" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ee3baf41-e8d6-4d8c-aa17-ddc9ee4499e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_7733e754-7c47-41fc-aa3d-b2f76e8eda61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc202103-6cfc-48ae-b101-8963d81e983b" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_7733e754-7c47-41fc-aa3d-b2f76e8eda61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_41332bc7-a375-45ae-91b3-672ce67d0b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc202103-6cfc-48ae-b101-8963d81e983b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_41332bc7-a375-45ae-91b3-672ce67d0b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_BasicAndDilutedEarningsPerShareAbstract_a62bf09d-0969-4a90-ac36-c6f488c3c167" xlink:href="evh-20220930.xsd#evh_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fc202103-6cfc-48ae-b101-8963d81e983b" xlink:to="loc_evh_BasicAndDilutedEarningsPerShareAbstract_a62bf09d-0969-4a90-ac36-c6f488c3c167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_935fad80-9f9c-4cd2-b979-a5149bacbe45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_BasicAndDilutedEarningsPerShareAbstract_a62bf09d-0969-4a90-ac36-c6f488c3c167" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_935fad80-9f9c-4cd2-b979-a5149bacbe45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_44c2dbb2-04ec-4746-a088-267f4c058efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_935fad80-9f9c-4cd2-b979-a5149bacbe45" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_44c2dbb2-04ec-4746-a088-267f4c058efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_4e8154ce-14a7-4335-95b1-fc367dfc7a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_935fad80-9f9c-4cd2-b979-a5149bacbe45" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_4e8154ce-14a7-4335-95b1-fc367dfc7a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ecf47a93-4245-4f04-8a82-ac5c1b604fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_935fad80-9f9c-4cd2-b979-a5149bacbe45" xlink:to="loc_us-gaap_EarningsPerShareBasic_ecf47a93-4245-4f04-8a82-ac5c1b604fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_fcc34dc6-5230-4f3f-923a-8d8e5ab53ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_BasicAndDilutedEarningsPerShareAbstract_a62bf09d-0969-4a90-ac36-c6f488c3c167" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_fcc34dc6-5230-4f3f-923a-8d8e5ab53ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_e4227f5b-068c-4624-93d9-7372e27db856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_fcc34dc6-5230-4f3f-923a-8d8e5ab53ed6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_e4227f5b-068c-4624-93d9-7372e27db856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_7412b244-b398-440a-867a-1848bcb676ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_fcc34dc6-5230-4f3f-923a-8d8e5ab53ed6" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_7412b244-b398-440a-867a-1848bcb676ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_25199b5f-96c4-43b8-9742-87420b3e96b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_fcc34dc6-5230-4f3f-923a-8d8e5ab53ed6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_25199b5f-96c4-43b8-9742-87420b3e96b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#IncomeLossPerCommonShareAntidilutiveSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeLossPerCommonShareAntidilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_93fc156e-776f-4613-9eb6-9f0655a4bc76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c0496625-a88f-44e9-a419-1dd5d30ea489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_93fc156e-776f-4613-9eb6-9f0655a4bc76" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c0496625-a88f-44e9-a419-1dd5d30ea489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a6853564-e30b-437d-bc17-30027d6dcbd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c0496625-a88f-44e9-a419-1dd5d30ea489" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a6853564-e30b-437d-bc17-30027d6dcbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3938948b-4613-4205-91ef-004c5b4927ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_a6853564-e30b-437d-bc17-30027d6dcbd0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3938948b-4613-4205-91ef-004c5b4927ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_f3dba875-1bad-4be5-89cb-9803a16f9ecd" xlink:href="evh-20220930.xsd#evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3938948b-4613-4205-91ef-004c5b4927ff" xlink:to="loc_evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember_f3dba875-1bad-4be5-89cb-9803a16f9ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2d6a80bd-f9bf-4509-9747-4e481ab98846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3938948b-4613-4205-91ef-004c5b4927ff" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2d6a80bd-f9bf-4509-9747-4e481ab98846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_67fe9777-4b96-412e-8f11-37282f45fd1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3938948b-4613-4205-91ef-004c5b4927ff" xlink:to="loc_us-gaap_ConvertibleDebtMember_67fe9777-4b96-412e-8f11-37282f45fd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_47523696-2214-41b6-9e1f-072ddc7eafe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c0496625-a88f-44e9-a419-1dd5d30ea489" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_47523696-2214-41b6-9e1f-072ddc7eafe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8746d252-768f-4103-9e04-e0220be78b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_47523696-2214-41b6-9e1f-072ddc7eafe8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8746d252-768f-4103-9e04-e0220be78b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#StockbasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23a9dcbd-234c-4a75-a05c-b2964f33f8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d856def4-d3f9-42c5-9552-ad8cde270016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_23a9dcbd-234c-4a75-a05c-b2964f33f8b3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d856def4-d3f9-42c5-9552-ad8cde270016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b71d7a11-03e7-4f78-a1ae-29c71d1c6e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d856def4-d3f9-42c5-9552-ad8cde270016" xlink:to="loc_us-gaap_AwardTypeAxis_b71d7a11-03e7-4f78-a1ae-29c71d1c6e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3a39572-0207-403d-9739-fadbfd70ab96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b71d7a11-03e7-4f78-a1ae-29c71d1c6e58" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3a39572-0207-403d-9739-fadbfd70ab96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1c19dbe4-4e54-4f47-8ede-dae3d2fbc45d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3a39572-0207-403d-9739-fadbfd70ab96" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1c19dbe4-4e54-4f47-8ede-dae3d2fbc45d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3c9aa6e1-61bc-4e6a-832c-250323b49356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3a39572-0207-403d-9739-fadbfd70ab96" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3c9aa6e1-61bc-4e6a-832c-250323b49356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_LeveragedStockUnitsLSUsMember_a9a62961-4608-4ce1-9e8f-621013ae9333" xlink:href="evh-20220930.xsd#evh_LeveragedStockUnitsLSUsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3a39572-0207-403d-9739-fadbfd70ab96" xlink:to="loc_evh_LeveragedStockUnitsLSUsMember_a9a62961-4608-4ce1-9e8f-621013ae9333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_55fe484d-878f-449f-a240-07506faa5df0" xlink:href="evh-20220930.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e3a39572-0207-403d-9739-fadbfd70ab96" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_55fe484d-878f-449f-a240-07506faa5df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f3617c0a-3782-4a71-ab13-0d69b2301580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d856def4-d3f9-42c5-9552-ad8cde270016" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f3617c0a-3782-4a71-ab13-0d69b2301580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8849bd7a-a98a-45b8-b1f7-991034a4ba76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f3617c0a-3782-4a71-ab13-0d69b2301580" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8849bd7a-a98a-45b8-b1f7-991034a4ba76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_696c4a75-620e-4f18-b25f-c1a6cccb5d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8849bd7a-a98a-45b8-b1f7-991034a4ba76" xlink:to="loc_us-gaap_CostOfSalesMember_696c4a75-620e-4f18-b25f-c1a6cccb5d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3a70e43b-9888-41ab-8738-bd0ae62d9a51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8849bd7a-a98a-45b8-b1f7-991034a4ba76" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3a70e43b-9888-41ab-8738-bd0ae62d9a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_97dff280-b07e-42f4-8532-6d2921bfec48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d856def4-d3f9-42c5-9552-ad8cde270016" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_97dff280-b07e-42f4-8532-6d2921bfec48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_24cad10f-ff8a-4787-ae43-ab6c9834e745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_97dff280-b07e-42f4-8532-6d2921bfec48" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_24cad10f-ff8a-4787-ae43-ab6c9834e745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#StockbasedCompensationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d57bc6fa-7092-40eb-bafa-16c2aca92c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_0710305b-1f89-4228-a82a-b5f5311c4891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d57bc6fa-7092-40eb-bafa-16c2aca92c09" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_0710305b-1f89-4228-a82a-b5f5311c4891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e05367b5-697a-4ed0-865e-45c969cbd97b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7eead3d-2aef-4a41-90df-fbb13137f92b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e05367b5-697a-4ed0-865e-45c969cbd97b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7eead3d-2aef-4a41-90df-fbb13137f92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_81cf4ea3-ed2c-496b-a843-f823293f493a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7eead3d-2aef-4a41-90df-fbb13137f92b" xlink:to="loc_us-gaap_AwardTypeAxis_81cf4ea3-ed2c-496b-a843-f823293f493a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9b31278-9abd-4301-9474-88ebc5b542cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_81cf4ea3-ed2c-496b-a843-f823293f493a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9b31278-9abd-4301-9474-88ebc5b542cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_84b694fd-0366-409b-a0f2-fc1e93ec595a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9b31278-9abd-4301-9474-88ebc5b542cd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_84b694fd-0366-409b-a0f2-fc1e93ec595a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_790c047d-e449-44b3-882a-9c1601192c4f" xlink:href="evh-20220930.xsd#evh_PerformanceBasedRestrictedStockUnitsPSUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9b31278-9abd-4301-9474-88ebc5b542cd" xlink:to="loc_evh_PerformanceBasedRestrictedStockUnitsPSUsMember_790c047d-e449-44b3-882a-9c1601192c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77e64c42-026c-41d9-a78a-88e7972b80bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a7eead3d-2aef-4a41-90df-fbb13137f92b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77e64c42-026c-41d9-a78a-88e7972b80bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5ba2df01-67a1-47a9-9ad4-f52b5fc37ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_77e64c42-026c-41d9-a78a-88e7972b80bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5ba2df01-67a1-47a9-9ad4-f52b5fc37ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5576c11a-83f0-40fd-8cc0-0a5f2d06ef1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_357a330d-cad9-4a43-8547-5726ef40decb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5576c11a-83f0-40fd-8cc0-0a5f2d06ef1e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_357a330d-cad9-4a43-8547-5726ef40decb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a82dba6b-a34b-4430-9b9c-2f0f3a692c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5576c11a-83f0-40fd-8cc0-0a5f2d06ef1e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a82dba6b-a34b-4430-9b9c-2f0f3a692c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ca85248b-b472-4725-b407-5e844aed723b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5576c11a-83f0-40fd-8cc0-0a5f2d06ef1e" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ca85248b-b472-4725-b407-5e844aed723b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_289c9979-0d5a-4473-af2a-26c11c499ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5576c11a-83f0-40fd-8cc0-0a5f2d06ef1e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_289c9979-0d5a-4473-af2a-26c11c499ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders_d63e6ff4-5829-4c05-9005-b0fdf6ba8c0a" xlink:href="evh-20220930.xsd#evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5576c11a-83f0-40fd-8cc0-0a5f2d06ef1e" xlink:to="loc_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders_d63e6ff4-5829-4c05-9005-b0fdf6ba8c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#InvestmentsinEquityMethodInvesteesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_3c51b7c1-e5cf-40a1-a3ab-eb5928785ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cc701e8b-8b5c-4a6b-bdd1-0da279e18cce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_3c51b7c1-e5cf-40a1-a3ab-eb5928785ee1" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cc701e8b-8b5c-4a6b-bdd1-0da279e18cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1a5aa8de-83e5-4f6a-b57d-2b676970b3a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cc701e8b-8b5c-4a6b-bdd1-0da279e18cce" xlink:to="loc_srt_RangeAxis_1a5aa8de-83e5-4f6a-b57d-2b676970b3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0df4f2b5-351d-4401-85f8-bae080a4cf27" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1a5aa8de-83e5-4f6a-b57d-2b676970b3a4" xlink:to="loc_srt_RangeMember_0df4f2b5-351d-4401-85f8-bae080a4cf27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6e86caf2-e0ff-4b77-8143-8c512e76bdbe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0df4f2b5-351d-4401-85f8-bae080a4cf27" xlink:to="loc_srt_MinimumMember_6e86caf2-e0ff-4b77-8143-8c512e76bdbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3737f99d-0c9a-408c-9b20-58fff1f259fa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0df4f2b5-351d-4401-85f8-bae080a4cf27" xlink:to="loc_srt_MaximumMember_3737f99d-0c9a-408c-9b20-58fff1f259fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_08e00c60-2539-4054-9fb7-1b47b5d51ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cc701e8b-8b5c-4a6b-bdd1-0da279e18cce" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_08e00c60-2539-4054-9fb7-1b47b5d51ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_8b4a7a19-a47a-4d93-af94-3bb37df16ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_08e00c60-2539-4054-9fb7-1b47b5d51ca1" xlink:to="loc_us-gaap_RelatedPartyDomain_8b4a7a19-a47a-4d93-af94-3bb37df16ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvesteeMember_e8fbd408-9c18-4db4-a025-e0f6ebd6dffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvesteeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_8b4a7a19-a47a-4d93-af94-3bb37df16ed1" xlink:to="loc_us-gaap_EquityMethodInvesteeMember_e8fbd408-9c18-4db4-a025-e0f6ebd6dffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1a327b9b-24a4-46f0-b1e0-442ff10b873e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cc701e8b-8b5c-4a6b-bdd1-0da279e18cce" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1a327b9b-24a4-46f0-b1e0-442ff10b873e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_53773e93-3fc8-43ef-83cf-c4bdf573b845" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1a327b9b-24a4-46f0-b1e0-442ff10b873e" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_53773e93-3fc8-43ef-83cf-c4bdf573b845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ServicesAgreementsMember_539cbcc1-395d-4e5c-87c6-19b4b911bb3c" xlink:href="evh-20220930.xsd#evh_ServicesAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_53773e93-3fc8-43ef-83cf-c4bdf573b845" xlink:to="loc_evh_ServicesAgreementsMember_539cbcc1-395d-4e5c-87c6-19b4b911bb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9c2343f2-68fe-451a-b3b0-a4df6458c09e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cc701e8b-8b5c-4a6b-bdd1-0da279e18cce" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9c2343f2-68fe-451a-b3b0-a4df6458c09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_540184bd-1769-428a-9d61-e51d56b0f0c9" xlink:href="evh-20220930.xsd#evh_EquityMethodInvestmentEconomicInterestPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9c2343f2-68fe-451a-b3b0-a4df6458c09e" xlink:to="loc_evh_EquityMethodInvestmentEconomicInterestPercentage_540184bd-1769-428a-9d61-e51d56b0f0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EquityMethodInvestmentVotingInterestPercentage_5bcbe5b0-1547-4ef1-b8ed-03727f410bcf" xlink:href="evh-20220930.xsd#evh_EquityMethodInvestmentVotingInterestPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9c2343f2-68fe-451a-b3b0-a4df6458c09e" xlink:to="loc_evh_EquityMethodInvestmentVotingInterestPercentage_5bcbe5b0-1547-4ef1-b8ed-03727f410bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3d6e53b8-47b2-4d40-85ce-3b2486be2f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9c2343f2-68fe-451a-b3b0-a4df6458c09e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_3d6e53b8-47b2-4d40-85ce-3b2486be2f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_9e84003f-861e-4420-93f6-9f41da792654" xlink:href="evh-20220930.xsd#evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_9c2343f2-68fe-451a-b3b0-a4df6458c09e" xlink:to="loc_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement_9e84003f-861e-4420-93f6-9f41da792654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c3e2aece-6ff7-4c27-931a-fbb6031f5ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8354ae40-34c3-43d5-bf0c-98cab44008fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c3e2aece-6ff7-4c27-931a-fbb6031f5ce9" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8354ae40-34c3-43d5-bf0c-98cab44008fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_177eb947-fc9a-40a6-aadb-ec54b8dda30b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8354ae40-34c3-43d5-bf0c-98cab44008fe" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_177eb947-fc9a-40a6-aadb-ec54b8dda30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cdaf5e0-d596-49cc-b53e-1db3a09fa510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_177eb947-fc9a-40a6-aadb-ec54b8dda30b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cdaf5e0-d596-49cc-b53e-1db3a09fa510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f62ec7f8-fc32-43aa-998e-45a7ee3b894e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cdaf5e0-d596-49cc-b53e-1db3a09fa510" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f62ec7f8-fc32-43aa-998e-45a7ee3b894e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6325499a-39b3-4808-be41-f01ba0af0675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cdaf5e0-d596-49cc-b53e-1db3a09fa510" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6325499a-39b3-4808-be41-f01ba0af0675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_651828ec-05f4-42d8-a7bd-207211631b06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4cdaf5e0-d596-49cc-b53e-1db3a09fa510" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_651828ec-05f4-42d8-a7bd-207211631b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0524dff5-ea78-4f48-be1a-54960b609596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8354ae40-34c3-43d5-bf0c-98cab44008fe" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0524dff5-ea78-4f48-be1a-54960b609596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c44e14df-4d1f-4ff2-bc86-aa39c892c39b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0524dff5-ea78-4f48-be1a-54960b609596" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c44e14df-4d1f-4ff2-bc86-aa39c892c39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_da5cf220-076c-4cda-8e93-1b332d04478d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c44e14df-4d1f-4ff2-bc86-aa39c892c39b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_da5cf220-076c-4cda-8e93-1b332d04478d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_704c238c-b3b4-4778-ac15-7513251fb098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_8354ae40-34c3-43d5-bf0c-98cab44008fe" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_704c238c-b3b4-4778-ac15-7513251fb098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_f2cdde11-2111-40e6-9099-0ca70bddbc46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_704c238c-b3b4-4778-ac15-7513251fb098" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_f2cdde11-2111-40e6-9099-0ca70bddbc46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ab96df86-b155-462b-931b-052e7ebd0e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_f2cdde11-2111-40e6-9099-0ca70bddbc46" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ab96df86-b155-462b-931b-052e7ebd0e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_421e54fe-2067-4ea9-b4a2-23c8d8530620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_f2cdde11-2111-40e6-9099-0ca70bddbc46" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_421e54fe-2067-4ea9-b4a2-23c8d8530620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#FairValueMeasurementChangesinContingentConsiderationandOtherDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_85bd8315-9b1f-41d7-b2a9-20265d336813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_252750a5-ec93-41d2-bb85-81fd52b65c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_85bd8315-9b1f-41d7-b2a9-20265d336813" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_252750a5-ec93-41d2-bb85-81fd52b65c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a4ab5928-15ab-478e-889f-381744153c90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_252750a5-ec93-41d2-bb85-81fd52b65c5d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a4ab5928-15ab-478e-889f-381744153c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_93dab3f6-7e83-4191-a79e-77bdc8a44165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_252750a5-ec93-41d2-bb85-81fd52b65c5d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_93dab3f6-7e83-4191-a79e-77bdc8a44165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_94bbfd6d-29fe-4966-bb2b-9fd5d2e0719f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_252750a5-ec93-41d2-bb85-81fd52b65c5d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_94bbfd6d-29fe-4966-bb2b-9fd5d2e0719f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_365acde7-372c-47c9-9af9-13c1682d5280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_252750a5-ec93-41d2-bb85-81fd52b65c5d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_365acde7-372c-47c9-9af9-13c1682d5280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_cb3b2d15-93b8-4ec7-9edc-01f08697ca81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_252750a5-ec93-41d2-bb85-81fd52b65c5d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_cb3b2d15-93b8-4ec7-9edc-01f08697ca81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c34f2d95-b018-4058-a851-8e83bbb6237b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_eaa7f8d5-9929-4ac6-b6fa-c901555895dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c34f2d95-b018-4058-a851-8e83bbb6237b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_eaa7f8d5-9929-4ac6-b6fa-c901555895dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7edb0d6a-16c2-47c9-a0a5-72326af7c8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_eaa7f8d5-9929-4ac6-b6fa-c901555895dc" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7edb0d6a-16c2-47c9-a0a5-72326af7c8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2ccd738d-940e-4d59-8351-09ada246754e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7edb0d6a-16c2-47c9-a0a5-72326af7c8d3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2ccd738d-940e-4d59-8351-09ada246754e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_a8892385-03c5-4982-940a-8549cf174968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2ccd738d-940e-4d59-8351-09ada246754e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_a8892385-03c5-4982-940a-8549cf174968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9206e559-56d4-4f7d-9702-25d363a77080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_eaa7f8d5-9929-4ac6-b6fa-c901555895dc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9206e559-56d4-4f7d-9702-25d363a77080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a16f6d68-2e92-400a-8f99-aa982e952a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9206e559-56d4-4f7d-9702-25d363a77080" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a16f6d68-2e92-400a-8f99-aa982e952a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_286b8337-9b65-4730-9895-6523627990cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a16f6d68-2e92-400a-8f99-aa982e952a9c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_286b8337-9b65-4730-9895-6523627990cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_d51df59c-9f9f-4bd0-b782-a83cae265ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_eaa7f8d5-9929-4ac6-b6fa-c901555895dc" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_d51df59c-9f9f-4bd0-b782-a83cae265ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6267839a-68fa-4e74-bab3-67a554eaf7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d51df59c-9f9f-4bd0-b782-a83cae265ebe" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6267839a-68fa-4e74-bab3-67a554eaf7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_8b1d7bfe-2004-4000-b9b0-429b0827aef0" xlink:href="evh-20220930.xsd#evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6267839a-68fa-4e74-bab3-67a554eaf7b4" xlink:to="loc_evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember_8b1d7bfe-2004-4000-b9b0-429b0827aef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_2f2697a9-a576-4a40-83f3-62a2fb4bda8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_6267839a-68fa-4e74-bab3-67a554eaf7b4" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_2f2697a9-a576-4a40-83f3-62a2fb4bda8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_83299e16-e52d-4dee-a8c8-d887c6a5643d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_eaa7f8d5-9929-4ac6-b6fa-c901555895dc" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_83299e16-e52d-4dee-a8c8-d887c6a5643d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_110d9500-10ef-4839-93d9-57394a45cbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_83299e16-e52d-4dee-a8c8-d887c6a5643d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_110d9500-10ef-4839-93d9-57394a45cbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_48b73c04-d218-422a-8a2d-f9eb10319181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_83299e16-e52d-4dee-a8c8-d887c6a5643d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_48b73c04-d218-422a-8a2d-f9eb10319181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8106d386-7787-4357-8f30-33a6db52ad51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_83299e16-e52d-4dee-a8c8-d887c6a5643d" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_8106d386-7787-4357-8f30-33a6db52ad51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#RelatedPartiesAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_7e53d009-48dc-4510-ac0b-6425eeb071df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bc2e3fe9-8265-4058-9a38-a674c14972da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_7e53d009-48dc-4510-ac0b-6425eeb071df" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bc2e3fe9-8265-4058-9a38-a674c14972da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_232a64e5-7408-40c1-be9b-3f821cf87d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bc2e3fe9-8265-4058-9a38-a674c14972da" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_232a64e5-7408-40c1-be9b-3f821cf87d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e2ea0210-a1b2-4ca2-8a58-c3a19a0a45bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_232a64e5-7408-40c1-be9b-3f821cf87d8a" xlink:to="loc_us-gaap_RelatedPartyDomain_e2ea0210-a1b2-4ca2-8a58-c3a19a0a45bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_91949642-1645-429b-a200-2bbd7e82a37d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_e2ea0210-a1b2-4ca2-8a58-c3a19a0a45bc" xlink:to="loc_srt_AffiliatedEntityMember_91949642-1645-429b-a200-2bbd7e82a37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_a9fd31cd-9afb-476e-ae57-ecc412c7944c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bc2e3fe9-8265-4058-9a38-a674c14972da" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_a9fd31cd-9afb-476e-ae57-ecc412c7944c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_7bd5fa85-48dd-45a7-af89-df272b1ec61e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a9fd31cd-9afb-476e-ae57-ecc412c7944c" xlink:to="loc_us-gaap_AssetsAbstract_7bd5fa85-48dd-45a7-af89-df272b1ec61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_29383b11-a9b8-4215-a242-5136c9720808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7bd5fa85-48dd-45a7-af89-df272b1ec61e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_29383b11-a9b8-4215-a242-5136c9720808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_09338c7b-6b35-403a-ae1a-f05e4e21d310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7bd5fa85-48dd-45a7-af89-df272b1ec61e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_09338c7b-6b35-403a-ae1a-f05e4e21d310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_0508a50e-23d6-4232-8482-40c4c7beef3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7bd5fa85-48dd-45a7-af89-df272b1ec61e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_0508a50e-23d6-4232-8482-40c4c7beef3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_2c0859d4-c5cc-4b92-b1ce-91a8a6507424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_a9fd31cd-9afb-476e-ae57-ecc412c7944c" xlink:to="loc_us-gaap_LiabilitiesAbstract_2c0859d4-c5cc-4b92-b1ce-91a8a6507424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_04cbed4d-e675-44bf-a4a3-c82cf7452319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_2c0859d4-c5cc-4b92-b1ce-91a8a6507424" xlink:to="loc_us-gaap_AccountsPayableCurrent_04cbed4d-e675-44bf-a4a3-c82cf7452319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_0555ca19-5158-44ec-bbd2-1c492bf84540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_2c0859d4-c5cc-4b92-b1ce-91a8a6507424" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_0555ca19-5158-44ec-bbd2-1c492bf84540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_fe8c4225-ca4a-4aa6-8bcc-49f5fa807802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_2c0859d4-c5cc-4b92-b1ce-91a8a6507424" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense_fe8c4225-ca4a-4aa6-8bcc-49f5fa807802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#RelatedPartiesRevenuesandExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_2dfd4a0e-3efb-4049-b01a-7140efea531e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8a1396a3-022e-46b3-8718-0d8e58311946" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_2dfd4a0e-3efb-4049-b01a-7140efea531e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8a1396a3-022e-46b3-8718-0d8e58311946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_956b998a-fbe2-4622-80b8-594f48a88ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8a1396a3-022e-46b3-8718-0d8e58311946" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_956b998a-fbe2-4622-80b8-594f48a88ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c487d3bf-f72e-422b-a6d2-a4ed1452a85d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_956b998a-fbe2-4622-80b8-594f48a88ae6" xlink:to="loc_us-gaap_RelatedPartyDomain_c487d3bf-f72e-422b-a6d2-a4ed1452a85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_4bd1b21a-8c71-489a-8637-22da4e8467f0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_c487d3bf-f72e-422b-a6d2-a4ed1452a85d" xlink:to="loc_srt_AffiliatedEntityMember_4bd1b21a-8c71-489a-8637-22da4e8467f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e5753930-d2bf-4ebe-aa61-d1e2b1943090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8a1396a3-022e-46b3-8718-0d8e58311946" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e5753930-d2bf-4ebe-aa61-d1e2b1943090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_412ed734-db89-462c-a838-3f5068ec854e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e5753930-d2bf-4ebe-aa61-d1e2b1943090" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_412ed734-db89-462c-a838-3f5068ec854e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_6f6bed09-dbcb-4203-b571-bf92114cb025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_412ed734-db89-462c-a838-3f5068ec854e" xlink:to="loc_us-gaap_CostOfSalesMember_6f6bed09-dbcb-4203-b571-bf92114cb025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0d8f8233-3ee7-4e0c-b8d7-4a9e7f89d503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_412ed734-db89-462c-a838-3f5068ec854e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0d8f8233-3ee7-4e0c-b8d7-4a9e7f89d503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_e65013c1-a4d0-40bd-bde0-a81df65e9e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_8a1396a3-022e-46b3-8718-0d8e58311946" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_e65013c1-a4d0-40bd-bde0-a81df65e9e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_a97c9d7b-e504-47cb-a435-d26d6eefe050" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e65013c1-a4d0-40bd-bde0-a81df65e9e41" xlink:to="loc_us-gaap_RevenueFromRelatedParties_a97c9d7b-e504-47cb-a435-d26d6eefe050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_ccb82d6f-8e6a-4518-938b-4059a7d5ca19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_e65013c1-a4d0-40bd-bde0-a81df65e9e41" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_ccb82d6f-8e6a-4518-938b-4059a7d5ca19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#RepositioningandOtherChangesDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_30749c8a-33c9-4784-9d65-6fe078cead14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d21df77d-9ecd-4464-87de-f8177fe1a1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_30749c8a-33c9-4784-9d65-6fe078cead14" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d21df77d-9ecd-4464-87de-f8177fe1a1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_251a52bd-012d-473e-8371-adbcdcb42591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d21df77d-9ecd-4464-87de-f8177fe1a1f5" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_251a52bd-012d-473e-8371-adbcdcb42591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_5655775a-5f50-4644-a8e6-9d4fb5be7b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_251a52bd-012d-473e-8371-adbcdcb42591" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_5655775a-5f50-4644-a8e6-9d4fb5be7b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_237250d9-d63e-4c22-9591-ffeb1f8c6cc6" xlink:href="evh-20220930.xsd#evh_EmployeeSeveranceAndTerminationBenefitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_5655775a-5f50-4644-a8e6-9d4fb5be7b30" xlink:to="loc_evh_EmployeeSeveranceAndTerminationBenefitsMember_237250d9-d63e-4c22-9591-ffeb1f8c6cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_7020eaf0-0ea2-4afc-805b-cf8d87f8b0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_5655775a-5f50-4644-a8e6-9d4fb5be7b30" xlink:to="loc_us-gaap_FacilityClosingMember_7020eaf0-0ea2-4afc-805b-cf8d87f8b0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ProfessionalServicesRestructuringMember_73db5966-bad6-4a22-b934-3516651c0e7e" xlink:href="evh-20220930.xsd#evh_ProfessionalServicesRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_5655775a-5f50-4644-a8e6-9d4fb5be7b30" xlink:to="loc_evh_ProfessionalServicesRestructuringMember_73db5966-bad6-4a22-b934-3516651c0e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_b1b80bc9-88fc-445b-ba00-6524e081d533" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d21df77d-9ecd-4464-87de-f8177fe1a1f5" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_b1b80bc9-88fc-445b-ba00-6524e081d533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_61d06352-a494-49b0-878e-f3c1eee93a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b1b80bc9-88fc-445b-ba00-6524e081d533" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_61d06352-a494-49b0-878e-f3c1eee93a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_ba0a1299-4b08-468a-a013-3d54b7e0ae8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_b1b80bc9-88fc-445b-ba00-6524e081d533" xlink:to="loc_us-gaap_RestructuringCharges_ba0a1299-4b08-468a-a013-3d54b7e0ae8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#SegmentReportingAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_94d63653-327f-470f-8450-f7dd54ac1835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1088e207-e07e-4e7b-921f-d1f0ea8fc1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_94d63653-327f-470f-8450-f7dd54ac1835" xlink:to="loc_us-gaap_NumberOfOperatingSegments_1088e207-e07e-4e7b-921f-d1f0ea8fc1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#SegmentReportingRevenuefromSegmentstoConsolidatedDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c1064b7b-5c42-428f-89cf-8ee3eb5689e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_975a837d-c7a6-4a20-baf8-08cfb199eb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c1064b7b-5c42-428f-89cf-8ee3eb5689e6" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_975a837d-c7a6-4a20-baf8-08cfb199eb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_6590a645-f5a4-460b-9f73-c7c09a3671a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_975a837d-c7a6-4a20-baf8-08cfb199eb7b" xlink:to="loc_srt_ConsolidationItemsAxis_6590a645-f5a4-460b-9f73-c7c09a3671a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_95f8ea34-e03e-43b8-9582-6d51b66cebfa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_6590a645-f5a4-460b-9f73-c7c09a3671a4" xlink:to="loc_srt_ConsolidationItemsDomain_95f8ea34-e03e-43b8-9582-6d51b66cebfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntersegmentEliminationMember_0a6ae18b-0aea-446a-8102-d0b433433914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntersegmentEliminationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_95f8ea34-e03e-43b8-9582-6d51b66cebfa" xlink:to="loc_us-gaap_IntersegmentEliminationMember_0a6ae18b-0aea-446a-8102-d0b433433914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_54c06458-9065-4b8c-8045-71d0af4e2a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_95f8ea34-e03e-43b8-9582-6d51b66cebfa" xlink:to="loc_us-gaap_OperatingSegmentsMember_54c06458-9065-4b8c-8045-71d0af4e2a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_a9fde9d1-06a6-43b0-af90-22e1cabc2d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_95f8ea34-e03e-43b8-9582-6d51b66cebfa" xlink:to="loc_us-gaap_CorporateNonSegmentMember_a9fde9d1-06a6-43b0-af90-22e1cabc2d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0f2695db-0025-4abe-9b53-d93b9bb8f441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_975a837d-c7a6-4a20-baf8-08cfb199eb7b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0f2695db-0025-4abe-9b53-d93b9bb8f441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d01edc9a-6c20-4cbd-8111-b3f98259069b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0f2695db-0025-4abe-9b53-d93b9bb8f441" xlink:to="loc_us-gaap_SegmentDomain_d01edc9a-6c20-4cbd-8111-b3f98259069b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_0fee3a6e-d761-44fd-8eea-8153ecbf2370" xlink:href="evh-20220930.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d01edc9a-6c20-4cbd-8111-b3f98259069b" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_0fee3a6e-d761-44fd-8eea-8153ecbf2370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_9bf86e12-0739-49c8-850e-a2a840485901" xlink:href="evh-20220930.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d01edc9a-6c20-4cbd-8111-b3f98259069b" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_9bf86e12-0739-49c8-850e-a2a840485901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_45bd3876-9636-4c3c-8542-661ccb097dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_975a837d-c7a6-4a20-baf8-08cfb199eb7b" xlink:to="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_45bd3876-9636-4c3c-8542-661ccb097dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f976a10d-2ce8-4d8a-8df3-8c5d85de5a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_45bd3876-9636-4c3c-8542-661ccb097dd7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f976a10d-2ce8-4d8a-8df3-8c5d85de5a24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_3369dfbe-ffdf-440b-a67d-95f7c42a29c6" xlink:href="evh-20220930.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_45bd3876-9636-4c3c-8542-661ccb097dd7" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_3369dfbe-ffdf-440b-a67d-95f7c42a29c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="simple" xlink:href="evh-20220930.xsd#SegmentReportingReconciliationofAdjustedEBITDADetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1cfa90ae-0ab9-4e9e-903b-651abba2fde4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:to="loc_us-gaap_NetIncomeLoss_1cfa90ae-0ab9-4e9e-903b-651abba2fde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_47b82e14-2044-4e57-98d9-ea2407ab51c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:to="loc_us-gaap_InvestmentIncomeInterest_47b82e14-2044-4e57-98d9-ea2407ab51c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_20837fec-3074-4605-8869-5ea6bd3cdcb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:to="loc_us-gaap_InterestExpense_20837fec-3074-4605-8869-5ea6bd3cdcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_40b151a9-d5fc-4111-a1c6-9623e83268e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_40b151a9-d5fc-4111-a1c6-9623e83268e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ChangesInTaxReceivablesAgreementLiability_12d33437-16df-4359-83c9-715d8340b85b" xlink:href="evh-20220930.xsd#evh_ChangesInTaxReceivablesAgreementLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:to="loc_evh_ChangesInTaxReceivablesAgreementLiability_12d33437-16df-4359-83c9-715d8340b85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_8161fede-1bdd-44b8-851b-8d59e84cf6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:to="loc_us-gaap_DepreciationAndAmortization_8161fede-1bdd-44b8-851b-8d59e84cf6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_GainOnTransferOfMembership_2da7b7cf-3090-4f0b-99c6-877d5a7b4a65" xlink:href="evh-20220930.xsd#evh_GainOnTransferOfMembership"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:to="loc_evh_GainOnTransferOfMembership_2da7b7cf-3090-4f0b-99c6-877d5a7b4a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e9942e2e-1371-4fb3-87a4-8765da7568ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e9942e2e-1371-4fb3-87a4-8765da7568ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_26cdb350-bfc3-40cc-8d8e-79e070514fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_26cdb350-bfc3-40cc-8d8e-79e070514fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e7db8bf0-5320-424a-afd3-8c2d357b85a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e7db8bf0-5320-424a-afd3-8c2d357b85a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4293f12d-408d-430a-858a-bbe600f327e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4293f12d-408d-430a-858a-bbe600f327e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_83aa68a4-3f3d-422d-ab62-16c90a36413a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:to="loc_us-gaap_RestructuringCharges_83aa68a4-3f3d-422d-ab62-16c90a36413a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment_5660bee1-50d6-4f1c-bed7-a32e070f503e" xlink:href="evh-20220930.xsd#evh_SharebasedCompensationIncludingOnetimeAdjustment"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:to="loc_evh_SharebasedCompensationIncludingOnetimeAdjustment_5660bee1-50d6-4f1c-bed7-a32e070f503e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_fde52c6e-e3b6-4df5-a5ec-acf1278d30e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:to="loc_us-gaap_SeveranceCosts1_fde52c6e-e3b6-4df5-a5ec-acf1278d30e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_1c1b7700-8c54-435f-8ba9-5f7b18c2aba2" xlink:href="evh-20220930.xsd#evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:to="loc_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments_1c1b7700-8c54-435f-8ba9-5f7b18c2aba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ShareholderAdvisoryServices_8b5aa02d-d3ef-473b-8862-05bed64bc856" xlink:href="evh-20220930.xsd#evh_ShareholderAdvisoryServices"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:to="loc_evh_ShareholderAdvisoryServices_8b5aa02d-d3ef-473b-8862-05bed64bc856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_TransactionCosts_1d2adf1f-ef1f-4ba9-83a2-f76e0e3f6ac8" xlink:href="evh-20220930.xsd#evh_TransactionCosts"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:to="loc_evh_TransactionCosts_1d2adf1f-ef1f-4ba9-83a2-f76e0e3f6ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b2ecd755-65b8-41ba-9b5a-4628964b2e84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b2ecd755-65b8-41ba-9b5a-4628964b2e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_b2d0fe27-e2e0-4603-b4b8-0b907f5344fb" xlink:href="evh-20220930.xsd#evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:to="loc_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization_b2d0fe27-e2e0-4603-b4b8-0b907f5344fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_f93793ea-e749-4e7c-89bf-5b367411f3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c495b503-26d7-400c-95c8-1c4963a52a95" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_f93793ea-e749-4e7c-89bf-5b367411f3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#ReservesforClaimsandPerformanceBasedArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_7529f3ba-8568-4d23-a283-5186a2d53a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_e254a628-3c49-433b-abf9-e73f5351181e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_7529f3ba-8568-4d23-a283-5186a2d53a05" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_e254a628-3c49-433b-abf9-e73f5351181e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_559e3ab2-30b5-410b-b021-5d6af82df568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_e254a628-3c49-433b-abf9-e73f5351181e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_559e3ab2-30b5-410b-b021-5d6af82df568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f6025c51-ff05-4887-9c8c-282f6103b299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_559e3ab2-30b5-410b-b021-5d6af82df568" xlink:to="loc_us-gaap_SegmentDomain_f6025c51-ff05-4887-9c8c-282f6103b299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_cfef1cc1-3157-4723-9f74-abf59717f476" xlink:href="evh-20220930.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f6025c51-ff05-4887-9c8c-282f6103b299" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_cfef1cc1-3157-4723-9f74-abf59717f476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_ClinicalSolutionsSegmentMember_0a233604-bcef-4118-adc6-48e4f191706a" xlink:href="evh-20220930.xsd#evh_ClinicalSolutionsSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_f6025c51-ff05-4887-9c8c-282f6103b299" xlink:to="loc_evh_ClinicalSolutionsSegmentMember_0a233604-bcef-4118-adc6-48e4f191706a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_c1bc7d8e-bfb5-45bc-b071-a8568bf44030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable_e254a628-3c49-433b-abf9-e73f5351181e" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_c1bc7d8e-bfb5-45bc-b071-a8568bf44030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_a9fb7e60-0f2e-4498-a03b-d3fc5b620fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems_c1bc7d8e-bfb5-45bc-b071-a8568bf44030" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_a9fb7e60-0f2e-4498-a03b-d3fc5b620fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_edee1b30-d38c-4bf5-82cf-86437e329513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_a9fb7e60-0f2e-4498-a03b-d3fc5b620fec" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_edee1b30-d38c-4bf5-82cf-86437e329513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_45efa560-be37-441c-92cf-105cad22a3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_a9fb7e60-0f2e-4498-a03b-d3fc5b620fec" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_45efa560-be37-441c-92cf-105cad22a3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_567c328d-f675-498b-873e-661d76fe0a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_45efa560-be37-441c-92cf-105cad22a3ba" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_567c328d-f675-498b-873e-661d76fe0a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_d1bc8b0f-d256-4787-aec7-de5095911f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_45efa560-be37-441c-92cf-105cad22a3ba" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_d1bc8b0f-d256-4787-aec7-de5095911f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_c6a6dfa4-eabe-4327-b323-aa6ce1d614be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_45efa560-be37-441c-92cf-105cad22a3ba" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_c6a6dfa4-eabe-4327-b323-aa6ce1d614be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_ff7a3d75-0c3c-4682-ad51-19b84fcaca0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_a9fb7e60-0f2e-4498-a03b-d3fc5b620fec" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_ff7a3d75-0c3c-4682-ad51-19b84fcaca0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_1051fb8a-5ba5-4a3b-9cb5-ccd56d7342b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_ff7a3d75-0c3c-4682-ad51-19b84fcaca0a" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_1051fb8a-5ba5-4a3b-9cb5-ccd56d7342b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_06ff2927-bdaf-42cb-8b57-d4323ce1c55b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_ff7a3d75-0c3c-4682-ad51-19b84fcaca0a" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_06ff2927-bdaf-42cb-8b57-d4323ce1c55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_dde597f5-c5d3-4889-acf9-7b1ed7dff93e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_ff7a3d75-0c3c-4682-ad51-19b84fcaca0a" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_dde597f5-c5d3-4889-acf9-7b1ed7dff93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_06c999b1-b535-4fd3-b0b4-6595034e4058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_a9fb7e60-0f2e-4498-a03b-d3fc5b620fec" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_06c999b1-b535-4fd3-b0b4-6595034e4058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#SupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_d17d14e0-70ee-4af5-ab68-6ead23ee0bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a9698d7e-a27d-4923-9016-b9537a433a68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_d17d14e0-70ee-4af5-ab68-6ead23ee0bc0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a9698d7e-a27d-4923-9016-b9537a433a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_560d3bd7-b3ad-4850-aa46-31f02264f8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a9698d7e-a27d-4923-9016-b9537a433a68" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_560d3bd7-b3ad-4850-aa46-31f02264f8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_a47348bd-cf2d-4f32-8edd-f8bfe7dd50f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a9698d7e-a27d-4923-9016-b9537a433a68" xlink:to="loc_us-gaap_StockIssued1_a47348bd-cf2d-4f32-8edd-f8bfe7dd50f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_StockIssuedInConnectionWithDebtRepayment_2a290bd7-4620-42c3-99dd-cb67063ed939" xlink:href="evh-20220930.xsd#evh_StockIssuedInConnectionWithDebtRepayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a9698d7e-a27d-4923-9016-b9537a433a68" xlink:to="loc_evh_StockIssuedInConnectionWithDebtRepayment_2a290bd7-4620-42c3-99dd-cb67063ed939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_234c0d98-efc5-46b8-b79b-a6c2c8bdd9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_a9698d7e-a27d-4923-9016-b9537a433a68" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_234c0d98-efc5-46b8-b79b-a6c2c8bdd9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_CashFlowLesseeAbstract_f0b67fda-8391-4c8b-8202-4576fa2b57a8" xlink:href="evh-20220930.xsd#evh_CashFlowLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_d17d14e0-70ee-4af5-ab68-6ead23ee0bc0" xlink:to="loc_evh_CashFlowLesseeAbstract_f0b67fda-8391-4c8b-8202-4576fa2b57a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_1527f842-b7c6-4e3f-9390-4b59430fbd81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_CashFlowLesseeAbstract_f0b67fda-8391-4c8b-8202-4576fa2b57a8" xlink:to="loc_us-gaap_OperatingLeasePayments_1527f842-b7c6-4e3f-9390-4b59430fbd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3f909d3c-a6ba-416f-b895-4201e18dcd97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_CashFlowLesseeAbstract_f0b67fda-8391-4c8b-8202-4576fa2b57a8" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3f909d3c-a6ba-416f-b895-4201e18dcd97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_RightOfUseAssetAcquiredAndDisposedOf_675848d1-ac2f-4cf9-8f4c-c6ba57efadfe" xlink:href="evh-20220930.xsd#evh_RightOfUseAssetAcquiredAndDisposedOf"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_evh_CashFlowLesseeAbstract_f0b67fda-8391-4c8b-8202-4576fa2b57a8" xlink:to="loc_evh_RightOfUseAssetAcquiredAndDisposedOf_675848d1-ac2f-4cf9-8f4c-c6ba57efadfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_5bc6a3c7-5de7-4886-8031-03995688b3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_d17d14e0-70ee-4af5-ab68-6ead23ee0bc0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_5bc6a3c7-5de7-4886-8031-03995688b3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_db47ac72-901b-4c8d-a130-377b8c7a2c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5bc6a3c7-5de7-4886-8031-03995688b3a9" xlink:to="loc_us-gaap_InterestPaidNet_db47ac72-901b-4c8d-a130-377b8c7a2c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_fa495836-5e5f-4d24-8c41-8c405be7ea6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5bc6a3c7-5de7-4886-8031-03995688b3a9" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_fa495836-5e5f-4d24-8c41-8c405be7ea6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.evolenthealth.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="evh-20220930.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.evolenthealth.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_2a36745b-0590-4f20-a51e-838a34879870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_1d0d15fb-db24-4676-8e32-977abe818336" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_2a36745b-0590-4f20-a51e-838a34879870" xlink:to="loc_us-gaap_SubsequentEventTable_1d0d15fb-db24-4676-8e32-977abe818336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_70ba4e4f-b568-4141-a263-84ae97839289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1d0d15fb-db24-4676-8e32-977abe818336" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_70ba4e4f-b568-4141-a263-84ae97839289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0b985185-3677-41a4-b9d7-9baa19618e33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_70ba4e4f-b568-4141-a263-84ae97839289" xlink:to="loc_us-gaap_SegmentDomain_0b985185-3677-41a4-b9d7-9baa19618e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_evh_EvolentHealthServicesSegmentMember_c1b827af-6482-44e9-acba-2f2bc11b2641" xlink:href="evh-20220930.xsd#evh_EvolentHealthServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0b985185-3677-41a4-b9d7-9baa19618e33" xlink:to="loc_evh_EvolentHealthServicesSegmentMember_c1b827af-6482-44e9-acba-2f2bc11b2641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_dc3a54f6-0ddd-4ef8-a660-316221dd95b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1d0d15fb-db24-4676-8e32-977abe818336" xlink:to="loc_us-gaap_SubsequentEventLineItems_dc3a54f6-0ddd-4ef8-a660-316221dd95b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_e11eb963-28d2-4a9d-bcd9-8543905279ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_dc3a54f6-0ddd-4ef8-a660-316221dd95b3" xlink:to="loc_us-gaap_Goodwill_e11eb963-28d2-4a9d-bcd9-8543905279ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123028744160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Evolent Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0454912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">800 N. Glebe Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Arlington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">22203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">389-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EVH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,190,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001628908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123030768848">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 156,756<span></span>
</td>
<td class="nump">$ 266,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrent', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,057<span></span>
</td>
<td class="nump">75,685<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">187,633<span></span>
</td>
<td class="nump">130,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">24,328<span></span>
</td>
<td class="nump">51,391<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">393,774<span></span>
</td>
<td class="nump">523,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,005<span></span>
</td>
<td class="nump">12,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,222<span></span>
</td>
<td class="nump">5,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">94,645<span></span>
</td>
<td class="nump">81,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets - operating</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">50,696<span></span>
</td>
<td class="nump">50,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,064<span></span>
</td>
<td class="nump">6,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNetNoncurrent', window );">Contract cost assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,588<span></span>
</td>
<td class="nump">32,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">451,398<span></span>
</td>
<td class="nump">279,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">722,790<span></span>
</td>
<td class="nump">426,297<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,759,182<span></span>
</td>
<td class="nump">1,419,458<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">61,863<span></span>
</td>
<td class="nump">96,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">132,238<span></span>
</td>
<td class="nump">107,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability - current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,053<span></span>
</td>
<td class="nump">7,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,646<span></span>
</td>
<td class="nump">51,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,524<span></span>
</td>
<td class="nump">11,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">135,698<span></span>
</td>
<td class="nump">171,294<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">382,022<span></span>
</td>
<td class="nump">445,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">412,444<span></span>
</td>
<td class="nump">215,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,260<span></span>
</td>
<td class="nump">5,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TaxReceivableAgreementLiability', window );">Tax receivable agreement liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,870<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - noncurrent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57,840<span></span>
</td>
<td class="nump">57,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,608<span></span>
</td>
<td class="nump">1,403<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">903,044<span></span>
</td>
<td class="nump">725,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (See Note $11)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Shareholders' Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Class A common stock - $0.01 par value; 750,000,000 shares authorized; 101,159,072 and 90,758,318 shares issued, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,012<span></span>
</td>
<td class="nump">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in-capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,472,098<span></span>
</td>
<td class="nump">1,340,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,044)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(594,805)<span></span>
</td>
<td class="num">(626,779)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost; 1,537,582 shares issued, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,123)<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">856,138<span></span>
</td>
<td class="nump">693,633<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders' equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,759,182<span></span>
</td>
<td class="nump">$ 1,419,458<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivableAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Receivable Agreement Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivableAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123029446928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">750,000,000<span></span>
</td>
<td class="nump">750,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">101,159,072<span></span>
</td>
<td class="nump">90,758,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, at cost</a></td>
<td class="nump">1,537,582<span></span>
</td>
<td class="nump">1,537,582<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123029823584">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 352,585<span></span>
</td>
<td class="nump">$ 222,471<span></span>
</td>
<td class="nump">$ 969,581<span></span>
</td>
<td class="nump">$ 659,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">266,617<span></span>
</td>
<td class="nump">163,126<span></span>
</td>
<td class="nump">736,061<span></span>
</td>
<td class="nump">493,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">68,521<span></span>
</td>
<td class="nump">51,292<span></span>
</td>
<td class="nump">186,408<span></span>
</td>
<td class="nump">152,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,196<span></span>
</td>
<td class="nump">14,859<span></span>
</td>
<td class="nump">47,414<span></span>
</td>
<td class="nump">44,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12,700)<span></span>
</td>
<td class="num">(225)<span></span>
</td>
<td class="num">(5,822)<span></span>
</td>
<td class="num">(819)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">339,634<span></span>
</td>
<td class="nump">229,052<span></span>
</td>
<td class="nump">964,061<span></span>
</td>
<td class="nump">689,796<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,951<span></span>
</td>
<td class="num">(6,581)<span></span>
</td>
<td class="nump">5,520<span></span>
</td>
<td class="num">(30,197)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">425<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">765<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,754)<span></span>
</td>
<td class="num">(6,367)<span></span>
</td>
<td class="num">(9,143)<span></span>
</td>
<td class="num">(18,978)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,392<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">3,940<span></span>
</td>
<td class="nump">12,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_GainOnTransferOfMembership', window );">Gain on transfer of membership</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment/repayment of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(10,192)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,192)<span></span>
</td>
<td class="num">(19,158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ChangesInTaxReceivablesAgreementLiability', window );">Change in tax receivable agreement liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(42,870)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(42,870)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(345)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from continuing operations before income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(43,393)<span></span>
</td>
<td class="num">(12,806)<span></span>
</td>
<td class="num">(51,850)<span></span>
</td>
<td class="num">(32,401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(45,516)<span></span>
</td>
<td class="nump">234<span></span>
</td>
<td class="num">(44,498)<span></span>
</td>
<td class="nump">936<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Income (loss) from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,123<span></span>
</td>
<td class="num">(13,040)<span></span>
</td>
<td class="num">(7,352)<span></span>
</td>
<td class="num">(33,337)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (loss) from discontinued operations, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(463)<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common shareholders of Evolent Health, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,123<span></span>
</td>
<td class="num">(13,040)<span></span>
</td>
<td class="num">(7,815)<span></span>
</td>
<td class="num">(31,954)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,123<span></span>
</td>
<td class="num">$ (13,040)<span></span>
</td>
<td class="num">$ (7,815)<span></span>
</td>
<td class="num">$ (31,954)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic income (loss) per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.02<span></span>
</td>
<td class="num">(0.15)<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
<td class="num">(0.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.02<span></span>
</td>
<td class="num">(0.15)<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
<td class="num">(0.39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_WeightedAverageCommonSharesOutstandingAbstract', window );"><strong>Weighted-average common shares outstanding</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">95,286<span></span>
</td>
<td class="nump">85,800<span></span>
</td>
<td class="nump">91,643<span></span>
</td>
<td class="nump">85,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">99,308<span></span>
</td>
<td class="nump">85,800<span></span>
</td>
<td class="nump">91,643<span></span>
</td>
<td class="nump">85,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Comprehensive income (loss)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,123<span></span>
</td>
<td class="num">$ (13,040)<span></span>
</td>
<td class="num">$ (7,815)<span></span>
</td>
<td class="num">$ (31,954)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of taxes, related to:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(262)<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(682)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income (loss) attributable to common shareholders of Evolent Health, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,861<span></span>
</td>
<td class="num">$ (13,036)<span></span>
</td>
<td class="num">$ (8,497)<span></span>
</td>
<td class="num">$ (32,039)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Includes $(0.5)&#160;million loss on disposal of discontinued operations for the nine months ended September 30, 2022 and $1.9&#160;million gain on disposal of discontinued operations for the nine months ended September 30, 2021, respectively</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ChangesInTaxReceivablesAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes In Tax Receivables Agreement Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ChangesInTaxReceivablesAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainOnTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain On Transfer Of Membership</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainOnTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_WeightedAverageCommonSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Common Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_WeightedAverageCommonSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123032256384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Gain on disposal of discontinued operations</a></td>
<td class="num">$ (0.5)<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123024464608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th">
<div>Additional Paid-In Capital </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
<th class="th">
<div>Retained Earnings (Accumulated Deficit) </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 619,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">$ 1,229,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (278)<span></span>
</td>
<td class="num">$ (589,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">11,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">11,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">11,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(3,397)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">(3,401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(31,954)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,954)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">607,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 874<span></span>
</td>
<td class="nump">1,249,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(363)<span></span>
</td>
<td class="num">(621,132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">619,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 859<span></span>
</td>
<td class="nump">1,229,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(278)<span></span>
</td>
<td class="num">(589,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 693,633<span></span>
</td>
<td class="num">$ (66,383)<span></span>
</td>
<td class="nump">$ 908<span></span>
</td>
<td class="nump">1,340,989<span></span>
</td>
<td class="num">$ (106,172)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
<td class="num">(626,779)<span></span>
</td>
<td class="nump">$ 39,789<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2021</a></td>
<td class="nump">$ 614,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 872<span></span>
</td>
<td class="nump">1,242,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(367)<span></span>
</td>
<td class="num">(608,092)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">4,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(255)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(255)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(13,040)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,040)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">607,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 874<span></span>
</td>
<td class="nump">1,249,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(363)<span></span>
</td>
<td class="num">(621,132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">693,633<span></span>
</td>
<td class="num">$ (66,383)<span></span>
</td>
<td class="nump">$ 908<span></span>
</td>
<td class="nump">1,340,989<span></span>
</td>
<td class="num">$ (106,172)<span></span>
</td>
<td class="num">(362)<span></span>
</td>
<td class="num">(626,779)<span></span>
</td>
<td class="nump">$ 39,789<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">19,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">3,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">3,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(6,187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">(6,192)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exchange/conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Exchange/conversion</a></td>
<td class="nump">101,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">101,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued for acquisition</a></td>
<td class="nump">130,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">130,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Leveraged stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Leveraged stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(11,232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">(11,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(682)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(682)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(7,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">856,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,012<span></span>
</td>
<td class="nump">1,472,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,044)<span></span>
</td>
<td class="num">(594,805)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2022</a></td>
<td class="nump">613,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 916<span></span>
</td>
<td class="nump">1,231,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(782)<span></span>
</td>
<td class="num">(596,928)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,123)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">6,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">2,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested, net of shares withheld for taxes</a></td>
<td class="num">(948)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exchange/conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Exchange/conversion</a></td>
<td class="nump">101,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="nump">101,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued for acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Shares issued for acquisition</a></td>
<td class="nump">130,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">130,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">2,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 856,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,012<span></span>
</td>
<td class="nump">$ 1,472,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,044)<span></span>
</td>
<td class="num">$ (594,805)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,123)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123030540480">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows Used In Operating Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (7,815)<span></span>
</td>
<td class="num">$ (31,954)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,822)<span></span>
</td>
<td class="num">(819)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_GainLossOnDispositionOfAssetsOperatingActivities', window );">Loss (gain) on discontinued operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">463<span></span>
</td>
<td class="num">(1,904)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,940)<span></span>
</td>
<td class="num">(12,725)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,414<span></span>
</td>
<td class="nump">45,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,350<span></span>
</td>
<td class="nump">11,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred tax benefit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(46,385)<span></span>
</td>
<td class="num">(288)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of contract cost assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,768<span></span>
</td>
<td class="nump">9,928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,762<span></span>
</td>
<td class="nump">13,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_GainOnTransferOfMembership', window );">Gain on transfer of membership</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(22,969)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment/repayment of debt, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,192<span></span>
</td>
<td class="nump">19,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_IncreaseDecreaseInTaxReceivableAgreement', window );">Change in tax receivable agreement liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,870<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other current operating cash inflows (outflows), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,163<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of acquisitions:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset', window );">Accounts receivable, net and contract assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(34,796)<span></span>
</td>
<td class="num">(52,878)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current and non-current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,409)<span></span>
</td>
<td class="num">(140)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_IncreaseDecreaseInCapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,732)<span></span>
</td>
<td class="num">(8,439)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,936<span></span>
</td>
<td class="nump">8,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(27,903)<span></span>
</td>
<td class="num">(13,893)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,451)<span></span>
</td>
<td class="num">(12,811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,741)<span></span>
</td>
<td class="nump">3,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(35,596)<span></span>
</td>
<td class="nump">16,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Right-of-use operating assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">831<span></span>
</td>
<td class="nump">6,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,223)<span></span>
</td>
<td class="num">(4,589)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,184)<span></span>
</td>
<td class="nump">1,208<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash and restricted cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(47,248)<span></span>
</td>
<td class="num">(27,909)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows Provided by (Used In) Investing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for asset acquisitions and business combinations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(245,021)<span></span>
</td>
<td class="num">(1,889)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates', window );">Proceeds from transfer of membership and release of Passport escrow</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,969<span></span>
</td>
<td class="nump">42,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet', window );">Disposal of non-strategic assets and divestiture of discontinued operations, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,164)<span></span>
</td>
<td class="nump">3,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Return of equity method investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,175<span></span>
</td>
<td class="nump">14,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities', window );">Purchases of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,994)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ProceedsFromMaturityOfInvestments', window );">Maturities and sales of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherProductiveAssets', window );">Investments in internal-use software and purchases of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(27,618)<span></span>
</td>
<td class="num">(17,739)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash and restricted cash provided by (used in) investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(254,659)<span></span>
</td>
<td class="nump">38,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows Provided by (Used In) Financing Activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities', window );">Changes in working capital balances related to claims processing on behalf of partners</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(48,322)<span></span>
</td>
<td class="nump">1,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Repayment of Credit Agreement including settlement of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(98,420)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,280<span></span>
</td>
<td class="nump">11,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long term debt, net of offering costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">219,740<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Distributions to Sponsors</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(14,884)<span></span>
</td>
<td class="num">(1,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes withheld and paid for vesting of equity awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(17,419)<span></span>
</td>
<td class="num">(3,397)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash and restricted cash provided by (used in) financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">142,395<span></span>
</td>
<td class="num">(90,446)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash and cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(612)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(160,124)<span></span>
</td>
<td class="num">(79,826)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash as of beginning-of-period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">354,942<span></span>
</td>
<td class="nump">361,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash as of end-of-period</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 194,818<span></span>
</td>
<td class="nump">$ 281,755<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the nine months ended September 30, 2021. See Note 5.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainLossOnDispositionOfAssetsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Disposition Of Assets, Operating Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainLossOnDispositionOfAssetsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainOnTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain On Transfer Of Membership</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainOnTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInCapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Capitalized Contract Cost, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInCapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncreaseDecreaseInTaxReceivableAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Tax Receivable Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncreaseDecreaseInTaxReceivableAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Claims Processing, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ProceedsFromMaturityOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Maturity Of Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ProceedsFromMaturityOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow through purchase of long-term held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033270544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text">Organization <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations to move their business models from traditional fee for service reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022, the Company had unrestricted cash and cash equivalents of $156.8 million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s headquarters is located in Arlington, Virginia.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evolent Health LLC Governance</span></div>Our operations are conducted through Evolent Health LLC. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#8217;s business and affairs and is responsible for the management of its business.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033182864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</a></td>
<td class="text">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#8220;GAAP&#8221;) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2021 Form 10-K. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See &#8220;Part II - Item 8. Financial Statements and Supplementary Data - Note 2&#8221; in our 2021 Form 10-K for a complete summary of our significant accounting policies.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassification</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current period presentation specifically as it relates to the reclassification of assets, liabilities, operating results and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Cash and Restricted Investments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,057&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,005&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,755&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the nine months ended September 30, 2021. See Note 5.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Costs</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss). Total research and development costs for the three and nine months ended September 30, 2022, was $3.8&#160;million and $11.7&#160;million, respectively, and, $4.2&#160;million and $11.1&#160;million for the three and nine months ended September 30, 2021, respectively.  </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 21 for additional discussion regarding our reserves for claims and performance-based arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Right of Offset</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of September&#160;30, 2022, and December&#160;31, 2021, approximately 47% and 42%, respectively, of gross accounts receivable was netted against claims payable in lieu of cash receipt. Furthermore, as of September&#160;30, 2022, approximately 11% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 12 for additional lease disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div>See Note 6 for further discussion of our policies related to revenue recognition.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033160160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recently Issued Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text">Recently Issued Accounting Standards<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8&#160;million, reduced additional paid-in capital by $106.2&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1&#160;million and $41.3&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Effective</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. This new standard is effective for our interim and annual periods beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the adoption impacts on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033240704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Transactions</a></td>
<td class="text">Transactions<div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Implantable Provider Group</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022, the Company completed its acquisition of Implantable Provider Group, Inc. (&#8220;IPG&#8221;), including 100% of the voting equity interests. IPG is a leader in providing surgical management solutions for musculoskeletal conditions. The transaction is expected to accelerate our strategy to become a leading provider of value-based specialty care solutions as well as diversify our revenue streams with a larger customer portfolio. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total merger consideration, net of cash on hand and certain closing adjustments, was $461.7&#160;million, based on the closing price of the Company&#8217;s Class A common stock on the NYSE on August 1, 2022. The merger consideration consisted of $256.5&#160;million of cash consideration, 3.7&#160;million shares of Class A common stock, fair valued at $130.2&#160;million as of August 1, 2022, and an earn-out of up to $87.0&#160;million, fair valued at $75.0&#160;million as of August 1, 2022 is payable in cash and/or shares of the Company&#8217;s Class A Common Stock, at the Company&#8217;s option. See Note</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17 for additional information regarding the fair value determination of the earn-out consideration.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and the corporate trade name will be amortized on a straight-line basis over their preliminary estimated useful lives of 20 years, 5 years, and 15 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary customer relationship management and analytics platform that supports reporting to payors with respect to medical device pricing and associated analytics. The corporate trade name reflects the value that we believe the IPG brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. The Company received carryover tax basis in the assets and liabilities acquired; accordingly, the Company recognized net deferred tax liabilities associated with the difference between the book basis and the tax basis for the assets and liabilities acquired. The goodwill is not deductible for tax purposes. Additionally, a discrete tax benefit of $46.8&#160;million was recorded in the consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2022, to account for the valuation allowance release primarily related to the acquired intangible assets, which resulted in a deferred tax liability that provided a source of income supporting realization of other deferred tax assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts above reflect management&#8217;s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. Any necessary adjustments are expected to be finalized by the end of the third quarter of 2023.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vital Decisions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2021, the Company completed its acquisition of Vital Decisions, including 100% of the voting equity interests. Vital Decisions is a leading provider of technology-enabled advance care planning services, ensuring that the care of individuals with serious illness aligns with their values and changing preferences throughout their health journey and, in particular, as they approach end-of-life decisions. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total merger consideration, net of cash on hand and certain closing adjustments, was $117.7 million, based on the closing price of the Company&#8217;s Class A common stock on the NYSE on October 1, 2021. The merger consideration consisted of $46.5 million of cash consideration, 1.8&#160;million shares of Class A common stock, fair valued at $56.6 million as of October 1, 2021, and an earn-out of up to $45.0&#160;million, fair valued at $14.6 million as of October 1, 2021 is payable in cash and/or shares of the Company&#8217;s Class A Common Stock, at the Company&#8217;s option. See Note 17 for additional information regarding the fair value determination of the earn-out consideration.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and corporate trade names will be amortized on a straight-line basis over their preliminary estimated useful lives of 13 years, 5 years, and 15 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary advance care planning documentation portal where patients can input information, and doctor/patient conversations are populated for later reference. The corporate trade name reflects the value that we believe the Vital Decisions brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. Goodwill is considered to be an indefinite lived asset. $69.6&#160;million of the goodwill recorded on the transaction is deductible for tax purposes.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033130384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text">Discontinued Operations<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the &#8220;True Health SPA&#8221;) with Bright Health Management, Inc. (&#8220;Bright HealthCare&#8221;), pursuant to which EH Holdings agreed to sell all of its equity interests in True Health to Bright HealthCare. Closing of the transactions contemplated by the True Health SPA occurred on March 31, 2021 (the &#8220;True Health Closing&#8221;) and the Company has had no continuing involvement with True Health subsequent to the closing except a pre-existing services agreement for claims processing and other health plan administrative functions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 205, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.291%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine <br/>Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.291%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million for the nine months ended September 30, 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses include intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million for the nine months ended September 30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business during the nine months ended September 30, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"/><td style="width:89.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033105056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily third-party administration (&#8220;TPA&#8221;) services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into performance-based arrangements that may include capitation and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal vs. Agent</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the goods and services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer thereby recognizing revenue on a net basis.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:114.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,054&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,328&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,857&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,257&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,614&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,521&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,557&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,060&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,042&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to the Remaining Performance Obligations</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contracts with a term greater than one year, we have allocated approximately $69.1 million of transaction price to performance obligations that are unsatisfied as of September&#160;30, 2022. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately 37%, 85% and 98% of these remaining performance obligations by December 31, 2022, 2023 and 2024, respectively, with the remaining balance to be recognized thereafter. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be less or greater than this estimate and the timing of recognition may not be as expected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of September&#160;30, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the nine months ended September 30, 2022 are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:102.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,445)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in a previous period was $10.4&#160;million and $56.4&#160;million for the three and nine months ended September 30, 2022, due primarily to net gain share as well as changes in other estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Cost Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of September&#160;30, 2022 and December 31, 2021, the Company had $3.6 million and $5.2 million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amortiza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tion expense of $0.3 million and $2.0 million for the three and nine months ended September 30, 2022, respectively, and $0.3 million and $1.3 million for the three and nine months ended September 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our platform and operations arrangements, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of September&#160;30, 2022 and December 31, 2021, the Company had $21.0 million and $27.4 million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense including the acceleration of amortization of contract costs for certain customers of $1.3 million and $12.8 million for the three and nine months ended September 30, 2022, respectively, and $1.3 million and $8.6 million for the three and nine months ended September 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be the shorter of the contract term or five years. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123034321568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentTextBlock', window );">Credit Losses</a></td>
<td class="text">Credit Losses <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic and current inflationary pressures on our customers&#8217; and other third parties&#8217; ability to pay. We did not observe notable increases in delinquencies during the three and nine months ended September 30, 2022. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the three and nine months ended September 30, 2022.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable from Revenue Transactions</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#8217;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#8217;s consolidated balance sheets. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets as of&#160;September&#160;30, 2022,&#160;83% were current, 9%&#160;were past due less than 60 days, with 11% past due less than 120 days and at December 31, 2021, 90% was current, 2% was past due less than 60 days, with 3% past due less than 120 days. As of&#160;September&#160;30, 2022 and December 31, 2021, in total we reported on the consolidated balance sheet&#160;$201.5 million&#160;and $171.5&#160;million of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other assets, net of allowances of&#160;$9.4 million and $3.4 million, respectively. The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,374)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPG acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,949)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge-offs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,355)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,929)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Charge offs for the nine months ended September 30, 2021, are due to balances written-off that were previously fully reserved as part of the Passport transaction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922895-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919272-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919236-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919269-210447<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919244-210447<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919230-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033118464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,707)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,365&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalized $8.0 million and $21.5 million for the three and nine months ended September 30, 2022, respectively, and $5.4 million and $16.5 million for the three and nine months ended September 30, 2021, respectively, of internal-use software development costs. The net book value of capitalized internal-use software development costs was $73.0 million and $71.2 million as of September&#160;30, 2022 and December 31, 2021, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $7.7 million and $23.1 million for the three and nine months ended September 30, 2022, respectively, and $7.4 million and $22.8 million for the three and nine months ended September 30, 2021, respectively, of which amortization expense related to capitalized internal-use software development costs was $6.4 million and $19.6 million for the three and nine months ended September 30, 2022, respectively, and $6.7 million and $20.0 million for the three and nine months ended September 30, 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123032990336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets, Net</a></td>
<td class="text">Goodwill and Intangible Assets, Net<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three reporting units, each with </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our annual goodwill impairment review occurs on October 31 of each fiscal </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the three and nine months ended September 30, 2022</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We will perform our annual impairment test on October 31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Goodwill Impairment Test</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest the fair value of any of our three reporting units was below their respective carrying values. As a result, a quantitative goodwill impairment analysis was not required.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,230&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508,560&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,790&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,335&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $575.5 million as of both December 31, 2021 and 2020.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Goodwill acquired from the addition of IPG in the third quarter of 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) as of September&#160;30, 2022 and December&#160;31, 2021 are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,753&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,623&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378,396&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,212&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,814&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451,398&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,376&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,592&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to intangible assets was $9.5 million and $24.3 million for the three and nine months ended September 30, 2022, respectively, and $7.4 million and $22.1 million for the three and nine months ended September 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of September&#160;30, 2022, is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:478.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,487&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,057&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,751&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451,398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#8217; carrying value. We did not identify any circumstances during&#160;the three and nine months ended September 30, 2022, that would require an impairment test for our intangible assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033048832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-term Debt</a></td>
<td class="text">Long-term Debt<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2022 (&#8220;IPG Closing Date&#8221;), the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent and revolver agent, together with the Company (the &#8220;2022 Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial term loan in the aggregate principal amount of $175.0&#160;million (the &#8220;Initial Term Loan Facility&#8221;) and (ii) a revolving credit facility in the aggregate principal amount of up to $50.0&#160;million, to be determined by reference to the lesser of $50.0&#160;million and a borrowing base (the &#8220;Revolving Facility&#8221; and, together with the Initial Term Loan Facility, the &#8220;Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrowers borrowed the loan under the Initial Term Loan Facility on August 1, 2022 (the &#8220;Initial Term Loan&#8221;), and also borrowed $50.0&#160;million under the Revolving Facility on the IPG Closing Date. The Credit Facilities are guaranteed by the Company and the Company&#8217;s domestic subsidiaries, subject to certain exceptions. The Credit Facilities are secured by a first priority security interest in all of the capital stock of each borrower and guarantor (other than the Company) and substantially all of the assets of each borrower and guarantor, subject to certain exceptions. The Initial Term Loan and loans under the Revolving Facility will mature on the date that is the earliest of (a) August 1, 2027, (b) the date on which all amounts outstanding under the 2022 Credit Agreement have been declared or have automatically become due and payable under the terms of the Credit Agreement and (c) the date that is ninety-one (91) days prior to the maturity date of any Junior Debt (as defined in the 2022 Credit Agreement) unless certain liquidity conditions are satisfied.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds of the Initial Term Loan and Revolving Facility were used to finance the IPG transaction and fund fees and expenses incurred in connection therewith and thereafter may be used to fund acquisitions, ongoing working capital needs and other growth capital investments and to pay fees and expenses in connection therewith. The interest rate for each loan under the Credit Facilities is calculated, at the option of the Borrowers, (a) in the case of a Term Loan, at either the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus 5.50%, or the base rate plus 4.50% and (b) in the case of a Revolving Loan, at either the Adjusted Term SOFR Rate plus 3.50%, or the base rate plus 2.50%. A commitment fee of (a) 2.00% of the aggregate amount of the commitments in respect of the Term Loan Facility as of the closing and (b) 2.00% of the aggregate amount of the commitments in respect of the Revolving Facility was paid as of the closing. The Company recorded $2.9&#160;million in interest expense related to our 2022 Credit Agreement for the three and nine months ended September 30, 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts outstanding under the Credit Facility may be prepaid at the option of the Company subject to applicable premiums and a call protection premium payable on the amount prepaid in certain instances as follows: (1) 3.00% of the principal amount so prepaid after the closing but prior to the first anniversary of the IPG Closing Date; (2) 2.00% of the principal amount so prepaid after the first anniversary of the closing but prior to the second anniversary of the IPG Closing Date; (3) 1.00% of the principal amount so prepaid after the second anniversary of the closing but prior to the third anniversary of the IPG Closing Date; and (4) 0.00% of the principal amount so prepaid on or after the third anniversary of the IPG Closing Date. Amounts outstanding under the Credit Facility are subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facilities contain customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company is required to comply at certain times with certain financial covenants comprised of a minimum liquidity test commencing upon closing of the Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending September 30, 2022. If an event of default occurs, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Credit Facilities. We incurred $5.3&#160;million of debt issuance costs in connection with this Credit Agreement, which was included in long-term debt, net of discount on our consolidated balance sheets and amortized into interest expense over the life of the agreement. The Company recorded $0.2&#160;million in interest expense related to the amortization of the debt discount and the issuance costs for the three and nine months ended September 30, 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2024 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company issued $117.1&#160;million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 (the &#8220;2024 Notes&#8221;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $84.2 million aggregate principal amount of 2024 Notes in exchange for $84.2 million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $2.5&#160;million, and issued $32.8 million aggregate principal amount of New Notes for cash at par. We incurred $3.0&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes,  since this method was not materially different from the effective interest method. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to 3.50% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#8217;s Class A common stock. We recorded interest expense of $0.5 million and $2.5 million for the three and nine months ended September 30, 2022, respectively, and $1.0 million and $3.0 million for the three and nine months ended September 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $18.23 per share of the Company&#8217;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into 6.4&#160;million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2024 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $78.9&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $38.1&#160;million before issuance costs and was recorded within additional paid-in capital. Issuance costs of $1.7&#160;million and $1.3&#160;million were allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $38.1&#160;million, $1.7&#160;million of issuance costs was amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $38.1&#160;million decrease in additional paid-in capital and a $1.3&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and an $11.7&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2024 Notes. These adjustments resulted in an increase of $25.1&#160;million to the debt component of the 2024 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2024 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2024 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $0.1 million and $0.5 million for the three and nine months ended September 30, 2022, respectively, and $2.0 million and $5.9 million for the three and nine months ended September 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#8217;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 11, 2022, the Company entered into exchange agreements with certain holders of the 2024 Notes. Pursuant to the agreements, these holders exchanged $92.8&#160;million in aggregate principal amount of such notes for shares of the Company&#8217;s Class A common stock. On August 17 and 18, 2022, the Company consummated the exchanges and issued an aggregate of 5,394,165 shares of Class A common stock to the holders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The August 2022 exchanges of the 2024 Notes for Class A common stock resulted in a $10.2&#160;million loss on extinguishment/repayment of debt, net, on the consolidated statements of operations and comprehensive income (loss).</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Credit Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#8220;Borrower&#8221;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the &#8220;2019 Credit Agreement&#8221;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial secured term loan in the aggregate principal amount of $75.0 million (the &#8220;Initial Term Loan Facility&#8221;) and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $50.0 million (the &#8220;DDTL Facility&#8221; and, together with the Initial Term Loan Facility, the &#8220;Senior Credit Facilities&#8221;), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the Initial Term Loan Facility on December 30, 2019. The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport Asset Purchase Agreement and pay fees and expenses incurred in connection therewith. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2020, an amendment to the Company's 2019 Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company repaid all outstanding amounts owed under and terminated the 2019 Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the 2019 Credit Agreement in connection with the prepayment was $98.6&#160;million, which included $9.7&#160;million for the make-whole premium as well as $0.2&#160;million in accrued interest. As a result of this transaction, the Company recorded a loss on the repayment of debt of $19.2&#160;million, representing the remaining unamortized debt issuance costs of $9.5&#160;million, the make-whole premium and $35&#160;thousand of legal expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrant Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Company&#8217;s entry into the 2019 Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock at a per share purchase price equal to $8.05. The holders could exercise the warrants at any time until thirty days after the maturity of the 2019 Credit Agreement.  The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 8, 2021, the Company settled the outstanding warrants associated with the 2019 Credit Agreement for $13.7&#160;million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2025 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the &#8220;2025 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The 2025 Notes were issued at par for net proceeds of $166.6 million. We incurred $5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $150.0 million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018 and the Company completed the offering and sale of an additional $22.5 million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#8217; exercise in full of their option to purchase additional notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;1.50%&#160;per annum. The Company recorded interest expense of $0.6 million and $1.9 million for both the three and nine months ended September 30, 2022 and 2021, respectively. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $33.43 per share of the Company&#8217;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company&#8217;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The option to settle the 2025 Notes in cash or shares of the Company&#8217;s Class A common stock, or a combination of cash and shares of the Company&#8217;s Class A common stock, at the Company&#8217;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $100.7 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $71.8 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $3.4 million and $2.5 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $71.8 million, $3.4 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $71.8&#160;million decrease in additional paid-in capital and a $2.5&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and a $28.1&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2025 Notes. These adjustments resulted in an increase of $41.3&#160;million to the debt component of the 2025 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2025 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2025 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $0.4 million and $1.0 million for the three and nine months ended September 30, 2022, respectively, and $2.5 million and $7.4 million for the three and nine months ended September 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale price of the Company&#8217;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Notes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2016, the Company issued $125.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2021 (the &#8220;2021 Notes&#8221;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of $120.4 million. We incurred $4.6 million of debt issuance costs in connection with the 2021 Notes, which we amortized to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December&#160;5, 2016.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, as part of the issuance of the 2024 Notes, the Company issued $84.2&#160;million aggregate principal amount of the 2024 Notes in exchange for $84.2&#160;million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $4.8&#160;million, including an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we also repurchased $14.0&#160;million of the 2021 Notes with $13.9&#160;million of cash and recorded an immaterial gain on extinguishment of debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon maturity of the 2021 Notes on December 1, 2021, outstanding 2021 Notes with a principal amount of $26.7&#160;million were settled, at the option of the holders, by converting $26.3&#160;million aggregate principal amount of 2021 Notes to common shares and cash repayment of $0.4&#160;million aggregate principal amount of 2021 Notes. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Convertible Senior Notes Carrying Value</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 Notes and 2025 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of September&#160;30, 2022. However, the 2024 Notes and 2025 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2024 Notes and 2025 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term convertible debt as of September&#160;30, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,251&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Fair values for notes are derived from available trading prices closest to the respective balance sheet date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033191184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letters of Credit</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2022 and December&#160;31, 2021, the Company was party to irrevocable standby letters of credit&#160;with a bank for $13.1&#160;million and&#160;$15.4 million, respectively, for the benefit of regulatory authorities, real estate and risk-sharing agreements. As such, we held $13.1&#160;million and $15.4 million, respectively, in restricted cash and restricted investments as collateral as of September&#160;30, 2022 and December&#160;31, 2021. The letters of credit have current expiration dates between December 2022 and March 2032 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnifications</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pre-IPO Investor Registration Rights Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the three and nine months ended September 30, 2022, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guarantees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#8220;Molina&#8221;) entered into an Asset Purchase Agreement (the &#8220;Molina APA&#8221;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#8217;s rights under the Passport Medicaid Contract. On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#8220;Molina Closing&#8221;) and the Passport Medicaid Contract was novated to Molina. In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#8220;KY DOI&#8221;) regarding the wind down of its operations throughout 2021 and 2022. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of September&#160;30, 2022, no amounts have been funded under this guarantee.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reinsurance Agreements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the &#8220;Passport Closing&#8221;). As part of the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport. On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#8217;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business was officially transferred to Molina effective September 1, 2021. As of September&#160;30, 2022, there are no material outstanding amounts under this reinsurance agreement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">UPMC Reseller Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#8220;UPMC Reseller Agreement&#8221;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#8217;s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company&#8217;s customers. Revenue associated with the UPMC Reseller Agreement in the three and nine months ending September 30, 2022 was $0.1&#160;million and $1.2&#160;million, respectively, and is in wind-down. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#8220;TRA&#8221;) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the reduction in the Company&#8217;s valuation allowance primarily resulting from deferred tax liabilities established as part of the IPG acquisition, the Company has recorded a partial TRA liability of $42.9&#160;million as of September 30, 2022, which represents 85% </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the deferred tax assets related to the Company&#8217;s unrealized tax benefits on historical pre-IPO losses and tax basis increases from exchanges, offset with the related valuation allowance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will assess the realizability of the deferred tax assets at each reporting period, and a change in our estimate of our liability associated with the tax receivable agreement may result as additional information becomes available, including results of operations in future periods. The realizability of the deferred tax assets is evaluated based on all positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division. An amended complaint was filed on January 10, 2020, a second amended complaint was filed on June 8, 2020, and a third amended complaint, now titled Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley, was filed on December 2, 2021. On July 13, 2022, the parties to the class action executed a term sheet for settlement of the litigation, subject to documentation of the settlement and approval of the court after notice to class members. On August 2, 2022, the lead plaintiff in the case filed an unopposed motion seeking preliminary approval of the settlement and related exhibits, including draft notice to class members and a proposed final order. The settlement stipulation is subject to preliminary and final approval by the court. The Final Settlement Hearing is scheduled for November 18, 2022. If the settlement is approved, we expect that the agreed-upon settlement payment of $23.5&#160;million will be funded entirely by applicable directors&#8217; and officers&#8217; liability insurance. As such, we do not expect to incur a significant net loss or cash outflow as a result of the settlement of this matter.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#8217;s Board was negligent in its oversight of the Company&#8217;s relationship with Passport Health Plan. The case is Lincolnshire Police Pension Fund, derivatively on behalf of Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#8217;Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc. (&#8220;Derivative Action&#8221;). The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021. Plaintiffs have not yet responded to the motion to dismiss and there is not currently a briefing schedule on file with the Delaware Chancery Court. Based on the Company&#8217;s investigation, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit and Concentration Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of September&#160;30, 2022, approximately 98.2% of our $194.8 million of cash and cash equivalents, restricted cash and restricted investments were held in bank deposits with FDIC participating banks and approximately 1.0% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable, as of September&#160;30, 2022 and December&#160;31, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bright Health Management, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three and nine months ended September 30, 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:327.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2%</span></td></tr></table></div>We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033269136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses.  The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2032. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#8217;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with various lease agreements, the Company is required to maintain $2.3 million and $3.8 million in letters of credit as of September&#160;30, 2022 and December&#160;31, 2021. As of September&#160;30, 2022 and December&#160;31, 2021, the Company held $2.3 million </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $3.8 million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of September&#160;30, 2022 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:237.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edison, NJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpharetta, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,096&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,822&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,368&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of September&#160;30, 2022, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,893&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033065232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Common Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Income (Loss) Per Common Share</a></td>
<td class="text">Income (Loss) Per Common Share<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,040)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,352)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,337)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,040)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,815)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,954)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental diluted shares from stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental diluted shares from Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic income (loss) per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted net earnings per common share, if any, gives effect to diluted stock options (calculated based on the treasury stock method), shares issuable upon debt conversion (calculated using an as-if converted method).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,007&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,712&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,390&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,404&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033118464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">Stock-based Compensation<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,992&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,395&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,350&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,754&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,992&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,395&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,350&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,754&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No stock-based compensation was capitalized as software development costs for the three and nine months ended September 30, 2022 and 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards were granted as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:327.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033164944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For interim periods, we recognize an income tax provision (benefit) based on our estimated annual effective tax rate expected for the full year, adjusted for discrete items recognized during the interim period. Discrete items (e.g., significant or unusual items) are separately recognized in the quarter during which they occur and can cause the effective tax rate to vary from quarter to quarter.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An income tax benefit of $(45.5)&#160;million and $(44.5)&#160;million and was recognized for the three and nine months ended September 30, 2022, respectively, which resulted in effective tax rates of 104.9% and 85.8%, respectively. An income tax expense of $0.2&#160;million and $0.9&#160;million was recognized for the three and nine months ended September 30, 2021, respectively, which resulted in effective tax rates of (1.8)% and (2.9)%, respectively. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components. The income tax benefit recorded during the three and nine months ended September 30, 2022 primarily relates to the $46.8&#160;million reduction in the valuation allowance resulting from deferred tax liabilities established as part of the IPG acquisition accounting, partially offset by state and foreign taxes. The income tax expense recorded during the three and nine months ended September 30, 2021, primarily relates to foreign taxes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2021, the Company had unrecognized tax benefits of $0.6 million that, if recognized, would not affect the effective tax rate due to the valuation allowance against its net deferred tax asset. As of September 30, 2022, the Company has additional unrecognized tax benefits of $0.4&#160;million that, if recognized, would affect the effective tax rate. The Company is not currently subject to income tax audits in any U.S., state, or foreign jurisdictions for any tax year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivables Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering Reorganization, the Company entered into the TRA with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. See Note 11 above for discussion of our TRA.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033105056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Equity Method Investees<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Investments in Equity Method Investees</a></td>
<td class="text">Investments in Equity Method InvesteesThe Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;September&#160;30, 2022 and December&#160;31, 2021, the Company&#8217;s economic interests in its equity method investments ranged between 4% and 38% and 4% and 39%, respectively, and voting interests in its equity method investments ranged between 25% and 40%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#8217; earnings and losses for each reporting period. The Company&#8217;s proportional share of the gain from these investments was approximately $1.4 million and $3.9 million for the three and nine months ended September 30, 2022, respectively, and $0.1 million and $12.7 million for the three and nine months ended September 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $5.0 million and $12.5 million for the three and nine months ended September 30, 2022, respectively, and $4.0 million and $12.6 million for the three and nine months ended September 30, 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123034321568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of earn-out consideration related to the IPG and Vital transactions as described in Note 4.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the three and nine months ended September 30, 2022 and 2021, respectively.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the acquisitions of IPG and Vital Decisions include a provision for additional equity consideration, at the Company&#8217;s option, contingent upon the Company obtaining certain performance metrics. The earnout period for the Vital Decisions contingent considering is the three months ending December 31, 2022, and the earnout periods for IPG are the four months ended December 31, 2022 and the nine months ended September 30, 2023. The fair value of the contingent equity considerations was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurements of the IPG and Vital Decisions contingent considerations are the risk-neutral (probability weighted) earnout consideration and the applicable discount rate. A significant increase in the risk-neutral (probability weighted) earnout consideration or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 10 for information regarding the fair value of the 2024 Notes and 2025 Notes.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033165760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text">Related Parties  <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As discussed in Note&#160;16, the Company had economic interests in several entities that are accounted for under the equity method of accounting. The Company has allocated its proportional share of the investees&#8217; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also works with UPMC, one of its founding investors. The Company&#8217;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. This relationship is currently in wind-down.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:319.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123030582208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Repositioning and Other Changes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Repositioning and Other Changes</a></td>
<td class="text">Repositioning and Other Changes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#8220;Repositioning Plan&#8221;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives that will provide future benefit to the Company. The Repositioning Plan concluded in the fourth quarter of 2021.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total costs associated with the Repositioning Plan by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Costs Incurred through December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred For the Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,593&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,043&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033240704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Reporting</a></td>
<td class="text">Segment Reporting<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We define our reportable segments based on the way the CODM, the chief executive officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into two reportable segments as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Clinical Solutions, which includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is defined as net income (loss) attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, provision (benefit) for income taxes, depreciation and amortization expenses, adjusted to exclude gain on transfer of membership, loss on extinguishment/repayment of debt, net, gain from equity method investees, changes in fair value of contingent consideration, change in the tax receivable agreement liability, other income (expense), net, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, strategy and shareholder advisory services, acquisition-related costs and gain (loss) from discontinued operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,315&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,614&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(458)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,507&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,303&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,353)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,530&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,765)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,765&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(626)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,924&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,031&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,356)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,854&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,988&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,793)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,120&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,456&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,558)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,018&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:327.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,040)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,815)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,954)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,754)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,978)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from (provision for) income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(936)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivable agreement liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,870)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,870)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment/repayment of debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,043)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,992)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,395)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,754)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(996)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,055&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,765&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,049&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,018&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes $(0.5)&#160;million loss on disposal of discontinued operations for the nine months ended September 30, 2022 and $1.9&#160;million gain on disposal of discontinued operations for the nine months ended September 30, 2021, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123030780432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceDisclosureTextBlock', window );">Reserves for Claims and Performance-Based Arrangements</a></td>
<td class="text">Reserve for Claims and Performance-Based Arrangements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements for our EHS and Clinical Solutions segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 11.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs based on authorizations per thousand members basis and assigning an average cost per authorization. This is also adjusted for the impact of copays, deductibles, unit cost and historic discontinuation rates for treatment are considered. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:226.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:37.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:41.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred health care costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year to date period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year to date period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims incurred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,714)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year to date period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,801)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229,315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250,116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year to date period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,846)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,390)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,406)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,580)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,846)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(488,098)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(498,944)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,975)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330,721)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370,696)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,058&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,640&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,698&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,469&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,409&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,878&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -URI https://asc.fasb.org/topic&amp;trid=2303980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033164944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text">Supplemental Cash Flow Information <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued in connection with business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued in connection with debt repayment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued net working capital adjustment with business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets disposed of (obtained in) exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,771)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(955)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(734)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -URI https://asc.fasb.org/topic&amp;trid=2134446<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033305600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsGoodwill ImpairmentOn October 11, 2022, our Evolent Health Services segment was notified by Bright Health Group that it intended to exit its Individual and Family lines of business. Due to an expected decrease in projected future cash flows which could impact our estimated fair value, our existing goodwill in the EHS segment may require an adjustment. Such adjustment could be material. As of the date of this filing, the Company has not yet completed the analysis due to the complexities and time involved in determining the implied fair value of the goodwill. The analysis will be completed in the fourth quarter of 2022. As of September 30, 2022, goodwill in our EHS segment is $214.2&#160;million. If the fair value of the EHS segment is determined to be less than the carrying value, an adjustment to goodwill will be required, and such amount could be material.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123028863056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationIn our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#8220;GAAP&#8221;) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (&#8220;SEC&#8221;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2021 Form 10-K.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassification</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current period presentation specifically as it relates to the reclassification of assets, liabilities, operating results and cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates and Assumptions</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting Estimates and Assumptions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principles of Consolidation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Net</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets, Net </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div>Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#8217;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">Research and Development CostsResearch and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityReserveEstimatePolicy', window );">Reserves for Claims and Performance-based Arrangements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Claims and Performance-based Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. </span></div>The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_RightOfOffsetPolicyPolicyTextBlock', window );">Right of Offset</a></td>
<td class="text">Right of OffsetCertain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following 5-step model, outlined in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), to determine revenue recognition from our contracts with customers:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the contract(s) with a customer</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Identify the performance obligations in the contract</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Determine the transaction price</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Allocate the transaction price to performance obligations</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> Recognize revenue when (or as) the entity satisfies a performance obligation</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from platform and operations services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily third-party administration (&#8220;TPA&#8221;) services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our Clinical Solutions segment, we enter into performance-based arrangements that may include capitation and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts with Multiple Performance Obligations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Principal vs. Agent</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the goods and services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer thereby recognizing revenue on a net basis.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of New Accounting Standards and Recent Accounting Pronouncements Not Yet Effective</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#8217;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#8217;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#8217;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#8217;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8&#160;million, reduced additional paid-in capital by $106.2&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1&#160;million and $41.3&#160;million, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Effective</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU 2021-08, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. This new standard is effective for our interim and annual periods beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the adoption impacts on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonrecurring Fair Value Measurements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Fair Value Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfOffsetPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of Offset, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfOffsetPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -URI https://asc.fasb.org/subtopic&amp;trid=2560295<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123028742864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restricted Cash And Cash Equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral for letters of credit for facility leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,269&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collateral with financial institutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims processing services </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current restricted cash and restricted investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,057&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,685&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-current restricted cash and restricted investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,005&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,755&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the nine months ended September 30, 2021. See Note 5.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash And Cash Equivalents</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash and restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,755&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the nine months ended September 30, 2021. See Note 5.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) as of September&#160;30, 2022 and December&#160;31, 2021 are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,753&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,623&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378,396&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,212&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,814&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451,398&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,376&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,592&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123032995808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Allocation of Purchase Price</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Net Assets Acquired</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,663&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,393&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,184&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,818&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,663&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.428%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Class A common stock issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tangible assets acquired:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,373&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable intangible assets acquired:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable intangible assets acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123032990336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Discontinued Operations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of operations of the Company&#8217;s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2021:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.291%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine <br/>Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform and operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(930)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes and non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.427%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.291%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(326)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(521)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million for the nine months ended September 30, 2021.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Selling, general and administrative expenses include intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million for the nine months ended September 30, 2021.</span></div>Cash flows related to the True Health business during the nine months ended September 30, 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"><tr><td style="width:1.0%"/><td style="width:89.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,002&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,494)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123029324736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents Evolent&#8217;s revenue disaggregated by segment and end-market for (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:114.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,054&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,857&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,850&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,335&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,463&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,328&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,857&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,257&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,614&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,521&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,557&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,060&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,042&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Contract with Customer, Asset and Liability</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of September&#160;30, 2022 and December 31, 2021 (in thousands):</span></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185,590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term receivables </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Excludes pharmacy claims receivable and premiums receivable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in deferred revenue for the nine months ended September 30, 2022 are as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:102.25pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning-of-period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reclassification to revenue, as a result of performance obligations satisfied</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,445)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash received in advance of satisfaction of performance obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,773&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033125664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossAbstract', window );"><strong>Credit Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock', window );">Schedule of Changes in Allowance for Accounts Receivable</a></td>
<td class="text">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,374)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,056)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPG acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for credit losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,134)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,949)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge-offs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,355)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,929)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Charge offs for the nine months ended September 30, 2021, are due to balances written-off that were previously fully reserved as part of the Passport transaction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033165760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our property and equipment (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer hardware</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,970&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal-use software development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,463&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(141,707)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,645&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,365&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033003600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.705%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.772%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,334&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,297&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill acquired</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296,597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,230&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508,560&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,790&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of September 30, 2021</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,335&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,675&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349,010&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Net of cumulative inception to date impairment of $575.5 million as of both December 31, 2021 and 2020.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Goodwill acquired from the addition of IPG in the third quarter of 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets Details</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes the estimated useful lives by asset classification:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:438.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:97.75pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 20 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 - 25 years</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 - 5 years</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of our intangible assets (in thousands, except weighted-average useful lives) as of September&#160;30, 2022 and December&#160;31, 2021 are presented below:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:72.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:46.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:45.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:44pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted- Average Remaining Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Carrying Value</span></td></tr><tr style="height:24pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate trade name</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,753&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">465,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,623&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378,396&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,019&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,322&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below market lease, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,218&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provider network contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,553&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,596&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,874&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638,212&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,814&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451,398&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442,376&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,592&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279,784&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Estimated Amortization of Intangible Assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future estimated amortization of intangible assets (in thousands) as of September&#160;30, 2022, is as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:478.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,487&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,057&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,751&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future amortization of intangible assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451,398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033165760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Convertible Debt</a></td>
<td class="text">The following table summarizes the carrying value of the long-term convertible debt as of September&#160;30, 2022 and December 31, 2021 (in thousands):<div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,281&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,051&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt discount and issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining amortization period (years)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,625&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177,251&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Fair values for notes are derived from available trading prices closest to the respective balance sheet date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123030582208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Major Customers</a></td>
<td class="text">The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable, as of September&#160;30, 2022 and December&#160;31, 2021:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:354.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:88.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals System</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.4%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bright Health Management, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three and nine months ended September 30, 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:327.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cook County Health and Hospitals Systems</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida Blue Medicare, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123028512032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Primary Office Leases and Maturity of Lease Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our primary office leases as of September&#160;30, 2022 (in thousands, other than term):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:237.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:94.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease Termination Term (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Future Minimum Lease Commitments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Letter of Credit Amount Required</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arlington, VA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,579&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Riverside, IL </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Edison, NJ</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpharetta, GA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pune, India</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brea, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of lease liabilities (in thousands) as of September&#160;30, 2022, is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating lease expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,756&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,893&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Expense, Weighted-Average Discount Rate and Weighted-remaining Lease Terms</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of our lease expense (in thousands): </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,599&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,096&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,696&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,822&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,368&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123017444288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,040)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,352)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33,337)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,040)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,815)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,954)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental diluted shares from stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incremental diluted shares from Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,306&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (loss) per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic income (loss) per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted net earnings per common share, if any, gives effect to diluted stock options (calculated based on the treasury stock method), shares issuable upon debt conversion (calculated using an as-if converted method).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,012&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,007&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,712&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,390&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,404&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123030515376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Award Type</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:288.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:58.00pt"/><td style="width:1.0pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by award type</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,992&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,395&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,350&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,754&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Line Item</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,024&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,364&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total compensation expense by financial statement line item</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,992&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,395&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,350&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,754&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of Share-Based Awards Granted</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based awards were granted as follows (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:327.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123032303504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Assets and Liabilities on Recurring Basis</a></td>
<td class="text">The following table summarizes the Company&#8217;s assets and liabilities measured at fair value on a recurring basis (in thousands): <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.594%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:325.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total fair value of liabilities measured on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents the fair value of earn-out consideration related to the IPG and Vital transactions as described in Note 4.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Contingent Consideration Measured at Fair Value</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,700&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Valuation Techniques and Significant Unobservable Inputs</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.821%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Valuation</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assumption or</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Input Ranges</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Real options approach</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-neutral expected earnout consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,935&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123029802944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Parties</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents assets and liabilities attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.872%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other noncurrent assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for claims and performance-based arrangements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenues and expenses attributable to our related parties (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:319.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:54.25pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,195&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue (exclusive of depreciation and amortization expenses)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,121&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123030575808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Repositioning and Other Changes (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule of Costs Associated with the Repositioning Plan</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of our total costs associated with the Repositioning Plan by major type of cost (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.207%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cumulative Costs Incurred through December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incurred For the Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and termination benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office space consolidation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,593&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,043&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123034205424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock', window );">Schedule of Revenue from Segments to Consolidated</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present our segment information (in thousands):</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352,585&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,315&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,614&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(458)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,507&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,303&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,353)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,530&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,765)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,765&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:145.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:52.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:60.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:61.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:67.00pt"/><td style="width:1.0pt"/></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intersegment<br/>Eliminations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(626)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223,924&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,031&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,356)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">659,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:33pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Evolent Health Services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,854&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,988&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,793)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,120&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,456&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,558)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,018&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Reconciliation of Adjusted EBITDA to Net Loss</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. (in thousands): </span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:327.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income (loss) attributable to common shareholders of Evolent Health, Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,040)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,815)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,954)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,754)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,367)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,978)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from (provision for) income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(936)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax receivable agreement liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,870)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,870)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,196)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,962)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on transfer of membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment/repayment of debt, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from equity method investees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(345)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repositioning costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,043)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,992)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,395)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,754)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(996)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of contract cost assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(433)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strategy and shareholder advisory expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,513)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,207)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,473)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,277)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain (loss) from discontinued operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,055&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,765&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,049&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,018&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt">Includes $(0.5)&#160;million loss on disposal of discontinued operations for the nine months ended September 30, 2022 and $1.9&#160;million gain on disposal of discontinued operations for the nine months ended September 30, 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033254080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Schedule of Activity in Claims Reserves</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity in reserves for claims and performance-based arrangements was as follows (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"><tr><td style="width:1.0pt"/><td style="width:226.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:37.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:41.50pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:57.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:3.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:40.00pt"/><td style="width:1.0pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EHS </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Clinical Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Incurred health care costs:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year to date period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year to date period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims incurred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,714)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,149&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,747&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year to date period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(369,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,801)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229,315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(250,116)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior year to date period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,846)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,390)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,236)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,406)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,580)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total claims paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,846)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(488,098)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(498,944)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,975)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(330,721)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(370,696)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,058&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,640&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,698&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,469&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,409&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,878&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt">Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033153632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental Cash Flow Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Cash Flow, Supplemental Disclosures</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents supplemental cash flow information (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"><tr><td style="width:1.0pt"/><td style="width:433.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:48.25pt"/><td style="width:1.0pt"/></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosure of Non-cash Investing and Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued property and equipment purchases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued in connection with business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class A common stock issued in connection with debt repayment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued net working capital adjustment with business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effects of Leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Operating cash flows from operating leases </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Leased assets disposed of (obtained in) exchange for operating lease liabilities </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental Disclosures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,269)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,771)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(955)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(734)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123034213776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 156,756<span></span>
</td>
<td class="nump">$ 266,280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123029889776">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Current restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 25,057<span></span>
</td>
<td class="nump">75,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsCurrent', window );">Total current restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,057<span></span>
</td>
<td class="nump">75,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Non-current restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,005<span></span>
</td>
<td class="nump">12,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent', window );">Total non-current restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,005<span></span>
</td>
<td class="nump">12,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">156,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 252,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndInvestments', window );">Restricted cash and restricted investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">194,818<span></span>
</td>
<td class="nump">354,942<span></span>
</td>
<td class="nump">$ 281,755<span></span>
</td>
<td class="nump">$ 361,581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember', window );">Collateral for letters of credit for facility leases</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,269<span></span>
</td>
<td class="nump">3,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember', window );">Collateral with financial institutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,873<span></span>
</td>
<td class="nump">11,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember', window );">Claims processing services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,904<span></span>
</td>
<td class="nump">73,226<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforOtherContractualCommitmentsMember', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the nine months ended September 30, 2021. See Note 5.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforLettersofCreditforFacilityLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforBenefitManagementServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforOtherContractualCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_RestrictedCashforOtherContractualCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123024408720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>source </div>
<div>reporting_unit </div>
<div>option_to_renew_lease</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="nump">$ 11.7<span></span>
</td>
<td class="nump">$ 11.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable', window );">Accounts receivable netted against claims payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement', window );">Accounts receivable, net eligible for net basis settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_NumberOfOptionsToRenewLeases', window );">Number of leases option | option_to_renew_lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_NumberOfSourcesOfRevenue', window );">Number of sources of revenue | source</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_NumberOfOptionsToRenewLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Options To Renew Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_NumberOfOptionsToRenewLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_NumberOfSourcesOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Sources Of Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_NumberOfSourcesOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123023781152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123025727808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Recently Issued Accounting Standards (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="nump">$ 856,138<span></span>
</td>
<td class="nump">$ 613,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 693,633<span></span>
</td>
<td class="nump">$ 607,484<span></span>
</td>
<td class="nump">$ 614,190<span></span>
</td>
<td class="nump">$ 619,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member', window );">2025 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,383)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="num">(594,805)<span></span>
</td>
<td class="num">(596,928)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(626,779)<span></span>
</td>
<td class="num">(621,132)<span></span>
</td>
<td class="num">(608,092)<span></span>
</td>
<td class="num">(589,178)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="nump">$ 1,472,098<span></span>
</td>
<td class="nump">$ 1,231,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,340,989<span></span>
</td>
<td class="nump">$ 1,249,228<span></span>
</td>
<td class="nump">$ 1,242,900<span></span>
</td>
<td class="nump">$ 1,229,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (106,172)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 | Cumulative Effect, Period of Adoption, Adjustment | 2024 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 | Cumulative Effect, Period of Adoption, Adjustment | 2025 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 | Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 | Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | 2024 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 | Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | 2025 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06 | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123024000960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions - Narrative (Details) - USD ($)<br> $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,021<span></span>
</td>
<td class="nump">$ 1,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (45,516)<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
<td class="num">$ (44,498)<span></span>
</td>
<td class="nump">$ 936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting interests acquired</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="nump">$ 461,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="nump">$ 256,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued or issuable, number of shares (in shares)</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of Class A common stock issued</a></td>
<td class="nump">$ 130,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration arrangements (up to)</a></td>
<td class="nump">87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill, expected tax deductible amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG | Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG | Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Voting interests acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Equity interest issued or issuable, number of shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of Class A common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Contingent consideration arrangements (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill, expected tax deductible amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123025147392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions - Allocation of Acquisition Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2022</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,021<span></span>
</td>
<td class="nump">$ 1,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 722,790<span></span>
</td>
<td class="nump">$ 349,010<span></span>
</td>
<td class="nump">$ 426,297<span></span>
</td>
<td class="nump">$ 349,029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="nump">$ 256,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of Class A common stock issued</a></td>
<td class="nump">130,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Fair value of contingent consideration</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="nump">461,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Tangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="nump">34,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">1,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets', window );">Total tangible assets acquired</a></td>
<td class="nump">36,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">195,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">7,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">8,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="nump">48,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation', window );">Operating lease liabilities</a></td>
<td class="nump">1,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="nump">66,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">296,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">461,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG | Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">23,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember', window );">IPG | Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 17,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract', window );"><strong>Purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of Class A common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Tangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets', window );">Total tangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits', window );">Accrued compensation and employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember', window );">Vital Decisions | Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract', window );"><strong>Identifiable intangible assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease obligation assumed in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_ImplantableProviderGroupIMPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=evh_VitalDecisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123025499808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Summary of Results of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (463)<span></span>
</td>
<td class="nump">$ 1,383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense', window );">Claims expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations', window );">Depreciation and amortization expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,763<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(930)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Other loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Loss before income taxes and non-controlling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(847)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(326)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(521)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health | Platform and operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health | Premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember', window );">Discontinued Operations, Disposed of by Sale | True Health | Services Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Claims Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortizationDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=26872618&amp;loc=d3e7436-122677<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1063-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1060-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PlatformsAndOperationsServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_PremiumsRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_PremiumsRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=evh_ServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=evh_ServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033081344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations - Summary of Cash Flows (Details) - True Health - Discontinued Operations, Disposed of by Sale<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations', window );">Cash flows provided by operating activities</a></td>
<td class="nump">$ 5,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations', window );">Cash flows used in investing activities</a></td>
<td class="num">$ (2,494)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=evh_TrueHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123030709440">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 352,585<span></span>
</td>
<td class="nump">$ 222,471<span></span>
</td>
<td class="nump">$ 969,581<span></span>
</td>
<td class="nump">$ 659,599<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">107,328<span></span>
</td>
<td class="nump">62,857<span></span>
</td>
<td class="nump">306,521<span></span>
</td>
<td class="nump">222,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services | Medicaid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">60,054<span></span>
</td>
<td class="nump">41,857<span></span>
</td>
<td class="nump">183,542<span></span>
</td>
<td class="nump">154,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services | Medicare</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,335<span></span>
</td>
<td class="nump">4,816<span></span>
</td>
<td class="nump">21,031<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services | Commercial and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,939<span></span>
</td>
<td class="nump">16,184<span></span>
</td>
<td class="nump">101,948<span></span>
</td>
<td class="nump">48,207<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">245,257<span></span>
</td>
<td class="nump">159,614<span></span>
</td>
<td class="nump">663,060<span></span>
</td>
<td class="nump">437,042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions | Medicaid</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">79,664<span></span>
</td>
<td class="nump">51,829<span></span>
</td>
<td class="nump">226,684<span></span>
</td>
<td class="nump">148,816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions | Medicare</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">111,632<span></span>
</td>
<td class="nump">105,219<span></span>
</td>
<td class="nump">315,334<span></span>
</td>
<td class="nump">281,763<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions | Commercial and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 53,961<span></span>
</td>
<td class="nump">$ 2,566<span></span>
</td>
<td class="nump">$ 121,042<span></span>
</td>
<td class="nump">$ 6,463<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_MedicaidCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_MedicaidCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_MedicareCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_MedicareCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_CommercialAndOtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_CommercialAndOtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123023782368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance obligation</a></td>
<td class="nump">$ 69.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | December 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Remaining performance obligation, percentage</a></td>
<td class="nump">37.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | December 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Remaining performance obligation, percentage</a></td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">15 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-01 | December 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Remaining performance obligation, percentage</a></td>
<td class="nump">98.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">27 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-10-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis=evh_December312022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis=evh_December312022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis=evh_December312023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis=evh_December312023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis=evh_December312024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis=evh_December312024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123116421872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Contract Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent', window );">Short-term receivables</a></td>
<td class="nump">$ 185,590<span></span>
</td>
<td class="nump">$ 185,590<span></span>
</td>
<td class="nump">$ 129,012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent', window );">Long-term receivables</a></td>
<td class="nump">884<span></span>
</td>
<td class="nump">884<span></span>
</td>
<td class="nump">4,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Short-term deferred revenue</a></td>
<td class="nump">7,524<span></span>
</td>
<td class="nump">7,524<span></span>
</td>
<td class="nump">11,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term deferred revenue</a></td>
<td class="nump">3,185<span></span>
</td>
<td class="nump">3,185<span></span>
</td>
<td class="nump">$ 4,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance as of beginning-of-period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Reclassification to revenue, as a result of performance obligations satisfied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,445)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations', window );">Cash received in advance of satisfaction of performance obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance as of end of period</a></td>
<td class="nump">10,709<span></span>
</td>
<td class="nump">10,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenue recognized from performed obligations</a></td>
<td class="nump">$ 10,400<span></span>
</td>
<td class="nump">$ 56,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ChangeInContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ChangeInContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of accounts and financing receivables, classified as noncurrent. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123023690416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Contract Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,768<span></span>
</td>
<td class="nump">$ 9,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortizationPeriod', window );">Amortization period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember', window );">Bonuses and Commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember', window );">Contract Fulfillment Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Contract Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Contract cost assets</a></td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Contract cost amortization</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 12,800<span></span>
</td>
<td class="nump">$ 8,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131251-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905575&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAxis=evh_BonusesAndCommissionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAxis=evh_ContractFulfillmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123029190528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Losses - Accounts Receivable (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_FinancingReceivablePercentNotPastDue', window );">Percentage of receivables, current</a></td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">$ 201,500<span></span>
</td>
<td class="nump">$ 171,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts, current</a></td>
<td class="nump">$ 9,355<span></span>
</td>
<td class="nump">$ 3,374<span></span>
</td>
<td class="nump">$ 3,929<span></span>
</td>
<td class="nump">$ 7,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember', window );">Past due less than 60 days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablePercentPastDue1', window );">Percentage of receivables, past due</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember', window );">Past due less than 120 days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems', window );"><strong>Accounts Receivable, Noncurrent, Past Due [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivablePercentPastDue1', window );">Percentage of receivables, past due</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_FinancingReceivablePercentNotPastDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Percent Not Past Due</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_FinancingReceivablePercentNotPastDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126942793&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNoncurrentPastDueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNoncurrentPastDueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablePercentPastDue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of financing receivable balance that is past due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablePercentPastDue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan60DaysMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivablesPeriodPastDueAxis=evh_FInancialAssetLessThan120DaysPastDueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123034065664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward', window );"><strong>Accounts Receivable, Allowance for Credit Loss [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Balance as of beginning of period</a></td>
<td class="num">$ (3,374)<span></span>
</td>
<td class="num">$ (7,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod', window );">IPG acquisition</a></td>
<td class="num">(5,269)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for credit losses</a></td>
<td class="num">(1,134)<span></span>
</td>
<td class="num">(1,949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs', window );">Charge-offs</a></td>
<td class="nump">422<span></span>
</td>
<td class="nump">5,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Balance as of end of period</a></td>
<td class="num">$ (9,355)<span></span>
</td>
<td class="num">$ (3,929)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance for Credit Loss, Acquired During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct write-downs of accounts receivable charged against the allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123023911472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 236,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 236,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization expenses</a></td>
<td class="num">(141,707)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141,707)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119,098)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">94,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">7,700<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="nump">23,100<span></span>
</td>
<td class="nump">$ 22,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAmortization1', window );">Capitalized computer software, amortization</a></td>
<td class="nump">6,400<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">19,600<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">27,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">4,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Internal-use software development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">181,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,587<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAdditions', window );">Capitalized computer software additions</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="nump">21,500<span></span>
</td>
<td class="nump">$ 16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 23,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,325<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additions made to capitalized computer software costs during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for amortization of capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128487-111756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123029122400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Impairment Testing (Details) - reporting_unit<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123023655168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>reporting_unit</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | reporting_unit</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 349,010<span></span>
</td>
<td class="nump">$ 426,297<span></span>
</td>
<td class="nump">$ 349,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722,790<span></span>
</td>
<td class="nump">349,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Cumulative inception to date impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575,500<span></span>
</td>
<td class="nump">$ 575,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of beginning of period</a></td>
<td class="nump">214,335<span></span>
</td>
<td class="nump">214,334<span></span>
</td>
<td class="nump">214,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,230<span></span>
</td>
<td class="nump">214,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 134,675<span></span>
</td>
<td class="nump">211,963<span></span>
</td>
<td class="nump">134,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">296,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance as of end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 508,560<span></span>
</td>
<td class="nump">$ 134,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123024962336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 638,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 638,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 442,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">186,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,592<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">451,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">9,500<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="nump">$ 24,300<span></span>
</td>
<td class="nump">$ 22,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Corporate trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">43,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">9,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,693<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">33,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">465,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 311,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">86,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,697<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">378,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 378,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">111,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">78,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,378<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">33,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember', window );">Below market lease, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">1,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">950<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember', window );">Provider network contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted- Average Remaining Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">16,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">10,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,874<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 5,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,543<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=evh_BelowMarketLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123028757936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 10,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">40,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">34,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">33,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">32,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">299,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total future amortization of intangible assets</a></td>
<td class="nump">$ 451,398<span></span>
</td>
<td class="nump">$ 279,784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123025634000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2022 Credit Agreement (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 01, 2022 </div>
<div>USD ($) </div>
<div>day</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long term debt, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219,740<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | 2022 Credit Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of the debt discount and the issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity', window );">Number of days prior to any junior debt maturity | day</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Line of Credit | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long term debt, net of offering costs</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=evh_A2022CreditFacilitiesMember', window );">2022 Credit Facilities | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent', window );">Prepayment penalty prior to first anniversary of closing date (in percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent', window );">Prepayment penalty after first anniversary of closing date but prior to second anniversary of closing date (in percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent', window );">Prepayment penalty after second anniversary of closing date but prior to third anniversary of closing date (in percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent', window );">Prepayment penalty on or after third anniversary of closing date (in percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Period Four, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Period One, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Period Three, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Penalty, Period Two, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_A2022CreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_A2022CreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=evh_SecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=evh_SecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=evh_A2022CreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=evh_A2022CreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123020285024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2024 Notes (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 18, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 11, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (856,138,000)<span></span>
</td>
<td class="num">$ (607,484,000)<span></span>
</td>
<td class="num">$ (856,138,000)<span></span>
</td>
<td class="num">$ (607,484,000)<span></span>
</td>
<td class="num">$ (613,088,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (693,633,000)<span></span>
</td>
<td class="num">$ (614,190,000)<span></span>
</td>
<td class="num">$ (619,600,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,762,000<span></span>
</td>
<td class="nump">13,399,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment/repayment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,192,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,192,000)<span></span>
</td>
<td class="num">(19,158,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,012,000)<span></span>
</td>
<td class="num">(874,000)<span></span>
</td>
<td class="num">(1,012,000)<span></span>
</td>
<td class="num">(874,000)<span></span>
</td>
<td class="num">(916,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(908,000)<span></span>
</td>
<td class="num">(872,000)<span></span>
</td>
<td class="num">(859,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,472,098,000)<span></span>
</td>
<td class="num">(1,249,228,000)<span></span>
</td>
<td class="num">(1,472,098,000)<span></span>
</td>
<td class="num">(1,249,228,000)<span></span>
</td>
<td class="num">(1,231,005,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,340,989,000)<span></span>
</td>
<td class="num">(1,242,900,000)<span></span>
</td>
<td class="num">(1,229,320,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (106,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">594,805,000<span></span>
</td>
<td class="nump">621,132,000<span></span>
</td>
<td class="nump">594,805,000<span></span>
</td>
<td class="nump">621,132,000<span></span>
</td>
<td class="nump">$ 596,928,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">626,779,000<span></span>
</td>
<td class="nump">$ 608,092,000<span></span>
</td>
<td class="nump">$ 589,178,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,789,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Initial conversion amount (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtIssuanceCostsNetDebtComponent', window );">Debt issuance costs, net, debt component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount', window );">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice', window );">Repurchase covenant, sale price as a percentage of conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum', window );">Repurchase covenant, trading days, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum', window );">Consecutive trading days, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice', window );">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment/repayment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Common Stock | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate per $ 1000 principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0548667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Equity Component of Long Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Deferred Financing Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member', window );">2024 Notes | Senior Notes | Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member', window );">2021 Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt conversion, original debt, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,800,000<span></span>
</td>
<td class="nump">26,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion issued (in share) | shares</a></td>
<td class="nump">5,394,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_NewNotesMember', window );">New Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtIssuanceCostsNetDebtComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs, Net, Debt Component</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtIssuanceCostsNetDebtComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=evh_EquityComponentOfLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=evh_EquityComponentOfLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=evh_DeferredFinancingFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=evh_DeferredFinancingFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_NewNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_NewNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123025040288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2019 Credit Agreement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 08, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,269<span></span>
</td>
<td class="nump">$ 3,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment/repayment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,192)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (10,192)<span></span>
</td>
<td class="num">$ (19,158)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_InitialTermLoanFacilityMember', window );">Initial Term Loan Facility | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember', window );">Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment/repayment of debt</a></td>
<td class="nump">$ 19,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Unamortized debt issuance cost</a></td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal expenses</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember', window );">Credit Agreement | Line of Credit | DDTL Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember', window );">Senior Credit Facilities | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayments of long-term lines of credit</a></td>
<td class="nump">98,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_PaymentsOfMakeWholePremium', window );">Payments of make-whole premium</a></td>
<td class="nump">9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_PaymentsOfMakeWholePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Of Make-Whole Premium</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_PaymentsOfMakeWholePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_InitialTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_InitialTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=evh_DelayedDrawTermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=evh_DelayedDrawTermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123028542144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-term Debt - Warrant Agreement (Details) - Class A Common Stock - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Jan. 08, 2021</div></th>
<th class="th"><div>Dec. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightUnissued', window );">Warrants agreed to be sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,513,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants or rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement', window );">Period during which warrants or rights exercisable, after maturity of credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Payments to settle outstanding warrants</a></td>
<td class="nump">$ 13.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123019064464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2025 Notes (Details)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 24, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 22, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (856,138,000)<span></span>
</td>
<td class="num">$ (607,484,000)<span></span>
</td>
<td class="num">$ (856,138,000)<span></span>
</td>
<td class="num">$ (607,484,000)<span></span>
</td>
<td class="num">$ (613,088,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (693,633,000)<span></span>
</td>
<td class="num">$ (614,190,000)<span></span>
</td>
<td class="num">$ (619,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,762,000<span></span>
</td>
<td class="nump">13,399,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember', window );">Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,012,000)<span></span>
</td>
<td class="num">(874,000)<span></span>
</td>
<td class="num">(1,012,000)<span></span>
</td>
<td class="num">(874,000)<span></span>
</td>
<td class="num">(916,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(908,000)<span></span>
</td>
<td class="num">(872,000)<span></span>
</td>
<td class="num">(859,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,472,098,000)<span></span>
</td>
<td class="num">(1,249,228,000)<span></span>
</td>
<td class="num">(1,472,098,000)<span></span>
</td>
<td class="num">(1,249,228,000)<span></span>
</td>
<td class="num">(1,231,005,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,340,989,000)<span></span>
</td>
<td class="num">(1,242,900,000)<span></span>
</td>
<td class="num">(1,229,320,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (106,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">594,805,000<span></span>
</td>
<td class="nump">621,132,000<span></span>
</td>
<td class="nump">594,805,000<span></span>
</td>
<td class="nump">621,132,000<span></span>
</td>
<td class="nump">$ 596,928,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">626,779,000<span></span>
</td>
<td class="nump">$ 608,092,000<span></span>
</td>
<td class="nump">$ 589,178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,789,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="nump">172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 33.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Initial conversion amount (in shares) | shares</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying amount</a></td>
<td class="nump">$ 100,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">166,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount', window );">Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice', window );">Repurchase covenant, sale price as a percentage of conversion price (at least)</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum', window );">Repurchase covenant, trading days, minimum</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum', window );">Consecutive trading days, minimum</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice', window );">Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="nump">$ 71,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Common Stock | Class A Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Initial conversion rate per $ 1000 principal amount</a></td>
<td class="nump">0.0299135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Equity Component of Long Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Additional Paid-In Capital | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06 | Deferred Financing Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 2025 Notes | Retained Earnings (Accumulated Deficit) | Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Covenant, Trading Days, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=evh_EquityComponentOfLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=evh_EquityComponentOfLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=evh_DeferredFinancingFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=evh_DeferredFinancingFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123017535504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - 2021 Notes (Details) - Senior Notes - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2022</div></th>
<th class="th"><div>Dec. 01, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost', window );">Net loss on extinguishment of debt, including fees paid to lenders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2021 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt conversion, original debt, amount</a></td>
<td class="nump">$ 92,800,000<span></span>
</td>
<td class="nump">26,300,000<span></span>
</td>
<td class="nump">84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Face amount of debt repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of senior debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 117,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,281,000<span></span>
</td>
<td class="nump">$ 117,051,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Debt conversion, converted instrument, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_ConvertibleSeniorNotesdue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123028806208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-term Debt - Convertible Senior Notes Carrying Value (Details) - Senior Notes - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Oct. 24, 2018</div></th>
<th class="th"><div>Oct. 22, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible Debt, Total</a></td>
<td class="nump">$ 23,879,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,361,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="nump">402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 24,281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,051,000<span></span>
</td>
<td class="nump">$ 117,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization period (years)</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2024 Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value</a></td>
<td class="nump">$ 49,290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible Debt, Total</a></td>
<td class="nump">168,565,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,315,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="nump">3,935,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,500,000<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Remaining amortization period (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">2025 Notes | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value</a></td>
<td class="nump">$ 215,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177,251,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=evh_SeniorConvertibleNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123025046208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 02, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and restricted investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_LineOfCreditFacilityAutomaticExtensionPeriod', window );">Automatic extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension', window );">Automatic extension after each period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid', window );">Percent of tax savings to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TaxReceivableAgreementLiability', window );">Tax receivable agreement liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,870<span></span>
</td>
<td class="nump">$ 42,870<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=evh_UPMCResellerAgreementMember', window );">UPMC Reseller Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_NumberOfCustomers', window );">Number of customers | customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=evh_ShareholderClassActionComplaintMember', window );">Shareholder Class Action Complaint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement payment</a></td>
<td class="nump">$ 23,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember', window );">Collateral with financial institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and restricted investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,873<span></span>
</td>
<td class="nump">10,873<span></span>
</td>
<td class="nump">11,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,100<span></span>
</td>
<td class="nump">13,100<span></span>
</td>
<td class="nump">15,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Line of Credit | Collateral with financial institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems', window );"><strong>Restricted Cash and Cash Equivalents Items [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and restricted investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,100<span></span>
</td>
<td class="nump">$ 13,100<span></span>
</td>
<td class="nump">$ 15,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_LineOfCreditFacilityAutomaticExtensionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Automatic Extension Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_LineOfCreditFacilityAutomaticExtensionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Period Before Each Automatic Extension</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Customers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivableAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Receivable Agreement Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivableAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Receivables Agreement, Percent of Tax Savings To Be Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=evh_UPMCResellerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=evh_UPMCResellerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=evh_ShareholderClassActionComplaintMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=evh_ShareholderClassActionComplaintMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=evh_CollateralwithFinancialInstitutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123017476768">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Concentration Risk (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_CashFDICInsuredAmountPercentage', window );">Percentage of cash and cash equivalents held with FDIC participating bank</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">98.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents (including restricted cash)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 194,818<span></span>
</td>
<td class="nump">$ 281,755<span></span>
</td>
<td class="nump">$ 194,818<span></span>
</td>
<td class="nump">$ 281,755<span></span>
</td>
<td class="nump">$ 354,942<span></span>
</td>
<td class="nump">$ 361,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_CashHeldInInternationalBanksPercentage', window );">Percentage of cash held in international banks (less than)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember', window );">Cook County Health and Hospitals System | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember', window );">Cook County Health and Hospitals System | Customer Concentration Risk | Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21.20%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember', window );">Florida Blue Medicare, Inc. | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember', window );">Florida Blue Medicare, Inc. | Customer Concentration Risk | Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13.70%<span></span>
</td>
<td class="nump">13.80%<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="nump">14.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_MolinaHealthcareMember', window );">Molina Healthcare | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=evh_BrightHealthManagementIncMember', window );">Bright Health Management, Inc. | Customer Concentration Risk | Accounts Receivable | Trade Accounts Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (in percent)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#8217;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the nine months ended September 30, 2021. See Note 5.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashFDICInsuredAmountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, FDIC Insured Amount, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashFDICInsuredAmountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashHeldInInternationalBanksPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Held In International Banks, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashHeldInInternationalBanksPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_CookCountyHealthAndHospitalsSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_FloridaBlueMedicareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_MolinaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_MolinaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=evh_BrightHealthManagementIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=evh_BrightHealthManagementIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123025818272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>option_to_renew_lease</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_NumberOfOptionsToRenewLeases', window );">Number of leases option | option_to_renew_lease</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and restricted investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember', window );">Lease Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding, amount</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and restricted investments</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_NumberOfOptionsToRenewLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Options To Renew Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_NumberOfOptionsToRenewLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123025864880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Primary Office Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 83,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_VA', window );">Arlington, VA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 33,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 1,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_IL', window );">Riverside, IL</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 38,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NJ', window );">Edison, NJ</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 1,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IN', window );">Pune, India</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">Brea, CA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 4,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_GA', window );">GEORGIA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease Termination Term (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Future Minimum Lease Commitments</a></td>
<td class="nump">$ 1,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of Credit Amount Required</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_VA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_VA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_GA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_GA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123029928448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2,221<span></span>
</td>
<td class="nump">$ 2,417<span></span>
</td>
<td class="nump">$ 6,726<span></span>
</td>
<td class="nump">$ 9,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,599<span></span>
</td>
<td class="nump">1,183<span></span>
</td>
<td class="nump">4,096<span></span>
</td>
<td class="nump">3,696<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 3,820<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 10,822<span></span>
</td>
<td class="nump">$ 13,368<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123031941696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturity of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2022</a></td>
<td class="nump">$ 2,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">10,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">10,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">10,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">8,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">40,377<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">83,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Interest</a></td>
<td class="nump">18,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 64,893<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033318976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">6.34%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123029822560">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Common Share - Computation of Earnings per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Income (loss) from continuing operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,123<span></span>
</td>
<td class="num">$ (13,040)<span></span>
</td>
<td class="num">$ (7,352)<span></span>
</td>
<td class="num">$ (33,337)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Income (loss) from discontinued operations, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(463)<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) attributable to common shareholders of Evolent Health, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,123<span></span>
</td>
<td class="num">(13,040)<span></span>
</td>
<td class="num">(7,815)<span></span>
</td>
<td class="num">(31,954)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) attributable to common shareholders of Evolent Health, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,123<span></span>
</td>
<td class="num">$ (13,040)<span></span>
</td>
<td class="num">$ (7,815)<span></span>
</td>
<td class="num">$ (31,954)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">95,286<span></span>
</td>
<td class="nump">85,800<span></span>
</td>
<td class="nump">91,643<span></span>
</td>
<td class="nump">85,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards', window );">Incremental diluted shares from stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,915<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Incremental diluted shares from Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,107<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Convertible notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">99,308<span></span>
</td>
<td class="nump">85,800<span></span>
</td>
<td class="nump">91,643<span></span>
</td>
<td class="nump">85,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations, basic (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic income (loss) per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.02<span></span>
</td>
<td class="num">(0.15)<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
<td class="num">(0.37)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.02<span></span>
</td>
<td class="num">(0.15)<span></span>
</td>
<td class="num">(0.08)<span></span>
</td>
<td class="num">(0.39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations, diluted (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.01)<span></span>
</td>
<td class="nump">0.02<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.02<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.09)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Includes $(0.5)&#160;million loss on disposal of discontinued operations for the nine months ended September 30, 2022 and $1.9&#160;million gain on disposal of discontinued operations for the nine months ended September 30, 2021, respectively</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental Common Shares Attributable to Dilutive Effect Of Stock Options Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613673-111683<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868656-224227<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=120398118&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2029-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123017549952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income (Loss) Per Common Share - Antidilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share</a></td>
<td class="nump">9,007<span></span>
</td>
<td class="nump">16,712<span></span>
</td>
<td class="nump">14,390<span></span>
</td>
<td class="nump">16,404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember', window );">Restricted stock units ("RSUs"), performance-based RSUs (&#8220;PSUs&#8221;) and leveraged stock units ("LSUs")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,012<span></span>
</td>
<td class="nump">1,818<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,004<span></span>
</td>
<td class="nump">1,858<span></span>
</td>
<td class="nump">2,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Number of antidilutive securities excluded from the calculation of earning per share</a></td>
<td class="nump">9,007<span></span>
</td>
<td class="nump">12,696<span></span>
</td>
<td class="nump">10,714<span></span>
</td>
<td class="nump">12,696<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123029821856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 6,992<span></span>
</td>
<td class="nump">$ 4,395<span></span>
</td>
<td class="nump">$ 19,350<span></span>
</td>
<td class="nump">$ 11,754<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">2,986<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">5,968<span></span>
</td>
<td class="nump">4,264<span></span>
</td>
<td class="nump">16,364<span></span>
</td>
<td class="nump">10,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="nump">945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">4,830<span></span>
</td>
<td class="nump">2,381<span></span>
</td>
<td class="nump">12,778<span></span>
</td>
<td class="nump">6,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember', window );">LSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">387<span></span>
</td>
<td class="nump">995<span></span>
</td>
<td class="nump">1,544<span></span>
</td>
<td class="nump">2,302<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 1,697<span></span>
</td>
<td class="nump">$ 745<span></span>
</td>
<td class="nump">$ 4,697<span></span>
</td>
<td class="nump">$ 1,725<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_LeveragedStockUnitsLSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033156752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation capitalized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123034082944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Share-based Awards Granted (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">1,067<span></span>
</td>
<td class="nump">1,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="nump">319<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=evh_PerformanceBasedRestrictedStockUnitsPSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123023869792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="num">$ (45,516)<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
<td class="num">$ (44,498)<span></span>
</td>
<td class="nump">$ 936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">104.90%<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
<td class="nump">85.80%<span></span>
</td>
<td class="num">(2.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Reduction of valuation allowance</a></td>
<td class="nump">$ 46,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders', window );">Amount of tax benefit percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Receivable Agreement, Percent Of Cash Savings Paid To Shareholders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123023639408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Equity Method Investees (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="nump">$ 1,392<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="nump">$ 3,940<span></span>
</td>
<td class="nump">$ 12,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember', window );">Equity Method Investee | Services Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement', window );">Revenue related to services agreements</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 12,500<span></span>
</td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EquityMethodInvestmentEconomicInterestPercentage', window );">Economic interest percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EquityMethodInvestmentVotingInterestPercentage', window );">Voting interest percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EquityMethodInvestmentEconomicInterestPercentage', window );">Economic interest percentage</a></td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_EquityMethodInvestmentVotingInterestPercentage', window );">Voting interest percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EquityMethodInvestmentEconomicInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Economic Interest Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EquityMethodInvestmentEconomicInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_EquityMethodInvestmentVotingInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Voting Interest Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_EquityMethodInvestmentVotingInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Equity Method Investments, Services Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_EquityMethodInvesteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=evh_ServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=evh_ServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123030728624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details) - Fair Value, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">$ 95,700<span></span>
</td>
<td class="nump">$ 28,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">95,700<span></span>
</td>
<td class="nump">28,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">95,700<span></span>
</td>
<td class="nump">28,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities measured on a recurring basis</a></td>
<td class="nump">$ 95,700<span></span>
</td>
<td class="nump">$ 28,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123034234224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Changes in Contingent Consideration and Other (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of beginning of period</a></td>
<td class="nump">$ 28,700<span></span>
</td>
<td class="nump">$ 13,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Additions</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,730)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Unrealized (gains) losses, net</a></td>
<td class="num">(8,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of end of period</a></td>
<td class="nump">$ 95,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123029856336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details) - Fair Value, Recurring<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value</a></td>
<td class="nump">$ 95,700<span></span>
</td>
<td class="nump">$ 28,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value</a></td>
<td class="nump">$ 95,700<span></span>
</td>
<td class="nump">$ 28,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Risk-neutral expected earnout consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Assumption or input ranges</a></td>
<td class="nump">95,699<span></span>
</td>
<td class="nump">30,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Assumption or input ranges</a></td>
<td class="nump">0.122<span></span>
</td>
<td class="nump">0.0604<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123029222944">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Related Parties - Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 187,633<span></span>
</td>
<td class="nump">$ 130,604<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">24,328<span></span>
</td>
<td class="nump">51,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,064<span></span>
</td>
<td class="nump">6,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">61,863<span></span>
</td>
<td class="nump">96,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">132,238<span></span>
</td>
<td class="nump">107,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,752<span></span>
</td>
<td class="nump">2,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expenses and other noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">884<span></span>
</td>
<td class="nump">4,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">432<span></span>
</td>
<td class="nump">1,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">954<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense', window );">Reserve for claims and performance-based arrangements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 734<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of policy reserves (provided for future obligations including unpaid claims and claims adjustment expenses) and policy benefits (liability for future policy benefits) as of the balance sheet date; grouped amount of all the liabilities associated with the company's insurance policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123023910496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Revenues and Expenses (Details) - Affiliated Entity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue</a></td>
<td class="nump">$ 36,321<span></span>
</td>
<td class="nump">$ 9,775<span></span>
</td>
<td class="nump">$ 111,195<span></span>
</td>
<td class="nump">$ 35,718<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses</a></td>
<td class="nump">30,121<span></span>
</td>
<td class="nump">751<span></span>
</td>
<td class="nump">93,266<span></span>
</td>
<td class="nump">1,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses</a></td>
<td class="nump">$ 443<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 745<span></span>
</td>
<td class="nump">$ 186<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123023625632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Repositioning and Other Changes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative Costs Incurred through December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Incurred For the Nine Months Ended September 30, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=evh_EmployeeSeveranceAndTerminationBenefitsMember', window );">Severance and termination benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative Costs Incurred through December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Incurred For the Nine Months Ended September 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Office space consolidation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative Costs Incurred through December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Incurred For the Nine Months Ended September 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=evh_ProfessionalServicesRestructuringMember', window );">Professional services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Cumulative Costs Incurred through December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Incurred For the Nine Months Ended September 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=evh_EmployeeSeveranceAndTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=evh_EmployeeSeveranceAndTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=evh_ProfessionalServicesRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=evh_ProfessionalServicesRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123033375056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123025005440">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Revenue from Segments to Consolidated (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 352,585<span></span>
</td>
<td class="nump">$ 222,471<span></span>
</td>
<td class="nump">$ 969,581<span></span>
</td>
<td class="nump">$ 659,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28,055<span></span>
</td>
<td class="nump">13,765<span></span>
</td>
<td class="nump">74,049<span></span>
</td>
<td class="nump">42,018<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">107,328<span></span>
</td>
<td class="nump">62,857<span></span>
</td>
<td class="nump">306,521<span></span>
</td>
<td class="nump">222,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">245,257<span></span>
</td>
<td class="nump">159,614<span></span>
</td>
<td class="nump">663,060<span></span>
</td>
<td class="nump">437,042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Intersegment Eliminations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">295<span></span>
</td>
<td class="num">(458)<span></span>
</td>
<td class="num">(626)<span></span>
</td>
<td class="num">(1,356)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">352,585<span></span>
</td>
<td class="nump">222,471<span></span>
</td>
<td class="nump">969,581<span></span>
</td>
<td class="nump">659,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">34,810<span></span>
</td>
<td class="nump">20,530<span></span>
</td>
<td class="nump">93,842<span></span>
</td>
<td class="nump">62,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Evolent Health Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">107,033<span></span>
</td>
<td class="nump">63,315<span></span>
</td>
<td class="nump">307,147<span></span>
</td>
<td class="nump">223,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,507<span></span>
</td>
<td class="num">(3,353)<span></span>
</td>
<td class="nump">41,854<span></span>
</td>
<td class="nump">9,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Clinical Solutions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">245,257<span></span>
</td>
<td class="nump">159,614<span></span>
</td>
<td class="nump">663,060<span></span>
</td>
<td class="nump">437,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,303<span></span>
</td>
<td class="nump">23,883<span></span>
</td>
<td class="nump">51,988<span></span>
</td>
<td class="nump">53,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (6,755)<span></span>
</td>
<td class="num">$ (6,765)<span></span>
</td>
<td class="num">$ (19,793)<span></span>
</td>
<td class="num">$ (20,558)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingRevenueReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123024930288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Reconciliation of Adjusted EBITDA (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 2,123<span></span>
</td>
<td class="num">$ (13,040)<span></span>
</td>
<td class="num">$ (7,815)<span></span>
</td>
<td class="num">$ (31,954)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">425<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">765<span></span>
</td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(4,754)<span></span>
</td>
<td class="num">(6,367)<span></span>
</td>
<td class="num">(9,143)<span></span>
</td>
<td class="num">(18,978)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from (provision for) income taxes</a></td>
<td class="nump">45,516<span></span>
</td>
<td class="num">(234)<span></span>
</td>
<td class="nump">44,498<span></span>
</td>
<td class="num">(936)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ChangesInTaxReceivablesAgreementLiability', window );">Change in tax receivable agreement liability</a></td>
<td class="num">(42,870)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(42,870)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="num">(17,196)<span></span>
</td>
<td class="num">(14,859)<span></span>
</td>
<td class="num">(47,414)<span></span>
</td>
<td class="num">(44,962)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_GainOnTransferOfMembership', window );">Gain on transfer of membership</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment/repayment of debt, net</a></td>
<td class="num">(10,192)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,192)<span></span>
</td>
<td class="num">(19,158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Gain from equity method investees</a></td>
<td class="nump">1,392<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">3,940<span></span>
</td>
<td class="nump">12,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">12,700<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="nump">5,822<span></span>
</td>
<td class="nump">819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(345)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="num">(73)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Repositioning costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,043)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_SharebasedCompensationIncludingOnetimeAdjustment', window );">Stock-based compensation expense</a></td>
<td class="num">(6,992)<span></span>
</td>
<td class="num">(4,395)<span></span>
</td>
<td class="num">(19,350)<span></span>
</td>
<td class="num">(11,754)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs</a></td>
<td class="num">(996)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,035)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments', window );">Amortization of contract cost assets</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(110)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
<td class="num">(433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_ShareholderAdvisoryServices', window );">Strategy and shareholder advisory expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,513)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_TransactionCosts', window );">Acquisition costs</a></td>
<td class="num">(2,595)<span></span>
</td>
<td class="num">(1,207)<span></span>
</td>
<td class="num">(6,473)<span></span>
</td>
<td class="num">(3,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Gain (loss) from discontinued operations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(463)<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization', window );">Adjusted EBITDA</a></td>
<td class="nump">$ 28,055<span></span>
</td>
<td class="nump">$ 13,765<span></span>
</td>
<td class="nump">74,049<span></span>
</td>
<td class="nump">42,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Gain on disposal of discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (500)<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ChangesInTaxReceivablesAgreementLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes In Tax Receivables Agreement Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ChangesInTaxReceivablesAgreementLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_GainOnTransferOfMembership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain On Transfer Of Membership</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_GainOnTransferOfMembership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_SharebasedCompensationIncludingOnetimeAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation, Including One-time Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_SharebasedCompensationIncludingOnetimeAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_ShareholderAdvisoryServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shareholder Advisory Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_ShareholderAdvisoryServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109227538&amp;loc=d3e44648-109337<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123023881344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reserves for Claims and Performance-Based Arrangements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Balance, beginning of period</a></td>
<td class="nump">$ 171,294<span></span>
</td>
<td class="nump">$ 178,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract', window );"><strong>Incurred health care costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year to date period</a></td>
<td class="nump">471,502<span></span>
</td>
<td class="nump">383,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior year to date period</a></td>
<td class="num">(8,154)<span></span>
</td>
<td class="nump">619<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total claims incurred</a></td>
<td class="nump">463,348<span></span>
</td>
<td class="nump">383,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Claims paid related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year to date period</a></td>
<td class="num">(369,708)<span></span>
</td>
<td class="num">(250,116)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior year to date period</a></td>
<td class="num">(129,236)<span></span>
</td>
<td class="num">(120,580)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total claims paid</a></td>
<td class="num">(498,944)<span></span>
</td>
<td class="num">(370,696)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Balance, end of period</a></td>
<td class="nump">135,698<span></span>
</td>
<td class="nump">191,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Balance, beginning of period</a></td>
<td class="nump">25,618<span></span>
</td>
<td class="nump">56,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract', window );"><strong>Incurred health care costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year to date period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior year to date period</a></td>
<td class="num">(5,714)<span></span>
</td>
<td class="nump">527<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total claims incurred</a></td>
<td class="num">(5,714)<span></span>
</td>
<td class="nump">7,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Claims paid related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year to date period</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,801)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior year to date period</a></td>
<td class="num">(10,846)<span></span>
</td>
<td class="num">(19,174)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total claims paid</a></td>
<td class="num">(10,846)<span></span>
</td>
<td class="num">(39,975)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Balance, end of period</a></td>
<td class="nump">9,058<span></span>
</td>
<td class="nump">23,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember', window );">Clinical Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Balance, beginning of period</a></td>
<td class="nump">145,676<span></span>
</td>
<td class="nump">122,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract', window );"><strong>Incurred health care costs:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year to date period</a></td>
<td class="nump">471,502<span></span>
</td>
<td class="nump">376,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior year to date period</a></td>
<td class="num">(2,440)<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total claims incurred</a></td>
<td class="nump">469,062<span></span>
</td>
<td class="nump">376,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Claims paid related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year to date period</a></td>
<td class="num">(369,708)<span></span>
</td>
<td class="num">(229,315)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior year to date period</a></td>
<td class="num">(118,390)<span></span>
</td>
<td class="num">(101,406)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total claims paid</a></td>
<td class="num">(488,098)<span></span>
</td>
<td class="num">(330,721)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Balance, end of period</a></td>
<td class="nump">$ 126,640<span></span>
</td>
<td class="nump">$ 168,409<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_ClinicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123025094400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosure of Non-cash Investing and Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued property and equipment purchases</a></td>
<td class="nump">$ 1,014<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Class A common stock issued in connection with business combinations</a></td>
<td class="nump">130,175<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_StockIssuedInConnectionWithDebtRepayment', window );">Class A common stock issued in connection with debt repayment</a></td>
<td class="nump">101,999<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Accrued net working capital adjustment with business combinations</a></td>
<td class="nump">791<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_CashFlowLesseeAbstract', window );"><strong>Effects of Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">14,453<span></span>
</td>
<td class="nump">9,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Leased assets disposed of (obtained in) exchange for operating lease liabilities</a></td>
<td class="nump">4,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_evh_RightOfUseAssetAcquiredAndDisposedOf', window );">Leased assets disposed of (obtained in) exchange for operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,157)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="num">(6,269)<span></span>
</td>
<td class="num">(3,771)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes, net</a></td>
<td class="num">$ (955)<span></span>
</td>
<td class="num">$ (734)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_CashFlowLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_CashFlowLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_RightOfUseAssetAcquiredAndDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset Acquired And Disposed Of</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_RightOfUseAssetAcquiredAndDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_evh_StockIssuedInConnectionWithDebtRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued in Connection with Debt Repayment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">evh_StockIssuedInConnectionWithDebtRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>evh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140123031828784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 722,790<span></span>
</td>
<td class="nump">$ 426,297<span></span>
</td>
<td class="nump">$ 349,010<span></span>
</td>
<td class="nump">$ 349,029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember', window );">Evolent Health Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 214,230<span></span>
</td>
<td class="nump">$ 214,334<span></span>
</td>
<td class="nump">$ 214,335<span></span>
</td>
<td class="nump">$ 214,354<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=evh_EvolentHealthServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>evh-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:evh="http://www.evolenthealth.com/20220930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="evh-20220930.xsd" xlink:type="simple"/>
    <context id="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if244d443b7414b5a802b83cdda1133e3_I20221028">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2022-10-28</instant>
        </period>
    </context>
    <context id="i4e7829cceaeb4c139799230c0383d092_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic1c85bf2a0144950a682573f957154ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i17e8b3c5da9a4abf8639a0d3c5015910_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icb83f20a7c61479b93a83e23998b1c89_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idfb31ce6eb9e4668992f11294921cfad_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibc0ca7083bdc4ebe842729dbd273685c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1dd537792b6e421ba9639adbfe4474c4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0a15fb8f7fe94bf88c8a8a9847578001_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic9f34759559a4dfd86efcb145ce3357e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i34fded2f74a147099334cfa413800c2c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2946b2f4742c436b9ec38ed088adddf3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i774f0c895b93475580cf9bffc1f4d401_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3d92a7bff72d4283b5a2abc070339ddf_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic61eea28d6e24e17b1c838a89e833091_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0deb2b8e664f400a93e847d75c9f7461_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1f7fbb4a3598436a82370c985cafd671_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7743c9436eda44b9a29866c882a8d051_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idf7540828b6542ccbb0c439bd8d9be10_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i47799e4f502f42c98c9d834440ff6d03_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib3859fe1f193413e80c660d7cd13bb43_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2153e00392cb428692eb552f22b89475_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie13e8e5c1c8f442db97081f5b187e36a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i22d0f81c708f4d62b2c2ba75e4549659_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i08eed5034fa6469aa0775ddf5e8edf38_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i89f4cf78a38147c4a67ccbc5f1b70b5e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if579391e2dd946e28f4975df65264f3e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i434deea731b3493cafdecab4e0f513df_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic863a6e2b5314131a58086e3e72c0388_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib1d69eae660647b891b8545b7593243a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie40e239beadc4317b3c499f7eea02fb6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6f69dcb0c02046a8b06f845c2daa4737_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i179c3fe310ef4e61a6d5a2f2721eedc5_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i63b3ddd7486946c2a0a8151832317d14_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic2bb3fdaea8f41d1a5b926350a34b34f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f6814f5fa1246a687d35a28833137b0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9f73e9dc3b2a45679bdcc5b130649934_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i04896f930bff47dda34bb3798c357daf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb4cc675813847809003fabf765db881_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia396cf00f66343f282dc8aa9862707b9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic7382beeecb6460d9d7d2b36a822b970_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i749e0b18e9154afab9acf4c974f1cf8b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie2ed53ed57f5412e8fa51e1b7648fde0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i44adf89b2b3d45209e9135d9c2231fda_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia1ad6cf9dd3347cb949a440b44766e97_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifc261b79d9f841ad8560ed98593f9621_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if90b80996d524ed6b89fbfebe2cedda5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i694c8eca95b44aa281ff19a36e240b13_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic5b6a0decc62412fb5b58744bd94543b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i57e089b648ff473aba749cdaa85824a5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i93b026baeacf472babb208203c15aa89_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idcb7e5d5de6d4fb9bd1b47d49e170108_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7eb7badc179d4dd4b0b439120c44e492_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i38d9971f78fb49c3a0ecdff39b8115f9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifd86661e66444c48b5ef3429b01488ee_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaa111bc1b6fc47e39a435526dc19640d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibee79f04f3964be9b790dfd8e4d6f320_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2301f18558fd44eda53696a9fcbd9108_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforLettersofCreditforFacilityLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia95931a1eeb74ea2a219a48e6a5e3328_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie2575f96f53440259166edbd4dbce19b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7fd66acfff6549699d6732faf4b2192f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id22c0c0a7d0e4c22bc5e825bcd93a594_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforBenefitManagementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83916efaa57f426f9c3bed9248c24cd6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibbbe90d495a24914843d600386432165_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:RestrictedCashforOtherContractualCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie70e3951b11d47189d49176b477c53cb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4553368113754e9985da5aee1e1e2e13_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9941ebd90552418b96575575d27a7ebe_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i30eb020f19524dfb97afd3fef2c5b9ea_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia71efd024b264a23aa0d21ad75741277_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i495e837d54f24a0d9dc7d49185d44a77_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i10d8689dfe304f3bb138eb921170cc2a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i102291920e804daab7d25e75918ff73b_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i2e521093d1374140ac95361a6c2a311e_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i970cc1ff98954def888f92d6e27ed9e0_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="if6b921fd4b544f439a08e3802c74b054_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="iae24c6c30eb94d5c82ae99d747a61a52_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i0aac7a30651e4f168f37aa5b96ca404e_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i47850eb51205454eb531a4e4a24c6b67_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i81468ffa8e794bc0b59baa9867b5834c_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="id2def591b7f54106a7fa0735840fe2d2_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i76392d607ac741ffa9749e4c5191c116_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="ib13556ea35bd419f840924ad34329091_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i8980c17573b14788b07301046fa212f8_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i873c819d3f8246cda155f0714de1ce57_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i011e460895d3476ea9ce07169b756846_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:ImplantableProviderGroupIMPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibdafd4f64587494f9814a1d89347c981_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ief648c5f4b1449d2be6c08727632b653_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i63c007d9f492486b853449a269099b25_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ie493e2b859384dbab23b7cc294e31dbe_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i522030bffa474e539994d8f7437146bb_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ib15c968ec28447719bfe672cf73f9c1f_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i9acb52a4a7c949db9847508394a446ad_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i644999860f68467f8589953496d35dcd_D20211001-20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">evh:VitalDecisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-01</endDate>
        </period>
    </context>
    <context id="i47a4ccf5040a4a66b194e116ca3958b2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4d45489205434204959192b27c4c154c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PlatformsAndOperationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8eeb2030bc104024b411081939f02ec5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5a06e059e5d544dfae30aab44f20002e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:PremiumsRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i084df9c8155a461a930377e4e05f1fda_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsDisposedOfBySaleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">evh:TrueHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0eabf8957ae644bea9de5ff585037c2e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia0f69a9ba3a84c17bce7dd867c4d59f5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i275229cc10b9470089d55c668922f2bd_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i367c749bbd734fe5936e4963fe777810_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i94fd241bcaa64da1931a65e62a56ec7c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9cdccd94a8564ff29b795220b3f3ab9b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9ee4e484cf964a788bb699155c8d3460_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i942d2a04b516474fad491df3467fe4a1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicaidCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iae1fd07e7a684627bcc4060576e5441e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0fa189959b70490991b00541c0e766b4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if7cb9ce8372844c4a246769d6a86d26f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i20e72ff3374e40b7b9ef61f986ed1c3f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic60baf9264bb4217b1b8574383a06caf_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic8ff5e19f6d8424a8f324dfbee51fafc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9f643fc0caed4180a8f4262624ceb1d5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0d938e0b3b4949498896da9cf968d0e2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MedicareCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1f0e4a5e2538465489ed74ed4df71f17_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7c0881f057a14f60b11d5202ba4254d6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia663b5d5862c44d3bb9df7816b437214_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia2145c8132b345cdbc155aef50b5b24d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if5ecc514fd2f4b63b7f68dd819b7abdd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1cf09e09764f4e7ba983e1073e89d28e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9d1acdaafc0b49afb61eac49debda354_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i21f251cda7464cffa6ec9eebf7e8f211_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CommercialAndOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibde168bb02b0431892729b1d49c5bbbd_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5b5c3ea113b04213b765d3be37ec88ce_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6ab4a9b7f10b466b8aed9afde209544a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5053a77df20d49178d0acdd07e80fb9f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieef521b6cb2644d59433c4a98ac67edb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if4dfdc7272dc4a849a6c7e48dfcc4f74_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5af61dbd97844f2cb160b48a3a35d4e8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8e55c1b3affc496aa10cbd0b6538c957_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iba9bddef4c7947819c9a666d386809f7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="evh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis">evh:December312022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7717c83097bb48c298d7cd0c08b877cc_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="evh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis">evh:December312023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i622d6d21df814836a91bfc0e4f88e5e0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-10-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="evh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis">evh:December312024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8df943109acf43b1beae85454cf38885_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9767cf7dd34a49aca4c626b25a0137e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1edb69a16cb6459691cb056b595c5885_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id614a39adbe643b4aa5b5af050be49fd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i632714a677b64a15983dae3dbbde9997_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7383d04203184df1accf6ee901f03030_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:BonusesAndCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id740d1bbcfed47e0aaa7894c6b8e4f13_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i60bde46c214b463b872f8fed94fe0fd3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id8d6b3d636ef48789c73c450718514b3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if801b9c8aab245d5b731f391ad5348b2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i21ab12969f634adfa6cdd08a0aaf4fad_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5994da9b8f9641029f5d64b5faece604_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedContractCostAxis">evh:ContractFulfillmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibff905a18b1f40209cb5ca0efef086b5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5637ed5c72c44080978d3cd0ea34cfda_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i04596f10134947b6acb9bac1698947da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan60DaysMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i124df651628843dabf0bf39cef2a4f10_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancingReceivablesPeriodPastDueAxis">evh:FInancialAssetLessThan120DaysPastDueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5730da3ff5444c0fbe524c644c202af4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia3e288bad13b4a5e8fbf6a82c2389ad6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5c4d433d31d4a2a84d11ae0257cc18f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4ebfbd6230a54574b1ed03cade006714_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iabc0377cf6c84950aafa636df7d7c185_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id32484f46aaa490dafecdb5a20db36fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i311d2b7cdbe24f8ebdf190a94aa1332f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i49599e7727614d2697e205fcf5b794f4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i216238f5c4204e818ee9557f67bc5b08_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idadb3eda60994bfc9bf46cb46e81e8b4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4ab5726f3d7c43e9b4c48c383620aa05_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i597e5acb0181498a985baa0c47467de9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic75e54e0b5564ba5bdf3845c85ae6efa_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="if2b23b62d2314ba29f31148feecadf97_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c9b3945ac9741d4843b49c10f8dcd40_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iffa15ee70390496c89f205bdc8f3731b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i358169d308bf4641ad0dca36755b47d1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if0291d88c45549ebb15674a1bf82c1a2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b7c2c9eb4d24e95a2fb3597a736a55d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1859c2ae121649f09ad595e92fb8e96c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i44a8b1c85fc24294af85eb3f3327612d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifaa4680cab4245c48c966ba93e130b60_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i84135b0576f249ae8003b7e81a024ba5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic68a9db5aae1478fadff12a779202797_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if41217b3022a48ed94e3723c3e0071e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie6843d02651b4eb19d0b68edf6087afd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i25182b4f6fce43fda0e5ebbe2cc7f240_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i59ff2088dd3d487c93a983e025043b03_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie0792eb2a4584a8b95e0d513e6752d62_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie2ec2a15830e4d0e87fe2230ea0e7474_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6cdb2defd328413a8f5c7e2f8ae2c1f0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i58352bc33d9d47e7b266d367548f4196_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7bd97829624644b3a76e8a12f04957c7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i34a0859bcb414bc7b9fafe316f673bca_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic0f42e14adcf450990dc48ddf76f1496_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie0fd0d41813c458fa01a9b4a323d16c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">evh:BelowMarketLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1df90080b3ad4844b8125e0a4c7547e9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7c22c7e8a0aa46c294ef5bcb1985120c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie029cabfd7164a66bdeb9807be351813_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8f3b6e992ace40abb1f986f35d3efc3c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i23031c0b6b3349ac87a0dd3718ded62f_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="if02e0ede9ff94b57bd4e150fe4f1c424_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="ib85258a5944847a799568304dbd3b847_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i397f99c968184e23a3239fd5df224e34_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="ia09ce527d9154016aed6990fcdea728d_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i023a2e0781824e51aac26656357a04e5_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i3728ee01b28446c5b8e4e913f63db0c1_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">evh:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="ia11fc3353efe46e19266ef78af24da63_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="i8f90d550a67b49a1b9b6999f0941d947_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i89cb6508f7a645e3b79e3ad7df4206de_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia44b9d3c20ff4e6cb60de6ff8ecd5783_D20220801-20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-01</endDate>
        </period>
    </context>
    <context id="if44e132eb50c4b2b961cecf1fb497c82_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:A2022CreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i0e534dd28b704e32ae748c0e79ebc74b_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i971d328b42fe456798f158d581d7e9f1_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="ib6070c04ec514eb1b72630be44af9d9d_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i0b673721ad2140dc92b0e7de4a1c58b1_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i173d3fd170d1453abafbccbcc3311581_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:NewNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i247174c3d444488082c85f25293301f0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i703a0ee08afb4b42a1e3c2eed2680471_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9412f1389708421ebab698307b0652e5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i54f3f1eeedc94eaf8493438a2310988b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibf3800946de143f0bb536bae6a5686d3_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i8e4ac76e97a341ee8fbcc6dfa4aba611_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="i281bd5c057904435bc8629de116dd37a_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:EquityComponentOfLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="ia1cdd64507cd4f068665c06a3f09861d_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:DeferredFinancingFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i5a248420ba824c9d8f7efebff5855664_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i0780a0fee7594b46b08c694f8172b826_D20220811-20220811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-11</startDate>
            <endDate>2022-08-11</endDate>
        </period>
    </context>
    <context id="i2d823b0fe92347a08c084c665a3f3d9b_D20220817-20220818">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-17</startDate>
            <endDate>2022-08-18</endDate>
        </period>
    </context>
    <context id="ic25d64a2c23948ee96a46fb336fc19be_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="if893b79edc40422a846ee7d717983c69_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:InitialTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="ic570e916fb874a79be763e4769336d66_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">evh:DelayedDrawTermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="if526c9a8decf4411aa6798f771fb8f2e_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="if34c7918f26d4075a90353ac93a20071_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="i237f03b5f1ae46209253a55eef0acbd7_I20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-30</instant>
        </period>
    </context>
    <context id="i346643136a3d4c2ca53d05972479a685_D20191230-20191230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-30</endDate>
        </period>
    </context>
    <context id="id1b9711d99314be699395b69414db087_D20210108-20210108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-08</startDate>
            <endDate>2021-01-08</endDate>
        </period>
    </context>
    <context id="iaadf8da35c2642b1baae4f9f8ec5b1ec_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i83e14bd5c2bc4351a905d0c781f6f2e1_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i83a29e272d0e42f1a62606a14f9bcb44_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i943bcfabb119462c92e5b274885f9058_I20181022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-22</instant>
        </period>
    </context>
    <context id="ib6a0939c098e417591c54c728c4656b1_I20181024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-24</instant>
        </period>
    </context>
    <context id="i73b993a88b6d4a83ba73f75a35a0dd70_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i82c2c5f321e645a3b56a3aecae93056e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id732329530cf43d0808c84c8df54ccc4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i26243e36f2374ba5a987cdb451132b3d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9de8dee931674cb18c65e45a7b1e4f2c_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i3ac8f2155d3b40999c6630d7228cc990_I20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="i1ad79143dac24d9fb4e767f03a9199d5_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:EquityComponentOfLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i7f199ebd90ef433e8b368de1394c5180_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">evh:DeferredFinancingFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i9fb3858a372e487fb6337c1636d1f938_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="i7a62eaff28ea42a28e86090e3e7b8dd7_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i5e5305e5d35d418385b8e523b11422f4_D20161201-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i3e0b4bf0b8594fd0baf9242862d641ec_D20211201-20211201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:ConvertibleSeniorNotesdue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-01</endDate>
        </period>
    </context>
    <context id="iada79ebd92cc43c4a68b4aa5846a5940_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id2ba2e5b9e234d4fb2a1474c09951db0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5270f847008248a6bad1874588389f6f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6bce8ea980fc40fe86deba0a1244f385_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i624e27774ed54173a7c197935a253285_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if03270431ded404994880052552c5e20_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i21df7ec9dc5145d0bad6dac81a893732_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2d09652a0b6b48dbbae7e55d51a86ced_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0effece2bf1a40ffaf0063bf427e9d14_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i13ee5de32afb476bb8a168331d1b1c9c_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">evh:SeniorConvertibleNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i9d2101c3205e40fbb7350d3a97444a2b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5bc1e4679a644ab9ac8f129c984adf2c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7e2f3f30574a46129384a30992e3c3f9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i56823a0a37a14bc28d21c2c9d3140588_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">evh:CollateralwithFinancialInstitutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1fefdbdcfbff4feb9724eb08693b3aae_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">evh:UPMCResellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8a7f1b54fe7b435899399c232e3c82eb_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">evh:UPMCResellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia13de1649ce14d5ba2486e13d566c4de_D20220802-20220802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">evh:ShareholderClassActionComplaintMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-02</startDate>
            <endDate>2022-08-02</endDate>
        </period>
    </context>
    <context id="i812113f21d0f4ddab105da97d5259847_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iebb100753030431db53c2c0fcb076812_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9a78877350444f218b04a44d9a5a67f2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:MolinaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9063068a17484ebd913c39f47d497ab4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:BrightHealthManagementIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6d9342a7219542d0b80d6351bbbf951e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id66d64f0da484276ac264af8e9113d8b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if15154cdcab04d8c8d65acb536587c6c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5853227e398a4d7793e949610404e4cb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:CookCountyHealthAndHospitalsSystemMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i65657a6b51904fa0b718ad005efbdff6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8be069ea831c4019bdd30e5903c02c34_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icb0f8ea17a2a4c8084b696133732c541_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia751c62398344050a4fa0f25431a1c20_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">evh:FloridaBlueMedicareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5109fae1e1f447d9ba05497deddbfdc1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib8a8fe953a844510b46e6007aa3d8a39_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c22768950824185b381d31f0d376c88_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:VA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6b26e20c9d404df3839bead28654fb46_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia01578a302554a74b33916abc13ae563_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i911c93fdeef8463595874d62c2e77c23_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:GA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib15e0e31d88444c0b1538bbb061a978e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i159210da82754513ad12fdb0f55d6185_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8493de5c288b4d2a960001285f09a7d5_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i13c42161e64b48038d3f19a5af627a85_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iae5571384d234210beca38a208484402_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i698aa6c02364400ebedf039f90402307_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">evh:RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3fd339cb95b94daea292e551ad2fe6f3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3bcd97c207a54e5ab3166f83c04c3bb0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i31ffa1624215451292f3bc38304028d0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i22491be6a23246d796d54f3c45790776_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5bef61a150eb4c7a881bdf01c6a5f488_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if9dbe0e582d74777ae8810f8d192e1d8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i22bf8d1d47ce4219b999f81df2fed5e7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifd9f231f9ee2464db9a170de0151bca4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifb50d04ea7474a3ca01d54e55b1a55f6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i325a5d1124ab41b9a84347a873d3e51b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iea400d223b0743bdad51be17ed4b50ee_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id2a7bc06fc954c4b817161cd6406f509_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i582d7dedfcac46f99a84eb6ef808e641_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8aa29b39545e4c3ba7d7690b3e215975_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4b17f35850394b8dba4f2022f71b47ca_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5a875e7e581644ddb5ae0ea1dd6d828d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i80cf2c1a304b4b419a652fc1e0cb1937_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7c541a9c8aa847a880c6ab10e684b4c9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8cc6de998c6c41a2918343e7a2029cbe_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i44b9048d914e4b6fbb6f301354a4b9b0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:LeveragedStockUnitsLSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i647fb470e87444d6a627e33d5d70965b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ide5f51cc3ef84de6a0fd4b47abd3c1e8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idcffb900db284c32b9e3d8cb934a505f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iee1649a9b5bf47f7917cfe5843b5b4a8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">evh:PerformanceBasedRestrictedStockUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i725c229475cf49689226a91cc11b751c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2612dbadf05a4362aad60d096eb1a7e4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iada2bf5d0400417ba62e194126135b75_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic6f6b8c71225423c8a5684cc55be31ce_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i631da77b97724fd1b7043025f1733fe1_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if1a0e6a4f8b84f88b30c7341d4f1c393_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idd568013557c46eb981fa85a87040eba_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3e14d567f9f24b93870cd21943387f1c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i595e611ec9ae489dbce4f7eda441f246_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7eda68985c9842cdaf3b26312b15d4c2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if02fc4db2c9b4fa8b2f8b4664e01eea1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i277f0bf297354d94af61e257c3ec7ff7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iebd3f639166d44039bd8edc98238a383_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id4b322c66f3e45b08685a4ae028887d8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i396bb0edd68c430189127d5633e8e1a4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2240a4a6255943e4bf456dfd07e73621_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">evh:ServicesAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:EquityMethodInvesteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if1d99a70db5f43208858b7f0f954c2d1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4e61be204d694c09879235c63a790f71_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7bc89218c26643328b21b1506819b3a0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i88c58b8bf6804181b9ae7aa0ce6fa7e0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i328717c857f2404dba9ba20b9433ea18_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id142ae030d514564a81b2bb1eadfeaba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i867837f495ba4b65886161a03a0def38_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c1e69c3b48346c3b0514ad1ccceb5f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5a543708cce4e1587fc2f618e7c92b7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i28495d82fa994f08b28b8dfc1e3a47e6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibd65a2db6ad04df8b047a7d81b2023ee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">evh:MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30e706fd844d4e009a8b34652d74f93b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb038b091b7344c29e48adca13ed03ae_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6387c494ab8746e7b6c8beed248da58e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie08f13f16382418ea5ec290830f60d8c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i12e6f929d457432287e5c6cd1f183f5f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic5df79eb68c444ab9cb77a56bf677989_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6cace99351664c7ca949a3e0200ac20d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i60fada84ac4946cb9b4e805a57e3cf0b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic9bdab906b4a4d49a48fe38f018eb8bc_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4a5ea59bbc694c93968f7c1ff417d386_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5d139443bb3e4ce086f6d2c6a7b557b2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i73540c5f613d403b832d91b574a59f07_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ice64acee7f3f46179553cd75809b106f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic86b2c3d20a443a49da566ae4eaf14cd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia91f376f9d6846eb84ca11a8a358cf74_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia6e2ba14bf4d472691df13b609cc514b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie38f3231de914c44a9c3146fc55eb3b8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:EmployeeSeveranceAndTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3044ccef126a4375824fc8fc3a6c3ce3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i91cfb2c56b99413c9fb95814cfb285f4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3adb4e55cc4e45a7911caff2dbcc7a00_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ed21b2abe494c07b71ec32367fb20d9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">evh:ProfessionalServicesRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i806263fe61f14f33b5cdbd7eee333ff7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iacbe24e15241450eb5814aef67850f85_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib7b76ebaaef241a09456df69e9f56730_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id47a9c894a7d46569bed9ed6ad4e9987_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie593e243a4f94ded8dcc0cbd2124556d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5e9c2f26074c434280c915a00ab6b2fe_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i26289f6ee3444cf484ed38a01409bbfe_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i338af69a6f0948e5a6b88db8f9f14704_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifbee25bccde9417b9684147c13bfd340_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8f35093a1db04660afd25caee273d0f0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifd61671a0d0442d5ad34be35130c449e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if1cf7a17cbbf4a65b3324ddb3a731532_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0870ad9619a8495f9f783b300266e2bf_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia108ecb595104f0e8ed9def9f229176e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i59101f8a3ac14ae493956a62379f494f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iceebbb78aaf945b48c2e1e0c956749dd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:EvolentHealthServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3311fd1bb12e4f44944b34e49f4f81c7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">evh:ClinicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i71b35f78e61e4fd6a8f76ed882b8104b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i14e6f529e4db48d8894cb30eac5feba5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8abf6d4aad764b85af854f18bc243f26_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001628908</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="reporting_unit">
        <measure>evh:reporting_unit</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="option_to_renew_lease">
        <measure>evh:option_to_renew_lease</measure>
    </unit>
    <unit id="source">
        <measure>evh:source</measure>
    </unit>
    <unit id="day">
        <measure>evh:day</measure>
    </unit>
    <unit id="customer">
        <measure>evh:customer</measure>
    </unit>
    <unit id="segment">
        <measure>evh:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180L2ZyYWc6MzlkYWEwOWVjZjU3NDQ0ZWI2OWI5NWU0OGE5ZDgwMmEvdGFibGU6NGU5M2U0MWIwY2RlNDJlZDkwNmQ5ZTZiNGMzNDYzMjkvdGFibGVyYW5nZTo0ZTkzZTQxYjBjZGU0MmVkOTA2ZDllNmI0YzM0NjMyOV8xLTEtMS0xLTY2OTEw_6d371aad-169a-439b-94f8-7bdfb250d232">0001628908</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180L2ZyYWc6MzlkYWEwOWVjZjU3NDQ0ZWI2OWI5NWU0OGE5ZDgwMmEvdGFibGU6NGU5M2U0MWIwY2RlNDJlZDkwNmQ5ZTZiNGMzNDYzMjkvdGFibGVyYW5nZTo0ZTkzZTQxYjBjZGU0MmVkOTA2ZDllNmI0YzM0NjMyOV8yLTEtMS0xLTY2OTEw_02ca41c5-8dde-4fc6-b4b6-ee0e5d38ea37">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180L2ZyYWc6MzlkYWEwOWVjZjU3NDQ0ZWI2OWI5NWU0OGE5ZDgwMmEvdGFibGU6NGU5M2U0MWIwY2RlNDJlZDkwNmQ5ZTZiNGMzNDYzMjkvdGFibGVyYW5nZTo0ZTkzZTQxYjBjZGU0MmVkOTA2ZDllNmI0YzM0NjMyOV8zLTEtMS0xLTY2OTEw_36276d4b-9de8-4a10-a510-f757925a4b66">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180L2ZyYWc6MzlkYWEwOWVjZjU3NDQ0ZWI2OWI5NWU0OGE5ZDgwMmEvdGFibGU6NGU5M2U0MWIwY2RlNDJlZDkwNmQ5ZTZiNGMzNDYzMjkvdGFibGVyYW5nZTo0ZTkzZTQxYjBjZGU0MmVkOTA2ZDllNmI0YzM0NjMyOV80LTEtMS0xLTY2OTEw_d069254b-ab8f-4d37-80e8-ab49e1ba2903">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180L2ZyYWc6MzlkYWEwOWVjZjU3NDQ0ZWI2OWI5NWU0OGE5ZDgwMmEvdGFibGU6NGU5M2U0MWIwY2RlNDJlZDkwNmQ5ZTZiNGMzNDYzMjkvdGFibGVyYW5nZTo0ZTkzZTQxYjBjZGU0MmVkOTA2ZDllNmI0YzM0NjMyOV81LTEtMS0xLTY2OTEw_f17ad16f-9769-402d-8688-a68226895afe">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="ia396cf00f66343f282dc8aa9862707b9_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNS0wLTEtMS02NjkxMA_408fa599-0cbb-46b4-89df-85994f18cc54">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="iba9bddef4c7947819c9a666d386809f7_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181OC9mcmFnOjVmY2U5YjA3YTNhZDRmMDBhNzcxYzhmZjE5MzAyMjg2L3RhYmxlOjJhOGMzYzM5ZmJmZTQwNzY4MGUxMmY1NzQ4ZjRkZTU2L3RhYmxlcmFuZ2U6MmE4YzNjMzlmYmZlNDA3NjgwZTEyZjU3NDhmNGRlNTZfMi0xLTEtMS02NjkxMA_a3452b3f-a39d-4993-8e10-eefa876e5921">P3M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i7717c83097bb48c298d7cd0c08b877cc_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181OC9mcmFnOjVmY2U5YjA3YTNhZDRmMDBhNzcxYzhmZjE5MzAyMjg2L3RhYmxlOjJhOGMzYzM5ZmJmZTQwNzY4MGUxMmY1NzQ4ZjRkZTU2L3RhYmxlcmFuZ2U6MmE4YzNjMzlmYmZlNDA3NjgwZTEyZjU3NDhmNGRlNTZfMy0xLTEtMS02NjkxMA_5ca169fc-1959-4b91-a821-57b538ce8124">P15M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i622d6d21df814836a91bfc0e4f88e5e0_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181OC9mcmFnOjVmY2U5YjA3YTNhZDRmMDBhNzcxYzhmZjE5MzAyMjg2L3RhYmxlOjJhOGMzYzM5ZmJmZTQwNzY4MGUxMmY1NzQ4ZjRkZTU2L3RhYmxlcmFuZ2U6MmE4YzNjMzlmYmZlNDA3NjgwZTEyZjU3NDhmNGRlNTZfNC0xLTEtMS02NjkxMA_404cff94-93ca-4826-9fd7-6b1237a96e9c">P27M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i0effece2bf1a40ffaf0063bf427e9d14_D20200801-20200831"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183My9mcmFnOjU0N2I3NzVmODhjNzQ5ZTk4MWVmNGQ3OWQzZTlmYmQ4L3RleHRyZWdpb246NTQ3Yjc3NWY4OGM3NDllOTgxZWY0ZDc5ZDNlOWZiZDhfNQ_f52872cc-8f72-4c10-aa6f-f0fd17005b3e"
      unitRef="number">0.0548667</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i13ee5de32afb476bb8a168331d1b1c9c_D20181001-20181031"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183My9mcmFnOjU0N2I3NzVmODhjNzQ5ZTk4MWVmNGQ3OWQzZTlmYmQ4L3RleHRyZWdpb246NTQ3Yjc3NWY4OGM3NDllOTgxZWY0ZDc5ZDNlOWZiZDhfMjE1_ca0941d5-7679-4927-b76d-e24f0fe9048e"
      unitRef="number">0.0299135</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <dei:DocumentType
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8yMzEw_6a9e881f-d43a-409e-8d4f-9fee8c5328e8">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8yMzEx_64814b67-e062-4cc9-8308-656c22c27ff2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8yMDc_a4fdf488-89b4-4fbd-8af4-bded1990434d">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8yMTY_137c4c8f-5f9c-4d48-a31c-6a15505f73a2">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8zOTg_b7934118-ab08-46f6-a12f-9720e23b7de0">001-37415</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV80Mjg_cee9713a-b8a3-492f-ad03-1b62e648a7fd">Evolent Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGFibGU6MmJjYTkwNDYyZjBkNGIwZjhiMzM2NjNkZWM4MWE4NWUvdGFibGVyYW5nZToyYmNhOTA0NjJmMGQ0YjBmOGIzMzY2M2RlYzgxYTg1ZV8wLTEtMS0xLTY2OTEw_27383283-fc7f-4139-9058-1e46c4eabe0f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGFibGU6MmJjYTkwNDYyZjBkNGIwZjhiMzM2NjNkZWM4MWE4NWUvdGFibGVyYW5nZToyYmNhOTA0NjJmMGQ0YjBmOGIzMzY2M2RlYzgxYTg1ZV8wLTktMS0xLTY2OTEw_396bedc1-33c5-443f-a02f-6e22a7f431cf">32-0454912</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGFibGU6MmJjYTkwNDYyZjBkNGIwZjhiMzM2NjNkZWM4MWE4NWUvdGFibGVyYW5nZToyYmNhOTA0NjJmMGQ0YjBmOGIzMzY2M2RlYzgxYTg1ZV8zLTEtMS0xLTY2OTEw_75bd89c6-555e-4b68-a1af-8925481755ce">800 N. Glebe Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGFibGU6MmJjYTkwNDYyZjBkNGIwZjhiMzM2NjNkZWM4MWE4NWUvdGFibGVyYW5nZToyYmNhOTA0NjJmMGQ0YjBmOGIzMzY2M2RlYzgxYTg1ZV8zLTMtMS0xLTY2OTEw_fb1be725-6bca-430e-bd7c-82c168344f87">Suite 500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGFibGU6MmJjYTkwNDYyZjBkNGIwZjhiMzM2NjNkZWM4MWE4NWUvdGFibGVyYW5nZToyYmNhOTA0NjJmMGQ0YjBmOGIzMzY2M2RlYzgxYTg1ZV8zLTUtMS0xLTY2OTEw_8418d2f2-da7a-4921-b3c6-d19620e1cd4f">Arlington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGFibGU6MmJjYTkwNDYyZjBkNGIwZjhiMzM2NjNkZWM4MWE4NWUvdGFibGVyYW5nZToyYmNhOTA0NjJmMGQ0YjBmOGIzMzY2M2RlYzgxYTg1ZV8zLTctMS0xLTY2OTEw_f7691103-1d2c-4e1d-99f4-8a3ad5cc6e08">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGFibGU6MmJjYTkwNDYyZjBkNGIwZjhiMzM2NjNkZWM4MWE4NWUvdGFibGVyYW5nZToyYmNhOTA0NjJmMGQ0YjBmOGIzMzY2M2RlYzgxYTg1ZV8zLTktMS0xLTY2OTEw_d50e8fa1-f716-4fa7-8cd7-64f9086c63a2">22203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV81MzY_da560835-7329-4441-8592-726dab6907e2">571</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV81NDA_63fb70f2-dd8f-48c1-9154-b26a353025ba">389-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGFibGU6ZDhkNmU3ZWQzZDU3NDk5ZGIwYTAzZGM5ZjMzNDUyZDcvdGFibGVyYW5nZTpkOGQ2ZTdlZDNkNTc0OTlkYjBhMDNkYzlmMzM0NTJkN18xLTAtMS0xLTY2OTEw_0c9c6c68-029f-4884-9b46-32702218d2ad">Class A Common Stock of Evolent Health, Inc., par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGFibGU6ZDhkNmU3ZWQzZDU3NDk5ZGIwYTAzZGM5ZjMzNDUyZDcvdGFibGVyYW5nZTpkOGQ2ZTdlZDNkNTc0OTlkYjBhMDNkYzlmMzM0NTJkN18xLTEtMS0xLTY2OTEw_0c5672b6-82cc-406b-884a-7171e7e5b074">EVH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGFibGU6ZDhkNmU3ZWQzZDU3NDk5ZGIwYTAzZGM5ZjMzNDUyZDcvdGFibGVyYW5nZTpkOGQ2ZTdlZDNkNTc0OTlkYjBhMDNkYzlmMzM0NTJkN18xLTItMS0xLTY2OTEw_2b29fd34-b70e-4a98-8aa1-96391c540d8c">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8xMDQx_74883968-e846-4a4a-888a-be2cd809d28e">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8xMzYz_c6078621-bf12-425d-9c2a-ff69f4112cc2">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8xNzMw_6a0faa6c-7043-4fc6-82fb-57f3b80209fe">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8xODEx_b20c7469-f673-492a-a301-78e2b2d11208">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8yMzEy_abe9356c-1423-4024-8d40-5ab9aa443db1">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8zMjk4NTM0ODg1NjQz_507c83c6-073e-44e7-909d-94eeb8d22ed1">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="if244d443b7414b5a802b83cdda1133e3_I20221028"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xL2ZyYWc6YWEwZjIzZmI0MTgzNDZmY2JmMDM3YzMxMzQxNmYzMzkvdGV4dHJlZ2lvbjphYTBmMjNmYjQxODM0NmZjYmYwMzdjMzEzNDE2ZjMzOV8yMjQ3_5a02aead-f43d-42e7-af19-de42fb496202"
      unitRef="shares">101190965</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMy0xLTEtMS02NjkxMA_4adfd785-0067-43b4-8b3f-7f733aa313f9"
      unitRef="usd">156756000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMy0zLTEtMS02NjkxMA_10feef25-ed4e-4e73-ac78-859bb8e9ed56"
      unitRef="usd">266280000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNC0xLTEtMS02NjkxMA_91f8298f-7423-4369-9cdf-9245fd3a7b3a"
      unitRef="usd">25057000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNC0zLTEtMS02NjkxMA_ddf47620-1f0e-4c3a-b99b-0657990da4d4"
      unitRef="usd">75685000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNS0xLTEtMS02NjkxMA_f64a8628-8343-4da0-954d-ffe1f203e1f5"
      unitRef="usd">187633000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNS0zLTEtMS02NjkxMA_6db68019-f8ed-4595-afcd-b595ba408e42"
      unitRef="usd">130604000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNi0xLTEtMS02NjkxMA_d3e0c599-491f-46df-a5b8-1ef55dddf91e"
      unitRef="usd">24328000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNi0zLTEtMS02NjkxMA_3fbe5349-c50f-488a-926f-cebbbb5e3145"
      unitRef="usd">51391000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNy0xLTEtMS02NjkxMA_bbfedc42-271b-48ec-83b3-88dbfd6e1cfd"
      unitRef="usd">393774000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNy0zLTEtMS02NjkxMA_5809fd6a-aa3c-44b2-b176-a6bf491aeffa"
      unitRef="usd">523960000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfOC0xLTEtMS02NjkxMA_7c9340cb-1c01-49f5-8e41-7cf9f8f84437"
      unitRef="usd">13005000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfOC0zLTEtMS02NjkxMA_ace7db65-a5ad-4488-94ef-6b3f08425d70"
      unitRef="usd">12977000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfOS0xLTEtMS02NjkxMA_5b1b24d3-3d00-4f4f-b03a-0e84cb51ecb4"
      unitRef="usd">5222000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfOS0zLTEtMS02NjkxMA_e3dcdbfd-e50d-43eb-949e-356b1e41e7f4"
      unitRef="usd">5458000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTAtMS0xLTEtNjY5MTA_afd7dd72-13e1-4019-8f2b-eecdd8dc03ad"
      unitRef="usd">94645000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTAtMy0xLTEtNjY5MTA_10f88e74-65af-4b0e-ba13-ea8fd7267221"
      unitRef="usd">81365000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTEtMS0xLTEtNjY5MTA_aa891742-4094-4888-8ae4-85e864e0f131"
      unitRef="usd">50696000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTEtMy0xLTEtNjY5MTA_4f16e435-bcd1-4cee-8b62-65cac9dcb2ae"
      unitRef="usd">50203000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTItMS0xLTEtNjY5MTA_34f9420f-1f29-4dd2-a3b4-4616ca572376"
      unitRef="usd">3064000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTItMy0xLTEtNjY5MTA_e780754b-becf-412a-9a90-ad6423472439"
      unitRef="usd">6790000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTMtMS0xLTEtNjY5MTA_03df4466-d0fc-4feb-9cf7-513baacda088"
      unitRef="usd">24588000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTMtMy0xLTEtNjY5MTA_2ef3278d-14d5-443b-acb1-ce6d55f69fad"
      unitRef="usd">32624000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTQtMS0xLTEtNjY5MTA_e39dbb61-b4fc-4cb4-a7d9-946c1955edb1"
      unitRef="usd">451398000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTQtMy0xLTEtNjY5MTA_b24711c5-29f6-4f33-9f01-e9ce3d3fe8fe"
      unitRef="usd">279784000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTUtMS0xLTEtNjY5MTA_65819eec-0816-4a9c-8506-a0082b6b7b1d"
      unitRef="usd">722790000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTUtMy0xLTEtNjY5MTA_cb55692b-0968-444a-a243-a4d27f84daeb"
      unitRef="usd">426297000</us-gaap:Goodwill>
    <us-gaap:Assets
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTYtMS0xLTEtNjY5MTA_d7087929-e588-4ca2-bb48-02bd86ed9f5c"
      unitRef="usd">1759182000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTYtMy0xLTEtNjY5MTA_49bb6714-bf55-4ddf-9d19-0c81beb10450"
      unitRef="usd">1419458000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjAtMS0xLTEtNjY5MTA_48d0844c-9fb0-4d5c-b7d4-6304a399f74d"
      unitRef="usd">61863000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjAtMy0xLTEtNjY5MTA_c65b73ea-18ea-457b-b53e-8321cc519932"
      unitRef="usd">96084000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjEtMS0xLTEtNjY5MTA_503f1e92-bc1a-4c1c-88de-3f62af41dfea"
      unitRef="usd">132238000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjEtMy0xLTEtNjY5MTA_f0410fb4-f54a-4562-8220-80148a84a87a"
      unitRef="usd">107241000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjItMS0xLTEtNjY5MTA_04bd69df-f408-4689-8a25-0109a3dd5a7f"
      unitRef="usd">7053000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjItMy0xLTEtNjY5MTA_81ea11e8-3476-42d3-8240-0d0374899629"
      unitRef="usd">7069000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjMtMS0xLTEtNjY5MTA_32bce8b5-71d3-4131-8757-918414ba8082"
      unitRef="usd">37646000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjMtMy0xLTEtNjY5MTA_39020dbe-d7bb-4cd2-a69c-05da8dfd8506"
      unitRef="usd">51861000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjQtMS0xLTEtNjY5MTA_577ab0ee-3da1-4651-863a-0c108f9e8742"
      unitRef="usd">7524000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjQtMy0xLTEtNjY5MTA_9966f0b3-8f73-4028-96a9-4af3eed4f33b"
      unitRef="usd">11944000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjUtMS0xLTEtNjY5MTA_48ec7316-cea1-4cf6-8f66-13d156e589bd"
      unitRef="usd">135698000</evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements>
    <evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjUtMy0xLTEtNjY5MTA_e4abb8b3-aa8f-4832-83bc-f87e164b3de8"
      unitRef="usd">171294000</evh:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements>
    <us-gaap:LiabilitiesCurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjYtMS0xLTEtNjY5MTA_1f23f22f-de10-4269-80de-8b0c4780db86"
      unitRef="usd">382022000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjYtMy0xLTEtNjY5MTA_b076bd94-8e42-4154-b8a7-6eb3fd077bb5"
      unitRef="usd">445493000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjctMS0xLTEtNjY5MTA_07633416-b668-474d-a51f-e076f902ddfc"
      unitRef="usd">412444000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjctMy0xLTEtNjY5MTA_e6794af0-5740-4652-b74d-c5577529d558"
      unitRef="usd">215676000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjgtMS0xLTEtNjY5MTA_6bcf8df3-1f3e-4110-8fbe-403dcf4265d6"
      unitRef="usd">4260000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjgtMy0xLTEtNjY5MTA_1cc51f0e-522f-43b1-9a37-b00971772025"
      unitRef="usd">5531000</us-gaap:OtherLiabilitiesNoncurrent>
    <evh:TaxReceivableAgreementLiability
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjktMS0xLTEtODA2Njg_9a496223-f052-45ce-935c-30ad89ccc804"
      unitRef="usd">42870000</evh:TaxReceivableAgreementLiability>
    <evh:TaxReceivableAgreementLiability
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjktMy0xLTEtODA2Njg_3af20049-5783-4027-a3cd-840d9e5ccf75"
      unitRef="usd">0</evh:TaxReceivableAgreementLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjktMS0xLTEtNjY5MTA_99b85750-cdfb-4bd0-8efe-20fd4bd40323"
      unitRef="usd">57840000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjktMy0xLTEtNjY5MTA_d673bef3-2fc4-42a1-b84d-e280e7c881ff"
      unitRef="usd">57722000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzAtMS0xLTEtNjY5MTA_6e5826cc-b3e1-42cb-ab83-bd95c48808df"
      unitRef="usd">3608000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzAtMy0xLTEtNjY5MTA_9693fc96-e549-4337-b656-e96f0527ecb3"
      unitRef="usd">1403000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:Liabilities
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzEtMS0xLTEtNjY5MTA_47154242-d084-4ecf-a000-d5c6e891903b"
      unitRef="usd">903044000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzEtMy0xLTEtNjY5MTA_8af1a695-4490-4992-b64d-fc670dbfdcc2"
      unitRef="usd">725825000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzItMS0xLTEtNjY5MTA_a3907a8a-681e-4466-a3ea-5c096b1e7038"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzItMy0xLTEtNjY5MTA_fb0f0850-e771-4b3a-9d24-baa3570a403c"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzQtMC0xLTEtNjY5MTAvdGV4dHJlZ2lvbjpjY2MxZTA0MTBmNGE0YTU2YWMzMGQ5ZGE2Yzc1MWVmZl8yNw_89e56627-9dff-4f3a-9d1c-145ef23da800"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzQtMC0xLTEtNjY5MTAvdGV4dHJlZ2lvbjpjY2MxZTA0MTBmNGE0YTU2YWMzMGQ5ZGE2Yzc1MWVmZl8yNw_d6bda1de-12ac-4feb-bba6-9f12835a8748"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzQtMC0xLTEtNjY5MTAvdGV4dHJlZ2lvbjpjY2MxZTA0MTBmNGE0YTU2YWMzMGQ5ZGE2Yzc1MWVmZl80MQ_bacb8716-28de-42d2-bdfc-96e83b094286"
      unitRef="shares">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzQtMC0xLTEtNjY5MTAvdGV4dHJlZ2lvbjpjY2MxZTA0MTBmNGE0YTU2YWMzMGQ5ZGE2Yzc1MWVmZl80MQ_e9268d07-25bc-4e71-917d-10e91701bd67"
      unitRef="shares">750000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzQtMC0xLTEtNjY5MTAvdGV4dHJlZ2lvbjpjY2MxZTA0MTBmNGE0YTU2YWMzMGQ5ZGE2Yzc1MWVmZl82Mw_d8bf4457-41ef-4170-b6ed-6c10468f215e"
      unitRef="shares">101159072</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzQtMC0xLTEtNjY5MTAvdGV4dHJlZ2lvbjpjY2MxZTA0MTBmNGE0YTU2YWMzMGQ5ZGE2Yzc1MWVmZl83MA_e17f93a7-f0a2-481d-8b2a-0fe7900b2c68"
      unitRef="shares">90758318</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzQtMS0xLTEtNjY5MTA_8c14fd40-e9e9-40d3-9277-dd38fada9422"
      unitRef="usd">1012000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzQtMy0xLTEtNjY5MTA_3914b511-5143-430e-aca7-8f3a2be387a9"
      unitRef="usd">908000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzUtMS0xLTEtNjY5MTA_86e95e50-fb8f-437d-adb0-64ce9abe4c4a"
      unitRef="usd">1472098000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzUtMy0xLTEtNjY5MTA_bed9321f-f495-4306-ba88-1c3a06a356ea"
      unitRef="usd">1340989000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzYtMS0xLTEtNjY5MTA_29bd24d4-2038-4c5d-9146-a11e9b144621"
      unitRef="usd">-1044000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzYtMy0xLTEtNjY5MTA_38adf771-f3e9-41e0-a762-4430b7f614e9"
      unitRef="usd">-362000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzctMS0xLTEtNjY5MTA_7be390ca-e381-4216-8870-d8c2ff949cf6"
      unitRef="usd">-594805000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzctMy0xLTEtNjY5MTA_d98e4361-c5f9-450a-b1e9-db0f3c342ebf"
      unitRef="usd">-626779000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzgtMC0xLTEtNjY5MTAvdGV4dHJlZ2lvbjpjZDRkOTE0NWY2YjE0NDgzYjdlZTI4ZGQwNzdkOTVjYV8yOQ_7940e372-b959-4569-8642-c17453427740"
      unitRef="shares">1537582</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzgtMC0xLTEtNjY5MTAvdGV4dHJlZ2lvbjpjZDRkOTE0NWY2YjE0NDgzYjdlZTI4ZGQwNzdkOTVjYV8yOQ_eb0d6f78-7309-48b6-a45f-59899b6d93b9"
      unitRef="shares">1537582</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzgtMS0xLTEtNjY5MTA_d165f017-1aea-400c-a845-dec2600a1fe1"
      unitRef="usd">21123000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzgtMy0xLTEtNjY5MTA_63609d96-b151-4c0b-8923-5f09e6b8c420"
      unitRef="usd">21123000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzktMS0xLTEtNjY5MTA_f1bd6b3d-c4f8-4882-a901-68dc59456666"
      unitRef="usd">856138000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMzktMy0xLTEtNjY5MTA_21641b07-f2b3-421a-9e2c-c2d877b1cb87"
      unitRef="usd">693633000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNDAtMS0xLTEtNjY5MTA_08962c34-3324-42a2-a9b1-8bf22cbe3f80"
      unitRef="usd">1759182000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNDAtMy0xLTEtNjY5MTA_d50e60ec-4d1e-498e-9f2f-fe4101bd5341"
      unitRef="usd">1419458000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi0xLTEtMS02NjkxMA_28d6ffce-89e9-459b-a59c-bdfa2cfd0ac0"
      unitRef="usd">352585000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi0zLTEtMS02NjkxMA_a61cab80-88da-43a6-aa65-391f42890dab"
      unitRef="usd">222471000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi01LTEtMS02NjkxMA_5f2e275b-70f9-47fe-8b15-566555a7bfb6"
      unitRef="usd">969581000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi03LTEtMS02NjkxMA_1ca38dea-5804-491f-b6f7-af17f48eb3ee"
      unitRef="usd">659599000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS0xLTEtMS02NjkxMA_c1e43070-1906-4b95-918c-de3e2d6ad751"
      unitRef="usd">266617000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS0zLTEtMS02NjkxMA_edb76492-aae3-4861-9dce-2a945e70053d"
      unitRef="usd">163126000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS01LTEtMS02NjkxMA_b18d0ce1-acbd-45aa-9cdc-ac7e018922e2"
      unitRef="usd">736061000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS03LTEtMS02NjkxMA_a4472a6b-b093-4b73-b6c8-ee80bcaf0c75"
      unitRef="usd">493071000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi0xLTEtMS02NjkxMA_db29f41c-bce7-4327-9bf4-be3e93d52a0f"
      unitRef="usd">68521000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi0zLTEtMS02NjkxMA_11533d2f-70b8-49ef-8326-e453614be690"
      unitRef="usd">51292000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi01LTEtMS02NjkxMA_526c1f97-4796-4d78-a5f7-ea1044f251d4"
      unitRef="usd">186408000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi03LTEtMS02NjkxMA_34edd863-f4e2-4813-bb92-2662eebf4a0a"
      unitRef="usd">152582000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNy0xLTEtMS02NjkxMA_8cf27764-39ba-43f9-a774-acdaffc6eec4"
      unitRef="usd">17196000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNy0zLTEtMS02NjkxMA_c994bc94-f58b-4e09-b211-f2ad27149c61"
      unitRef="usd">14859000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNy01LTEtMS02NjkxMA_a16c83d4-4057-438b-8635-020c271210de"
      unitRef="usd">47414000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNy03LTEtMS02NjkxMA_1f9a20af-f6db-43f0-94da-97b51e885fc5"
      unitRef="usd">44962000</us-gaap:DepreciationAndAmortization>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfOC0xLTEtMS02NjkxMA_ce1251f6-9f9e-43fc-bb5d-00975c50a02e"
      unitRef="usd">-12700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfOC0zLTEtMS02NjkxMA_d35a970b-472e-45d2-9394-6354fff787ac"
      unitRef="usd">-225000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfOC01LTEtMS02NjkxMA_cc39e450-2fec-4dac-9c5f-625c9729584d"
      unitRef="usd">-5822000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfOC03LTEtMS02NjkxMA_ff4c8aff-f4ef-48ed-aa69-ec78ffccaf2b"
      unitRef="usd">-819000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:CostsAndExpenses
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfOS0xLTEtMS02NjkxMA_df740d3d-b758-415f-9fce-43790a591e34"
      unitRef="usd">339634000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfOS0zLTEtMS02NjkxMA_788123dc-e3e5-499b-8c3b-46151962c333"
      unitRef="usd">229052000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfOS01LTEtMS02NjkxMA_2c4d0b9d-5892-40c6-9725-5f5343d0ae48"
      unitRef="usd">964061000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfOS03LTEtMS02NjkxMA_cac853f7-c4e1-45e5-9b99-85be0d714298"
      unitRef="usd">689796000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTAtMS0xLTEtNjY5MTA_4cefd6fc-bcfa-4c2e-a4a8-1e4c697204a0"
      unitRef="usd">12951000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTAtMy0xLTEtNjY5MTA_52de9c7b-1d7f-43cc-9884-018d9db34861"
      unitRef="usd">-6581000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTAtNS0xLTEtNjY5MTA_917cee60-3db9-4ef2-afb5-0d1acf755f83"
      unitRef="usd">5520000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTAtNy0xLTEtNjY5MTA_f54ffe7a-4434-48f7-8a84-a27e4b8bbce6"
      unitRef="usd">-30197000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTEtMS0xLTEtNjY5MTA_85192df2-d85c-4f99-8f26-9626ed56fe53"
      unitRef="usd">425000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTEtMy0xLTEtNjY5MTA_ace17bc9-5e30-4b68-8e5e-0a96691a1f67"
      unitRef="usd">120000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTEtNS0xLTEtNjY5MTA_a5cf1b7e-ae1f-4538-9aba-233f19a72974"
      unitRef="usd">765000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTEtNy0xLTEtNjY5MTA_9ecbcb71-682f-4063-968b-6ff5cf81c8b7"
      unitRef="usd">311000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTItMS0xLTEtNjY5MTA_47b0e39d-ee84-420a-b763-82e814acb7c5"
      unitRef="usd">4754000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTItMy0xLTEtNjY5MTA_90682a5a-c38f-4944-858e-d6eb2b7beb74"
      unitRef="usd">6367000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTItNS0xLTEtNjY5MTA_904a8787-e2ee-4f22-a129-a4fc1568c6e1"
      unitRef="usd">9143000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTItNy0xLTEtNjY5MTA_845803bd-53d6-48c4-971f-7bc75d32752a"
      unitRef="usd">18978000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTMtMS0xLTEtNjY5MTA_be789f20-1dac-4bdb-9cd6-a0bab8ffa879"
      unitRef="usd">1392000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTMtMy0xLTEtNjY5MTA_4e2953e3-7c26-447a-9170-e7d8df3759aa"
      unitRef="usd">63000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTMtNS0xLTEtNjY5MTA_12a64fcc-617a-460d-a25a-25f1254e3cd8"
      unitRef="usd">3940000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTMtNy0xLTEtNjY5MTA_7da8184d-dc94-4aa8-b552-2d9b9cea41d2"
      unitRef="usd">12725000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <evh:GainOnTransferOfMembership
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTQtMS0xLTEtNjY5MTA_dd009c38-9f13-486a-8906-b86db72ae488"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTQtMy0xLTEtNjY5MTA_c254f828-f544-415e-bb39-cd9480c82cf1"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTQtNS0xLTEtNjY5MTA_e43a9971-a203-42c1-aae7-af910959b912"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTQtNy0xLTEtNjY5MTA_f8eaf329-d45e-430c-8c44-b53825eda753"
      unitRef="usd">22969000</evh:GainOnTransferOfMembership>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTUtMS0xLTEtNjY5MTA_30662400-ab2b-45da-aa42-5052d1522eef"
      unitRef="usd">-10192000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTUtMy0xLTEtNjY5MTA_1418a7af-3ac3-41d6-affb-116a9832c16f"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTUtNS0xLTEtNjY5MTA_fc7355c4-8b0e-4186-b51a-c10578aa6e54"
      unitRef="usd">-10192000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTUtNy0xLTEtNjY5MTA_0d0c5c35-6e8c-4caa-8b8e-f196b5f3e571"
      unitRef="usd">-19158000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <evh:ChangesInTaxReceivablesAgreementLiability
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTctMS0xLTEtNzY5NTc_6844db84-1c59-43e7-abee-eb35b5597679"
      unitRef="usd">42870000</evh:ChangesInTaxReceivablesAgreementLiability>
    <evh:ChangesInTaxReceivablesAgreementLiability
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTctMy0xLTEtNzY5NTc_baac1a98-c0f1-4e9e-a05c-b742bad4a5ad"
      unitRef="usd">0</evh:ChangesInTaxReceivablesAgreementLiability>
    <evh:ChangesInTaxReceivablesAgreementLiability
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTctNS0xLTEtNzY5NTc_4037720a-0584-41f6-8dbe-5d796b69e39a"
      unitRef="usd">42870000</evh:ChangesInTaxReceivablesAgreementLiability>
    <evh:ChangesInTaxReceivablesAgreementLiability
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTctNy0xLTEtNzY5NTc_8a30c784-ee64-43a2-8de5-fa1603112c72"
      unitRef="usd">0</evh:ChangesInTaxReceivablesAgreementLiability>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTYtMS0xLTEtNjY5MTA_0102d585-287d-45d5-9cd1-010b0ae47c35"
      unitRef="usd">-345000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTYtMy0xLTEtNjY5MTA_c8ae7ebd-4b5d-42bf-a41d-88eaca0689f4"
      unitRef="usd">-41000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTYtNS0xLTEtNjY5MTA_9ff522d7-d156-46e2-bcff-c423a4ffdb42"
      unitRef="usd">130000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTYtNy0xLTEtNjY5MTA_28358777-4249-4e26-b31c-92eb1f1ff38f"
      unitRef="usd">-73000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTctMS0xLTEtNjY5MTA_ee96c530-b53d-4103-be3f-f3b607529c48"
      unitRef="usd">-43393000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTctMy0xLTEtNjY5MTA_7f61cc81-24c2-4080-be6f-de32fb665c70"
      unitRef="usd">-12806000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTctNS0xLTEtNjY5MTA_cfe93f6e-f0ed-44eb-83d4-64354b27e8a7"
      unitRef="usd">-51850000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTctNy0xLTEtNjY5MTA_a5f680ae-5526-4aea-9f54-9b7864e39929"
      unitRef="usd">-32401000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTgtMS0xLTEtNjY5MTA_4e279b5d-c2e2-4ec4-acc4-f1e51cb41a17"
      unitRef="usd">-45516000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTgtMy0xLTEtNjY5MTA_bd1f43ed-086f-4b62-970c-4c156caed6b4"
      unitRef="usd">234000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTgtNS0xLTEtNjY5MTA_6461e9ad-ce80-4045-97f3-2868333b6e54"
      unitRef="usd">-44498000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTgtNy0xLTEtNjY5MTA_fb90a166-5486-4401-b195-5e493574c446"
      unitRef="usd">936000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTktMS0xLTEtNjY5MTA_e6d82b3d-96a8-469c-9b36-a0745946c155"
      unitRef="usd">2123000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTktMy0xLTEtNjY5MTA_52b4c26f-4fd8-4024-acd6-e8cd828ae0d1"
      unitRef="usd">-13040000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTktNS0xLTEtNjY5MTA_814325c3-c4f8-43f1-9549-889093d349d2"
      unitRef="usd">-7352000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMTktNy0xLTEtNjY5MTA_748f7b05-deb5-4d61-92cf-0fd288b80628"
      unitRef="usd">-33337000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtMS0xLTEtNjY5MTA_0f209cfa-8504-4ac9-b758-ac2a0a61b1b2"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtMy0xLTEtNjY5MTA_43c76fef-6b2e-4467-b3ef-343e76af8f09"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtNS0xLTEtNjY5MTA_00f03ad2-b82d-44e7-b7c4-221872011c79"
      unitRef="usd">-463000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtNy0xLTEtNjY5MTA_d20e63e0-6ca3-40ec-8951-ef7d1c289504"
      unitRef="usd">1383000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjEtMS0xLTEtNjY5MTA_2b938c91-768d-4a4f-8358-38803e7bee1a"
      unitRef="usd">2123000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjEtMS0xLTEtNjY5MTA_8a5e256b-80e4-42cf-af24-64cd9b4784bb"
      unitRef="usd">2123000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjEtMy0xLTEtNjY5MTA_397a327f-e62b-4749-b951-90aced6dbbc5"
      unitRef="usd">-13040000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjEtMy0xLTEtNjY5MTA_a78aadeb-78c2-4ac2-9c9d-3eccc69aefe1"
      unitRef="usd">-13040000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjEtNS0xLTEtNjY5MTA_24b21c64-6c5a-4a02-97de-8f53c437bf87"
      unitRef="usd">-7815000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjEtNS0xLTEtNjY5MTA_d788c378-db82-467c-8e05-8cfe8f97a8bc"
      unitRef="usd">-7815000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjEtNy0xLTEtNjY5MTA_429a395c-c7d4-453c-8ccb-d8c9dcda3225"
      unitRef="usd">-31954000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjEtNy0xLTEtNjY5MTA_54c48a0b-87c4-4c6d-afdd-8e3229629feb"
      unitRef="usd">-31954000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjUtMS0xLTEtNjY5MTA_5d78348a-1ede-42f3-9c66-3e19d04d192b"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjUtMy0xLTEtNjY5MTA_94406da4-bba3-4f7b-9a48-470977dba9ed"
      unitRef="usdPerShare">-0.15</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjUtNS0xLTEtNjY5MTA_04698b35-8bc1-4fd1-b051-1674a602e6ca"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjUtNy0xLTEtNjY5MTA_594c02a6-9adc-4b51-8a3b-49e7df85a3ba"
      unitRef="usdPerShare">-0.39</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjYtMS0xLTEtNjY5MTA_b04bb2aa-e06c-4725-a979-417393867246"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjYtMy0xLTEtNjY5MTA_51f2919e-d948-43e1-b8fe-353c355f98aa"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjYtNS0xLTEtNjY5MTA_b02eb601-91c3-4df9-824f-4b86bfd50033"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjYtNy0xLTEtNjY5MTA_92a71a9f-9843-4f08-bcfa-9a531cf1884c"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjctMS0xLTEtNjY5MTA_3532a326-e3a6-4a72-bf8a-62b392719771"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjctMy0xLTEtNjY5MTA_6531b55f-f41b-4ab9-ba40-c11e9a2c2159"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjctNS0xLTEtNjY5MTA_dc29ff25-a8f0-4a3c-a9ac-cc086468d8e9"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjctNy0xLTEtNjY5MTA_ee2b491b-a03c-4b79-b603-6b46c67d2ad3"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzEtMS0xLTEtNzcwMTU_c0bc64f5-cd2d-48be-8ace-aa6e4d481486"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzEtMy0xLTEtNzcwMTU_2ebf6c1c-71c6-4384-8606-b4152dbb6d7d"
      unitRef="usdPerShare">-0.15</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzEtNS0xLTEtNzcwMTU_b559917c-1929-4bc9-bf4d-69a8feff1d5d"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzEtNy0xLTEtNzcwMTU_01899fe7-98ba-4bca-a762-25a2204f5eb5"
      unitRef="usdPerShare">-0.39</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzItMS0xLTEtNzcwMTU_df0eb775-ca69-403d-b4d5-5d2a0bbb0973"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzItMy0xLTEtNzcwMTU_13066bf6-b1e7-43da-9b52-2cc3045e00a7"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzItNS0xLTEtNzcwMTU_ddf5b5b3-765f-4c63-a2d4-44bb2fbb4d0b"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzItNy0xLTEtNzcwMTU_4f04f922-c15e-48e6-b6d7-1344cd429489"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzMtMS0xLTEtNzcwMjk_1cc75002-3e6b-4439-886b-d35b708cfd77"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzMtMy0xLTEtNzcwMjk_180fac62-bd77-4452-89a2-404577c7ea37"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzMtNS0xLTEtNzcwMjk_6642db39-b9b4-4146-856f-f11cc4bccf6d"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzMtNy0xLTEtNzcwMjk_dfa295c9-4f3f-4d71-8344-393a4f8a3c2f"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzAtMS0xLTEtNjY5MTA_c9125b58-b588-457a-a723-f2fd3650c980"
      unitRef="shares">95286000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzAtMy0xLTEtNjY5MTA_ce167901-b270-400d-bedc-5241c8a1b3bb"
      unitRef="shares">85800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzAtNS0xLTEtNjY5MTA_f9c66f3f-75a5-4c1d-9db9-f53c0be43420"
      unitRef="shares">91643000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzAtNy0xLTEtNjY5MTA_60086fc8-e0b2-4a6a-94cc-387bd5265ddc"
      unitRef="shares">85306000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzItMS0xLTEtNzY3NDY_2341bad9-a548-48e7-9ae5-631e4a6a4c60"
      unitRef="shares">99308000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzItMy0xLTEtNzY3NDY_48dcf8ec-89b1-44ba-8bb9-2bcdb2fa21e7"
      unitRef="shares">85800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzItNS0xLTEtNzY3NDY_2f7662e5-8c53-4a1b-854c-c2af04a62059"
      unitRef="shares">91643000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzItNy0xLTEtNzY3NDY_c728ec08-cae6-40f3-877d-ae2ae8416dec"
      unitRef="shares">85306000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzMtMS0xLTEtNjY5MTA_db47e02e-7f1a-4e61-b286-4de56945e7e6"
      unitRef="usd">2123000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzMtMy0xLTEtNjY5MTA_64aec95c-81a6-44c0-a970-9e909a3957c6"
      unitRef="usd">-13040000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzMtNS0xLTEtNjY5MTA_3e88cc78-18a0-4adc-b8d6-a701c458dbb0"
      unitRef="usd">-7815000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzMtNy0xLTEtNjY5MTA_acbd1652-d79b-4d22-948a-3fda768396e0"
      unitRef="usd">-31954000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzUtMS0xLTEtNjY5MTA_4eae2c3e-c6aa-453c-bb6e-cb34ad35f488"
      unitRef="usd">-262000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzUtMy0xLTEtNjY5MTA_c35d7758-f955-4f9d-b0b0-456a4439a547"
      unitRef="usd">4000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzUtNS0xLTEtNjY5MTA_e300779e-1394-4a3e-87ea-c494325e1d82"
      unitRef="usd">-682000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzUtNy0xLTEtNjY5MTA_64f2ab62-14a2-4db0-9354-ad14d788ce39"
      unitRef="usd">-85000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzYtMS0xLTEtNjY5MTA_c27d981f-7481-40b8-8bb4-c699be76a053"
      unitRef="usd">1861000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzYtMy0xLTEtNjY5MTA_4799c6d3-59a7-4164-847e-74d7db487516"
      unitRef="usd">-13036000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzYtNS0xLTEtNjY5MTA_93998ada-86a1-48a5-ac8e-12eaed3cc39b"
      unitRef="usd">-8497000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMzYtNy0xLTEtNjY5MTA_04ffe756-b1a5-4c14-bf50-8a61d64aebf8"
      unitRef="usd">-32039000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfMjY5_cd162837-63ed-45d0-8343-6d6ea621bb0f"
      unitRef="usd">-500000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfMzQy_d4a7dbf8-c781-4433-9ce3-297fee23c41b"
      unitRef="usd">1900000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i17e8b3c5da9a4abf8639a0d3c5015910_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMy0xLTEtMS02NjkxMA_39e26d99-02ba-4da4-9eaf-9802e09b396f"
      unitRef="shares">91657000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i17e8b3c5da9a4abf8639a0d3c5015910_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMy0zLTEtMS02NjkxMA_9ead2206-283d-4fb8-8ea5-2a3ca123ef8d"
      unitRef="usd">916000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icb83f20a7c61479b93a83e23998b1c89_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMy01LTEtMS02NjkxMA_1d3f820a-4052-4b92-a156-6a5226ed0c6d"
      unitRef="usd">1231005000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idfb31ce6eb9e4668992f11294921cfad_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMy03LTEtMS02NjkxMA_3a3cc4a9-3790-4f8e-b01d-01317616d9c6"
      unitRef="usd">-782000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibc0ca7083bdc4ebe842729dbd273685c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMy05LTEtMS02NjkxMA_46a812a1-e91e-4754-8af7-d06bd023dbe4"
      unitRef="usd">-596928000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1dd537792b6e421ba9639adbfe4474c4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMy0xMS0xLTEtNjY5MTA_c1f6b2fd-5f5d-4e67-9bfe-8fd143718d59"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0a15fb8f7fe94bf88c8a8a9847578001_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMy0xMy0xLTEtNjY5MTA_4751d7bc-bcab-480a-90e5-dcdcfcd40a0d"
      unitRef="usd">613088000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic9f34759559a4dfd86efcb145ce3357e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNS01LTEtMS02NjkxMA_3f21cb08-4283-48b0-80b4-15a70869d0a7"
      unitRef="usd">6992000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNS0xMy0xLTEtNjY5MTA_6ecf5a8f-612c-41f4-84e9-e22352c1c537"
      unitRef="usd">6992000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i34fded2f74a147099334cfa413800c2c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNi0xLTEtMS03Mzc2Ng_f7829d29-0114-46c1-b983-a7c335ff922f"
      unitRef="shares">317000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i34fded2f74a147099334cfa413800c2c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNi0zLTEtMS03Mzc2Ng_2dad9e36-9c71-4a57-a655-fe2535d05ff6"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic9f34759559a4dfd86efcb145ce3357e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNi01LTEtMS03Mzc2Ng_aeb77b99-a0e9-45e3-8bc2-8cad6cbb88d9"
      unitRef="usd">2967000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNi0xMy0xLTEtNzM3NDk_2a1913b2-4e0d-4161-89c4-157ddaac0ad4"
      unitRef="usd">2971000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i34fded2f74a147099334cfa413800c2c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNi0xLTEtMS02NjkxMA_1e1fb9ad-ceaf-4a62-b720-4bf0e94494a6"
      unitRef="shares">50000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i34fded2f74a147099334cfa413800c2c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNi0zLTEtMS02NjkxMA_5c86ac7d-5a51-4a44-8db1-fba33de28096"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ic9f34759559a4dfd86efcb145ce3357e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNi01LTEtMS02NjkxMA_a04a0b0b-cf2d-47ee-9a2f-0b586d8befa9"
      unitRef="usd">-949000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNi0xMy0xLTEtNjY5MTA_83b1d0ce-15bd-46ea-9949-034a62ca90bf"
      unitRef="usd">-948000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i34fded2f74a147099334cfa413800c2c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfOC0xLTEtMS03NDczNA_8bd3d415-e87f-44d2-83eb-4d83fc28b928"
      unitRef="shares">5394000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i34fded2f74a147099334cfa413800c2c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfOC0zLTEtMS03NDczNA_6a20ec9a-f365-438f-9d95-0955412d9f5d"
      unitRef="usd">54000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ic9f34759559a4dfd86efcb145ce3357e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfOC01LTEtMS03NDc0Nw_a113a05b-2b32-436d-9e7d-07eb1be47956"
      unitRef="usd">101945000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfOC0xMy0xLTEtNzM3NTQ_31f73cae-fc5e-4984-bffb-414199aeb113"
      unitRef="usd">101999000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="i34fded2f74a147099334cfa413800c2c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfOS0xLTEtMS03NDczNA_8390c0ee-b44e-4002-b0d1-b1a698f462a9"
      unitRef="shares">3742000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i34fded2f74a147099334cfa413800c2c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfOS0zLTEtMS03NDczNA_5cc3da95-5d44-4a3c-b6da-b23c0c1c507e"
      unitRef="usd">37000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ic9f34759559a4dfd86efcb145ce3357e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfOS01LTEtMS03NDc0Nw_623bfdff-f3c2-48ee-bd95-545e15016b48"
      unitRef="usd">130138000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfOS0xMy0xLTEtNzM5NDI_ce07d0fa-fa32-4464-b0ed-2dfe501df581"
      unitRef="usd">130175000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i2946b2f4742c436b9ec38ed088adddf3_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNy03LTEtMS02NjkxMA_0f15e2d8-d0ee-4f63-a5aa-b02f2b2e8e5d"
      unitRef="usd">-262000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfNy0xMy0xLTEtNjY5MTA_bc4a1f4b-c077-46c9-b3b2-0be2571ee56d"
      unitRef="usd">-262000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i774f0c895b93475580cf9bffc1f4d401_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfOC05LTEtMS02NjkxMA_b567e840-f996-4731-a6f4-80ce5a799a19"
      unitRef="usd">2123000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfOC0xMy0xLTEtNjY5MTA_bf53d59d-9b51-4eb2-b142-97e7fc61004f"
      unitRef="usd">2123000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i3d92a7bff72d4283b5a2abc070339ddf_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTAtMS0xLTEtNjY5MTA_c86d81b0-995d-4d8d-9d10-4d9c77bd2e3d"
      unitRef="shares">101160000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i3d92a7bff72d4283b5a2abc070339ddf_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTAtMy0xLTEtNjY5MTA_dac48440-c315-4072-82d4-4dad8b48f650"
      unitRef="usd">1012000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic61eea28d6e24e17b1c838a89e833091_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTAtNS0xLTEtNjY5MTA_39f27395-1c69-4e18-a052-72d1d91ffbe1"
      unitRef="usd">1472098000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0deb2b8e664f400a93e847d75c9f7461_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTAtNy0xLTEtNjY5MTA_480f1b86-9fc4-4a5f-b25d-9f36f68da627"
      unitRef="usd">-1044000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1f7fbb4a3598436a82370c985cafd671_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTAtOS0xLTEtNjY5MTA_8da86ca4-cd37-4d18-8f7f-2f43158769c4"
      unitRef="usd">-594805000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7743c9436eda44b9a29866c882a8d051_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTAtMTEtMS0xLTY2OTEw_9228f31c-11b8-4083-9022-0133a878a3e0"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTAtMTMtMS0xLTY2OTEw_33ed2410-042f-49f9-96b0-7b385d5d2cf8"
      unitRef="usd">856138000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="idf7540828b6542ccbb0c439bd8d9be10_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTYtMS0xLTEtNjY5MTA_1617f15b-f9bc-4c7a-8793-69cc63b95a62"
      unitRef="shares">87195000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="idf7540828b6542ccbb0c439bd8d9be10_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTYtMy0xLTEtNjY5MTA_bec9dbda-9537-479f-a419-2e533736a447"
      unitRef="usd">872000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i47799e4f502f42c98c9d834440ff6d03_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTYtNS0xLTEtNjY5MTA_ac78ce41-386b-421a-99ee-5626ddff759b"
      unitRef="usd">1242900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib3859fe1f193413e80c660d7cd13bb43_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTYtNy0xLTEtNjY5MTA_5108ffe1-06fb-4b69-a7b1-9c727b43b3da"
      unitRef="usd">-367000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2153e00392cb428692eb552f22b89475_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTYtOS0xLTEtNjY5MTA_3e363657-36dd-40f6-9839-32102cc59472"
      unitRef="usd">-608092000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie13e8e5c1c8f442db97081f5b187e36a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTYtMTEtMS0xLTY2OTEw_61e0a7b6-b487-4f4d-b896-5850504256c1"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i22d0f81c708f4d62b2c2ba75e4549659_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTYtMTMtMS0xLTY2OTEw_62964db2-8d93-41ad-883e-d377f1e2089c"
      unitRef="usd">614190000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i08eed5034fa6469aa0775ddf5e8edf38_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTgtNS0xLTEtNjY5MTA_21d45f1d-3ae3-492f-8786-9b0c662fd141"
      unitRef="usd">4395000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTgtMTMtMS0xLTY2OTEw_1dbe0eb4-920b-4bc6-a7af-1577d6650d56"
      unitRef="usd">4395000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i89f4cf78a38147c4a67ccbc5f1b70b5e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTktMS0xLTEtNjY5MTA_2efe3cde-62ba-469d-837d-4199d2bba21f"
      unitRef="shares">242000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i89f4cf78a38147c4a67ccbc5f1b70b5e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTktMy0xLTEtNjY5MTA_8bc5de01-fad5-4b05-aded-9b5b56135bbc"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i08eed5034fa6469aa0775ddf5e8edf38_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTktNS0xLTEtNjY5MTA_6a8e0cb9-5514-4af0-b58c-eccc51a2c794"
      unitRef="usd">2188000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMTktMTMtMS0xLTY2OTEw_f12d1071-7fb2-4078-b464-9ab9b492c9e1"
      unitRef="usd">2190000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i89f4cf78a38147c4a67ccbc5f1b70b5e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjAtMS0xLTEtNjY5MTA_36f16806-dfae-4e32-89ff-b456ae55b6dd"
      unitRef="shares">19000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i89f4cf78a38147c4a67ccbc5f1b70b5e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjAtMy0xLTEtNjY5MTA_61faa8b3-9615-44d0-80ab-a95222920457"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i08eed5034fa6469aa0775ddf5e8edf38_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjAtNS0xLTEtNjY5MTA_23c1d218-3106-42d6-b92d-2b4e6371798f"
      unitRef="usd">-255000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjAtMTMtMS0xLTY2OTEw_c5dabb05-8f8c-4ec0-baa0-9d71c652f3b6"
      unitRef="usd">-255000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="if579391e2dd946e28f4975df65264f3e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjEtNy0xLTEtNjY5MTA_b43cc33d-487e-42cd-a266-c7933a8c0284"
      unitRef="usd">4000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjEtMTMtMS0xLTY2OTEw_6f166f4e-769c-49c5-babb-21a6a46fb440"
      unitRef="usd">4000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i434deea731b3493cafdecab4e0f513df_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjItOS0xLTEtNjY5MTA_9b8ac5fa-f639-48cf-8d47-90dcf2df818b"
      unitRef="usd">-13040000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjItMTMtMS0xLTY2OTEw_d646aedb-d737-469b-b8bd-ce6ef7c8602b"
      unitRef="usd">-13040000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="ic863a6e2b5314131a58086e3e72c0388_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjQtMS0xLTEtNjY5MTA_cabf45c8-83c7-4785-a7a6-8f2dc133c18b"
      unitRef="shares">87456000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ic863a6e2b5314131a58086e3e72c0388_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjQtMy0xLTEtNjY5MTA_4b589964-d80b-4d03-a958-df616c238f30"
      unitRef="usd">874000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib1d69eae660647b891b8545b7593243a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjQtNS0xLTEtNjY5MTA_403e0953-790a-4aa8-a7c4-c45941f98896"
      unitRef="usd">1249228000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie40e239beadc4317b3c499f7eea02fb6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjQtNy0xLTEtNjY5MTA_9ec3fb31-4bae-4039-ab22-0009df35a026"
      unitRef="usd">-363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6f69dcb0c02046a8b06f845c2daa4737_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjQtOS0xLTEtNjY5MTA_22a31e7b-4f10-4b28-82d7-1951be8ae313"
      unitRef="usd">-621132000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i179c3fe310ef4e61a6d5a2f2721eedc5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjQtMTEtMS0xLTY2OTEw_789c5b3b-8194-4827-b5a9-517f0346fa44"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i63b3ddd7486946c2a0a8151832317d14_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjI0YWE0OGUwYmZjZTQ2YjJiNTJjMTE2M2I4MDMzYWUyL3RhYmxlcmFuZ2U6MjRhYTQ4ZTBiZmNlNDZiMmI1MmMxMTYzYjgwMzNhZTJfMjQtMTMtMS0xLTY2OTEw_0e77e516-2947-40f2-b923-43cda8af0502"
      unitRef="usd">607484000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="ic2bb3fdaea8f41d1a5b926350a34b34f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMy0xLTEtMS02NjkxMA_0bf767b4-ee8a-41bc-a930-39c244542b6b"
      unitRef="shares">90759000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ic2bb3fdaea8f41d1a5b926350a34b34f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMy0zLTEtMS02NjkxMA_e3370fe5-f3ee-4ada-bdb9-29b607e75487"
      unitRef="usd">908000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4f6814f5fa1246a687d35a28833137b0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMy01LTEtMS02NjkxMA_f0b43f31-912a-4657-9264-568dded85ec6"
      unitRef="usd">1340989000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9f73e9dc3b2a45679bdcc5b130649934_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMy03LTEtMS02NjkxMA_b9311462-512c-489b-9a04-a9c2e1ba52c1"
      unitRef="usd">-362000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i04896f930bff47dda34bb3798c357daf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMy05LTEtMS02NjkxMA_dee04778-ba85-4744-ac67-133374ec1839"
      unitRef="usd">-626779000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icb4cc675813847809003fabf765db881_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMy0xMS0xLTEtNjY5MTA_61cf36be-bc70-439f-9baa-55277bcfa992"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMy0xMy0xLTEtNjY5MTA_e091bff5-6551-4b65-b6f2-9327a9ed7b51"
      unitRef="usd">693633000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic7382beeecb6460d9d7d2b36a822b970_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNS01LTEtMS02NjkxMA_bef13197-b762-496d-a06f-3cf08e21cdd7"
      unitRef="usd">-106172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i749e0b18e9154afab9acf4c974f1cf8b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNS05LTEtMS02NjkxMA_b79c8ceb-9c09-4bc4-8e7c-fbd0e935c954"
      unitRef="usd">39789000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie2ed53ed57f5412e8fa51e1b7648fde0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNS0xMy0xLTEtNjY5MTA_b8b39b49-1708-4760-9414-8ac23d50a9a6"
      unitRef="usd">-66383000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i44adf89b2b3d45209e9135d9c2231fda_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNi01LTEtMS02NjkxMA_847b1431-6b8a-4df7-8b37-ad6b6138fcb1"
      unitRef="usd">19350000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNi0xMy0xLTEtNjY5MTA_d0c5d108-2191-46ee-aef5-eec98688c543"
      unitRef="usd">19350000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNy0xLTEtMS02NjkxMA_c96eea06-87db-4c77-904f-70afcd9f4cf8"
      unitRef="shares">354000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNy0zLTEtMS02NjkxMA_898504c3-8dde-4282-b0c1-be7908856900"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i44adf89b2b3d45209e9135d9c2231fda_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNy01LTEtMS02NjkxMA_8ef9cda3-df79-410e-bd5c-b43c464f0d78"
      unitRef="usd">3277000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfNy0xMy0xLTEtNjY5MTA_4d950940-c7c2-4781-9b64-1bf79d117562"
      unitRef="usd">3280000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfOC0xLTEtMS02NjkxMA_4e0f47a4-526e-4f21-ba51-0555741af4c7"
      unitRef="shares">452000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfOC0zLTEtMS02NjkxMA_1c9890aa-d2f5-4e1e-8156-550e91e0926f"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i44adf89b2b3d45209e9135d9c2231fda_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfOC01LTEtMS02NjkxMA_f27c1a2f-4a49-46e4-bc8c-a494d92ef546"
      unitRef="usd">-6192000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfOC0xMy0xLTEtNjY5MTA_51bf60ac-dc3e-42ca-8fef-7d4d57fa7e78"
      unitRef="usd">-6187000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfOS0xLTEtMS02NjkxMA_7e0caa00-3dcd-42d1-89f0-599917334d92"
      unitRef="shares">459000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfOS0zLTEtMS02NjkxMA_9c7749b9-bf4b-4ffe-8b68-794c952092dc"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i44adf89b2b3d45209e9135d9c2231fda_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfOS01LTEtMS02NjkxMA_fb26f1a1-426e-4275-9d93-49adb55a6d15"
      unitRef="usd">-11237000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfOS0xMy0xLTEtNjY5MTA_337b298b-3e68-4859-a5b6-5c842dd59bc0"
      unitRef="usd">-11232000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTAtMS0xLTEtNzM5MDQ_18de8dc2-d707-4699-86c1-f50dc96bafe0"
      unitRef="shares">5394000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTAtMy0xLTEtNzM5MDQ_d0348ab4-5ea3-409e-888f-a63919e65c1e"
      unitRef="usd">54000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i44adf89b2b3d45209e9135d9c2231fda_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTAtNS0xLTEtNzM5MTI_cd054396-e463-4abd-adac-29190bcec057"
      unitRef="usd">101945000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTAtMTMtMS0xLTczNzU3_bab27c5b-c181-46f5-a3f7-4eff11a9e330"
      unitRef="usd">101999000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTEtMS0xLTEtNzM5MDQ_736c8676-b3c8-40f5-8a2c-fb521a4fb4f4"
      unitRef="shares">3742000</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="ieaf0a02eefde4d2c8a041e13690add6b_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTEtMy0xLTEtNzM5MDQ_35144496-5748-4225-ae6d-7fefe1e49935"
      unitRef="usd">37000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i44adf89b2b3d45209e9135d9c2231fda_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTEtNS0xLTEtNzM5MTI_a3b234c2-5093-4b17-a2ad-2e6e755467d9"
      unitRef="usd">130138000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTEtMTMtMS0xLTczOTEy_8a056915-e831-4918-97a0-0c9a94f86c46"
      unitRef="usd">130175000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia1ad6cf9dd3347cb949a440b44766e97_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTAtNy0xLTEtNjY5MTA_607ef50f-a8cf-4299-9ef6-fb4377a55437"
      unitRef="usd">-682000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTAtMTMtMS0xLTY2OTEw_0c143692-86df-4fad-857f-cb571a6722f0"
      unitRef="usd">-682000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="ifc261b79d9f841ad8560ed98593f9621_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTEtOS0xLTEtNjY5MTA_7ac6edfa-6534-4f05-aed6-41563cff77da"
      unitRef="usd">-7815000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTEtMTMtMS0xLTY2OTEw_b257de4b-898c-4bed-bc13-1bacc2c10046"
      unitRef="usd">-7815000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i3d92a7bff72d4283b5a2abc070339ddf_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTMtMS0xLTEtNjY5MTA_d6206b06-5614-4ea8-9391-364f20ca13fc"
      unitRef="shares">101160000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i3d92a7bff72d4283b5a2abc070339ddf_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTMtMy0xLTEtNjY5MTA_73144995-6e37-4233-9f56-a741c7d09b47"
      unitRef="usd">1012000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic61eea28d6e24e17b1c838a89e833091_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTMtNS0xLTEtNjY5MTA_f295a54d-bd33-420f-aedb-3cd50a96dca3"
      unitRef="usd">1472098000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0deb2b8e664f400a93e847d75c9f7461_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTMtNy0xLTEtNjY5MTA_c369e976-105d-42af-a9b2-aaad5dfc1f45"
      unitRef="usd">-1044000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1f7fbb4a3598436a82370c985cafd671_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTMtOS0xLTEtNjY5MTA_f853f9e5-0804-460d-8983-85f6fe0be1cd"
      unitRef="usd">-594805000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7743c9436eda44b9a29866c882a8d051_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTMtMTEtMS0xLTY2OTEw_aeeda320-8f00-4165-a206-6d476d481c66"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTMtMTMtMS0xLTY2OTEw_2256e004-9ea4-4a8c-b371-c98339bba103"
      unitRef="usd">856138000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="if90b80996d524ed6b89fbfebe2cedda5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTktMS0xLTEtNjY5MTA_ce71d873-298c-4368-84fe-640111cfbfb7"
      unitRef="shares">85895000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="if90b80996d524ed6b89fbfebe2cedda5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTktMy0xLTEtNjY5MTA_00d1c866-8d7d-46ee-b42d-5a6327afa624"
      unitRef="usd">859000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i694c8eca95b44aa281ff19a36e240b13_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTktNS0xLTEtNjY5MTA_08b52ba6-0668-4f92-aa3a-c9393a8ea7dc"
      unitRef="usd">1229320000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5b6a0decc62412fb5b58744bd94543b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTktNy0xLTEtNjY5MTA_a56fd276-fa12-45ae-b9a5-ef6389534dd8"
      unitRef="usd">-278000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i57e089b648ff473aba749cdaa85824a5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTktOS0xLTEtNjY5MTA_4a7f654b-ff26-4abf-97cb-a2ee7a3800be"
      unitRef="usd">-589178000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i93b026baeacf472babb208203c15aa89_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTktMTEtMS0xLTY2OTEw_f84c2edc-7bc0-454b-8c70-6a580b6e85e5"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idcb7e5d5de6d4fb9bd1b47d49e170108_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMTktMTMtMS0xLTY2OTEw_caf4a4db-ad7f-44d0-adf6-b0af8c156917"
      unitRef="usd">619600000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7eb7badc179d4dd4b0b439120c44e492_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjEtNS0xLTEtNjY5MTA_e4f2bf72-dcbb-4b4b-b814-9e86ad5f38a5"
      unitRef="usd">11754000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjEtMTMtMS0xLTY2OTEw_ac72c109-8065-404c-b763-433374663e35"
      unitRef="usd">11754000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i38d9971f78fb49c3a0ecdff39b8115f9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjItMS0xLTEtNjY5MTA_2d203560-10bd-4e94-8dd0-48fbf77a5421"
      unitRef="shares">1142000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i38d9971f78fb49c3a0ecdff39b8115f9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjItMy0xLTEtNjY5MTA_dc050d6c-fa99-43a5-8ef3-62d21dbd15a9"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7eb7badc179d4dd4b0b439120c44e492_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjItNS0xLTEtNjY5MTA_6c350b0d-077b-4f7a-ab5d-4c96f202b969"
      unitRef="usd">11555000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjItMTMtMS0xLTY2OTEw_39f7f084-da74-442b-836b-5e8ca8de5f0d"
      unitRef="usd">11566000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i38d9971f78fb49c3a0ecdff39b8115f9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjMtMS0xLTEtNjY5MTA_cd59a74d-b6be-4df4-a75e-dfd07c42d122"
      unitRef="shares">419000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i38d9971f78fb49c3a0ecdff39b8115f9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjMtMy0xLTEtNjY5MTA_66304911-ae0b-48d6-999f-3dd287acad35"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i7eb7badc179d4dd4b0b439120c44e492_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjMtNS0xLTEtNjY5MTA_2988f04d-f3b8-41e4-a088-28d15b5325f6"
      unitRef="usd">-3401000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjMtMTMtMS0xLTY2OTEw_4f667ce4-e772-4948-b26a-cae479ca8cc6"
      unitRef="usd">-3397000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ifd86661e66444c48b5ef3429b01488ee_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjQtNy0xLTEtNjY5MTA_8d7b88f7-e528-4304-839d-467361fdbccd"
      unitRef="usd">-85000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjQtMTMtMS0xLTY2OTEw_6a245b19-7975-47f7-9104-0e581538d542"
      unitRef="usd">-85000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="iaa111bc1b6fc47e39a435526dc19640d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjUtOS0xLTEtNjY5MTA_09bede0f-a35a-41fa-b3ca-63d5380bd03a"
      unitRef="usd">-31954000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjUtMTMtMS0xLTY2OTEw_aa25776d-cb9d-41e9-8166-5e35841adc9c"
      unitRef="usd">-31954000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="ic863a6e2b5314131a58086e3e72c0388_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjctMS0xLTEtNjY5MTA_fc05456f-98d7-485c-acb4-c1e8f7cf8094"
      unitRef="shares">87456000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ic863a6e2b5314131a58086e3e72c0388_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjctMy0xLTEtNjY5MTA_78f196a8-22eb-4281-a340-5d2fcd101f0b"
      unitRef="usd">874000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib1d69eae660647b891b8545b7593243a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjctNS0xLTEtNjY5MTA_55fffb17-450d-4f3b-82f8-5cef428a3e97"
      unitRef="usd">1249228000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie40e239beadc4317b3c499f7eea02fb6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjctNy0xLTEtNjY5MTA_cffe47a7-32cd-4eac-ae53-3e8e8cd56b61"
      unitRef="usd">-363000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6f69dcb0c02046a8b06f845c2daa4737_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjctOS0xLTEtNjY5MTA_909bd3eb-0ef2-45f5-b3b8-36c2de88a4a8"
      unitRef="usd">-621132000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i179c3fe310ef4e61a6d5a2f2721eedc5_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjctMTEtMS0xLTY2OTEw_2929f1c6-5fa3-4820-94c8-44d71b02ab68"
      unitRef="usd">-21123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i63b3ddd7486946c2a0a8151832317d14_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zMS9mcmFnOmYxMmUxYWExZWI0MTRkNzI5MzkwY2I4ZWM2NGY4NzY5L3RhYmxlOjA1MTE5NzlhODNiYzQ4MjhhODlmNTIyMjMwMWI0ZWI4L3RhYmxlcmFuZ2U6MDUxMTk3OWE4M2JjNDgyOGE4OWY1MjIyMzAxYjRlYjhfMjctMTMtMS0xLTY2OTEw_622fca40-e571-422e-9e83-6d6550a6af24"
      unitRef="usd">607484000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMy0xLTEtMS02NjkxMA_e873b4e1-dc10-41a1-82c5-76afe4338f8a"
      unitRef="usd">-7815000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMy0zLTEtMS02NjkxMA_68da5375-ea96-41fa-bae1-cb96d4bc8f12"
      unitRef="usd">-31954000</us-gaap:NetIncomeLoss>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNS0xLTEtMS02NjkxMA_cd5ea9b0-b7bc-4de5-9fb9-24deba3ec14f"
      unitRef="usd">-5822000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNS0zLTEtMS02NjkxMA_0949f868-71b1-43d3-a6c8-8164a5c830ea"
      unitRef="usd">-819000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <evh:GainLossOnDispositionOfAssetsOperatingActivities
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNi0xLTEtMS02NjkxMA_cf92af18-7633-408c-8c6d-2422ed22a452"
      unitRef="usd">-463000</evh:GainLossOnDispositionOfAssetsOperatingActivities>
    <evh:GainLossOnDispositionOfAssetsOperatingActivities
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNi0zLTEtMS02NjkxMA_0ee84394-1291-4483-a036-00d281db5d25"
      unitRef="usd">1904000</evh:GainLossOnDispositionOfAssetsOperatingActivities>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNy0xLTEtMS02NjkxMA_dd2ffd14-a0a3-4d8b-a439-b55efbf2322d"
      unitRef="usd">3940000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNy0zLTEtMS02NjkxMA_5a8d492d-41c9-4e26-85e6-7c29af52dbb9"
      unitRef="usd">12725000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfOC0xLTEtMS02NjkxMA_e6871801-8b23-46e1-825c-35446641906c"
      unitRef="usd">47414000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfOC0zLTEtMS02NjkxMA_b8e65f39-64ec-48fb-a304-6879dbb89764"
      unitRef="usd">45122000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfOS0xLTEtMS02NjkxMA_70757c0d-6b5b-489c-b292-c1c40d6abc32"
      unitRef="usd">19350000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfOS0zLTEtMS02NjkxMA_c858871a-3fd6-4389-ac22-23a597fe152d"
      unitRef="usd">11754000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTAtMS0xLTEtNjY5MTA_0a12d864-9432-40aa-b050-60ba81a2872e"
      unitRef="usd">-46385000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTAtMy0xLTEtNjY5MTA_af006232-bb42-4c19-b5da-2010fd660399"
      unitRef="usd">-288000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTEtMS0xLTEtNjY5MTA_f279e84b-f9fd-4579-a7d6-9c959ef624bf"
      unitRef="usd">14768000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTEtMy0xLTEtNjY5MTA_c6560d9f-8530-4f19-96ac-2e70439ae2d3"
      unitRef="usd">9928000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTItMS0xLTEtNjY5MTA_946b06dd-5a63-4788-be67-1f7d51455aa1"
      unitRef="usd">1762000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTItMy0xLTEtNjY5MTA_47f1b3b9-cc7b-49b6-b2ec-471da60a5bb8"
      unitRef="usd">13399000</us-gaap:AmortizationOfFinancingCosts>
    <evh:GainOnTransferOfMembership
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTMtMS0xLTEtNjY5MTA_c2bd18cc-bb92-4cf1-8175-5fa555c03a30"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTMtMy0xLTEtNjY5MTA_ced8dcd4-5ad4-481b-b0ef-0d428cc99216"
      unitRef="usd">22969000</evh:GainOnTransferOfMembership>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTQtMS0xLTEtNjY5MTA_82c1c7f1-81f8-43f1-b92c-6d39f16d5366"
      unitRef="usd">-10192000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTQtMy0xLTEtNjY5MTA_2d5a299c-972a-4f44-9e20-a53196bb9ab6"
      unitRef="usd">-19158000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <evh:IncreaseDecreaseInTaxReceivableAgreement
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTYtMS0xLTEtODI0Mjk_cbd9c093-7ba7-4457-a61d-89f3b8245b60"
      unitRef="usd">42870000</evh:IncreaseDecreaseInTaxReceivableAgreement>
    <evh:IncreaseDecreaseInTaxReceivableAgreement
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTYtMy0xLTEtODI0Mjk_22a2d863-c626-43a6-8589-27f970a40b02"
      unitRef="usd">0</evh:IncreaseDecreaseInTaxReceivableAgreement>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTUtMS0xLTEtNjY5MTA_f19b780d-ded3-47af-9ac2-31d152834306"
      unitRef="usd">-2163000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTUtMy0xLTEtNjY5MTA_ec8efb31-c10e-45f8-8c6f-dab69c18d67d"
      unitRef="usd">-472000</us-gaap:OtherNoncashIncomeExpense>
    <evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTctMS0xLTEtNjY5MTA_346ed3d9-f515-4d6c-835e-f966d865c428"
      unitRef="usd">34796000</evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset>
    <evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTctMy0xLTEtNjY5MTA_4722bb63-4f5a-497a-a0ae-f7623be3e314"
      unitRef="usd">52878000</evh:IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTgtMS0xLTEtNjY5MTA_0c650ec6-6cec-4730-99a7-299a1ca1cd16"
      unitRef="usd">2409000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTgtMy0xLTEtNjY5MTA_bf0b7347-0eef-4baf-a960-1a55e040f513"
      unitRef="usd">140000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <evh:IncreaseDecreaseInCapitalizedContractCostNet
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTktMS0xLTEtNjY5MTA_c1d62c9b-5d8a-4e00-8835-101df96e3a5a"
      unitRef="usd">6732000</evh:IncreaseDecreaseInCapitalizedContractCostNet>
    <evh:IncreaseDecreaseInCapitalizedContractCostNet
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMTktMy0xLTEtNjY5MTA_5d64e769-7122-486b-9208-277b6a41f7dd"
      unitRef="usd">8439000</evh:IncreaseDecreaseInCapitalizedContractCostNet>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjAtMS0xLTEtNjY5MTA_34fc9ecc-19ae-4669-a80c-29ad81fc7e20"
      unitRef="usd">5936000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjAtMy0xLTEtNjY5MTA_1a095815-755b-430a-a157-5c7969ad689e"
      unitRef="usd">8164000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjEtMS0xLTEtNjY5MTA_c8ae6885-35e1-4601-97ca-11a0a35b2020"
      unitRef="usd">-27903000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjEtMy0xLTEtNjY5MTA_2015ef77-e189-4e5d-a7ed-3036556b8586"
      unitRef="usd">-13893000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjItMS0xLTEtNjY5MTA_20ff68c8-897f-4c93-9115-c23fe7003985"
      unitRef="usd">-14451000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjItMy0xLTEtNjY5MTA_085a238a-acac-47bf-840f-a84eb0c64368"
      unitRef="usd">-12811000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjMtMS0xLTEtNjY5MTA_71737941-a975-49ea-b551-2156e386e25e"
      unitRef="usd">-4741000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjMtMy0xLTEtNjY5MTA_b1dd39a5-aa45-46be-b0b8-7cc7373e72c2"
      unitRef="usd">3103000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjQtMS0xLTEtNjY5MTA_374fe97c-27ee-4b44-8610-d7135d8efec5"
      unitRef="usd">-35596000</evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities>
    <evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjQtMy0xLTEtNjY5MTA_1cdc273c-6788-436a-8ce6-38933c9ddbb7"
      unitRef="usd">16784000</evh:IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities>
    <evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjUtMS0xLTEtNjY5MTA_bb6855be-b587-4532-ace6-6fb564eba406"
      unitRef="usd">-831000</evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjUtMy0xLTEtNjY5MTA_8b9f9121-2b56-4362-ac98-61863ee0590a"
      unitRef="usd">-6408000</evh:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjYtMS0xLTEtNjY5MTA_c912519b-aa68-4191-a448-0b473d6a3375"
      unitRef="usd">-1223000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjYtMy0xLTEtNjY5MTA_8f75fe9e-3f94-44e7-b3dc-1d72a1daacf5"
      unitRef="usd">-4589000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjctMS0xLTEtNjY5MTA_636ac5ac-c613-4c01-8727-565f57b86c51"
      unitRef="usd">-1184000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjctMy0xLTEtNjY5MTA_85af2b81-ef56-4ecd-8f79-bd179f23b174"
      unitRef="usd">1208000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjgtMS0xLTEtNjY5MTA_d3d4e1a6-f234-4fc7-8fba-71e80f67f366"
      unitRef="usd">-47248000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMjgtMy0xLTEtNjY5MTA_1c3b6552-19fb-47ae-94b9-91aa76434542"
      unitRef="usd">-27909000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzAtMS0xLTEtNjY5MTA_8225014a-5090-4ad3-8aac-4fa98f13a583"
      unitRef="usd">245021000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzAtMy0xLTEtNjY5MTA_dcdb9759-184b-4fc6-b3fc-73715ae12ac5"
      unitRef="usd">1889000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzEtMS0xLTEtNjY5MTA_40019bc0-802a-4f30-8582-ced62940fc7e"
      unitRef="usd">22969000</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
    <us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzEtMy0xLTEtNjY5MTA_d9e5a00a-ff22-49a4-8a3b-097b47648f81"
      unitRef="usd">42996000</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
    <evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzItMS0xLTEtNjY5MTA_0b7a5ea8-072a-4104-a9af-ab339a28b1f0"
      unitRef="usd">9164000</evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet>
    <evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzItMy0xLTEtNjY5MTA_d49cb400-e8c0-4280-9a1e-41a53ea4d276"
      unitRef="usd">-3490000</evh:PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzMtMS0xLTEtNjY5MTA_a4f05a3d-3fa9-44c4-afe6-2a4efc973f62"
      unitRef="usd">4175000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzMtMy0xLTEtNjY5MTA_525521ef-08f4-44a6-be77-81ff1dd328d1"
      unitRef="usd">14218000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzQtMS0xLTEtNjY5MTA_feced0ce-c5d9-4f58-890a-20ff82e941ea"
      unitRef="usd">0</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <us-gaap:PaymentsToAcquireHeldToMaturitySecurities
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzQtMy0xLTEtNjY5MTA_f8c5e768-2c21-4dac-9005-d2274e7e1ff0"
      unitRef="usd">2994000</us-gaap:PaymentsToAcquireHeldToMaturitySecurities>
    <evh:ProceedsFromMaturityOfInvestments
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzUtMS0xLTEtNjY5MTA_d723bd14-d027-4019-99ee-80f514d2e355"
      unitRef="usd">0</evh:ProceedsFromMaturityOfInvestments>
    <evh:ProceedsFromMaturityOfInvestments
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzUtMy0xLTEtNjY5MTA_38c51cf7-48c1-4bd3-b7d9-d1a1a85a05e6"
      unitRef="usd">500000</evh:ProceedsFromMaturityOfInvestments>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzYtMS0xLTEtNjY5MTA_f71975f9-5950-478a-b3e3-05b9a64904b3"
      unitRef="usd">27618000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:PaymentsToAcquireOtherProductiveAssets
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzYtMy0xLTEtNjY5MTA_59160ee5-2108-4298-b277-fc010dd3bd8b"
      unitRef="usd">17739000</us-gaap:PaymentsToAcquireOtherProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzctMS0xLTEtNjY5MTA_70f74ce9-b6de-4c29-b27b-b5b5ac8e42fd"
      unitRef="usd">-254659000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzctMy0xLTEtNjY5MTA_860c3791-df15-4868-83e2-21b1211d770b"
      unitRef="usd">38582000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzktMS0xLTEtNjY5MTA_fabcc330-3292-4939-91f2-f5de49edf3a7"
      unitRef="usd">48322000</evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities>
    <evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfMzktMy0xLTEtNjY5MTA_b46d6bf0-5c01-466d-beef-76139eb49e90"
      unitRef="usd">-1105000</evh:PaymentsForProceedsFromClaimsProcessingFinancingActivities>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDAtMS0xLTEtNjY5MTA_8518db18-19a7-43be-b063-c35081dbf20a"
      unitRef="usd">0</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDAtMy0xLTEtNjY5MTA_5186fde9-e180-4e3e-bd85-77df948b9242"
      unitRef="usd">98420000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDEtMS0xLTEtNjY5MTA_9ab9943f-da7d-48ae-9726-1847cab38362"
      unitRef="usd">3280000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDEtMy0xLTEtNjY5MTA_6900504d-6f2d-4d58-ac21-ab0d89581c60"
      unitRef="usd">11566000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDMtMS0xLTEtNzc1Mjk_a25950f7-48a4-46d0-9d07-0ab318829570"
      unitRef="usd">219740000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDMtMy0xLTEtNzc1Mjk_e5b88252-3834-43f9-b87c-a9461910f60e"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDItMS0xLTEtNjY5MTA_b125e3df-411a-42d7-8bcd-28caf973ba88"
      unitRef="usd">14884000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDItMy0xLTEtNjY5MTA_eb2d0d54-17cf-4cee-9a81-f923a037c836"
      unitRef="usd">1300000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDMtMS0xLTEtNjY5MTA_346908e5-002e-465b-b662-c1f67c80c980"
      unitRef="usd">17419000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDMtMy0xLTEtNjY5MTA_dd673fd7-a2c0-4ff7-a6c3-4801f3179487"
      unitRef="usd">3397000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDQtMS0xLTEtNjY5MTA_9482cfb7-1948-4e69-8834-8feeb4e314ed"
      unitRef="usd">142395000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDQtMy0xLTEtNjY5MTA_28ee3810-8b39-40cd-b376-20f773479af2"
      unitRef="usd">-90446000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDUtMS0xLTEtNjY5MTA_e75b1a9e-3baf-49b0-b003-c4e9ec1fb08f"
      unitRef="usd">-612000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDUtMy0xLTEtNjY5MTA_70a3862f-2fb4-41e4-895d-cadb51d7d7ce"
      unitRef="usd">-53000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDYtMS0xLTEtNjY5MTA_f6e473b2-6106-4f54-a64a-d118e178d303"
      unitRef="usd">-160124000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDYtMy0xLTEtNjY5MTA_ece28c07-70dc-4837-8fa3-3d8c40168144"
      unitRef="usd">-79826000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDctMS0xLTEtNjY5MTA_503dff85-023e-41ac-9baf-a5d4bdb07ad4"
      unitRef="usd">354942000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idcb7e5d5de6d4fb9bd1b47d49e170108_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDctMy0xLTEtNjY5MTA_f538f3d6-8112-40a3-81e2-b534540a0098"
      unitRef="usd">361581000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDgtMS0xLTEtNjY5MTA_b751326e-4f93-4c44-a804-68bbee4f159f"
      unitRef="usd">194818000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i63b3ddd7486946c2a0a8151832317d14_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDgtMy0xLTEtNjY5MTA_922cadfc-cfbc-4114-8f67-576e593a58f6"
      unitRef="usd">281755000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180MC9mcmFnOmIzNmQ3YmVhMTlkNjQ3MzJhOTE0MmZhMGJjMjc4ZDI2L3RleHRyZWdpb246YjM2ZDdiZWExOWQ2NDczMmE5MTQyZmEwYmMyNzhkMjZfMTA3Ng_a405cecf-33e7-4b04-ad14-0fa129b48ab7">Organization &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Evolent Health, Inc. was incorporated in December 2014 in the state of Delaware and through its subsidiaries supports leading health systems and physician organizations to move their business models from traditional fee for service reimbursement to value-based care, which we consider to be an integrated clinical and financial responsibility for populations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022, the Company had unrestricted cash and cash equivalents of $156.8 million. The Company believes it has sufficient liquidity for the next twelve months as of the date the financial statements were available to be issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s headquarters is located in Arlington, Virginia.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Evolent Health LLC Governance&lt;/span&gt;&lt;/div&gt;Our operations are conducted through Evolent Health LLC. Evolent Health, Inc. is a holding company whose only business is to act as the sole managing member of Evolent Health LLC. As such, it controls Evolent Health LLC&#x2019;s business and affairs and is responsible for the management of its business.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180MC9mcmFnOmIzNmQ3YmVhMTlkNjQ3MzJhOTE0MmZhMGJjMjc4ZDI2L3RleHRyZWdpb246YjM2ZDdiZWExOWQ2NDczMmE5MTQyZmEwYmMyNzhkMjZfNTMw_b645a4c1-ff9c-457d-99ab-0d0a6667626c"
      unitRef="usd">156800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1NjI_407ace48-b3c6-4bec-8310-3d9c98b64a9a">Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#x201c;GAAP&#x201d;) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2021 Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain GAAP policies that significantly affect the determination of our financial position, results of operations and cash flows, are summarized below. See &#x201c;Part II - Item 8. Financial Statements and Supplementary Data - Note 2&#x201d; in our 2021 Form 10-K for a complete summary of our significant accounting policies.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to current period presentation specifically as it relates to the reclassification of assets, liabilities, operating results and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Estimates and Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Cash and Restricted Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral for letters of credit for facility leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral with financial institutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims processing services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:5.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the nine months ended September 30, 2021. See Note 5.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#x2019;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value. See Note 9 for additional discussion regarding our intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss). Total research and development costs for the three and nine months ended September 30, 2022, was $3.8&#160;million and $11.7&#160;million, respectively, and, $4.2&#160;million and $11.1&#160;million for the three and nine months ended September 30, 2021, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Claims and Performance-based Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known. See Note 21 for additional discussion regarding our reserves for claims and performance-based arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Right of Offset&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable. As of September&#160;30, 2022, and December&#160;31, 2021, approximately 47% and 42%, respectively, of gross accounts receivable was netted against claims payable in lieu of cash receipt. Furthermore, as of September&#160;30, 2022, approximately 11% of our accounts receivable, net could ultimately be settled on a net basis, once the criteria for netting have been met.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 12 for additional lease disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the following 5-step model, outlined in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), to determine revenue recognition from our contracts with customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the contract(s) with a customer&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the performance obligations in the contract&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Determine the transaction price&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Allocate the transaction price to performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Recognize revenue when (or as) the entity satisfies a performance obligation&lt;/span&gt;&lt;/div&gt;See Note 6 for further discussion of our policies related to revenue recognition.</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1NDY_7fa9cdcd-d92c-471d-b858-be16a0f4ceba">Basis of PresentationIn our opinion, the accompanying unaudited interim consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to fairly state our financial position, results of operations and cash flows. The interim consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain footnote disclosures normally included in financial statements prepared in accordance with United States of America generally accepted accounting principles (&#x201c;GAAP&#x201d;) have been omitted pursuant to instructions, rules and regulations prescribed by the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). The disclosures provided herein should be read in conjunction with the audited financial statements and notes thereto included in our 2021 Form 10-K.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTY0OTI2NzQ1Nzk1MA_4cf16aab-c9b1-41e8-8671-47060bfea313">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to current period presentation specifically as it relates to the reclassification of assets, liabilities, operating results and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1OTA_9ba9b2f7-2e56-4cf1-8d6a-54015c7ae31b">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting Estimates and Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the reporting period. Those estimates are inherently subject to change and actual results could differ from those estimates. In the accompanying consolidated financial statements, estimates are used for, but not limited to, the valuation of assets (including intangibles assets, goodwill and long-lived assets), liabilities, consideration related to business combinations and asset acquisitions, revenue recognition (including variable consideration), estimated selling prices for performance obligations in contracts with multiple performance obligations, reserves for claims and performance-based arrangements, credit losses, depreciable lives of assets, impairment of long-lived assets, stock-based compensation, deferred income taxes and valuation allowance, contingent liabilities, purchase price allocation in taxable stock transactions and useful lives of intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1Mjg_a605dda8-5a58-42cd-87e8-2f255f7c44bf">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Evolent Health, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1Mjk_937ee52d-52ef-40c0-bb0c-3acd8c7522af">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company holds materially all of our cash in bank deposits with FDIC participating banks, at cost, which approximates fair value. Cash and cash equivalents held in money market funds are carried at fair value, which approximates cost.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1ODA_95ac106a-e804-41a4-b209-cd43160bc622">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash and restricted investments include cash and investments used to collateralize various contractual obligations (in thousands) as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral for letters of credit for facility leases &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collateral with financial institutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims processing services &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total non-current restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents restricted cash related to collateral for letters of credit required in conjunction with lease agreements. See Note 12 for further discussion of our lease commitments. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents collateral held with financial institutions for risk-sharing and other arrangements which are held in a FDIC participating bank account. See Note 17 for discussion of fair value measurement and Note 11 for discussion of our risk-sharing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Represents cash held by the Company related to claims processing services on behalf of partners. These are pass-through amounts and can fluctuate materially from period to period depending on the timing of when the claims are processed.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:5.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the nine months ended September 30, 2021. See Note 5.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ibee79f04f3964be9b790dfd8e4d6f320_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfMS0xLTEtMS02NjkxMA_bc2fe1e4-a011-421a-85e4-ca6431917e58"
      unitRef="usd">2269000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i2301f18558fd44eda53696a9fcbd9108_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfMS0zLTEtMS02NjkxMA_97bb17f4-bd1c-433a-8a92-2a03f78dcc1c"
      unitRef="usd">3769000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ia95931a1eeb74ea2a219a48e6a5e3328_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfMi0xLTEtMS02NjkxMA_3f11d6c8-1df6-4f3c-8059-3e0e23cfaa18"
      unitRef="usd">10873000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ie2575f96f53440259166edbd4dbce19b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfMi0zLTEtMS02NjkxMA_87419269-d9f7-41b2-810a-84df9bc1e81a"
      unitRef="usd">11662000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i7fd66acfff6549699d6732faf4b2192f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfMy0xLTEtMS02NjkxMA_61052676-b224-4d4d-9aaa-57df620f1e0a"
      unitRef="usd">24904000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="id22c0c0a7d0e4c22bc5e825bcd93a594_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfMy0zLTEtMS02NjkxMA_6b01fa22-dac0-477d-9e88-5a48eddfc737"
      unitRef="usd">73226000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i83916efaa57f426f9c3bed9248c24cd6_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfNC0xLTEtMS02NjkxMA_089da846-c4af-4bc2-a90d-5b22ede8ad43"
      unitRef="usd">16000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ibbbe90d495a24914843d600386432165_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfNC0zLTEtMS02NjkxMA_d81e4ed1-478f-44a1-84f6-08c6b7f0c350"
      unitRef="usd">5000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfNS0xLTEtMS02NjkxMA_1798bffc-f23a-4d68-ac68-270dcbd0ac96"
      unitRef="usd">38062000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfNS0zLTEtMS02NjkxMA_0f341ad0-f39d-4146-960d-c438e200f8a1"
      unitRef="usd">88662000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfNy0xLTEtMS02NjkxMA_1b9c2c61-2b46-4599-ab02-31d7e8e6549f"
      unitRef="usd">25057000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfNy0zLTEtMS02NjkxMA_e1baf76b-c2b8-42da-b3af-ad1768092684"
      unitRef="usd">75685000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfOC0xLTEtMS02NjkxMA_95163017-d824-4572-9fba-14af76044333"
      unitRef="usd">25057000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndInvestmentsCurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfOC0zLTEtMS02NjkxMA_88130127-6b6b-4918-9a69-743fc379a33d"
      unitRef="usd">75685000</us-gaap:RestrictedCashAndInvestmentsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfMTAtMS0xLTEtNjY5MTA_efa64363-cfb5-4315-a9e8-e68140897e0b"
      unitRef="usd">13005000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfMTAtMy0xLTEtNjY5MTA_686c1417-bc0b-4071-ac63-9c2f69d56229"
      unitRef="usd">12977000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfMTEtMS0xLTEtNjY5MTA_b591a5a6-8da9-4052-8b70-90695bce3419"
      unitRef="usd">13005000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:RestrictedCashAndInvestmentsNoncurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmFlZWJjNmE4M2JiMzQ5Yzk5YTA5MzM4YmM3NDAxZTU0L3RhYmxlcmFuZ2U6YWVlYmM2YTgzYmIzNDljOTlhMDkzMzhiYzc0MDFlNTRfMTEtMy0xLTEtNjY5MTA_e288ec88-47e4-4884-a812-639bc9af78ec"
      unitRef="usd">12977000</us-gaap:RestrictedCashAndInvestmentsNoncurrent>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1Mzc_14ba165f-6d06-4eb4-ad55-cec88c9c9013">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the consolidated statements of cash flows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash and restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:5.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the nine months ended September 30, 2021. See Note 5.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOjBiMzBmZTg1MGE0NTQzN2RhZWYxYzNiMWM5NzgyYTYxL3RhYmxlcmFuZ2U6MGIzMGZlODUwYTQ1NDM3ZGFlZjFjM2IxYzk3ODJhNjFfMi0xLTEtMS02NjkxMA_34fb1274-220f-4ec9-9c8e-84a7f98af9a7"
      unitRef="usd">156756000</evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations>
    <evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations
      contextRef="i63b3ddd7486946c2a0a8151832317d14_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOjBiMzBmZTg1MGE0NTQzN2RhZWYxYzNiMWM5NzgyYTYxL3RhYmxlcmFuZ2U6MGIzMGZlODUwYTQ1NDM3ZGFlZjFjM2IxYzk3ODJhNjFfMi0zLTEtMS02NjkxMA_f86e3cc7-81ea-4059-a2fc-707ded796c67"
      unitRef="usd">252496000</evh:CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOjBiMzBmZTg1MGE0NTQzN2RhZWYxYzNiMWM5NzgyYTYxL3RhYmxlcmFuZ2U6MGIzMGZlODUwYTQ1NDM3ZGFlZjFjM2IxYzk3ODJhNjFfMy0xLTEtMS02NjkxMA_98132348-3030-442e-b9d2-1d73e15079e6"
      unitRef="usd">38062000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:RestrictedCashAndInvestments
      contextRef="i63b3ddd7486946c2a0a8151832317d14_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOjBiMzBmZTg1MGE0NTQzN2RhZWYxYzNiMWM5NzgyYTYxL3RhYmxlcmFuZ2U6MGIzMGZlODUwYTQ1NDM3ZGFlZjFjM2IxYzk3ODJhNjFfMy0zLTEtMS02NjkxMA_7860cd96-e3e4-48f0-b4d9-219a20654206"
      unitRef="usd">29259000</us-gaap:RestrictedCashAndInvestments>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOjBiMzBmZTg1MGE0NTQzN2RhZWYxYzNiMWM5NzgyYTYxL3RhYmxlcmFuZ2U6MGIzMGZlODUwYTQ1NDM3ZGFlZjFjM2IxYzk3ODJhNjFfNC0xLTEtMS02NjkxMA_9a2d0dac-46dd-4725-b9fb-d738c7e63b9f"
      unitRef="usd">194818000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i63b3ddd7486946c2a0a8151832317d14_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOjBiMzBmZTg1MGE0NTQzN2RhZWYxYzNiMWM5NzgyYTYxL3RhYmxlcmFuZ2U6MGIzMGZlODUwYTQ1NDM3ZGFlZjFjM2IxYzk3ODJhNjFfNC0zLTEtMS02NjkxMA_b194b343-9996-4a67-a145-ae9f467687f0"
      unitRef="usd">281755000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1NjA_3963482e-a1dd-4802-b985-f80ed1cc08aa">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Companies acquired during each reporting period are reflected in the results of the Company effective from their respective dates of acquisition through the end of the reporting period. The Company allocates the fair value of purchase consideration to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Critical estimates used to value certain identifiable assets include, but are not limited to, expected long-term revenues, future expected operating expenses, cost of capital and appropriate discount rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of the fair value of purchase consideration over the fair value of the assets acquired and liabilities assumed in the acquired entity is recorded as goodwill. Goodwill is assigned to the reporting unit that benefits from the synergies arising from the business combination. If the Company obtains new information about facts and circumstances that existed as of the acquisition date during the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded on the Company's consolidated statements of operations and comprehensive income (loss). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contingent consideration recorded as a liability, the Company initially measures the amount at fair value as of the acquisition date and adjusts the liability, if needed, to fair value at each reporting period. Changes in the fair value of contingent consideration, other than measurement period adjustments, are recognized as operating income or expense. Acquisition-related expenses are recognized separately from the business combination and are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1MzM_a6b8d11c-7e8a-4c23-982e-655e12b76619">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the excess of the purchase price, plus the fair value of any non-controlling interests in the acquiree, over the fair value of identifiable net assets acquired as goodwill. Goodwill is not amortized, but is reviewed at least annually for indications of impairment, with consideration given to financial performance and other relevant factors. We perform impairment tests of goodwill at a reporting unit level. Following the sale of True Health, the Company has three reporting units and our annual goodwill impairment review occurs during the fourth quarter of each year. We perform impairment tests between annual tests if an event occurs, or circumstances change, that we believe would more likely than not reduce the fair value of a reporting unit below its carrying amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our goodwill impairment analysis first assesses qualitative factors to determine whether events or circumstances existed that would lead the Company to conclude it is more likely than not that the fair value of a reporting unit is below its carrying amount. If the Company determines that it is more likely than not that the fair value of a reporting unit is below the carrying amount, a quantitative goodwill assessment is required. In the quantitative evaluation, the fair value of the relevant reporting unit is determined and compared to the carrying value. If the fair value is greater than the carrying value, then the carrying value is deemed to be recoverable and no further action is required. If the fair value estimate is less than the carrying value, goodwill is considered impaired for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value and a charge is reported in goodwill impairment on our consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfReportingUnits
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfNzU0MQ_bcede2eb-d3a6-4fa1-8dc8-e5be4d66e5a3"
      unitRef="reporting_unit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1Nzc_424d11a9-f211-4ac0-b0d6-32464934d62e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Identified intangible assets are recorded at their estimated fair values at the date of acquisition and are amortized over their respective estimated useful lives using a method of amortization that reflects the pattern in which the economic benefits of the intangible assets are used. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the asset&#x2019;s carrying value. The Company evaluates recoverability by determining whether the undiscounted cash flows expected to result from the use and eventual disposition of that asset or group exceed the carrying value at the evaluation date. If the undiscounted cash flows are not sufficient to cover the carrying value, the Company measures an impairment loss as the excess of the carrying amount of the long-lived asset or group over its fair value.</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1ODc_7f203da8-e4cf-4561-abef-8aa17902f5b7">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes the estimated useful lives by asset classification:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:438.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:97.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 20 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 - 25 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 - 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details of our intangible assets (in thousands, except weighted-average useful lives) as of September&#160;30, 2022 and December&#160;31, 2021 are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:45.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Below market lease, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ie70e3951b11d47189d49176b477c53cb_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmQ1NThkMDNiYWU2MzRhMmRiZDA1NDFmNWY3ZmFmMzg0L3RhYmxlcmFuZ2U6ZDU1OGQwM2JhZTYzNGEyZGJkMDU0MWY1ZjdmYWYzODRfMC0xLTEtMS02NjkxMC90ZXh0cmVnaW9uOjVkOWUzNGY5OGYzZDQ0MTVhNDlhNTE1NGU2ZTU5ZTBkXzQ_28794a19-ba99-4c18-96b2-6bdaf6c404e1">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i4553368113754e9985da5aee1e1e2e13_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmQ1NThkMDNiYWU2MzRhMmRiZDA1NDFmNWY3ZmFmMzg0L3RhYmxlcmFuZ2U6ZDU1OGQwM2JhZTYzNGEyZGJkMDU0MWY1ZjdmYWYzODRfMC0xLTEtMS02NjkxMC90ZXh0cmVnaW9uOjVkOWUzNGY5OGYzZDQ0MTVhNDlhNTE1NGU2ZTU5ZTBkXzk_1e590f07-5e67-4b6e-86ae-30388c250d16">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i9941ebd90552418b96575575d27a7ebe_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmQ1NThkMDNiYWU2MzRhMmRiZDA1NDFmNWY3ZmFmMzg0L3RhYmxlcmFuZ2U6ZDU1OGQwM2JhZTYzNGEyZGJkMDU0MWY1ZjdmYWYzODRfMS0xLTEtMS02NjkxMC90ZXh0cmVnaW9uOjE5NGVkYTcyZDNmZjQ0MjNhOTBmMWRlMDM5OGQ2MGY2XzQ_43323b38-f3eb-4194-8c9c-cc0766405766">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i30eb020f19524dfb97afd3fef2c5b9ea_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmQ1NThkMDNiYWU2MzRhMmRiZDA1NDFmNWY3ZmFmMzg0L3RhYmxlcmFuZ2U6ZDU1OGQwM2JhZTYzNGEyZGJkMDU0MWY1ZjdmYWYzODRfMS0xLTEtMS02NjkxMC90ZXh0cmVnaW9uOjE5NGVkYTcyZDNmZjQ0MjNhOTBmMWRlMDM5OGQ2MGY2Xzk_ad592482-72c1-486a-95d5-b0d570c55450">P25Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ia71efd024b264a23aa0d21ad75741277_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmQ1NThkMDNiYWU2MzRhMmRiZDA1NDFmNWY3ZmFmMzg0L3RhYmxlcmFuZ2U6ZDU1OGQwM2JhZTYzNGEyZGJkMDU0MWY1ZjdmYWYzODRfMi0xLTEtMS02NjkxMA_95e81e27-ff29-426c-893f-239da3c2aeb0">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i495e837d54f24a0d9dc7d49185d44a77_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmQ1NThkMDNiYWU2MzRhMmRiZDA1NDFmNWY3ZmFmMzg0L3RhYmxlcmFuZ2U6ZDU1OGQwM2JhZTYzNGEyZGJkMDU0MWY1ZjdmYWYzODRfMy0xLTEtMS02NjkxMC90ZXh0cmVnaW9uOmU1OTYxM2RlODg4ODRhMWE4MmRmNTBjZjQ2MDU0YjYwXzQ_7bba5db2-ec87-4689-9e88-078bad88804d">P3Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i10d8689dfe304f3bb138eb921170cc2a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RhYmxlOmQ1NThkMDNiYWU2MzRhMmRiZDA1NDFmNWY3ZmFmMzg0L3RhYmxlcmFuZ2U6ZDU1OGQwM2JhZTYzNGEyZGJkMDU0MWY1ZjdmYWYzODRfMy0xLTEtMS02NjkxMC90ZXh0cmVnaW9uOmU1OTYxM2RlODg4ODRhMWE4MmRmNTBjZjQ2MDU0YjYwXzk_99f3a309-1b66-4549-816f-1d455b512226">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1NTk_66881a08-9670-4c9b-b09e-263dda847f48">Research and Development CostsResearch and development costs consist primarily of personnel and related expenses (including stock-based compensation and employee taxes and benefits) for employees engaged in research and development activities as well as third-party fees. All such costs are expensed as incurred. We focus our research and development efforts on activities that support our technology infrastructure, clinical program development, data analytics and network development capabilities. Research and development costs are recorded within cost of revenue and selling, general and administrative expenses on our consolidated statements of operations and comprehensive income (loss).</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTA1Nzg_16c16dd8-fc83-46ec-8563-b666ff03bf87"
      unitRef="usd">3800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTA1ODU_95990dfd-780b-4129-89d7-375d25694963"
      unitRef="usd">11700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTA5OTUxMTY0NDEzNA_c67453c0-95c4-4b34-990d-380f46d8d515"
      unitRef="usd">4200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTA5OTUxMTY0NDE0OQ_2472f029-cd22-4394-8d5e-d474f9bce578"
      unitRef="usd">11100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LiabilityReserveEstimatePolicy
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1MzA_fd98227c-cfd3-459b-af04-b3ea3b14dbfe">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Claims and Performance-based Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for claims and performance-based arrangements reflect estimates of payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. The Company uses actuarial principles and assumptions that are consistently applied in each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions. &lt;/span&gt;&lt;/div&gt;The process of estimating reserves involves a considerable degree of judgment by the Company and, as of any given date, is inherently uncertain. The methods for making such estimates and for establishing the resulting liability are continually reviewed and adjustments are reflected in current results of operations in the period in which they are identified as experience develops or new information becomes known.</us-gaap:LiabilityReserveEstimatePolicy>
    <evh:RightOfOffsetPolicyPolicyTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1NTE_f716d33e-4d36-4b49-9cf2-c476452577ea">Right of OffsetCertain customer arrangements give the Company the legal right to net payment for amounts due from customers and claims payable.</evh:RightOfOffsetPolicyPolicyTextBlock>
    <evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTIyMzE_a4acdd27-f8b5-4ab3-8dd1-ec87065fa9f4"
      unitRef="number">0.47</evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable>
    <evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTIyMzg_e91309e8-c0b4-416b-bbfa-df65961de01f"
      unitRef="number">0.42</evh:RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable>
    <evh:RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTIzNjY_80541f21-fb6a-4079-ab38-555444ea1496"
      unitRef="number">0.11</evh:RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1NzE_ea900311-91f7-4129-94b4-9a71d4ec01af">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various office space, data center and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised at the inception of the lease. The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the terms of the respective leases. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also enters into sublease agreements for some of its leased office space. Rental income attributable to subleases is immaterial and is offset against rent expense over the terms of the respective leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <evh:NumberOfOptionsToRenewLeases
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfNDk0NzgwMjM0MDgyOQ_75d88115-4bea-40de-8d71-0d256ba42d5c"
      unitRef="option_to_renew_lease">1</evh:NumberOfOptionsToRenewLeases>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTU1NDQ_0d9fae46-d8b7-4a2b-965c-d7c0ec9a97dd">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue from two sources: (1) transformation services and (2) platform and operations services. Transformation services consist of implementation services whereby we assist the customer in launching its population health or health plan programs, or implement certain platform and operations services. In certain cases, transformation services can also include revenue associated with our support of certain one-time wind-down activities for clients who are exiting a line of business or population. Platform and operations services generally include multi-year arrangements with customers to provide various population health, health plan operations, specialty care management and claims processing services on an ongoing basis, as well as transition or run-out services to customers receiving primarily TPA services. Revenue is recognized when control of the services is transferred to our customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the following 5-step model, outlined in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), to determine revenue recognition from our contracts with customers:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the contract(s) with a customer&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Identify the performance obligations in the contract&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Determine the transaction price&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Allocate the transaction price to performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt; Recognize revenue when (or as) the entity satisfies a performance obligation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue primarily from platform and operations services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily third-party administration (&#x201c;TPA&#x201d;) services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our Clinical Solutions segment, we enter into performance-based arrangements that may include capitation and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts with Multiple Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principal vs. Agent&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the goods and services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer thereby recognizing revenue on a net basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <evh:NumberOfSourcesOfRevenue
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180My9mcmFnOjg5MDk5ODE4NzhkMDRmZmJhNGRkOWM4ZjMyZjViODBmL3RleHRyZWdpb246ODkwOTk4MTg3OGQwNGZmYmE0ZGQ5YzhmMzJmNWI4MGZfMTQwNjI_39fe363c-e511-42e6-9f82-5d6d9b1bb202"
      unitRef="source">2</evh:NumberOfSourcesOfRevenue>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180Ni9mcmFnOjNjN2U2YmYyNmI5ODRjMjNhOWYxNWM2Mzk1ZWEzZTAxL3RleHRyZWdpb246M2M3ZTZiZjI2Yjk4NGMyM2E5ZjE1YzYzOTVlYTNlMDFfMzE3OA_a4532529-610d-41a4-b585-d3b94a384fd7">Recently Issued Accounting Standards&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Simplifying the Accounting for Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#x2019;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#x2019;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#x2019;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8&#160;million, reduced additional paid-in capital by $106.2&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1&#160;million and $41.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. This new standard is effective for our interim and annual periods beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the adoption impacts on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180Ni9mcmFnOjNjN2U2YmYyNmI5ODRjMjNhOWYxNWM2Mzk1ZWEzZTAxL3RleHRyZWdpb246M2M3ZTZiZjI2Yjk4NGMyM2E5ZjE1YzYzOTVlYTNlMDFfMzE4MQ_95d4ff0b-6af4-4c9b-b1f5-9fd79e517522">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Simplifying the Accounting for Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The amendments in the ASU remove certain exceptions to the intraperiod tax allocation of losses and gains from different financial statement components and to the method of recognizing income taxes on interim period losses and the recognition of deferred tax liabilities for outside basis differences. In addition, the new guidance simplifies aspects of the accounting for franchise taxes and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The Company adopted this standard starting in the first quarter of 2021, which did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts in an entity&#x2019;s own equity. Specifically, the ASU removes the separation models for convertible debt with a cash conversion feature or convertible instruments with a beneficial conversion feature and no longer permits the use of the treasury stock method from calculating earnings per share. As a result, after adopting the ASU&#x2019;s guidance, we do not separately present in equity an embedded conversion feature of such debt. Instead, we account for a convertible debt instrument wholly as debt unless (i) a convertible instrument contains features that require bifurcation as a derivative or (ii) a convertible debt instrument was issued at a substantial premium. Additionally, the ASU removes certain conditions for equity classification related to contracts in an entity&#x2019;s own equity (e.g., warrants) and amends certain guidance related to the computation of earnings per share for convertible instruments and contracts on an entity&#x2019;s own equity. The Company adopted the standard using a modified retrospective method on January 1, 2022, with adjustments which increased retained earnings by $39.8&#160;million, reduced additional paid-in capital by $106.2&#160;million and increased the net carrying amount of the 2024 and 2025 Notes by $25.1&#160;million and $41.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU 2021-08, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. This new standard is effective for our interim and annual periods beginning after December 15, 2022, with early adoption permitted. We are currently evaluating the adoption impacts on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i102291920e804daab7d25e75918ff73b_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180Ni9mcmFnOjNjN2U2YmYyNmI5ODRjMjNhOWYxNWM2Mzk1ZWEzZTAxL3RleHRyZWdpb246M2M3ZTZiZjI2Yjk4NGMyM2E5ZjE1YzYzOTVlYTNlMDFfMjIxMQ_91785114-3287-4a48-8e23-99d67f29a438"
      unitRef="usd">39800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2e521093d1374140ac95361a6c2a311e_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180Ni9mcmFnOjNjN2U2YmYyNmI5ODRjMjNhOWYxNWM2Mzk1ZWEzZTAxL3RleHRyZWdpb246M2M3ZTZiZjI2Yjk4NGMyM2E5ZjE1YzYzOTVlYTNlMDFfMjI1Mw_a680eea7-15a4-453c-a9a9-2d3642e21022"
      unitRef="usd">106200000</us-gaap:StockholdersEquity>
    <us-gaap:LongTermDebt
      contextRef="i970cc1ff98954def888f92d6e27ed9e0_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180Ni9mcmFnOjNjN2U2YmYyNmI5ODRjMjNhOWYxNWM2Mzk1ZWEzZTAxL3RleHRyZWdpb246M2M3ZTZiZjI2Yjk4NGMyM2E5ZjE1YzYzOTVlYTNlMDFfMjMyNA_bd22018a-724a-44d0-8359-26c7c9113a03"
      unitRef="usd">25100000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="if6b921fd4b544f439a08e3802c74b054_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180Ni9mcmFnOjNjN2U2YmYyNmI5ODRjMjNhOWYxNWM2Mzk1ZWEzZTAxL3RleHRyZWdpb246M2M3ZTZiZjI2Yjk4NGMyM2E5ZjE1YzYzOTVlYTNlMDFfMjMzMQ_23fbdf86-ab7d-44ea-8876-5e3ccefa0bfa"
      unitRef="usd">41300000</us-gaap:LongTermDebt>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMzI5ODUzNDg5MTMzOQ_5a8ad1af-119d-4d28-98d4-0a1d882b2e92">Transactions&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Implantable Provider Group&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2022, the Company completed its acquisition of Implantable Provider Group, Inc. (&#x201c;IPG&#x201d;), including 100% of the voting equity interests. IPG is a leader in providing surgical management solutions for musculoskeletal conditions. The transaction is expected to accelerate our strategy to become a leading provider of value-based specialty care solutions as well as diversify our revenue streams with a larger customer portfolio. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total merger consideration, net of cash on hand and certain closing adjustments, was $461.7&#160;million, based on the closing price of the Company&#x2019;s Class A common stock on the NYSE on August 1, 2022. The merger consideration consisted of $256.5&#160;million of cash consideration, 3.7&#160;million shares of Class A common stock, fair valued at $130.2&#160;million as of August 1, 2022, and an earn-out of up to $87.0&#160;million, fair valued at $75.0&#160;million as of August 1, 2022 is payable in cash and/or shares of the Company&#x2019;s Class A Common Stock, at the Company&#x2019;s option. See Note&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17 for additional information regarding the fair value determination of the earn-out consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and the corporate trade name will be amortized on a straight-line basis over their preliminary estimated useful lives of 20 years, 5 years, and 15 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary customer relationship management and analytics platform that supports reporting to payors with respect to medical device pricing and associated analytics. The corporate trade name reflects the value that we believe the IPG brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. The Company received carryover tax basis in the assets and liabilities acquired; accordingly, the Company recognized net deferred tax liabilities associated with the difference between the book basis and the tax basis for the assets and liabilities acquired. The goodwill is not deductible for tax purposes. Additionally, a discrete tax benefit of $46.8&#160;million was recorded in the consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2022, to account for the valuation allowance release primarily related to the acquired intangible assets, which resulted in a deferred tax liability that provided a source of income supporting realization of other deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts above reflect management&#x2019;s preliminary estimate of the fair value of the tangible and intangible assets acquired and liabilities assumed. Any necessary adjustments are expected to be finalized by the end of the third quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vital Decisions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2021, the Company completed its acquisition of Vital Decisions, including 100% of the voting equity interests. Vital Decisions is a leading provider of technology-enabled advance care planning services, ensuring that the care of individuals with serious illness aligns with their values and changing preferences throughout their health journey and, in particular, as they approach end-of-life decisions. The transaction is expected to deepen our capabilities, allowing us to cross-sell across customers and enhance our value proposition to partners. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total merger consideration, net of cash on hand and certain closing adjustments, was $117.7 million, based on the closing price of the Company&#x2019;s Class A common stock on the NYSE on October 1, 2021. The merger consideration consisted of $46.5 million of cash consideration, 1.8&#160;million shares of Class A common stock, fair valued at $56.6 million as of October 1, 2021, and an earn-out of up to $45.0&#160;million, fair valued at $14.6 million as of October 1, 2021 is payable in cash and/or shares of the Company&#x2019;s Class A Common Stock, at the Company&#x2019;s option. See Note 17 for additional information regarding the fair value determination of the earn-out consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The fair value of the receivables acquired, as shown in the table above, approximates the gross contractual amounts and is expected to be collectible in full. Identifiable intangible assets associated with customer relationships, technology and corporate trade names will be amortized on a straight-line basis over their preliminary estimated useful lives of 13 years, 5 years, and 15 years, respectively. The customer relationships are primarily attributable to existing contracts with current customers. The technology consists primarily of a proprietary advance care planning documentation portal where patients can input information, and doctor/patient conversations are populated for later reference. The corporate trade name reflects the value that we believe the Vital Decisions brand name carries in the market. The fair value of the intangible assets was determined using the income approach and the relief from royalty approach. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money. The relief from royalty approach estimates the fair value of an asset by calculating how much an entity would have to spend to lease a similar asset. Goodwill is calculated as the difference between the acquisition date fair value of the total consideration and the fair value of the net assets acquired and represents the future economic benefits that we expect to achieve as a result of the acquisition. The goodwill is attributable primarily to cross-selling opportunities and the acquired assembled workforce and was all allocated to the Clinical Solutions segment. Goodwill is considered to be an indefinite lived asset. $69.6&#160;million of the goodwill recorded on the transaction is deductible for tax purposes.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfNTQ5NzU1ODE3NzI3_e1843a42-2e87-420a-a659-3af4cbcb1da4"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i0aac7a30651e4f168f37aa5b96ca404e_D20220801-20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTY0OTI2NzQ1NTE2Mg_9ab3bf2a-bfef-4ddf-af96-41d6d8ea59e2"
      unitRef="usd">461700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i0aac7a30651e4f168f37aa5b96ca404e_D20220801-20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTY0OTI2NzQ1NTE5Mw_48ace1e9-585e-4cbf-94ef-b549b753f368"
      unitRef="usd">256500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="i0aac7a30651e4f168f37aa5b96ca404e_D20220801-20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfNTQ5NzU1ODIxNjQ2_cb628c7f-b65c-4867-861e-fd03dac4c9a2"
      unitRef="shares">3700000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i0aac7a30651e4f168f37aa5b96ca404e_D20220801-20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTY0OTI2NzQ1NTIyNA_2b2ca61c-cb35-4f83-af5c-72f8b1ea8dc7"
      unitRef="usd">130200000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMzI5ODUzNDg5MTM0MQ_9f4e11ee-642f-4ea5-b2c2-1022cd06718c"
      unitRef="usd">87000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTY0OTI2NzQ1NTI1NA_08b0d0ad-53b2-4b02-a4c4-782344305747"
      unitRef="usd">75000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMzI5ODUzNDg5MTM1NQ_6aff2c5c-6113-4c0b-99a6-b6c03a0de059">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMzI5ODUzNDg5MTM1NQ_9dd8cab4-21a8-482d-97a4-b832eb916c7c">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of August 1, 2022, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price was allocated to the assets acquired and liabilities assumed based on their estimated fair values as of October 1, 2021, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Class A common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable intangible assets acquired:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total identifiable intangible assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and employee benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i0aac7a30651e4f168f37aa5b96ca404e_D20220801-20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMS0xLTEtMS03MDk0Mw_7ed07a22-8f7e-4a77-b7d3-85bd1c5d189a"
      unitRef="usd">256488000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i0aac7a30651e4f168f37aa5b96ca404e_D20220801-20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMi0xLTEtMS03MDk0Mw_5a580672-756b-4bb9-aab5-1fff747ad337"
      unitRef="usd">130175000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i0aac7a30651e4f168f37aa5b96ca404e_D20220801-20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMy0xLTEtMS03MDk0Mw_6615ca5a-7e01-47c9-bc25-5ca4c4797466"
      unitRef="usd">75000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i0aac7a30651e4f168f37aa5b96ca404e_D20220801-20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfNC0xLTEtMS03MDk0Mw_06437636-b35b-4682-93c2-e24b3587cd95"
      unitRef="usd">461663000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfOC0xLTEtMS03MDk0NQ_7cc1a360-375b-4b6f-9be7-2b0faeecb791"
      unitRef="usd">34155000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfOS0xLTEtMS03MDk0NQ_f73b0187-c34a-4eb8-a655-39f50283978b"
      unitRef="usd">636000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMTAtMS0xLTEtNzA5NDU_2a881e55-6ca8-4fa1-83b7-4b975d49f1f3"
      unitRef="usd">1393000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets
      contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMTEtMS0xLTEtNzA5NDU_676cccc1-4c34-403b-a869-2af37dbf9cc4"
      unitRef="usd">36184000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i47850eb51205454eb531a4e4a24c6b67_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMTQtMS0xLTEtNzA5NDc_37508e68-de66-4e07-a86c-3835bd9dac24"
      unitRef="usd">154000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i81468ffa8e794bc0b59baa9867b5834c_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMTUtMS0xLTEtNzA5NDc_4efe1544-1e10-453f-aeb5-df96e8e2799f"
      unitRef="usd">23900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="id2def591b7f54106a7fa0735840fe2d2_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMTYtMS0xLTEtNzA5NDc_92be7502-22d5-439a-9ac7-527d4e28cd21"
      unitRef="usd">17800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMTctMS0xLTEtNzA5NDc_56bd4a9d-2633-4b6e-989f-4dc6ec504ab6"
      unitRef="usd">195700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMjAtMS0xLTEtNzA5NDk_2ff0d706-6711-472f-81db-293a1de81cd2"
      unitRef="usd">7997000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities
      contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMjEtMS0xLTEtNzA5NDk_aa080676-fe1b-4153-b0b0-c0be2875fcfa"
      unitRef="usd">8083000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits
      contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMjItMS0xLTEtNzA5NDk_561bed46-b490-4dd3-a24f-072fbbcba318"
      unitRef="usd">423000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMjMtMS0xLTEtNzA5NDk_dea6e7b5-7ed3-4cb6-97da-68966d03eb08"
      unitRef="usd">48671000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMjQtMS0xLTEtNzA5NDk_5a5cbdb2-0ac7-4ea3-8c60-81ae086a59f1"
      unitRef="usd">321000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation
      contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMjUtMS0xLTEtNzA5NDk_39c679cf-2949-4969-9065-97085eab3f80"
      unitRef="usd">1323000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMjYtMS0xLTEtNzA5NDk_f515a826-3737-4a75-82de-68333ffb6de2"
      unitRef="usd">66818000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:Goodwill
      contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMjgtMS0xLTEtNzA5NTE_e5828527-46c8-481d-bec7-b645912a21c7"
      unitRef="usd">296597000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOmNmZDI1NGY1ODI1MjRiNjRiMDczZmVmZjk4ZjM5ZjcwL3RhYmxlcmFuZ2U6Y2ZkMjU0ZjU4MjUyNGI2NGIwNzNmZWZmOThmMzlmNzBfMjktMS0xLTEtNzA5NTE_f87a8763-917a-41d1-bf55-65c889d3f1af"
      unitRef="usd">461663000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i76392d607ac741ffa9749e4c5191c116_D20220801-20220801"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfNTQ5NzU1ODIwMDMz_cd5951b2-67cd-4819-9556-9500b0e5622b">P20Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ib13556ea35bd419f840924ad34329091_D20220801-20220801"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfNTQ5NzU1ODIwMDM2_976d5626-23c1-4cc5-b44e-866e86c18c71">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i8980c17573b14788b07301046fa212f8_D20220801-20220801"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfNTQ5NzU1ODIwMDM3_961f5431-371f-4b47-b7bf-a9650c5069b9">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="iae24c6c30eb94d5c82ae99d747a61a52_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTY0OTI2NzQ1NjU3MQ_24d7de49-cd53-4568-a7c9-a977ec7b5610"
      unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i873c819d3f8246cda155f0714de1ce57_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTA5OTUxMTYyOTI2NTA_05d2ac44-56b7-489c-b5fc-c9f4e6817da2"
      unitRef="usd">46800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i011e460895d3476ea9ce07169b756846_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTA5OTUxMTYyOTI2NTA_0c34e346-9254-46a0-9ab1-fed07d6b9ec8"
      unitRef="usd">46800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTU2_eb0e64c0-cb74-4ba6-b085-d8de3ba76487"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ief648c5f4b1449d2be6c08727632b653_D20211001-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfNzE2_03db4d6e-4d7a-47c1-9a3d-6e0ab1c1fd93"
      unitRef="usd">117700000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ief648c5f4b1449d2be6c08727632b653_D20211001-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfODU1_cf6d7012-f8ad-43d2-9758-8606e5112c51"
      unitRef="usd">46500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="ief648c5f4b1449d2be6c08727632b653_D20211001-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfODgx_24511eee-a45a-42e4-842b-6ba99ac17c0a"
      unitRef="shares">1800000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="ief648c5f4b1449d2be6c08727632b653_D20211001-20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfOTMx_0b88134e-8bd0-4dad-8c9c-d9dbe2c3fec2"
      unitRef="usd">56600000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfOTgy_204dd09a-0c10-4f23-86be-0544978b2d69"
      unitRef="usd">45000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTAwMQ_616051d9-6331-4a2a-a62f-f7f43e074889"
      unitRef="usd">14600000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="ief648c5f4b1449d2be6c08727632b653_D20211001-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMS0xLTEtMS02NjkxMA_78c1693c-3e0d-43f6-ae03-eb3d6476a171"
      unitRef="usd">46500000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="ief648c5f4b1449d2be6c08727632b653_D20211001-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMi0xLTEtMS02NjkxMA_0994733e-6d17-414e-b0a0-3d72ff21ae49"
      unitRef="usd">56626000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="ief648c5f4b1449d2be6c08727632b653_D20211001-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMy0xLTEtMS02NjkxMA_d7ce9d59-9df0-4927-a64a-d0b60d3315db"
      unitRef="usd">14600000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ief648c5f4b1449d2be6c08727632b653_D20211001-20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfNC0xLTEtMS02NjkxMA_a7cf7dcd-75cc-4bd4-91c7-1f85ced5af49"
      unitRef="usd">117726000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfNy0xLTEtMS02NjkxMA_b8328458-4c74-4dc1-9d79-ae55a1646873"
      unitRef="usd">1430000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfOC0xLTEtMS02NjkxMA_c898fe06-0b92-46b4-bf36-517cba2d5c6c"
      unitRef="usd">3301000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfOS0xLTEtMS02NjkxMA_b8677de2-c448-41a3-9ef2-2371bd85db2d"
      unitRef="usd">78000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMTAtMS0xLTEtNjY5MTA_6593d958-9a0d-40e5-8ec5-fe47a49b6eaa"
      unitRef="usd">2564000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets
      contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMTEtMS0xLTEtNjY5MTA_8eaa07d8-03a5-410f-93a4-1719cc141f2e"
      unitRef="usd">7373000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i63c007d9f492486b853449a269099b25_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMTQtMS0xLTEtNjY5MTA_c0fc205c-de5c-4aaf-8ff9-c8eb7ade0c6d"
      unitRef="usd">32500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ie493e2b859384dbab23b7cc294e31dbe_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMTUtMS0xLTEtNjY5MTA_d96c3194-f93f-41f5-ace6-fe4626074715"
      unitRef="usd">5000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i522030bffa474e539994d8f7437146bb_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMTYtMS0xLTEtNjY5MTA_d39d4ff3-cdcb-48e2-a8f5-d1f80f4ed317"
      unitRef="usd">2500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMTctMS0xLTEtNjY5MTA_8c3b5d51-7b78-4c68-b2b8-c776ed9df51f"
      unitRef="usd">40000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMjAtMS0xLTEtNjY5MTA_c8e48c78-4894-41c6-9440-3048ddb9089c"
      unitRef="usd">93000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities
      contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMjEtMS0xLTEtNjY5MTA_a4c5876a-a27e-4c89-8551-c0b7f84cf066"
      unitRef="usd">661000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities>
    <evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits
      contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMjItMS0xLTEtNjY5MTA_e2a7527c-c8a9-4488-8ad8-1da473c7392d"
      unitRef="usd">970000</evh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMjMtMS0xLTEtNjY5MTA_cd6a8036-799d-4e92-bb20-84305d445bcd"
      unitRef="usd">499000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue
      contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMjQtMS0xLTEtNjY5MTA_657627ab-c5a2-4baf-8376-502abb1f7136"
      unitRef="usd">2000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation
      contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMjUtMS0xLTEtNjY5MTA_c0bb51dd-90bd-4f10-a01f-579c67ff00d3"
      unitRef="usd">2712000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMjYtMS0xLTEtNjY5MTA_14471d5c-1c2a-49fd-8ab0-6f3c980fd243"
      unitRef="usd">6935000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:Goodwill
      contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMjgtMS0xLTEtNjY5MTA_6e3255b3-b78d-4b48-93ba-139847b97c72"
      unitRef="usd">77288000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RhYmxlOjE4YjYxODE1YzY3NjRkM2NhNjE1OWI3NjJhYjA3Nzc2L3RhYmxlcmFuZ2U6MThiNjE4MTVjNjc2NGQzY2E2MTU5Yjc2MmFiMDc3NzZfMjktMS0xLTEtNjY5MTA_845c5c43-7363-4316-811a-37835ead3b44"
      unitRef="usd">117726000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ib15c968ec28447719bfe672cf73f9c1f_D20211001-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTY2Nw_7ea253ce-73c6-4b1b-82db-1ab802bf8f64">P13Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i9acb52a4a7c949db9847508394a446ad_D20211001-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTY3MQ_dccd83ec-2ae1-4c09-acba-c1c6b4744904">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i644999860f68467f8589953496d35dcd_D20211001-20211001"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMTY3OQ_8dc165c8-75e2-46f8-ada2-3e6aeb99bcbc">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
      contextRef="ibdafd4f64587494f9814a1d89347c981_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM180OS9mcmFnOjNlM2Y2MWIyZDJlNjRiZDc5NDU5YmQyNWYyMWFmNDEyL3RleHRyZWdpb246M2UzZjYxYjJkMmU2NGJkNzk0NTliZDI1ZjIxYWY0MTJfMzE0NQ_cedb4ab8-9ea1-4d4d-b2d2-3c0bbb1b92b7"
      unitRef="usd">69600000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RleHRyZWdpb246MGQ3MjhiYjYzZWI4NDYyNzg2YWE5NWM1MDE0YTFkNzFfMjI3Nw_1bf85e92-f976-4ae4-8048-a6a64865fb60">Discontinued Operations&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 11, 2021, Evolent Health LLC, EH Holdings and True Health, each wholly owned subsidiaries of the Company, entered into a Stock Purchase Agreement (the &#x201c;True Health SPA&#x201d;) with Bright Health Management, Inc. (&#x201c;Bright HealthCare&#x201d;), pursuant to which EH Holdings agreed to sell all of its equity interests in True Health to Bright HealthCare. Closing of the transactions contemplated by the True Health SPA occurred on March 31, 2021 (the &#x201c;True Health Closing&#x201d;) and the Company has had no continuing involvement with True Health subsequent to the closing except a pre-existing services agreement for claims processing and other health plan administrative functions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the first quarter of 2021, the Company determined that True Health met the discontinued operations criteria under ASC 205, and as such, True Health assets and liabilities as of December 31, 2020, and the results of operations for all periods presented are classified as discontinued operations and are not included in continuing operations in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the Company&#x2019;s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine &lt;br/&gt;Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes and non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million for the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Selling, general and administrative expenses include intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million for the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated statements of cash flows for all periods have not been adjusted to separately disclose cash flows related to discontinued operations. Cash flows related to the True Health business during the nine months ended September 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows used in investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RleHRyZWdpb246MGQ3MjhiYjYzZWI4NDYyNzg2YWE5NWM1MDE0YTFkNzFfMjI3OA_86a7bbe6-7833-4ac2-9705-62dae1e0d3ad">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the results of operations of the Company&#x2019;s True Health business, which are included in income from discontinued operations in the consolidated statements of operations and comprehensive income (loss) for the three and nine months ended September 30, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine &lt;br/&gt;Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Platform and operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes and non-controlling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(326)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Cost of revenue includes intercompany expenses between the Company and True Health that are recorded in income from continuing operations in the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $2.8&#160;million for the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Selling, general and administrative expenses include intercompany expenses between the Company and True Health that are recorded in income from continuing operations on the consolidated statements of operations and comprehensive income (loss) related to an existing services agreement for claims processing and other health plan administrative functions of $1.1 million for the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;Cash flows related to the True Health business during the nine months ended September 30, 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.638%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:89.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash flows used in investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i47a4ccf5040a4a66b194e116ca3958b2_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMi0xLTEtMS02NjkxMA_f375ded6-1674-493b-a30e-06d0fe73a516"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i4d45489205434204959192b27c4c154c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMi0zLTEtMS02NjkxMA_d0d37891-4568-4af6-a94c-a639cb0dce3a"
      unitRef="usd">38000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i8eeb2030bc104024b411081939f02ec5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMy0xLTEtMS02NjkxMA_62b2ba33-fbf7-4c70-8985-1a157f134145"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i5a06e059e5d544dfae30aab44f20002e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMy0zLTEtMS02NjkxMA_69234b36-410b-44b9-9162-e74dc0412f40"
      unitRef="usd">44795000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfNC0xLTEtMS02NjkxMA_966d2a48-8912-43a0-8970-e02d16c13d34"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfNC0zLTEtMS02NjkxMA_e067b113-3934-4820-934f-a992d0cd2b7e"
      unitRef="usd">44833000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfNy0xLTEtMS02NjkxMA_b86d92c5-671e-406b-a715-4bf357e17ea7"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfNy0zLTEtMS02NjkxMA_d712ae54-e231-42fb-8344-9605e4e9bb10"
      unitRef="usd">5885000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense
      contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfOC0xLTEtMS02NjkxMA_caa44b40-4a68-45da-922c-897ca7bf890c"
      unitRef="usd">0</evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense>
    <evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense
      contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfOC0zLTEtMS02NjkxMA_f1ec7f47-e5ee-4dcf-baf1-f1a39e7f8d66"
      unitRef="usd">33954000</evh:DisposalGroupIncludingDiscontinuedOperationClaimsExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfOS0xLTEtMS02NjkxMA_f64dc046-5310-4240-b527-a8fee9d1f1b8"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfOS0zLTEtMS02NjkxMA_37985853-f2ed-453e-ac0d-8860c0994686"
      unitRef="usd">5764000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTAtMS0xLTEtNjY5MTA_606a499b-68ad-4ddc-90b1-29725f6806fb"
      unitRef="usd">0</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTAtMy0xLTEtNjY5MTA_bf9e02af-332c-41db-8264-a313a1ada123"
      unitRef="usd">160000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTEtMS0xLTEtNjY5MTA_82486c70-aaac-4b85-8bb4-fa18b758c293"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTEtMy0xLTEtNjY5MTA_e14fdeec-c5f9-438b-b96b-1e126e7988a2"
      unitRef="usd">45763000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTItMS0xLTEtNjY5MTA_9166ab02-b5af-4413-ad82-f54a0ac10ed4"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTItMy0xLTEtNjY5MTA_5b1e980c-c1df-4ae6-ba66-697af34a4107"
      unitRef="usd">-930000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome
      contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTMtMS0xLTEtNjY5MTA_edcfa9e3-4000-489a-85d8-382471b5e9a5"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome
      contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTMtMy0xLTEtNjY5MTA_1befb93d-1aa7-4c00-be0f-6abe86f118dc"
      unitRef="usd">112000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTQtMS0xLTEtNjY5MTA_464ff927-4984-49c6-bb2d-0efa5bd485fe"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTQtMy0xLTEtNjY5MTA_6f8c226a-8100-4be7-81d6-06d584f310ee"
      unitRef="usd">4000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTUtMS0xLTEtNjY5MTA_cbfe76d9-b7db-442c-86a5-148ac5bc49bb"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTUtMy0xLTEtNjY5MTA_b424e1bb-54e5-4afb-93db-22fee388437a"
      unitRef="usd">25000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTYtMS0xLTEtNjY5MTA_a0f7eeee-7588-4609-bbde-11a45d3b5093"
      unitRef="usd">0</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
      contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTYtMy0xLTEtNjY5MTA_005baebf-431f-497f-9a0a-13dde90d27f4"
      unitRef="usd">-847000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTctMS0xLTEtNjY5MTA_7fe478cc-bdc5-4cf0-88d8-01eca2229323"
      unitRef="usd">0</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation
      contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTctMy0xLTEtNjY5MTA_11f078a1-4781-4d0e-a41e-dea5be4756c3"
      unitRef="usd">-326000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTgtMS0xLTEtNjY5MTA_d0d49db4-af68-4d94-bb0c-7f13540d5863"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmJkYTIxZTc1OGNjMTRmNmQ4YzYyYzBhNmFkMWFlMTEwL3RhYmxlcmFuZ2U6YmRhMjFlNzU4Y2MxNGY2ZDhjNjJjMGE2YWQxYWUxMTBfMTgtMy0xLTEtNjY5MTA_05476485-20f7-428a-ab7e-2d1573826cd2"
      unitRef="usd">-521000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i084df9c8155a461a930377e4e05f1fda_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RleHRyZWdpb246MGQ3MjhiYjYzZWI4NDYyNzg2YWE5NWM1MDE0YTFkNzFfMTY4NQ_891cd1e8-4faf-4ca8-bddd-6634b395c5a8"
      unitRef="usd">2800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="i084df9c8155a461a930377e4e05f1fda_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RleHRyZWdpb246MGQ3MjhiYjYzZWI4NDYyNzg2YWE5NWM1MDE0YTFkNzFfMjA1NA_bc39560f-2417-49e3-b62e-4be540185477"
      unitRef="usd">1100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
      contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmQ2NDFhOTk3NzUwNDQ2MGVhMjg0MjE2OWU5Y2VkOTJmL3RhYmxlcmFuZ2U6ZDY0MWE5OTc3NTA0NDYwZWEyODQyMTY5ZTljZWQ5MmZfMC0xLTEtMS02NjkxMA_4734c035-3e7b-4fed-95ef-a79b9cecd30a"
      unitRef="usd">5002000</us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations>
    <us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
      contextRef="i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181Mi9mcmFnOjBkNzI4YmI2M2ViODQ2Mjc4NmFhOTVjNTAxNGExZDcxL3RhYmxlOmQ2NDFhOTk3NzUwNDQ2MGVhMjg0MjE2OWU5Y2VkOTJmL3RhYmxlcmFuZ2U6ZDY0MWE5OTc3NTA0NDYwZWEyODQyMTY5ZTljZWQ5MmZfMS0xLTEtMS02NjkxMA_75a859d0-4e8f-4557-8595-c8899f04935d"
      unitRef="usd">-2494000</us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfOTQ5MA_167a9738-ba1a-430f-bbcd-a07a46d38c1e">Revenue Recognition&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We derive revenue primarily from platform and operations services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Platform and operations services are typically multi-year arrangements with customers to provide various clinical and administrative solutions. In our Clinical Solutions segment, our solutions are designed to lower the medical expenses of our partners and include our total cost of care and specialty care management services. In our Evolent Health Services segment, our solutions are designed to provide comprehensive health plan operations and claims processing services, and also include transition or run-out services to customers receiving primarily third-party administration (&#x201c;TPA&#x201d;) services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our Clinical Solutions segment, we enter into performance-based arrangements that may include capitation and/or gainshare features. We recognize capitation revenue on a gross basis when we have established control over the services within our scope and recognize capitation revenue on a net basis when we do not have control over the services within our scope. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our performance obligation in these arrangements is to provide an integrated suite of services, including access to our platform that is customized to meet the specialized needs of our customers and members. Generally, we will apply the series guidance to the performance obligation as we have determined that each time increment is distinct. We primarily utilize a variable fee structure for these services that typically includes a monthly payment that is calculated based on a specified per member per month rate, multiplied by the number of members that our partners are managing under a value-based care arrangement or a percentage of plan premiums. Our arrangements may also include other variable fees related to service level agreements, shared medical savings arrangements and other performance measures. Variable consideration is estimated using the most likely amount based on our historical experience and best judgment at the time. Due to the nature of our arrangements, certain estimates may be constrained if it is probable that a significant reversal of revenue will occur when the uncertainty is resolved. We recognize revenue from platform and operations services over time using the time elapsed output method. Fixed consideration is recognized ratably over the contract term. In accordance with the series guidance, we allocate variable consideration to the period to which the fees relate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts with Multiple Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with customers may contain multiple performance obligations, primarily when the customer has requested both transformation services and platform and operations services as these services are distinct from one another. When a contract has multiple performance obligations, we allocate the transaction price to each performance obligation based on the relative standalone selling price using the expected cost margin approach. This approach requires estimates regarding both the level of effort it will take to satisfy the performance obligation as well as fees that will be received under the variable pricing model. We also take into consideration customer demographics, current market conditions, the scope of services and our overall pricing strategy and objectives when determining the standalone selling price.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Principal vs. Agent&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We occasionally use third parties to assist in satisfying our performance obligations. In order to determine whether we are the principal or agent in the arrangement, we review each third-party relationship on a contract by contract basis. As we integrate goods and services provided by third parties into our overall service, we control the goods and services provided to the customer prior to its delivery. As such, we are the principal and we will recognize revenue on a gross basis. In certain cases, we act as an agent and do not control the services from third parties before it is delivered to the customer thereby recognizing revenue on a net basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents Evolent&#x2019;s revenue disaggregated by segment and end-market for (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:114.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Transaction Price Allocated to the Remaining Performance Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For contracts with a term greater than one year, we have allocated approximately $69.1 million of transaction price to performance obligations that are unsatisfied as of September&#160;30, 2022. We do not include variable consideration that is allocated entirely to a wholly unsatisfied performance obligation accounted for under the series guidance in the calculation. As a result, the balance represents the value of the fixed consideration in our long-term contracts that we expect will be recognized as revenue in a future period and excludes the majority of our platform and operations revenue, which is primarily derived based on variable consideration as discussed in Note 2. We expect to recognize revenue on approximately 37%, 85% and 98% of these remaining performance obligations by December 31, 2022, 2023 and 2024, respectively, with the remaining balance to be recognized thereafter. However, because our existing contracts may be canceled or renegotiated including for reasons outside our control, the amount of revenue that we actually receive may be less or greater than this estimate and the timing of recognition may not be as expected.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Balances&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract balances consist of accounts receivable, contract assets and deferred revenue. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. We classify contract assets as current or non-current based on the timing of our rights to the unconditional payments. Our contract assets are generally classified as current and recorded within prepaid expenses and other current assets on our consolidated balance sheets. Our current accounts receivables are classified within accounts receivable, net on our consolidated balance sheets and our non-current accounts receivable are classified within prepaid expenses and other non-current assets on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred revenue includes advance customer payments and billings in excess of revenue recognized. We classify deferred revenue as current or non-current based on the timing of when we expect to recognize revenue. Our current deferred revenue is recorded within deferred revenue on our consolidated balance sheets and non-current deferred revenue is recorded within other long-term liabilities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of September&#160;30, 2022 and December 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Excludes pharmacy claims receivable and premiums receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in deferred revenue for the nine months ended September 30, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:102.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning-of-period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to revenue, as a result of performance obligations satisfied&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received in advance of satisfaction of performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of revenue recognized from performance obligations satisfied (or partially satisfied) in a previous period was $10.4&#160;million and $56.4&#160;million for the three and nine months ended September 30, 2022, due primarily to net gain share as well as changes in other estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Cost Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain bonuses and commissions earned by our sales team are considered incremental costs of obtaining a contract with a customer that we expect to be recoverable. The capitalized contract acquisition costs are classified as non-current assets and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within selling, general and administrative expenses on the accompanying consolidated statements of operations and comprehensive income (loss). As of September&#160;30, 2022 and December 31, 2021, the Company had $3.6 million and $5.2 million, respectively, of contract acquisition cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;amortiza&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tion expense of $0.3 million and $2.0 million for the three and nine months ended September 30, 2022, respectively, and $0.3 million and $1.3 million for the three and nine months ended September 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our platform and operations arrangements, we incur certain costs related to the implementation of our platform before we begin to satisfy our performance obligation to the customer. The costs, which we expect to recover, are considered costs to fulfill a contract. Our contract fulfillment costs primarily include our employee labor costs and third-party vendor costs. The capitalized contract fulfillment costs are classified as non-current and recorded within contract cost assets on our consolidated balance sheets. Amortization expense is recorded within cost of revenue on the accompanying consolidated statements of operations and comprehensive income (loss). As of September&#160;30, 2022 and December 31, 2021, the Company had $21.0 million and $27.4 million, respectively, of contract fulfillment cost assets, net of accumulated amortization recorded in contract cost assets on the consolidated balance sheets. In addition, the Company recorded amortization expense including the acceleration of amortization of contract costs for certain customers of $1.3 million and $12.8 million for the three and nine months ended September 30, 2022, respectively, and $1.3 million and $8.6 million for the three and nine months ended September 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These costs are deferred and then amortized on a straight-line basis over a period of benefit that we have determined to be the shorter of the contract term or five years. The period of benefit was based on our technology, the nature of our customer arrangements and other factors.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfOTQ5Mg_5ec092db-aa98-4dcb-b2f1-40e7d262c9ca">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents Evolent&#x2019;s revenue disaggregated by segment and end-market for (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:114.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;315,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;281,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0eabf8957ae644bea9de5ff585037c2e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfMy0xLTEtMS02NjkxMA_bc5f89c2-4a20-435d-a31d-e6cd41113bac"
      unitRef="usd">60054000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia0f69a9ba3a84c17bce7dd867c4d59f5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfMy0zLTEtMS02NjkxMA_2ac0a0b1-6447-49e4-ba4e-776ddaa878a6"
      unitRef="usd">41857000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i275229cc10b9470089d55c668922f2bd_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfMy01LTEtMS02NjkxMA_63b1e65e-3b08-43ad-82b3-bde4ecfc0d6e"
      unitRef="usd">79664000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i367c749bbd734fe5936e4963fe777810_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfMy03LTEtMS02NjkxMA_ecd81185-7f30-4883-b06c-c0eabf346b54"
      unitRef="usd">51829000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94fd241bcaa64da1931a65e62a56ec7c_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfMy05LTEtMS02NjkxMA_a29c9c52-4e62-4950-b6b8-e268ad908332"
      unitRef="usd">183542000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9cdccd94a8564ff29b795220b3f3ab9b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfMy0xMS0xLTEtNjY5MTA_02fefc65-94b0-47f7-b573-becf022ca28d"
      unitRef="usd">154850000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ee4e484cf964a788bb699155c8d3460_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfMy0xMy0xLTEtNjY5MTA_b78e4dc9-28f7-437f-b052-2970f7938d02"
      unitRef="usd">226684000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i942d2a04b516474fad491df3467fe4a1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfMy0xNS0xLTEtNjY5MTA_29350379-d18e-4432-bb9a-145b51a4ca70"
      unitRef="usd">148816000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae1fd07e7a684627bcc4060576e5441e_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNC0xLTEtMS02NjkxMA_050c0bfa-a877-42de-8e93-939bd54623a2"
      unitRef="usd">6335000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0fa189959b70490991b00541c0e766b4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNC0zLTEtMS02NjkxMA_a71964b2-998a-432b-8575-930d69f9b56f"
      unitRef="usd">4816000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7cb9ce8372844c4a246769d6a86d26f_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNC01LTEtMS02NjkxMA_78952fd9-b67d-4e9a-bb04-dc388f380057"
      unitRef="usd">111632000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20e72ff3374e40b7b9ef61f986ed1c3f_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNC03LTEtMS02NjkxMA_6b79ff1d-9059-4be7-bd9c-df37adb2139a"
      unitRef="usd">105219000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic60baf9264bb4217b1b8574383a06caf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNC05LTEtMS02NjkxMA_50573f30-467a-4fcf-91e8-af08a1860e08"
      unitRef="usd">21031000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8ff5e19f6d8424a8f324dfbee51fafc_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNC0xMS0xLTEtNjY5MTA_04cb8c9f-9785-47c8-b539-25cf94d2a67f"
      unitRef="usd">19500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f643fc0caed4180a8f4262624ceb1d5_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNC0xMy0xLTEtNjY5MTA_5b983d81-98e9-4aa7-93f9-b0ed0f7f1228"
      unitRef="usd">315334000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d938e0b3b4949498896da9cf968d0e2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNC0xNS0xLTEtNjY5MTA_ed4f461f-b8de-4385-a2aa-256be70c653c"
      unitRef="usd">281763000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1f0e4a5e2538465489ed74ed4df71f17_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNS0xLTEtMS02NjkxMA_f8fbc7bc-d8b1-4158-a439-33a1925301ea"
      unitRef="usd">40939000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c0881f057a14f60b11d5202ba4254d6_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNS0zLTEtMS02NjkxMA_3a1126c4-ff11-4317-8e93-9a90d1fa8d21"
      unitRef="usd">16184000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia663b5d5862c44d3bb9df7816b437214_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNS01LTEtMS02NjkxMA_94718ac4-bea1-47b2-9e9d-b05499152db5"
      unitRef="usd">53961000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2145c8132b345cdbc155aef50b5b24d_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNS03LTEtMS02NjkxMA_7c614cc4-e1f6-4dc6-8982-38f3aefb4b0a"
      unitRef="usd">2566000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5ecc514fd2f4b63b7f68dd819b7abdd_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNS05LTEtMS02NjkxMA_99104fed-5a62-48ec-9181-51d2c949d3d4"
      unitRef="usd">101948000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cf09e09764f4e7ba983e1073e89d28e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNS0xMS0xLTEtNjY5MTA_2115bc0a-7131-47f4-a5a9-999b8eef6e63"
      unitRef="usd">48207000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d1acdaafc0b49afb61eac49debda354_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNS0xMy0xLTEtNjY5MTA_42cae10b-ea09-44e1-91bd-90f93e9743b2"
      unitRef="usd">121042000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21f251cda7464cffa6ec9eebf7e8f211_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNS0xNS0xLTEtNjY5MTA_1d32d5a2-9eee-40d8-a7cd-3631547b7a4d"
      unitRef="usd">6463000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibde168bb02b0431892729b1d49c5bbbd_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNi0xLTEtMS02NjkxMA_126399ec-d566-4a54-9777-9cd159fb1e7a"
      unitRef="usd">107328000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b5c3ea113b04213b765d3be37ec88ce_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNi0zLTEtMS02NjkxMA_f8d16b12-dce5-4166-83ee-47a9469aac2b"
      unitRef="usd">62857000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ab4a9b7f10b466b8aed9afde209544a_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNi01LTEtMS02NjkxMA_35e2dc2e-8e37-467d-8b69-83c8b491d8ad"
      unitRef="usd">245257000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5053a77df20d49178d0acdd07e80fb9f_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNi03LTEtMS02NjkxMA_e1b51453-9884-42ad-be42-4dd5149a2772"
      unitRef="usd">159614000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieef521b6cb2644d59433c4a98ac67edb_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNi05LTEtMS02NjkxMA_d94c034b-d28c-47ef-8050-ef2e4819c423"
      unitRef="usd">306521000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4dfdc7272dc4a849a6c7e48dfcc4f74_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNi0xMS0xLTEtNjY5MTA_6a709b2e-d39a-4b4f-969d-79c1c52d07d3"
      unitRef="usd">222557000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5af61dbd97844f2cb160b48a3a35d4e8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNi0xMy0xLTEtNjY5MTA_efa86eca-b6b2-4096-804f-de9a16ebf36c"
      unitRef="usd">663060000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e55c1b3affc496aa10cbd0b6538c957_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjRiMDA2NzAyZjcyZDRhY2ViODIxOTIyMmNiZjFkMDIzL3RhYmxlcmFuZ2U6NGIwMDY3MDJmNzJkNGFjZWI4MjE5MjIyY2JmMWQwMjNfNi0xNS0xLTEtNjY5MTA_bd4df381-bcd4-46f3-9655-a7b81099d1ff"
      unitRef="usd">437042000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfNDM0OQ_74e51dde-b54b-497a-8f49-a19a6e418689"
      unitRef="usd">69100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="iba9bddef4c7947819c9a666d386809f7_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfNDk2OA_50c8d199-683a-442d-b37f-767a7aa67961"
      unitRef="number">0.37</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i7717c83097bb48c298d7cd0c08b877cc_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfNDk3Mg_e2785dac-258d-4411-b4ac-67f876b6874d"
      unitRef="number">0.85</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="i622d6d21df814836a91bfc0e4f88e5e0_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfNDk3OQ_5908af02-d128-4165-b396-fe869796bf91"
      unitRef="number">0.98</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfOTQ4OA_c16267b8-c205-48ea-8650-dd645528132c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information about receivables, contract assets and deferred revenue from contracts with customers as of September&#160;30, 2022 and December 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term receivables &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Excludes pharmacy claims receivable and premiums receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in deferred revenue for the nine months ended September 30, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:102.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning-of-period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reclassification to revenue, as a result of performance obligations satisfied&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash received in advance of satisfaction of performance obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOmUyYjk0N2M4NGQ5YzQxMGViMDhlMjBkZDgzNjAxNThmL3RhYmxlcmFuZ2U6ZTJiOTQ3Yzg0ZDljNDEwZWIwOGUyMGRkODM2MDE1OGZfMS0xLTEtMS02NjkxMA_ef5ebf8a-c322-4d9e-95c4-5fd82235a5f8"
      unitRef="usd">185590000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOmUyYjk0N2M4NGQ5YzQxMGViMDhlMjBkZDgzNjAxNThmL3RhYmxlcmFuZ2U6ZTJiOTQ3Yzg0ZDljNDEwZWIwOGUyMGRkODM2MDE1OGZfMS0zLTEtMS02NjkxMA_2a7ca601-19eb-43b7-b9b5-4a944ab8f906"
      unitRef="usd">129012000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOmUyYjk0N2M4NGQ5YzQxMGViMDhlMjBkZDgzNjAxNThmL3RhYmxlcmFuZ2U6ZTJiOTQ3Yzg0ZDljNDEwZWIwOGUyMGRkODM2MDE1OGZfMi0xLTEtMS02NjkxMA_b59bb1d3-da8c-42c1-ae0f-0bfd42004aab"
      unitRef="usd">884000</us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent>
    <us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOmUyYjk0N2M4NGQ5YzQxMGViMDhlMjBkZDgzNjAxNThmL3RhYmxlcmFuZ2U6ZTJiOTQ3Yzg0ZDljNDEwZWIwOGUyMGRkODM2MDE1OGZfMi0zLTEtMS02NjkxMA_5ff71e38-ce98-431d-951c-3ed932f1dda1"
      unitRef="usd">4877000</us-gaap:LongTermAccountsNotesAndLoansReceivableNetNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOmUyYjk0N2M4NGQ5YzQxMGViMDhlMjBkZDgzNjAxNThmL3RhYmxlcmFuZ2U6ZTJiOTQ3Yzg0ZDljNDEwZWIwOGUyMGRkODM2MDE1OGZfMy0xLTEtMS02NjkxMA_a11c78f3-2e50-41a4-8cf0-32f119d8f7a7"
      unitRef="usd">7524000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOmUyYjk0N2M4NGQ5YzQxMGViMDhlMjBkZDgzNjAxNThmL3RhYmxlcmFuZ2U6ZTJiOTQ3Yzg0ZDljNDEwZWIwOGUyMGRkODM2MDE1OGZfMy0zLTEtMS02NjkxMA_d575817f-094a-4f3e-8a8e-e5dea6c97e79"
      unitRef="usd">11944000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOmUyYjk0N2M4NGQ5YzQxMGViMDhlMjBkZDgzNjAxNThmL3RhYmxlcmFuZ2U6ZTJiOTQ3Yzg0ZDljNDEwZWIwOGUyMGRkODM2MDE1OGZfNC0xLTEtMS02NjkxMA_53eb670d-b796-41c8-9d05-56bdf7ef4edc"
      unitRef="usd">3185000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOmUyYjk0N2M4NGQ5YzQxMGViMDhlMjBkZDgzNjAxNThmL3RhYmxlcmFuZ2U6ZTJiOTQ3Yzg0ZDljNDEwZWIwOGUyMGRkODM2MDE1OGZfNC0zLTEtMS02NjkxMA_5d6cf9c0-50f1-4dcd-9a90-422ed1f7208b"
      unitRef="usd">4437000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjMyODZiZDRlODBiMDQyYmRhNDFkYzhjN2RlMDc4NGI3L3RhYmxlcmFuZ2U6MzI4NmJkNGU4MGIwNDJiZGE0MWRjOGM3ZGUwNzg0YjdfMS0xLTEtMS02NjkxMA_5a7384d4-6d74-48b9-986e-069db310fd72"
      unitRef="usd">16381000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjMyODZiZDRlODBiMDQyYmRhNDFkYzhjN2RlMDc4NGI3L3RhYmxlcmFuZ2U6MzI4NmJkNGU4MGIwNDJiZGE0MWRjOGM3ZGUwNzg0YjdfMi0xLTEtMS02NjkxMA_6b4d5052-d75c-40eb-a773-3a41a4ae2352"
      unitRef="usd">11445000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjMyODZiZDRlODBiMDQyYmRhNDFkYzhjN2RlMDc4NGI3L3RhYmxlcmFuZ2U6MzI4NmJkNGU4MGIwNDJiZGE0MWRjOGM3ZGUwNzg0YjdfMy0xLTEtMS02NjkxMA_a04d5e42-c5b6-42cd-9980-77ec6ebc5a27"
      unitRef="usd">5773000</evh:ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RhYmxlOjMyODZiZDRlODBiMDQyYmRhNDFkYzhjN2RlMDc4NGI3L3RhYmxlcmFuZ2U6MzI4NmJkNGU4MGIwNDJiZGE0MWRjOGM3ZGUwNzg0YjdfNC0xLTEtMS02NjkxMA_74af4943-914b-4111-b0bb-0c14d0300846"
      unitRef="usd">10709000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfNzE3Nw_8c9cfa59-a3b9-4a7d-b55a-aed7044ed6f3"
      unitRef="usd">10400000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfNzE4NA_7d47d725-6b33-4788-b56d-5a551da3351c"
      unitRef="usd">56400000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i8df943109acf43b1beae85454cf38885_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfNzgzNA_51f5a9b1-7cb5-463d-a93a-d77f27e734ac"
      unitRef="usd">3600000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i9767cf7dd34a49aca4c626b25a0137e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfNzg0MQ_a39453b0-4ef5-4388-a277-0ff4f2016d84"
      unitRef="usd">5200000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i1edb69a16cb6459691cb056b595c5885_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfODA1NQ_ed06f713-0e00-4cbf-b0d0-8a55cd4f3a25"
      unitRef="usd">300000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="id614a39adbe643b4aa5b5af050be49fd_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfODA2Mg_784fbb55-3003-4fb9-8c30-7c2ef3eb3fbc"
      unitRef="usd">2000000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i632714a677b64a15983dae3dbbde9997_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfODA5MQ_6adb04ae-9211-4314-b33f-8b9702edd811"
      unitRef="usd">300000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i7383d04203184df1accf6ee901f03030_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfODA5OA_5d682521-9582-4ace-9d87-49e5dd1d934c"
      unitRef="usd">1300000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostNet
      contextRef="id740d1bbcfed47e0aaa7894c6b8e4f13_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfODg0MQ_4c493ec9-77ce-4db1-9011-0c6f36374980"
      unitRef="usd">21000000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="i60bde46c214b463b872f8fed94fe0fd3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfODg0OA_498eacdd-9f6f-4abe-b05f-3250937cda56"
      unitRef="usd">27400000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="id8d6b3d636ef48789c73c450718514b3_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfOTE0NQ_717d2f1e-1b48-43e2-aad5-20cd1eb78d27"
      unitRef="usd">1300000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="if801b9c8aab245d5b731f391ad5348b2_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfOTE1Mg_c99740f5-3c6d-44d9-bbe9-5be7eea7244c"
      unitRef="usd">12800000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i21ab12969f634adfa6cdd08a0aaf4fad_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfOTE4MQ_f3649059-4c40-4e28-845e-bbdb10096a8e"
      unitRef="usd">1300000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="i5994da9b8f9641029f5d64b5faece604_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfOTE4OA_f7fc2dad-6b3a-45d8-ba3a-4802afb4e23e"
      unitRef="usd">8600000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortizationPeriod
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM181NS9mcmFnOjRmNjI3MGQ2YzBkYzQxMGU5YmFkNWVhMDQ4NzU5Njk1L3RleHRyZWdpb246NGY2MjcwZDZjMGRjNDEwZTliYWQ1ZWEwNDg3NTk2OTVfOTM3NA_d13fc8cc-f84c-47a7-995b-dcdae8bbaeb0">P5Y</us-gaap:CapitalizedContractCostAmortizationPeriod>
    <us-gaap:CreditLossFinancialInstrumentTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMzAwMg_d80a9861-9c7c-433d-b06c-ad494013daae">Credit Losses &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to credit losses primarily through our accounts receivable from revenue transactions, investments held at amortized cost and other notes receivable. We estimate expected credit losses based on past events, current conditions and reasonable and supportable forecasts. Expected credit losses are measured over the remaining contractual life of these assets. As part of our consideration of current and forward-looking economic conditions, we considered the impact of the COVID-19 pandemic and current inflationary pressures on our customers&#x2019; and other third parties&#x2019; ability to pay. We did not observe notable increases in delinquencies during the three and nine months ended September 30, 2022. Given the nature of our business, our past collection experience during recessionary and pre-recessionary periods and our forecasted impact of the COVID-19 pandemic on our business, we did not record material changes in our allowances due to the COVID-19 pandemic during the three and nine months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable from Revenue Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable represent the amounts owed to the Company for goods or services provided to customers or third parties. Current accounts receivables are classified within accounts receivable, net on the Company&#x2019;s consolidated balance sheets, while non-current accounts receivables are classified within prepaid expenses and other noncurrent assets on the Company&#x2019;s consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We monitor our ongoing credit exposure through active review of counterparty balances against contract terms, due dates and business strategy. Our activities include timely account reconciliation, dispute resolution and payment confirmation. We may employ legal counsel to pursue recovery of defaulted receivables. In addition, the Company will establish a general reserve based on delinquency rates. Historical loss rates are determined for each delinquency bucket in 30-day past-due intervals and then applied to the composition &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the reporting date balance based on delinquency. The allowance implied from application of the historical loss rates is then adjusted, as necessary, for current conditions and reasonable and supportable forecasts.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on an aging analysis of our trade accounts receivable, non-trade accounts receivable and contract assets as of&#160;September&#160;30, 2022,&#160;83% were current, 9%&#160;were past due less than 60 days, with 11% past due less than 120 days and at December 31, 2021, 90% was current, 2% was past due less than 60 days, with 3% past due less than 120 days. As of&#160;September&#160;30, 2022 and December 31, 2021, in total we reported on the consolidated balance sheet&#160;$201.5 million&#160;and $171.5&#160;million of accounts receivable, certain non-trade accounts receivable included in prepaid expenses and other assets, net of allowances of&#160;$9.4 million and $3.4 million, respectively. The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPG acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charge-offs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Charge offs for the nine months ended September 30, 2021, are due to balances written-off that were previously fully reserved as part of the Passport transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:CreditLossFinancialInstrumentTextBlock>
    <evh:FinancingReceivablePercentNotPastDue
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMjM2OQ_86601d28-5948-46af-9234-946b14fbac31"
      unitRef="number">0.83</evh:FinancingReceivablePercentNotPastDue>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="ibff905a18b1f40209cb5ca0efef086b5_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMjM4Ng_b671c353-e398-470f-a455-886e6dae63ec"
      unitRef="number">0.09</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="i5637ed5c72c44080978d3cd0ea34cfda_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMjQyNw_d301c781-025b-469d-93c2-f15da2c37439"
      unitRef="number">0.11</us-gaap:FinancingReceivablePercentPastDue1>
    <evh:FinancingReceivablePercentNotPastDue
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMjQ4NA_c1b80880-9346-4242-8ec4-88713b2eccf8"
      unitRef="number">0.90</evh:FinancingReceivablePercentNotPastDue>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="i04596f10134947b6acb9bac1698947da_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMjUwMA_455279ca-961a-4b27-944f-1539f84419b0"
      unitRef="number">0.02</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:FinancingReceivablePercentPastDue1
      contextRef="i124df651628843dabf0bf39cef2a4f10_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMjU0MA_3b4d54a3-0cdc-4c8b-8b51-e3f1985d4dc4"
      unitRef="number">0.03</us-gaap:FinancingReceivablePercentPastDue1>
    <us-gaap:AccountsReceivableNet
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMjY1OQ_a2a0a9b3-d92c-447f-baf8-0c8fb5560b08"
      unitRef="usd">201500000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMjY2Ng_03272d06-fe1d-43c3-833c-4d1a5fc563f6"
      unitRef="usd">171500000</us-gaap:AccountsReceivableNet>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMjc5OQ_1eaf78bd-38a5-4bed-a83b-af42a00a2682"
      unitRef="usd">9400000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMjgwNg_88d90117-a0bc-420a-a966-a798007f4a7f"
      unitRef="usd">3400000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RleHRyZWdpb246NDc0MjM4YjhmNmY5NDE2Y2E5YjRlZTFjNWQ5ZTRjNTlfMzAwMw_915d36ac-f5e8-4950-9811-8ad89de740c9">The following table summarizes the changes in allowance for credit losses on our accounts receivables, certain non-trade accounts receivable and contract assets (in thousands):&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.816%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,056)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPG acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for credit losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Charge-offs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Charge offs for the nine months ended September 30, 2021, are due to balances written-off that were previously fully reserved as part of the Passport transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RhYmxlOjc0NTQxOTQyZjY3MTRlYTQ5ZjIzNGNhZWNlMjJmYzdhL3RhYmxlcmFuZ2U6NzQ1NDE5NDJmNjcxNGVhNDlmMjM0Y2FlY2UyMmZjN2FfMi0xLTEtMS02NjkxMA_e874da1a-f6a2-4043-93f7-22357d9364c8"
      unitRef="usd">3374000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="idcb7e5d5de6d4fb9bd1b47d49e170108_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RhYmxlOjc0NTQxOTQyZjY3MTRlYTQ5ZjIzNGNhZWNlMjJmYzdhL3RhYmxlcmFuZ2U6NzQ1NDE5NDJmNjcxNGVhNDlmMjM0Y2FlY2UyMmZjN2FfMi0zLTEtMS02NjkxMA_85e0cc7c-b175-44a9-bde0-2e29037e2377"
      unitRef="usd">7056000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RhYmxlOjc0NTQxOTQyZjY3MTRlYTQ5ZjIzNGNhZWNlMjJmYzdhL3RhYmxlcmFuZ2U6NzQ1NDE5NDJmNjcxNGVhNDlmMjM0Y2FlY2UyMmZjN2FfMy0xLTEtMS03NTg3OA_a5ba634d-e12b-4f83-abbb-fea9415849a5"
      unitRef="usd">5269000</evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod>
    <evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RhYmxlOjc0NTQxOTQyZjY3MTRlYTQ5ZjIzNGNhZWNlMjJmYzdhL3RhYmxlcmFuZ2U6NzQ1NDE5NDJmNjcxNGVhNDlmMjM0Y2FlY2UyMmZjN2FfMy0zLTEtMS03NTg3OA_1090cb9f-6917-4506-8546-320eb76b995a"
      unitRef="usd">0</evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RhYmxlOjc0NTQxOTQyZjY3MTRlYTQ5ZjIzNGNhZWNlMjJmYzdhL3RhYmxlcmFuZ2U6NzQ1NDE5NDJmNjcxNGVhNDlmMjM0Y2FlY2UyMmZjN2FfMy0xLTEtMS02NjkxMA_f5cb19de-5c96-4d5b-a014-f098dc7ea631"
      unitRef="usd">1134000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RhYmxlOjc0NTQxOTQyZjY3MTRlYTQ5ZjIzNGNhZWNlMjJmYzdhL3RhYmxlcmFuZ2U6NzQ1NDE5NDJmNjcxNGVhNDlmMjM0Y2FlY2UyMmZjN2FfMy0zLTEtMS02NjkxMA_469ce924-f75c-40de-8c6b-3000753f3942"
      unitRef="usd">1949000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RhYmxlOjc0NTQxOTQyZjY3MTRlYTQ5ZjIzNGNhZWNlMjJmYzdhL3RhYmxlcmFuZ2U6NzQ1NDE5NDJmNjcxNGVhNDlmMjM0Y2FlY2UyMmZjN2FfNC0xLTEtMS02NzgzNA_59c12260-245a-41c5-bdd1-2a957851b4d5"
      unitRef="usd">422000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RhYmxlOjc0NTQxOTQyZjY3MTRlYTQ5ZjIzNGNhZWNlMjJmYzdhL3RhYmxlcmFuZ2U6NzQ1NDE5NDJmNjcxNGVhNDlmMjM0Y2FlY2UyMmZjN2FfNC0zLTEtMS02NzgzNA_0ac7a671-7690-4cb6-8d29-9c10560d44c1"
      unitRef="usd">5076000</us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RhYmxlOjc0NTQxOTQyZjY3MTRlYTQ5ZjIzNGNhZWNlMjJmYzdhL3RhYmxlcmFuZ2U6NzQ1NDE5NDJmNjcxNGVhNDlmMjM0Y2FlY2UyMmZjN2FfNC0xLTEtMS02NjkxMA_c8abfc32-1a2d-4988-a25f-42f550889c75"
      unitRef="usd">9355000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i63b3ddd7486946c2a0a8151832317d14_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182MS9mcmFnOjQ3NDIzOGI4ZjZmOTQxNmNhOWI0ZWUxYzVkOWU0YzU5L3RhYmxlOjc0NTQxOTQyZjY3MTRlYTQ5ZjIzNGNhZWNlMjJmYzdhL3RhYmxlcmFuZ2U6NzQ1NDE5NDJmNjcxNGVhNDlmMjM0Y2FlY2UyMmZjN2FfNC0zLTEtMS02NjkxMA_cc953e08-7cc1-43ce-be3b-81b2905a0cce"
      unitRef="usd">3929000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfNjg1_64cd2db3-bbdf-4cee-9e2a-f1d0c02b8d18">Property and Equipment, Net&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes our property and equipment (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalized $8.0 million and $21.5 million for the three and nine months ended September 30, 2022, respectively, and $5.4 million and $16.5 million for the three and nine months ended September 30, 2021, respectively, of internal-use software development costs. The net book value of capitalized internal-use software development costs was $73.0 million and $71.2 million as of September&#160;30, 2022 and December 31, 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was $7.7 million and $23.1 million for the three and nine months ended September 30, 2022, respectively, and $7.4 million and $22.8 million for the three and nine months ended September 30, 2021, respectively, of which amortization expense related to capitalized internal-use software development costs was $6.4 million and $19.6 million for the three and nine months ended September 30, 2022, respectively, and $6.7 million and $20.0 million for the three and nine months ended September 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfNjg3_b2f984d1-76ef-48b3-b05f-95cb149f8bd2">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes our property and equipment (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer hardware&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Internal-use software development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(141,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(119,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5730da3ff5444c0fbe524c644c202af4_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfMS0xLTEtMS02NjkxMA_09a56522-0e72-41eb-9876-b2dd49f89694"
      unitRef="usd">27988000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia3e288bad13b4a5e8fbf6a82c2389ad6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfMS0zLTEtMS02NjkxMA_c1fedc26-11b4-4ec7-95fc-99e63950a4bb"
      unitRef="usd">21970000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib5c4d433d31d4a2a84d11ae0257cc18f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfMi0xLTEtMS02NjkxMA_239b6f93-6433-4ff6-94b2-b6c07246b7fb"
      unitRef="usd">4141000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4ebfbd6230a54574b1ed03cade006714_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfMi0zLTEtMS02NjkxMA_a84a635c-7e70-4eb8-bed5-755933361cad"
      unitRef="usd">3581000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iabc0377cf6c84950aafa636df7d7c185_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfMy0xLTEtMS02NjkxMA_69c11a69-6214-4788-9a2a-c61286376313"
      unitRef="usd">181063000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id32484f46aaa490dafecdb5a20db36fc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfMy0zLTEtMS02NjkxMA_32e322a7-d696-48e0-914b-87ab9eb7c578"
      unitRef="usd">159587000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i311d2b7cdbe24f8ebdf190a94aa1332f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfNC0xLTEtMS02NjkxMA_e69aa5de-23e4-49a4-a1eb-2a91d6ee26a8"
      unitRef="usd">23160000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i49599e7727614d2697e205fcf5b794f4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfNC0zLTEtMS02NjkxMA_5ab0d0cf-67ad-452f-886d-41d1244984a6"
      unitRef="usd">15325000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfNS0xLTEtMS02NjkxMA_67907508-7e30-4e3c-801e-8a54c8bd3abd"
      unitRef="usd">236352000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfNS0zLTEtMS02NjkxMA_4c5500c4-66b0-4602-8a8c-8afefd5d6756"
      unitRef="usd">200463000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfNi0xLTEtMS02NjkxMA_ff37573d-4502-4b3d-bc61-057e80b7847f"
      unitRef="usd">141707000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfNi0zLTEtMS02NjkxMA_91e1df6a-1cc1-4f8b-a626-c5a1018631d0"
      unitRef="usd">119098000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfNy0xLTEtMS02NjkxMA_053cc2c0-5938-4fa1-ae9f-a6cb95aaf2f5"
      unitRef="usd">94645000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RhYmxlOjc2ZGNmZjIwMDU2NzQwYjBiNjQ4MTA0ZjIwZDBkNjI1L3RhYmxlcmFuZ2U6NzZkY2ZmMjAwNTY3NDBiMGI2NDgxMDRmMjBkMGQ2MjVfNy0zLTEtMS02NjkxMA_052dd2c3-8725-44c2-9f4f-d2bbdb8b6c72"
      unitRef="usd">81365000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="i216238f5c4204e818ee9557f67bc5b08_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfMTM5_9ada03ba-008b-4700-8c54-75d57412d79e"
      unitRef="usd">8000000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="idadb3eda60994bfc9bf46cb46e81e8b4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfMTQ2_cc0b5eee-16ff-4b3f-acec-592366dd370e"
      unitRef="usd">21500000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="i4ab5726f3d7c43e9b4c48c383620aa05_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfMTc1_7bad5e54-70d7-490c-8903-1cb1c671170e"
      unitRef="usd">5400000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:CapitalizedComputerSoftwareAdditions
      contextRef="i597e5acb0181498a985baa0c47467de9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfMTgy_9695ee68-a96d-4793-b6fe-a90b42455538"
      unitRef="usd">16500000</us-gaap:CapitalizedComputerSoftwareAdditions>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="iabc0377cf6c84950aafa636df7d7c185_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfMzI5_23ab527d-40a7-4221-b66d-a6d25934088f"
      unitRef="usd">73000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id32484f46aaa490dafecdb5a20db36fc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfMzM2_55b6620c-fc3f-410e-8979-1929c1532491"
      unitRef="usd">71200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfNDQ2_6b185cc9-b9b1-4581-8815-b6d6012e69c2"
      unitRef="usd">7700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfNDUz_d228e24c-eeaf-4909-a409-3a04231c1244"
      unitRef="usd">23100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfNDgy_52bc6a15-5c3e-49f9-97d6-56562f6517f8"
      unitRef="usd">7400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfNDg5_734e4c9b-44c3-4c7d-831d-2a907f044c79"
      unitRef="usd">22800000</us-gaap:Depreciation>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfNjEx_5be75d1b-56e3-418e-8d8d-da39d90da9ab"
      unitRef="usd">6400000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfNjE4_5b1c2f75-2440-4291-80a4-dbd851e8fe56"
      unitRef="usd">19600000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfNjQ3_90684fb6-4379-48d4-b34a-21fa582d2819"
      unitRef="usd">6700000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:CapitalizedComputerSoftwareAmortization1
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182NC9mcmFnOmFiMTk3ODE2ZGQ4MTQwYTVhNGE1ZTMxZGVmNGIzY2UxL3RleHRyZWdpb246YWIxOTc4MTZkZDgxNDBhNWE0YTVlMzFkZWY0YjNjZTFfNjU0_f832d1af-c80b-415d-bb32-f0d1c0a72cf1"
      unitRef="usd">20000000</us-gaap:CapitalizedComputerSoftwareAmortization1>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMjkyOA_6f5ab9e4-5128-42b5-ba89-39ae72358dd1">Goodwill and Intangible Assets, Net&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill has an estimated indefinite life and is not amortized; rather, it is reviewed for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three reporting units, each with &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;discrete financial information. Our assets and liabilities are employed in and relate to the operations of our reporting units. Therefore, the equity carrying value and future cash flows must be estimated each time a&#160;goodwill impairment&#160;analysis is performed on a reporting unit. As a result, our assets, liabilities and cash flows are assigned to reporting units using reasonable and consistent allocation methodologies. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our annual goodwill impairment review occurs on October 31 of each fiscal &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year. We evaluate qualitative factors that could cause us to believe the estimated fair value of each of our reporting units may be lower than the carrying value and trigger a quantitative assessment, including, but not limited to (i) macroeconomic conditions, (ii) industry and market considerations, (iii) our overall financial performance, including an analysis of our current and projected cash flows, revenues and earnings, (iv) a sustained decrease in share price and (v) other relevant entity-specific events including changes in management, strategy, partners, or litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not identify any qualitative factors that would trigger a quantitative goodwill impairment test during &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the three and nine months ended September 30, 2022&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We will perform our annual impairment test on October 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Goodwill Impairment Test&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 31, 2021, the Company performed its annual goodwill impairment review for fiscal year 2021. Based on our qualitative assessment, we did not identify sufficient indicators of impairment that would suggest the fair value of any of our three reporting units was below their respective carrying values. As a result, a quantitative goodwill impairment analysis was not required.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Change in Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Net of cumulative inception to date impairment of $575.5 million as of both December 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Goodwill acquired from the addition of IPG in the third quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details of our intangible assets (in thousands, except weighted-average useful lives) as of September&#160;30, 2022 and December&#160;31, 2021 are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:72.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:46.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:45.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:44pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted- Average Remaining Useful Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;465,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Below market lease, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provider network contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,957&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:35pt"&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;638,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;442,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to intangible assets was $9.5 million and $24.3 million for the three and nine months ended September 30, 2022, respectively, and $7.4 million and $22.1 million for the three and nine months ended September 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future estimated amortization of intangible assets (in thousands) as of September&#160;30, 2022, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:478.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed for impairment if circumstances indicate the Company may not be able to recover the assets&#x2019; carrying value. We did not identify any circumstances during&#160;the three and nine months ended September 30, 2022, that would require an impairment test for our intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMzE3_a24f4fa5-771f-4062-9496-e22a16a37dad"
      unitRef="reporting_unit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:NumberOfReportingUnits
      contextRef="ic75e54e0b5564ba5bdf3845c85ae6efa_D20211001-20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMTg4NA_fb82980a-8f04-4f7a-96d5-09064a651de8"
      unitRef="reporting_unit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMjkzMQ_5c075a6a-d6c4-496b-86e2-69da7cb5da1f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill, by reportable segment, for the periods presented (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.705%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.985%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;211,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill acquired&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Net of cumulative inception to date impairment of $575.5 million as of both December 31, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Goodwill acquired from the addition of IPG in the third quarter of 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="if2b23b62d2314ba29f31148feecadf97_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMS0xLTEtMS02NjkxMA_80cefe02-a148-4915-9a30-25a188aadb8d"
      unitRef="usd">214334000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2c9b3945ac9741d4843b49c10f8dcd40_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMS0zLTEtMS02NjkxMA_74b50f94-3011-486b-9c6c-337a88353d5b"
      unitRef="usd">211963000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMS01LTEtMS02NjkxMA_fb048d8f-fa3f-4bfb-98b4-6fad24811ea1"
      unitRef="usd">426297000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="if4dfdc7272dc4a849a6c7e48dfcc4f74_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMi0xLTEtMS03NTA3MQ_ab5c9fd8-2a7e-4ca4-b529-810d9700b87d"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i8e55c1b3affc496aa10cbd0b6538c957_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMi0zLTEtMS03NTA2Mw_59661b2a-8074-414a-a180-2d96afaf2049"
      unitRef="usd">296597000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMi01LTEtMS03NTA3OQ_b69a95c3-aae7-459a-931b-8e7b8b8f1aaf"
      unitRef="usd">296597000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ieef521b6cb2644d59433c4a98ac67edb_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMi0xLTEtMS02NjkxMA_5a0fdce0-32d0-4299-a527-ecca6a8eaafd"
      unitRef="usd">-104000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i5af61dbd97844f2cb160b48a3a35d4e8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMi0zLTEtMS02NjkxMA_600a1c42-5388-40c9-bfbd-946453f28335"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMi01LTEtMS02NjkxMA_025bd8f3-6cf0-4453-9cd7-83d6d4ee924c"
      unitRef="usd">-104000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="iffa15ee70390496c89f205bdc8f3731b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMy0xLTEtMS02NjkxMA_386b3d97-6683-40c3-a066-a07ea1fc04b0"
      unitRef="usd">214230000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i358169d308bf4641ad0dca36755b47d1_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMy0zLTEtMS02NjkxMA_e04793f4-6834-47c6-a8cc-bfca04bb9f62"
      unitRef="usd">508560000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfMy01LTEtMS02NjkxMA_b61b59dd-508c-4a56-ba2d-e76d23a2aa18"
      unitRef="usd">722790000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="if0291d88c45549ebb15674a1bf82c1a2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfNS0xLTEtMS02NjkxMA_dbe3665b-45fa-4d81-a63b-07d70092f8b2"
      unitRef="usd">214354000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5b7c2c9eb4d24e95a2fb3597a736a55d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfNS0zLTEtMS02NjkxMA_6308fab7-e31b-4338-9d9a-257ca29a5c2f"
      unitRef="usd">134675000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="idcb7e5d5de6d4fb9bd1b47d49e170108_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfNS01LTEtMS02NjkxMA_82f61258-1587-4730-a777-0fa090afdb78"
      unitRef="usd">349029000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="if4dfdc7272dc4a849a6c7e48dfcc4f74_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfNi0xLTEtMS02NjkxMA_1d3f8bdb-a111-4985-b63a-78336bb0b9b7"
      unitRef="usd">-19000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i8e55c1b3affc496aa10cbd0b6538c957_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfNi0zLTEtMS02NjkxMA_76078246-11c5-4cfe-b059-65187bfa8851"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfNi01LTEtMS02NjkxMA_04708167-b821-42b6-9632-334631447ec7"
      unitRef="usd">-19000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i1859c2ae121649f09ad595e92fb8e96c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfNy0xLTEtMS02NjkxMA_fd253cf7-5cab-4878-8bdc-41d761189f02"
      unitRef="usd">214335000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i44a8b1c85fc24294af85eb3f3327612d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfNy0zLTEtMS02NjkxMA_d4d92524-0a9a-4ec6-928b-c71d6bc68aef"
      unitRef="usd">134675000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i63b3ddd7486946c2a0a8151832317d14_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOmQ2NWQ3ZWEzZWI2NjQyZjJhODIwMTdmY2ViY2VlMzRlL3RhYmxlcmFuZ2U6ZDY1ZDdlYTNlYjY2NDJmMmE4MjAxN2ZjZWJjZWUzNGVfNy01LTEtMS02NjkxMA_58f59b7f-d22f-4044-8ef2-bef8e2971de9"
      unitRef="usd">349010000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="idcb7e5d5de6d4fb9bd1b47d49e170108_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMjI0OQ_23658686-52b6-45ac-8d68-3386d01d8373"
      unitRef="usd">575500000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMjI0OQ_315f8c02-6299-40e1-95a0-7c6b2b058ed6"
      unitRef="usd">575500000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ifaa4680cab4245c48c966ba93e130b60_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMi0xLTEtMS02NjkxMA_463b69c2-c129-46c9-ab11-e35ff460bba9">P13Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i84135b0576f249ae8003b7e81a024ba5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMi0zLTEtMS02NjkxMA_28ce3999-2c0a-46aa-8505-dce608f5b703"
      unitRef="usd">43600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i84135b0576f249ae8003b7e81a024ba5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMi01LTEtMS02NjkxMA_3dee55d8-215f-4a22-8c47-c39030223a3b"
      unitRef="usd">9847000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i84135b0576f249ae8003b7e81a024ba5_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMi03LTEtMS02NjkxMA_0806a3ed-8203-419c-ae5d-375775717dfd"
      unitRef="usd">33753000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ic68a9db5aae1478fadff12a779202797_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMi05LTEtMS02NjkxMA_cc564afc-e40e-4759-99c7-b294eb4be2d7">P12Y4M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if41217b3022a48ed94e3723c3e0071e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMi0xMS0xLTEtNjY5MTA_9c82ed26-f05a-44c1-b77c-bd2f4bb6244e"
      unitRef="usd">25800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if41217b3022a48ed94e3723c3e0071e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMi0xMy0xLTEtNjY5MTA_2455fde7-31f3-4d1c-a9b7-5c8c15f367f9"
      unitRef="usd">7693000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if41217b3022a48ed94e3723c3e0071e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMi0xNS0xLTEtNjY5MTA_529a7903-e556-469b-a024-adf3b24415a8"
      unitRef="usd">18107000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ie6843d02651b4eb19d0b68edf6087afd_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMy0xLTEtMS02NjkxMA_beba97bb-8f44-445f-95bf-c6dd4b2e124e">P16Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i25182b4f6fce43fda0e5ebbe2cc7f240_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMy0zLTEtMS02NjkxMA_98105468-ec9c-4168-bf01-998620151f8e"
      unitRef="usd">465019000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i25182b4f6fce43fda0e5ebbe2cc7f240_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMy01LTEtMS02NjkxMA_611011b0-ce91-4055-8853-19e6c5a56745"
      unitRef="usd">86623000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i25182b4f6fce43fda0e5ebbe2cc7f240_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMy03LTEtMS02NjkxMA_95187c19-45ec-4f7f-9ed1-7cd55b3c4c04"
      unitRef="usd">378396000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i59ff2088dd3d487c93a983e025043b03_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMy05LTEtMS02NjkxMA_eafc9251-0566-42ce-b1c8-4633d4f3899a">P14Y10M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie0792eb2a4584a8b95e0d513e6752d62_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMy0xMS0xLTEtNjY5MTA_d079c6ab-6abc-4f2d-b84e-2822be3038e0"
      unitRef="usd">311019000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie0792eb2a4584a8b95e0d513e6752d62_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMy0xMy0xLTEtNjY5MTA_07c88f58-9d80-4209-abd3-16c7441e0a41"
      unitRef="usd">72697000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie0792eb2a4584a8b95e0d513e6752d62_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfMy0xNS0xLTEtNjY5MTA_8e1e585a-ff64-4d34-918c-c3cb52862251"
      unitRef="usd">238322000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ia71efd024b264a23aa0d21ad75741277_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNC0xLTEtMS02NjkxMA_863cb776-822f-43da-9fe0-f72fc421401d">P2Y10M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie2ec2a15830e4d0e87fe2230ea0e7474_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNC0zLTEtMS02NjkxMA_58ee607e-306c-467d-a828-a9648e992d8d"
      unitRef="usd">111822000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie2ec2a15830e4d0e87fe2230ea0e7474_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNC01LTEtMS02NjkxMA_e2483fc1-7dfd-4adb-ad1a-8e31761a8245"
      unitRef="usd">78648000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie2ec2a15830e4d0e87fe2230ea0e7474_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNC03LTEtMS02NjkxMA_1dcf7d51-5e7f-420d-bf34-b41cda145f3d"
      unitRef="usd">33174000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i6cdb2defd328413a8f5c7e2f8ae2c1f0_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNC05LTEtMS02NjkxMA_cb306163-730b-4f8c-bd6f-350b27bc5293">P2Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i58352bc33d9d47e7b266d367548f4196_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNC0xMS0xLTEtNjY5MTA_cb1a4028-235a-4b7a-9fde-95ac1badc82e"
      unitRef="usd">87922000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i58352bc33d9d47e7b266d367548f4196_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNC0xMy0xLTEtNjY5MTA_cdb7e4b3-5deb-4e05-90a3-bbe68cfc232e"
      unitRef="usd">73378000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i58352bc33d9d47e7b266d367548f4196_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNC0xNS0xLTEtNjY5MTA_18b42cec-9a01-41a5-93d5-1901730f717a"
      unitRef="usd">14544000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i7bd97829624644b3a76e8a12f04957c7_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNS0xLTEtMS02NjkxMA_f84f8d08-4919-4dfa-9bde-7c767c5be3a0">P0Y7M6D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i34a0859bcb414bc7b9fafe316f673bca_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNS0zLTEtMS02NjkxMA_a1f6f567-1bc7-47b1-bc08-b931f30c8964"
      unitRef="usd">1218000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i34a0859bcb414bc7b9fafe316f673bca_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNS01LTEtMS02NjkxMA_c4229759-595f-4ed9-a0cf-38c4f0c48279"
      unitRef="usd">1100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i34a0859bcb414bc7b9fafe316f673bca_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNS03LTEtMS02NjkxMA_55e88f9e-5f9c-47b2-b518-bbc3c718e885"
      unitRef="usd">118000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ic0f42e14adcf450990dc48ddf76f1496_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNS05LTEtMS02NjkxMA_b01e3ffb-4c87-4623-afa4-b58bc45156cb">P1Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie0fd0d41813c458fa01a9b4a323d16c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNS0xMS0xLTEtNjY5MTA_1a7cc326-1ee8-4a57-9757-c6086ae61b2d"
      unitRef="usd">1218000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie0fd0d41813c458fa01a9b4a323d16c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNS0xMy0xLTEtNjY5MTA_6daf6af7-7b07-41a7-a0a6-f977cbf8ee4e"
      unitRef="usd">950000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie0fd0d41813c458fa01a9b4a323d16c6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNS0xNS0xLTEtNjY5MTA_4841d1b7-5e40-4f7c-b9b7-9869b00ab819"
      unitRef="usd">268000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i1df90080b3ad4844b8125e0a4c7547e9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNi0xLTEtMS02NjkxMA_f1c467ae-bb8a-4893-bc78-79e7c09f3db6">P1Y6M</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7c22c7e8a0aa46c294ef5bcb1985120c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNi0zLTEtMS02NjkxMA_d1ef59b2-1291-4676-9b21-5daaa0aa0857"
      unitRef="usd">16553000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7c22c7e8a0aa46c294ef5bcb1985120c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNi01LTEtMS02NjkxMA_aa243966-c4e6-4dad-8c5c-beee383553de"
      unitRef="usd">10596000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7c22c7e8a0aa46c294ef5bcb1985120c_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNi03LTEtMS02NjkxMA_3108f620-ee4f-4349-85b7-b1e71a64ffaf"
      unitRef="usd">5957000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ie029cabfd7164a66bdeb9807be351813_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNi05LTEtMS02NjkxMA_ad024bca-5829-490b-95eb-d80348d4a1b0">P2Y2M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8f3b6e992ace40abb1f986f35d3efc3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNi0xMS0xLTEtNjY5MTA_ccd452c8-b6fb-410f-b1ea-6e141ed3bb5d"
      unitRef="usd">16417000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8f3b6e992ace40abb1f986f35d3efc3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNi0xMy0xLTEtNjY5MTA_172685b9-5d5e-46e2-a268-8c5c2e9f6879"
      unitRef="usd">7874000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8f3b6e992ace40abb1f986f35d3efc3c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNi0xNS0xLTEtNjY5MTA_9c1fc180-c572-4774-806f-fdc13f97c8b5"
      unitRef="usd">8543000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNy0zLTEtMS02NjkxMA_ff4b57b3-e764-48a9-b29c-98a2c5e4d0a3"
      unitRef="usd">638212000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNy01LTEtMS02NjkxMA_ea08ed5d-3052-4e5e-a29c-9c201860fc3f"
      unitRef="usd">186814000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNy03LTEtMS02NjkxMA_148de35c-51d6-4b31-910b-bb61feb88897"
      unitRef="usd">451398000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNy0xMS0xLTEtNjY5MTA_9f7243b7-f87b-4724-9b90-2a9b6d8dfb0b"
      unitRef="usd">442376000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNy0xMy0xLTEtNjY5MTA_848880cb-5a5a-4498-bee5-c442735a6937"
      unitRef="usd">162592000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjlkODk1YzI3YjFiZDQ0MDY5YjgyNGNhZjQ3ZmMwZmQ5L3RhYmxlcmFuZ2U6OWQ4OTVjMjdiMWJkNDQwNjliODI0Y2FmNDdmYzBmZDlfNy0xNS0xLTEtNjY5MTA_96132551-e09f-4bd2-8515-a659fa0bab39"
      unitRef="usd">279784000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMjQ5OA_47fdc3d7-654b-4405-8899-3ae25f2f4eff"
      unitRef="usd">9500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMjUwNQ_8dbb8e33-4400-43b4-bdad-b3b673dfd071"
      unitRef="usd">24300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMjUzNA_4cfa7b3d-43a2-4115-b76b-6c19f365fd8d"
      unitRef="usd">7400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMjU0MQ_393a05b4-cc6b-419f-8a09-191070f802dc"
      unitRef="usd">22100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RleHRyZWdpb246ZmRlMzhjMWRjOGRhNDZkYjhmODk1OGRjYjZlYjFiN2VfMjkyMQ_551b8a75-4657-42d4-8847-e1b2c2d72884">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future estimated amortization of intangible assets (in thousands) as of September&#160;30, 2022, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:478.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjk3Yjk0ZjI2ZTI0MjQxNDNhNTQxYjI0MDU3Y2EzNDBhL3RhYmxlcmFuZ2U6OTdiOTRmMjZlMjQyNDE0M2E1NDFiMjQwNTdjYTM0MGFfMC0xLTEtMS02NjkxMA_07a4f6b3-7c3a-4b2b-a05d-94355868cc2f"
      unitRef="usd">10620000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjk3Yjk0ZjI2ZTI0MjQxNDNhNTQxYjI0MDU3Y2EzNDBhL3RhYmxlcmFuZ2U6OTdiOTRmMjZlMjQyNDE0M2E1NDFiMjQwNTdjYTM0MGFfMS0xLTEtMS02NjkxMA_ad4b946e-7774-49d1-986c-d8c6e9e3f0ca"
      unitRef="usd">40487000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjk3Yjk0ZjI2ZTI0MjQxNDNhNTQxYjI0MDU3Y2EzNDBhL3RhYmxlcmFuZ2U6OTdiOTRmMjZlMjQyNDE0M2E1NDFiMjQwNTdjYTM0MGFfMi0xLTEtMS02NjkxMA_e498ee66-46fa-43bd-acac-6b55605ccc41"
      unitRef="usd">34603000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjk3Yjk0ZjI2ZTI0MjQxNDNhNTQxYjI0MDU3Y2EzNDBhL3RhYmxlcmFuZ2U6OTdiOTRmMjZlMjQyNDE0M2E1NDFiMjQwNTdjYTM0MGFfMy0xLTEtMS02NjkxMA_2929b9e2-c6af-4f6d-a1b1-f14e5d70f214"
      unitRef="usd">33057000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjk3Yjk0ZjI2ZTI0MjQxNDNhNTQxYjI0MDU3Y2EzNDBhL3RhYmxlcmFuZ2U6OTdiOTRmMjZlMjQyNDE0M2E1NDFiMjQwNTdjYTM0MGFfNC0xLTEtMS02NjkxMA_0e73cdc6-0413-4e7f-b0f3-af53c5f7fe95"
      unitRef="usd">32880000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <evh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjk3Yjk0ZjI2ZTI0MjQxNDNhNTQxYjI0MDU3Y2EzNDBhL3RhYmxlcmFuZ2U6OTdiOTRmMjZlMjQyNDE0M2E1NDFiMjQwNTdjYTM0MGFfNS0xLTEtMS02NjkxMA_ea86a4be-27e4-4ccb-9f7e-debe70cd0ebb"
      unitRef="usd">299751000</evh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM182Ny9mcmFnOmZkZTM4YzFkYzhkYTQ2ZGI4Zjg5NThkY2I2ZWIxYjdlL3RhYmxlOjk3Yjk0ZjI2ZTI0MjQxNDNhNTQxYjI0MDU3Y2EzNDBhL3RhYmxlcmFuZ2U6OTdiOTRmMjZlMjQyNDE0M2E1NDFiMjQwNTdjYTM0MGFfNi0xLTEtMS02NjkxMA_854e0cd5-9451-4bc1-b917-2e261738e3e8"
      unitRef="usd">451398000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTc3MTE_3f122f8b-5b15-4c66-ba09-c234cda7c3bf">Long-term Debt&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2022 Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2022 (&#x201c;IPG Closing Date&#x201d;), the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#x201c;Borrower&#x201d;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent and revolver agent, together with the Company (the &#x201c;2022 Credit Agreement&#x201d;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial term loan in the aggregate principal amount of $175.0&#160;million (the &#x201c;Initial Term Loan Facility&#x201d;) and (ii) a revolving credit facility in the aggregate principal amount of up to $50.0&#160;million, to be determined by reference to the lesser of $50.0&#160;million and a borrowing base (the &#x201c;Revolving Facility&#x201d; and, together with the Initial Term Loan Facility, the &#x201c;Credit Facilities&#x201d;), subject to the satisfaction of specified conditions. The Borrowers borrowed the loan under the Initial Term Loan Facility on August 1, 2022 (the &#x201c;Initial Term Loan&#x201d;), and also borrowed $50.0&#160;million under the Revolving Facility on the IPG Closing Date. The Credit Facilities are guaranteed by the Company and the Company&#x2019;s domestic subsidiaries, subject to certain exceptions. The Credit Facilities are secured by a first priority security interest in all of the capital stock of each borrower and guarantor (other than the Company) and substantially all of the assets of each borrower and guarantor, subject to certain exceptions. The Initial Term Loan and loans under the Revolving Facility will mature on the date that is the earliest of (a) August 1, 2027, (b) the date on which all amounts outstanding under the 2022 Credit Agreement have been declared or have automatically become due and payable under the terms of the Credit Agreement and (c) the date that is ninety-one (91) days prior to the maturity date of any Junior Debt (as defined in the 2022 Credit Agreement) unless certain liquidity conditions are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds of the Initial Term Loan and Revolving Facility were used to finance the IPG transaction and fund fees and expenses incurred in connection therewith and thereafter may be used to fund acquisitions, ongoing working capital needs and other growth capital investments and to pay fees and expenses in connection therewith. The interest rate for each loan under the Credit Facilities is calculated, at the option of the Borrowers, (a) in the case of a Term Loan, at either the Adjusted Term SOFR Rate (as defined in the Credit Agreement) plus 5.50%, or the base rate plus 4.50% and (b) in the case of a Revolving Loan, at either the Adjusted Term SOFR Rate plus 3.50%, or the base rate plus 2.50%. A commitment fee of (a) 2.00% of the aggregate amount of the commitments in respect of the Term Loan Facility as of the closing and (b) 2.00% of the aggregate amount of the commitments in respect of the Revolving Facility was paid as of the closing. The Company recorded $2.9&#160;million in interest expense related to our 2022 Credit Agreement for the three and nine months ended September 30, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts outstanding under the Credit Facility may be prepaid at the option of the Company subject to applicable premiums and a call protection premium payable on the amount prepaid in certain instances as follows: (1) 3.00% of the principal amount so prepaid after the closing but prior to the first anniversary of the IPG Closing Date; (2) 2.00% of the principal amount so prepaid after the first anniversary of the closing but prior to the second anniversary of the IPG Closing Date; (3) 1.00% of the principal amount so prepaid after the second anniversary of the closing but prior to the third anniversary of the IPG Closing Date; and (4) 0.00% of the principal amount so prepaid on or after the third anniversary of the IPG Closing Date. Amounts outstanding under the Credit Facility are subject to mandatory prepayment upon the occurrence of certain events and conditions, including non-ordinary course asset dispositions, receipt of certain casualty proceeds, issuances of certain debt obligations and a change of control transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Facilities contain customary borrowing conditions, affirmative, negative and reporting covenants, representations and warranties, and events of default, including cross-defaults to other material indebtedness. In addition, the Company is required to comply at certain times with certain financial covenants comprised of a minimum liquidity test commencing upon closing of the Credit Facilities and a total secured leverage ratio commencing on the last day of the fiscal quarter ending September 30, 2022. If an event of default occurs, the lenders would be entitled to take enforcement action, including foreclosure on collateral and acceleration of amounts owed under the Credit Facilities. We incurred $5.3&#160;million of debt issuance costs in connection with this Credit Agreement, which was included in long-term debt, net of discount on our consolidated balance sheets and amortized into interest expense over the life of the agreement. The Company recorded $0.2&#160;million in interest expense related to the amortization of the debt discount and the issuance costs for the three and nine months ended September 30, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2024 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company issued $117.1&#160;million aggregate principal amount of its 3.50% Convertible Senior Notes due 2024 (the &#x201c;2024 Notes&#x201d;) in privately negotiated exchange and/or subscription agreements, with certain holders of its outstanding 2021 Notes and certain new investors. The Company issued $84.2 million aggregate principal amount of 2024 Notes in exchange for $84.2 million aggregate principal amount of the 2021 Notes and an aggregate cash payment of $2.5&#160;million, and issued $32.8 million aggregate principal amount of New Notes for cash at par. We incurred $3.0&#160;million of debt issuance costs in connection with the 2024 Notes, which we are amortizing to non-cash interest expense using the straight-line method over the contractual term of the 2024 Notes,  since this method was not materially different from the effective interest method. The closing of the private placement of the 2024 Notes occurred on August 19, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes are entitled to cash interest payments, which are payable semiannually in arrears on June 1 and December 1 of each year, beginning on December 1, 2020, at a rate equal to 3.50% per annum. The 2024 Notes will mature on December 1, 2024, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Upon maturity the principal amount of the notes may be settled via shares of the Company&#x2019;s Class A common stock. We recorded interest expense of $0.5 million and $2.5 million for the three and nine months ended September 30, 2022, respectively, and $1.0 million and $3.0 million for the three and nine months ended September 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes are convertible into cash, shares of the Company's Class A common stock, or a combination of cash and shares of the Company's Class A common stock, at the Company's election, based on an initial conversion rate of 54.8667 shares of Class A common stock per $1,000 principal amount of the 2024 Notes, which is equivalent to an initial conversion price of approximately $18.23 per share of the Company&#x2019;s Class A common stock. In the aggregate, the 2024 Notes are initially convertible into 6.4&#160;million shares of the Company&#x2019;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole provision upon a fundamental change or a notice of redemption under the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The option to settle the 2024 Notes in cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election, resulted in a bifurcation of the carrying value of the 2024 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $78.9&#160;million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $38.1&#160;million before issuance costs and was recorded within additional paid-in capital. Issuance costs of $1.7&#160;million and $1.3&#160;million were allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $38.1&#160;million, $1.7&#160;million of issuance costs was amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $38.1&#160;million decrease in additional paid-in capital and a $1.3&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and an $11.7&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2024 Notes. These adjustments resulted in an increase of $25.1&#160;million to the debt component of the 2024 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2024 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2024 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $0.1 million and $0.5 million for the three and nine months ended September 30, 2022, respectively, and $2.0 million and $5.9 million for the three and nine months ended September 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2024 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2024 Notes prior to March 1, 2023. The Company may redeem for cash all or any portion of the 2024 Notes, at its option, on or after March 1, 2023, if the last reported sale price of the Company&#x2019;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 11, 2022, the Company entered into exchange agreements with certain holders of the 2024 Notes. Pursuant to the agreements, these holders exchanged $92.8&#160;million in aggregate principal amount of such notes for shares of the Company&#x2019;s Class A common stock. On August 17 and 18, 2022, the Company consummated the exchanges and issued an aggregate of 5,394,165 shares of Class A common stock to the holders.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The August 2022 exchanges of the 2024 Notes for Class A common stock resulted in a $10.2&#160;million loss on extinguishment/repayment of debt, net, on the consolidated statements of operations and comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2019, the Company entered into a credit agreement, by and among the Company, Evolent Health LLC, as the borrower (the &#x201c;Borrower&#x201d;), certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent, together with the Company (the &#x201c;2019 Credit Agreement&#x201d;), pursuant to which the lenders agreed to extend credit to the Borrower in the form of (i) an initial secured term loan in the aggregate principal amount of $75.0 million (the &#x201c;Initial Term Loan Facility&#x201d;) and (ii) a delayed draw secured term loan facility in the aggregate principal amount of up to $50.0 million (the &#x201c;DDTL Facility&#x201d; and, together with the Initial Term Loan Facility, the &#x201c;Senior Credit Facilities&#x201d;), subject to the satisfaction of specified conditions. The Borrower borrowed the loan under the Initial Term Loan Facility on December 30, 2019. The proceeds of the Initial Term Loan were used to finance the transactions contemplated by the Passport Asset Purchase Agreement and pay fees and expenses incurred in connection therewith. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 19, 2020, an amendment to the Company's 2019 Credit Agreement became effective. The amendment effected changes to, among other things, permit the Company's use of cash in the exchange transactions in connection with the issuance of the 2024 Notes, permit the issuance of the 2024 Notes and permit certain note repurchases, as well as to implement amendments to certain minimum liquidity thresholds.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 8, 2021, the Company repaid all outstanding amounts owed under and terminated the 2019 Credit Agreement with Ares Capital Corporation. The total amount paid to Ares Capital Corporation under the 2019 Credit Agreement in connection with the prepayment was $98.6&#160;million, which included $9.7&#160;million for the make-whole premium as well as $0.2&#160;million in accrued interest. As a result of this transaction, the Company recorded a loss on the repayment of debt of $19.2&#160;million, representing the remaining unamortized debt issuance costs of $9.5&#160;million, the make-whole premium and $35&#160;thousand of legal expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrant Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the Company&#x2019;s entry into the 2019 Credit Agreement, the Company entered into warrant agreements whereby it agreed to sell to the holders of the warrants an aggregate of 1,513,786 shares of Class A common stock at a per share purchase price equal to $8.05. The holders could exercise the warrants at any time until thirty days after the maturity of the 2019 Credit Agreement.  The Company, at its sole discretion, could elect to pay the holders in cash in an amount determined based on the fair market value of the Class A common stock for the shares of Class A common stock issuable upon exercise of the warrants in lieu of delivering the shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 8, 2021, the Company settled the outstanding warrants associated with the 2019 Credit Agreement for $13.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2025 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company issued $172.5 million aggregate principal amount of its 1.50% Convertible Senior Notes due 2025 (the &#x201c;2025 Notes&#x201d;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). The 2025 Notes were issued at par for net proceeds of $166.6 million. We incurred $5.9 million of debt issuance costs in connection with the 2025 Notes. The closing of the private placement of $150.0 million aggregate principal amount of the 2025 Notes occurred on October&#160;22, 2018 and the Company completed the offering and sale of an additional $22.5 million aggregate principal amount of the 2025 Notes on October&#160;24, 2018, pursuant to the initial purchasers&#x2019; exercise in full of their option to purchase additional notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2025 Notes are entitled to cash interest payments, which are payable semiannually in arrears on&#160;April 15&#160;and&#160;October 15&#160;of each year, beginning on&#160;April&#160;15, 2019, at a rate equal to&#160;1.50%&#160;per annum. The Company recorded interest expense of $0.6 million and $1.9 million for both the three and nine months ended September 30, 2022 and 2021, respectively. The 2025 Notes will mature on&#160;October&#160;15, 2025, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the close of business on the business day immediately preceding April&#160;15, 2025, the 2025 Notes will be convertible at the option of the holders only upon the satisfaction of certain conditions, as described in the indenture, dated as of October&#160;22, 2018, between the Company and U.S. Bank National Association, as trustee. At any time on or after April&#160;15, 2025, until the close of business on the business day immediately preceding the maturity date, holders may convert, at their option, all or any portion of their notes at the conversion rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2025 Notes will be convertible at an initial conversion rate of 29.9135 shares of Class A common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $33.43 per share of the Company&#x2019;s Class A common stock. In the aggregate, the 2025 Notes are initially convertible into 5.2 million shares of the Company&#x2019;s Class A common stock (excluding any shares issuable by the Company upon a conversion in connection with a make-whole fundamental change or a notice of redemption as described in the governing indenture). The conversion rate may be adjusted under certain circumstances. Upon &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;conversion, the Company will pay or deliver, as the case may be, cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The option to settle the 2025 Notes in cash or shares of the Company&#x2019;s Class A common stock, or a combination of cash and shares of the Company&#x2019;s Class A common stock, at the Company&#x2019;s election, resulted in a bifurcation of the carrying value of the 2025 Notes into a debt component and an equity component prior to the adoption of ASU 2020-06. The debt component was determined to be $100.7 million, before issuance costs, based on the fair value of a nonconvertible debt instrument with the same term. The equity component was determined to be $71.8 million, before issuance costs, and was recorded within additional paid-in capital. The equity component is the difference between the aggregate principal amount of the debt and the debt component. Issuance costs of $3.4 million and $2.5 million are allocated to the debt and equity components in proportion to the allocation of proceeds. Along with the equity component of $71.8 million, $3.4 million of issuance costs will be amortized to interest expense on the consolidated statements of operations and comprehensive income (loss) using the effective interest method over the contractual term of the 2025 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, we adopted ASU 2020-06 using the retrospective transition method. As a result, prior period financial information and disclosures are not adjusted and continue to be reported under the accounting standards that were in effect prior to the adoption of ASU 2020-06. The adoption of ASU 2020-06 resulted in the combination of the debt and equity components of the 2024 Notes into a single debt instrument recorded in long term debt, net on the consolidated balance sheet. This resulted in a $71.8&#160;million decrease in additional paid-in capital and a $2.5&#160;million increase in additional paid-in capital from the previously bifurcated equity component from deferred financing fees, respectively, and a $28.1&#160;million decrease to the January 1, 2022 accumulated deficit, representing the cumulative non-cash interest expense recognized related to the amortization of the debt discount associated with the bifurcated equity component of the 2025 Notes. These adjustments resulted in an increase of $41.3&#160;million to the debt component of the 2025 Notes. Additionally, the allocation of the issuance costs to the equity component and all issuance costs related to the 2025 Notes are being amortized to interest expense using the effective interest method over the contractual term of the 2025 Notes which is included in the cumulative adjustment to the opening balance of accumulated deficit. The Company recorded interest expense related to the amortization of the issuance costs of $0.4 million and $1.0 million for the three and nine months ended September 30, 2022, respectively, and $2.5 million and $7.4 million for the three and nine months ended September 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the 2025 Notes may require the Company to repurchase all or part of their notes upon the occurrence of a fundamental change at a price equal to 100.0% of the principal amount of the notes being repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date. The Company may not redeem the 2025 Notes prior to October&#160;20, 2022. The Company may redeem for cash all or any portion of the 2025 Notes, at its option, on or after October&#160;20, 2022, if the last reported sale price of the Company&#x2019;s Class A common stock has been at least 130.0% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100.0% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2016, the Company issued $125.0 million aggregate principal amount of its 2.00% Convertible Senior Notes due 2021 (the &#x201c;2021 Notes&#x201d;) in a private placement to qualified institutional buyers within the meaning of Rule 144A under the Securities Act. The 2021 Notes were issued at par for net proceeds of $120.4 million. We incurred $4.6 million of debt issuance costs in connection with the 2021 Notes, which we amortized to non-cash interest expense using the straight-line method over the contractual term of the 2021 Notes, since this method was not materially different from the effective interest method. The closing of the private placement of the 2021 Notes occurred on December&#160;5, 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, as part of the issuance of the 2024 Notes, the Company issued $84.2&#160;million aggregate principal amount of the 2024 Notes in exchange for $84.2&#160;million aggregate principal of its 2021 Notes. There was no cash consideration in these exchanges outside of an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. These exchanges were accounted for as an extinguishment resulting in a net loss on extinguishment of debt of $4.8&#160;million, including an aggregate cash payment of $2.5&#160;million paid to exchanging noteholders. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, we also repurchased $14.0&#160;million of the 2021 Notes with $13.9&#160;million of cash and recorded an immaterial gain on extinguishment of debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon maturity of the 2021 Notes on December 1, 2021, outstanding 2021 Notes with a principal amount of $26.7&#160;million were settled, at the option of the holders, by converting $26.3&#160;million aggregate principal amount of 2021 Notes to common shares and cash repayment of $0.4&#160;million aggregate principal amount of 2021 Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Convertible Senior Notes Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2024 Notes and 2025 Notes are recorded on our accompanying consolidated balance sheets at their net carrying values as of September&#160;30, 2022. However, the 2024 Notes and 2025 Notes are privately traded by qualified institutional buyers (within the meaning of Rule 144A under the Securities Act) and their fair values are Level 2 inputs. The 2024 Notes and 2025 Notes also have embedded conversion options and contingent interest provisions, which have not been recorded as separate financial instruments. The following table summarizes the carrying value of the long-term convertible debt as of September&#160;30, 2022 and December 31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Fair values for notes are derived from available trading prices closest to the respective balance sheet date.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i23031c0b6b3349ac87a0dd3718ded62f_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM1ODMy_3f32bbdd-5b2c-404a-ade9-58fa288fbb6e"
      unitRef="usd">175000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="if02e0ede9ff94b57bd4e150fe4f1c424_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM1ODQ4_ecd17bb4-181a-48d7-89a1-02e58f249292"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="if02e0ede9ff94b57bd4e150fe4f1c424_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM2NDcw_962aaab0-c0bd-4342-a4a1-082540cdd01f"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ib85258a5944847a799568304dbd3b847_D20220801-20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM2NDU1_9c949999-92a7-4853-9ebe-75368f8d3af1"
      unitRef="usd">50000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <evh:DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity
      contextRef="i397f99c968184e23a3239fd5df224e34_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNDk0NzgwMjM1MjAwMA_8a9c65b4-ca63-4f54-90c4-576c7b6e4e76"
      unitRef="day">91</evh:DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia09ce527d9154016aed6990fcdea728d_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM3NzM2_7c11899b-de79-4158-b667-dbfbd0b114f7"
      unitRef="number">0.0550</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i023a2e0781824e51aac26656357a04e5_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM3NzQz_ca1a5f7b-0618-4c07-ae5a-66658fbf821a"
      unitRef="number">0.0450</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i3728ee01b28446c5b8e4e913f63db0c1_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM3NzY0_1cf74287-7e6b-49f5-856b-fd1ecfa5d328"
      unitRef="number">0.0350</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia11fc3353efe46e19266ef78af24da63_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM3Nzc3_fa867048-ef0c-4efa-9b6f-feed6c41aa5a"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i397f99c968184e23a3239fd5df224e34_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM3NzUw_42a2d3c7-36c4-4dc2-bfef-254c290f1b66"
      unitRef="number">0.0200</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ib85258a5944847a799568304dbd3b847_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM3NzU3_3835d48d-dda5-4aaf-9932-adddcdc891a2"
      unitRef="number">0.0200</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="i8f90d550a67b49a1b9b6999f0941d947_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM3NzMw_66445607-7ecf-4ad0-92be-8ae09092acd8"
      unitRef="usd">2900000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i89cb6508f7a645e3b79e3ad7df4206de_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM3NzMw_f00e4ead-5d45-4a86-9181-defc3d1cc54b"
      unitRef="usd">2900000</us-gaap:InterestExpenseDebt>
    <evh:DebtInstrumentPrepaymentPenaltyPeriodOnePercent
      contextRef="ia44b9d3c20ff4e6cb60de6ff8ecd5783_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM2NDQw_db6bd4b2-49a6-431a-ab65-bbdfd2662e7c"
      unitRef="number">0.0300</evh:DebtInstrumentPrepaymentPenaltyPeriodOnePercent>
    <evh:DebtInstrumentPrepaymentPenaltyPeriodTwoPercent
      contextRef="ia44b9d3c20ff4e6cb60de6ff8ecd5783_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM2NDQ3_b59d54d2-4c3c-4559-8840-d8f68fb50728"
      unitRef="number">0.0200</evh:DebtInstrumentPrepaymentPenaltyPeriodTwoPercent>
    <evh:DebtInstrumentPrepaymentPenaltyPeriodThreePercent
      contextRef="ia44b9d3c20ff4e6cb60de6ff8ecd5783_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM2NDI2_e950375f-bde5-4fcf-bf52-352686183011"
      unitRef="number">0.0100</evh:DebtInstrumentPrepaymentPenaltyPeriodThreePercent>
    <evh:DebtInstrumentPrepaymentPenaltyPeriodFourPercent
      contextRef="ia44b9d3c20ff4e6cb60de6ff8ecd5783_D20220801-20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM2NDMz_613ad07b-c007-4d77-a42f-40f213caa34e"
      unitRef="number">0.0000</evh:DebtInstrumentPrepaymentPenaltyPeriodFourPercent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="if44e132eb50c4b2b961cecf1fb497c82_I20220801"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM2MzIz_419780e6-42b2-4e19-bfac-94739669fe1e"
      unitRef="usd">5300000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i8f90d550a67b49a1b9b6999f0941d947_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM2NDIw_1a33688a-df47-4f27-ab60-802dcf65e414"
      unitRef="usd">200000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i89cb6508f7a645e3b79e3ad7df4206de_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODM2NDIw_3fdc9130-5855-4927-9e18-45d79fb50d09"
      unitRef="usd">200000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0e534dd28b704e32ae748c0e79ebc74b_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNzg_b2250822-d64b-4af5-95af-e8dc4c836da3"
      unitRef="usd">117100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0e534dd28b704e32ae748c0e79ebc74b_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTE1_1b14e0e4-3216-4d12-aaa6-42c850c9d277"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i971d328b42fe456798f158d581d7e9f1_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMzMz_1e0ecd06-bdb4-4409-b52d-4441fcef9932"
      unitRef="usd">84200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="ib6070c04ec514eb1b72630be44af9d9d_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNDAx_71aad370-5ab5-47a2-bdd2-338ed77db3ef"
      unitRef="usd">84200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i0b673721ad2140dc92b0e7de4a1c58b1_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNDkw_fcd624bc-8326-4db4-ae9c-48a47b62fbef"
      unitRef="usd">2500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i173d3fd170d1453abafbccbcc3311581_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTA1_b1c9c2f5-6f47-4386-9799-15057e18be55"
      unitRef="usd">32800000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i0e534dd28b704e32ae748c0e79ebc74b_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTg1_d830bb43-f5f3-4f5a-9297-b487db53edcc"
      unitRef="usd">3000000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0e534dd28b704e32ae748c0e79ebc74b_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTA1Nw_a3ff8c3b-e432-4846-8448-0030be13d75d"
      unitRef="number">0.0350</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="i247174c3d444488082c85f25293301f0_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODQwMTUz_266f88de-de79-467c-9a38-3201f4a74f0c"
      unitRef="usd">500000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i703a0ee08afb4b42a1e3c2eed2680471_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTM2NQ_b6df7e23-3737-4296-8934-23366a1cf411"
      unitRef="usd">2500000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i9412f1389708421ebab698307b0652e5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODQwMTU5_15b5592c-0a29-4094-abdb-7fe4bbc33266"
      unitRef="usd">1000000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i54f3f1eeedc94eaf8493438a2310988b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ5NzU1ODQwMTY3_2513281d-e372-4ef3-9c7f-bad96646498a"
      unitRef="usd">3000000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i0e534dd28b704e32ae748c0e79ebc74b_I20200831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTc5NQ_26fc7eed-a82a-4436-a435-4179fbeb3c08"
      unitRef="usdPerShare">18.23</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="i971d328b42fe456798f158d581d7e9f1_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTkxMQ_3f360ed6-689d-4b7c-906f-c9b38f5d93f2"
      unitRef="shares">6400000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:LongTermDebt
      contextRef="i0e534dd28b704e32ae748c0e79ebc74b_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMjgyNg_199f831f-ab84-42e7-98c2-96c9cf74ba07"
      unitRef="usd">78900000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ibf3800946de143f0bb536bae6a5686d3_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMjk3NQ_1f020dc2-b0e7-487d-9d2f-01c10d864be9"
      unitRef="usd">38100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <evh:DebtIssuanceCostsNetDebtComponent
      contextRef="i0e534dd28b704e32ae748c0e79ebc74b_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMzA3MA_fc890f63-0dba-4d24-9514-b78ee2b67037"
      unitRef="usd">1700000</evh:DebtIssuanceCostsNetDebtComponent>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i8e4ac76e97a341ee8fbcc6dfa4aba611_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMzA3Nw_1b8dde56-7af9-4d17-a42e-fde6372b38cb"
      unitRef="usd">1300000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="ibf3800946de143f0bb536bae6a5686d3_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMzIwOQ_5c040089-ebfc-4201-be4e-c4c224012e8f"
      unitRef="usd">38100000</us-gaap:ProceedsFromIssuanceOfDebt>
    <evh:DebtIssuanceCostsNetDebtComponent
      contextRef="i0e534dd28b704e32ae748c0e79ebc74b_I20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMzIxMw_d5ce3b6f-d8aa-4509-aaca-f66c0d143c9f"
      unitRef="usd">1700000</evh:DebtIssuanceCostsNetDebtComponent>
    <us-gaap:StockholdersEquity
      contextRef="i281bd5c057904435bc8629de116dd37a_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMzg5Mg_f0bf83fc-e973-458f-b0c6-caa34f9af066"
      unitRef="usd">-38100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia1cdd64507cd4f068665c06a3f09861d_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMzk0MA_b7320d94-61d2-474b-9b15-d7c40ff49d9a"
      unitRef="usd">1300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5a248420ba824c9d8f7efebff5855664_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNDA4MQ_1e8aec21-8bef-48cd-846c-0249a9c1698c"
      unitRef="usd">-11700000</us-gaap:StockholdersEquity>
    <us-gaap:LongTermDebt
      contextRef="i970cc1ff98954def888f92d6e27ed9e0_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNDM2Mw_bd22018a-724a-44d0-8359-26c7c9113a03"
      unitRef="usd">25100000</us-gaap:LongTermDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i247174c3d444488082c85f25293301f0_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNDgzNg_6ec1442a-6be9-4525-9fdc-885ec680a78f"
      unitRef="usd">100000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i703a0ee08afb4b42a1e3c2eed2680471_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNDg0Mw_85ac9ed6-5f58-4a72-b8d8-bc99dcfcf079"
      unitRef="usd">500000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i9412f1389708421ebab698307b0652e5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNDg3Mg_2c6b61a8-f49b-436c-be21-5f37083af623"
      unitRef="usd">2000000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i54f3f1eeedc94eaf8493438a2310988b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNDg3OQ_9b60ed56-d4db-48c3-bdb6-867812f58a0d"
      unitRef="usd">5900000</us-gaap:AmortizationOfFinancingCosts>
    <evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount
      contextRef="i971d328b42fe456798f158d581d7e9f1_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTA2MA_fc7cfea9-91b5-4894-a845-95c3035f7db4"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount>
    <evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice
      contextRef="i971d328b42fe456798f158d581d7e9f1_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTQ4MQ_53ac4485-c2bf-459f-82c4-9b767411ca1f"
      unitRef="number">1.300</evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice>
    <evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum
      contextRef="i971d328b42fe456798f158d581d7e9f1_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTUzNg_bac6f0f8-f2e0-498c-9bcb-fc5e02b41614">P20D</evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum>
    <evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum
      contextRef="i971d328b42fe456798f158d581d7e9f1_D20200801-20200831"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTU5Mg_772caf3b-be85-45f9-955a-9cc7ef4cda1f">P30D</evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum>
    <evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice
      contextRef="i971d328b42fe456798f158d581d7e9f1_D20200801-20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNTgzMA_5b770848-d82e-42ff-ac8b-8c21c0b77f5a"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="i0780a0fee7594b46b08c694f8172b826_D20220811-20220811"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMzI5ODUzNDkwODkxMQ_15a293f0-287b-454c-b734-25554ec55a07"
      unitRef="usd">92800000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i2d823b0fe92347a08c084c665a3f3d9b_D20220817-20220818"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMzI5ODUzNDkwODkyNg_68bd29a4-c1a8-4a80-b697-dc299de2321e"
      unitRef="shares">5394165</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic25d64a2c23948ee96a46fb336fc19be_D20220801-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMzI5ODUzNDkwODkzNg_88cb7da1-c282-49e5-a87d-472c16601f36"
      unitRef="usd">10200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if893b79edc40422a846ee7d717983c69_I20191230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNjUxMA_4b9ca727-894a-4fbb-a8ae-dce3abcc3fd6"
      unitRef="usd">75000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic570e916fb874a79be763e4769336d66_I20191230"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNjY0Mg_2136c47a-f3fc-4231-a5f5-ac1cfe825c5e"
      unitRef="usd">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="if526c9a8decf4411aa6798f771fb8f2e_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNzc0MA_ade22167-9ae3-4f23-a7e3-b7d5d483d8b5"
      unitRef="usd">98600000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <evh:PaymentsOfMakeWholePremium
      contextRef="if526c9a8decf4411aa6798f771fb8f2e_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNzc1OQ_6d7ee723-0ada-48cb-bdc3-e01cfb70d13f"
      unitRef="usd">9700000</evh:PaymentsOfMakeWholePremium>
    <us-gaap:InterestPaidNet
      contextRef="if526c9a8decf4411aa6798f771fb8f2e_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNzgwMA_97777e92-b583-4bc6-a914-33157bb162ee"
      unitRef="usd">200000</us-gaap:InterestPaidNet>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="if34c7918f26d4075a90353ac93a20071_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNzkxMw_c31661dd-0931-4e41-893f-5db840fd5c7c"
      unitRef="usd">19200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="if34c7918f26d4075a90353ac93a20071_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfNzk3OQ_510ebfd9-8fab-4cbc-b701-4e3f07e9b538"
      unitRef="usd">9500000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:LegalFees
      contextRef="if34c7918f26d4075a90353ac93a20071_D20210108-20210108"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfODAxMA_d659ae8e-ab5a-4db5-88b0-86187c0c8ef1"
      unitRef="usd">35000</us-gaap:LegalFees>
    <us-gaap:ClassOfWarrantOrRightUnissued
      contextRef="i237f03b5f1ae46209253a55eef0acbd7_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfODI0MQ_90ca7643-0c31-473e-969a-bc4a188fc70e"
      unitRef="shares">1513786</us-gaap:ClassOfWarrantOrRightUnissued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i237f03b5f1ae46209253a55eef0acbd7_I20191230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfODMxNA_e57e3d1c-0801-4541-876c-020021fed935"
      unitRef="usdPerShare">8.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <evh:ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement
      contextRef="i346643136a3d4c2ca53d05972479a685_D20191230-20191230"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfODM3Ng_74e506a8-c2fb-4afc-9399-d7162c1d4c32">P30D</evh:ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="id1b9711d99314be699395b69414db087_D20210108-20210108"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfODgxMg_41d723a3-5975-43bc-b658-51e756791943"
      unitRef="usd">13700000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iaadf8da35c2642b1baae4f9f8ec5b1ec_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfODg2NQ_ffd7523b-1298-4753-b50c-c99571c6ef3a"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaadf8da35c2642b1baae4f9f8ec5b1ec_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfODkwMg_fcbc34de-64bd-4d6e-8bd0-0a88f929c35d"
      unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i83e14bd5c2bc4351a905d0c781f6f2e1_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfOTE3MA_c0c935c8-98c4-4017-bb6d-62a70446741d"
      unitRef="usd">166600000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i83a29e272d0e42f1a62606a14f9bcb44_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfOTE4Ng_90a9c369-0448-4c5b-b8dc-0f6d34333058"
      unitRef="usd">5900000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i943bcfabb119462c92e5b274885f9058_I20181022"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfOTI4Nw_f9586bb9-0f47-483f-8288-50e0754ac851"
      unitRef="usd">150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ib6a0939c098e417591c54c728c4656b1_I20181024"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfOTQxNQ_6cc22883-f382-4cbd-adbb-ead87ff212c9"
      unitRef="usd">22500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaadf8da35c2642b1baae4f9f8ec5b1ec_I20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfOTc1NQ_fcbc34de-64bd-4d6e-8bd0-0a88f929c35d"
      unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt
      contextRef="i73b993a88b6d4a83ba73f75a35a0dd70_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfOTgxMA_34037426-bacd-4194-82c2-80b87caf869b"
      unitRef="usd">600000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i82c2c5f321e645a3b56a3aecae93056e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfOTgxMA_cf91793f-f9d7-4ac5-91e9-a38584ce066c"
      unitRef="usd">600000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="id732329530cf43d0808c84c8df54ccc4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfOTgxNw_5f02a564-df74-4608-b916-473a63b501a7"
      unitRef="usd">1900000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i26243e36f2374ba5a987cdb451132b3d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfOTgxNw_92824a03-d90c-4fcf-bab0-4f78c766ffa4"
      unitRef="usd">1900000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="iaadf8da35c2642b1baae4f9f8ec5b1ec_I20181031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTA3MTU_1174e24a-9829-46b5-85d3-f97d57fcb340"
      unitRef="usdPerShare">33.43</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="i83e14bd5c2bc4351a905d0c781f6f2e1_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTA4MzE_e0a45810-02cd-4c47-9633-e76f2980b326"
      unitRef="shares">5200000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:LongTermDebt
      contextRef="iaadf8da35c2642b1baae4f9f8ec5b1ec_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTE3Mzk_00bea8f4-dbb7-4276-82ab-2648f8a416fe"
      unitRef="usd">100700000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i9de8dee931674cb18c65e45a7b1e4f2c_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTE4ODg_2db2666b-8811-4569-bb32-045fa44e2470"
      unitRef="usd">71800000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="iaadf8da35c2642b1baae4f9f8ec5b1ec_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTIwOTk_e58c4bf3-3409-42a3-b35d-a53cdbcf2120"
      unitRef="usd">3400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i3ac8f2155d3b40999c6630d7228cc990_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTIxMDY_0af1a8c4-d825-4a64-b92e-88c28357e497"
      unitRef="usd">2500000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i9de8dee931674cb18c65e45a7b1e4f2c_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTIyMzc_2db2666b-8811-4569-bb32-045fa44e2470"
      unitRef="usd">71800000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="iaadf8da35c2642b1baae4f9f8ec5b1ec_I20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTIyNDE_e58c4bf3-3409-42a3-b35d-a53cdbcf2120"
      unitRef="usd">3400000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:StockholdersEquity
      contextRef="i1ad79143dac24d9fb4e767f03a9199d5_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTI5Njc_2a1b401e-aa3c-4549-979a-a18f3c14022e"
      unitRef="usd">-71800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7f199ebd90ef433e8b368de1394c5180_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTMwMTU_8edcaede-1e73-47d3-931f-622646a6d2a9"
      unitRef="usd">2500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9fb3858a372e487fb6337c1636d1f938_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTMxNTU_9496a2dd-984c-4494-9573-fd7c2118c10b"
      unitRef="usd">-28100000</us-gaap:StockholdersEquity>
    <us-gaap:LongTermDebt
      contextRef="if6b921fd4b544f439a08e3802c74b054_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTM0Mzc_23fbdf86-ab7d-44ea-8876-5e3ccefa0bfa"
      unitRef="usd">41300000</us-gaap:LongTermDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i73b993a88b6d4a83ba73f75a35a0dd70_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTM5MTA_8e1cdb22-d668-4fd1-b9a7-597f16fe3e11"
      unitRef="usd">400000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i82c2c5f321e645a3b56a3aecae93056e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTM5MTc_7697f343-5f21-48d2-9857-fcbdfc90313e"
      unitRef="usd">1000000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i26243e36f2374ba5a987cdb451132b3d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTM5NDY_cb7ca025-6bc6-46e4-bcdb-aae1b76d1013"
      unitRef="usd">2500000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="id732329530cf43d0808c84c8df54ccc4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTM5NTM_b98cb1db-f0ca-48e0-ad6d-6752ec0bee4f"
      unitRef="usd">7400000</us-gaap:AmortizationOfFinancingCosts>
    <evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount
      contextRef="i83e14bd5c2bc4351a905d0c781f6f2e1_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTQxMzQ_288e32a5-27c0-41ab-bebb-169b9cb3b8e9"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount>
    <evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice
      contextRef="i83e14bd5c2bc4351a905d0c781f6f2e1_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTQ1MzM_e30adaac-b7b5-4308-8d5a-a31a39a95c3d"
      unitRef="number">1.300</evh:DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice>
    <evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum
      contextRef="i83e14bd5c2bc4351a905d0c781f6f2e1_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTQ1ODg_93596d4a-0cba-4346-84a8-1bc500af29fc">P20D</evh:DebtInstrumentRepurchaseCovenantTradingDaysMinimum>
    <evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum
      contextRef="i83e14bd5c2bc4351a905d0c781f6f2e1_D20181001-20181031"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTQ2NDQ_a00fa5ae-6756-4d25-bce1-087005af5f6c">P30D</evh:DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum>
    <evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice
      contextRef="i83e14bd5c2bc4351a905d0c781f6f2e1_D20181001-20181031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTQ4ODI_d5e75c47-854c-4114-95c0-e4d2100b2155"
      unitRef="number">1.000</evh:DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i7a62eaff28ea42a28e86090e3e7b8dd7_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTUwNTA_2107fc3c-0a08-4ead-bb85-3b9c88844ddd"
      unitRef="usd">125000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7a62eaff28ea42a28e86090e3e7b8dd7_I20161231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTUwODc_45a36d4f-7038-483a-97de-063603e509a0"
      unitRef="number">0.0200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i5e5305e5d35d418385b8e523b11422f4_D20161201-20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTUzMTA_ab4b46ec-976c-4256-9e93-a2bc5ac45225"
      unitRef="usd">120400000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i7a62eaff28ea42a28e86090e3e7b8dd7_I20161231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTUzMjY_30d36488-2d49-4f5e-889f-470018636761"
      unitRef="usd">4600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i971d328b42fe456798f158d581d7e9f1_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTU3NDQ_3b3a0a67-9fa2-47a0-b58a-aa8b56f18170"
      unitRef="usd">84200000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="ib6070c04ec514eb1b72630be44af9d9d_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTU4MDg_91400fe7-9607-46f7-b494-c695497e28ca"
      unitRef="usd">84200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i0b673721ad2140dc92b0e7de4a1c58b1_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTU5NDE_57da2af0-fed6-48ef-922d-7480c4fc0b48"
      unitRef="usd">2500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost
      contextRef="i0b673721ad2140dc92b0e7de4a1c58b1_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTYwODU_6b416b40-e704-453c-9e22-956c93fd6b10"
      unitRef="usd">-4800000</us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i0b673721ad2140dc92b0e7de4a1c58b1_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTYxMjg_ab1d89f8-8d21-402c-9560-296636ce3327"
      unitRef="usd">2500000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="ib6070c04ec514eb1b72630be44af9d9d_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTYyMDE_92df11eb-4a1a-4545-b32b-8a716c9854ca"
      unitRef="usd">14000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="ib6070c04ec514eb1b72630be44af9d9d_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTYyMjc_35ccda57-2eb0-4ff5-8a08-c619a1305bd8"
      unitRef="usd">13900000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i3e0b4bf0b8594fd0baf9242862d641ec_D20211201-20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTY0MDE_a26afe22-43b1-4d75-b60b-568cca712921"
      unitRef="usd">26700000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="i3e0b4bf0b8594fd0baf9242862d641ec_D20211201-20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTY0NjI_12741b7d-4801-4bca-986d-7c34fb7e9401"
      unitRef="usd">26300000</us-gaap:DebtConversionOriginalDebtAmount1>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="i3e0b4bf0b8594fd0baf9242862d641ec_D20211201-20211201"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTY1NDU_8a799a36-9353-4d90-be9c-b809ee8e6b43"
      unitRef="usd">400000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RleHRyZWdpb246MDgyMjVlYWRkMTlmNDE2ZGFlNjI0NjEwZjYwZDU0M2FfMTc3MTQ_ef985399-5c00-489e-839c-8977f20602aa">The following table summarizes the carrying value of the long-term convertible debt as of September&#160;30, 2022 and December 31, 2021 (in thousands):&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2024 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2025 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining amortization period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Fair values for notes are derived from available trading prices closest to the respective balance sheet date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:ConvertibleDebt
      contextRef="iada79ebd92cc43c4a68b4aa5846a5940_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMi0xLTEtMS02NjkxMA_c1c89bcc-4765-46b2-9120-e988b132f8a8"
      unitRef="usd">23879000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="id2ba2e5b9e234d4fb2a1474c09951db0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMi0zLTEtMS02NjkxMA_b9934545-7a21-499b-b2f8-217881589beb"
      unitRef="usd">89361000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="iada79ebd92cc43c4a68b4aa5846a5940_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMy0xLTEtMS02NjkxMA_c2c1524d-5c5c-4dfe-a0b4-6ea7b1b0dc3f"
      unitRef="usd">402000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="id2ba2e5b9e234d4fb2a1474c09951db0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMy0zLTEtMS02NjkxMA_4c823b1d-fb4f-4f21-8382-d3fc48f3b2bc"
      unitRef="usd">27690000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iada79ebd92cc43c4a68b4aa5846a5940_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfNC0xLTEtMS02NjkxMA_15a92b0c-ce01-4a3f-aa3a-d2214f497263"
      unitRef="usd">24281000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id2ba2e5b9e234d4fb2a1474c09951db0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfNC0zLTEtMS02NjkxMA_a0da10ea-0477-4dab-90ba-1a032930a664"
      unitRef="usd">117051000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i703a0ee08afb4b42a1e3c2eed2680471_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfNS0xLTEtMS02NjkxMA_134fad69-5815-4713-b7dd-7ddc2f8ac39c">P2Y2M12D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i54f3f1eeedc94eaf8493438a2310988b_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfNS0zLTEtMS02NjkxMA_075a2492-8bd1-4aed-a39b-324ff02f5f2b">P2Y10M24D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:LongTermDebtFairValue
      contextRef="i5270f847008248a6bad1874588389f6f_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfNi0xLTEtMS02NjkxMA_699c2c38-ce06-4f51-b6ff-6f744f276f15"
      unitRef="usd">49290000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i6bce8ea980fc40fe86deba0a1244f385_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfNi0zLTEtMS02NjkxMA_fc47b596-9768-4f3d-895f-907c65f88997"
      unitRef="usd">195445000</us-gaap:LongTermDebtFairValue>
    <us-gaap:ConvertibleDebt
      contextRef="i624e27774ed54173a7c197935a253285_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfOS0xLTEtMS02NjkxMA_214a8859-6eca-4d39-baf1-6de838240dad"
      unitRef="usd">168565000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="if03270431ded404994880052552c5e20_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfOS0zLTEtMS02NjkxMA_9515ec76-4d15-4873-b652-cff38557a29a"
      unitRef="usd">126315000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i624e27774ed54173a7c197935a253285_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMTAtMS0xLTEtNjY5MTA_2f36e7af-196b-4806-9d83-12d70302b84d"
      unitRef="usd">3935000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="if03270431ded404994880052552c5e20_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMTAtMy0xLTEtNjY5MTA_b57a7f58-18e5-4400-b3c1-d07a8a31b017"
      unitRef="usd">46185000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i624e27774ed54173a7c197935a253285_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMTEtMS0xLTEtNjY5MTA_719173e5-5263-4990-a0c5-c8458b7a101d"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="if03270431ded404994880052552c5e20_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMTEtMy0xLTEtNjY5MTA_fda624de-8e5c-47b4-bfcb-4fc8c41f9fb3"
      unitRef="usd">172500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="i82c2c5f321e645a3b56a3aecae93056e_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMTItMS0xLTEtNjY5MTA_fc94665d-3915-4ea2-a296-bf058c6366a6">P3Y</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="id732329530cf43d0808c84c8df54ccc4_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMTItMy0xLTEtNjY5MTA_9c5b8a0a-9634-4f53-a934-65d4a23c4184">P3Y9M18D</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:LongTermDebtFairValue
      contextRef="i21df7ec9dc5145d0bad6dac81a893732_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMTMtMS0xLTEtNjY5MTA_af7a8a82-0d19-4b0a-b651-a9415493fc47"
      unitRef="usd">215625000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="i2d09652a0b6b48dbbae7e55d51a86ced_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183MC9mcmFnOjA4MjI1ZWFkZDE5ZjQxNmRhZTYyNDYxMGY2MGQ1NDNhL3RhYmxlOjNiZGUxOTYxZDJkMjQzMTNhNzIyYzExYjJmNTExYjE2L3RhYmxlcmFuZ2U6M2JkZTE5NjFkMmQyNDMxM2E3MjJjMTFiMmY1MTFiMTZfMTMtMy0xLTEtNjY5MTA_fc835432-a851-4a9d-a2af-d344a8336f2c"
      unitRef="usd">177251000</us-gaap:LongTermDebtFairValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMTIzNTA_0a16aeef-3c35-49db-a75f-52ce161589fa">Commitments and Contingencies &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2022 and December&#160;31, 2021, the Company was party to irrevocable standby letters of credit&#160;with a bank for $13.1&#160;million and&#160;$15.4 million, respectively, for the benefit of regulatory authorities, real estate and risk-sharing agreements. As such, we held $13.1&#160;million and $15.4 million, respectively, in restricted cash and restricted investments as collateral as of September&#160;30, 2022 and December&#160;31, 2021. The letters of credit have current expiration dates between December 2022 and March 2032 and will automatically extend without amendment for an additional one-year period and will continue to automatically extend after each one-year term from the expiry date unless the bank elects not to extend beyond the initial or any extended expiry date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s customer agreements generally include a provision by which the Company agrees to defend its partners against third-party claims (a) for death, bodily injury, or damage to personal property caused by Company negligence or willful misconduct, (b) by former or current Company employees arising from such managed service agreements, (c) for intellectual property infringement under specified conditions and (d) for Company violation of applicable laws, and to indemnify them against any damages and costs awarded in connection with such claims. To date, the Company has not incurred any material costs as a result of such indemnities and has not accrued any liabilities related to such obligations in the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pre-IPO Investor Registration Rights Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into a registration rights agreement with The Advisory Board, UPMC, TPG and another investor to register for sale under the Securities Act shares of our Class A common stock, including those delivered in exchange for Class B common stock and Class B common units. Subject to certain conditions and limitations, this agreement provides these investors with certain demand, piggyback and shelf registration rights. The registration rights granted under the registration rights agreement will terminate upon the date the holders of shares that are a party thereto no longer hold any such shares that are entitled to registration rights. Pursuant to our contractual obligations under this agreement, we filed a registration statement on Form S-3 with the SEC on July 28, 2016, which was declared effective on August 12, 2016.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will pay all expenses relating to any demand, piggyback or shelf registration, other than underwriting discounts and commissions and any transfer taxes, subject to specified conditions and limitations. The registration rights agreement includes customary indemnification provisions, including indemnification of the participating holders of shares of Class A common stock and their directors, officers and employees by us for any losses, claims, damages or liabilities in respect thereof and expenses to which such holders may become subject under the Securities Act, state law or otherwise. We did not incur any expenses related to secondary offerings or other sales of shares by our investor stockholders during the three and nine months ended September 30, 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 16, 2020, EVH Passport, Evolent Health LLC and Molina Healthcare, Inc. (&#x201c;Molina&#x201d;) entered into an Asset Purchase Agreement (the &#x201c;Molina APA&#x201d;), which contemplated the sale by EVH Passport to Molina of certain assets, including certain intellectual property rights of EVH Passport and EVH Passport&#x2019;s rights under the Passport Medicaid Contract. On September 1, 2020, EVH Passport and Molina consummated the transactions contemplated by the Molina APA (the &#x201c;Molina Closing&#x201d;) and the Passport Medicaid Contract was novated to Molina. In connection with the Molina Closing, the Company continued to provide administrative support services relating to the Passport Medicaid Contract to Molina through the end of 2020. Following the Molina Closing, EVH Passport began working with regulatory authorities including the Kentucky Department of Insurance (&#x201c;KY DOI&#x201d;) regarding the wind down of its operations throughout 2021 and 2022. As part of that wind down process, the Company, as the parent of EVH Passport, entered into a guarantee for the benefit of the KY DOI to satisfy any EVH Passport liability or obligation in the event EVH Passport is not able to meet its wind down liabilities or obligations. As of September&#160;30, 2022, no amounts have been funded under this guarantee.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reinsurance Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 30, 2019, UHC, PHS I, the Company and EVH Passport consummated the transactions contemplated by the Passport APA (the &#x201c;Passport Closing&#x201d;). As part of the Passport Closing, EVH Passport and UHC entered into an agreement that provided for the administration and assumption of the financial risks by EVH Passport of the D-SNP Business until such time as EVH Passport became certified as a Medicare Advantage Organization and the D-SNP Business could be transferred to EVH Passport. On October 1, 2020, the D-SNP Business was transferred from UHC to EVH Passport.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Molina Closing, Molina and EVH Passport entered into an agreement that provided for the assumption of the financial risks by Molina of the D-SNP Business until such time as Molina&#x2019;s Kentucky health plan becomes certified as a Medicare Advantage Organization and the D-SNP Business is transferred to Molina. The Company and EVH Passport continued to administer the D-SNP Business until January 1, 2021, at which time Molina became responsible for its administration until the D-SNP Business was officially transferred to Molina effective September 1, 2021. As of September&#160;30, 2022, there are no material outstanding amounts under this reinsurance agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;UPMC Reseller Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and UPMC are parties to a reseller, services and non-competition agreement, dated August 31, 2011, which was amended and restated by the parties on June 27, 2013 (as amended through the date hereof, the &#x201c;UPMC Reseller Agreement&#x201d;). Under the terms of the UPMC Reseller Agreement, UPMC has appointed the Company as a non-exclusive reseller of certain services, subject to certain conditions and limitations specified in the UPMC Reseller Agreement. In consideration for the Company&#x2019;s obligations under the UPMC Reseller Agreement and subject to certain conditions described therein, UPMC has agreed not to sell certain products and services directly to a defined list of 20 of the Company&#x2019;s customers. Revenue associated with the UPMC Reseller Agreement in the three and nine months ending September 30, 2022 was $0.1&#160;million and $1.2&#160;million, respectively, and is in wind-down. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Receivables Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Offering Reorganization, the Company entered into the Tax Receivables Agreement (the &#x201c;TRA&#x201d;) with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the reduction in the Company&#x2019;s valuation allowance primarily resulting from deferred tax liabilities established as part of the IPG acquisition, the Company has recorded a partial TRA liability of $42.9&#160;million as of September 30, 2022, which represents 85% &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the deferred tax assets related to the Company&#x2019;s unrealized tax benefits on historical pre-IPO losses and tax basis increases from exchanges, offset with the related valuation allowance.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We will assess the realizability of the deferred tax assets at each reporting period, and a change in our estimate of our liability associated with the tax receivable agreement may result as additional information becomes available, including results of operations in future periods. The realizability of the deferred tax assets is evaluated based on all positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are engaged from time to time in certain legal disputes arising in the ordinary course of business, including employment claims. When the likelihood of a loss contingency becomes probable and the amount of the loss can be reasonably estimated, we accrue a liability for the loss contingency. We continue to review accruals and adjust them to reflect ongoing negotiations, settlements, rulings, advice of legal counsel, and other relevant information. To the extent new information is obtained, and our views on the probable outcomes of claims, suits, assessments, investigations or legal proceedings change, changes in our accrued liabilities would be recorded in the period in which such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 8, 2019, a shareholder of the Company filed a class action complaint against the Company, asserting claims under Section 10(b) and 20(a) of the Securities Exchange Act of 1934, in the United States District Court, Eastern District of Virginia, Alexandria Division. An amended complaint was filed on January 10, 2020, a second amended complaint was filed on June 8, 2020, and a third amended complaint, now titled Plymouth County Retirement System v. Evolent Health, Inc., Frank Williams, Nicholas McGrane, Seth Blackley, was filed on December 2, 2021. On July 13, 2022, the parties to the class action executed a term sheet for settlement of the litigation, subject to documentation of the settlement and approval of the court after notice to class members. On August 2, 2022, the lead plaintiff in the case filed an unopposed motion seeking preliminary approval of the settlement and related exhibits, including draft notice to class members and a proposed final order. The settlement stipulation is subject to preliminary and final approval by the court. The Final Settlement Hearing is scheduled for November 18, 2022. If the settlement is approved, we expect that the agreed-upon settlement payment of $23.5&#160;million will be funded entirely by applicable directors&#x2019; and officers&#x2019; liability insurance. As such, we do not expect to incur a significant net loss or cash outflow as a result of the settlement of this matter.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 8, 2021, a shareholder of the Company filed a derivative action in the Delaware Chancery Court against some current and former Board members and against the Company as a nominal defendant, alleging that the Company&#x2019;s Board was negligent in its oversight of the Company&#x2019;s relationship with Passport Health Plan. The case is Lincolnshire Police Pension Fund, derivatively on behalf of Evolent Health, Inc., v. Blackley, Williams, Scott, Holder, Farner, D&#x2019;Amato, Duffy, Felt, Samet, Hobart, and Payson, and Evolent Health, Inc. (&#x201c;Derivative Action&#x201d;). The Company and the Director-Defendants filed a motion to dismiss the complaint on August 27, 2021, and Plaintiffs responded by filing an amended complaint on October 26, 2021. Defendants filed a motion to dismiss the amended complaint on December 17, 2021. Plaintiffs have not yet responded to the motion to dismiss and there is not currently a briefing schedule on file with the Delaware Chancery Court. Based on the Company&#x2019;s investigation, we believe the case has little legal or factual merit. However, the outcome of any litigation is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Credit and Concentration Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to significant concentrations of credit risk related to cash and cash equivalents and accounts receivable. As of September&#160;30, 2022, approximately 98.2% of our $194.8 million of cash and cash equivalents, restricted cash and restricted investments were held in bank deposits with FDIC participating banks and approximately 1.0% were held in international banks. While the Company maintains its cash and cash equivalents with financial institutions with high credit ratings, it often maintains these deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any realized losses on cash and cash equivalents to date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also subject to significant concentration of accounts receivable risk as a substantial portion of our trade accounts receivable is derived from a small number of our partners. The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable, as of September&#160;30, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molina Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bright Health Management, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is subject to significant concentration of revenue risk as a substantial portion of our revenue is derived from a small number of contractual relationships with our operating partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three and nine months ended September 30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:327.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;We derive a significant portion of our revenues from our largest partners. The loss, termination or renegotiation of our relationship or contract with any significant partner or multiple partners in the aggregate could have a material adverse effect on the Company's financial condition and results of operations.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i9d2101c3205e40fbb7350d3a97444a2b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMTc1_dce5dbf1-7bd3-41bc-b6dd-fd4f93315258"
      unitRef="usd">13100000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i5bc1e4679a644ab9ac8f129c984adf2c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMTgy_a3c59891-62c3-471d-b391-7df725899cca"
      unitRef="usd">15400000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i7e2f3f30574a46129384a30992e3c3f9_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMzAx_1405b632-2a72-4e28-b10f-5fec6e9c8e2e"
      unitRef="usd">13100000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i56823a0a37a14bc28d21c2c9d3140588_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMzA4_13f6d4ad-08ae-4109-bd1f-2f9d207cdaf7"
      unitRef="usd">15400000</us-gaap:RestrictedCashAndCashEquivalents>
    <evh:LineOfCreditFacilityAutomaticExtensionPeriod
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMzI5ODUzNDg5NTczNQ_a49b5667-b6dc-48d8-922d-12772ecfa335">P1Y</evh:LineOfCreditFacilityAutomaticExtensionPeriod>
    <evh:LineOfCreditFacilityPeriodBeforeEachAutomaticExtension
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMzI5ODUzNDg5NTc1Mg_bdf3188c-399b-4962-9001-5fe9c3c42304">P1Y</evh:LineOfCreditFacilityPeriodBeforeEachAutomaticExtension>
    <evh:NumberOfCustomers
      contextRef="i1fefdbdcfbff4feb9724eb08693b3aae_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMzI5ODUzNDg5NTczNw_64117647-004c-4e43-961f-52bad7ed5e02"
      unitRef="customer">20</evh:NumberOfCustomers>
    <us-gaap:Revenues
      contextRef="i8a7f1b54fe7b435899399c232e3c82eb_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMjE5OTAyMzI4MTM2MA_48a16293-7082-4ad6-8941-0de4e3649d7d"
      unitRef="usd">100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1fefdbdcfbff4feb9724eb08693b3aae_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMjE5OTAyMzI4MTM0NQ_cafcf00d-e008-4583-a7a7-7c35acc90eab"
      unitRef="usd">1200000</us-gaap:Revenues>
    <evh:TaxReceivablesAgreementPercentOfTaxSavingsToBePaid
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfNjY3Ng_3f679ec3-ec6d-428e-a2c6-99841d9f9eab"
      unitRef="number">0.85</evh:TaxReceivablesAgreementPercentOfTaxSavingsToBePaid>
    <evh:TaxReceivableAgreementLiability
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMTY0OTI2NzQ1NzMxMA_32e1965f-c2c8-4b16-9498-6ee5303c3715"
      unitRef="usd">42900000</evh:TaxReceivableAgreementLiability>
    <evh:TaxReceivablesAgreementPercentOfTaxSavingsToBePaid
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMzI5ODUzNDg5NzAxNw_accd48f0-96f3-47a0-ab19-3c1ddb9de70b"
      unitRef="number">0.85</evh:TaxReceivablesAgreementPercentOfTaxSavingsToBePaid>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="ia13de1649ce14d5ba2486e13d566c4de_D20220802-20220802"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfOTE0NQ_c8f47e07-e00a-458a-8f15-460707b132e2"
      unitRef="usd">23500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <evh:CashFDICInsuredAmountPercentage
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMTA2NDc_fb77f755-f128-4102-b276-dc8f8ef46f60"
      unitRef="number">0.982</evh:CashFDICInsuredAmountPercentage>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMTA2NTc_8b8065b7-7021-4f8a-aca7-3b6dcfe05689"
      unitRef="usd">194800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <evh:CashHeldInInternationalBanksPercentage
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMTA4MDg_b56b1aa9-0632-4bab-aba9-44c450089091"
      unitRef="number">0.010</evh:CashHeldInInternationalBanksPercentage>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RleHRyZWdpb246YmViZTE2NzUxNTNlNDAzMTk0OTgxMzQyOWU5ZTI0NTNfMTIzNTk_940012d8-86fa-4634-9f05-db74b3d85a5e">The following table summarizes the partners who represented at least 10.0% of our consolidated short-term trade accounts receivable, excluding pharmacy claims receivable and premiums receivable, as of September&#160;30, 2022 and December&#160;31, 2021:&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:354.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:88.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals System&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Molina Healthcare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bright Health Management, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;* &#160;&#160;&#160;&#160;Represents less than 10.0% of the respective balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes those partners who represented at least 10.0% of our consolidated revenue for the three and nine months ended September 30, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:327.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cook County Health and Hospitals Systems&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Florida Blue Medicare, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i812113f21d0f4ddab105da97d5259847_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjNjZmUwYTgyODI3MjQ5MWQ4YWE5ZjUyMjkxNDgwNTkzL3RhYmxlcmFuZ2U6M2NmZTBhODI4MjcyNDkxZDhhYTlmNTIyOTE0ODA1OTNfMS0xLTEtMS02NjkxMA_9f43ed97-49a8-4125-978e-72a6f0b9bff5"
      unitRef="number">0.301</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iebb100753030431db53c2c0fcb076812_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjNjZmUwYTgyODI3MjQ5MWQ4YWE5ZjUyMjkxNDgwNTkzL3RhYmxlcmFuZ2U6M2NmZTBhODI4MjcyNDkxZDhhYTlmNTIyOTE0ODA1OTNfMi0zLTEtMS02NjkxMA_d51345da-f09a-4e5f-97d4-694f37a82555"
      unitRef="number">0.464</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9a78877350444f218b04a44d9a5a67f2_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjNjZmUwYTgyODI3MjQ5MWQ4YWE5ZjUyMjkxNDgwNTkzL3RhYmxlcmFuZ2U6M2NmZTBhODI4MjcyNDkxZDhhYTlmNTIyOTE0ODA1OTNfMy0zLTEtMS02NjkxMA_a6ccc832-9790-4fb2-96f7-07aa0c27f3e5"
      unitRef="number">0.104</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9063068a17484ebd913c39f47d497ab4_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjNjZmUwYTgyODI3MjQ5MWQ4YWE5ZjUyMjkxNDgwNTkzL3RhYmxlcmFuZ2U6M2NmZTBhODI4MjcyNDkxZDhhYTlmNTIyOTE0ODA1OTNfNS0xLTEtMS02NjkxMA_72ac79ca-7e0a-4ef3-938b-7ea6347c6d50"
      unitRef="number">0.122</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6d9342a7219542d0b80d6351bbbf951e_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjMxMzkxMjI4NTQ0NzQwYTk4Nzk1MGE4MDU2ZjQ2ODkwL3RhYmxlcmFuZ2U6MzEzOTEyMjg1NDQ3NDBhOTg3OTUwYTgwNTZmNDY4OTBfMi0xLTEtMS02NjkxMA_1b86b76d-b9e0-4025-a498-880c43f0f961"
      unitRef="number">0.212</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id66d64f0da484276ac264af8e9113d8b_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjMxMzkxMjI4NTQ0NzQwYTk4Nzk1MGE4MDU2ZjQ2ODkwL3RhYmxlcmFuZ2U6MzEzOTEyMjg1NDQ3NDBhOTg3OTUwYTgwNTZmNDY4OTBfMi0zLTEtMS02NjkxMA_e51365b2-a22e-4453-8101-eb627e64c6b5"
      unitRef="number">0.290</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if15154cdcab04d8c8d65acb536587c6c_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjMxMzkxMjI4NTQ0NzQwYTk4Nzk1MGE4MDU2ZjQ2ODkwL3RhYmxlcmFuZ2U6MzEzOTEyMjg1NDQ3NDBhOTg3OTUwYTgwNTZmNDY4OTBfMi01LTEtMS02NjkxMA_74d52a8c-c26d-4cdc-a512-57e7459c2e2d"
      unitRef="number">0.230</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5853227e398a4d7793e949610404e4cb_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjMxMzkxMjI4NTQ0NzQwYTk4Nzk1MGE4MDU2ZjQ2ODkwL3RhYmxlcmFuZ2U6MzEzOTEyMjg1NDQ3NDBhOTg3OTUwYTgwNTZmNDY4OTBfMi03LTEtMS02NjkxMA_85626ae8-5b95-45b9-b331-add38650217d"
      unitRef="number">0.290</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i65657a6b51904fa0b718ad005efbdff6_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjMxMzkxMjI4NTQ0NzQwYTk4Nzk1MGE4MDU2ZjQ2ODkwL3RhYmxlcmFuZ2U6MzEzOTEyMjg1NDQ3NDBhOTg3OTUwYTgwNTZmNDY4OTBfMy0xLTEtMS02NjkxMA_b17f3314-3df6-4878-af66-b93cb017dc5d"
      unitRef="number">0.137</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8be069ea831c4019bdd30e5903c02c34_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjMxMzkxMjI4NTQ0NzQwYTk4Nzk1MGE4MDU2ZjQ2ODkwL3RhYmxlcmFuZ2U6MzEzOTEyMjg1NDQ3NDBhOTg3OTUwYTgwNTZmNDY4OTBfMy0zLTEtMS02NjkxMA_e38a8f5a-2da5-4a51-be0a-8af530b3100c"
      unitRef="number">0.138</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icb0f8ea17a2a4c8084b696133732c541_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjMxMzkxMjI4NTQ0NzQwYTk4Nzk1MGE4MDU2ZjQ2ODkwL3RhYmxlcmFuZ2U6MzEzOTEyMjg1NDQ3NDBhOTg3OTUwYTgwNTZmNDY4OTBfMy01LTEtMS02NjkxMA_9fad2ff1-5f3c-4147-9239-bdfbe313b2e8"
      unitRef="number">0.125</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia751c62398344050a4fa0f25431a1c20_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183Ni9mcmFnOmJlYmUxNjc1MTUzZTQwMzE5NDk4MTM0MjllOWUyNDUzL3RhYmxlOjMxMzkxMjI4NTQ0NzQwYTk4Nzk1MGE4MDU2ZjQ2ODkwL3RhYmxlcmFuZ2U6MzEzOTEyMjg1NDQ3NDBhOTg3OTUwYTgwNTZmNDY4OTBfMy03LTEtMS02NjkxMA_24c2048a-5e32-468b-afcc-cf10780a3fad"
      unitRef="number">0.142</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RleHRyZWdpb246YjI2OTBkMTE4NDk4NGQxNDk0Zjc4YTBjNzdiNGY5MDZfMzI1Ng_6eb64f0c-63dd-4649-9caa-38ace5e5c6b3">Leases&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into various office space, data center, and equipment lease agreements in conducting its normal business operations. At the inception of any contract, the Company evaluates the agreement to determine whether the contract contains a lease. If the contract contains a lease, the Company then evaluates the term and whether the lease is an operating or finance lease. Most leases include one or more options to renew or may have a termination option. The Company determines whether these options are reasonably certain to be exercised or not at the inception of the lease. In addition, some leases contain escalation clauses.  The rent expense is recognized on a straight-line basis in the consolidated statements of operations and comprehensive income (loss) over the term of the lease. Leases with an initial term of 12 months or less are not recorded on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. We use the implicit rate when readily determinable. Further, the Company treats all lease and non-lease components as a single combined lease component for all classes of underlying assets. The Company also enters into sublease agreements for some of its leased office space. Immaterial rental income attributable to subleases is offset against rent expense over the terms of the respective leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases office space and computer and other equipment under operating lease agreements expiring at various dates through 2032. Under the lease agreements, in addition to base rent, the Company is generally responsible for operating and maintenance costs and related fees. Several of these agreements include tenant improvement allowances, rent holidays or rent escalation clauses. When such items are included in a lease agreement, we record a deferred rent asset or liability on our consolidated balance sheets equal to the difference between rent expense and future minimum lease payments due. The rent expense related to these items is recognized on a straight-line basis over the terms of the leases. The Company&#x2019;s primary office location is in Arlington, Virginia, which has served as its corporate headquarters since 2013. The Arlington, Virginia office lease expires in January 2032. Certain leases acquired as part of the Valence Health transaction included existing sublease agreements for office locations in Chicago, Illinois. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with various lease agreements, the Company is required to maintain $2.3 million and $3.8 million in letters of credit as of September&#160;30, 2022 and December&#160;31, 2021. As of September&#160;30, 2022 and December&#160;31, 2021, the Company held $2.3 million &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $3.8 million in restricted cash and restricted investments on the consolidated balance sheet as collateral for the letters of credit, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our primary office leases as of September&#160;30, 2022 (in thousands, other than term):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:237.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Termination Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Future Minimum Lease Commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Letter of Credit Amount Required&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Arlington, VA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Riverside, IL &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Edison, NJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alpharetta, GA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pune, India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brea, CA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of our lease expense (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity of lease liabilities (in thousands) as of September&#160;30, 2022, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <evh:NumberOfOptionsToRenewLeases
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RleHRyZWdpb246YjI2OTBkMTE4NDk4NGQxNDk0Zjc4YTBjNzdiNGY5MDZfNDk0NzgwMjMyODI1NA_e3bae14c-0ba8-4de4-8e97-56bab14e8b3a"
      unitRef="option_to_renew_lease">1</evh:NumberOfOptionsToRenewLeases>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i5109fae1e1f447d9ba05497deddbfdc1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RleHRyZWdpb246YjI2OTBkMTE4NDk4NGQxNDk0Zjc4YTBjNzdiNGY5MDZfMjY2Mw_4e7f7733-d7cd-475e-b945-40e20014b4c6"
      unitRef="usd">2300000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ib8a8fe953a844510b46e6007aa3d8a39_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RleHRyZWdpb246YjI2OTBkMTE4NDk4NGQxNDk0Zjc4YTBjNzdiNGY5MDZfMjY3MA_aa53630d-0ba0-4d59-86d8-462db1bb67b3"
      unitRef="usd">3800000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i5109fae1e1f447d9ba05497deddbfdc1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RleHRyZWdpb246YjI2OTBkMTE4NDk4NGQxNDk0Zjc4YTBjNzdiNGY5MDZfMjc0NQ_a520a399-d923-4b38-913c-a895ba211a7c"
      unitRef="usd">2300000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ib8a8fe953a844510b46e6007aa3d8a39_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RleHRyZWdpb246YjI2OTBkMTE4NDk4NGQxNDk0Zjc4YTBjNzdiNGY5MDZfMjc1Mg_f9863d21-2ef1-4d00-b72a-27d47e145d39"
      unitRef="usd">3800000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RleHRyZWdpb246YjI2OTBkMTE4NDk4NGQxNDk0Zjc4YTBjNzdiNGY5MDZfMzI1Nw_e73ef9d3-a136-4f7a-b701-1b6a46814327">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our primary office leases as of September&#160;30, 2022 (in thousands, other than term):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:237.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:94.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease Termination Term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Future Minimum Lease Commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Letter of Credit Amount Required&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Arlington, VA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Riverside, IL &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Edison, NJ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Alpharetta, GA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pune, India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brea, CA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity of lease liabilities (in thousands) as of September&#160;30, 2022, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:87.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i1c22768950824185b381d31f0d376c88_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfMS0yLTEtMS02NjkxMA_b2e04241-822c-4e67-9b0e-cb87862d6bd0">P9Y3M18D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i1c22768950824185b381d31f0d376c88_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfMS00LTEtMS02NjkxMA_be3152f8-7d13-4439-984c-08e3eb4f7649"
      unitRef="usd">33212000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i1c22768950824185b381d31f0d376c88_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfMS02LTEtMS02NjkxMA_f2b6b422-c29c-4e7d-a53a-e06643bb55fe"
      unitRef="usd">1579000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i6b26e20c9d404df3839bead28654fb46_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfMi0yLTEtMS02NjkxMA_d051dfe5-b730-4fc3-b0e2-65803d7c6fde">P8Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i6b26e20c9d404df3839bead28654fb46_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfMi00LTEtMS02NjkxMA_a5effcd7-e048-4afd-8fda-a867e1145274"
      unitRef="usd">38940000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i6b26e20c9d404df3839bead28654fb46_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfMi02LTEtMS02NjkxMA_a5e56b6b-9091-4bb8-8e5e-fecfd4520e01"
      unitRef="usd">232000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ia01578a302554a74b33916abc13ae563_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfMy0yLTEtMS02NjkxMA_09ada3e6-b2be-4cf9-8323-a99573fdb8f4">P3Y7M6D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ia01578a302554a74b33916abc13ae563_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfMy00LTEtMS02NjkxMA_6f8f04a3-ae73-4946-9709-07c727bf991c"
      unitRef="usd">1839000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ia01578a302554a74b33916abc13ae563_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfMy02LTEtMS02NjkxMA_086e37cd-402b-444d-be98-55982e922eb7"
      unitRef="usd">222000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i911c93fdeef8463595874d62c2e77c23_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfNC0yLTEtMS03NjUyMA_5a78ddbd-738c-4b12-8632-8dad69fa6d5c">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i911c93fdeef8463595874d62c2e77c23_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfNC00LTEtMS03NjUxMg_a3786327-000a-4e64-a300-0ab4526427b0"
      unitRef="usd">1409000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i911c93fdeef8463595874d62c2e77c23_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfNC02LTEtMS03NjUxMg_dc28a832-c8de-4be9-b452-371e66a77cdd"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ib15e0e31d88444c0b1538bbb061a978e_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfNC0yLTEtMS02NjkxMA_4f50814f-467b-4f97-8689-21c849c42f2f">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ib15e0e31d88444c0b1538bbb061a978e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfNC00LTEtMS02NjkxMA_07680628-fb0c-4d62-9aa9-caff296810a1"
      unitRef="usd">621000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="ib15e0e31d88444c0b1538bbb061a978e_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfNC02LTEtMS02NjkxMA_f4bdac00-4e3e-44b8-af89-84c39191fb34"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i159210da82754513ad12fdb0f55d6185_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfNS0yLTEtMS02NjkxMA_fbf72c2a-cdb2-43d0-ab6d-a3091f715251">P4Y8M12D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i159210da82754513ad12fdb0f55d6185_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfNS00LTEtMS02NjkxMA_2857c4af-4a48-46e2-8978-9034709338bf"
      unitRef="usd">4304000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i159210da82754513ad12fdb0f55d6185_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOmY2ZWE4ODhhYjZjYjQxZTQ5YWU5ZTc3NTliOWJlMjc3L3RhYmxlcmFuZ2U6ZjZlYTg4OGFiNmNiNDFlNDlhZTllNzc1OWI5YmUyNzdfNS02LTEtMS02NjkxMA_4f9c25ba-fd8a-436b-a716-e1f31a58c44c"
      unitRef="usd">0</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RleHRyZWdpb246YjI2OTBkMTE4NDk4NGQxNDk0Zjc4YTBjNzdiNGY5MDZfMzI1OA_6b27d369-b9e0-4e5e-94cc-b56e5d9fc382">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the components of our lease expense (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.013%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our weighted-average discount rate and our weighted remaining lease terms (in years) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfMi0xLTEtMS02NjkxMA_8c3a304a-4327-4df0-bd80-2f5d56e6d6b6"
      unitRef="usd">2221000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfMi0zLTEtMS02NjkxMA_7a73f198-b1d9-415c-838f-34c8abe54188"
      unitRef="usd">2417000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfMi01LTEtMS02NjkxMA_3688d43c-320d-4d86-aa2b-4edd7c798735"
      unitRef="usd">6726000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfMi03LTEtMS02NjkxMA_07961bb2-6978-48b3-9333-09b4438241ba"
      unitRef="usd">9672000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfMy0xLTEtMS02NjkxMA_960d09ff-88ff-4d50-80a1-0d32ab77de28"
      unitRef="usd">1599000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfMy0zLTEtMS02NjkxMA_70385cb1-a279-4d4b-940b-3ad0d3a32910"
      unitRef="usd">1183000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfMy01LTEtMS02NjkxMA_473d05d9-a850-427b-a282-31c56b398fd7"
      unitRef="usd">4096000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfMy03LTEtMS02NjkxMA_0734defa-bd85-4a4b-a138-ad30db7f4ba6"
      unitRef="usd">3696000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfNC0xLTEtMS02NjkxMA_d8750a3e-16b8-4fd6-8f32-a3d8c5426b7f"
      unitRef="usd">3820000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfNC0zLTEtMS02NjkxMA_bdf0dce7-9586-4536-9f4d-b3178be1beb5"
      unitRef="usd">3600000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfNC01LTEtMS02NjkxMA_44681fe4-f064-42c1-a35e-75274e49cf9f"
      unitRef="usd">10822000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjllYTVlYjY0OTMyYTQxNmZiMTczZWQzMTM1ZjhmMzg0L3RhYmxlcmFuZ2U6OWVhNWViNjQ5MzJhNDE2ZmIxNzNlZDMxMzVmOGYzODRfNC03LTEtMS02NjkxMA_d3941d0f-827d-42c4-9142-ec21baff26bd"
      unitRef="usd">13368000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjBlODdlODdmZjhkYTQyYzhiMzFmMTg0OWI2MjdjMDE1L3RhYmxlcmFuZ2U6MGU4N2U4N2ZmOGRhNDJjOGIzMWYxODQ5YjYyN2MwMTVfMS0xLTEtMS02NjkxMA_660d39c5-2a8a-446b-b2f1-4bd680e0ea5f"
      unitRef="usd">2756000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjBlODdlODdmZjhkYTQyYzhiMzFmMTg0OWI2MjdjMDE1L3RhYmxlcmFuZ2U6MGU4N2U4N2ZmOGRhNDJjOGIzMWYxODQ5YjYyN2MwMTVfMi0xLTEtMS02NjkxMA_a950231f-d276-4651-af84-83dedc49704e"
      unitRef="usd">10865000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjBlODdlODdmZjhkYTQyYzhiMzFmMTg0OWI2MjdjMDE1L3RhYmxlcmFuZ2U6MGU4N2U4N2ZmOGRhNDJjOGIzMWYxODQ5YjYyN2MwMTVfMy0xLTEtMS02NjkxMA_70903f2e-dca5-4ef8-99e0-27c2f7722967"
      unitRef="usd">10595000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjBlODdlODdmZjhkYTQyYzhiMzFmMTg0OWI2MjdjMDE1L3RhYmxlcmFuZ2U6MGU4N2U4N2ZmOGRhNDJjOGIzMWYxODQ5YjYyN2MwMTVfNC0xLTEtMS02NjkxMA_1d689e64-bfcd-42f3-b950-d6a7a90ae818"
      unitRef="usd">10012000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjBlODdlODdmZjhkYTQyYzhiMzFmMTg0OWI2MjdjMDE1L3RhYmxlcmFuZ2U6MGU4N2U4N2ZmOGRhNDJjOGIzMWYxODQ5YjYyN2MwMTVfNS0xLTEtMS02NjkxMA_b4ad7628-ab99-49cf-9a61-8c686dd18bc0"
      unitRef="usd">8987000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <evh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjBlODdlODdmZjhkYTQyYzhiMzFmMTg0OWI2MjdjMDE1L3RhYmxlcmFuZ2U6MGU4N2U4N2ZmOGRhNDJjOGIzMWYxODQ5YjYyN2MwMTVfNi0xLTEtMS02NjkxMA_eff69bc0-83d7-420c-8312-855a3cecc02c"
      unitRef="usd">40377000</evh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjBlODdlODdmZjhkYTQyYzhiMzFmMTg0OWI2MjdjMDE1L3RhYmxlcmFuZ2U6MGU4N2U4N2ZmOGRhNDJjOGIzMWYxODQ5YjYyN2MwMTVfNy0xLTEtMS02NjkxMA_f7b32fe7-b7a8-4db2-aca3-8d1354ade619"
      unitRef="usd">83592000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjBlODdlODdmZjhkYTQyYzhiMzFmMTg0OWI2MjdjMDE1L3RhYmxlcmFuZ2U6MGU4N2U4N2ZmOGRhNDJjOGIzMWYxODQ5YjYyN2MwMTVfOS0xLTEtMS02NjkxMA_7109ed96-3b3e-4c2a-b014-d704095f3d8b"
      unitRef="usd">18699000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjBlODdlODdmZjhkYTQyYzhiMzFmMTg0OWI2MjdjMDE1L3RhYmxlcmFuZ2U6MGU4N2U4N2ZmOGRhNDJjOGIzMWYxODQ5YjYyN2MwMTVfMTAtMS0xLTEtNjY5MTA_39efe2a1-646e-444b-9009-0b0b79affbb6"
      unitRef="usd">64893000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjlmYmY3NTEyMGMwYjQ3ZjY5ZTg0ZTNiOGU2M2RiZTYxL3RhYmxlcmFuZ2U6OWZiZjc1MTIwYzBiNDdmNjllODRlM2I4ZTYzZGJlNjFfMS0xLTEtMS02NjkxMA_bfaf5dbf-737c-4380-b5d8-82e1c9960041"
      unitRef="number">0.0634</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM183OS9mcmFnOmIyNjkwZDExODQ5ODRkMTQ5NGY3OGEwYzc3YjRmOTA2L3RhYmxlOjlmYmY3NTEyMGMwYjQ3ZjY5ZTg0ZTNiOGU2M2RiZTYxL3RhYmxlcmFuZ2U6OWZiZjc1MTIwYzBiNDdmNjllODRlM2I4ZTYzZGJlNjFfMi0xLTEtMS02NjkxMA_1900dcdc-272a-47a6-a56f-faab76f5b7c5">P8Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RleHRyZWdpb246MDE4NzgwODhmZDkxNGIwMDk1YzExYjY1MzkxNDgzMjlfMzQ2_9f3e0d28-bd7a-4d5f-a9d8-ab697a70bf58">Income (Loss) Per Common Share&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,337)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incremental diluted shares from stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incremental diluted shares from Restricted stock units ("RSUs"), performance-based RSUs (&#x201c;PSUs&#x201d;) and leveraged stock units ("LSUs")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic income (loss) per share attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted net earnings per common share, if any, gives effect to diluted stock options (calculated based on the treasury stock method), shares issuable upon debt conversion (calculated using an as-if converted method).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units ("RSUs"), performance-based RSUs (&#x201c;PSUs&#x201d;) and leveraged stock units ("LSUs")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RleHRyZWdpb246MDE4NzgwODhmZDkxNGIwMDk1YzExYjY1MzkxNDgzMjlfMzQ4_49ac7917-18d4-4a52-8f83-290a74a35fe8">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(33,337)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incremental diluted shares from stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incremental diluted shares from Restricted stock units ("RSUs"), performance-based RSUs (&#x201c;PSUs&#x201d;) and leveraged stock units ("LSUs")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income (loss) per common share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic income (loss) per share attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.08)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.09)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per common share is calculated using the weighted average number of common shares outstanding during the period. Diluted net earnings per common share, if any, gives effect to diluted stock options (calculated based on the treasury stock method), shares issuable upon debt conversion (calculated using an as-if converted method).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMi0xLTEtMS02NjkxMA_e6d82b3d-96a8-469c-9b36-a0745946c155"
      unitRef="usd">2123000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMi0zLTEtMS02NjkxMA_52b4c26f-4fd8-4024-acd6-e8cd828ae0d1"
      unitRef="usd">-13040000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMi01LTEtMS02NjkxMA_814325c3-c4f8-43f1-9549-889093d349d2"
      unitRef="usd">-7352000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMi03LTEtMS02NjkxMA_748f7b05-deb5-4d61-92cf-0fd288b80628"
      unitRef="usd">-33337000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy0xLTEtMS02NjkxMA_0f209cfa-8504-4ac9-b758-ac2a0a61b1b2"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy0zLTEtMS02NjkxMA_43c76fef-6b2e-4467-b3ef-343e76af8f09"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy01LTEtMS02NjkxMA_00f03ad2-b82d-44e7-b7c4-221872011c79"
      unitRef="usd">-463000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy03LTEtMS02NjkxMA_d20e63e0-6ca3-40ec-8951-ef7d1c289504"
      unitRef="usd">1383000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNC0xLTEtMS02NjkxMA_1c62408f-d7c4-4bf3-9201-aa2f5ad07bff"
      unitRef="usd">2123000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNC0xLTEtMS02NjkxMA_418e1725-6f05-4986-9c4a-b48ab9c60da6"
      unitRef="usd">2123000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNC0zLTEtMS02NjkxMA_3bf755bd-69e0-4e5d-8db0-7be22ff376fc"
      unitRef="usd">-13040000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNC0zLTEtMS02NjkxMA_6d8f73ae-488a-4e7c-9c41-0a500eacbb30"
      unitRef="usd">-13040000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNC01LTEtMS02NjkxMA_73a898f4-adfb-4ae1-a5b1-997c8d436a45"
      unitRef="usd">-7815000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNC01LTEtMS02NjkxMA_817b6502-2ab5-48ff-bb32-0a656ebaf587"
      unitRef="usd">-7815000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNC03LTEtMS02NjkxMA_374bb7fe-b864-4da2-80a1-d5a2e7df2874"
      unitRef="usd">-31954000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNC03LTEtMS02NjkxMA_d88ca28a-da35-453e-a5b9-58cb61aa0014"
      unitRef="usd">-31954000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNi0xLTEtMS02NjkxMA_fa3febef-4e8c-48f9-b9c0-b0b1c2b8e6d0"
      unitRef="shares">95286000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNi0zLTEtMS02NjkxMA_8196ecfc-cd41-4565-8cc6-e3c48f677fa0"
      unitRef="shares">85800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNi01LTEtMS02NjkxMA_16f5ddf6-4ec8-448a-b76d-5f5c2a3b2f18"
      unitRef="shares">91643000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNi03LTEtMS02NjkxMA_60086fc8-e0b2-4a6a-94cc-387bd5265ddc"
      unitRef="shares">85306000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <evh:IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNy0xLTEtMS03Njg3MQ_88dc22c6-bd00-43a8-9b26-c16ad9084659"
      unitRef="shares">1915000</evh:IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards>
    <evh:IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNy0zLTEtMS03Njg3MQ_40475a77-835e-4253-9b3a-c4bfb8333747"
      unitRef="shares">0</evh:IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards>
    <evh:IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNy01LTEtMS03Njg3MQ_34d5faf8-0d86-4e04-abad-ee870e368f40"
      unitRef="shares">0</evh:IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards>
    <evh:IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNy03LTEtMS03Njg3MQ_dd749c70-c610-4809-9f4b-a899120bf135"
      unitRef="shares">0</evh:IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfOC0xLTEtMS03Njg3MQ_95202291-db92-424f-bbee-43648a311ab3"
      unitRef="shares">2107000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfOC0zLTEtMS03Njg3MQ_d2ec16d5-b61e-41af-8d80-13cb97a1502d"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfOC01LTEtMS03Njg3MQ_cb281853-d3eb-48d6-a740-9f6b2be4d5b6"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfOC03LTEtMS03Njg3MQ_5edd8829-0e3b-4f1b-97f3-0f717a8be55b"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfOS0xLTEtMS03Njg3MQ_a51971cc-ad60-42ed-9222-875192e7941c"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfOS0zLTEtMS03Njg3MQ_8fb72867-5bfb-49b1-9911-3de1ae33b146"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfOS01LTEtMS03Njg3MQ_635c65e1-130e-4fec-96b2-5f63b51c55bf"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfOS03LTEtMS03Njg3MQ_1e4cd097-c301-4d53-9481-8ca3260ea8a6"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNy0xLTEtMS03Njc2MA_b0d31914-371d-462f-84e7-2bd333824083"
      unitRef="shares">99308000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNy0zLTEtMS03Njc2MA_cc7c99d8-3fb3-4661-87b0-934f99532027"
      unitRef="shares">85800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNy01LTEtMS03Njc2MA_435dc0d5-1b7d-4db0-b15d-0dc3636c2b52"
      unitRef="shares">91643000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfNy03LTEtMS03Njc2MA_7f8bc27a-b11a-4130-9e66-f9d46247fb96"
      unitRef="shares">85306000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTAtMS0xLTEtNjY5MTA_5d78348a-1ede-42f3-9c66-3e19d04d192b"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTAtMy0xLTEtNjY5MTA_94406da4-bba3-4f7b-9a48-470977dba9ed"
      unitRef="usdPerShare">-0.15</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTAtNS0xLTEtNjY5MTA_04698b35-8bc1-4fd1-b051-1674a602e6ca"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTAtNy0xLTEtNjY5MTA_594c02a6-9adc-4b51-8a3b-49e7df85a3ba"
      unitRef="usdPerShare">-0.39</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTEtMS0xLTEtNjY5MTA_b04bb2aa-e06c-4725-a979-417393867246"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTEtMy0xLTEtNjY5MTA_51f2919e-d948-43e1-b8fe-353c355f98aa"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTEtNS0xLTEtNjY5MTA_b02eb601-91c3-4df9-824f-4b86bfd50033"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTEtNy0xLTEtNjY5MTA_92a71a9f-9843-4f08-bcfa-9a531cf1884c"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTItMS0xLTEtNjY5MTA_3532a326-e3a6-4a72-bf8a-62b392719771"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTItMy0xLTEtNjY5MTA_6531b55f-f41b-4ab9-ba40-c11e9a2c2159"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTItNS0xLTEtNjY5MTA_dc29ff25-a8f0-4a3c-a9ac-cc086468d8e9"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTItNy0xLTEtNjY5MTA_ee2b491b-a03c-4b79-b603-6b46c67d2ad3"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTgtMS0xLTEtNzcxMDE_c0bc64f5-cd2d-48be-8ace-aa6e4d481486"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTgtMy0xLTEtNzcxMDE_2ebf6c1c-71c6-4384-8606-b4152dbb6d7d"
      unitRef="usdPerShare">-0.15</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTgtNS0xLTEtNzcxMDE_b559917c-1929-4bc9-bf4d-69a8feff1d5d"
      unitRef="usdPerShare">-0.08</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTgtNy0xLTEtNzcxMDE_01899fe7-98ba-4bca-a762-25a2204f5eb5"
      unitRef="usdPerShare">-0.39</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTktMS0xLTEtNzcxMDE_df0eb775-ca69-403d-b4d5-5d2a0bbb0973"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTktMy0xLTEtNzcxMDE_13066bf6-b1e7-43da-9b52-2cc3045e00a7"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTktNS0xLTEtNzcxMDE_ddf5b5b3-765f-4c63-a2d4-44bb2fbb4d0b"
      unitRef="usdPerShare">-0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMTktNy0xLTEtNzcxMDE_4f04f922-c15e-48e6-b6d7-1344cd429489"
      unitRef="usdPerShare">0.02</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMjAtMS0xLTEtNzcxMDE_1cc75002-3e6b-4439-886b-d35b708cfd77"
      unitRef="usdPerShare">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMjAtMy0xLTEtNzcxMDE_180fac62-bd77-4452-89a2-404577c7ea37"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMjAtNS0xLTEtNzcxMDE_6642db39-b9b4-4146-856f-f11cc4bccf6d"
      unitRef="usdPerShare">-0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMjAtNy0xLTEtNzcxMDE_dfa295c9-4f3f-4d71-8344-393a4f8a3c2f"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RleHRyZWdpb246MDE4NzgwODhmZDkxNGIwMDk1YzExYjY1MzkxNDgzMjlfMzQy_b7c4b515-6536-4c8e-a5d3-2b3da5fa33a8">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units ("RSUs"), performance-based RSUs (&#x201c;PSUs&#x201d;) and leveraged stock units ("LSUs")&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8493de5c288b4d2a960001285f09a7d5_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfMi0xLTEtMS02NjkxMA_32e8124b-7b42-4605-b0cd-cda29f3653e4"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i13c42161e64b48038d3f19a5af627a85_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfMi0zLTEtMS02NjkxMA_482cacb5-4f92-4089-a04f-eb0046675d5c"
      unitRef="shares">2012000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iae5571384d234210beca38a208484402_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfMi01LTEtMS02NjkxMA_2006ad33-b340-4641-8ac2-3fa7b7a1b8aa"
      unitRef="shares">1818000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i698aa6c02364400ebedf039f90402307_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfMi03LTEtMS02NjkxMA_3b9bf999-c7b8-40a4-ab06-79bca6657176"
      unitRef="shares">1700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3fd339cb95b94daea292e551ad2fe6f3_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfMy0xLTEtMS02NjkxMA_ccd4f28e-e0b8-4778-b180-a4fa6d7ddb88"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3bcd97c207a54e5ab3166f83c04c3bb0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfMy0zLTEtMS02NjkxMA_5bacad76-3719-4406-bb32-638a7458e70a"
      unitRef="shares">2004000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i31ffa1624215451292f3bc38304028d0_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfMy01LTEtMS02NjkxMA_5bfb02c2-b365-4764-b47e-4c27dce28738"
      unitRef="shares">1858000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i22491be6a23246d796d54f3c45790776_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfMy03LTEtMS02NjkxMA_9386354a-6f62-42fa-9c03-83e77c2c8ac4"
      unitRef="shares">2008000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5bef61a150eb4c7a881bdf01c6a5f488_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfNC0xLTEtMS02NjkxMA_a4ecb97d-5c66-4ebc-ae94-83312b223b91"
      unitRef="shares">9007000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if9dbe0e582d74777ae8810f8d192e1d8_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfNC0zLTEtMS02NjkxMA_9d74756a-87c7-4faf-bea4-53236be98f44"
      unitRef="shares">12696000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i22bf8d1d47ce4219b999f81df2fed5e7_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfNC01LTEtMS02NjkxMA_9ce00062-bc43-45f6-a09f-c48c198d0e13"
      unitRef="shares">10714000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifd9f231f9ee2464db9a170de0151bca4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfNC03LTEtMS02NjkxMA_51394b76-9bf3-48be-b242-e67e175e6a22"
      unitRef="shares">12696000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfNS0xLTEtMS02NjkxMA_7e271efd-9778-46ac-9cd2-20199dd5a1a4"
      unitRef="shares">9007000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfNS0zLTEtMS02NjkxMA_6d1e3d2a-88dc-478a-866b-4eae7999c9f6"
      unitRef="shares">16712000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfNS01LTEtMS02NjkxMA_283e6942-27f6-4752-8a83-f2a92e611b2f"
      unitRef="shares">14390000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOmE5NTkyYTBkNTYxNjQ5NjU5ZDE4ZmQ1OTcyNzMyODk4L3RhYmxlcmFuZ2U6YTk1OTJhMGQ1NjE2NDk2NTlkMThmZDU5NzI3MzI4OThfNS03LTEtMS02NjkxMA_db67400a-419b-4ab6-af7a-604bb788b36d"
      unitRef="shares">16404000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RleHRyZWdpb246MjNiNDZhY2JmOWVmNDJkYWJkMGQ1NzA3MDBiOGZiODlfMzI1_741d07cb-4129-4a2e-9554-bd0f2f5e9005">Stock-based Compensation&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Award Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by award type&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by financial statement line item&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No stock-based compensation was capitalized as software development costs for the three and nine months ended September 30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based awards were granted as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:327.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RleHRyZWdpb246MjNiNDZhY2JmOWVmNDJkYWJkMGQ1NzA3MDBiOGZiODlfMzIz_85e20798-8647-4357-a7eb-d11506c5828f">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total compensation expense by award type and line item in our consolidated financial statements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Award Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:288.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:58.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;LSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by award type&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total compensation expense by financial statement line item&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifb50d04ea7474a3ca01d54e55b1a55f6_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMy0xLTEtMS02NjkxMA_35038b35-3fa5-417d-b435-800c2b2f39a5"
      unitRef="usd">78000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i325a5d1124ab41b9a84347a873d3e51b_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMy0zLTEtMS02NjkxMA_33129632-a0c2-434b-bba7-b517171544ca"
      unitRef="usd">274000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iea400d223b0743bdad51be17ed4b50ee_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMy01LTEtMS02NjkxMA_fecd3647-7947-496d-9dd4-af7a3a621ed2"
      unitRef="usd">331000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id2a7bc06fc954c4b817161cd6406f509_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMy03LTEtMS02NjkxMA_b394d885-3f59-4b3e-8401-4b480865c6d1"
      unitRef="usd">945000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i582d7dedfcac46f99a84eb6ef808e641_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNC0xLTEtMS02NjkxMA_958f02e8-96fc-47f1-bb95-579c988f71a9"
      unitRef="usd">4830000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8aa29b39545e4c3ba7d7690b3e215975_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNC0zLTEtMS02NjkxMA_c0ce85f1-66b9-4b8b-b229-24ceedf07e6b"
      unitRef="usd">2381000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4b17f35850394b8dba4f2022f71b47ca_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNC01LTEtMS02NjkxMA_d854e0ca-5c41-43d2-adce-85ef1c952280"
      unitRef="usd">12778000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5a875e7e581644ddb5ae0ea1dd6d828d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNC03LTEtMS02NjkxMA_a9efa066-8a28-4c1f-b7b8-67b8c3adde4e"
      unitRef="usd">6782000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i80cf2c1a304b4b419a652fc1e0cb1937_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNS0xLTEtMS02NjkxMA_a7b7fe5e-4377-4a7f-88b9-74c6e828aa7b"
      unitRef="usd">387000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7c541a9c8aa847a880c6ab10e684b4c9_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNS0zLTEtMS02NjkxMA_55eb214d-131f-4062-91fd-cb1338ea4120"
      unitRef="usd">995000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8cc6de998c6c41a2918343e7a2029cbe_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNS01LTEtMS02NjkxMA_314b3dc6-3223-4655-b49c-7804ad5b4ef9"
      unitRef="usd">1544000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i44b9048d914e4b6fbb6f301354a4b9b0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNS03LTEtMS02NjkxMA_c4b2bf8a-cca2-42da-a07d-189117fc044b"
      unitRef="usd">2302000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i647fb470e87444d6a627e33d5d70965b_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNi0xLTEtMS02NjkxMA_eb78fff3-c5cf-468a-bfa4-4146bb9efad9"
      unitRef="usd">1697000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ide5f51cc3ef84de6a0fd4b47abd3c1e8_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNi0zLTEtMS02NjkxMA_01e26313-efb8-4156-ac35-d8612ab45835"
      unitRef="usd">745000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idcffb900db284c32b9e3d8cb934a505f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNi01LTEtMS02NjkxMA_46725409-9210-42d1-8f55-03893e116cfe"
      unitRef="usd">4697000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iee1649a9b5bf47f7917cfe5843b5b4a8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNi03LTEtMS02NjkxMA_73759c57-4a63-4a20-ad2c-3b9efe29cf3a"
      unitRef="usd">1725000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNy0xLTEtMS02NjkxMA_b9e514bf-8be2-4b93-8a33-047c09e3f24d"
      unitRef="usd">6992000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNy0zLTEtMS02NjkxMA_497ed6dc-5fec-44b0-abe8-c58f4235ca79"
      unitRef="usd">4395000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNy01LTEtMS02NjkxMA_734923d9-5776-4971-86de-6a93d1a5771e"
      unitRef="usd">19350000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfNy03LTEtMS02NjkxMA_cda4ae22-f7ad-4022-abc6-a0eff3a9f5c0"
      unitRef="usd">11754000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i725c229475cf49689226a91cc11b751c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTAtMS0xLTEtNjY5MTA_db16ac50-1b27-47c2-b3ba-fd66e1840168"
      unitRef="usd">1024000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2612dbadf05a4362aad60d096eb1a7e4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTAtMy0xLTEtNjY5MTA_0e559c3b-4654-4f60-a5e6-1f90db982b0e"
      unitRef="usd">131000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iada2bf5d0400417ba62e194126135b75_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTAtNS0xLTEtNjY5MTA_9a5d91c3-1b44-4900-a174-63c3908cd090"
      unitRef="usd">2986000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic6f6b8c71225423c8a5684cc55be31ce_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTAtNy0xLTEtNjY5MTA_6ad7fe09-2e3e-4363-9259-927e33ac662a"
      unitRef="usd">1618000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i631da77b97724fd1b7043025f1733fe1_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTEtMS0xLTEtNjY5MTA_ba613533-5a47-4c6b-a665-844c5c520987"
      unitRef="usd">5968000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if1a0e6a4f8b84f88b30c7341d4f1c393_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTEtMy0xLTEtNjY5MTA_0b19a74c-578b-4f05-b5b8-8924e5b12208"
      unitRef="usd">4264000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idd568013557c46eb981fa85a87040eba_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTEtNS0xLTEtNjY5MTA_cce601f9-56c8-4248-a4f0-eceb5d0fa21a"
      unitRef="usd">16364000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3e14d567f9f24b93870cd21943387f1c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTEtNy0xLTEtNjY5MTA_4bc03b8a-3c94-48b3-af3e-be994b8aa203"
      unitRef="usd">10136000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTItMS0xLTEtNjY5MTA_0bd756fe-2943-4396-8d0f-033cb54c7234"
      unitRef="usd">6992000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTItMy0xLTEtNjY5MTA_307c6c29-0861-4c6f-9744-9771d65bad52"
      unitRef="usd">4395000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTItNS0xLTEtNjY5MTA_be1bc892-0de8-47a6-a62e-0a7773fb8451"
      unitRef="usd">19350000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOmY0ODI2ZjY2NTJiYzRiM2ZiNmEwN2MzOThjZWVlNDk4L3RhYmxlcmFuZ2U6ZjQ4MjZmNjY1MmJjNGIzZmI2YTA3YzM5OGNlZWU0OThfMTItNy0xLTEtNjY5MTA_cda4ae22-f7ad-4022-abc6-a0eff3a9f5c0"
      unitRef="usd">11754000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RleHRyZWdpb246MjNiNDZhY2JmOWVmNDJkYWJkMGQ1NzA3MDBiOGZiODlfMTcx_046eefaa-53ce-4b80-a817-19a264f26177"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RleHRyZWdpb246MjNiNDZhY2JmOWVmNDJkYWJkMGQ1NzA3MDBiOGZiODlfMTcx_a1db02d9-5a0e-4541-ba11-93ed1fd4dd86"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RleHRyZWdpb246MjNiNDZhY2JmOWVmNDJkYWJkMGQ1NzA3MDBiOGZiODlfMTcx_ce5c0492-d41b-4f41-b076-f336b2e623e0"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RleHRyZWdpb246MjNiNDZhY2JmOWVmNDJkYWJkMGQ1NzA3MDBiOGZiODlfMTcx_e6d840af-19eb-48fd-b7a9-325a8c4bb3ca"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RleHRyZWdpb246MjNiNDZhY2JmOWVmNDJkYWJkMGQ1NzA3MDBiOGZiODlfMzI0_eec913d6-4e33-4073-b8e4-cdfdd071c906">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based awards were granted as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:327.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i582d7dedfcac46f99a84eb6ef808e641_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOjg1YThiMWU5YmQ4YTQ4ODY5YTJmOGQwMDQ1NmEyYzMwL3RhYmxlcmFuZ2U6ODVhOGIxZTliZDhhNDg4NjlhMmY4ZDAwNDU2YTJjMzBfMi0xLTEtMS02NjkxMA_bef6fd9e-3401-403e-a097-4ff1d0b7dc16"
      unitRef="shares">87000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8aa29b39545e4c3ba7d7690b3e215975_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOjg1YThiMWU5YmQ4YTQ4ODY5YTJmOGQwMDQ1NmEyYzMwL3RhYmxlcmFuZ2U6ODVhOGIxZTliZDhhNDg4NjlhMmY4ZDAwNDU2YTJjMzBfMi0zLTEtMS02NjkxMA_71b52c7b-7ba2-4e24-b654-081e7d16634b"
      unitRef="shares">134000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i4b17f35850394b8dba4f2022f71b47ca_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOjg1YThiMWU5YmQ4YTQ4ODY5YTJmOGQwMDQ1NmEyYzMwL3RhYmxlcmFuZ2U6ODVhOGIxZTliZDhhNDg4NjlhMmY4ZDAwNDU2YTJjMzBfMi01LTEtMS02NjkxMA_44705ffd-0365-4f1e-b999-9ce989905cf2"
      unitRef="shares">1067000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i5a875e7e581644ddb5ae0ea1dd6d828d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOjg1YThiMWU5YmQ4YTQ4ODY5YTJmOGQwMDQ1NmEyYzMwL3RhYmxlcmFuZ2U6ODVhOGIxZTliZDhhNDg4NjlhMmY4ZDAwNDU2YTJjMzBfMi03LTEtMS02NjkxMA_b8dfef62-caab-4861-a274-91cea36b158d"
      unitRef="shares">1162000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i647fb470e87444d6a627e33d5d70965b_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOjg1YThiMWU5YmQ4YTQ4ODY5YTJmOGQwMDQ1NmEyYzMwL3RhYmxlcmFuZ2U6ODVhOGIxZTliZDhhNDg4NjlhMmY4ZDAwNDU2YTJjMzBfMy0xLTEtMS02NjkxMA_3f9a05d0-9f5c-4c76-8e28-c3b647dceb07"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ide5f51cc3ef84de6a0fd4b47abd3c1e8_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOjg1YThiMWU5YmQ4YTQ4ODY5YTJmOGQwMDQ1NmEyYzMwL3RhYmxlcmFuZ2U6ODVhOGIxZTliZDhhNDg4NjlhMmY4ZDAwNDU2YTJjMzBfMy0zLTEtMS02NjkxMA_2642b91a-7bcf-4db8-89a0-7fffcb5d7c52"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idcffb900db284c32b9e3d8cb934a505f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOjg1YThiMWU5YmQ4YTQ4ODY5YTJmOGQwMDQ1NmEyYzMwL3RhYmxlcmFuZ2U6ODVhOGIxZTliZDhhNDg4NjlhMmY4ZDAwNDU2YTJjMzBfMy01LTEtMS02NjkxMA_09e68e83-00fc-4bf8-bf29-3d80923b2a97"
      unitRef="shares">479000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="iee1649a9b5bf47f7917cfe5843b5b4a8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184NS9mcmFnOjIzYjQ2YWNiZjllZjQyZGFiZDBkNTcwNzAwYjhmYjg5L3RhYmxlOjg1YThiMWU5YmQ4YTQ4ODY5YTJmOGQwMDQ1NmEyYzMwL3RhYmxlcmFuZ2U6ODVhOGIxZTliZDhhNDg4NjlhMmY4ZDAwNDU2YTJjMzBfMy03LTEtMS02NjkxMA_3761510b-618b-43c8-a5e5-f1cab7ce049c"
      unitRef="shares">319000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMTYwNw_1c6c2b1f-6eb0-45b9-8a77-3012020f95ce">Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For interim periods, we recognize an income tax provision (benefit) based on our estimated annual effective tax rate expected for the full year, adjusted for discrete items recognized during the interim period. Discrete items (e.g., significant or unusual items) are separately recognized in the quarter during which they occur and can cause the effective tax rate to vary from quarter to quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;An income tax benefit of $(45.5)&#160;million and $(44.5)&#160;million and was recognized for the three and nine months ended September 30, 2022, respectively, which resulted in effective tax rates of 104.9% and 85.8%, respectively. An income tax expense of $0.2&#160;million and $0.9&#160;million was recognized for the three and nine months ended September 30, 2021, respectively, which resulted in effective tax rates of (1.8)% and (2.9)%, respectively. The Company and its U.S. subsidiaries continue to record a valuation allowance against its net deferred tax assets, with the exception of indefinite lived components. The income tax benefit recorded during the three and nine months ended September 30, 2022 primarily relates to the $46.8&#160;million reduction in the valuation allowance resulting from deferred tax liabilities established as part of the IPG acquisition accounting, partially offset by state and foreign taxes. The income tax expense recorded during the three and nine months ended September 30, 2021, primarily relates to foreign taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2021, the Company had unrecognized tax benefits of $0.6 million that, if recognized, would not affect the effective tax rate due to the valuation allowance against its net deferred tax asset. As of September 30, 2022, the Company has additional unrecognized tax benefits of $0.4&#160;million that, if recognized, would affect the effective tax rate. The Company is not currently subject to income tax audits in any U.S., state, or foreign jurisdictions for any tax year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Receivables Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Offering Reorganization, the Company entered into the TRA with certain of its investors, which provides for the payment by the Company to these investors of 85% of the amount of the tax benefits, if any, that the Company is deemed to realize as a result of increases in our tax basis related to exchanges of Class B common units as well as tax benefits attributable to the future utilization of pre-IPO NOLs. See Note 11 above for discussion of our TRA.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMjEw_009f1efe-7f5e-44be-8f6f-504af2ec0e7c"
      unitRef="usd">-45500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMjE3_7faa7a94-2c89-4075-a3c5-9cf3b9f90f16"
      unitRef="usd">-44500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMzI5ODUzNDg4NzY5Nw_f34a02cf-cc8c-43da-94e3-da280e3c3bc7"
      unitRef="number">1.049</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMzI5ODUzNDg4NzcwNQ_49b0951f-0fa8-4056-b072-f4ee41f5b388"
      unitRef="number">0.858</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMzYy_f471ec16-d05a-48b8-9b85-23e04a1dd377"
      unitRef="usd">200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMzY5_408c62fb-5c9b-449c-9cdb-a9024f793d07"
      unitRef="usd">900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMzI5ODUzNDg4NzcxMg_c01e5088-a393-4618-b9cb-2dfbb5e274f8"
      unitRef="number">-0.018</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMzI5ODUzNDg4NzcyMA_ca0393a0-02f7-45ba-9c59-df17981ade67"
      unitRef="number">-0.029</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMTA5OTUxMTYyODIxNzQ_32380c11-d002-4281-814b-322d5fc877cf"
      unitRef="usd">46800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMTA5OTUxMTYyODIxNzQ_d4b90e54-3119-48f0-bc72-24a23d029f60"
      unitRef="usd">46800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfNzg1_aa6ca4b9-227a-45b7-9b94-9d427c92ecc8"
      unitRef="usd">600000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfNTQ5NzU1ODE4MDgw_ded24e86-ecda-45eb-9597-5ded0cff82ad"
      unitRef="usd">400000</us-gaap:UnrecognizedTaxBenefits>
    <evh:TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184OC9mcmFnOjQzZmRmZTYyNDQyNTQxYzE5YWE4MjdhMDIyYzY0YzllL3RleHRyZWdpb246NDNmZGZlNjI0NDI1NDFjMTlhYTgyN2EwMjJjNjRjOWVfMTMxMA_ede6fcdb-0a5e-4c92-a71c-e9b2f55069b1"
      unitRef="number">0.85</evh:TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMjE5MQ_75b51e12-c739-4c64-a797-f685aba0b047">Investments in Equity Method InvesteesThe Company holds ownership interests in joint ventures and other entities which are accounted for under the equity method. The Company evaluates its interests in these entities to determine whether they meet the definition of a VIE and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both (i) the power to direct the activities that most significantly impact the economic performance of the VIE and (ii) a variable interest that could potentially be significant to the VIE. To determine whether or not a variable interest the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company's involvement with the VIE. The Company has determined that its interests in these entities meet the definition of a variable &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;interest, however, the Company is not the primary beneficiary since it does not have the power to direct activities, therefore, the Company did not consolidate the VIEs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;September&#160;30, 2022 and December&#160;31, 2021, the Company&#x2019;s economic interests in its equity method investments ranged between 4% and 38% and 4% and 39%, respectively, and voting interests in its equity method investments ranged between 25% and 40%, respectively. The Company determined that it has significant influence over these entities but that it does not have control over any of the entities. Accordingly, the investments are accounted for under the equity method of accounting and the Company is allocated its proportional share of the entities&#x2019; earnings and losses for each reporting period. The Company&#x2019;s proportional share of the gain from these investments was approximately $1.4 million and $3.9 million for the three and nine months ended September 30, 2022, respectively, and $0.1 million and $12.7 million for the three and nine months ended September 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company signed services agreements with certain of the aforementioned entities to provide certain management, operational and support services to help manage elements of their service offerings. Revenue related to these services agreements were $5.0 million and $12.5 million for the three and nine months ended September 30, 2022, respectively, and $4.0 million and $12.6 million for the three and nine months ended September 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="i595e611ec9ae489dbce4f7eda441f246_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTI0NA_87ea46dd-d3cf-463c-be0d-1af733b12e29"
      unitRef="number">0.04</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="i7eda68985c9842cdaf3b26312b15d4c2_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTI1MQ_aa1e05ec-e3d3-4962-a2eb-ca7b3d1050b5"
      unitRef="number">0.38</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="if02fc4db2c9b4fa8b2f8b4664e01eea1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTI1OA_405ae3cb-b6a1-45cc-866e-eb2e9c4a1226"
      unitRef="number">0.04</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentEconomicInterestPercentage
      contextRef="i277f0bf297354d94af61e257c3ec7ff7_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTI2NQ_b7afa911-bcef-4c0a-b8cb-fb24cc1a8a96"
      unitRef="number">0.39</evh:EquityMethodInvestmentEconomicInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="i595e611ec9ae489dbce4f7eda441f246_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTM1Mg_0405e20a-4b2b-40de-afb5-c6d4d4a263ed"
      unitRef="number">0.25</evh:EquityMethodInvestmentVotingInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="if02fc4db2c9b4fa8b2f8b4664e01eea1_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTM1Mg_90264cca-f456-43e0-a02a-29114e8946e3"
      unitRef="number">0.25</evh:EquityMethodInvestmentVotingInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="i7eda68985c9842cdaf3b26312b15d4c2_I20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTM1OQ_5177940d-6e0c-4107-8b09-719c4f633380"
      unitRef="number">0.40</evh:EquityMethodInvestmentVotingInterestPercentage>
    <evh:EquityMethodInvestmentVotingInterestPercentage
      contextRef="i277f0bf297354d94af61e257c3ec7ff7_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTM1OQ_f0ef8058-59e9-455b-be19-7397e846ee51"
      unitRef="number">0.40</evh:EquityMethodInvestmentVotingInterestPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTgwMQ_7739a3c9-8e47-4f50-9bbe-9f121eedd433"
      unitRef="usd">1400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTgwOA_52219cca-dc2f-4445-8e6a-43a5ce1d28be"
      unitRef="usd">3900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTgzNw_83ca4237-efb5-4a36-8a62-5a8d69572c9b"
      unitRef="usd">100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMTg0NA_b134175f-9d25-4610-b656-8331030b48c7"
      unitRef="usd">12700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement
      contextRef="iebd3f639166d44039bd8edc98238a383_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMjExOQ_229f8612-011f-4076-a082-c97fdea5e527"
      unitRef="usd">5000000</evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement>
    <evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement
      contextRef="id4b322c66f3e45b08685a4ae028887d8_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMjEyNg_3bf8388d-f44f-4fae-87b9-a4f2275d181f"
      unitRef="usd">12500000</evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement>
    <evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement
      contextRef="i396bb0edd68c430189127d5633e8e1a4_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMjE1NQ_d10688e3-7a9e-4d0a-96a5-8704a53a7e20"
      unitRef="usd">4000000</evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement>
    <evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement
      contextRef="i2240a4a6255943e4bf456dfd07e73621_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185MS9mcmFnOjU0MDFkMmIwYTI1MjQ0MWQ4YjcwZDcyMWFmZDVhMDM4L3RleHRyZWdpb246NTQwMWQyYjBhMjUyNDQxZDhiNzBkNzIxYWZkNWEwMzhfMjE2Mg_15d42def-7043-4500-af45-74f6417d5499"
      unitRef="usd">12600000</evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGV4dHJlZ2lvbjphNWY5MTFjNThlOGI0OTU5YjUwN2JkOGY3Mzc2NTc2MF8zMjk4NTM0ODg5MDUy_94fa398f-ad3b-47ac-a3e1-8a69c8fb125d">Fair Value Measurement&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Fair Value Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGV4dHJlZ2lvbjphNWY5MTFjNThlOGI0OTU5YjUwN2JkOGY3Mzc2NTc2MF8zMjk4NTM0ODg5MDUz_3aff9ff4-824e-48b2-850f-dc2ed5a02d4a">Fair Value Measurement&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) assuming an orderly transaction in the most advantageous market at the measurement date. GAAP also establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - inputs to the valuation methodology are quoted prices available in active markets for identical instruments as of the reporting date;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - inputs to the valuation methodology are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date and the fair value can be determined through the use of models or other valuation methodologies; and &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - inputs to the valuation methodology are unobservable inputs in situations where there is little or no market activity for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the particular asset or liability being measured. These items are recorded in accrued liabilities on our consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with GAAP, certain assets and liabilities are required to be recorded at fair value on a recurring basis. The following table summarizes the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents the fair value of earn-out consideration related to the IPG and Vital transactions as described in Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes any transfers between levels within the hierarchy as of the beginning of the reporting period. There were no transfers between fair value levels during the three and nine months ended September 30, 2022 and 2021, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the absence of observable market prices, the fair value is based on the best information available and involves a significant degree of judgment, taking into consideration a combination of internal and external factors, including the appropriate risk adjustments for non-performance and liquidity risks.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 4, the acquisitions of IPG and Vital Decisions include a provision for additional equity consideration, at the Company&#x2019;s option, contingent upon the Company obtaining certain performance metrics. The earnout period for the Vital Decisions contingent considering is the three months ending December 31, 2022, and the earnout periods for IPG are the four months ended December 31, 2022 and the nine months ended September 30, 2023. The fair value of the contingent equity considerations was estimated based on the real options approach, a form of the income approach, which estimated the probability of the Company achieving future revenues under the agreement. The significant unobservable inputs used in the fair value measurements of the IPG and Vital Decisions contingent considerations are the risk-neutral (probability weighted) earnout consideration and the applicable discount rate. A significant increase in the risk-neutral (probability weighted) earnout consideration or decrease in discount rate in isolation would result in a significantly higher fair value of the contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gain, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nonrecurring Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the assets and liabilities that are recorded at fair value on a recurring basis, the Company records certain assets and liabilities at fair value on a nonrecurring basis as required by GAAP. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges. This includes assets and liabilities recorded in business combinations or asset acquisitions, goodwill, intangible assets, property, plant and equipment, held-to-maturity investments and equity method investments. While not carried at fair value on a recurring basis, these items are continually monitored for indicators of impairment that would indicate current carrying value is greater than fair value. In those situations, the assets are considered impaired and written down to current fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Fair Value Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and cash equivalents (those not held in a money market fund), restricted cash, receivables, prepaid expenses, accounts payable, accrued liabilities and accrued compensation approximate their fair values because of the relatively short-term maturities of these items and financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 10 for information regarding the fair value of the 2024 Notes and 2025 Notes.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGV4dHJlZ2lvbjphNWY5MTFjNThlOGI0OTU5YjUwN2JkOGY3Mzc2NTc2MF8zMjk4NTM0ODg5MDU0_fe61535c-5d86-4c25-9aa9-77a8095141da">The following table summarizes the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis (in thousands): &lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:325.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total fair value of liabilities measured on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Represents the fair value of earn-out consideration related to the IPG and Vital transactions as described in Note 4.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if1d99a70db5f43208858b7f0f954c2d1_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTBlZGY2MWM1NTVkNGY1YWFlZDM2YjA5ZjJlYmNlMDkvdGFibGVyYW5nZTo1MGVkZjYxYzU1NWQ0ZjVhYWVkMzZiMDlmMmViY2UwOV8zLTEtMS0xLTc0ODAy_d377e277-b26e-4457-8539-6c3561f50d19"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4e61be204d694c09879235c63a790f71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTBlZGY2MWM1NTVkNGY1YWFlZDM2YjA5ZjJlYmNlMDkvdGFibGVyYW5nZTo1MGVkZjYxYzU1NWQ0ZjVhYWVkMzZiMDlmMmViY2UwOV8zLTMtMS0xLTc0ODAy_c5ba6073-8b72-4ea2-a693-24790a87779f"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7bc89218c26643328b21b1506819b3a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTBlZGY2MWM1NTVkNGY1YWFlZDM2YjA5ZjJlYmNlMDkvdGFibGVyYW5nZTo1MGVkZjYxYzU1NWQ0ZjVhYWVkMzZiMDlmMmViY2UwOV8zLTUtMS0xLTc0ODAy_3745a046-d2f3-4a3e-9039-a67008754088"
      unitRef="usd">95700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i88c58b8bf6804181b9ae7aa0ce6fa7e0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTBlZGY2MWM1NTVkNGY1YWFlZDM2YjA5ZjJlYmNlMDkvdGFibGVyYW5nZTo1MGVkZjYxYzU1NWQ0ZjVhYWVkMzZiMDlmMmViY2UwOV8zLTctMS0xLTc0ODAy_8b38c9e4-3aad-4d99-95a6-f651c7bc0253"
      unitRef="usd">95700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if1d99a70db5f43208858b7f0f954c2d1_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTBlZGY2MWM1NTVkNGY1YWFlZDM2YjA5ZjJlYmNlMDkvdGFibGVyYW5nZTo1MGVkZjYxYzU1NWQ0ZjVhYWVkMzZiMDlmMmViY2UwOV80LTEtMS0xLTc0ODAy_bbe7d6b5-c5bc-4a61-9f72-87643dfff1db"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4e61be204d694c09879235c63a790f71_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTBlZGY2MWM1NTVkNGY1YWFlZDM2YjA5ZjJlYmNlMDkvdGFibGVyYW5nZTo1MGVkZjYxYzU1NWQ0ZjVhYWVkMzZiMDlmMmViY2UwOV80LTMtMS0xLTc0ODAy_030a37ad-7128-4de0-a451-f185d26766df"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7bc89218c26643328b21b1506819b3a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTBlZGY2MWM1NTVkNGY1YWFlZDM2YjA5ZjJlYmNlMDkvdGFibGVyYW5nZTo1MGVkZjYxYzU1NWQ0ZjVhYWVkMzZiMDlmMmViY2UwOV80LTUtMS0xLTc0ODAy_d9ffefb3-9a1f-4cf5-b46d-88d98a72b9ff"
      unitRef="usd">95700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i88c58b8bf6804181b9ae7aa0ce6fa7e0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTBlZGY2MWM1NTVkNGY1YWFlZDM2YjA5ZjJlYmNlMDkvdGFibGVyYW5nZTo1MGVkZjYxYzU1NWQ0ZjVhYWVkMzZiMDlmMmViY2UwOV80LTctMS0xLTc0ODAy_2864e523-3353-4e7c-9e4a-7a15d4b40c7f"
      unitRef="usd">95700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i328717c857f2404dba9ba20b9433ea18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTNjYjczNGQ4ODg3NGI1N2ExMGEyYjBkYzhlMjMxOGEvdGFibGVyYW5nZTo1M2NiNzM0ZDg4ODc0YjU3YTEwYTJiMGRjOGUyMzE4YV8zLTEtMS0xLTc0ODAy_fafd1b2c-03dd-472f-99b0-810c83f9aa36"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id142ae030d514564a81b2bb1eadfeaba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTNjYjczNGQ4ODg3NGI1N2ExMGEyYjBkYzhlMjMxOGEvdGFibGVyYW5nZTo1M2NiNzM0ZDg4ODc0YjU3YTEwYTJiMGRjOGUyMzE4YV8zLTMtMS0xLTc0ODAy_fea7124a-d38f-486a-aa83-86da7c30dcfe"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i867837f495ba4b65886161a03a0def38_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTNjYjczNGQ4ODg3NGI1N2ExMGEyYjBkYzhlMjMxOGEvdGFibGVyYW5nZTo1M2NiNzM0ZDg4ODc0YjU3YTEwYTJiMGRjOGUyMzE4YV8zLTUtMS0xLTc0ODAy_a4da73cc-0cad-4c7f-bcbb-065b2ea0cd97"
      unitRef="usd">28700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9c1e69c3b48346c3b0514ad1ccceb5f8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTNjYjczNGQ4ODg3NGI1N2ExMGEyYjBkYzhlMjMxOGEvdGFibGVyYW5nZTo1M2NiNzM0ZDg4ODc0YjU3YTEwYTJiMGRjOGUyMzE4YV8zLTctMS0xLTc0OTQ0_b1f05b1f-0139-4ec2-817e-ec3126c83f1a"
      unitRef="usd">28700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i328717c857f2404dba9ba20b9433ea18_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTNjYjczNGQ4ODg3NGI1N2ExMGEyYjBkYzhlMjMxOGEvdGFibGVyYW5nZTo1M2NiNzM0ZDg4ODc0YjU3YTEwYTJiMGRjOGUyMzE4YV80LTEtMS0xLTc0ODAy_bce6f1c0-94cc-444a-9417-739837374228"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id142ae030d514564a81b2bb1eadfeaba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTNjYjczNGQ4ODg3NGI1N2ExMGEyYjBkYzhlMjMxOGEvdGFibGVyYW5nZTo1M2NiNzM0ZDg4ODc0YjU3YTEwYTJiMGRjOGUyMzE4YV80LTMtMS0xLTc0ODAy_f137315c-4bf3-46cf-bd09-a2ebbf606f31"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i867837f495ba4b65886161a03a0def38_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTNjYjczNGQ4ODg3NGI1N2ExMGEyYjBkYzhlMjMxOGEvdGFibGVyYW5nZTo1M2NiNzM0ZDg4ODc0YjU3YTEwYTJiMGRjOGUyMzE4YV80LTUtMS0xLTc0ODAy_37a1b184-3d35-4751-8044-68350081d0b7"
      unitRef="usd">28700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9c1e69c3b48346c3b0514ad1ccceb5f8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6NTNjYjczNGQ4ODg3NGI1N2ExMGEyYjBkYzhlMjMxOGEvdGFibGVyYW5nZTo1M2NiNzM0ZDg4ODc0YjU3YTEwYTJiMGRjOGUyMzE4YV80LTctMS0xLTc0ODAy_fec6a459-ea31-4853-b8ae-f4fc77cbc76a"
      unitRef="usd">28700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGV4dHJlZ2lvbjphNWY5MTFjNThlOGI0OTU5YjUwN2JkOGY3Mzc2NTc2MF8zMjk4NTM0ODg5MDU1_80d3283d-ed4b-47ce-8bf3-8e554e77209c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in our liabilities measured at fair value for which the Company uses Level 3 inputs to determine fair value are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized gain, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OGQ4OGVkZGM1OGY1NDE5MTgxZWI3Mjc2NmZhNmE3NWUvdGFibGVyYW5nZTo4ZDg4ZWRkYzU4ZjU0MTkxODFlYjcyNzY2ZmE2YTc1ZV8yLTEtMS0xLTc0ODAy_9ed744fa-615b-4d43-9af4-058fadc3ee13"
      unitRef="usd">28700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="idcb7e5d5de6d4fb9bd1b47d49e170108_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OGQ4OGVkZGM1OGY1NDE5MTgxZWI3Mjc2NmZhNmE3NWUvdGFibGVyYW5nZTo4ZDg4ZWRkYzU4ZjU0MTkxODFlYjcyNzY2ZmE2YTc1ZV8yLTMtMS0xLTc0ODAy_f1595d0a-531d-4900-862f-f5be05c16eb8"
      unitRef="usd">13730000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OGQ4OGVkZGM1OGY1NDE5MTgxZWI3Mjc2NmZhNmE3NWUvdGFibGVyYW5nZTo4ZDg4ZWRkYzU4ZjU0MTkxODFlYjcyNzY2ZmE2YTc1ZV8zLTEtMS0xLTc0ODAy_d2bf8946-c43e-4fa5-b9dc-da526a19a17b"
      unitRef="usd">75000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OGQ4OGVkZGM1OGY1NDE5MTgxZWI3Mjc2NmZhNmE3NWUvdGFibGVyYW5nZTo4ZDg4ZWRkYzU4ZjU0MTkxODFlYjcyNzY2ZmE2YTc1ZV8zLTMtMS0xLTc0ODAy_f654655b-62f3-4bc2-a55d-45e63e3972be"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OGQ4OGVkZGM1OGY1NDE5MTgxZWI3Mjc2NmZhNmE3NWUvdGFibGVyYW5nZTo4ZDg4ZWRkYzU4ZjU0MTkxODFlYjcyNzY2ZmE2YTc1ZV80LTEtMS0xLTc0ODAy_e3b35051-459e-49e0-a6f9-ec853b127a8b"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OGQ4OGVkZGM1OGY1NDE5MTgxZWI3Mjc2NmZhNmE3NWUvdGFibGVyYW5nZTo4ZDg4ZWRkYzU4ZjU0MTkxODFlYjcyNzY2ZmE2YTc1ZV80LTMtMS0xLTc0ODAy_9a847713-0bee-4d34-a74e-f30edbfd2821"
      unitRef="usd">13730000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OGQ4OGVkZGM1OGY1NDE5MTgxZWI3Mjc2NmZhNmE3NWUvdGFibGVyYW5nZTo4ZDg4ZWRkYzU4ZjU0MTkxODFlYjcyNzY2ZmE2YTc1ZV81LTEtMS0xLTc0ODAy_0c81ca24-0f6f-4d36-a5f0-0544bd5d320c"
      unitRef="usd">8000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OGQ4OGVkZGM1OGY1NDE5MTgxZWI3Mjc2NmZhNmE3NWUvdGFibGVyYW5nZTo4ZDg4ZWRkYzU4ZjU0MTkxODFlYjcyNzY2ZmE2YTc1ZV81LTMtMS0xLTc0ODAy_1224de57-a6d1-4025-ba75-44ffe6b98844"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OGQ4OGVkZGM1OGY1NDE5MTgxZWI3Mjc2NmZhNmE3NWUvdGFibGVyYW5nZTo4ZDg4ZWRkYzU4ZjU0MTkxODFlYjcyNzY2ZmE2YTc1ZV82LTEtMS0xLTc0ODAy_b459ea44-5750-404e-a1c4-bec045a9d8b5"
      unitRef="usd">95700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i63b3ddd7486946c2a0a8151832317d14_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OGQ4OGVkZGM1OGY1NDE5MTgxZWI3Mjc2NmZhNmE3NWUvdGFibGVyYW5nZTo4ZDg4ZWRkYzU4ZjU0MTkxODFlYjcyNzY2ZmE2YTc1ZV82LTMtMS0xLTc0ODAy_4ec9b714-30da-4fbd-9ed9-9a05914b110e"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGV4dHJlZ2lvbjphNWY5MTFjNThlOGI0OTU5YjUwN2JkOGY3Mzc2NTc2MF8zMjk4NTM0ODg5MDU2_dabb7fb3-3640-48c4-b027-3a4434b55d49">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value (in thousands), valuation techniques and significant unobservable inputs of our Level 3 fair value measurements as of the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.205%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.821%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assumption or&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Input Ranges&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Real options approach&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-neutral expected earnout consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7bc89218c26643328b21b1506819b3a0_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6Zjg4N2FiOTNhOWNlNDU5ZTkwNDc4NjUzMTZhN2U3MzMvdGFibGVyYW5nZTpmODg3YWI5M2E5Y2U0NTllOTA0Nzg2NTMxNmE3ZTczM18zLTEtMS0xLTc0OTUw_26c631ad-df5f-4194-884f-4c685d878031"
      unitRef="usd">95700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ib5a543708cce4e1587fc2f618e7c92b7_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6Zjg4N2FiOTNhOWNlNDU5ZTkwNDc4NjUzMTZhN2U3MzMvdGFibGVyYW5nZTpmODg3YWI5M2E5Y2U0NTllOTA0Nzg2NTMxNmE3ZTczM18zLTctMS0xLTc0OTUw_47b3e0f9-a6e2-4b4b-971e-2437d21e6be6"
      unitRef="usd">95699000</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i28495d82fa994f08b28b8dfc1e3a47e6_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6Zjg4N2FiOTNhOWNlNDU5ZTkwNDc4NjUzMTZhN2U3MzMvdGFibGVyYW5nZTpmODg3YWI5M2E5Y2U0NTllOTA0Nzg2NTMxNmE3ZTczM180LTctMS0xLTc0OTUw_61fc7008-a03e-42a4-9266-37907f64f279"
      unitRef="number">0.122</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i867837f495ba4b65886161a03a0def38_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OTZjNWQ5MDQ3M2ZmNDYxNGFmNmI1MzUxYTUyODJiN2MvdGFibGVyYW5nZTo5NmM1ZDkwNDczZmY0NjE0YWY2YjUzNTFhNTI4MmI3Y18zLTEtMS0xLTc0OTUy_86624291-67e1-453b-b42b-70b17caeb462"
      unitRef="usd">28700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ibd65a2db6ad04df8b047a7d81b2023ee_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OTZjNWQ5MDQ3M2ZmNDYxNGFmNmI1MzUxYTUyODJiN2MvdGFibGVyYW5nZTo5NmM1ZDkwNDczZmY0NjE0YWY2YjUzNTFhNTI4MmI3Y18zLTctMS0xLTc0OTUy_86e5b232-8ae3-4129-bf14-d746683381b9"
      unitRef="usd">30935000</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i30e706fd844d4e009a8b34652d74f93b_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yMzE2L2ZyYWc6YTVmOTExYzU4ZThiNDk1OWI1MDdiZDhmNzM3NjU3NjAvdGFibGU6OTZjNWQ5MDQ3M2ZmNDYxNGFmNmI1MzUxYTUyODJiN2MvdGFibGVyYW5nZTo5NmM1ZDkwNDczZmY0NjE0YWY2YjUzNTFhNTI4MmI3Y180LTctMS0xLTc0OTUy_591d95e8-9590-4d14-9bd6-7a4d5f1a3507"
      unitRef="number">0.0604</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RleHRyZWdpb246OTkyNjg0NjEzNWViNDc1YTg3NGU4Mjc2ZjNhZmFjZDZfMTE3NA_399b75a6-feec-41d0-b8f8-eedd5dcbd6ef">Related Parties  &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The entities described below are considered related parties and the balances and/or transactions with them are reported in our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As discussed in Note&#160;16, the Company had economic interests in several entities that are accounted for under the equity method of accounting. The Company has allocated its proportional share of the investees&#x2019; earnings and losses each reporting period. In addition, Evolent has entered into services agreements with certain of the entities to provide certain management, operational and support services to help the entities manage elements of their service offerings. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also works with UPMC, one of its founding investors. The Company&#x2019;s relationship with UPMC is a subcontractor relationship where UPMC has agreed to execute certain tasks (primarily TPA services) relating to certain customer commitments. This relationship is currently in wind-down.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents assets and liabilities attributable to our related parties (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenues and expenses attributable to our related parties (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:319.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:49.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:49.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:49.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RleHRyZWdpb246OTkyNjg0NjEzNWViNDc1YTg3NGU4Mjc2ZjNhZmFjZDZfMTE3Ng_0ee7ea29-f009-4a81-9916-f7ce3c150392">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents assets and liabilities attributable to our related parties (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.872%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.494%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve for claims and performance-based arrangements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenues and expenses attributable to our related parties (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:319.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:49.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:49.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:49.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:54.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of revenue (exclusive of depreciation and amortization expenses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="idb038b091b7344c29e48adca13ed03ae_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfMi0xLTEtMS02NjkxMA_08c2e60b-8c3f-4bbe-83fc-d7b0063d6c9e"
      unitRef="usd">10752000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6387c494ab8746e7b6c8beed248da58e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfMi0zLTEtMS02NjkxMA_3ad3eb98-b45d-4bdc-9a10-34e272eb84a4"
      unitRef="usd">2719000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="idb038b091b7344c29e48adca13ed03ae_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfMy0xLTEtMS02NjkxMA_53021713-5b6c-420a-8f2b-fa58b48827a3"
      unitRef="usd">0</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6387c494ab8746e7b6c8beed248da58e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfMy0zLTEtMS02NjkxMA_20ae3468-8d5b-497e-9441-1eb6ecd0cc7e"
      unitRef="usd">15000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="idb038b091b7344c29e48adca13ed03ae_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfNC0xLTEtMS02NjkxMA_f5b51c4c-8b66-4ab2-84c2-06bd51b7b4ed"
      unitRef="usd">884000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent
      contextRef="i6387c494ab8746e7b6c8beed248da58e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfNC0zLTEtMS02NjkxMA_4a44b13e-c071-4da4-9389-5b90ecdaa76d"
      unitRef="usd">4877000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="idb038b091b7344c29e48adca13ed03ae_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfNy0xLTEtMS02NjkxMA_719eb63f-2c06-4b85-9f9b-9c97f2c77275"
      unitRef="usd">432000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6387c494ab8746e7b6c8beed248da58e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfNy0zLTEtMS02NjkxMA_e5912507-033d-431a-a07f-dc3cb2111d3f"
      unitRef="usd">1967000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="idb038b091b7344c29e48adca13ed03ae_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfOC0xLTEtMS02NjkxMA_58aa18ad-5924-4515-8d90-9c7e08e8273a"
      unitRef="usd">954000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i6387c494ab8746e7b6c8beed248da58e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfOC0zLTEtMS02NjkxMA_9630fc12-6e22-44ce-9fcf-375789b2fa19"
      unitRef="usd">1120000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="idb038b091b7344c29e48adca13ed03ae_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfOS0xLTEtMS02NjkxMA_bb03de77-0d99-44c9-aa71-910233c62bc5"
      unitRef="usd">0</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i6387c494ab8746e7b6c8beed248da58e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjI5MTk3ODU4NGYxMTQ2NGViZTk4YWY1MDZkNDBkZThhL3RhYmxlcmFuZ2U6MjkxOTc4NTg0ZjExNDY0ZWJlOThhZjUwNmQ0MGRlOGFfOS0zLTEtMS02NjkxMA_a8f6f7bc-6aed-4d95-a397-0149e3fd01e0"
      unitRef="usd">734000</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:RevenueFromRelatedParties
      contextRef="ie08f13f16382418ea5ec290830f60d8c_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfMi0xLTEtMS02NjkxMA_40a91c7a-2d48-4648-91d7-a77f52089951"
      unitRef="usd">36321000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i12e6f929d457432287e5c6cd1f183f5f_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfMi0zLTEtMS02NjkxMA_ba1caec4-c74b-4c28-914d-0231c4e517e3"
      unitRef="usd">9775000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="ic5df79eb68c444ab9cb77a56bf677989_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfMi01LTEtMS02NjkxMA_785724da-d4b5-4061-829b-c077b45495cd"
      unitRef="usd">111195000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i6cace99351664c7ca949a3e0200ac20d_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfMi03LTEtMS02NjkxMA_a5ccae19-0bf6-4f44-9fef-95b3a2afd86e"
      unitRef="usd">35718000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i60fada84ac4946cb9b4e805a57e3cf0b_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfNS0xLTEtMS02NjkxMA_ece5d465-47cf-4023-8b0f-811ebb17d0a9"
      unitRef="usd">30121000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ic9bdab906b4a4d49a48fe38f018eb8bc_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfNS0zLTEtMS02NjkxMA_d30a06cc-e429-43c3-991c-a7bf0ae839e1"
      unitRef="usd">751000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i4a5ea59bbc694c93968f7c1ff417d386_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfNS01LTEtMS02NjkxMA_303bd1be-6789-4028-b699-fc29b0bbb4a2"
      unitRef="usd">93266000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i5d139443bb3e4ce086f6d2c6a7b557b2_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfNS03LTEtMS02NjkxMA_b9a2b6e7-11e5-470d-9d72-be63cd68383c"
      unitRef="usd">1850000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i73540c5f613d403b832d91b574a59f07_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfNi0xLTEtMS02NjkxMA_17bd9dd7-ef18-4ed1-a59e-9a119fab9ac0"
      unitRef="usd">443000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ice64acee7f3f46179553cd75809b106f_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfNi0zLTEtMS02NjkxMA_efde17ff-233b-4599-8988-a97190913a90"
      unitRef="usd">74000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ic86b2c3d20a443a49da566ae4eaf14cd_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfNi01LTEtMS02NjkxMA_8c0741b9-80ac-4c71-a78f-5f11493ec7ae"
      unitRef="usd">745000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ia91f376f9d6846eb84ca11a8a358cf74_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM185Ny9mcmFnOjk5MjY4NDYxMzVlYjQ3NWE4NzRlODI3NmYzYWZhY2Q2L3RhYmxlOjk4ZDk3MTVkYjIyODRkZDA5NDFjY2Q3OTlkN2FhZWNkL3RhYmxlcmFuZ2U6OThkOTcxNWRiMjI4NGRkMDk0MWNjZDc5OWQ3YWFlY2RfNi03LTEtMS02NjkxMA_6a86a354-bc84-4a1e-9949-41055ad9d7ee"
      unitRef="usd">186000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDAvZnJhZzplMTQ2MjMwNThlYjQ0NjgyYmVjZDZiNTk5YTI4ZTc0Mi90ZXh0cmVnaW9uOmUxNDYyMzA1OGViNDQ2ODJiZWNkNmI1OTlhMjhlNzQyXzE0NjU_4e1a0319-b391-4cf0-b445-e8978241fd41">Repositioning and Other Changes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We continually assess opportunities to improve operational effectiveness and efficiency to better align our expenses with revenues, while continuing to make investments in our solutions, systems and people that we believe are important to our long-term goals. Across 2020, we divested or agreed to divest a majority of our health plan assets, including certain assets of EVH Passport, which represented a significant revenue stream for the Company. In parallel with these divestitures, we contracted with a third-party vendor to review our operating model and organizational design in order to improve our profitability, create value through our solutions and invest in strategic opportunities in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2020, we committed to certain operational efficiency and profitability actions that we are taking in order to accomplish these objectives (&#x201c;Repositioning Plan&#x201d;). These actions included making organizational changes across our business as well as other profitability initiatives expected to result in reductions in force, re-aligning of resources as well as other potential operational efficiency and cost-reduction initiatives that will provide future benefit to the Company. The Repositioning Plan concluded in the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of our total costs associated with the Repositioning Plan by major type of cost (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cumulative Costs Incurred through December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Incurred For the Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office space consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDAvZnJhZzplMTQ2MjMwNThlYjQ0NjgyYmVjZDZiNTk5YTI4ZTc0Mi90ZXh0cmVnaW9uOmUxNDYyMzA1OGViNDQ2ODJiZWNkNmI1OTlhMjhlNzQyXzE0NjQ_a06ce549-1ccc-4eb7-9fb3-1c3e20504ccc">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of our total costs associated with the Repositioning Plan by major type of cost (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.094%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cumulative Costs Incurred through December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Incurred For the Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office space consolidation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="ia6e2ba14bf4d472691df13b609cc514b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDAvZnJhZzplMTQ2MjMwNThlYjQ0NjgyYmVjZDZiNTk5YTI4ZTc0Mi90YWJsZTplODc5OWM0ZjdkYjk0NDM4OWJhNGFjMWVjM2IxYjkyZC90YWJsZXJhbmdlOmU4Nzk5YzRmN2RiOTQ0Mzg5YmE0YWMxZWMzYjFiOTJkXzEtMS0xLTEtNjY5MTA_386c6142-a1e0-405e-abfa-574a6d45312a"
      unitRef="usd">185000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="ie38f3231de914c44a9c3146fc55eb3b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDAvZnJhZzplMTQ2MjMwNThlYjQ0NjgyYmVjZDZiNTk5YTI4ZTc0Mi90YWJsZTplODc5OWM0ZjdkYjk0NDM4OWJhNGFjMWVjM2IxYjkyZC90YWJsZXJhbmdlOmU4Nzk5YzRmN2RiOTQ0Mzg5YmE0YWMxZWMzYjFiOTJkXzEtNS0xLTEtNjY5MTA_4d863d38-a8e7-4161-8be0-6167e806aa4d"
      unitRef="usd">185000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i3044ccef126a4375824fc8fc3a6c3ce3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDAvZnJhZzplMTQ2MjMwNThlYjQ0NjgyYmVjZDZiNTk5YTI4ZTc0Mi90YWJsZTplODc5OWM0ZjdkYjk0NDM4OWJhNGFjMWVjM2IxYjkyZC90YWJsZXJhbmdlOmU4Nzk5YzRmN2RiOTQ0Mzg5YmE0YWMxZWMzYjFiOTJkXzItMS0xLTEtNjY5MTA_2ed49512-7f68-4775-9c1c-ebc9dd443ede"
      unitRef="usd">2742000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="i91cfb2c56b99413c9fb95814cfb285f4_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDAvZnJhZzplMTQ2MjMwNThlYjQ0NjgyYmVjZDZiNTk5YTI4ZTc0Mi90YWJsZTplODc5OWM0ZjdkYjk0NDM4OWJhNGFjMWVjM2IxYjkyZC90YWJsZXJhbmdlOmU4Nzk5YzRmN2RiOTQ0Mzg5YmE0YWMxZWMzYjFiOTJkXzItNS0xLTEtNjY5MTA_d9144da4-82a9-4650-8823-84f83aa964b9"
      unitRef="usd">2071000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i3adb4e55cc4e45a7911caff2dbcc7a00_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDAvZnJhZzplMTQ2MjMwNThlYjQ0NjgyYmVjZDZiNTk5YTI4ZTc0Mi90YWJsZTplODc5OWM0ZjdkYjk0NDM4OWJhNGFjMWVjM2IxYjkyZC90YWJsZXJhbmdlOmU4Nzk5YzRmN2RiOTQ0Mzg5YmE0YWMxZWMzYjFiOTJkXzMtMS0xLTEtNjY5MTA_76e5f86e-8022-43de-ae78-12201478b8b4"
      unitRef="usd">5666000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="i3ed21b2abe494c07b71ec32367fb20d9_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDAvZnJhZzplMTQ2MjMwNThlYjQ0NjgyYmVjZDZiNTk5YTI4ZTc0Mi90YWJsZTplODc5OWM0ZjdkYjk0NDM4OWJhNGFjMWVjM2IxYjkyZC90YWJsZXJhbmdlOmU4Nzk5YzRmN2RiOTQ0Mzg5YmE0YWMxZWMzYjFiOTJkXzMtNS0xLTEtNjY5MTA_32a72054-8445-48ec-8626-7ca4d5cfe846"
      unitRef="usd">3787000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDAvZnJhZzplMTQ2MjMwNThlYjQ0NjgyYmVjZDZiNTk5YTI4ZTc0Mi90YWJsZTplODc5OWM0ZjdkYjk0NDM4OWJhNGFjMWVjM2IxYjkyZC90YWJsZXJhbmdlOmU4Nzk5YzRmN2RiOTQ0Mzg5YmE0YWMxZWMzYjFiOTJkXzQtMS0xLTEtNjY5MTA_e603de34-02bd-4aa7-a225-0315f93d15cb"
      unitRef="usd">8593000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringCharges
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDAvZnJhZzplMTQ2MjMwNThlYjQ0NjgyYmVjZDZiNTk5YTI4ZTc0Mi90YWJsZTplODc5OWM0ZjdkYjk0NDM4OWJhNGFjMWVjM2IxYjkyZC90YWJsZXJhbmdlOmU4Nzk5YzRmN2RiOTQ0Mzg5YmE0YWMxZWMzYjFiOTJkXzQtNS0xLTEtNjY5MTA_d356d476-612a-4947-9578-f492b87372c9"
      unitRef="usd">6043000</us-gaap:RestructuringCharges>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90ZXh0cmVnaW9uOmUzNTdjZjJjZWI1MDQ4MmFiNzMwNGMyZmNjZTBhNjA2XzMwODA_997d0a2c-b98e-4d32-bb96-68b03d041824">Segment Reporting&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We define our reportable segments based on the way the CODM, the chief executive officer, manages the operations for purposes of allocating resources and assessing performance. We classify our operations into two reportable segments as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Evolent Health Services, which houses our Administrative Simplification solution and certain supporting population health infrastructure; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt"&gt;Clinical Solutions, which includes our specialty care management and physician-oriented total cost of care solutions, along with the New Century Health and Evolent Care Partners brands. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, our reportable segments enter into transactions with one another. While intersegment transactions are treated like third-party transactions to determine segment performance, the revenues and expenses recognized by the segment that is the counterparty to the transaction are eliminated in consolidation and do not affect consolidated results.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CODM uses revenue in accordance with U.S. GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of our businesses and may be different than similarly-titled segment performance financial measures used by other companies. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Adjusted EBITDA is defined as net income (loss) attributable to common shareholders of Evolent Health, Inc. before interest income, interest expense, provision (benefit) for income taxes, depreciation and amortization expenses, adjusted to exclude gain on transfer of membership, loss on extinguishment/repayment of debt, net, gain from equity method investees, changes in fair value of contingent consideration, change in the tax receivable agreement liability, other income (expense), net, repositioning costs, stock-based compensation expense, severance costs, amortization of contract cost assets, strategy and shareholder advisory services, acquisition-related costs and gain (loss) from discontinued operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management considers revenue and Adjusted EBITDA to be the appropriate metrics to evaluate and compare the ongoing operating performance of our segments on a consistent basis across reporting periods as they eliminate the effect of items which are not indicative of each segment's core operating performance. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present our segment information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:327.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit from (provision for) income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(936)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax receivable agreement liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on transfer of membership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment/repayment of debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain from equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repositioning costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(996)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of contract cost assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strategy and shareholder advisory expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) from discontinued operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Includes $(0.5)&#160;million loss on disposal of discontinued operations for the nine months ended September 30, 2022 and $1.9&#160;million gain on disposal of discontinued operations for the nine months ended September 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset information by segment is not a key measure of performance used by the CODM. Accordingly, we have not disclosed asset information by segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90ZXh0cmVnaW9uOmUzNTdjZjJjZWI1MDQ4MmFiNzMwNGMyZmNjZTBhNjA2XzI0Mg_c6763688-a6b8-4053-967d-fc2ce601b195"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90ZXh0cmVnaW9uOmUzNTdjZjJjZWI1MDQ4MmFiNzMwNGMyZmNjZTBhNjA2XzMwNzY_b72625e2-b0f0-4a0a-840d-0cae57bfd597">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present our segment information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(458)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:145.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:52.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:60.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:61.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:67.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intersegment&lt;br/&gt;Eliminations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;659,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Evolent Health Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Consolidated Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,558)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Corporate includes various finance, human resources, legal, executive and other corporate infrastructure expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i806263fe61f14f33b5cdbd7eee333ff7_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzMtMS0xLTEtNjY5MTA_a15f5ed7-343f-47f1-b95f-4c60cbc4faa5"
      unitRef="usd">107033000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iacbe24e15241450eb5814aef67850f85_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzMtMy0xLTEtNjY5MTA_8e00e519-d988-4a53-bd8f-191e40be7a6e"
      unitRef="usd">245257000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib7b76ebaaef241a09456df69e9f56730_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzMtNS0xLTEtNjY5MTA_337d4b5c-6f56-4d5f-975b-3bf1bc0588fb"
      unitRef="usd">295000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id47a9c894a7d46569bed9ed6ad4e9987_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzMtNy0xLTEtNjY5MTA_3385a705-8762-4553-9668-6a220cf79811"
      unitRef="usd">352585000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie593e243a4f94ded8dcc0cbd2124556d_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzMtOS0xLTEtNjY5MTA_b00c13c9-cdbc-4e87-9aec-f5356f81dfbc"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzMtMTEtMS0xLTY2OTEw_6d0969e3-fe5f-4519-97b5-870a4d492108"
      unitRef="usd">352585000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e9c2f26074c434280c915a00ab6b2fe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzYtMS0xLTEtNjY5MTA_ff74aeb7-8c94-4c0c-b880-bddcbb6f50e1"
      unitRef="usd">63315000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26289f6ee3444cf484ed38a01409bbfe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzYtMy0xLTEtNjY5MTA_5faf0c04-bde5-427d-a7b2-8b4477f306bd"
      unitRef="usd">159614000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i338af69a6f0948e5a6b88db8f9f14704_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzYtNS0xLTEtNjY5MTA_0950d7b5-17cf-4668-8bc3-a5a42ad8de6d"
      unitRef="usd">-458000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifbee25bccde9417b9684147c13bfd340_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzYtNy0xLTEtNjY5MTA_9cee1b69-97e1-4500-b798-751529ee6204"
      unitRef="usd">222471000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f35093a1db04660afd25caee273d0f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzYtOS0xLTEtNjY5MTA_255c6a2e-5408-489b-9f10-99085f0be9ca"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzYtMTEtMS0xLTY2OTEw_db0c11c7-13e1-4415-92b0-98f4b4285a3b"
      unitRef="usd">222471000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i806263fe61f14f33b5cdbd7eee333ff7_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzEwLTEtMS0xLTY2OTEw_03c4026c-1dc9-4748-9207-1b5f19a3ed76"
      unitRef="usd">18507000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="iacbe24e15241450eb5814aef67850f85_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzEwLTMtMS0xLTY2OTEw_35863bf5-e760-4853-8165-f6146ade2289"
      unitRef="usd">16303000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="id47a9c894a7d46569bed9ed6ad4e9987_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzEwLTUtMS0xLTY2OTEw_aa15c947-f579-4c38-adf7-01955663fe0c"
      unitRef="usd">34810000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ie593e243a4f94ded8dcc0cbd2124556d_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzEwLTctMS0xLTY2OTEw_d55edef2-1989-4268-ac7c-f207637df64d"
      unitRef="usd">-6755000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzEwLTktMS0xLTY2OTEw_6fa21dda-6025-4e38-a3fa-5dc728efece9"
      unitRef="usd">28055000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i5e9c2f26074c434280c915a00ab6b2fe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzEzLTEtMS0xLTY2OTEw_c64d1736-5193-4c39-9b48-68692fffa270"
      unitRef="usd">-3353000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i26289f6ee3444cf484ed38a01409bbfe_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzEzLTMtMS0xLTY2OTEw_47e01476-eb7a-4652-a815-9964b1280a90"
      unitRef="usd">23883000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ifbee25bccde9417b9684147c13bfd340_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzEzLTUtMS0xLTY2OTEw_7d9fd000-d297-43b4-93bc-2b9118818b1a"
      unitRef="usd">20530000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i8f35093a1db04660afd25caee273d0f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzEzLTctMS0xLTY2OTEw_a954d418-5b37-4fb4-86e9-19c4da48ea7c"
      unitRef="usd">-6765000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTo1OGRjYjNkYzZhN2M0YjNjYTQxNjcyNmQ3NTAyNGViYi90YWJsZXJhbmdlOjU4ZGNiM2RjNmE3YzRiM2NhNDE2NzI2ZDc1MDI0ZWJiXzEzLTktMS0xLTY2OTEw_3ce847db-4f92-48ce-878c-698454a89632"
      unitRef="usd">13765000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd61671a0d0442d5ad34be35130c449e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzMtMS0xLTEtNjY5MTA_8ef5dc9a-dd98-4307-b064-11b9a03d0ec7"
      unitRef="usd">307147000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1cf7a17cbbf4a65b3324ddb3a731532_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzMtMy0xLTEtNjY5MTA_1a2ae0d3-a95d-46da-bb4e-7d5b417b297a"
      unitRef="usd">663060000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0870ad9619a8495f9f783b300266e2bf_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzMtNS0xLTEtNjY5MTA_77cd9b9e-fc2b-4204-9201-6ac32a0ec954"
      unitRef="usd">-626000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia108ecb595104f0e8ed9def9f229176e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzMtNy0xLTEtNjY5MTA_9938df44-921d-4d34-92c7-083b90c334b4"
      unitRef="usd">969581000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59101f8a3ac14ae493956a62379f494f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzMtOS0xLTEtNjY5MTA_6e565580-3c97-41d7-a8be-f07b73837585"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzMtMTEtMS0xLTY2OTEw_7867b864-e80b-47b2-9f69-5245df5b0d8f"
      unitRef="usd">969581000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iceebbb78aaf945b48c2e1e0c956749dd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzYtMS0xLTEtNjY5MTA_1d03f357-49cf-44d6-ab6b-360478925df0"
      unitRef="usd">223924000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3311fd1bb12e4f44944b34e49f4f81c7_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzYtMy0xLTEtNjY5MTA_2e312c49-5836-4143-b229-c4b1d59a6cfd"
      unitRef="usd">437031000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i71b35f78e61e4fd6a8f76ed882b8104b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzYtNS0xLTEtNjY5MTA_10b5d017-f23a-41d1-b6aa-c985815e3850"
      unitRef="usd">-1356000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14e6f529e4db48d8894cb30eac5feba5_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzYtNy0xLTEtNjY5MTA_68a8a27a-e173-4b42-9c8f-333a6be1937f"
      unitRef="usd">659599000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8abf6d4aad764b85af854f18bc243f26_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzYtOS0xLTEtNjY5MTA_1feb478a-1bb8-4be9-9aeb-4ed8bd6395c0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzYtMTEtMS0xLTY2OTEw_39565f45-90a0-4579-8f1c-6235a33574b7"
      unitRef="usd">659599000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ifd61671a0d0442d5ad34be35130c449e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzEwLTEtMS0xLTY2OTEw_2a37ae34-ed92-4f80-aadc-1b5725b4a5a1"
      unitRef="usd">41854000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="if1cf7a17cbbf4a65b3324ddb3a731532_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzEwLTMtMS0xLTY2OTEw_487a488e-276a-4b00-a84c-3400f3be313b"
      unitRef="usd">51988000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="ia108ecb595104f0e8ed9def9f229176e_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzEwLTUtMS0xLTY2OTEw_a77b860f-c811-4720-99dc-bc97cdb95b43"
      unitRef="usd">93842000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i59101f8a3ac14ae493956a62379f494f_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzEwLTctMS0xLTY2OTEw_e3a2ec66-79d7-4ea8-85d1-b5a980337789"
      unitRef="usd">-19793000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzEwLTktMS0xLTY2OTEw_a7242b0d-9928-4820-9f99-53a89b62b7b9"
      unitRef="usd">74049000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="iceebbb78aaf945b48c2e1e0c956749dd_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzEzLTEtMS0xLTY2OTEw_e3a95099-9d53-4ae2-8cd5-9511f5cb7a1a"
      unitRef="usd">9120000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i3311fd1bb12e4f44944b34e49f4f81c7_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzEzLTMtMS0xLTY2OTEw_c86ca6fe-e904-4194-bf37-8cc1c850bdd6"
      unitRef="usd">53456000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i14e6f529e4db48d8894cb30eac5feba5_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzEzLTUtMS0xLTY2OTEw_a89314c2-d62e-4f16-96e5-bc7985bda355"
      unitRef="usd">62576000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i8abf6d4aad764b85af854f18bc243f26_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzEzLTctMS0xLTY2OTEw_ef619b6b-e8b5-4785-821f-28ff882d1bf2"
      unitRef="usd">-20558000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTozOTAzODNmN2Q1NjU0NTg0YTJlY2YzYWEzNTUyZjZiYy90YWJsZXJhbmdlOjM5MDM4M2Y3ZDU2NTQ1ODRhMmVjZjNhYTM1NTJmNmJjXzEzLTktMS0xLTY2OTEw_9fe03c72-ba45-4ec5-831d-7915019b0be5"
      unitRef="usd">42018000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90ZXh0cmVnaW9uOmUzNTdjZjJjZWI1MDQ4MmFiNzMwNGMyZmNjZTBhNjA2XzMwNzg_02e4741c-c4e8-47d6-ba63-e9d2b11c56dd">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net income (loss) attributable to common shareholders of Evolent Health, Inc. (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:327.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income (loss) attributable to common shareholders of Evolent Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,040)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,978)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit from (provision for) income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(936)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax receivable agreement liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,870)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,414)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on transfer of membership&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment/repayment of debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain from equity method investees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repositioning costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,043)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,992)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,754)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(996)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of contract cost assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(79)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(433)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strategy and shareholder advisory expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,513)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquisition costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,207)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain (loss) from discontinued operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjusted EBITDA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:11.94pt"&gt;Includes $(0.5)&#160;million loss on disposal of discontinued operations for the nine months ended September 30, 2022 and $1.9&#160;million gain on disposal of discontinued operations for the nine months ended September 30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzItMS0xLTEtNjY5MTA_caa7cda7-3cac-4e59-aa54-07d756a654f7"
      unitRef="usd">2123000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzItMy0xLTEtNjY5MTA_38f004e3-9cff-402f-b687-f3fa9b29250d"
      unitRef="usd">-13040000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzItNS0xLTEtNjY5MTA_10955c01-f722-43fd-ab8b-1a080d194611"
      unitRef="usd">-7815000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzItNy0xLTEtNjY5MTA_f88f8deb-4af6-48ef-afde-6988130f9d21"
      unitRef="usd">-31954000</us-gaap:NetIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzQtMS0xLTEtNjY5MTA_85192df2-d85c-4f99-8f26-9626ed56fe53"
      unitRef="usd">425000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzQtMy0xLTEtNjY5MTA_d3a6469d-2976-4321-b114-52347be18f37"
      unitRef="usd">120000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzQtNS0xLTEtNjY5MTA_a5cf1b7e-ae1f-4538-9aba-233f19a72974"
      unitRef="usd">765000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzQtNy0xLTEtNjY5MTA_a3c095e4-b462-4cf0-8dda-3d2a3585447c"
      unitRef="usd">311000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzUtMS0xLTEtNjY5MTA_47b0e39d-ee84-420a-b763-82e814acb7c5"
      unitRef="usd">4754000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzUtMy0xLTEtNjY5MTA_d3df82f7-ab86-4f9a-9d31-e5e9827ea22b"
      unitRef="usd">6367000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzUtNS0xLTEtNjY5MTA_904a8787-e2ee-4f22-a129-a4fc1568c6e1"
      unitRef="usd">9143000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzUtNy0xLTEtNjY5MTA_84c06e08-85bf-4961-bb4a-c677f5b7c40f"
      unitRef="usd">18978000</us-gaap:InterestExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzYtMS0xLTEtNjY5MTA_0d0eb2b0-09bd-4929-95c2-e2db4e43818a"
      unitRef="usd">-45516000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzYtMy0xLTEtNjY5MTA_8a7ced05-4c23-44cb-bfe6-ec9cec66afbb"
      unitRef="usd">234000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzYtNS0xLTEtNjY5MTA_9ba73afe-5a22-4111-87af-1f9cecc83f45"
      unitRef="usd">-44498000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzYtNy0xLTEtNjY5MTA_ba3be594-48bd-4d02-8913-b66c15944a7e"
      unitRef="usd">936000</us-gaap:IncomeTaxExpenseBenefit>
    <evh:ChangesInTaxReceivablesAgreementLiability
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzctMS0xLTEtODAzMzU_3f8af3fc-8665-444d-acec-66fad7476471"
      unitRef="usd">42870000</evh:ChangesInTaxReceivablesAgreementLiability>
    <evh:ChangesInTaxReceivablesAgreementLiability
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzctMy0xLTEtODAzMzU_c7c9b365-9d3d-4a1c-bc00-baf77ceb7c63"
      unitRef="usd">0</evh:ChangesInTaxReceivablesAgreementLiability>
    <evh:ChangesInTaxReceivablesAgreementLiability
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzctNS0xLTEtODAzMzU_82aba65e-e4ac-4e1b-a3f3-22efe04b6584"
      unitRef="usd">42870000</evh:ChangesInTaxReceivablesAgreementLiability>
    <evh:ChangesInTaxReceivablesAgreementLiability
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzctNy0xLTEtODAzMzU_55efbc15-6c58-4fac-be01-55975e485349"
      unitRef="usd">0</evh:ChangesInTaxReceivablesAgreementLiability>
    <us-gaap:DepreciationAndAmortization
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzctMS0xLTEtNjY5MTA_4febb18e-b545-4f0d-9fb2-c6bc46ca5366"
      unitRef="usd">17196000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzctMy0xLTEtNjY5MTA_1476fd83-0915-4ded-b18a-df8dd6f0f132"
      unitRef="usd">14859000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzctNS0xLTEtNjY5MTA_8761ca06-f9fc-49a4-8f5c-53bcfd8327d4"
      unitRef="usd">47414000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzctNy0xLTEtNjY5MTA_242f8be7-626d-4cda-b56c-b6593c8ac4d0"
      unitRef="usd">44962000</us-gaap:DepreciationAndAmortization>
    <evh:GainOnTransferOfMembership
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzgtMS0xLTEtNjY5MTA_cb85489c-6f0d-49da-9781-cebf5611f7dc"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzgtMy0xLTEtNjY5MTA_6ff20a6f-1155-4b91-b891-d80b33f4d04a"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzgtNS0xLTEtNjY5MTA_8c59907f-44c0-4708-b2f0-27872999609c"
      unitRef="usd">0</evh:GainOnTransferOfMembership>
    <evh:GainOnTransferOfMembership
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzgtNy0xLTEtNjY5MTA_f864d378-5bd6-4a0a-ba81-f68b0fadd65a"
      unitRef="usd">22969000</evh:GainOnTransferOfMembership>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzktMS0xLTEtNjY5MTA_5e42a7a1-1921-47c5-bcd8-94879ff1d171"
      unitRef="usd">-10192000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzktMy0xLTEtNjY5MTA_575262f0-8248-445e-a8a0-b7bac172a647"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzktNS0xLTEtNjY5MTA_9021fc7a-982c-4354-94d6-a2011268533f"
      unitRef="usd">-10192000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzktNy0xLTEtNjY5MTA_5c929f9c-5f52-4d44-a06b-2b9566e0fc10"
      unitRef="usd">-19158000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEwLTEtMS0xLTY2OTEw_f3ec9730-cc89-488e-9c61-8b649698cbf4"
      unitRef="usd">1392000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEwLTMtMS0xLTY2OTEw_e1da764b-f4aa-48f6-9e5d-9eea0eedd3c8"
      unitRef="usd">63000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEwLTUtMS0xLTY2OTEw_ea7ccc5a-04f0-4e07-9f71-2e99afde943c"
      unitRef="usd">3940000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEwLTctMS0xLTY2OTEw_a46f6a32-85a9-4816-8f16-40dd58605ac5"
      unitRef="usd">12725000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzExLTEtMS0xLTY2OTEw_adbd047c-e7da-4373-b479-58b1873cb565"
      unitRef="usd">-12700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzExLTMtMS0xLTY2OTEw_509f2e88-be39-462b-9227-89d15fd7a22f"
      unitRef="usd">-225000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzExLTUtMS0xLTY2OTEw_e66ce63e-fe3a-4ba3-80bf-a7ba65daec17"
      unitRef="usd">-5822000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzExLTctMS0xLTY2OTEw_45d8a5e9-0164-423d-9417-ce25e9e49b12"
      unitRef="usd">-819000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEyLTEtMS0xLTY2OTEw_7f5633e1-1711-4576-a418-8865837b0e32"
      unitRef="usd">-345000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEyLTMtMS0xLTY2OTEw_73c811b8-be36-4604-8eb9-e8becfe561f4"
      unitRef="usd">-41000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEyLTUtMS0xLTY2OTEw_760a8ab0-a887-4d27-8474-2173b047d978"
      unitRef="usd">130000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEyLTctMS0xLTY2OTEw_eac41071-1f1b-4e33-bd0c-77f335aba105"
      unitRef="usd">-73000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:RestructuringCharges
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEzLTEtMS0xLTY2OTEw_28aad537-dc42-4c8d-83b9-d7fd2ad48c09"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEzLTMtMS0xLTY2OTEw_fbdf844f-b64e-4faf-852b-75426727a381"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEzLTUtMS0xLTY2OTEw_255e3eea-85ef-4a39-a6bb-bf3ad28edd2a"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzEzLTctMS0xLTY2OTEw_6b8e5f6d-2af4-45bc-9cd7-9e84aa1821ee"
      unitRef="usd">6043000</us-gaap:RestructuringCharges>
    <evh:SharebasedCompensationIncludingOnetimeAdjustment
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE0LTEtMS0xLTY2OTEw_a99e27d7-e518-4299-a6ac-8b4b7a6a31db"
      unitRef="usd">6992000</evh:SharebasedCompensationIncludingOnetimeAdjustment>
    <evh:SharebasedCompensationIncludingOnetimeAdjustment
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE0LTMtMS0xLTY2OTEw_69118ed2-4cc2-43a8-8acb-51a02bc8d020"
      unitRef="usd">4395000</evh:SharebasedCompensationIncludingOnetimeAdjustment>
    <evh:SharebasedCompensationIncludingOnetimeAdjustment
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE0LTUtMS0xLTY2OTEw_406dfd05-d5af-4101-91b1-af488f44da60"
      unitRef="usd">19350000</evh:SharebasedCompensationIncludingOnetimeAdjustment>
    <evh:SharebasedCompensationIncludingOnetimeAdjustment
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE0LTctMS0xLTY2OTEw_68a7e5bd-697d-41a1-b345-31ae216f2f21"
      unitRef="usd">11754000</evh:SharebasedCompensationIncludingOnetimeAdjustment>
    <us-gaap:SeveranceCosts1
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE1LTEtMS0xLTY2OTEw_f09b6676-6589-48b5-978d-f21500d2dc45"
      unitRef="usd">996000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE1LTMtMS0xLTY2OTEw_1319bf77-2aad-45f0-961f-c5eec3231e07"
      unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE1LTUtMS0xLTY2OTEw_b71c39ec-7310-4204-b25f-5d78685a50b4"
      unitRef="usd">1035000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE1LTctMS0xLTY2OTEw_0faca54b-6b19-44c4-9a9c-3ba9fb3d6d0a"
      unitRef="usd">52000</us-gaap:SeveranceCosts1>
    <evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE2LTEtMS0xLTY2OTEw_1115ab41-1cca-4ddd-85af-c5b42e0b8f48"
      unitRef="usd">25000</evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments>
    <evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE2LTMtMS0xLTY2OTEw_fb62645e-455b-4b95-a080-a5f9ea7da022"
      unitRef="usd">110000</evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments>
    <evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE2LTUtMS0xLTY2OTEw_2cb3798b-8820-4531-8c5e-0f57de9bf97a"
      unitRef="usd">79000</evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments>
    <evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE2LTctMS0xLTY2OTEw_6ab5bd06-6ef4-4c8d-9b09-2e88c398b69e"
      unitRef="usd">433000</evh:CapitalizedContractCostAmortizationPurchaseAccountingAdjustments>
    <evh:ShareholderAdvisoryServices
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE3LTEtMS0xLTY2OTEw_1620a4b6-431c-42f1-9613-0c7e4f59b2e4"
      unitRef="usd">0</evh:ShareholderAdvisoryServices>
    <evh:ShareholderAdvisoryServices
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE3LTMtMS0xLTY2OTEw_6a8021a3-6611-40e9-be44-ccaadb936782"
      unitRef="usd">0</evh:ShareholderAdvisoryServices>
    <evh:ShareholderAdvisoryServices
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE3LTUtMS0xLTY2OTEw_f041a61e-168a-42b1-9aaf-7441781a238b"
      unitRef="usd">0</evh:ShareholderAdvisoryServices>
    <evh:ShareholderAdvisoryServices
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE3LTctMS0xLTY2OTEw_b2f7619c-fc92-4385-8e82-dca3680f53d2"
      unitRef="usd">6513000</evh:ShareholderAdvisoryServices>
    <evh:TransactionCosts
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE4LTEtMS0xLTY2OTEw_98a403af-7fe2-4efb-b46c-8327f2391968"
      unitRef="usd">2595000</evh:TransactionCosts>
    <evh:TransactionCosts
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE4LTMtMS0xLTY2OTEw_d2201ef6-7750-4e68-85af-554453bb6ada"
      unitRef="usd">1207000</evh:TransactionCosts>
    <evh:TransactionCosts
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE4LTUtMS0xLTY2OTEw_c290cdc0-d358-4451-a536-2666a3293798"
      unitRef="usd">6473000</evh:TransactionCosts>
    <evh:TransactionCosts
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE4LTctMS0xLTY2OTEw_b6f7146d-9f55-4253-bd57-b0f59c4fc619"
      unitRef="usd">3277000</evh:TransactionCosts>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE5LTEtMS0xLTY2OTEw_0f3f1e42-b028-4ad8-82ff-e31136f81e66"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE5LTMtMS0xLTY2OTEw_bce5d4fe-a79d-4aff-b23e-1041b79bc187"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE5LTUtMS0xLTY2OTEw_03bea6d6-9beb-486b-9e8c-a0700c93a8d0"
      unitRef="usd">-463000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzE5LTctMS0xLTY2OTEw_c89021c2-f5a6-40c5-b06d-40e177f9e480"
      unitRef="usd">1383000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzIwLTEtMS0xLTY2OTEw_8d530af7-7e0e-4df7-9c1e-e539d2fe3c17"
      unitRef="usd">28055000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i7665a5478cbc4b1dbaccfa9a40bd8e80_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzIwLTMtMS0xLTY2OTEw_a880952c-1c60-4738-897a-57c22aa45857"
      unitRef="usd">13765000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzIwLTUtMS0xLTY2OTEw_2d07f6df-f264-481d-be6b-5b1c59bccb06"
      unitRef="usd">74049000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90YWJsZTpmZjRhYjg3MDg0MDQ0NzZiOTgzZjNkODU1ZWQ3NjViYy90YWJsZXJhbmdlOmZmNGFiODcwODQwNDQ3NmI5ODNmM2Q4NTVlZDc2NWJjXzIwLTctMS0xLTY2OTEw_f65c497a-27c7-405f-a949-3b8aa06dfecb"
      unitRef="usd">42018000</evh:AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90ZXh0cmVnaW9uOmUzNTdjZjJjZWI1MDQ4MmFiNzMwNGMyZmNjZTBhNjA2XzI3NTg_cd162837-63ed-45d0-8343-6d6ea621bb0f"
      unitRef="usd">-500000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDMvZnJhZzplMzU3Y2YyY2ViNTA0ODJhYjczMDRjMmZjY2UwYTYwNi90ZXh0cmVnaW9uOmUzNTdjZjJjZWI1MDQ4MmFiNzMwNGMyZmNjZTBhNjA2XzI4NTg_d4a7dbf8-c781-4433-9ce3-297fee23c41b"
      unitRef="usd">1900000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:InsuranceDisclosureTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90ZXh0cmVnaW9uOjA4NDJkMTViYzY3MTRmZjRhMDYxZGEyMGI5NTcxODYxXzQ2MjU_5c6289f4-f417-42e5-8d97-2762a16df38b">Reserve for Claims and Performance-Based Arrangements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains reserves for its liabilities related to payments to providers and pharmacies under performance-based arrangements related to its total cost of care and specialty care management services. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Reserves for claims and performance-based arrangements for our EHS and Clinical Solutions segments reflect actual payments under performance-based arrangements and the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process), and other medical care expenses and services payable that are primarily composed of accruals for incentives and other amounts payable to health care professionals and facilities. Reserves for claims and performance-based arrangements also reflect estimated amounts owed under the reinsurance agreements, as discussed further in Note 11.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses actuarial principles and assumptions that are consistently applied each reporting period and recognizes the actuarial best estimate of the ultimate liability along with a margin for adverse deviation. This approach is consistent with actuarial standards of practice that the liabilities be adequate under moderately adverse conditions.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This liability predominately consists of incurred but not reported amounts and reported claims in process including expected development on reported claims. The liability for reserves related to its total cost of care and specialty care management services is primarily calculated using "completion factors" developed by comparing the claim incurred date to the date claims were paid. Completion factors are impacted by several key items including changes in: 1)&#160;electronic (auto-adjudication) versus manual claim processing, 2)&#160;provider claims submission rates, 3)&#160;membership and 4)&#160;the mix of products.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy for reserves related to its total cost of care and specialty care management services is to use historical completion factors combined with an analysis of current trends and operational factors to develop current estimates of completion factors. The Company estimates the liability for claims incurred in each month by applying the current estimates of completion factors to the current paid claims data. This approach implicitly assumes that historical completion rates will be a useful indicator for the current period. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For more recent months, and for newer lines of business where there is not sufficient paid claims history to develop completion factors, the Company expects to rely more heavily on medical cost trend and expected loss ratio analysis that reflects expected claim payment patterns and other relevant operational considerations, or authorization analysis. Medical cost trend is primarily impacted by medical service utilization and unit costs that are affected by changes in the level and mix of medical benefits offered, including inpatient, outpatient and pharmacy, the impact of copays and deductibles, changes in provider practices and changes in consumer demographics and consumption behavior. Authorization analysis projects costs based on authorizations per thousand members basis and assigning an average cost per authorization. This is also adjusted for the impact of copays, deductibles, unit cost and historic discontinuation rates for treatment are considered. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each reporting period, the Company compares key assumptions used to establish the reserves for claims and performance-based arrangements to actual experience. When actual experience differs from these assumptions, reserves for claims and performance-based arrangements are adjusted through current period net income. Additionally, the Company evaluates expected future developments and emerging trends that may impact key assumptions. The process used to determine this liability requires the Company to make critical accounting estimates that involve considerable judgment, reflecting the variability inherent in forecasting future claim payments. These estimates are highly sensitive to changes in the Company's key assumptions, specifically completion factors and medical cost trends.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity in reserves for claims and performance-based arrangements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:226.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:37.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:41.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred health care costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total claims incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims paid related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229,315)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129,236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total claims paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(488,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(498,944)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(330,721)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(370,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:InsuranceDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90ZXh0cmVnaW9uOjA4NDJkMTViYzY3MTRmZjRhMDYxZGEyMGI5NTcxODYxXzQ2Mjc_98cb659b-5248-4569-9b31-0cc85208e245">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity in reserves for claims and performance-based arrangements was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:539.25pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:226.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:37.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:41.50pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:57.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:3.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:40.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;EHS &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Clinical Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Incurred health care costs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total claims incurred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;469,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims paid related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(369,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(229,315)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(250,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior year to date period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129,236)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19,174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total claims paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(488,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(498,944)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39,975)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(330,721)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(370,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;126,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:31.5pt;text-align:justify;text-indent:-31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:25.44pt"&gt;Costs incurred to provide specialty care management and EVH Passport are recorded within cost of revenue in our statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="if2b23b62d2314ba29f31148feecadf97_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzMtMS0xLTEtNjY5MTA_a2bb0832-c1e5-4487-90ca-b7228592557a"
      unitRef="usd">25618000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i2c9b3945ac9741d4843b49c10f8dcd40_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzMtMy0xLTEtNjY5MTA_99b1ab20-603e-4fdd-b7de-85c581dd415f"
      unitRef="usd">145676000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ic1c85bf2a0144950a682573f957154ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzMtNS0xLTEtNjY5MTA_a5cf5cab-27b6-4e81-901d-d3917a6e5189"
      unitRef="usd">171294000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="if0291d88c45549ebb15674a1bf82c1a2_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzMtNy0xLTEtNjY5MTA_deca7ced-7a41-4dc0-b45f-61a90088fb72"
      unitRef="usd">56295000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i5b7c2c9eb4d24e95a2fb3597a736a55d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzMtOS0xLTEtNjY5MTA_9095b140-dc99-4021-aa51-ca5366dfb120"
      unitRef="usd">122532000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="idcb7e5d5de6d4fb9bd1b47d49e170108_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzMtMTEtMS0xLTY2OTEw_189a138f-2a0c-4982-a6b2-77ac0c701ccc"
      unitRef="usd">178827000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="ieef521b6cb2644d59433c4a98ac67edb_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzUtMS0xLTEtNjY5MTA_9c290c1b-8797-48a0-9fc5-a839e3511834"
      unitRef="usd">0</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i5af61dbd97844f2cb160b48a3a35d4e8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzUtMy0xLTEtNjY5MTA_a2c3381c-2df4-40fc-a4c4-a8ab9932a72f"
      unitRef="usd">471502000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzUtNS0xLTEtNjY5MTA_6120cecc-aec0-4a0d-b710-5dc2c54ac91c"
      unitRef="usd">471502000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="if4dfdc7272dc4a849a6c7e48dfcc4f74_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzUtNy0xLTEtNjY5MTA_fb0786c5-5d7a-42ea-ac33-005f281b09b7"
      unitRef="usd">6622000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i8e55c1b3affc496aa10cbd0b6538c957_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzUtOS0xLTEtNjY5MTA_14164e0c-9df8-4852-99c7-013a477d0ed0"
      unitRef="usd">376506000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzUtMTEtMS0xLTY2OTEw_b91097b6-989f-45c3-87b6-2f9839b5cb4d"
      unitRef="usd">383128000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ieef521b6cb2644d59433c4a98ac67edb_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzYtMS0xLTEtNjY5MTA_d7d56845-9de8-48c7-a5bb-d00eb87a7686"
      unitRef="usd">-5714000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i5af61dbd97844f2cb160b48a3a35d4e8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzYtMy0xLTEtNjY5MTA_138cf0ac-c3e7-4941-89ee-5bd9cf8f200e"
      unitRef="usd">-2440000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzYtNS0xLTEtNjY5MTA_4a37ec0e-8ab1-4350-88b0-4d4707572b46"
      unitRef="usd">-8154000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="if4dfdc7272dc4a849a6c7e48dfcc4f74_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzYtNy0xLTEtNjY5MTA_d1505e3e-9c79-421e-bf5a-2376c9eab1e2"
      unitRef="usd">527000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i8e55c1b3affc496aa10cbd0b6538c957_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzYtOS0xLTEtNjY5MTA_915e800c-8c79-44d4-9bf3-50df9fe8f839"
      unitRef="usd">92000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzYtMTEtMS0xLTY2OTEw_107d1c77-b4ae-411e-a429-1fb4e7850014"
      unitRef="usd">619000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ieef521b6cb2644d59433c4a98ac67edb_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzctMS0xLTEtNzQxMzc_c92f354b-2ddc-4b84-a4ef-d26f80127d65"
      unitRef="usd">-5714000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i5af61dbd97844f2cb160b48a3a35d4e8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzctMy0xLTEtNzQxNTM_102b24ae-b258-4aaa-9ec2-9df34a599a2e"
      unitRef="usd">469062000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzctNS0xLTEtNzQxNjE_5453da15-a740-46b7-b9f8-6363086228f9"
      unitRef="usd">463348000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="if4dfdc7272dc4a849a6c7e48dfcc4f74_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzctNy0xLTEtNzQxNDU_7e0c9cd3-680a-4e55-b019-e331e1247cc7"
      unitRef="usd">7149000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i8e55c1b3affc496aa10cbd0b6538c957_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzctOS0xLTEtNzQxNzI_b3a60fc4-0f5a-4662-8486-723408f624d9"
      unitRef="usd">376598000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzctMTEtMS0xLTc0MTgw_3bf6f6b7-db84-4769-9abb-8843d24b7827"
      unitRef="usd">383747000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ieef521b6cb2644d59433c4a98ac67edb_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzgtMS0xLTEtNjY5MTA_f101d90e-fae5-40fe-a90b-2345da2ebf4e"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i5af61dbd97844f2cb160b48a3a35d4e8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzgtMy0xLTEtNjY5MTA_7b9bd2c0-a6fa-40c4-b995-144ac03d568f"
      unitRef="usd">369708000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzgtNS0xLTEtNjY5MTA_7c173228-98d4-4a63-88b7-e4647b899c30"
      unitRef="usd">369708000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="if4dfdc7272dc4a849a6c7e48dfcc4f74_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzgtNy0xLTEtNjY5MTA_e9dacc34-3685-4488-a120-d31ecda9c7eb"
      unitRef="usd">20801000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i8e55c1b3affc496aa10cbd0b6538c957_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzgtOS0xLTEtNjY5MTA_85f4a15c-dd0a-4747-aba4-6c3c2c250dfb"
      unitRef="usd">229315000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzgtMTEtMS0xLTY2OTEw_cd38edf3-ae5b-4074-b79c-4de8d7c17d3b"
      unitRef="usd">250116000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ieef521b6cb2644d59433c4a98ac67edb_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzktMS0xLTEtNjY5MTA_889d654e-a376-4b6a-b394-da803907dd28"
      unitRef="usd">10846000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i5af61dbd97844f2cb160b48a3a35d4e8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzktMy0xLTEtNjY5MTA_f9952286-7522-425b-8eac-d4519b7738ee"
      unitRef="usd">118390000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzktNS0xLTEtNjY5MTA_9a8230d3-8926-4b14-b630-57b0682c6277"
      unitRef="usd">129236000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="if4dfdc7272dc4a849a6c7e48dfcc4f74_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzktNy0xLTEtNjY5MTA_3fb62c79-087c-4006-89c4-6cf670eec545"
      unitRef="usd">19174000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i8e55c1b3affc496aa10cbd0b6538c957_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzktOS0xLTEtNjY5MTA_577d6e3e-5c43-4efe-9851-d4e59877c315"
      unitRef="usd">101406000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzktMTEtMS0xLTY2OTEw_30d9b28b-5a60-4e4e-b40e-be6f78ccf384"
      unitRef="usd">120580000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="ieef521b6cb2644d59433c4a98ac67edb_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzEwLTEtMS0xLTY2OTEw_8307450a-3526-40ae-8f7b-1c21af8158d3"
      unitRef="usd">10846000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i5af61dbd97844f2cb160b48a3a35d4e8_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzEwLTMtMS0xLTY2OTEw_a36811d5-32b7-4b07-9485-25ad9c85f3f0"
      unitRef="usd">488098000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzEwLTUtMS0xLTY2OTEw_63359b7b-8d3f-4fef-b50b-65835b364e93"
      unitRef="usd">498944000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="if4dfdc7272dc4a849a6c7e48dfcc4f74_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzEwLTctMS0xLTY2OTEw_a8304b60-a59f-4447-bb29-6d066dc819a5"
      unitRef="usd">39975000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i8e55c1b3affc496aa10cbd0b6538c957_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzEwLTktMS0xLTY2OTEw_ca330808-11b5-4a7d-834f-d582aff72780"
      unitRef="usd">330721000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzEwLTExLTEtMS02NjkxMA_1cc163f8-932f-423f-920c-51bed8fa7477"
      unitRef="usd">370696000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="iffa15ee70390496c89f205bdc8f3731b_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzE0LTEtMS0xLTY2OTEw_8f9e1686-6527-40cc-b27a-679097ef020d"
      unitRef="usd">9058000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i358169d308bf4641ad0dca36755b47d1_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzE0LTMtMS0xLTY2OTEw_15a63003-872b-4def-9d39-500e4a5d1606"
      unitRef="usd">126640000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i4e7829cceaeb4c139799230c0383d092_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzE0LTUtMS0xLTY2OTEw_87e79cf9-be69-4af0-829d-46f9be427175"
      unitRef="usd">135698000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i1859c2ae121649f09ad595e92fb8e96c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzE0LTctMS0xLTY2OTEw_19f40a39-c658-4051-bdee-4f053eac0b52"
      unitRef="usd">23469000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i44a8b1c85fc24294af85eb3f3327612d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzE0LTktMS0xLTY2OTEw_640c37d6-f5d2-4b9f-9fed-9cc09804d925"
      unitRef="usd">168409000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i63b3ddd7486946c2a0a8151832317d14_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDYvZnJhZzowODQyZDE1YmM2NzE0ZmY0YTA2MWRhMjBiOTU3MTg2MS90YWJsZTo0MjkxYWI2ZjBhMDE0ZTc4OWJiNzgyN2IxZjUyZDNkMi90YWJsZXJhbmdlOjQyOTFhYjZmMGEwMTRlNzg5YmI3ODI3YjFmNTJkM2QyXzE0LTExLTEtMS02NjkxMA_b1b756fa-4d60-4c32-873e-8bbddedc7025"
      unitRef="usd">191878000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90ZXh0cmVnaW9uOjliZWQ0NmQ1ZTQ0NjRjMDRiN2Q4ODJiYWEyZGY1MTI2XzEzNA_a69f0bd2-ed07-4498-bb64-c90e97ec0a31">Supplemental Cash Flow Information &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents supplemental cash flow information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Disclosure of Non-cash Investing and Financing Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued property and equipment purchases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A common stock issued in connection with business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A common stock issued in connection with debt repayment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued net working capital adjustment with business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effects of Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Operating cash flows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Leased assets disposed of (obtained in) exchange for operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Disclosures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,771)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(955)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(734)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90ZXh0cmVnaW9uOjliZWQ0NmQ1ZTQ0NjRjMDRiN2Q4ODJiYWEyZGY1MTI2XzEyOQ_bc6f1c32-4bd9-426f-ba64-0363b71a6d77">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following represents supplemental cash flow information (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:540.00pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:433.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:48.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Disclosure of Non-cash Investing and Financing Activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued property and equipment purchases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A common stock issued in connection with business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Class A common stock issued in connection with debt repayment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued net working capital adjustment with business combinations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effects of Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Operating cash flows from operating leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;Leased assets disposed of (obtained in) exchange for operating lease liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Supplemental Disclosures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,269)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,771)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(955)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(734)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzMtMS0xLTEtNjY5MTA_12275fac-bf2c-4bfd-b77d-6a945b3bc2da"
      unitRef="usd">1014000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzMtMy0xLTEtNjY5MTA_cf50f527-e2d9-417e-b20a-282b91d6e747"
      unitRef="usd">497000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:StockIssued1
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzQtMS0xLTEtNzczNzg_5d243207-4b88-4716-99b6-08987dbccfa7"
      unitRef="usd">130175000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzQtMy0xLTEtNzczNzg_158221ce-d5ab-4bbb-bbd0-e6d6cebf0f7c"
      unitRef="usd">0</us-gaap:StockIssued1>
    <evh:StockIssuedInConnectionWithDebtRepayment
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzUtMS0xLTEtNzczOTQ_8aad34d7-6d02-447c-bc78-74f9c5863389"
      unitRef="usd">101999000</evh:StockIssuedInConnectionWithDebtRepayment>
    <evh:StockIssuedInConnectionWithDebtRepayment
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzUtMy0xLTEtNzczOTQ_1227e65c-575b-43b8-8692-8d7010a83b39"
      unitRef="usd">0</evh:StockIssuedInConnectionWithDebtRepayment>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzYtMS0xLTEtNzc1MDA_af9d0769-4ada-48e8-bc64-ab5ea307294a"
      unitRef="usd">791000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzYtMy0xLTEtNzc1MDA_fac1588c-cbac-4682-867b-22dd3317d1c6"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:OperatingLeasePayments
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzUtMS0xLTEtNjY5MTA_391f5772-09b4-4315-8759-fd8833eb7ce5"
      unitRef="usd">14453000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzUtMy0xLTEtNjY5MTA_1f0cca75-a6fc-42e4-997d-f3ac5fddc940"
      unitRef="usd">9854000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzYtMS0xLTEtNjY5MTA_a6a947f9-d452-4c38-b339-9bd5e9a4dfed"
      unitRef="usd">4305000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <evh:RightOfUseAssetAcquiredAndDisposedOf
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzYtMy0xLTEtNjY5MTA_034a62ab-cbd6-4297-ac4e-4fb880d25ac7"
      unitRef="usd">2157000</evh:RightOfUseAssetAcquiredAndDisposedOf>
    <us-gaap:InterestPaidNet
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzExLTEtMS0xLTc5MTgz_afabf729-6f08-4428-b0ec-ba118bfe0b30"
      unitRef="usd">6269000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzExLTMtMS0xLTc5MTgz_2844da75-90cf-4b3b-a343-52190b52d643"
      unitRef="usd">3771000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzEyLTEtMS0xLTc5MTgz_8324e217-4ddc-4ad2-aa7f-180f7f111cfd"
      unitRef="usd">-955000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMDkvZnJhZzo5YmVkNDZkNWU0NDY0YzA0YjdkODgyYmFhMmRmNTEyNi90YWJsZToxZTIxMmI1ZWM1YjE0Yjg3OWU0NjI5N2EzMWQwYmZjMy90YWJsZXJhbmdlOjFlMjEyYjVlYzViMTRiODc5ZTQ2Mjk3YTMxZDBiZmMzXzEyLTMtMS0xLTc5MTgz_51d8fab1-f144-473d-9125-48936bbbbfa9"
      unitRef="usd">-734000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMTIvZnJhZzoxYzY4MmVjNzQxMWM0ZWM4YWJmNjdkMDA0ZjFmN2MyNS90ZXh0cmVnaW9uOjFjNjgyZWM3NDExYzRlYzhhYmY2N2QwMDRmMWY3YzI1XzY4MDc_c0994c6f-5fe6-4a88-8bb1-a80d944a7031">Subsequent EventsGoodwill ImpairmentOn October 11, 2022, our Evolent Health Services segment was notified by Bright Health Group that it intended to exit its Individual and Family lines of business. Due to an expected decrease in projected future cash flows which could impact our estimated fair value, our existing goodwill in the EHS segment may require an adjustment. Such adjustment could be material. As of the date of this filing, the Company has not yet completed the analysis due to the complexities and time involved in determining the implied fair value of the goodwill. The analysis will be completed in the fourth quarter of 2022. As of September 30, 2022, goodwill in our EHS segment is $214.2&#160;million. If the fair value of the EHS segment is determined to be less than the carrying value, an adjustment to goodwill will be required, and such amount could be material.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:Goodwill
      contextRef="iffa15ee70390496c89f205bdc8f3731b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18xMTIvZnJhZzoxYzY4MmVjNzQxMWM0ZWM4YWJmNjdkMDA0ZjFmN2MyNS90ZXh0cmVnaW9uOjFjNjgyZWM3NDExYzRlYzhhYmY2N2QwMDRmMWY3YzI1XzE2NDkyNjc0NjMzMDk_0c5f6c12-52a3-48fe-b791-caca5b212296"
      unitRef="usd">214200000</us-gaap:Goodwill>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTItMy0xLTEtNjY5MTA_e780754b-becf-412a-9a90-ad6423472439"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTItMy0xLTEtNjY5MTA_e780754b-becf-412a-9a90-ad6423472439"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjEtMy0xLTEtNjY5MTA_f0410fb4-f54a-4562-8220-80148a84a87a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjEtMy0xLTEtNjY5MTA_f0410fb4-f54a-4562-8220-80148a84a87a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjUtMS0xLTEtNjY5MTA_48ec7316-cea1-4cf6-8f66-13d156e589bd"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjUtMS0xLTEtNjY5MTA_48ec7316-cea1-4cf6-8f66-13d156e589bd"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNS0zLTEtMS02NjkxMA_6db68019-f8ed-4595-afcd-b595ba408e42"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNS0zLTEtMS02NjkxMA_6db68019-f8ed-4595-afcd-b595ba408e42"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjAtMS0xLTEtNjY5MTA_48d0844c-9fb0-4d5c-b7d4-6304a399f74d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjAtMS0xLTEtNjY5MTA_48d0844c-9fb0-4d5c-b7d4-6304a399f74d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNi0zLTEtMS02NjkxMA_3fbe5349-c50f-488a-926f-cebbbb5e3145"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNi0zLTEtMS02NjkxMA_3fbe5349-c50f-488a-926f-cebbbb5e3145"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjAtMy0xLTEtNjY5MTA_c65b73ea-18ea-457b-b53e-8321cc519932"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjAtMy0xLTEtNjY5MTA_c65b73ea-18ea-457b-b53e-8321cc519932"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNS0xLTEtMS02NjkxMA_f64a8628-8343-4da0-954d-ffe1f203e1f5"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNS0xLTEtMS02NjkxMA_f64a8628-8343-4da0-954d-ffe1f203e1f5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTItMS0xLTEtNjY5MTA_34f9420f-1f29-4dd2-a3b4-4616ca572376"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTItMS0xLTEtNjY5MTA_34f9420f-1f29-4dd2-a3b4-4616ca572376"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjUtMy0xLTEtNjY5MTA_e4abb8b3-aa8f-4832-83bc-f87e164b3de8"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjUtMy0xLTEtNjY5MTA_e4abb8b3-aa8f-4832-83bc-f87e164b3de8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNi0xLTEtMS02NjkxMA_d3e0c599-491f-46df-a5b8-1ef55dddf91e"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNi0xLTEtMS02NjkxMA_d3e0c599-491f-46df-a5b8-1ef55dddf91e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjEtMS0xLTEtNjY5MTA_503f1e92-bc1a-4c1c-88de-3f62af41dfea"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjEtMS0xLTEtNjY5MTA_503f1e92-bc1a-4c1c-88de-3f62af41dfea"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RleHRyZWdpb246Y2NiZWRlZjE1MGEzNDA0Y2E0MWUyMzkzN2Y0YjU0YWVfMTkw_99d40318-14a9-4059-9180-0d35bf3232a0" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RleHRyZWdpb246Y2NiZWRlZjE1MGEzNDA0Y2E0MWUyMzkzN2Y0YjU0YWVfMTkw_99d40318-14a9-4059-9180-0d35bf3232a0" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 18 for amounts attributable to related parties included in these line items.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTItMy0xLTEtNjY5MTA_e780754b-becf-412a-9a90-ad6423472439"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RleHRyZWdpb246Y2NiZWRlZjE1MGEzNDA0Y2E0MWUyMzkzN2Y0YjU0YWVfMTkw_99d40318-14a9-4059-9180-0d35bf3232a0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjEtMy0xLTEtNjY5MTA_f0410fb4-f54a-4562-8220-80148a84a87a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RleHRyZWdpb246Y2NiZWRlZjE1MGEzNDA0Y2E0MWUyMzkzN2Y0YjU0YWVfMTkw_99d40318-14a9-4059-9180-0d35bf3232a0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjUtMS0xLTEtNjY5MTA_48ec7316-cea1-4cf6-8f66-13d156e589bd"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RleHRyZWdpb246Y2NiZWRlZjE1MGEzNDA0Y2E0MWUyMzkzN2Y0YjU0YWVfMTkw_99d40318-14a9-4059-9180-0d35bf3232a0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNS0zLTEtMS02NjkxMA_6db68019-f8ed-4595-afcd-b595ba408e42"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RleHRyZWdpb246Y2NiZWRlZjE1MGEzNDA0Y2E0MWUyMzkzN2Y0YjU0YWVfMTkw_99d40318-14a9-4059-9180-0d35bf3232a0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjAtMS0xLTEtNjY5MTA_48d0844c-9fb0-4d5c-b7d4-6304a399f74d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RleHRyZWdpb246Y2NiZWRlZjE1MGEzNDA0Y2E0MWUyMzkzN2Y0YjU0YWVfMTkw_99d40318-14a9-4059-9180-0d35bf3232a0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNi0zLTEtMS02NjkxMA_3fbe5349-c50f-488a-926f-cebbbb5e3145"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RleHRyZWdpb246Y2NiZWRlZjE1MGEzNDA0Y2E0MWUyMzkzN2Y0YjU0YWVfMTkw_99d40318-14a9-4059-9180-0d35bf3232a0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjAtMy0xLTEtNjY5MTA_c65b73ea-18ea-457b-b53e-8321cc519932"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RleHRyZWdpb246Y2NiZWRlZjE1MGEzNDA0Y2E0MWUyMzkzN2Y0YjU0YWVfMTkw_99d40318-14a9-4059-9180-0d35bf3232a0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNS0xLTEtMS02NjkxMA_f64a8628-8343-4da0-954d-ffe1f203e1f5"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RleHRyZWdpb246Y2NiZWRlZjE1MGEzNDA0Y2E0MWUyMzkzN2Y0YjU0YWVfMTkw_99d40318-14a9-4059-9180-0d35bf3232a0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMTItMS0xLTEtNjY5MTA_34f9420f-1f29-4dd2-a3b4-4616ca572376"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RleHRyZWdpb246Y2NiZWRlZjE1MGEzNDA0Y2E0MWUyMzkzN2Y0YjU0YWVfMTkw_99d40318-14a9-4059-9180-0d35bf3232a0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjUtMy0xLTEtNjY5MTA_e4abb8b3-aa8f-4832-83bc-f87e164b3de8"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RleHRyZWdpb246Y2NiZWRlZjE1MGEzNDA0Y2E0MWUyMzkzN2Y0YjU0YWVfMTkw_99d40318-14a9-4059-9180-0d35bf3232a0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfNi0xLTEtMS02NjkxMA_d3e0c599-491f-46df-a5b8-1ef55dddf91e"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RleHRyZWdpb246Y2NiZWRlZjE1MGEzNDA0Y2E0MWUyMzkzN2Y0YjU0YWVfMTkw_99d40318-14a9-4059-9180-0d35bf3232a0"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RhYmxlOmExNDIwODI4ZTc2ODQ5NDI5NjBjYTBhNTNkYWNjODc4L3RhYmxlcmFuZ2U6YTE0MjA4MjhlNzY4NDk0Mjk2MGNhMGE1M2RhY2M4NzhfMjEtMS0xLTEtNjY5MTA_503f1e92-bc1a-4c1c-88de-3f62af41dfea"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yNS9mcmFnOmNjYmVkZWYxNTBhMzQwNGNhNDFlMjM5MzdmNGI1NGFlL3RleHRyZWdpb246Y2NiZWRlZjE1MGEzNDA0Y2E0MWUyMzkzN2Y0YjU0YWVfMTkw_99d40318-14a9-4059-9180-0d35bf3232a0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy01LTEtMS02NjkxMA_00f03ad2-b82d-44e7-b7c4-221872011c79"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy01LTEtMS02NjkxMA_00f03ad2-b82d-44e7-b7c4-221872011c79"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtMy0xLTEtNjY5MTA_43c76fef-6b2e-4467-b3ef-343e76af8f09"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtMy0xLTEtNjY5MTA_43c76fef-6b2e-4467-b3ef-343e76af8f09"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy0xLTEtMS02NjkxMA_0f209cfa-8504-4ac9-b758-ac2a0a61b1b2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy0xLTEtMS02NjkxMA_0f209cfa-8504-4ac9-b758-ac2a0a61b1b2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy03LTEtMS02NjkxMA_d20e63e0-6ca3-40ec-8951-ef7d1c289504"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy03LTEtMS02NjkxMA_d20e63e0-6ca3-40ec-8951-ef7d1c289504"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtMS0xLTEtNjY5MTA_0f209cfa-8504-4ac9-b758-ac2a0a61b1b2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtMS0xLTEtNjY5MTA_0f209cfa-8504-4ac9-b758-ac2a0a61b1b2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy0zLTEtMS02NjkxMA_43c76fef-6b2e-4467-b3ef-343e76af8f09"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy0zLTEtMS02NjkxMA_43c76fef-6b2e-4467-b3ef-343e76af8f09"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtNS0xLTEtNjY5MTA_00f03ad2-b82d-44e7-b7c4-221872011c79"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtNS0xLTEtNjY5MTA_00f03ad2-b82d-44e7-b7c4-221872011c79"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtNy0xLTEtNjY5MTA_d20e63e0-6ca3-40ec-8951-ef7d1c289504"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtNy0xLTEtNjY5MTA_d20e63e0-6ca3-40ec-8951-ef7d1c289504"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDA5_2476b5e9-95ac-459d-a77e-7144819457ee" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDA5_2476b5e9-95ac-459d-a77e-7144819457ee" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes $(0.5)&#160;million loss on disposal of discontinued operations for the nine months ended September 30, 2022 and $1.9&#160;million gain on disposal of discontinued operations for the nine months ended September 30, 2021, respectively</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy01LTEtMS02NjkxMA_00f03ad2-b82d-44e7-b7c4-221872011c79"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDA5_2476b5e9-95ac-459d-a77e-7144819457ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtMy0xLTEtNjY5MTA_43c76fef-6b2e-4467-b3ef-343e76af8f09"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDA5_2476b5e9-95ac-459d-a77e-7144819457ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy0xLTEtMS02NjkxMA_0f209cfa-8504-4ac9-b758-ac2a0a61b1b2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDA5_2476b5e9-95ac-459d-a77e-7144819457ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy03LTEtMS02NjkxMA_d20e63e0-6ca3-40ec-8951-ef7d1c289504"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDA5_2476b5e9-95ac-459d-a77e-7144819457ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtMS0xLTEtNjY5MTA_0f209cfa-8504-4ac9-b758-ac2a0a61b1b2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDA5_2476b5e9-95ac-459d-a77e-7144819457ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM184Mi9mcmFnOjAxODc4MDg4ZmQ5MTRiMDA5NWMxMWI2NTM5MTQ4MzI5L3RhYmxlOjUwYWIzYjJhNzRmZjRmMjlhMzliMTJhNGUwN2MzYjI4L3RhYmxlcmFuZ2U6NTBhYjNiMmE3NGZmNGYyOWEzOWIxMmE0ZTA3YzNiMjhfMy0zLTEtMS02NjkxMA_43c76fef-6b2e-4467-b3ef-343e76af8f09"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDA5_2476b5e9-95ac-459d-a77e-7144819457ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtNS0xLTEtNjY5MTA_00f03ad2-b82d-44e7-b7c4-221872011c79"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDA5_2476b5e9-95ac-459d-a77e-7144819457ee"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMjAtNy0xLTEtNjY5MTA_d20e63e0-6ca3-40ec-8951-ef7d1c289504"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDA5_2476b5e9-95ac-459d-a77e-7144819457ee"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi0zLTEtMS02NjkxMA_11533d2f-70b8-49ef-8326-e453614be690"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi0zLTEtMS02NjkxMA_11533d2f-70b8-49ef-8326-e453614be690"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi01LTEtMS02NjkxMA_5f2e275b-70f9-47fe-8b15-566555a7bfb6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi01LTEtMS02NjkxMA_5f2e275b-70f9-47fe-8b15-566555a7bfb6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS0xLTEtMS02NjkxMA_c1e43070-1906-4b95-918c-de3e2d6ad751"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS0xLTEtMS02NjkxMA_c1e43070-1906-4b95-918c-de3e2d6ad751"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS0zLTEtMS02NjkxMA_edb76492-aae3-4861-9dce-2a945e70053d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS0zLTEtMS02NjkxMA_edb76492-aae3-4861-9dce-2a945e70053d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi01LTEtMS02NjkxMA_526c1f97-4796-4d78-a5f7-ea1044f251d4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi01LTEtMS02NjkxMA_526c1f97-4796-4d78-a5f7-ea1044f251d4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS03LTEtMS02NjkxMA_a4472a6b-b093-4b73-b6c8-ee80bcaf0c75"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS03LTEtMS02NjkxMA_a4472a6b-b093-4b73-b6c8-ee80bcaf0c75"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi0xLTEtMS02NjkxMA_db29f41c-bce7-4327-9bf4-be3e93d52a0f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi0xLTEtMS02NjkxMA_db29f41c-bce7-4327-9bf4-be3e93d52a0f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi0zLTEtMS02NjkxMA_a61cab80-88da-43a6-aa65-391f42890dab"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi0zLTEtMS02NjkxMA_a61cab80-88da-43a6-aa65-391f42890dab"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS01LTEtMS02NjkxMA_b18d0ce1-acbd-45aa-9cdc-ac7e018922e2"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS01LTEtMS02NjkxMA_b18d0ce1-acbd-45aa-9cdc-ac7e018922e2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi03LTEtMS02NjkxMA_34edd863-f4e2-4813-bb92-2662eebf4a0a"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi03LTEtMS02NjkxMA_34edd863-f4e2-4813-bb92-2662eebf4a0a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi0xLTEtMS02NjkxMA_28d6ffce-89e9-459b-a59c-bdfa2cfd0ac0"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi0xLTEtMS02NjkxMA_28d6ffce-89e9-459b-a59c-bdfa2cfd0ac0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi03LTEtMS02NjkxMA_1ca38dea-5804-491f-b6f7-af17f48eb3ee"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi03LTEtMS02NjkxMA_1ca38dea-5804-491f-b6f7-af17f48eb3ee"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDE0_fb645b76-e589-4eda-a1e7-a776efc5d3ae" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDE0_fb645b76-e589-4eda-a1e7-a776efc5d3ae" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 18 for amounts attributable to unconsolidated related parties included in these line items.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi0zLTEtMS02NjkxMA_11533d2f-70b8-49ef-8326-e453614be690"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDE0_fb645b76-e589-4eda-a1e7-a776efc5d3ae"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi01LTEtMS02NjkxMA_5f2e275b-70f9-47fe-8b15-566555a7bfb6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDE0_fb645b76-e589-4eda-a1e7-a776efc5d3ae"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS0xLTEtMS02NjkxMA_c1e43070-1906-4b95-918c-de3e2d6ad751"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDE0_fb645b76-e589-4eda-a1e7-a776efc5d3ae"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS0zLTEtMS02NjkxMA_edb76492-aae3-4861-9dce-2a945e70053d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDE0_fb645b76-e589-4eda-a1e7-a776efc5d3ae"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi01LTEtMS02NjkxMA_526c1f97-4796-4d78-a5f7-ea1044f251d4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDE0_fb645b76-e589-4eda-a1e7-a776efc5d3ae"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS03LTEtMS02NjkxMA_a4472a6b-b093-4b73-b6c8-ee80bcaf0c75"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDE0_fb645b76-e589-4eda-a1e7-a776efc5d3ae"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi0xLTEtMS02NjkxMA_db29f41c-bce7-4327-9bf4-be3e93d52a0f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDE0_fb645b76-e589-4eda-a1e7-a776efc5d3ae"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi0zLTEtMS02NjkxMA_a61cab80-88da-43a6-aa65-391f42890dab"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDE0_fb645b76-e589-4eda-a1e7-a776efc5d3ae"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNS01LTEtMS02NjkxMA_b18d0ce1-acbd-45aa-9cdc-ac7e018922e2"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDE0_fb645b76-e589-4eda-a1e7-a776efc5d3ae"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfNi03LTEtMS02NjkxMA_34edd863-f4e2-4813-bb92-2662eebf4a0a"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDE0_fb645b76-e589-4eda-a1e7-a776efc5d3ae"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi0xLTEtMS02NjkxMA_28d6ffce-89e9-459b-a59c-bdfa2cfd0ac0"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDE0_fb645b76-e589-4eda-a1e7-a776efc5d3ae"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RhYmxlOmUzMDJkNjJmMzhiNDRjZjA5MzQ5Y2MxOWI5ODY3MDdlL3RhYmxlcmFuZ2U6ZTMwMmQ2MmYzOGI0NGNmMDkzNDljYzE5Yjk4NjcwN2VfMi03LTEtMS02NjkxMA_1ca38dea-5804-491f-b6f7-af17f48eb3ee"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18yOC9mcmFnOjc1MDM5ZjgxOThjMTRhYjBiMjJmNDZiMTkzZTdkOWIwL3RleHRyZWdpb246NzUwMzlmODE5OGMxNGFiMGIyMmY0NmIxOTNlN2Q5YjBfNDE0_fb645b76-e589-4eda-a1e7-a776efc5d3ae"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDctMS0xLTEtNjY5MTA_503dff85-023e-41ac-9baf-a5d4bdb07ad4"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDctMS0xLTEtNjY5MTA_503dff85-023e-41ac-9baf-a5d4bdb07ad4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDgtMy0xLTEtNjY5MTA_922cadfc-cfbc-4114-8f67-576e593a58f6"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDgtMy0xLTEtNjY5MTA_922cadfc-cfbc-4114-8f67-576e593a58f6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDgtMS0xLTEtNjY5MTA_b751326e-4f93-4c44-a804-68bbee4f159f"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDgtMS0xLTEtNjY5MTA_b751326e-4f93-4c44-a804-68bbee4f159f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDctMy0xLTEtNjY5MTA_f538f3d6-8112-40a3-81e2-b534540a0098"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDctMy0xLTEtNjY5MTA_f538f3d6-8112-40a3-81e2-b534540a0098"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RleHRyZWdpb246YTVkOWE1YzhmNDI0NGI1OTljNmI2ZjhkMTgwNGUxNmZfNTY3_7b3fb7d1-25f9-4617-9e42-722c10fba725" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RleHRyZWdpb246YTVkOWE1YzhmNDI0NGI1OTljNmI2ZjhkMTgwNGUxNmZfNTY3_7b3fb7d1-25f9-4617-9e42-722c10fba725" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As a result of the closing of the sale of True Health during the first quarter of 2021, the consolidated statement of operations and related financial information reflect the Company&#x2019;s operations and assets and liabilities of True Health as discontinued operations. Cash flows and comprehensive income have not been adjusted and are included in the consolidated statements of cash flows and consolidated statements of comprehensive income (loss) for the nine months ended September 30, 2021. See Note 5.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDctMS0xLTEtNjY5MTA_503dff85-023e-41ac-9baf-a5d4bdb07ad4"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RleHRyZWdpb246YTVkOWE1YzhmNDI0NGI1OTljNmI2ZjhkMTgwNGUxNmZfNTY3_7b3fb7d1-25f9-4617-9e42-722c10fba725"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDgtMy0xLTEtNjY5MTA_922cadfc-cfbc-4114-8f67-576e593a58f6"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RleHRyZWdpb246YTVkOWE1YzhmNDI0NGI1OTljNmI2ZjhkMTgwNGUxNmZfNTY3_7b3fb7d1-25f9-4617-9e42-722c10fba725"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDgtMS0xLTEtNjY5MTA_b751326e-4f93-4c44-a804-68bbee4f159f"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RleHRyZWdpb246YTVkOWE1YzhmNDI0NGI1OTljNmI2ZjhkMTgwNGUxNmZfNTY3_7b3fb7d1-25f9-4617-9e42-722c10fba725"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RhYmxlOjVhYzY1YWYxMzc5YjQwMGJhZTVjNTU2NmUxYjA2MWY5L3RhYmxlcmFuZ2U6NWFjNjVhZjEzNzliNDAwYmFlNWM1NTY2ZTFiMDYxZjlfNDctMy0xLTEtNjY5MTA_f538f3d6-8112-40a3-81e2-b534540a0098"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjRhMjVmMDYwYWJjOTQ2ZjI4YzRhMDA5NTQyMmMyNTEzL3NlYzo0YTI1ZjA2MGFiYzk0NmYyOGM0YTAwOTU0MjJjMjUxM18zNC9mcmFnOmE1ZDlhNWM4ZjQyNDRiNTk5YzZiNmY4ZDE4MDRlMTZmL3RleHRyZWdpb246YTVkOWE1YzhmNDI0NGI1OTljNmI2ZjhkMTgwNGUxNmZfNTY3_7b3fb7d1-25f9-4617-9e42-722c10fba725"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>114
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M0K& 4*=U"2.>VAXI;V^T3/)3V;G46D;YY4IP7RCS ;Q?2*GW-^8?% ?[H_\
M4$L#!!0    ( (Z#8U5/T4C4$0@  *\A   8    >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&ULM9I;;]LX%L>_"N$M=F< .Q9)7=,D0.)D=@ITVB+I[#XL]H&1
MF5BH)'HH.FGVT\^AI$BV>'$'R#ZTL>3#H__AY?P.*9\]"_FMV7"NT/>JK)OS
MV4:I[>ERV>0;7K'F1&QY#=\\"%DQ!9?R<=EL)6?KME%5+DD0Q,N*%?7LXJR]
M]T5>G(F=*HN:?Y&HV545DR]7O!3/YS,\>[UQ6SQNE+ZQO#C;LD=^Q]7OVR\2
MKI:#EW51\;HI1(TD?SB?7>+3Z[!MT%K\J^#/S=YGI$.Y%^*;OOBP/I\%6A$O
M>:ZT"P9_GOB*EZ7V!#K^Z)W.AF?JAON?7[W_T@8/P=RSAJ]$^>]BK3;GLW2&
MUOR![4IU*YY_Y7U D?:7B[)I_T?/O6TP0_FN4:+J&X."JJB[O^Q[WQ%[#3!U
M-"!] S)M$#H:T+X!_=$&8=\@;'NF"Z7MAVNFV,69%,](:FOPIC^TG=FVAO"+
M6H_[G9+P;0'MU,7J\Z>[SQ\_7%]^O;E&5Y<?+S^M;M#=KS<W7^_0 OU^=XU^
M>O<S>H>*&GW=B%W#ZG5SME3P9-U^F?=/675/(8ZGW/'M":+!')& $$OS:W_S
M:YY#<]PVQX?-EQ#O$#09@B:M/^H*>B<EKQ5B3<-5<VJ+IW,0VAWHQ7C:;%G.
MSV>PVAHNG_CLXN]_PW'PWA;=&SD[B)4.L5*?]XL5:S8(1@WE^@/_8U<\L1*"
MMXYBYRIN7>F,\72!HSB)XK/ETWX\IAF)8Y(&@]F!TG!0&GJ5WO)&R2)7O->J
M1<OQ7E$_P47EDM[YCO8U14&43)2;5A!=&MF%1X/PR"O\,L_%#F2!VIQ#]]Z7
M?(YJKBPRK_R>_H/_:XLM,E3C-(DIG01G,:-!'(3VZ.(ANMBKZ8OD6U:L$?\.
MK&EXTXZ+4!LN(3_MKR-;N'[7CG!C<RA#2M))M*95A&F&[<$F0[")5]%7H5AY
M/*Y58CR<9C1)PHE&TRPB-(L="R4=1*;_QX62VF9)$$V46ZQ(EB1VX=D@//,*
M_S JTT#1R4B]H(JKC7B5S;E5=&;I2$V2 \T6HS!*[9)Q, (R.#+_H<B2H%-W
MLY:\U0&X%OBJ][:O(@OC<-J_%K,4T]B1B? >SK%_;N@Z9R$>%KN&]_,7.*XC
M8*JH'ZV*L=EO09Q-D[[5C 34H7AD,?;BSY=?:E$?3S%'W#MR3-_J8 4'\73]
M6JSB)',L7SPB&1]ALJB5A(H7Y:+Q99G>S6$FC-)I)K2841(31]['(X^Q'\@?
M:L7JQP)PUFMT3WJ3JZ'.QH92"Z63+$E=4D<"8S\X_RG$^KDH2ZLXDXL)(?O#
MV(LS[4+HQLR1]/ (4.S'7 <5SS";*,-)E.%TFN!LAB'.W$ENQ!Y.?J@B+@MV
M7Y2%*KB]+,9>?/[5NOBMO!T&/6(4^SDZU&U;]J*+-FMV\;MP91<3GS%.XVG!
M9C&#XL"Y&D;,8C]G(3"Y@TI@;S2ML?F]N&(S,8LI(=18ZQ:[("&AHT(C(Y")
M'\B?7V&&2@X[_B'*%P!=CPOKCLXD;A)$TR&Q6L690_.(9>+'\NN(Y*+2E&/=
MF8<N**IM*5XX1_>\Y@^%/4$0$[TTB<,IH2UF$<PZ5X?O[9;]"+WF#QRZ51>9
M3[S>V=;)BIBD3"(RY:G%"D/^<DQX,@*5^(%ZVV4']"!@4U*RHNJJ")@H[<E8
MG?.%/AQ:(R8E((V[BN.K(\]Q+ EB AC3*#;P9[-+H*YVQ3^2FOA)?;AM\2_[
M%3$A3-/N8.90K07J811FCHJ/C+ F?EA_%/7C0G%9H36_=U?2Q,)C3,+0F%2F
M'=''%K%#Y\AMXN?VY[8(+0>UQ_K5I#/4#],JPV(51=2U1D> DR,;5_9][_@!
ML4?)VUD^9D>K9'.#&I(T,32;9HX:F(SP)7YRNK(X="[D\;'RM\HVN1E!$6G(
MMIDE>_/\4/J(5^('XY /%73ZGF[W3#912('S4[D68(:N_14=<4G]N.QRPY&Y
M2RV[UH &QEJSV"4D2HECWTI'0%(_(%>BJHK^:$"G;KU%@LG!ZUQ/B)_N@)"?
MA.+H'<8_6P/PNK>7DLA6D[Z!H\,N&#%+_:?2=QLF^4:4:RZ;?Z";]G#$&NJ;
MGDV_E;?#H/=.IX]LA4O8%Z%+71A54!(U2N3?8/V_"TX"#'6Y1$^LW/'W*(F"
M>1"T_U"C.PJFR4YMA"S^Q]?O$0[P'$?9' K,=OIDP3R)TCG%Z:MUT310@,WU
M0=F6MR^;2GOO6A@=X"D;+599X-B%T1'CU(_QR_6ZT)4AK%=])+(HZD7.M@6L
M7ZM2D\\X3$A@E!TV0QJ"G:.LI2/)Z=&3[UVU*YD^=NR/A*' A5FL7PQ"/5:*
MQIYN3&0OL"7;6,QH[,C?=.0Z]7/]EBL&MZ#X9K*&) /YA>T%LH8Z/"^4/<V8
M]%Y$69@:YZ<VPYC$2>+J\Y'T] CI)?!R)U^ZM3)'K#M&@C4PCV@RAV3\EZ>\
MB?<%P9A,]T;'[0Y#&FL!ZJ\%.D0U!_F/N_.?B?4TBK&Q ;78Q1G=?VUR*'?D
M/_7SWR!JFW)^6'YFOF2SGO;8#'VG/:$N"0[OC/@-_?B%C<V 6,B9>A_%JNYP
MA"DEB_N=:NM*)6 V=<L$DG,;>U'GY6[=OG= D +:4J[FJ%"\:DYLC%CNO:VN
MN'QLW_HWJ#V+Z=YK#G>'7Q9<M2_@I_?#X'0%4=N^P?!-]]N!\1'=3QE^8_*Q
MJ!LH.Q_@<<%) A-$=K\.Z"Z4V+;OR^^%4J)J/VXX@V'5!O#]@X!>ZB_T X;?
M:%S\"5!+ P04    " ".@V-56E[,/+0"   X!P  &    'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;*V576_:,!2&_XJ535,K=>2+0-=!) I4K=2UJ'3;Q;0+
M$P[$JA-GM@/M?OV.'8B@3;^D<4'LY+ROG]=Q[-Y:R#N5 FARG_%<]9U4Z^+$
M=5620D952Q20XY.%D!G5V)5+5Q42Z-R*,NX&GM=Q,\IR)^[9>Q,9]T2I.<MA
M(HDJLXS*AU/@8MUW?&=[XX8M4VUNN'&OH$N8@OY>3"3VW-IESC+(%1,YD;#H
M.P/_9-@Q];;@!X.UVFD3DV0FQ)WI7,S[CF> @$.BC0/%RPJ&P+DQ0HP_&T^G
M'M((=]M;]S.;';/,J(*AX#_97*=]Y]@A<UC0DNL;L3Z'39[(^"6"*_M/UE5M
MU'5(4BHMLHT8"3*65U=ZOYF''8'??D80; 3!6P7A1A#:H!69C36BFL8]*=9$
MFFIT,PT[-U:-:5ANWN)42WS*4*?CX?75]/KR8C2X'8_(Z>!R<#4<D^GY>'P[
M)0<3*B'7*6B64'Y(/I./Q"4JQ;NJYVH<W7BXR6:DTVJDX)F1IE"T2.@=D< +
M@@;Y\&7Y"!*4^U;N[\M=S%P'#^K@@?4+G\/15 ,N1TW$@IRQG.8)HYQ,A&)V
M??T:S)26N,I^-T6MO-O-WN;+.U$%3:#OX*>E0*[ B3]]\#O>UZ;@_\EL;QK"
M>AK"E]SCH<@R3(OK++D[(@659$5Y">2 Y60N.*=2D0)D]=8/FZ:B\N]:?[-G
MK&*OY>$;6NU&?*5H#[U=H[??@5XM2T)+G0K)_L*\B;4RC'8PNI%7_1X!OZ5R
MCSJJJ:/W4S.ERF;BZ F'[_E^],7K!H^(GU9B470<^L?-P)T:N/,B\"T>#JJ4
M#UMDJDDBE&Z"[3R%C4)D>(SZ>EU%ZN[L:^9,^4;EDN6*<%B@TFMUT4)6^W35
MT:*P6]U,:-PX;3/%HPVD*<#G"R'TMF-VS_JPC/\!4$L#!!0    ( (Z#8U5*
M[V?L,PH  .LS   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULQ5M=;]LZ
M$OTKA+=8)$ <BZ0D2]DD0!K+VP!M$M2Y]SX4?9 MQM9>??A*M-/LKU]24BR;
M'-'I5HOM0V/+AR/.X7!XAJ(N7_+BSW+%&$<_TB0KKP8KSM<7HU&Y6+$T+,_S
M-<O$+\]YD89<?"V6HW)=L#"J&J7)B%B6.TK#.!M<7U;7'HOKRWS#DSACCP4J
M-VD:%J\?69*_7 WPX.W"UWBYXO+"Z/IR'2[9C/'?UH^%^#;:68GBE&5EG&>H
M8,]7@QM\,;6);% A?H_92[GW&4E7YGG^I_QR%UT-+-DCEK %ER9"\6?+;EF2
M2$NB'W\U1@>[>\J&^Y_?K$\KYX4S\[!DMWGR1QSQU=7 &Z"(/8>;A'_-7SZQ
MQB%'VEOD25G]CUX:K#5 BTW)\[1I+'J0QEG]-_S1$+'7 -..!J1I0-0&3D<#
MVC2@:@.[HX'=-+#?>P>G:>"\]PYNT\"MN*_)JIB>A#R\OBSR%U1(M+ F/U3#
M5;46!,>9C*P9+\2OL6C'KV\?[F</G^\F-T_!!,V>Q)\OP?W3##U,T<-C\/7F
MZ4X T,W]!-T^?'G\&GP*[F=WOP?H[EY\#]#)YX?9[!0-T6^S"3KY<(K*55BP
M$L49>EKEFS+,HO(,?3CX?CGBHN/R]J-%T\G;NI.DHY,4?<DSOBI1D$4L MH'
MYO:^H?U($+9CC;RQ=DN,!F=L?8ZH=8:(10C0G\G[FV/(G5^[^_2_OOL!&707
M0K2R1SOLW66+/&5HQD/.1,[AZ-O-O.2%R!G?H:&NC=FP,9E(+\IUN&!7 Y$I
M2U9LV>#Z[W_#KO4/B.<^C05]&IOV9.Q@1.S=B-@FZ]=?V99E&P9TZZ.YX3<,
M#EG=R*T:R:5J>TT=XGC.Y6B[/Q@ZC!!BC_$A+-!AONL[G@*;ZC#7\1W?W\$.
MJ'%VU#C&8 U^B#6Y9& 2<OJ,S#Z-!7T:F_9D[(!^=T>_:PRPV[SD*'\6FJ2*
M4'3"?BR232G$A;P:,7'+11S6FB.+4)CF!8__75]@S="AJE\99Q$JV3HL1-I)
M7M%<BJ13*.3-/>H(^;J1LQ_+KNOBL1+R.@R[%!-7"7D=-J:NY:HAK\-LGUI[
M$^B \_&.\['1PYF0;7&V/$-+EK$B3&IF(R$F8IFFI;+;<0OQ9[;>P=]8<\7U
M'*(X/-%1#B8^4=C34=AS;<M3V -@,DL1F#UOQYYG]&_RKIB$*/#T_HRQKX3&
M!$#9GN,K%.@H>VQC6V$ 0-F^VT& OR/ -T_959@MF51PSV%<H&V8;*K)NA"2
M2H257/#%QS*.6%%Q E'A:QT;8C*V+(4+ $:(LLH$ $@,LA(S4P#EX8ZU UNM
M6+:,7#SE7,P?4=9)5[.E<?@;4_M=H-1WJ3)H$P!'B&\YZBP <+Z8!5H2 7"N
MYX_W N_0^;U* 1N=?]BY'=>*[R3)RQ)*N;>-I8.H)KZC3G\ -G0U)1  ,,<A
MENHW8(Q:V!]W^$U:OXG1[SNQU(@5AS=N@_X2?>:I@3L!0%CU(@! 8]=17=5!
M%'>L$KB5\=BH25L_FZ@&':4ZR?;8T6(:@+G4':O. C ?VU1U%X!A$=)>A\>M
M3,9FN?O/4&:U(D\1^VL3\U>4,K[*(S'06\$#ZYC7MCZ,5%VS)@#*I:K[.H;Z
MMA;7P/W(>"^Z#IUOA3 V"KW:>;&$"0F0E<^LD#D]9>F<%>4J7H.>.UI/U Q^
M'!(<ATP!B$B);E?Z;L4G-FN]SR)?H6K5EFEL$Y<K6:^."J$B7ZO*M=*@<PXZ
MKXNS(1;I11MX':<Q\#Y34Q#G8Z<K[EM!B,V:K5W2>?A#:/$%B[?A/&$H7!:L
MKN&3.)S'B9@3(!>ZU!K:Q!MKT:#C-"[>9VIJ-'5(0ZOLL%G:/?"5"/NWQ:S)
M>J=G*&-P!.CR:DAM+<L#*%M;T0#51S67 4MCVN%TJ^:P6<Y5<Z#*>;6 V\@%
MO5$T0L:).NHY+]@;*R(^.K(@(+!LH6^H2@<H_3Q+K9 @G(,]1R,%P%%B6QVK
M'VFE'3%+N\<BW\;5?KGP'YW,1:WT'/.*J=.C;!!=<PUMQ\&JV =P1!6$ 6A,
M"'FUW@%P/NU0>:15><2L\N[VM9TA4$ := E&,%%# D -1?2K"U\ X<94U<53
M"$;%OP[=1UK=1X[I/HV)*"X;,EBTQT65,N3B(0($JJ"/W.@; 4MHHJL\-<$>
MAP0 9&BK4F0*H##U.I(-:24E,4O*>\8/BP44<E[$\PVOEAN>B]A*4S'GJL<&
MJSP1160IB0RV>2*7H4\L3/CJ#(FQ. <YTJ4A%'&0@(0B#L"-/:S*;PA&L;^G
M@@_I:O4H,>M129>DZ5=80D,TB9,-!Y^3W!)@CQ;@2T?!? $XB"\ 9N*KE;#$
MO)G[,2SCQ07H9Z][N;U:"WJU-NW+VN$0M)*:'-O0A43$B9"649XDH8A3<;4.
M7'"GH#$_WL]@YY8JJ@'4T#I7 RV 8=I&(0RC'>4%:64U,<OJ";PZ_ P;1P7S
MY#@D:"">0H.Z403 #J@_9*%5U<2LJJM)J63]G=>_E-E^@D?/[%I#I8X"HPJ$
M6;Y*)PCKE"&M8">^,<DUV1Q.<T:M_]-IKD]K0:_6IGU9.WS"W58'U%P=_&J:
M:\P?"4@ !04D#-/2' SK2G.TK1"HN4+X]31'=<FNIKGCD*"!'$MS *P[S=&V
M.J!FT=Y,R_]SHFLZ>63Y!%!@7($P+='!L*Y$1_>.D9C/D?Q1G0)CT3#<BIA:
ML@/*!%D;7O(PB\0<!)GH]UQ)OP=+^CU9\K\X6D+;(H6:BY1Z?9<A6@\,')?Z
MIK7O$$_=#P%@GN.ISP4#R!IVM><$H#5J=6R)T+;,H.:=\K>I?LQG?=?:]ZF:
MEB< #/09L ;Y#%GK]KG5]=0U3L;;/!71LY)'2+?L^ ,_:JP2?GKV]6DMZ-7:
MM"]KA^/2UAC47&-H.RK@:(S?4^4#*+#*AW! E0_!#%4^;0L*ZAE#L=ZF7W0'
MY/[V&RO/4,&24,Y7GH.BF1KKEY^.U3ZM!;U:F_9E[7#@VLJ%FA\U3/-"+.D9
M6FR*@F6+U_I18](<I8G^M2FY?-8$CA%T%,35=(V.4C?3(4.NI^XA0RBOXPFK
MW18-]GM.BQ@"M^_=T*8_^U,0>^H!D0F DO.>JH]D()QG^\I#_"D$H\3JJC-L
M66<<7FDUMWUDHQQ_GS&&[G/.$/:J!S5AFF\RKN^8;C)Y*"E/XJA*!6\I81T6
M/*[.IR^2353)=R322\F0O!>*.4O+\V_D^UW]>XD^G%CGSFD]*=(X263H)LUC
MY"@NUWDI#P0]=ST9J/HH;H R:3ZM3Z$S>0H=S=B:5X_;=T>YJ^-E'_"Y?WB[
M9?.@ON?;89DHRS6K7NU(7J$9/]I[KR!EQ;)Z Z0442HHKX_<[J[NWC+Y6+U;
MH5R_Q1<3#%P/\,44NGYCXXO AG\AXI?J'J.V2_5K,%_"8AD+$A+V++IGG8_%
M?"[J-TOJ+SQ?5V]"S'/.\[3ZN&*AF&42('Y_SD5D-5_D#7;O]US_!U!+ P04
M    " ".@V-5J. ?^ID"  #M!0  &    'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;*U476_:,!3]*U=9-;722D*@W=J%2'RD*U+Y$*'=P[0'DUS 6A)GMH'N
MW^\Z"1GMH-K#7F)?^Y[C>^S<X^V$_*'6B!J>TR13'6NM=7YKVRI:8\I40^28
MT<Y2R)1I"N7*5KE$%A>@-+%=Q[FV4\8SR_>*M:GT/;'1"<]P*D%MTI3)7SU,
MQ*YC-:W]PHROUMHLV+Z7LQ6&J!_SJ:3(KEEBGF*FN,A XK)C=9NW_;;)+Q*>
M..[4P1R,DH40/TPPC#N68PK"!"-M&!@-6^QCDA@B*N-GQ6G51QK@X7S/?E=H
M)RT+IK ODJ\\UNN.]<F"&)=LD^B9V-UCI>?*\$4B4<47=E6N8T&T45JD%9@J
M2'E6CNRYNH<# /$<![@5P'T-:)\ M"I JQ!:5E;(&C#-?$^*'4B336QF4MQ-
M@28U/#.O&&I)NYQPVN]/QN'D83CHSH,!A',:1L%X'L+D#B;38-:=#RD!NN,!
M]">CZ2RX#\;A\"F X9CB ,X?)F%X >=3)C'3:]0\8LD%7,)C.(#SLPLX Y[!
MB"<)O9GR;$TEFX/MJ"JO5Y;GGBCO!D:">!4$68SQ2[Q-4FN][EYOSWV3,,2\
M 2WG [B.ZQZII__O\.8;Y;3JZV\5?*T3?,,L$BE"J)E&Z@T-W[H+I27]W-^/
M759)UCY.9AK^5N4LPHY%':U0;M'RW[]K7CN?CRG]3V0O=+=KW>VWV/TOY"]
M71QSE0O%$A!+,X_HL7FVP1C(IB33IWZ:DORF(#<^M?4OG<:59V\/]?V=U&S<
MU#EEV?9!YZ0H5X6A*(C$)M/E3U6OUI[5+5KUU7J/O*RTGC\TI1&.F%SQ3$&"
M2Z)T&A_)"61I+F6@15[TYT)HZO9BNB8_1FD2:'\IA-X'YH#:X?W?4$L#!!0
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M9,:$4&,1&$'0WPZWJ#4#$8W[ V8RAF3'T_41_7W,G7+)A<>MU7\J&>I5<IF
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M1KG:5G1HNS%@(G*WK76U0PA=I;O"MJ8 R*UI[%;EKO)P<*'QX<I6&D[0I?(
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MZ6L93<5P?<NSG5@:,8UW567*03TW9AC)U,F^<0N6AVU=NIU)1RV"J> R9UB
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M4&+P(+@ OL??-0A_X 'QAW;>_B]02P,$%     @ CH-C59MVY[T)!P  4A$
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M[%&2P,4QUI?(&<?L>#1]H/'KH^GH<!?9-@@&<<QKUNY0N/;.XKK(PT44TV]
M\3UF> X=ILTO171YG9)I]LRXF1Y,3H=T*8F0[D.VEF#]7+:O/KI&%W0Z.7[]
M;L]$2E4 %@K\:!+1/W<W#:&R^QF5\G:5/DI *;2=LET'A[ZZT+^]WO[9@Q%3
M)(DRKP;+K0/%O0-2\LM^)?I#\@QE=>);W" ->?8E/5ZJK+\/>8.2<9[TPW>?
MVRGAGR^NZ$3&] >^8=ORRTY*'V#]4$WCG4H;A6Q:76123[8^K8I=$!(1 7N'
M]&\-"4BM4MK3C3(M=\!DM^L[$O?<%U'>$GV_<R:>L>A$TZV?*&9>:6M3X:<)
MU"_QT^,'K8HN-!T)"(X\#<$'(_H5,?=]$'"(!9SJQU@ODS>N\.=7KGV?3>.=
M[UPD9Y6^YB5&J.W\R=L_[7\PF.?OY/OC^=>&GY1?R2PR7$%T,GIS/""?O^#S
M371-^FI>NHA*2)=KC$GV<@#O*P<^Z&[$0/\SRL5_ 5!+ P04    " ".@V-5
MF6UEJ#<+  !0(0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6SM6EF/
MXS82_BN$,QLD@-IMR6?/T4!/YQI@DQFDLUDL%OM 2[3%C"PJ)&6/\^OW*Y(Z
M?'5/[R)/NP])VQ*K6.=7A^?U3NF/)A?"LD^;HC1O!KFUU<OK:Y/F8L/-4%6B
MQ)N5TAMN\56OKTVE!<\<T::X3D:CV?6&RW)P^]H]^Z!O7ZO:%K(4'S0S]6;#
M]?ZM*-3NS2 >- ]^ENO<TH/KV]<57XL'8?]6?=#X=MURR>1&E$:JDFFQ>C.X
MBU^^G=!Y=^!7*7:F]YF1)DNE/M*7=]F;P8@$$H5(+7'@^+,5]Z(HB!'$^#WP
M'+17$F'_<\/].Z<[=%ER(^Y5\7>9V?S-8#%@F5CQNK _J]T/(N@S)7ZI*HS[
M/]OYL]/)@*6UL6H3B"'!1I;^+_\4[- C6(PN$"2!('%R^XN<E-]PRV]?:[5C
MFDZ#&WUPJCIJ""=+<LJ#U7@K06=O?]&\--Q9R+R^MN!(SZ_30/W64R<7J&_8
MCZJTN6'?EIG(#NFO(4DK3M*(\S9YE.&#J(9L/(I8,DJ21_B-6_7&CM_X K^W
MM<$38]B]VBQER7TDE!F[,P81?Y?^7DLCW=-_WBV-U3#%O\[9P5\S.7\-9<Y+
M4_%4O!D@-8S06S&X_?*+>#9Z]8@2DU:)R6/<G_31H]3G9>NS9.>,9-B[357P
MTO)E(=@'K;8R$YI]KU5=L?<ENZO7"$X6>T]%S.:"R"M>[EF*OX6P(F/2&N1=
M9V.U>H1MQ-Z5Z9!]]>47BR09O7KWX7OW*7[U=<1DF19U)LLUBT>COQ ?NG"K
M+#T2N,#N<<8** B,8J!E$E>S C@%_K)DE;N+CIM:KV7*"Z11"=P!PEAF5%%[
MM8%S;%.;M"Z4^0CPL#B8JC)S"H#U+[C7=M:C:\2G"A@#=:V"MBF(-+>"J1K@
M9^GC>D^OE@*&$4$H$J1JU(<Z6U[4XHKP)6,&["0OH%+*M>C)Q@W; ;_H;P8L
MTT:N]NX:+;:BK 5=)_@&IZ3-Z2*NUV#O800?*J7M2A52/:E&)@1@W_%.><67
MLH#^PD2,%X!Q$KXV="[5RI@KXX1RG]O+C$LS4>:\3+TMG(JD=*5".(!!Q;4M
M<1H2*3(U*)W(4)=,XV(Q8B5R%49*N<D9Z')B3?^E0EL4'I;"6204SW[#]>11
MB+J#F5Y,9O%P#N L"L?(&YBNAOX-5:4EB;CJ!S&%7CQ_A9PH.+2ZHZ#>@ [*
MI1\;!C_]X^%;^GR8#-ZXYQ3QWPS9&+>]2*:SX;21K=7O2/5Q)SXS.>+!T,ES
M4D5LQ64P,\QCV8MX/!HF+35WE,>)ZTW)!-?E%8HV'4&&PS,O%O/AJ+/<,>_Y
MM'M[EC6%5,7W+M')1:0;+KM&?G5Z/&;Q>Z_;@]<-=YX[K"HRTY ]"+A#(>OB
MN4MAGOF,14C)TO<NOHU8<^V2CYAU.B'@ 1Z;ID($R5JC'/C$^[>J=9HCFD+T
M4+!1;J0\9!#1<RHR 0&U\"%;R#:;Z'V]P?-^5$(B8)C<.#Z=@.:2^PBQ*"<-
M^TH2 U4;7&.^?LD^-!(>2/^2W9,G7C!$7S19+-AWG1$N!!8\:<CM"*<HGD^/
M*,"=4)A0]##8Y]-H-!J%O#Y\]8(A+Z/9;,Q^X>5:4H@<V>HE:G.J:B0R?)8*
MN75Q-)Y$\72*NB$J+C.'6*41'FH4C$=8IS6)$MC-QC/VWKTH57EU]#*.QC?C
M()^]( <;SZ)X,6'O,A#*E0SA?.DXK-N K1:%KZ2YK'#7=.*M(=*\5(5"24C&
MT0V>W"L-7*:" 3S.!"OYAJ(X6K2VDY]W-XMOIM$<5'\]#;&>.9N<G$<W-W-Z
MK,FW_;!<1*/%N'U#U1Q6[EHG@0JN]LBWI2C%BDK\)!FS;\1*:)+"\D]];AZ\
M)XMH-H^[0TW!&B<Q>U^YL$!.HC B7/NBP$5)XZ)SF3.;18MXP;Y7*ML!BUAR
M,XNF4.LG84_,TPNZP]P/V=[%64?D$LSD:E<RZ3'?=RY\J;8"+RN4LT\N68U[
MN_8U$"E!G60-J?G&FYTL=U1DEY2:A9M/ DBNZJ(8/AEKQBCT!\3$U?GT;,2A
M)>M"C2YW%>]<K#G#019(JJW\PR,1=ZT+C317U% 21$%Z**T#2*&7+"0!IM[W
M *LV CK 55N/[\F([8&BD&;:?"!9XO8;Z@ 9!.>+O0?6\^HPZH0 M9@<90&%
MK-5R67MGP)3B$\HJA5!C>M/8QF=\VY6$SJ<S32C)IL<<<G/7IVB)]@_ZG16I
MWS[Z(LJ+O94I..$0E1Q8"E7+U!7U781C]-?5'NI[]DH'(8,-Z#%BVK6FF=A2
M5:':XOH:XM^YO;TJ6.R<5S'<4F3YL/1Q[L394=X6$OGGWE"GO-3$WU&AX=24
M7R'889"/P@XO),QI:%(5;"JIBX:FTJ)_=[TOY0M/\S8@*8C$BJVTVC"M]J[I
M;0[Y:X\IFU@S?8%<Q2^]%(<]GAMYX*&N7%'U6[F""8Z_]9,1-<QU[BC(^ZY^
M#VE,">=ZQ!2/F30.5'U+Q*%-@!K?_Z_PP-:Z](8_<(@/)/A 2_/1!5R:PR>-
MN?KW!$M!:]%I@=HL0KX\9L*>M>R)"SN#T:!18.+Q* RTPP3DG,0(B,!OI^HB
M0]N]=<F&:"V=S3Q> RH !)@U&GNU: S$:!B3B;P0F5RA" B:"I;"[H3PCNJ/
MB1F9[S3>[)E.HC'/Z>GR3 F@TTA#'Q/!)C5<A%8/;-5&IEU1:[+%([:?[7*7
M-]3J4=+6A6TNZTGOO;+NV>  K#J8.1B?R/#* 45=AA(7-.N$AS(;L,C<H@LA
M#PO2H=!ZGK:?]^#JT.2AG2"-6!-@>1F;>=T7/A?>6N\]QJ.(>\@/2-!8\KB#
M#<*]HL%7N<ZZV!]N \!=K4M75\@EV84^X:2L/1(KM.0+XK7IT0I,6/ 9$I^Z
MJ50D75:'<NSX@"L:?0RL EA[U\X4I"-WZ8\,#Y?[N'&#W60V7+2S$;F';* S
M6HB$R1.^P!R>.6V-Q1\WLQ*QJD)H>]&I^](BIRWHM@7#KS"XFJ];36VNA0^%
MDDKUQJ_D!*WD,!=58+Z$2YNM6A36% 1<+0O*G)!0-$RXF1W (L* $R+6H59O
MO&DB\Z008/C.99J')/%Z\_.NW_M$"[N0C-!$U=K/XT'=4$$I1;3@A?RC'=)\
MSW_ UPO@O=OV7M2M-0#<J]OM%'FNF6E2^PP.M<J69W1_<MQ#("$M2B2=,71A
M;VGAJLI1B[B"6(5+GU"5"'P;27*I,_9[S;7U:R0X>#QDOTH"RF]$*HT+I/<E
M>Y]:15'@!\?X&0N[(V;/WL4="]/NY8Y78%U3=B5*[H".9UL7BFX/1GO#TBWP
MA*;N"*(@+6KMBV;8#[B3+G0R"<[HP$.3!2*)V9@A*]VN$S9=EZ:%FMZ<35F7
MDT^=?"( $!4$K>IU3OL 3Y C&$']&^(5U9@(([=IA#<D%3T=A9K7+\AE=J56
MZ*E7M',(-OG?6<?%\?S/7\<=Q?IG[^,FG[&.BWO(_MQUW'0VG!VMS$[2\O(Z
M;C)];!T73Y[B_?]]W)^QCSMUX'^\D)O,HNEH](Q]W'06S9+9YZ[CXDDTN[B.
M0UY&<_"ZO(Z[#_'B X=@'E>ZF@7J:#(>G5_81>-1_(Q]W7QQ>5V71-/9Y*EU
MW3P:S\?_];9NG#A7])9U?I=Y=E<7SCYK53<9.7Z?MZF[&9]=T\UF\7.6=#?S
MT5-+NIN;TPU=X@1];$>71/,X>6Q'%]V,I]U0.)]'R6)Q84/7Q.&Y7TVO>[]R
M.S2GW_)IV09C^1^\VZ?M/Q>X\[^2=\?]OS7XD6N4=P-E5B =#>?3 29Q]_N]
M_V)5Y7XS7RJ+^' ?<_=3(AW ^Y4"MH4O=$'[CRAN_PU02P,$%     @ CH-C
M5<+1,0I9!@  PA$  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&ULU5A;
M;]LX%OXKA*<8V(#'%]ENG"N0I)WM+-IIT&1W'A;S0$O'%J<2J9*4G<ROW^]0
M%\N9)&@+[ #[D%@BS_G._1Q29SMC/[N4R(O[/-/NO)=Z7YR,QRY.*9=N9 K2
MV%D;FTN/5[L9N\*23 )3GHVCR>3U.)=*]R[.PMJ-O3@SI<^4IALK7)GGTCY<
M469VY[UIKUGXI#:IYX7QQ5DA-W1+_E_%C<7;N$5)5$[:*:.%I?5Y[W)Z<C5G
M^D#P;T4[UWD6;,G*F,_\\DMRWINP0I11[!E!XF=+UY1E# 0UOM28O58D,W:?
M&_2?@^VP924=79OL-Y7X]+RW[(F$UK+,_">S>T>U/0O&BTWFPG^QJV@7BYZ(
M2^=-7C-#@USIZE?>UW[H,"PGSS!$-4,4]*X$!2W?2"\OSJS9"<O40..'8&K@
MAG)*<U!NO<6N I^_>*-<;+17NJ1$?"S(2G:6.QM[@#/).*Z!KBJ@Z!F@8_$!
M.*D3;W5"R2'_&$JUFD6-9E?1BX"W5(S$;#(4T22*7L";M9;. M[LVRP54B<"
M>X5Q,A/_L*8LG/C/Y<IYBXSY_2E'5'+F3\OA*CIQA8SIO(<R<62WU+OX\8?I
MZ\GI"U;,6ROF+Z%_2[R^"TA\U.*?4I<H4#&=!N?C_]NMR4A[\8YDYE/Q_OTU
MUMZ)=R9+E-Y4/KRS)=4$0T$R3L4N-5GV(,Q.0X0K5TXE2EI%3IBU\"F):Y,7
M4C^ 7'NR(%+:&R'%K3?Q9W%3VCA%P8G+C27*67Z?N7[\81E%D]../'%[<QE6
MIZ<#U \6KBQ78[/]06HT&$88BE]T/!+]&N. [%I::E"&HBBM*R5D0J-=JF#.
M@<&L4L)[:#"9D/B#3<H[05]*Y1_8$ECDL*!TUS7,\A>I(W&=&0?@QC'(/>UD
M7$6$PT1YD4D/B:N'0/#(>&'BN+3L032Z#Q)^$[,Z>,_ZK!;9^HUCV F*@.OQ
MEPAM1)THK*#22(5M%8W@Z2XDQQCV4^4U!HMKN^@^IL(CM"B)G^A>.<^K7!PJ
MIMJ= 1-C!DQ2Y0ZD!GN!G74SP+,BK23!&^CH"1JBXD+ESB[6I:X\-A*7;8JM
ME75>?$$^(QZ\6"5TU]"$L 4DCF<J_8%%.<8BTR;=:C'[:HFM K.2HD37L^+R
M]AH"%L.@,/SGRAC%T 64SI&O"B93<J4RY;D@9%#X#<64KX!3!V\R;*."7,*<
M"50=\>PMSCVL*).PR]!P-.<)LHK]"/>M%05=GC,AJ IJ;3RB&V=E$@JQ&_0.
M-39"7/%L,I6$G%PK+76LT#Z=QP+'$3&X8^^C 9@=0WBYRJ@>_>I/6/R\48?-
M@?-S>G3J#KRX*I$6R(UA79JL?U=W/)L<XJW)G[7[*4OV^C_2B9T$2/@WY0/)
MEAH1?22X&X1 A,)-D<B!6D-!D5<CD7@D"@PT7X>WFFK3$_%SS7<7^+H3] GR
MEOI7QOY$6X)-X@:-@0]G59'L57X5BGX:G>)IMA0WEG)5HJR:U?E\>'2\$'?&
M(W"V!NML+F<S\?8>AS^':%T;5!%<TM#U4=!9&1R!U83@&"1 =<[B?,J-]>K/
M:H$:D'UV.BHD]"1,AQ6?"P>B/QVTPA?#Y7*!_A2Z0,O=[,YFP^/%'.[),-(V
M0[$A#9NS2NYA1VAY^U$7_>CU'*7V52HW3)C>M:=J#X>>]HAHSM"S9IB"@G.C
MW>T?SR8#C)]J+C3YTPJ81ON]&GG/.A^(CZ']'2)&BX%XSRLK0@:T.>GE/54I
MJXW^B9/?FN"LSE1J,9;SHP&2PVQ5.&=S(A_ M(2SZ/5 _(I^&'3H9E=_$>VC
M]\T_(?2/\ZLN9E=I'->=NO7XBOR.2!^T\4=GD*J7<V- G(U]HC%\?8/[[K9@
MJ9K:?*KAK/K?SCU6[E4T6N*>@'#7P61COJ87C4*1?%-5U4'Z^V-D_L]C-!U-
MOS-&=R^;'4N7BC4:ZE^/!JG<5C-^Q4&1R1^X6S8GV+89\ZR$5Z@+U/'/,Z,4
MQ]<GR1\?5)NI+9+2AC/!5YI]TL4ON%4EU4EXWXO#Y;XZ2KU"AY],HBY/Z9K,
MVI)[3-^/AO/C^>"IN]FX<Z_.R6["UP,^D)?:5U?L=K7]0'%9W<OWY-77#1S*
M-PKASV@-ULGH:-$3MOIB4+UX4X1;^LIXW/G#(_()ATHFP/[:&-^\L(#VL\W%
M?P%02P,$%     @ CH-C57G\3&"N#P  B2\  !D   !X;"]W;W)K<VAE971S
M+W-H965T,3,N>&ULS5I9<]M&$OXK4XJ3LJL@BN"M^*BRE623JG7BLKW)P]8^
M#($A@1C ,!A ,O/K]^N> P /2=ZC=E\D$AST?7S=P(L[77\RF5*-^%P6E7EY
MD37-[MNK*Y-DJI1FI'>JPB\;79>RP==Z>V5VM9(IWU065Y/Q>'%5RKRZ>/6"
MK[VK7[W0;5/DE7I7"].6I:SW;U2A[UY>Q!?^POM\FS5TX>K5BYW<J@^J^=ON
M78UO5X%*FI>J,KFN1*TV+R]>Q]^^F=%Y/O!KKNY,[[,@3=9:?Z(O/Z4O+\8D
MD"I4TA %B7^WZD85!1&"&'\XFA>!)=W8_^RI_\"Z0Y>U-.I&%[_E:9.]O%A=
MB%1M9%LT[_7=C\KI,R=ZB2X,_Q5W]NQL>2&2UC2Z=#=#@C*O['_YV=FA=\-J
M?.:&B;MAPG);1BSE=[*1KU[4^D[4=!K4Z .KRG=#N+PBIWQH:OR:X[[FU7MU
MJZI6B?<JT=LJ)TN]N&I F'Z^2AR1-Y;(Y R1:_%65TUFQ/=5JM+A_5<0*$@U
M\5*]F=Q+\(/:C<1T'(G)>#*YA]XT:#EE>M,'M-S4NA0WD+5&-,#2329NV,:J
M%G]_O39\_1^G#&#IST[3I\SYUNQDHEY>(#6,JF_5Q:MOOHH7X^?W2#\+TL_N
MH_Y8'WTQ$?&;0@#7R JDE_UU5^?(S;S86U/M"ME0X@M9I0*%H)9TGQ&D89XH
M,Q+O'C@A9*U$L]_EB2Q M42RY)=[)6O\4,MJJY#@C;&N2)PKC&@T)-&W>:K$
M+<31K1$)%"(BS$BF2(6<W$4Y+8PN6F8[$C]50K>UN/&G/_B?(-&6>$7\>[B#
MY4N5R;>52HDOJA2"H<F4*%7*)-1G5$ #5?2&[]W)NJE(2I(DKY*BA9CT0Z,;
M'$^T:>AH0I3IB-FI))=%L[>72EE)JW;/C$[L[V]U03_\J' ^$Q^\$1\IN[=9
MHDN$84:E$];)+#'XLNI[B$1+"IF7ANX#%Y-7VR!29.U<&!U4A+5!D -'UZ)N
MJTL4^<[1X-\YL%:)RF^)8!=139;7Z259;S]P(.@]_>:KU60R?O[QW6O^%#]_
M=FR<^WQZIP3^PW%Y1790-;>K*E&75++38; UF6S@AGW0+)&[O+&20.LK:+=%
M.S,9V7>C9-/6),9OE":</'\.;O&Y0W>+;:V-H3Z1(ZCA 9(LD_"",HU<%SDJ
M-<Q.%0BE7M^Z4 M&I#S(K;HF@;/8"P]SK="]ASQ3+2K=6-:/9S<2OU" =^83
M&C)O+4<<Q,U&#8V9#[)5TK%&;>%7Z&G:O%&4"UU469-38,B$8HYNYJ3R=82=
M Z(VEJ T1W9)^(1%M\G$URNETI"57>R1R4I5KO%Y)/ZBD*I4>CA&[O("!62W
MXVAD.^2PPK;-4U86C.CR&?VE"<Y,%6(-$4S"D;Q*)IEH %9(O]HF-W1($>&X
MT'#L=(F X"4%X#<J;H@*BC)(T]1M0K$FP-V9NLLN8M/541>Y4%:4U'IQ:2?W
MS#<84!9)6[ ?; YPI+#]-CF^0DMG)ON1R CR6V2K]*Z@4VMKJ:KE@["ULZQE
M,RR'OKB1=UL@@9HU+%J?A+8B=L%#9402\P1?4!.)/%<I%*\R;TMCPW$0;I2V
M@ZJD(5X],"15'ZLW_.D,* JD"UR_K94E% E.[S14>2.I7)DA-VYJS* ?$Z62
MQI:$7SU;I)A!_+MR!NLCW>%N$J+ENLH-A3I#D7]2\)8L=5LUG6?(DAG"1=>A
MYR VB1O)L 8Y\7N;<K43TJ8"Q=M(?->&N*VX4OF$Z"L2B435#6I:D,M:<FTE
M1QGF6,XW(N?803JO62_V,J(&+091DTAPI\)3&\@(/KX(<5[I) %;+D D35LY
MGBCW.?D$?>M6I0=UM.XCLX?@AJM@E&>=5?DK'+YC2[;-#DVI5$VFP>J'_+,M
MMT/G!/8I!3P4W7>U,?'HD#*<>P\*E:YM@6"8<J)R<'%!8NH$INV"<<BXJRZY
MYMB\R_+$DNM%[2C@4X>*WMID5.)=+P1_"67)<(XDPWNZ8DA>IA_)]Z6G=+K
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M:J= [U=*V?W&.>CGS,4_4$L#!!0    ( (Z#8U6W6Y\ ^@@  +$6   9
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;+U8:V\;-Q;]*X0:%#8PE>8MR;$-
MV$Z;&F@W09PV'Q;[@9JA)&ZHH4)RK&A__9Y+CEZV%&]38 %#YO!Q[[GO2UZN
MM/ELYT(X]G6A&GO5FSNWO!@,;#47"V[[>BD:K$RU67"'3S,;V*41O/:'%FJ0
MQG$Y6'#9]*XO_=Q[<WVI6Z=D(]X;9MO%@IOUK5!Z==5+>IN)#W(V=S0QN+Y<
M\IEX$.Z/Y7N#K\&62BT7HK%2-\R(Z57O)KFXS6F_W_"G%"N[-V8DR43KS_1Q
M7U_U8@(DE*@<4>#X]RCNA%)$"#"^=#1[6Y9T<'^\H?Z+EQVR3+@5=UI]DK6;
M7_5&/5:+*6^5^Z!7OXI.GH+H55I9_\M686^1]5C56J<7W6$@6,@F_.=?.SWL
M'1C%)PZDW8'4XPZ,/,HWW/'K2Z-7S-!N4*.!%]6?!CC9D%$>G,&JQ#EW_5;K
M>B658KRIV7WC>#.3$R78C;7"V8C]0[C+@0,CVCZH.J*W@6AZ@NB8_:X;-[?L
MYZ86]>'Y 0!N4:8;E+?I-PD^B&6?97'$TCA-OT$OVTJ=>7K9=TG-WDA;*6U;
M(]@_;R;6&?C.OXZI(7#)CW.A>+JP2UZ)JQX"Q@KS*'K7/_Z0E/'K;\B0;V7(
MOT7]>RWWMXFR[9[M8,XM#C!AG42<B)I)V'TJ&^D$4W(J/#5I6:,=XPMMG/R/
MJ%\SP]U<F(A)1XM&/"+D<!B9ALG%DDN#X,<!QY3@%H.F:;E2:X;UU5PTXE$8
MAI\&%L-4-0=88<&;5=)4[<("?>4G:ED!%G-ST )+5G%CUK*9$9@6+/343W,2
M$L&U]D G I J#28<&NBSC]AQIX&K67N!W=P(VK(D>4"KA;C0D.#5'#'LYJR&
M%QD!OM $D$BN "6D4>2C/GO7FL#2>OTHR2=222<!F</SQ&*I]-HKTZ\;H;P0
MVF-%5C:>CB7T&J2>(/& D>&T$9$_(;ZTTJUWLC]RU0;+3%M'KEYQ.V=39&G+
M%D@\I("=1;U8^, )-MO8?=]*#5=K"S/B#]!(3)RBM/L$6!^^Y"<M\F;DD?/.
MN0XT %Q[@$@AV"9G#:A"!4^$9:VE,:J2U0V9*YR'=J1U'IY2NO+Z8@OAYKK6
M2L_ I[."]ZRC<@6O9+JJ6F-)GG>5TQ,X7I:0XKU:IC TCJ\%-WWV"5HCU9*M
MOH"J=)SJ#ILBAVAC@Q-6NE4D7VL%H)- $Z$D?#E8:JOU*6!TAMHP.VYM[[4P
M&)0%;.#1'#KZSMC.R-D,>SBA:]P&'MG 6A(9\=A4JJUQ+&*3UOE@4'(A75#]
MF3P'M\IH!$>C%[(B/=?2^V*$52PCXN! 9NT9HM9_%BX8H]XXK=^(G22*#S%H
M?1<FG0-1^.ZAH12S=;-.#;"*">Y7LZ71_T:M%_N.$Y$!1=-V'@4+-:#DV3^>
M0P<6.-&YX$PM*G(?0>%FY^1O2R.KH+,S[-64JR@(85TP%*2Z]4]V*2HYA0ZZ
M/+0#NY>.( CZFZ!;*B9.S-816W+C&F& !<F+O'[6Y05X4"UKKW8H#'RFI,CU
M:6]:>6\Z8=AC3NW@8:QN#>$D-PFIC"2%=@1;A.(MJ'@SE%XG%M[CN_K+/$1/
MLS-4B.(01$_9'(1,(-"GWV17/NYW1S[2D7?/CB0AA6W2[R[!2)\\7XI>JBA[
M0>HI]MDMK.U3%*'?5^Y^+*R.&,.V4YA<$H.NMI IX)'[LN\,8UO8Q8;*<QC0
M)$OGR$>K"5NASDRH<:;#DMR/',Z#/ QM^R2M_@].L TE8D+R&:H01M1]=N=]
MEUQW:R.J?E.-++KR3N-S;&CD4<MM2#8[CS]19#<PD%?6G:R!D)@%;9.AZ"P,
M+'6-2D)M4T,A?>:IZM;"2^WY!?OYUP=VA^Y%DE$?M&I#+;S#CU:R]MGSEBM*
M(; G,7\CJLZ/.Y]B9\DY>\72)(^R+/>C)!J7&49Y6D;I>+@3GU=!-^PL/6<_
M_C!*D_0U2\=E5&#7YC^N";@$-%U2JM8(2=Y8%<K.61+GNZ/AZQ#@D4@+Z-(L
MQJB(1U%1TFB8IM%P'+\@7[PO7T'R)5D>E<,"HRP?1W$Z?@GQ>!_P^$6\R5:;
MQ7-N2;RA]9?_>4&H\P13]'6M"DZ-7 L$A!15B2R^[]W8^JH8%OT"ER:E_/W/
M@YX@CQ]Q!<I]I+.^-_!SLT^-7H0>L0ZECFC=OW^[<78WEZ:FF#,.9+$6\MR)
M#OJ-0-%1VR(F=[NZ?O# V]%3?B5)D8OHBBGJGSA5S!FU#F+:*A2/1V'/3WL1
M"7=$9%_B-O'EL\S%L=//3W[:X& W'9 /@N[_%.Q_!$B_4=?_UFB+D-SD@9N0
M!VZJSH;@>A,N \'?2#/;S7_Z'/G_XW2G#=*1;[ -KP5K.%K=).M3O.595,8T
M&$>C?$@.G47#(F-)VO=IHXA&?GD8E6/*'LDH2N(AN_.W]] TA*YG+I>6)26(
MYF6!D!BS41F5:<:RX2C*QB5+\OX8>D[\VC %/627#&NPPT=1S1MJ6]<LQ:X$
MNT:8QLDR'Q&D9)AC)6:C832FA2P"69",BCQG_OEETXO1?0J=58-AW ?7*$VP
M$:!CD,6HGW5SXR)F:3EB[XU^I.:-CM K"W5S_E9L?6PF"+,$.9!T$B,5EJR(
MQ@6@]U.:SY,A=#,"/&2P/&,?M?-WH2=>'P"]8B4$1MA[19;1*"$=YT4"!8UH
ME*>0JZ35,@4OGR2'XV@XR@^-++XN16-%=V_RK>OS0*/:]VJ\GR40*Z_2'!K8
MS&QJTE]KDJ*]6JW0[7FZ0_C+(:.TG_P]1LDAHS[[)5SF=G<(OJ\4:E*^G6U.
MYY&([G98#&V O=B4*)B\1+7!5\;R.,I'0QKGC/)_G-&X(/>,"S]?LBR-1J,X
M7$_YE/)E.H;]BJ1SC.XZ^C+NG5O</UNC[';J14%.3[\0[)K,O7< WZ3X6Z=_
M#]@]%EA?H8:OGW1CIWOX0[[?W8)'^_UEU[?1]>AI\TV"'ZTP_6,/4(.]9T3D
MK9E_++5T66U<>%'<SF[?8V_",^1N>WC,_9V;F40_IL041^/^L.@Q$QY(PX?3
M2_\HB7J,).F'<X'$:V@#UJ=:N\T',=B^4E__%U!+ P04    " ".@V-5O]EX
M<9@8  ![:   &0   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6SM/5ESVT::
M?Z5+HYV5JF"*( E)C(\JV9Y,O.4D+CN9/&SM0Q-H4AB# (,&)'-__7Y'=Z-Q
MD")MY=@9O]@B@>[^[AO@L_NB_*AOE:K$IW66Z^<GMU6U^>;B0L>W:BWUJ-BH
M'*XLBW(M*_A8KB[TIE0RH47K[&(R'E]>K&6:G[QX1M^]*U\\*^HJ2W/UKA2Z
M7J]EN7VILN+^^4EX8K]XGZYN*_SBXL6SC5RI#ZKZ>?.NA$\7;I<D7:M<IT4N
M2K5\?G(3?O-RAO?3#?](U;WV_A:(R:(H/N*'-\GSDS$"I#(55[B#A/_NU"N5
M9;@1@/&KV?/$'8D+_;_M[M\2[H#+0FKUJLA^29/J]OG)]8E(U%+66?6^N/].
M&7PBW"\N,DW_BGN^=W)U(N):5\7:+ 8(UFG._\M/A@[>@NOQC@43LV!"</-!
M!.5K6<D7S\KB7I1X-^R&?Q"JM!J 2W-DRH>JA*LIK*M>O"WRU9-*E6OQ6BVJ
M9Q<5[(E7+F*S_B6OG^Q8/Q??%WEUJ\7?\D0E[?47 (L#:&(!>CG9N^$'M1F)
MZ3@0D_%DLF>_J4-P2OM-=^R':(G7J8ZS0M>E$O]]L]!5"<+P/T/(\EZSX;U0
M0;[1&QFKYR>@ 5J5=^KDQ5__$EZ.G^Z!=.8@G>W;_0!6'+.>Z"=>E2I)*W&S
M*I4"5:K$C[FXJ5<@5R)D$HNSO_[E>C(9/WWS[N_B%1 IS5<"1$G1U^'3\T!4
MMTJ\*M8;F6\%[*%@3Y'F52&DB'E_:?</Q&(K9)X(N09H_)6!^-M=D2$(WRF9
M5;?B[=M7@9":[ED4)1!+E>(,/QF 7IHO&T!B559@9\""+'2:I+),E1;%LGT,
M;+FJ92D!P%(S\'!LHDHMEF6Q%A78% ' T_\;659;O*=451$0Y#? 6?%*;M)*
M9K!KN2E*B0:$=I8)Z&"* H3&!/!&A' 5Z&$&1"MA3?-EJ0#E.T"+O@)8BI7"
MLT#'@0 ^67V\!QG7$&%3E[H&[!"'^]LTOFVA2)Q(\)KZ5"D$C#="A.$V2U/@
M'WU&JXX4/$O/ 6+X-JU20(&D*"OH&[I/KF#?%2 H-F6:Q^D&\5P7-8 !JT_#
MJV@T!O.496AI?63>F!U_PAW?XH[?RCC-TFIK,2)*G:4(@"$82J !>VEN/@R.
M>H-XGD;C!A@DNE@H,-2($VA,@A(*EA\XGL?*TB53&M29</%7LR@;\42PT &T
M\'OO(.[@A4N'.+Z;("RK9E_#?W,-Y+P1 )#^?X)/LZ!K$$6]E.SD  &]47&Z
M3!7*9 Y[P-=Z)'[RF*^MOB6,.P)1H_@\ * H^L9C'ZL;D(F,F2Z:@]MD;D[O
MTQ-/);@Z]HEQZM%)2##RQ@ HYK:O: B)]QE!#*^>:I$4:Z6K-&[9EA:MK?%1
MGV*U\:@Z#(%6<5WR\5(LTQ)H!A);E(@076.A1F,*EV!;F676E,7&^(#SCS_B
METJ"ECL;B2@X"R?."I*OZE;F/F*L5HA,!?<!6[*M?X0$<:_T WL?A'Y?7' /
ME"F]GZWWP'N(9"ITRH;%"2HV8 ($8;^@9)FE2" T4?*\+7U7@3A;G#<+81.V
MAX@G&P7 L*Z0 @D>W8 S[!MO)9CTA5(Y6(LXD\@^(#!]*VL(Q$#18B+D0L4@
M+B*I%2&[D5NYR)2W/]J:QC-USR&#%Y_W4<[!/E7;)T4.-F8>GL/%K6:QL<I.
M]$+J,<9+@3+]7W6.MY#7/P,G!4$I&3IC,P>1/0=HT>@YOF;IKS7(/6S=F V6
M9+(O8$^8WYNRB$&O'';#_!_B-XBZJ#4[)P!0DODUB@T.-=?&AN'Z98W_*%0F
M^$-]@AQ$PP<P^77)X0>"F9O0GOPW65BCWI">+($'0"YD5G,J[BIC0%0S@@$(
MS:I ,#%W(+]C="\G''$[UJ\5Z ?L;R^G^1V()1*2;X+-00H&(1X$E&GI]+]$
M;H(O9FWL&.2^@0%1 4&,:XPXP,F \.!]Q<:Z -_3 XZH.4868O1?*#8-OVB]
M2HT54>(F^2?H&!",[OCPX[?OQ7L$;T"R^D*UR6HMHE$T_H\ =8=B.SR2$*2+
M,[S(*K 8 *L1G&-@HYVG^XZ=X,61N %NK-<I<0ZY90W+9#0&J*QQ=$%&$UH0
ME&XI\14XMT'C:*X.^$OIM"0VCLOB_0CG#:D8'+B1:=(_V+@JXP1+L%]E@EYX
M,IH[)YSFC4 :^84[2<90OHNZW&$WEX;DU2U\0RBB(1-K3@PQ,$T$I'656B^
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MK#+%)2"BI-5?S&+W!&DC\8MJXM73:#1UCI;P6%1.5>!(775#15,P &GH^MO
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MFF? 6 /1(?=%;4<!]',*GFG?;X[].F.>M!/<1\QG)]U\-O(:Q8^3S^ZNSF#
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MK3(<KP@>-"SUWN2Z"VE]%%N3Z4T+Q+4[=G8[NA[QG3=@W>IM<;\1U- NMJ>
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M466_>A"TYE5-&,SPZ.<#'O'L<UWBN:U? D)-J9?A> L 9V(")VY "OOO%>E
MCEI&KT!&U).$)VYM@,DBI[UBUHI'_FR;WKX7POE"V@J=$(6PC<YI$&<P^_0>
M7*^@9NM%!DY^K2;Y2&[UTT^)@%^U?96A,GWS7K1>B7L78]LO\9D:O<685M@1
M.WW^S=#"_B*/MJ_:\)V*R32XOIK#']?S8'H9BI^[\X"MUYUUXH_9>"(F5\'E
M?(P-]+:"G>(PQ^0ZA#_"\"H81Z%X[Z8.6QFW#==Q]$'C"T-A4["0WS8- GR%
MZ:F8S8,)G 3[S:-@-HM\(>GA%5Y>!]%EA']-+H-I&!V'V3283R,QNPS"ZV@(
MM_!J$D3CL??78<CA2WFFX*IZR$W"*+B<$+Q75\$$J$4YV.3IT?_1AM]Z*K<L
M7$.[1*D#*X#^%Z,M>2?3C.38IC>4=VCNR&M7?FFJ!VVKQ8G!T"^/7'@_"+-6
MY8I^]H9&&?.*?QO&?>M^6>>&?U"FN9U_EN=[68([UI O+F'I>'05G8B2?^J&
M/U3%AGY>9E%45;&F/V\5&+@2;X#KRP*P-Q_P /=[0R_^#U!+ P04    " ".
M@V-5DK6AD;,4  "!.@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6RM
M6_MOVT:V_E<&WF:1%K)LR4Z;M$D QTZ:[":-4:<M+A;[PX@<2=-0I,HA+6O_
M^OM]9QXD92F/NQ<H&DODG#G/[SQF]'13U1_=TIA&W:V*TCT[6C;-^L>3$Y<M
MS4J[<;4V)9[,JWJE&WRL%R=N71N=RZ)5<3(]/?W^9*5M>?3\J7QW73]_6K5-
M84MS72O7KE:ZWKXP1;5Y=C0YBE_\:A?+AE^</'^ZU@MS8YK?UM<U/ITD*KE=
MF=+9JE2UF3\[NIC\^.*<[\L+OUNS<;V_%2695=5'?GB3/SLZ)4.F,%E#"AK_
MW)I+4Q0D!#;^"C2/TI9<V/\[4G\ELD.6F7;FLBK^L'FS?';T^$CE9J[;HOFU
MVKPV09Y'I)=5A9/_JXU_]]'T2&6M:ZI56 P.5K;T_^J[H(?>@L>G!Q9,PX*I
M\.TW$BZO=*.?/ZVKC:KY-JCQ#Q%55H,Y6](H-TV-IQ;KFN>7U6IE&VBY<4J7
MN;JLRL:6"U-FUKBG)PVVX(LG62#WPI.;'B#W1+T#@:53+\O<Y,/U)V M\3>-
M_+V8?I+@C5F/U=GI2$U/I]-/T#M+\IX)O;/_B[SJRKJLJ%Q;&_6OBYEK:CC-
MO_=IP6]ROG\3!M*/;JTS\^P(D>),?6N.GO_];Y/O3W_ZA CG283S3U'_>I/]
M%^14_^E;TS2F=JJ:J\O:Y+91%_(!-FK,:F;J9"@A=&6R\.U$OL7_FZ4AQ;4N
MMVJCG5KKNMFJIE*VKLUME>E9891KL'JV546W7>:WV]AFJ32BL/RH@$?JF\G9
M>(*H* H)<.SYS>31^#Q^,P)JN+61N"^V(UE"#F:F-'.0 ^':+-I"-U6]5;IM
MEE5M&TC-A;I0!IPT1NC6UGT\=DM=0S-*+VIC1"5C:L"UV7*D-D8M39%_+4^6
MT 9'LUEC<I5IM_3[==_9\A8?@GV<0L"#85.#/_U5VA^K#Y#]OE*7^M8 :6"
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M2K,H+$'"<"U--6\+.+F#P?(V:T;JX>Q;+F#= *GQ4O2Q2,*LUD6UI30(*\?
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M&#:HPP40;K:0<*5NQSN'#/XH8:1>U;R"\@>3O*9G_@*7J I.&K*?\0B^=F-
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M62!JC87\^%&N?)2-_X5@^C;]OO+"_ZRP>]W_./.=YF"&;C['TM/Q#X^._$W
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MFGC&A)>JPK@OV]2R,5I,*V-5V2ACOQ2R_O.GAH<MA20XH! U"I'SNS;DO/S
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MWXQ.AC\\$N^DBW?RF/<GR_'UU@*D%<H$<JH4%?[;S/?%BJ"DU"Z-^HN$--C
M%@'YJ9R]4ZRU@P49RE4X9+YG DNV=H)\4) !%J0QM=2"\IQ85&SO\).@^PI+
MV()V(4)!(J^U%FN2KB]D]AY\;G_+4 U'L%"!2O\IJ$QDM5-FR<:[X2=<PBVC
M TJ625]X!<M<I=($ <^UJ7V,CO<<"HEZ>ZID#$^OMP]2A@_Y6$N'8S;GK@J5
M%O&'M;!I"MC29 *^\5=[8HL]N(,5=^AI(G>V[#QBL?V:B/E.KML$"YN+9P>3
MX^3X$-K6FML4CL/:Y/.UE=S)TB:_H7!$O,& #*)LY$A1C@)B0@X6B&2CJ#Y<
M^*H)7J_[+5BLH8<U&?D2FX]1CH:3Y/0YGS,]3J;/=QU]#B^RP"!9$=XP&>]B
M&R:GW<+_ 6KTKT$=C)+I80/J8)R<'GZ!ZBUBN;1E)<V:=ZG@Q;OD-L$(6WB5
M*>D4/*4(3YF:21#!. @$;-"U;.:.QN"3)@6@)8:D#^S&8-YB>)!S"#%&);VG
M$!6J0M&P[#X%U.@!H2I@SY4!IX5&<& DPK*&#"8RA[F'7$TLNXKZ9W1!3X#B
MG6+=:$X;,$8_SR8GR;0K(S#4S9!M-;4/?5.0& B+9 >\5G*AM HQG6@S<J$5
M1AKRZ 64RSJ);J^N?\88_UBC3;4C/;5U3/ZRS_L43H-L\QRI%(NU@*?0H 6S
M,)]-/(R^S-B&K_\Y8^#BWI1]=OR<Z?>2TM9XM#$.6X0K9(9>MJ6.K=KZ5EHG
M70E"(4-?J'Q+3N"2K37BMD%(5L!#W2MKR/M0Y9[F[0;2OHZSB\EC#&1</;3H
MI^!-O@;>H]!V-:P\)P-=W4$Y*!%T_)Z-[38=9)W%&%1L6&L6?+^A4C_.ETTM
MWX,C/E/,>\^M*^Z.]G'<)7SGN$&)U1WH#!K,ER 2KK-!7)G8,TQ[+^T$_P;1
M,^UN")=L"9!<B-T,4AR)W-7:@KV]F3<N4G(!=>)NP='?04G6^4U#Y/F>D>^Z
M;"77' Z$LGU"X]?3)P_1Y?3X^4:%LHRBVSQMEXTK!!]]KM>.5Z0^B_"SIDM*
MS1<0L*'M"TV3PW3'C8-3'V\<[%MZY5LML3'Z8B'-LFGAEQK\$Q>Q'4*9(%2$
M#K<K7//CYPZI9 A.+>K87CJ^YW6(-\(ZH/TT^8YN<;/[[NKZC7C]YE?(]18-
MX+6%3D8C(1<6]-K<8&KO6XL8+DJ1[+L##K:NYR6Y);^$Q+F!-#8W]6ZU>\^9
M-]?[3]N;EZ17TBVA1:$IA^DP^?ZX)USSXM$\!%OQ97]A UX=^&N!=S5R<0-^
MSRV M _Q@.[M;_8W4$L#!!0    ( (Z#8U711=>]5 4  ) .   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;+57VVX;-Q#]%6+CI"D@Z&;9<1);@)VX
M: H$")(V?2CZ0.V.M&RXY(;D2G&_OF?(U7HER^XEZ8NTO,R<F3,7DN<;ZS[Y
MDBB(+Y4V_B(K0ZA?C$8^+ZF2?FAK,EA96E?)@*%;C7SM2!91J-*CZ7A\.JJD
M,MG\/,Z]<_-SVP2M#+USPC=5)=W-%6F[N<@FV7;BO5J5@2=&\_-:KN@#A5_J
M=PZC4:>E4!49KZP1CI87V>7DQ=6,]\<-'Q5M?.];L"<+:S_QX$UQD8W9(-*4
M!]8@\;>F5Z0U*X(9GUN=60?)@OWOK?8?HN_P92$]O;+Z5U6$\B([RT1!2]GH
M\-YN?J36GQ/6EUOMXZ_8I+TGIYG(&Q]LU0K#@DJ9]"^_M#ST!,[&]PA,6X%I
MM#L!12M?RR#GY\YNA./=T,8?T=4H#>.4X:!\" ZK"G)A_L:LR0>P'+Q01EQ_
M;E2X$6\IE+80:9'(GX\"L%ABE+=ZKY+>Z3UZGXNWUH32BVM34+$K/X*-G:'3
MK:%7TP<5?J!Z*([' S$=3Z</Z#ON'#^.^H[OT7?(TT2#-(7XR2H3Q$>,&T=>
M_':Y\,$A@WX_Q$0"FAT&XJIZX6N9TT6&LO'DUI3-GSR:G(Y?/N#&K'-C]I#V
MKXC?M]#[<TGBE:UJ:6Y$:77AA=T8<KY4-:0"P=\D_T?D<[WEDRFVH20G,*."
MPM2F5'DII",4:FX;"!<"/4<TR!\GL%=0LJ&*-@Q%'YO64C<R0(V*>#UD2'JZ
MA0D6-8MEE!(!DZ(1^&&]:(&,@YI61L6>89="BH]OKJ/!O=T=L/+H3+#+P5JH
MSJWQ5JL"INP!#\5E5 2!WJ9"+&ZBR;53W!/%@@S0<X7O04L))!BQE@[.AU(&
M44HO%J!//%7?IS6[8;O@&@S)DQ>QW;4^LU!E?1!>K8R"?FF"!C!\:'<3C+*5
MRD5-+G9ZDQ-[SVM;_Y\JP$FQED[)A::.YJ0?,=,%+ GLL=2:?>GCL7FM-L3N
M4!00;&/#/0C[>?8OX 8[XLR^0DJU%'YNI%9!\M$0G<28(Y8FEJ#'.@[Q2KI"
MF5749"0G\0!H?R89)FQ+5@OS'>?>VNHU<0FAIP/JUON^-XAE1T61J/R['+XW
M4^\0-P!;&UJ3&^QG+3,=4^=NXL$QCKX*HK"4=I9R30<S[3;+(@).5,O4],$*
M540=>[7!5'!5>#8=S3U0M8#J;8>/Q+ZFO)V=Q-G)CN8GC\ZFDV<O_6WR[I#&
M+.ZT#(Y(U].<-"LN/PH;(B-FCR/@\5GZWPZ?/QX@^+ZF>'?0J$F>7MO N?#?
MT:8G+<QX3_]N;MS-BY@N_2Q79JD;BL6Z3JVIGRB+)G22N[$$8\'ALA&E&*M-
MWUZ[0A>..<]>\U+?GW_<IF->IHU,&3N]EXBH79O'5ICZH*VMXXR66OB2<?8L
M:Z,N2#H#E>DLT=9[N,>&D$3/=!2U !']3.V=%EW>W ^VPFU6+)VM6D;[OF\0
M EE#]@LJ)R!HXF@RG.%NIG6\9L*<H^/A\VZ"C6*=H724^H7AKE>EZQ'Q]>A
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M(P)Y =XO+,1,-\R@_[1[]E]02P,$%     @ CH-C5>+AKMDG!0  L@L  !D
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M/?1)8'_/O?-G3T:'PU<[Z$\W]*>[T/]/PG8"/D[W/[S0%Z8":=:V4<:L287
M(9"K:^=C8[.&T9&N:N_N&1/LE: I0SR?<VI%*R8"C1%=:+;%6FQF'",\*:,7
MEESCB;]C!P(^.B,NL1' LN'0I]52FPT-H0GC2MTQ:7N/'&/GB '?"2,XTXA_
MF(5UB%QESS6[&AAQJ2*M&*Z-!CPIST(=L2@;!58@C+.+/3"K:.&4"?LH%^\0
M <H2Q0GK4HM;U)$#^X5G?,$TCY("M:_.Z[@F-T]X2U8&\=1&V:1?!#=M"].4
M$DO!<*Z[&;%Y\_D=7>-7:*7@"Q$CI<R*5T4!BFE(*:1;F0A5S*HB[-Z(DNG*
M5;6RZWUZ;ZE6'LECDW7%;.ABT&B.I'"65_H #M(RA87:EWLP1BCP40JR$W^R
M!4M@;;(11.5*P(O0.#64U3^Z&BA9N*;D^)+]5JD  5]S'=5,&^C5IP(A1*9[
M91K)E7?-8KF=U>0CIUU I74C+W3Q2T5B:MY(;$B\UZX,20?190XX1/>M05C@
M [DW:2U<5>D8<S:[M/Q2T%WYIIIZ2#Z=.D*P*S$IK:CN1)V'T:L";FJC0Y<(
M-_N:NR30\V=/CL?CX:OMGKQ&W:2)T:L7^_0I&77.<AF!<94]_:)^T3:QR@4L
M2LZ:H',_HLUP1,K;I8[?#D>+DBKSDKXL6EU0+C@&)23/9;.A(757<!^#>ZF?
M$YFYK(;3@A]SYR+*68/E#HD+%^+>QM$6J:RS!J24DRZYR_@,^PT"$;);C0#E
MZ-_*2MVW&NH=%3+*]G-G<+E)6Y":83]I70?IR7S9Z9H^NB@) '^)/;A"JTUK
MQ<>9S-9YZZ"XKEEPQ)J>)UJN"= CO#BAJZ9J3-( H0GZ>ULTWDMVVH9YS057
M,U"?C-)9.OJYY&V[._R!&M@ZO@F';VRMAJW5+786KVS!*16R(6J;\M1)'.@I
MC8X/VN='21WV(3EA1%7TK"[S^G'_:#K&<W@THFN4&>HOIUL.(2WE<= _/#RD
M2?_H^(@^)>F>TG'_X.4$[\/^<#JAQT[4P8/K4,5^D2Y] <X;&_/-:#.ZN5=>
MY.O4S^7Y4OI!^85&*1N>PW2X?W30(Y\O>ODGNCI=KF8NXJJ6/K&QHZME >;G
M#@7=_HB#S6W[_!]02P,$%     @ CH-C5?*= 4C@"0  HAL  !D   !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&ULQ5EK;]LX%OTKA*>8=0#5UM./- F0IIU.
M@6FG:#H['Q;[@9;HB%M)U)"2'<^OWW-)2;:;1Q.@B_UBRQ)YG^>>>RF?;97^
M:G(A&G9;%I4Y'^5-4Y].IR;-1<G-1-6BPI.UTB5O\%/?3$VM!<_LIK*8AKX_
MFY9<5J.+,WOOD[XX4VU3R$I\TLRT9<GU[K4HU/9\%(SZ&Y_E3=[0C>G%6<UO
MQ+5H_J@_:?R:#E(R68K*2%4Q+=;GH\O@]'5,Z^V"?TJQ-0?7C#Q9*?65?KS/
MSD<^&20*D38D@>-K(ZY$49 @F/%7)W,TJ*2-A]>]]%^L[_!EQ8VX4L6?,FOR
M\]%BQ#*QYFW1?%;;7T7G3T+R4E48^\FV;FVX'+&T-8TJN\VPH)25^^:W71P.
M-BS\!S:$W8;0VNT462O?\(9?G&FU99I60QI=6%?M;A@G*TK*=:/Q5&)?<W$M
M;A#BAGT6M=*-K&[.I@W$TL-IVHEX[42$#XA8L@^J:G+#WE:9R([W3V'.8%/8
MV_0Z?%3@M:@G+/(]%OIA^(B\:/ QLO*BI_K(_G6Y,HT&(OY]G[M.6GR_-*J2
M4U/S5)R/4 9&Z(T87?S\4S#S7SUB:SS8&C\F_6GY>*8(]J<@H&(94ZU&*=%]
MOBH$,VZIL<#.&*JDR07;\IW]OOK]S0?/7J6Y%&LF;D7:4A$QM5[+5&@/2*Q0
MNL8N E%H3J5F&,B"U:VNE<$SM6:\*%3*K2T(&8Q(<9]7&>,&*PS=QV9+,54J
M)F1P6N"97.^LR0>B9=4HUFS5O6YP4@U=6W/*?OYI$8:S5^SM1A44CE\%+YJ<
M72-AL-UX;)O+-&>Y:JV1T'*9H< D <,Z>2W+NI!PU&IF1A6M(Q+8#><;,!ZX
MK.Z#7*NZ+=S2W*F2U5ISB&O3IM7BE=W86W6%K$%RP:X[L8-!LDJ+-NM,,K5(
M)83M6,JUZ,)MLTO"ZGQG))Y7+Y66N(D4-JJ!T%29AN)N-YF]!EXH6+J5,(XR
M]A&D>85]K=[UX2&Q?<2N:/<GKIM*:$!$XYF9L/<.)$IGL@*-0U>K#4&"K5ID
M$NGT'H09V:B[%$*<X:E+JK5( 9^\4A"N@8!<8J.D]=WNXQUD6H,N1#X7\BM^
MY%)G+VM8NSM>"5V9@)B2\-_+.D";0[@6&U&U'2K%+7H>H4*+5-U4\F\H6;F:
M&(S)><.D SXB0'9VNI6]=V""M544$@98<P&;%(:I0F9\ %2F&%QG?+U&NSIX
MCO6H&+081/Y+5Y.L=;99BTD<3U.D@YQQD?QC<CUA[RXO/UG1E]E_T$<@Z.WK
M]U_>7%*1.(\+L>%PY9Z8L%)P \S:Z&%5T<(2N^MP$5)^$)*NH%VEBWV=3^X8
M@+#Q>[6"HO -O/?Z79C!-@1 3GZOVX)MJ-EWRM4&S% 4>X:@!P2_'HQ=2DMP
MV@HT*$E6ET"4+Y)2<%WL7C:R*6#ADZPR9(A%A 4KLE76O)(/N.J8EZB.51BR
M4-ZJ%&Q<*&-.&&\:+5>M*Q/$&L]*XIH<F,E5D9'?<.B8PSS48#J!.S"QJQ%A
M>LG>_D8'8X_56FVD':/&*U'!GN;$4G1G2\-OB0\S@7X&/P=,\I*H[6]WHZ\)
MD$CO(V'CUI(5NR$RI/9!L$>$R>A2E"O8G\O:8^0MLU*(*UMI<@KS%!S!=S;@
M6)^)5>-1C#PG;JU5R<1?K415E:+)%97.!HX)LB)%_JCST$(N-2.06DBB=D@'
M":4RDED'C'X+[; 5RF^IOH7<V.#S&RT<LQ:2KV0!K5Z7WSYE70A..B.)X(PD
MT43_1+DP"P-;^O6E:Z>$"VPXBA]6"((L :O;<A3FS@&:31R+4X=T@N&&N-G9
MS!S@ ^E ;A6(V R=C:>(FC/M)<K<LHA59C?;X';XLS'.I'%!:VD&&%KMA'W8
MMYL^E'O>N8]:@(B5XPE> W2UED0%2)Z6Z3&7V"9*=:/=>O0E16'LU!\/!'U-
M#TQ# '4F03NL0[R)5%)-,-/#W ,14F6F8[S=GH2M2N&X%K)E(TK3M5\RB)A8
M5IGM_';:88+C4:?^'P:JM;C?5,?2;@BA1[:R#;.3(L%\[P6-!_9<8>O2@A*C
M"/78D].'AI9[Q@9PP4&/O&Y7;@*X4IB^"#%L')S@UT$_^6(7?.[2B+.-C<:7
M'/@_FN2AM6YL#0_#>+>WA\ +%OASSX\B7(5QXH7)G*Z6"3ZC)/22!5W1R!.$
MKP[N/4=G<$?G+/*B@ 0'R=*;!3&NQG&R."'58>C%\^!(:7_O&2%]>A2?%[UO
MRP4N++S$IZ %,R_R*8Y1["T"GWR:>?,DL5XM/#]Y;M3NZAHC;DED!4;>8F&3
MYGM)U"N;665!1%?_!P!^I/GLN?B+@+\@I@#.  M_YGP)9^3)<K8$VH[!T-][
MAM*[  P1OV5(N(LC@C^I& <(KE4[ RJ3Y?)(;7_O?XK!)P7P+BSBP%LDY$P2
M>,O%@H($>,2A=6KIS9<6,O/8\^/E\^)V5]?2"T)*41)Y<3*CP( 0YG0Q)BBZ
M(HY#SP\6??2>_=6%J0_:<)S:<#2#UG3C'!IQWH*Q]W,JAA1QPPOOX)A+3:H?
M\?;R#@]UPUAT+^_WM&^Z Q$Z5HK)XK#3[Y,Y-#>7]GM:ZX\='[]M.4^FEV?A
MS0)A?_7QA[J 4@2@(HM45'_L$WS&<Q"HI;)Q!$0G\0G[#>> 4\=3^T$9.$L8
MP9'H+@J"_?,NI^@J8&!L!SE&LSF^ =\8U3 &:R_GP.IK-TR[*6J\G[+1UT^.
MAFN&YI@$,Z \@KPX]N+E N(B$,;5?BC][D *BT)O,8>; ]:_O?'F24,\7 !O
M+F?D"_I-LL1%//?B@+R%><M9>,+>/3K3#QJ__4:[!<NRWYXS\<,,'_:$!X[U
M-XB# B*&=]\[$S!0\#+$>,! S[&/W'ISI'@?X*>=$^P^WX<?"4N\!9"[");L
M]X=/ L!9G%#<P#L!NNEX#HQ\OGLX>#!BP)=/N+K^SMF!%BYM3&)XFKC81(E/
M%X&#ZO7QX0(8HR3O@XIN1?L2"+E\PK$#@+5J M(QMRB)K*'?.XL,0'O$YR2
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M_KO8D3P_J#M9I$T0W#B".J)*+!1/7J@:;ZP;=;#)%Z%4<1A[*1:,_."KC.(
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M/IGG >CA(1DZ5G6^>!?*TE/@FPV]O:A= ,W72ME]QRTPON;K?P!02P,$%
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MU?L7\Z8-#U<E-1X<8E!5MBS.WFF$X-$Y4VFR2-Q2-=@8#:_"\*!"YP L\2Q
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MV<;P-=)7J]@!!5HBOMCG,F+"C3$=YC9;']P%](XI1X/H(#:-64GJ'31 F0O
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M>SQ5GC!&5X"[0BG<>\2V^,^R'? JN 5?!BAGTM(CJ&RM*2='41R,Q)F.L$0
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M /R.UZK[/W""\(]GO/P_4$L#!!0    ( (Z#8U5@KK7.W0<  &H8   9
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MBMH)T/U:*=MLG('V?X[EWU!+ P04    " ".@V-5W"'<*\X$  !Y"P  &0
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MQP'HIE\W$ZLJWR.WRE+']<."GCC4SH#V<Z7L[<0%Z![-Y2]02P,$%     @
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M<95P*ULZ:RW<=KVY%\L&]=M18,B-50Y6!\A9#\E?@"S@B^Q,I>%#5V+YK7U
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M'T%E%6A]+:4Y#JR#X0]G\C=02P,$%     @ CH-C5= %N_2>!   00T  !D
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MZ(RH%.NB82\F5F6^25XJ2RVW'R;TC8/:':#]E:+WI9PX ]57T_0?4$L#!!0
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ME:41Y9<Y_1-0.P/ZGBEE]QOGX/"7F?X#4$L#!!0    ( (Z#8U5<2;X%P08
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M:J- C;\><[>7%CXNC=+E5&]X+LXGR <MU%9,+EY^Y\7N#\_8&NYL#9^3?K%
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M#F5M->UR\K.K==>V BG+E@FX8J:&&SHGN)7]>;O$C;ZP7* 9+R)+ 9U;5.S
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MO'_G/C"]X91_@16YQB>S:0"Z?SOZB56M[]>YLM3]_;"FYQ:U,Z#]2BF[G[@
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M?#%U];[@.X-.'ZR14[*1\L$%GXL4!VX@X) ;QT#M9P<+X-P1V3$>!TX\MG3
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M,*8 +?XIA!Z]&0 W5EFQ,/O*Q^]S5M$.6]H&\EQE2KPP^WPZ$-4%*E?36@N
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M#%)"\__X1[$.!P"_?P;@%P#_%."? ;0*0.M20+L M$\ W>X90*< ="[UT"T
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MZB>PTEBL.'!6X"[F8>PT@6>D2@=HCCN:XZ/T0)_VZ2&(=V12+SJV%T/JX6(
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M_QT^;=Z(5PTL=T\#>]/ /K:!LVG@[#;P]C1P-PW<8_?@;1IX.PUL?T\#?]/
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M:,K=U:1]57=ETY3;_L>-;#NVJCN@_?U]639?'G05/)75Q_ZTK_\/4$L#!!0
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M5YSJO.5*\:RXW#(:,V$JZ-_7G*O'&T-0'SU>_ =02P,$%     @ CH-C50D
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MI-65INI%\$UY!>>>"\'C\G'-:,#2HH/\_(%SL7\I")J+98O_ %!+ P04
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MBSX5Y0GZ^()S];Q15K#]$'CR+U!+ P04    " ".@V-5/#,AKF07  !1DP$
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M:B:J6:AFHYJ#:BZJ>:CFHUJ :B&J1:@6HUJ":BFE":DXZWLQ9B/T]-P,;:)
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MLU'-0347U3Q4\U$M0+40U2)4BU$M0;64TL3(ZSL"%NJ.@/]S59K:'YR!:,\
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ML3:(G"Z"_3F2D,H>\.Q,"6OA F8ZSSD)"]+)(P_?+^:POW< >^"#S81!"[*
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M>02:-D,U!]5<5/-0S4>U -5"5(M0+4:U!-522A,7%!F"9Z8RSS)Z'J%F3NT
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M:W-H965T<R]S:&5E=#<U+GAM;+6::V_;-A2&_PKA#4,+))%(RY=DMH$DNBQ
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M@$:/H#2_IFENZ%\;W0":+(+2(BB:[H8V7,36.*H(GKW3P;-=W+G]H&DB*"T
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M5^NJJQW)-N6RWA<F)<O*S36-%Y07%ZCS2Z9F*O5.4:!9W3[[#U!+ P04
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M+02E15"T[DG+0[A.C,GI"\EF(^XL"[#K$<T:VUQGJ)LTA?%$K5TT?U &+1R
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M;?.R8^YA>T'Z[C<Q_G=@RAL#9 LOL/-\" W/RWE>^[ :JO6K^ZB?<_LGN)]
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M:ZA/NC0VX5#UH-)<5)J'2O-1:0$6K2RTK0P?Q0Y2.1%+-Y@T%Y7FH=)\5%J
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M?7V>ZF>1GQ@'FZV)D_\ 4$L#!!0    ( (Z#8U7/!=_S"P,  "D*   9
M>&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;+5676_:,!3]*U=9-742:T+X"AU$
M*K!IE=JJ*NOV,$V522[$:F)GMH%.VH^?[4 &+63M1%_ =NX]/N?8UW9OR<6]
M3! 5/&0IDWTG42H_=5T9)9@1><)S9/K+E(N,*-T5,U?F DELD[+4]3VO[6:$
M,B?LV;%K$?;X7*64X;4 .<\R(GX-,.7+OE-WU@,W=)8H,^"&O9S,<(SJ-K\6
MNN>6*#'-D$G*&0B<]IVS^NFP:^)MP%>*2[G1!J-DPOF]Z9S'?<<SA##%2!D$
MHO\6.,0T-4":QL\5IE-.:1(WVVOT3U:[UC(A$H<\_49CE?2=P($8IV2>JAN^
M_(PK/2V#%_%4VE]8%K%-'1S-I>+9*EDSR"@K_LG#RH?-A.:>!'^5X#]*\/T]
M"8U50L,*+9A962.B2-@3? G"1&LTT[#>V&RMAC*SBF,E]%>J\U1X@=H#">_A
MB@A!C*5P/$)%:"K?P1%0!E\2/I>$Q;+G*CVA27.C%?B@ /?W@'?ADC.52/C(
M8HRW\UU-M&3KK]D._$K ,>8GT/!JX'N^#[?C$1P?O0.>FQUQI_B=0(;+N]1H
MVL%V6 T^PDB#URUX?0U>0;I16MRPN(V]%DN)6 -K=0U&*"-!+67X?J%CX5QA
M)G_LLK< ;NX&-@5^*G,28=_1%2Q1+- )W[ZIM[T/N]0?"&S+@V;I0;,*/;R:
M9Q,4P*>0%ANN6#/X_>S%&Q03M.P$YFQ:A/6>N]@46$GA/P6V2H&M2H$W*)6@
MD<(8(B(3T 6C#[ERC+*%[NC33^TLHTKLEZYS =;>,"H(VFV_-&M+7[O4UZ[4
M9S<OG,T$XEX5E0@O57$@L"VQG5)LY[4JMG-(#PX$MN5!4'H0_&/!E4(A3<E&
M F.J0+\!I-+[FK)9#4C&YTSM<B!XLOW\AN<]*M7@23$W@HV@+<;=DG'W%4NP
M^QS:3X-VT'8W;N,,Q<P^4B1$QK#B8BY'RW?0F;W^W;_AQ2/JDH@995(?FE.=
MZIUTM&.B>)@4'<5S>[=/N-(O!=M,]%L.A0G0WZ><JW7'3%"^#L,_4$L#!!0
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M&V A2'N!.;\60K\V[ 9GN3^]_!]02P,$%     @ CH-C5:>*1BKO @  E@D
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M =< ]7[)F-Q-=(*Z%0O_ %!+ P04    " ".@V-5T5XD!\4"  !/"   &0
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M7J#FEXS)MXXN0MT_1/X'4$L#!!0    ( (Z#8U7'62 P) (  -P$   9
M>&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;)5476O;,!3]*T*#L<$:.8Z;E<PV
M- UC@PY"LJT/8P^*?1.+RI8G*7'[[W<E?S0#-[ 76Q_W')USKZ[B1NE'4P!8
M\E3*RB2TL+9>,&:R DIN)JJ&"G?V2I?<XE0?F*DU\-R#2LG"()BSDHN*IK%?
M6^LT5D<K105K3<RQ++E^7H)434*GM%_8B$-AW0)+XYH?8 OV1[W6.&,#2RY*
MJ(Q0%=&P3^CM=+&,7+P/^"F@,6=CXISLE'ITDZ]Y0@,G""1DUC%P_)W@#J1T
M1"CC3\=)AR,=\'S<LW_VWM'+CANX4_)!Y+9(Z TE.>SY4=J-:KY Y^?:\65*
M&O\E31<;4)(=C55E!T8%I:C:/W_J\G &F$:O ,(.$'K=[4%>Y8I;GL9:-42[
M:&1S V_5HU&<J%Q1ME;CKD"<3>\!+1ER11Z\?LBO^ DTEH.LA,G4L;)DPRT0
M7N4O(1I<N45U(!Y.OH,N#7FW LN%-.]C9E&9XV=9IV+9J@A?4;&%>D)FP0<2
M!F'X+YRAH<%5.+@*/=_LLJM?MSMC-1;^]YBDEB(:IW#-L# USR"A>-L-Z!/0
M].V;Z3SX=$'@;! XN\2>]JDD?;;S/ML:LSVFMN6;MAETK79*@TDPGT4Q.XT(
MB08AT?\)>:FM]+6U6-LQ/9=I;\@S<&W&,L7.+JOK^V]<'T1E\+@]4@63C]>4
MZ+:7VHE5M;^_.V6Q&_RPP.<'M O _;U2MI^XEA@>M/0O4$L#!!0    ( (Z#
M8U4:4II?% 8  , <   9    >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;,59
M;6^;.A3^*Q:KIE1* C9Y7QII34";M%U5S>W=AVD?2' 2-,"YV&FW?[]C0TD
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M(5BD+G?4@SDA ?!\PV"3E]W(#O)#R]DO4$L#!!0    ( (Z#8U7Y0.%?, 0
M %(6   9    >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;,U876^C.!3]*Q8C
MC5II6C[RW2:1VL!J*G565;,S^[#:!Q=N$JM@L[9)NO]^;4-I2"C3[EJKO@1L
M[CV^/L<Y8$]WC#^*#8!$3UE*Q<S92)E?N*Z(-Y!A<<YRH.K)BO$,2]7D:U?D
M''!BDK+4#3QOZ&:84&<^-7UW?#YEA4P)A3N.1)%EF/]]#2G;S1S?>>ZX)^N-
MU!WN?)KC-2Q!?L_ON&JY-4I",J"",(HXK&;.E7\1^3V=8")^$-B)O7NDI_+
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M*(9#G5G72>;K) MTDH6:R#I9MZW=5ZBE?NF):$93$HDW10Y"@*,5Y)%(-EZ
M],NRIBO_VK)D75F]@S*H5KTT>>>)!EI%PU=%NX[O???;2L<_4TZRQ=E^V[)6
M'+XW3]6:%_M]EFB@531\5;3KM[/SVU%/4OCEU"2E1EY:K[2R^5K9 JULH2ZV
M;D9W*QSV6RQQV%K7.+2R^5K9 JULH2ZV;O)W"QVV>J7CX@FK)RLK[O5A =6T
M\M#D[RS10*MH>$)T>** [I9%;/6ZR(435E_6BJ/W ZWK&V=I!EHUP]<T:[/-
MO0V"%/)%M97#4$2+C-=KNNW5=KOHMMHD.;A^9]],;<EUW[X)ZLV@'7V]-_6
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M@=H9T/>M4O9AXC9H_U.2'U!+ P04    " ".@V-5;O[@WTH#  "]#0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6S%5UUOVC 4_2M65DVMU)(O"- !
M4EM4K5(K5;!V#],>3+B U<1.;0<Z:3]^MA-2TJ81:)'Z0N+DGN-[CT_P]6##
M^)-8 4CT$D=4#*V5E,FY;8MP!3$6+98 56\6C,=8JB%?VB+A@.<&%$>VYSB!
M'6-"K=' /+OGHP%+940HW',DTCC&_,\E1&PSM%QK^V!"EBNI']BC08*7, 7Y
MD-QS-;(+ECF)@0K"*.*P&%H7[OF5ZVF B7@DL!$[]TB7,F/L20]NYD/+T1E!
M!*'4%%A=UG %4:295![/.:E5S*F!N_=;]FM3O"IFA@5<L>@GF<O5T.I9: X+
MG$9RPC;?(2^HH_E"%@GSBS9YK&.A,!62Q3E891 3FEWQ2R[$#L#S/@!X.<#;
M%^#G -\4FF5FRAICB4<#SC:(ZVC%IF^,-@:MJB%4+^-4<O66*)P<76/"T2..
M4D!W@$7*0:V11&?F&39*_X!P1<ES"@)A.D=3LJ1D04*LPAXHFPG@:SR+ -W0
M))4"'8]!8A*)$T7RRGZ*)A"FG!.Z1$>(*-852X7B$P-;JCIT-G:8YWR9Y>Q]
MD/,4DA;RG5/D.9Z''J9C='QT4D%S54\SAE#1N(;&K::QE9J%I%XAJ6=X_<,D
MS>71$E9J^^M6\: ;";'X7:5)-FF[>E+]M9^+!(<PM-3GK-<$K-'7+V[@?*M2
MIB&RDCY^H8]?QY[IL];Z5)6980.#U?]!ZU&_TW6<@;W>S?]]E-?;C2HEUBX2
M:]<F=@MKB)!?E54M\%#Q&R(KU=@I:NQ\ACD[3>K3$%E)GZ#0)_@/<P9[F?-]
M5(TYNT5BW7W,B?ZB"1%/9Q12R7&$X"51&R+,$6!.U3:-0J:VV#EPLX15-=1.
M<^A2-4164J17*-+[#"OWFM2G(;*2/OU"GWZM8RZ$ZLT24S[C:LM5LB".Z1(J
MM]R,JU.R=M#OO['V^RC?Z?N=:FN[SFL3XNQI[C$1(4NISE16?H+U3(>N3U-L
MY;IWFB_W,RR<S]J41@VQE35Z[:;<VF;D0!OG9&Y[QZ).R_6\-T;>QG5*<4[@
MM-]XV=[IK?7!Y@[S):$"1;!00*?550P\.RMD \D2TV[/F%3-N[E=J?,5<!V@
MWB\8D]N![N"+$]OH'U!+ P04    " ".@V-5/.QE_U,$  #:$0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Y-"YX;6RM6&V/FS@0_BL65YU:J5TP$"![2:3=
MI-6==*VB37OWX70?')@D5@%SMI/L_ONS#24);]UV\R4!,\_C>>P99LSDR/A7
ML0.0Z#%+<S&U=E(6M[8MXAUD1-RP G+U9,-X1J2ZY5M;%!Q(8D!9:KN.$]@9
MH;DUFYBQ)9]-V%ZF-(<E1V*?980_W4/*CE,+6]\&'NAV)_6 /9L49 LKD%^*
M)5=W=LV2T QR05F..&RFUAV^7>"Q!AB+OR@<Q=DUTE+6C'W5-W\D4\O1'D$*
ML=041/T=8 YIJIF4'_]5I%8]IP:>7W]C_V#$*S%K(F#.TK]I(G=3*[)0 ANR
M3^4#._X.E:"1YHM9*LPO.E:VCH7BO9 LJ\#*@XSFY3]YK!;B#("]'H!; =PF
MP.\!>!7 >R[ KP"^69E2BEF'!9%D-N'LB+BV5FSZPBRF02OY--?[OI)</:4*
M)V</D!()"5H2+BD(] [="0%2()(GZ$]*UC2EYL'K!4A"4_%&F7Q9+=#K5V_0
M*T1S]'G']D)9BXDME4.:UHZKR>?EY&[/Y"LH;I#GO$6NX[H=\,4P? &Q@F,#
MQY=P6RU#O19NO1:NX?-Z^.Y6J_>?5UTR2IS?C=.I>2L*$L/44KDG@!_ FOWZ
M"PZ<W[I$78GL0J)72_2&V&=W<<SVN=I>#C'0 UFG\!;E(#O\O!]F^@?_V[52
M)2@P(/W..<QP% :>-[$/YVO08>8Y@>/79A?J_%J=/^C3DD-!:(+@4;T6!91!
MS.0.N$HESB&7B)CH[I([3-TCMP2-SG2XON=&#;5MJQ'VQKA;[*@6._I9L3G+
MOZ]WF+U'[ZBE1&V;WY#;-@K"L=.M-JC5!H.Y>?8JZO(KN&:"7HGL0F=8ZPR?
MEZ %>=+9V;5SPPP].Q>V-P5'03,OVU;CP(EZTC*J-47?T\3WJL:D@WMX/TS2
M(RMJ.8P]U_6:&=AAYH2NWY."XUK8>%C89J/TF/KY/I=4/G5Y.$CQHZ%Y);(+
MM=@Y]0K.3Q;("G@EE==BNY1YUA+A:Q7)>475B*R1VXB_#C,WQ./N\,.GA@4/
M-@LO*GCSBOO<)Z?I=ML$CWJ</K4@>+AS>&'AFE?TYTY%4;,&=1CY41CV^'YJ
M,+#_DC*$!YN('TZ#*[%=:CWU%WBX!7A&*9KC=JU7_4]S+]I&>!ST[<6I(\"#
MA?B9965>L5S4M%$K7-I&&+L]/0L^%7,\7(L?RFU!ZGR.XI30K SV K@YL><Q
MO-.'U@01SDF^!76@[HGYL-4PMW*U;1)Z/94;Z])].7*J>7BXZ*E"O ) GY@$
MA",CC61EH! I.5WOI8X6))EZ?Y:'RZ(Z7-(\3O>)&E#'1I7O I F1U1")FZZ
M8M8^.]AFP+?F X% )B[+0T\]6G^$N#=G]=9X=#M7JKN>C-43\]W"/DU1?O7X
M2/B6Y@*EL%'3.3>AB@]>?D@H;R0KS-%ZS:0ZJ)O+'9 $N#90SS=,K5)UHR>H
M/^?,_@=02P,$%     @ CH-C5:V5 UIZ P  "A   !D   !X;"]W;W)K<VAE
M971S+W-H965T.34N>&ULM5=M;]LV$/XKA%H4+=!%[[*=V@(22\,*K$ 0M]N'
M81\8ZVP3E4B7I.WDWX^D9-66%2'MV'R(2>IYGN/=42?>],#X5[$!D.BQ*JF8
M.1LIM]>N*Y8;J+"X8EN@ZLF*\0I+->5K5VPYX,*0JM(-/"]Q*TRHDT[-VAU/
MIVPG2T+ACB.QJRK,GVZA9(>9XSO'A7NRWDB]X*;3+5[# N27[1U7,[=5*4@%
M5!!&$8?5S+GQKW/?TP2#^(O 09R,D7;E@;&O>O*QF#F>WA&4L)1: JN?/<RA
M++62VL>W1M1I;6KBZ?BH_KMQ7CGS@ 7,6?DW*>1FYHP=5, *[TIYSPY_0.-0
MK/66K!3F/SHT6,]!RYV0K&K(:@<5H?4O?FP"<4)0.OV$H"$$74+T#"%L".%+
M+40-(7JIA;@A&-?=VG<3N Q+G$XY.R"NT4I-#TST#5O%BU!]4!:2JZ=$\61Z
M#R664* [S"4!@7Y#][ 'NE-#3 N4/ZH3*=3D;082DU*\4XB;U8J4Q-!R*HE\
M4FM?%AEZ^_H=>HT(19\W;"<474Q=J?:H+;G+9C^W]7Z"9_83HD^,RHU0R@44
M/?QLF#\9X+LJ-FV @F. ;H-!P05LKU#HO4>!%P0]^YF_G.[WN?/_K.<_;?TL
M&&%[6D*C%[[@M#RASQQ3@>L7_I\_%11]E%")?_NR7NM&_;JZ&EZ++5["S%'E
M3@#?@Y.^>>4GWH>^D-L4RVR*Y9;$SI(3M<F)AM33YL7MBWY-3 Q1?SKV:9B$
M^D3L3\-ZB9J,1O$Y*+L$^>IOTH'E/1;CD3]N46<>QJV'\:"'<R8D8BOU@7K6
MTT&!'SUG-L4RFV*Y);&S+"1M%I)?5 02F\FQ*9;9%,LMB9TE9]0F9S3XBAP_
MV'WAKYGQZ3OI^1=5X!(UBCN8[!(S"8,DZ=2 2Y0_CKW^$C!N_1L/^K=05TI"
MU^_1&BAP7)I;"B[4S8@(R;&^=2(8B,&@^H\>09MBF4VQW)+868HF;8HFOZ@^
M3&PFQZ989E,LMR1VEAS?^W[A]WZZ0C34T\]V%(6= M$#&D6= M&+Z=X1>D#^
M..G4!_>DMZF KTU3*="2[:BL+Z[M:MNXWIAVK;-^ZU_/_9[U3#>ZII?Z+E]W
MR9\P7Q,J4 DK9<J[&JE2QNO&LYY(MC6=U0.3JD\SPXUJUH%K@'J^8DP>)]I
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M&#5591\=]9; M^907JBWW+J2S2%=5]L=_+\UQ]V/ZB_=B[4[4!^Z%U%SK'_
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M0+Y_9$R\W)0?: _:5_\#4$L#!!0    ( (Z#8U4E5U9Z$ 0  %4.   :
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M(L_QO!Y[EN]7=P?,\1NW^@;/?X];[ZF,,BY+01!/T!^<747:T8]L2Z2B;(/
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MJK<#Z.U4;P?0VZO>'J"W5[T]0&^O>GN WE[U]@"]??6P&Z"W5[T]0&^O>GN
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M_W7Y=;&^-U>DV_N,\>DO4$L#!!0    ( (Z#8U71-?Q97P(  -<Y   3
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M4')O<',O87!P+GAM;%!+ 0(4 Q0    ( (Z#8U7MN3AA[0   "L"   1
M          "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( (Z#
M8U697)PC$ 8  )PG   3              "  <L!  !X;"]T:&5M92]T:&5M
M93$N>&UL4$L! A0#%     @ CH-C591@86[[!0  Y!\  !@
M ("!# @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( (Z#
M8U5/T4C4$0@  *\A   8              " @3T.  !X;"]W;W)K<VAE971S
M+W-H965T,BYX;6Q02P$"% ,4    " ".@V-56E[,/+0"   X!P  &
M        @(&$%@  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%
M  @ CH-C54KO9^PS"@  ZS,  !@              ("!;AD  'AL+W=O<FMS
M:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( (Z#8U6HX!_ZF0(  .T%   8
M              " @=<C  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"
M% ,4    " ".@V-559^;<XH/    NP  &               @(&F)@  >&PO
M=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ CH-C5<?*:L$/"P
MH2T  !@              ("!9C8  'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;%!+ 0(4 Q0    ( (Z#8U6H_H*[B@,  ( '   8              " @:M!
M  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " ".@V-5QL%P
M[IT7  !T1P  &               @(%K10  >&PO=V]R:W-H965T<R]S:&5E
M=#DN>&UL4$L! A0#%     @ CH-C59MVY[T)!P  4A$  !D
M ("!/ET  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " ".
M@V-5F6UEJ#<+  !0(0  &0              @(%^9   >&PO=V]R:W-H965T
M<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( (Z#8U7"T3$*608  ,(1   9
M          " @>QO  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#
M%     @ CH-C57G\3&"N#P  B2\  !D              ("!?'8  'AL+W=O
M<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " ".@V-5&6\?HT,'  !Q
M$@  &0              @(%AA@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM
M;%!+ 0(4 Q0    ( (Z#8U5U[@ONM@,  ',*   9              " @=N-
M  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ CH-C5;=;
MGP#Z"   L18  !D              ("!R)$  'AL+W=O<FMS:&5E=',O<VAE
M970Q-BYX;6Q02P$"% ,4    " ".@V-5O]EX<9@8  ![:   &0
M    @('YF@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (
M (Z#8U62M:&1LQ0  ($Z   9              " @<BS  !X;"]W;W)K<VAE
M971S+W-H965T,3@N>&UL4$L! A0#%     @ CH-C5>XN:&]Z"   RA0  !D
M             ("!LL@  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"
M% ,4    " ".@V-5332>Q (%   >#@  &0              @(%CT0  >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( (Z#8U5TXK]KK@,
M ,0(   9              " @9S6  !X;"]W;W)K<VAE971S+W-H965T,C$N
M>&UL4$L! A0#%     @ CH-C55W%^/&@!0  "0X  !D              ("!
M@=H  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " ".@V-5
MT477O50%  "0#@  &0              @(%8X   >&PO=V]R:W-H965T<R]S
M:&5E=#(S+GAM;%!+ 0(4 Q0    ( (Z#8U5N'H W;PH  .8=   9
M      " @>/E  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%
M  @ CH-C5>+AKMDG!0  L@L  !D              ("!B?   'AL+W=O<FMS
M:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " ".@V-5#)6&[AX%  !Y"P
M&0              @('G]0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+
M 0(4 Q0    ( (Z#8U7RG0%(X D  *(;   9              " @3S[  !X
M;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ CH-C50M#*RRQ
M"0  EAD  !D              ("!4P4! 'AL+W=O<FMS:&5E=',O<VAE970R
M."YX;6Q02P$"% ,4    " ".@V-5X4:@K7,#  #9!P  &0
M@($[#P$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( (Z#
M8U6ZTJ7^DP,   ((   9              " @>42 0!X;"]W;W)K<VAE971S
M+W-H965T,S N>&UL4$L! A0#%     @ CH-C533&>4'C'@  2&,  !D
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M=#,U+GAM;%!+ 0(4 Q0    ( (Z#8U6?_>DU1P,  $ '   9
M  " @9!, 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @
MCH-C50M95$T% P  AP8  !D              ("!#E ! 'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6Q02P$"% ,4    " ".@V-5+Z X;LD%  "*#@  &0
M            @(%*4P$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4
M Q0    ( (Z#8U7H/OU;:P,  +,'   9              " @4I9 0!X;"]W
M;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ CH-C5;Q%_NA] P
M8P@  !D              ("![%P! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6Q02P$"% ,4    " ".@V-5DS_9=',$  !C"@  &0              @(&@
M8 $ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( (Z#8U6.
M4#&/. 4  / .   9              " @4IE 0!X;"]W;W)K<VAE971S+W-H
M965T-#(N>&UL4$L! A0#%     @ CH-C504$!B2B P  [0@  !D
M     ("!N6H! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (Z#8U78JSW8(@0   @)   9              "
M@5B! 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ CH-C
M5<TTQ#F# P  S <  !D              ("!L84! 'AL+W=O<FMS:&5E=',O
M<VAE970T.2YX;6Q02P$"% ,4    " ".@V-5NE4#1T0"   R!0  &0
M        @(%KB0$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0
M   ( (Z#8U5TO=DTBP8  %HF   9              " @>:+ 0!X;"]W;W)K
M<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ CH-C5:M_?4%(!   J10
M !D              ("!J)(! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q0
M2P$"% ,4    " ".@V-5Q9])U9D#  !E$@  &0              @($GEP$
M>&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( (Z#8U4G%=I?
MH0D   *'   9              " @?>: 0!X;"]W;W)K<VAE971S+W-H965T
M-30N>&UL4$L! A0#%     @ CH-C55_X!<)V"@  *H,  !D
M ("!SZ0! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " ".
M@V-5#CF4P2 ,  #JE0  &0              @(%\KP$ >&PO=V]R:W-H965T
M<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( (Z#8U6)NE0F$P8  (8L   9
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M970V,2YX;6Q02P$"% ,4    " ".@V-5,FKL<0 $  #0%P  &0
M    @($+TP$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    (
M (Z#8U5'_R96G ,  +H2   9              " @4+7 0!X;"]W;W)K<VAE
M971S+W-H965T-C,N>&UL4$L! A0#%     @ CH-C58IN%?,- P  BP@  !D
M             ("!%=L! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"
M% ,4    " ".@V-52J\<A8(%  !D)@  &0              @(%9W@$ >&PO
M=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( (Z#8U4)K?XG90(
M /T%   9              " @1+D 0!X;"]W;W)K<VAE971S+W-H965T-C8N
M>&UL4$L! A0#%     @ CH-C57O\@[F3!0  B2<  !D              ("!
MKN8! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " ".@V-5
M>GN_'L8'  #>/P  &0              @(%X[ $ >&PO=V]R:W-H965T<R]S
M:&5E=#8X+GAM;%!+ 0(4 Q0    ( (Z#8U6PKP10X (  ,H)   9
M      " @77T 0!X;"]W;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%
M  @ CH-C52#NJ1(B!P  %#P  !D              ("!C/<! 'AL+W=O<FMS
M:&5E=',O<VAE970W,"YX;6Q02P$"% ,4    " ".@V-5/#,AKF07  !1DP$
M&0              @('E_@$ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+
M 0(4 Q0    ( (Z#8U6PCNC)K@4  .HM   9              " @8 6 @!X
M;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ CH-C57\@PFH(
M P  =@@  !D              ("!91P" 'AL+W=O<FMS:&5E=',O<VAE970W
M,RYX;6Q02P$"% ,4    " ".@V-5/1>QDD81  !*"0$ &0
M@(&D'P( >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( (Z#
M8U5F"XI4L@4  .DN   9              " @2$Q @!X;"]W;W)K<VAE971S
M+W-H965T-S4N>&UL4$L! A0#%     @ CH-C51]Q!_K5!0  *#   !D
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M=#@P+GAM;%!+ 0(4 Q0    ( (Z#8U6GBD8J[P(  )8)   9
M  " @0M2 @!X;"]W;W)K<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @
MCH-C5=%>) ?% @  3P@  !D              ("!,54" 'AL+W=O<FMS:&5E
M=',O<VAE970X,BYX;6Q02P$"% ,4    " ".@V-5QUD@,"0"  #<!   &0
M            @($M6 ( >&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4
M Q0    ( (Z#8U4:4II?% 8  , <   9              " @8A: @!X;"]W
M;W)K<VAE971S+W-H965T.#0N>&UL4$L! A0#%     @ CH-C5?E X5\P!
M4A8  !D              ("!TV " 'AL+W=O<FMS:&5E=',O<VAE970X-2YX
M;6Q02P$"% ,4    " ".@V-5!"8+X>8$  #T(0  &0              @($Z
M90( >&PO=V]R:W-H965T<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    ( (Z#8U5%
M;@.<E (  -X'   9              " @5=J @!X;"]W;W)K<VAE971S+W-H
M965T.#<N>&UL4$L! A0#%     @ CH-C54?16%TB P  N@T  !D
M     ("!(FT" 'AL+W=O<FMS:&5E=',O<VAE970X."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (Z#8U5N_N#?2@,  +T-   9              "
M@;M_ @!X;"]W;W)K<VAE971S+W-H965T.3,N>&UL4$L! A0#%     @ CH-C
M53SL9?]3!   VA$  !D              ("!/(," 'AL+W=O<FMS:&5E=',O
M<VAE970Y-"YX;6Q02P$"% ,4    " ".@V-5K94#6GH#   *$   &0
M        @('&AP( >&PO=V]R:W-H965T<R]S:&5E=#DU+GAM;%!+ 0(4 Q0
M   ( (Z#8U4)^&X[BP0  $HA   9              " @7>+ @!X;"]W;W)K
M<VAE971S+W-H965T.38N>&UL4$L! A0#%     @ CH-C52]L._LF @  L@0
M !D              ("!.9 " 'AL+W=O<FMS:&5E=',O<VAE970Y-RYX;6Q0
M2P$"% ,4    " ".@V-5)I(S=G4&  !2*P  &0              @(&6D@(
M>&PO=V]R:W-H965T<R]S:&5E=#DX+GAM;%!+ 0(4 Q0    ( (Z#8U5#L*@$
M4@8  ,$:   9              " @4*9 @!X;"]W;W)K<VAE971S+W-H965T
M.3DN>&UL4$L! A0#%     @ CH-C53"ZAGW<!0  =!\  !H
M ("!RY\" 'AL+W=O<FMS:&5E=',O<VAE970Q,# N>&UL4$L! A0#%     @
MCH-C52575GH0!   50X  !H              ("!WZ4" 'AL+W=O<FMS:&5E
M=',O<VAE970Q,#$N>&UL4$L! A0#%     @ CH-C56K:>JFS @  Q0H  !H
M             ("!)ZH" 'AL+W=O<FMS:&5E=',O<VAE970Q,#(N>&UL4$L!
M A0#%     @ CH-C5<IBS1U> P  >!8   T              ( !$JT" 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " ".@V-5EXJ[',     3 @  "P
M        @ &;L ( 7W)E;',O+G)E;'-02P$"% ,4    " ".@V-5H)/!_V4'
M  #F0@  #P              @ &$L0( >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ CH-C5>U(Q+7D @  \3L  !H              ( !%KD" 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ CH-C5=$U_%E? @
MUSD  !,              ( !,KP" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     &X ;@ \'@  PKX"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>382</ContextCount>
  <ElementCount>422</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>105</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Recently Issued Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards</Role>
      <ShortName>Recently Issued Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Transactions</Role>
      <ShortName>Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Credit Losses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLosses</Role>
      <ShortName>Credit Losses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Goodwill and Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet</Role>
      <ShortName>Goodwill and Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt</Role>
      <ShortName>Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Income (Loss) Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeLossPerCommonShare</Role>
      <ShortName>Income (Loss) Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Investments in Equity Method Investees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees</Role>
      <ShortName>Investments in Equity Method Investees</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Repositioning and Other Changes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RepositioningandOtherChanges</Role>
      <ShortName>Repositioning and Other Changes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReporting</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Reserves for Claims and Performance-Based Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Supplemental Cash Flow Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformation</Role>
      <ShortName>Supplemental Cash Flow Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/TransactionsTables</Role>
      <ShortName>Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/Transactions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/DiscontinuedOperations</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RevenueRecognition</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Credit Losses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesTables</Role>
      <ShortName>Credit Losses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/CreditLosses</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables</Role>
      <ShortName>Goodwill and Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Long-term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtTables</Role>
      <ShortName>Long-term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/LongtermDebt</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/CommitmentsandContingencies</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/Leases</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Income (Loss) Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeLossPerCommonShareTables</Role>
      <ShortName>Income (Loss) Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/IncomeLossPerCommonShare</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/StockbasedCompensation</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/FairValueMeasurement</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Related Parties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesTables</Role>
      <ShortName>Related Parties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RelatedParties</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Repositioning and Other Changes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RepositioningandOtherChangesTables</Role>
      <ShortName>Repositioning and Other Changes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RepositioningandOtherChanges</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SegmentReporting</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Supplemental Cash Flow Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables</Role>
      <ShortName>Supplemental Cash Flow Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SupplementalCashFlowInformation</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/OrganizationDetails</Role>
      <ShortName>Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/Organization</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails</Role>
      <ShortName>Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Recently Issued Accounting Standards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails</Role>
      <ShortName>Recently Issued Accounting Standards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Transactions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/TransactionsNarrativeDetails</Role>
      <ShortName>Transactions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Transactions - Allocation of Acquisition Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails</Role>
      <ShortName>Transactions - Allocation of Acquisition Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Discontinued Operations - Summary of Results of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails</Role>
      <ShortName>Discontinued Operations - Summary of Results of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Discontinued Operations - Summary of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails</Role>
      <ShortName>Discontinued Operations - Summary of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue Recognition - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails</Role>
      <ShortName>Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Revenue Recognition - Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails</Role>
      <ShortName>Revenue Recognition - Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Revenue Recognition - Contract Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails</Role>
      <ShortName>Revenue Recognition - Contract Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails</Role>
      <ShortName>Credit Losses - Accounts Receivable (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails</Role>
      <ShortName>Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Impairment Testing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Long-term Debt - 2022 Credit Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails</Role>
      <ShortName>Long-term Debt - 2022 Credit Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Long-term Debt - 2024 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails</Role>
      <ShortName>Long-term Debt - 2024 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Long-term Debt - 2019 Credit Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails</Role>
      <ShortName>Long-term Debt - 2019 Credit Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Long-term Debt - Warrant Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails</Role>
      <ShortName>Long-term Debt - Warrant Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Long-term Debt - 2025 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails</Role>
      <ShortName>Long-term Debt - 2025 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Long-term Debt - 2021 Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails</Role>
      <ShortName>Long-term Debt - 2021 Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails</Role>
      <ShortName>Long-term Debt - Convertible Senior Notes Carrying Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Commitments and Contingencies - Concentration Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails</Role>
      <ShortName>Commitments and Contingencies - Concentration Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Leases - Primary Office Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails</Role>
      <ShortName>Leases - Primary Office Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Leases - Maturity of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturity of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails</Role>
      <ShortName>Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Income (Loss) Per Common Share - Computation of Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails</Role>
      <ShortName>Income (Loss) Per Common Share - Computation of Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/IncomeLossPerCommonShareTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Income (Loss) Per Common Share - Antidilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeLossPerCommonShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Income (Loss) Per Common Share - Antidilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/IncomeLossPerCommonShareTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Stock-based Compensation - Schedule of Share-based Awards Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Share-based Awards Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - Investments in Equity Method Investees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails</Role>
      <ShortName>Investments in Equity Method Investees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails</Role>
      <ShortName>Fair Value Measurement - Changes in Contingent Consideration and Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails</Role>
      <ShortName>Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - Related Parties - Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails</Role>
      <ShortName>Related Parties - Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - Related Parties - Revenues and Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails</Role>
      <ShortName>Related Parties - Revenues and Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0000096 - Disclosure - Repositioning and Other Changes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails</Role>
      <ShortName>Repositioning and Other Changes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/RepositioningandOtherChangesTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>0000097 - Disclosure - Segment Reporting - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails</Role>
      <ShortName>Segment Reporting - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>0000098 - Disclosure - Segment Reporting - Revenue from Segments to Consolidated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails</Role>
      <ShortName>Segment Reporting - Revenue from Segments to Consolidated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>0000099 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails</Role>
      <ShortName>Segment Reporting - Reconciliation of Adjusted EBITDA (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>0000100 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails</Role>
      <ShortName>Reserves for Claims and Performance-Based Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables</ParentRole>
      <Position>100</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>0000101 - Disclosure - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails</Role>
      <ShortName>Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="evh-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>0000102 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolenthealth.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolenthealth.com/role/SubsequentEvents</ParentRole>
      <Position>102</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:DebtInstrumentConvertibleConversionRatio1, us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 -  evh-20220930.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="evh-20220930.htm">evh-20220930.htm</File>
    <File>a93022exhibit311.htm</File>
    <File>a93022exhibit312.htm</File>
    <File>a93022exhibit321.htm</File>
    <File>a93022exhibit322.htm</File>
    <File>evh-20220930.xsd</File>
    <File>evh-20220930_cal.xml</File>
    <File>evh-20220930_def.xml</File>
    <File>evh-20220930_lab.xml</File>
    <File>evh-20220930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1298">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>120
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "evh-20220930.htm": {
   "axisCustom": 1,
   "axisStandard": 39,
   "contextCount": 382,
   "dts": {
    "calculationLink": {
     "local": [
      "evh-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "evh-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "evh-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "evh-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "evh-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "evh-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 717,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 6,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 11
   },
   "keyCustom": 59,
   "keyStandard": 363,
   "memberCustom": 47,
   "memberStandard": 53,
   "nsprefix": "evh",
   "nsuri": "http://www.evolenthealth.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "role": "http://www.evolenthealth.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Recently Issued Accounting Standards",
     "role": "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards",
     "shortName": "Recently Issued Accounting Standards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ic1c85bf2a0144950a682573f957154ba_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000100 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Details)",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
     "shortName": "Reserves for Claims and Performance-Based Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ic1c85bf2a0144950a682573f957154ba_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000101 - Disclosure - Supplemental Cash Flow Information (Details)",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails",
     "shortName": "Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000102 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.evolenthealth.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Transactions",
     "role": "http://www.evolenthealth.com/role/Transactions",
     "shortName": "Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Discontinued Operations",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperations",
     "shortName": "Discontinued Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Revenue Recognition",
     "role": "http://www.evolenthealth.com/role/RevenueRecognition",
     "shortName": "Revenue Recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CreditLossFinancialInstrumentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Credit Losses",
     "role": "http://www.evolenthealth.com/role/CreditLosses",
     "shortName": "Credit Losses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CreditLossFinancialInstrumentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Property and Equipment, Net",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Goodwill and Intangible Assets, Net",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet",
     "shortName": "Goodwill and Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Long-term Debt",
     "role": "http://www.evolenthealth.com/role/LongtermDebt",
     "shortName": "Long-term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Commitments and Contingencies",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Leases",
     "role": "http://www.evolenthealth.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Income (Loss) Per Common Share",
     "role": "http://www.evolenthealth.com/role/IncomeLossPerCommonShare",
     "shortName": "Income (Loss) Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Stock-based Compensation",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Income Taxes",
     "role": "http://www.evolenthealth.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Investments in Equity Method Investees",
     "role": "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees",
     "shortName": "Investments in Equity Method Investees",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Fair Value Measurement",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Related Parties",
     "role": "http://www.evolenthealth.com/role/RelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Repositioning and Other Changes",
     "role": "http://www.evolenthealth.com/role/RepositioningandOtherChanges",
     "shortName": "Repositioning and Other Changes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Segment Reporting",
     "role": "http://www.evolenthealth.com/role/SegmentReporting",
     "shortName": "Segment Reporting",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Reserves for Claims and Performance-Based Arrangements",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements",
     "shortName": "Reserves for Claims and Performance-Based Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InsuranceDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Supplemental Cash Flow Information",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformation",
     "shortName": "Supplemental Cash Flow Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Subsequent Events",
     "role": "http://www.evolenthealth.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Transactions (Tables)",
     "role": "http://www.evolenthealth.com/role/TransactionsTables",
     "shortName": "Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Discontinued Operations (Tables)",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsTables",
     "shortName": "Discontinued Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Revenue Recognition (Tables)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionTables",
     "shortName": "Revenue Recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Credit Losses (Tables)",
     "role": "http://www.evolenthealth.com/role/CreditLossesTables",
     "shortName": "Credit Losses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Goodwill and Intangible Assets, Net (Tables)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables",
     "shortName": "Goodwill and Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Long-term Debt (Tables)",
     "role": "http://www.evolenthealth.com/role/LongtermDebtTables",
     "shortName": "Long-term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Leases (Tables)",
     "role": "http://www.evolenthealth.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Income (Loss) Per Common Share (Tables)",
     "role": "http://www.evolenthealth.com/role/IncomeLossPerCommonShareTables",
     "shortName": "Income (Loss) Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Stock-based Compensation (Tables)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Fair Value Measurement (Tables)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Related Parties (Tables)",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesTables",
     "shortName": "Related Parties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Repositioning and Other Changes (Tables)",
     "role": "http://www.evolenthealth.com/role/RepositioningandOtherChangesTables",
     "shortName": "Repositioning and Other Changes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Segment Reporting (Tables)",
     "role": "http://www.evolenthealth.com/role/SegmentReportingTables",
     "shortName": "Segment Reporting (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Reserves for Claims and Performance-Based Arrangements (Tables)",
     "role": "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables",
     "shortName": "Reserves for Claims and Performance-Based Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Supplemental Cash Flow Information (Tables)",
     "role": "http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables",
     "shortName": "Supplemental Cash Flow Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Organization (Details)",
     "role": "http://www.evolenthealth.com/role/OrganizationDetails",
     "shortName": "Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ic1c85bf2a0144950a682573f957154ba_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Restricted Cash and Restricted Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ic75e54e0b5564ba5bdf3845c85ae6efa_D20211001-20211031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unitRef": "reporting_unit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ie70e3951b11d47189d49176b477c53cb_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles - Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ie70e3951b11d47189d49176b477c53cb_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Recently Issued Accounting Standards (Details)",
     "role": "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails",
     "shortName": "Recently Issued Accounting Standards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Transactions - Narrative (Details)",
     "role": "http://www.evolenthealth.com/role/TransactionsNarrativeDetails",
     "shortName": "Transactions - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "iae24c6c30eb94d5c82ae99d747a61a52_I20220801",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Transactions - Allocation of Acquisition Cost (Details)",
     "role": "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
     "shortName": "Transactions - Allocation of Acquisition Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i0aac7a30651e4f168f37aa5b96ca404e_D20220801-20220801",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Discontinued Operations - Summary of Results of Operations (Details)",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
     "shortName": "Discontinued Operations - Summary of Results of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i8dbb10f34136499a9b5286ba2ff8c2b4_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Discontinued Operations - Summary of Cash Flows (Details)",
     "role": "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
     "shortName": "Discontinued Operations - Summary of Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i45f340fc7b5645cc80d58967cdf6d731_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
     "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i0eabf8957ae644bea9de5ff585037c2e_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "if90b80996d524ed6b89fbfebe2cedda5_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails",
     "shortName": "Revenue Recognition - Transaction Price Allocated to the Remaining Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsNotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Revenue Recognition - Contract Balances (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails",
     "shortName": "Revenue Recognition - Contract Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ic1c85bf2a0144950a682573f957154ba_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsNotesAndLoansReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostAmortization",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Revenue Recognition - Contract Costs (Details)",
     "role": "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails",
     "shortName": "Revenue Recognition - Contract Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i9767cf7dd34a49aca4c626b25a0137e8_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CapitalizedContractCostNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "evh:FinancingReceivablePercentNotPastDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Credit Losses - Accounts Receivable (Narrative) (Details)",
     "role": "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails",
     "shortName": "Credit Losses - Accounts Receivable (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "evh:FinancingReceivablePercentNotPastDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ic1c85bf2a0144950a682573f957154ba_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)",
     "role": "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails",
     "shortName": "Credit Losses - Schedule of Changes in Allowance for Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "evh:AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Property and Equipment, Net (Details)",
     "role": "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ic1c85bf2a0144950a682573f957154ba_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ic75e54e0b5564ba5bdf3845c85ae6efa_D20211001-20211031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unitRef": "reporting_unit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Goodwill and Intangible Assets, Net - Impairment Testing (Details)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Impairment Testing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ic75e54e0b5564ba5bdf3845c85ae6efa_D20211001-20211031",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportingUnits",
      "reportCount": 1,
      "unitRef": "reporting_unit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Schedule of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "iff4396c9e1e445ceab67b876cfca1052_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Intangible Assets, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ic1c85bf2a0144950a682573f957154ba_I20211231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)",
     "role": "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Amortization of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "evh:GainLossOnDispositionOfAssetsOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Long-term Debt - 2022 Credit Agreement (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
     "shortName": "Long-term Debt - 2022 Credit Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i8f90d550a67b49a1b9b6999f0941d947_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Long-term Debt - 2024 Notes (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
     "shortName": "Long-term Debt - 2024 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i247174c3d444488082c85f25293301f0_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InterestExpenseDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestPaidNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Long-term Debt - 2019 Credit Agreement (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
     "shortName": "Long-term Debt - 2019 Credit Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "if893b79edc40422a846ee7d717983c69_I20191230",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i237f03b5f1ae46209253a55eef0acbd7_I20191230",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightUnissued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Long-term Debt - Warrant Agreement (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails",
     "shortName": "Long-term Debt - Warrant Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i237f03b5f1ae46209253a55eef0acbd7_I20191230",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightUnissued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Long-term Debt - 2025 Notes (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
     "shortName": "Long-term Debt - 2025 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i83a29e272d0e42f1a62606a14f9bcb44_I20181031",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i0b673721ad2140dc92b0e7de4a1c58b1_D20200801-20200831",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfDebtIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Long-term Debt - 2021 Notes (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
     "shortName": "Long-term Debt - 2021 Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i0b673721ad2140dc92b0e7de4a1c58b1_D20200801-20200831",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "iada79ebd92cc43c4a68b4aa5846a5940_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Long-term Debt - Convertible Senior Notes Carrying Value (Details)",
     "role": "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
     "shortName": "Long-term Debt - Convertible Senior Notes Carrying Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "iada79ebd92cc43c4a68b4aa5846a5940_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ic1c85bf2a0144950a682573f957154ba_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "lang": "en-US",
      "name": "evh:LineOfCreditFacilityAutomaticExtensionPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "evh:CashFDICInsuredAmountPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Commitments and Contingencies - Concentration Risk (Details)",
     "role": "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
     "shortName": "Commitments and Contingencies - Concentration Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i812113f21d0f4ddab105da97d5259847_D20220101-20220930",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "evh:NumberOfOptionsToRenewLeases",
      "reportCount": 1,
      "unitRef": "option_to_renew_lease",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5109fae1e1f447d9ba05497deddbfdc1_I20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Organization",
     "role": "http://www.evolenthealth.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Leases - Primary Office Leases (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails",
     "shortName": "Leases - Primary Office Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i1c22768950824185b381d31f0d376c88_I20220930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Leases - Maturity of Lease Liabilities (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturity of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)",
     "role": "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails",
     "shortName": "Leases - Weighted-average Discount Rate and Weighted-remaining Lease Terms (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Income (Loss) Per Common Share - Computation of Earnings per Share (Details)",
     "role": "http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails",
     "shortName": "Income (Loss) Per Common Share - Computation of Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "evh:IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Income (Loss) Per Common Share - Antidilutive Securities (Details)",
     "role": "http://www.evolenthealth.com/role/IncomeLossPerCommonShareAntidilutiveSecuritiesDetails",
     "shortName": "Income (Loss) Per Common Share - Antidilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails",
     "shortName": "Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Stock-based Compensation - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i582d7dedfcac46f99a84eb6ef808e641_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Stock-based Compensation - Schedule of Share-based Awards Granted (Details)",
     "role": "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
     "shortName": "Stock-based Compensation - Schedule of Share-based Awards Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i582d7dedfcac46f99a84eb6ef808e641_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - Income Taxes - Narrative (Details)",
     "role": "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles",
     "role": "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples",
     "shortName": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - Investments in Equity Method Investees (Details)",
     "role": "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
     "shortName": "Investments in Equity Method Investees (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "iebd3f639166d44039bd8edc98238a383_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "evh:IncomeLossFromEquityMethodInvestmentsServicesAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i88c58b8bf6804181b9ae7aa0ce6fa7e0_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
     "shortName": "Fair Value Measurement - Assets and Liabilities on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i88c58b8bf6804181b9ae7aa0ce6fa7e0_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ic1c85bf2a0144950a682573f957154ba_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - Fair Value Measurement - Changes in Contingent Consideration and Other (Details)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails",
     "shortName": "Fair Value Measurement - Changes in Contingent Consideration and Other (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ic1c85bf2a0144950a682573f957154ba_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i88c58b8bf6804181b9ae7aa0ce6fa7e0_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)",
     "role": "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
     "shortName": "Fair Value Measurement - Valuation Techniques and Significant Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ib5a543708cce4e1587fc2f618e7c92b7_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i4e7829cceaeb4c139799230c0383d092_I20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - Related Parties - Assets and Liabilities (Details)",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
     "shortName": "Related Parties - Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "idb038b091b7344c29e48adca13ed03ae_I20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ie08f13f16382418ea5ec290830f60d8c_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - Related Parties - Revenues and Expenses (Details)",
     "role": "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
     "shortName": "Related Parties - Revenues and Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ie08f13f16382418ea5ec290830f60d8c_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ic1c85bf2a0144950a682573f957154ba_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000096 - Disclosure - Repositioning and Other Changes (Details)",
     "role": "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails",
     "shortName": "Repositioning and Other Changes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ic1c85bf2a0144950a682573f957154ba_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000097 - Disclosure - Segment Reporting - Additional Information (Details)",
     "role": "http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails",
     "shortName": "Segment Reporting - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i31c6cf3d5d054984ac5d83d05997e3d9_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000098 - Disclosure - Segment Reporting - Revenue from Segments to Consolidated (Details)",
     "role": "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails",
     "shortName": "Segment Reporting - Revenue from Segments to Consolidated (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "ib7b76ebaaef241a09456df69e9f56730_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000099 - Disclosure - Segment Reporting - Reconciliation of Adjusted EBITDA (Details)",
     "role": "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails",
     "shortName": "Segment Reporting - Reconciliation of Adjusted EBITDA (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "evh-20220930.htm",
      "contextRef": "i5f3dda00534e4afd9a20c1bf338bae47_D20220701-20220930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "evh:SharebasedCompensationIncludingOnetimeAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 105,
   "tag": {
    "country_IN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INDIA",
        "terseLabel": "Pune, India"
       }
      }
     },
     "localname": "IN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r828"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "evh_A2022CreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Credit Facilities",
        "label": "2022 Credit Facilities [Member]",
        "terseLabel": "2022 Credit Facilities"
       }
      }
     },
     "localname": "A2022CreditFacilitiesMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Allowance for Credit Loss, Acquired During Period",
        "label": "Accounts Receivable, Allowance for Credit Loss, Acquired During Period",
        "negatedTerseLabel": "IPG acquisition"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossAcquiredDuringPeriod",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization",
        "label": "Adjusted Earnings Before Interest, Taxes, Depreciation And Amortization",
        "terseLabel": "Adjusted EBITDA"
       }
      }
     },
     "localname": "AdjustedEarningsBeforeInterestTaxesDepreciationAndAmortization",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_BasicAndDilutedEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and Diluted Earnings Per Share",
        "label": "Basic and Diluted Earnings Per Share [Abstract]",
        "verboseLabel": "Income (loss) per common share"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_BelowMarketLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Below Market Leases [Member]",
        "label": "Below Market Leases [Member]",
        "terseLabel": "Below market lease, net"
       }
      }
     },
     "localname": "BelowMarketLeasesMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_BonusesAndCommissionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonuses And Commissions [Member]",
        "label": "Bonuses And Commissions [Member]",
        "terseLabel": "Bonuses and Commissions"
       }
      }
     },
     "localname": "BonusesAndCommissionsMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_BrightHealthManagementIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bright Health Management, Inc",
        "label": "Bright Health Management, Inc [Member]",
        "terseLabel": "Bright Health Management, Inc."
       }
      }
     },
     "localname": "BrightHealthManagementIncMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets",
        "totalLabel": "Total tangible assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Compensation And Employee Benefits",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedCompensationAndEmployeeBenefits",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CapitalizedContractCostAmortizationPurchaseAccountingAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments",
        "label": "Capitalized Contract Cost, Amortization, Purchase Accounting Adjustments",
        "negatedLabel": "Amortization of contract cost assets"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortizationPurchaseAccountingAdjustments",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations",
        "label": "Cash and Cash Equivalents, at Carrying Value, Excluding Discontinued Operations",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueExcludingDiscontinuedOperations",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_CashFDICInsuredAmountPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, FDIC Insured Amount, Percentage",
        "label": "Cash, FDIC Insured Amount, Percentage",
        "terseLabel": "Percentage of cash and cash equivalents held with FDIC participating bank"
       }
      }
     },
     "localname": "CashFDICInsuredAmountPercentage",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_CashFlowLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Flow, Lessee [Abstract]",
        "label": "Cash Flow, Lessee [Abstract]",
        "terseLabel": "Effects of Leases"
       }
      }
     },
     "localname": "CashFlowLesseeAbstract",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_CashHeldInInternationalBanksPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Held In International Banks, Percentage",
        "label": "Cash, Held In International Banks, Percentage",
        "terseLabel": "Percentage of cash held in international banks (less than)"
       }
      }
     },
     "localname": "CashHeldInInternationalBanksPercentage",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_ChangeInContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer, Liability [Roll Forward]",
        "label": "Change In Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityRollForward",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_ChangesInTaxReceivablesAgreementLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 18.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes In Tax Receivables Agreement Liability",
        "label": "Changes In Tax Receivables Agreement Liability",
        "negatedTerseLabel": "Change in tax receivable agreement liability"
       }
      }
     },
     "localname": "ChangesInTaxReceivablesAgreementLiability",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement",
        "label": "Class Of Warrant Or Right, Period During Which Warrants Or Rights Exercisable, After Maturity Of Credit Agreement",
        "terseLabel": "Period during which warrants or rights exercisable, after maturity of credit agreement"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPeriodDuringWhichWarrantsOrRightsExercisableAfterMaturityOfCreditAgreement",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_ClinicalSolutionsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Solutions Segment",
        "label": "Clinical Solutions Segment [Member]",
        "terseLabel": "Clinical Solutions"
       }
      }
     },
     "localname": "ClinicalSolutionsSegmentMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CollateralwithFinancialInstitutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateral with Financial Institutions [Member]",
        "label": "Collateral with Financial Institutions [Member]",
        "terseLabel": "Collateral with financial institutions"
       }
      }
     },
     "localname": "CollateralwithFinancialInstitutionsMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CommercialAndOtherCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial And Other Customers",
        "label": "Commercial And Other Customers [Member]",
        "terseLabel": "Commercial and other"
       }
      }
     },
     "localname": "CommercialAndOtherCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ContractFulfillmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Fulfillment Costs [Member]",
        "label": "Contract Fulfillment Costs [Member]",
        "terseLabel": "Contract Fulfillment Costs"
       }
      }
     },
     "localname": "ContractFulfillmentCostsMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations",
        "label": "Contract With Customer, Liability, Cash Received In Advance Of Satisfaction Of Performance Obligations",
        "terseLabel": "Cash received in advance of satisfaction of performance obligations"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCashReceivedInAdvanceOfSatisfactionOfPerformanceObligations",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ConvertibleSeniorNotesdue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes due 2021 [Member]",
        "label": "Convertible Senior Notes due 2021 [Member]",
        "terseLabel": "2021 Notes"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesdue2021Member",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CookCountyHealthAndHospitalsSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cook County Health And Hospitals System [Member]",
        "label": "Cook County Health And Hospitals System [Member]",
        "terseLabel": "Cook County Health and Hospitals System"
       }
      }
     },
     "localname": "CookCountyHealthAndHospitalsSystemMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity",
        "label": "Debt Instrument, Maturity, Days Prior To Any Junior Debt Maturity",
        "terseLabel": "Number of days prior to any junior debt maturity"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDaysPriorToAnyJuniorDebtMaturity",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evh_DebtInstrumentPrepaymentPenaltyPeriodFourPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty, Period Four, Percent",
        "label": "Debt Instrument, Prepayment Penalty, Period Four, Percent",
        "terseLabel": "Prepayment penalty on or after third anniversary of closing date (in percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPeriodFourPercent",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentPrepaymentPenaltyPeriodOnePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty, Period One, Percent",
        "label": "Debt Instrument, Prepayment Penalty, Period One, Percent",
        "terseLabel": "Prepayment penalty prior to first anniversary of closing date (in percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPeriodOnePercent",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentPrepaymentPenaltyPeriodThreePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty, Period Three, Percent",
        "label": "Debt Instrument, Prepayment Penalty, Period Three, Percent",
        "terseLabel": "Prepayment penalty after second anniversary of closing date but prior to third anniversary of closing date (in percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPeriodThreePercent",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentPrepaymentPenaltyPeriodTwoPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Prepayment Penalty, Period Two, Percent",
        "label": "Debt Instrument, Prepayment Penalty, Period Two, Percent",
        "terseLabel": "Prepayment penalty after first anniversary of closing date but prior to second anniversary of closing date (in percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPeriodTwoPercent",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum",
        "label": "Debt Instrument, Repurchase Covenant, Consecutive Trading Days, Minimum",
        "terseLabel": "Consecutive trading days, minimum"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantConsecutiveTradingDaysMinimum",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price",
        "label": "Debt Instrument, Repurchase Covenant, Sale Price As A Percentage Of Conversion Price",
        "terseLabel": "Repurchase covenant, sale price as a percentage of conversion price",
        "verboseLabel": "Repurchase covenant, sale price as a percentage of conversion price (at least)"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantSalePriceAsAPercentageOfConversionPrice",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentRepurchaseCovenantTradingDaysMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Covenant, Trading Days, Minimum",
        "label": "Debt Instrument, Repurchase Covenant, Trading Days, Minimum",
        "terseLabel": "Repurchase covenant, trading days, minimum"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseCovenantTradingDaysMinimum",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price",
        "label": "Debt Instrument, Repurchase Price Due To Change In Sale Price As Percentage Of Conversion Price",
        "terseLabel": "Repurchase covenant, repurchase price due to change in sale price as percentage of conversion price"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasePriceDueToChangeInSalePriceAsPercentageOfConversionPrice",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount",
        "label": "Debt Instrument, Repurchase Price Due To Fundamental Change As Percentage Of Principal Amount",
        "verboseLabel": "Repurchase covenant, repurchase price due to fundamental change as percentage of principal amount"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasePriceDueToFundamentalChangeAsPercentageOfPrincipalAmount",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_DebtIssuanceCostsNetDebtComponent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Issuance Costs, Net, Debt Component",
        "label": "Debt Issuance Costs, Net, Debt Component",
        "terseLabel": "Debt issuance costs, net, debt component"
       }
      }
     },
     "localname": "DebtIssuanceCostsNetDebtComponent",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_December312022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 31, 2022",
        "label": "December 31, 2022 [Member]",
        "terseLabel": "December 31, 2022"
       }
      }
     },
     "localname": "December312022Member",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_December312023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 31, 2023",
        "label": "December 31, 2023 [Member]",
        "terseLabel": "December 31, 2023"
       }
      }
     },
     "localname": "December312023Member",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_December312024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 31, 2024",
        "label": "December 31, 2024 [Member]",
        "terseLabel": "December 31, 2024"
       }
      }
     },
     "localname": "December312024Member",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_DeferredFinancingFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Financing Fees",
        "label": "Deferred Financing Fees [Member]",
        "terseLabel": "Deferred Financing Fees"
       }
      }
     },
     "localname": "DeferredFinancingFeesMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_DelayedDrawTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Delayed Draw Term Loan Facility [Member]",
        "label": "Delayed Draw Term Loan Facility [Member]",
        "terseLabel": "DDTL Facility"
       }
      }
     },
     "localname": "DelayedDrawTermLoanFacilityMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_DisposalGroupIncludingDiscontinuedOperationClaimsExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Claims Expense",
        "label": "Disposal Group, Including Discontinued Operation, Claims Expense",
        "terseLabel": "Claims expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationClaimsExpense",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_EmployeeSeveranceAndTerminationBenefitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Severance And Termination Benefits",
        "label": "Employee Severance And Termination Benefits [Member]",
        "terseLabel": "Severance and termination benefits"
       }
      }
     },
     "localname": "EmployeeSeveranceAndTerminationBenefitsMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_EquityComponentOfLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Component of Long Term Debt",
        "label": "Equity Component of Long Term Debt [Member]",
        "terseLabel": "Equity Component of Long Term Debt"
       }
      }
     },
     "localname": "EquityComponentOfLongTermDebtMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_EquityMethodInvestmentEconomicInterestPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Economic Interest Percentage",
        "label": "Equity Method Investment, Economic Interest Percentage",
        "terseLabel": "Economic interest percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentEconomicInterestPercentage",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EquityMethodInvestmentVotingInterestPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Voting Interest Percentage",
        "label": "Equity Method Investment, Voting Interest Percentage",
        "terseLabel": "Voting interest percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentVotingInterestPercentage",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_EvolentHealthServicesSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evolent Health Services Segment",
        "label": "Evolent Health Services Segment [Member]",
        "terseLabel": "Evolent Health Services"
       }
      }
     },
     "localname": "EvolentHealthServicesSegmentMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FInancialAssetLessThan120DaysPastDueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FInancial Asset, Less Than 120 Days Past Due [Member]",
        "label": "FInancial Asset, Less Than 120 Days Past Due [Member]",
        "terseLabel": "Past due less than 120 days"
       }
      }
     },
     "localname": "FInancialAssetLessThan120DaysPastDueMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FInancialAssetLessThan60DaysMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FInancial Asset, Less Than 60 Days [Member]",
        "label": "FInancial Asset, Less Than 60 Days [Member]",
        "terseLabel": "Past due less than 60 days"
       }
      }
     },
     "localname": "FInancialAssetLessThan60DaysMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_FinancingReceivablePercentNotPastDue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing Receivable, Percent Not Past Due",
        "label": "Financing Receivable, Percent Not Past Due",
        "terseLabel": "Percentage of receivables, current"
       }
      }
     },
     "localname": "FinancingReceivablePercentNotPastDue",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_FloridaBlueMedicareIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Florida Blue Medicare, Inc.",
        "label": "Florida Blue Medicare, Inc. [Member]",
        "terseLabel": "Florida Blue Medicare, Inc."
       }
      }
     },
     "localname": "FloridaBlueMedicareIncMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_GainLossOnDispositionOfAssetsOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Disposition Of Assets, Operating Activities",
        "label": "Gain (Loss) On Disposition Of Assets, Operating Activities",
        "negatedLabel": "Loss (gain) on discontinued operations"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssetsOperatingActivities",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_GainOnTransferOfMembership": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 13.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain On Transfer Of Membership",
        "label": "Gain On Transfer Of Membership",
        "negatedTerseLabel": "Gain on transfer of membership",
        "terseLabel": "Gain on transfer of membership"
       }
      }
     },
     "localname": "GainOnTransferOfMembership",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ImplantableProviderGroupIMPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Implantable Provider Group (\"IMP\")",
        "label": "Implantable Provider Group (\"IMP\") [Member]",
        "terseLabel": "IPG"
       }
      }
     },
     "localname": "ImplantableProviderGroupIMPMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_IncomeLossFromEquityMethodInvestmentsServicesAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) From Equity Method Investments, Services Agreement",
        "label": "Income (Loss) From Equity Method Investments, Services Agreement",
        "verboseLabel": "Revenue related to services agreements"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsServicesAgreement",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset",
        "label": "Increase (Decrease) In Accounts Receivable And Contract With Customer, Asset",
        "negatedTerseLabel": "Accounts receivable, net and contract assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableAndContractWithCustomerAsset",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInCapitalizedContractCostNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Capitalized Contract Cost, Net",
        "label": "Increase (Decrease) In Capitalized Contract Cost, Net",
        "negatedTerseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInCapitalizedContractCostNet",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities",
        "label": "Increase (Decrease) In Insurance And Performance-Based Arrangements Liabilities",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "IncreaseDecreaseInInsuranceAndPerformanceBasedArrangementsLiabilities",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "negatedTerseLabel": "Right-of-use operating assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncreaseDecreaseInTaxReceivableAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Tax Receivable Agreement",
        "label": "Increase (Decrease) In Tax Receivable Agreement",
        "terseLabel": "Change in tax receivable agreement liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInTaxReceivableAgreement",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental Common Shares Attributable to Dilutive Effect Of Stock Options Awards",
        "label": "Incremental Common Shares Attributable to Dilutive Effect Of Stock Options Awards",
        "terseLabel": "Incremental diluted shares from stock options"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsAwards",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "evh_InitialTermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Term Loan Facility [Member]",
        "label": "Initial Term Loan Facility [Member]",
        "terseLabel": "Initial Term Loan Facility"
       }
      }
     },
     "localname": "InitialTermLoanFacilityMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_LeveragedStockUnitsLSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leveraged Stock Units (LSUs) [Member]",
        "label": "Leveraged Stock Units (LSUs) [Member]",
        "verboseLabel": "LSUs"
       }
      }
     },
     "localname": "LeveragedStockUnitsLSUsMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements",
        "label": "Liability For Future Policy Benefits And Unpaid Claims And Claims Adjustment Expense And Performance-Based Arrangements",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpenseAndPerformanceBasedArrangements",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_LineOfCreditFacilityAutomaticExtensionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Automatic Extension Period",
        "label": "Line Of Credit Facility, Automatic Extension Period",
        "terseLabel": "Automatic extension period"
       }
      }
     },
     "localname": "LineOfCreditFacilityAutomaticExtensionPeriod",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_LineOfCreditFacilityPeriodBeforeEachAutomaticExtension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line Of Credit Facility, Period Before Each Automatic Extension",
        "label": "Line Of Credit Facility, Period Before Each Automatic Extension",
        "terseLabel": "Automatic extension after each period"
       }
      }
     },
     "localname": "LineOfCreditFacilityPeriodBeforeEachAutomaticExtension",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "evh_MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Risk-neutral Expected Earnout Consideration",
        "label": "Measurement Input, Risk-neutral Expected Earnout Consideration [Member]",
        "terseLabel": "Risk-neutral expected earnout consideration"
       }
      }
     },
     "localname": "MeasurementInputRiskNeutralExpectedEarnoutConsiderationMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MedicaidCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicaid Customers",
        "label": "Medicaid Customers [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MedicareCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare Customers",
        "label": "Medicare Customers [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareCustomersMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_MolinaHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Molina Healthcare",
        "label": "Molina Healthcare [Member]",
        "terseLabel": "Molina Healthcare"
       }
      }
     },
     "localname": "MolinaHealthcareMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NewNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Notes",
        "label": "New Notes [Member]",
        "terseLabel": "New Notes"
       }
      }
     },
     "localname": "NewNotesMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_NumberOfCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Customers",
        "label": "Number Of Customers",
        "terseLabel": "Number of customers"
       }
      }
     },
     "localname": "NumberOfCustomers",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evh_NumberOfOptionsToRenewLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Options To Renew Leases",
        "label": "Number Of Options To Renew Leases",
        "terseLabel": "Number of leases option"
       }
      }
     },
     "localname": "NumberOfOptionsToRenewLeases",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evh_NumberOfSourcesOfRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Sources Of Revenue",
        "label": "Number Of Sources Of Revenue",
        "terseLabel": "Number of sources of revenue"
       }
      }
     },
     "localname": "NumberOfSourcesOfRevenue",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "evh_PaymentsForProceedsFromClaimsProcessingFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For (Proceeds From) Claims Processing, Financing Activities",
        "label": "Payments For (Proceeds From) Claims Processing, Financing Activities",
        "negatedTerseLabel": "Changes in working capital balances related to claims processing on behalf of partners"
       }
      }
     },
     "localname": "PaymentsForProceedsFromClaimsProcessingFinancingActivities",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net",
        "label": "Payments For (Proceeds From) Disposal Of Non-Strategic Assets And Divestiture Of Discontinued Operations, Net",
        "negatedTerseLabel": "Disposal of non-strategic assets and divestiture of discontinued operations, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromDisposalOfNonStrategicAssetsAndDivestitureOfDiscontinuedOperationsNet",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PaymentsOfMakeWholePremium": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments Of Make-Whole Premium",
        "label": "Payments Of Make-Whole Premium",
        "terseLabel": "Payments of make-whole premium"
       }
      }
     },
     "localname": "PaymentsOfMakeWholePremium",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_PerformanceBasedRestrictedStockUnitsPSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance-Based Restricted Stock Units (PSUs) [Member]",
        "label": "Performance-Based Restricted Stock Units (PSUs) [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceBasedRestrictedStockUnitsPSUsMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PlatformsAndOperationsServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Platforms And Operations Services [Member]",
        "label": "Platforms And Operations Services [Member]",
        "verboseLabel": "Platform and operations"
       }
      }
     },
     "localname": "PlatformsAndOperationsServicesMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_PremiumsRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premiums Revenue [Member]",
        "label": "Premiums Revenue [Member]",
        "terseLabel": "Premiums"
       }
      }
     },
     "localname": "PremiumsRevenueMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ProceedsFromMaturityOfInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Maturity Of Investments",
        "label": "Proceeds From Maturity Of Investments",
        "terseLabel": "Maturities and sales of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturityOfInvestments",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ProfessionalServicesRestructuringMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Professional Services, Restructuring",
        "label": "Professional Services, Restructuring [Member]",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "ProfessionalServicesRestructuringMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashforBenefitManagementServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash for Benefit Management Services [Member]",
        "label": "Restricted Cash for Benefit Management Services [Member]",
        "terseLabel": "Claims processing services"
       }
      }
     },
     "localname": "RestrictedCashforBenefitManagementServicesMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashforLettersofCreditforFacilityLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash for Letters of Credit for Facility Leases [Member]",
        "label": "Restricted Cash for Letters of Credit for Facility Leases [Member]",
        "verboseLabel": "Collateral for letters of credit for facility leases"
       }
      }
     },
     "localname": "RestrictedCashforLettersofCreditforFacilityLeasesMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedCashforOtherContractualCommitmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash for Other Contractual Commitments [Member]",
        "label": "Restricted Cash for Other Contractual Commitments [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "RestrictedCashforOtherContractualCommitmentsMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Stock and Restricted Stock Units [Member]",
        "label": "Restricted Stock Units (RSUs), Performance-based Restricted Stock Units (PBRSUs), And Leveraged Stock Units (LSUs) [Member]",
        "terseLabel": "Restricted stock units (\"RSUs\"), performance-based RSUs (\u201cPSUs\u201d) and leveraged stock units (\"LSUs\")"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUsPerformanceBasedRestrictedStockUnitsPBRSUsAndLeveragedStockUnitsLSUsMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateAxis",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "evh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Domain]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Domain]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, End Date [Domain]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionEndDateDomain",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement",
        "label": "Right of Offset, Percentage of Accounts Receivable, Net Eligible for Net Basis Settlement",
        "terseLabel": "Accounts receivable, net eligible for net basis settlement"
       }
      }
     },
     "localname": "RightOfOffsetPercentageOfAccountsReceivableNetEligibleForNetBasisSettlement",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable",
        "label": "Right of Offset, Percentage of Accounts Receivable Netted Against Claims Payable",
        "terseLabel": "Accounts receivable netted against claims payable"
       }
      }
     },
     "localname": "RightOfOffsetPercentageOfAccountsReceivableNettedAgainstClaimsPayable",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_RightOfOffsetPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Offset, Policy",
        "label": "Right of Offset, Policy [Policy Text Block]",
        "terseLabel": "Right of Offset"
       }
      }
     },
     "localname": "RightOfOffsetPolicyPolicyTextBlock",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "evh_RightOfUseAssetAcquiredAndDisposedOf": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-Of-Use Asset Acquired And Disposed Of",
        "label": "Right-Of-Use Asset Acquired And Disposed Of",
        "negatedTerseLabel": "Leased assets disposed of (obtained in) exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetAcquiredAndDisposedOf",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_SecuredOvernightFinancingRateSOFRMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured Overnight Financing Rate (SOFR)",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "terseLabel": "Secured Overnight Financing Rate (SOFR)"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSOFRMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SeniorConvertibleNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Convertible Notes Due 2024",
        "label": "Senior Convertible Notes Due 2024 [Member]",
        "terseLabel": "2024 Notes"
       }
      }
     },
     "localname": "SeniorConvertibleNotesDue2024Member",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SeniorConvertibleNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Convertible Notes Due 2025 [Member]",
        "label": "Senior Convertible Notes Due 2025 [Member]",
        "terseLabel": "2025 Notes"
       }
      }
     },
     "localname": "SeniorConvertibleNotesDue2025Member",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SeniorCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Credit Facilities [Member]",
        "label": "Senior Credit Facilities [Member]",
        "terseLabel": "Senior Credit Facilities"
       }
      }
     },
     "localname": "SeniorCreditFacilitiesMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_ServicesAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Services Agreements [Member]",
        "label": "Services Agreements [Member]",
        "terseLabel": "Services Agreements"
       }
      }
     },
     "localname": "ServicesAgreementsMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_SharebasedCompensationIncludingOnetimeAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 16.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation, Including One-time Adjustment",
        "label": "Share-based Compensation, Including One-time Adjustment",
        "negatedLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "SharebasedCompensationIncludingOnetimeAdjustment",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ShareholderAdvisoryServices": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholder Advisory Services",
        "label": "Shareholder Advisory Services",
        "negatedLabel": "Strategy and shareholder advisory expenses"
       }
      }
     },
     "localname": "ShareholderAdvisoryServices",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_ShareholderClassActionComplaintMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholder Class Action Complaint",
        "label": "Shareholder Class Action Complaint [Member]",
        "terseLabel": "Shareholder Class Action Complaint"
       }
      }
     },
     "localname": "ShareholderClassActionComplaintMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_StockIssuedInConnectionWithDebtRepayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued in Connection with Debt Repayment",
        "label": "Stock Issued in Connection with Debt Repayment",
        "terseLabel": "Class A common stock issued in connection with debt repayment"
       }
      }
     },
     "localname": "StockIssuedInConnectionWithDebtRepayment",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_TaxReceivableAgreementLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivable Agreement Liability",
        "label": "Tax Receivable Agreement Liability",
        "terseLabel": "Tax receivable agreement liability"
       }
      }
     },
     "localname": "TaxReceivableAgreementLiability",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivable Agreement, Percent Of Cash Savings Paid To Shareholders",
        "label": "Tax Receivable Agreement, Percent Of Cash Savings Paid To Shareholders",
        "terseLabel": "Amount of tax benefit percent"
       }
      }
     },
     "localname": "TaxReceivableAgreementPercentOfCashSavingsPaidToShareholders",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TaxReceivablesAgreementPercentOfTaxSavingsToBePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Receivables Agreement, Percent of Tax Savings To Be Paid",
        "label": "Tax Receivables Agreement, Percent of Tax Savings To Be Paid",
        "terseLabel": "Percent of tax savings to be paid"
       }
      }
     },
     "localname": "TaxReceivablesAgreementPercentOfTaxSavingsToBePaid",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "evh_TransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 5.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction Costs",
        "label": "Transaction Costs",
        "negatedLabel": "Acquisition costs"
       }
      }
     },
     "localname": "TransactionCosts",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "evh_TrueHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "True Health",
        "label": "True Health [Member]",
        "terseLabel": "True Health"
       }
      }
     },
     "localname": "TrueHealthMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_UPMCResellerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UPMC Reseller Agreement",
        "label": "UPMC Reseller Agreement [Member]",
        "terseLabel": "UPMC Reseller Agreement"
       }
      }
     },
     "localname": "UPMCResellerAgreementMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_VitalDecisionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vital Decisions",
        "label": "Vital Decisions [Member]",
        "terseLabel": "Vital Decisions"
       }
      }
     },
     "localname": "VitalDecisionsMember",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "evh_WeightedAverageCommonSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Common Shares Outstanding",
        "label": "Weighted Average Common Shares Outstanding [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageCommonSharesOutstandingAbstract",
     "nsuri": "http://www.evolenthealth.com/20220930",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r461",
      "r680",
      "r681",
      "r683",
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r145",
      "r217",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r239",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r358",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r145",
      "r217",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r239",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r355",
      "r356",
      "r358",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r150",
      "r161",
      "r167",
      "r266",
      "r509",
      "r510",
      "r511",
      "r529",
      "r530",
      "r591",
      "r594",
      "r597",
      "r598",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r150",
      "r161",
      "r167",
      "r266",
      "r509",
      "r510",
      "r511",
      "r529",
      "r530",
      "r591",
      "r594",
      "r597",
      "r598",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect Period Of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r150",
      "r161",
      "r167",
      "r266",
      "r509",
      "r510",
      "r511",
      "r529",
      "r530",
      "r591",
      "r594",
      "r597",
      "r598",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect Period Of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r246",
      "r441",
      "r447",
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r367",
      "r406",
      "r464",
      "r466",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r776",
      "r780",
      "r817",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r367",
      "r406",
      "r464",
      "r466",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r776",
      "r780",
      "r817",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r246",
      "r441",
      "r447",
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r242",
      "r343",
      "r344",
      "r441",
      "r445",
      "r707",
      "r775",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r242",
      "r343",
      "r344",
      "r441",
      "r445",
      "r707",
      "r775",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r322",
      "r342",
      "r343",
      "r344",
      "r345",
      "r367",
      "r406",
      "r453",
      "r464",
      "r466",
      "r498",
      "r499",
      "r500",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r776",
      "r780",
      "r817",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r322",
      "r342",
      "r343",
      "r344",
      "r345",
      "r367",
      "r406",
      "r453",
      "r464",
      "r466",
      "r498",
      "r499",
      "r500",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r776",
      "r780",
      "r817",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r243",
      "r244",
      "r441",
      "r446",
      "r778",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r243",
      "r244",
      "r441",
      "r446",
      "r778",
      "r797",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "Brea, CA"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_GA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GEORGIA",
        "terseLabel": "GEORGIA"
       }
      }
     },
     "localname": "GA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_IL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ILLINOIS",
        "terseLabel": "Riverside, IL"
       }
      }
     },
     "localname": "IL",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NJ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW JERSEY",
        "terseLabel": "Edison, NJ"
       }
      }
     },
     "localname": "NJ",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_VA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "VIRGINIA",
        "terseLabel": "Arlington, VA"
       }
      }
     },
     "localname": "VA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "auth_ref": [
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r597",
      "r598",
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.",
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "Accounting Standards Update 2020-06"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202006Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r153",
      "r154",
      "r155",
      "r157",
      "r253",
      "r254",
      "r263",
      "r264",
      "r265",
      "r266",
      "r269",
      "r270",
      "r509",
      "r510",
      "r511",
      "r529",
      "r530",
      "r557",
      "r558",
      "r559",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r630",
      "r631",
      "r640",
      "r641",
      "r648",
      "r649",
      "r650",
      "r670",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r248",
      "r249",
      "r749"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable.",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Short-term receivables"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r60",
      "r688"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]",
        "terseLabel": "Schedule of Changes in Allowance for Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r749",
      "r801"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r248",
      "r249"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "netLabel": "Accounts receivable, net",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNoncurrentPastDueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts Receivable, Noncurrent, Past Due [Line Items]",
        "terseLabel": "Accounts Receivable, Noncurrent, Past Due [Line Items]"
       }
      }
     },
     "localname": "AccountsReceivableNoncurrentPastDueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsReceivableNoncurrentPastDueTable": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about aging analysis for accounts receivable, classified as noncurrent.",
        "label": "Accounts Receivable, Noncurrent, Past Due [Table]",
        "terseLabel": "Accounts Receivable, Noncurrent, Past Due [Table]"
       }
      }
     },
     "localname": "AccountsReceivableNoncurrentPastDueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r41",
      "r315"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Accumulated depreciation and amortization expenses"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r53",
      "r76",
      "r77",
      "r78",
      "r755",
      "r788",
      "r792"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted- Average Remaining Useful Life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r51",
      "r688"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in-capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r509",
      "r510",
      "r511",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r153",
      "r154",
      "r155",
      "r157",
      "r167",
      "r253",
      "r254",
      "r263",
      "r264",
      "r265",
      "r266",
      "r269",
      "r270",
      "r509",
      "r510",
      "r511",
      "r527",
      "r528",
      "r529",
      "r530",
      "r557",
      "r558",
      "r559",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r630",
      "r631",
      "r640",
      "r641",
      "r648",
      "r649",
      "r650",
      "r651",
      "r670",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r709",
      "r710",
      "r711",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r468",
      "r513",
      "r514"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash and restricted cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r57",
      "r250",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedPeriodEndLabel": "Balance as of end of period",
        "negatedPeriodStartLabel": "Balance as of beginning of period",
        "terseLabel": "Allowance for doubtful accounts, current"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails",
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff",
        "terseLabel": "Charge-offs"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r99",
      "r126",
      "r387",
      "r645"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r126",
      "r387",
      "r399",
      "r400",
      "r645"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of the debt discount and the issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r126",
      "r302",
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Number of antidilutive securities excluded from the calculation of earning per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r75",
      "r78",
      "r84",
      "r85",
      "r86",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r44",
      "r142",
      "r225",
      "r231",
      "r237",
      "r261",
      "r348",
      "r349",
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r359",
      "r361",
      "r362",
      "r577",
      "r582",
      "r620",
      "r686",
      "r688",
      "r732",
      "r751"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r37",
      "r58",
      "r142",
      "r261",
      "r348",
      "r349",
      "r350",
      "r352",
      "r353",
      "r354",
      "r355",
      "r357",
      "r359",
      "r361",
      "r362",
      "r577",
      "r582",
      "r620",
      "r686",
      "r688"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r492",
      "r493",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r586",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principles"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciples"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r463",
      "r465",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r463",
      "r465",
      "r545",
      "r546",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Equity interest issued or issuable, number of shares (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Voting interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r571"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill, expected tax deductible amount"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r562",
      "r563",
      "r565"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total consideration",
        "totalLabel": "Total consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Consideration Transferred [Abstract]",
        "terseLabel": "Purchase consideration:"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r562",
      "r563"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Fair value of Class A common stock issued"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r560",
      "r562",
      "r563",
      "r567"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r125",
      "r572"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 6.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "negatedLabel": "Change in fair value of contingent consideration",
        "terseLabel": "Change in fair value of contingent consideration",
        "verboseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r570"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "terseLabel": "Contingent consideration arrangements (up to)"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r561",
      "r564",
      "r569"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Fair value of contingent consideration",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "verboseLabel": "Assumption or input ranges"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r551",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Transactions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Transactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]",
        "terseLabel": "Tangible assets acquired:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease obligation assumed in business combination.",
        "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 4.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 1.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 2.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill [Abstract]",
        "terseLabel": "Identifiable intangible assets acquired:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r547",
      "r548"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "totalLabel": "Total liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]",
        "terseLabel": "Liabilities assumed:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 3.0,
       "parentTag": "evh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "verboseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r131",
      "r132",
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Accrued property and equipment purchases"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAdditions": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions made to capitalized computer software costs during the period.",
        "label": "Capitalized Computer Software, Additions",
        "terseLabel": "Capitalized computer software additions"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAdditions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAmortization1": {
     "auth_ref": [
      "r819",
      "r821"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for amortization of capitalized computer software costs.",
        "label": "Capitalized Computer Software, Amortization",
        "terseLabel": "Capitalized computer software, amortization"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAmortization1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Amortization",
        "terseLabel": "Amortization of contract cost assets",
        "verboseLabel": "Contract cost amortization"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortizationPeriod": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Capitalized Contract Cost, Amortization Period",
        "terseLabel": "Amortization period"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortizationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_CapitalizedContractCostAxis": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Axis]",
        "terseLabel": "Capitalized Contract Cost [Axis]"
       }
      }
     },
     "localname": "CapitalizedContractCostAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostDomain": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost capitalized in obtaining and fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Domain]",
        "terseLabel": "Capitalized Contract Cost [Domain]"
       }
      }
     },
     "localname": "CapitalizedContractCostDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalizedContractCostLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Capitalized Contract Cost [Line Items]",
        "terseLabel": "Capitalized Contract Cost [Line Items]"
       }
      }
     },
     "localname": "CapitalizedContractCostLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalizedContractCostNet": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "Capitalized Contract Cost, Net",
        "terseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "CapitalizedContractCostNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostNetNoncurrent": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.",
        "label": "Capitalized Contract Cost, Net, Noncurrent",
        "terseLabel": "Contract cost assets"
       }
      }
     },
     "localname": "CapitalizedContractCostNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostTable": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cost capitalized in obtaining or fulfilling contract with customer.",
        "label": "Capitalized Contract Cost [Table]",
        "terseLabel": "Capitalized Contract Cost [Table]"
       }
      }
     },
     "localname": "CapitalizedContractCostTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r36",
      "r39",
      "r128"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r121",
      "r128",
      "r134"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash as of end-of-period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash as of beginning-of-period",
        "totalLabel": "Total cash and cash equivalents and restricted cash shown in the consolidated statements of cash flows",
        "verboseLabel": "Cash and cash equivalents (including restricted cash)"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r121",
      "r632"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental Disclosure of Non-cash Investing and Financing Activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Cash Flow, Supplemental Disclosures [Text Block]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r25",
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations",
        "terseLabel": "Cash flows used in investing activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": {
     "auth_ref": [
      "r25",
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations",
        "terseLabel": "Cash flows provided by operating activities"
       }
      }
     },
     "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r140",
      "r142",
      "r173",
      "r177",
      "r184",
      "r187",
      "r189",
      "r197",
      "r198",
      "r199",
      "r261",
      "r348",
      "r353",
      "r354",
      "r355",
      "r361",
      "r362",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r620",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r418",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants or rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r418",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightUnissued": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights.",
        "label": "Class of Warrant or Right, Unissued",
        "terseLabel": "Warrants agreed to be sold (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightUnissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r69",
      "r736",
      "r759"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (See Note $11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r339",
      "r340",
      "r341",
      "r346",
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Class A Common Stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r147",
      "r148",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r50",
      "r688"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Class A common stock - $0.01 par value; 750,000,000 shares authorized; 101,159,072 and 90,758,318 shares issued, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r80",
      "r82",
      "r83",
      "r96",
      "r742",
      "r765"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income (loss) attributable to common shareholders of Evolent Health, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer hardware"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r206",
      "r207",
      "r246",
      "r617",
      "r618",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r206",
      "r207",
      "r246",
      "r617",
      "r618",
      "r794",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r206",
      "r207",
      "r246",
      "r617",
      "r618",
      "r794",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r206",
      "r207",
      "r246",
      "r617",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "verboseLabel": "Concentration risk (in percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r204",
      "r206",
      "r207",
      "r208",
      "r617",
      "r619",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r206",
      "r207",
      "r246",
      "r617",
      "r618",
      "r802"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r136",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right received from contract, including, but not limited to, advertising contract, broadcast rights, franchise agreement, lease agreement, licensing agreement, and use rights.",
        "label": "Contract-Based Intangible Assets [Member]",
        "terseLabel": "Provider network contracts"
       }
      }
     },
     "localname": "ContractBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Contract with Customer, Asset and Liability"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r419",
      "r420",
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning-of-period"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r419",
      "r420",
      "r442"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Short-term deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r419",
      "r420",
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "negatedTerseLabel": "Reclassification to revenue, as a result of performance obligations satisfied"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenue recognized from performed obligations"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r47",
      "r734",
      "r753"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "totalLabel": "Convertible Debt, Total"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r367",
      "r377",
      "r378",
      "r379",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r397",
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r239",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r93",
      "r94"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "terseLabel": "Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)"
       }
      }
     },
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Loss [Abstract]",
        "terseLabel": "Credit Loss [Abstract]"
       }
      }
     },
     "localname": "CreditLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditLossFinancialInstrumentTextBlock": {
     "auth_ref": [
      "r272",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security.",
        "label": "Credit Loss, Financial Instrument [Text Block]",
        "terseLabel": "Credit Losses"
       }
      }
     },
     "localname": "CreditLossFinancialInstrumentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLosses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r205",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r131",
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Debt conversion, converted instrument, amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r131",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Debt conversion issued (in share)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "auth_ref": [
      "r131",
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Original Debt, Amount",
        "terseLabel": "Debt conversion, original debt, amount"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r139",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r381",
      "r388",
      "r389",
      "r391",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r141",
      "r145",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r377",
      "r378",
      "r379",
      "r380",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r397",
      "r398",
      "r399",
      "r400",
      "r646",
      "r733",
      "r734",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r366",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r66",
      "r366",
      "r410",
      "r411",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Initial conversion rate per $ 1000 principal amount"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": {
     "auth_ref": [
      "r66",
      "r366",
      "r410",
      "r411",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.",
        "label": "Debt Instrument, Convertible, Number of Equity Instruments",
        "terseLabel": "Initial conversion amount (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Convertible, Remaining Discount Amortization Period",
        "terseLabel": "Remaining amortization period (years)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r364",
      "r397",
      "r398",
      "r644",
      "r646",
      "r647"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount",
        "verboseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r65",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r67",
      "r141",
      "r145",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r377",
      "r378",
      "r379",
      "r380",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r397",
      "r398",
      "r399",
      "r400",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r67",
      "r141",
      "r145",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r377",
      "r378",
      "r379",
      "r380",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r390",
      "r397",
      "r398",
      "r399",
      "r400",
      "r410",
      "r412",
      "r413",
      "r414",
      "r643",
      "r644",
      "r646",
      "r647",
      "r747"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r377",
      "r392",
      "r397",
      "r398",
      "r645"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ConvertibleDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "verboseLabel": "Unamortized debt discount and issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r377",
      "r645"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r518",
      "r519"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred tax benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r126",
      "r313"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r126",
      "r313"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 10.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "negatedLabel": "Depreciation and amortization expenses",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortizationDiscontinuedOperations": {
     "auth_ref": [
      "r26",
      "r126"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.",
        "label": "Depreciation and Amortization, Discontinued Operations",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationAndAmortizationDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r126",
      "r220"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Technology",
        "verboseLabel": "Technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r441",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r472",
      "r473",
      "r505",
      "r506",
      "r507",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": {
     "auth_ref": [
      "r9",
      "r11",
      "r15",
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.",
        "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax",
        "terseLabel": "Gain on disposal of discontinued operations"
       }
      }
     },
     "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSSParenthetical",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r12",
      "r15",
      "r23",
      "r92",
      "r762"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "totalLabel": "Loss before income taxes and non-controlling interests"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r15",
      "r23",
      "r29",
      "r520",
      "r535",
      "r538"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results.",
        "label": "Discontinued Operations, Disposed of by Sale [Member]",
        "terseLabel": "Discontinued Operations, Disposed of by Sale"
       }
      }
     },
     "localname": "DiscontinuedOperationsDisposedOfBySaleMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r24",
      "r32"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of revenue (exclusive of depreciation and amortization expenses presented separately below)"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": {
     "auth_ref": [
      "r13",
      "r14",
      "r24",
      "r33"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestIncome": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Interest Income",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "negatedTerseLabel": "Other loss"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r24",
      "r32"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r34",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r463",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Income (loss) per common share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r97",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r170",
      "r173",
      "r187",
      "r188",
      "r189",
      "r193",
      "r194",
      "r598",
      "r599",
      "r743",
      "r766"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Basic income (loss) per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r97",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r173",
      "r187",
      "r188",
      "r189",
      "r193",
      "r194",
      "r598",
      "r599",
      "r743",
      "r766"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Diluted income (loss) per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Income (Loss) Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r632"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate on cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r504"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Stock-based compensation capitalized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareAntidilutiveSecuritiesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r84",
      "r85",
      "r86",
      "r147",
      "r148",
      "r149",
      "r154",
      "r164",
      "r166",
      "r196",
      "r266",
      "r409",
      "r415",
      "r509",
      "r510",
      "r511",
      "r529",
      "r530",
      "r597",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r676",
      "r783",
      "r784",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvesteeMember": {
     "auth_ref": [
      "r258",
      "r717",
      "r719",
      "r721",
      "r723",
      "r725",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity that issued voting stock held by an investor and that is accounted for under the equity method of accounting by the investor.",
        "label": "Equity Method Investee [Member]",
        "terseLabel": "Equity Method Investee"
       }
      }
     },
     "localname": "EquityMethodInvesteeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "terseLabel": "Investments in Equity Method Investees"
       }
      }
     },
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvestees"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Face amount of debt repaid"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FacilityClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Facility Closing [Member]",
        "terseLabel": "Office space consolidation"
       }
      }
     },
     "localname": "FacilityClosingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Valuation Techniques and Significant Unobservable Inputs"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r604",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r379",
      "r397",
      "r398",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r462",
      "r605",
      "r692",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r604",
      "r605",
      "r607",
      "r608",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r379",
      "r454",
      "r455",
      "r460",
      "r462",
      "r605",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r379",
      "r397",
      "r398",
      "r454",
      "r455",
      "r460",
      "r462",
      "r605",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r379",
      "r397",
      "r398",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r462",
      "r605",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Assets and Liabilities on Recurring Basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r609",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Changes in Contingent Consideration Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r610"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Unrealized (gains) losses, net"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": {
     "auth_ref": [
      "r611"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r611"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r609"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementChangesinContingentConsiderationandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r379",
      "r397",
      "r398",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r462",
      "r692",
      "r693",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r612",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "verboseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails",
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancingReceivablePercentPastDue1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of financing receivable balance that is past due.",
        "label": "Financing Receivable, Percent Past Due",
        "terseLabel": "Percentage of receivables, past due"
       }
      }
     },
     "localname": "FinancingReceivablePercentPastDue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinancingReceivablesPeriodPastDueAxis": {
     "auth_ref": [
      "r251",
      "r276",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by period in which financial asset is past due or not past due.",
        "label": "Financial Asset, Aging [Axis]",
        "terseLabel": "Financial Asset, Period Past Due [Axis]"
       }
      }
     },
     "localname": "FinancingReceivablesPeriodPastDueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancingReceivablesPeriodPastDueDomain": {
     "auth_ref": [
      "r251",
      "r276",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which financial asset is past due or not past due. For past due, element name and standard label in Financial Asset, [numeric lower end] to [numeric higher end] [date measure] Past Due [Member] or Financial Asset, Greater than [low end numeric value] [date measure] Past Due [Member] or Financial Asset, Less than [high end numeric value] [date measure] Past Due [Member] formats.",
        "label": "Financial Asset, Aging [Domain]",
        "terseLabel": "Financial Asset, Period Past Due [Domain]"
       }
      }
     },
     "localname": "FinancingReceivablesPeriodPastDueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesAccountsReceivableNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-lived intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r43",
      "r308"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r303",
      "r305",
      "r308",
      "r311",
      "r708",
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r308",
      "r715"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r303",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r308",
      "r708"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total future amortization of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetAmortizationofIntangibleAssetsDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r126",
      "r401",
      "r402"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 11.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on extinguishment/repayment of debt, net",
        "terseLabel": "Loss on extinguishment/repayment of debt",
        "verboseLabel": "Loss on extinguishment/repayment of debt, net"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r401",
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the difference between the fair value of payments made to legally extinguish a debt and its carrying value at that time. This item excludes the write-off of amounts previously capitalized as debt issuance costs.",
        "label": "Gain (Loss) on Extinguishment of Debt, before Write off of Debt Issuance Cost",
        "terseLabel": "Net loss on extinguishment of debt, including fees paid to lenders"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r42",
      "r287",
      "r288",
      "r295",
      "r299",
      "r688",
      "r730"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance as of end of period",
        "periodStartLabel": "Balance as of beginning of period",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r289",
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill acquired"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Net"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r298",
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r288",
      "r295",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Cumulative inception to date impairment"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r102",
      "r127",
      "r159",
      "r160",
      "r161",
      "r162",
      "r185",
      "r189",
      "r574"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income (loss) from continuing operations",
        "totalLabel": "Income (loss) from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r90",
      "r225",
      "r230",
      "r233",
      "r236",
      "r239",
      "r728",
      "r739",
      "r745",
      "r767"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r87",
      "r97",
      "r153",
      "r159",
      "r160",
      "r161",
      "r162",
      "r173",
      "r187",
      "r188",
      "r599",
      "r737",
      "r740",
      "r743",
      "r761"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Continuing operations, basic (in dollars per share)",
        "verboseLabel": "Continuing operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r87",
      "r97",
      "r153",
      "r159",
      "r160",
      "r161",
      "r162",
      "r173",
      "r187",
      "r188",
      "r189",
      "r599",
      "r743",
      "r761",
      "r764",
      "r766"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Continuing operations, diluted (in dollars per share)",
        "verboseLabel": "Continuing operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r12",
      "r15",
      "r29",
      "r32",
      "r539",
      "r762"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 15.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net loss",
        "verboseLabel": "Gain (loss) from discontinued operations"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r12",
      "r15",
      "r23",
      "r29",
      "r575"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Income (loss) from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r92",
      "r97",
      "r177",
      "r187",
      "r188",
      "r743",
      "r762",
      "r764",
      "r766"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Discontinued operations, basic (in dollars per share)",
        "verboseLabel": "Discontinued operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r177",
      "r187",
      "r188",
      "r584"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Discontinued operations, diluted (in dollars per share)",
        "verboseLabel": "Discontinued operations (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r91",
      "r126",
      "r222",
      "r259",
      "r738",
      "r760"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 9.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Gain from equity method investees",
        "terseLabel": "Gain from equity method investees"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r463",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r7",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r27",
      "r30",
      "r31",
      "r32",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofCashFlowsDetails",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r317",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r143",
      "r522",
      "r524",
      "r526",
      "r534",
      "r536",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r144",
      "r165",
      "r166",
      "r223",
      "r520",
      "r535",
      "r537",
      "r768"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 7.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Benefit from (provision for) income taxes",
        "terseLabel": "Provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for taxes, net"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r125",
      "r702"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in assets and liabilities, net of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r125",
      "r662"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "auth_ref": [
      "r182",
      "r183",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r189",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Incremental diluted shares from Restricted stock units (\"RSUs\"), performance-based RSUs (\u201cPSUs\u201d) and leveraged stock units (\"LSUs\")"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InsuranceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance [Abstract]",
        "terseLabel": "Insurance [Abstract]"
       }
      }
     },
     "localname": "InsuranceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InsuranceDisclosureTextBlock": {
     "auth_ref": [
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the types of coverages and products sold, and the assets, obligations, recorded liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.",
        "label": "Insurance Disclosure [Text Block]",
        "terseLabel": "Reserves for Claims and Performance-Based Arrangements"
       }
      }
     },
     "localname": "InsuranceDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r137",
      "r307",
      "r704",
      "r705",
      "r706",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r301",
      "r306"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r88",
      "r219",
      "r642",
      "r645",
      "r744"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 14.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r106",
      "r385",
      "r396",
      "r399",
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r119",
      "r122",
      "r130"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "negatedTerseLabel": "Cash paid for interest",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntersegmentEliminationMember": {
     "auth_ref": [
      "r217",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eliminating entries used in operating segment consolidation.",
        "label": "Intersegment Eliminations [Member]",
        "terseLabel": "Intersegment Eliminations"
       }
      }
     },
     "localname": "IntersegmentEliminationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r105",
      "r218"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "verboseLabel": "Investments in equity method investees"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAgreementsMember": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.",
        "label": "Lease Agreements [Member]",
        "terseLabel": "Lease Agreements"
       }
      }
     },
     "localname": "LeaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r666",
      "r668"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Lease Expense, Weighted-Average Discount Rate and Weighted-remaining Lease Terms"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Legal expenses"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Primary Office Leases and Maturity of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r667"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Future Minimum Lease Commitments",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r667"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r667"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r667"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r667"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r667"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r667"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease Termination Term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of Credit Amount Required",
        "verboseLabel": "Letters of credit outstanding, amount"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails",
      "http://www.evolenthealth.com/role/LeasesPrimaryOfficeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r62",
      "r142",
      "r232",
      "r261",
      "r348",
      "r349",
      "r350",
      "r353",
      "r354",
      "r355",
      "r357",
      "r359",
      "r361",
      "r362",
      "r578",
      "r582",
      "r583",
      "r620",
      "r686",
      "r687"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r56",
      "r142",
      "r261",
      "r620",
      "r688",
      "r735",
      "r757"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r38",
      "r64",
      "r142",
      "r261",
      "r348",
      "r349",
      "r350",
      "r353",
      "r354",
      "r355",
      "r357",
      "r359",
      "r361",
      "r362",
      "r578",
      "r582",
      "r583",
      "r620",
      "r686",
      "r687",
      "r688"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r604"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total fair value of liabilities measured on a recurring basis"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementAssetsandLiabilitiesonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r769",
      "r772"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r752",
      "r769",
      "r772"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of policy reserves (provided for future obligations including unpaid claims and claims adjustment expenses) and policy benefits (liability for future policy benefits) as of the balance sheet date; grouped amount of all the liabilities associated with the company's insurance policies.",
        "label": "Liability for Future Policy Benefits and Unpaid Claims and Claims Adjustment Expense",
        "terseLabel": "Reserve for claims and performance-based arrangements"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]",
        "terseLabel": "Claims paid related to:"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r771"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "negatedTerseLabel": "Current year to date period"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r771"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "negatedTerseLabel": "Prior year to date period"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "auth_ref": [
      "r770"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "totalLabel": "Total claims incurred"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]",
        "terseLabel": "Incurred health care costs:"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityReserveEstimatePolicy": {
     "auth_ref": [
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for estimating its liability as of the balance sheet date for the ultimate cost of settling reported and unreported claims incurred and claims adjustment expenses (including effects of inflation and other societal and economic factors).",
        "label": "Liability Reserve Estimate, Policy [Policy Text Block]",
        "terseLabel": "Reserves for Claims and Performance-based Arrangements"
       }
      }
     },
     "localname": "LiabilityReserveEstimatePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Settlement payment"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermAccountsNotesAndLoansReceivableNetNoncurrent": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as noncurrent. Includes, but is not limited to, notes and loan receivable.",
        "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Long-term receivables"
       }
      }
     },
     "localname": "LongTermAccountsNotesAndLoansReceivableNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r47",
      "r378",
      "r393",
      "r397",
      "r398",
      "r734",
      "r753"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt, net",
        "verboseLabel": "Carrying amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r67",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/FairValueMeasurementValuationTechniquesandSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash and restricted cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows Provided by (Used In) Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash and restricted cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows Provided by (Used In) Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r121",
      "r124",
      "r127"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash and restricted cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows Used In Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r32",
      "r79",
      "r81",
      "r86",
      "r95",
      "r127",
      "r142",
      "r153",
      "r159",
      "r160",
      "r161",
      "r162",
      "r165",
      "r166",
      "r185",
      "r225",
      "r230",
      "r233",
      "r236",
      "r239",
      "r261",
      "r348",
      "r349",
      "r350",
      "r353",
      "r354",
      "r355",
      "r357",
      "r359",
      "r361",
      "r362",
      "r599",
      "r620",
      "r741",
      "r763"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r170",
      "r171",
      "r186",
      "r189",
      "r225",
      "r230",
      "r233",
      "r236",
      "r239"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net income (loss) attributable to common shareholders of Evolent Health, Inc.",
        "totalLabel": "Net income (loss) attributable to common shareholders of Evolent Health, Inc."
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r172",
      "r178",
      "r179",
      "r180",
      "r181",
      "r186",
      "r189"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net income (loss) attributable to common shareholders of Evolent Health, Inc.",
        "totalLabel": "Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r5",
      "r151",
      "r152",
      "r155",
      "r156",
      "r167",
      "r168",
      "r169",
      "r255",
      "r256",
      "r267",
      "r268",
      "r531",
      "r532",
      "r533",
      "r595",
      "r601",
      "r602",
      "r603",
      "r627",
      "r628",
      "r629",
      "r652",
      "r653",
      "r671",
      "r677",
      "r712",
      "r713",
      "r714",
      "r787",
      "r788",
      "r789",
      "r790",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r150",
      "r153",
      "r154",
      "r155",
      "r157",
      "r158",
      "r161",
      "r167",
      "r193",
      "r253",
      "r254",
      "r263",
      "r264",
      "r265",
      "r266",
      "r269",
      "r270",
      "r509",
      "r510",
      "r511",
      "r527",
      "r528",
      "r529",
      "r530",
      "r557",
      "r558",
      "r559",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r630",
      "r631",
      "r640",
      "r641",
      "r648",
      "r649",
      "r650",
      "r651",
      "r670",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r709",
      "r710",
      "r711",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Adoption of New Accounting Standards and Recent Accounting Pronouncements Not Yet Effective"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "auth_ref": [
      "r131",
      "r132",
      "r133"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "terseLabel": "Accrued net working capital adjustment with business combinations"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetImpairmentTestingDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r225",
      "r230",
      "r233",
      "r236",
      "r239"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r660",
      "r668"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Gross Difference [Abstract]",
        "terseLabel": "Less:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesGrossDifferenceAmountAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r655"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesMaturityofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r655"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability - current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r655"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities - noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r656",
      "r662"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r654"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets - operating"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r665",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r664",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesWeightedaverageDiscountRateandWeightedremainingLeaseTermsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r35",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r575",
      "r576",
      "r580"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of taxes, related to:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other current operating cash inflows (outflows), net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 12.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "auth_ref": [
      "r123",
      "r771"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "negatedTotalLabel": "Total claims paid"
       }
      }
     },
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.",
        "label": "Payments for Repurchase of Warrants",
        "terseLabel": "Payments to settle outstanding warrants"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebtWarrantAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "Payment for Debt Extinguishment or Debt Prepayment Cost",
        "negatedTerseLabel": "Repayment of Credit Agreement including settlement of warrants"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Payments of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes withheld and paid for vesting of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r110",
      "r566"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      },
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedTerseLabel": "Cash paid for asset acquisitions and business combinations",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": {
     "auth_ref": [
      "r109",
      "r257"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities.",
        "label": "Payments to Acquire Held-to-Maturity Securities",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireHeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherProductiveAssets": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.",
        "label": "Payments to Acquire Other Productive Assets",
        "negatedTerseLabel": "Investments in internal-use software and purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.",
        "label": "Payments to Noncontrolling Interests",
        "negatedTerseLabel": "Distributions to Sponsors"
       }
      }
     },
     "localname": "PaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "netLabel": "Prepaid expenses and other current assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent": {
     "auth_ref": [
      "r44",
      "r731",
      "r750"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Noncurrent",
        "verboseLabel": "Prepaid expenses and other noncurrent assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates": {
     "auth_ref": [
      "r108"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.",
        "label": "Proceeds from Divestiture of Interest in Subsidiaries and Affiliates",
        "terseLabel": "Proceeds from transfer of membership and release of Passport escrow"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "auth_ref": [
      "r108",
      "r120"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "terseLabel": "Return of equity method investments"
       }
      }
     },
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuance of long term debt, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r112",
      "r508"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r321",
      "r804",
      "r805",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r40",
      "r314"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r316",
      "r688",
      "r746",
      "r758"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r98",
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "negatedTerseLabel": "Provision for credit losses"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CreditLossesScheduleofChangesinAllowanceforAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r230",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Adjusted EBITDA to Net Loss"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r229",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r229",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of Revenue from Segments to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r461",
      "r680",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r461",
      "r680",
      "r681",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r680"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "verboseLabel": "Expenses"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r461",
      "r680",
      "r683",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r678",
      "r679",
      "r681",
      "r684",
      "r685"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-Term Lines of Credit",
        "terseLabel": "Repayments of long-term lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "terseLabel": "Repayments of senior debt"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r516",
      "r703",
      "r820"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r39",
      "r128",
      "r134",
      "r729",
      "r754"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted funds",
        "verboseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.evolenthealth.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r39",
      "r128",
      "r134"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndInvestmentsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "verboseLabel": "Current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "terseLabel": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restricted Cash and Cash Equivalents Items [Line Items]",
        "terseLabel": "Restricted Cash and Cash Equivalents Items [Line Items]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsItemsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r128",
      "r134",
      "r799"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestrictedCashAndInvestmentsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "verboseLabel": "Non-current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestments": {
     "auth_ref": [
      "r798",
      "r800"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and investments whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements. For use in an unclassified balance sheet.",
        "label": "Restricted Cash and Investments",
        "terseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsCurrent": {
     "auth_ref": [
      "r58",
      "r798",
      "r800"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current cash, cash equivalents and investments that are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes current cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.",
        "label": "Restricted Cash and Investments, Current",
        "terseLabel": "Restricted cash and restricted investments",
        "totalLabel": "Total current restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndInvestmentsNoncurrent": {
     "auth_ref": [
      "r798",
      "r800"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The noncurrent cash, cash equivalents and investments that is restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits classified as long-term; that is not expected to be released from such existing restrictions within one year of the balance sheet date or operating cycle, whichever is longer. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. Includes noncurrent cash equivalents and investments that are similarly restricted as to withdrawal, usage or disposal.",
        "label": "Restricted Cash and Investments, Noncurrent",
        "totalLabel": "Total non-current restricted cash and restricted investments",
        "verboseLabel": "Restricted cash and restricted investments"
       }
      }
     },
     "localname": "RestrictedCashAndInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r324",
      "r326",
      "r329",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Repositioning and Other Changes"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChanges"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r325",
      "r328",
      "r334",
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Cumulative Costs Incurred through December 31, 2021"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r126",
      "r323",
      "r332",
      "r334"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 8.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "negatedLabel": "Repositioning costs",
        "terseLabel": "Incurred For the Nine Months Ended September 30, 2021"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails",
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r325",
      "r326",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r52",
      "r415",
      "r688",
      "r756",
      "r787",
      "r792"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings (accumulated deficit)"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r147",
      "r148",
      "r149",
      "r154",
      "r164",
      "r166",
      "r266",
      "r509",
      "r510",
      "r511",
      "r529",
      "r530",
      "r597",
      "r783",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r216",
      "r217",
      "r229",
      "r234",
      "r235",
      "r242",
      "r243",
      "r246",
      "r440",
      "r441",
      "r707"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r206",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r138",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r430",
      "r431",
      "r444",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r101",
      "r351",
      "r353",
      "r354",
      "r360",
      "r361",
      "r362",
      "r796"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "terseLabel": "Remaining performance obligation, percentage"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RevenueRecognitionTransactionPriceAllocatedtotheRemainingPerformanceObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r89",
      "r142",
      "r216",
      "r217",
      "r229",
      "r234",
      "r235",
      "r242",
      "r243",
      "r246",
      "r261",
      "r348",
      "r349",
      "r350",
      "r353",
      "r354",
      "r355",
      "r357",
      "r359",
      "r361",
      "r362",
      "r620",
      "r745"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsSummaryofResultsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r663",
      "r668"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Leased assets disposed of (obtained in) exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareAntidilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r545",
      "r546",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Allocation of Purchase Price"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash And Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Cash Flow, Supplemental Disclosures"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r7",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r27",
      "r30",
      "r31",
      "r32",
      "r319",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of Discontinued Operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/DiscontinuedOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r502",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r32",
      "r142",
      "r260",
      "r261",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/InvestmentsinEquityMethodInvesteesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r303",
      "r307",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r303",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets",
        "verboseLabel": "Schedule of Intangible Assets Details"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Schedule of Activity in Claims Reserves"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of Net Assets Acquired"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/TransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r682",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesAssetsandLiabilitiesDetails",
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of Related Parties"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": {
     "auth_ref": [
      "r134",
      "r729",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesRestrictedCashandRestrictedInvestmentsDetails",
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r134",
      "r729",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Restricted Cash And Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r330",
      "r331",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule of Costs Associated with the Repositioning Plan"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r484",
      "r491",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Awards Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r467",
      "r469",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r492",
      "r493",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Future Estimated Amortization of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r204",
      "r206",
      "r207",
      "r208",
      "r617",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Major Customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]",
        "terseLabel": "Secured Debt"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r212",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r246",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r299",
      "r328",
      "r336",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r212",
      "r214",
      "r215",
      "r225",
      "r228",
      "r233",
      "r237",
      "r238",
      "r239",
      "r240",
      "r242",
      "r245",
      "r246",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReporting"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Revenue Reconciling Item [Line Items]",
        "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingRevenueReconcilingItemLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RelatedPartiesRevenuesandExpensesDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2021NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebtConvertibleSeniorNotesCarryingValueDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails": {
       "order": 17.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "negatedLabel": "Severance costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SegmentReportingReconciliationofAdjustedEBITDADetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r492",
      "r493",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/StockbasedCompensationScheduleofSharebasedAwardsGrantedDetails",
      "http://www.evolenthealth.com/role/StockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]",
        "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Line Items]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable": {
     "auth_ref": [
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.",
        "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]",
        "terseLabel": "Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "verboseLabel": "Internal-use software development costs"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r16",
      "r212",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r239",
      "r246",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r299",
      "r318",
      "r328",
      "r336",
      "r775"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetScheduleofGoodwillDetails",
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails",
      "http://www.evolenthealth.com/role/RevenueRecognitionDisaggregationofRevenueDetails",
      "http://www.evolenthealth.com/role/SegmentReportingRevenuefromSegmentstoConsolidatedDetails",
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r140",
      "r142",
      "r173",
      "r177",
      "r184",
      "r187",
      "r189",
      "r197",
      "r198",
      "r199",
      "r261",
      "r348",
      "r353",
      "r354",
      "r355",
      "r361",
      "r362",
      "r404",
      "r405",
      "r407",
      "r408",
      "r409",
      "r620",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r72",
      "r84",
      "r85",
      "r86",
      "r147",
      "r148",
      "r149",
      "r154",
      "r164",
      "r166",
      "r196",
      "r266",
      "r409",
      "r415",
      "r509",
      "r510",
      "r511",
      "r529",
      "r530",
      "r597",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r676",
      "r783",
      "r784",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r196",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r131",
      "r132",
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Class A common stock issued in connection with business combinations"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "auth_ref": [
      "r49",
      "r50",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.",
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "terseLabel": "Shares issued for acquisition (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r71",
      "r382",
      "r409",
      "r410",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Exchange/conversion (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r49",
      "r50",
      "r409",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock units vested, net of shares withheld for taxes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r49",
      "r50",
      "r409",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Leveraged stock units vested, net of shares withheld for taxes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r49",
      "r50",
      "r409",
      "r415",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r72",
      "r409",
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Shares issued for acquisition"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r72",
      "r409",
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Exchange/conversion"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r409",
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Restricted stock units vested, net of shares withheld for taxes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r49",
      "r50",
      "r415",
      "r492"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Leveraged stock units vested, net of shares withheld for taxes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r72",
      "r409",
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r50",
      "r54",
      "r55",
      "r142",
      "r252",
      "r261",
      "r620",
      "r688"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "negatedTerseLabel": "Stockholders' equity",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Stockholders' equity",
        "totalLabel": "Total shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY",
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r639",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r689",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "terseLabel": "Supplemental Cash Flow Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosures"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/SupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r770"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "verboseLabel": "Current year to date period"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r770"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "terseLabel": "Prior year to date period"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/ReservesforClaimsandPerformanceBasedArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business.",
        "label": "Trade Accounts Receivable [Member]",
        "terseLabel": "Trade Accounts Receivable"
       }
      }
     },
     "localname": "TradeAccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CommitmentsandContingenciesConcentrationRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Corporate trade name"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsNetDetails",
      "http://www.evolenthealth.com/role/TransactionsAllocationofAcquisitionCostDetails",
      "http://www.evolenthealth.com/role/TransactionsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r74",
      "r416",
      "r417"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "negatedTerseLabel": "Treasury stock, at cost; 1,537,582 shares issued, respectively"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r70",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r153",
      "r154",
      "r155",
      "r157",
      "r167",
      "r253",
      "r254",
      "r263",
      "r264",
      "r265",
      "r266",
      "r269",
      "r270",
      "r509",
      "r510",
      "r511",
      "r527",
      "r528",
      "r529",
      "r530",
      "r557",
      "r558",
      "r559",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r630",
      "r631",
      "r640",
      "r641",
      "r648",
      "r649",
      "r650",
      "r651",
      "r670",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r709",
      "r710",
      "r711",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2024NotesDetails",
      "http://www.evolenthealth.com/role/LongtermDebt2025NotesDetails",
      "http://www.evolenthealth.com/role/RecentlyIssuedAccountingStandardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r325",
      "r326",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/RepositioningandOtherChangesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r517",
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r209",
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Accounting Estimates and Assumptions"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/BasisofPresentationSummaryofSignificantAccountingPoliciesandChangeinAccountingPrinciplesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r525"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Reduction of valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r661",
      "r668"
     ],
     "calculation": {
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2022CreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r172",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r170",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMELOSS",
      "http://www.evolenthealth.com/role/IncomeLossPerCommonShareComputationofEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.",
        "label": "Write off of Deferred Debt Issuance Cost",
        "terseLabel": "Unamortized debt issuance cost"
       }
      }
     },
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.evolenthealth.com/role/LongtermDebt2019CreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1060-107759"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "230",
   "URI": "https://asc.fasb.org/topic&trid=2134446"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1063-107759"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2029-109256"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=126960272&loc=d3e32014-111567"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919269-210447"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919272-210447"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919236-210447"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "80",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131251-203054"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905575&loc=SL49131252-203054"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/subtopic&trid=2122178"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL108322424-203045"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5227-128473"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(13)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671315-158438"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/subtopic&trid=2560295"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "944",
   "URI": "https://asc.fasb.org/topic&trid=2303980"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128487-111756"
  },
  "r822": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r823": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r824": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r825": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r826": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r827": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r828": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>121
<FILENAME>0001628908-22-000141-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628908-22-000141-xbrl.zip
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M2X,*,&V.I?7)&*4@]WIH8[)(X\NEP(#B'K(575C KEZ5"6J4F-+1%JN5%/[
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MWA<YE'"[ Y%:8_=SZS@R?*>-G7,7_P)59IET#N C52K1R(ZH74BTSRLYQ-C
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MW8_]DW\4Q*5S#WC2SRBG+L6!QR79LO5 R<I "0Y$?MZ/#I0@ K,KM5R!)<7
M[H!_('+V!O!\?P#?;@;'- ^78'"F<.%=W?XP*NM$*2)>FNV[4&T/ 1%6C>39
M@BHU*L"T.1;&)6.4@MSIH8W)(HTOEP(-DCO(5G1A ;MZ52:H46!*1UN,DB)V
MYRVF#(V(!=>"'!">U+CBE).FTA#1<$%N'"MQJ5L90(,LE@KJ5"#]%E$I.54<
M=,L9L2 LV,/3GV76AG^%0()8%+ _Q)^C".Q[3(3[$Q-5$5@-B:W3Z%ID;)^
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M ,4;)BP52@I0=:DQ;^ASP_09:"QEP^2L_!>J VVX58#5K'/P$"OQQNWT%3@
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M>Z=S$=^2#1<1#//1>]MI$#TZ/AE+R[0Y]L+<UW*]V4^SZ>G)HYV?;QJ@N!J
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MR> %:HYY2.5_^@_O[8_# 687C*]61"583AD*Q&*C]484IQK2QM ]A[>CX;C
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MF7[KY+G]X5<$R(EL,:I6X+9%K"+VM48NY$(<>IS\NUAN5-87+H #UM9P=JI
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M'";UEKB[(8ZE.,>(2)PAIB4/80V#K$L=#:5 <DZJ2?V.ILY.*A4V\]Z ?DI
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MEV[":M+HKO^P MUNX6*QW+BZ=+4NO0/6G\HC6L[IJI7A09O6]ER_/_KG/0R
M5!SH>QSH:L[3R;FV0IH,<<X=8CH32!'ED9"4,T%RSHU;VQ 8)XWUY%W+:0?J
MH>P/4*'1XC&*(2Y@_7A:!:_]>H_\!#9-*YN^ATW7;]JTUT2[G'*4:1-*YF"'
MM,T-$M203*2,>9&O;>P/"V#7'./*EBM;7IHMOX%?=WO-[GD5A[R/)7^\:<F"
M$6&II\BJ7(6]6X)T"HNU)3*CV!%CF5_;V PI44>#;J>RY,J2EV;),1JSV_NG
MU_U:=$RU[[ 0>S<S*W>>24)"<H:E!C%'+)+2,R14JBPW)G-8K&U\*L)N?*$>
M9]^A,H,;9O!/%_2\=5B<E9MOE8Y_5\=GHNZ68R>\(LCG)$/,JQP)8W.4,2^Q
MR$P6CX)0$$.ZW(![.#GTXY$92EY@6'2DXR%UZJP'*%^<J5;B+IP9#HJO(:/*
M%\;U%QQ7?SG3!ZB0!%CXN;CQG25?'GA6[VD.3"TQJ_YA:>&K]C.Y_N]Q#K0]
M]$3%;TM<0H,;N-ESZMDNFC^<@TM@4?QB%<^P2#G*T]"/G3&"!)>A)%YFE<XD
MSAVL>3PGLRO>[\L\L/^^"[#YSW&W\TL>#""-K<TO62A5B(.#;85'3!B").$,
M:9JIE*>8<JW6-E(A48;G(V7/("'Z.OW]?_]+4)*_[B<#UW)G0>I))XJ]EL!*
MWQJ&U2A18*-).'"][-7D>6/Y*I<P>Q9BND.]OE-U8-D'@>])<?:!#_>*00%W
M+ \8N)ZSR=FPUQ^&DP:#;@)7Q!P"0G_3OP<V'8X-;YK!J_L#QNM;'O9Q,_@Y
MP^.4ZP=G\%.^K#1P(99T8R+Q_>]\AT?)[^%1/G5YU/M5J6P6@U8\0N.4.4Y,
M2_7[#W!JGLDS]E1<]/8OV[K;^NU!?NWS>,+&Z!Q4%**[,,>J<P0O=)+SXP)>
MN4:OVPK@/B219;$^?+NPMN4>']V7'4@<+1R7A.IH7\^2<)?AP\.MX]-&^V-Z
M^/G#U>'6Q[2Q=<H/W^V<P_=<';X+S3?J<)^/EX=;9B9\>':Z^PZ>HVE;AUN-
MTT;3X-UFZ_3@Y$]XIL;IP56K7;\"XM[\^[01QMC<O!D^Q$:"##*!,)6!L0N&
MI&892FF.0]=92Y5=VW@3 "O93,+):U#W_4'7G 9#N.V88RTY4[WDJVH-7?+?
ML :04-4CZ1__6&9_90GWL801]);(6YG!/<Q@>]8,>)93G86D#H,8SC0"4U H
M)SEQN>,:YVQM8_O37Y4*+QG,MT?+:GF\?'93-"RZSWX_]/&T?&?F'%;H_6=3
MAG2.'6)*"B24(DAFJ20&'!0K#+ <T)6#;N]T!/-C@7Q3\V^/M-\CGOXXP?;[
M%I#9Z=B0K^X2?9F88P=/WPYEC\^/73PR$=S.J3/POY'?DV/53WS1 H=5M5KP
M9JA4%_S8_PR+X,6"\ZK=Z *XY\213</ABK*:U\B=G?*"QS,>7-SP=JCFE5AX
M%\AUN/2LYXR+5)O0));_[">_P?W 6)+^$(AH_[@;#N*/RVD-CM5@=NSGZN8H
MPQ#+#X^>X?=:HCHV^8V6SZC!Y.!]?0)/$*Z/E\*'PBA&]PE%^_IQ$'&0JC](
M)$ZLNNRO)\N,NY;[R6^&O1X,H*P5&-;"@1H,^\\2)7XX!GM1W_IP\24'%I=*
MH'1. )%C"I8Q(81"VE%C!9:6"E@_#ES_SOCK/6UO<56R]Y<2;;MWV:BDT4TF
MQ1)?'$P%\P7+;1># =BZ:X$%][J=0"E:EXD#>G$)O!W@0IFX*[VE!JJLJS2#
M8M?WF([-[0WA2H9Y *H]=S0L^PXE^ZB9_!:"D_EKFM+UT06#XR*6"3D+94*6
M#6GE>"=(Y?J_/P8.34UEF,D1+/UJ.'1U</7%9#@76<BQ]*&Q&N4624,5\CX+
M'8@),&UZ.P[]TD#T@I$(C%\E+=4#:J., 23JJ0 GP3A[@6[<^FH"FH%N?:/?
M!@B#;^F-UWPPYS;,PF4ML"NX'5"2$*8_2HYZW?/!\?CM]>FMDWWGXC"M\T4G
M5B&-^3IA>X_"$]\QV/@V>3V^[.X+QE?</=;QE8%MC2Z^8]SC*XM.B;J$:D3'
M_'&:-*XG\UNIJZ@]CU*EK_<&Q'+4[5W>XDW&BZ+ S.BB9^I8_CA4-Z[JH5T/
M]DIE!N68I8AY$P(A7B.>^U0+#+/K@3*^O]T8*OB>P/?F[-Q,T#Q ^RTP=OWV
M_ET \>#IO&>E]Y4QTOCD?P[[\,W]?E7EO33+W:WMBR^:8I.S3"*?Y;'6H$(J
MA;G,A:.:6J!0(7_],<N\/VTEWGLF%&S?OGPNRY#N.:JEV]'XL=_%IWY3/G1E
M3Y-V4)=?E'8RY;#,$4;!GC!EH2L=1EQIJ11CJ=5DM=LF/ F=N^<@=_PW.'?(
MBKO552C\;?&*&*6 1;+3C4&&8;\DZ6 P9=^E6WH& .4/W]6Z#%]^7L!7!YOO
MP+-UPZKZM>C'1;>C.B:8-2S%H>I;N+@_ .ZM>K:?A.-6A;TK^RA-?E._?X=O
M/PG:WN4QWI;H1>GZ=8GQU7('?L"9[!^[5FL"\+^!YD0_KJQ)^VTGZ?>1&W@
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M:'D.ZAPQX-*I7GQF[2Z[0=E'@RVK\8+:#7JN ]-0=&ZLN('.@'SZ07U"H0!
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MVC26VQK&Q*A'282ON75IN44_>HXA%!2%/?*2RP6A'S9%3D9JX,NSZ[$'$N#
M^(:127=;TPASU 4<Z 0 " '.81DE@?L.IV(D9?#KYMI?2UP';M6*T-$9MG5@
MVX'G30]\5.TW"< 4PT.N70S;86/%W/P:\#ECP\E '76A(F]7 Q1P-FF[>//@
M#(RA;FI9'#U2&98M/"R080;!HZV5M[_)>R* 52K]2&OC[='(=F"E 8" N "
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M"7+9@NRY\DA@F8X,^%:6?1D=$6P!]>N$HPT@X>,.#/6HRG]\7.L"S*O%*CY
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MWYBLYTNY[T,&/.II/\,R""N%L(@VYZ6$']].\'4KTYF&IC_4P;TTB2=ZN#D
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M^^24+B+J6H4S5M=L%T4I*K-=BMG.T :C.<\DU0C+3"#&F$**LA0I9FGN!;,
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M ,;V?L&*2@T?70UQ_<,76,RUR$F&:.COR:BE2%MOD,R<2#66C(9J/@]3JF7
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M?*=*/>NW4* 86I<W<89: A1D5NHD"#?*""'\M P%0#?+NA[ ZZ/2#]_RHA[
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MWL/.D1# ..J)*9$A$%0D+L68C]6\9ZSB-J'?VA:L:^5\L:*V'ZF77RF;95(
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MZ%*8]_ZO<R6]BDN;BDLKN(^HN/1@!0A.<4F@,2%H0YAQI6UX#,2;J(C+QTD
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M LE&XJFG&0B4*U6OR];8VIZW"M;^AF?#$: =KL>*!6W&@EGO)0I*M;9(F+!
MP&528#0Z$L""X!)9-'QK6YE*!384".[.V5>!H-5 ,'>]FGB6/2<,2E7XF/F
M%1*(BPRB-B:@L"4\NATX<(>MC*8J;EON##D<3ES_.J?A W0UFB[(;$QP68<K
M"\S>**^D=8M_V[+3JUB@=I\\#QDG>,E1<W9PU*NFU1T=;^;K!G(=K6&):#",
M /6FY.4""<I:CUJY+..M;=8U:K[%Y5*)-2O0I_4HUE^1]=$C:SOB'2O&WA?&
MSM!ST-8&%061UFD"3 $QH#%#;M31@]&2G48_BOGLQ=LV!*CX6O&UXNM].D\K
MOMX3OL[Z0:VPUKCHB%$N<UCC)''!(&$<'481@K"E*&X7[.KZK51XK?!:X?4^
M7=(57N\+7F?H*X644$M%/)L6(P;BDZ3$.,5BR>SQR6QM"Y[IZ^KZ]#T@OC;^
MZ9\;WVO^-_8^;O]O_M_9Q"^,5:XX>NG+_6LE+UKY__]_AC/^R\+_?!/([).=
MKATIR/R4F3.X[@TB#B9/"9L6)UGIH\HG_ ;/^LN'X;A7=M/3)GHVJ_\O1?J$
M/RF3G)6E&V,9(,,6^[;Y5CII<Z,I?[>8[(F=1GMF[4C#X60PG.!:@E$?__7J
MRU]_Q@^>@SKX^L>G_:_]XY?/]F3^GL\'^7OW__DBS^M-_NX7>;R#_@'/ /7^
MUW3P;(^^35Z!]%H1E,82P$S9'$--G-8*4R;BPF'!\ND"O1HVUT.3R8>G/__\
MZ=.G)Y_]J/]D.'KW,Z=4_#S*+_]\]MZM[=>(G8.RK,R4TZ#CCC.X3,9S5RDG
M^>08-*#1Q&&?Q6-_<'D79>'W!J%_$O,?>H/.Y C'V"FB[?0F>#Q^TJ#;V5=N
M/QY%XE616J1(._(M!ZV\1$NL=(& M+'H$!+-  RS(#7>6I%>3#5@W/G'?9K5
M\DK>]ZPW+M_4&YQ@?/D!1TU\P3]=;U#RD%X.\LMY5[M^*<UVR1O/*>(I"U3K
MR0)OO5_V,XM[&R)3W A-E,"8]TNDI2&I("HJ=(HS[VG3D/22"('I)4]6ZW[9
M >5ZNI/_C:>K7FZAXX5U[PS/%G[<H'"&T,Z@ .AQ?L?1N(.#@JVO\4/&4X^C
MCJ#=3MD/'3>(G7_<HYTA[VJ;W<02>71[\.M_OKR-X'3,I@()NMPT@A#$!A2$
M6YT0N0C _-9V!O@K[AG/MN"[+),[V(*LY&:-/V HQV+_R_='_9,KS_JCLZ/K
M24G!F3]?/_7BY.CL@OW"YT[M&WK^$><S*SF97/V1"Y9'R$0"1ZLF$?9&=D<A
M6BZ4Z!4W^))/YH9UC0NUVKU(K)[W!FX0>ED^KR?Y#R44;'SU,K;DV?CW$[SX
M_S+91FG!<9FHHLX'"RIQ$\!1:B5P'KADXJU@6V<?.AJ=<\)W2/P(W=_$I?Q\
M3UW_D_LRWOKYNV4X[@W.)B14GO&B6V'[?_WHYWEB>O6+]R^(']??:R31V?OO
MR]_V#@X[_]K;^>WP7]W.BX/=!]P^-YSU[LN#UR]_>_%LYW#O6>?U8?YG/S_#
MZ\[+YYW=?^T<_'/O=7Z.SNM_[;S:^]?+WY[MO7K=&.7ZE\[>?_YX<?BF10]X
MN8+\=#)P)S%;0[$[M9"&)WFX>*%$W.S,C]WH7=[5Q<Z825*\R<Z]?)02)]C8
M<]_ M'$)Y47HNP]C?'KVPR_EC.B[+T][@^91F@_]<CK6*0++><NGF>/TY5,-
MM.H)%XT2-K&+W[Q8I_KYI'EIQL,U?4W $U#ZRI?I$W;E:]<-"T^,MK<:]?K7
M)+_=)Z]=@B<&S)K,]:[653"Y\KDR>))MK769;)87K,N.A2=27_UJN^::%Y;"
MS29[&GA]U0WBC_/?[=Q[+[G8F\+Z_5Q@S7J0+J_E^_S4"C@\&F7NNC\U _:N
ML$2_NZ^X(E2=7A.J_L-5/%_$*V\RKBN!T;[EW>V[\;BSD^E_$Z3^>C(,?]^D
MML4/G_ZZ0@RCX:>Y+*#-6,Z=/-=B$&;+Z7?7B^3%H+/K/O0FKE\7]?:+&L+)
M\<G4U3^MV?)]@>\7I^D7O]VTP'==YTO7^15.7/YC[.RYT2#/>MSYZ>+2/\/4
M"[U)7>';K_#A"-WX9/2EXNRR"]ED8;V^D%+US1;_OY/>Y,L-B #CRQ"!&XAH
M[19UVA=GF5UYTXVY<4NWTUQ8WV#I%EB==K[U!W9(NWLHS#J2+Q?FKZ[O!@$[
MKLG3_/?) "\W,!;,9U\NY/(>(PM_>+5_BQ9?3*/Q(LA8LF&<3T8)ZVC,?Z%,
M6D;?OFANEM6/<@VG&/5B/#[!N!:1@U_W7Y_>UQV_^;Q__,?G-W_N??[KSQ=T
M__#5WP=?7\C]KW]_>L-?P%]_[O.#?[Z!@Z]OY+?(P?<O:'X_??G//SZ].?[K
M_5]Y;F_>_[MW<)C'/]SC^_ES^\_VO[[Y\X\OLY&#^_FYWAS^!_XZ_+7WU_%!
MO[D3/'[!\K-\WC]\\_7-^W>?]K\>'/UU^.]TEO2R_YKR@_=_?][?>2LL<A6M
M)91[1R Z(!9=(M90CM1Z856:-O63\X'9MRM8TYK@ZR4+\*Y+;/7-]'SAXKRM
MCYQ>$M_FXQE6!F[%*CCELU,>6U%L,13[.H-B&;)B67G"C8@$4LF01B<)=R(X
MQ@4F$PN*+=UXL$)8A;!UAK#@C4B<.AT4 VV]%<X(Y"4YR[-@[#(05EG:RO"-
MS> ;BR*9+#8"5'("WG+BF%1$.<FYPDB#BJ4"!!>L2^E\A&!%N8IRZXYRBT0Z
MQ^0%"ZC06P2EC+4\,<8M6,Y"<O%JF+LBP+E2MF4A3<P:GIF:!7"6"&UIIFP&
MB:<L$LH$TXIEF[2TF]*K*(Q8<:SB6'N>>Q$<\X$&IZD1/@9 CP:XYC;ZR+50
M1H:5X%CE;2L#.3D#<J"<8=PQ@I8A 2V!&)<TB53Y2+F('F%K6UK5M=Q4H/OA
M<SQFE-M0B&,Q2J&UY5XA<.:=+5ZUZ!,": A0(:Y=$/=YKCHA2\KS%(E,,I:>
MQIK8+#UB4F0@-#-1VJUMSBYM:KPZB-L(?'OD$+=>*+< R%''9/(FZ806?#(F
M&&><-9D1:$,IJVZWEF#;7%5 R:+V@?C@/ %#';$4)8DAAA0B4$?CUK8J90'-
M/']KJ=?MBC@IMDQM[U;V=*MCU#$>RQ@;%:]U^7G;''ZDE#R)36%^'(RGO0GQ
M<_D9-Z4QX<W8Q[>"4;5G5)52E=*]7:#;)#(KM%):!S%%4XIB>5;*FP@A-2[<
M5>&\"\_X<'B>5U32BEX,3I.*FFC(!OAV+^#>*\P6P+@WP=<X^M@+^'M^]F%\
MA6'X;M",\E_7/\%J(*S*0#AX/7<O+Q)GP5-#@!N1[0-/B:$>")/%:Z]LI$YG
M^Z!K[?PU5L6$5F-"1>XJI2JE*J7'(Z6'["U56= :L: Y-ZG"D*0SB2C& P&6
M2O,4M 0Y%Y('%J1H(0U:V&5R>3_#-KM,]C[C*/3&6!+<QL5]TAE^:*KNW<I7
M<LGSKSFR79K#)B!%C#QI< PTM58(",D!$X;2P,/"X-8XKJ:Y;,].1GGIIA@U
MS7%K7GPYE<J9N&)%I$40J?<MJTWL?PW\X-W;I VWD5M"&0,"*C#B;;;0G [9
M2D_)<IZVM@5;.J7MFA:G#]0RY)%J\B75CN])C1M^4;5X!5K\=4:+>731HE#$
M!LT(.*F)4U*2A%R*4L0Z);6U#56'-U:'5^YMO84.5\-A90K.9A3<H=?:6TL<
MS=8"2!3$^,")"2ZJX+TQL82.=:VJ!_6:*?GM7#Y52E5*54I52NLHI8=TGU9:
M\Z#>AV_^T*_[XN#9WV^Y8Y8)SPD@C:69-"/&AG(MK+/<7: N0L-K-&L1KWD$
M(62O<#P9]4(I<SEUAQ8E'7<^YC^7:OD#G#2>TL8QU_G4FQP=83]..Y2XS]?4
MS'M<]T$M\)J>"[)YV\XG-XI-?Y_GPU'"WN2DF6"%L=LX4;\5G4"6O'5Y(Y>"
M8. 4)UYS2L"G;*X!V/RGK6U)6W2E4^]YU]B'6G7Z[ERJ9SHM@U$NZ$BDD\6E
M"D!,](PD[X2(R VU6:>79B55I=N;<+L"G^IUF;=5N>_=G7JFW(Z"HYYZ$A+/
M9H=&)-FR3(1Z:50T'I.S6]L6END 7C5['7P_54I52E5*54KK**5%N,P*'*F5
MR[2"R\S%E!KA6:0!"9,^DQF%CMA,70@5Q1,1G*6^%":'%91-JL&D-PPF#4=N
M\*X))LW:!-.FPC62M"T^T=WA(*_4.$_K99K^/.GY/K[&D-\ZZ979U4N?U0#6
MR]WSD-.#9^'K0<8K'T4$)@D:G0A Y,0(] 2B$2EPXRTW6]NR*VP-6-L4I7]@
MA^D-%+[J]"(Z_75&IU6FDQBL(TDH24"81&RTDE K)3 >;9(QZW15Z,U5Z'N-
M0*TG^'UJ.[N@[?3@TUO'F'!4>L*]X%G;5206=214HV<^6Y-6EKL1RKH6EBZQ
M7U5^'7P_54I52E5*54KK**6VQJ-6DG.O;HKO8E,/__-6L*1%<$A2D$C &B ^
M)4^  ;/69:K#Q"G+L?,7Q34Z]2X+'$[C3GN-WC11IRY,BUODI:^QIVWQL^Z<
M"Z5BU>JPZO6\2U58&B@B\0 9JBCEQ-/(B&=.69- \1+/(KH:VE16I%[RKK%+
M]7O=KNJ[B/K.>D]E""(Z*XF,  2<",2KZ(CG(M!2%(AJS.J[JK;257?;I[OW
MZCVMY_(=*?:LHU1QX5-,B201. %33NAR+2)!(I.4*0\FFQ""=C-&5^U>+^VN
M07)52E5*54J/1TIM=916/G-7?H8+/E%Y\.S%VX!41YI<WE[EYA<4$$\Q$AX3
M9CX3DS3LE-#H5357KT&G-U+.Y\-1_G70"2>C$0["E\YDE ?K3QN_N&]5@Q]7
M%&J]@*M2JE*J4GH\4EHD*8A;* UI00,/()2W&(3!2(W)CQV3N'U2T,O)$8Y*
M\?D1'N%@W/N(+P9A>(RGA]3NZ1EU6(ZHZ3QW!O'P_, ZKW+?I L=NL^_#T?-
M"Y/)J.=/)L[W\7#XN\O#3"JK6R2#Z L5,]G0-#&)/!H2RQ42)"6(D\YE9L<3
M]QP-EN!=KN;OCFZ>0%1AH()UE5*5TCI*J1UYMO5(;?&1.I>4ZP,XEL"30+4N
M?14L\:7.(?7(I6:(4K7I3'T$,6-YUW=ZC<8\K@"QZEJO4JI2JE*J4JI2:I.4
M%B#56D.BP5CI;0F2DH:&9'U*(3.L")0M?)F8N<"4//\V'-<;PU5F4<@9WY*7
M2J,!2I*UBH 6C#A5NA[2@-)I:QUK&I<P+EIT75@5N,+LADCI(6,V*LS>?;+:
MF;\A21&EC<3Z4JX8/2>> 2=6HTY!Y;T J7TX>^IV./NNLXT[U<]5^R;K&'6,
M.L;=C[%1OD1]Z:'ZJ^N[0<".&Y<2?Z_QPP2//8XZ@G9+P3^^C(?1#T<11V0R
M_/"TP.IXV._%SMD3;1#_N#P_-5KN=#;M-(_ C?#2<>=#YAQ"V!C3VQ<WC!9M
M!I^&BU;BL2KBD8E&L>V^(QZA%$QGGA)K92PU_#(%B8SFGVS0VD>.(DZSY#/)
M6!'UN+&*/+!E<;>J?G^@>#--_\>=B7$!\;4)X2[)T%T5O)5@^*-A/R_?>.__
M3GJ3+Q7D5@IR,]95= $, "5!,$F :DY,EF &.1>-!Y.4I!GDNI2M*K^^0ER%
MN/8\]R*)S(HA.FZB0@[(M&?!"..,12,$M:Q"7#L@[F"&QPF;N!96$A:4)5ER
MAC@J.<DG%8N6I>2Q9/9T0?,NM:M*5JXP5V&N/<^]2* ?C>BY-Z@4I#R:LP(-
MZ*AEL$F#N@;GKNNC40'O[@!OAM.!H8EYHXA-H11=D8EXGDU8FX1*RD2GN&XX
M'<Q7K5ZX<4;%N8IS[7GN17".)9V\!R>D-2"4,UQH&JR1P:6H=,6YMN'<RQEB
MEY',J." A"ATME@SL3-9IH0GR,:LT<H&V-J6%KJ&SJ=L5Z2K2/=(D$YK$,%F
MC,/H +QUW!JE@C'<F4AE1;JV(=W^--0LH]T;_O)P[]-;R[E)@@7",K$C0(T@
M-HN,4":$,]HX@71KF[-+HR JTE6D6V.D6P#H +7A-C^^0P^!":NMY8(&*HR(
MU/+JHFL+ONU_CV]"8.3 **' $P&;++'*4Z*],#+*R$,R6]M&JA66$[QSE+M%
M#-@BH2OGTQ=Y@G%XXOLX-_\;#%2_LWYGN[_S;A6IOK6^]3;A?C\>WLZ]]Q*:
M&3 3F-'#$*[+8P"?#T>=R1%V#H]&B)W]_/ZC<6=O$#'.!P2R[T[=RQ65BV44
MU5Z&'-\?V-<%6+9O>7?[;CSN['1VA\?'F<XV7//*L,I+<?.*I[]NGX^&G^;B
M-#=C.7?R7 L+=/W.[ZX7R8M!9]=]Z$U<OR[J[1<UA)/CD[Z;9)UORG-TOJO/
MT9DFOW1^*NDO<^Z%NLXW7N=7.''YC[&SYT:#/.MQYZ>+2_\,4R_T)G6%;[_"
MAR-TXY/1EXJSRR[D,$-JIPD_/_6,-&F2^I?.U$-R R+ ^,I-WQ]:[NU>U&DT
M_S*[<D%#;7.6;N=X>')-T=^V&Q>KLT,V+^WHWR<#O-S J!E'-\\XBDE+H(8;
MKR3P$+RG 83UT43KD='&&<ZHJAE'#^,&?S.7<<04TXE)3Y+U@4#0CAAM!5$V
M!"6\E4[QK6VCN\RNJ@1]O>JK5WWM>>X%KOI6AFZ77/55&%L,QF8K-F"PT4='
MK"QQ6=HFXH!9PE$*H85R +K 6,THJACVJ#$,M+86(4G*4\8P:[+>& $ -"45
MJ5@&PRI/6QW S684N:!-0&!$&.4)<):ASB(2J;B*,>63R?H28,^!=RVMN>$5
MYC8/YA:)/RU!/#8A2\P*8 (-#4K1J$-DPGNX!N<6B#^MF+88ILV0-LFH25E&
MA*J4,<TK2YSVC-B@N<XR\B*ZK6VAYELUU_#2"F2/!,@XDP(I%98'#]PHR]%+
MR1/GWEC0<B5 5IG;ZE!N-F5(H%!"24U$)FHD\VQ%K!&6B"PU'H+,0N1;VXJ:
M+K7+-#!X+$CWF&%N0S$."T%#&5@P"8!';S4U+$G/C,[:XRK&M0SCYI*%%$.:
MN9LB'HPFD""2?#PI(HVDD@*7*K![2!;:"(![Y!BW7C"W")/CD2;#0L:VK!^*
M>QZX=UHB2+!*VNIZ:PNXS60**6X51,^)B5808"X28P22*+1.##DU-F0&QZ#+
M[-IXWFJUZ#I&'6/#QMBHL*W+#]SF]"/>C;$\XO$''(R;CHP=_%Q^KOWH;G[&
MM(@L5RE5*3VTE!:I5V<0HZ0"DE.@K'-4:QECDF@P)F&:YB[LK+D+^W'V_WD_
MV?'A\#R]J&07O1B<YA8U09$-\.U>P+U7F$V <6^"KW'TL1?P]_SLP_@*P_#=
MH!GEOZY_@M5"6)V%\&[N<IZS"#*Q2(3#;"!8GHC1I1B>+[>./$4&;&L;NF)E
M,905%"IT5RE5*54I52D]8"M1I:23H$WP 3R+>15"<M8!]=&@H94&;30-FG.4
MYAV %#T0RVD)Z F*..T285+KF/<*C5*UCP<M[#29\<"L@=-D[S..0F^,)=-M
M7!PHG>&'LNI7IX%>!VV7//^:0]NER6S&)@BI%#HT#'0 IW3(0)>)OM?42UP8
MW1K7U32I[=G)*"_=%*2FR6[-BR^G4CD35ZR0M! D_3V7WL8QH0@1B>+>D6RJ
M1V*$C@28M9%[[S@KG3QAZ;R0RS'A3EG*39W)CTN5YUG*?>EQPS"J&J]$C6<B
MA4T65\0LH.2BS,2"2N(B-OUYO51,2.]#5N.JQ!NKQ"OWN-Y"B:OML#H-GW6A
M*F>0!F^)E*PT$$F4>&D"P1""9(X';:%IN6V6KL5:M7P=W#Y52E5*54I52NLH
MI8=TH59>\["6RZQ/-#$>L_P8T<GSTNW6$ \*B'7>>K \V-(*DJ\B='2%:OX(
M LE>X7@RZH52\W+J$BU:.NY\S'_&V.T,<-)X2QOG7.=3;W)TA/U8=*4S<9^O
M*:#WN"Z%6N Y/1=D\[:=3VX4#W#R,CT?CA+V)B?-!"N.W1S'WN_,.5*%2DP9
MJDA,#@F@X"1+.64LD\JAE%[%N+7-;(ON=>IM[QK[46^FU!>92^I]QDB^XFA8
ME7U199]QMRJ6G#->$*N8) "1$D.=)\Y*SKGE%*3^9HM4C5\OC5^H+_/R7M?K
M,G27TOVJXPOI^%S,J@@L<F:(8/E4!QX5\99'PCV@$III:\K-J%Q!%].JVJWV
M#E4I52E5*54IK:.4%FI)O+RKM9*9=I"9.2]KD-'Y$A9BD@D$,%#B,ULE-FH6
ME.1)>-4B-O,(0D[S]LZ_#CKA9#3"0?C2F8SR8/UIKJ[[%N?]N )0Z_5=E5*5
M4I72XY'2 OPL26V%9<ACM*"0FP16RYCR\:T@B<7]RTT7P>^:"$Y[")X>3;NG
M)]-A.9BFT]L9Q,/S8^H\&ZDA;(?N\^_#4?/")%,Z?S)QOH^'P]]='F92.=Q"
M'&YOKAJP!Q&"$)& T4B AT@<5XJ$O"N$,X%R UO;T*)+\@H %::KE*J4VGB8
MKCRNK!ZF;3Y,YVL6)J94 B1:V4# !DF\\YYPYI0#E3P ;==I^@A"SO+.[_2'
MXT<6.U8]Z55*54I52E5*54IMDM(B=X<@("(Z+9@78$5P*7-EYP%IDDS$=/N[
MP\P)ID3ZMTP,:B[&ZDCQB[E.+-8;%V1R)"EA"9B0B(F@B:4Q)!Z38:;TT!-=
M"O.Y&#7JJ:UZ7-%V':34CDB-BK9WAK9S+HBH0#F,GD1=>C(KZXDW/N]D5)AT
M,(KREL%M[8E0QZAC;-@8&^57U)>>K;^ZOAL$[+AQ25E]C1\F>.QQU!&TVRD'
MY#+^QM-&--/'>RHRLL;AB>_CMV8TR_6Q:AU/62S3-9]BPBGD7@H&3# G#34*
M!6H>J##FM*?3CU/AFL&G(:25EJR.EOQG+I$U6^T)9##$B)!9B3:RU"A5Q&0+
M,# A0F,$&MT%J5;;RVD%*O3 %LH#8\6F]+Q;Q?JL)X;.FWHK ]#:GGUII)P)
MR (OC;4*2#2EFG.DHB0 &Q*38BIP85(62D;*I2^1*TQ6F*PP>2U,>A:518=*
M407:&\N\D2"]EE9P$&X9F*QL<W48.IME#50@M5(0;:DCX)S);#, "2 ML&2-
ML6IKFW4YV"[G2Y>VK$A:D?0Q(NE"S>:!(A?6HXL!!-->!+ V:41'>?+J:BA=
MH-E\A<W%8'.&>EH,(GG!"/A2;8H*2YSGG.1-9&,2,DLJPZ90J^LE7[&R8F7%
MREFL5$G9&#P-E%-0SGBJD@$9>'0.M- KP<K*/U<'I+,A+YP[P5!G\STQFM&4
M&V)XU(19R3P:AX*)K6W%69>)^?8)%4PKF%8P7168,FTSJ\D:1S$!*N94E(XG
MKCE#C$%6,&T9F.;QOH]HT<8&Z84GAED@8+@F7CI+)-.)"E#)06E2D<&45V9:
MP;2"Z9WY0Y7P(L:HP2@+*G!'G6&2&<&S11\95']H6R!T)BB0HM8HF2+<@LZ6
M?>*E[*0@($)TQB4J*<^$E.HNF,VY6&IBD'YN4ESSO['W<?M_\__.)G[L1N]Z
M@^;K90.<T\?SHY^WOSUJ.SYS\;$#9GT<K=\HIY C5![BPW#<- =^.L*2I?P1
M?_G4BY.C,SRZ\*G3S4///^)\WB<GDZL_<M7\[B_IE)<IO4;LN!"&Q_FKO^2-
MW#D83O+@DV%G=SAHMKHK/1">]P9N$'JNWWD]R7]H>C!?N88M>33Q_00O_O_H
M6Q3O!_<.B1^A^YNXE*?ZU/4_N2_CK9^_WUMY8UW<&;-"O7IKM7JSWV"4!I7.
MMWF#A%E^??=AC$_/?O@E]L8?^N[+T]Z@$4/SH5].1S_5C?(%,RC8?-_TY=,5
MU5P_D70:4#VZB-ZG"_Z$7D8=IR]RJ9YH>?7KUW[XVA>!G4UJQ0.+)_Q.)BS@
M"5VK"=_9"K,[VA*,FCM:BKN:L>%W-/"=;6)[5P/?T;C:WESK;I%+\N,0>#OW
MWDOLW2FR/XQA=WE\^O/2-.D(.P?YE<Y^?OO1N+,WB)EUS,6J\^_(_>6+R.DR
MBWB^AE?2_NMB_]NWNKM]-QYW=C*=.S[.5G-CTEX9\2\6>/KK4C%&PT]S*02;
ML9P[>:Z%X&<F_+OK1?)BT-EU'WH3UZ^+>OM%#>'D^*3?6!I-):G.=Z6D.M.D
MS,Y/)2USSE%:U_G&Z_P*)R[_,7;VW&B09SWN_'1QZ9]AZH7>I*[P[5?X,%N2
MXY/1EXJSRR[D<%*<#27QZ=0!VR3RZU\Z4T?L#8@ XTNQJ1^OZ-HMZC2/;)E=
M>=.-N7%+MW,\/+FF'OVM-E8[WWH+9=J\+-EG&$X-#[:R)-E'F@/+O1<I.G0F
M 8O,26^Y$I(Z 5Y FM[%,2Y8S8&]> NWP_8/]^3!U_[1RV<'^;O^ _OOC_+/
M_>.#PQ=?]M_O?]K/8^7Q8.X6[EG^_L._Q<L_]V"?__O]P;-W>8Y[\/+/-VS_
M??[LUYW/;]Z_ZK]Y?Y3.LKKV7U-^\/[OS_L[;ZE/6FD/!-$X LP'XJR@1-C
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M/<^]"-)I#2+8C'$8'8"WCENC5#"&.Q.IK$C7-J0[+ZIY&A/A,(M.<$I,HI0
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MT1'V8U&@SL1]OJ9PW^.Z7VJ!O_5<D,W;=CZY43S R<OT?#A*V)N<-!.LX+8
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M'I*=7!1(_KF/IYTE=R[(I<+8JF#LY>Y\?)<RFIDL+^-Y)B<*2WR7#$1( *6
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M1_W>^:?/_Q0'.W\L.>4/=K[ ?;_PO<.3^.#MW]_VWW[J'_5?1Y_>_IV@HQX
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M/ZO3B5;E2]7!^FG"5UW]6R="73; IAZV&CM7Z,+G8F*273-M*]*UIC/>E,+
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M8O*MYA'G=@0O59C.+PLW0!_/63E$=_FO,[0@?230]-V0RAF?0W!2E%\+C(;
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M5L *C>'0>)^6%J4[MR33QW<[B+0 K(W.0UH;*#,5GC,7O@U)1#Y7IQFOKX.
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M178FVLX[@?"XKJT=WRNUG?S[G/QM@ 83XJBEN?>X<K6,M,MRG\OR;M)*N$$
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MM!Y;OIT,W7,;<Q'7_'1;:M'V_B90NZI%VH#:-X+:W([!\UXYEW3%4)D&QZZ
M8Y<K."8E$1[(,%(1II,K;Y#S5"#XD'NNC.)2YKW&-EX3.'W+-MW-Z5EYM]IQ
M.*N"@K^(75_K=LWU1_WS1[G7Y>Q>*[?\7OO6KM?Y!KZW -]7C.%NP/KK8'WT
M9 6LL>1,22:18P)(I]04&>8IBI3#)UKY8$2)^VY+N2E7Q?>1GAOB^))KC93B
M!]]*47%NS=X:8G>%9\SUED&70C^7LUWL[L+C[Y>;8/W6U;'MG93T;4O[KX\V
M,NAK#,#-1O,.&B=U0HU)G;MLJ#>6R):C%:^BP5;CE_)47"&"Z4F5+*'ZYM_3
M26SVGK:F^5XL:;ZCE^^4]\0RB1%36?,YF9!Q42'J<+(Q>J<,V3M@O$W$C;TM
MNV>F[#2@_36(.1?BI(Q[=4ZS7\JS3)*K5(JC\2+?69BKY_A9-<7P_1=Y?JMK
M#;1=!]I>K4!;3@"+B5;(LYQG,#J=SZT+Q$P2F&IFE'9[!\#Z&R_R#Y7?LL1;
M,-YH"S#6L+5;@K$RBT?]GI^'LX:J;<VC?/QX- D5.OK\.+?I';5:DP@()GV.
M;$Z6(,V< M9FE C<))+8W@%I,W-C'\7N4;4[Y%$>;;#K;\+3;N!H?M#0%S^>
M;A7V)CZ;!N^VC7?/5O!.*NGA/P1Q8'"(8^:0U=(@:A-3P27C/0?;5+:)YHU3
M]F9.V0V]?7 ^V7DXR(FJ&A?M-L\H3/);54&]_=[PM'/>\/Z-RH\K+4#Q"4*Q
MX (L6,&(Y9';K!.=5+?!^Y]/9:+1?EO4?B^7M)]_QY3 .DH- RHEXA&KK/T\
M8IH)%TRPGN:T>X+?SPB2G0:RX^A/>_"ND\O&][H)O#3A4J=D=52&.X^=,*[4
M(%9.:,9] U[W!KS^60$O'E,$:.*(1()S.:"$+*@O%)*144>JC$E[!Y2US<VQ
MJW&_7H^$]0?G_9+W=#2P(19I:RC8)A0+-,0D#'$J"4ZPM"I9K)C0'*=(PZVX
M7AL4^RXH]F8%Q0QU$5@8190&@7+!*&2L5TA0%7@^"!8HR9EHVOH^,K [Y''M
M7,UJ;QRP]V/OJ0' [P* ?@4 A72!6Q,0E8SEZ*"(C#8Y,[*7T0O,K9, @$:T
MU=9X7.."?> NV#]7,P\U[M8;1<36:0D;EG^7E%P=)S9_H9[/OZKI;%3?UE3?
M^^5@BP_O:$HX*"R15"2?WZ,):1(<HH99$J(F0/[W#E3;F$TILN\P]=]U6!OD
M!+WS&>H:-^P.!E#8*\-:GL^Y3QIDVQZR+8=5?'AG+<X9%B1*D3C$B6#(88>1
MQRY2K43RN2JS;F.]K:-NC6OV>LB6R[#%WK"N;IJK,YV==_N7,;9<[,74:6)E
M[P'>/9F;9"" S^HI_JV>X0;FK@5SSU=@3DCB8N 2.6YPKN7$D*4\(0Q4SCGO
M+"-Z[X#3>Q@KN],@]S16)]I;(_MIGL.50FP-C[M+)NID*H_MIX:]?1=8.UR!
MM1"MC,H)I&+(>>V=1$8%BZ0V4@;,HL,9UG0;[-:&OMT.LM55/AN2=I? ;)6H
M3>;S[VHZ&^BZ%G0M1S1^R*G]O N.(IPWT7FT#&DO,=+$1JRE%2;EL^;TQKC5
M,++K'<@\+_F&>B>YX/$PSI.RAH_=*0BSY[FN_9]Y%E\X&,[RN(:/;0_4EB,=
M/[QCQDME?$+4<(.XD089+ 60,JQ%M(XEC<NAS)L;F@T=^X;0H#5U;&["RYHP
MH-V!N\;F_"X8MQP'^>%=$D18325BBJE<H$(@34,$FY,QEI*3(9=%E[*MR;;J
M4]R!** OA9=<\QG?.PKH#J+W'_U^N.ATNXT1_;TA>3+2#89N#T-/%C'T^-F[
M*#35@@)\2I_+$I* 7 0SV$DN#*&6DEP(FQK9%DU$R0\6NJ,X^EJH^!41O"[C
MLISBM$D3?=.A:5![.T1Z O9K"37(0:,$MJ<$/JPH@:25U4HR9(BRB)- D$LY
MH1.L VT"2\2F[Y1G^D;BMYT*<2NUW]9\,JGS.NG6-:KK;J@8.WG2+E3E);2N
MRIL6*JGD&KRSK,4S)53*Y@Y/^Q>]5JF9&UM5H3'K^A\C7#P_'_0_E1*\PW+U
M))=J+'"3E\S8=EOVK(H ST%$G6%))>KKPK\NETSM=N'O3EVR/HV[W?W6US*@
M#(=]WRE5?R\ZH].67YO3H]T:38_(EY?GYODU)T];&8QR6Z"EL) ^5_6%+<S)
MP.8Q0WG\<N%A:#UT>E"7'CZ'MW5R&??!Y5P9XO$P0A]:W<['6(H0?ZD^-TBA
MH4%B9;WB)"5K%#>1>T$,\83(M<G\%R%X@JF_=P#NXY_PUKF3217LOBX3'\-C
M:+H]B?^4!O[928O!V["2_*,P'EQ&.[B;R/K-!;RAO>+H\S\9B2\.GQY^?N>#
M,((XBJ3R(?-D@XP0$GY@[' 4DE('/!DOEY9LY<&#=?>E.7>$P:.BS0DT.#%)
M<VPHMX%Q1@TVI)GSVYAS^LXH&6!B):*L9/OR CG.(])21BT]T5Z1O0.Q:<HS
MOGQIVK71V!,E%'.$*ZT=5@P3S&4"JXLFW4S[;4P[>V<D28(S@I@B"7''<]U;
MEY U4F OL#3.Y PWF^9]$(=9G<%D="_W6UFMKE=&+3N(H#% 20Q F[?L:#3H
MN'&E2D$1QD^=8=G]G"C.X42S5=EI)P\=5N^84VRE=- P'[":/ARTCH4_^_!)
M'&7MM+9)+2 1L$;.2O);6+WP5_<2:!0\";Z4EPOH.0MT;'P.&K/4-,C_YD9"
M@\_M97]0-[(>@_PQ$/A,Q,!J^-CQI<,^WU">/U/:TU?5([9.)P]BRKR@(A45
M2RG-N<@!R-U._!C+E>=__=%R@_S\<I>W@T'>9:FI"@S(ASBJWK)*=U:)Q05P
MG1!'<0!JO>CRTMOR50\#6+$=ZT^G=")3@)A::= _:PWZE[8[NIQ^J7KM\IT3
MIC"<;Q",-CRR:D4F&A4#R2\ DC',,S2K>&>'IZW4[5_D&>^_GZ=2)[&7-]'A
M;W=9;B[/VV_]-?W>W,UY/8;.L)SFRE,"BP!Z4R%,JTP&O&P01^-!KQKXA0F9
M5$1N#3K##V7!^5.8D\EPS;^G'BGH=9SUXJS?B[6\?&D(YT9KM#*%LP&#%6Z[
M?MRM @B J[;.QF626IE&PO,N^N-N:)W:CT788+7VRIA5H09 ](#&=>U@,EX3
M^S2SU<F#\Q!5C0B=E"((I<\+<7018S51A2]7Q9];(0_?ZGH;K=;ZF@[/ZK=[
MJPZA\FT0PVI-U&,RABF*+3"[>_TST#J3Z/RIM%1\.W>WFJ.\+,I<#\?=T>1E
M<ZVO9N5D;@P6P&H&,_!$G\D^J)-N-P]\OP!%]CMTXFSB9XV'SIS!(X"T]P<?
M8,G#".8O9:&S\";X?]_;>CGG.Y_ 4PN:O,JEM#-LM8;Q) -6U<8<O6Y[E[79
M4I;W8'!9,73[J2;L-1),1K*W>&9KTKA?X3> H6QL=B_;U=MG3Z\]&F5*PH;0
MX16CY MKQ?7['^KF3<5CVN",!5=H\>HT?7\'D-CD 'H\6SY_C0?^%,3J+X#^
M^+B:4OAX(E//:NOOV'YZ&L.X,OP>%PMQT>V3.I]B0)_CH#_U^. '1E8.C]_@
M%\?/Z='GE^3H_3_L\.4[RH,*D1L$)@I#7$B-;"[K"):CBEXY(0G>.^CU5_PV
M>>%.AKM:8K#@SL>@>(<1U/#C$,KL@0S"\K=%,P#XU^NR@I2,%?]UG>1KBGDP
MG0)+&CKN@R5")*P(#Y'X*%1-><F$\AJ&O[S:GA=5"BNG+E51'U.YFKM0/KC%
M\UA &S[!(KHLB^CX\3LL K6><R1D3MFNC4=.)(^\23Q*352P]'K5" F)7&)M
M!-BO"JQ:XR/,,)!F!4N33QP8JIGB'S;%GO'(N$2&"HZXM!@9ZPA*,6 5I#/1
MY]!\N;\:)+'!UPO4J)N705;361<. $@F6C5SF>RM+5IO.()_S@HQ :3HG]<4
MIU)A^3CA()["G&;66)/BG[I 'WZ>:KS1Z2!6E*"7'6[ $4>G0Z!P^86OXCD\
MW(%J9[C=RHNI75&:0F"GC\@,JB96H'HN;-:\0# +SYLQE\)>9SQCRE!6#()V
MZ^*TXT]KLE3UVZZG )<5X0+>^K&3&PRLLC_.% ?&HNYN;4EEJC2(MMOY7+4T
M#U8I1[+PW*H!^]=W)=\!%S3%M0MZZAK.SN2)A3%GF/[/_].4J%^':WVM$^ZZ
MAFA/9[&W9E(7Z?2:V#Q0A\#[>L JA\/\0AOR2%4K.YM-2Q[L!,WJ%GY8FUW9
MNIBTY+0S"*W_&]L!&)7Y0UBY;&E25W<@YJ:K'C(F84Q!5Q<E_6AB??UZT0FC
MT\G^W]Q=]58%GMUBW3"3Z,VWS*T+#SV-@UM:%H0NC<[<S]-IM-0Y+!#D0(H^
M()N@L8]L]\)>#O=^6=RXZ?30_  N]WVSP&Q[#VAIBBL]986VPGKIHK \"6.E
MP5+*X @.DBF_5Y>W'\?P.*L^[BD720DK2.#<>\TX32X$XDEPE)F];VWQ=YCC
M\L1'.1*\XZ\PZ__)WVP]!84^S"IC,G@_NG$KR:!*XUH;P?1VQ_B+(_JBUWKA
M1_VL,4E1F&31K,T*N1N+3IM 8NV] )1:FHYVUF#=<;:.-UN9P,K@94L$T06;
M D^2"ZVXX<EHPBT)VK!<C5Z38F@2D,@%0_/YT>]7L33C(",5(,&+])]^5JO/
M,VZ!>IA&&DRI(:(/CAO^0]]%AZ/D'B/O%)!!9R5R6 L4=(C,626Y5H"X:]+F
M_?=$@7TL ]O*CD&@.)W) .\O+Y'B)\H.M;)(:A94--[,5XUBSQ;_CPT?"S/S
MQ2G>M;U>O@D6>G8:PVH#EC@>5+Y$H%250W%0,RF0ODX8PS*IO"Q9.OIC>'VW
MFY='JXC><.J!F3"#FH2>9B90VA=KOTSVDPWZXY/3_GA4WW *W SN?@_TK1?+
MSG%>_ZUSFX,,QET[:->NP'D_92^@?D+=3HIE'9<QJ7WUN8!Z+2Q+V]\A1K!R
M6O BZ.#YW"GT0EYS0Z%G"VXV$-1J?WVR'U"EYNB=EO',#ZJ(4/;^UZJ_\M8/
M1KVR>W '>&'QDD+?3G*1T7EG:3F=/_6!0\].JWT+F-@X&%F8(P\&1=EOF#&V
M=C%<KN.WB !7VHO$'>'<!.JB]%@KJB2C3@I6C-J"66@=>&WVDLV%23V9[]=Q
M7B$5]2>-I;MVV^[S,_H.L^!XD!'QD .7E"=@VK* 9,1@X7J2@LFEYXC:7XU=
M;=56;'MQ=V6R7O(^U=1ZJ#7DU/9XT@6[H/4X:TPP24$<^O[#Y %';UX]R[\O
MJ=I*\M>MX<E^70S7=:=M?5G^92^+A!SW:W4Y6:=Q^$<&F68IKEN*+Y[^0][Y
M)(/"A**D;4"<!8J,$AIIB644A% O2/&RK-:KGJS$*8XM0=S&%3$\!1TX_%%8
M-<>SGA7=/^56S\%(CN'%(/^;U?E1X7TOTJO2ONIJLW36+YV33^_ A",DQH@L
M%X!B-'*D.75(.FN,]41Y; '%UOCG%MUQU7+(JV@=/K7GO")E<_>N*,"UB^UQ
M+TQ66[.RUJZLX\-/[[#3FK <LN1"3C8%R*2]\2B8X"+U+$5/]PZ$W%\M-CT%
M)5M6U(KA6/&L5K2#'LI$&;XS/L_$\CK+ZMMLP:NNIFRF@#9;6%>/!["P*D_B
M\._\VXOT8CS*OMCA?[)D_ MH9[.@UB^HD\MW%/,0L+$(^UQ )U$&"LY%A 7
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MJ[FIY$/3Z9^?X:.7[WP,C@,M1R9:('"!!^1H )V>(U6 N!OJU-Z!-/N;7$R
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M3I;DDK3&*<P-!I/.82PX\3@J*1UOMD'OF)PO!\M91<!B=Q09HW/!(^J0%DJ
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M.6LTBZ#!6=0F4!V;S80[)NDK$0*4$.$\MD@1EKE[XL@*:Y QQFE8X3)*MG?
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M0KFETRL?PS+RXVZY=;_U&!K0&L3AN#MJEZO.=LN7!_$</H8F#<O''VUW',L
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M\*V+TUB1WN)JR&*VR.ZR($!_/G9R>SJE2:$L1=O-%&[8/XNP?O-"S0(Y6=#
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M_>M\_$7PN1TO1V5OOQ+8HC,+G#C.L9\63)V9"H'E5[?96'\C^4L!$2TP* K
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M+KA6H[^JQ*"H6LE-1<Y'%F-IB5R?$%S>>YF<J3MV[YM+E1KY9R<D]ES2TI^
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M1)[I:$YX>0C7EF,_!_.]],XO]M$O]VIK6.<\/\]DB5>\14GX\]J-N4YYBTK
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M*W+4;G QP8\R92+?.0V+J0;>]H\;J=T][S=.@:DSB$Q0L=A2^ 6N*".G1R,
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M:UL0P\B-6Q#;7"#T'!B>^08;6[^07V?\\_?M1OV"6E#=]/(_37NI1!UE3M)
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M'\<P;,=NNL9D>3<<#'MQFB3?EHK87M9#]V ]O[>[_NN+([>O%T!N8&DX;95
M7 J%. T<5!:N4"2.>AH4A=\V&A%X\BP??6\8-]93TRY/&58Z !3)VK6=5KV[
M:8&J_4NK RS2'<)C0_]7^&O^VI@O2E-J(F%;_?R-U&VWN^?]5ZOACINN*RRE
M&?,--K1MS_KQU>B'WT*K?]:V%Z]:G6);BHM^.[6]HU9G9.PM:#!5/+#\^+?S
M5A@<OQ(<;V)<)CWWI@W'\F.RB1<YI,H/07<87;OP\VLOOO9#L<2-%R=R$_J8
M3<^>PD>4*?0^B?//W!5XJU?\:;Q\CY$K."\L/\=3VP+-H?<19&U6T?:+8O&?
MWQ7XE>V??,6P'GJP]P'N^^G[[O;N,:P)O@>_;__-]NG;'[O;OQ_/N0+W0NOC
MWN?3'1"[<-W%[O9;O$/?DMWM=RWX_7QW+YSL[^U@>(>T\V:N-1I6EB?I&%*>
MY3&PU"'0# ,RG FAI?:>IJ*_BZ1+-G!]@F*:)3$X%?_WW#"875E"\U+ZUCX-
M-NW"\_?.8_M;W"E,G!J65@9+\Y/H;.#.<!F1RM5]W 22V]UZ%+27T426L+<;
M6QPWN5ZR&G]MT.=Y:H#\%NCS0DN+GP:6LH:T=]ZMT6AE:#3?/S9RHV.4$G&9
M;/:Y!V2]]4@Z(206WGM.-K88;TJ\_A7'+T))$K62]'1HE!W"-1ZM#(\NYO"(
M&FJ<B11Y:1,"^PWPB#B"$N%1!(43)1SPB#7QLJW\U@9VGJ=V)&OM:/WPZ%UW
M6/N05@9'NPM\2%$Q'[Q$F!.&X* 3<CCE076">9%4BD8 '-&FUK4/Z>F9=N\X
M]J)-@]BKE:1[@E+\=GP-(&4,\C.9_*_SOM>HM')4FG<A1:NEY2XBJB)'W'N'
M3%(1MM=%A7W T3D0VL8TE9A/<WC.6M+SZA.5RICZC9'T945$7</P>!M4"X2Z
MN.%I<'_>6:<%CP#O ADN".+.$^0,48A&*HEB.K*H[]H=X.%9:<5%#]--P'^F
MDH</<WE6MI=K'KZUXGD,16YBZ_3,MGJGL3-HM%+#MWI^>-J'JSRLHM4)L).#
M6"0PONG"-SL7C5-[T>AT!PT']\PW'G3AAKX+VUY\K7S.__T_FA+U6\/;7N\"
M#JWQS;:'<;/Q)38"'&F^OA7@F; UC7S3R\\-PQY<4]+871*P!\=VT#CO#ML!
MEE;TY8>+I]]T$/N#XNU!NYP7H3/IE@]2%3/J:RGA'.='$5;I5"4L3UU5<0Z>
M7&(=,,EP</4E<U,9GH@4<U[$I5V=^G=>;H'AW%*1L,36><-EHMISB[$1G%)/
M!6&'"F^,+CKN3?3,HX@<&&M?46&OO;+M<WO1W_CWI8TX;770]*[/;MC5Q[8.
M_*T6;NIN%YB3X,U&XX&3>[>C&VRW^K[=[8,6NB9YNFSG325Z3U[SG1.X[LN[
MKP?;;\5!%J.GGX\/]O9!+.Y_WWF_#_?[1+)HG<W3W=D^NH UMO>_?/ZZL]<^
M!3$*8OM=>Q?$[^[)V_.#D_WS@VUX+GV7=O8\V]E[>\@2H31IAX0C FPF*9'+
M>>&>,NZ#59ZY5&I,@!E@V&8-QDKBN1(I6"#J%)+34E&?*#4"]CO:V<3>/[J=
M(P3$?-K(>W_EJ(K[)H1/ UMYF#<O]/*+">8C$=[*I CG";ZFF>:@/1B@.XOI
MT^4H%W=\U0+KJ>5OA5"4-M[T8F@-&J^/0.)D4?$XN<5/ <@?.XW7PR-80H.4
M<K/Q2Y;:%/_VX<_WC3? Z5EN;X/X+_Y,?ONU>4D/*(0)"& 0G]V&;?ARX^QH
MXYH-=U&(;+!8X3Y35S8;;[]UVUD,_R?:]N"X\<<?;YHYGSM_!S3 7O<<I/DO
M^;=J0;]7?YPLQ(.29UNP9T/7;X66[;5BD3%^Z3%PRZ.A[5E88*]?+KZ=E89>
MOY%ZW=/& +8SJR_%?\]L;W"1O].+@VY9M?6Z!S=]8\\R!<%=>V?=7L$GQ9UM
M ('2Z@]ZA<2&]\XOE*\J4L%A:^":R1]!Y>JVLXI4_ G6TCV*^5F-\Q9LP/2V
M3K_W0HJ<;,+9L-<?VJS.=!OGQRU_?.D5BY,H"EN!XF)>6'FC_,+PM=&>-HK$
M^UB86GD'?VG]6BA+8)BUX!4*!&IWB[^4^MT1W/<H*X5GH*3YUEE^SU-0]@?Y
MZF4JG<!@!(3 3CK&N+%>*XM#8(IHT.LD3941J3&YOL#I#R#MCZG<IG?6M]JM
MP<6._=XZ'9Z6+PET#*<(GPPNGD6YTZ/+-5BOV/WQ-_FXO9/_N0 !QZAS(8"
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M^-CY!U24+';R&Y$Q_"+ZTO!WHI2RW1\[]%!Y0K0Q#M1U91 G(@\OE@H%EUS
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M@9[Z56Y3(W?F[XYCX[WH8^ML,'UO;_O#3(OC-( \9Z!,!NQ/?R_D)(NN ^/
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MH;7>H%O)^59Z(S^AN<ESQ2S)- .]D2E!M'&&E,$+8RSG#'O::4<\>6>]D8O
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MJ4^_')Z>%-Y2(9@FA?$*'&V6$Q6<)5+FWA8RTR4FM+*./?UPZOJWBW^'Q<]
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M;E3Y6O4$UD5]:*9QNG[J_]P&'JMYEF.-X& 4/UD$E.H,4S8B'98J4FPZ"_J
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M^H!'EY6BG8 UF(1*&#&#<P%K'?H^]E6FJO**)Z]1R97%2WF7N!/FK9;KA[F
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MVJLJQU)5BYO%(I=\J=ZWUI)-L61L\0'A^12%: ![MZX-PD XU9$A7GU_.JN
MH\WL"EW.BG,J>KI>QT,$$+D_9C 0*L1>JY#B+=9=QAJVWIZ-@DD5YZFB^3SA
M7K4'N?CU>J I0IN_0 7\7W4)8F''.+H]")K?KD;;B.N(>W!_' B_L8+G5*LL
M=YDM)0U%8#YFI5'Z8_?2ZC;84L]\]8XX?HE<5S:S$*I;B1Q^@HB,EL28PI&"
MZ3(3 L%?<$<414<-1JT:=WM_^GGYWV92H)GRK&0N\X(%J@M60$Q(00\::X3H
MUH%;QJNO77D!\;?*-.B[0A%89C"*8'00IM.2+!2."\YYELL;8/;J0^^E \PU
M=5MSA5)1\ Y&DTJ555@)2XIQ4^AN]-^#-H:"VUXPJYC/#2N%E'D [2)K86)L
MZV/=JSB]$H>7)T'ELC &Q"D(Y&'DB" E(93*?%;F0EN94U DU]=[7^]C+0I1
MC3 8<RV5LYZ",NQ^QZ5.I8T+;?!83%I7.8Y"\!4*486&AD"%"\0-&Y&I%3J#
M6-YF2GI!RUQ1FPM;,M"K15X8VHB?V(K?O8H?W/?-26$M W'C)'!LN;7@WFEG
M#/':R3($1D$?8/_EW3W\9>E;%CJQ4X6*%TO8(77[59V;&4^JL[QYZ@XT9IAA
MJ6X-ICDGI)Z#;L[%,F)&/.Z<PX;XI'D+/Q^+:E+V;M1;)*>H:W'K>M!XYJ2O
M8JYTXL_[>CB<(>I_],1!=6A\QC"MWQZL^:!'\_0;J(3T0YT%J#^ (7D-M[Z"
MBY'!^+0_3/YX^S;I1YK7?94)-PH%JS[R2M_8!HP/6*U8BIF#KP@8TQI?Q!)[
M6-#;TB1LZ/64W"C%83C@M0LMN=$E#V4.8J(SY\K-20]J>7B9QK.-H-:+R"D6
M^G"1\5*P@AAM043 ]T3H3$9D9F1I=9"%,L^>;Q(4P=4V#XC#4@A82),7FFMO
MM8>URPN_,9/!=D4W6U$;%"VQ[#,H!ZZLMCE1U"NBN<REL#XK"HMEQZL1\?W!
MT;N2,\Y4SC,;!'>9S*2%9TL7P*FT5FP,1[\5@@V$ .*9/&1,YX4@+I2"B"*3
MQ"A:8)&,+F!/9E27&VUK5C#!/2\" W5A=*X5J =G1$XI9X:[C=DEMBNZV8HJ
M)IG0&2=.99:(8 .H;)/!3Z6T95&$H!&-O"/A<3W1@!E5"8[-V$KB%SMH!U:2
MK_"H5.#@&R]S(?)(?B:#_\Z& S^!)^KQH ]/6D!%KV$F$8[7UEAJ56<$>"(Q
M?5.G:B  P7*&%H!YA*K[P<$E7[?Y;#$Y%7TQ@U1<?M[RT?R^'F-V)0; M9EV
MK*JI,;/3H8*>5JQ;;<3WIO9R",]HV!66&]'K;MAY&WK,^3L_L>.^F=-]]4$8
MARA*.[T$#Z5CE-69/L'P9GJ)4._M' I*[;O=M[N]7_7P8^]05R'I7E4P4>.G
M0' QF7J_V]MK%7&U(>H[)RE5>7WM_"]4!.%K[C2SB&C[U93O5//=1-L[ZW'W
M&WJ+:HE:2.?C'WM3="FC5;%M@<PL30U.(%.[BO+\IK(FC)3^B^[ ^W3F7X:I
MT;QALD.6DD]Z4)V@=8^@H3?0%Q?CT>?^>1*5N]2;WBWZ9M?'WJTCQ27\Y:=;
M87IPO,</CM^=4%H*CYR02C(%#A@V4.2.@U->NKR$P!P"KV?/.=\5JZR\K9KC
MC>!47RUATZRH;3UN\GF#JX5=$(OK-RN O_<ST+7"=1CS24<AD?'.O[*M#ELG
M@N+@R\L3GVF1P[R3C&%H;T5)5,$Y\26LCX( G[,"C\A6NP$;!W%S4-_>3PV\
M=[1$U1V:HL\*JJ6VQ]$ET&VEUW'\IMN-9!T<-VCT.C'O.YV(4V0>C5G/QIVH
M:@:6E3^:6U,SBS:($XVSTA_;V3D67UH\$WR';[(!ZN330X_D#QP]\D8TR"7T
M2"\8!+]6.>:%<#*7+ 2FI>4L2*OH=T2/O'8=YE*^6!<8G2,L%X?M5%5<-\"'
M%H]PTG;82:<6=T+\WDE;%?YD$*^E]OXC:12>8M[AAGK:^>58__[H2UMO]&WG
M!VVI)GS9X-?5_H]DM7:6 *5K6O560&GU>'R%RGNA'V'AE2/BYQ*1=L3Z'*Y2
M8%^THV;MYL'KWMMW$0F+9$4R#DLWO(RFI6F;2&08W[ZF=DO5?A=_Z"4_^/+Q
M),N,US((XHPIB6!E0233AL#\RR"UH$7PB1-EM5Z^U_2U&P]SO,SUO=/1-],(
M*/HFP[:SG:J.&C=V7F,T0?@TE*DD<BO2^M5"IYR7SGO%:5$*:ZBT1>Y%KDN0
M.!&8W=8M?GM9%$?[IR?,&584A2$225)$7BABP!\GF<B#%A@YEA >EK2#IN-&
M441=AY+2'-)6!;BM$@P$-R/1.$1<LS7BUD_&W_6QU"ARH;93:C?7FT0YKZN8
M%O4G!*M?!1MR7]IS6WJYD?"^@C%\//&YM,($3KC(%"A2S8GAN2,ZY]89B^5*
MF-O8%?=WH,BUE7#?/'?<P$.5LD7!,U<R)JU5*MNN][=9[\_P+B>9#E1C@;63
M+"="%X(8Q3SH+LLDSTLO5(E\YM<5IXTC[_+()I3&T:)^6-8\T7&]&(_J-';M
MGZ4;5!Y:7;N_V]L;((1H8T57]-BFE;A;(_G=Y>[JX(N]'R.YM2J/8+7A\_NP
M*MC)MNA6U"<^<\PR!.5=*5J[1^:9WFQ2G^(U0,CS)Y[[Z=D(XH1/5<<3BA^^
M1JRK](GW8*G;X,?-8+3ZW!L^Q,LJ#(<5:(7@K4D=^^EX5!<<),C#Z-564[N
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MW 9F:AZ:OZC!).?^5?*WZ58?K=%''+-7W'"=Z:(D*F@&6DAGQ.12$ZVER8M
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M7$+7UHC #R^(M!@.,=Q]#]D;(_E2NV[W?TU:B(;(!--/](()Z;.3]&Q9O):
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M*Q:++:4H3PFK,QQJECBB.6*!"<25($ACSI'43&"L2<!N;F'7@JH%50NJ/E'
MN*#J4Z*JGSY^]])R85"TC""N!4-.VX@23UXI[[R2<XL-+PVJ/K# ;WY)G'=J
M07C'-M?F#EVNS?R38\4FO5.+Z9L34>FF_D$B:F,AZ;/Z3C/_(9X,XK#J=S_5
M5KB?&M$.>JA_.I7LVZC>K^Z[FJ]Y_^>[JC/F/^T<P!\-8#"UT.2^F0"'0S]H
MN[H9<*L_B@U^G^:^CUC_5>F!NW?9<+1J8GO8J_J0YG]6DYERHV871U]C[$VZ
M75_I6WW9K/JR4[V+A^U>+Y^.S+2N/X%!]NN>S8/8^)K_Z/5O>-"5G3!^9CBM
MSEOR[49'@QBK18>'Q$87WO$H=YW.[7=G.^)5/\P*L@GCR)VFLW!TSC8;MXO]
M.C0VKCJ[.Y"MNI?WE<;QXS[P)X.VG[0COS+=TSW'7>XXWN[5MD&6/_O%MCO5
MC?+$MGM?^ITO><-<ZS\>XF%>(WCPI/4W/,A^SBM8-5"_+M(6_GUQAETW-A_%
M00_D.3\")K7^Q[A=>!.^]IW3,-D.]N1DT(>W 51H#-K#SPT;\NQ7O:NK)O>@
M21%LO.H5\G34C73_>]H.N9UXON1>';_',\VR<IE%W8MVJO]SO8QBK(7QY26P
M.OW.Z>CV2V:JPIYI-S$Z-3M7_CP:7&+E841N$.UG9!,,]E?;^6K/AAN_7"_.
M;_?0U0F<?O?;Y6P!77J)U=PFZL'']3PY:PTWR0;,/0]&8WWK<CRO=+\"- 2S
M_70XO*K7:DFV'O9UO<$J/+ZN'K?!FA]67]4B!+\''.A_J3ZL9"4KO'PQ_#@W
M. ?YN":JS=QL^J8>U?V3^FM_6:-S>C*&D(EZZ;O<5#V+[:2_^E6I[,81(-*P
MT@V5[L^JO]87U<CRG:;?XLK3)L.L(&9X14]<JH?\U72M-FU6TS.:>68-'=7T
M#6(-DOW3P75E,W.SBWO=03&Q^DVOVSSYVBLO==,2@/H%50NH#'Y9MH.NH36(
M7V>\%L,:&*T_@E>L?+O) V#M^]UXY>NO1VU_=.66^4?PG1MG#4VNFZPC7-..
M7_)LIM,1>([PU"^Q=PH;''R06*^4S?B?(;A^RZNZX;1W11FU>R>G -.GXZT\
MI8S&61<UE(]'<=N.OF$OC.=KLH 9Z5$OGH*YT6G\=/4%:W&+X>>+33"EH,;+
M"E/6@9?( \\2"#[7J $_B9N-5]=>$6885F(8)Z_T\"?#'@07_.)FUYZ:/VB#
M#JE_^;5_V@G9Q#GMY %<5\B=,[#4#L'H^OY^N_;LS6>T<\Q#'+=K/>VGDB>(
MESZQ( (6W #J>Q$T@W\8HR(+YM_MBB.)8((NR9*N1T\N0B97PB@[XZR@W=Z'
M24;0[SDAZ..5+?X^[W#XNM_S<%4ULWLPKM\[??]Y98,I__#POW]T#FCGBSL^
M.6I]VA<[>V^/6WM'G=UW[S$\1^P??_S:HG]\WGT';W3N:6O/TYVW^GSG^#-O
M[>W@W>U#L;/]D?RK<6 4U@+%P!WBRD>D\WF>CD+PJ!0LAM\ </+V)&^]P6E<
M4K6<<<X?69"DK%X;65O<F$$&&O2*$&8M4^/O58@%/!PVQG0%$XP$LSE$,*RZ
M6;=<N4.&-YO55:?3_SIL_%1A3O\47B4,?_[U=B]GO7B2.&-+0(JS)BP^E#V&
MG<8\G,3G60D>WHZMS%86L)W:>'LS:[P]E@QC'@PB-P1HEWQRLUI]#/'*U3=^
M<3-W)T:I-2)@N?G(['?;J>,WE2]P+<I8^VP//"#Y 4'/>I^T_NCEU^84U1.O
MA4O48L*Y$=A*385BR0A%!+][MM^%'[!SZ9Q^:H^.9FS^X76C?WC=1;BHR:GN
M]3(.7W?SH6MF27VW0\ O(*WM-^ W''X[^/2>[1R#C] ].&IUW[#6IX_3AZ\\
M'[H>?/KPN7K>,8QK[_.WW>VWG?UC?]8ZWZ<'W3=T?\^3@W_TV4SNM8E!<9XL
MDD2 CQ%X9J].'&&ADPV>Q4C88@Y??TS^M0+I*B\]&^4E)9L$[U04080H T_.
MN$ <5X&;2!0FN$XVP04FUP(F9Q*JA1$!6R08"8@;C)&6-*$D7,3"$QF=WM@B
MK*G8PF%RKBDHS\RF]APB_VI\D',[5R&]WPO?"/$K#74/"@HO O-N@;SWP^%I
M'!;,FR/FS7)X!>J2-EPBSUE$8",*Y$SP*%A!I27&$N4VMI1HXJ6JV9X3R40!
M@XO^F8DS(SV8.9%SX:-U4CFM ""\)5C0"@S(! S(4H#!&A:3/1T.3-L^4G I
MP#N45>=XYRFR0H 5)*)DD1E%W5+28[W48.#?<33JU)D!#[)P;GCE]0.U9;=P
MKBQB0;;Y(-LL\4!DC@DL"$"9 0O'Y#Z8,AD4O1;,$:JLGGMGX26*<:TY&ORT
M1C;.K7!0O)['8L*4M6.LYDH1AK"+@ F!<605CR@Q'(-+@0(8W!KI^?DYT."E
MQG$^]G).)UP0&H>VW6LV>G'TPD(Z]X&X9;=XWL$:_J<_'+ZO\Z_#^]X;.\BG
MV 7QYHEX9,8*PEX3;RE'.,F4$4^"?Y<P@FW"'6P71K'?V-(WAGGN#G@EPK.\
MSM"R6S]WA8;B&ST"%:;L($(I#U$H\(@".$B8"N2L$HCSE*)T1FO.7UC4IQJ/
MJE)3E]HPNIX-%GOAT7E@A96CL'+<79WPJ#0U,$$V.NX),\H8RK#'+-N;AMZU
M[79)E%AVM4%GN3QS*,URCH02&-0&>,Z6>(Y<])@+:X)V8NVZ=1>*I +&RPK&
MDCD60E!<2\.EIQ9;3031C#*B N%U<N]2@'$QWQ^!PU/F.X_>.$4X8CA8Q),+
MR,1@D+%8&,(=(7A^A[9+ \0WL"K]<JWV]5$T"4]10OMJ.(RCX:M>^'XM+?R@
MU>\-KHE6OGY<1.N/>NW_GL;A7IZ)4E-[45-+_PW6.94<0TQRL$]T-DTP58B!
MS<*X$R)PLS(UM75A:\7V4E>CGG:[=E"Q%$W1!5PO?6U6G];%\:.+S5+5\O^(
MCB 3YIP.+@IP;V,DN*0\FG!&C.FL8OCU:<B%GK8^%]3R)JY5\RWUN?]S6]$I
MY9M$J5N_QIODUN^^=UN]2;%XT%V__QTW?.YC)6I3:;TB@V5P6_JP]7J&F26;
MH.'O=-MQX.S!M;F4/+RX&2R"9RHAG65%NZF@=)$%RRM6<YLME<9CRI7G4JN\
M8I-V89J5B;NG>%Z:(V7J[C=UX$F<=D_&5$D+ K75FI'*P;K#-EK;";AP#%_R
M)%P-6#7JB-5+GHYJ!AH?*G*F^Z#$6J3*7W8%O4[PMKAJZ+4.O+^DN+IR7AM*
MM*=2<L:H=I0X(K#4Q#AF\5T/.4NOVEM"YP?'A[Q%W[9W]UI'NY]:G=;V1W&P
M]_EK:]MS^.WYSM[!48M^9#OG.U.A\Y-N[E^P_^F]V*%OQ#[]B%M[G<[NWBO<
M.C^DK;V=;SGD?K#GSV&<U^L>]SY^_9=*+QFQ 84D$N+$<*0UA[]YJ4702N/<
M/&L11YA+?T)YGWNL),_4S;#PX2;NV+OX(\LXOTNG;3Y<I8"-WS(/?0PWD[XN
M8LZ+;B^Z?4JW.V$%9PIKF (>B= J>9HDT5%Y0YU:H&Z_<KI>6>9%U\]7U_OK
MNIXKQR).!ED9*>*..V04B8C"\@=*HG115KI>&K,JNO[>CMM=\^3+/=:ZGNK3
MF'"]86%4]G"*R/U!JK=48-RH<0#&71Q,*1VJN0'W@B9K#$\8_$GM=$B>1&:Y
MBO)FI;,8G3-6*X@6O7(7O8)G](HDR8-[J)'%F3N'6HX,E1(Q9;!*DB>JS,86
MH9MT.4HGGD,\_F<VW'C_AG@/[3M54DI*2LG2#+:DE,P_I>19#U6FVQ_=R%)>
MDDI*4DE)*BE)):LT=26II"25E*22DE12DDI*4DDY>)K[P9.62C.5N!'.<B>%
MUI)(8C&S.,3$]%T[L92DDMOJ,?<.CEN?_A([VW^Q'7K0;6WO?VN]>]MM=>&Z
M\X_?]O<^GNUN_]%NT>F 8%^TNCOD8+L*'IX?=/=QZ_@-WO^T3_>//YZW]MX>
MM?;>\YWN>[8_FU1R]J^6DG)J")(J9KY)YI#CU"&%'5$^$R5(^E1]5DI2R3+
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M7OVYV7@7>P#%G<Y9\^+F/QCPS7?.+S(\[8PR;4\;!M\>=*L ]I$=',;A9@/
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MVB]L-AY5_;EB)1"WEHG%.U7 W#^A:2YIK@M-E;WY[H]-H%JQ'I2O)N']RV.
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M#?'*(AJX1ES"'X8$A:Q225"LC1%D8XO))LL(N1I-]4JST0)ZBP$]0J-,AIK
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MXM%JI$4N-1'6:,R84MIL;!'35(:5,I."8LMOALV-3*Y@U[)AU^=I,XQRZG
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M+V5+]P0@,LO$B(V34DDD1<7$Z$3N"QD0X([ .-#@N=C8,D8N1YRS'%<L>_K
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M8',N,:!O$=_U%-^Y.OQ%?!<KOE.NOJ<&^^ Q"DQH!")+D!5,(BIE;MUN<I)
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MOZ9C$4?$(A;=-C:S/![I7/-9:&BVY>B:[X>Z9L>VIWN.9X8V2!&^:CB=%'%
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M%NYVU$O?IV,VCO"WDPCT<E#2>;$)^FV=ZK(M:MXZI>U>%GGO_5;V/\?F)(I
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M:O>O)R<?:\PC8;E=3DL6KR5948HTE;.K7?F^9'7JFB(75>%ZDHM541FHK*6
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MR"2ZT:.M'AD$!5QB+2'46".R5LCXQV9O<A'F4_$BB=<%J:'CZ0!M(K*$1@7
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MCXUU2-PA\?VSXT!UK*Z6[F%Z/<S 790U.^+OB'_S6$+5,;<M(')@M-\A\E-
MY.?8PB?P.EFLP^(#QF++4;VM"V@>&"8?K2QF&$N>K'WK7=# $0NP(,YFX9#?
MJBEMM\K#6.6^C'$8T.I6><]8\U13E1;JC+-"8<H_&G]Y6KE)GM-[G"HLC[#7
M+D=A>_2P>E:''H?>4F(?QSA.<G%ZCU/V\.C(Y3C1P^X]3O7 HT./0Q]C39,?
M_<B+J6U3?'I'DOD*(!T&LS""WN.4T#D89K'#H-7#0P_3ZCU.4XBC0X]NC"=
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M#-X^JT+$;@VMALBY+@!P7\+H-@0CWLV;: LW;G=SF$GVO!PW>40P-1X8IL<
MLPX/[QL/[\K^@IO/X?"@)(5DY5^<#4%_^,SSRS2ZIF3;4X?7&_@3KD7YG UG
MJ)45V^#8?@<8WJQV$0A.>0Q+2>.=90WL4]+(AC#87=;(7J2,;+AK5U=U9UNG
M[58 >*"$D>TOT@ZYCQVY;4/UG5TG1.U3-E2'PL>.PEZ@NF['GSOD/D;D=H _
MW[;I^OTB]]9"_SX%-FXE].='$Z.XJ<2K6M8M:R/N8_G#XSPD6_6-KEOOGA^2
M81BJNW7QI^Z8'OJ8=$<UC4=LJ_P4+&AOLM&(YU$J$P2RZ8#GQY*6NRG/UM7
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M/X!I,F13.)H1 @_.?UUZ+MK.Z2#PAX^G'T^5A/-B.T2L!WG^[W+ZC^7T&R8
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MK#2'SPLI"^JJG 69/E4L9AAZ/;.58&A9/5<F&+I^G7RX@_S"GG+13 M,JZS
M.J$-5H1SL.B_LU3D\% +LC\P[T5YRZ.TJ/+]/GS\==O4PZ5</\IPNR'53^0N
M\4;.'XNB?,:&[>0_7.9/?IWTII:S43Y;.Y,-7VVD(E:OIN-BEK-QE1R([^F-
M(Z!$O;K'>)6LU4YEK)>/WYMU>N52TIZ[F+1G]ZP-DO9XSA\K:^^D1@QZI^!
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M8< *WG<ZB4'!^H_XP^$7IBZ<G^GGKU&S0/:U*RI6VVE+#:O5?4@%B[A*V9P
MB\OUK0'3"(!+1=<!BDJ6@LJ0"KV+UAB#:GXM2L'IMXI*1@<M^*(H'F=262N+
MQ/WU0*-I9<C?1CE5J0,7#6(_Q8/=<NJ?$,@B\R&;$G;^!Q\'Z@-EYB2'=]-X
ME-TB(]<^Q6O.*+1,Y+&D_6QTNKW&XPTI^ZQH1/"1!8GU!PMSDFAG=!?7F+@*
M_TP#T T).GL-FV60H+J^/[&GQ! -3T LZQIU64#@LE'#".%SH^ S+.$SU.$#
MOPF-[N6KMM-[K0A=_&TS:B<1+"B=%(F #8(0D)=K%%S3$Z:"Y/"W/Q 7K/=
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M%?07?AU$D7!B A-T>Y()W@C/!H)DJ$ B[">MNR+B#+ J'N7"PBRGLTH*QCP
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M'-8[MR\$,1%PK.V;)11Z!6"_(@Z')!X2@"TB9A(S1[A?\'%DL21\%UM[XU
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M?<>BC6JCF?D*U695"K0NAM"3; #!;$F0+$HK-6CSU8B\6:#97?.JJ$;><Z(
M;CY043B)[.E4-_.AZ94=8P=LEH :R32^-K**)B#I3 6TE,OB=T.:T6C&,S)8
M_R&2%C*W_8S([DQF=8"-7%9XM61O)2NA50U57L@6ZE,4,UB>,I^ZN*E]K*D0
M(]VZ92R'[C28"\A+$T00>2DK<L^^(,9A@<,7&^JDLN?^7Q+QQAF<#:?GO=U0
M7T6"D7?]W9-<WK.R1%A7)0U)<:WDO.[S0LVFY68R#+QWCW(BKC5[PZB%Q!N>
M'&K4NZM!&FG5C&M5GC%J)85\@\_W_D$\N&O:-XLPC"1I1JXU$I)0_^F<_'[X
M$'W$RR7E:@B_R+^#@,FRBY_X+T1JKF",W,W_A M%PR"*PT1-A4GHS/F8)&)!
MGB=DRBZ2P,6J&XD]1@_\1N . IZ1D:<>>\!^;P&N7@<(WT8B$-VG P_[$3E
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MP!(R_^)2I$5]*#L,:P1GZ\@D+/@0&1F,VGP[&A!A=(%8 ##?WJ23;/$:K3*
MK4V0[C9&WA7^0;[/&=@F141TXP8E+XNMU<RXK HGL9ZZHP$OU%"3.;-B9@MF
M+"VVR24\QQ)&3$T[_)=TYJER9:XQW$]M"O& 7N3,R0)__N7_ 5!+ P04
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MTX;N^.7[]8\:$/S;G_X?4$L#!!0    ( (Z#8U7!PQ6C^9(  *6.!@ 4
M979H+3(P,C(P.3,P7V1E9BYX;6SLO5F36SF2+OC>OR(GYW70B7UIZ^IKD9*R
M2M>4DD92==UYHF%QA-C%(-5<E*G^]>,@@XJ-$4'R (<,*LS*5+$ESP?W[P#N
M\.W?_]>?%Z.?OL)T-IR,__(S^U?Z\T\PCI,T')__Y>>_?_J-V)__UW_\R[_\
M^_]%R/_Y]<.;GUY.XN("QO.?7DS!SR']],=P_OFG?R28_?.G/)U<_/2/R?2?
MPZ^>D/]8_D<O)E^^38?GG^<_<<KY[=]._RUH!T)D3V2&2"23AC@'FOBL!5A@
MDEKQ_YS_FU$\)ILLR9Z5/].*6,4MD48Q9BRS6H?EAXZ&XW_^6_DG^!G\A(L;
MSY;?_N7GS_/YEW_[Y9<__OCC7_\,T]&_3J;GOW!*Q2_KO_[Y\L__O//W?XCE
M7S/GW"_+WW[_T]EPTQ_BQ[)?_L_O;S[&SW#AR7 \F_MQO'H /C[-O_^'U]&H
M7U:_Q#^=#?]MMOSOWTRBGR_5\^@2?KKW+\IW9/UGI/R(,$X$^]<_9^GG__B7
MGWY:2<Y/XW0R@@^0?[K\\N\?7M]%.AS/?TG#BU\N_^87/QHAXN4GS+]]@;_\
M/!M>?!G!^F>?IY#O1;]><@&E"IS_NWS:+YTQ?48@T[@(0/"G,"X$KXAQTZ=W
MQ_S]LTB"[!>C>47$=S^[*M[)A1_6%/"=CZZ =OE!Y (N DQK0KWQN==PKD'>
M1E@^$K[B#\?SS^!'\\__&B<7ORPQOGCW]N.[-Z]?GGUZ]?+C)_SW]U=O/WU\
M]]N+OYV]_>NKCZ_??OS;V8=7?WOWYN6K#Q]?_;]_?_WI_WM\)?#U,RG;+W6"
M+A'O\Y1KZT("#<?#LB>]P6\O'U7@][)"^',.XP3IYY^&Z2\_#R/US$C.O1)&
M6D-M<#YP'2B+(4OE!OL\L*QUO=K1)-YX_JCLQY/O!!KY */E3P>+&3GW_LO@
MXQR/QG)*HGC@-7XY&T@ 3:73Q 8?\-C"S=?C"4>L%-($&6ST\B[]9FLZ9S\+
M2P)>/N*7HLY?8#2?K7^R5/!2N?>C6.EP_W6]'D<\]6?P$E;__WK\<3Z)__P\
M&26T(%[]]V(X__9A,AK]-IG^X:=IH /C-"1%>#1 I**4H$H<X1Z/=B=D HB5
M%[TCQ)L2N>+UV70MF\O-8\_=I9A$5;DQG_2GDA4M<'T__S29XL?]Y6?:E4$?
M/_LIS%[/9@M(@QR]5HQKPAF>HQ(M0&*9241)QJB(SH"L38_KS^]?]TV5-:DD
MZ;M:9YVU?F>5 ^N$ 1X9L2D[Y+Q3Q'O\"HQDX*EBN'57WP]OHSAQ!G23^ET>
M\*X\.$O_M9C-R^8W^S0Y2VDI;#]Z[X?I]?B%_S*<^]&2M\5)22\F%U_0!%SZ
M/A\ %S ;SN$C3+\.([R'Z7"2/D"<G*]4]I]^M(!!<(PY"IPXBNR65E%B=5DI
M-3XAZRT-H3*K6J_IM#EZ5(RXRWA19>=;;<(O%]/A^'P%<[4Y+W_Y[DL!.WOU
M)[J30USC@#HIDN66,"8XOJ,B$1^D(2DI&FC6PH)IL3/NA/*T6=E8:W=Y)AOQ
M;/D.; 8<6-0B"45 9$MDB(E8%Q+)SF=$G!)5NA^:W0_RAV19)9W=)9EJNIE]
M@-E\.HQS2,L_.ROB>0OS=QE%E6$X7^#?#(RAGAH0!+USC;LQNCN>ZTP4""\"
M4Y!\[?.Y,^@?DH2-='J7E+KESK<5?F>5TM2@N("9U<X=0LR$2R>X93%1R#UN
MA,^4[%6C=QEIFFZ3+R;CRVC;N[SZ>CX,(S1B(_[I?(CH.<W&<FV)MP[1B\1(
M$/B5TU*#MIZAE='G'ODHXA^2C2VT>9>+MN7N^#AX(8/TF3ETF6)$>P/\,BY+
M&%7&.A>4T:['K?&9B3WI\BX17=--\2RN?/EB[0X0)N/:H!-E$:.TN'O;; .Q
M@<MDA2_;=Y_[WW5P/R3!.NIHPWUR]S#" Z_"#: I9:,S8G0F4"(A<!*<\T0S
MC] 5NE&VI\N4.]A^2"YUT] &*M6)3=Q[UU/^_?7VU>. 9<,5%9)0E@.123LT
M,%TD- $W/.H LE<W=C/,'Y)@U?2V@6N=XQ\/WOALAFPU.BRLO!G:(&09-+%4
MX"G.55(6!!J4O,]KNF>FU=;:!J)U#CN\FW^&:4$TA<\EB^HK"BA.+@#% </S
M\8O%= KC^.W3U"/BN%35."V_&RT7<!6663K7G_R?[R?3Y2_FZ'Z'Q=RC<?EI
M\AX7/YX//%<HP^1)$I$6:R 2"SR3*(V/NF1-YMJQW%X7>-KT/EZN;'@S.@=*
M$.-J>6\FL]E )2.X0*=(6W3,9>"4."<,$1:T,313&VHS]P: TV;6_K+>H/GN
MT8OK"3$B2&HIM<0QA31T2A(GJ"',@ "OG(;Z0=9[4X^J)-3X2&.0C*)7GW!%
MTE)\L9@B0E ID]-2<M%S0LT>"2(Q3A;C.9ZQ'^=^G)" L[]_27X.KTK.YZQ<
M:;P9SN8#PYTU,5FB("ODDO"X6'0:LLC4"V&MCM7S/+:#]N03"ENHH$E*V>6J
M/Y7C9:"]SUY(20*@K26Y3/B5240D:R2W/C%9_Z;R.H**>K]63-%<VQW$N$FI
M/ZU2X_\MCB9H$O_EY_ET 5<_G(SG\.?\U6CYP+_\/(/SBSO650<FK+:@8LE,
MQB6AZ.S/X6P0F DY^$2B50YIZ@SQ2F04CF,"[7*O8OT\PP< 5>3) P4N#_!F
M#T7?QYG. F^P+]S"]'*YAVX%:G"KY*82&S8"JGE*W%<R]  'NBMNTDKJO5'"
M2>E=H)J 0"L)$67B(6EB))4@7=:<^J=+A1O56(=GPB[";L  A',Q63DZOR^M
MJ0%N?2"%BR0&C4N,UI&0@BNWSDS$[#7+M8/L=T#T;RI64,ZDIF0;%)C<DT-\
M"4[[G&T$3J*2HABMBB"[.:$T>Q\\Y4!KY_H\".@4*%!/X@W>_+-)'+X>Q]&B
M%+1OO)=Z.QD7PQ1EB)]Q_AI-5/32YY?H*22:'<W$T9"1S/B5M2@7E=#!E@I=
M'U$[2;8;XI,@5'\Z:U#C\@'F* !(K_QTC.!FEZ@D&'3'."?&<4-D5IPX8?&U
M2-$*S;73IK8?LAG)*3"D@HP;U'I\*A>JB^FWZZ<A&(B1,2!*L%)X9X%X9B+Q
MPAF6@6I/4V6U;X!Q"CKO*MV*11>SZ7SP8G&Q*/&/K_ J9XCS54SP73Y+DV76
M_M*0IEH[YH0F> JBEVUB("'31 !2Q+THI4"WLC+Q@=<TC]]=:7U;+$_XWJ&)
MN"ON_-O@NWP!MD&XRSU$1V(<XC*BC39WH$H'550T4'= "DEQJU@B#C@B31P]
M*LDLD4!-=%9'&[9R6HZ8+/=<5QP+5W;10,\<N8J^7YZ)*@H6E  2J42$$3UQ
MFXTG"OTM+J2(BF[55*'KF7,+5W\F2"N][G(:=5'*O9<B__[++=F]P6\[-1OZ
MU<^&LTE^C]X3_G:9S?%Q<7'AI]\F^>/P?#S,P^C'\ZN0X/O):!B',//C].*S
M'Y_#<'SME]/A. Z_C*[7C;WP,_R[=/6#U^.O<%GP_;)8\:/9S75OU;[H.'#7
M:HAT'*NYH85;+9:<B=:5\@'IF=3:6*%*UY#$ U*7>S<XCB5T==RO/^MLO/R_
MXL=\]45KLV6P]2KJZC0NWJ$;PS3WQ9>AN(N )\9HF2A3Z(?4ODK<#6'WBXR'
MGS;0-#F:E231H!DO@V+$4BF(2M%E9D&KZKGUCV'JW]%MR)J[MQX5%=+@ZOTQ
M?&?S%WXZ_88O^*HUAZ8VY>0IT1$M-YGQ9/0<-.$1/7>)R*.KG<2S(\0?FDY=
MU-7@)O\.W&L'P"I'=3[P/N<$KHA#\=(? 5\ 8071 (P"#UI4[VFQ!:P?BT4=
MU=+D1OYA:91HPB521<&8@ Z!\"4M5"=# FA#K+<2HDS*V[ZWI"MT/Q:/ZBBI
MP37_0XR_AC)3QYT(CEC)!9%":N*<#$3RZ+56B3E>/^"S#;(?BT;=E5,Q<(".
M[&"KP_;5GY?ASY?#68ET#L<+2.^^P-2OBB9!4ZH1*PD,T-(3VA.;)"7>FI2,
M9X)G]H@/70O+2=+I((IJT+'IH==AH+P'#2(3;K)!ZD,FWI3*6W0<7*19^]2G
MM7221*JNB 8=E JB6RN_ _?F#ZX[G:AB:V2PQ*B QEV.FEA PL<,UL6L@LZT
M=B9=%\ G3;/^5-FB;U+\#&DQ@G?Y,8FM8LDJ" 8@%!'2.7QMN")!*4<<NJ9.
M<"%4J%[#M1O$OHI">F182R4=2T7)8RN[QS(H@4BA4N(Z,P*X9Q,)F:);XCUA
MZ*'0J$Q2U3LF[8_V8#DA+3FTHU]929=]7'AMA7R=A;T%]D8%+UUP'Z8NIB^.
M5*%F!P4?&TD9]50H'HF.:/)*[05Q*F:2I4@"?27'9.WDR.,CYR.5.D^1F[OH
MM2(GB]-^$W>>3-_ ? [3V22_F$(:SO$GO_DX' WGW]Z4]@??4X=]L705H@T^
MEN"&)"%#("YPCA:Q3,[=&L^S\4)ES\<?GT]23[^3?I53,:ZYO 2:C$8>,?I1
MF7/XVW#LQW'H1Z_'L_EPOEC>\:Q3?,!XQXPD+);<9I".H-G""#I-@<IDF+[M
MC6R^DMOV@3\(9]HHH/6N\RN,42'SW_W8GR]]D\LA%6NLWCEF4U0DZE*CXL 2
M3ZTCD2KF36#<&;W/=O/(<W\0SC151\4 Y4:LE^V8QO.IC_.%'Y4*R^'JHG!-
M]"2I#@E/<U-"%KZ<ZY(SDJS165)NI*?[D.?1)_^H]*FKDGM#DD\GO_,U?MCX
MO+2".9O-8#Y["_/C2^9\ .2Q9VYN*]];:9JEOW.T*J!=!%+9[)"2CD9(2JG,
M%#1+TWP ;S?W\K>B&W@S_%KR/6\^X^HZTT@0)B7T<Z+C1#*&EJ&S'-]%3J/6
MD1E6.P*Q#:ZNKO7]S_C[#/)B]&:88<!2"F!T(KAT1Z3@'NT='8C)(;L(2(?J
M?<RVP=7_25&=*;<]XNKJ:#%=\_O%Z@/B6-VIAIQ"270@>=G!&STHXD$:DEW0
M#+Q.65=O8;PUNK[B)LU)TT@AQQ(H>6!1OW[[W?_79/IBY&>KVZ@$-$H5$UI'
MO/2+LX8$GPR!8 ,XP7Q(M3NN[ #O\*&0N@39>O/JIJ@&-\H/0+T"^M9?P&4-
MUS9P&T4Z=H1ZF.!&,]5O3[%J>CL"NAD-@AHEB!"F-([-I:FWQF,^)^-H2AYB
MC]M8?S1[)$QQK"S;15T-V/5IZA,4..N+ @/.&&,9D=3&8B *X@S71 1MLXS@
MHZK==>XVAJ.RS;LK[4Z;D X2;V"2OUC,YI,+F'Z 5;?TV>?AES4T'4/V@/8D
ME;G4:Y5V*%HZ0G4 L!HE(&JW;'X SFGSHI8>&FP2+^$KC"9?('V"^'D\&4W.
MOWT8GG_^?KFH/7AN3"2X>*2QIHP@*$$H!>^LU$FXVI4$CT Z;:K4U$>#<J;U
M1?1RZL@=8:P@1M <#$,*RQ+0*$VP; R&4$_Q]/60@Y>U=Y;'89TV;6KKI6+I
M4NE9\:%<WR[M+Z.5S*X,0')&$CP"<9%9&R(5,THI'R%NE7;S2(>0[P\\4=]Z
M?Z%6[CVU!+&V=K: 4;'!U+5']]]%:D_AWU9?!\E5[O5S X[B+ -08F) 3$Q8
MM$D<;APF>&6 )YUK-'UJKL '.CM5UM\. JNLM]]14A>+B[5YX())Y>1@5J)[
MFQQ#AZ/$ "!X"\QDQ;>:V/:(YFX\M-_N2GN+?5)#9A6=M"40_^=U(,FSZ!*2
MD)><21X2\3PKXH-!B%8& 5L93H\I[_I#GZ#R]I;9O6]>_>2'#Q#QIZ-OJXE+
M&\;:[)^RL/5'UTHTV&\MM](#O%<A"FUCF=LEE M)"*6 "@42M,B#K9_2=03;
M']>3""9C_#(N U.S=]-5FL'K36D&5R&Y$!(K#"4!'!3>XE<N.L(!!(OHLV>[
M58^['=R;SJ ;C/PRT>F$]BEQWN.+)U29S<89$59%$;5T7-7V\AX;^=6'4]<O
M?S9. ]U?#PVN&-],QN>?8'KQ$L)\D*T0,2@@8ME@-SA-?,J1>*LYPUU9T%#[
MU;C^_!^-#7O+OL$]XKZ26+G -DD-O@P,7'95B>5J@FD@%C(8"MXG77LSZ02X
MKQR1P_*K/YT>2T[)5>_4V6^3Z0/K7WJ.7(20#>>$L3+[C@(G7D6+!FWB+BM@
M,=8.H>P$\%!W7SWRYLXXF%;Z:Q&?Q;^[:MM[Z<]L@ZE11LDF/(=)&VFHQML1
MVUHZZ(L? M\-(1,G/.=<VF0$/.8YD.B4!.J<IKYVWYS^>/%(GL>!:;&+Z%M,
MD[IO-BXJC%)]"3+YK'6*C#CF\;PW7A*+T$@6P>#.&0.K'J_="EC_MGEW'6X[
MG'AO!;3(PGYPN**CD;*D+$%WP"(X4ZXZRZB"H'*PUE%I:CMH1SF0]G 62CW]
M-(CNWS,X:0M0/_K\VIT4M]W4TCVDWMO\6BNMIF 9\5F42)DQQ-'2G5G2$(/1
MBJK:S3.>ROS:^DS81=A-NJQLG'?';98Y!$8"+7V\(G/$A6)C<4L%IS8X5K_9
MU#'/%-Q)3=O-%-Q%QKV/LZ622U%:LM/ 3$EPY<19EHE" TL'8VFFU2W-IS#.
MM@L/ZDF\[TE0RZW/H0&$9B_)"@U>*<O6)YTGP0M(Q=^2E&W#B"<\<;!_P[*)
M=BJG_VTY$6L;A,\#"O?0YNY#Y_91Q6$&%&86.21>QNU!B7]RW&XM(O61)F]H
M-M1L54M\Q&3I.J"P,5=VT<"A!Q0RL,9K)0D8CCLLVE7$.AU)4MP8*L%KN54)
MU(\PH' GO7894+B+4AJ8N25\7EIZ31<%TZI[84E4DB81FB3#@SA+$K0U1!A<
MNW4V9U%[OMI=%#^.#5-)$Q6'96Q&=*U88QM<C2[%[L-TF'NQKCI[D (=!=ZD
M7NX>?%Q(#D9D KA;(3Y=#EDJ\360(5(0&1WW)TV$1V[%^N+!+G*NW&GQ(XR'
MD]*+[2M,YZ6*Y^UD#K.7BQ( DI=GF0O6I0".E(8[)>H8B96@"!<Q2<>SE;<S
MF3;VQ]OB4?W?=]31R:2=0"OW7WT(GEK?R1B1P.'!RIE-1":&1I*CD8@0=>1,
MIY!=1WVK'T+?^PBTP?Y><BKGESF5)8*\2B4PTB?#9"G*=HA)"+1I&!K&*>D,
M+&A#:R=Z;<+QXQF$G;718*S5;4SK=V(+5(T,PLV(#F,.=M?8(Q3H(.X>MHLU
M.AJ#%5D3[LOD-2MD&8:L"'/@>(A"45D[G[E/$CQB"O;&@1VDW$#WJ]-L>81]
M+^.E8&/@1$!21)93S&IIB:;,!/ FZUR]K^%M$/V;"36T<SM+II-H[S4#Z]?Y
M?9KZ\<S'95.7MWXZ75Y[[5_;]^#'U:KGVQ[SK1J^:(PT(:C(/954)*=Y,L ,
MQ7^-=7GPX"=W>]E^7<R&8YC-SN)_+X:S]=(OBQP2EQ9MPTQB<&B/*F60'-83
M&KAAV2L71.VDV(?P=-U8-GSV>[362M?D<WB7_W-2K*S78WSG8#9?_=44TL"6
MBEJ&R^;+256461+08"9>!Q-95*[^I>5^2/O?HJJQY_9&U8.J&MQXKU&_F%R$
MX7C9D@J=LMDP78Z.7;['&:8(E0V,E8YI8TC0,90!ZI38J!)1911V HE;;^U<
MKUWPG2"9JJNE@?'SWG];.H"?)I>D7H.'V5^GD]EL0-'I4YEFDLNA+X,!XO$$
M)U$$*7@2U+O:O2H?PW1"5*DJ_@:9Q!L6OLJ6^KX7KNK\WTW+_Y=[@K>+(LIW
M^>-GC[]?_78 (5 *Z"H(%PR1X"AQY2XY)>%D]L)J7;MC91WD)T2U ZBR8OK1
M'GOKQM65J=F7RQNXS&T6FA(*9208#8+@]LM)TB8&&BG(T,K<K #_!*G9MU(;
M!)HW+Z58C[C-WUC4&?I5X]4DJ=FRG\Z[_&XQ1^\.9O_I1POXV_#\,[K+EN;2
M30=R>=M\&5C'>2(,?,HN&]<71?==P<FSM!?5-KC^WGXU;X8^+.<I#C@7 :+,
MA%LOB$PV$6N9(CG:'*3VM)U_O@/,'Y)R^RGI+J]T]_+6E6_\0+O,?T#IA(O;
M]E<$?P[71M\XR:EC41 E$CI#EDKBG./$J)B,H)))6[L8I0O>$V):;VJ[2SG3
MXIYM,8V?_0S>3X<1SD;+S\ ?_W4R27\,1Z-7?WZ!,IOOD__S):1%7 :QSRY*
MX'.@LD\)/!#N.!H00"D)@7&2K::94I&2K3T)K.H"3HB4AU/L79;:KBQ]/2X&
M  (K&,<SN)PG.K!6:F>U(@84"HBY1$(9_,5#EH'ZI(*I?=U[#Y038DX-8=_E
M@*LW6VW#RF>_?KOVW2KI0N%!'G#_1/L0-U4)J30"4X$H8Y()D1M1O4!W5XQ]
M]=!JQI6F2CF6CE@;EK;JFNR\LL8X$E@NUSFTM%QE@3 =DO(BF\AJ9SC< ^7P
M'=Y;J/_Q$VUG-32( FR"M3((OP\UV )@H[2H1\$=)D.JBBJWH$=W/1R$,#IY
MKVC)$F<"2C%0(#Y;Q"TUC<($:E5M5^Y 1'DDB^HP/-E%_)73ZU]??!EY]!UQ
MKWP_G7PM5Q1_G4X67U[__G[=O<E1P1TXHH/+1-*8B0OER%8FH'&NDG6WPD$;
MDZT??=!1&+1=%#-I)=7*&?;_6;H;O(0X+&_$U="T'!F@A<US6$YE\,33,N<H
M".4D@ U>;:'E39]]2HKM++M^!UK>F<1(F3-!!$:@H)1)4N(EFMY,4<D9=9R&
M_J:''^%,WAZLRE;J:I!0L.LPK6W@/D_F;:#ZCC-3]]%;OQO91MA!Q:AB*O<(
M>')*+4M>EHDD2N6!T>2 U;Z,.PJ:59S,VR?+=E%7 W8]- _4&<H\TYQD;G$_
M#ZG4201/,J-<<<U+O51E)CWIN:P[J7*'N:R[Z*%)4XJ'YX &;9,V-A(%P:+1
M3@4)?!FCR$JZ3'VL7I+XY.>R=J%*37VTZ!5^9_*T][Y,GR9FF?^90!''#!"G
MN &5F?"I-C^>WJSO+H3H)/%[#>2V%4I7<<])ON9(O)C,YG5JEK9X0(LJIEW7
M=:NN*85@K;'&2*8E]]%KZTJ'BB31_1;*#'9\5L-*)\$XM2A\$@S/1$HTEQS@
MMR)&QSPRF&[78O'(*IVV2. \"[/EA.-!0C6Y[-*R6 9%H$2YX@C$*.>#!N.B
M:95GL0/,H[AIVH\W';)L]U)2 ^OIT?*(S!.(S"+Q99:Z3%80Q[TFV6;E,@O,
M\-I1AN.M3FFFV%V+5G;12L/@5(UT<N6<2\88HM%,(%*(2&PR@8#Q/&FA55*U
M[:^3J!'HBXN'TG7#6JLMEK+.]AW"[/4X+LJ/!L;P$""5\D'CB.2E,:A0D5#*
M*8N41Z@^$Z0;XF=R5M3H84NMV ! 2&#H>'D+%+=\BE\9YH@)R1G!?0ZQ=IGH
MTZ@N/D*N[::M?HJD/D"<G(^'_X,>?T+;8IB'_KO/O\Y-Q[WZVFN"OUM<X ]7
M?[(6H<DZ:,U0A%%K(FG6Q#O\RGLFE5+:IMP##RNMYK2=CT.HO!]K<^^5O?"S
MS_B+8JE\]>6V9#8(/'HMO"2)<T%D$(%XD1TNT6K!A-)*M>H&TF9%1[$5'X1[
M#5^)CL0Y]M>BV$/C^>HO\5, %XG_Y6S 5;"!ER:3JJ1]BZ")]:6U>>EE*?"7
M(K;J*]!R7<^OR+&2J!^WK\X:WT_ABQ^FRPH8_/MW\\\P7?UN$%V6*I46;%%'
M(I5CI?I8$:&D3#Z:X,*3>7,>6NCSJ_1D:-:/"[OWHI?+>CM9.>?KQ0^X<2E+
MRDA0"5VV&"4)D7,"6C$EDA4^M*J?:;:HYW?F*.E3T1$O><<U%_?I1HQ^H%,&
M)X0D3(+#MSYD8EWI:9:,4XZ"MK?;YF[,_&Z'\(=G^!$1H)_>)GNO['8"RO(]
M_O39?R\Y_ZX'YIA@N&Z2K2\'7ND\Q&D@5%+G-?@HJT\..<A"GV^E>B3*D3L<
M5XN>#7)0SGF>4/+XJDN(B3CO#6$AF*BXLB$=LTMQ;2E/^WAH1,1>7IW=6'3D
MUU;7?[(6.7<1]ZN(VQ-CJHP57^Y;E%"/(@\"_:'<0]93S24]'P=-E'_DWO#E
M%<#U7ZP&Q\S>^V^K1HPA Z,\$FIH:<1()9JE"8A2'/\_9142'#'3'UW@TSXD
M.M.S_?52)6Y5KF[?<Z%^ZX5.%S>T,T@4@HU!DZ1R\:5HF=SJ2W,UIR0-3AMA
MVCG3>^-^?CV>!&,J^A>]K14_O-PUKUJMCM.KBR^CR3=8]_B:#4Q@8$+);H',
MRU0&25P U%L61H= #:/Y6-Z81];R_!8]668=N0'W$E;)8)_\G]?W#LZLI#R7
MZJ?,B.0AHOF,*_2*!H6_BD(=\R76YE4]OT5'S*(CSR^\NU>LU_P!OL)X 0.O
M6?+6.V*7?44U3<3SQ$B6# 1E^,MPU!E:CRWP^>UY&MPZ\D#*"_^E=#IZ WX&
M[\)H>+[\N(&V,:F4+(G<6=PJC"'6:$D OY*X=A5S#V.I*J_J^94Y8A8U:'K?
M2/H#;8!Y:8J!R='>% F(E7B8&JND$3JS?-3YC<\F6+\7S3OQI4$C_G6 :4!I
M4MG*1)Q1#G'XDHU0)MN9F&( JX.N'>58/_N$PA%[B?-XS.GOX<9-K'T+<UR6
MLHG[2'(JTS,C1#1S! K(4 %)<)/LD1C.CRWEA$AW#,IN8,GNW(]19)^HB8%D
M6LHGLK$DL"1(3$Z$S(4)U3O!/<G.^UVXUE0IQ]YY/U$-609%6"B#ZA+7Q*)+
M1ZARD68CK/=]-,A^2CU2=U+_EIWW=U'#01JI;P/PN?/^SJK<N:/Z/GHX"&&4
MB5DG+5"0IK2P,YH$[B1)7E'IT2'VS?+PGD;G_;8\V47\O7?>QXU2"Q4E<5+R
M,D[:$.O+MX8G0\M@7W.K*^GI=-[?23$[==[?1:I]=-Y'>]IY $%HR( K%98X
M90VN5$J*[.;>;C-?X:ETWM]7L9UE=^#.^P9HU-(QPE6Y[0&TB2RP4N&M7,XY
M"F=J][HXQ<[[7:S*5NHZ@L[[V\!][KS?0/4=>Z+OH[<CZ+QO959X^-@2VBP3
M3V@FP5M.-%=6>Q5IH+6OC(^"9A4[[_?)LEW4U7/G?2&98@KM>025B2PYD(Z"
M)RDGY6E@+$95F4E/NO/^3JK<H?/^+GHX0.=]7*(2T7#T K7#M\4HA&?1=$Q.
M9F^$$-7=Y"??>;\+56KJHX_.^S%PJC6CA$;FB2SA-XN,):JTA8G"LL1J)Z8\
MO<[[70C12>(]=MY_.9R5T,!PO(#T[LME.\79Q\7%A9]^F^0/,$-+:C;)5[_;
MOPG__L^JU8^_TFIOM>:G(2D' KA25CH5'/KE7*/?+IG41MC!_H^M,97]X]S/
MEU&?7_W(CR-\_ PP/QNGLY26<O2C@F\TF2VF@'87?O-E,O.CY350Z=<Z6J3A
M^'SS&JY"92$ZEYT7) MK\65Q!AU-Q8DQ,7GAO<%?5]Y1>EQ>UPWX,N7Q6E\+
MW/EM%I*$4.P'+PSQ@?O2W,)+*JVBIO:,A-L8^M^ CY6/MS?O3MIJ8>U=%\'#
M$ECGUB8=RF140Z)*B4B:,G&JI'+1,J4,SQHM:Q>H[HZR?P9VT^QMHZ^M6AK8
M@9=XQN>7#<VNY)!<QK4J14P,RS&= E\7-$^,"XFS%/'?VG[EO6">-Z;[&%='
M?PV(M<.K4(80S=[EDE,U^S@9I4&IW$3[B1/K2[US*:4)D'6YIU8Z2@^F>G?U
M#G#[)V<EI>^_>7726.4H\"ZP1WYX,;L4VL!9P7D,E*1D5?' .7%!"-R(<TS,
M,N%"?,1_Z?+\ITZ;WF3?(#BT ^Z_PAB_&BTW_0M449'8?/@5OJ^$:L6B*8M0
MC$@365D)(S9E8R7/!M^%P^U5CZ!_ZAP\L#X;U#R_A"]3B,-U2?;9Q60Z'_[/
M\MO-9L2 .V$A:$H8+S5SG%D$[#T!G[,-2D5O0O6+W1U!G@S/FFJG02W##B_&
M;8D-+'>><1N(8PX=H4 =\=0#$=JGX+RWPM:NC>\ ]V0HUI/&&A0=[ -]Y6>]
M*6/TO-89,L6=5TA'I!1 /"24GQ&:A8AV@:[M<'9#_.R5UB3QGDPXK'6X'J^W
M C_(/#.5G2,\ J %P32Q8 51W.!>+W /J)ZBMC?89_968&\'_;<P'G<'OCXZ
M0 2(- 42+)X:,G!TR&PHS4RR!:\IDZSV.,7]T3Y3MR)U]V' @2W5TN%W#5L8
MCJ86:!(%HP@[&N)<X 1-'>.9,"ZIVA,I]H3ZS-H:YL*^NF]C[VYZK=9FS&^H
MCXU_\BODR116?_C)_SG@(CH1M"$IXEDAE>$$7T%&@C<\"3!:T^H>?!WHSY1^
M@-*]<Z-!IY>-&!'7JYPASM_EC;\?Z)R,YJ+,=!6)R,@D00>4$HX_C$IR;WP#
M,WAWH,_TW8F^5?7>H!_+%J_7["T@^O)B>9\%E38236VYY[6\S(M,)(-EVIL8
M ZN]Z>Z"[YF:]U&SF9;O,M+6861+F:YJNH!RSW!!) 3IT>_,C#B-!CR/%, 9
M3I6NO>'VM+2^FGX\+?8?%Z..I?7(C64N4[>'>1C]]T)X2D7F>$01#;PD7'-'
MK.>">)"60G#&9]W25;P+Z5!%HT?)HH><PH[:;)W?=!/>9;' -@ ;590^"NXP
M-:155;H]73KHXR#$21"242H0HV+I@NO1C)8J$^^3$\ M?M/@/N 0A'FD&O2P
M?-E%#6UXLF%?7<'&G^1?OWWT([BL)5+,"Q=H22#&W58F%HESPA%O9=0R<^%=
M+Q[W/?CZ]V8JJW<;][B&;AJ4"K0_ZU?5V#R*I%D@R9;2.%4RYFDI:9,YT&QT
M=KIV?6D_*WNVT>ZWT8Z06ZWS 1X#?+TUQ1:P^S  MX=\&+/P&%GTD+70F *M
M;<X=X'/GN%8I$.:](#+@/XXEA4>7D8;)D)DVI\S<1^S3$R;N+IJO7-#Q:;J
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M(+8P!K9Y5G\&0D653!K*LW(SW_=3N!@N+F:7K1 N =$R2S$Z("# $&F5) $
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M%'C0,;OBV:'=Q37:72HZ9';RDH%T&>K/S]P2W(_'FSV4TF#,Q#U 5Q>N249
M0]T08Y>#-K4MIB 0E1RW/*--$'LB3*]!F$,P8W>!'SI@\AC5R]42I9%:IR5)
M(J*@6&3$)EL$%9G5.1A5/>7D 3B'"G_44_F6N\RNHN_O5+KT++<!UZA-[8/
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M/H^CS)5J29NEEQ!2[=R\[=&=(DNJ::.1T?EB,OX*TV**K;XJ$\^OS*TEO=F
M>A],%)($'2P>HJED'B&_M9?6:LFHR2TVRVVPG0YGJFNB49.=*YSOIL/SX=B/
MRD_7 &,"GQ48HGE$/YT;@0!#(&BE9Y&,"J+Z<)I'09TB1[K*OD$0ZOVJUG;V
M+M^I>1M$'<""+05O3A,)X-%GBYKD$)BGEBK/:\^<?@#.:1"BEKR;W&]MKK?5
M,CN9$0=G'+<OR,5&XLA0B0=>L%*97)L&1U_7W&U/Z"[GBKURUK VM>_11@=J
MM2#"Y=)JF1L2+.-$,9$"DUE*6EOU1]T>J8O:N\JW8B^<S<N\M&!*T^2K(^M#
M*7)E T'16^)*$60B&KV1,>*8+TU'8P8(U*18.S:]-;C3H$<;753LEK,#T/?3
M802&GA)GZ&\G@I9,"?_$@.)PEE@7(H+5287:R:A;@_MA2+.'+BIVTGD4Z-M%
MD=J[_.J_%\/YMZL_F0V\,$&AHTTX%,,8?2@28D+AY"R=5SF#:AM-W0;EB=.H
MCG8:]."YT>Q8)JL]4$5X5@Y=J!B),]80'K.+B$-37?MP.LZFTETXL+=$6[38
MV=SA>@F-LJ1U1LX9(TN"KM6XAY41(!P,\TPXFFI?:]V/YC147TG:-7O>?.\+
M=JL)S^H^Y>++9+QL#\>8$8(#R>@V$QDR&D&&46*\@*2%%];?NAB_O^7:0P]Z
MVFJN+\L6K6H^SB?QGY\G(_RXV>JX&8!$UMFHB B)HG>$KC$:*X:(& 2E>-"
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MY3P5BAQ#F!/:,!.YDYU&/]:PGITHK]R,ZFBG 8O1X_$.(Q%!<6\4T0(,>MW
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M_2Y_A^G^;N PJ(J7GSN!#'_[>:J&IJW$.YCNL\ =3@=/M*>^T-0&XDVAE4#
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M1$FRXE[E( Q4'YLWU-HN,/=1U]I[7P6=PVB:EC,=GVQ:1OY@4H(H(N%06+)
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M_KC]"/&?_L>__\N__.O_!>'_>O?U,WA?L-6#R&MP50I2"PY^9/4]^#L7U3^
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M%RYK.G6'L".2=:#0I-3K#L#7A.QPY(%ID5GU6%1D^=>R6#U^RMERQ94/JR_
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M5->\BWP2"D13*4E@6KG?1.#<^'FC,VB5[KNZ74O0ZPV^:\TMJOL;(7^<4<?
M<V2RW(%RW2&O,,?2JC> #4!G- TP$C-9-P$;H[?;#%@]-\ROU+V0;LKB*5/\
M]N[YCTH?;*P+*ETR);NAP+V-A:M%2-(XH7ZJN(?'.BH?09S*!'K<2P,2,)D0
MHR8B3K29'4_IX/(V(O^QLTGG^VV"]LG:(#OW\+PY,W,+)YN)L1E.3\+-%OR_
M:%M EO\*-N7A-O9<'&B6[C WR0FRCOR_\W29U.]S MMK?\_-H,.85W>@JY^U
M/UGD(J^[@"*/>B(6*8<BU5TE&&*08N9#7\0DCE/,DL1JA[Y7RMR8LE42K+4<
M&*>U'U$SOCL;IY%YS!XB:V(Z"H$CPMDO8U(B.6KF:X(X_F$W 9O;)2K[YFP$
MAUX2(K7%TXV@6*1[RT0Q3&E**$EYE!"KNFNG1<Z-$MX/+X1K@*\9)[A%;62"
MV G?O'A9W19\;U4>,9#S,#XC!73N$?BF@9V' 3@5X'GDR8&5(/3IE>"ZT&3W
MG1=A(#&B"4Q(%$"4! %,D>*4T&.AC)!(*;;:J^U(F!N%= H>;[%D")X989P%
MR<C\L(W&"%QPT'17E15VQI^V@L(A\W8J)1S\H-U[+)[N%_O;55_65Z0LG]4&
MI:F^U1Y.JW\=V.ZG- EPA#PHO0!#1/2&(F4Q9$PF :<"D\@HB=F50G-CB773
M]Z86@-B89489SN;I.,.\!?I3G,QHX)L?MBRZ *0&O5%]Z<&U7=8'-.-,%R]8
M4[NY[3XZIVE[H=D___09KT2NL6X7+C5JLQAY:>@U"Y(S,9.L7ZY!Z9<[Y^,.
M3&?JPC*?/Q;E'_DCR?C5DF0/E5:K_8'_QZJJ]>O051;Y(NIUZ'@B0QF(.($$
MT0@JUSB&-(PI1&G,6110%F-NE?!TCC9S6Q?7QC0UT5IS0&M&^]JW/VY, IU-
MX/O78KG4C:ATQR';Q*FS)M3,2Y]LFD9>0$>?(?L4+1?(NDKB.DN7:=.\7,"V
MDPCF9-"!E\I+4E77\N]$E^&OK\NONB7/YW58<H@88X':C:21%T(4AH'B7<Q@
M1'$82101P9#5K?%1<7,CUD9;'5_1Z:N0!8W&9T2,GP#<\,K7&8QC[QS.0]#^
MQM8(&%=7LL>%37OG:F3XSJ6JV5/G)+"_;/E5;>I*AU0$J< )9#%1U!*E&.(D
M#6!,8U\2$= XM"K9=ES<W*BE56](JOI!0 U=*F<PC>TS=0GKKUH#5N#[*#6W
MS7!QFK9^4-@;9*Z?,GQ_\OK)I^Q/4MMKW-]%?5_P3[EN?JS]GK\56DK??6NK
MCUR(>,*I'\$X3&.(/$)@FBH^B:0?>90%C";"],S43O3<&*754^>(M\WF'D_W
MESL7_-,'H>-!.C+[=$$<K>9@H_H%Z'!>-_4SZ.-W+L[F)YCCX3W16:53W*T.
M)(=!=^3HT7+ R0X9AQFZ?9PX< 3[Q>!E\\6OXK%K?G)5/(E<>:Q71:YSO738
M]6U)FK-+\ES]GN79P^IAX?F!QU*1ZL8R*41,%TA4+B=D(>?"2Z*(2N.UX2Q-
MYK94;"D+ZE9;P)6Z%^"A5=B<R<Z;H=,+R&2XC[R>[#2%W9@">EN:KEWKB>G,
M >^;B?E]VHDQ7W$FFZ")%J"Q)\IJ37("[I$EZKSQ)UNQG,"PO8"Y&=#=>M;T
M\GJ_$K?%QU7.2?,U7UXU#14OJ\U*>BW5!W.6/9)EESC,)!,1HP&,O"2 "(41
MQ'[$H(\)QE%*&<%R\21*6IRSR U5S^;UWE9RO+=[ZV5FZY>YW/SR45L*^*HI
MHRLWQH*VNR4@U=:^2I]K/O86 W(\"7G\[\+PQ72*^7W#];4Q#RC[P&T!MBP$
MK8G@LMK:3.C4U+69IS++QY_4\Q?B*29W!FOS>)/L9,4^=Q8&+.*#1;[YNGXN
M6"9+_=DRAB;Q/F9*D*YBUM8G$.6W0M8_VI($99W]5_,.^0L>(U^@B,,0<0X1
M9JG:O$H/^@GG)$4B0HE1Z0!;P;/;JV[T5DMVJSBH.LTO]*J[UMTV-==P)@RO
M9$? =^S+V2UH>YW!MS6TER;0#LBIM</)6?JLH=B),V7MP-A-BK5\?FB3KJ7N
MFG=#ROJY2]4,$:(BI3Z,=3@(DM2#E 0<BC .:!3[J8=BNX9;KT7,C8@Z#4&C
MXL"TUSU FK'+>?",S".6R QH+G7(>&>-HG8$3-STZ9"!NPV<#G[299>!S^MX
M))RPR OC",:2Z.;LD79#8@Q)$ J.B(B#V.H]/R%O;B_]L:KYGX>&@)W"W":0
MPPF2$T5R# 714?^!'6A&[4'P^6WBP Q--^M%L/O8,)+Y2+*R23'8RJ6]*989
M>V[_?Q/#Y,5A& :(*KKQ)$0I\2".&84\D"E*)"/$KM>YL>2Y$8]6O,W( 5NJ
MV_&,.>QFC#,*F"-SSWX<+T"K,?C>_7>4D#)KO!P1DKG<2:G)&H[7)&4_P#"Z
MNBV;\9^;5NIJ7_50Y(W8!<=$B(!*&")/.4.>]&$J40HCRKR8$>PA,:2S^2%Y
M1J_1](W->W5!I?5M<@A94=7_+_ OHC"YB'#0%M*M0-:TH=<7+)5N*9H]B>6S
M'84=G HSQCH+V6D(:HWFMQ;-5LN+EK/<<=$I)!Q1ST$QDS+-*6-?$\O)SP\L
M[+%Z?%R*[F295/<?E\6/#^TOJG4BG!][*4%Q OT088@2H?O?^@*&/!4XC.,$
M$ZL,&Q.A<W-VMG5NDY2UUJ!7VZ0IS? ),&,2U[".S"H.$+6O*V(!D:M2(R8B
MIZT^8@'"3D$2FV?=4=*GO.D!WE2I[5^*,/*Q+Q4-)80SQ4IA##%B/I0Q)3SF
MGHR)56U#0[FS)B:=%K\LM.-IF;=C"OIP)CH3RK<AHRVE)^.C(T"-2$G[I+XY
M*QV!PH28CCT^C)LV;;;;ZOU-!8HLO]N4H+@1Y7M=\E_PIH;_(I ^"B7UH8@Q
MARC4O2=#AB +1!HP$:4TB,VBWP;K,+\0MXW2??UJI37X)<L!+Y9+4E:;5B>_
MVO&8_01Q)%G ?+57QB%1RP@6D/HRA(E,(R$\-4>!5=F.4:=GHLC[W<FY +Q5
M^8UFR6S=&17[D5>@5G?PB];^U[ZMS'HFKK=F0G>5Z8QHN\NX6X\& ^AH9;*7
M/^D:-1B>UZO5\(&&K5MM$ZIKN4Z&_2;N&I]]04(<R%1YT5PD^KR02^5%!P(&
MF,4813@BTLJ+/BAI;C2WZ<NU::%0=;K:L=EA<,U8RPED([/3!JU-KONW4VA9
MT\]))!S1S&$YD]+)27-?T\;I!QQ$?.:-HWQ55/4742]0XM&8)Q0BDJI=MI?J
MVTX<02%Q2B+FH32QJZYS4-3<"*)7K[DYZ)J9GQ&^^1)6,V9P ];(U/ R1+/#
M3*MY 92B(T5E[@5CC#C,EX+>+O)RK\%'8RWW/^&N3LZZ)-@->6Y(Z*O0P5Y<
M$]3'K&)D^;\%*1>$DIC'G@?5?DHY&$+]A$F:0"F)P%A$3"*KY@/#59D;P>@O
MWOG5=0RGP8QPI@%W9$(Z4)7G JPMN="I<U2 &Y)QG:'3V:/=F]8BH$T:MW"/
M':PC%O4Q5.3-"_[8 692#,ARQ&'4^=>BX#^RY?+S.G:2B2@4"4V@'W"A_"I.
M($54P#1)&%.;+YH2JP"R'0ES([I>P3/B47=1-".TL[ 9F:?L8+$FG8.F.^*2
MW?$GI8B#YKU^\P]_<.#]9$WJYJ+A6O87#9N;^I1R*=)8P!#I9'</(TAQ*I3+
MPP)/>3Q41(G5I>0187-[S=>ZZG5T?8=V1FC$,: -+R(=P3?V[>-PY.RO' T@
M<77/>$S4M)>+!D;OW"B:/#.@#4OQ\"!*EI'E9<ZOZWM17JVJNE"_J[KN0"R,
M>.1'' HO)A AY$%*N0=YC*- )$G $L^XQ\HI:7,CD8W"3=7Q0JMLT8SC)+C'
M><,Y9&.?O6S04LJ"1ENP5O=T8Z8! %JT*G$)Y%1]2(X"ZJBMB"DNQWJ&G!QC
MNH8@IN:\Z/9A_) =PW*1+3[DM=K377*NOAA5P^+79=.65YFRH)QB%D0Q1+Z^
M[Q+$ASA4FR\?\R3 ,D8\-#J..B5H;KS:Z@HZ92] HZXN==XK;,81)_$]SJ\N
M41N96H<#9DP&IFCL<<<JP?Y\5SS]IH9H/3'UP\8!.SGP).1@:E[/"\:?/S/#
MKVF167T63V+I=XN:]&2( NE#PE&B>TA$,/494_\,@HA)0C&.!N7T[<J:&S$T
MN@%_8-K>'BS-=F:.$!J9!#:I>1=M&]Q*IP@W@(W0]=( $]?I=WLDO4W"W6&3
M#Z;8'7G$?EO61-E04K552D1>-8[FI[SK-W:=BSI[$)LN-PO!.4:Q3K3#2#D2
M89K E/D^3!+?"PE#B$O>)]J=WJ?9BC=Z1U[FW8U^^E.P?\#&A*8(4F\#$&T_
M(/,]B/54G-[3C0+O1&=#6O4.UVWE-2'U71"5_E ;L-6=:T2XS7> 8\(^T8;0
M-?Q6.\6A^!W9.%H/.=D^<JBQV]O*P6,,3@<H^YR#)B6SD5]=UG69T55-Z%+<
M%E=%_J3\.*7'M=25_IJ>SEF=B6KA,^(G(HX@EYX/$55K")&"P8@3'C/LD= N
ML?),?>;FFK::UIE2&^1%;9O3=.[LF#FR$V(^\DJS94F7XMV&EU=@VQ@=.M%$
M)NNZXA^D^KJVMQ9K"_6_FBJH&R.=!JB[0-M=N/I9VDP=O.X"NCVA[$Z&M7?9
MCX9TW!;OA [ON92*J708QT?UGBP88H@G%,$PTB4!?4\1+M5-F;#D) Q33T1&
MI<*&B9\;O][>BU(0K:&YMS@ ]-/N^;A0CDR;)N%FMP5XUX>;-78T 69 6S(J
M].:N^KA3,)&S/M946#GMPY$\XK8/&'0RQWVXP=NN^QFC#'/>VULGM4THQ;W:
M*2AW9I.5]474U_*6_+P19:;[1[&R+3O7_G<=A!+$:>)S$4/&> !1A*G:*882
M<BY(R(6'_#2T\=_/5VEN2TQ[@<JV30)9E^FXU)F.%T#MR;3+6).?HM)UF-I"
MK77Q%SMOW\%TFCG\TT[2R(M7=\']8GY>9*(V21QZ?I15H\0CN8/3D5/O0*%)
M_7IW +YV[1V.;._=WZA=1;9ZJ+Z*)Y'K>GK-Y5(DXR",H@@*GTOEMNMR"@$C
M,&218"Q-O90:._![)<R-0'LES=W$_<"==L+/AF-DJNKU YV" Z*;]D-C[B2?
M#=%$?K ]5%8>[E$8CCBQ^Y^;S$\]JO:V*WK\@\.\S<L?I.2WZMG+GUFUH%&2
M,H\PR"6E$#&?*!I+,$Q9$'M1F&"66J6 O!A];A36* >T=LJ!4/I9AH&_1,[,
M1QN,Q\@<9@Z%M1^UUV1'+M'+L2?U;O::]=I1V?\A>Y_CB_CQ1=\S= M#+!B1
M/D(PCI':WJ41@D30$'(4)OI-I3PUJHVQ._3<7E&E'?AB?L.R!ZO3_L5P!$9^
M*=?&#_ H7J%@[DH,1V,B'^+T5\+*9]AO[Q%GX=4#DWD)^Q7==@\.?&*87_".
M5%FE.[B)JI_3RYQ_R^[R3&:,Y/4E8[JG6Y;?-17$,U%M:N*'@1<*E H84QW,
M[,L 4E_XD&,O]0)?^IRE-F[$.<K,C=(:6_3!Q;8U%^#;ZN&!E,_Z#UMV@8UA
MH+>LR3_I.C-F^8M/M.WVEK87TF?-M9GC,]4,CDS)>R>OF9!3D_9]E#8)+F!U
MY(N=I<JDKIL+T%Y[>D[&'%A#3?S8&KPL<O4C:RL?7Y<M3WS*MS_1D<3G=<IZ
M$'E",![!B"JG$@F,(<8XA9[TJ:_6/NQ%PJK6VKD:S8VSM<_Q@F>W3=*Y%\?I
M^(SZ N=/KAD_3SIE$_C-H\^6?0TY5PB[JC5WMC[3UJ1S!=].[3IG P^E[UJG
M<3?)1%SP=\]_5()_RM<7SI>Z^4L;^,<3SC#R IAX<:CV_2R$:4 ]& <8"^'Y
MH:\KRQ<U69KRM*EH*T)>*S#F*UX#INL1:-=+#5R7&=.WL\WO5CHF6KW<F_J9
M9&V(+?L:SXTIS8Z!^.A\6K?%'WJU 7T&O_S1HOSK5E#+Y6F8!]"F+6+.^-%8
M\,1$: O(+N-9CS PDF5_T,S5JBQUOD:$0I]'O@>%1PE$(6&0!NHGZL=8$BYE
M@JUJTAP7-S>?<O/:++6Z8-GK"R!@K<J6@2;'T38C*'<8CDQ*QT+IKD[ 9Q\+
M8H2*JSB/X\*FC>$P,GPG/L/LJ8%EKMB]X*NEN)8?'AZ7Q;,0WT3YE#'1Q'>_
M>YUC<[ELIK>)\/XJ6*$VY/\E>!L=HFN05K<Z$GQ!)/9\E*90I#&'2 8"$H$9
M9(RA6"0L3J55K^91M)P;A6WGH'6E"L%E66J7N>T4^J%-L>3MD>6F".P%N'S0
M_C3XWMAE6W]KE&^ &3^^^;R.3*OME+X;<4KM"X.-";FKBF*CZ#AM*;(Q8=ZI
M83:J,'>=MO^>U?=_Y 6ME'9:1)O:KU7(F5K3&I6^ZIRA4JUVS1GP>K7[)NJZ
M:T"W0*E/8YIPZ D=5A/C%-(HP5!MZ",>!4GBR= L)W]\98W(:-H,_HURYS?Q
M=C2C9JO%&\_2]+5(MNP$/Y2A8-O2KE()>&FKKG/=60L:<U^X\B9S[Z2YN-MI
M&;$;N2-%W[Q]N5O 3?J=.Y8X;)7YVN:1W)"R?KY5?E6ESR:+_'VA*WPO_#0(
MJ>Z2'L5>"!$ERKU.(P]*CX8TE+[@B57\Y5%I<]M.=,J"1ENPI2[XWBILN4\X
M#K49@SL#<&02/@,[:_HTPL01 QZ7-2F)&9G]FH?,'AK8_*1GIX]%^7%5*Y9K
M0@N>WXE<R*RN+G/^1_Y(,GZU)-F#_F?WP[K,2+>96R0$HP1Q'\9QP"%2DP )
M%QQRBG&<!@GW?&K5"\659O.C*+UX"""+$K!&Y68?_"C*IJ.K^AYUQR%DLV>V
M=%K=S:H9P[W)7(W,AFN;FHEJK6I#L9Y!;U<S<:UEX&HSE=V/&^OZ$P^'75=<
M(^ZJ"8LSO:;MR>(:SIT6+<X%G'OR?9G7&>]JW6Q*EGSXJ<M)"=ZV[GQ0SFUW
M9/*!E+ER:77OSN9\I3WPE)X,PI!B**ENHY<*!G&:)# 2S,=^*+D7637 <JO>
MW)B_MTX'?V[;MU5-"/06]EURUS;JAWHKFS:YC9WGGGX[^1;8'GM//;=CGW>_
MP;2><0+N$GWG1]].E'NC,V^7P!X^['8JQ3Z-[&.6*Q=5C?A5,)$U9R!J:*86
MJ"]%?4.J^OU*+ 3RHT0?06!&$QUDYL-48 2E3$B"8A80\^0R$X%S(_I.07+7
M<$*Y5KRZL O+, ;\. ./ >/8!\*]NF"C;],=7FNL<[> UADHI1TC:9[EYAK1
MB7+?'"!KE1QG ].1E#FC829+I+,Q:CN]SNHY>W+6Y0<_Y55=-E^DFU(\MM?O
M-R(GR_JYO>R\_5%T,A<ID812@6$4$P11'%*8QD3J](W$\YF?^-SHJ'B [-E1
M]EIA\-AJ#)KJ@4!FI6Z1G>>9KO+8I=>Q95'I5XCKOAETI9Y1UI6Z?&BEKP+X
MT<__DN7ZM$>C\*LY>]G.[>DE8<09&WEU:$JP;E2_ %NSUVG?4)K2'R@#UO0V
M'MKFR\:(J$^T@CA'WVH]&8C?D:7%=L3)5IF!IFXO.$.'&':ZU/<:OBTNV7^N
MLE+\3['DM\7OI-;;E.>M^M,T2M.4H0@*XC.(DBB&- X"&&./>C[V/182NV@6
M8]GS"TZY40/=DTHT6<%9_B3:$S_+0W]S\,W.:]P".E$=K4YGO1)W6@.M-JP+
MV"L^2NUN:[ <G9R8RYWT4,0:CM?G'?8#G!T)KL34S[^+^EZ7_%N_@Y_72; Q
M38@?HP1&0:A;[)$4IJGN=$ZQ'T@2L-3L4,->]-Q\Y>T#SU9WT"H/MK0_(V'9
M8E)LCYY=0CWAL?*9*)\3+VT(F/L@Z%."WRJRV1"0(^'*IB,,K+JS4EM-4557
MQ0/-\CXBK8MW_L25J$QF^N3ALJI$777\RB]SWE]2*EI5?U,>(^_2;=I/;LXL
MJD6* ]GDN@0QCB#"'$-,$@H#Y;_%81"&@HJ%V@#3PK@^SP1JV[S=V\J/]Y)W
M2>'5UB&Q9=V=*6;;C&7G-H,C\W-O+MBRMPE$[BP&VR:#UI+>*6U37[;,!IW=
MZ\3#[H&+K5-:A^[JE%/EJC;0%"I/6T-HPDG8J34TI>SS>A@\9.WZV,7<1@'W
M:!2'4.*$0!0D :0)BJ ?\0#+, X]/J@OP4LQ<W.YU[7L>S4'QC,? -6,X,^'
M:F1*'H#2X)K^^T%P7*?_E9 WJ;V_W]!#]?0/?'I@='*1W]V*\D&?8GY16G=E
M" 3U$\&0!U$28HAB'D(J$Q^R0/F>)(B11ZPZ6N\7,S<*T%I")>@!<*5GTUO$
M,BIX/YIF[_[Y&(W\[C?P: V;!GT77<25OG3K/:KN\,CIN=]Q6%P%U>X7,FV$
M[%%#=\)=CW_:_F9;%YOYN"Q^M)V4UEUMT@ CGZ(4AM@G.ND@@BD.$8P#S^=A
MH'P1GYM>8.\7,3<6:+M2-C<%364,BZK6!S \?5%\/C(CO_M-92FMH>Y@KW4T
MZ>9CBH_YU>[Y.$UT@SL(+ZM;VN-0'+F,/?#@9'>NQQ7?OEH]\4E[CON:W=W7
MU_):2K61:M,#VO_?%$H.?.$E1%(8$:(\'TP(3!,:0Q8E 8\%8FED'%AY6MS<
MN*_16#-?J[/YFVV [&D6=(O7R(SX"JJ+/G/I>_=?DTK20V T)TNW<$Y$G =@
M=<.9YH@<X4^#02;C4G.#MGG5XJGS<EYU*$3  X_3((#"PQ2B0#*UE52L2FF$
MI<^I$%3:E$/=&MN*/2>H=WJK9:Q+!%K7,=U&S7#+. R+L?>)!@ ,3L=T'^"Q
M/?*;I$0>"=+8]Q$753[_+C0%"'[YI'Y[)[X*?934_U%O*_T%];G'!$60,_W>
M^IZ$)"84AH(%+,8H#JA5N7E;!>;F&O4: ]*J#,I>YZXTJ#XX.J<6J,&<&!XB
MCXCTV,?+K^N%KE'OU =K_=M/@-MCJ)]90M0<NE&*BAJ(?\,RH^;@'"\\:C'.
MP "T_<7J-J4?WCUO/M)%Q34MX3ZO8Z P#P..9 A3$B00>9S!E"L?1@2AVA#&
MB>\'1H=@[E2:&SMN%QG=MFF[+*4N2+ZW&&G3UO",8+;S)]B,6*>=MI&I=KN&
MZ.D9>S=TQNP#XYR!["I@[GR%I@VD<P;@3H"=NY'MJ+PJZ\6WFM2-D+^*XJXD
MC_<9(\NFJ:OP0Q+'6, T"B14CJG:8?*(PT YJ3&3B8_,NGH?E3(WPMW6SZHQ
M[G$LCQ.A,X1&YC8;<(P)RLCX8YRC!MCB&_6O#=<<'WL2^C RKV<$LP\[;;73
MQO&^:'RQOD"BQ(M23%(8,!)!)+T4$D$2B ,<81HP002V:XUFJ\+<Z&%]_U3M
MZ0?S*?\5K&TQZ0?C:I[,W*QQT1^9>DZTX=D'N].KP?-!'+<SSS$%YM"AQP @
MPTX])B.=EW_0Q(Q6F7;"-O50KN7?"BWU4ZYX1BFPCBS5G7S2$"?Z'"\,(1)^
MI':Q<01%3)DD'DVDL KJ&J;&W)BR55.]G)V>@'2*#LL2L)P3,T8<'^F167$=
MR;]EP3IKO2OBTTW$VHQU)+_[H/QA.#H.L[=4XDT"YX<!=2@4?N!H,TC24O2N
M_J#3RI[(4@??+N+(\[TH"&%"_1@BG@A%JUX$9:"CX@(<!]@J2'Y<=>=&NE=]
M5\BF%:38*/J&J5F[<VQ'SF\_<U.1N.-TK/Z[\,'@:_"V>5@'9V>.&5B[RO[S
MYEX=!'[4K*O#4L\O!6]6B[C]]8WZY(TN?_6_!2DK?^&+U"<!BF"4H$"M/;&
MJ2 Q#+G B?H=]2GN2[O<#JL'?X9Z1HSULOK+[23EQW3]L&>EHBY=TI0)>VQJ
M\PPO_'[.'-H%^$PQ)6]1]-VBLOM%_R=MFZZ(I:>S,6^<FN\.X!ZAXOLY6KU9
MO7<'4!ZK]NYB>/M8\N:FZ[Y8JD^KH?7F1B\V^F),"<KKW\4#%>6"AEX<"1E!
M#XDFFRZ&NH4I%)0Q'4*0$FF</F,D<6Z>_I;2H-$:M&J#M=[FT=%FD!]GUE&
MG.*J_BB&X'NKM$6HN1F8YM'FSD&=*.#\C"^H5>RY%3Y'PL_-QIDL MW*K.T@
M=+L'[?B9BVSQ0;GZ];/.ER[R;W7!_M$(K*Y7=54K1R/+[Q:)CX/0%QQ*+TV5
M'ZV+\^* PECHI,>0(T72)N1L)FYNS-QJ#%J50:/S11OM4X$MM9MBNE7S:\-:
MNH;H'^=I]YB.3-*&<)Y/)G;([/%!*\'^?%<\_:8&:MU/]</&ZS0<?A*"L3.U
M9Q?+I]SU(:[6O_R?F2C5D/?/7?4/@8CG!Q1#G/IJQRYC"5.>>E!B)@-/4-W6
MS>:TV$KZW(AGTXH6K#5M]GY?+O\VL.B*W6R8[;U'PWAD(CH/7B=M>D_"-&+G
MW<.RW[R9[DE83/KCGAYD:,O;IV+YI(CQJA0\JS\2UNRO^WT %I&'4 S3,.%J
M'ZM83!&8VLPB+I03)66(C&(LC:3-C;#6RH)66]"K:]OI]AC"9J3D#+>12>@@
M9*=WJ@,ZW1I@XJS3[3%9$W>Z-3![M].MR4,#:].7Q:,HZ^<;]4VHNXN31TU9
MF^1U/XH"&20)Y*&O:"0F'%+!$YBVW0Q]0GA@5]3TM%";MV*:DJ3;=8=[_=<W
MH(WREG7I3P-OQBYNP1R98GIE+T"C[DL N_9^1E48[$O1&\/DJ@;]:8'3%I\W
M!F"GZKSYDX/=&)&O1-NE+V^B+?^>U?=7JZHN'D3YNII&ZD?(]ST/(C^.H-J%
M44A"M3$+HC")4\%]:9?99R=^AHZ.UKZ/Z= '<M8NC@WZQC[/2)B.[P0U<'8=
M25O5P0^E.^B5MRH7,\0S&H"<.U?)1OC4OM, 8/8X4T-&L3_+?M]=A=RJ1Q=1
M(GR$0Z%V83K=3<@4$A\G4&(L:(S]1/&7Z:GU]L!S(Z->-Z"5,S]Y?H'5Z3/F
MH0B,3!UFQEN=&>^S=-#I\(N!)CL'WJ?^]HGOWK_;7^O?DI];!;8O[THAVFY>
M3;SRM51__T;T!JJZ+=X)'4ZPH %F"0X9C!-?YY^F,22Q%##R>,!H&$>^9W2-
M-$S\W%[;OL^IVMO4Y">H6FUUS!450 =JF%]1#YB+XR_\^ B/3 M*N>UV!6"M
M_J:_K,)=?ZJS =P6X)UH8J9&Q=T\3F!<_"<*&AAE'JS""8;#>"2V8,"@DP4:
M##=X.^K@C%'LUY)/.2MU%9OWHOWOI_R*/&8U6>I@Y-YCO"JJ^HNH%Y&,<$(9
M@EZ ,42,((C]*(6<LM0+4<RIC"V">FWE&[UDTT?MKG=-K- ]@IN@;7,BLYJ
MTTN'<SRG631ZM<$OO>(Z#QELZ;[9G&KM+\ 7F]*O5B";KQ-C@3W1"N$6=*NE
M80AR1Q8%J^$F6PZ&&+F]$ QZ?F"HR&Y+^JIM"]SUHV^KV @44J&V#8$0*40H
M]"'U"8,!PHC%/* D0E8A(B92Y[9YZ)0FRS9];-WD6JL,E,Y6E6[L\#<[BW2.
MZLC<OP/HY9V^E'55$V<0+*Z"/XQD3AOT80/#3K"'U</#J.A*VZ&YK4F,RZI_
MO!,YNW\@Y3^ZT"B6<BS3&,-4<1%$(990$4\ PS1&1/"4^QZU8:%3 N=&0"_T
M!5IAL-9X8&S:2<S-F,<EDB.3SGD@6I./*3*.>.>DN$DIQ]3XUVQC_-S0:]BJ
M+E=,MX/*[[0;=9ES]3M1/K6K;>0%(I$X@52F#"+!$DBH+V',(BIY&++$DW;W
MKD?ES8UF7JC;G/$/\FQ.H6QZO^H,N]$O5&UA&W!E:@2&LSO2X](FOA0U,GWW
M%M3LL<&;IZP6G[,G75*K5E^&;)V\_SOYCZ+-'?JBOC/=8DH(XT)Z,0R9AQ6Q
M8 9I3#V8!D$2XS"A"%N5K;>4/S>B:=6'C?Y@8\"Z]W%C0Y?WIJT8&G]O.4O&
MFZVQL!]_V^48]B%;LB'@N=N<64F?>ILV!)H]&[9!PPPL8R]T@7QEGZ;8RE_$
MC,N XA@J=RF"R$]TH[)(P%A(DH0HDJE _7V!&=6]DC#@1F!D,ELKV-P&6-:*
M>HV?&04-P62BI/ U&%='P; OP+[?9%?5U%^-/FUI]/VF[=0Y/_"QP6'Q3 A>
MZ3 Q'>ZJH^WK^X*W]4'U5<3[3!<.S7EU7;[/E#.5T97>E55?A7*J\FO9G4RK
M39/P"4LY% FA$,4R: MXIAQ'*?,#%MLU9G>FV=R\GE8]?04O&K/ 0V,7R-:&
M69*'NSDTHYTWF9F1":NWJ0V';:T"K5E@8]<%V#9'EY?KI[*SR&D8OUN0W47[
M.])KZJ0 MW#NR1UP+&"@)]87ON^+S7T3=PVG-&<N4K)$2$2AX%SW.XP9)"1"
M,,),)E$B"!)&#62-I,V->'O=!IUF'<?5T%]SA=;HWIL94/;>FPD KGRYH[*F
M]>Q,S-[Q\XP>&D82[P55=%2Q9:$3MS<I+Q$.0Q[Y,>2A+@B&B \)375],"D)
MCG&4A($-/1R0,S=B^%SD=U!W2 1:83M>. 2E&2,X &AD+M :@HV*X/LHN4 G
M<'!$"8>D3$H&)TQ]30.G/F[?JTIY*GS%:EV-\)LHGS(FJN[@$\4I(S024'AA
M"A&1,20122&./(93$1%*C K!')4RMY>_4[3)T.TTM3QG/@[J<2)P!M7X^R-[
ME*RZ5YU$X8SN58?'GJQ[U4GSMKM7G?[PT))SW^[%<JGKV)'\>9$@/Y*I;IO,
MHP0BZ4N(<<(@EL)+62H09T;74?N'G]N+WM5 :U0$G8ZV->->P'?\S3X?E)%?
M:2L\!A2 VV?V&07?7@PW<8&W?:;L%G3;^ZEA#OIN / E8^5*;!>"7XB88>[1
M!+*0^6JY3CV8^EX(:80%]KP$ZWHE%MZZB="YO=2=AF"Y4='.?S="VLR9=XW?
MR.__OB2 + <]HI\-$+7V\VT@<N3T&XF<= =@ \+K[8#5LP.OA-K>N-5MT36@
MN*[O1=FY)-E3=XF\P R3(, ("E_H^QZFG(<TI9!ZDM(T9G'(H@%]'LRD#[C^
MG2(A;'/86^E7J6G;EI,E7*FWK"ID_8.H';1VH1^5Q'LU?96^.WC<KK(D!E99
M,ILTPPL>=W,PT>ZD4U@G<G<J@T9GL%&Z"V]Q>$-CA9*KZQ<SH=/>K5@!L7-Q
M8O>TH]2"I@#7(D:1VNEP"2G&$41>("#QHQARCV./)"E7#M99"06-F+GY3'LB
MX-N"9.?F#K2@FG',^5"-S"D#4#H_.> %"&.E!+1"WC81X(6A)\/_7WYZ8'\K
MH8A$7*N5ENB.CI^U][1NU-*3T/N5^")^UK<_Q/))_%[D]7VU((@'?H1]B'W$
M(0IH#%.A.$,2+"3B7F 9V#)4D;G1B/JBA9;MJ89.@1FE3 'LR*33FG !UD:
MQHJ+]6[L^:(K5M,VFM*-@L!U[J (DRL07;65&JK&M'VDS@1KIW'4N>,Y:]G=
MAK"LV]Y^JBJUQ[PN]7\U%W]9Z9*\U[)M7-#^=<%CQ'P_(#"*(@(1"A1EAG$(
MPR3P$8X$"KA5<(D;M>9&FUUL6=_2&V2-EFJ^FI^T%1<@;^S0>\.VMXE]FQ/'
M4VM&P--/V,ATO+\S>#>#O5'@TWH&/ZUG\,MZ!EO31FT3?@;(X[4-'Z+46[<1
M/P-(@[;BYXP^-,[G22R+1WWXQ>[S8EG</7_-[N[KJBOKG_IAC*705P8"041]
M!+%'4TA"7V>D);&,C(H#&LJ;&Q5OM+2-^3D.JX]3&7HLAD'"*$0)CR#Q2 (I
M3U(F T:#B-H5DG<([#15Y,>"UFPA<@C7R"O,6E.P416TNH[0C,(0%V?A5L>E
M31QV963Z;OB5V6/V]?=T8->G7&<G-S7^2O'8^O<W(B=+Y>TWQ574UJZK_K>(
M?2+#*$Q@&$4"(IDJUI9^"%,4)%Z$@S1,(]-"KI:RY\;;&X7!8ZLQ>&PZ+JNM
ML<Q*78LOSS-%=!4IG[4/IJ/G]&:Z::RM?>G'UC!#9WK(=!TGJI$G8732HLKK
M7:NN^UVO)Z33?ET<2QFP+CLZ'MKFE?M&1'VBXGW.T;>JWS<0OR,E_&Q'G*R*
MWT!3MPOY#1W"/JKW4LILF>F+[C88J?.7@I2'5*I5(_92K$MF44A3(:!$*$F4
M\^\3'YN&].X7,;?%8:,E:-4T#^(]@.%Q*G>#S,B,O0.*0^?R- !G1.X>&'BR
ML-WCAFW'[)[XI/T;?57D5;',>+.<?*K%0Q]1CK$?11Y*8<BX\@1UMPU"U"L>
M^2RE@0BY#(UNK8\)F=M;_4)/T"@Z($K_(*2G7W$70(U_8VV/D=5K?@J$,U[T
M@T-/]JJ?,F[[93_YV<%A*CN->IKXE\M\'>#WW%R&;Q+-9!*2.$H83$D:0Q3A
M!.(X4.3 _4BD(0TB9E6L;H .<R.+[1:&^SM;7;318$W$W=HHZ^@7Z[DR.[T:
M>0;&9Z&]@*]_W]7Z7?][ZVI;3\>FP.RH;1+/ -E=7(ZU!E,'[0R%:$]$S^"A
MAG<D:[=7'W+^7KEE"S_!R LB 4/?TS6I2 33*,)0$C](N!_P)$UL6Y.]D# W
M&ERWZ>H. Y2:0.MIWZ[L)9#'6<P)/&,?8-DB,ZB7V5[KSVIJ]G+$R;N;[35H
M7YNS_1\<YA-=,E:L<AT.\ZU6ZP,I>?7'HS[(50AY7MR?<\04AXE/8(RX>KD#
MSG7L20SCA,8H$2%FU*COH)74N;WP&Z7!6FO0J@VTWM"+[7P<,^S-O!KGB(Y]
M9'(:S!%NZ*Q0<N2(F,F<U/6P@N&ULV'W\$!6:O-I8E]Y%512&),X59LOGT%,
MO 12PB2F@H8LC1=U49.E(>U89]9L!A_Q,E_+L.IO]0HF0X:86UJ1ZXRA43*"
MWB+CYWA&CY.,G3[:]6-1?B[4@+H6@O[ADO_'JDVQ^_#S4>256 1A% LD,,0L
M#"#RB(2$)5)Y^-277IB*-)7K1$3S5]%8 :,O[*M<Q,E>6K8DV4-ET=K4'G^S
ME]LMG!-%X_<[4R"+$OR1:Q1U76R-J#ZJZ'[<F  Z&R[Z/[EIJ3D80\=)AZ?E
MODG>H3$<AU(/S0<X-\SGJ^@S?Z^*)Y&3O/Y&EN*FS)BXK"Z[6V!R)Z[E59'K
M ):LR)N_+F3D)1&1'L21]C28[T&:A!PFH62QC'P_H$;%'ASJ-+?MS\80P#I+
M+D"E;-'104PH!P:0/O)'V=,$!JTM:C\S-$)E^+Q&J9\&.! P"<(8(I$B2&4H
MH9<(B7V$2"A"LUC1-YK9:>))'<PM^(748"E(-3SL:_@T'U\DWVCJQCYE>QVH
MM#6)5^M)U':!1G5PJ=92L+$-7#?7-_TDWKS-"SHTM&R2&7RKD+,Q9_*,<+2S
M,3<.4QLNZ8W"U\Z&YG!8V_E##SR#62Z+'[H3@O+?WA<K6LO5LCO[J3:WB'\O
MLUJ)EM4BBB(?!9Z DB8"HA0CF'I!#/V84(_@-/!BH_*6 ^7/S5VZNB?EG8"%
M4LWR4,<2=\/3G_'0G.:DN-JZNKX :W.:O>-5*7A6 [VYN "-#0IVAP=+P[!S
M=0)E*7W:HZIAT.R<:0T<QD5][DM:-9?G"XE$$@G$(!8(0Q3[ 238\V& $2$X
MY")-K?K?[A<S-Y[:J4#=*VI9KN8 J&;L=#Y44SC;=BB=6:7[-0BC%.E>"WG#
M&MVO#3U>HGOGT\,HX ,I\RR_TTVVFX3@]?<U\&./<H+4J\]"B%A"(?$%AQ@I
M)R804>@3JRH+AP3-C08^Y:QX4)MXA7+UJ][JJPW^PT/1U46PHX*#X)J1@0O(
M1J:#7D6]"6M+$(S""*>0<,0)!\5,R@JGC'W-"R<_/[@VL'H1UNU!/NM)4CNJ
MI@\-9=B+(J3+V/D$(H(X)&$0P3A16]D@]@EC5A["$5DSY8>UKJ!7=E"[GV,@
MFY&$(^A&YHG!J TI_7L*#W<5?P]*FKK0[RF3]]3W/?G(P-.2O,YXMESIFIK?
M!%N53:W@#S_9<L4%UVW+=.GR57N4>"U?D]>[Y_T#-&]$1(6GW \?TDA?P4<$
M0\J5=Q(BG$1A[".&D=7)RGBZSHVVMC4%&U4'D=:84VQXB#./B1O[P&?8G-D?
MZXR/IJLCH!$UG?:X:'S(=XZ6)A Y;,FX+0D7NZ=<7=AO+%&2),K#]/Q ;41]
M/X%$M_Y->1@$J<^1Y+$-Z1^5-C?:;I0%>TY^[1C[.,)FG.L,MY%9\R!D(X11
M&V'BB/N.RYJ4O8S,?LT_9@_91SZMZ]DUWZ#J6GX53R)?B05/=;<(ZD$11%P1
MAXP@95X"$>+<9YQBYJ>FH4R'A,R-+S;U(-LQF\8/9:NK>4S#04B/,X4KH$8F
MB ZC:PDZ)?6/7YUA9![(X0*KB2(S!F%F%6%Q"HPC(1,''YTL!N*4\MM!#2<_
M.[ A]W8=7<^/4>#S$!(L4UT9TH-48 X%"1.DFTYX 5H\-MESWVI2UF:>T]#J
MN:\%C?<U?2?NLER[K8"297,K/KBB\0L\=<9-HC-Y"9=4+2!2^:!2AC D*2>I
M"+PD\CL\/^1\"C1[,2,>[>?</9!FKN9,RS2W:EUTA9@=MBL?KV#RVY4]-BE>
M[+ $\6Y[LJM56>J:?33"1"!.8!SY""+,(EW"1,(@32A./"8P3NVJY!Z49?-=
MG2:>^>R^A8=QC5$4<3]1_C36_X>4HXV91#")<()$' AIUL79*:K_%+T@#V-J
M>/KI JFQSRYWVSM>@$Y-IVG,QY%PE[I\0,[4Z<K'S=V3HGSB@8'.9E?Y2#NO
M.CR7U:M2.0N7.?\JECKS\*JHZJKMTR69SU$4<QCS-(0HUF7@!8HAQ7["PSA.
M!;,JF6 A>V[,L5TPZH7R746B1GW0Z#^L59K-O!BZ8N.@/;:GYA!H>W?.'C)7
MWIZ%Y&F=07M(=GS% 4,,([<OHKXBU?U-63QE7/!WSW]4@G_*/V:YV@AID;I?
M9-NP.?$3*3FF,/(]I \6A>Z*K7:('DLB'E.1(F13E\%<M!6U39 &KC0'3*G>
MO&"Z[TB9,?V.-;][[.P!]!G\LE(F@2S_%<C>*D#69MG1G<5,F;'=./B/?9ZI
MH-=:@YMMF/_H85XK#RY/PVQ-=O:(.>(Z"\&34IT](*^9;L ( UM5%OG=K2@?
M=&#Q1Y*5?R/+E5@(DG+&?0S#6 ?^BECJ<!L/!A$C5 J.8FQ4RONHE+EY9EHQ
M\*0ULVPUN1=",[(Y&YB1>47K![6"0&MX 1J,_G84(_LVD,<P<-7C<:^,:1LX
M'C-SISOCT0^?6]WNIEAF3,=M]+'H48C]-.04IJ'0I?MC_5.<PCCF(L*!"(2P
M*NQ[6-3<7OJMTFN]JH.S?HX ;'RHXP"V\4]UAB!V1GFZ0V XKTFW(^B-"M$=
M,OAP];F#3PR-^V\;!W8U:30++5(4(1FA"!*<"K6[H2&D/@H@BCVU \(4)=RJ
M@=\>&7,CAW7;3='J:!O7OPNB&0^<"<W(!+!&95V!2BOH,GK_H/7.HO9W)4P<
MK7_0Q-TH_<,?'9CN]_"X+)Z%Z,Y,]EQ!A*&7>*E._O4(4B]X'$ 2^Q$,J>_'
M5)% F!A%31E+G-N+W]]<L.)!H]YFJ>A3#=%9 JC(A<QL:U2>AMZ,()P".C)=
M]+K"LCMR'?<ZR!@:5_F")^5-FSAH:OY.!J'Q@\-8YV^DS/3!;--H7I_3+FCD
M(>HG'L2!KJ,=^A)BZ1/(6* <BPA'-+2Z/-Z1,#=6Z15L*H/IXF*589O"PQB:
MT<59R(Q,#VM0&N4NF@L9=VQPT')';__N^).^[0?->_UV'_[@P&/#+-<UEII2
M,UT&@? %I5Z<0IH$GJZ(FT"*J(1I0E*AM@@B]JSV![LBYO8^:PV;OC^-CI:'
MAKL &IX8G@7+V,>%+Q 9(=GBL/6N#@IW!4Q[2GC0P)TCPL.?'/9.7]?WHKPJ
M'AZRIAYMFXNI9AP% 5,O=!#HBM="Y_N'/HQQF 8!X;%(A,U;O4_(W-[K1D>P
MI>2@#-F]<)J]X^>"-/);;HV/]6M^# !'+_I>$9.^ZL>,?/VR'_WLP : #7/H
M,G'=K2)9;NHL;OK(I9XO H]Q& 6)\M+C0*WH/ YA(@-/) D726@5NF4F=FZ4
ML%54SS9 P1!G,V9PC][(7/&B&N%:YZT"K^#[.#WWK(!RU6;/3.BTG?6L@-AI
MIF?W])":]:SQ74)?H1EVGK",4\^C*8*^OI-$)/ AB:B /I9)B@1G/C5*]SXD
M8&[LTNL(0O]"-WP*;4I/[\'O.)>X0&5DUM@!Y/16P@P9FPK;YR$T6;ELTZ^.
M9:WKP]8?+5R]Y[$)JU ?5OIE2>DCGSNG4%K#DTT1#7TIN\KRN^M'43;?@.J=
MD$4IVL_=DI^ZZD9=$B5#\6KYW/1U_J),U,U+BZ62=-=?_"Q$HB.NHA3&R&<0
M)2S16[ 81E*&,:44!]*W"3 =45<K8IT@(E4;"?271'=HZ,P$Q=I.0!M#0=96
M)JNUJ4-JMXTS[V8>X4QF<^0%H:_(^;FIR-G,Z,94<+TSH]WG&W,OP$OS0&^?
MZX)SHTZ"TX)UXVCZ!@7O1H5\?\&\<44.[&!7"MTPK(L1N,QY<U[0-L?K;Y:#
M"*N->\1@A.,8(B\4, V2$/(HB4./T B'5L5\#63.S<_N5.[#>=K.:D5SFL5:
MC0=UGC1!GX0IY9Q2&/A1 !$7$A*!*/0"Y',:H3 ,_44N#*LPN,)^W2IP[*(,
M;XB\V3+J^-L\\G+8P]FIVZ#9GLJV&H\05V$!D*M6@ 82IVT": [!3OL_BT<'
MIN.*.[W=?%\\D"Q?1(P*W<X-IHBI/4.H]PRQ]'73-^'AU$=)9%6<^<7H<Z/U
M3KD*?&_ULTV8?8&<&5T,QF-D8C"'PCZE=9_)KI)67XP];5KJ/K-V$D_W?FAH
MPQ4IU O/M[Q$Q0?JO^U9:[4($?(2JARU).8)1+[RUK",.)2ZV#$*>!S:W;B<
M$CBWU[G75^_'^SA+V_8K)R V>\E= C?Z@6F'V?;&MW$+U$]=.(;#C$]39)SU
M:3DA;N*.+6;&[_9N,7S.CE>JLEY<K1Y62Z*+\GZ04K#ZIJD/=BTO>?&H-Z:]
M5R!QBD.=JHYQI-N7QY#&1.T(><II2+GG!8D)LYB+G!NW;+0&K=J@U5N7,NPU
MMW0C+/ _3COCH#KV_>YK0"]Z1 L;1(T9R!ZD8QRD1MOB'_6O#?=8")J$?>P-
M[_EGP)/G5@3Z:U'P']ERV5:9"8(@%'$BH QT9&CH$TB02& D6")8(*2/K *]
M#\B9&]=L%Z#I%3VWI,]+8 WW*N?#-?:N90A29]3DV8N#\_H[+Z6\4:V=O:8>
MKJNS_^/V81V?\JS.R%*GL'\N2/Z1,)U,\MS=PB<!P0DA D9,N2 H323$+$PA
M8X+ZG,="^$;E)4Y*FALE=,J"IJ*"5A?T^IK'-1R']C@E. 5L]"N_0U@-" 8Y
M#IIY5(@S\"8*#SD'1*N $2-@CD2.'']^LA 2(S.V8TG,'AA8L..A*.OLO[IF
M+.O:/TV1,[5SU'U FT8*BR!F(4^3&))4"*A3YV"*_!02[B=!&*51X%D%Z9L*
MGAN];NNM?8GZ7@"NF]7R3N/F1$3_-JNJ55/26B?AV99N-9T6,_=L#+!'IN;7
M.#<-@3_UD+8E%372:]T=5@6Q1,M5C1!3L=-6#+$$8Z=^B.WS;OH+;X+>J8]1
M$*$4RC"*%'%) K&7!%"PB$@<)!39]1 ]*&EN3/4RGNFF2Z=1;].W\SL,V^84
M. %M9,;9UV-XE+R!DV",U&;XC;(#3II[JM'PN3D ^G#J=_(?17FUJFKU2I1M
MGER<I"+RTAB&@<1JAR@I3'T60\8)2S@A"3.K0+)_^+FQ0:^<59[A >1.GS&?
MA\?HY\EF4%@=&!^V^(S#X3V#3G80?-B@[4/?(Y\:FO7?%@5Y_BHJ43Z)#U6=
M/9!:--7'GA>$1"@@'H?<"T/UTD8!Q&E$8$)]E(3J?X):75P?%S>WE[A3L@*R
M4*OYDF0/K1.LF%+]YD&[QI 279'WLBS5@TW39<NMQXD),%OOW<$Z,A>L%06=
MIJ!7]:(M/?@,OG?_'<47, /*6>&!H\(F+D)@8OAN00*CIX;D"-*ZWUTV>Y,O
MHM:_T[UJB[PI6,9PDD8A51L'W8<FX@324#+(19Q$)$T2/XK,$P9/2)L;\32[
M[Y<'&A<@%_5%>_;!>KUM4N=. 7[ZF-DIC",3S9[SBPOP12/8_.5J# 1M,A$=
M(CE96N*9B%IF*QHB=#1U\=08$^8Q&IKS,JG1]"%[ O[PGRM%Z^N1KN5V>>KN
M#@7[7N3)Q(/$ISJV* YT]4@"O1B'0O)0(FE\IV<@;VXDW*J\^6+K8U&M-5@7
M3S<G#Q.X3Q.P8Q#'/N YB=^ 6S\3(,UYV#&@$S'Q&5],*PZV0.<("YN,,AD/
M6YBTS<0VCPW;A[];55DNJDK)H%G>?(&^"E;<Y=E_"?Z)*Z&9;,K]M0DFETQI
M5 I^F6^7]51_4]^_%[_IJ]7[89**M&V722'2_6XI0ACR"(L4!3$.?*O[Q)'U
MG=M:L*6BSFK36O_%;I\_]@2;'13,:-I&7GUZ2\&6J1=@8RS8MK;+L0.]O<TI
MS_:<=R9?O/CE&"T2)IH@1R<<8VL[Z1')1-"_/F.92NS@*BBE+C#[7K3__91W
MJ?'Y75-X=GU"M! (B201*40T4?^GPU:H%V#HA6GJ,9RP)+9*1C>6/+>U8JUF
M5Q1Z<$-A<^S-R'\41$>F\5YG\$NO]:\@R\$&XT;S-2T?#KH<4@#$#BUWY3P,
MY4Y=G,,.CCVE-BP'&,987;7[&U+6S[<ER2O=AK+(/RN2;:IU+!#'81!SQ4S$
M]R'"7$?5L4!G,7"%C.\CLU)TI@+GQD]]G]Q&8;"E,?BN=0:-TI;I#"=!-V,H
MEU".3$QGHFA-1Z;0.&*AD^(F)1]3XU]SCO%S [.C=+C,.WT!?+7556;[+OC=
M\^8S-^19_^[R!REY\W^W2JIRXV[4]^J+^J9U&86>2+'P!8*A),J/XJD'*:8$
M)HJC. DEHF:GKF,J.3=*:S0%6M6A!2/&F$DSSGOK^1F9)VVFQC[_:T3L7"6/
MC:'BM)EG(X*\D[8VIJQA)/]7-4355@F_SC_\U/[J*JON'YISX*8#8!2EDD0^
M@9$0L7(H=<,4GWKJNY R]0<1L,#J;/6DQ+G1;U.34WD^XH6NO^D"2<T$Z0L*
M;GQ?9@Z\C#P/QW$(HY1BB%CBP]3C(?0#WP]IFGI1@A:YN-,^P.W4^*\+L;T2
M__;3T(22N)X+'X5A@(FN9JM\%Q1R 4D:(TACE- P\IB/V>))E+1XD]=@6_)_
MTQDP<S><HCJR[Z!U[1,J%*HOM>VSE-QY$\;0.'(-3LN;=)TW-O_UHFW^X,"V
M)J2ZORF+IXP+_N[YCTK7V_F4/XE*2[I4.[JGYG"UR6UJ"K@*OJG?ND@%QIPK
M3B(T]"&26*J?1 3C-*51Z(>Q1T.K;B?G:#.WE5L; ^2R^%&!E8YC5N];UML"
MR-H8R_8H9\V7&8U--@LC4UPS ;TA@#Z#7_YHY^%7L#8';.RY -L6;57)=MAF
MQ06RKKJOG*7+M$U97,"VTZO%R:#GEO[YF.59+3YG3UI\K;Z]V?HVLBDJLLE.
M3(2,?<9"B%-!(8J(;AB)(NAC$DD6BB!)K.X !^@P-X;=+H2ST;P+.!A:,\A\
M1H(@]3'V4BB)+A&>>,HCEVIO2DD<J5]31%%DYY://"?3..I'9T6YE37)EA/,
MCN$)X;B(C[S";4/=Z@\; _;@WM:'&B?SYPP0G9>1,M?@C4I,64-TN/R4_5 #
M-PG%P^-*$;H.U7S46X^^AS&F) PX@Y1&'*(0J8V _F<<>#A),&'$MZI4=T#.
MW):=7DUP3TK^P[H P2$T#9WS\S$:V^WNX5FK.$)GXQ,PN/*1#TB9UOL];NJ.
M7WOBXP-;IK2';-5MT07)]:%UHOIK6535@A*,DR"5T,.1!U%,8HA9DL*01W[B
M"Z9^E@/.BT_)G>EQ<;/U;'I.Z/3FIE>'VO(K ZJL;;RD@V!I'T;+-N&)MAT]
M3DV+D (W\^ CCT%$1 2IYP4P]$,4A5XH*496;6Q<S,?$AS".(37C:9= C4S8
MO:J@+OHH;;#1]@(T^CILC6*(C*N^**?$3=L4Q=#XG8XHIL^-=!';MNKZ>ZG\
MS6LI]>_:ZNRO\RAU;GD@$ L5U\04HH"'$/. 0AX$'L*>1VEH5#3=N69S8Z8O
M:DE8[KW3VMQD93E;KK@^II1"5.V"HE[2I<C5U%HN%>ZFV-%EV!@3-X=+LXN^
MJV)CFOJMW%_T;\++-5NHI[J$,]9K7I=UMG!:7^I9"[!C?2ZRQ8>\;FJ/W&4Z
MER6O=4S/@OF">"&*(0T# 1'S):0!1C!! 0MP$ 38#TS(^Y" N7%PJR/8* FT
MEF:\>A#$X_3H IJ16<X2%6.Z.F7Z'M:I!/OS7?'TFWJT)1SUPX9G#@XX"5V<
M,J=_ZT]^SD4/[?W75,K'N):WY.>-*-^1*F-->-\B$'Z,(\ZAST($4>0+B%,I
MH"=2+_6I\&).[>XM!NLRO]N+%W? 6[VO?U$K/R^62U(J/TR4H-+J_WI.^VN;
M*8L$$3R*$(R\2'G51 801P&'A"<\5?OY%'&KRJ^33-@DU9SV3Y?RP;3*;SQK
M9H[R)',Q\I*QI^'X@6"*OM+U8U&19>,8[_]<4_](_UU9W31) HWA)RK^GMF*
M? #XHS0:M]'C#=N(#X#K>)/P(0,.S614"W'&:L'U">%ESMO0C^:,91'$7'WC
M0P8E(4WN(H48A1&, ^&IA3,,/&E43M=$V-P(=:,K8/H06[^NY>9WV49SVRS&
M(X";$:4K&$?FPBT$KWH$/QG -B!M\?^P][;-C>/(FNA?8>R]<6]WA'&6($$0
MV/WD>NOCC>HNWZKJF3C1'Q1XM7E&ECRB5-T^OWX!DI(H2Z( "J0Y&W<BIDN6
M2&;F ^(!D$AD7L8CV)'%#E$C'U>\;/3Q446'>WHZ3IL*4-5##[?@MS\UV6:1
M@BR%UAVJ)04($4,J"19 "(85@V;.K9V2;GI+GAK#;+7S=%\Z ^WHGAP"OJ'=
MC]MB;S6EO KQN=D5@QLGWZ\W@J&\BLYRQ_4:^L)QY!7T?D#/X-,-+]4_-X;\
M/OZHMI1:(:9<D336 *,8V<-&&E#."5 TD2PCD"#M%V)Z3M+4*&FO:%1KZAF>
M>!91-RX*@M/ W',$T4 512YB$2IB\*R<<>,"+YE[%/UW\8:^[L1RL[+["KNL
M=VDJ4A;S'&0RQV;"(A) J<8@(:GA 2V0SKQ604<2IL8".P5=LL\Y@NCJ KH"
MFL%=.QZH]/"_G+$\F%_E]?-']I><,>_8#W+NPIZ#_%*O;6CJ!_5#S9?M,%.N
M,19*"I"841T@D2K *86 \(QJD1+&3+?V.[5P3M;TO/MF8J56"S8'FU)%9:-W
M)/>*]ZEP>!YKQ^$_!'Y##_];K%I*#A#6>Q&*4*/_63GCCOZ7S#T:_2_><)T;
MX]-RI8J'Q?O-:J46HL[K-*^\L#9FP;II9P32#,4P-80AD<UVG-GP?P8D8EDN
M24*RO)<?X[+HJ<T7&HTCT:@<K?<Z]W-N.,#OY]T("^I([HV;:(OL5N^HI7C4
M"L(*[\QP!RRP-\-!\)NX,]P!.>?/\'A"S^-)3<VV*B.=W3!Z+)[+9@2.8Y3#
M3&9 41N3JFWF7&9XB\<XUAG.8AY[Q;]WR)H:/>UJ Z[:NGJ>5>J UHV) @$V
M,/7LL#I0<XAS2Y?A"'5VJ4/2N.>7+IM\=(;)X9:^(8^W4JYL2G#S\<OJ^_+/
MQ4P8DN"0Q "J/#8<D4O *,(@C35GQ"R.$'8JQ-@A8VK<T(3X-7K>1%93@V-D
M=?4-?SP&M)L9 L$T,"/T0JA'*.19#*Z(ACQ^YL@!D6>-.HZ)/']ISZ*K-M_U
MOG2'33F=$Y2 I$Y(#05@&$N09I1RD9@?D5?@W.'CI]:M:^UZNR]?8><VP/='
M9. >[ Z&?ZG3DS:'*FUZ^/!Q2YF>-.RH=.GIJ_IUV%VF^H]_V:2DK?=/TE1D
M0E.;^]/TW3B#@#+S27.I:::A3J27I^&LI*EUXZU^?KWW/)!N'3D(/ /WZ7UM
MBJV2@_3OBU $ZNKGY8S:ZR^:^YH +M_0<]=BO13_L ><E/RP69GGWZM5L91_
M8_.-V@=Q55=5.8FKR-!/RY56Q7ICWK.92K$0&4( <88!PAD#--8)R+,$0HP@
MCY571I)K%9H:L[1B$TNK=+19%.LRLM%PM@+7H@ZYKJ+DR^C/8OWXJ.9U#H,U
M^\N7D*YN3<?MDQ';:.A=EJI-:ENBVIBHMN8FJNRQ5=9V+5A?7=FTBY9OV15P
M5R80PJ$V;ZY59]P]GD#@'6T%A7INWWB1BJ\>[!;4QWGQU.0O:7R#C&"H4I6!
M1*@4(,%20 1'($^8$JG B$+/\TH=TJ9&LFUEHY:VWB7*NA!VX\9@N U,?&<A
M&\ %ZX1)L/"3+EDCAZ(XF'T<EN)R4]^L<HMR.2]D]<0ZLG4?."D0(6G*8[/B
MD\2L_1*;[30S?V94YEF>9Q)*O]1RYX5-C3_N#9N+XGENIF!F1#_0W#?37 ?"
MCMLW@7 ;>O^FK>8XX>\NR 1+0]<A:N1<=)>-/DY(YW"/'X64J_7LUV)1/&V>
MFN%00R+S/): *YT!E&<:,!+'($8B%HA*SHG3PN_HR5,CAT8Y-R(XQJF[UU]E
M_<!=O-$KX(3@K+5=W=;<U.JRYJ]]=SU^WBA]\ZP9VXYX_H)^ W>5A69A5A@;
M.RTPW?N'6JWM897Z8VFK+-O.#F<95AG2.@$BP79GU0SE/$XPT% IR31)L? J
M!^HL>6J]]FY1K LVC\1.SVC%UJK*2?!_1S".X^BY'O7-1>QIN5EXEK!Q;Q.W
M<7\0I =FB#K%UD[IFZBE]O:/"OI*\W S 6^L DT+W.6..D?PAN/UA,'_ 7X\
MIGX\GJB8_)W]]54)5?RHZL$_K%15$V\&>29RFN; K#ZT]2@+8.85#" J($MR
M+D7F1&$^0J?&7N\?;8E 6\!FS?Z*5CN%([;5>%>(_7R1\/Y-T,U80P$[N,?C
MN/CZW<)F.XGVBD<[S0> 52Y%U<&J>?GH\!Y(GS[,SH-"'[SJ\<#<67%\3-.X
MXGFO1XU"\7V,V[)[KWL#)7>Q_]A\Z#_8W)Z9O%V_9ZO52[%XJ+SELUA!K'%*
M@50: B0A!01R;CXIGC.<9QBG?D>B/#7PZ3CC')2JH[77[=0OPCN5MF\[N$U-
M!\1V8,X_E1FF^M#2_J8Y]! P/6Q/P(9*'7-!^MMFDW&#YF*"&<?'](V2,$O'
M.EGLIV+!S*J1S>^7=66!7<R/PH2@/*8@31/#:33+ &&, $8DPQ3C).%.J5Q]
MA$YMWKK3N:F/5&L=;=7N'2?IU !N9!8:UH$9+ "B/:(/W"$*%F'@('+D* )W
M$(XC!3SN[7NLXN.36CT8@OMEM?QS_6B+T+#%RRQ1-,4I5(!Q&0.4:P:H2F(@
MS*+:S+K,+\S)+7]!SM2(ISD\L-4UJI6-&FU]#UB<AK:;7P("-C"E],2JQU&+
M3B2N.&YQ^KDC'[GH-.[XV$7WY;W+Q#TM%U7$T3U;?5E5O%,')-VK59T25^($
MYYPD !+% ,(<&T*@'#!*%<LARS/I5S'ZLLRID4.M<AU_>1,]LU7TPZH;)%>Q
M2Q.X34P" SLPB328?JLQ-0K;HUJURG7@9)5!.'#N8 ^(PM6CNRAQ[-ITKA"<
MJ%/G?*N_?__W^U_?FU69FL_5:N=6:O; A58Y3U@&5)Y2@#*" !$)!0G4:8J5
MPAESXJ +<J;&.U;5:*MK'\]R%Z:7??2!D!J82,Z =#GJP LM=]=[(-1&\K;[
MOF)>7G4'*#H<Z5UWC^8[=S"A[2YWN;QO"$==4*A>#U:UA&R:]9G.<X:1S &.
M90I0DF+ <VS6:Y*D2990K;#P"]@X*6=JU%A%#A3;XEP]4H"=P]-MKA4 I8%I
M\;AZ65V@(60012<&P4(F3DL9.4"BT]3C<(CNR_LOUHHZ!;KU5U=5%Q[40A2J
MM%48YLMRLVKE F62L]16^L:QF3*EF0),ZQ30#+,DU4(32'R7;<[2I\86+>7K
M+9RV^M%>_][^9;^V<5_/#8+X""N[4&#W6N%Y@Q9PK><N>_15GS<LI]9__@_I
M1W:W\C\W3;V'3\O5;^K/6R%LC*4]-;=:+LQ'H6I-_BK*&412YV:):#.@2_.?
M- 942P@,!Z8B0R+EN=<DR$OZU,BNI7QU#MBH'^WUCPX-,)W0F.#)=GZ-X\9V
M@T$^,-NUD/VV-G3'5K*,?G^6-E;X K;>Y-8+HT#DYB=[5'+K!<MK<NOWD'[D
M]HD5J\IMMJ?-=DT'(1*8Y +D$&< H20#1.$$*$KBU,S;$A([)3=SDC8U\K+*
M-O[?7Q6SNKI[O-S@=:.C8* -3#\MO%J:#E3IP0F40'S3+6M4?G$R^S6?N-W4
MCS_>;<IB85.P+9]X<[[WJQ++AT7Q7TK>2=-A"EVP72V:6_'/36&6HV;2]KD)
M^C93-O/;YLF&/ST7:S:O$D1]X?/BH?9PHM@L&V.) 508VDAZ0T+2T%&FH(I)
M JFD7J=YAU=Y:DRV3WPTK\*9YWL[_.ALA-9VX\1IM>' Q+HU-FI9:W.Y;.V-
MV@;7];RBK<75LG=K\TO4F'P35=9&>W/#,?-X31.(WD=0>-0Q8KP&>#W0C"C9
M/]+L^XI)0X'?7I[X<CX32"'-5084@\RFB+"%"+ &6FJ<4Z[L[-8UMNS@R5/C
M_D:YJ-;./7KL$*YN5KX*A(')T]%^KXBPD[;VB@$[?-)H45\G#6C'>9V^H&]X
MYZ=BKG[;5)O7"&&,I:9 :6)]9$D*&-$(("6ADIE.$^V4V^G4PZ?6]9K@1*M@
M5&OH&[S9 NYR#[P&CH$[H0<2/4(SCTV^(AZS];"1@S"/S3B.O#QQC7]X4\]A
MFIT<INOS1NT?A%AMS _+)YO=LWJZ&> _/CW/ER]*O5,+I8MU.<N1>6MB)8"V
MB9J00!J07&9 T"2'C$KN. !/Q:"ID4^C=21::E>+ =4H'O%&<_>HI"G@[! L
M-@4U)T2^/9:/Y>GUH]TTW:T@MX<\6S_>1-NWKHU.9.")MOA$[_XUWSKWH+LI
MJ#O!Z+Y_L;?0*[AP2DW>$<4X"35'"Y><A+4GXC(GI9?_Y/%7)0O!5FI;96E;
MT LG7"1I1D%*L5G.:9Z9^5R6 \T2Q$@N(,/.<?%G9$QMBK55TWTH.P?>Y3E-
M $@&GF9L-8QV*O:(>S\'D/OP&P"HD4;$8\#"C$87$.@8(,[=.1IG7U"]3:.7
M+NVWG?E]5>WTOU0GBYI#1E4]@UF,F8XATR#-A 0H@1F@/$L 18SGA,32$)S/
M+N1925-CN:VBVS.'K"YS[;=Q>!Y7M_V^(&@-[FEN@&H.$M9JWM0'!P,65+B(
M1:!]L?-R1MW.NFCNZUVHRS?T#)4J%L5:?2Y^F&F:&1P6#\5^DO:T7*V+_ZH&
MC*:JS7\HMOIDWJV9(DI#969",LL@0%S'@$H6 YZFF).<DSCV*D353XVIL8IY
MV[!G*%4_^-WX97A0!R:?V@!061#M3:@7TC=5P:LJ=53;FIO(&A)92P(&9EV%
M9*B(K7Y*C!O*=1501S%>USVM=Q&&*L#^[\7Z<3L/V\6:_&9@J)>G,R*0R-*4
M [-$-',G06+ $*= YE@13H2$U*N@BZ/<J7'>Y^7B 1A!3Y%L3F5%*_5#+3:.
M*TA?V-VH;P P!^:ZK<95C;'=ZNEF'^9T$^WU#EJSP0>H<.4;G*2.7<G!!XH3
M11V\;N^=R-/0G+ 9]3Z8;C9?/E>%:&H&G&F6IC3.)* BQP"E"@+.& 4(IC@5
MBHA,Y3Z<U"EM:DRT5;;RJ\N]NGU.+W?#[,9!P< ;F'D.<&MINBTH&C3MYF5$
MPB79[) U=DK-RV:?2*#I<%//7 =%^;PLV?R7U7+S_'[.RK+0A:C]ZO9$F?5Q
M(XQBD$)NSS8G C F,. ZC7G*B,:Y7Y&*;GE3(Y*MNE&E;W2H<*\#?9< =R.4
M@# .3"E7(>B?*,$-EU )$RY(&S=Q@IOI1PD4'&\;)MGX3#"4"(Y3H#$D "7*
M4(M*,,@XPZD66#!./:<IG0*G1C"MK-=ZLY#^<Y-N>"7C1*=2@2RV-88DQX 0
MI '&VK"XE"E#+&SR=A^ Q\G6_O4P2WLUMVEE;B\6ML!S==XT,/C.<\-@@ X_
M/;R8HGV\S.SA9XG=XB:5>[UCKNAV7\_LZG:CX1TK7T5@K%:V!H[M0^]>]I?<
MLQ?[555@V:JP?MD7+BJ_K!_5ZOLC6WQYKFK9_F(>L2[O%G6AYEF*B9E;"@G,
M:E4!A',*")(2( TUEEK$!'FEF1A+\:F-+Y5VIK_:_*EUY7K/I*FCM;@;6TZQ
M'0=FW<H>4!GT*N)O;W7$7Z+V=8WE467Z350;WRK_5D:5^=':V!\U -Q$-02V
ME%4-0L T]2,W6ZA4]V.I/6ZZ_)$;XRCE_MCRKUV[5#OMOR^*=?GUV^]-Q!;G
M.>.0IH#@/ =(Z 00A2#(<Y5H9#VOTJN$2*>TJ8TJ1K'>D^538/K.E*^$:+QI
M<J5H5&D:_611^SE@B5XO7(+/DD_)>J,I<H?9Y^?'73?U(XR/6BNQ+GZHNX58
M/BE;O8VM59V\;5,L'IHT%8:G9D+2G&() <RUF=1"RFVV2+,XQXGF*2$BUEZ9
M_MU%3XU*=IK7Y3.-UG[$X@&Z&\L, ^7 E+-'L=:ZKN%H$Z/9V/N%*.9%$Q)C
MAD81=-O8'Z] 5.0A>%1>\@?D-4GU>(+_08</2E2DET*#+&H&8DT5(QPI0*$2
M '$< R:T/<.>I%1R%*=NO'1.P-389ZMCE,*;R*KI'LI_$K]NB@F!RM#;-:\!
MZ7'(X20R[B<<KD5HI.,-[J^.U^F&+NL[CC:<O&VT<PU=2K</-71>USM&SXYG
M-1]^+<I_O'MYIQ;B\8FM_E%MJ&K-,4,Z!KF.E?4?(L!YQD"2Y"(V\RR,F%<@
MS"6!4Z.X WTCJW"TT[?7#O9%Q-WF62%Q')@4KX&P3QB>$R[AXN^ZQ8T=>.=D
M_(F(.[?[^I',[Z7ZHC^6Z^+)S,/*F:0DYUBD(.,I BCE%! JN%G'93!.&4((
M>F5L/'S\U BDE79YIV.U]5<=TJT=;WX,\@I.-[[H#]+ [& 4LP5?=ZJ9-=9R
M7HB7Z(_FWT$2Q)Z&(Q IO'KXJ!1PVK#7'?[,5<&2O.Y3R>[3&<M4*0R)!BJS
M*7UH)@%'- 82&SHP/T*:>LTDW,1.C0Z^K]BB9*)'MW>$V8T.PH,W,$V<2A!R
M4*)C$)KP@VFXC*.GA+YUUM .(!PR?W;=W8^&[A;"'NU49I54_7NW:(;>\IZ]
MV(P9,R8$0I+DP.86,],-C0&':0PTB7.&8*I)YE0QVEGBU,AGJU[T7.OG1T"7
M 7;CGJ"P#4P[6UVCG[;:_FPW^'= WE\ TIMQG,$)1#:7Y8W*,\[FOZ88]QO]
M?;UU2L4O>I=,8I9+PK7"ADF4@@ 9W@ <5Y6GH<I)RF,(G9CDY-.GQAJU@G:2
M+BZF(G' [K*3]RI$!B:$!HPOVB$OBP,8[G[=JT 9R:GK XZ76_>L\1T^W>-[
M1G/HGE6W[<T]?]&HM39^62[EG\5\?C+-NJTSJ@@5B&4IP)3;*C]Y DC*&$B8
MR)3.DA0J.ELO;3;VODN/$'IZL>9.VP'[@EI'K,Y3R!H31JFF<;$]>R\0QVZE
M-UA1.J><O(FVEMZ<SSX9M(CMP WRMM4R+FKYUHO=D% 'JHOA+*YG.%85+?JK
M6C\NY=W^D(^1]K^6Q6+]-_.'K12U*Q4+<X93216@&1$ J=1,B6.A 1$L1Y#$
M&?,[<N I?VJ3YB9FO-8_:AE0T45E0K2UH7<Q7]\V<J/^ 9$?F-)#@^X?S=4/
MNE A79[2QXWKZ@?-47!7S\=<6?^R5>+1IB7Y?;'DI5K]L*Q\MWC>K,O#0$'[
MYV:U*A8/[UA9E+OL)=6S9DHF.<HQ @K3%*!$YX!G+ $\IXK$F+%<J]ES%83_
M;<U6:S?"'$17G\[]6N,!IVYL;LO5F_FU]4IP]5 L%G:#U?SQW'WT9L16%L*L
MC@36($?<#(AI+@!'>0I@GB&90LD$(DTK?S1#^+]2&V_U':N%E6'O2;6MVT#Z
MYJTU\'"[+^EZTZZ!6R?>:AL9U58>15/O[(PJ0ULYNNK'#E 0=HBF"%U(-JB.
M;U. =@B8SQ:N'418H'C*YL  >U!PQG.)TUPR0!/, :)8 J;S# B5R%@R@@F!
M?NDDNL3Y$,4XJ20. P%7-A#0'JQ^KG7V/%G=B;0;/X=";V":/8Z?W)U#,9H.
M&#IY HZAPB;;HMXV9/*$T1?#)4_=T_?4;)7QLYQ!2K2(9084S&QH)$2&-9 $
M4A$$*62:*^5W0+9^\-3\)%_[I#C=H>36S_O8/G"?WJH4\ACKH9'!3JPVCQWY
M<.JA,<?G4%_]WC,?R\9,%/ZYL>D ?U1>A*VC+%4H@RC60.5Y A"3!# D!2 R
MB3.10T03YI4_Y8R@J?7&O9Y1K6AOU^19:-VZ; C !N["O;#R3_UQ 8A0J3K.
MB1DWM<8%8X]285RZON<DOBXN;K=?MKF(WR_+=3M3^C;/DD P-X,SB+.8&I[0
M&:!YGH)4T00B0FC*O"(*G25/C3C:&O;RT[AC[CBW'P+)H2?Z>YVC719SJ_7-
M06&&X.F%O+$*M0IPECONDL 7CJ/U@?<#KDBQLQ'KC?5EW"[D5S5G-G6=D67_
M?U=G2I??EQ_,UW!&"$M3K"3(!($ "14#+I0 F42I2C 2F'A-:OS$3XVQWF^>
M-D9?F_3!:EM&6WVC]>-JN7EXC%X?488]<O:XMX[K4F8HS =?\+04K[9C&]4;
M@K/_;37!,OK0E<ND7Y(?;]Q"9OUQ%SY^&B!O8$[F!?)_2K! 1T.S92&;M![5
M$:NZ@DHK,&:KPTPBBKCB&N0*IV;.1B1@TLS96,XII#&&"J,KSZ%YJ#,U6JSV
M='Y83W@5\%TE37E05>V'EDU71S+Z-)@;,X[7# ,SY>FXQ -;HI8Q-P>QAUM[
M!HT[[('K<.&%/LJ\=11A#^ <@@7[/+7W$;LZH=*I@Z<J10+E*0$T(00@B:E-
M@X2!3/(8<:;23'K5NN@2-C76W*<-ZW#I^D/JQGRA@!J8UUJIU08_M^L"2;@#
M=.=%C7UV[J+1)X[-7;[GJJVL3T;/9CIXSU:6C&8L2?,LI12(&!NFH D")*4Y
M@"E3BB,4,^$U SLK:6HT<<UFUPD<O7:_KD-GG.VPR+[4NX5AHV;P+;+S2(3=
M,SLAYRTVT<Z;>V97K>.&OD$Q3\\K]:C,-&6;E/$WM?ZB#>V8O^8;:988]]8W
MMES<KM>K@F_6-G;G^](6^[,.M.7<//WA;F'ZJ%EH[K:2),48)QD$BD!L9APT
M!BQE D 2BX10DG+N63AT$#VGQD('9D9%/2S_9,C?M[C!4.WJZ.%_^]8:>C_@
MH*&:^=-/GVU#58?+[ K=6'L3[>R-&H.CML76FW9H<[0U>I MRX$;)E@(TC!:
MCAR]-"C4QX%/PXJ[9E5JNX4=N4[FKLYXDM LAX!ALR)%A*2 )8D]H9;K!"(J
M),E\SC!?%NE%^B,<1[YKTWP]SQ([M:/E3N\^J]=.Z"5.12JU "S#""!(%*#F
M(] RQI!EC,:)U[G P-"/YQP8'WH?]T$H0,=Q(M2#8(WE7N-HK_+A^/AZ-#33
MVJ!)W-TA#.ITZ!3X!JX'%P!..R"<[NPW.C05<,HO^H/BZX]_V?V,35$^VB^K
MC5];1!.B+&, YF:$0(:8 %6Y "))-!12H9SBV4(]V 71=W>BNBC8J5O1NEL=
MB1]R+?[<E+\RW>?]2LEB'=T^K%1]MJ?8335+M5[/U?;"/]FJJA[D1V*7&\>-
MP\)@/0Z%;8N+Z>4JLMI&A^I&VZ_O5[N&L":$8RMGL *1U65YHW*5L_FOJ<K]
MQIYNDJJO?6*B.HWT8?G$BL4LYCQ%/"= (ILU%5,"B+!%;Y@@6@FH,NA5X?>4
MD*E-F!K2V2H9_5&KZ9MH_12<CJZ%*T$:VB_@BX__$KX#@%#K[U,BQET\=QAY
MM/+MNK9?=V^' W[19DULFKC897F9)0E#<8XXT'FL3<?G9MU$>0Y0AD@BJ,0Q
M]SH U"UN:A1P$.]JIA?%3M\FJ98?%US VHT5PB$X,#^\!F^O:I/&*AQ1N&$2
MB#(N"!N5/-P,?TTCCG?UG#_,3=?XHO]>S\2_K+X6#X]FFJ)6HBC5_:H0:O=C
MV?Q:PIF6)%>$24!UDAF>L94X(60 49$0E<0B3;VB@GMI,37ZV>H;/5N%V^L;
M.SU?54I79Y?E<CYGJ](>>:@+1/MNH?1J,\=9S- M,?0TQ^IOL6^4M-!76MY$
MN_:YW[;/WUOM4YL2<#9T#9"AIDN]=!AW/G4-3$<3KJL>UG<CH=Z7N&=%E2F3
M8\8%SB6(DS0%*"4$T"SA(.=Q3'/S^HK8*T[EU?.G1GKO6?D8/1O=*M=$T2CK
MZY4^A)#&5$N8:< 4,J-+DB/ .,R ^<#S1'*$\KR';ZT/DN-[TH8 U-6GW_M-
M&]R!W^P\6]4LD6_=B>W#;]N+;K8>??/[K2WI680-"#H#4S G_>'31_;(GS3M
MV/U^^K*>Y^G%HY*;N:'F;7+2?2PKSB GV$PLE8W\0\S\A^1$@0PF(HTQU!)Y
M.;(Z9$V-6+>JVGG*5EG/T_0=P+HQ0B"X!F:'4TA%?WRO]NT&"11V@"74"?L.
M2>,>LK]L\M$Y>X=;>F899BN;N;&\5ZMO=OED,W*)F9"9@(PP@!72 .D, T9B
M#F*.$X331".5^(1KG)0RM0B-2JG#<+S]LC)BK[:PS55/RT7]X^-R;A"OEDH?
M?QAUS5+IWQ6;KQ^KR+!_"[)0/=U0;MQS-?P#L\Y6/WNP/JHTO*D2$HJ B8&[
M( B5_O>DC'&3_':9>93*M_/B/B79^?IN80^BVAVY_?;IO5J8SO!2'[G_9-Z:
M)EW7+*$)RC,I 27:3$EX:CY)@0%/4*RQR$6BG$XL]1$^M3E*:[?YN58YLL[C
M5<2T$1^M'XN5C-AB4?PPRK#52W4ZU)"4G9I+LZ#JD<FO5YMU,\[0+3$P$57[
M_GO=;]HQ (WZ-TWVC\A:L,L#."#@/I7GAP-^M*KTH1O LWI]/P0[*]M[/G+$
MJO?]C&W74.K]C(%&E^^F)=2VYZ1:Y%QH#C#.,H (8H!G- ,4\RQ#)*-<)T&'
ME[;T?X'QI1Y92IN;MWMH,=->NQ%C!B,S\7W3D>B@?0,-17U;;4)C467"4(/1
M >:!1Z.^V$]P.')L@_#CT2D,KQV0#IXYK1'IE+G>0]+)A_3SH'Q69:G4SD_^
MV18_W:4TWX8L?MBH_U!L58F=R43@7" ,(*(8H%PQ0+,T R3/<HJT(CA)?3RQ
MWAI,;6PR[VCFYPWQ!]W-4S(HE ,/&+7N[2V;2OU648<;.WYSU6S]6!MJU@KG
M9NF-7R 7C+_\4=TSO>%Y[;KI_Z!K-Y;.U'^JM@AF.LEC!;$ 4F?(IFV6@ B>
M <:RF&(&29SVW&/J$CLU.FMOHIROB%;OJOAF=79K!]\MJ5#HCK@[U1_8*_:H
M7' *OEW5*?2-=JY<@#B_B>5T=S^B^DW]V=2=MT>A5\N%^2A4?6QD]?[1O$W[
MRO35%<5"%,]S5?<;:LA+IWD&<IHJ@!#7@.DX R+-M!(LQR+V.BM[E393HS5C
M3+37-3HTQWJJ:X,BL_H_N*RQJ1_A7=>>;CPX6BL-3(\MU+^MV4*RE2RCWY\K
MGXQ-^'IE^WCS9A!< ]'I=;J,RK)!8'M-OF$>VC?]T.IY:2:JZK?EXIMZL$)_
MK1([SW NT]0L>T$B<0*0S%+ 598#P[XI2A'$G'HF$#HC:6I<NE/4-^'/.23=
MF"X(/@.SV$['&YLT!S1J1G_4B@9-DW,!C&");L[)&3E5S05SCY/-7+HA6/IH
MEW+K)\NLO[=951?K]@\UAY5F$5Q- ;@2"I&4 QHC;):D*01$2@TXT0C%6*DT
M\UJ2CJK]U&AKJU[T7.MW=1KJ 1O>C1$GVYP#L^SI)-=[TZ.V[<VIQ6AK?36;
M;&>];@"XB1H(VC_>1+NWYO["6Q,B-_;PK3=<*NT!=7_KS-O#-XM#HNX1E.A[
M\*G<K&R][5-)J#422&EATW;9X^?8S)0I2A5(>$XPHSCES"F,P478U :<K\H6
M$C8,8P_PO)^SXJFLR.=>K<PW3]8*\(Z5AI)N[5&TAWI%XWO"IP-\MU$D%*0#
MD_Y.S3$2@%]&)-@QGPY1(Y_YN6ST\0$@AWNNR[SU??EKL5BNBO7+MU:T^DS)
M6"FB)2"JVH;6R"R^4PRPR"AF6 M!DBO2;IV6ZM0;QC\I:,"OP_MMPC.[2_KM
MV7Q8KGJFTSJ#N!N9! !PU$1:94=^VX!G!=U@"9PRZXRP-\F7U6WXN619%^ZZ
M=CNX*CQ5"%MKBI6/9O)D_['[.S_8O!*_G\90+G6.8Y#E(@:(YC&@M@Z>041
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M>7#O >,*  ,-)7TT&'60N0*BU\//-8^Z<J;:)%5&)(-2QR W4U. 8CO<:$X
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M@S-<?O.>>HR=Z?PZN$[D/+_R@?VKB'TR4MC\/Q1;?3+?E#.5:#,SYAKD2<X
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MXNH/T.L5UA5/NO(4CMVVO#,?RYE64FE"!,""4X XDX#&,02<DT01Q@F'7F5
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MJ6ZJ[(NV!H:DV@ X!V/<:W09F7@#P';,OR$>VH^&?UDNY9_%?#[#><PT@1K
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MW=W/&Q^HIY\0,&HG/V_@Z_[=<66?4M'UZNA3L6 +8285GY0JFP!&1+'"/.4
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M@4]W'Z>"2J/IODIVZ5DFV[<-,B8)Y1D#&F)DV\# GT )XDQILP9+H)9>(]^
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M;N-TW2/[&_*WRW*S-J=:7]27O"ZF'6(6YIA', X%@9C$$N:<<!CG"8\#(F5
MF:O]?FJ@R1&K-C?W@JH745W<LU;Y67#MK?1K(1O#.'='JY=1W@6%1UO\Y#"C
MF^!=RIZRO#NO[[F)ORV+I2C+&_:/;5&:E@GFQ[5HOL:)3%&>IA@R&BF.$&D
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M&)($4\A#CM3O4B2BQ&6Q.#/.U)A^)R9HY'2C^'-PVO&S!Y &)M=C? ;8?[T
M@R<R.S?*J$QT0=77-'+I\MYE@YI=$[V=TJ10XRR+0A;  .448J&X@&"60!F3
M0.8L201S"M8^.<K4WO^6D*"L3AF6[F<NIP&UXX"K81J8 =H(F4W408K]G(?
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MCL19JL5DJWWQ)=./YN^VFR^KS7^+S5=2\'D2BPB).(5QK+OH)3R$-%2$Q'&
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MS6!K;<"!.I=/WSU/C'U!P-$F:*2Z@-=-E)^B@%XP[:@->-WS1RL1Z 6&=J5
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M9/R8"#)J9 1%U8C*=.<R)I"IC*;+JZ\6"WT27"P5]8O2-?/'UY3:T>\;3-3
M=-P6%^SDG8&Z<5@='Z7Y )R[M)[A?:LQ?P3M&6]/A.U+JE$)W#.4KPG=]^,]
M^_WWZGEUX;$@##*"DASR3&]ZI@F"-(\E#!DB.$Y2]9?TXN[OQYR: =SIDLZ
M%KQGY3>;";C2V^\'Z\ T^GFU?*@3,N\/TC$'J/[F@,S0CGQKQ&GX[\<06+OM
M)VYU;\/P7;#MNMB\A(C>%YN%F+,XR3(B4I@'3"@7/!20<"%@)'(:"2R4%8EM
M>S"\?OC4:,4(I?VZ$/U"?P6-N/8M&([0ZZ:*:S$9F!-<X7!JOW!.[UZ]%XX>
M-EKCA7-JM+LNG+VF9PV;]0-9UJ4'=(^[U:+@YA^*#+ZJ^6].X._DIV))EJP@
MB^_J$^.:EJ=VKQ-&$0UTM]4@U-U6<PDSP7(H9(0RB7 >QD[G![X%G!I-M/5S
M+'_C>^KL3)&WG)"!.:JMV@P<*&>LPK9ZFLIV"H*]AL.?80PU ;ZJZ_@6;]RZ
M.P.!>U219ZAQ^G37Y@4C!=\%>=217X+*(!")+LN3Z182*84Y3W.(*(U9C%,F
ML'5\XIDQID;&C9@N795/@]?-I9X@&9@.&PGWX3^]VDZ?!LBEH?350(W6*OHU
M8+[:/W<BT-G8^?2=([9L[A3]L!ES]Z7NS/9=+(O56M'K#^7CZEV(+ZN-*#]L
MA<()-[W%\@B'61K"5 0(8D(3F+-$PBB)XC2-0Q)3JVJ,EN--C?&T9,"(:?]*
MV\!ZF?\\@S7T0:V1%K3$K5 #2F!@0'2G1AL<[6G2,YXC4>9%7/TPJ ,X'6QJ
M\Y31F-5!I3;+NMS6M[%]N=&=SW1JXK(4Y3R) R00RZ#BU03BG"N3DL<)3#.>
MA D*4L:%RP'QZP&F=M);U79<[6HEB%I.U\[RKV"T<\^O 6=@#C6B5<<KEQ#I
MT?K]M-K>FKN_>OS([=M/*W?<H/W,=3T#[;:T-(U@-A]_F-I$35OP*"=YR'$$
M49;H5LH14B]TGL*,8!QCGB8)<6J_?FZ@J1E+>SF!$?2*MNMGL;5[RWT@-K3%
MU LL]ZBU"TCX"DL[-\RX<6<7E#T*++MT?<_(,4$WM\MRLS86XOZ[FZ9)C&48
M0LHQA3BB#%*4II F(H[3* G"Q*I/\X5QID8+6DRPE_,*5C@'K!TI>(!K8$[H
MA91[G%0W#K[BGLZ,,FX<4[>J1W%)%R[O1P<GZB J(\0$?)B:AU5M*L?^"VX/
MG=!W_%0M4V/T5A$P+>$'Z;#0#S=/[X3CX*.^*OV >?T&]7Q*3T]Z0<KR3OZ-
MK-=DN;E;?RL>'C<F!GR.1)0F!$4P#ZGRJ4/)(=$N=D"3/(D0$3*UBJ2Y/-34
M5ELCJ3Y]K655B (C;9T<X;CD=F!LZ7![06YHU[LW:.Z>^$4\?/GDYP<:USN_
MJ/"1GW[Y#H^$\?NR*,NMX/,HDV$>RPB&*.00HYQ#&A$.<Q;22 89R;%3J8/.
MT:9&&[64)2 /:Z&+)IK61^5JP<$OQ1*4CT2-]JL'[MC!?05]] 'QK1AD!AII
M!^:0UZ ,22.[L=Z>25ZK;44F1S?UW '<K-C?;\V3/FS750W"8L6_FY?%_/F.
ME((K8TAO.%9G5(21/,F5_T]E)"$64:ZW V*(L>"4A"3 D5-[NQXR3(U[/HL?
M8DT>%.N46IFJX3/X(<J-[E*P5%Z!KMUJ% )_%IO'1Z%82:H7K$H0Z\U/?:;/
M<O]QV$D9>FNR@KJ2?P:J?]9_0R,X^$I>S [%C7ZK'D25"D*D^K: 3ZNU%(5N
MW.5Q%[,_GKXV.'M(,.[>9W^(CK9%KWA4SUYXI%C_%UELFU80!RT@?A-$Q_+Q
M.]T^8KO6 JD+OJR6Z^:?2IRBU/<;6>X%>UP6_]B*<K]#B)FD/*0,QCD*==D6
M"K.8Z%I6H: YB@E*G<*NAQ9X:A2M]05&85!K9U[_V^7SMCZSW&D#]NI<L=4[
M^#?"CLBG-,\#L_Z04^S>2' DW'VU(AQ:W'&;&8X$_E$[Q+'&[9DO7-D\RIDP
MYP1J?=2UQDU0P1P+D@<Y)C B0A='I &D<49@$@5ADJ.(J8^=\H3/CS6UI:$1
M51OI7!]@%;6T@*V<*S1T86S'V)Z0&YALVZ!5IWX-:.\[07//_[T,AZ^\WXZ1
MQLWWO:SR49ZOQ2T]$PA/MI9^F6<TB60H)0SR*(*8\0AF01Y#%$99C"7)4^04
M"W!FG,F1196[ WX8.T-]^1=:7/=6IY?@M>,*#Z -S!/GN],/W73^Q3,]G!ME
M FWC7\[1PJ7+>^X:5B6=OXEGW=9\^7 JUS3#B*6!H@>:"0)Q$H4P3R6!*<D%
MC84(D'"J.V(QYM2HHBG;OI/9<7// F7+S3R_V V]>?<:MN$S;AT \K4;9S'B
MN+MO]A <[;8YW-J7<$S5M+^(I:*SA8['X$_%LBA-9>4?H@F'KE-J" E#&244
MLB# .AU!48^I1$)Q'I.(!2P1;M3C,/KT2,@(/P,/E?AF'X0<*- S?\%M4FR9
M:B"H!^>L&N6_M% ^E'V7$W$YD:P'?_6 S1N3N8P],J?U@.68W?H\Y+H-FD^K
MM6)3]>5\5%;;[NBWG.=<(!'F&>11("$.20H)IPP*GB6YC$B"\J3/)LV9\:;&
M9;L]A\T*E&)CZ@UM-^5&O6S:3/BS%KO?ALTYS-TV;3P@.=;&C3Y_WLO:BOP8
M8//F BR>-W#.C?8FFS@75#^WD7/IMC[)\LQL/_\0ZZ4.(:GKCBP?OI&-^'[W
MZ5N]4M.,LQ0C#FFBRX)PD2F2T<>-61KQ&*5QPE/[A'FK,:=&-+788"<WV D.
MM.3@%RV[9;"&"_;=9#,0HH/;1E9@]LJOMT/5)<?>.[JCY=E?]Y5US+9W@JDS
MX][N22-FW3NI=IAY[W:K.X5_7:^8$-S4%_Z-;$R=P#MYN]219F;5F$>$QED6
M!1 E&848,P:I8'J3/D D(SC.<JM=>:O1ID;;M9!%77.])'4'KF(OLCVY7,;Z
M,EE[17!HN["6%6AA02,MN)/@=ACX[%G9*XPC\?%U<#JQL34\'3Q\^1FC,;"U
M.FWNM;^I9WR?<ODWPI2\OE7?G:KF=1WE\:2W/?^YZ]:^+,5_"[*^_W,U3_,P
M%6& (:)!!G$68IBEG,$$RR@5F1!19&5*7R7%U%BZL^B/1_#M'/?!(1V8MBOY
MZV+L>PVJ9-29V71D&_6KMC(SH/4 2A&/\6[7X.@KB*V7#.-&IET#TU&XV54/
MZT>$K8"VFR4W@=:/JX6ZO]2EY3<ONRSP2,U.)A,.,8ESB'D:0)K@ (J 2!$E
M&$D>NG"?[<!3H[O/MS?O;C_?WM]^_ YNOGP W_]Z\^WC7^\^?_CX[?O__7]E
M*$S_ WS\?W^_O?]O-U*TG@@['AP"WH&IKR7RKJ>',K&&2+IW1<<3H5D/.RJ'
MN8+QFK:<[^\9N+9Y%&N=XK$6CXK_%$M6?7<^K=:B>%B^WZ[78LE>[M=D6:K1
MJD1_\Z]%E?;/_V=;&8]?Q.9.WI.?7S6GJE]L-NN";C>F5]OJ*U&/V<QCG*<D
MRP)%=[GZ(V0YS$2,(4$B"&422\&<CF9&E7YJG%DK"5BM)=CL%0-DIYECI-VH
MWP<[UIWL+ ],W49O<*#X80^V&6B^ PT&H 6"H?L6#&"/@VG>K#=]%!8S4*,!
MVG#HT\,*$(\1B&\QC[[B&D>5?=QHR;>8EJ,8S#<1PGUS^>/3\V+U(L1WD\RL
M\-5BB/53707GG5@*66R:>)XXI)0'!$.<";WH40I)$H8PTWT#!$[#,+1N'N T
M\M36JIW0AI0V>[$!K>6VWS1UFX++^\^# 3OP\M#(#?;@WFC&;X';R-[CV- -
M9?MMZL'0'FG+V@%U/QO7O0#KV,1V>]YH&]J]U&QO;O=[@/L*\$$LR(O@'];D
M3_WXSRNR_$28R1BH7X8T0C1+:0KSG.2Z &BH?HH$S/298XQ1$-LE_5B--C6F
M__#A_C-H1+2GF\NH7B9RKU@-3-ZUK$ +:\@#:'%WP/4@[,L(VI.T5R1'(N:K
M$75B96N$.ICX\C-&8U]K==J,:W^3GPRJ;XK9EUOQ36B%U##+!YWO_7E7ZR&.
M&<DI2F 4Y3'$,9>Z&F0 &4^2B)%0Y-*M(+O;^%-CXJ,4H1FH-0 M%4Q-AVM*
MN#M.DMV6SX#0#TSLWE&_.D_+$KN!<K8NC?ZF^5N6T%S*Y;)]3-_#Q$WQ8!;/
M[R:<7P]]\[3:JC__).HY_'YE=D^^DO7F91X(E''*0EW>DD$LL@AF*,(PI%F4
MI9*R@#JEE#J-/CT*;$0&SU7(N.OQH0OTMF>( P$Z^$%B(S?8"SX#E>B@EEUO
M&U?;UD9\GV>+/5#S=L#H,O;(IXP]8#D^:NSSD+[==)Z?JQ'(XG8I5^LG,_"G
MU?KK6O>*VKR\)^66+#8OM\MR:_SXWY?J\7^N"TT8U3[P1D=IO%^0XDF?C=8_
M[#: ZTB..4USCE,BH:1<,2&+=4<.18<TT?9A(#"-D_D/L:8K^PX]8PGO\MZW
M51CN]:^%!R\Z*$J]Y5R'RS^;BH&N/7]&^P98VIJ3G-6!V;R93A/C5HEKMN;K
M'_>B-QFY/GL5C8VWM^Y'HPD^<C^EL2?DN$/3Z!+T6[YN&-/K8OF5O.@#Q7K@
M.<:2X9P'D!,40ZS7&T+"&&:1P$$D8ZS6(;>EYO1 TUL6&CFU?:T%=5L+SL"I
M6V&B.(I@RD,"<:A;988)@0F/,YQE64BD4VV*Z\$<PUD9!$J[)?!Z@ 9>KG;8
MU!+.ZH@7C]$IW1AX6D+.##(JW7<K^IJ:+US=CT:_"=U]BVU,V>GWCV3](,HY
MC6F8<%VW 9E8Z(C"G$<(9D&8A %*4Q([Y8&<&F1J[_SMTD3O<1W(!92/!;[H
M'<'?5LO-8PD^+K5'_5U-J=E-!U$PT\V@0S=B.(DURO,PC:,8TB#E"NM$QV &
M:M5"*.=,)#E":+X4RBL4?&"T\PKM]F##X:VW[*KF5'H3MD?ETI-HVI'LM=_'
M@2GV0#Q0R^>/7KNT]T2N)X<8E5J[E'Q-K)W7]BE<<;ZC>=R$H^4,Y0E/(0M0
M C%*E5U%> (9INKM5_2:I%:MCRS'FQK9:LF $=.E>L)E6"]')G@&:_ C+"TM
M:(E;H0:4P," V*<*Q64<72I0>,5SM.H35^/J6(#"&J7.XA.7GS)BX0EKE0Z+
M3MC?YJW[JQJN++@I+;M:FE!E*;2MM\LYDPG%.),<BBR+(4[B%-)8F6,B39CB
MXBC%L5.WDAXR3(VBOS:%MEA;\']WL]'ZS(6="3<PP@/S^JF>O#-PH !H:3!6
M8UY;!(?KSGM1@K=NT6L+D46?7NM']>/!*FM#9R?I(A-JL$VQW"H#MZZQK0;_
M*M:ZA0<S':;F*"%$\"15GF>4*D<4,YC%E,$P)4F8XD3DF+GMG#I*,+TMU;W(
M8+63V;2_XZO%@JQ+?>Q6M<)S[(3G.CE$IB*6)E\EC""6Z@\2!0(F,0L88WF4
M!%;I*R-,S2@]ET]-S Q0+?";S(_=HC4@Z@,O6 ?)CD S)6C-P5UK#I0&P*A0
MM2_TMU[U!,_36N4Z^JCK5$]H7J]1?1_3;WWZFSXQO)-2MX"I%K[7K6#F&2<1
MB1,,J<P)Q'G$(9$T@1'AA""<Q3E&+JQW><BI$=WOZI>F,HHR H][/;EQF@7@
M=C3F%\:!F<L("U925IV?:H/ZN 64/Z*RA\<3-UD,."H=V0/PFH$<[G0C'2Z*
M^4?%9YN73\5"K-^3C7A8K5_F""5<?6^$;O:B6]!S!$DJ,41I2!F. XJ0U3[L
MF>=/C4XJ$8&1$31"VK'(.02[*<,#+@/S@QLDUF1P0?$3;WXIV+\]K'[\'W5G
M]=*K'_;O^KGGC?)B7U"F>8LO7=;33A"Z.*URBZN>Y5^V>H_P3E;-D>_V]?2-
M83*/ RX291G 4&8ZU#1%,-=59?.8A$S$891$D9L7ZS3^]'S8=SN?J%?+=C?T
M$64(I22%'$4)Q"2-8*X[[:4HRW <!IQF3BD/@V$_!MDVPD-22:],MJ>G53,/
M!ZT@8.6Z#CDUEJ;=4( /;>75<H-:<%!)KFV^2G;0$GY6.:@>+;X^J/DR_IS&
M'M<.[ /+D4G8ZR$]4R*.:KLIEWBQU8\_6</FB\)!><D*DX7.-%LJ5A'E9G>2
MD2',N<QSO86J@R>E,BXC&4(<J'5(L"@.F5,8E5_QID:79D9K[?Z?NCBB8SZ#
MW^FS8\RWFY2A8P]:BC7S,0,[Y<[6*CM4$#0:#G*&-0SXOI(4_ HW;B+"(, >
M)1L,,\H5D;"%+C[]GI2/.F]!_:6E^D$6NB+[Z4]O?A;E' >,YVF:Z[Z-$F*J
M^YQ%A,,(B3BA*$FH#)SC97N),C52WVL"M+158I/^H26W8@8EN6.Q@RMFRX[7
MQYF#@3G<!_S]XDNO0LYG%&H_0<:/5;T*L),1K=<]L4>WGP79Z(0QG?.U/S+Z
M+M8_"K;KJQI0@464A9 D,H98<@))GL50Q@*E 1$L5C:QU?Z,[9#3VY)II#:O
MX_[\VJ%9C0W2W30W!'H#D]E.7%/F;R\P:"3N$0QKA:1#YQ_/B([5_.=Z9-TZ
M #G U-4$R.8QX_4!<E#JH!60RWW7A()]5U\CD]G[CBST<=KW1R$VID$P-WDX
M9+'OA%Z^>U'_>%Z59/&7]6K[7.X,<WU-%1D@6N+>:P-]GJ8DDG$>0D1DI#N9
M$Y@A1B!2A$^S+&2$.871CB3WU(SF1@-0J=!VNMM:M%_4/XPBCC;T6%\+.X-[
M@I,]\((VP#SWC*H:#76OT5C#2_T&45RC3<7IZ*_QAN^Y1?^X6F_XMGKBK@2%
MCE736T#EKO";^?V=K&I/?! _Q&+UK-6Z7S7M7%X^[RHAXDRHQ2I.82!#72$^
M3R )40X3SE&0J?^74>2T43^ D%-;I(R.L%$2[+0$.S5GX%!1?1A7%[5IZ:JW
MC'?:7E/]<H@OAN41P!M/]] ' 6:F/[S%3+L?" PX%;Z.!880<=S#@0%!/CHB
M&'*L-RF<]W5=K-961=.0C-, 9RED0D?3Z 4J1TD 4\3"*"<QH9%3TL=8@D]M
MJ3*"OWFY//MYMUQU)CB;0^\ FHG\URN4YXSU-,KDV8O]KU0DSWDR/)?(<Q_?
M_2CF\/Q'B?A9;/38*_E^+90CISYI^@-\%J3<[72',B6!3*5R?RB%&"<<9CQ%
MD&,F)"&<$XGM3V=Z2C&] YOW.IM024X60,D,%I4:VLIE1A'SJ6S:6RR,+O9G
M$'TGZ_(!SP@3,/(!M@;Z\Q[^]WOX=]U%*DUZG 7UG0?[XZ$1YF.D$Z,!Y\7I
M).E*1#L.E_H^>;3SIBM5;Q]!7?NHJUNS?R+%^K_(8BOVFXN[,$R4I'F&<P0E
M"SC$C$E(XRB%A"$F913&(7?R@NR&G9H/TY*Z=]_U+I3M? [_V V\?K0$G@$M
M,C R@[W00_=?M\#)?_?UKD'?JO>Z!1 =G==M[NY92'IAYE-P$X#^3M$;U]UO
ME05NUM#&*0]R2K.$*1K*A( X0B$D*.60T !Q&E,68^94"=EJV*G1D!$64BVM
M3F?:B0O$!9?[&NCMN,D_H(/OJVLLC:"ZF++9N;A9*W_QH6[HXGT;PPTB7X66
M[08=M_"R$Q!'A9C=[NY'2^J)3X79#C!;!.8T]4$LF>+"N1 RC/,XAS2BB7+3
M%2M1W> TB(C@@J010T[QYAUC38V 6J)6FW]M8<$OWT55R1'\[S!TS'3M MR.
M@3S!.##M="+HCVLLP/!$,%TCC<HJ%BJ_IA*;6]PK77P7;+M6SMK'G^Q1+R=?
MU-=AGB%$1:I8@J4$0XQ(!K,LRF">Y#D. DDYM^K)>6Z J3%%(R-HA 1:2OMB
M%R=!["8"'] ,;72XH>)4[Z)+]5X%+TX^<+2*%UWJM$M>=%[7<_%?D+*\DW\C
MVAS<W*V_Z1SH#ZLG4BSGE&0DHXS"*,<(8II12+0W$@9)$L2)>HT3M\7__%A3
M>Z6-J'I_L19680J,N."/2F#'F*$NF"V7?#_@#;WD]\?-?=V_C(BO=;]CI''7
M_<LJ'ZW[%K?T[8OUCVVQ%OQ3L2PVXG/Q0_#;Y49]&W2Q[9NR%)OR54F%WTLA
MMXO/A=2;'!D+ ZS, \%3B(D0D*!<F/HM02XXXVX1)]<(,S7RV95SV=48^2;T
M?.EP[4IJH,5V[15UQ6Q9[HN,- <#<UBC!JCT@$81L-<$5*K,P%$I&)O)Z=&C
MZGI4O76RND*4D?M=70_:<5<L#\_LT>1E7ZWDAO\HRM7ZI4G9FO,DE1F/(HB2
MA.DHB@Q227,8!UF PS#(D:!V+9TNC&3U>H[:U>G[9JVKOKV8G85R+SD@M>C-
M1K%+XY<.J+LIT =\(^X%UU U8NZR+_U Y=#3Q0]D8_5RZ06=6_N6RX!TM6WI
MN'N\=BV753AHTV)Q^75]6[\))HH?.B/HB]C,49K0.*8!I'&F#$]),DB$3L@1
M2/<D"'E*G$IEG1QE:A;EKI7F>B?E#"R%8UGGTX#:VH97PC2XT5<C]*V%$)$;
M_:HO%JL_31J*CC*J XYT[7+_?4A/HN.Y#>GA&&_2A?2DFN>:D)Z^V-V.>F^V
MS,K;Y3WYN7]F>?.P%N84=)>],4\1HBB6 D:)H-I!#2%A:0ZEXH@\0C$/TZ"Q
MJN[M.N=9#][#T+H?8S^LVL$MEF!#?K98!)!& [!H5+ W(NRGY++UY1?AD7;+
M*IF5;PF4U"WJ*<%.[GTBVQ"XVIMJ@^ [DN'F"6<G2\X9KPZ[SOY9HUEYSNJU
M;3[WFZ^HLJIK^BL*G^="1"),,R@%)8K5PQSF.*,P1"Q&$H4)8TX5H]L/GYJ]
M5VW#W^SJ0&M134,/P36'J_E="F:BJ?XL-H^ -DWBV+YGF&/PYP'4=B9A7P"'
M=I -6)5<GNN'OE+69_7/YM'CU^Y\I=3)RINOK^GW.N\B,]L5(TP]B&+Y\$E]
M;Y>L((M=78GWY-E\D3_ODNPS*;)$AAFD1 8ZFDG #.<<AB+F,9<\Q\2J!X<O
M@:9&&_NP95VXW*@$C$Z@46H&=FJ!G5Z@4>R*H@I7SZT=YXPY8P/SU#B3Y4QT
MOA#V1(Y7BS,JH?H"[S4)>WMNWX+'A[43OHD?8KD5NO?;=_%@8M+N5[I)Z6I1
M\,JE_;EYIX#Y^YPD"64Q#V#* JE/. 0D:1XHRI99'H4$)VY66W]1ID;6W]FC
MX-N%[C@&:BVJ=HF-'KH$05L3U[+'O>?,CHK'F8F!2?BX&HW55-35U8!6"1B=
MO%9%OA98;U61>PLR<E7D:P$[KHI\]1-[9CI6Z91W=3IEJVO)S9/>39U3B7-!
M&(.,(:;;T&%($IHI.UAYP3G6FYO4K6O5I2%=WM9QDNP_'V75K]HM>X@1VS'W
M\1+N&25"<IG"6(A4X1[%NJUR#K,H9930(*3$*:G+)^JC9)4:>5L9VY68BBZK
MH K/<-LM03Y!''BA.4YY/V@S==/]G75/*[5$QE="Z:7AQDTEM53^*(G4]KY^
MW-[4?/FJOABZ4*:NI_]<;9<V3G"8$(Q1&D"N+&6(0UU51<0,IAAG611G+$BQ
M"\M<'G)J/--(;,*"=N)>L3%A@;H=V?C%<F"Z:82= 2-N'S2=.<<>($^L8S'@
MJ+QC#\!KYG&XLZ\'OS-@FXJ(?RLVC^^WY6;U)-8??];E>'48I/H?OR<_YSS%
M/*)Q ED0$(A)1"$-<0;S5)F9. T8$8Z]BIQEF!H[U2JX>N+NV,=!F&,9*0L_
MCY'Z(Y0PER&"61;GD0B"C KB9N8/C/XXEO]H^.<\2Q.&<A@QO1#'*(193"04
M+ W3+%#>%A?SI=B\+?:[.)+-.+@[GBGV =YV[VG0+_/@FTZM+:9&_NHDM]%
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M 0)#95>$X "+,@$PQ1ABDF0B<>JB8#_UW*Q,6[QN!(S^T"(ZYK@XP&YG7\*
M&=C:..$X(*W.%1)OB776$T^<6N<*R'%RG?,(P\S27S8;_N=RM?JZ6:V4JZ7#
MW@N.DQCF2:SLC\@ S&,.*%6_2L(@33"!&68N]N?$'',S-*V(T1]:R*B1TM'6
MG,+2SJB,1"BP]7 %Q]F ]*COR5*<FF%2D]"CXLMWO^^C R-4F_6=)MC73N:M
M&L)L=Q1FG+.,@+B@ZBUG2 !,"02)Q"Q+RC+-,J?\V5.3S.TU?]YJX"K2<@YR
M*TXB:AGW&8E3Z!C.L\X"=A"YAV)Z,/ 55CDUQ;0ADAXEC\(=?9\=]M*__Z'O
MM!^7U;T.DMQ(/;0ZWSRN=XN4)9S&6:SV]D*H_V ""$\SD"*<\ QGA<R0RZM_
M?JJY&8 /ZL\Z,4J)5D<MU*E[*W1XR>W][P'7S@KX@2RP+7@N9!NFN(IJ0?V9
M@\M@>#(*/1--:AHN*_S20%@\,30N\=#<RM](;86TZ?^DNY3=R+=;P9>[A3(6
M)2I+W8](7TLEJ00T%3$HF2Q)DDB8(Z<"]XLSSLUH' 36K\!J[T.LM-#Z3\R(
M[1J8N(2[;3S"(YK!PQ!=( ^>QJ<6R+?]0 Z(3%B"XRT@<6F^B>,0ENH?AQ]L
M'QQ,C;4UB5UD]=9T/*T;BE_O=MLE?=R9"N=-;\GT(A8,)GE> "2%\F&PLDHH
M%ADH"91Q+$@)2ZN6!?Y$FIO9ZF@4\>7J40< 34Y/59?>&HK))3-_-OUF']=+
M]6;^\H]?O_U>_>.O5R>Z&^A_B7[YG_\#I6G\KU_4+^;'Y%]_-=>[*_$DMN3N
M:+Q/9CQG:JNQWQ [^SGMN@<VL-TEK[6I,RNKJ*N/SI)XI[\0RR<1O9=2,./;
M7<C!]'@?Y0]S?_Q18P6:FA;*$X GV)Y\C3SPV$JV:^7I5E]$G0SZKK9<A[+O
MM(1I7DJ0)7&BSJYE#@B&FB&>\XRDZJ_<[>S:/]_<C'HCGF/-Y250+<^L_J *
M?7!M)-6M0VJ[=A4UT@8I>;1$QM<I]L)LTQYE[50_.L]:/N;>$>LM>5@JZ[7\
MN\XAKWDI]/U]]VK_B_J>W2OS=<V8/D'KJO1]-E&U$"*5,F$ER K=$0NF1)UW
M,08I2U#&"URD";/K0>%#'*NW:M(F%2]35UA+X:(3?B)25<*E]=7HY>JW79,M
MP40MO ^J'*ASM#)7+\H06X6B@T:=O,LIU\>^R=64ZS11?ZO@Z^74V,H7P#T]
MK49/,5D[*U]@=#M9>1MSF.]\L[TCZV8>-7^U62UY6[_Z17VMV^_[/K6-K/:\
MK@=>#9PR1'/(058R75E/)2"L)("G9<[2(DNSPBFRXD6JN?GA7:4T+V5'+1,+
MZ2JF-\F]:@>6:"OVC8#K;.?T3[YZ@7?0J1;.^0SA%6A/)PT_,DUZ'O$*X\M3
MB]_!W<\VM^3'5\'$\DG'8:[OML*,O*^56+"2ID)F!<!(2 #U%3\E"09",(Z5
MZ4X0M<K<LYAK;@99EY1O]_)&I!5X7]9J6;MJ _/E(X='\ +;0XW;0=1H+^N^
MK:I'W.R/ A[QF\C3'X&CDP]OB4R/BWYIA,D\<$M5N@ZV[2.#FZ'9=RWXK+X,
M[S;?R7*]*#B315(RP'A1 IC"%.!"]^$1 B)24)2ZY5,-E&-N)OEY8Y-("QK]
M48OJZ/ .71@[%W<"N ,;\4%(#VEP-@8G?XW-!DDQ=4.S,5"=:&0V:CAW3[,.
M2@C>QNG?"+G9BH]K93=$M3-D2GV-A;-8HJ+,&("<8P 19P#Q% /"DYQ13GE"
MK'+&QHLR-Z/8:A.]?_/Q]MVUO7,U<D4N^ZS3X1S8&AX@;J\!:U6B5A=#0"4J
MTR7ZP.5W_8++;[*EL7>+IUNBB;SFT$OEY%K[0;?'\QXYP62.N1\@NGZ[IQ&'
MN?4?R'+[5[)Z%+\)HON3Z>^UIAW[?;VAE=B:L\3']<.C)B;3Z*BCA)E6_?:X
MU?V7WY!J6>T/&;I*7U0+F0I.DQ@"7"8I@%B4 ,N"*,\?(9+!!,;8B?TAB)3S
MV_WJ=G&.O!!A5M#N=/#JZQ)XM]3Z14;!JZBC8MV0I:MD5&L9/5?S*MHK&AE-
MKPX1CZL]HX7'Y,&@Z^'IC!)&QDE/,$%A?GF^"3O9P$3$[P^KS4\AOJGYE[KA
MY2EFRF[GKJ8EU-\%_V+8QPQKR*=] UV4(Q@+2 !C>0)@F5--,IF"."[*A%!8
MQ-!IO_ LW]QVBCH;F9[O!=C0/M54OIV+][8\;41?9=]+;[?1O.*"!MYB+O9U
M]+.6[FF;81#WE>;I6;IITT+#0'N41AIHFI$'C7JO^B2>Q"K]37RG8KLHL#H2
M%+P$:9GJ!HJB )2S'!02\A2BC*=N9'$]<\W-E!O9HG2@RW\"2T?'?1Q"$[K?
MM:#*@:X!B_ZHI?5H\2PP\>T"GYCI=1S9\RJ?=4=['AEF(=X\5KJ,LKIF__VX
MK);=A, O6V7 #J:J98'16Z.NT;LE/]X)_LAV2WWS65,-E+E '&<()&E> D@+
M#K"R,Z 4$"$H$2Z)$X6+5^GF9H5:D:],+QQ3]K@C/R*^%[OAA7 S4WX7U,ZP
MO=HR!3:%K5Y11[&KZ+!NK1:F?<1!#^]T%$'P]616_<HVJ2$. NM+TQUFDJ'4
M&MU8Q8ULKFC7=U^V&[G<?=I4E>Z>VW3(K&XWAY1"39W>-H+.,!10)V"7.<X!
M+(L<8(BP<A\Y+B2-)878C7_#AUAS,^]M]W6=L_M<0_V7%[>NN@+ZL]A%6E=7
MV@XO:VIGZ*=?J< 6_GAA]BI%M4[1+UJK7VN&@E8QO5Q=U:(_;DU .E"3<)^@
M>R,6\2+4Q.PC/H$\IBCQ.KI[ALR;[?+N?O?OIAON;V1-ZEC6QS5K#JDY*61"
M. .8$&6V*2L!S6 )4(R0C/,T0\B*Q=EBKKG9XEK<J)8W.@AL^L_^LWU>Q26(
M+^>T> 0NM//;A]GE2( S=O9))QXQG"BKI!=+/[DBEJ#T)(-<&F&R; ]+5;KI
M'+:/N%E5+I:+IG?'AV7%R$IW\'B_YN^4R5XP 2DL<0Q*&7, F4P 2761?@YC
M"$L.BRRQ,:=]D\S-CK9]<&I!33N<2(D::5GM+$$OI/WFTQ=0@>WF((RL7W4;
M$$ZX>)5@_WRW>?H7]7CMW:D?#DY=[Z"3O/8V:K7ON]5G!_)2JX.Z$'O/[9-0
MI_3])?[O:Z[3F]4Q7/#W/Y@^T]=!LCSC6)F"%+!8)U[QI 08YSKQ2A1)6@A!
M4J?S\" IYF8JVE0Z1QKK00M@=W@-#FM@PU++?]4YH1H5GJ4W==6(:CV\1R-'
MX>B+3'N0#-.R;8^!Z8B.>]1@[F?)#\OU<J=F>!)<O<CJ6VABD)I)IXU.=M-A
MKZ5ZU[45_J"^[(LT@XP)?9U,4TW7D*: BE("P4M.XD+;0^M2BQ%RS,T@WMXK
M>TBTA/9GIC'+</DL.A&XH>^KC1; J!$=](B,(IT[FN?T-D:;VCG3^DRS)/9'
MW(F69J+C;]@E<CHF>P"VYP@]9O3)CM<>(.@>O7T,Y[Y!U8V2?Q.[^XV:]DDT
MG3>5^IOO2]8ZGU^$^@8KH>[$(LXQ+7*,0)GJ2RN9<H"@.KTG.$\@YC#/[7K8
M#9E\;EM1*VFT;$35S,J-K/:6T'D)+N]((8$-O W5HD>U[-%!>&7>6K1;^:,O
M4Z!MO]F$1'VB'<8S^DY;RE#X>O81YR$GVSR&*MO=,0:/,3 )]NP&U<F(3UB6
MYT61@A@3"2"1&<"P9" A(F$)3M*,0Z=L6(M)Y[8M]+IIU8CR!:L5L OB^,;U
M-0\GEI"ZY]0Z8.0KN=9FRFFS;!U .$JW=7G6*ZO\ G*40%9@0#*4 9CR&&">
M%P!2GF0,299F>+';[,C*S@Z=F<?)].QG"_>>M%SHRS7;?!?1+RN3<Z.\TKI!
M2$1>=(M@=2\)\X_WFY7"W;3K>?^D!%ZW%ZWU[7[TRW(=\<UJ1=1G]B,Z=O\X
MMUQV1LO#(H3V7L_STP<GI?=LBL[-,@<2^G,&Y]+'A]F8ST+?@*OW2><>73^1
MY:KNEM'TT= M<9IWI_TZ2QD39OHP<DR5%\0I0!E"($V*LF0ERS)=$FIO?9PE
MF)M=TCF9VA:-,D#@XJOD:?D(9"A%D( <Z^5+LU)O(Q20F&<Q3%(HI5-)5]CE
MF\"CU<OW?$L9L8ZA5\]N+PFZ)H%W&;T<'YOEJ+-J]PK4&;5U@ZB.#@%VH<$
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M/'93<+&=F'T^+&SGH7'B7^L99FB\N]IMEYHZYRVI[J_7'9:$_:&!Y")-&&0
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MM4#KF6OJ)FB7U3[1!LWB(?><\B_;#7]DNYMMLZ?4#1.1^FY (D'&E>&&LL0
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MGW[USR(S%$A/5MEY^DF-[%!P7MK,P>,XQM9V#]O%7Z\765'D"<DY*!A3%JW
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M70_$YP\'P:/-7O(K_?=&=E>6"[>%L7-Z \(=V$ WDG>YYCO"1S<=R+]<AGP
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MSYFO[MI^4C_]VS^T?U'_T9V7_NT?_B]02P,$%     @ CH-C54*281OLZ@
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MO9FFUW@FCZQ,H'CFY;#$(U)834($3F+2-%L9$A>V"B#N+;L7'$3[<#A>EHV
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M GB4U5^_/TO4L./-^C V=?4PL*%991H6[Z;WVFPM=O39TA@(\.0,FLNN\4G
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MB4B+PQ.)!9Y)E,9'S9QSN7:%0H,]Y?XI;M':!4X#N^I^BU65C. " TYM$\.
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M;;(\U>[8L1=AP[X";0:J_2FS"8R^!EP[CCN]XM<36%]FXCDQ7X[_L;KVC]Q
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MFO0/6SGX\L!^<9TW'?R^GTTO<)VKUQ".=R1W?$@]M_$Y"FM5'.#'[T"<3LR
MBQ@[9/"KKC_>H)$SDD*2!O_7UO:(=E-2X;( +>BR0/U6DG=X1@.=C/.:4&_1
M;@<G2B:)$1:B%1H#M4Q%93:?)&C@._G3L; CWU])_$V;DU>SJZOQ:KQ]>>+5
MU1)<P+14A!^?Z'_V,ROF_0^CO]8UP-VJ9UNK[H AEU+DP"PQL0SO-@A(KQTC
M )!E<L+:4'U@S"$$UG+.%N<95XI0+LK6M[;CQ7_^\KW\^1;7F<TWDCU)1.H,
M>@*B3"L.KDR^XT XE\QE9YR"VBWSCB!SX&N#WE#VF*O5EP:;-H&K?B7'^U*;
M_[RB%_4H595LV&J!N^)A[A0/01$($D\TSPRQN A).<GL0U2<U7ZX?Y^".LU_
MUD5PTXONPV\OYG_U9?+O@PMZZ2'A_SB20S"(X7(EQC%(R$EDSC*G0M9G^F R
MA[5")^!D=W^@_E340#ZMX^G5;+'M,!JK-&4R$VV]0S8".HS"4/1,J; 2-&.L
M]E.(1T@9-B]6%4VGB[KI@VE5QEMN\C_ O#@#L^FG2Y3RT4?5,Q]8[_ ZA/)*
MQ]D;/Y^B32D+=DO=0LPHF2FH2!RHXJ=P6[II!D*Y#51[Z:BI'2D_1DN]9/WV
M"J6O1^QJT"?7RP>/<80!+KW11 E1GO0Z7497*%)Z$"5M&$13>Q;-D:0.>]15
MP=#C^?G^E-; P7?'YAG&*:FP-/X*GR"60QTCEC??RI,%2*LBS:LOU\MUA+$M
ME8WR2:NS]TR21,L(/F7QZ"]AC8G>9::BA]C?/5,M+H8];GM&]""J;OK,_K1$
M=D(9"%\XA^G"G_3PY,F/JSC(=6^J*SX77.4O2L;A;LF/,/&ED0YZ=8L.(AU1
M'_SW^T.$<PJ<6I>(T!1MHV2,N. -B2J*F%,T^%W]=QDG4%RQ%<_&VF71M[/;
MP^1VV;/YO+3J6E$PZ3Z]VW]WO[C]*8M?NLJLK2,H9)6-3P8]:5N>KTN!NQ(]
M:>>#8U8'I7-_[[=?D-'A'Q2^T%YXHGE0H[!JRK/9S>A9Q./O8>+"Y$!-XAC0
M@H>B%_Q*.T>T0&U18[D6M>..XR@=UD-I OV]*;9I7V57Y]"C/94G/JR>G[(O
MQ96\E-OE-AY*WY6VX.=K%2BAD!!Y3*,!<]*62(U3I6GRO'90_10]U5K\;K3V
M6$LYG>-N1.=^CKY[UT!TLYV<,3QY1SAR2V0VB3B.NQ%BE-HZ;RC4=L2.(G38
M$[X:CA[M_=N;TAHX?P]A\O?I+)2A)\4FO)MBY%G>TT\C_BN_U9DI>ZHL=\13
MY%PRB4:<L4QX%-XEF86.0P)W7SZ&/;N;P'4O*F\)]NOF2_>:+NT0!O[";[/I
M_)YLRK]?2R%>3L?_=0W;E<#!I<0X"))<0-UX$XD3H%%+P6JNDY>ZMU.L3\:&
M+9+M?V,T XJF/=QU$/'!SY>G%+3M_)B:K5^>H[):VY?;A;YO]@*]*YCT7G*5
M%8D:G0*93.FG(1V!$!&Q*03E:E>J/4=3S9Z&NU?:?B9-M>;1:\)X:8(;(D:4
M-GAB(T?'2%AGJQ?"'$KCT.U?*J+HJ3Z$U=75N*WZ,ELU=$1#[:?I'']COIJY
M<(KE>O9#:]JQPSBH9M40=]>Q5 ]U!]X:..OLS69KZTR9!J<UB2(A5KC4Q,OH
M">7"<NVS5GU,-]V/N,KC(QXNV672-H) 6G9G4+@_NYGN.A"?,R7,@LX8 P8M
M^^LOO!>)0UNY/E#US!2)JEIKVMI]@HN2O"LF8UYJ 8^_(=W]017O1O>@M)(E
MVU[JKO."24E)#!G* +OBD"<2T!''X\X;'IGPU%:?\_((+:</5MR,SF\;NY5:
M@?62B\^S5WC.SR;C5'; QJ,;DU5F/! 5E2N3"20&3LX2)FG*/AC+3>TW \=3
M.ZSUJH*DA],67T1U#>1>MCF]+5G^,)_E57.E?;BV5%/+E2]CX3U:ZX2^:;2"
M9.Y%8&B]7:X?3M6@?-BTXHN ]P54VO0!O!X.OLBS^:N)'U^5YW,?8([?7I5&
M8MUEZ.:%_PDAR%$+U0Q+3N>TT@'_;KJXGI=%[R8_(IIL$I)PP0*1+'OBDS)$
M*ZX1TRY15[L7P0,BZH4>MX\YWL[FOT^_^'%:2;P\7UM]D?[C>M$]:5L_TQ]Y
M<-XID4F@T91G:YXX&5,9#IT%M\$&WE^ZY7!ZASW63\//X\%'SWIKVA!^NOZ"
M1JRPYB=E=MK;R>R/=]/..IQ6NKG7YU:,4P[GHU;8LF/E-Q.X7Z@#'++A&IT_
MFV,)7Q-Q@GN",7-4$B*"J?H;A#WHJCLCL:RPN>IF@_WMM*73P%(D@I9H7GC<
M2 D]FZ0EHM]09VQ_0^H.(G7@0*8VMIZ>G]B/ INV?^?S"S]=]\YY#4L_GAQC
M[79]2CW;]BR-E2S9YCIW_O^X&[NT.3.YZ[6%Y_#83VZG;&Q.\T[6Q92)*AV&
M)"N/&5!.! ,4C_&#53;5?K=2A?"3.];L'$!ZMGSEY_/O&&EU%]<CJ5/*W!HB
M0ND]EB7'""H;8I+GFCN6C:WM\.U%V+!V[N61]Z#A377M-6WV^IJ$?G\:M"^)
M_)L?O)MB%+KJYW&\H6V#[O8GTI^@A_X'UP>>D^'%>0BIM#H.@E@F'-&<!N=C
MPMBM=F*PB<'UQ84:J2 8@%!$2->UD58D*.6(R]*BVR:$"GT66.Q!8K,#ZP_!
MS0D#ZP]64Q,I^Z>9>N1X^S9>C(1**+G,"/BDB81,B?7>$Q9 TZA,4KKV .+C
MJ1TX'.L31 \R]B^BT1\6N[_"58#YB%%/A>*1Z B92.T%<2IFDJ5(0@KM6/69
MCZ?0VT!5QPM@J@J4CU#P@&!&3W6+SSR;OX=E^>197DVEP9^\];'+-*\: :U9
ME-Y"]%TC A]+5"%)R%#&2W N@Y7);;?P?^ 7G[#\CPC)8[ Q>UE%#=HXO##Y
M:C8I-51S/_ECO+R\C9O?31?+\?*Z*R9=LZ7 >,>,)"RR4E8E'0FE3770.5"9
M#-/;+NE._.V]X-#C\@9 7#_*:,W>_0)3R./EKW[J5[?)GV#^=1QO]X]WCMD4
M2VET:9KIP!)/K2.1*N9-8-QMMY[?S] ]L^ZPKV':L' U5=,:[%:5UNL)E==^
MLM$Y]F93)4EUF=UDC0Q$^N*]2,Y(LD9G2;F1GAX#O&=7W@MZ\I\;>G75\P,$
M+.^6<+5X/YY"]\7(Z2"%0V/.-/>XM1@E#L 38[1,E"EFJD];.XS"@>O=&@JJ
M3]#<#X#+D:;)T:PDB48F=&(5(Y9*052*+I<B>E7]\NDYFMJ./D[!PX'0.T@Y
M/P#8MJ_.-+4I)T_Q.!%E6+E$!X.#)CP"U1(YC:YV-ZT#26P[+'E!*)ZBNB;F
M93U@<./.Z]7UO*ACY'W."5P1H%J_G+3""J(!& 4>M%"U2T_W(*OM4*5/#)ZH
MHN,MXFSI)R]B$7^;3>.:,T7!8%"5B/"*HF^=# F@#;'>2H@R*6]?VAC>4==V
MS/*"=O!(A35O C?XRM1Q)X(K\98@4DA=NG%@#%8>E6N5F..U"S'WHVPO$*I_
M1A">KJ@!;6&7Z]S'J5AU2<;O2HUI-]OG&M+Z5=)LNAB!IK1T-B"! 7K#0GMB
MDZ3$6Y.2\4SP[<=CNW/2%6C9"XKZ!X;B($IK,839V'HCY3UH$)EPDPUN,\C$
MET=O&@,S%VG6/KVD?[@7",T/#,+J2FD 8(6#+4D]8._^#S83 @B/D@^UQ*A0
M&A5&3<KU(XD9K(M9!9UK%U*?1/!>$+7_!!!].;56.\E_I!KBLY2Z-CKE>O3V
M 5=[)<-/DME^A?#^4NZ_()A3F;7V:-8A9R*MX,1Y-.O*)1NCY0&]AQ^F(/BW
MZW*G56XSU@_X?Y^.<=OCWF;!I$BL7O7-YL2JR$@T$%Q@U-KJW1!V4])L>>\A
M*-@VR16$WH"_4-[J(P'E_'@-7V$R^[+YYEB'+$/RDM",?TB&9X;W,A.E2E9,
MH%MD>KB]>9R@8?/E/0&IG@J&KI(87UPNS_-YS@M8?H!Y&6OK+\K4HI7@T&6)
M,.[Z!O]6JM_2V84?3Q?+U8OW#_Y[=]D:(Z4^6$92ZIP5D8AE$G>1B-0G$)RK
M_,SY6XV887/CE?$VC(I^*$R^F8POR@#ZM[,Y?M?Y09]0#*O'R:/HM<D<A>YM
MPE!094^LRY1D"CI2&[C<]ADJ(/-)DH;-FP^.SWKJ&ABE-[[$^9=5Q]791YC"
M'ZM"X%%0UH!3G/C2Q4L:[XG3/!%G<C242HC6[P&[I]88-O7= XZJ";018'R:
M7>->6-RV@!MQ+WUTRA)@8(D43I$@%! A+-.@+=IA=P HMC]_V 1TCX X29#_
M1[ZO?H<?-NW,[*H%/EK:]C(C3Q#9?EYD7PGWGQ7QGFG&#271E]GO&KV[$GX0
MXZ))P)@TL?8(M9=X)OUVC*$YO!]_+4_1[\MZ5> 9<@KE1I-D"R4UZR3Q( W)
M+F@&7J>L^YN[^!QUS69/#D'+XX^CJRJG@8S*$_S\\OU7_Q]=4\3%ZHEC AJE
MBHE(SQ61P1H2RIQ&"#: $\R'9"OC[@#R6GGY7!<AVP->>E)7VTB\8^PW?P6O
M9U<8Y8^,!D&-$NC[X*:6+CM2^JGCID[&T90\.L8OA\9=) X\5:XOJ.P/R9/U
MU@ L/\]]@D+^S5L<#,:,,98126U$%YP+#,6X)B)HFV4$'U7MR0C;-#0+K-,5
M/JLH_0;0\^IZL9Q=P;P;UU!B^\OQEQM6= S9 PL$@\3RGH%EXK5TA.H 8#5*
MK/H$X"?(&7A4X MBJI9.&H#7^@:F=""/E]/99';QO<M)WK+CP7-C2A=*@UM&
M4T:0"4$H!>^LU$FXVM6KSY T\."]%X193=TT +6;]ZE=/_0'PENQ%$%S, RW
MBRQOI(7EQ$8,MJBGZ&%XR,'+VA;M>;*&O79X4<M664<#PFXQ7XX^EB14YY\:
MK61V.: \C"1XS*-0LB[7),PHI7R$N%<3(_S4#5#A=W> NK=@*P]^>XDECQ=M
M"WBX\0,59QF $A-#:6PO+![4#E%M@E<&>-)YKS?C^R!B2*?[!&5MJ_L(R0VL
M\%\1_E?75S<'I@LF%7O(K"P3SAQ#UU\'8B!X"\QD=3<8]P25WUMT8*4?H[)9
M#?D-K7C_;9/PY%ETI:,E+ZW5>$C$\ZR(#P99LC((V,NM>$[QFXL.<P)44_S1
M\FOB;=X3Q][[VP)U(T&8A$<?1,=1-ABT.5>\&<-IU#HRPVI7_^]#U[ !SO!I
MZ.,4U$" \SA/OR\@7T_>CS.,6$H!C$X$67(E_82.N2XV-(?L(K#_G[TW76XK
M2=)$G\AM8E]^*I6I:EU3IF0I59?=7[!8/"1T4X &()6I?OKQP$)2)$ABB8,3
M9/786#8EJ@!?OO!P]_ E.6Q=8KH/7=TF!(]$P]YP.U(U79=&U**QV>7%C[?+
MY57=*+M]T?Q(G.>PR"=,A]_[HUNN5SN&F^&+!TI(9/.8 2WJ-!E&ERSA)("+
MJ))..3'_C%HJ\*_;I1KS&?V8ULL?WF]6;+_=5<RQO@E<5@8#UYO>_51/)3<(
MCDZ&91A"-JW3-B<1W&V)P2&8NM>@<385=G#7WNR+6ZZJ81]D?17U"AECL4(
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MC4]?PO7LA&N]<<\E)SE!<:%>S75DF& 1F&(^& Q)H>CX$MJ;T3X<P:XS@,.
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M:FHT* A*%XHRLI<H'/TAG@^D/<P@;PJ!_>%UA#[Z -B.<[AFD_ZF_/+C8[C
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MD+RM-#PF\GU,Z\#^-(I?>IE-F^C_C*AX7F=@N_=\S>RDB,)U+7 3"9&\)&[
MU7X\+2S=29+LS1 =IL<1^])?MLZ._!.P\+P\E"VCVRL.9<3$<H3HZ'9345"P
MZV*=BU<<!L.XXJUWWA]/[;C^R0N&_3%H.!SW?HW[&7XF$>9/HSCH=3O'EEMI
M!7F5:"!)SHC;9,'[*("\.ANXM#[KUOOPCB1UW!DE+Q#X1^.@*]3O.M!;Q^T-
MJ7'G/_D%RWR!ZW_X*?P]$3)Y&8V%G.B&4]H*H,//(08KLD1K#!N@W[@%Z>/.
M0WM&I^+L..DC$+C/$_'Q6RF8+M^7G;^?F)*M$=+60">#2EP!A?H,!/UETDH$
M&\[2$/T4H7M!W_TO](?&0 ?._QY'>?D'$K?U$(=0)%,N@6&NO@(X 4&6# 4=
M-\&F%'EK8W\(?7O!VO^[PWHPC3_G>6VOP_++FXOY7\--:;OW#6>;S?8X;R--
M9'/!>,Q!482H"ZA2%$05(B1FBS$Z955:U\,>2&+_E?B;"FYRGU*1NHYG)EN0
M68*@.(7>Q3KGR#[H* <QRO\[D>UH1(\VD>T K'3CG P^,2$;H;2. <RJQ2?4
MU:HI!'+>M! ^!TYWZ[,[0?]&\^$. ?4XDV .05@'Y^X@!F]-CY IIX)U/;$+
MB=@D)02;"S#!G<C%:S[$I?Z_DV!:H*[1))A#(-#;)!B?7'1%9(BU TZ)PN@G
M+R#%*$QPQNJX3[OLRY@$<Y B'YL$<XA4>[-].\9%FJ*LLD)!L8%N&\<X!.\4
M,":BD#Y%BX/:N".GP#[C-I;3;_F6.NT;HIO#&X/AG!$'!IFD6 0]1&T2)"Z2
MTRFQPEJO@WJ2J([,X*D0.'@*["'ZZ -@^T\7)2="%FL,1;NF-M>0#(--$IP.
MBFF60@X#U("\F"FP!T'CE"FPA^BI PR>,YWN2F Y9 ?9V$RB81F\DQR,UE+&
MY+)4K3M7>AMD\8P+79]#%N XK'5P#.OCP8?%_/LT8_[EQS_)K+R]*?1]E2ZG
MW]<;.G?W:G#)?)""@8FU_+=>K0&10S$L:Q=93*9U \-)!+_TM,"1,)R/A8E.
M#\#;V7=<[L6LER)A$*D.CS,DYA3 <QO %2LC7;J.Y=;.T4D$O_18<K@#, PF
MFAV (=[4-\-)-HOA-BU[X?/G!:YWR-:U8*M_<?RC^L%?T>Y5_33N&CVK;[ZB
M5FJ\)BC5A\9_32^_O+Y:7M))65P_/C)ILR!/!Y2L54<J&' \&]#!9(.FE-A\
M[<N>I#6(16\)_?U6Z&NG+V@*700=H"Q"G=)9F^U\+""$35JB\.@'F%ST(#U=
MS"AJBI4=$6<;;71PL]_<,YMEEQ_Q\VKRXRHAY*+)+!8%+/&Z-$4:\ P3:&L2
ML\D6%5J?J$<)&CV/T4CO\Z&4T .BUK1O,CL\^.PX.1<12ZC[5QEXDR/8C)(%
MIYEOOB_N)P+&14Q#Q=Z%S-%2'OG!\;>UH[%^'=L.G-UPLTG2N<*M=DY X?75
MK28P0O2"6(HZ*>FYS_X)EVF_;QH9',>K<#Z8/$=&QVOZRVD*%Q_G%U?K LZ?
M.,&D37*F %OU3V,,$$NPD)"3^8V(3.4]D/'XMXP;_K5!14,YCKPJXO?P7_/%
MUGU;V\WB@C#:&2BI3C+3N6YQDYY8X)[I(#5S>W68/+$CXOXWCXN,YNY' _&.
M#(Y:JO&^_,3#]N XQ10S$M!P<O(-"^"3%D ,^)2ER\GME7-Z B,/$C#>KHA3
M-3IO+=Z1KY3?,9,EG.9KD5POM_!,28& @<Z)(F<, J<#A,J&PG4N,>]3Z/3
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MPMLD><S)5/$$2>>$X@((*5O0CM-M'GVVHG7F]Z!;;+"BM<%NL4,D>N(M]O,
ME]/1L*YJP'RKO/BFT&$%<QX,K\V%))=4"UEB!L>L EU,XD47&>U0<'F2N#YN
MM[:.<EN-/./W]AU_-5AQT<-?=;;RHCVY'>7)W6MCBF0>R"1*4)PK"-H5,.B+
MB#IR'5N_ZISUR?TF/_)F.IM>XKOI=[SWM>N4"7HOK ATVCQZNO7)ZD<G,P@3
MG#$Z9RM;]QKL3UT?46)[3#W\E-I47QUX:8_P\\N/W\-_S1>O+\)R_2244F9,
M<0_24 2M,L_@ SF@)=)]4U@60;<.-0\@KY>7U[8(N;^O9A!U]8W$&\;^"%^W
M#>4B)9^Y5Q3_U%7H7"AP.DLZSRG&4@LD6.L[XD 21]]D.0Q4]H?DR7KK )84
MB6>LY&\'#@07#7)RLIURD8(O0;+*5@,=7:ZL<C::UKB[2T.WP#I=X?.&TN\
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MEH)$-,T'49Y";[>AYI'HN3?EZ$RJ[ "VC_"X'D'FL616& /E,%%L3?\)20A
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M2Z8#>0*Z-AL#83P30=0!>*"<:!U['?F<X.0%1\=@JI'D.\#08Z7M@ E3(IF
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M>1^&'[E1UD7#;*ASWC%SYJTAM\:D8$.*.;C6+X=Z*1X]_*9E$]" 0X2L,I.
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M%6L/6-C>$O)<=)'1,&5$KO,4!?.F>!8!N>>@4Y$[#2+<!0UC5A,<H:R[ZCY
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MZIEL,6:;RVYGV5'9 AS5I6VEY[N79VV$W@%\'MEGVPA 21=#9%*#9MH6SJ)
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MB54A^2 3V>P3! %WR.K$)6L%A1W\_F/TTBG4EM<)S*VISF!2D;).RJW]Q>A
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MK_-%[<0]D48ZP\$P3!3[D< HS(S>,"]*-C):D\Q@\?E03'7BI1Z+ST>#I2[
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M",V'?/T[5COL@Z<VU0[[**Z#,WR/6]1@; S! RL191T/18$TCYZ94(>=@O>
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M4$L! A0#%     @ CH-C5>56^O3B!   :14  !0              ( !Y!
M &$Y,S R,F5X:&EB:70S,C$N:'1M4$L! A0#%     @ CH-C51GY0ZC1!
M(14  !0              ( !^!4  &$Y,S R,F5X:&EB:70S,C(N:'1M4$L!
M A0#%     @ CH-C5?--Y_%Z;@, ,:$F !               ( !^QH  &5V
M:"TR,#(R,#DS,"YH=&U02P$"% ,4    " ".@V-5[\UPF*P:  #\-@$ $
M            @ &CB0, 979H+3(P,C(P.3,P+GAS9%!+ 0(4 Q0    ( (Z#
M8U5@V,00/#   "OM 0 4              "  7VD P!E=F@M,C R,C Y,S!?
M8V%L+GAM;%!+ 0(4 Q0    ( (Z#8U7!PQ6C^9(  *6.!@ 4
M  "  >O4 P!E=F@M,C R,C Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( (Z#8U4@
MF6,58ED! '\I#@ 4              "  19H! !E=F@M,C R,C Y,S!?;&%B
M+GAM;%!+ 0(4 Q0    ( (Z#8U5"DF$;[.H  *!T"@ 4              "
M :K!!0!E=F@M,C R,C Y,S!?<')E+GAM;%!+!08     "@ * (P"  #(K 8
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
